Tricuspid	O
valve	B-UNK
regurgitation	B-DISEASE
and	O
lithium	B-CHEMICAL
carbonate	I-CHEMICAL
toxicity	B-UNK
in	O
a	O
newborn	O
infant	B-DISEASE
.	O

A	O
newborn	O
with	O
massive	O
tricuspid	B-UNK
regurgitation	B-DISEASE
,	O
atrial	B-DISEASE
flutter	I-DISEASE
,	O
congestive	B-DISEASE
heart	I-DISEASE
failure	I-DISEASE
,	O
and	O
a	O
high	B-UNK
serum	B-UNK
lithium	B-CHEMICAL
level	B-UNK
is	O
described	B-UNK
.	O
This	O
is	O
the	O
first	O
patient	B-UNK
to	O
initially	B-UNK
manifest	O
tricuspid	B-UNK
regurgitation	B-DISEASE
and	O
atrial	B-DISEASE
flutter	I-DISEASE
,	O
and	O
the	O
11th	O
described	B-UNK
patient	B-UNK
with	O
cardiac	B-UNK
disease	B-DISEASE
among	O
infants	B-UNK
exposed	B-UNK
to	O
lithium	B-CHEMICAL
compounds	I-CHEMICAL
in	O
the	O
first	O
trimester	O
of	O
pregnancy	B-DISEASE
.	O
Sixty	O
-	O
three	O
percent	O
of	O
these	O
infants	B-UNK
had	O
tricuspid	B-UNK
valve	B-UNK
involvement	B-UNK
.	O
Lithium	O
carbonate	O
may	O
be	O
a	O
factor	B-UNK
in	O
the	O
increasing	B-UNK
incidence	B-UNK
of	O
congenital	B-DISEASE
heart	B-DISEASE
disease	I-DISEASE
when	O
taken	O
during	O
early	B-UNK
pregnancy	B-DISEASE
.	O
It	O
also	O
causes	B-UNK
neurologic	B-DISEASE
depression	B-DISEASE
,	O
cyanosis	B-DISEASE
,	O
and	O
cardiac	B-DISEASE
arrhythmia	I-DISEASE
when	O
consumed	O
prior	B-UNK
to	O
delivery	B-UNK
.	O

Phenobarbital	O
-	O
induced	B-UNK
dyskinesia	B-DISEASE
in	O
a	O
neurologically	O
-	O
impaired	B-UNK
child	B-UNK
.	O

A	O
2-year	O
-	O
old	B-UNK
child	B-UNK
with	O
known	B-UNK
neurologic	B-DISEASE
impairment	B-UNK
developed	B-UNK
a	O
dyskinesia	B-DISEASE
soon	O
after	O
starting	B-UNK
phenobarbital	B-CHEMICAL
therapy	B-UNK
for	O
seizures	B-DISEASE
.	O
Known	O
causes	B-UNK
of	O
movement	B-DISEASE
disorders	I-DISEASE
were	O
eliminated	O
after	O
evaluation	B-UNK
.	O
On	O
repeat	B-UNK
challenge	B-UNK
with	O
phenobarbital	B-CHEMICAL
,	O
the	O
dyskinesia	B-DISEASE
recurred	O
.	O
Phenobarbital	O
should	O
be	O
added	O
to	O
the	O
list	O
of	O
anticonvulsant	O
drugs	B-UNK
that	O
can	O
cause	B-UNK
movement	B-DISEASE
disorders	I-DISEASE
.	O

Acute	B-UNK
changes	B-UNK
of	O
blood	B-UNK
ammonia	B-CHEMICAL
may	O
predict	O
short	B-UNK
-	O
term	B-UNK
adverse	B-UNK
effects	B-UNK
of	O
valproic	B-CHEMICAL
acid	I-CHEMICAL
.	O

Valproic	O
acid	B-UNK
(	O
VPA	B-UNK
)	O
was	O
given	B-UNK
to	O
24	O
epileptic	B-UNK
patients	B-UNK
who	O
were	O
already	O
being	O
treated	B-UNK
with	O
other	O
antiepileptic	B-UNK
drugs	B-UNK
.	O
A	O
standardized	O
loading	B-UNK
dose	I-UNK
of	O
VPA	B-UNK
was	O
administered	B-UNK
,	O
and	O
venous	B-UNK
blood	B-UNK
was	O
sampled	O
at	B-DISEASE
0	O
,	O
1	O
,	O
2	B-DISEASE
,	O
3	O
,	O
and	O
4	O
hours	B-UNK
.	O
Ammonia	O
(	O
NH3	O
)	O
was	O
higher	B-UNK
in	O
patients	B-UNK
who	O
,	O
during	O
continuous	B-UNK
therapy	B-UNK
,	O
complained	O
of	O
drowsiness	O
(	O
7	O
patients	B-UNK
)	O
than	O
in	O
those	O
who	O
were	O
symptom	O
-	O
free	B-UNK
(	O
17	B-DISEASE
patients	B-UNK
)	O
,	O
although	O
VPA	B-UNK
plasma	B-UNK
levels	B-UNK
were	O
similar	B-UNK
in	O
both	O
groups	B-UNK
.	O
By	O
measuring	B-UNK
VPA	B-UNK
-	O
induced	B-UNK
changes	B-UNK
of	O
blood	B-UNK
NH3	O
content	B-UNK
,	O
it	O
may	O
be	O
possible	B-UNK
to	O
identify	B-UNK
patients	B-UNK
at	B-DISEASE
higher	B-UNK
risk	B-UNK
of	O
obtundation	O
when	O
VPA	B-UNK
is	O
given	B-UNK
chronically	B-UNK
.	O

Effects	O
of	O
calcitonin	B-CHEMICAL
on	O
rat	B-UNK
extrapyramidal	B-UNK
motor	B-UNK
system	B-UNK
:	O
behavioral	B-UNK
and	O
biochemical	B-UNK
data	B-UNK
.	O

The	O
effects	B-UNK
of	O
i.v.c	O
.	O
injection	B-UNK
of	O
human	B-UNK
and	O
salmon	B-CHEMICAL
calcitonin	I-CHEMICAL
on	O
biochemical	B-UNK
and	O
behavioral	B-UNK
parameters	B-UNK
related	B-UNK
to	O
the	O
extrapyramidal	B-UNK
motor	B-UNK
system	B-UNK
,	O
were	O
investigated	B-UNK
in	O
male	B-UNK
rats	B-UNK
.	O
Calcitonin	O
injection	B-UNK
resulted	B-UNK
in	O
a	O
potentiation	B-UNK
of	O
haloperidol	B-CHEMICAL
-	O
induced	B-UNK
catalepsy	B-DISEASE
and	O
a	O
partial	B-UNK
prevention	O
of	O
apomorphine	B-CHEMICAL
-	O
induced	B-UNK
hyperactivity	B-UNK
.	O
Moreover	O
calcitonin	B-CHEMICAL
induced	B-UNK
a	O
significant	B-UNK
decrease	B-UNK
in	O
nigral	O
GAD	B-UNK
activity	B-UNK
but	O
no	O
change	B-UNK
in	O
striatal	B-UNK
DA	B-UNK
and	O
DOPAC	O
concentration	B-UNK
or	O
GAD	B-UNK
activity	B-UNK
.	O
The	O
results	B-UNK
are	O
discussed	O
in	O
view	O
of	O
a	O
primary	B-UNK
action	B-UNK
of	O
calcitonin	B-CHEMICAL
on	O
the	O
striatonigral	O
GABAergic	B-UNK
pathway	B-UNK
mediating	O
the	O
DA	B-UNK
-	O
related	B-UNK
behavioral	B-UNK
messages	O
of	O
striatal	B-UNK
origin	B-UNK
.	O

Development	O
of	O
isoproterenol	B-CHEMICAL
-	O
induced	B-UNK
cardiac	B-UNK
hypertrophy	B-DISEASE
.	O

The	O
development	B-UNK
of	O
cardiac	B-UNK
hypertrophy	B-DISEASE
was	O
studied	B-UNK
in	O
adult	B-UNK
female	B-UNK
Wistar	B-UNK
rats	I-UNK
following	B-UNK
daily	B-UNK
subcutaneous	B-UNK
injections	B-UNK
of	O
isoproterenol	B-CHEMICAL
(	O
ISO	O
)	O
(	O
0.3	B-UNK
mg	B-UNK
/	O
kg	B-UNK
body	B-DISEASE
weight	I-DISEASE
)	O
.	O
A	O
time	B-UNK
course	B-UNK
was	O
established	B-UNK
for	O
the	O
change	B-UNK
in	O
tissue	B-UNK
mass	B-UNK
,	O
RNA	B-UNK
and	O
DNA	B-UNK
content	B-UNK
,	O
as	O
well	O
as	O
hydroxyproline	B-CHEMICAL
content	B-UNK
.	O
Heart	O
weight	B-UNK
increased	B-UNK
44	O
%	O
after	O
8	O
days	B-UNK
of	O
treatment	B-UNK
with	O
a	O
half	O
time	B-UNK
of	O
3.4	B-UNK
days	B-UNK
.	O
Ventricular	B-UNK
RNA	B-UNK
content	B-UNK
was	O
elevated	B-UNK
26	O
%	O
after	O
24	O
h	B-UNK
of	O
a	O
single	B-UNK
injection	B-UNK
and	O
reached	B-UNK
a	O
maximal	O
level	B-UNK
following	B-UNK
8	O
days	B-UNK
of	O
therapy	B-UNK
.	O
The	O
half	O
time	B-UNK
for	O
RNA	B-UNK
accumulation	B-UNK
was	O
2.0	B-UNK
days	B-UNK
.	O
The	O
total	B-UNK
content	B-UNK
of	O
hydroxyproline	B-CHEMICAL
remained	B-UNK
stable	B-UNK
during	O
the	O
first	O
2	B-DISEASE
days	B-UNK
of	O
treatment	B-UNK
but	O
increased	B-UNK
46	B-DISEASE
%	O
after	O
4	O
days	B-UNK
of	O
therapy	B-UNK
.	O
Ventricular	B-UNK
DNA	B-UNK
content	B-UNK
was	O
unchanged	B-UNK
during	O
the	O
early	B-UNK
stage	B-UNK
(	O
1	O
-	O
4	O
days	B-UNK
)	O
of	O
hypertrophic	O
growth	B-UNK
but	O
increased	B-UNK
to	O
a	O
new	B-UNK
steady	O
-	O
state	B-UNK
level	B-UNK
19	O
%	O
above	O
the	O
controls	B-UNK
after	O
8	O
days	B-UNK
of	O
treatment	B-UNK
.	O
Intraventricular	O
pressures	B-UNK
and	O
coronary	B-UNK
flow	B-UNK
measures	B-UNK
were	O
similar	B-UNK
for	O
control	B-UNK
and	O
experimental	B-UNK
animals	B-UNK
following	B-UNK
4	O
days	B-UNK
of	O
developed	B-UNK
hypertrophy	B-DISEASE
.	O
However	O
,	O
dP	O
/	O
dt	O
in	O
the	O
ISO	O
-	O
treated	B-UNK
hearts	O
was	O
slightly	O
but	O
significantly	B-UNK
(	O
P	B-UNK
less	O
than	O
0.05	O
)	O
elevated	B-UNK
.	O
These	O
data	B-UNK
indicate	B-UNK
that	O
the	O
adaptive	O
response	B-UNK
to	O
ISO	O
shows	B-UNK
an	O
early	B-UNK
hypertrophic	O
phase	B-UNK
(	O
1	O
-	O
4	O
days	B-UNK
)	O
characterized	B-UNK
by	O
a	O
substantial	O
increase	B-UNK
in	O
RNA	B-UNK
content	B-UNK
and	O
cardiac	B-UNK
mass	B-UNK
in	O
the	O
absence	B-UNK
of	O
changes	B-UNK
in	O
DNA	B-UNK
.	O
However	O
,	O
prolonged	B-UNK
stimulation	B-UNK
(	O
8	O
-	O
12	O
days	B-UNK
)	O
appears	B-UNK
to	O
represent	B-UNK
a	O
complex	B-UNK
integration	O
of	O
both	O
cellular	B-UNK
hypertrophy	B-DISEASE
and	O
hyperplasia	B-DISEASE
within	O
the	O
heart	B-UNK
.	O

Co-carcinogenic	O
effect	B-UNK
of	O
retinyl	O
acetate	O
on	O
forestomach	B-UNK
carcinogenesis	B-DISEASE
of	O
male	B-UNK
F344	O
rats	B-UNK
induced	B-UNK
with	O
butylated	B-CHEMICAL
hydroxyanisole	I-CHEMICAL
.	O

The	O
potential	B-UNK
modifying	O
effect	B-UNK
of	O
retinyl	O
acetate	O
(	O
RA	B-UNK
)	O
on	O
butylated	B-CHEMICAL
hydroxyanisole	I-CHEMICAL
(	O
BHA)-induced	O
rat	B-UNK
forestomach	B-UNK
tumorigenesis	O
was	O
examined	B-UNK
.	O
Male	B-UNK
F344	O
rats	B-UNK
,	O
5	O
weeks	B-UNK
of	O
age	B-UNK
,	O
were	O
maintained	O
on	O
diet	B-UNK
containing	B-UNK
1	O
%	O
or	O
2	B-DISEASE
%	O
BHA	O
by	O
weight	B-UNK
and	O
simultaneously	B-UNK
on	O
drinking	B-CHEMICAL
water	I-CHEMICAL
supplemented	O
with	O
RA	B-UNK
at	B-DISEASE
various	O
concentrations	B-UNK
(	O
w	O
/	O
v	O
)	O
for	O
52	O
weeks	B-UNK
.	O
In	O
groups	B-UNK
given	B-UNK
2	B-DISEASE
%	O
BHA	O
,	O
although	O
marked	B-UNK
hyperplastic	B-UNK
changes	B-UNK
of	O
the	O
forestomach	B-UNK
epithelium	B-UNK
were	O
observed	B-UNK
in	O
all	O
animals	B-UNK
,	O
co-administration	O
of	O
0.25	B-UNK
%	O
RA	B-UNK
significantly	B-UNK
(	O
P	B-UNK
less	O
than	O
0.05	O
)	O
increased	B-UNK
the	O
incidence	B-UNK
of	O
forestomach	B-UNK
tumors	B-UNK
(	O
squamous	O
cell	B-UNK
papilloma	B-DISEASE
and	O
carcinoma	B-DISEASE
)	O
to	O
60	O
%	O
(	O
9/15	O
,	O
2	B-DISEASE
rats	B-UNK
with	O
carcinoma	B-DISEASE
)	O
from	O
15	O
%	O
(	O
3/20	O
,	O
one	O
rat	B-UNK
with	O
carcinoma	B-DISEASE
)	O
in	O
the	O
group	B-UNK
given	B-UNK
RA	B-UNK
-	O
free	B-UNK
water	B-CHEMICAL
.	O
In	O
rats	B-UNK
given	I-UNK
1	O
%	O
BHA	O
,	O
RA	B-UNK
co-administered	O
at	B-DISEASE
a	O
dose	B-UNK
of	O
0.05	O
,	O
0.1	B-UNK
,	O
0.2	B-UNK
or	O
0.25	B-UNK
%	O
showed	B-UNK
a	O
dose	B-UNK
-	O
dependent	B-UNK
enhancing	B-UNK
effect	B-UNK
on	O
the	O
development	B-UNK
of	O
the	O
BHA	O
-	O
induced	B-UNK
epithelial	B-UNK
hyperplasia	B-DISEASE
.	O
Tumors	O
,	O
all	O
papillomas	O
,	O
were	O
induced	B-UNK
in	O
3	O
rats	B-UNK
(	O
17	B-DISEASE
%	O
)	O
with	O
0.25	B-UNK
%	O
RA	B-UNK
and	O
in	O
one	O
rat	B-UNK
(	O
10	O
%	O
)	O
with	O
0.05	O
%	O
RA	B-UNK
co-administration	O
.	O
RA	B-UNK
alone	O
did	O
not	O
induce	B-UNK
hyperplastic	B-UNK
changes	B-UNK
in	O
the	O
forestomach	B-UNK
.	O
These	O
findings	B-UNK
indicate	B-UNK
that	O
RA	B-UNK
acted	O
as	O
a	O
co-carcinogen	O
in	O
the	O
BHA	O
forestomach	B-UNK
carcinogenesis	B-DISEASE
of	O
the	O
rat	B-UNK
.	O

Ketanserin	O
pretreatment	B-UNK
reverses	B-UNK
alfentanil	B-CHEMICAL
-	O
induced	B-UNK
muscle	B-DISEASE
rigidity	I-DISEASE
.	O

Systemic	B-UNK
pretreatment	B-UNK
with	O
ketanserin	B-CHEMICAL
,	O
a	O
relatively	B-UNK
specific	B-UNK
type-2	O
serotonin	B-CHEMICAL
receptor	B-UNK
antagonist	I-UNK
,	O
significantly	B-UNK
attenuated	B-UNK
the	O
muscle	B-DISEASE
rigidity	I-DISEASE
produced	B-UNK
in	O
rats	B-UNK
by	O
the	O
potent	B-UNK
short	B-UNK
-	O
acting	B-UNK
opiate	B-UNK
agonist	B-UNK
alfentanil	B-CHEMICAL
.	O
Following	O
placement	O
of	O
subcutaneous	B-UNK
electrodes	B-UNK
in	O
each	O
animal'	O
s	O
left	B-UNK
gastrocnemius	B-UNK
muscle	B-UNK
,	O
rigidity	B-UNK
was	O
assessed	B-UNK
by	O
analyzing	O
root	B-UNK
-	O
mean	B-UNK
-	O
square	O
electromyographic	B-UNK
activity	I-UNK
.	O
Intraperitoneal	O
ketanserin	B-CHEMICAL
administration	B-UNK
at	B-DISEASE
doses	B-UNK
of	O
0.63	O
and	O
2.5	B-UNK
mg	B-UNK
/	O
kg	B-UNK
prevented	B-UNK
the	O
alfentanil	B-CHEMICAL
-	O
induced	B-UNK
increase	B-UNK
in	O
electromyographic	B-UNK
activity	I-UNK
compared	B-UNK
with	O
animals	B-UNK
pretreated	B-UNK
with	O
saline	B-UNK
.	O
Chlordiazepoxide	O
at	B-DISEASE
doses	B-UNK
up	O
to	O
10	O
mg	B-UNK
/	O
kg	B-UNK
failed	B-UNK
to	O
significantly	B-UNK
influence	B-UNK
the	O
rigidity	B-UNK
produced	B-UNK
by	O
alfentanil	B-CHEMICAL
.	O
Despite	B-UNK
the	O
absence	B-UNK
of	O
rigidity	B-UNK
,	O
animals	B-UNK
that	O
received	B-UNK
ketanserin	B-CHEMICAL
(	O
greater	B-UNK
than	O
0.31	O
mg	B-UNK
/	O
kg	B-UNK
i.p	B-UNK
.	O
)	O
followed	B-UNK
by	O
alfentanil	B-CHEMICAL
were	O
motionless	O
,	O
flaccid	O
,	O
and	O
less	O
responsive	B-UNK
to	O
external	O
stimuli	O
than	O
were	O
animals	B-UNK
receiving	B-UNK
alfentanil	B-CHEMICAL
alone	O
.	O
Rats	O
that	O
received	B-UNK
ketanserin	B-CHEMICAL
and	O
alfentanil	B-CHEMICAL
exhibited	B-UNK
less	O
rearing	O
and	O
exploratory	O
behavior	B-UNK
at	B-DISEASE
the	O
end	B-UNK
of	O
the	O
60-min	O
recording	O
period	B-UNK
than	O
did	O
animals	B-UNK
that	O
received	B-UNK
ketanserin	B-CHEMICAL
alone	O
.	O
These	O
results	B-UNK
,	O
in	O
combination	B-UNK
with	O
previous	B-UNK
work	B-UNK
,	O
suggest	B-UNK
that	O
muscle	B-DISEASE
rigidity	I-DISEASE
,	O
a	O
clinically	B-UNK
relevant	B-UNK
side	O
-	O
effect	B-UNK
of	O
parenteral	O
narcotic	O
administration	B-UNK
,	O
may	O
be	O
partly	O
mediated	B-UNK
via	O
serotonergic	B-UNK
pathways	B-UNK
.	O
Pretreatment	O
with	O
type-2	O
serotonin	B-CHEMICAL
antagonists	I-CHEMICAL
may	O
be	O
clinically	B-UNK
useful	B-UNK
in	O
attenuating	B-UNK
opiate	B-UNK
-	O
induced	B-UNK
rigidity	B-UNK
,	O
although	O
further	O
studies	B-UNK
will	O
be	O
necessary	O
to	O
assess	B-UNK
the	O
interaction	B-UNK
of	O
possibly	B-UNK
enhanced	B-UNK
CNS	O
,	O
cardiovascular	B-UNK
,	O
and	O
respiratory	B-UNK
depression	B-DISEASE
.	O

Glycopyrronium	O
requirements	O
for	O
antagonism	B-UNK
of	O
the	O
muscarinic	O
side	O
effects	B-UNK
of	O
edrophonium	B-CHEMICAL
.	O

We	O
have	O
compared	B-UNK
,	O
in	O
60	O
adult	B-UNK
patients	B-UNK
,	O
the	O
cardiovascular	B-UNK
effects	B-UNK
of	O
glycopyrronium	O
5	O
micrograms	B-UNK
kg-1	I-UNK
and	O
10	O
micrograms	B-UNK
kg-1	I-UNK
given	B-UNK
either	O
simultaneously	B-UNK
or	O
1	O
min	B-UNK
before	O
edrophonium	B-CHEMICAL
1	O
mg	B-UNK
kg-1	O
.	O
Significant	B-UNK
differences	B-UNK
between	O
the	O
four	O
groups	B-UNK
were	O
detected	B-UNK
(	O
P	B-UNK
less	O
than	O
0.001	B-UNK
)	O
.	O
Both	O
groups	B-UNK
receiving	B-UNK
10	O
micrograms	B-UNK
kg-1	I-UNK
showed	B-UNK
increases	B-UNK
in	O
heart	B-UNK
rate	I-UNK
of	O
up	O
to	O
30	O
beat	O
min-1	O
(	O
95	O
%	O
confidence	B-UNK
limits	B-UNK
28	O
-	O
32	O
beat	O
min-1	O
)	O
.	O
Use	O
of	O
glycopyrronium	O
5	O
micrograms	B-UNK
kg-1	I-UNK
provided	B-UNK
greater	B-UNK
cardiovascular	B-UNK
stability	B-UNK
and	O
,	O
given	B-UNK
1	O
min	B-UNK
before	O
the	O
edrophonium	B-CHEMICAL
,	O
was	O
sufficient	O
to	O
minimize	O
early	B-UNK
,	O
edrophonium	B-CHEMICAL
-	O
induced	B-UNK
bradycardias	O
.	O
This	O
low	B-UNK
dose	B-UNK
of	O
glycopyrronium	O
provided	B-UNK
good	B-UNK
control	B-UNK
of	O
oropharyngeal	O
secretions	O
.	O

Involvement	O
of	O
locus	B-UNK
coeruleus	B-UNK
and	O
noradrenergic	O
neurotransmission	B-UNK
in	O
fentanyl	B-CHEMICAL
-	O
induced	B-UNK
muscular	B-UNK
rigidity	B-UNK
in	O
the	O
rat	B-UNK
.	O

Whereas	O
muscular	B-UNK
rigidity	B-UNK
is	O
a	O
well	O
-	O
known	B-UNK
side	O
effect	B-UNK
that	O
is	O
associated	B-UNK
with	O
high	B-UNK
-	O
dose	B-UNK
fentanyl	B-CHEMICAL
anesthesia	B-UNK
,	O
a	O
paucity	O
of	O
information	B-UNK
exists	B-UNK
with	O
regard	O
to	O
its	O
underlying	B-UNK
mechanism(s	O
)	O
.	O
We	O
investigated	B-UNK
in	O
this	O
study	B-UNK
the	O
possible	B-UNK
engagement	O
of	O
locus	B-UNK
coeruleus	B-UNK
of	O
the	O
pons	O
in	O
this	O
phenomenon	B-UNK
,	O
using	O
male	B-UNK
Sprague	B-UNK
-	O
Dawley	B-UNK
rats	B-UNK
anesthetized	B-UNK
with	O
ketamine	B-CHEMICAL
.	O
Under	O
proper	B-UNK
control	B-UNK
of	O
respiration	O
,	O
body	B-UNK
temperature	B-UNK
and	O
end	B-UNK
-	O
tidal	O
CO2	O
,	O
intravenous	B-UNK
administration	B-UNK
of	O
fentanyl	B-CHEMICAL
(	O
50	O
or	O
100	O
micrograms	B-UNK
/	O
kg	B-UNK
)	O
consistently	O
promoted	O
an	O
increase	B-UNK
in	O
electromyographic	B-UNK
activity	I-UNK
recorded	B-UNK
from	O
the	O
gastrocnemius	B-UNK
and	O
abdominal	B-UNK
rectus	O
muscles	B-UNK
.	O
Such	O
an	O
induced	B-UNK
muscular	B-UNK
rigidity	B-UNK
by	O
the	O
narcotic	O
agent	B-UNK
was	O
significantly	B-UNK
antagonized	B-UNK
or	O
even	O
reduced	B-UNK
by	O
prior	B-UNK
electrolytic	O
lesions	B-UNK
of	O
the	O
locus	B-UNK
coeruleus	B-UNK
or	O
pretreatment	B-UNK
with	O
the	O
alpha	B-UNK
-	O
adrenoceptor	B-UNK
blocker	B-UNK
,	O
prazosin	B-CHEMICAL
.	O
Microinjection	O
of	O
fentanyl	B-CHEMICAL
(	O
2.5	B-UNK
micrograms/50	O
nl	O
)	O
directly	B-UNK
into	O
this	O
pontine	O
nucleus	B-UNK
,	O
on	O
the	O
other	O
hand	B-DISEASE
,	O
elicited	B-UNK
discernible	O
electromyographic	B-UNK
excitation	B-UNK
.	O
It	O
is	O
speculated	O
that	O
the	O
induction	B-UNK
of	O
muscular	B-UNK
rigidity	B-UNK
by	O
fentanyl	B-CHEMICAL
may	O
involve	B-UNK
the	O
coerulospinal	O
noradrenergic	O
fibers	B-UNK
to	O
the	O
spinal	B-UNK
motoneurons	O
.	O

Cerebral	O
sinus	B-DISEASE
thrombosis	I-DISEASE
as	O
a	O
potential	B-UNK
hazard	B-UNK
of	O
antifibrinolytic	O
treatment	B-UNK
in	O
menorrhagia	B-DISEASE
.	O

We	O
describe	O
a	O
42-year	O
-	O
old	B-UNK
woman	B-UNK
who	O
developed	B-UNK
superior	B-UNK
sagittal	B-UNK
and	O
left	B-UNK
transverse	O
sinus	B-DISEASE
thrombosis	I-DISEASE
associated	B-UNK
with	O
prolonged	B-UNK
epsilon	O
-	O
aminocaproic	B-CHEMICAL
acid	I-CHEMICAL
therapy	B-UNK
for	O
menorrhagia	B-DISEASE
.	O
This	O
antifibrinolytic	O
agent	B-UNK
has	O
been	O
used	O
in	O
women	B-UNK
with	O
menorrhagia	B-DISEASE
to	O
promote	B-UNK
clotting	O
and	O
reduce	B-UNK
blood	B-DISEASE
loss	I-DISEASE
.	O
Although	O
increased	B-UNK
risk	I-UNK
of	O
thromboembolic	B-UNK
disease	B-DISEASE
has	O
been	O
reported	B-UNK
during	O
treatment	B-UNK
with	O
epsilon	O
-	O
aminocaproic	B-CHEMICAL
acid	I-CHEMICAL
,	O
cerebral	B-UNK
sinus	B-DISEASE
thrombosis	I-DISEASE
has	O
not	O
been	O
previously	B-UNK
described	B-UNK
.	O
Careful	O
use	B-UNK
of	O
epsilon	O
-	O
aminocaproic	B-CHEMICAL
acid	I-CHEMICAL
therapy	B-UNK
is	O
recommended	B-UNK
.	O

Hemorrhagic	O
cystitis	B-DISEASE
complicating	O
bone	B-UNK
marrow	B-UNK
transplantation	B-UNK
.	O

Hemorrhagic	O
cystitis	B-DISEASE
is	O
a	O
potentially	B-UNK
serious	O
complication	B-UNK
of	O
high	B-UNK
-	O
dose	B-UNK
cyclophosphamide	B-CHEMICAL
therapy	B-UNK
administered	B-UNK
before	O
bone	B-UNK
marrow	B-UNK
transplantation	B-UNK
.	O
As	O
standard	B-UNK
practice	O
at	B-DISEASE
our	O
institution	O
,	O
patients	B-UNK
who	O
are	O
scheduled	O
to	O
receive	B-UNK
a	O
bone	B-UNK
marrow	B-UNK
transplant	B-UNK
are	O
treated	B-UNK
prophylactically	O
with	O
forced	B-UNK
hydration	B-UNK
and	O
bladder	B-UNK
irrigation	B-UNK
.	O
In	O
an	O
attempt	O
to	O
obviate	O
the	O
inconvenience	O
of	O
bladder	B-UNK
irrigation	B-UNK
,	O
we	O
conducted	O
a	O
feasibility	O
trial	B-UNK
of	O
uroprophylaxis	O
with	O
mesna	B-CHEMICAL
,	O
which	O
neutralizes	O
the	O
hepatic	B-UNK
metabolite	B-UNK
of	O
cyclophosphamide	B-CHEMICAL
that	O
causes	B-UNK
hemorrhagic	B-UNK
cystitis	B-DISEASE
.	O
Of	O
97	O
patients	B-UNK
who	O
received	B-UNK
standard	B-UNK
prophylaxis	B-UNK
,	O
4	O
had	O
symptomatic	B-UNK
hemorrhagic	B-UNK
cystitis	B-DISEASE
.	O
In	O
contrast	B-UNK
,	O
two	O
of	O
four	O
consecutive	B-UNK
patients	B-UNK
who	O
received	B-UNK
mesna	B-CHEMICAL
uroprophylaxis	O
before	O
allogeneic	O
bone	B-UNK
marrow	B-UNK
transplantation	B-UNK
had	O
severe	B-UNK
hemorrhagic	B-UNK
cystitis	B-DISEASE
for	O
at	B-DISEASE
least	O
2	B-DISEASE
weeks	B-UNK
.	O
Because	O
of	O
this	O
suboptimal	O
result	B-UNK
,	O
we	O
resumed	O
the	O
use	B-UNK
of	O
bladder	B-UNK
irrigation	B-UNK
and	O
forced	B-UNK
hydration	B-UNK
to	O
minimize	O
the	O
risk	B-UNK
of	O
hemorrhagic	B-UNK
cystitis	B-DISEASE
.	O

Reversal	O
of	O
central	B-UNK
benzodiazepine	O
effects	B-UNK
by	O
flumazenil	B-CHEMICAL
after	O
intravenous	B-UNK
conscious	B-UNK
sedation	B-UNK
with	O
diazepam	B-CHEMICAL
and	O
opioids	O
:	O
report	B-UNK
of	O
a	O
double-blind	B-UNK
multicenter	O
study	B-UNK
.	O
The	O
Flumazenil	O
in	O
Intravenous	B-UNK
Conscious	O
Sedation	B-UNK
with	O
Diazepam	O
Multicenter	O
Study	B-UNK
Group	B-UNK
II	B-UNK
.	O

The	O
efficacy	B-UNK
and	O
safety	B-UNK
of	O
a	O
new	B-UNK
benzodiazepine	O
antagonist	B-UNK
,	O
flumazenil	B-CHEMICAL
,	O
were	O
assessed	B-UNK
in	O
a	O
double-blind	B-UNK
multicenter	O
study	B-UNK
.	O
Flumazenil	O
(	O
mean	B-UNK
dose	B-UNK
,	O
0.76	O
mg	B-UNK
)	O
or	O
placebo	B-UNK
(	O
mean	B-UNK
dose	B-UNK
,	O
8.9	O
ml	B-UNK
)	O
was	O
administered	B-UNK
intravenously	B-UNK
to	O
130	O
and	O
67	O
patients	B-UNK
,	O
respectively	O
,	O
who	O
had	O
been	O
given	B-UNK
diazepam	B-CHEMICAL
in	O
conjunction	O
with	O
an	O
opioid	B-UNK
(	O
fentanyl	B-CHEMICAL
,	O
meperidine	B-CHEMICAL
,	O
or	O
morphine	B-CHEMICAL
)	O
for	O
the	O
induction	B-UNK
and	O
maintenance	B-UNK
of	O
intravenous	B-UNK
conscious	B-UNK
sedation	B-UNK
for	O
diagnostic	B-UNK
or	O
therapeutic	B-UNK
surgical	B-UNK
procedures	B-UNK
.	O
The	O
group	B-UNK
assessable	O
for	O
efficacy	B-UNK
comprised	O
122	O
patients	B-UNK
treated	B-UNK
with	O
flumazenil	B-CHEMICAL
and	O
64	O
patients	B-UNK
given	B-UNK
placebo	B-UNK
.	O
After	O
5	O
minutes	B-UNK
,	O
80/115	O
(	O
70	O
%	O
)	O
flumazenil	B-CHEMICAL
-	O
treated	B-UNK
patients	B-UNK
,	O
compared	B-UNK
with	O
21/63	O
(	O
33	O
%	O
)	O
placebo	B-UNK
-	O
treated	B-UNK
patients	B-UNK
,	O
were	O
completely	B-UNK
awake	O
and	O
alert	O
,	O
as	O
indicated	B-UNK
by	O
a	O
score	B-UNK
of	O
5	O
on	O
the	O
Observer'	O
s	O
Assessment	B-UNK
of	O
Alertness	O
/	O
Sedation	B-UNK
Scale	B-UNK
.	O
Ninety	O
-	O
five	O
percent	O
of	O
patients	B-UNK
in	O
each	O
group	B-UNK
who	O
attained	O
a	O
score	B-UNK
of	O
5	O
at	B-DISEASE
the	O
5-minute	O
assessment	B-UNK
showed	B-UNK
no	O
loss	B-UNK
of	O
alertness	O
throughout	O
the	O
180-minute	O
assessment	B-UNK
period	B-UNK
.	O
Flumazenil	O
-	O
treated	B-UNK
patients	B-UNK
also	O
performed	B-UNK
significantly	B-UNK
better	B-UNK
on	O
the	O
Finger	O
-	O
to	O
-	O
Nose	O
Test	O
and	O
the	O
recall	B-UNK
of	O
pictures	O
shown	B-UNK
at	B-DISEASE
the	O
5-minute	O
assessment	B-UNK
.	O
Flumazenil	O
was	O
well	O
tolerated	B-UNK
,	O
with	O
no	O
serious	O
adverse	B-UNK
effects	B-UNK
reported	B-UNK
.	O
Thirty	O
-	O
nine	O
(	O
30	O
%	O
)	O
of	O
flumazenil	B-CHEMICAL
-	O
treated	B-UNK
patients	B-UNK
,	O
compared	B-UNK
with	O
17	B-DISEASE
(	O
25	O
%	O
)	O
of	O
placebo	B-UNK
-	O
treated	B-UNK
patients	B-UNK
had	O
one	O
or	O
more	O
drug	B-UNK
-	O
related	B-UNK
adverse	B-UNK
experiences	O
.	O
The	O
most	O
common	B-UNK
adverse	B-UNK
effects	B-UNK
were	O
nausea	B-DISEASE
and	O
vomiting	B-DISEASE
in	O
the	O
flumazenil	B-CHEMICAL
group	B-UNK
and	O
nausea	B-DISEASE
and	O
injection	B-UNK
-	O
site	B-UNK
pain	B-DISEASE
in	O
the	O
placebo	B-UNK
group	B-UNK
.	O
Flumazenil	O
was	O
found	B-UNK
to	O
promptly	B-UNK
reverse	B-UNK
sedation	B-UNK
induced	B-UNK
by	O
diazepam	B-CHEMICAL
in	O
the	O
presence	O
of	O
opioids	O
.	O

Hepatic	B-UNK
adenomas	O
and	O
focal	B-DISEASE
nodular	I-DISEASE
hyperplasia	I-DISEASE
of	O
the	O
liver	B-DISEASE
in	O
young	B-UNK
women	B-UNK
on	O
oral	B-UNK
contraceptives	O
:	O
case	B-UNK
reports	B-UNK
.	O

Two	O
cases	B-UNK
of	O
hepatic	B-UNK
adenoma	B-DISEASE
and	O
one	O
of	O
focal	B-DISEASE
nodular	I-DISEASE
hyperplasia	I-DISEASE
presumably	O
associated	B-UNK
with	O
the	O
use	B-UNK
of	O
oral	B-UNK
contraceptives	O
,	O
are	O
reported	B-UNK
.	O
Special	O
reference	B-UNK
is	O
made	O
to	O
their	O
clinical	B-UNK
presentation	O
,	O
which	O
may	O
be	O
totally	O
asymptomatic	B-UNK
.	O
Liver	B-UNK
-	O
function	B-UNK
tests	B-UNK
are	O
of	O
little	B-UNK
diagnostic	B-UNK
value	B-UNK
,	O
but	O
valuable	O
information	B-UNK
may	O
be	O
obtained	B-UNK
from	O
both	O
liver	B-DISEASE
scanning	B-UNK
and	O
hepatic	B-UNK
angiography	B-UNK
.	O
Histologic	O
differences	B-UNK
and	O
clinical	B-UNK
similarities	O
between	O
hepatic	B-UNK
adenoma	B-DISEASE
and	O
focal	B-DISEASE
nodular	I-DISEASE
hyperplasia	I-DISEASE
of	O
the	O
liver	B-DISEASE
are	O
discussed	O
.	O

Arterial	O
thromboembolism	B-DISEASE
in	O
patients	B-UNK
receiving	B-UNK
systemic	B-UNK
heparin	B-CHEMICAL
therapy	B-UNK
:	O
a	O
complication	B-UNK
associated	B-UNK
with	O
heparin	B-CHEMICAL
-	O
induced	B-UNK
thrombocytopenia	B-DISEASE
.	O

Arterial	O
thromboembolism	B-DISEASE
is	O
a	O
recognized	B-UNK
complication	B-UNK
of	O
systemic	B-UNK
heparin	B-CHEMICAL
therapy	B-UNK
.	O
Characteristic	O
of	O
the	O
entity	O
is	O
arterial	B-UNK
occlusion	B-UNK
by	O
platelet	B-UNK
-	O
fibrin	O
thrombi	O
with	O
distal	B-UNK
ischemia	B-DISEASE
occurring	B-UNK
four	O
to	O
twenty	O
days	B-UNK
after	O
the	O
initiation	O
of	O
heparin	B-CHEMICAL
therapy	B-UNK
,	O
preceded	O
by	O
profound	B-UNK
thrombocytopenia	B-DISEASE
with	O
platelet	B-UNK
counts	B-UNK
in	O
the	O
range	B-UNK
of	O
30,000	O
to	O
40,000	O
per	O
cubic	B-UNK
millimeter	O
.	O
The	O
clinically	B-UNK
apparent	O
occlusion	B-UNK
may	O
be	O
preceded	O
by	O
gastrointestinal	B-UNK
and	O
musculoskeletal	O
symptoms	B-UNK
that	O
appear	O
to	O
be	O
ischemic	B-UNK
in	O
origin	B-UNK
,	O
and	O
might	O
serve	O
to	O
warn	O
the	O
clinician	O
of	O
these	O
complications	B-UNK
.	O
Previous	B-UNK
reports	B-UNK
of	O
these	O
phenomena	O
as	O
well	O
as	O
recent	B-UNK
studies	B-UNK
of	O
the	O
effect	B-UNK
of	O
heparin	B-CHEMICAL
are	O
reviewed	B-UNK
.	O
The	O
common	B-UNK
factor	B-UNK
relating	O
thromboembolism	B-DISEASE
and	O
thrombocytopenia	B-DISEASE
is	O
heparin	B-CHEMICAL
-	O
induced	B-UNK
platelet	B-DISEASE
aggregation	I-DISEASE
.	O
Appropriate	O
treatment	B-UNK
consists	B-UNK
of	O
discontinuation	B-UNK
of	O
heparin	B-CHEMICAL
,	O
and	O
anticoagulation	B-UNK
with	O
sodium	B-CHEMICAL
warfarin	B-CHEMICAL
if	O
necessary	O
.	O
Vascular	O
procedures	B-UNK
are	O
performed	B-UNK
as	O
indicated	B-UNK
.	O

Long	O
-	O
term	B-UNK
prognosis	B-UNK
for	O
transplant	B-UNK
-	O
free	B-UNK
survivors	B-UNK
of	O
paracetamol	B-UNK
-	O
induced	B-UNK
acute	B-DISEASE
liver	I-DISEASE
failure	I-DISEASE
.	O

BACKGROUND	O
:	O
The	O
prognosis	B-UNK
for	O
transplant	B-UNK
-	O
free	B-UNK
survivors	B-UNK
of	O
paracetamol	B-UNK
-	O
induced	B-UNK
acute	B-DISEASE
liver	I-DISEASE
failure	I-DISEASE
remains	B-UNK
unknown	B-UNK
.	O
AIM	O
:	O
To	O
examine	O
whether	O
paracetamol	B-UNK
-	O
induced	B-UNK
acute	B-DISEASE
liver	I-DISEASE
failure	I-DISEASE
increases	B-UNK
long	B-UNK
-	O
term	B-UNK
mortality	B-UNK
.	O
METHODS	O
:	O
We	O
followed	B-UNK
up	O
all	O
transplant	B-UNK
-	O
free	B-UNK
survivors	B-UNK
of	O
paracetamol	B-UNK
-	O
induced	B-UNK
acute	B-UNK
liver	B-DISEASE
injury	B-UNK
,	O
hospitalized	O
in	O
a	O
Danish	B-UNK
national	B-UNK
referral	O
centre	O
during	O
1984	O
-	O
2004	O
.	O
We	O
compared	B-UNK
age	B-UNK
-	O
specific	B-UNK
mortality	B-UNK
rates	B-UNK
from	O
1	O
year	B-UNK
post-discharge	O
through	O
2008	O
between	O
those	O
in	O
whom	O
the	O
liver	B-DISEASE
injury	B-UNK
led	B-UNK
to	O
an	O
acute	B-DISEASE
liver	I-DISEASE
failure	I-DISEASE
and	O
those	O
in	O
whom	O
it	O
did	O
not	O
.	O
RESULTS	B-UNK
:	O
We	O
included	B-UNK
641	O
patients	B-UNK
.	O
On	O
average	B-UNK
,	O
age	B-UNK
-	O
specific	B-UNK
mortality	B-UNK
rates	B-UNK
were	O
slightly	O
higher	B-UNK
for	O
the	O
101	O
patients	B-UNK
whose	O
paracetamol	B-UNK
-	O
induced	B-UNK
liver	B-DISEASE
injury	B-UNK
had	O
caused	B-UNK
an	O
acute	B-DISEASE
liver	I-DISEASE
failure	I-DISEASE
(	O
adjusted	B-UNK
mortality	B-UNK
rate	B-UNK
ratio	B-UNK
=	O
1.70	O
,	O
95	O
%	O
CI	B-UNK
1.02	O
-	O
2.85	O
)	O
,	O
but	O
the	O
association	B-UNK
was	O
age	B-UNK
-	O
dependent	B-UNK
,	O
and	O
no	O
survivors	B-UNK
of	O
acute	B-DISEASE
liver	I-DISEASE
failure	I-DISEASE
died	B-UNK
of	O
liver	B-DISEASE
disease	I-DISEASE
,	O
whereas	O
suicides	O
were	O
frequent	B-UNK
in	O
both	O
groups	B-UNK
.	O
These	O
observations	B-UNK
speak	O
against	O
long	B-UNK
-	O
term	B-UNK
effects	B-UNK
of	O
acute	B-DISEASE
liver	I-DISEASE
failure	I-DISEASE
.	O
More	O
likely	B-UNK
,	O
the	O
elevated	B-UNK
mortality	B-UNK
rate	B-UNK
ratio	B-UNK
resulted	B-UNK
from	O
incomplete	O
adjustment	O
for	O
the	O
greater	B-UNK
prevalence	O
of	O
substance	B-DISEASE
abuse	I-DISEASE
among	O
survivors	B-UNK
of	O
acute	B-DISEASE
liver	I-DISEASE
failure	I-DISEASE
.	O
CONCLUSIONS	O
:	O
Paracetamol	O
-	O
induced	B-UNK
acute	B-DISEASE
liver	I-DISEASE
failure	I-DISEASE
did	O
not	O
affect	B-UNK
long	B-UNK
-	O
term	B-UNK
mortality	B-UNK
.	O
Clinical	B-UNK
follow	B-UNK
-	O
up	O
may	O
be	O
justified	O
by	O
the	O
cause	B-UNK
of	O
the	O
liver	B-DISEASE
failure	I-DISEASE
,	O
but	O
not	O
by	O
the	O
liver	B-DISEASE
failure	I-DISEASE
itself	O
.	O

Serotonin	O
6	O
receptor	B-UNK
gene	B-UNK
is	O
associated	B-UNK
with	O
methamphetamine	B-CHEMICAL
-	O
induced	B-UNK
psychosis	B-UNK
in	O
a	O
Japanese	O
population	B-UNK
.	O

BACKGROUND	O
:	O
Altered	O
serotonergic	B-UNK
neural	B-UNK
transmission	B-UNK
is	O
hypothesized	O
to	O
be	O
a	O
susceptibility	B-UNK
factor	B-UNK
for	O
psychotic	B-DISEASE
disorders	I-DISEASE
such	O
as	O
schizophrenia	B-DISEASE
.	O
The	O
serotonin	B-CHEMICAL
6	O
(	O
5-HT6	O
)	O
receptor	B-UNK
is	O
therapeutically	O
targeted	O
by	O
several	O
second	B-UNK
generation	B-UNK
antipsychotics	B-UNK
,	O
such	O
as	O
clozapine	B-CHEMICAL
and	O
olanzapine	B-CHEMICAL
,	O
and	O
d	B-UNK
-	O
amphetamine	B-CHEMICAL
-	O
induced	B-UNK
hyperactivity	B-UNK
in	O
rats	B-UNK
is	O
corrected	O
with	O
the	O
use	B-UNK
of	O
a	O
selective	B-UNK
5-HT6	O
receptor	B-UNK
antagonist	I-UNK
.	O
In	O
addition	O
,	O
the	O
disrupted	O
prepulse	B-UNK
inhibition	B-UNK
induced	B-UNK
by	O
d	B-UNK
-	O
amphetamine	B-CHEMICAL
or	O
phencyclidine	B-CHEMICAL
was	O
restored	B-UNK
by	O
5-HT6	O
receptor	B-UNK
antagonist	I-UNK
in	O
an	O
animal	B-UNK
study	B-UNK
using	O
rats	B-UNK
.	O
These	O
animal	B-UNK
models	B-UNK
were	O
considered	B-UNK
to	O
reflect	O
the	O
positive	B-UNK
symptoms	B-UNK
of	O
schizophrenia	B-DISEASE
,	O
and	O
the	O
above	O
evidence	B-UNK
suggests	B-UNK
that	O
altered	B-UNK
5-HT6	O
receptors	B-UNK
are	O
involved	B-UNK
in	O
the	O
pathophysiology	O
of	O
psychotic	B-DISEASE
disorders	I-DISEASE
.	O
The	O
symptoms	B-UNK
of	O
methamphetamine	B-CHEMICAL
(	O
METH)-induced	O
psychosis	B-UNK
are	O
similar	B-UNK
to	O
those	O
of	O
paranoid	O
type	B-UNK
schizophrenia	B-DISEASE
.	O
Therefore	O
,	O
we	O
conducted	O
an	O
analysis	B-UNK
of	O
the	O
association	B-UNK
of	O
the	O
5-HT6	O
gene	B-UNK
(	O
HTR6	O
)	O
with	O
METH	B-UNK
-	O
induced	B-UNK
psychosis	B-UNK
.	O
METHOD	O
:	O
Using	O
five	O
tagging	O
SNPs	O
(	O
rs6693503	O
,	O
rs1805054	O
,	O
rs4912138	O
,	O
rs3790757	O
and	O
rs9659997	O
)	O
,	O
we	O
conducted	O
a	O
genetic	B-UNK
association	B-UNK
analysis	B-UNK
of	O
case	B-UNK
-	O
control	B-UNK
samples	B-UNK
(	O
197	O
METH	B-UNK
-	O
induced	B-UNK
psychosis	B-UNK
patients	B-UNK
and	O
337	O
controls	B-UNK
)	O
in	O
the	O
Japanese	O
population	B-UNK
.	O
The	O
age	B-UNK
and	O
sex	O
of	O
the	O
control	B-UNK
subjects	B-UNK
did	O
not	O
differ	B-UNK
from	O
those	O
of	O
the	O
methamphetamine	B-CHEMICAL
dependence	B-DISEASE
patients	B-UNK
.	O
RESULTS	B-UNK
:	O
rs6693503	O
was	O
associated	B-UNK
with	O
METH	B-UNK
-	O
induced	B-UNK
psychosis	B-UNK
patients	B-UNK
in	O
the	O
allele	O
/	O
genotype	O
-	O
wise	O
analysis	B-UNK
.	O
Moreover	O
,	O
this	O
association	B-UNK
remained	B-UNK
significant	B-UNK
after	O
Bonferroni	O
correction	O
.	O
In	O
the	O
haplotype	O
-	O
wise	O
analysis	B-UNK
,	O
we	O
detected	B-UNK
an	O
association	B-UNK
between	O
two	O
markers	B-UNK
(	O
rs6693503	O
and	O
rs1805054	O
)	O
and	O
three	O
markers	B-UNK
(	O
rs6693503	O
,	O
rs1805054	O
and	O
rs4912138	O
)	O
in	O
HTR6	O
and	O
METH	B-UNK
-	O
induced	B-UNK
psychosis	B-UNK
patients	B-UNK
,	O
respectively	O
.	O
CONCLUSION	O
:	O
HTR6	O
may	O
play	B-UNK
an	O
important	B-UNK
role	B-UNK
in	O
the	O
pathophysiology	O
of	O
METH	B-UNK
-	O
induced	B-UNK
psychosis	B-UNK
in	O
the	O
Japanese	O
population	B-UNK
.	O

Effect	O
of	O
increasing	B-UNK
intraperitoneal	O
infusion	B-UNK
rates	B-UNK
on	O
bupropion	B-CHEMICAL
hydrochloride	B-UNK
-	O
induced	B-UNK
seizures	B-DISEASE
in	O
mice	B-UNK
.	O

BACKGROUND	O
:	O
It	O
is	O
not	O
known	B-UNK
if	O
there	O
is	O
a	O
relationship	B-UNK
between	O
input	O
rate	B-UNK
and	O
incidence	B-UNK
of	O
bupropion	B-CHEMICAL
-	O
induced	B-UNK
seizures	B-DISEASE
.	O
This	O
is	O
important	B-UNK
,	O
since	O
different	B-UNK
controlled	B-UNK
release	B-UNK
formulations	O
of	O
bupropion	B-CHEMICAL
release	B-UNK
the	O
active	B-UNK
drug	B-UNK
at	B-DISEASE
different	B-UNK
rates	B-UNK
.	O
METHODS	O
:	O
We	O
investigated	B-UNK
the	O
effect	B-UNK
of	O
varying	O
the	O
intraperitoneal	O
infusion	B-UNK
rates	B-UNK
of	O
bupropion	B-CHEMICAL
HCl	O
120	O
mg	B-UNK
/	O
kg	B-UNK
,	O
a	O
known	B-UNK
convulsive	B-UNK
dose	B-UNK
50	O
(	O
CD50	O
)	O
,	O
on	O
the	O
incidence	B-UNK
and	O
severity	B-UNK
of	O
bupropion	B-CHEMICAL
-	O
induced	B-UNK
convulsions	B-DISEASE
in	O
the	O
Swiss	B-UNK
albino	B-UNK
mice	B-UNK
.	O
A	O
total	B-UNK
of	O
69	O
mice	B-UNK
,	O
approximately	B-UNK
7	O
weeks	B-UNK
of	O
age	B-UNK
,	O
and	O
weighing	O
21.0	O
to	O
29.1	O
g	B-UNK
were	O
randomly	B-UNK
assigned	B-UNK
to	O
bupropion	B-CHEMICAL
HCl	O
120	O
mg	B-UNK
/	O
kg	B-UNK
treatment	B-UNK
by	O
intraperitoneal	O
(	O
IP	O
)	O
administration	B-UNK
in	O
7	O
groups	B-UNK
(	O
9	O
to	O
10	O
animals	B-UNK
per	O
group	B-UNK
)	O
.	O
Bupropion	O
HCl	O
was	O
infused	O
through	O
a	O
surgically	O
implanted	B-UNK
IP	O
dosing	B-UNK
catheter	B-UNK
with	O
infusions	O
in	O
each	O
group	B-UNK
of	O
0	O
min	B-UNK
,	O
15	O
min	B-UNK
,	O
30	O
min	B-UNK
,	O
60	O
min	B-UNK
,	O
90	O
min	B-UNK
,	O
120	O
min	B-UNK
,	O
and	O
240	O
min	B-UNK
.	O
The	O
number	B-UNK
,	O
time	B-UNK
of	O
onset	B-UNK
,	O
duration	B-UNK
and	O
the	O
intensity	B-UNK
of	O
the	O
convulsions	B-DISEASE
or	O
absence	B-UNK
of	O
convulsions	B-DISEASE
were	O
recorded	B-UNK
.	O
RESULTS	B-UNK
:	O
The	O
results	B-UNK
showed	B-UNK
that	O
IP	O
administration	B-UNK
of	O
bupropion	B-CHEMICAL
HCl	O
120	O
mg	B-UNK
/	O
kg	B-UNK
by	O
bolus	B-UNK
injection	B-UNK
induced	B-UNK
convulsions	B-DISEASE
in	O
6	O
out	O
of	O
10	O
mice	B-UNK
(	O
60	O
%	O
of	O
convulsing	O
mice	B-UNK
)	O
in	O
group	B-UNK
1	O
.	O
Logistic	O
regression	B-UNK
analysis	B-UNK
revealed	B-UNK
that	O
infusion	B-UNK
time	B-UNK
was	O
significant	B-UNK
(	O
p	B-UNK
=	I-UNK
0.0004	O
;	O
odds	B-UNK
ratio	B-UNK
=	O
0.974	O
)	O
and	O
increasing	B-UNK
the	O
IP	O
infusion	B-UNK
time	B-UNK
of	O
bupropion	B-CHEMICAL
HCl	O
120	O
mg	B-UNK
/	O
kg	B-UNK
was	O
associated	B-UNK
with	O
a	O
91	O
%	O
reduced	B-UNK
odds	B-UNK
of	O
convulsions	B-DISEASE
at	B-DISEASE
infusion	B-UNK
times	B-UNK
of	O
15	O
to	O
90	O
min	B-UNK
compared	B-UNK
to	O
bolus	B-UNK
injection	B-UNK
.	O
Further	O
increase	B-UNK
in	O
infusion	B-UNK
time	B-UNK
resulted	B-UNK
in	O
further	O
reduction	B-UNK
in	O
the	O
odds	B-UNK
of	O
convulsions	B-DISEASE
to	O
99.8	O
%	O
reduction	B-UNK
at	B-DISEASE
240	O
min	B-UNK
.	O
CONCLUSION	O
:	O
In	O
conclusion	O
,	O
the	O
demonstration	O
of	O
an	O
inverse	O
relationship	B-UNK
between	O
infusion	B-UNK
time	B-UNK
of	O
a	O
fixed	B-UNK
and	O
convulsive	B-UNK
dose	B-UNK
of	O
bupropion	B-CHEMICAL
and	O
the	O
risk	B-UNK
of	O
convulsions	B-DISEASE
in	O
a	O
prospective	B-UNK
study	B-UNK
is	O
novel	B-UNK
.	O

Detailed	O
spectral	B-UNK
profile	B-UNK
analysis	B-UNK
of	O
penicillin	O
-	O
induced	B-UNK
epileptiform	B-UNK
activity	B-UNK
in	O
anesthetized	B-UNK
rats	B-UNK
.	O

Penicillin	O
model	B-UNK
is	O
a	O
widely	B-UNK
used	O
experimental	B-UNK
model	B-UNK
for	O
epilepsy	B-DISEASE
research	B-UNK
.	O
In	O
the	O
present	B-UNK
study	B-UNK
we	O
aimed	O
to	O
portray	O
a	O
detailed	B-UNK
spectral	B-UNK
analysis	B-UNK
of	O
penicillin	O
-	O
induced	B-UNK
epileptiform	B-UNK
activity	B-UNK
in	O
comparison	O
with	O
basal	B-UNK
brain	B-UNK
activity	B-UNK
in	O
anesthetized	B-UNK
Wistar	B-UNK
rats	I-UNK
.	O
Male	B-UNK
Wistar	I-UNK
rats	B-UNK
were	O
anesthetized	B-UNK
with	O
i.p	B-UNK
.	O
urethane	B-CHEMICAL
and	O
connected	O
to	O
an	O
electrocorticogram	O
setup	O
.	O
After	O
a	O
short	B-UNK
period	B-UNK
of	O
basal	B-UNK
activity	B-UNK
recording	O
,	O
epileptic	B-UNK
focus	O
was	O
induced	B-UNK
by	O
injecting	O
400IU/2	O
microl	B-UNK
penicillin	O
-	O
G	O
potassium	B-CHEMICAL
into	O
the	O
left	B-UNK
lateral	B-UNK
ventricle	O
while	O
the	O
cortical	B-UNK
activity	B-UNK
was	O
continuously	B-UNK
recorded	B-UNK
.	O
Basal	O
activity	B-UNK
,	O
latent	O
period	B-UNK
and	O
the	O
penicillin	O
-	O
induced	B-UNK
epileptiform	B-UNK
activity	B-UNK
periods	B-UNK
were	O
then	O
analyzed	B-UNK
using	O
both	O
conventional	B-UNK
methods	B-UNK
and	O
spectral	B-UNK
analysis	B-UNK
.	O
Spectral	O
analyses	B-UNK
were	O
conducted	O
by	O
dividing	O
the	O
whole	O
spectrum	O
into	O
different	B-UNK
frequency	B-UNK
bands	O
including	B-UNK
delta	O
,	O
theta	O
(	O
slow	O
and	O
fast	O
)	O
,	O
alpha	B-UNK
-	O
sigma	B-UNK
,	O
beta	B-UNK
(	O
1	O
and	O
2	B-DISEASE
)	O
and	O
gamma	O
(	O
1	O
and	O
2	B-DISEASE
)	O
bands	O
.	O
Our	O
results	B-UNK
show	O
that	O
the	O
most	O
affected	B-UNK
frequency	B-UNK
bands	O
were	O
delta	O
,	O
theta	O
,	O
beta-2	O
and	O
gamma-2	O
bands	O
during	O
the	O
epileptiform	B-UNK
activity	B-UNK
and	O
there	O
were	O
marked	B-UNK
differences	B-UNK
in	O
terms	O
of	O
spectral	B-UNK
densities	O
between	O
three	O
investigated	B-UNK
episodes	B-UNK
(	O
basal	B-UNK
activity	B-UNK
,	O
latent	O
period	B-UNK
and	O
epileptiform	B-UNK
activity	B-UNK
)	O
.	O
Our	O
results	B-UNK
may	O
help	O
to	O
analyze	O
novel	B-UNK
data	B-UNK
obtained	B-UNK
using	O
similar	B-UNK
experimental	B-UNK
models	B-UNK
and	O
the	O
simple	O
analysis	B-UNK
method	B-UNK
described	B-UNK
here	O
can	O
be	O
used	O
in	O
similar	B-UNK
studies	B-UNK
to	O
investigate	O
the	O
basic	B-UNK
neuronal	B-UNK
mechanism	B-UNK
of	O
this	O
or	O
other	O
types	O
of	O
experimental	B-UNK
epilepsies	B-DISEASE
.	O

High	B-UNK
dose	B-UNK
dexmedetomidine	B-CHEMICAL
as	O
the	O
sole	B-UNK
sedative	B-UNK
for	O
pediatric	B-UNK
MRI	B-UNK
.	O

OBJECTIVE	O
:	O
This	O
large	B-UNK
-	O
scale	B-UNK
retrospective	O
review	B-UNK
evaluates	O
the	O
sedation	B-UNK
profile	B-UNK
of	O
dexmedetomidine	B-CHEMICAL
.	O
AIM	O
:	O
To	O
determine	B-UNK
the	O
hemodynamic	B-UNK
responses	B-UNK
,	O
efficacy	B-UNK
and	O
adverse	B-UNK
events	B-UNK
associated	B-UNK
with	O
the	O
use	B-UNK
of	O
high	B-UNK
dose	B-UNK
dexmedetomidine	B-CHEMICAL
as	O
the	O
sole	B-UNK
sedative	B-UNK
for	O
magnetic	B-UNK
resonance	I-UNK
imaging	B-UNK
(	O
MRI	B-UNK
)	O
studies	B-UNK
.	O
BACKGROUND	O
:	O
Dexmedetomidine	O
has	O
been	O
used	O
at	B-DISEASE
our	O
institution	O
since	O
2005	O
to	O
provide	B-UNK
sedation	B-UNK
for	O
pediatric	B-UNK
radiological	O
imaging	B-UNK
studies	B-UNK
.	O
Over	O
time	B-UNK
,	O
an	O
effective	B-UNK
protocol	B-UNK
utilizing	O
high	B-UNK
dose	B-UNK
dexmedetomidine	B-CHEMICAL
as	O
the	O
sole	B-UNK
sedative	B-UNK
agent	B-UNK
has	O
evolved	O
.	O
METHODS	O
/	O
MATERIALS	O
:	O
As	O
part	O
of	O
the	O
ongoing	O
Quality	O
Assurance	O
process	B-UNK
,	O
data	B-UNK
on	O
all	O
sedations	O
are	O
reviewed	B-UNK
monthly	O
and	O
protocols	B-UNK
modified	B-UNK
as	O
needed	B-UNK
.	O
Data	O
were	O
analyzed	B-UNK
from	O
all	O
747	O
consecutive	B-UNK
patients	B-UNK
who	O
received	B-UNK
dexmedetomidine	B-CHEMICAL
for	O
MRI	B-UNK
sedation	B-UNK
from	O
April	O
2005	O
to	O
April	O
2007	O
.	O
RESULTS	B-UNK
:	O
Since	O
2005	O
,	O
the	O
10-min	O
loading	B-UNK
dose	I-UNK
of	O
our	O
dexmedetomidine	B-CHEMICAL
protocol	B-UNK
increased	B-UNK
from	O
2	B-DISEASE
to	O
3	O
microg.kg(-1	O
)	O
,	O
and	O
the	O
infusion	B-UNK
rate	B-UNK
increased	B-UNK
from	O
1	O
to	O
1.5	B-UNK
to	O
2	B-DISEASE
microg.kg(-1).h(-1	O
)	O
.	O
The	O
current	B-UNK
sedation	B-UNK
protocol	B-UNK
progressively	O
increased	B-UNK
the	O
rate	B-UNK
of	O
successful	B-UNK
sedation	B-UNK
(	O
able	O
to	O
complete	B-UNK
the	O
imaging	B-UNK
study	B-UNK
)	O
when	O
using	O
dexmedetomidine	B-CHEMICAL
alone	O
from	O
91.8	O
%	O
to	O
97.6	O
%	O
(	O
P	B-UNK
=	I-UNK
0.009	O
)	O
,	O
reducing	B-UNK
the	O
requirement	O
for	O
adjuvant	O
pentobarbital	B-CHEMICAL
in	O
the	O
event	B-UNK
of	O
sedation	B-UNK
failure	B-UNK
with	O
dexmedetomidine	B-CHEMICAL
alone	O
and	O
decreased	B-UNK
the	O
mean	B-UNK
recovery	B-UNK
time	B-UNK
by	O
10	O
min	B-UNK
(	O
P	B-UNK
<	I-UNK
0.001	B-UNK
)	O
.	O
Although	O
dexmedetomidine	B-CHEMICAL
sedation	B-UNK
was	O
associated	B-UNK
with	O
a	O
16	O
%	O
incidence	B-UNK
of	O
bradycardia	B-DISEASE
,	O
all	O
concomitant	B-UNK
mean	B-UNK
arterial	B-UNK
blood	B-UNK
pressures	B-UNK
were	O
within	O
20	O
%	O
of	O
age	B-UNK
-	O
adjusted	B-UNK
normal	B-UNK
range	B-UNK
and	O
oxygen	B-CHEMICAL
saturations	O
were	O
95	O
%	O
or	O
higher	B-UNK
.	O
CONCLUSION	O
:	O
Dexmedetomidine	O
in	O
high	B-UNK
doses	B-UNK
provides	B-UNK
adequate	B-UNK
sedation	B-UNK
for	O
pediatric	B-UNK
MRI	B-UNK
studies	B-UNK
.	O
While	O
use	B-UNK
of	O
high	B-UNK
dose	B-UNK
dexmedetomidine	B-CHEMICAL
is	O
associated	B-UNK
with	O
decreases	B-UNK
in	O
heart	B-UNK
rate	I-UNK
and	O
blood	B-UNK
pressure	B-UNK
outside	O
the	O
established	B-UNK
'	O
awake	O
'	O
norms	O
,	O
this	O
deviation	B-UNK
is	O
generally	B-UNK
within	O
20	O
%	O
of	O
norms	O
,	O
and	O
is	O
not	O
associated	B-UNK
with	O
adverse	B-UNK
sequelae	O
.	O
Dexmedetomidine	O
is	O
useful	B-UNK
as	O
the	O
sole	B-UNK
sedative	B-UNK
for	O
pediatric	B-UNK
MRI	B-UNK
.	O

Methamphetamine	O
causes	B-UNK
alterations	B-UNK
in	O
the	O
MAP	O
kinase	B-UNK
-	O
related	B-UNK
pathways	B-UNK
in	O
the	O
brains	O
of	O
mice	B-UNK
that	O
display	O
increased	B-UNK
aggressiveness	O
.	O

Aggressive	O
behaviors	B-UNK
have	O
been	O
reported	B-UNK
in	O
patients	B-UNK
who	O
suffer	O
from	O
some	O
psychiatric	B-UNK
disorders	B-UNK
,	O
and	O
are	O
common	B-UNK
in	O
methamphetamine	B-CHEMICAL
(	O
METH	B-UNK
)	O
abusers	O
.	O
Herein	O
,	O
we	O
report	B-UNK
that	O
multiple	B-UNK
(	O
but	O
not	O
single	B-UNK
)	O
injections	B-UNK
of	O
METH	B-UNK
significantly	B-UNK
increased	B-UNK
aggressiveness	O
in	O
male	B-UNK
CD-1	O
mice	B-UNK
.	O
This	O
increase	B-UNK
in	O
aggressiveness	O
was	O
not	O
secondary	B-UNK
to	O
METH	B-UNK
-	O
induced	B-UNK
hyperactivity	B-UNK
.	O
Analysis	O
of	O
protein	B-UNK
expression	B-UNK
using	O
antibody	B-UNK
microarrays	O
and	O
Western	B-UNK
blotting	O
revealed	B-UNK
differential	B-UNK
changes	B-UNK
in	O
MAP	O
kinase	B-UNK
-	O
related	B-UNK
pathways	B-UNK
after	O
multiple	B-UNK
and	O
single	B-UNK
METH	B-UNK
injections	B-UNK
.	O
There	O
were	O
statistically	B-UNK
significant	I-UNK
(	O
p<0.05	O
)	O
decreases	B-UNK
in	O
MEK1	O
,	O
Erk2p	O
,	O
GSK3alpha	O
,	O
14	O
-	O
3	O
-	O
3e	O
,	O
and	O
MEK7	O
in	O
the	O
striata	O
of	O
mice	B-UNK
after	O
multiple	B-UNK
injections	B-UNK
of	O
METH	B-UNK
.	O
MEK1	O
was	O
significantly	B-UNK
decreased	B-UNK
also	O
after	O
a	O
single	B-UNK
injection	B-UNK
of	O
METH	B-UNK
,	O
but	O
to	O
a	O
much	O
lesser	B-UNK
degree	B-UNK
than	O
after	O
multiple	B-UNK
injections	B-UNK
of	O
METH	B-UNK
.	O
In	O
the	O
frontal	B-UNK
cortex	B-UNK
,	O
there	O
was	O
a	O
statistically	B-UNK
significant	I-UNK
decrease	B-UNK
in	O
GSK3alpha	O
after	O
multiple	B-UNK
(	O
but	O
not	O
single	B-UNK
)	O
injections	B-UNK
of	O
METH	B-UNK
.	O
These	O
findings	B-UNK
suggest	B-UNK
that	O
alterations	B-UNK
in	O
MAP	O
kinase	B-UNK
-	O
related	B-UNK
pathways	B-UNK
in	O
the	O
prefronto	O
-	O
striatal	B-UNK
circuitries	O
might	O
be	O
involved	B-UNK
in	O
the	O
manifestation	B-UNK
of	O
aggressive	B-UNK
behaviors	B-UNK
in	O
mice	B-UNK
.	O

Lamotrigine	O
associated	B-UNK
with	O
exacerbation	O
or	O
de	B-UNK
novo	B-UNK
myoclonus	B-DISEASE
in	O
idiopathic	B-UNK
generalized	B-UNK
epilepsies	B-DISEASE
.	O

Five	O
patients	B-UNK
with	O
idiopathic	B-UNK
generalized	B-UNK
epilepsies	B-DISEASE
(	O
IGE	O
)	O
treated	B-UNK
with	O
lamotrigine	B-CHEMICAL
(	O
LTG	B-UNK
)	O
experienced	B-UNK
exacerbation	O
or	O
de	B-UNK
novo	B-UNK
appearance	O
of	O
myoclonic	B-UNK
jerks	B-UNK
(	O
MJ	B-UNK
)	O
.	O
In	O
three	O
patients	B-UNK
,	O
LTG	B-UNK
exacerbated	B-UNK
MJ	B-UNK
in	O
a	O
dose	B-UNK
-	O
dependent	B-UNK
manner	B-UNK
with	O
early	B-UNK
aggravation	O
during	O
titration	O
.	O
MJ	B-UNK
disappeared	B-UNK
when	O
LTG	B-UNK
dose	B-UNK
was	O
decreased	B-UNK
by	O
25	O
to	O
50	O
%	O
.	O
In	O
two	O
patients	B-UNK
,	O
LTG	B-UNK
exacerbated	B-UNK
MJ	B-UNK
in	O
a	O
delayed	B-UNK
but	O
more	O
severe	B-UNK
manner	B-UNK
,	O
with	O
myoclonic	B-UNK
status	B-UNK
that	O
only	O
ceased	O
after	O
LTG	B-UNK
withdrawal	B-UNK
.	O

rTMS	O
of	O
supplementary	B-UNK
motor	I-UNK
area	B-UNK
modulates	O
therapy	B-UNK
-	O
induced	B-UNK
dyskinesias	B-DISEASE
in	O
Parkinson	O
disease	B-DISEASE
.	O

The	O
neural	B-UNK
mechanisms	B-UNK
and	O
circuitry	O
involved	B-UNK
in	O
levodopa	B-CHEMICAL
-	O
induced	B-UNK
dyskinesia	B-DISEASE
are	O
unclear	O
.	O
Using	O
repetitive	O
transcranial	O
magnetic	O
stimulation	B-UNK
(	O
rTMS	O
)	O
over	O
the	O
supplementary	B-UNK
motor	I-UNK
area	B-UNK
(	O
SMA	O
)	O
in	O
a	O
group	B-UNK
of	O
patients	B-UNK
with	O
advanced	B-UNK
Parkinson	O
disease	B-DISEASE
,	O
the	O
authors	B-UNK
investigated	B-UNK
whether	O
modulation	O
of	O
SMA	O
excitability	B-UNK
may	O
result	B-UNK
in	O
a	O
modification	O
of	O
a	O
dyskinetic	B-UNK
state	B-UNK
induced	B-UNK
by	O
continuous	B-UNK
apomorphine	B-CHEMICAL
infusion	B-UNK
.	O
rTMS	O
at	B-DISEASE
1	O
Hz	O
was	O
observed	B-UNK
to	O
markedly	B-UNK
reduce	B-UNK
drug	B-UNK
-	O
induced	B-UNK
dyskinesias	B-DISEASE
,	O
whereas	O
5-Hz	O
rTMS	O
induced	B-UNK
a	O
slight	O
but	O
not	O
significant	B-UNK
increase	B-UNK
.	O

Assessment	B-UNK
of	O
the	O
onset	B-UNK
and	O
persistence	O
of	O
amnesia	B-DISEASE
during	O
procedural	B-UNK
sedation	B-UNK
with	O
propofol	B-CHEMICAL
.	O

OBJECTIVES	O
:	O
To	O
assess	B-UNK
patients	B-UNK
'	O
ability	B-UNK
to	O
repeat	B-UNK
and	O
recall	B-UNK
words	B-UNK
presented	B-UNK
to	O
them	O
while	O
undergoing	B-UNK
procedural	B-UNK
sedation	B-UNK
with	O
propofol	B-CHEMICAL
,	O
and	O
correlate	O
their	O
recall	B-UNK
with	O
their	O
level	B-UNK
of	O
awareness	O
as	O
measured	B-UNK
by	O
bispectral	O
index	B-UNK
(	O
BIS	O
)	O
monitoring	B-UNK
.	O
METHODS	O
:	O
This	O
was	O
a	O
prospective	B-UNK
,	O
single	B-UNK
-	O
intervention	O
study	B-UNK
of	O
consenting	O
adult	B-UNK
patients	B-UNK
undergoing	B-UNK
procedural	B-UNK
sedation	B-UNK
with	O
propofol	B-CHEMICAL
between	O
December	O
28	O
,	O
2002	O
,	O
and	O
October	O
31	O
,	O
2003	O
.	O
BIS	O
monitoring	B-UNK
was	O
initiated	O
starting	B-UNK
3	O
minutes	B-UNK
before	O
the	O
procedure	B-UNK
and	O
continuing	O
until	O
the	O
patient	B-UNK
had	O
regained	O
baseline	B-UNK
mental	B-UNK
status	I-UNK
.	O
At	O
1-minute	O
intervals	B-UNK
during	O
the	O
procedural	B-UNK
sedation	B-UNK
,	O
until	O
the	O
patient	B-UNK
regained	O
baseline	B-UNK
mental	B-UNK
status	I-UNK
at	B-DISEASE
the	O
end	B-UNK
of	O
the	O
procedure	B-UNK
,	O
a	O
word	B-UNK
from	O
a	O
standardized	O
list	O
was	O
read	B-UNK
aloud	B-UNK
,	O
and	O
the	O
patient	B-UNK
was	O
asked	O
to	O
immediately	B-UNK
repeat	B-UNK
the	O
word	B-UNK
to	O
the	O
investigator	O
.	O
The	O
BIS	B-UNK
score	I-UNK
at	B-DISEASE
the	O
time	B-UNK
the	O
word	B-UNK
was	O
read	B-UNK
and	O
the	O
patient'	O
s	O
ability	B-UNK
to	O
repeat	B-UNK
the	O
word	B-UNK
were	O
recorded	B-UNK
.	O
After	O
the	O
procedure	B-UNK
,	O
the	O
patient	B-UNK
was	O
asked	O
to	O
state	B-UNK
all	O
of	O
the	O
words	B-UNK
from	O
the	O
list	O
that	O
he	O
or	O
she	O
could	O
recall	B-UNK
,	O
and	O
to	O
identify	B-UNK
the	O
last	O
word	B-UNK
recalled	B-UNK
from	O
prior	B-UNK
to	O
the	O
start	O
of	O
the	O
procedure	B-UNK
and	O
the	O
first	O
word	B-UNK
recalled	B-UNK
from	O
after	O
the	O
procedure	B-UNK
was	O
completed	O
.	O
RESULTS	B-UNK
:	O
Seventy	O
-	O
five	O
consenting	O
patients	B-UNK
were	O
enrolled	O
;	O
one	O
patient	B-UNK
was	O
excluded	O
from	O
data	B-UNK
analysis	B-UNK
for	O
a	O
protocol	B-UNK
violation	O
.	O
No	O
serious	O
adverse	B-UNK
events	B-UNK
were	O
noted	O
during	O
the	O
procedural	B-UNK
sedations	O
.	O
The	O
mean	B-UNK
(	O
+	O
/-standard	O
deviation	B-UNK
)	O
time	B-UNK
of	O
data	B-UNK
collection	O
was	O
16.4	O
minutes	B-UNK
(	O
+	O
/-7.1	O
;	O
range	B-UNK
5	O
to	O
34	O
minutes	B-UNK
)	O
.	O
The	O
mean	B-UNK
initial	B-UNK
(	O
preprocedure	O
)	O
BIS	B-UNK
score	I-UNK
was	O
97.1	O
(	O
+	O
/-2.3	O
;	O
range	B-UNK
92	O
to	O
99	O
)	O
.	O
The	O
mean	B-UNK
lowest	B-UNK
BIS	I-UNK
score	B-UNK
occurring	B-UNK
during	O
these	O
procedural	B-UNK
sedations	O
was	O
66.9	O
(	O
+	O
/-14.4	O
;	O
range	B-UNK
33	O
to	O
91	O
)	O
.	O
The	O
mean	B-UNK
lowest	B-UNK
BIS	I-UNK
score	B-UNK
corresponding	I-UNK
to	O
the	O
ability	B-UNK
of	O
the	O
patient	B-UNK
to	O
immediately	B-UNK
repeat	B-UNK
words	B-UNK
read	B-UNK
from	O
the	O
list	O
was	O
77.1	O
(	O
95	O
%	O
CI	B-UNK
=	I-UNK
74.3	O
to	O
80.0	O
)	O
.	O
The	O
mean	B-UNK
highest	B-UNK
BIS	B-UNK
score	I-UNK
corresponding	B-UNK
to	O
the	O
inability	O
to	O
repeat	B-UNK
words	B-UNK
was	O
81.5	O
(	O
95	O
%	O
CI	B-UNK
=	I-UNK
78.1	O
to	O
84.8	O
)	O
.	O
The	O
mean	B-UNK
BIS	B-UNK
score	I-UNK
corresponding	B-UNK
to	O
the	O
last	O
word	B-UNK
recalled	B-UNK
from	O
prior	B-UNK
to	O
the	O
initiation	O
of	O
the	O
sedation	B-UNK
was	O
96.7	O
(	O
+	O
/-2.4	O
;	O
range	B-UNK
84	O
to	O
98	O
)	O
.	O
The	O
mean	B-UNK
BIS	B-UNK
score	I-UNK
corresponding	B-UNK
to	O
the	O
first	O
word	B-UNK
recalled	B-UNK
after	O
the	O
procedure	B-UNK
was	O
completed	O
was	O
91.2	O
(	O
95	O
%	O
CI	B-UNK
=	I-UNK
88.1	O
to	O
94.3	O
)	O
.	O
All	O
patients	B-UNK
recalled	B-UNK
at	B-DISEASE
least	O
one	O
word	B-UNK
that	O
had	O
been	O
read	B-UNK
to	O
them	O
during	O
the	O
protocol	B-UNK
.	O
The	O
mean	B-UNK
lowest	B-UNK
BIS	I-UNK
score	B-UNK
for	O
any	O
recalled	B-UNK
word	B-UNK
was	O
91.5	O
(	O
+	O
/-11.1	O
;	O
range	B-UNK
79	O
to	O
98	O
)	O
,	O
and	O
no	O
words	B-UNK
were	O
recalled	B-UNK
when	O
the	O
corresponding	B-UNK
BIS	B-UNK
score	I-UNK
was	O
less	O
than	O
90	O
.	O
CONCLUSIONS	O
:	O
There	O
is	O
a	O
range	B-UNK
of	O
BIS	O
scores	B-UNK
during	O
which	O
sedated	O
patients	B-UNK
are	O
able	O
to	O
repeat	B-UNK
words	B-UNK
read	B-UNK
to	O
them	O
but	O
are	O
not	O
able	O
to	O
subsequently	B-UNK
recall	B-UNK
these	O
words	B-UNK
.	O
Furthermore	O
,	O
patients	B-UNK
had	O
no	O
recall	B-UNK
of	O
words	B-UNK
repeated	B-UNK
prior	B-UNK
to	O
procedural	B-UNK
sedation	B-UNK
in	O
BIS	O
ranges	O
associated	B-UNK
with	O
recall	B-UNK
after	O
procedural	B-UNK
sedation	B-UNK
,	O
suggestive	O
of	O
retrograde	O
amnesia	B-DISEASE
.	O

Assessment	B-UNK
of	O
perinatal	O
hepatitis	B-DISEASE
B	B-UNK
and	O
rubella	B-DISEASE
prevention	O
in	O
New	B-UNK
Hampshire	O
delivery	B-UNK
hospitals	B-UNK
.	O

OBJECTIVE	O
:	O
To	O
evaluate	B-UNK
current	B-UNK
performance	B-UNK
on	O
recommended	B-UNK
perinatal	O
hepatitis	B-DISEASE
B	B-UNK
and	O
rubella	B-DISEASE
prevention	O
practices	O
in	O
New	B-UNK
Hampshire	O
.	O
METHODS	O
:	O
Data	O
were	O
extracted	O
from	O
2021	O
paired	O
mother	O
-	O
infant	B-DISEASE
records	B-UNK
for	O
the	O
year	B-UNK
2000	O
birth	B-UNK
cohort	B-UNK
in	O
New	B-UNK
Hampshire'	O
s	O
25	O
delivery	B-UNK
hospitals	B-UNK
.	O
Assessment	B-UNK
was	O
done	O
on	O
the	O
following	B-UNK
:	O
prenatal	B-UNK
screening	B-UNK
for	O
hepatitis	B-DISEASE
B	B-UNK
and	O
rubella	B-DISEASE
,	O
administration	B-UNK
of	O
the	O
hepatitis	B-DISEASE
B	B-UNK
vaccine	B-UNK
birth	B-UNK
dose	B-UNK
to	O
all	O
infants	B-UNK
,	O
administration	B-UNK
of	O
hepatitis	B-DISEASE
B	B-UNK
immune	B-UNK
globulin	B-UNK
to	O
infants	B-UNK
who	O
were	O
born	O
to	O
hepatitis	B-DISEASE
B	B-UNK
surface	I-UNK
antigen	B-UNK
-	O
positive	B-UNK
mothers	B-UNK
,	O
rubella	B-DISEASE
immunity	O
,	O
and	O
administration	B-UNK
of	O
in	O
-	O
hospital	B-UNK
postpartum	O
rubella	B-CHEMICAL
vaccine	I-CHEMICAL
to	O
rubella	B-DISEASE
nonimmune	O
women	B-UNK
.	O
RESULTS	B-UNK
:	O
Prenatal	O
screening	B-UNK
rates	B-UNK
for	O
hepatitis	B-DISEASE
B	B-UNK
(	O
98.8	O
%	O
)	O
and	O
rubella	B-DISEASE
(	O
99.4	O
%	O
)	O
were	O
high	B-UNK
.	O
Hepatitis	B-UNK
B	I-UNK
vaccine	B-UNK
birth	B-UNK
dose	B-UNK
was	O
administered	B-UNK
to	O
76.2	O
%	O
of	O
all	O
infants	B-UNK
.	O
All	O
infants	B-UNK
who	O
were	O
born	O
to	O
hepatitis	B-DISEASE
B	B-UNK
surface	I-UNK
antigen	B-UNK
-	O
positive	B-UNK
mothers	B-UNK
also	O
received	B-UNK
hepatitis	B-DISEASE
B	B-UNK
immune	B-UNK
globulin	B-UNK
.	O
Multivariate	O
logistic	O
regression	B-UNK
showed	B-UNK
that	O
the	O
month	O
of	O
delivery	B-UNK
and	O
infant	B-DISEASE
birth	B-DISEASE
weight	I-DISEASE
were	O
independent	B-UNK
predictors	O
of	O
hepatitis	B-DISEASE
B	B-UNK
vaccination	O
.	O
The	O
proportion	B-UNK
of	O
infants	B-UNK
who	O
were	O
vaccinated	O
in	O
January	O
and	O
February	O
2000	O
(	O
48.5	O
%	O
and	O
67.5	O
%	O
,	O
respectively	O
)	O
was	O
less	O
than	O
any	O
other	O
months	B-UNK
,	O
whereas	O
the	O
proportion	B-UNK
who	O
were	O
vaccinated	O
in	O
December	O
2000	O
(	O
88.2	O
%	O
)	O
was	O
the	O
highest	B-UNK
.	O
Women	O
who	O
were	O
born	O
between	O
1971	O
and	O
1975	O
had	O
the	O
highest	B-UNK
rate	B-UNK
of	O
rubella	B-DISEASE
nonimmunity	O
(	O
9.5	O
%	O
)	O
.	O
In	O
-	O
hospital	B-UNK
postpartum	O
rubella	B-CHEMICAL
vaccine	I-CHEMICAL
administration	B-UNK
was	O
documented	B-UNK
for	O
75.6	O
%	O
of	O
nonimmune	O
women	B-UNK
.	O
CONCLUSION	O
:	O
This	O
study	B-UNK
documents	O
good	B-UNK
compliance	O
in	O
New	B-UNK
Hampshire'	O
s	O
birthing	O
hospitals	B-UNK
with	O
national	B-UNK
guidelines	O
for	O
perinatal	O
hepatitis	B-DISEASE
B	B-UNK
and	O
rubella	B-DISEASE
prevention	O
and	O
highlights	O
potential	B-UNK
areas	B-UNK
for	O
improvement	B-UNK
.	O

Expression	O
of	O
p300	B-UNK
protects	B-UNK
cardiac	B-UNK
myocytes	O
from	O
apoptosis	B-UNK
in	O
vivo	B-UNK
.	O

Doxorubicin	B-UNK
is	O
an	O
anti-tumor	O
agent	B-UNK
that	O
represses	O
cardiac	B-UNK
-	O
specific	B-UNK
gene	B-UNK
expression	B-UNK
and	O
induces	B-UNK
myocardial	B-UNK
cell	B-UNK
apoptosis	B-UNK
.	O
Doxorubicin	B-UNK
depletes	O
cardiac	B-UNK
p300	B-UNK
,	O
a	O
transcriptional	O
coactivator	O
that	O
is	O
required	B-UNK
for	O
the	O
maintenance	B-UNK
of	O
the	O
differentiated	O
phenotype	O
of	O
cardiac	B-UNK
myocytes	O
.	O
However	O
,	O
the	O
role	B-UNK
of	O
p300	B-UNK
in	O
protection	B-UNK
against	O
doxorubicin	B-CHEMICAL
-	O
induced	B-UNK
apoptosis	B-UNK
is	O
unknown	B-UNK
.	O
Transgenic	O
mice	B-UNK
overexpressing	O
p300	B-UNK
in	O
the	O
heart	B-UNK
and	O
wild	O
-	O
type	B-UNK
mice	B-UNK
were	O
subjected	O
to	O
doxorubicin	B-CHEMICAL
treatment	B-UNK
.	O
Compared	O
with	O
wild	O
-	O
type	B-UNK
mice	B-UNK
,	O
transgenic	B-UNK
mice	B-UNK
exhibited	B-UNK
higher	B-UNK
survival	B-UNK
rate	B-UNK
as	O
well	O
as	O
more	O
preserved	O
left	B-UNK
ventricular	I-UNK
function	B-UNK
and	O
cardiac	B-UNK
expression	B-UNK
of	O
alpha	B-UNK
-	O
sarcomeric	O
actin	B-UNK
.	O
Doxorubicin	B-UNK
induced	B-UNK
myocardial	B-UNK
cell	B-UNK
apoptosis	B-UNK
in	O
wild	O
-	O
type	B-UNK
mice	B-UNK
but	O
not	O
in	O
transgenic	B-UNK
mice	B-UNK
.	O
Expression	O
of	O
p300	B-UNK
increased	B-UNK
the	O
cardiac	B-UNK
level	B-UNK
of	O
bcl-2	O
and	O
mdm-2	O
,	O
but	O
not	O
that	O
of	O
p53	O
or	O
other	O
members	O
of	O
the	O
bcl-2	O
family	B-UNK
.	O
These	O
findings	B-UNK
demonstrate	B-UNK
that	O
overexpression	O
of	O
p300	B-UNK
protects	B-UNK
cardiac	B-UNK
myocytes	O
from	O
doxorubicin	B-CHEMICAL
-	O
induced	B-UNK
apoptosis	B-UNK
and	O
reduces	B-UNK
the	O
extent	B-UNK
of	O
acute	B-UNK
heart	B-DISEASE
failure	I-DISEASE
in	O
adult	B-UNK
mice	B-UNK
in	O
vivo	B-UNK
.	O

Mitochondrial	O
DNA	B-UNK
and	O
its	O
respiratory	B-UNK
chain	I-UNK
products	O
are	O
defective	O
in	O
doxorubicin	B-CHEMICAL
nephrosis	B-DISEASE
.	O

BACKGROUND	O
:	O
Doxorubicin	B-UNK
induces	B-UNK
a	O
self	O
-	O
perpetuating	O
nephropathy	B-DISEASE
characterized	B-UNK
by	O
early	B-UNK
glomerular	B-UNK
and	O
late	B-UNK
-	O
onset	B-UNK
tubular	B-UNK
lesions	B-UNK
in	O
rats	B-UNK
.	O
We	O
investigated	B-UNK
the	O
potential	B-UNK
role	B-UNK
of	O
mitochondrial	B-UNK
injury	B-UNK
in	O
the	O
onset	B-UNK
of	O
these	O
lesions	B-UNK
.	O
METHODS	O
:	O
Rats	O
were	O
treated	B-UNK
with	O
intravenous	B-UNK
doxorubicin	B-CHEMICAL
(	O
1	O
mg	B-UNK
kg(-1	B-UNK
)	O
week(-1	O
)	O
)	O
for	O
7	O
weeks	B-UNK
and	O
were	O
sacrificed	O
either	O
1	O
week	B-UNK
(	O
'	O
short	B-UNK
-	O
term	B-UNK
'	O
)	O
or	O
30	O
weeks	B-UNK
(	O
'	O
long	B-UNK
-	O
term	B-UNK
'	O
)	O
following	B-UNK
the	O
last	O
dose	B-UNK
.	O
Additional	O
rats	B-UNK
received	I-UNK
a	O
single	B-UNK
dose	B-UNK
either	O
6	O
days	B-UNK
or	O
2	B-DISEASE
h	B-UNK
prior	B-UNK
to	O
euthanasia	O
.	O
All	O
rats	B-UNK
were	O
killed	O
at	B-DISEASE
48	O
weeks	B-UNK
of	O
age	B-UNK
.	O
Glomerular	O
and	O
tubular	B-UNK
injury	B-UNK
was	O
monitored	B-UNK
and	O
correlated	B-UNK
to	O
the	O
activity	B-UNK
or	O
expression	B-UNK
of	O
respiratory	B-UNK
chain	I-UNK
components	B-UNK
.	O
Finally	O
,	O
we	O
quantified	O
both	O
nuclear	B-UNK
and	O
mitochondrial	B-UNK
DNA	B-UNK
(	O
mtDNA	B-UNK
)	O
as	O
well	O
as	O
superoxide	B-UNK
production	B-UNK
and	O
the	O
4834	O
base	O
pair	O
'	O
common	B-UNK
'	O
mtDNA	B-UNK
deletion	B-UNK
.	O
RESULTS	B-UNK
:	O
The	O
'	O
long	B-UNK
-	O
term	B-UNK
'	O
group	B-UNK
had	O
significant	B-UNK
glomerular	B-UNK
and	O
tubular	B-UNK
lesions	B-UNK
,	O
depressed	B-UNK
activities	B-UNK
of	O
mtDNA	B-UNK
-	O
encoded	B-UNK
NADH	O
dehydrogenase	B-UNK
and	O
cytochrome	B-UNK
-	O
c	B-UNK
oxidase	B-UNK
(	O
COX	B-UNK
)	O
and	O
increased	B-UNK
citrate	O
synthase	B-UNK
activity	B-UNK
.	O
In	O
addition	O
,	O
expression	B-UNK
of	O
the	O
mtDNA	B-UNK
-	O
encoded	B-UNK
COX	B-UNK
subunit	B-UNK
I	O
was	O
reduced	B-UNK
and	O
mtDNA	B-UNK
levels	B-UNK
were	O
decreased	B-UNK
.	O
In	O
'	O
short	B-UNK
-	O
term	B-UNK
'	O
rats	B-UNK
,	O
there	O
were	O
fewer	B-UNK
tubular	B-UNK
lesions	B-UNK
,	O
but	O
similar	B-UNK
numbers	O
of	O
glomerular	B-UNK
lesions	B-UNK
activity	B-UNK
.	O
Among	O
all	O
animals	B-UNK
,	O
glomerular	B-UNK
and	O
tubular	B-UNK
injury	B-UNK
were	O
inversely	O
correlated	B-UNK
with	O
mtDNA	B-UNK
levels	B-UNK
,	O
mtDNA	B-UNK
-	O
encoded	B-UNK
respiratory	I-UNK
chain	O
activities	B-UNK
and	O
with	O
the	O
expression	B-UNK
of	O
the	O
mtDNA	B-UNK
-	O
encoded	B-UNK
respiratory	I-UNK
chain	O
subunit	B-UNK
COX	B-UNK
-	O
I.	O
Injury	O
was	O
positively	O
correlated	B-UNK
with	O
superoxide	B-UNK
production	B-UNK
and	O
the	O
activities	B-UNK
of	O
nucleus	B-UNK
-	O
encoded	B-UNK
mitochondrial	B-UNK
or	O
cytoplasmic	B-UNK
enzymes	B-UNK
.	O
Kidneys	O
from	O
the	O
'	O
long	B-UNK
-	O
term	B-UNK
'	O
group	B-UNK
showed	B-UNK
more	O
mtDNA	B-UNK
deletions	O
than	O
in	O
'	O
short	B-UNK
-	O
term	B-UNK
'	O
animals	B-UNK
and	O
these	O
were	O
not	O
observed	B-UNK
in	O
the	O
other	O
groups	B-UNK
.	O
CONCLUSIONS	O
:	O
These	O
results	B-UNK
suggest	B-UNK
an	O
important	B-UNK
role	B-UNK
for	O
quantitative	B-UNK
and	O
qualitative	O
mtDNA	B-UNK
alterations	B-UNK
through	O
the	O
reduction	B-UNK
of	O
mtDNA	B-UNK
-	O
encoded	B-UNK
respiratory	I-UNK
chain	O
function	B-UNK
and	O
induction	B-UNK
of	O
superoxide	B-UNK
in	O
doxorubicin	B-CHEMICAL
-	O
induced	B-UNK
renal	B-UNK
lesions	B-UNK
.	O

Amphotericin	O
B	B-UNK
-	O
induced	B-UNK
seizures	B-DISEASE
in	O
a	O
patient	B-UNK
with	O
AIDS	O
.	O

OBJECTIVE	O
:	O
To	O
report	B-UNK
a	O
case	B-UNK
of	O
multiple	B-UNK
episodes	B-UNK
of	O
seizure	B-UNK
activity	B-UNK
in	O
an	O
AIDS	O
patent	O
following	B-UNK
amphotericin	B-UNK
B	B-UNK
infusion	B-UNK
.	O
CASE	B-UNK
SUMMARY	B-UNK
:	O
A	O
46-year	O
-	O
old	B-UNK
African	B-UNK
-	O
American	B-UNK
man	B-UNK
experienced	B-UNK
recurrent	B-UNK
grand	O
mal	O
seizures	B-DISEASE
during	O
intravenous	B-UNK
infusion	I-UNK
of	O
amphotericin	B-UNK
B	B-UNK
,	O
then	O
petit	O
mal	O
seizures	B-DISEASE
as	O
the	O
infusion	B-UNK
was	O
stopped	O
and	O
the	O
drug	B-UNK
concentrations	B-UNK
decreased	B-UNK
with	O
time	B-UNK
.	O
The	O
patients	B-UNK
concurrent	O
medications	B-UNK
included	B-UNK
didanosine	B-CHEMICAL
,	O
hydroxyzine	B-CHEMICAL
,	O
promethazine	B-CHEMICAL
,	O
hydrocortisone	B-CHEMICAL
,	O
and	O
prochlorperazine	B-CHEMICAL
.	O
Despite	B-UNK
administration	B-UNK
of	O
phenytoin	B-CHEMICAL
and	O
lorazepam	B-CHEMICAL
,	O
the	O
seizures	B-DISEASE
persisted	B-UNK
and	O
occurred	B-UNK
only	O
during	O
amphotercin	O
B	B-UNK
administration	B-UNK
.	O
DISCUSSION	O
:	O
AIDS	O
and	O
cryptococcal	O
meningitis	B-DISEASE
,	O
both	O
of	O
which	O
the	O
patient	B-UNK
had	O
,	O
can	O
potentially	B-UNK
cause	B-UNK
seizures	B-DISEASE
.	O
The	O
patient	B-UNK
had	O
a	O
history	B-UNK
of	O
alcohol	B-UNK
abuse	B-UNK
;	O
alcohol	B-UNK
intake	B-UNK
as	O
well	O
as	O
withdrawal	B-UNK
can	O
also	O
cause	B-UNK
seizures	B-DISEASE
.	O
Didanosine	O
also	O
has	O
a	O
potential	B-UNK
for	O
inducing	B-UNK
seizures	B-DISEASE
.	O
However	O
,	O
these	O
other	O
potential	B-UNK
causes	B-UNK
of	O
seizure	B-UNK
were	O
ruled	O
out	O
.	O
The	O
time	B-UNK
course	B-UNK
of	O
events	B-UNK
suggested	B-UNK
that	O
amphotericin	B-UNK
B	B-UNK
was	O
the	O
cause	B-UNK
of	O
the	O
seizures	B-DISEASE
in	O
this	O
AIDS	O
patient	B-UNK
.	O
CONCLUSIONS	O
:	O
Amphotericin	O
B	B-UNK
seems	O
to	O
be	O
the	O
probable	B-UNK
cause	B-UNK
of	O
the	O
seizures	B-DISEASE
.	O
To	O
date	O
,	O
only	O
three	O
cases	B-UNK
of	O
seizures	B-DISEASE
associated	B-UNK
with	O
amphotericin	B-UNK
B	B-UNK
have	O
been	O
reported	B-UNK
in	O
the	O
literature	B-UNK
,	O
but	O
healthcare	O
providers	O
should	O
be	O
aware	O
of	O
the	O
potential	B-UNK
for	O
this	O
rare	B-UNK
adverse	B-UNK
effect	B-UNK
.	O

Therapeutic	O
drug	B-UNK
monitoring	B-UNK
of	O
tobramycin	B-CHEMICAL
:	O
once	O
-	O
daily	B-UNK
versus	B-UNK
twice	B-UNK
-	O
daily	B-UNK
dosage	B-UNK
schedules	B-UNK
.	O

OBJECTIVE	O
:	O
To	O
evaluate	B-UNK
the	O
effect	B-UNK
of	O
dosage	B-UNK
regimen	B-UNK
(	O
once	O
-	O
daily	B-UNK
vs	B-UNK
.	O
twice	B-UNK
-	O
daily	B-UNK
)	O
of	O
tobramicyn	O
on	O
steady	O
-	O
state	B-UNK
serum	B-UNK
concentrations	B-UNK
and	O
toxicity	B-UNK
.	O
MATERIALS	O
AND	O
METHODS	O
:	O
Patients	B-UNK
undergoing	B-UNK
treatment	B-UNK
with	O
i.v	B-UNK
.	O
tobramycin	B-CHEMICAL
(	O
4	O
mg	B-UNK
/	O
kg	B-UNK
/	O
day	B-UNK
)	O
were	O
randomised	B-UNK
to	O
two	O
groups	B-UNK
.	O
Group	B-UNK
OD	B-UNK
(	O
n	B-UNK
=	O
22	O
)	O
received	B-UNK
a	O
once	O
-	O
daily	B-UNK
dose	B-UNK
of	O
tobramycin	B-CHEMICAL
and	O
group	B-UNK
TD	O
(	O
n	B-UNK
=	O
21	O
)	O
received	B-UNK
the	O
same	O
dose	B-UNK
divided	O
into	O
two	O
doses	B-UNK
daily	B-UNK
.	O
Tobramycin	O
serum	B-UNK
concentrations	B-UNK
(	O
peak	B-UNK
and	O
trough	O
)	O
were	O
measured	B-UNK
by	O
enzyme	B-UNK
multiplied	O
immunoassay	B-UNK
.	O
The	O
renal	B-DISEASE
and	O
auditory	B-UNK
functions	B-UNK
of	O
the	O
patients	B-UNK
were	O
monitored	B-UNK
before	O
,	O
during	O
and	O
immediately	B-UNK
after	O
treatment	B-UNK
.	O
RESULTS	B-UNK
:	O
The	O
two	O
groups	B-UNK
were	O
comparable	B-UNK
with	O
respect	O
to	O
sex	O
,	O
age	B-UNK
,	O
body	B-DISEASE
weight	I-DISEASE
and	O
renal	B-UNK
function	B-UNK
.	O
No	O
statistically	B-UNK
significant	I-UNK
differences	B-UNK
were	O
found	B-UNK
in	O
mean	B-UNK
daily	B-UNK
dose	B-UNK
,	O
duration	B-UNK
of	O
treatment	B-UNK
,	O
or	O
cumulative	B-UNK
dose	B-UNK
.	O
Trough	O
concentrations	B-UNK
were	O
<	O
2	B-DISEASE
g	B-UNK
/	O
ml	B-UNK
in	O
the	O
two	O
groups	B-UNK
(	O
100	O
%	O
)	O
.	O
Peak	O
concentrations	B-UNK
were	O
>	O
6	O
microg	B-UNK
/	O
ml	B-UNK
in	O
100	O
%	O
of	O
the	O
OD	B-UNK
group	B-UNK
and	O
in	O
67	O
%	O
of	O
the	O
TD	O
group	B-UNK
(	O
P	B-UNK
<	I-UNK
0.01	B-UNK
)	O
.	O
Mean	O
peak	B-UNK
concentrations	B-UNK
were	O
markedly	B-UNK
different	B-UNK
:	O
11.00+/-2.89	O
microg	B-UNK
/	O
ml	B-UNK
in	O
OD	B-UNK
vs	B-UNK
.	O
6.53+/-1.45	O
microg	B-UNK
/	O
ml	B-UNK
in	O
TD	O
(	O
P	B-UNK
<	I-UNK
0.01	B-UNK
)	O
.	O
The	O
pharmacokinetics	O
parameters	B-UNK
were	O
:	O
Ke	O
,	O
(	O
0.15+/-0.03	O
/	O
h	B-UNK
in	O
OD	B-UNK
vs	B-UNK
.	O
0.24+/-0.06	O
/	O
h	B-UNK
in	O
TD	O
)	O
,	O
t1/2	O
,	O
(	O
4.95+/-1.41	O
h	B-UNK
in	O
OD	B-UNK
vs	B-UNK
.	O
3.07+/-0.71	O
h	B-UNK
in	O
TD	O
)	O
,	O
Vd	O
(	O
0.35+/-0.11	O
l	B-UNK
/	O
kg	B-UNK
in	O
OD	B-UNK
vs	B-UNK
.	O
0.33+/-0.09	O
l	B-UNK
/	O
kg	B-UNK
in	O
TD	O
)	O
,	O
Cl	O
(	O
0.86+/-0.29	O
ml	B-UNK
/	O
min	B-UNK
/	O
kg	B-UNK
in	O
OD	B-UNK
vs	B-UNK
.	O
1.28+/-0.33	O
ml	B-UNK
/	O
min	B-UNK
/	O
kg	B-UNK
in	O
TD	O
)	O
.	O
Increased	B-UNK
serum	B-UNK
creatinine	B-CHEMICAL
was	O
observed	B-UNK
in	O
73	O
%	O
of	O
patients	B-UNK
in	O
OD	B-UNK
versus	B-UNK
57	O
%	O
of	O
patients	B-UNK
in	O
TD	O
,	O
without	O
evidence	B-UNK
of	O
nephrotoxicity	B-UNK
.	O
In	O
TD	O
group	B-UNK
,	O
three	O
patients	B-UNK
developed	B-UNK
decreased	B-UNK
auditory	B-UNK
function	B-UNK
,	O
of	O
which	O
one	O
presented	B-UNK
with	O
an	O
auditory	B-UNK
loss	B-UNK
of	O
-30	O
dB	B-UNK
,	O
whereas	O
in	O
the	O
OD	B-UNK
group	B-UNK
only	O
one	O
patient	B-UNK
presented	B-UNK
decreased	B-UNK
auditory	B-UNK
function	B-UNK
.	O
CONCLUSION	O
:	O
This	O
small	B-UNK
study	B-UNK
suggests	B-UNK
that	O
a	O
once	O
-	O
daily	B-UNK
dosing	B-UNK
regimen	B-UNK
of	O
tobramycin	B-CHEMICAL
is	O
at	B-DISEASE
least	O
as	O
effective	B-UNK
as	O
and	O
is	O
no	O
more	O
and	O
possibly	B-UNK
less	O
toxic	B-UNK
than	O
the	O
twice	B-UNK
-	O
daily	B-UNK
regimen	B-UNK
.	O
Using	O
a	O
single	B-UNK
-	O
dose	B-UNK
therapy	B-UNK
,	O
peak	B-UNK
concentration	B-UNK
determination	O
is	O
not	O
necessary	O
,	O
only	O
trough	O
samples	B-UNK
should	O
be	O
monitored	B-UNK
to	O
ensure	O
levels	B-UNK
below	O
2	B-DISEASE
microg	B-UNK
/	O
ml	B-UNK
.	O

Chronic	B-UNK
effects	B-UNK
of	O
a	O
novel	B-UNK
synthetic	O
anthracycline	O
derivative	B-UNK
(	O
SM-5887	O
)	O
on	O
normal	B-UNK
heart	B-UNK
and	O
doxorubicin	B-CHEMICAL
-	O
induced	B-UNK
cardiomyopathy	B-DISEASE
in	O
beagle	B-UNK
dogs	B-UNK
.	O

This	O
study	B-UNK
was	O
designed	O
to	O
investigate	O
the	O
chronic	B-UNK
cardiotoxic	B-UNK
potential	B-UNK
of	O
SM-5887	O
and	O
a	O
possible	B-UNK
deteriorating	B-UNK
effect	B-UNK
of	O
SM-5887	O
on	O
low	B-UNK
-	O
grade	B-UNK
cardiotoxicity	B-DISEASE
pre	B-UNK
-	O
induced	B-UNK
by	O
doxorubicin	B-CHEMICAL
in	O
beagle	B-UNK
dogs	B-UNK
.	O
In	O
the	O
chronic	B-UNK
treatment	B-UNK
,	O
beagle	B-UNK
dogs	B-UNK
of	O
each	O
sex	O
were	O
given	B-UNK
intravenously	B-UNK
once	O
every	O
3	O
weeks	B-UNK
,	O
either	O
a	O
sublethal	O
dose	B-UNK
of	O
doxorubicin	B-CHEMICAL
(	O
1.5	B-UNK
mg	B-UNK
/	O
kg	B-UNK
)	O
or	O
SM-5887	O
(	O
2.5	B-UNK
mg	B-UNK
/	O
kg	B-UNK
)	O
.	O
The	O
experiment	B-UNK
was	O
terminated	O
3	O
weeks	B-UNK
after	O
the	O
ninth	O
dosing	B-UNK
.	O
Animals	O
which	O
received	B-UNK
over	O
six	O
courses	O
of	O
doxorubicin	B-CHEMICAL
demonstrated	B-UNK
the	O
electrocardiogram	O
(	O
ECG	B-UNK
)	O
changes	B-UNK
,	O
decrease	B-UNK
of	O
blood	B-UNK
pressure	B-UNK
and	O
high	B-UNK
-	O
grade	B-UNK
histopathological	O
cardiomyopathy	B-DISEASE
,	O
while	O
animals	B-UNK
which	O
were	O
terminally	O
sacrificed	O
after	O
the	O
SM-5887	O
administration	B-UNK
did	O
not	O
show	O
any	O
changes	B-UNK
in	O
ECG	B-UNK
,	O
blood	B-UNK
pressure	B-UNK
and	O
histopathological	O
examinations	B-UNK
.	O
To	O
examine	O
a	O
possibly	B-UNK
deteriorating	B-UNK
cardiotoxic	B-UNK
effect	B-UNK
of	O
SM-5887	O
,	O
low	B-UNK
-	O
grade	B-UNK
cardiomyopathy	B-DISEASE
was	O
induced	B-UNK
in	O
dogs	B-UNK
by	O
four	O
courses	O
of	O
doxorubicin	B-CHEMICAL
(	O
1.5	B-UNK
mg	B-UNK
/	O
kg	B-UNK
)	O
.	O
Nine	O
weeks	B-UNK
after	O
pre	B-UNK
-	O
treatment	B-UNK
,	O
dogs	B-UNK
were	O
given	B-UNK
four	O
courses	O
of	O
either	O
doxorubicin	B-CHEMICAL
(	O
1.5	B-UNK
mg	B-UNK
/	O
kg	B-UNK
)	O
or	O
SM-5887	O
(	O
2.5	B-UNK
mg	B-UNK
/	O
kg	B-UNK
)	O
once	O
every	O
3	O
weeks	B-UNK
.	O
The	O
low	B-UNK
-	O
grade	B-UNK
cardiotoxic	B-UNK
changes	B-UNK
were	O
enhanced	B-UNK
by	O
the	O
additional	B-UNK
doxorubicin	B-CHEMICAL
treatment	B-UNK
.	O
On	O
the	O
contrary	O
,	O
the	O
SM-5887	O
treatment	B-UNK
did	O
not	O
progress	O
the	O
grade	B-UNK
of	O
cardiomyopathy	B-DISEASE
.	O
In	O
conclusion	O
,	O
SM-5887	O
does	O
not	O
have	O
any	O
potential	B-UNK
of	O
chronic	B-UNK
cardiotoxicity	B-DISEASE
and	O
deteriorating	B-UNK
effect	B-UNK
on	O
doxorubicin	B-CHEMICAL
-	O
induced	B-UNK
cardiotoxicity	B-DISEASE
in	O
dogs	B-UNK
.	O

Posteroventral	O
medial	B-UNK
pallidotomy	B-UNK
in	O
advanced	B-UNK
Parkinson'	O
s	O
disease	B-DISEASE
.	O

BACKGROUND	O
:	O
Posteroventral	O
medial	B-UNK
pallidotomy	B-UNK
sometimes	O
produces	B-UNK
striking	B-UNK
improvement	B-UNK
in	O
patients	B-UNK
with	O
advanced	B-UNK
Parkinson'	O
s	O
disease	B-DISEASE
,	O
but	O
the	O
studies	B-UNK
to	O
date	O
have	O
involved	B-UNK
small	B-UNK
numbers	O
of	O
patients	B-UNK
and	O
short	B-UNK
-	O
term	B-UNK
follow	B-UNK
-	O
up	O
.	O
METHODS	O
:	O
Forty	O
patients	B-UNK
with	O
Parkinson'	O
s	O
disease	B-DISEASE
underwent	B-UNK
serial	B-UNK
,	O
detailed	B-UNK
assessments	O
both	O
after	O
drug	B-UNK
withdrawal	B-UNK
(	O
"	O
off	O
"	O
period	B-UNK
)	O
and	O
while	O
taking	B-UNK
their	O
optimal	B-UNK
medical	B-UNK
regimens	B-UNK
(	O
"	O
on	O
"	O
period	B-UNK
)	O
.	O
All	O
patients	B-UNK
were	O
examined	B-UNK
preoperatively	O
and	O
39	O
were	O
examined	B-UNK
at	B-DISEASE
six	O
months	B-UNK
;	O
27	O
of	O
the	O
patients	B-UNK
were	O
also	O
examined	B-UNK
at	B-DISEASE
one	O
year	B-UNK
,	O
and	O
11	O
at	B-DISEASE
two	O
years	B-UNK
.	O
RESULTS	B-UNK
:	O
The	O
percent	O
improvements	B-UNK
at	B-DISEASE
six	O
months	B-UNK
were	O
as	O
follows	O
:	O
off	O
-	O
period	B-UNK
score	B-UNK
for	O
overall	B-UNK
motor	B-UNK
function	B-UNK
,	O
28	O
percent	O
(	O
95	O
percent	B-UNK
confidence	I-UNK
interval	B-UNK
,	O
19	O
to	O
38	O
percent	O
)	O
,	O
with	O
most	O
of	O
the	O
improvement	B-UNK
in	O
the	O
contralateral	B-UNK
limbs	B-UNK
;	O
off	O
-	O
period	B-UNK
score	B-UNK
for	O
activities	B-UNK
of	O
daily	B-UNK
living	B-UNK
,	O
29	O
percent	O
(	O
95	O
percent	B-UNK
confidence	I-UNK
interval	B-UNK
,	O
19	O
to	O
39	O
percent	O
)	O
;	O
on	O
-	O
period	B-UNK
score	B-UNK
for	O
contralateral	B-UNK
dyskinesias	B-DISEASE
,	O
82	O
percent	O
(	O
95	O
percent	B-UNK
confidence	I-UNK
interval	B-UNK
,	O
72	O
to	O
91	O
percent	O
)	O
;	O
and	O
on	O
-	O
period	B-UNK
score	B-UNK
for	O
ipsilateral	O
dyskinesias	B-DISEASE
,	O
44	O
percent	O
(	O
95	O
percent	B-UNK
confidence	I-UNK
interval	B-UNK
,	O
29	O
to	O
59	O
percent	O
)	O
.	O
The	O
improvements	B-UNK
in	O
dyskinesias	B-DISEASE
and	O
the	O
total	B-UNK
scores	B-UNK
for	O
off	O
-	O
period	B-UNK
parkinsonism	B-DISEASE
,	O
contralateral	B-UNK
bradykinesia	O
,	O
and	O
rigidity	B-UNK
were	O
sustained	B-UNK
in	O
the	O
11	O
patients	B-UNK
examined	B-UNK
at	B-DISEASE
two	O
years	B-UNK
.	O
The	O
improvement	B-UNK
in	O
ipsilateral	O
dyskinesias	B-DISEASE
was	O
lost	O
after	O
one	O
year	B-UNK
,	O
and	O
the	O
improvements	B-UNK
in	O
postural	O
stability	B-UNK
and	O
gait	O
lasted	B-UNK
only	O
three	O
to	O
six	O
months	B-UNK
.	O
Approximately	O
half	O
the	O
patients	B-UNK
who	O
had	O
been	O
dependent	B-UNK
on	O
assistance	O
in	O
activities	B-UNK
of	O
daily	B-UNK
living	B-UNK
in	O
the	O
off	O
period	B-UNK
before	O
surgery	B-UNK
became	O
independent	B-UNK
after	O
surgery	B-UNK
.	O
The	O
complications	B-UNK
of	O
surgery	B-UNK
were	O
generally	B-UNK
well	O
tolerated	B-UNK
,	O
and	O
there	O
were	O
no	O
significant	B-UNK
changes	B-UNK
in	O
the	O
use	B-UNK
of	O
medication	B-UNK
.	O
CONCLUSIONS	O
:	O
In	O
late	B-UNK
-	O
stage	B-UNK
Parkinson'	O
s	O
disease	B-DISEASE
,	O
pallidotomy	B-UNK
significantly	B-UNK
reduces	B-UNK
levodopa	B-CHEMICAL
-	O
induced	B-UNK
dyskinesias	B-DISEASE
and	O
off	O
-	O
period	B-UNK
disability	O
.	O
Much	O
of	O
the	O
benefit	B-UNK
is	O
sustained	B-UNK
at	B-DISEASE
two	O
years	B-UNK
,	O
although	O
some	O
improvements	B-UNK
,	O
such	O
as	O
those	O
on	O
the	O
ipsilateral	O
side	O
and	O
in	O
axial	O
symptoms	B-UNK
,	O
wane	O
within	O
the	O
first	O
year	B-UNK
.	O
The	O
on	O
-	O
period	B-UNK
symptoms	B-UNK
that	O
are	O
resistant	B-UNK
to	O
dopaminergic	B-UNK
therapy	B-UNK
do	O
not	O
respond	O
to	O
pallidotomy	B-UNK
.	O

Neuropeptide	O
-	O
Y	O
immunoreactivity	B-UNK
in	O
the	O
pilocarpine	B-CHEMICAL
model	B-UNK
of	O
temporal	B-UNK
lobe	I-UNK
epilepsy	B-DISEASE
.	O

Neuropeptide	O
-	O
Y	O
(	O
NPY	B-UNK
)	O
is	O
expressed	O
by	O
granule	B-UNK
cells	B-UNK
and	O
mossy	B-UNK
fibres	B-UNK
of	O
the	O
hippocampal	B-UNK
dentate	B-UNK
gyrus	B-UNK
during	O
experimental	B-UNK
temporal	B-UNK
lobe	I-UNK
epilepsy	B-DISEASE
(	O
TLE	O
)	O
.	O
This	O
expression	B-UNK
may	O
represent	B-UNK
an	O
endogenous	B-UNK
damping	O
mechanism	B-UNK
since	O
NPY	B-UNK
has	O
been	O
shown	B-UNK
to	O
block	B-UNK
seizure	B-DISEASE
-	O
like	B-UNK
events	B-UNK
following	B-UNK
high	B-UNK
-	O
frequency	B-UNK
stimulation	B-UNK
in	O
hippocampal	B-UNK
slices	O
.	O
The	O
pilocarpine	B-CHEMICAL
(	O
PILO	O
)	O
model	B-UNK
of	O
epilepsy	B-DISEASE
is	O
characterized	B-UNK
by	O
an	O
acute	B-UNK
period	B-UNK
of	O
status	B-DISEASE
epilepticus	I-DISEASE
followed	B-UNK
by	O
spontaneous	B-UNK
recurrent	B-UNK
seizures	B-DISEASE
and	O
related	B-UNK
brain	B-DISEASE
damage	I-DISEASE
.	O
We	O
report	B-UNK
peroxidase	O
-	O
antiperoxidase	O
immunostaining	O
for	O
NPY	B-UNK
in	O
several	O
brain	B-UNK
regions	B-UNK
in	O
this	O
model	B-UNK
.	O
PILO	O
-	O
injected	B-UNK
animals	B-UNK
exhibited	B-UNK
NPY	B-UNK
immunoreactivity	B-UNK
in	O
the	O
region	B-UNK
of	O
the	O
mossy	B-UNK
fibre	O
terminals	O
,	O
in	O
the	O
dentate	B-UNK
gyrus	B-UNK
inner	B-UNK
molecular	B-UNK
layer	B-UNK
and	O
,	O
in	O
a	O
few	O
cases	B-UNK
,	O
within	O
presumed	O
granule	B-UNK
cells	B-UNK
.	O
NPY	B-UNK
immunoreactivity	B-UNK
was	O
also	O
dramatically	O
changed	B-UNK
in	O
the	O
entorhinal	O
cortex	B-UNK
,	O
amygdala	O
and	O
sensorimotor	O
areas	B-UNK
.	O
In	O
addition	O
,	O
PILO	O
injected	B-UNK
animals	B-UNK
exhibited	B-UNK
a	O
reduction	B-UNK
in	O
the	O
number	B-UNK
of	O
NPY	B-UNK
-	O
immunoreactive	O
interneurons	O
compared	B-UNK
with	O
controls	B-UNK
.	O
The	O
results	B-UNK
demonstrate	B-UNK
that	O
changes	B-UNK
in	O
NPY	B-UNK
expression	B-UNK
,	O
including	B-UNK
expression	B-UNK
in	O
the	O
granule	B-UNK
cells	B-UNK
and	O
mossy	B-UNK
fibres	B-UNK
and	O
the	O
loss	B-UNK
of	O
vulnerable	O
NPY	B-UNK
neurons	B-UNK
,	O
are	O
present	B-UNK
in	O
the	O
PILO	O
model	B-UNK
of	O
TLE	O
.	O
However	O
,	O
the	O
significance	O
of	O
this	O
changed	B-UNK
synthesis	O
of	O
NPY	B-UNK
remains	B-UNK
to	O
be	O
determined	O
.	O

Effect	O
of	O
myopic	O
excimer	O
laser	B-UNK
photorefractive	O
keratectomy	O
on	O
the	O
electrophysiologic	O
function	B-UNK
of	O
the	O
retina	O
and	O
optic	B-UNK
nerve	I-UNK
.	O

PURPOSE	O
:	O
To	O
assess	B-UNK
by	O
electrophysiologic	O
testing	B-UNK
the	O
effect	B-UNK
of	O
photorefractive	O
keratectomy	O
(	O
PRK	O
)	O
on	O
the	O
retina	O
and	O
optic	B-UNK
nerve	I-UNK
.	O
SETTING	O
:	O
Eye	O
Clinic	B-UNK
,	O
S.	O
Salvatore	O
Hospital	O
,	O
L'	O
Aquila	O
University	B-UNK
,	O
Italy	O
.	O
METHODS	O
:	O
Standard	O
pattern	B-UNK
electroretinograms	O
(	O
P	B-UNK
-	O
ERGs	O
)	O
and	O
standard	B-UNK
pattern	B-UNK
visual	B-UNK
evoked	I-UNK
potentials	O
(	O
P	B-UNK
-	O
VEPs	O
)	O
were	O
done	O
in	O
25	O
eyes	B-UNK
of	O
25	O
patients	B-UNK
who	O
had	O
myopic	O
PRK	O
for	O
an	O
attempted	O
correction	O
between	O
5.00	O
and	O
15.00	O
diopters	O
(	O
D	B-UNK
)	O
(	O
mean	B-UNK
8.00	O
D	B-UNK
)	O
.	O
Testing	O
was	O
done	O
preoperatively	O
and	O
3	O
,	O
6	O
,	O
12	O
,	O
and	O
18	O
months	B-UNK
postoperatively	O
.	O
The	O
contralateral	B-UNK
eyes	B-UNK
served	O
as	O
controls	B-UNK
.	O
During	O
the	O
follow	B-UNK
-	O
up	O
,	O
3	O
patients	B-UNK
(	O
12	O
%	O
)	O
developed	B-UNK
steroid	B-UNK
-	O
induced	B-UNK
elevated	B-UNK
intraocular	B-UNK
pressure	B-UNK
(	O
IOP	B-UNK
)	O
that	O
resolved	B-UNK
after	O
corticosteroid	O
therapy	B-UNK
was	O
discontinued	O
.	O
RESULTS	B-UNK
:	O
No	O
statistically	B-UNK
significant	I-UNK
differences	B-UNK
were	O
seen	B-UNK
between	O
treated	B-UNK
and	O
control	B-UNK
eyes	B-UNK
nor	O
between	O
treated	B-UNK
eyes	B-UNK
preoperatively	O
and	O
postoperatively	O
.	O
CONCLUSION	O
:	O
Myopic	O
excimer	O
laser	B-UNK
PRK	O
did	O
not	O
seem	O
to	O
affect	B-UNK
the	O
posterior	B-UNK
segment	B-UNK
.	O
The	O
transient	B-UNK
steroid	B-UNK
-	O
induced	B-UNK
IOP	B-UNK
rise	B-UNK
did	O
not	O
seem	O
to	O
cause	B-UNK
functional	B-UNK
impairment	B-UNK
.	O

Liposomal	O
daunorubicin	B-CHEMICAL
in	O
advanced	B-UNK
Kaposi'	O
s	O
sarcoma	B-DISEASE
:	O
a	O
phase	B-UNK
II	B-UNK
study	B-UNK
.	O

We	O
report	B-UNK
a	O
non-randomized	O
Phase	O
II	B-UNK
clinical	B-UNK
trial	B-UNK
to	O
assess	B-UNK
the	O
efficacy	B-UNK
and	O
safety	B-UNK
of	O
liposomal	O
daunorubicin	B-CHEMICAL
(	O
DaunoXome	O
)	O
in	O
the	O
treatment	B-UNK
of	O
AIDS	O
related	B-UNK
Kaposi'	O
s	O
sarcoma	B-DISEASE
.	O
Eleven	O
homosexual	O
men	O
with	O
advanced	B-UNK
Kaposi'	O
s	O
sarcoma	B-DISEASE
were	O
entered	O
in	O
the	O
trial	B-UNK
.	O
Changes	O
in	O
size	O
,	O
colour	O
and	O
associated	B-UNK
oedema	O
of	O
selected	O
'	O
target	O
'	O
lesions	B-UNK
were	O
measured	B-UNK
.	O
Clinical	B-UNK
,	O
biochemical	B-UNK
and	O
haematological	O
toxicities	B-UNK
were	O
assessed	B-UNK
.	O
Ten	O
subjects	B-UNK
were	O
evaluated	B-UNK
.	O
A	O
partial	B-UNK
response	B-UNK
was	O
achieved	B-UNK
in	O
four	O
,	O
of	O
whom	O
two	O
subsequently	B-UNK
relapsed	O
.	O
Stabilization	O
of	O
Kaposi'	O
s	O
sarcoma	B-DISEASE
occurred	B-UNK
in	O
the	O
remaining	B-UNK
six	O
,	O
maintained	O
until	O
the	O
end	B-UNK
of	O
the	O
trial	B-UNK
period	B-UNK
in	O
four	O
.	O
The	O
drug	B-UNK
was	O
generally	B-UNK
well	O
tolerated	B-UNK
,	O
with	O
few	O
mild	B-UNK
symptoms	B-UNK
of	O
toxicity	B-UNK
.	O
The	O
main	B-UNK
problem	B-UNK
encountered	B-UNK
was	O
haematological	O
toxicity	B-UNK
,	O
with	O
three	O
subjects	B-UNK
experiencing	O
severe	B-UNK
neutropenia	B-DISEASE
(	O
neutrophil	O
count	B-UNK
<	O
0.5	B-UNK
x	B-UNK
10(9)/l	O
)	O
.	O
There	O
was	O
no	O
evidence	B-UNK
of	O
cardiotoxicity	B-DISEASE
.	O
In	O
this	O
small	B-UNK
patient	B-UNK
sample	O
,	O
liposomal	O
daunorubicin	B-CHEMICAL
was	O
an	O
effective	B-UNK
and	O
well	O
tolerated	B-UNK
agent	B-UNK
in	O
the	O
treatment	B-UNK
of	O
Kaposi'	O
s	O
sarcoma	B-DISEASE
.	O

Failure	O
of	O
ancrod	B-CHEMICAL
in	O
the	O
treatment	B-UNK
of	O
heparin	B-CHEMICAL
-	O
induced	B-UNK
arterial	B-UNK
thrombosis	B-DISEASE
.	O

The	O
morbidity	O
and	O
mortality	B-UNK
associated	B-UNK
with	O
heparin	B-CHEMICAL
-	O
induced	B-UNK
thrombosis	B-DISEASE
remain	B-UNK
high	B-UNK
despite	B-UNK
numerous	O
empirical	O
therapies	B-UNK
.	O
Ancrod	O
has	O
been	O
used	O
successfully	B-UNK
for	O
prophylaxis	B-UNK
against	O
development	B-UNK
of	O
thrombosis	B-DISEASE
in	O
patients	B-UNK
with	O
heparin	B-CHEMICAL
induced	B-UNK
platelet	B-DISEASE
aggregation	I-DISEASE
who	O
require	O
brief	B-DISEASE
reexposure	O
to	O
heparin	B-CHEMICAL
,	O
but	O
its	O
success	O
in	O
patients	B-UNK
who	O
have	O
developed	B-UNK
the	O
thrombosis	B-DISEASE
syndrome	B-DISEASE
is	O
not	O
well	O
defined	O
.	O
The	O
authors	B-UNK
present	B-UNK
a	O
case	B-UNK
of	O
failure	B-UNK
of	O
ancrod	B-CHEMICAL
treatment	B-UNK
in	O
a	O
patient	B-UNK
with	O
heparin	B-CHEMICAL
-	O
induced	B-UNK
thrombosis	B-DISEASE
.	O

Seizure	O
after	O
flumazenil	B-CHEMICAL
administration	B-UNK
in	O
a	O
pediatric	B-UNK
patient	B-UNK
.	O

Flumazenil	O
is	O
a	O
benzodiazepine	O
receptor	B-UNK
antagonist	I-UNK
used	O
to	O
reverse	B-UNK
sedation	B-UNK
and	O
respiratory	B-UNK
depression	B-DISEASE
induced	B-UNK
by	O
benzodiazepines	B-CHEMICAL
.	O
Seizures	O
and	O
cardiac	B-UNK
arrhythmias	B-DISEASE
have	O
complicated	O
its	O
use	B-UNK
in	O
adult	B-UNK
patients	B-UNK
.	O
Overdose	O
patients	B-UNK
who	O
have	O
coingested	O
tricyclic	B-UNK
antidepressants	B-UNK
have	O
a	O
higher	B-UNK
risk	B-UNK
of	O
these	O
complications	B-UNK
.	O
Little	O
information	B-UNK
exists	B-UNK
concerning	B-UNK
adverse	B-UNK
effects	B-UNK
of	O
flumazenil	B-CHEMICAL
in	O
children	B-UNK
.	O
We	O
report	B-UNK
the	O
occurrence	O
of	O
a	O
generalized	B-UNK
tonic	B-DISEASE
-	I-DISEASE
clonic	I-DISEASE
seizure	I-DISEASE
in	O
a	O
pediatric	B-UNK
patient	B-UNK
following	B-UNK
the	O
administration	B-UNK
of	O
flumazenil	B-CHEMICAL
.	O

Remodelling	O
of	O
nerve	B-UNK
structure	B-UNK
in	O
experimental	B-UNK
isoniazid	B-CHEMICAL
neuropathy	B-DISEASE
in	O
the	O
rat	B-UNK
.	O

The	O
neuropathy	B-DISEASE
caused	B-UNK
by	O
a	O
single	B-UNK
dose	B-UNK
of	O
isoniazid	B-CHEMICAL
in	O
rats	B-UNK
was	O
studied	B-UNK
with	O
a	O
computer	O
-	O
assisted	O
morphometric	O
method	B-UNK
.	O
Scatter	O
diagrams	O
of	O
the	O
g	B-UNK
ratio	B-UNK
(	O
quotient	O
fibre	O
diameter	B-UNK
/	O
axon	B-UNK
diameter	B-UNK
)	O
define	B-UNK
regenerating	O
fibres	B-UNK
as	O
a	O
distinct	O
population	B-UNK
,	O
distinguishable	O
from	O
the	O
surviving	O
fibres	B-UNK
by	O
reduced	B-UNK
sheath	O
thickness	B-UNK
and	O
reduced	B-UNK
axon	B-UNK
calibre	O
.	O
There	O
was	O
also	O
evidence	B-UNK
of	O
a	O
subtle	O
direct	B-UNK
toxic	B-UNK
effect	B-UNK
on	O
the	O
entire	B-UNK
fibre	O
population	B-UNK
,	O
causing	B-UNK
axon	B-UNK
shrinkage	O
masked	O
by	O
readjustment	O
of	O
the	O
myelin	O
sheath	O
.	O

Selective	O
injection	B-UNK
of	O
iopentol	B-CHEMICAL
,	O
iohexol	B-CHEMICAL
and	O
metrizoate	O
into	O
the	O
left	B-UNK
coronary	B-UNK
artery	I-UNK
of	O
the	O
dog	O
.	O
Induction	O
of	O
ventricular	B-DISEASE
fibrillation	I-DISEASE
and	O
decrease	B-UNK
of	O
aortic	B-UNK
pressure	B-UNK
.	O

In	O
twenty	O
beagle	B-UNK
dogs	B-UNK
selective	B-UNK
injections	B-UNK
were	O
made	O
into	O
the	O
left	B-UNK
coronary	B-UNK
artery	I-UNK
with	O
iopentol	B-CHEMICAL
,	O
iohexol	B-CHEMICAL
and	O
metrizoate	O
in	O
doses	B-UNK
of	O
4	O
ml	B-UNK
,	O
8	O
ml	B-UNK
and	O
16	O
ml	B-UNK
.	O
Thirty	O
-	O
six	O
iopentol	B-CHEMICAL
injections	B-UNK
,	O
35	O
iohexol	B-CHEMICAL
injections	B-UNK
and	O
37	O
metrizoate	O
injections	B-UNK
were	O
made	O
.	O
Frequencies	O
of	O
ventricular	B-DISEASE
fibrillation	I-DISEASE
were	O
significantly	B-UNK
lower	B-UNK
(	O
p	B-UNK
less	O
than	O
0.05	O
)	O
after	O
iopentol	B-CHEMICAL
(	O
0	O
%	O
)	O
and	O
iohexol	B-CHEMICAL
(	O
3	O
%	O
)	O
than	O
after	O
metrizoate	O
(	O
22	O
%	O
)	O
.	O
Iopentol	O
and	O
iohexol	B-CHEMICAL
also	O
produced	B-UNK
significantly	B-UNK
less	O
decrease	B-UNK
in	O
aortic	B-UNK
blood	B-UNK
pressure	B-UNK
than	O
metrizoate	O
at	B-DISEASE
the	O
different	B-UNK
doses	B-UNK
.	O

Magnetic	O
resonance	B-UNK
imaging	I-UNK
of	O
cerebral	B-UNK
venous	B-DISEASE
thrombosis	I-DISEASE
secondary	B-UNK
to	O
"	O
low	B-UNK
-	O
dose	B-UNK
"	O
birth	B-UNK
control	B-UNK
pills	O
.	O

The	O
clinical	B-UNK
and	O
radiographic	B-UNK
features	B-UNK
of	O
cerebral	B-UNK
deep	B-UNK
venous	B-DISEASE
thrombosis	I-DISEASE
in	O
a	O
21-year	O
-	O
old	B-UNK
white	B-UNK
woman	B-UNK
are	O
presented	B-UNK
.	O
This	O
nulliparous	O
patient	B-UNK
presented	B-UNK
with	O
relatively	B-UNK
mild	B-UNK
clinical	B-UNK
symptoms	B-UNK
and	O
progressing	O
mental	B-UNK
status	I-UNK
changes	B-UNK
.	O
The	O
only	O
known	B-UNK
risk	B-UNK
factor	B-UNK
was	O
"	O
low	B-UNK
-	O
dose	B-UNK
"	O
oral	B-UNK
contraceptive	O
pills	O
.	O
The	O
magnetic	B-UNK
resonance	I-UNK
image	O
(	O
MRI	B-UNK
)	O
showed	B-UNK
increased	B-UNK
signal	O
intensity	B-UNK
from	O
the	O
internal	B-UNK
cerebral	B-UNK
veins	O
,	O
vein	O
of	O
Galen	O
,	O
and	O
straight	O
sinus	B-UNK
.	O
The	O
diagnosis	B-UNK
was	O
confirmed	B-UNK
by	O
arterial	B-UNK
angiography	B-UNK
.	O

Relation	O
of	O
perfusion	B-UNK
defects	B-UNK
observed	B-UNK
with	O
myocardial	B-UNK
contrast	B-UNK
echocardiography	O
to	O
the	O
severity	B-UNK
of	O
coronary	B-DISEASE
stenosis	I-DISEASE
:	O
correlation	B-UNK
with	O
thallium-201	B-UNK
single	B-UNK
-	O
photon	B-UNK
emission	B-UNK
tomography	B-UNK
.	O

It	O
has	O
been	O
previously	B-UNK
shown	B-UNK
that	O
myocardial	B-UNK
contrast	B-UNK
echocardiography	O
is	O
a	O
valuable	O
technique	B-UNK
for	O
delineating	O
regions	B-UNK
of	O
myocardial	B-UNK
underperfusion	O
secondary	B-UNK
to	O
coronary	B-DISEASE
occlusion	I-DISEASE
and	O
to	O
critical	B-UNK
coronary	B-UNK
stenoses	O
in	O
the	O
presence	O
of	O
hyperemic	O
stimulation	B-UNK
.	O
The	O
aim	O
of	O
this	O
study	B-UNK
was	O
to	O
determine	B-UNK
whether	O
myocardial	B-UNK
contrast	B-UNK
echocardiography	O
performed	B-UNK
with	O
a	O
stable	B-UNK
solution	B-UNK
of	O
sonicated	O
albumin	O
could	O
detect	B-UNK
regions	B-UNK
of	O
myocardial	B-UNK
underperfusion	O
resulting	B-UNK
from	O
various	O
degrees	O
of	O
coronary	B-DISEASE
stenosis	I-DISEASE
.	O
The	O
perfusion	B-UNK
defect	B-UNK
produced	B-UNK
in	O
16	O
open	B-UNK
chest	B-UNK
dogs	B-UNK
was	O
compared	B-UNK
with	O
the	O
anatomic	B-UNK
area	B-UNK
at	B-DISEASE
risk	B-UNK
measured	B-UNK
by	O
the	O
postmortem	O
dual	B-UNK
-	O
perfusion	B-UNK
technique	B-UNK
and	O
with	O
thallium-201	B-UNK
single	B-UNK
-	O
photon	B-UNK
emission	B-UNK
tomography	B-UNK
(	O
SPECT	O
)	O
.	O
During	O
a	O
transient	B-UNK
(	O
20-s	O
)	O
coronary	B-DISEASE
occlusion	I-DISEASE
,	O
a	O
perfusion	B-UNK
defect	B-UNK
was	O
observed	B-UNK
with	O
contrast	B-UNK
echocardiography	O
in	O
14	O
of	O
the	O
15	O
dogs	B-UNK
in	O
which	O
the	O
occlusion	B-UNK
was	O
produced	B-UNK
.	O
The	O
perfusion	B-UNK
defect	B-UNK
correlated	B-UNK
significantly	B-UNK
with	O
the	O
anatomic	B-UNK
area	B-UNK
at	B-DISEASE
risk	B-UNK
(	O
r	B-UNK
=	I-UNK
0.74	O
;	O
p	B-UNK
less	O
than	O
0.002	O
)	O
.	O
During	O
dipyridamole	B-CHEMICAL
-	O
induced	B-UNK
hyperemia	B-DISEASE
,	O
12	O
of	O
the	O
16	O
dogs	B-UNK
with	O
a	O
partial	B-UNK
coronary	B-DISEASE
stenosis	I-DISEASE
had	O
a	O
visible	O
area	B-UNK
of	O
hypoperfusion	O
by	O
contrast	B-UNK
echocardiography	O
.	O
The	O
four	O
dogs	B-UNK
without	O
a	O
perfusion	B-UNK
defect	B-UNK
had	O
a	O
stenosis	B-DISEASE
that	O
resulted	B-UNK
in	O
a	O
mild	B-UNK
(	O
0	O
%	O
to	O
50	O
%	O
)	O
reduction	B-UNK
in	O
dipyridamole	B-CHEMICAL
-	O
induced	B-UNK
hyperemia	B-DISEASE
.	O
The	O
size	O
of	O
the	O
perfusion	B-UNK
defect	B-UNK
during	O
stenosis	B-DISEASE
correlated	B-UNK
significantly	B-UNK
with	O
the	O
anatomic	B-UNK
area	B-UNK
at	B-DISEASE
risk	B-UNK
(	O
r	B-UNK
=	I-UNK
0.61	O
;	O
p	B-UNK
=	I-UNK
0.02	O
)	O
.	O
Thallium-201	O
SPECT	O
demonstrated	B-UNK
a	O
perfusion	B-UNK
defect	B-UNK
in	O
all	O
14	O
dogs	B-UNK
analyzed	B-UNK
during	O
dipyridamole	B-CHEMICAL
-	O
induced	B-UNK
hyperemia	B-DISEASE
;	O
the	O
size	O
of	O
the	O
perfusion	B-UNK
defect	B-UNK
correlated	B-UNK
with	O
the	O
anatomic	B-UNK
area	B-UNK
at	B-DISEASE
risk	B-UNK
(	O
r	B-UNK
=	I-UNK
0.58	O
;	O
p	B-UNK
less	O
than	O
0.03	B-UNK
)	O
and	O
with	O
the	O
perfusion	B-UNK
defect	B-UNK
by	O
contrast	B-UNK
echocardiography	O
(	O
r	B-UNK
=	I-UNK
0.58	O
;	O
p	B-UNK
less	O
than	O
0.03	B-UNK
)	O
.	O
Thus	O
,	O
myocardial	B-UNK
contrast	B-UNK
echocardiography	O
can	O
be	O
used	O
to	O
visualize	O
and	O
quantitate	O
the	O
amount	O
of	O
jeopardized	O
myocardium	B-UNK
during	O
moderate	B-UNK
to	O
severe	B-UNK
degrees	O
of	O
coronary	B-DISEASE
stenosis	I-DISEASE
.	O
The	O
results	B-UNK
obtained	B-UNK
show	O
a	O
correlation	B-UNK
with	O
the	O
anatomic	B-UNK
area	B-UNK
at	B-DISEASE
risk	B-UNK
similar	B-UNK
to	O
that	O
obtained	B-UNK
with	O
thallium-201	B-UNK
SPECT	O
.	O

Potential	O
deleterious	O
effect	B-UNK
of	O
furosemide	B-CHEMICAL
in	O
radiocontrast	O
nephropathy	B-DISEASE
.	O

The	O
purpose	O
of	O
the	O
study	B-UNK
was	O
to	O
determine	B-UNK
the	O
efficacy	B-UNK
of	O
furosemide	B-CHEMICAL
in	O
addition	O
to	O
intravenous	B-UNK
fluids	O
in	O
the	O
prevention	O
of	O
radiocontrast	O
nephropathy	B-DISEASE
.	O
18	O
patients	B-UNK
,	O
referred	O
to	O
a	O
radiocontrast	O
study	B-UNK
,	O
considered	B-UNK
at	B-DISEASE
risk	B-UNK
because	O
of	O
preexisting	O
renal	B-DISEASE
insufficiency	I-DISEASE
,	O
were	O
enrolled	O
in	O
a	O
prospective	B-UNK
,	O
randomized	B-UNK
,	O
controlled	B-UNK
trial	B-UNK
,	O
performed	B-UNK
at	B-DISEASE
the	O
secondary	B-UNK
care	B-UNK
center	B-UNK
of	O
a	O
1,100-bed	O
private	O
university	O
hospital	B-UNK
.	O
In	O
addition	O
to	O
fluids	O
,	O
the	O
treatment	B-UNK
group	B-UNK
received	B-UNK
furosemide	B-CHEMICAL
(	O
mean	B-UNK
dose	B-UNK
110	O
mg	B-UNK
)	O
intravenously	B-UNK
30	O
min	B-UNK
prior	B-UNK
to	O
the	O
injection	B-UNK
of	O
contrast	B-UNK
material	O
.	O
The	O
control	B-UNK
group	B-UNK
received	B-UNK
fluids	O
(	O
mean	B-UNK
3	O
liters	O
)	O
.	O
Radiological	O
studies	B-UNK
were	O
mostly	O
angiographies	O
performed	B-UNK
with	O
both	O
ionic	O
and	O
non-ionic	O
contrast	B-UNK
material	O
,	O
at	B-DISEASE
an	O
average	B-UNK
dose	B-UNK
of	O
245	O
ml	B-UNK
.	O
Renal	B-UNK
function	B-UNK
significantly	B-UNK
deteriorated	O
in	O
the	O
group	B-UNK
pretreated	B-UNK
with	O
furosemide	B-CHEMICAL
(	O
p	B-UNK
<	I-UNK
0.005	O
by	O
ANOVA	O
)	O
,	O
with	O
a	O
rise	B-UNK
in	O
serum	B-UNK
creatinine	B-CHEMICAL
from	O
145	O
+	O
/-	O
13	O
to	O
182	O
+	O
/-	O
16	O
mumol	B-UNK
/	O
l	B-UNK
at	B-DISEASE
24	O
h	B-UNK
,	O
while	O
no	O
change	B-UNK
occurred	B-UNK
in	O
the	O
control	B-UNK
group	B-UNK
(	O
from	O
141	O
+	O
/-	O
6	O
to	O
142	O
+	O
/-	O
7	O
mumol	B-UNK
/	O
l	B-UNK
)	O
.	O
Renal	B-UNK
failure	B-UNK
was	O
associated	B-UNK
with	O
weight	B-DISEASE
loss	I-DISEASE
in	O
the	O
furosemide	B-CHEMICAL
-	O
treated	B-UNK
group	B-UNK
.	O
Furosemide	O
may	O
be	O
deleterious	O
in	O
the	O
prevention	O
of	O
radiocontrast	O
nephropathy	B-DISEASE
.	O

The	O
renal	B-DISEASE
pathology	O
in	O
a	O
case	B-UNK
of	O
lithium	B-CHEMICAL
-	O
induced	B-UNK
diabetes	B-DISEASE
insipidus	I-DISEASE
.	O

A	O
case	B-UNK
of	O
lithium	B-CHEMICAL
-	O
induced	B-UNK
diabetes	B-DISEASE
insipidus	I-DISEASE
is	O
reported	B-UNK
.	O
At	O
necropsy	O
microscopy	B-UNK
shoed	O
unique	B-UNK
and	O
extensive	B-UNK
damage	B-UNK
to	O
cells	B-UNK
lining	O
the	O
distal	B-UNK
nephron	O
.	O
It	O
is	O
suggested	B-UNK
that	O
these	O
changes	B-UNK
represent	B-UNK
a	O
specific	B-UNK
toxic	B-UNK
effect	B-UNK
of	O
lithium	B-CHEMICAL
,	O
reported	B-UNK
here	O
for	O
the	O
first	O
time	B-UNK
in	O
man	B-UNK
.	O

Etiologic	O
factors	B-UNK
in	O
the	O
pathogenesis	O
of	O
liver	B-DISEASE
tumors	B-UNK
associated	B-UNK
with	O
oral	B-UNK
contraceptives	O
.	O

Within	O
the	O
last	O
several	O
years	B-UNK
,	O
previously	B-UNK
rare	B-UNK
liver	B-DISEASE
tumors	B-UNK
have	O
been	O
seen	B-UNK
in	O
young	B-UNK
women	B-UNK
using	O
oral	B-UNK
contraceptive	O
steroids	B-CHEMICAL
.	O
The	O
Registry	O
for	O
Liver	B-UNK
Tumors	O
Associated	O
with	O
Oral	O
Contraceptives	O
at	B-DISEASE
the	O
University	B-UNK
of	O
California	O
,	O
Irvine	O
,	O
has	O
clearly	B-UNK
identified	B-UNK
27	O
cases	B-UNK
.	O
The	O
recent	B-UNK
literature	B-UNK
contains	O
44	O
case	B-UNK
reports	B-UNK
.	O
Common	O
to	O
these	O
71	O
cases	B-UNK
has	O
been	O
a	O
histopathologic	O
diagnosis	B-UNK
of	O
focal	B-DISEASE
nodular	I-DISEASE
hyperplasia	I-DISEASE
,	O
adenoma	B-DISEASE
,	O
hamartoma	B-DISEASE
,	O
and	O
hepatoma	O
.	O
Significant	B-UNK
statistical	O
etiologic	O
factors	B-UNK
include	B-UNK
prolonged	B-UNK
uninterrupted	O
usage	B-UNK
of	O
oral	B-UNK
contraceptive	O
steroids	B-CHEMICAL
.	O
Eight	O
deaths	O
and	O
liver	B-DISEASE
rupture	B-DISEASE
in	O
18	O
patients	B-UNK
attest	O
to	O
the	O
seriousness	O
of	O
this	O
new	B-UNK
potentially	B-UNK
lethal	B-UNK
adverse	B-UNK
phenomenon	B-UNK
.	O

Graft	O
-	O
versus	B-UNK
-	O
host	O
disease	B-DISEASE
prophylaxis	B-UNK
with	O
everolimus	B-CHEMICAL
and	O
tacrolimus	B-CHEMICAL
is	O
associated	B-UNK
with	O
a	O
high	B-UNK
incidence	B-UNK
of	O
sinusoidal	B-UNK
obstruction	O
syndrome	B-DISEASE
and	O
microangiopathy	O
:	O
results	B-UNK
of	O
the	O
EVTAC	O
trial	B-UNK
.	O

A	O
calcineurin	B-UNK
inhibitor	B-UNK
combined	B-UNK
with	O
methotrexate	B-CHEMICAL
is	O
the	O
standard	B-UNK
prophylaxis	B-UNK
for	O
graft	O
-	O
versus	B-UNK
-	O
host	O
disease	B-DISEASE
(	O
GVHD	O
)	O
after	O
allogeneic	O
hematopoietic	O
stem	B-UNK
cell	I-UNK
transplantation	I-UNK
(	O
HSCT	O
)	O
.	O
Everolimus	O
,	O
a	O
derivative	B-UNK
of	O
sirolimus	B-CHEMICAL
,	O
seems	O
to	O
mediate	O
antileukemia	O
effects	B-UNK
.	O
We	O
report	B-UNK
on	O
a	O
combination	B-UNK
of	O
everolimus	B-CHEMICAL
and	O
tacrolimus	B-CHEMICAL
in	O
24	O
patients	B-UNK
(	O
median	B-UNK
age	B-UNK
,	O
62	O
years	B-UNK
)	O
with	O
either	O
myelodysplastic	O
syndrome	B-DISEASE
(	O
MDS	O
;	O
n	B-UNK
=	O
17	B-DISEASE
)	O
or	O
acute	B-UNK
myeloid	O
leukemia	B-DISEASE
(	O
AML	O
;	O
n	B-UNK
=	O
7	O
)	O
undergoing	B-UNK
intensive	B-UNK
conditioning	O
followed	B-UNK
by	O
HSCT	O
from	O
related	B-UNK
(	O
n	B-UNK
=	O
4	O
)	O
or	O
unrelated	O
(	O
n	B-UNK
=	O
20	O
)	O
donors	O
.	O
All	O
patients	B-UNK
engrafted	O
,	O
and	O
only	O
1	O
patient	B-UNK
experienced	B-UNK
grade	B-UNK
IV	B-UNK
mucositis	B-DISEASE
.	O
Nine	O
patients	B-UNK
(	O
37	O
%	O
)	O
developed	B-UNK
acute	B-UNK
grade	B-UNK
II	B-UNK
-	O
IV	B-UNK
GVHD	O
,	O
and	O
11	O
of	O
17	B-DISEASE
evaluable	O
patients	B-UNK
(	O
64	O
%	O
)	O
developed	B-UNK
chronic	B-UNK
extensive	B-UNK
GVHD	O
.	O
Transplantation	O
-	O
associated	B-UNK
microangiopathy	O
(	O
TMA	O
)	O
occurred	B-UNK
in	O
7	O
patients	B-UNK
(	O
29	O
%	O
)	O
,	O
with	O
2	B-DISEASE
cases	B-UNK
of	O
acute	B-DISEASE
renal	I-DISEASE
failure	I-DISEASE
.	O
The	O
study	B-UNK
was	O
terminated	O
prematurely	O
because	O
an	O
additional	B-UNK
6	O
patients	B-UNK
(	O
25	O
%	O
)	O
developed	B-UNK
sinusoidal	B-UNK
obstruction	O
syndrome	B-DISEASE
(	O
SOS	O
)	O
,	O
which	O
was	O
fatal	B-UNK
in	O
2	B-DISEASE
cases	B-UNK
.	O
With	O
a	O
median	B-UNK
follow	B-UNK
-	O
up	O
of	O
26	O
months	B-UNK
,	O
the	O
2-year	O
overall	B-UNK
survival	B-UNK
rate	B-UNK
was	O
47	B-DISEASE
%	O
.	O
Although	O
this	O
new	B-UNK
combination	B-UNK
appears	B-UNK
to	O
be	O
effective	B-UNK
as	O
a	O
prophylactic	B-UNK
regimen	B-UNK
for	O
acute	B-UNK
GVHD	O
,	O
the	O
incidence	B-UNK
of	O
TMA	O
and	O
SOS	O
is	O
considerably	B-UNK
higher	B-UNK
than	O
seen	B-UNK
with	O
other	O
regimens	B-UNK
.	O

Effect	O
of	O
some	O
convulsants	B-CHEMICAL
on	O
the	O
protective	B-UNK
activity	B-UNK
of	O
loreclezole	B-CHEMICAL
and	O
its	O
combinations	B-UNK
with	O
valproate	O
or	O
clonazepam	B-CHEMICAL
in	O
amygdala	O
-	O
kindled	O
rats	B-UNK
.	O

Loreclezole	O
(	O
5	O
mg	B-UNK
/	O
kg	B-UNK
)	O
exerted	O
a	O
significant	B-UNK
protective	B-UNK
action	B-UNK
in	O
amygdala	O
-	O
kindled	O
rats	B-UNK
,	O
reducing	B-UNK
both	O
seizure	B-DISEASE
and	O
afterdischarge	O
durations	O
.	O
The	O
combinations	B-UNK
of	O
loreclezole	B-CHEMICAL
(	O
2.5	B-UNK
mg	B-UNK
/	O
kg	B-UNK
)	O
with	O
valproate	O
,	O
clonazepam	B-CHEMICAL
,	O
or	O
carbamazepine	B-CHEMICAL
(	O
applied	O
at	B-DISEASE
their	O
subprotective	O
doses	B-UNK
)	O
also	O
exhibited	B-UNK
antiseizure	O
effect	B-UNK
in	O
this	O
test	B-UNK
.	O
However	O
,	O
only	O
two	O
first	O
combinations	B-UNK
occurred	B-UNK
to	O
be	O
of	O
pharmacodynamic	O
nature	O
.	O
Among	O
several	O
chemoconvulsants	O
,	O
bicuculline	B-CHEMICAL
,	O
N	B-UNK
-	O
methyl	O
-	O
D	B-UNK
-	O
aspartic	B-CHEMICAL
acid	I-CHEMICAL
and	O
BAY	O
k-8644	O
(	O
the	O
opener	O
of	O
L	B-UNK
-	O
type	B-UNK
calcium	B-CHEMICAL
channels	O
)	O
reversed	B-UNK
the	O
protective	B-UNK
activity	B-UNK
of	O
loreclezole	B-CHEMICAL
alone	O
and	O
its	O
combination	B-UNK
with	O
valproate	O
.	O
On	O
the	O
other	O
hand	B-DISEASE
,	O
bicuculline	B-CHEMICAL
,	O
aminophylline	B-CHEMICAL
and	O
BAY	O
k-8644	O
inhibited	B-UNK
the	O
anticonvulsive	O
action	B-UNK
of	O
loreclezole	B-CHEMICAL
combined	B-UNK
with	O
clonazepam	B-CHEMICAL
.	O
The	O
results	B-UNK
support	B-UNK
the	O
hypothesis	O
that	O
the	O
protective	B-UNK
activity	B-UNK
of	O
loreclezole	B-CHEMICAL
and	O
its	O
combinations	B-UNK
with	O
other	O
antiepileptics	O
may	O
involve	B-UNK
potentiation	B-UNK
of	O
GABAergic	B-UNK
neurotransmission	B-UNK
and	O
blockade	B-UNK
of	O
L	B-UNK
-	O
type	B-UNK
of	O
calcium	B-CHEMICAL
channels	O
.	O

Acute	B-UNK
liver	B-DISEASE
failure	I-DISEASE
with	O
concurrent	O
bupropion	B-CHEMICAL
and	O
carbimazole	B-CHEMICAL
therapy	B-UNK
.	O

OBJECTIVE	O
:	O
To	O
report	B-UNK
a	O
case	B-UNK
of	O
fatal	B-UNK
liver	B-DISEASE
failure	I-DISEASE
possibly	B-UNK
associated	B-UNK
with	O
concurrent	O
use	B-UNK
of	O
bupropion	B-CHEMICAL
and	O
carbimazole	B-CHEMICAL
.	O
CASE	B-UNK
SUMMARY	B-UNK
:	O
A	O
41-year	O
-	O
old	B-UNK
Chinese	O
man	B-UNK
with	O
a	O
history	B-UNK
of	O
hyperthyroidism	B-DISEASE
had	O
been	O
treated	B-UNK
with	O
carbimazole	B-CHEMICAL
and	O
propranolol	B-CHEMICAL
for	O
the	O
past	B-UNK
5	O
years	B-UNK
.	O
He	O
received	B-UNK
a	O
10-day	O
course	B-UNK
of	O
bupropion	B-CHEMICAL
as	O
an	O
aid	O
for	O
smoking	O
cessation	B-UNK
10	O
weeks	B-UNK
prior	B-UNK
to	O
presentation	O
.	O
He	O
developed	B-UNK
acute	B-DISEASE
liver	I-DISEASE
failure	I-DISEASE
with	O
rapid	B-UNK
deterioration	B-UNK
of	O
renal	B-UNK
function	B-UNK
.	O
Liver	B-UNK
biopsy	I-UNK
showed	B-UNK
evidence	B-UNK
of	O
nonspecific	O
drug	B-UNK
-	O
induced	B-UNK
acute	B-UNK
liver	B-DISEASE
injury	B-UNK
.	O
His	O
condition	B-UNK
was	O
further	O
complicated	O
by	O
sepsis	B-DISEASE
and	O
coagulopathy	O
.	O
Death	O
resulted	B-UNK
19	O
days	B-UNK
after	O
the	O
onset	B-UNK
of	O
symptoms	B-UNK
.	O
The	O
likelihood	O
that	O
bupropion	B-CHEMICAL
induced	B-UNK
hepatotoxicity	O
in	O
our	O
patient	B-UNK
was	O
possible	B-UNK
,	O
based	B-UNK
on	O
the	O
Naranjo	B-UNK
probability	B-UNK
scale	B-UNK
.	O
DISCUSSION	O
:	O
Although	O
there	O
is	O
increasing	B-UNK
evidence	B-UNK
of	O
hepatotoxicity	O
induced	B-UNK
by	O
bupropion	B-CHEMICAL
,	O
this	O
is	O
the	O
first	O
case	B-UNK
of	O
fatality	O
that	O
could	O
have	O
resulted	B-UNK
from	O
acute	B-DISEASE
liver	I-DISEASE
failure	I-DISEASE
in	O
a	O
patient	B-UNK
receiving	B-UNK
bupropion	B-CHEMICAL
while	O
on	O
concomitant	B-UNK
treatment	B-UNK
with	O
carbimazole	B-CHEMICAL
.	O
CONCLUSIONS	O
:	O
Clinicians	O
should	O
be	O
aware	O
of	O
the	O
possibility	O
of	O
acute	B-UNK
liver	B-DISEASE
insult	O
induced	B-UNK
by	O
bupropion	B-CHEMICAL
given	B-UNK
concurrently	O
with	O
other	O
hepatotoxic	B-UNK
drugs	B-UNK
.	O

Long	O
term	B-UNK
hormone	B-UNK
therapy	B-UNK
for	O
perimenopausal	O
and	O
postmenopausal	B-UNK
women	B-UNK
.	O

BACKGROUND	O
:	O
Hormone	O
therapy	B-UNK
(	O
HT	B-UNK
)	O
is	O
widely	B-UNK
used	O
for	O
controlling	O
menopausal	O
symptoms	B-UNK
and	O
has	O
also	O
been	O
used	O
for	O
the	O
management	B-UNK
and	O
prevention	O
of	O
cardiovascular	B-DISEASE
disease	I-DISEASE
,	O
osteoporosis	B-DISEASE
and	O
dementia	B-DISEASE
in	O
older	O
women	B-UNK
.	O
This	O
is	O
an	O
updated	O
version	B-UNK
of	O
the	O
original	B-UNK
Cochrane	B-UNK
review	B-UNK
first	O
published	B-UNK
in	O
2005	O
.	O
OBJECTIVES	O
:	O
To	O
assess	B-UNK
the	O
effect	B-UNK
of	O
long	B-UNK
-	O
term	B-UNK
HT	B-UNK
on	O
mortality	B-UNK
,	O
cardiovascular	B-UNK
outcomes	B-UNK
,	O
cancer	B-UNK
,	O
gallbladder	B-DISEASE
disease	B-DISEASE
,	O
cognition	O
,	O
fractures	B-DISEASE
and	O
quality	O
of	O
life	B-UNK
.	O
SEARCH	O
STRATEGY	O
:	O
We	O
searched	O
the	O
following	B-UNK
databases	O
to	O
November	O
2007	O
:	O
Trials	O
Register	B-UNK
of	O
the	O
Cochrane	B-UNK
Menstrual	O
Disorders	B-UNK
and	O
Subfertility	O
Group	B-UNK
,	O
Cochrane	B-UNK
Central	B-UNK
Register	B-UNK
of	O
Controlled	O
Trials	O
,	O
MEDLINE	O
,	O
EMBASE	O
,	O
Biological	O
Abstracts	O
.	O
Also	O
relevant	B-UNK
non-indexed	O
journals	O
and	O
conference	O
abstracts	O
.	O
SELECTION	O
CRITERIA	O
:	O
Randomised	O
double-blind	B-UNK
trials	B-UNK
of	O
HT	B-UNK
versus	B-UNK
placebo	B-UNK
,	O
taken	O
for	O
at	B-DISEASE
least	O
one	O
year	B-UNK
by	O
perimenopausal	O
or	O
postmenopausal	B-UNK
women	B-UNK
.	O
HT	B-UNK
included	B-UNK
oestrogens	O
,	O
with	O
or	O
without	O
progestogens	O
,	O
via	O
oral	B-UNK
,	O
transdermal	O
,	O
subcutaneous	B-UNK
or	O
transnasal	O
routes	O
.	O
DATA	O
COLLECTION	O
AND	O
ANALYSIS	O
:	O
Two	O
authors	B-UNK
independently	B-UNK
assessed	B-UNK
trial	B-UNK
quality	O
and	O
extracted	O
data	B-UNK
.	O
MAIN	B-UNK
RESULTS	B-UNK
:	O
Nineteen	O
trials	B-UNK
involving	B-UNK
41,904	O
women	B-UNK
were	O
included	B-UNK
.	O
In	O
relatively	B-UNK
healthy	B-UNK
women	B-UNK
,	O
combined	B-UNK
continuous	B-UNK
HT	B-UNK
significantly	B-UNK
increased	B-UNK
the	O
risk	B-UNK
of	O
venous	B-UNK
thrombo	B-UNK
-	O
embolism	B-DISEASE
or	O
coronary	B-UNK
event	B-UNK
(	O
after	O
one	O
year'	O
s	O
use	B-UNK
)	O
,	O
stroke	B-UNK
(	O
after	O
three	O
years	B-UNK
)	O
,	O
breast	B-DISEASE
cancer	I-DISEASE
and	O
gallbladder	B-DISEASE
disease	B-DISEASE
.	O
Long	O
-	O
term	B-UNK
oestrogen	O
-	O
only	O
HT	B-UNK
significantly	B-UNK
increased	B-UNK
the	O
risk	B-UNK
of	O
venous	B-UNK
thrombo	B-UNK
-	O
embolism	B-DISEASE
,	O
stroke	B-UNK
and	O
gallbladder	B-DISEASE
disease	B-DISEASE
(	O
after	O
one	O
to	O
two	O
years	B-UNK
,	O
three	O
years	B-UNK
and	O
seven	O
years	B-UNK
'	O
use	B-UNK
respectively	O
)	O
,	O
but	O
did	O
not	O
significantly	B-UNK
increase	B-UNK
the	O
risk	B-UNK
of	O
breast	B-DISEASE
cancer	I-DISEASE
.	O
The	O
only	O
statistically	B-UNK
significant	I-UNK
benefits	O
of	O
HT	B-UNK
were	O
a	O
decreased	B-UNK
incidence	B-UNK
of	O
fractures	B-DISEASE
and	O
(	O
for	O
combined	B-UNK
HT	B-UNK
)	O
colon	B-DISEASE
cancer	I-DISEASE
,	O
with	O
long	B-UNK
-	O
term	B-UNK
use	B-UNK
.	O
Among	O
women	B-UNK
aged	B-UNK
over	O
65	O
who	O
were	O
relatively	B-UNK
healthy	B-UNK
(	O
i.e	O
.	O
generally	B-UNK
fit	O
,	O
without	O
overt	O
disease	B-DISEASE
)	O
and	O
taking	B-UNK
continuous	B-UNK
combined	B-UNK
HT	B-UNK
,	O
there	O
was	O
a	O
statistically	B-UNK
significant	I-UNK
increase	B-UNK
in	O
the	O
incidence	B-UNK
of	O
dementia	B-DISEASE
.	O
Among	O
women	B-UNK
with	O
cardiovascular	B-DISEASE
disease	I-DISEASE
,	O
long	B-UNK
-	O
term	B-UNK
use	B-UNK
of	O
combined	B-UNK
continuous	B-UNK
HT	B-UNK
significantly	B-UNK
increased	B-UNK
the	O
risk	B-UNK
of	O
venous	B-UNK
thrombo	B-UNK
-	O
embolism	B-DISEASE
.	O
One	O
trial	B-UNK
analysed	O
subgroups	O
of	O
2839	O
relatively	B-UNK
healthy	B-UNK
50	O
to	O
59	O
year	B-UNK
old	B-UNK
women	B-UNK
taking	B-UNK
combined	B-UNK
continuous	B-UNK
HT	B-UNK
and	O
1637	O
taking	B-UNK
oestrogen	O
-	O
only	O
HT	B-UNK
,	O
versus	B-UNK
similar	B-UNK
-	O
sized	O
placebo	B-UNK
groups	B-UNK
.	O
The	O
only	O
significantly	B-UNK
increased	B-UNK
risk	I-UNK
reported	B-UNK
was	O
for	O
venous	B-UNK
thrombo	B-UNK
-	O
embolism	B-DISEASE
in	O
women	B-UNK
taking	B-UNK
combined	B-UNK
continuous	B-UNK
HT	B-UNK
:	O
their	O
absolute	B-UNK
risk	B-UNK
remained	B-UNK
low	B-UNK
,	O
at	B-DISEASE
less	O
than	O
1/500	O
.	O
However	O
,	O
this	O
study	B-UNK
was	O
not	O
powered	O
to	O
detect	B-UNK
differences	B-UNK
between	O
groups	B-UNK
of	O
younger	O
women	B-UNK
.	O
AUTHORS	O
'	O
CONCLUSIONS	O
:	O
HT	B-UNK
is	O
not	O
indicated	B-UNK
for	O
the	O
routine	B-UNK
management	B-UNK
of	O
chronic	B-DISEASE
disease	I-DISEASE
.	O
We	O
need	B-UNK
more	O
evidence	B-UNK
on	O
the	O
safety	B-UNK
of	O
HT	B-UNK
for	O
menopausal	O
symptom	O
control	B-UNK
,	O
though	O
short	B-UNK
-	O
term	B-UNK
use	B-UNK
appears	B-UNK
to	O
be	O
relatively	B-UNK
safe	B-UNK
for	O
healthy	B-UNK
younger	O
women	B-UNK
.	O

Passage	O
of	O
mannitol	B-CHEMICAL
into	O
the	O
brain	B-UNK
around	O
gliomas	O
:	O
a	O
potential	B-UNK
cause	B-UNK
of	O
rebound	B-UNK
phenomenon	B-UNK
.	O
A	O
study	B-UNK
on	O
21	O
patients	B-UNK
.	O

AIM	O
:	O
Widespread	O
use	B-UNK
of	O
mannitol	B-CHEMICAL
to	O
reduce	B-UNK
brain	B-DISEASE
edema	I-DISEASE
and	O
lower	B-UNK
elevated	B-UNK
ICP	O
in	O
brain	B-DISEASE
tumor	I-DISEASE
patients	B-UNK
continues	O
to	O
be	O
afflicted	O
by	O
the	O
so	O
-	O
called	O
rebound	B-UNK
phenomenon	B-UNK
.	O
Leakage	O
of	O
mannitol	B-CHEMICAL
into	O
the	O
brain	B-UNK
parenchyma	O
through	O
an	O
altered	B-UNK
BBB	O
and	O
secondary	B-UNK
reversal	B-UNK
of	O
osmotic	B-UNK
gradient	O
is	O
considered	B-UNK
the	O
major	B-UNK
cause	B-UNK
of	O
rebound	B-UNK
.	O
This	O
has	O
only	O
been	O
demonstrated	B-UNK
experimentally	B-UNK
in	O
animals	B-UNK
.	O
As	O
a	O
contribution	O
to	O
this	O
issue	O
we	O
decided	O
to	O
research	B-UNK
the	O
possible	B-UNK
passage	O
of	O
mannitol	B-CHEMICAL
into	O
the	O
brain	B-UNK
after	O
administration	B-UNK
to	O
21	O
brain	B-DISEASE
tumor	I-DISEASE
patients	B-UNK
.	O
METHODS	O
:	O
Mannitol	O
(	O
18	O
%	O
solution	B-UNK
;	O
1	O
g	B-UNK
/	O
kg	B-UNK
)	O
was	O
administered	B-UNK
as	O
a	O
bolus	B-UNK
to	O
patients	B-UNK
(	O
ten	B-DISEASE
had	O
malignant	B-UNK
glioma	B-DISEASE
,	O
seven	O
brain	B-DISEASE
metastases	I-DISEASE
and	O
four	O
meningioma	B-DISEASE
)	O
about	O
30	O
minutes	B-UNK
before	O
craniotomy	O
.	O
During	O
resection	O
,	O
a	O
sample	O
of	O
the	O
surrounding	O
edematous	O
white	B-UNK
matter	I-UNK
was	O
taken	O
at	B-DISEASE
the	O
same	O
time	B-UNK
as	O
a	O
10	O
ml	B-UNK
venous	B-UNK
blood	B-UNK
sample	O
.	O
Mannitol	O
concentrations	B-UNK
were	O
measured	B-UNK
in	O
plasma	B-UNK
and	O
white	B-UNK
matter	I-UNK
by	O
a	O
modified	B-UNK
version	B-UNK
of	O
the	O
enzyme	B-UNK
assay	B-UNK
of	O
Blonquist	O
et	O
al	O
.	O
RESULTS	B-UNK
:	O
In	O
most	O
glioma	B-DISEASE
patients	B-UNK
,	O
mannitol	B-CHEMICAL
concentrations	B-UNK
in	O
white	B-UNK
matter	I-UNK
were	O
2	B-DISEASE
to	O
6	O
times	B-UNK
higher	B-UNK
than	O
in	O
plasma	B-UNK
(	O
mean	B-UNK
3.5	B-UNK
times	B-UNK
)	O
.	O
In	O
meningioma	B-DISEASE
and	O
metastases	O
patients	B-UNK
plasma	B-UNK
concentrations	B-UNK
of	O
mannitol	B-CHEMICAL
were	O
higher	B-UNK
than	O
white	B-UNK
matter	I-UNK
concentrations	B-UNK
except	O
in	O
three	O
cases	B-UNK
with	O
infiltration	O
by	O
neoplastic	B-DISEASE
cells	I-DISEASE
.	O
CONCLUSIONS	O
:	O
The	O
results	B-UNK
of	O
our	O
study	B-UNK
show	O
that	O
even	O
after	O
a	O
single	B-UNK
bolus	B-UNK
,	O
mannitol	B-CHEMICAL
may	O
leak	O
through	O
the	O
altered	B-UNK
BBB	O
near	O
gliomas	O
,	O
reversing	O
the	O
initial	B-UNK
plasma	B-UNK
-	O
to	O
-	O
blood	B-UNK
osmotic	B-UNK
gradient	O
,	O
aggravating	O
peritumoral	O
edema	B-DISEASE
and	O
promoting	O
rebound	B-UNK
of	O
ICP	O
.	O

Can	O
lidocaine	B-CHEMICAL
reduce	B-UNK
succinylcholine	B-CHEMICAL
induced	B-UNK
postoperative	B-UNK
myalgia	B-DISEASE
?	O

This	O
study	B-UNK
was	O
undertaken	O
to	O
determine	B-UNK
the	O
effect	B-UNK
of	O
lidocaine	B-CHEMICAL
pretreatment	B-UNK
on	O
reduction	B-UNK
of	O
succinylcholine	B-CHEMICAL
-	O
induced	B-UNK
myalgia	B-DISEASE
in	O
patients	B-UNK
undergoing	B-UNK
general	B-UNK
anesthesia	B-UNK
for	O
gynecological	O
surgery	B-UNK
.	O
One	O
hundred	O
and	O
thirty	B-UNK
-	O
five	O
patients	B-UNK
were	O
assigned	B-UNK
to	O
one	O
of	O
three	O
groups	B-UNK
in	O
a	O
prospective	B-UNK
,	O
double	B-UNK
blind	B-UNK
,	O
randomized	B-UNK
manner	B-UNK
.	O
Group	B-UNK
PS	B-UNK
,	O
the	O
control	B-UNK
group	B-UNK
,	O
received	B-UNK
normal	B-UNK
saline	B-UNK
and	O
succinylcholine	B-CHEMICAL
1.5	B-UNK
mg	B-UNK
x	B-UNK
kg(-1	B-UNK
)	O
;	O
Group	B-UNK
LS	B-UNK
,	O
lidocaine	B-CHEMICAL
1.5	B-UNK
mg	B-UNK
x	B-UNK
kg(-1	B-UNK
)	O
and	O
succinylcholine	B-CHEMICAL
1.5	B-UNK
mg	B-UNK
x	B-UNK
kg(-1	B-UNK
)	O
;	O
Group	B-UNK
PR	B-UNK
,	O
normal	B-UNK
saline	B-UNK
and	O
rocuronium	B-CHEMICAL
0.6	B-UNK
mg	B-UNK
x	B-UNK
kg(-1	B-UNK
)	O
.	O
Morphine	O
0.1	B-UNK
mg	B-UNK
x	B-UNK
kg(-1	B-UNK
)	O
iv	B-UNK
was	O
given	B-UNK
for	O
premedication	O
and	O
all	O
patients	B-UNK
were	O
monitored	B-UNK
with	O
a	O
noninvasive	O
blood	B-UNK
pressure	B-UNK
monitor	O
,	O
ECG	B-UNK
and	O
pulse	B-UNK
oximetry	O
.	O
Anesthesia	O
was	O
induced	B-UNK
with	O
5	O
mg.kg(-1	O
)	O
thiopental	B-CHEMICAL
iv	B-UNK
.	O
followed	B-UNK
by	O
succinylcholine	B-CHEMICAL
(	O
Group	B-UNK
PS	B-UNK
,	O
LS	B-UNK
)	O
or	O
rocuronium	B-CHEMICAL
(	O
Group	B-UNK
PR	B-UNK
)	O
for	O
tracheal	B-UNK
intubation	O
.	O
Following	O
administration	B-UNK
of	O
these	O
agents	B-UNK
,	O
the	O
presence	O
,	O
and	O
degree	B-UNK
of	O
fasciculation	B-DISEASE
were	O
assessed	B-UNK
visually	O
on	O
a	O
four	O
point	O
scale	B-UNK
by	O
one	O
investigator	O
who	O
was	O
blinded	O
to	O
the	O
drug	B-UNK
administered	B-UNK
.	O
The	O
blood	B-UNK
pressure	B-UNK
and	O
heart	B-UNK
rate	I-UNK
of	O
each	O
patient	B-UNK
were	O
monitored	B-UNK
on	O
nine	O
occasions	B-UNK
.	O
Twenty	O
-	O
four	O
hours	B-UNK
later	B-UNK
,	O
any	O
myalgia	B-DISEASE
experienced	B-UNK
was	O
assessed	B-UNK
according	B-UNK
to	O
a	O
structured	O
questionaire	O
and	O
graded	O
by	O
a	O
four	O
point	O
scale	B-UNK
by	O
one	O
investigator	O
blinded	O
to	O
the	O
intraoperative	O
management	B-UNK
.	O
The	O
results	B-UNK
indicate	B-UNK
that	O
muscle	B-UNK
fasciculation	B-DISEASE
was	O
not	O
found	B-UNK
in	O
Group	B-UNK
PR	B-UNK
while	O
the	O
patients	B-UNK
in	O
Group	B-UNK
LS	B-UNK
had	O
a	O
lower	B-UNK
incidence	B-UNK
of	O
muscle	B-UNK
fasciculation	B-DISEASE
than	O
those	O
in	O
Group	B-UNK
PS	B-UNK
(	O
p	B-UNK
<	I-UNK
0.001	B-UNK
)	O
.	O
At	O
24	O
h	B-UNK
,	O
the	O
incidence	B-UNK
of	O
myalgia	B-DISEASE
was	O
higher	B-UNK
in	O
Group	B-UNK
PS	B-UNK
than	O
in	O
Group	B-UNK
LS	B-UNK
and	O
PR	B-UNK
(	O
p	B-UNK
<	I-UNK
0.05	O
)	O
.	O
A	O
correlation	B-UNK
was	O
not	O
found	B-UNK
between	O
the	O
incidence	B-UNK
of	O
myalgia	B-DISEASE
and	O
the	O
occurrence	O
of	O
muscle	B-UNK
fasciculation	B-DISEASE
.	O
The	O
changes	B-UNK
in	O
systolic	B-UNK
and	O
diastolic	B-UNK
blood	B-UNK
pressure	B-UNK
and	O
heart	B-UNK
rate	I-UNK
were	O
not	O
significant	B-UNK
among	O
the	O
three	O
groups	B-UNK
.	O
In	O
conclusion	O
,	O
where	O
succinylcholine	B-CHEMICAL
is	O
used	O
,	O
lidocaine	B-CHEMICAL
is	O
proven	B-UNK
to	O
be	O
the	O
useful	B-UNK
pretreatment	B-UNK
agent	B-UNK
for	O
the	O
reduction	B-UNK
of	O
postoperative	B-UNK
myalgia	B-DISEASE
.	O

Open	O
-	O
label	O
assessment	B-UNK
of	O
levofloxacin	B-CHEMICAL
for	O
the	O
treatment	B-UNK
of	O
acute	B-UNK
bacterial	O
sinusitis	B-DISEASE
in	O
adults	O
.	O

PURPOSE	O
:	O
To	O
evaluate	B-UNK
the	O
efficacy	B-UNK
and	O
safety	B-UNK
of	O
levofloxacin	B-CHEMICAL
(	O
500	O
mg	B-UNK
orally	B-UNK
once	O
daily	B-UNK
for	O
10	O
to	O
14	O
days	B-UNK
)	O
in	O
treating	B-UNK
adult	B-UNK
outpatients	O
with	O
acute	B-UNK
bacterial	O
sinusitis	B-DISEASE
.	O
PATIENTS	O
AND	O
METHODS	O
:	O
A	O
total	B-UNK
of	O
329	O
patients	B-UNK
enrolled	O
in	O
the	O
study	B-UNK
at	B-DISEASE
24	O
centers	O
.	O
All	O
patients	B-UNK
had	O
a	O
pre	B-UNK
-	O
therapy	B-UNK
Gram'	O
s	O
stain	O
and	O
culture	O
of	O
sinus	B-UNK
exudate	O
obtained	B-UNK
by	O
antral	B-CHEMICAL
puncture	O
or	O
nasal	O
endoscopy	O
.	O
Clinical	B-UNK
response	B-UNK
was	O
assessed	B-UNK
on	O
the	O
basis	B-UNK
of	O
signs	B-DISEASE
and	I-DISEASE
symptoms	I-DISEASE
and	O
sinus	B-UNK
radiograph	O
or	O
computed	O
tomography	B-UNK
results	B-UNK
.	O
Microbiologic	O
cure	O
rates	B-UNK
were	O
determined	O
on	O
the	O
basis	B-UNK
of	O
presumed	O
plus	B-UNK
documented	B-UNK
eradication	B-UNK
of	O
the	O
pre	B-UNK
-	O
therapy	B-UNK
pathogen(s	O
)	O
.	O
RESULTS	B-UNK
:	O
The	O
most	O
common	B-UNK
pathogens	O
were	O
Haemophilus	O
influenzae	O
,	O
Streptococcus	O
pneumoniae	O
,	O
Staphylococcus	O
aureus	O
,	O
and	O
Moraxella	O
catarrhalis	O
.	O
Of	O
300	O
clinically	B-UNK
evaluable	O
patients	B-UNK
,	O
175	O
(	O
58	O
%	O
)	O
were	O
cured	O
and	O
90	O
(	O
30	O
%	O
)	O
were	O
improved	B-UNK
at	B-DISEASE
the	O
post-therapy	B-UNK
evaluation	B-UNK
,	O
resulting	B-UNK
in	O
a	O
clinical	B-UNK
success	O
rate	B-UNK
of	O
88	O
%	O
.	O
Thirty	O
-	O
five	O
patients	B-UNK
(	O
12	O
%	O
)	O
clinically	B-UNK
failed	B-UNK
treatment	B-UNK
.	O
The	O
microbiologic	O
eradication	B-UNK
rate	B-UNK
(	O
presumed	O
plus	B-UNK
documented	B-UNK
)	O
among	O
138	O
microbiologically	O
evaluable	O
patients	B-UNK
was	O
92	O
%	O
.	O
Microbiologic	O
eradication	B-UNK
rates	B-UNK
(	O
presumed	O
plus	B-UNK
documented	B-UNK
)	O
of	O
the	O
most	O
common	B-UNK
pathogens	O
ranged	B-UNK
from	O
93	O
%	O
(	O
M.	O
catarrhalis	O
)	O
to	O
100	O
%	O
(	O
S.	O
pneumoniae	O
)	O
at	B-DISEASE
the	O
post-therapy	B-UNK
visit	O
.	O
All	O
but	O
one	O
of	O
the	O
265	O
patients	B-UNK
who	O
were	O
cured	O
or	O
improved	B-UNK
at	B-DISEASE
post-therapy	B-UNK
returned	B-UNK
for	O
a	O
long	B-UNK
-	O
term	B-UNK
follow	B-UNK
-	O
up	O
visit	O
;	O
243	O
(	O
92	O
%	O
)	O
remained	B-UNK
well	O
4	O
to	O
6	O
weeks	B-UNK
after	O
therapy	B-UNK
;	O
and	O
21	O
(	O
8	O
%	O
)	O
had	O
a	O
relapse	O
of	O
symptoms	B-UNK
.	O
Adverse	B-UNK
events	B-UNK
considered	B-UNK
to	O
be	O
related	B-UNK
to	O
levofloxacin	B-CHEMICAL
administration	B-UNK
were	O
reported	B-UNK
by	O
29	O
patients	B-UNK
(	O
9	O
%	O
)	O
.	O
The	O
most	O
common	B-UNK
drug	B-UNK
-	O
related	B-UNK
adverse	B-UNK
events	B-UNK
were	O
diarrhea	B-DISEASE
,	O
flatulence	B-DISEASE
,	O
and	O
nausea	B-DISEASE
;	O
most	O
adverse	B-UNK
events	B-UNK
were	O
mild	B-UNK
to	O
moderate	B-UNK
in	O
severity	B-UNK
.	O
CONCLUSION	O
:	O
The	O
results	B-UNK
of	O
this	O
study	B-UNK
indicate	B-UNK
that	O
levofloxacin	B-CHEMICAL
500	O
mg	B-UNK
once	O
daily	B-UNK
is	O
an	O
effective	B-UNK
and	O
safe	B-UNK
treatment	B-UNK
for	O
acute	B-UNK
bacterial	O
sinusitis	B-DISEASE
.	O

Clinical	B-UNK
evaluation	B-UNK
on	O
combined	B-UNK
administration	B-UNK
of	O
oral	B-UNK
prostacyclin	O
analogue	B-UNK
beraprost	B-CHEMICAL
and	O
phosphodiesterase	O
inhibitor	B-UNK
cilostazol	B-CHEMICAL
.	O

Among	O
various	O
oral	B-UNK
antiplatelets	O
,	O
a	O
combination	B-UNK
of	O
a	O
novel	B-UNK
prostacyclin	O
analogue	B-UNK
beraprost	B-CHEMICAL
(	O
BPT	O
)	O
and	O
a	O
potent	B-UNK
phosphodiesterase	O
inhibitor	B-UNK
cilostazol	B-CHEMICAL
(	O
CLZ	O
)	O
may	O
result	B-UNK
in	O
untoward	O
clinical	B-UNK
effects	B-UNK
due	O
to	O
possible	B-UNK
synergistic	O
elevation	B-UNK
of	O
intracellular	B-UNK
cAMP	B-UNK
(	O
cyclic	O
adenosine	B-CHEMICAL
3',5'-monophosphate	O
)	O
.	O
Thereby	O
,	O
a	O
clinical	B-UNK
study	B-UNK
of	O
the	O
combined	B-UNK
administration	B-UNK
of	O
the	O
two	O
agents	B-UNK
was	O
attempted	O
.	O
Twelve	O
healthy	B-UNK
volunteers	O
were	O
assigned	B-UNK
to	O
take	O
BPT	O
/	O
CLZ	O
in	O
the	O
following	B-UNK
schedule	B-UNK
;	O
BPT	O
:	O
40	O
micrograms	B-UNK
at	B-DISEASE
day	B-UNK
1	O
and	O
120	O
micrograms	B-UNK
t.i.d	O
.	O
from	O
day	B-UNK
7	O
to	O
14	O
,	O
CLZ	O
:	O
200	O
mg	B-UNK
t.i.d	O
.	O
from	O
day	B-UNK
3	O
to	O
14	O
.	O
At	O
various	O
time	B-UNK
intervals	B-UNK
,	O
physical	B-UNK
examination	B-UNK
and	O
blood	B-UNK
collection	O
for	O
ex	B-UNK
vivo	B-UNK
platelet	B-DISEASE
aggregation	I-DISEASE
and	O
determination	O
of	O
intraplatelet	O
cAMP	B-UNK
were	O
performed	B-UNK
.	O
Throughout	O
the	O
observation	B-UNK
period	B-UNK
,	O
no	O
significant	B-UNK
alteration	O
in	O
vital	O
signs	B-UNK
was	O
observed	B-UNK
.	O
Seven	O
out	O
of	O
12	O
subjects	B-UNK
experienced	B-UNK
headache	B-DISEASE
of	O
a	O
short	B-UNK
duration	B-UNK
accompanying	O
facial	B-UNK
flush	O
in	O
one	O
and	O
nausea	B-DISEASE
in	O
one	O
,	O
especially	B-UNK
after	O
ingestion	B-UNK
of	O
CLZ	O
.	O
All	O
of	O
these	O
symptoms	B-UNK
,	O
probably	B-UNK
caused	B-UNK
by	O
the	O
vasodilating	O
effect	B-UNK
of	O
the	O
two	O
agents	B-UNK
,	O
were	O
of	O
mild	B-UNK
degree	B-UNK
and	O
no	O
special	O
treatment	B-UNK
was	O
required	B-UNK
.	O
Intraplatelet	O
cAMP	B-UNK
content	B-UNK
was	O
gradually	B-UNK
but	O
significantly	B-UNK
increased	B-UNK
to	O
9.84	O
+	O
/-	O
4.59	O
pmol	O
per	O
10(9	O
)	O
platelets	O
at	B-DISEASE
day	B-UNK
14	O
in	O
comparison	O
with	O
the	O
initial	B-UNK
value	B-UNK
(	O
6.87	O
+	O
/-	O
2.25	O
pmol	O
)	O
.	O
The	O
platelet	B-UNK
aggregability	O
was	O
significantly	B-UNK
suppressed	B-UNK
at	B-DISEASE
various	O
time	B-UNK
intervals	B-UNK
but	O
no	O
additive	O
or	O
synergistic	O
inhibitory	B-UNK
effect	B-UNK
by	O
the	O
combined	B-UNK
administration	B-UNK
was	O
noted	O
.	O
In	O
conclusion	O
,	O
the	O
combined	B-UNK
administration	B-UNK
of	O
BPT	O
/	O
CLZ	O
is	O
safe	B-UNK
at	B-DISEASE
doses	B-UNK
used	O
in	O
the	O
study	B-UNK
,	O
though	O
the	O
beneficial	B-UNK
clinical	B-UNK
effect	B-UNK
of	O
the	O
combined	B-UNK
administration	B-UNK
has	O
yet	O
to	O
be	O
elucidated	O
.	O

Gastrointestinal	O
tolerability	B-UNK
of	O
etoricoxib	B-CHEMICAL
in	O
rheumatoid	B-DISEASE
arthritis	I-DISEASE
patients	B-UNK
:	O
results	B-UNK
of	O
the	O
etoricoxib	B-CHEMICAL
vs	B-UNK
diclofenac	B-CHEMICAL
sodium	B-CHEMICAL
gastrointestinal	B-UNK
tolerability	B-UNK
and	O
effectiveness	O
trial	B-UNK
(	O
EDGE	O
-	O
II	B-UNK
)	O
.	O

OBJECTIVE	O
:	O
A	O
randomised	B-UNK
,	O
double-blind	B-UNK
study	B-UNK
to	O
compare	O
the	O
gastrointestinal	B-UNK
(	O
GI	B-UNK
)	O
tolerability	B-UNK
,	O
safety	B-UNK
and	O
efficacy	B-UNK
of	O
etoricoxib	B-CHEMICAL
and	O
diclofenac	B-CHEMICAL
in	O
patients	B-UNK
with	O
rheumatoid	B-DISEASE
arthritis	I-DISEASE
(	O
RA	B-UNK
)	O
.	O
PATIENTS	O
AND	O
METHODS	O
:	O
A	O
total	B-UNK
of	O
4086	O
patients	B-UNK
(	O
mean	B-UNK
age	B-UNK
60.8	O
years	B-UNK
)	O
diagnosed	B-UNK
with	O
RA	B-UNK
were	O
enrolled	O
and	O
received	B-UNK
etoricoxib	B-CHEMICAL
90	O
mg	B-UNK
daily	B-UNK
(	O
n	B-UNK
=	O
2032	O
)	O
or	O
diclofenac	B-CHEMICAL
75	O
mg	B-UNK
twice	B-UNK
daily	B-UNK
(	O
n	B-UNK
=	O
2054	O
)	O
.	O
Use	O
of	O
gastroprotective	O
agents	B-UNK
and	O
low	B-UNK
-	O
dose	B-UNK
aspirin	B-CHEMICAL
was	O
allowed	O
.	O
The	O
prespecified	O
primary	B-UNK
end	B-UNK
point	O
consisted	B-UNK
of	O
the	O
cumulative	B-UNK
rate	B-UNK
of	O
patient	B-UNK
discontinuations	O
due	O
to	O
clinical	B-UNK
and	O
laboratory	B-UNK
GI	B-UNK
adverse	B-UNK
experiences	O
(	O
AEs	B-UNK
)	O
.	O
General	O
safety	B-UNK
was	O
also	O
assessed	B-UNK
,	O
including	B-UNK
adjudicated	O
thrombotic	O
cardiovascular	B-UNK
event	B-UNK
data	B-UNK
.	O
Efficacy	O
was	O
evaluated	B-UNK
using	O
the	O
Patient	O
Global	O
Assessment	B-UNK
of	O
Disease	B-UNK
Status	B-UNK
(	O
PGADS	O
;	O
0	O
-	O
4	O
point	O
scale	B-UNK
)	O
.	O
RESULTS	B-UNK
:	O
Mean	O
(	O
SD	B-UNK
;	O
maximum	B-UNK
)	O
duration	B-UNK
of	O
treatment	B-UNK
was	O
19.3	O
(	O
10.3	O
;	O
32.9	O
)	O
and	O
19.1	O
(	O
10.4	O
;	O
33.1	O
)	O
months	B-UNK
in	O
the	O
etoricoxib	B-CHEMICAL
and	O
diclofenac	B-CHEMICAL
groups	B-UNK
,	O
respectively	O
.	O
The	O
cumulative	B-UNK
discontinuation	B-UNK
rate	B-UNK
due	O
to	O
GI	B-UNK
AEs	B-UNK
was	O
significantly	B-UNK
lower	B-UNK
with	O
etoricoxib	B-CHEMICAL
than	O
diclofenac	B-CHEMICAL
(	O
5.2	O
vs	B-UNK
8.5	O
events	B-UNK
per	O
100	O
patient	B-UNK
-	O
years	B-UNK
,	O
respectively	O
;	O
hazard	B-UNK
ratio	B-UNK
0.62	O
(	O
95	O
%	O
CI	B-UNK
:	O
0.47	O
,	O
0.81	O
;	O
p	B-UNK
<	I-UNK
or=0.001	O
)	O
)	O
.	O
The	O
incidence	B-UNK
of	O
discontinuations	O
for	O
hypertension	B-DISEASE
-	O
related	B-UNK
and	O
oedema	O
-	O
related	B-UNK
AEs	B-UNK
were	O
significantly	B-UNK
higher	B-UNK
with	O
etoricoxib	B-CHEMICAL
(	O
2.5	B-UNK
%	O
and	O
1.1	B-UNK
%	O
respectively	O
)	O
compared	B-UNK
with	O
diclofenac	B-CHEMICAL
(	O
1.5	B-UNK
%	O
and	O
0.4	O
%	O
respectively	O
;	O
p<0.001	O
for	O
hypertension	B-DISEASE
and	O
p<0.01	O
for	O
oedema	O
)	O
.	O
Etoricoxib	O
and	O
diclofenac	B-CHEMICAL
treatment	B-UNK
resulted	B-UNK
in	O
similar	B-UNK
efficacy	B-UNK
(	O
PGADS	O
mean	B-UNK
changes	B-UNK
from	O
baseline	B-UNK
-0.62	O
vs	B-UNK
-0.58	O
,	O
respectively	O
)	O
.	O
CONCLUSIONS	O
:	O
Etoricoxib	O
90	O
mg	B-UNK
demonstrated	B-UNK
a	O
significantly	B-UNK
lower	B-UNK
risk	B-UNK
for	O
discontinuing	O
treatment	B-UNK
due	O
to	O
GI	B-UNK
AEs	B-UNK
compared	B-UNK
with	O
diclofenac	B-CHEMICAL
150	O
mg	B-UNK
.	O
Discontinuations	O
from	O
renovascular	O
AEs	B-UNK
,	O
although	O
less	O
common	B-UNK
than	O
discontinuations	O
from	O
GI	B-UNK
AEs	B-UNK
,	O
were	O
significantly	B-UNK
higher	B-UNK
with	O
etoricoxib	B-CHEMICAL
.	O

Placebo	O
-	O
level	B-UNK
incidence	B-UNK
of	O
extrapyramidal	B-UNK
symptoms	B-UNK
(	O
EPS	O
)	O
with	O
quetiapine	B-UNK
in	O
controlled	B-UNK
studies	B-UNK
of	O
patients	B-UNK
with	O
bipolar	B-UNK
mania	B-DISEASE
.	O

OBJECTIVES	O
:	O
To	O
evaluate	B-UNK
extrapyramidal	B-UNK
symptoms	B-UNK
(	O
EPS	O
)	O
,	O
including	B-UNK
akathisia	B-DISEASE
,	O
with	O
quetiapine	B-UNK
in	O
patients	B-UNK
with	O
bipolar	B-UNK
mania	B-DISEASE
.	O
METHODS	O
:	O
Data	O
were	O
analyzed	B-UNK
from	O
four	O
similarly	O
designed	O
,	O
randomized	B-UNK
,	O
double-blind	B-UNK
,	O
3-	O
to	O
12-week	O
studies	B-UNK
.	O
Two	O
studies	B-UNK
evaluated	B-UNK
quetiapine	B-UNK
monotherapy	B-UNK
(	O
up	O
to	O
800	O
mg	B-UNK
/	O
day	B-UNK
)	O
(	O
n	B-UNK
=	O
209	O
)	O
versus	B-UNK
placebo	B-UNK
(	O
n	B-UNK
=	O
198	O
)	O
,	O
with	O
lithium	B-CHEMICAL
or	O
haloperidol	B-CHEMICAL
monotherapy	B-UNK
as	O
respective	B-UNK
active	B-UNK
controls	B-UNK
.	O
Two	O
studies	B-UNK
evaluated	B-UNK
quetiapine	B-UNK
(	O
up	O
to	O
800	O
mg	B-UNK
/	O
day	B-UNK
)	O
in	O
combination	B-UNK
with	O
a	O
mood	B-UNK
stabilizer	O
(	O
lithium	B-CHEMICAL
or	O
divalproex	O
,	O
QTP	B-UNK
+	I-UNK
Li	O
/	O
DVP	O
)	O
(	O
n	B-UNK
=	O
196	O
)	O
compared	B-UNK
to	O
placebo	B-UNK
and	O
mood	B-UNK
stabilizer	O
(	O
PBO	B-UNK
+	I-UNK
Li	O
/	O
DVP	O
)	O
(	O
n	B-UNK
=	O
203	O
)	O
.	O
Extrapyramidal	O
symptoms	B-UNK
were	O
evaluated	B-UNK
using	O
the	O
Simpson	O
-	O
Angus	O
Scale	B-UNK
(	O
SAS	O
)	O
,	O
the	O
Barnes	O
Akathisia	O
Rating	B-UNK
Scale	I-UNK
(	O
BARS	O
)	O
,	O
adverse	B-UNK
event	B-UNK
reports	B-UNK
and	O
anticholinergic	B-UNK
drug	B-UNK
usage	B-UNK
.	O
RESULTS	B-UNK
:	O
The	O
incidence	B-UNK
of	O
EPS	O
-	O
related	B-UNK
adverse	B-UNK
events	B-UNK
,	O
including	B-UNK
akathisia	B-DISEASE
,	O
was	O
no	O
different	B-UNK
with	O
quetiapine	B-UNK
monotherapy	B-UNK
(	O
12.9	O
%	O
)	O
than	O
with	O
placebo	B-UNK
(	O
13.1	O
%	O
)	O
.	O
Similarly	O
,	O
EPS	O
-	O
related	B-UNK
adverse	B-UNK
events	B-UNK
with	O
QTP	B-UNK
+	I-UNK
Li	O
/	O
DVP	O
(	O
21.4	O
%	O
)	O
were	O
no	O
different	B-UNK
than	O
with	O
PBO	B-UNK
+	I-UNK
Li	O
/	O
DVP	O
(	O
19.2	O
%	O
)	O
.	O
Adverse	B-UNK
events	B-UNK
related	B-UNK
to	O
EPS	O
occurred	B-UNK
in	O
59.6	O
%	O
of	O
patients	B-UNK
treated	B-UNK
with	O
haloperidol	B-CHEMICAL
(	O
n	B-UNK
=	O
99	O
)	O
monotherapy	B-UNK
,	O
whereas	O
26.5	O
%	O
of	O
patients	B-UNK
treated	B-UNK
with	O
lithium	B-CHEMICAL
(	O
n	B-UNK
=	O
98	O
)	O
monotherapy	B-UNK
experienced	B-UNK
adverse	B-UNK
events	B-UNK
related	B-UNK
to	O
EPS	O
.	O
The	O
incidence	B-UNK
of	O
akathisia	B-DISEASE
was	O
low	B-UNK
and	O
similar	B-UNK
with	O
quetiapine	B-UNK
monotherapy	B-UNK
(	O
3.3	O
%	O
)	O
and	O
placebo	B-UNK
(	O
6.1	O
%	O
)	O
,	O
and	O
with	O
QTP	B-UNK
+	I-UNK
Li	O
/	O
DVP	O
(	O
3.6	B-UNK
%	O
)	O
and	O
PBO	B-UNK
+	I-UNK
Li	O
/	O
DVP	O
(	O
4.9	O
%	O
)	O
.	O
Lithium	O
was	O
associated	B-UNK
with	O
a	O
significantly	B-UNK
higher	B-UNK
incidence	B-UNK
(	O
p	B-UNK
<	I-UNK
0.05	O
)	O
of	O
tremor	B-DISEASE
(	O
18.4	O
%	O
)	O
than	O
quetiapine	B-UNK
(	O
5.6	O
%	O
)	O
;	O
cerebellar	B-UNK
tremor	B-DISEASE
,	O
which	O
is	O
a	O
known	B-UNK
adverse	B-UNK
effect	B-UNK
of	O
lithium	B-CHEMICAL
,	O
may	O
have	O
contributed	O
to	O
the	O
elevated	B-UNK
rate	B-UNK
of	O
tremor	B-DISEASE
in	O
patients	B-UNK
receiving	B-UNK
lithium	B-CHEMICAL
therapy	B-UNK
.	O
Haloperidol	O
induced	B-UNK
a	O
significantly	B-UNK
higher	B-UNK
incidence	B-UNK
(	O
p	B-UNK
<	I-UNK
0.001	B-UNK
)	O
of	O
akathisia	B-DISEASE
(	O
33.3	O
%	O
versus	B-UNK
5.9	B-UNK
%	O
)	O
,	O
tremor	B-DISEASE
(	O
30.3	O
%	O
versus	B-UNK
7.8	O
%	O
)	O
,	O
and	O
extrapyramidal	B-UNK
syndrome	B-UNK
(	O
35.4	O
%	O
versus	B-UNK
5.9	B-UNK
%	O
)	O
than	O
quetiapine	B-UNK
.	O
No	O
significant	B-UNK
differences	B-UNK
were	O
observed	B-UNK
between	O
quetiapine	B-UNK
and	O
placebo	B-UNK
on	O
SAS	O
and	O
BARS	O
scores	B-UNK
.	O
Anticholinergic	O
use	B-UNK
was	O
low	B-UNK
and	O
similar	B-UNK
with	O
quetiapine	B-UNK
or	O
placebo	B-UNK
.	O
CONCLUSIONS	O
:	O
In	O
bipolar	B-UNK
mania	B-DISEASE
,	O
the	O
incidence	B-UNK
of	O
EPS	O
,	O
including	B-UNK
akathisia	B-DISEASE
,	O
with	O
quetiapine	B-UNK
therapy	B-UNK
is	O
similar	B-UNK
to	O
that	O
with	O
placebo	B-UNK
.	O

Contribution	O
of	O
the	O
sympathetic	B-UNK
nervous	B-UNK
system	I-UNK
to	O
salt	B-UNK
-	O
sensitivity	B-UNK
in	O
lifetime	O
captopril	B-CHEMICAL
-	O
treated	B-UNK
spontaneously	B-UNK
hypertensive	B-UNK
rats	B-UNK
.	O

OBJECTIVE	O
:	O
To	O
test	B-UNK
the	O
hypothesis	O
that	O
,	O
in	O
lifetime	O
captopril	B-CHEMICAL
-	O
treated	B-UNK
spontaneously	B-UNK
hypertensive	B-UNK
rats	B-UNK
(	O
SHR	O
)	O
,	O
the	O
sympathetic	B-UNK
nervous	B-UNK
system	I-UNK
contributes	B-UNK
importantly	O
to	O
the	O
hypertensive	B-UNK
effect	B-UNK
of	O
dietary	O
sodium	B-CHEMICAL
chloride	I-CHEMICAL
supplementation	B-UNK
.	O
METHODS	O
:	O
Male	B-UNK
SHR	O
(	O
aged	B-UNK
6	O
weeks	B-UNK
)	O
that	O
had	O
been	O
treated	B-UNK
from	O
conception	O
onward	O
with	O
either	O
captopril	B-CHEMICAL
or	O
vehicle	B-UNK
remained	B-UNK
on	O
a	O
basal	B-UNK
sodium	B-CHEMICAL
chloride	I-CHEMICAL
diet	B-UNK
or	O
were	O
fed	B-UNK
a	O
high	B-UNK
sodium	B-CHEMICAL
chloride	I-CHEMICAL
diet	B-UNK
.	O
After	O
2	B-DISEASE
weeks	B-UNK
,	O
the	O
rats	B-UNK
were	O
subjected	O
to	O
ganglionic	B-UNK
blockade	B-UNK
and	O
2	B-DISEASE
days	B-UNK
later	B-UNK
,	O
an	O
infusion	B-UNK
of	O
clonidine	B-CHEMICAL
.	O
RESULTS	B-UNK
:	O
Lifetime	O
captopril	B-CHEMICAL
treatment	B-UNK
significantly	I-UNK
lowered	O
mean	B-UNK
arterial	B-UNK
pressure	I-UNK
in	O
both	O
groups	B-UNK
.	O
Intravenous	B-UNK
infusion	B-UNK
of	O
the	O
ganglionic	B-UNK
blocker	B-UNK
hexamethonium	B-CHEMICAL
resulted	B-UNK
in	O
a	O
rapid	B-UNK
decline	O
in	O
MAP	O
that	O
eliminated	O
the	O
dietary	O
sodium	B-CHEMICAL
chloride	I-CHEMICAL
-	O
induced	B-UNK
increase	B-UNK
in	O
MAP	O
in	O
both	O
groups	B-UNK
.	O
Infusion	O
of	O
the	O
central	B-UNK
nervous	I-UNK
system	B-UNK
alpha2-adrenergic	O
receptor	B-UNK
agonist	B-UNK
clonidine	B-CHEMICAL
also	O
resulted	B-UNK
in	O
a	O
greater	B-UNK
reduction	B-UNK
in	O
MAP	O
in	O
both	O
groups	B-UNK
of	O
SHR	O
that	O
were	O
fed	B-UNK
the	O
high	B-UNK
(	O
compared	B-UNK
with	O
the	O
basal	B-UNK
)	O
sodium	B-CHEMICAL
chloride	I-CHEMICAL
diet	B-UNK
.	O
CONCLUSIONS	O
:	O
In	O
both	O
lifetime	O
captopril	B-CHEMICAL
-	O
treated	B-UNK
and	O
control	B-UNK
SHR	O
,	O
the	O
sympathetic	B-UNK
nervous	B-UNK
system	I-UNK
contributes	B-UNK
to	O
the	O
pressor	B-UNK
effects	B-UNK
of	O
a	O
high	B-UNK
sodium	B-CHEMICAL
chloride	I-CHEMICAL
diet	B-UNK
.	O

Dose	B-UNK
-	O
related	B-UNK
beneficial	B-UNK
and	O
adverse	B-UNK
effects	B-UNK
of	O
dietary	O
corticosterone	B-CHEMICAL
on	O
organophosphorus	O
-	O
induced	B-UNK
delayed	B-UNK
neuropathy	B-DISEASE
in	O
chickens	B-UNK
.	O

Tri-ortho-tolyl	O
phosphate	B-UNK
(	O
TOTP	O
)	O
,	O
360	O
mg	B-UNK
/	O
kg	B-UNK
,	O
po	O
,	O
and	O
0,0'-diisopropyl	O
phosphorofluoridate	O
(	O
DFP	O
)	O
,	O
1	O
mg	B-UNK
/	O
kg	B-UNK
sc	O
,	O
were	O
administered	B-UNK
to	O
adult	B-UNK
White	O
Leghorn	O
chickens	B-UNK
24	O
hr	B-UNK
after	O
they	O
were	O
placed	O
on	O
diets	B-UNK
containing	B-UNK
0	O
to	O
300	O
ppm	O
corticosterone	B-CHEMICAL
.	O
Supplemented	O
diets	B-UNK
were	O
continued	B-UNK
until	O
clinical	B-UNK
signs	B-UNK
and	O
lesions	B-UNK
of	O
delayed	B-UNK
neuropathy	B-DISEASE
appeared	B-UNK
.	O
Although	O
low	B-UNK
concentrations	B-UNK
(	O
less	O
than	O
or	O
equal	O
to	O
50	O
ppm	O
)	O
of	O
corticosterone	B-CHEMICAL
had	O
beneficial	B-UNK
effects	B-UNK
on	O
TOTP	O
-	O
induced	B-UNK
neuropathy	B-DISEASE
,	O
greater	B-UNK
than	O
or	O
equal	O
to	O
200	O
ppm	O
exacerbated	B-UNK
clinical	B-UNK
signs	B-UNK
in	O
chickens	B-UNK
given	B-UNK
either	O
TOTP	O
or	O
DFP	O
.	O
Neurotoxic	O
esterase	O
activities	B-UNK
24	O
hr	B-UNK
after	O
TOTP	O
or	O
DFP	O
were	O
less	O
than	O
20	O
%	O
of	O
values	B-UNK
measured	B-UNK
in	O
chickens	B-UNK
not	O
given	B-UNK
organophosphorous	O
compounds	B-UNK
.	O
Chickens	O
given	B-UNK
200	O
ppm	O
corticosterone	B-CHEMICAL
without	O
TOTP	O
or	O
DFP	O
had	O
significantly	B-UNK
elevated	B-UNK
activity	B-UNK
of	O
plasma	B-UNK
cholinesterase	B-UNK
and	O
significantly	B-UNK
inhibited	B-UNK
activity	B-UNK
of	O
liver	B-DISEASE
carboxylesterase	O
.	O
Degenerating	O
myelinated	O
fibers	B-UNK
were	O
also	O
evident	O
in	O
distal	B-UNK
levels	B-UNK
of	O
the	O
peripheral	B-UNK
nerves	B-UNK
of	O
chickens	B-UNK
given	B-UNK
TOTP	O
or	O
DFP	O
.	O

In	O
vivo	B-UNK
characterization	O
of	O
a	O
dual	B-UNK
adenosine	B-CHEMICAL
A2A	O
/	O
A1	O
receptor	B-UNK
antagonist	I-UNK
in	O
animal	B-UNK
models	B-UNK
of	O
Parkinson'	O
s	O
disease	B-DISEASE
.	O

The	O
in	O
vivo	B-UNK
characterization	O
of	O
a	O
dual	B-UNK
adenosine	B-CHEMICAL
A(2A)/A(1	O
)	O
receptor	B-UNK
antagonist	I-UNK
in	O
several	O
animal	B-UNK
models	B-UNK
of	O
Parkinson'	O
s	O
disease	B-DISEASE
is	O
described	B-UNK
.	O
Discovery	O
and	O
scale	B-UNK
-	O
up	O
syntheses	O
of	O
compound	B-UNK
1	O
are	O
described	B-UNK
in	O
detail	O
,	O
highlighting	O
optimization	O
steps	O
that	O
increased	B-UNK
the	O
overall	B-UNK
yield	O
of	O
1	O
from	O
10.0	O
%	O
to	O
30.5	O
%	O
.	O
Compound	O
1	O
is	O
a	O
potent	B-UNK
A(2A)/A(1	O
)	O
receptor	B-UNK
antagonist	I-UNK
in	O
vitro	B-UNK
(	O
A(2A	O
)	O
K(i	O
)	O
=	O
4.1	O
nM	O
;	O
A(1	O
)	O
K(i	O
)	O
=	O
17.0	O
nM	O
)	O
that	O
has	O
excellent	O
activity	B-UNK
,	O
after	O
oral	B-UNK
administration	B-UNK
,	O
across	O
a	O
number	B-UNK
of	O
animal	B-UNK
models	B-UNK
of	O
Parkinson'	O
s	O
disease	B-DISEASE
including	B-UNK
mouse	B-UNK
and	O
rat	B-UNK
models	B-UNK
of	O
haloperidol	B-CHEMICAL
-	O
induced	B-UNK
catalepsy	B-DISEASE
,	O
mouse	B-UNK
model	B-UNK
of	O
reserpine	B-CHEMICAL
-	O
induced	B-UNK
akinesia	O
,	O
rat	B-UNK
6-hydroxydopamine	O
(	O
6-OHDA	O
)	O
lesion	B-UNK
model	B-UNK
of	O
drug	B-UNK
-	O
induced	B-UNK
rotation	B-UNK
,	O
and	O
MPTP	O
-	O
treated	B-UNK
non-human	O
primate	O
model	B-UNK
.	O

An	O
extremely	O
rare	B-UNK
case	B-UNK
of	O
delusional	B-DISEASE
parasitosis	I-DISEASE
in	O
a	O
chronic	B-UNK
hepatitis	B-DISEASE
C	B-UNK
patient	B-UNK
during	O
pegylated	B-UNK
interferon	I-UNK
alpha-2b	O
and	O
ribavirin	B-CHEMICAL
treatment	B-UNK
.	O

During	O
treatment	B-UNK
of	O
chronic	B-UNK
hepatitis	B-DISEASE
C	B-UNK
patients	B-UNK
with	O
interferon	O
and	O
ribavirin	B-CHEMICAL
,	O
a	O
lot	O
of	O
side	O
effects	B-UNK
are	O
described	B-UNK
.	O
Twenty	O
-	O
three	O
percent	O
to	O
44	O
%	O
of	O
patients	B-UNK
develop	B-UNK
depression	B-DISEASE
.	O
A	O
minority	O
of	O
patients	B-UNK
evolve	O
to	O
psychosis	B-UNK
.	O
To	O
the	O
best	B-UNK
of	O
our	O
knowledge	O
,	O
no	O
cases	B-UNK
of	O
psychogenic	O
parasitosis	O
occurring	B-UNK
during	O
interferon	O
therapy	B-UNK
have	O
been	O
described	B-UNK
in	O
the	O
literature	B-UNK
.	O
We	O
present	B-UNK
a	O
49-year	O
-	O
old	B-UNK
woman	B-UNK
who	O
developed	B-UNK
a	O
delusional	B-DISEASE
parasitosis	I-DISEASE
during	O
treatment	B-UNK
with	O
pegylated	B-UNK
interferon	I-UNK
alpha-2b	O
weekly	O
and	O
ribavirin	B-CHEMICAL
.	O
She	O
complained	O
of	O
seeing	O
parasites	O
and	O
the	O
larvae	O
of	O
fleas	O
in	O
her	O
stools	O
.	O
This	O
could	O
not	O
be	O
confirmed	B-UNK
by	O
any	O
technical	O
examination	B-UNK
.	O
All	O
the	O
complaints	O
disappeared	B-UNK
after	O
stopping	O
pegylated	B-UNK
interferon	I-UNK
alpha-2b	O
and	O
reappeared	O
after	O
restarting	O
it	O
.	O
She	O
had	O
a	O
complete	B-UNK
sustained	B-UNK
viral	O
response	B-UNK
.	O

Possible	O
neuroleptic	B-DISEASE
malignant	I-DISEASE
syndrome	I-DISEASE
related	B-UNK
to	O
concomitant	B-UNK
treatment	B-UNK
with	O
paroxetine	B-CHEMICAL
and	O
alprazolam	B-CHEMICAL
.	O

A	O
74-year	O
-	O
old	B-UNK
man	B-UNK
with	O
depressive	O
symptoms	B-UNK
was	O
admitted	O
to	O
a	O
psychiatric	B-UNK
hospital	B-UNK
due	O
to	O
insomnia	B-DISEASE
,	O
loss	B-UNK
of	O
appetite	B-UNK
,	O
exhaustion	O
,	O
and	O
agitation	O
.	O
Medical	B-UNK
treatment	B-UNK
was	O
initiated	O
at	B-DISEASE
a	O
daily	B-UNK
dose	B-UNK
of	O
20	O
mg	B-UNK
paroxetine	B-CHEMICAL
and	O
1.2	O
mg	B-UNK
alprazolam	B-CHEMICAL
.	O
On	O
the	O
10th	O
day	B-UNK
of	O
paroxetine	B-CHEMICAL
and	O
alprazolam	B-CHEMICAL
treatment	B-UNK
,	O
the	O
patient	B-UNK
exhibited	B-UNK
marked	B-UNK
psychomotor	B-UNK
retardation	B-UNK
,	O
disorientation	O
,	O
and	O
severe	B-UNK
muscle	B-DISEASE
rigidity	I-DISEASE
with	O
tremors	O
.	O
The	O
patient	B-UNK
had	O
a	O
fever	B-DISEASE
(	O
38.2	O
degrees	O
C	B-UNK
)	O
,	O
fluctuating	O
blood	B-UNK
pressure	B-UNK
(	O
between	O
165/90	O
and	O
130/70	O
mg	B-UNK
mm	B-UNK
Hg	B-UNK
)	O
,	O
and	O
severe	B-UNK
extrapyramidal	B-UNK
symptoms	B-UNK
.	O
Laboratory	B-UNK
tests	B-UNK
showed	B-UNK
an	O
elevation	B-UNK
of	O
creatine	B-DISEASE
phosphokinase	I-DISEASE
(	O
2218	O
IU	O
/	O
L	B-UNK
)	O
,	O
aspartate	B-UNK
aminotransferase	B-UNK
(	O
134	O
IU	O
/	O
L	B-UNK
)	O
,	O
alanine	B-CHEMICAL
aminotransferase	B-UNK
(	O
78	O
IU	O
/	O
L	B-UNK
)	O
,	O
and	O
BUN	O
(	O
27.9	O
mg	B-UNK
/	O
ml	B-UNK
)	O
levels	B-UNK
.	O
The	O
patient	B-UNK
received	B-UNK
bromocriptine	B-CHEMICAL
and	O
diazepam	B-CHEMICAL
to	O
treat	O
his	O
symptoms	B-UNK
.	O
7	O
days	B-UNK
later	B-UNK
,	O
the	O
fever	B-DISEASE
disappeared	B-UNK
and	O
the	O
patient'	O
s	O
serum	B-UNK
CPK	O
levels	B-UNK
were	O
normalized	B-UNK
(	O
175	O
IU	O
/	O
L	B-UNK
)	O
.	O
This	O
patient	B-UNK
presented	B-UNK
with	O
symptoms	B-UNK
of	O
neuroleptic	B-DISEASE
malignant	I-DISEASE
syndrome	I-DISEASE
(	O
NMS	O
)	O
,	O
thus	O
demonstrating	O
that	O
NMS	O
-	O
like	B-UNK
symptoms	B-UNK
can	O
occur	O
after	O
combined	B-UNK
paroxetine	B-CHEMICAL
and	O
alprazolam	B-CHEMICAL
treatment	B-UNK
.	O
The	O
adverse	B-UNK
drug	I-UNK
reaction	B-UNK
score	B-UNK
obtained	B-UNK
by	O
the	O
Naranjo	B-UNK
algorithm	O
was	O
6	O
in	O
our	O
case	B-UNK
,	O
indicating	O
a	O
probable	B-UNK
relationship	B-UNK
between	O
the	O
patient'	O
s	O
NMS	O
-	O
like	B-UNK
adverse	B-UNK
symptoms	B-UNK
and	O
the	O
combined	B-UNK
treatment	B-UNK
used	O
in	O
this	O
case	B-UNK
.	O
The	O
involvement	B-UNK
of	O
physiologic	O
and	O
environmental	O
aspects	O
specific	B-UNK
to	O
this	O
patient	B-UNK
was	O
suspected	O
.	O
Several	O
risk	B-UNK
factors	I-UNK
for	O
NMS	O
should	O
be	O
noted	O
in	O
elderly	B-UNK
depressive	O
patients	B-UNK
whose	O
symptoms	B-UNK
often	O
include	B-UNK
dehydration	B-DISEASE
,	O
agitation	O
,	O
malnutrition	B-DISEASE
,	O
and	O
exhaustion	O
.	O
Careful	O
therapeutic	B-UNK
intervention	O
is	O
necessary	O
in	O
cases	B-UNK
involving	B-UNK
elderly	B-UNK
patients	B-UNK
who	O
suffer	O
from	O
depression	B-DISEASE
.	O

Pilocarpine	O
seizures	B-DISEASE
cause	B-UNK
age	B-UNK
-	O
dependent	B-UNK
impairment	B-UNK
in	O
auditory	B-UNK
location	I-UNK
discrimination	B-UNK
.	O

Children	O
who	O
have	O
status	B-DISEASE
epilepticus	I-DISEASE
have	O
continuous	B-UNK
or	O
rapidly	B-UNK
repeating	O
seizures	B-DISEASE
that	O
may	O
be	O
life	B-UNK
-	O
threatening	O
and	O
may	O
cause	B-UNK
life	B-UNK
-	O
long	B-UNK
changes	B-UNK
in	O
brain	B-UNK
and	O
behavior	B-UNK
.	O
The	O
extent	B-UNK
to	O
which	O
status	B-DISEASE
epilepticus	I-DISEASE
causes	B-UNK
deficits	B-UNK
in	O
auditory	B-UNK
discrimination	B-UNK
is	O
unknown	B-UNK
.	O
A	O
naturalistic	O
auditory	B-UNK
location	I-UNK
discrimination	B-UNK
method	B-UNK
was	O
used	O
to	O
evaluate	B-UNK
this	O
question	O
using	O
an	O
animal	B-UNK
model	B-UNK
of	O
status	B-DISEASE
epilepticus	I-DISEASE
.	O
Male	B-UNK
Sprague	B-UNK
-	O
Dawley	B-UNK
rats	B-UNK
were	O
injected	B-UNK
with	O
saline	B-UNK
on	O
postnatal	O
day	B-UNK
(	O
P	B-UNK
)	O
20	O
,	O
or	O
a	O
convulsant	O
dose	B-UNK
of	O
pilocarpine	B-CHEMICAL
on	O
P20	O
or	O
P45	O
.	O
Pilocarpine	O
on	O
either	O
day	B-UNK
induced	B-UNK
status	B-DISEASE
epilepticus	I-DISEASE
;	O
status	B-DISEASE
epilepticus	I-DISEASE
at	B-DISEASE
P45	O
resulted	B-UNK
in	O
CA3	O
cell	B-UNK
loss	B-UNK
and	O
spontaneous	B-UNK
seizures	B-DISEASE
,	O
whereas	O
P20	O
rats	B-UNK
had	O
no	O
cell	B-UNK
loss	B-UNK
or	O
spontaneous	B-UNK
seizures	B-DISEASE
.	O
Mature	O
rats	B-UNK
were	O
trained	O
with	O
sound	O
-	O
source	B-UNK
location	O
and	O
sound	O
-	O
silence	O
discriminations	B-UNK
.	O
Control	B-UNK
(	O
saline	B-UNK
P20	O
)	O
rats	B-UNK
acquired	B-UNK
both	O
discriminations	B-UNK
immediately	B-UNK
.	O
In	O
status	B-DISEASE
epilepticus	I-DISEASE
(	O
P20	O
)	O
rats	B-UNK
,	O
acquisition	O
of	O
the	O
sound	O
-	O
source	B-UNK
location	B-UNK
discrimination	I-UNK
was	O
moderately	O
impaired	B-UNK
.	O
Status	B-UNK
epilepticus	O
(	O
P45	O
)	O
rats	B-UNK
failed	B-UNK
to	O
acquire	O
either	O
sound	O
-	O
source	B-UNK
location	O
or	O
sound	O
-	O
silence	O
discriminations	B-UNK
.	O
Status	B-UNK
epilepticus	O
in	O
rat	B-UNK
causes	B-UNK
an	O
age	B-UNK
-	O
dependent	B-UNK
,	O
long	B-UNK
-	O
term	B-UNK
impairment	B-UNK
in	O
auditory	B-UNK
discrimination	B-UNK
.	O
This	O
impairment	B-UNK
may	O
explain	O
one	O
cause	B-UNK
of	O
impaired	B-UNK
auditory	B-UNK
location	I-UNK
discrimination	B-UNK
in	O
humans	O
.	O

Cardiovascular	O
risk	B-UNK
with	O
cyclooxygenase	B-CHEMICAL
inhibitors	I-CHEMICAL
:	O
general	B-UNK
problem	B-UNK
with	O
substance	B-UNK
specific	B-UNK
differences	B-UNK
?	O

Randomised	O
clinical	B-UNK
trials	B-UNK
and	O
observational	O
studies	B-UNK
have	O
shown	B-UNK
an	O
increased	B-UNK
risk	I-UNK
of	O
myocardial	B-DISEASE
infarction	I-DISEASE
,	O
stroke	B-UNK
,	O
hypertension	B-DISEASE
and	O
heart	B-DISEASE
failure	I-DISEASE
during	O
treatment	B-UNK
with	O
cyclooxygenase	B-CHEMICAL
inhibitors	I-CHEMICAL
.	O
Adverse	B-UNK
cardiovascular	B-UNK
effects	B-UNK
occurred	B-UNK
mainly	B-UNK
,	O
but	O
not	O
exclusively	O
,	O
in	O
patients	B-UNK
with	O
concomitant	B-UNK
risk	B-UNK
factors	I-UNK
.	O
Cyclooxygenase	O
inhibitors	B-UNK
cause	B-UNK
complex	B-UNK
changes	B-UNK
in	O
renal	B-DISEASE
,	O
vascular	B-UNK
and	O
cardiac	B-UNK
prostanoid	O
profiles	B-UNK
thereby	O
increasing	B-UNK
vascular	B-UNK
resistance	B-UNK
and	O
fluid	B-UNK
retention	B-UNK
.	O
The	O
incidence	B-UNK
of	O
cardiovascular	B-UNK
adverse	B-UNK
events	B-UNK
tends	O
to	O
increase	B-UNK
with	O
the	O
daily	B-UNK
dose	B-UNK
and	O
total	B-UNK
exposure	B-UNK
time	B-UNK
.	O
A	O
comparison	O
of	O
individual	O
selective	B-UNK
and	O
unselective	O
cyclooxygenase	B-CHEMICAL
inhibitors	I-CHEMICAL
suggests	B-UNK
substance	B-UNK
-	O
specific	B-UNK
differences	B-UNK
,	O
which	O
may	O
depend	O
on	O
differences	B-UNK
in	O
pharmacokinetic	B-UNK
parameters	B-UNK
or	O
inhibitory	B-UNK
potency	B-UNK
and	O
may	O
be	O
contributed	O
by	O
prostaglandin	B-UNK
-	O
independent	B-UNK
effects	B-UNK
.	O
Diagnostic	O
markers	B-UNK
such	O
as	O
N	B-UNK
-	O
terminal	B-UNK
pro	O
brain	B-UNK
natriuretic	O
peptide	O
(	O
NT	O
-	O
proBNP	O
)	O
or	O
high	B-UNK
-	O
sensitive	B-UNK
C	B-UNK
-	O
reactive	B-UNK
protein	B-UNK
might	O
help	O
in	O
the	O
early	B-UNK
identification	B-UNK
of	O
patients	B-UNK
at	B-DISEASE
risk	B-UNK
,	O
thus	O
avoiding	O
the	O
occurrence	O
of	O
serious	O
cardiovascular	B-UNK
toxicity	B-UNK
.	O

Predictors	O
of	O
decreased	B-UNK
renal	B-UNK
function	B-UNK
in	O
patients	B-UNK
with	O
heart	B-DISEASE
failure	I-DISEASE
during	O
angiotensin	B-UNK
-	O
converting	B-UNK
enzyme	B-UNK
inhibitor	B-UNK
therapy	B-UNK
:	O
results	B-UNK
from	O
the	O
studies	B-UNK
of	O
left	B-UNK
ventricular	I-UNK
dysfunction	B-UNK
(	O
SOLVD	O
)	O

BACKGROUND	O
:	O
Although	O
angiotensin	B-UNK
-	O
converting	B-UNK
enzyme	B-UNK
inhibitor	B-UNK
therapy	B-UNK
reduces	B-UNK
mortality	B-UNK
rates	B-UNK
in	O
patients	B-UNK
with	O
congestive	B-DISEASE
heart	I-DISEASE
failure	I-DISEASE
(	O
CHF	O
)	O
,	O
it	O
may	O
also	O
cause	B-UNK
decreased	B-UNK
renal	B-UNK
function	B-UNK
.	O
Little	O
information	B-UNK
is	O
available	B-UNK
to	O
predict	O
which	O
patients	B-UNK
are	O
at	B-DISEASE
highest	B-UNK
risk	B-UNK
for	O
this	O
complication	B-UNK
.	O
OBJECTIVE	O
:	O
To	O
quantify	O
specific	B-UNK
clinical	B-UNK
predictors	O
of	O
reduction	B-UNK
in	O
renal	B-DISEASE
function	B-UNK
in	O
patients	B-UNK
with	O
CHF	O
who	O
are	O
prescribed	B-UNK
angiotensin	B-UNK
-	O
converting	B-UNK
enzyme	B-UNK
inhibitor	B-UNK
therapy	B-UNK
.	O
METHOD	O
:	O
We	O
analyzed	B-UNK
data	B-UNK
from	O
the	O
Studies	O
of	O
Left	O
Ventricular	B-UNK
Dysfunction	O
(	O
SOLVD	O
)	O
,	O
a	O
randomized	B-UNK
,	O
double-blind	B-UNK
,	O
placebo	B-UNK
-	O
controlled	B-UNK
trial	B-UNK
of	O
enalapril	B-CHEMICAL
for	O
the	O
treatment	B-UNK
of	O
CHF	O
.	O
There	O
were	O
3379	O
patients	B-UNK
randomly	B-UNK
assigned	B-UNK
to	O
enalapril	B-CHEMICAL
with	O
a	O
median	B-UNK
follow	B-UNK
-	O
up	O
of	O
974	O
days	B-UNK
and	O
3379	O
patients	B-UNK
randomly	B-UNK
assigned	B-UNK
to	O
placebo	B-UNK
with	O
a	O
mean	B-UNK
follow	B-UNK
-	O
up	O
of	O
967	O
days	B-UNK
.	O
Decreased	O
renal	B-DISEASE
function	B-UNK
was	O
defined	O
as	O
a	O
rise	B-UNK
in	O
serum	B-UNK
creatinine	B-CHEMICAL
>	O
/=0.5	O
mg	B-UNK
/	O
dL	O
(	O
44	O
micromol	B-UNK
/	O
L	B-UNK
)	O
from	O
baseline	B-UNK
.	O
We	O
used	O
time	B-UNK
-	O
to	O
-	O
event	B-UNK
analysis	B-UNK
to	O
identify	B-UNK
potential	B-UNK
predictors	O
of	O
decrease	B-UNK
in	O
renal	B-UNK
function	B-UNK
including	B-UNK
age	B-UNK
,	O
baseline	B-UNK
ejection	B-UNK
fraction	I-UNK
,	O
baseline	B-UNK
creatinine	B-CHEMICAL
,	O
low	B-UNK
systolic	B-UNK
blood	B-UNK
pressure	B-UNK
(	O
<	O
100	O
mm	B-UNK
Hg	B-UNK
)	O
,	O
history	B-UNK
of	O
hypertension	B-DISEASE
,	O
diabetes	B-DISEASE
,	O
and	O
use	B-UNK
of	O
antiplatelet	O
,	O
diuretic	B-UNK
,	O
and	O
beta-blocker	B-UNK
therapy	B-UNK
.	O
RESULTS	B-UNK
:	O
Patients	B-UNK
randomly	B-UNK
assigned	B-UNK
to	O
enalapril	B-CHEMICAL
had	O
a	O
33	O
%	O
greater	B-UNK
likelihood	O
of	O
decreased	B-UNK
renal	B-UNK
function	B-UNK
than	O
controls	B-UNK
(	O
P	B-UNK
=	I-UNK
.003	O
)	O
.	O
By	O
multivariate	B-UNK
analysis	B-UNK
,	O
in	O
both	O
the	O
placebo	B-UNK
and	O
enalapril	B-CHEMICAL
groups	B-UNK
older	O
age	B-UNK
,	O
diuretic	B-UNK
therapy	B-UNK
,	O
and	O
diabetes	B-DISEASE
were	O
associated	B-UNK
with	O
decreased	B-UNK
renal	B-UNK
function	B-UNK
,	O
whereas	O
beta-blocker	B-UNK
therapy	B-UNK
and	O
higher	B-UNK
ejection	B-UNK
fraction	I-UNK
were	O
renoprotective	O
.	O
Older	O
age	B-UNK
was	O
associated	B-UNK
with	O
a	O
greater	B-UNK
risk	B-UNK
of	O
developing	O
decreased	B-UNK
renal	B-UNK
function	B-UNK
in	O
both	O
groups	B-UNK
,	O
but	O
significantly	B-UNK
more	O
so	O
in	O
the	O
enalapril	B-CHEMICAL
group	B-UNK
(	O
enalapril	B-CHEMICAL
:	O
risk	B-UNK
ratio	B-UNK
[	O
RR	B-UNK
]	O
1.42	O
per	O
10	O
years	B-UNK
,	O
95	O
%	O
confidence	B-UNK
interval	I-UNK
[	O
CI	B-UNK
]	O
1.32	O
-	O
1.52	O
with	O
enalapril	B-CHEMICAL
;	O
placebo	B-UNK
:	O
RR	B-UNK
1.18	O
,	O
95	O
%	O
CI	B-UNK
1.12	O
-	O
1.25	O
)	O
.	O
Diuretic	O
therapy	B-UNK
was	O
likewise	O
associated	B-UNK
with	O
a	O
greater	B-UNK
risk	B-UNK
of	O
decreased	B-UNK
renal	B-UNK
function	B-UNK
in	O
the	O
enalapril	B-CHEMICAL
group	B-UNK
(	O
RR	B-UNK
1.89	O
,	O
95	O
%	O
CI	B-UNK
1.70	O
-	O
2.08	O
)	O
than	O
in	O
the	O
placebo	B-UNK
group	B-UNK
(	O
RR	B-UNK
1.35	O
,	O
95	O
%	O
CI	B-UNK
1.09	O
-	O
1.66	O
)	O
.	O
Conversely	O
,	O
enalapril	B-CHEMICAL
had	O
a	O
relative	B-UNK
renoprotective	O
effect	B-UNK
(	O
RR	B-UNK
1.33	O
,	O
95	O
%	O
CI	B-UNK
1.13	O
-	O
1.53	O
)	O
compared	B-UNK
with	O
placebo	B-UNK
(	O
RR	B-UNK
1.96	O
,	O
95	O
%	O
CI	B-UNK
1.57	O
-	O
2.44	O
)	O
in	O
patients	B-UNK
with	O
diabetes	B-DISEASE
.	O
A	O
lower	B-UNK
risk	B-UNK
of	O
renal	B-UNK
impairment	B-UNK
was	O
seen	B-UNK
in	O
both	O
groups	B-UNK
with	O
beta-blocker	B-UNK
therapy	B-UNK
(	O
RR	B-UNK
0.70	O
,	O
95	O
%	O
CI	B-UNK
0.57	O
-	O
0.85	O
)	O
and	O
higher	B-UNK
baseline	B-UNK
ejection	B-UNK
fraction	I-UNK
(	O
RR	B-UNK
0.93	O
per	O
5	O
%	O
increment	O
,	O
95	O
%	O
CI	B-UNK
0.91	O
-	O
0	O
.	O
96	O
)	O
.	O
CONCLUSIONS	O
:	O
Enalapril	O
use	B-UNK
caused	B-UNK
a	O
33	O
%	O
increase	B-UNK
in	O
the	O
risk	B-UNK
of	O
decreased	B-UNK
renal	B-UNK
function	B-UNK
in	O
patients	B-UNK
with	O
CHF	O
.	O
Diuretic	O
use	B-UNK
and	O
advanced	B-UNK
age	B-UNK
increased	B-UNK
this	O
risk	B-UNK
.	O
Diabetes	O
was	O
associated	B-UNK
with	O
an	O
increased	B-UNK
risk	I-UNK
of	O
renal	B-UNK
impairment	B-UNK
in	O
all	O
patients	B-UNK
with	O
CHF	O
,	O
but	O
this	O
risk	B-UNK
was	O
reduced	B-UNK
in	O
the	O
enalapril	B-CHEMICAL
group	B-UNK
compared	B-UNK
with	O
the	O
placebo	B-UNK
group	B-UNK
.	O
beta-Blocker	O
therapy	B-UNK
and	O
higher	B-UNK
ejection	B-UNK
fraction	I-UNK
were	O
renoprotective	O
in	O
all	O
patients	B-UNK
regardless	O
of	O
therapy	B-UNK
.	O

Pemoline	O
induced	B-UNK
acute	B-UNK
choreoathetosis	B-DISEASE
:	O
case	B-UNK
report	B-UNK
and	O
review	B-UNK
of	O
the	O
literature	B-UNK
.	O

BACKGROUND	O
:	O
Pemoline	O
is	O
an	O
oxazolidine	B-CHEMICAL
derivative	B-UNK
that	O
is	O
structurally	O
different	B-UNK
from	O
amphetamines	B-CHEMICAL
and	O
used	O
in	O
the	O
treatment	B-UNK
of	O
attention	B-UNK
deficit	B-UNK
disorder	B-UNK
.	O
Pemoline	O
has	O
not	O
been	O
commonly	B-UNK
associated	B-UNK
in	O
the	O
literature	B-UNK
as	O
a	O
cause	B-UNK
of	O
acute	B-UNK
movement	B-DISEASE
disorders	I-DISEASE
.	O
The	O
following	B-UNK
case	B-UNK
describes	B-UNK
two	O
children	B-UNK
acutely	B-UNK
poisoned	O
with	O
pemoline	B-CHEMICAL
who	O
experienced	B-UNK
profound	B-UNK
choreoathetosis	B-DISEASE
.	O
CASE	B-UNK
REPORT	O
:	O
Two	O
,	O
3-year	O
-	O
old	B-UNK
male	B-UNK
,	O
identical	B-UNK
twin	O
siblings	O
presented	B-UNK
to	O
the	O
emergency	B-UNK
department	B-UNK
after	O
found	B-UNK
playing	O
with	O
a	O
an	O
empty	O
bottle	O
of	O
pemoline	B-CHEMICAL
originally	O
containing	B-UNK
59	O
tablets	B-UNK
.	O
The	O
children	B-UNK
had	O
a	O
medical	B-UNK
history	B-UNK
significant	B-UNK
for	O
attention	B-UNK
deficit	B-UNK
disorder	B-UNK
previously	B-UNK
treated	B-UNK
with	O
methylphenidate	B-CHEMICAL
without	O
success	O
.	O
This	O
was	O
their	O
first	O
day	B-UNK
of	O
pemoline	B-CHEMICAL
therapy	B-UNK
.	O
The	O
choreoathetoid	B-UNK
movements	B-UNK
began	B-UNK
45	O
min	B-UNK
to	O
1	O
h	B-UNK
after	O
ingestion	B-UNK
.	O
The	O
children	B-UNK
gave	O
no	O
history	B-UNK
of	O
prior	B-UNK
movement	B-DISEASE
disorders	I-DISEASE
and	O
there	O
was	O
no	O
family	B-UNK
history	B-UNK
of	O
movement	B-DISEASE
disorders	I-DISEASE
.	O
The	O
children	B-UNK
received	B-UNK
gastrointestinal	B-UNK
decontamination	O
and	O
high	B-UNK
doses	B-UNK
of	O
intravenous	B-UNK
benzodiazepines	B-CHEMICAL
in	O
an	O
attempt	O
to	O
control	B-UNK
the	O
choreoathetoid	B-UNK
movements	B-UNK
.	O
Despite	B-UNK
treatment	B-UNK
,	O
the	O
children	B-UNK
continued	B-UNK
to	O
have	O
choreoathetosis	B-DISEASE
for	O
approximately	B-UNK
24	O
hours	B-UNK
.	O
Forty	O
-	O
eight	O
hours	B-UNK
after	O
admission	O
,	O
the	O
children	B-UNK
appeared	B-UNK
to	O
be	O
at	B-DISEASE
their	O
baseline	B-UNK
and	O
were	O
discharged	O
home	B-UNK
.	O
CONCLUSION	O
:	O
Pemoline	O
associated	B-UNK
movement	B-UNK
disorder	B-UNK
has	O
been	O
rarely	B-UNK
reported	B-UNK
in	O
the	O
acute	B-UNK
toxicology	O
literature	B-UNK
.	O
The	O
possibility	O
of	O
choreoathetoid	B-UNK
movements	B-UNK
should	O
be	O
considered	B-UNK
in	O
patients	B-UNK
presenting	O
after	O
pemoline	B-CHEMICAL
overdose	B-UNK
.	O

Continuous	B-UNK
subcutaneous	B-UNK
administration	B-UNK
of	O
mesna	B-CHEMICAL
to	O
prevent	B-UNK
ifosfamide	B-CHEMICAL
-	O
induced	B-UNK
hemorrhagic	B-UNK
cystitis	B-DISEASE
.	O

Hemorrhagic	O
cystitis	B-DISEASE
is	O
a	O
major	B-UNK
potential	B-UNK
toxicity	B-UNK
of	O
ifosfamide	B-CHEMICAL
that	O
can	O
be	O
prevented	B-UNK
by	O
administering	O
mesna	B-CHEMICAL
along	O
with	O
the	O
cytotoxic	B-UNK
agent	B-UNK
.	O
Mesna	O
is	O
generally	B-UNK
administered	B-UNK
by	O
the	O
intravenous	B-UNK
route	B-UNK
,	O
although	O
experience	B-UNK
with	O
oral	B-UNK
delivery	B-UNK
of	O
the	O
drug	B-UNK
has	O
increased	B-UNK
.	O
The	O
continuous	B-UNK
subcutaneous	B-UNK
administration	B-UNK
of	O
mesna	B-CHEMICAL
has	O
the	O
advantage	O
of	O
not	O
requiring	O
intravenous	B-UNK
access	B-UNK
.	O
In	O
addition	O
,	O
subcutaneous	B-UNK
delivery	B-UNK
of	O
the	O
neutralizing	O
agent	B-UNK
will	O
not	O
be	O
associated	B-UNK
with	O
the	O
risk	B-UNK
of	O
inadequate	O
urinary	B-UNK
mesna	B-CHEMICAL
concentrations	B-UNK
,	O
such	O
as	O
in	O
a	O
patient	B-UNK
taking	B-UNK
oral	B-UNK
mesna	B-CHEMICAL
who	O
experiences	O
severe	B-UNK
ifosfamide	B-CHEMICAL
-	O
induced	B-UNK
emesis	O
and	O
is	O
unable	O
to	O
absorb	O
the	O
drug	B-UNK
.	O
Limited	O
clinical	B-UNK
experience	B-UNK
with	O
continuous	B-UNK
subcutaneous	B-UNK
mesna	B-CHEMICAL
administration	B-UNK
suggests	B-UNK
it	O
is	O
a	O
safe	B-UNK
,	O
practical	O
,	O
and	O
economic	O
method	B-UNK
of	O
drug	B-UNK
delivery	B-UNK
that	O
permits	O
ifosfamide	B-CHEMICAL
to	O
be	O
administered	B-UNK
successfully	B-UNK
in	O
the	O
outpatient	B-UNK
setting	B-UNK
.	O

Modification	O
of	O
drug	B-UNK
action	B-UNK
by	O
hyperammonemia	B-DISEASE
.	O

Pretreatment	O
with	O
ammonium	B-CHEMICAL
acetate	I-CHEMICAL
(	O
NH4Ac	B-UNK
)	O
(	O
6	O
mmol	B-UNK
/	O
kg	B-UNK
s.c	B-UNK
.	O
)	O
approximately	B-UNK
doubled	O
the	O
time	B-UNK
morphine	B-CHEMICAL
-	O
treated	B-UNK
mice	B-UNK
remained	B-UNK
on	O
a	O
hot	B-UNK
surface	O
and	O
similarly	O
increased	B-UNK
muscular	B-UNK
incoordination	O
by	O
diazepam	B-CHEMICAL
,	O
but	O
NH4Ac	B-UNK
treatment	B-UNK
alone	O
had	O
no	O
effect	B-UNK
.	O
Thus	O
,	O
hyperammonemia	B-DISEASE
is	O
capable	O
of	O
altering	O
drug	B-UNK
action	B-UNK
and	O
must	O
be	O
considered	B-UNK
along	O
with	O
impaired	B-UNK
drug	B-DISEASE
metabolism	I-DISEASE
in	O
enhanced	B-UNK
drug	B-UNK
responses	B-UNK
associated	B-UNK
with	O
liver	B-DISEASE
disease	I-DISEASE
.	O
Experiments	O
in	O
vitro	B-UNK
showed	B-UNK
that	O
acetylcholine	B-CHEMICAL
-	O
induced	B-UNK
catecholamine	B-UNK
release	B-UNK
from	O
bovine	O
adrenal	O
medulla	B-UNK
is	O
depressed	B-UNK
as	O
much	O
as	O
50	O
%	O
by	O
0.3	B-UNK
mM	O
NH4Ac	B-UNK
and	O
KCl	O
-	O
induced	B-UNK
contractions	O
of	O
guinea	B-UNK
-	O
pig	O
ileum	O
were	O
inhibited	B-UNK
20	O
%	O
by	O
5	O
mM	O
NH4Ac	B-UNK
.	O
Addition	O
of	O
excess	B-UNK
calcium	B-CHEMICAL
reversed	B-UNK
the	O
depression	B-DISEASE
in	O
both	O
tissues	B-UNK
,	O
but	O
calcium	B-CHEMICAL
-	O
independent	B-UNK
catecholamine	B-UNK
release	B-UNK
by	O
acetaldehyde	B-CHEMICAL
was	O
not	O
blocked	B-UNK
by	O
NH4Ac	B-UNK
.	O
These	O
results	B-UNK
suggested	B-UNK
that	O
ammonia	B-CHEMICAL
blocks	O
calcium	B-CHEMICAL
channels	O
.	O
Parallels	O
in	O
the	O
actions	B-UNK
of	O
NH4Ac	B-UNK
and	O
the	O
calcium	B-CHEMICAL
channel	B-UNK
blocker	B-UNK
verapamil	B-CHEMICAL
support	B-UNK
this	O
concept	O
.	O
Both	O
verapamil	B-CHEMICAL
(	O
10	O
mg	B-UNK
/	O
kg	B-UNK
i.p	B-UNK
.	O
)	O
and	O
NH4Ac	B-UNK
pretreatment	B-UNK
enhanced	B-UNK
morphine	B-CHEMICAL
analgesia-	O
and	O
diazepam	B-CHEMICAL
-	O
induced	B-UNK
muscular	B-UNK
incoordination	O
and	O
antagonized	B-UNK
amphetamine	B-CHEMICAL
-	O
induced	B-UNK
motor	B-UNK
activity	B-UNK
,	O
and	O
neither	O
verapamil	B-CHEMICAL
nor	O
NH4Ac	B-UNK
affected	B-UNK
the	O
convulsant	O
action	B-UNK
of	O
metrazol	O
.	O
The	O
data	B-UNK
suggest	B-UNK
that	O
hyperammonemia	B-DISEASE
exerts	B-UNK
a	O
calcium	B-CHEMICAL
channel	B-UNK
blocking	B-UNK
action	B-UNK
which	O
enhances	O
the	O
effects	B-UNK
of	O
central	B-CHEMICAL
nervous	I-CHEMICAL
system	I-CHEMICAL
depressants	I-CHEMICAL
and	O
certain	B-UNK
opioid	B-UNK
analgesics	B-CHEMICAL
.	O

Risk	O
of	O
nephropathy	B-DISEASE
after	O
consumption	B-UNK
of	O
nonionic	O
contrast	B-CHEMICAL
media	I-CHEMICAL
by	O
children	B-UNK
undergoing	B-UNK
cardiac	B-UNK
angiography	B-UNK
:	O
a	O
prospective	B-UNK
study	B-UNK
.	O

Despite	B-UNK
increasing	B-UNK
reports	B-UNK
on	O
nonionic	O
contrast	B-CHEMICAL
media	I-CHEMICAL
-	O
induced	B-UNK
nephropathy	B-DISEASE
(	O
CIN	O
)	O
in	O
hospitalized	O
adult	B-UNK
patients	B-UNK
during	O
cardiac	B-UNK
procedures	B-UNK
,	O
the	O
studies	B-UNK
in	O
pediatrics	O
are	O
limited	O
,	O
with	O
even	O
less	O
focus	O
on	O
possible	B-UNK
predisposing	O
factors	B-UNK
and	O
preventive	O
measures	B-UNK
for	O
patients	B-UNK
undergoing	B-UNK
cardiac	B-UNK
angiography	B-UNK
.	O
This	O
prospective	B-UNK
study	B-UNK
determined	O
the	O
incidence	B-UNK
of	O
CIN	O
for	O
two	O
nonionic	O
contrast	B-CHEMICAL
media	I-CHEMICAL
(	O
CM	O
)	O
,	O
iopromide	B-CHEMICAL
and	O
iohexol	B-CHEMICAL
,	O
among	O
80	O
patients	B-UNK
younger	O
than	O
18	O
years	B-UNK
and	O
compared	B-UNK
the	O
rates	B-UNK
for	O
this	O
complication	B-UNK
in	O
relation	O
to	O
the	O
type	B-UNK
and	O
dosage	B-UNK
of	O
CM	O
and	O
the	O
presence	O
of	O
cyanosis	B-DISEASE
.	O
The	O
80	O
patients	B-UNK
in	O
the	O
study	B-UNK
consecutively	O
received	B-UNK
either	O
iopromide	B-CHEMICAL
(	O
group	B-UNK
A	O
,	O
n	B-UNK
=	O
40	O
)	O
or	O
iohexol	B-CHEMICAL
(	O
group	B-UNK
B	B-UNK
,	O
n	B-UNK
=	O
40	O
)	O
.	O
Serum	B-UNK
sodium	B-CHEMICAL
(	O
Na	O
)	O
,	O
potassium	B-CHEMICAL
(	O
K	O
)	O
,	O
and	O
creatinine	B-CHEMICAL
(	O
Cr	O
)	O
were	O
measured	B-UNK
24	O
h	B-UNK
before	O
angiography	B-UNK
as	O
baseline	B-UNK
values	B-UNK
,	O
then	O
measured	B-UNK
again	O
at	B-DISEASE
12-	O
,	O
24-	O
,	O
and	O
48-h	O
intervals	B-UNK
after	O
CM	O
use	B-UNK
.	O
Urine	B-UNK
samples	B-UNK
for	O
Na	O
and	O
Cr	O
also	O
were	O
checked	O
at	B-DISEASE
the	O
same	O
intervals	B-UNK
.	O
Risk	O
of	O
renal	B-DISEASE
failure	I-DISEASE
,	O
Injury	O
to	O
the	O
kidney	B-UNK
,	O
Failure	O
of	O
kidney	B-UNK
function	B-UNK
,	O
Loss	O
of	O
kidney	B-UNK
function	B-UNK
,	O
and	O
End	O
-	O
stage	B-UNK
renal	B-UNK
damage	B-UNK
(	O
RIFLE	O
criteria	B-UNK
)	O
were	O
used	O
to	O
define	B-UNK
CIN	O
and	O
its	O
incidence	B-UNK
in	O
the	O
study	B-UNK
population	B-UNK
.	O
Accordingly	O
,	O
among	O
the	O
15	O
CIN	O
patients	B-UNK
(	O
18.75	O
%	O
)	O
,	O
7.5	B-UNK
%	O
of	O
the	O
patients	B-UNK
in	O
group	B-UNK
A	O
had	O
increased	B-UNK
risk	I-UNK
and	O
3.75	O
%	O
had	O
renal	B-UNK
injury	B-UNK
,	O
whereas	O
5	O
%	O
of	O
group	B-UNK
B	B-UNK
had	O
increased	B-UNK
risk	I-UNK
and	O
2.5	B-UNK
%	O
had	O
renal	B-DISEASE
injury	B-UNK
.	O
Whereas	O
33.3	O
%	O
of	O
the	O
patients	B-UNK
with	O
CIN	O
were	O
among	O
those	O
who	O
received	B-UNK
the	O
proper	B-UNK
dosage	B-UNK
of	O
CM	O
,	O
the	O
percentage	B-UNK
increased	B-UNK
to	O
66.6	O
%	O
among	O
those	O
who	O
received	B-UNK
larger	B-UNK
doses	B-UNK
,	O
with	O
a	O
significant	B-UNK
difference	B-UNK
in	O
the	O
incidence	B-UNK
of	O
CIN	O
related	B-UNK
to	O
the	O
different	B-UNK
dosages	O
of	O
CM	O
(	O
p	B-UNK
=	I-UNK
0.014	O
)	O
.	O
Among	O
the	O
15	O
patients	B-UNK
with	O
CIN	O
,	O
6	O
had	O
cyanotic	O
congenital	B-DISEASE
heart	B-DISEASE
diseases	I-DISEASE
,	O
but	O
the	O
incidence	B-UNK
did	O
not	O
differ	B-UNK
significantly	B-UNK
from	O
that	O
for	O
the	O
noncyanotic	O
patients	B-UNK
(	O
p	B-UNK
=	I-UNK
0.243	O
)	O
.	O
Although	O
clinically	B-UNK
silent	O
,	O
CIN	O
is	O
not	O
rare	B-UNK
in	O
pediatrics	O
.	O
The	O
incidence	B-UNK
depends	O
on	O
dosage	B-UNK
but	O
not	O
on	O
the	O
type	B-UNK
of	O
consumed	O
nonionic	O
CM	O
,	O
nor	O
on	O
the	O
presence	O
of	O
cyanosis	B-DISEASE
,	O
and	O
although	O
CIN	O
usually	B-UNK
is	O
reversible	B-UNK
,	O
more	O
concern	O
is	O
needed	B-UNK
for	O
the	O
prevention	O
of	O
such	O
a	O
complication	B-UNK
in	O
children	B-UNK
.	O

A	O
case	B-UNK
of	O
ventricular	B-DISEASE
tachycardia	I-DISEASE
related	B-UNK
to	O
caffeine	B-CHEMICAL
pretreatment	B-UNK
.	O

Suboptimal	O
seizure	B-DISEASE
duration	B-UNK
is	O
commonly	B-UNK
encountered	B-UNK
in	O
electroconvulsive	B-UNK
therapy	B-UNK
practice	O
,	O
especially	B-UNK
in	O
older	O
patients	B-UNK
with	O
higher	B-UNK
seizure	B-UNK
thresholds	B-UNK
.	O
Intravenous	B-UNK
caffeine	B-CHEMICAL
is	O
commonly	B-UNK
used	O
to	O
improve	O
seizure	B-UNK
duration	B-UNK
and	O
quality	O
in	O
such	O
patients	B-UNK
and	O
is	O
generally	B-UNK
well	O
tolerated	B-UNK
aside	O
from	O
occasional	O
reports	B-UNK
of	O
relatively	B-UNK
benign	O
ventricular	B-UNK
ectopy	O
.	O
We	O
describe	O
a	O
patient	B-UNK
with	O
no	O
previous	B-UNK
history	B-UNK
of	O
cardiac	B-UNK
disease	B-DISEASE
or	O
arrhythmia	B-DISEASE
who	O
developed	B-UNK
sustained	B-UNK
bigeminy	O
and	O
2	B-DISEASE
brief	B-DISEASE
runs	O
of	O
ventricular	B-DISEASE
tachycardia	I-DISEASE
after	O
caffeine	B-CHEMICAL
administration	B-UNK
.	O
Although	O
intravenous	B-UNK
caffeine	B-CHEMICAL
is	O
generally	B-UNK
well	O
tolerated	B-UNK
,	O
the	O
clinician	O
should	O
be	O
aware	O
of	O
the	O
potential	B-UNK
for	O
unpredictable	O
and	O
serious	O
ventricular	B-UNK
arrhythmias	B-DISEASE
.	O

Optical	O
coherence	O
tomography	B-UNK
can	O
measure	B-UNK
axonal	O
loss	B-UNK
in	O
patients	B-UNK
with	O
ethambutol	B-CHEMICAL
-	O
induced	B-UNK
optic	B-DISEASE
neuropathy	I-DISEASE
.	O

PURPOSE	O
:	O
To	O
map	O
and	O
identify	B-UNK
the	O
pattern	B-UNK
,	O
in	O
vivo	B-UNK
,	O
of	O
axonal	O
degeneration	B-UNK
in	O
ethambutol	B-CHEMICAL
-	O
induced	B-UNK
optic	B-DISEASE
neuropathy	I-DISEASE
using	O
optical	B-UNK
coherence	O
tomography	B-UNK
(	O
OCT	B-UNK
)	O
.	O
Ethambutol	O
is	O
an	O
antimycobacterial	O
agent	B-UNK
often	O
used	O
to	O
treat	O
tuberculosis	B-DISEASE
.	O
A	O
serious	O
complication	B-UNK
of	O
ethambutol	B-CHEMICAL
is	O
an	O
optic	B-DISEASE
neuropathy	I-DISEASE
that	O
impairs	O
visual	B-UNK
acuity	B-UNK
,	O
contrast	B-UNK
sensitivity	B-UNK
,	O
and	O
color	O
vision	B-DISEASE
.	O
However	O
,	O
early	B-UNK
on	O
,	O
when	O
the	O
toxic	B-DISEASE
optic	I-DISEASE
neuropathy	I-DISEASE
is	O
mild	B-UNK
and	O
partly	O
reversible	B-UNK
,	O
the	O
funduscopic	O
findings	B-UNK
are	O
often	O
subtle	O
and	O
easy	O
to	O
miss	O
.	O
METHODS	O
:	O
Three	O
subjects	B-UNK
with	O
a	O
history	B-UNK
of	O
ethambutol	B-CHEMICAL
(	O
EMB)-induced	O
optic	B-DISEASE
neuropathy	I-DISEASE
of	O
short-	O
,	O
intermediate-	O
,	O
and	O
long	B-UNK
-	O
term	B-UNK
visual	B-UNK
deficits	I-UNK
were	O
administered	B-UNK
a	O
full	O
neuro-ophthalmologic	O
examination	B-UNK
including	B-UNK
visual	B-UNK
acuity	B-UNK
,	O
color	O
vision	B-DISEASE
,	O
contrast	B-UNK
sensitivity	B-UNK
,	O
and	O
fundus	O
examination	B-UNK
.	O
In	O
addition	O
,	O
OCT	B-UNK
(	O
OCT	B-UNK
3000	O
,	O
Humphrey	O
-	O
Zeiss	O
,	O
Dublin	O
,	O
CA	O
)	O
was	O
performed	B-UNK
on	O
both	O
eyes	B-UNK
of	O
each	O
subject	B-UNK
using	O
the	O
retinal	O
nerve	B-UNK
fiber	I-UNK
layer	B-UNK
(	O
RNFL	O
)	O
analysis	B-UNK
protocol	B-UNK
.	O
OCT	B-UNK
interpolates	O
data	B-UNK
from	O
100	O
points	B-UNK
around	O
the	O
optic	B-UNK
nerve	I-UNK
to	O
effectively	O
map	O
out	O
the	O
RNFL	O
.	O
RESULTS	B-UNK
:	O
The	O
results	B-UNK
were	O
compared	B-UNK
to	O
the	O
calculated	O
average	B-UNK
RNFL	O
of	O
normal	B-UNK
eyes	B-UNK
accumulated	O
from	O
four	O
prior	B-UNK
studies	B-UNK
using	O
OCT	B-UNK
,	O
n=661	O
.	O
In	O
all	O
subjects	B-UNK
with	O
history	B-UNK
of	O
EMB	O
-	O
induced	B-UNK
optic	B-DISEASE
neuropathy	I-DISEASE
,	O
there	O
was	O
a	O
mean	B-UNK
loss	B-UNK
of	O
72	O
%	O
nerve	B-UNK
fiber	I-UNK
layer	B-UNK
thickness	B-UNK
in	O
the	O
temporal	B-UNK
quadrant	O
(	O
patient	B-UNK
A	O
,	O
with	O
eventual	O
recovery	B-UNK
of	O
visual	B-UNK
acuity	B-UNK
and	O
fields	B-UNK
,	O
58	O
%	O
loss	B-UNK
;	O
patient	B-UNK
B	B-UNK
,	O
with	O
intermediate	O
visual	B-UNK
deficits	I-UNK
,	O
68	O
%	O
loss	B-UNK
;	O
patient	B-UNK
C	B-UNK
,	O
with	O
chronic	B-UNK
visual	B-UNK
deficits	I-UNK
,	O
90	O
%	O
loss	B-UNK
)	O
,	O
with	O
an	O
average	B-UNK
mean	B-UNK
optic	B-UNK
nerve	I-UNK
thickness	B-UNK
of	O
26+/-16	O
microm	B-UNK
.	O
There	O
was	O
a	O
combined	B-UNK
mean	B-UNK
loss	B-UNK
of	O
46	B-DISEASE
%	O
of	O
fibers	B-UNK
from	O
the	O
superior	B-UNK
,	O
inferior	B-UNK
,	O
and	O
nasal	O
quadrants	O
in	O
the	O
(	O
six	O
)	O
eyes	B-UNK
of	O
all	O
three	O
subjects	B-UNK
(	O
mean	B-UNK
average	B-UNK
thickness	B-UNK
of	O
55+/-29	O
microm	B-UNK
)	O
.	O
In	O
both	O
sets	O
(	O
four	O
)	O
of	O
eyes	B-UNK
of	O
the	O
subjects	B-UNK
with	O
persistent	O
visual	B-UNK
deficits	I-UNK
(	O
patients	B-UNK
B	B-UNK
and	O
C	B-UNK
)	O
,	O
there	O
was	O
an	O
average	B-UNK
loss	B-UNK
of	O
79	O
%	O
of	O
nerve	B-UNK
fiber	I-UNK
thickness	B-UNK
in	O
the	O
temporal	B-UNK
quadrant	O
.	O
CONCLUSIONS	O
:	O
The	O
OCT	B-UNK
results	B-UNK
in	O
these	O
patients	B-UNK
with	O
EMB	O
-	O
induced	B-UNK
optic	B-DISEASE
neuropathy	I-DISEASE
show	O
considerable	O
loss	B-UNK
especially	B-UNK
of	O
the	O
temporal	B-UNK
fibers	B-UNK
.	O
This	O
is	O
consistent	B-UNK
with	O
prior	B-UNK
histopathological	O
studies	B-UNK
that	O
show	O
predominant	B-UNK
loss	B-UNK
of	O
parvo	O
-	O
cellular	B-UNK
axons	O
(	O
or	O
small	B-UNK
-	O
caliber	O
axons	O
)	O
within	O
the	O
papillo	O
-	O
macular	O
bundle	B-UNK
in	O
toxic	B-UNK
or	O
hereditary	O
optic	B-UNK
neuropathies	O
.	O
OCT	B-UNK
can	O
be	O
a	O
valuable	O
tool	B-UNK
in	O
the	O
quantitative	B-UNK
analysis	B-UNK
of	O
optic	B-UNK
neuropathies	O
.	O
Additionally	O
,	O
in	O
terms	O
of	O
management	B-UNK
of	O
EMB	O
-	O
induced	B-UNK
optic	B-DISEASE
neuropathy	I-DISEASE
,	O
it	O
is	O
important	B-UNK
to	O
properly	O
manage	O
ethambutol	B-CHEMICAL
dosing	B-UNK
in	O
patients	B-UNK
with	O
renal	B-UNK
impairment	B-UNK
and	O
to	O
achieve	O
proper	B-UNK
transition	B-UNK
to	O
a	O
maintenance	B-UNK
dose	B-UNK
once	O
an	O
appropriate	B-UNK
loading	B-UNK
dose	I-UNK
has	O
been	O
reached	B-UNK
.	O

Effects	O
of	O
the	O
cyclooxygenase-2	O
specific	B-UNK
inhibitor	B-UNK
valdecoxib	B-CHEMICAL
versus	B-UNK
nonsteroidal	B-UNK
antiinflammatory	I-UNK
agents	B-UNK
and	O
placebo	B-UNK
on	O
cardiovascular	B-UNK
thrombotic	I-UNK
events	B-UNK
in	O
patients	B-UNK
with	O
arthritis	B-DISEASE
.	O

There	O
have	O
been	O
concerns	O
that	O
the	O
risk	B-UNK
of	O
cardiovascular	B-UNK
thrombotic	I-UNK
events	B-UNK
may	O
be	O
higher	B-UNK
with	O
cyclooxygenase	O
(	O
COX)-2-specific	O
inhibitors	B-UNK
than	O
nonselective	B-UNK
nonsteroidal	B-UNK
antiinflammatory	I-UNK
drugs	B-UNK
(	O
NSAIDs	B-UNK
)	O
.	O
We	O
evaluated	B-UNK
cardiovascular	B-UNK
event	B-UNK
data	B-UNK
for	O
valdecoxib	B-CHEMICAL
,	O
a	O
new	B-UNK
COX-2-specific	O
inhibitor	B-UNK
in	O
approximately	B-UNK
8000	O
patients	B-UNK
with	O
osteoarthritis	B-DISEASE
and	O
rheumatoid	B-DISEASE
arthritis	I-DISEASE
treated	B-UNK
with	O
this	O
agent	B-UNK
in	O
randomized	B-UNK
clinical	B-UNK
trials	B-UNK
.	O
The	O
incidence	B-UNK
of	O
cardiovascular	B-UNK
thrombotic	I-UNK
events	B-UNK
(	O
cardiac	B-UNK
,	O
cerebrovascular	O
and	O
peripheral	B-UNK
vascular	B-UNK
,	O
or	O
arterial	B-UNK
thrombotic	O
)	O
was	O
determined	O
by	O
analyzing	O
pooled	O
valdecoxib	B-CHEMICAL
(	O
10	O
-	O
80	O
mg	B-UNK
daily	B-UNK
)	O
,	O
nonselective	B-UNK
NSAID	O
(	O
diclofenac	B-CHEMICAL
75	O
mg	B-UNK
bid	B-UNK
,	O
ibuprofen	B-CHEMICAL
800	O
mg	B-UNK
tid	O
,	O
or	O
naproxen	B-CHEMICAL
500	O
mg	B-UNK
bid	B-UNK
)	O
and	O
placebo	B-UNK
data	B-UNK
from	O
10	O
randomized	B-UNK
osteoarthritis	B-DISEASE
and	O
rheumatoid	B-DISEASE
arthritis	I-DISEASE
trials	B-UNK
that	O
were	O
6	O
-	O
52	O
weeks	B-UNK
in	O
duration	B-UNK
.	O
The	O
incidence	B-UNK
rates	B-UNK
of	O
events	B-UNK
were	O
determined	O
in	O
all	O
patients	B-UNK
(	O
n	B-UNK
=	O
7934	O
)	O
and	O
in	O
users	B-UNK
of	O
low	B-UNK
-	O
dose	B-UNK
(	O
<	O
or	O
=	O
325	O
mg	B-UNK
daily	B-UNK
)	O
aspirin	B-CHEMICAL
(	O
n	B-UNK
=	O
1051	O
)	O
and	O
nonusers	O
of	O
aspirin	B-CHEMICAL
(	O
n	B-UNK
=	O
6883	O
)	O
.	O
Crude	O
and	O
exposure	B-UNK
-	O
adjusted	B-UNK
incidences	O
of	O
thrombotic	B-UNK
events	I-UNK
were	O
similar	B-UNK
for	O
valdecoxib	B-CHEMICAL
,	O
NSAIDs	B-UNK
,	O
and	O
placebo	B-UNK
.	O
The	O
risk	B-UNK
of	O
serious	O
thrombotic	B-UNK
events	I-UNK
was	O
also	O
similar	B-UNK
for	O
each	O
valdecoxib	B-CHEMICAL
dose	B-UNK
.	O
Thrombotic	O
risk	B-UNK
was	O
consistently	O
higher	B-UNK
for	O
users	B-UNK
of	O
aspirin	B-CHEMICAL
users	B-UNK
than	O
nonusers	O
of	O
aspirin	B-CHEMICAL
(	O
placebo	B-UNK
,	O
1.4	O
%	O
vs	B-UNK
.	O
0	O
%	O
;	O
valdecoxib	B-CHEMICAL
,	O
1.7	O
%	O
vs	B-UNK
.	O
0.2	B-UNK
%	O
;	O
NSAIDs	B-UNK
,	O
1.9	O
%	O
vs	B-UNK
.	O
0.5	B-UNK
%	O
)	O
.	O
The	O
rates	B-UNK
of	O
events	B-UNK
in	O
users	B-UNK
of	O
aspirin	B-CHEMICAL
were	O
similar	B-UNK
for	O
all	O
3	O
treatment	B-UNK
groups	B-UNK
and	O
across	O
valdecoxib	B-CHEMICAL
doses	B-UNK
.	O
Short-	O
and	O
intermediate	O
-	O
term	B-UNK
treatment	B-UNK
with	O
therapeutic	B-UNK
(	O
10	O
or	O
20	O
mg	B-UNK
daily	B-UNK
)	O
and	O
supratherapeutic	O
(	O
40	O
or	O
80	O
mg	B-UNK
daily	B-UNK
)	O
valdecoxib	B-CHEMICAL
doses	B-UNK
was	O
not	O
associated	B-UNK
with	O
an	O
increased	B-UNK
incidence	B-UNK
of	O
thrombotic	B-UNK
events	I-UNK
relative	B-UNK
to	O
nonselective	B-UNK
NSAIDs	B-UNK
or	O
placebo	B-UNK
in	O
osteoarthritis	B-DISEASE
and	O
rheumatoid	B-DISEASE
arthritis	I-DISEASE
patients	B-UNK
in	O
controlled	B-UNK
clinical	B-UNK
trials	B-UNK
.	O

A	O
randomized	B-UNK
,	O
placebo	B-UNK
-	O
controlled	B-UNK
,	O
crossover	B-UNK
study	B-UNK
of	O
ephedrine	B-CHEMICAL
for	O
SSRI	O
-	O
induced	B-UNK
female	B-DISEASE
sexual	I-DISEASE
dysfunction	I-DISEASE
.	O

The	O
objective	B-UNK
of	O
this	O
study	B-UNK
was	O
to	O
determine	B-UNK
whether	O
ephedrine	B-CHEMICAL
,	O
an	O
alpha-	O
and	O
beta-adrenergic	B-UNK
agonist	B-UNK
previously	B-UNK
shown	B-UNK
to	O
enhance	B-UNK
genital	O
blood	B-UNK
flow	B-UNK
in	O
women	B-UNK
,	O
has	O
beneficial	B-UNK
effects	B-UNK
in	O
reversing	O
antidepressant	B-UNK
-	O
induced	B-UNK
sexual	B-DISEASE
dysfunction	I-DISEASE
.	O
Nineteen	O
sexually	O
dysfunctional	O
women	B-UNK
receiving	B-UNK
either	O
fluoxetine	B-CHEMICAL
,	O
sertraline	B-CHEMICAL
,	O
or	O
paroxetine	B-CHEMICAL
participated	O
in	O
an	O
eight	O
-	O
week	B-UNK
,	O
double-blind	B-UNK
,	O
placebo	B-UNK
-	O
controlled	B-UNK
,	O
cross-over	O
study	B-UNK
of	O
the	O
effects	B-UNK
of	O
ephedrine	B-CHEMICAL
(	O
50	O
mg	B-UNK
)	O
on	O
self	O
-	O
report	B-UNK
measures	B-UNK
of	O
sexual	B-UNK
desire	B-UNK
,	O
arousal	O
,	O
orgasm	O
,	O
and	O
sexual	B-UNK
satisfaction	O
.	O
Although	O
there	O
were	O
significant	B-UNK
improvements	B-UNK
relative	B-UNK
to	O
baseline	B-UNK
in	O
sexual	B-UNK
desire	B-UNK
and	O
orgasm	O
intensity	B-UNK
/	O
pleasure	O
on	O
50	O
mg	B-UNK
ephedrine	B-CHEMICAL
1-hr	O
prior	B-UNK
to	O
sexual	B-UNK
activity	B-UNK
,	O
significant	B-UNK
improvements	B-UNK
in	O
these	O
measures	B-UNK
,	O
as	O
well	O
as	O
in	O
sexual	B-UNK
arousal	O
and	O
orgasmic	O
ability	B-UNK
also	O
were	O
noted	O
with	O
placebo	B-UNK
.	O
These	O
findings	B-UNK
highlight	O
the	O
importance	O
of	O
conducting	O
placebo	B-UNK
-	O
controlled	B-UNK
trials	B-UNK
for	O
this	O
condition	B-UNK
.	O

Erectile	O
dysfunction	B-UNK
occurs	B-UNK
following	B-UNK
substantia	B-UNK
nigra	B-UNK
lesions	B-UNK
in	O
the	O
rat	B-UNK
.	O

Erectile	O
function	B-UNK
was	O
assessed	B-UNK
6	O
weeks	B-UNK
following	B-UNK
uni-	O
and	O
bilateral	B-UNK
injections	B-UNK
of	O
6-hydroxydopamine	O
in	O
the	O
substantia	B-UNK
nigra	B-UNK
nucleus	B-UNK
of	O
the	O
brain	B-UNK
.	O
Behavioral	B-UNK
apomorphine	B-CHEMICAL
-	O
induced	B-UNK
penile	O
erections	O
were	O
reduced	B-UNK
(	O
5/8	O
)	O
and	O
increased	B-UNK
(	O
3/8	O
)	O
in	O
uni-	O
and	O
bilateral	B-UNK
lesioned	B-UNK
animals	B-UNK
.	O
Intracavernous	O
pressures	B-UNK
,	O
following	B-UNK
electrical	B-UNK
stimulation	B-UNK
of	O
the	O
cavernous	B-UNK
nerve	B-UNK
,	O
decreased	B-UNK
in	O
lesioned	B-UNK
animals	B-UNK
.	O
Lesions	O
of	O
the	O
substantia	B-UNK
nigra	B-UNK
were	O
confirmed	B-UNK
by	O
histology	O
.	O
Concentration	O
of	O
dopamine	B-CHEMICAL
and	O
its	O
metabolites	B-UNK
were	O
decreased	B-UNK
in	O
the	O
striatum	O
of	O
substantia	B-UNK
nigra	B-UNK
lesioned	B-UNK
rats	B-UNK
.	O
Lesions	O
of	O
the	O
substantia	B-UNK
nigra	B-UNK
are	O
therefore	O
associated	B-UNK
with	O
erectile	B-DISEASE
dysfunction	I-DISEASE
in	O
rats	B-UNK
and	O
may	O
serve	O
as	O
a	O
model	B-UNK
to	O
study	B-UNK
erectile	B-DISEASE
dysfunction	I-DISEASE
in	O
Parkinson'	O
s	O
disease	B-DISEASE
.	O

Potential	O
therapeutic	B-UNK
use	B-UNK
of	O
the	O
selective	B-UNK
dopamine	B-CHEMICAL
D1	O
receptor	B-UNK
agonist	B-UNK
,	O
A-86929	O
:	O
an	O
acute	B-UNK
study	B-UNK
in	O
parkinsonian	B-UNK
levodopa	B-CHEMICAL
-	O
primed	O
monkeys	O
.	O

The	O
clinical	B-UNK
utility	O
of	O
dopamine	B-CHEMICAL
(	O
DA	B-UNK
)	O
D1	O
receptor	B-UNK
agonists	O
in	O
the	O
treatment	B-UNK
of	O
Parkinson'	O
s	O
disease	B-DISEASE
(	O
PD	O
)	O
is	O
still	O
unclear	O
.	O
The	O
therapeutic	B-UNK
use	B-UNK
of	O
selective	B-UNK
DA	B-UNK
D1	O
receptor	B-UNK
agonists	O
such	O
as	O
SKF-82958	O
(	O
6-chloro-7,8-dihydroxy-3-allyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzaze	O
pine	O
hydrobromide	B-UNK
)	O
and	O
A-77636	O
(	O
[	O
1R	O
,	O
3S	O
]	O
3-[1'-admantyl]-1-aminomethyl-3,4-dihydro-5,6-dihydroxy-1H-2-benzo	O
pyran	O
hydrochloride	B-UNK
)	O
seems	O
limited	O
because	O
of	O
their	O
duration	B-UNK
of	O
action	B-UNK
,	O
which	O
is	O
too	O
short	B-UNK
for	O
SKF-82958	O
(	O
<	O
1	O
hr	B-UNK
)	O
and	O
too	O
long	B-UNK
for	O
A-77636	O
(	O
>	O
20	O
hr	B-UNK
,	O
leading	B-UNK
to	O
behavioral	B-UNK
tolerance	B-UNK
)	O
.	O
We	O
therefore	O
conducted	O
the	O
present	B-UNK
acute	B-UNK
dose	B-UNK
-	O
response	B-UNK
study	B-UNK
in	O
four	O
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	B-CHEMICAL
(	O
MPTP)-exposed	O
cynomolgus	O
monkeys	O
primed	O
to	O
exhibit	B-UNK
levodopa	B-CHEMICAL
-	O
induced	B-UNK
dyskinesias	B-DISEASE
to	O
evaluate	B-UNK
the	O
locomotor	B-UNK
and	O
dyskinetic	B-UNK
effects	B-UNK
on	O
challenge	B-UNK
with	O
four	O
doses	B-UNK
(	O
from	O
0.03	B-UNK
to	O
1.0	B-UNK
mg	B-UNK
/	O
kg	B-UNK
)	O
of	O
A-86929	O
(	O
[	O
-]-[5aR,11bS]-4,5,5a,6,7,11b	O
-	O
hexahydro-2-propyl-3-thia-5-+	O
+	O
+	O
azacyclopent-1-	O
ena[c]phenathrene-9	O
-	O
10-diol	O
)	O
,	O
a	O
selective	B-UNK
and	O
full	O
DA	B-UNK
D1-like	O
receptor	B-UNK
agonist	B-UNK
with	O
an	O
intermediate	O
duration	B-UNK
of	O
action	B-UNK
.	O
Levodopa	O
and	O
the	O
DA	B-UNK
D2-like	O
receptor	B-UNK
agonist	B-UNK
,	O
LY-171555	O
(	O
[	O
4aR	O
-	O
trans]-4,4a,5,6,7,8,8a,9-o	O
-	O
dihydro-5n	O
-	O
propyl-2H	O
-	O
pyrazo	O
lo-3	O
-	O
4-quinoline	O
hydrochloride	B-UNK
)	O
were	O
also	O
used	O
for	O
comparison	O
.	O
Acute	B-UNK
administration	B-UNK
of	O
A-86929	O
was	O
as	O
efficacious	B-UNK
in	O
alleviating	O
MPTP	O
-	O
induced	B-UNK
parkinsonism	B-DISEASE
as	O
levodopa	B-CHEMICAL
and	O
LY-171555	O
,	O
but	O
was	O
less	O
likely	B-UNK
to	O
reproduce	O
the	O
levodopa	B-CHEMICAL
-	O
induced	B-UNK
dyskinesias	B-DISEASE
in	O
these	O
animals	B-UNK
than	O
with	O
either	O
LY-171555	O
or	O
subsequent	B-UNK
challenge	B-UNK
of	O
levodopa	B-CHEMICAL
.	O
Selective	O
stimulation	B-UNK
of	O
the	O
DA	B-UNK
D1	O
receptor	B-UNK
may	O
provide	B-UNK
better	B-UNK
integration	O
of	O
neural	B-UNK
inputs	O
transmitted	O
to	O
the	O
internal	B-UNK
segment	B-UNK
of	O
the	O
globus	B-UNK
pallidus	B-UNK
(	O
referred	O
to	O
as	O
the	O
basal	B-UNK
ganglia	B-UNK
output	B-UNK
)	O
compared	B-UNK
with	O
levodopa	B-CHEMICAL
and	O
selective	B-UNK
DA	B-UNK
D2	B-UNK
receptor	B-UNK
agonist	B-UNK
.	O
Potent	O
DA	B-UNK
D1	O
receptor	B-UNK
agents	B-UNK
with	O
an	O
intermediate	O
duration	B-UNK
of	O
efficacy	B-UNK
such	O
as	O
A-86929	O
(	O
approximately	B-UNK
4	O
hr	B-UNK
at	B-DISEASE
higher	B-UNK
doses	B-UNK
tested	B-UNK
)	O
are	O
potential	B-UNK
therapeutic	B-UNK
tools	O
in	O
PD	O
and	O
merit	O
further	O
attention	B-UNK
.	O

Deaths	O
from	O
local	B-UNK
anesthetic	B-UNK
-	O
induced	B-UNK
convulsions	B-DISEASE
in	O
mice	B-UNK
.	O

Median	O
convulsant	O
(	O
CD50	O
)	O
and	O
median	B-UNK
lethal	B-UNK
(	O
LD50	O
)	O
doses	B-UNK
of	O
three	O
representative	O
local	B-UNK
anesthetics	B-CHEMICAL
were	O
determined	O
in	O
adult	B-UNK
mice	B-UNK
to	O
evaluate	B-UNK
the	O
threat	O
to	O
life	B-UNK
of	O
local	B-UNK
anesthetic	B-UNK
-	O
induced	B-UNK
convulsions	B-DISEASE
.	O
The	O
CD50	O
and	O
LD50	O
,	O
respectively	O
,	O
were	O
57.7	O
and	O
58.7	O
mg	B-UNK
/	O
kg	B-UNK
for	O
bupivacaine	B-CHEMICAL
,	O
111.0	O
and	O
133.1	O
mg	B-UNK
/	O
kg	B-UNK
for	O
lidocaine	B-CHEMICAL
,	O
and	O
243.4	O
and	O
266.5	O
mg	B-UNK
/	O
kg	B-UNK
for	O
chloroprocaine	B-CHEMICAL
.	O
When	O
given	B-UNK
intraperitoneally	B-UNK
,	O
bupivacaine	B-CHEMICAL
thus	O
was	O
only	O
about	O
twice	B-UNK
as	O
toxic	B-UNK
as	O
lidocaine	B-CHEMICAL
and	O
four	O
times	B-UNK
as	O
toxic	B-UNK
as	O
chloroprocaine	B-CHEMICAL
.	O
Convulsions	O
always	O
preceded	O
death	B-DISEASE
,	O
except	O
after	O
precipitous	O
cardiopulmonary	B-UNK
arrest	B-UNK
from	O
extreme	O
doses	B-UNK
.	O
A	O
CD50	O
dose	B-UNK
of	O
local	B-UNK
anesthetic	B-UNK
(	O
causing	B-UNK
convulsions	B-DISEASE
in	O
50	O
%	O
of	O
mice	B-UNK
)	O
was	O
fatal	B-UNK
in	O
90	O
%	O
of	O
bupivacaine	B-CHEMICAL
-	O
induced	B-UNK
seizures	B-DISEASE
,	O
in	O
57	O
%	O
of	O
the	O
chloroprocaine	B-CHEMICAL
group	B-UNK
,	O
and	O
in	O
6	O
%	O
of	O
the	O
lidocaine	B-CHEMICAL
group	B-UNK
.	O
The	O
narrow	O
gap	O
between	O
convulsant	O
and	O
lethal	B-UNK
doses	B-UNK
of	O
local	B-UNK
anesthetics	B-CHEMICAL
indicates	B-UNK
that	O
untreated	B-UNK
convulsions	B-DISEASE
present	B-UNK
much	O
more	O
of	O
a	O
threat	O
to	O
life	B-UNK
than	O
heretofore	O
appreciated	O
.	O

Myoclonic	O
,	O
atonic	O
,	O
and	O
absence	B-UNK
seizures	B-DISEASE
following	B-UNK
institution	O
of	O
carbamazepine	B-CHEMICAL
therapy	B-UNK
in	O
children	B-UNK
.	O

Five	O
children	B-UNK
,	O
aged	B-UNK
3	O
to	O
11	O
years	B-UNK
,	O
treated	B-UNK
with	O
carbamazepine	B-CHEMICAL
for	O
epilepsy	B-DISEASE
,	O
had	O
an	O
acute	B-UNK
aberrant	B-UNK
reaction	B-UNK
characterized	B-UNK
by	O
the	O
onset	B-UNK
of	O
myoclonic	B-UNK
,	O
atypical	B-UNK
absence	B-UNK
and	O
/	O
or	O
atonic	O
(	O
minor	B-UNK
motor	B-UNK
)	O
seizures	B-DISEASE
within	O
a	O
few	O
days	B-UNK
.	O
When	O
the	O
carbamazepine	B-CHEMICAL
was	O
discontinued	O
,	O
two	O
of	O
the	O
children	B-UNK
returned	B-UNK
to	O
their	O
former	O
state	B-UNK
very	O
quickly	O
,	O
two	O
had	O
the	O
minor	B-UNK
motor	B-UNK
seizures	B-DISEASE
resolve	O
in	O
3	O
and	O
6	O
months	B-UNK
,	O
and	O
one	O
had	O
the	O
seizures	B-DISEASE
persist	O
.	O
The	O
child	B-UNK
in	O
whom	O
the	O
seizures	B-DISEASE
persisted	B-UNK
was	O
later	B-UNK
found	B-UNK
to	O
have	O
ceroid	B-DISEASE
lipofuscinosis	I-DISEASE
.	O
The	O
other	O
children	B-UNK
are	O
doing	O
well	O
on	O
other	O
anticonvulsants	B-CHEMICAL
.	O

Naloxone	O
reversal	B-UNK
of	O
hypotension	B-DISEASE
due	O
to	O
captopril	B-CHEMICAL
overdose	B-UNK
.	O

The	O
hemodynamic	B-UNK
effects	B-UNK
of	O
captopril	B-CHEMICAL
and	O
other	O
angiotensin	B-CHEMICAL
-	I-CHEMICAL
converting	I-CHEMICAL
enzyme	I-CHEMICAL
inhibitors	I-CHEMICAL
may	O
be	O
mediated	B-UNK
by	O
the	O
endogenous	B-UNK
opioid	B-UNK
system	B-UNK
.	O
The	O
opioid	B-UNK
antagonist	B-UNK
naloxone	B-CHEMICAL
has	O
been	O
shown	B-UNK
to	O
block	B-UNK
or	O
reverse	B-UNK
the	O
hypotensive	B-UNK
actions	B-UNK
of	O
captopril	B-CHEMICAL
.	O
We	O
report	B-UNK
a	O
case	B-UNK
of	O
an	O
intentional	O
captopril	B-CHEMICAL
overdose	B-UNK
,	O
manifested	O
by	O
marked	B-UNK
hypotension	B-DISEASE
,	O
that	O
resolved	B-UNK
promptly	B-UNK
with	O
the	O
administration	B-UNK
of	O
naloxone	B-CHEMICAL
.	O
To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
reported	B-UNK
case	B-UNK
of	O
captopril	B-CHEMICAL
-	O
induced	B-UNK
hypotension	B-DISEASE
treated	B-UNK
with	O
naloxone	B-CHEMICAL
.	O
Our	O
experience	B-UNK
demonstrates	B-UNK
a	O
possible	B-UNK
role	B-UNK
of	O
naloxone	B-CHEMICAL
in	O
the	O
reversal	B-UNK
of	O
hypotension	B-DISEASE
resulting	B-UNK
from	O
captopril	B-CHEMICAL
.	O

Carbamazepine	O
-	O
induced	B-UNK
cardiac	B-UNK
dysfunction	B-UNK
.	O
Characterization	O
of	O
two	O
distinct	O
clinical	B-UNK
syndromes	O
.	O

A	O
patient	B-UNK
with	O
sinus	B-UNK
bradycardia	B-DISEASE
and	O
atrioventricular	B-DISEASE
block	I-DISEASE
,	O
induced	B-UNK
by	O
carbamazepine	B-CHEMICAL
,	O
prompted	O
an	O
extensive	B-UNK
literature	B-UNK
review	B-UNK
of	O
all	O
previously	B-UNK
reported	B-UNK
cases	B-UNK
.	O
From	O
the	O
analysis	B-UNK
of	O
these	O
cases	B-UNK
,	O
two	O
distinct	O
forms	O
of	O
carbamazepine	B-CHEMICAL
-	O
associated	B-UNK
cardiac	B-UNK
dysfunction	B-UNK
emerged	B-UNK
.	O
One	O
patient	B-UNK
group	B-UNK
developed	B-UNK
sinus	B-UNK
tachycardias	O
in	O
the	O
setting	B-UNK
of	O
a	O
massive	O
carbamazepine	B-CHEMICAL
overdose	B-UNK
.	O
The	O
second	B-UNK
group	B-UNK
consisted	B-UNK
almost	O
exclusively	O
of	O
elderly	B-UNK
women	B-UNK
who	O
developed	B-UNK
potentially	B-UNK
life	B-UNK
-	O
threatening	O
bradyarrhythmias	O
or	O
atrioventricular	B-UNK
conduction	B-UNK
delay	B-UNK
,	O
associated	B-UNK
with	O
either	O
therapeutic	B-UNK
or	O
modestly	O
elevated	B-UNK
carbamazepine	B-CHEMICAL
serum	B-UNK
levels	B-UNK
.	O
Because	O
carbamazepine	B-CHEMICAL
is	O
widely	B-UNK
used	O
in	O
the	O
treatment	B-UNK
of	O
many	O
neurologic	B-DISEASE
and	O
psychiatric	B-UNK
conditions	B-UNK
,	O
the	O
recognition	O
of	O
the	O
latter	O
syndrome	B-UNK
has	O
important	B-UNK
implications	O
for	O
the	O
use	B-UNK
of	O
this	O
drug	B-UNK
in	O
elderly	B-UNK
patients	B-UNK
.	O

Glutamatergic	O
neurotransmission	B-UNK
mediated	B-UNK
by	O
NMDA	O
receptors	B-UNK
in	O
the	O
inferior	B-UNK
colliculus	O
can	O
modulate	O
haloperidol	B-CHEMICAL
-	O
induced	B-UNK
catalepsy	B-DISEASE
.	O

The	O
inferior	B-UNK
colliculus	O
(	O
IC	O
)	O
is	O
primarily	B-UNK
involved	B-UNK
in	O
the	O
processing	O
of	O
auditory	B-UNK
information	B-UNK
,	O
but	O
it	O
is	O
distinguished	O
from	O
other	O
auditory	B-UNK
nuclei	B-UNK
in	O
the	O
brainstem	B-UNK
by	O
its	O
connections	O
with	O
structures	B-UNK
of	O
the	O
motor	B-UNK
system	B-UNK
.	O
Functional	O
evidence	B-UNK
relating	O
the	O
IC	O
to	O
motor	B-UNK
behavior	B-UNK
derives	O
from	O
experiments	B-UNK
showing	B-UNK
that	O
activation	B-UNK
of	O
the	O
IC	O
by	O
electrical	B-UNK
stimulation	B-UNK
or	O
excitatory	B-UNK
amino	O
acid	B-UNK
microinjection	B-UNK
causes	B-UNK
freezing	O
,	O
escape	B-UNK
-	O
like	B-UNK
behavior	B-UNK
,	O
and	O
immobility	O
.	O
However	O
,	O
the	O
nature	O
of	O
this	O
immobility	O
is	O
still	O
unclear	O
.	O
The	O
present	B-UNK
study	B-UNK
examined	B-UNK
the	O
influence	B-UNK
of	O
excitatory	B-UNK
amino	O
acid	B-UNK
-	O
mediated	B-UNK
mechanisms	B-UNK
in	O
the	O
IC	O
on	O
the	O
catalepsy	B-DISEASE
induced	B-UNK
by	O
the	O
dopamine	B-CHEMICAL
receptor	B-UNK
blocker	B-UNK
haloperidol	B-CHEMICAL
administered	B-UNK
systemically	O
(	O
1	O
or	O
0.5	B-UNK
mg	I-UNK
/	O
kg	B-UNK
)	O
in	O
rats	B-UNK
.	O
Haloperidol	O
-	O
induced	B-UNK
catalepsy	B-DISEASE
was	O
challenged	O
with	O
prior	B-UNK
intracollicular	B-UNK
microinjections	O
of	O
glutamate	B-UNK
NMDA	O
receptor	B-UNK
antagonists	B-UNK
,	O
MK-801	O
(	O
15	O
or	O
30	O
mmol/0.5	O
microl	B-UNK
)	O
and	O
AP7	O
(	O
10	O
or	O
20	O
nmol/0.5	O
microl	B-UNK
)	O
,	O
or	O
of	O
the	O
NMDA	O
receptor	B-UNK
agonist	B-UNK
N	B-UNK
-	O
methyl	O
-	O
d	B-UNK
-	O
aspartate	B-UNK
(	O
NMDA	O
,	O
20	O
or	O
30	O
nmol/0.5	O
microl	B-UNK
)	O
.	O
The	O
results	B-UNK
showed	B-UNK
that	O
intracollicular	B-UNK
microinjection	B-UNK
of	O
MK-801	O
and	O
AP7	O
previous	B-UNK
to	O
systemic	B-UNK
injections	B-UNK
of	O
haloperidol	B-CHEMICAL
significantly	B-UNK
attenuated	B-UNK
the	O
catalepsy	B-DISEASE
,	O
as	O
indicated	B-UNK
by	O
a	O
reduced	B-UNK
latency	O
to	O
step	O
down	O
from	O
a	O
horizontal	O
bar	O
.	O
Accordingly	O
,	O
intracollicular	B-UNK
microinjection	B-UNK
of	O
NMDA	O
increased	B-UNK
the	O
latency	O
to	O
step	O
down	O
the	O
bar	O
.	O
These	O
findings	B-UNK
suggest	B-UNK
that	O
glutamate	B-UNK
-	O
mediated	B-UNK
mechanisms	B-UNK
in	O
the	O
neural	B-UNK
circuits	O
at	B-DISEASE
the	O
IC	O
level	B-UNK
influence	B-UNK
haloperidol	B-CHEMICAL
-	O
induced	B-UNK
catalepsy	B-DISEASE
and	O
participate	O
in	O
the	O
regulation	O
of	O
motor	B-UNK
activity	B-UNK
.	O

Metabotropic	O
glutamate	B-UNK
7	O
receptor	B-UNK
subtype	O
modulates	O
motor	B-UNK
symptoms	B-UNK
in	O
rodent	O
models	B-UNK
of	O
Parkinson'	O
s	O
disease	B-DISEASE
.	O

Metabotropic	O
glutamate	B-UNK
(	O
mGlu	O
)	O
receptors	B-UNK
modulate	O
synaptic	O
transmission	B-UNK
in	O
the	O
central	B-UNK
nervous	I-UNK
system	B-UNK
and	O
represent	B-UNK
promising	B-UNK
therapeutic	B-UNK
targets	O
for	O
symptomatic	B-UNK
treatment	B-UNK
of	O
Parkinson'	O
s	O
disease	B-DISEASE
(	O
PD	O
)	O
.	O
Among	O
the	O
eight	O
mGlu	O
receptor	B-UNK
subtypes	B-UNK
,	O
mGlu7	O
receptor	B-UNK
is	O
prominently	O
expressed	O
in	O
the	O
basal	B-UNK
ganglia	B-UNK
,	O
but	O
its	O
role	B-UNK
in	O
restoring	O
motor	B-UNK
function	B-UNK
in	O
animal	B-UNK
models	B-UNK
of	O
PD	O
is	O
not	O
known	B-UNK
.	O
The	O
effects	B-UNK
of	O
N	B-UNK
,	O
N'-dibenzhydrylethane-1,2-diamine	O
dihydrochloride	O
(	O
AMN082	B-UNK
)	O
,	O
the	O
first	O
selective	B-UNK
allosteric	O
activator	B-UNK
of	O
mGlu7	O
receptors	B-UNK
,	O
were	O
thus	O
tested	B-UNK
in	O
different	B-UNK
rodent	O
models	B-UNK
of	O
PD	O
.	O
Here	O
,	O
we	O
show	O
that	O
oral	B-UNK
(	O
5	O
mg	B-UNK
/	O
kg	B-UNK
)	O
or	O
intrastriatal	O
administration	B-UNK
(	O
0.1	B-UNK
and	O
0.5	B-UNK
nmol	O
)	O
of	O
AMN082	B-UNK
reverses	B-UNK
haloperidol	B-CHEMICAL
-	O
induced	B-UNK
catalepsy	B-DISEASE
in	O
rats	B-UNK
.	O
AMN082	B-UNK
(	O
2.5	B-UNK
and	O
5	O
mg	B-UNK
/	O
kg	B-UNK
)	O
reduces	B-UNK
apomorphine	B-CHEMICAL
-	O
induced	B-UNK
rotations	O
in	O
unilateral	B-UNK
6-hydroxydopamine	O
(	O
6-OHDA)-lesioned	O
rats	B-UNK
.	O
In	O
a	O
more	O
complex	B-UNK
task	B-UNK
commonly	B-UNK
used	O
to	O
evaluate	B-UNK
major	B-UNK
akinetic	O
symptoms	B-UNK
of	O
PD	O
patients	B-UNK
,	O
5	O
mg	B-UNK
/	O
kg	B-UNK
AMN082	B-UNK
reverses	B-UNK
the	O
increased	B-UNK
reaction	B-UNK
time	B-UNK
to	O
respond	O
to	O
a	O
cue	O
of	O
bilateral	B-UNK
6-OHDA	O
-	O
lesioned	B-UNK
rats	B-UNK
.	O
In	O
addition	O
,	O
AMN082	B-UNK
reduces	B-UNK
the	O
duration	B-UNK
of	O
haloperidol	B-CHEMICAL
-	O
induced	B-UNK
catalepsy	B-DISEASE
in	O
a	O
mGlu7	O
receptor	B-UNK
-	O
dependent	B-UNK
manner	B-UNK
in	O
wild	O
-	O
type	B-UNK
but	O
not	O
mGlu7	O
receptor	B-UNK
knockout	B-UNK
mice	B-UNK
.	O
Higher	O
doses	B-UNK
of	O
AMN082	B-UNK
(	O
10	O
and	O
20	O
mg	B-UNK
/	O
kg	B-UNK
p.o	B-UNK
.	O
)	O
have	O
no	O
effect	B-UNK
on	O
the	O
same	O
models	B-UNK
of	O
PD	O
.	O
Overall	O
these	O
findings	B-UNK
suggest	B-UNK
that	O
mGlu7	O
receptor	B-UNK
activation	B-UNK
can	O
reverse	B-UNK
motor	B-UNK
dysfunction	B-UNK
associated	B-UNK
with	O
reduced	B-UNK
dopamine	B-CHEMICAL
activity	B-UNK
.	O
Selective	O
ligands	O
of	O
mGlu7	O
receptor	B-UNK
subtypes	B-UNK
may	O
thus	O
be	O
considered	B-UNK
as	O
promising	B-UNK
compounds	B-UNK
for	O
the	O
development	B-UNK
of	O
antiparkinsonian	B-UNK
therapeutic	B-UNK
strategies	O
.	O

Nimodipine	O
prevents	B-UNK
memory	B-UNK
impairment	B-UNK
caused	B-UNK
by	O
nitroglycerin	B-CHEMICAL
-	O
induced	B-UNK
hypotension	B-DISEASE
in	O
adult	B-UNK
mice	B-UNK
.	O

BACKGROUND	O
:	O
Hypotension	O
and	O
a	O
resultant	O
decrease	B-UNK
in	O
cerebral	B-UNK
blood	B-UNK
flow	B-UNK
have	O
been	O
implicated	B-UNK
in	O
the	O
development	B-UNK
of	O
cognitive	B-DISEASE
dysfunction	I-DISEASE
.	O
We	O
tested	B-UNK
the	O
hypothesis	O
that	O
nimodipine	B-CHEMICAL
(	O
NIMO	O
)	O
administered	B-UNK
at	B-DISEASE
the	O
onset	B-UNK
of	O
nitroglycerin	B-CHEMICAL
(	O
NTG)-induced	O
hypotension	B-DISEASE
would	O
preserve	O
long	B-UNK
-	O
term	B-UNK
associative	O
memory	B-UNK
.	O
METHODS	O
:	O
The	O
passive	B-UNK
avoidance	B-UNK
(	O
PA	B-UNK
)	O
paradigm	B-UNK
was	O
used	O
to	O
assess	B-UNK
memory	B-UNK
retention	B-UNK
.	O
For	O
PA	B-UNK
training	O
,	O
latencies	O
(	O
seconds	O
)	O
were	O
recorded	B-UNK
for	O
entry	O
from	O
a	O
suspended	O
platform	B-UNK
into	O
a	O
Plexiglas	O
tube	O
where	O
a	O
shock	B-DISEASE
was	O
automatically	O
delivered	O
.	O
Latencies	O
were	O
recorded	B-UNK
48	O
h	B-UNK
later	B-UNK
for	O
a	O
testing	B-UNK
trial	B-UNK
.	O
Ninety	O
-	O
six	O
Swiss	B-UNK
-	O
Webster	O
mice	B-UNK
(	O
30	O
-	O
35	O
g	B-UNK
,	O
6	O
-	O
8	O
wk	O
)	O
,	O
were	O
randomized	B-UNK
into	O
6	O
groups	B-UNK
1	O
)	O
saline	B-UNK
(	O
control	B-UNK
)	O
,	O
2	B-DISEASE
)	O
NTG	O
immediately	B-UNK
after	O
learning	B-UNK
,	O
3	O
)	O
NTG	O
3	O
h	B-UNK
after	O
learning	B-UNK
,	O
4	O
)	O
NTG	O
and	O
NIMO	O
,	O
5	O
)	O
vehicle	B-UNK
,	O
and	O
6	O
)	O
NIMO	O
alone	O
.	O
The	O
extent	B-UNK
of	O
hypotension	B-DISEASE
and	O
changes	B-UNK
in	O
brain	B-UNK
tissue	B-UNK
oxygenation	O
(	O
PbtO(2	O
)	O
)	O
and	O
in	O
cerebral	B-UNK
blood	B-UNK
flow	B-UNK
were	O
studied	B-UNK
in	O
a	O
separate	B-UNK
group	B-UNK
of	O
animals	B-UNK
.	O
RESULTS	B-UNK
:	O
All	O
groups	B-UNK
exhibited	B-UNK
similar	B-UNK
training	O
latencies	O
(	O
17.0	O
+	O
/-	O
4.6	O
s	O
)	O
.	O
Mice	O
subjected	O
to	O
hypotensive	B-UNK
episodes	B-UNK
showed	B-UNK
a	O
significant	B-UNK
decrease	B-UNK
in	O
latency	O
time	B-UNK
(	O
178	O
+	O
/-	O
156	O
s	O
)	O
compared	B-UNK
with	O
those	O
injected	B-UNK
with	O
saline	B-UNK
,	O
NTG	B-UNK
+	I-UNK
NIMO	O
,	O
or	O
delayed	B-UNK
NTG	O
(	O
580	O
+	O
/-	O
81	O
s	O
,	O
557	O
+	O
/-	O
67	O
s	O
,	O
and	O
493	O
+	O
/-	O
146	O
s	O
,	O
respectively	O
)	O
.	O
A	O
Kruskal	O
-	O
Wallis	O
1-way	O
analysis	B-UNK
of	O
variance	O
indicated	B-UNK
a	O
significant	B-UNK
difference	B-UNK
among	O
the	O
4	O
treatment	B-UNK
groups	B-UNK
(	O
H	O
=	O
15.34	O
;	O
P	B-UNK
<	I-UNK
0.001	B-UNK
)	O
.	O
In	O
a	O
separate	B-UNK
group	B-UNK
of	O
mice	B-UNK
not	O
subjected	O
to	O
behavioral	B-UNK
studies	B-UNK
,	O
the	O
same	O
dose	B-UNK
of	O
NTG	O
(	O
n	B-UNK
=	O
3	O
)	O
and	O
NTG	B-UNK
+	I-UNK
NIMO	O
(	O
n	B-UNK
=	O
3	O
)	O
caused	B-UNK
mean	B-UNK
arterial	B-UNK
blood	B-UNK
pressure	B-UNK
to	O
decrease	B-UNK
from	O
85.9	O
+	O
/-	O
3.8	O
mm	B-UNK
Hg	B-UNK
sem	B-UNK
to	O
31.6	O
+	O
/-	O
0.8	B-UNK
mm	B-UNK
Hg	B-UNK
sem	B-UNK
and	O
from	O
86.2	O
+	O
/-	O
3.7	O
mm	B-UNK
Hg	B-UNK
sem	B-UNK
to	O
32.6	O
+	O
/-	O
0.2	B-UNK
mm	B-UNK
Hg	B-UNK
sem	B-UNK
,	O
respectively	O
.	O
Mean	O
arterial	B-UNK
blood	B-UNK
pressure	B-UNK
in	O
mice	B-UNK
treated	B-UNK
with	O
NIMO	O
alone	O
decreased	B-UNK
from	O
88.1	O
+	O
/-	O
3.8	O
mm	B-UNK
Hg	B-UNK
to	O
80.0	O
+	O
/-	O
2.9	O
mm	B-UNK
Hg	B-UNK
.	O
The	O
intergroup	O
difference	B-UNK
was	O
statistically	B-UNK
significant	I-UNK
(	O
P	B-UNK
<	I-UNK
0.05	O
)	O
.	O
PbtO(2	O
)	O
decreased	B-UNK
from	O
51.7	O
+	O
/-	O
4.5	B-UNK
mm	B-UNK
Hg	B-UNK
sem	B-UNK
to	O
33.8	O
+	O
/-	O
5.2	O
mm	B-UNK
Hg	B-UNK
sem	B-UNK
in	O
the	O
NTG	O
group	B-UNK
and	O
from	O
38.6	O
+	O
/-	O
6.1	O
mm	B-UNK
Hg	B-UNK
sem	B-UNK
to	O
25.4	O
+	O
/-	O
2.0	B-UNK
mm	B-UNK
Hg	B-UNK
sem	B-UNK
in	O
the	O
NTG	B-UNK
+	I-UNK
NIMO	O
groups	B-UNK
,	O
respectively	O
.	O
There	O
were	O
no	O
significant	B-UNK
differences	B-UNK
among	O
groups	B-UNK
.	O
CONCLUSION	O
:	O
In	O
a	O
PA	B-UNK
retention	B-UNK
paradigm	B-UNK
,	O
the	O
injection	B-UNK
of	O
NTG	O
immediately	B-UNK
after	O
learning	B-UNK
produced	B-UNK
a	O
significant	B-UNK
impairment	B-UNK
of	O
long	B-UNK
-	O
term	B-UNK
associative	O
memory	B-UNK
in	O
mice	B-UNK
,	O
whereas	O
delayed	B-UNK
induced	B-UNK
hypotension	B-DISEASE
had	O
no	O
effect	B-UNK
.	O
NIMO	O
attenuated	B-UNK
the	O
disruption	B-UNK
in	O
consolidation	O
of	O
long	B-UNK
-	O
term	B-UNK
memory	B-UNK
caused	B-UNK
by	O
NTG	O
but	O
did	O
not	O
improve	O
latency	O
in	O
the	O
absence	B-UNK
of	O
hypotension	B-DISEASE
.	O
The	O
observed	B-UNK
effect	B-UNK
of	O
NIMO	O
may	O
have	O
been	O
attributable	O
to	O
the	O
preservation	O
of	O
calcium	B-CHEMICAL
homeostasis	O
during	O
hypotension	B-DISEASE
,	O
because	O
there	O
were	O
no	O
differences	B-UNK
in	O
the	O
PbtO(2	O
)	O
indices	O
among	O
groups	B-UNK
.	O

Fatal	B-UNK
haemopericardium	O
and	O
gastrointestinal	B-UNK
haemorrhage	B-UNK
due	O
to	O
possible	B-UNK
interaction	B-UNK
of	O
cranberry	O
juice	O
with	O
warfarin	B-CHEMICAL
.	O

We	O
report	B-UNK
a	O
case	B-UNK
of	O
fatal	B-UNK
internal	B-UNK
haemorrhage	B-UNK
in	O
an	O
elderly	B-UNK
man	B-UNK
who	O
consumed	O
only	O
cranberry	O
juice	O
for	O
two	O
weeks	B-UNK
while	O
maintaining	O
his	O
usual	B-UNK
dosage	B-UNK
of	O
warfarin	B-CHEMICAL
.	O
We	O
propose	O
that	O
naturally	O
occurring	B-UNK
compounds	B-UNK
such	O
as	O
flavonoids	B-CHEMICAL
,	O
which	O
are	O
present	B-UNK
in	O
fruit	O
juices	O
,	O
may	O
increase	B-UNK
the	O
potency	B-UNK
of	O
warfarin	B-CHEMICAL
by	O
competing	O
for	O
the	O
enzymes	B-UNK
that	O
normally	O
inactivate	O
warfarin	B-CHEMICAL
.	O
While	O
traditionally	O
regarded	O
as	O
foodstuffs	O
,	O
consumption	B-UNK
of	O
fruit	O
juices	O
should	O
be	O
considered	B-UNK
when	O
patients	B-UNK
develop	B-UNK
adverse	B-UNK
drug	I-UNK
reactions	B-UNK
.	O

Isoproterenol	O
induces	B-UNK
primary	B-UNK
loss	B-UNK
of	O
dystrophin	O
in	O
rat	B-UNK
hearts	O
:	O
correlation	B-UNK
with	O
myocardial	B-UNK
injury	B-UNK
.	O

The	O
mechanism	B-UNK
of	O
isoproterenol	B-CHEMICAL
-	O
induced	B-UNK
myocardial	B-UNK
damage	B-UNK
is	O
unknown	B-UNK
,	O
but	O
a	O
mismatch	O
of	O
oxygen	B-CHEMICAL
supply	O
vs	B-UNK
.	O
demand	O
following	B-UNK
coronary	B-UNK
hypotension	B-DISEASE
and	O
myocardial	B-UNK
hyperactivity	B-UNK
is	O
the	O
best	B-UNK
explanation	B-UNK
for	O
the	O
complex	B-UNK
morphological	O
alterations	B-UNK
observed	B-UNK
.	O
Severe	B-UNK
alterations	B-UNK
in	O
the	O
structural	B-UNK
integrity	B-UNK
of	O
the	O
sarcolemma	O
of	O
cardiomyocytes	O
have	O
been	O
demonstrated	B-UNK
to	O
be	O
caused	B-UNK
by	O
isoproterenol	B-CHEMICAL
.	O
Taking	O
into	O
account	O
that	O
the	O
sarcolemmal	B-UNK
integrity	B-UNK
is	O
stabilized	O
by	O
the	O
dystrophin	O
-	O
glycoprotein	O
complex	B-UNK
(	O
DGC	O
)	O
that	O
connects	O
actin	B-UNK
and	O
laminin	O
in	O
contractile	B-UNK
machinery	O
and	O
extracellular	B-UNK
matrix	B-UNK
and	O
by	O
integrins	O
,	O
this	O
study	B-UNK
tests	B-UNK
the	O
hypothesis	O
that	O
isoproterenol	B-CHEMICAL
affects	B-UNK
sarcolemmal	B-UNK
stability	B-UNK
through	O
changes	B-UNK
in	O
the	O
DGC	O
and	O
integrins	O
.	O
We	O
found	B-UNK
different	B-UNK
sensitivity	B-UNK
of	O
the	O
DGC	O
and	O
integrin	O
to	O
isoproterenol	B-CHEMICAL
subcutaneous	B-UNK
administration	B-UNK
.	O
Immunofluorescent	O
staining	B-UNK
revealed	B-UNK
that	O
dystrophin	O
is	O
the	O
most	O
sensitive	B-UNK
among	O
the	O
structures	B-UNK
connecting	O
the	O
actin	B-UNK
in	O
the	O
cardiomyocyte	O
cytoskeleton	O
and	O
the	O
extracellular	B-UNK
matrix	B-UNK
.	O
The	O
sarcomeric	O
actin	B-UNK
dissolution	O
occurred	B-UNK
after	O
the	O
reduction	B-UNK
or	O
loss	B-UNK
of	O
dystrophin	O
.	O
Subsequently	O
,	O
after	O
lysis	O
of	O
myofilaments	O
,	O
gamma	O
-	O
sarcoglycan	O
,	O
beta-dystroglycan	O
,	O
beta1-integrin	O
,	O
and	O
laminin	O
alpha-2	B-UNK
expressions	O
were	O
reduced	B-UNK
followed	B-UNK
by	O
their	O
breakdown	O
,	O
as	O
epiphenomena	O
of	O
the	O
myocytolytic	O
process	B-UNK
.	O
In	O
conclusion	O
,	O
administration	B-UNK
of	O
isoproterenol	B-CHEMICAL
to	O
rats	B-UNK
results	B-UNK
in	O
primary	B-UNK
loss	B-UNK
of	O
dystrophin	O
,	O
the	O
most	O
sensitive	B-UNK
among	O
the	O
structural	B-UNK
proteins	B-UNK
that	O
form	B-UNK
the	O
DGC	O
that	O
connects	O
the	O
extracellular	B-UNK
matrix	B-UNK
and	O
the	O
cytoskeleton	O
in	O
cardiomyocyte	O
.	O
These	O
changes	B-UNK
,	O
related	B-UNK
to	O
ischaemic	B-UNK
injury	B-UNK
,	O
explain	O
the	O
severe	B-UNK
alterations	B-UNK
in	O
the	O
structural	B-UNK
integrity	B-UNK
of	O
the	O
sarcolemma	O
of	O
cardiomyocytes	O
and	O
hence	O
severe	B-UNK
and	O
irreversible	B-UNK
injury	B-UNK
induced	B-UNK
by	O
isoproterenol	B-CHEMICAL
.	O

High	B-UNK
fat	O
diet	B-UNK
-	O
fed	B-UNK
obese	O
rats	B-UNK
are	O
highly	B-UNK
sensitive	B-UNK
to	O
doxorubicin	B-CHEMICAL
-	O
induced	B-UNK
cardiotoxicity	B-DISEASE
.	O

Often	O
,	O
chemotherapy	B-UNK
by	O
doxorubicin	B-CHEMICAL
(	O
Adriamycin	O
)	O
is	O
limited	O
due	O
to	O
life	B-UNK
threatening	O
cardiotoxicity	B-DISEASE
in	O
patients	B-UNK
during	O
and	O
posttherapy	O
.	O
Recently	O
,	O
we	O
have	O
shown	B-UNK
that	O
moderate	B-UNK
diet	B-UNK
restriction	O
remarkably	B-UNK
protects	B-UNK
against	O
doxorubicin	B-CHEMICAL
-	O
induced	B-UNK
cardiotoxicity	B-DISEASE
.	O
This	O
cardioprotection	O
is	O
accompanied	O
by	O
decreased	B-UNK
cardiac	B-UNK
oxidative	B-UNK
stress	B-UNK
and	O
triglycerides	B-CHEMICAL
and	O
increased	B-UNK
cardiac	B-UNK
fatty	O
-	O
acid	B-UNK
oxidation	O
,	O
ATP	O
synthesis	O
,	O
and	O
upregulated	O
JAK	O
/	O
STAT3	B-UNK
pathway	B-UNK
.	O
In	O
the	O
current	B-UNK
study	B-UNK
,	O
we	O
investigated	B-UNK
whether	O
a	O
physiological	O
intervention	O
by	O
feeding	B-UNK
40	O
%	O
high	B-UNK
fat	O
diet	B-UNK
(	O
HFD	O
)	O
,	O
which	O
induces	B-UNK
obesity	B-DISEASE
in	O
male	B-UNK
Sprague	B-UNK
-	O
Dawley	B-UNK
rats	B-UNK
(	O
250	O
-	O
275	O
g	B-UNK
)	O
,	O
sensitizes	O
to	O
doxorubicin	B-CHEMICAL
-	O
induced	B-UNK
cardiotoxicity	B-DISEASE
.	O
A	O
LD(10	O
)	O
dose	B-UNK
(	O
8	O
mg	B-UNK
doxorubicin	B-CHEMICAL
/	O
kg	B-UNK
,	O
ip	O
)	O
administered	B-UNK
on	O
day	B-UNK
43	O
of	O
the	O
HFD	O
feeding	B-UNK
regimen	B-UNK
led	B-UNK
to	O
higher	B-UNK
cardiotoxicity	B-DISEASE
,	O
cardiac	B-UNK
dysfunction	B-UNK
,	O
lipid	B-UNK
peroxidation	B-UNK
,	O
and	O
80	O
%	O
mortality	B-UNK
in	O
the	O
obese	O
(	O
OB	O
)	O
rats	B-UNK
in	O
the	O
absence	B-UNK
of	O
any	O
significant	B-UNK
renal	B-UNK
or	O
hepatic	B-UNK
toxicity	B-UNK
.	O
Doxorubicin	B-UNK
toxicokinetics	O
studies	B-UNK
revealed	B-UNK
no	O
change	B-UNK
in	O
accumulation	B-UNK
of	O
doxorubicin	B-CHEMICAL
and	O
doxorubicinol	O
(	O
toxic	B-UNK
metabolite	B-UNK
)	O
in	O
the	O
normal	B-UNK
diet	B-UNK
-	O
fed	B-UNK
(	O
ND	O
)	O
and	O
OB	O
hearts	O
.	O
Mechanistic	O
studies	B-UNK
revealed	B-UNK
that	O
OB	O
rats	B-UNK
are	O
sensitized	O
due	O
to	O
:	O
(	O
1	O
)	O
higher	B-UNK
oxyradical	O
stress	B-UNK
leading	B-UNK
to	O
upregulation	O
of	O
uncoupling	O
proteins	B-UNK
2	B-DISEASE
and	O
3	O
,	O
(	O
2	B-DISEASE
)	O
downregulation	O
of	O
cardiac	B-UNK
peroxisome	B-CHEMICAL
proliferators	I-CHEMICAL
activated	B-UNK
receptor	B-UNK
-	O
alpha	B-UNK
,	O
(	O
3	O
)	O
decreased	B-UNK
plasma	B-UNK
adiponectin	B-CHEMICAL
levels	B-UNK
,	O
(	O
4	O
)	O
decreased	B-UNK
cardiac	B-UNK
fatty	O
-	O
acid	B-UNK
oxidation	O
(	O
666.9+/-14.0	O
nmol	O
/	O
min	B-UNK
/	O
g	B-UNK
heart	B-UNK
in	O
ND	O
versus	B-UNK
400.2+/-11.8	O
nmol	O
/	O
min	B-UNK
/	O
g	B-UNK
heart	B-UNK
in	O
OB	O
)	O
,	O
(	O
5	O
)	O
decreased	B-UNK
mitochondrial	B-UNK
AMP	O
-	O
alpha2	O
protein	B-UNK
kinase	B-UNK
,	O
and	O
(	O
6	O
)	O
86	O
%	O
drop	O
in	O
cardiac	B-UNK
ATP	O
levels	B-UNK
accompanied	O
by	O
decreased	B-UNK
ATP	O
/	O
ADP	O
ratio	B-UNK
after	O
doxorubicin	B-CHEMICAL
administration	B-UNK
.	O
Decreased	O
cardiac	B-UNK
erythropoietin	B-CHEMICAL
and	O
increased	B-UNK
SOCS3	O
further	O
downregulated	O
the	O
cardioprotective	O
JAK	O
/	O
STAT3	B-UNK
pathway	B-UNK
.	O
In	O
conclusion	O
,	O
HFD	O
-	O
induced	B-UNK
obese	O
rats	B-UNK
are	O
highly	B-UNK
sensitized	O
to	O
doxorubicin	B-CHEMICAL
-	O
induced	B-UNK
cardiotoxicity	B-DISEASE
by	O
substantially	O
downregulating	O
cardiac	B-UNK
mitochondrial	B-UNK
ATP	O
generation	B-UNK
,	O
increasing	B-UNK
oxidative	B-UNK
stress	B-UNK
and	O
downregulating	O
the	O
JAK	O
/	O
STAT3	B-UNK
pathway	B-UNK
.	O

Complete	O
atrioventricular	B-DISEASE
block	I-DISEASE
secondary	B-UNK
to	O
lithium	B-CHEMICAL
therapy	B-UNK
.	O

Sinus	O
node	B-UNK
dysfunction	B-UNK
has	O
been	O
reported	B-UNK
most	O
frequently	B-UNK
among	O
the	O
adverse	B-UNK
cardiovascular	B-UNK
effects	B-UNK
of	O
lithium	B-CHEMICAL
.	O
In	O
the	O
present	B-UNK
case	B-UNK
,	O
complete	B-UNK
atrioventricular	B-UNK
(	O
AV	O
)	O
block	B-UNK
with	O
syncopal	B-UNK
attacks	B-UNK
developed	B-UNK
secondary	B-UNK
to	O
lithium	B-CHEMICAL
therapy	B-UNK
,	O
necessitating	O
permanent	B-UNK
pacemaker	O
implantation	O
.	O
Serum	B-UNK
lithium	B-CHEMICAL
levels	B-UNK
remained	B-UNK
under	O
or	O
within	O
the	O
therapeutic	B-UNK
range	B-UNK
during	O
the	O
syncopal	B-UNK
attacks	B-UNK
.	O
Lithium	O
should	O
be	O
used	O
with	O
extreme	O
caution	B-UNK
,	O
especially	B-UNK
in	O
patients	B-UNK
with	O
mild	B-UNK
disturbance	O
of	O
AV	O
conduction	B-UNK
.	O

Neuroleptic	B-UNK
malignant	B-UNK
syndrome	B-DISEASE
induced	B-UNK
by	O
ziprasidone	B-CHEMICAL
on	O
the	O
second	B-UNK
day	B-UNK
of	O
treatment	B-UNK
.	O

Neuroleptic	B-UNK
malignant	B-UNK
syndrome	B-UNK
(	O
NMS	O
)	O
is	O
the	O
rarest	O
and	O
most	O
serious	O
of	O
the	O
neuroleptic	B-UNK
-	O
induced	B-UNK
movement	B-DISEASE
disorders	I-DISEASE
.	O
We	O
describe	O
a	O
case	B-UNK
of	O
neuroleptic	B-DISEASE
malignant	I-DISEASE
syndrome	I-DISEASE
(	O
NMS	O
)	O
associated	B-UNK
with	O
the	O
use	B-UNK
of	O
ziprasidone	B-CHEMICAL
.	O
Although	O
conventional	B-UNK
neuroleptics	O
are	O
more	O
frequently	B-UNK
associated	B-UNK
with	O
NMS	O
,	O
atypical	B-UNK
antipsychotic	B-UNK
drugs	B-UNK
like	B-UNK
ziprasidone	B-CHEMICAL
may	O
also	O
be	O
a	O
cause	B-UNK
.	O
The	O
patient	B-UNK
is	O
a	O
24-year	O
-	O
old	B-UNK
male	B-UNK
with	O
a	O
history	B-UNK
of	O
schizophrenia	B-DISEASE
who	O
developed	B-UNK
signs	B-DISEASE
and	I-DISEASE
symptoms	I-DISEASE
of	O
NMS	O
after	O
2	B-DISEASE
days	B-UNK
of	O
treatment	B-UNK
with	O
an	O
80-mg	O
/	O
day	B-UNK
dose	B-UNK
of	O
orally	B-UNK
administrated	O
ziprasidone	B-CHEMICAL
.	O
This	O
case	B-UNK
is	O
the	O
earliest	O
(	O
second	B-UNK
day	B-UNK
of	O
treatment	B-UNK
)	O
NMS	O
due	O
to	O
ziprasidone	B-CHEMICAL
reported	B-UNK
in	O
the	O
literature	B-UNK
.	O

Role	O
of	O
mangiferin	B-CHEMICAL
on	O
biochemical	B-UNK
alterations	B-UNK
and	O
antioxidant	B-UNK
status	B-UNK
in	O
isoproterenol	B-CHEMICAL
-	O
induced	B-UNK
myocardial	B-DISEASE
infarction	I-DISEASE
in	O
rats	B-UNK
.	O

The	O
current	B-UNK
study	B-UNK
dealt	O
with	O
the	O
protective	B-UNK
role	B-UNK
of	O
mangiferin	B-CHEMICAL
,	O
a	O
polyphenol	O
from	O
Mangifera	O
indica	O
Linn	O
.	O
(	O
Anacardiaceae	O
)	O
,	O
on	O
isoproterenol	B-CHEMICAL
(	O
ISPH)-induced	O
myocardial	B-DISEASE
infarction	I-DISEASE
(	O
MI	B-UNK
)	O
in	O
rats	B-UNK
through	O
its	O
antioxidative	O
mechanism	B-UNK
.	O
Subcutaneous	O
injection	B-UNK
of	O
ISPH	O
(	O
200	O
mg	B-UNK
/	O
kg	B-UNK
body	B-DISEASE
weight	I-DISEASE
in	O
1	O
ml	B-UNK
saline	B-UNK
)	O
to	O
rats	B-UNK
for	O
2	B-DISEASE
consecutive	B-UNK
days	B-UNK
caused	B-UNK
myocardial	B-UNK
damage	B-UNK
in	O
rat	B-UNK
heart	B-UNK
,	O
which	O
was	O
determined	O
by	O
the	O
increased	B-UNK
activity	B-UNK
of	O
serum	B-UNK
lactate	B-UNK
dehydrogenase	B-UNK
(	O
LDH	O
)	O
and	O
creatine	B-DISEASE
phosphokinase	I-DISEASE
isoenzymes	B-UNK
(	O
CK	O
-	O
MB	O
)	O
,	O
increased	B-UNK
uric	B-CHEMICAL
acid	I-CHEMICAL
level	B-UNK
and	O
reduced	B-UNK
plasma	B-UNK
iron	B-CHEMICAL
binding	B-UNK
capacity	B-UNK
.	O
The	O
protective	B-UNK
role	B-UNK
of	O
mangiferin	B-CHEMICAL
was	O
analyzed	B-UNK
by	O
triphenyl	O
tetrazolium	O
chloride	B-UNK
(	O
TTC	O
)	O
test	B-UNK
used	O
for	O
macroscopic	O
enzyme	B-UNK
mapping	B-UNK
assay	B-UNK
of	O
the	O
ischemic	B-UNK
myocardium	B-UNK
.	O
The	O
heart	B-UNK
tissue	B-UNK
antioxidant	B-UNK
enzymes	B-UNK
such	O
as	O
superoxide	B-UNK
dismutase	O
,	O
catalase	O
,	O
glutathione	B-CHEMICAL
peroxidase	O
,	O
glutathione	B-CHEMICAL
transferase	O
and	O
glutathione	B-DISEASE
reductase	I-DISEASE
activities	B-UNK
,	O
non-enzymic	O
antioxidants	B-CHEMICAL
such	O
as	O
cerruloplasmin	O
,	O
Vitamin	B-UNK
C	B-UNK
,	O
Vitamin	B-UNK
E	B-UNK
and	O
glutathione	B-CHEMICAL
levels	B-UNK
were	O
altered	B-UNK
in	O
MI	B-UNK
rats	B-UNK
.	O
Upon	O
pretreatment	B-UNK
with	O
mangiferin	B-CHEMICAL
(	O
100	O
mg	B-UNK
/	O
kg	B-UNK
body	B-DISEASE
weight	I-DISEASE
suspended	O
in	O
2	B-DISEASE
ml	B-UNK
of	O
dimethyl	O
sulphoxide	O
)	O
given	B-UNK
intraperitoneally	B-UNK
for	O
28	O
days	B-UNK
to	O
MI	B-UNK
rats	B-UNK
protected	O
the	O
above	O
-	O
mentioned	B-UNK
parameters	B-UNK
to	O
fall	O
from	O
the	O
normal	B-UNK
levels	B-UNK
.	O
Activities	O
of	O
heart	B-UNK
tissue	B-UNK
enzymic	O
antioxidants	B-CHEMICAL
and	O
serum	B-UNK
non-enzymic	O
antioxidants	B-CHEMICAL
levels	B-UNK
rose	B-UNK
significantly	B-UNK
upon	O
mangiferin	B-CHEMICAL
administration	B-UNK
as	O
compared	B-UNK
to	O
ISPH	O
-	O
induced	B-UNK
MI	B-UNK
rats	B-UNK
.	O
From	O
the	O
present	B-UNK
study	B-UNK
it	O
is	O
concluded	O
that	O
mangiferin	B-CHEMICAL
exerts	B-UNK
a	O
beneficial	B-UNK
effect	B-UNK
against	O
ISPH	O
-	O
induced	B-UNK
MI	B-UNK
due	O
to	O
its	O
antioxidant	B-UNK
potential	B-UNK
,	O
which	O
regulated	O
the	O
tissues	B-UNK
defense	O
system	B-UNK
against	O
cardiac	B-UNK
damage	B-UNK
.	O

Remifentanil	O
pretreatment	B-UNK
reduces	B-UNK
myoclonus	B-DISEASE
after	O
etomidate	B-CHEMICAL
.	O

STUDY	B-UNK
OBJECTIVE	O
:	O
The	O
aim	O
of	O
the	O
study	B-UNK
was	O
to	O
compare	O
the	O
effect	B-UNK
of	O
pretreatment	B-UNK
with	O
remifentanil	B-CHEMICAL
1	O
microg	B-UNK
/	O
kg	B-UNK
and	O
the	O
effect	B-UNK
of	O
gender	O
on	O
the	O
incidence	B-UNK
of	O
myoclonus	B-DISEASE
after	O
anesthesia	B-UNK
induction	B-UNK
with	O
etomidate	B-CHEMICAL
.	O
DESIGN	B-UNK
:	O
This	O
was	O
a	O
randomized	B-UNK
,	O
double-blind	B-UNK
study	B-UNK
.	O
SETTING	O
:	O
The	O
study	B-UNK
was	O
conducted	O
at	B-DISEASE
a	O
university	O
hospital	B-UNK
.	O
PATIENTS	O
:	O
Sixty	O
patients	B-UNK
were	O
pretreated	B-UNK
in	O
a	O
randomized	B-UNK
double-blinded	O
fashion	B-UNK
with	O
remifentanil	B-CHEMICAL
1	O
microg	B-UNK
/	O
kg	B-UNK
or	O
placebo	B-UNK
.	O
Two	O
minutes	B-UNK
after	O
remifentanil	B-CHEMICAL
or	O
placebo	B-UNK
injection	B-UNK
,	O
etomidate	B-CHEMICAL
0.3	B-UNK
mg	B-UNK
/	O
kg	B-UNK
was	O
given	B-UNK
.	O
MEASUREMENTS	O
:	O
Myoclonus	O
was	O
recorded	B-UNK
with	O
a	O
scale	B-UNK
of	O
0	O
to	O
3	O
.	O
The	O
grade	B-UNK
of	O
sedation	B-UNK
(	O
none	O
,	O
mild	B-UNK
,	O
moderate	B-UNK
,	O
severe	B-UNK
)	O
,	O
nausea	B-DISEASE
,	O
pruritus	B-DISEASE
,	O
and	O
apnea	B-DISEASE
were	O
recorded	B-UNK
after	O
injection	B-UNK
of	O
both	O
drugs	B-UNK
.	O
MAIN	B-UNK
RESULTS	B-UNK
:	O
The	O
incidence	B-UNK
of	O
myoclonus	B-DISEASE
was	O
significantly	B-UNK
lower	B-UNK
in	O
the	O
remifentanil	B-CHEMICAL
group	B-UNK
(	O
6.7	O
%	O
)	O
than	O
in	O
the	O
placebo	B-UNK
group	B-UNK
(	O
70	O
%	O
)	O
(	O
P	B-UNK
<	I-UNK
0.001	B-UNK
)	O
.	O
None	O
of	O
the	O
patients	B-UNK
experienced	B-UNK
sedation	B-UNK
,	O
apnea	B-DISEASE
,	O
nausea	B-DISEASE
,	O
or	O
pruritus	B-DISEASE
after	O
injection	B-UNK
of	O
both	O
drugs	B-UNK
.	O
In	O
the	O
placebo	B-UNK
group	B-UNK
,	O
male	B-UNK
patients	B-UNK
were	O
associated	B-UNK
with	O
significantly	B-UNK
increased	B-UNK
incidence	B-UNK
of	O
myoclonus	B-DISEASE
after	O
etomidate	B-CHEMICAL
administration	B-UNK
.	O
CONCLUSION	O
:	O
Pretreatment	O
with	O
remifentanil	B-CHEMICAL
1	O
microg	B-UNK
/	O
kg	B-UNK
reduced	B-UNK
myoclonus	B-DISEASE
after	O
etomidate	B-CHEMICAL
induction	B-UNK
without	O
side	O
effects	B-UNK
such	O
as	O
sedation	B-UNK
,	O
apnea	B-DISEASE
,	O
nausea	B-DISEASE
,	O
or	O
pruritus	B-DISEASE
.	O
Men	O
experience	B-UNK
increased	B-UNK
incidence	B-UNK
of	O
myoclonus	B-DISEASE
than	O
women	B-UNK
after	O
etomidate	B-CHEMICAL
administration	B-UNK
.	O

Daidzein	O
activates	O
choline	B-CHEMICAL
acetyltransferase	O
from	O
MC	O
-	O
IXC	O
cells	B-UNK
and	O
improves	B-UNK
drug	B-UNK
-	O
induced	B-UNK
amnesia	B-DISEASE
.	O

The	O
choline	B-CHEMICAL
acetyltransferase	O
(	O
ChAT	O
)	O
activator	B-UNK
,	O
which	O
enhances	O
cholinergic	B-UNK
transmission	B-UNK
via	O
an	O
augmentation	O
of	O
the	O
enzymatic	O
production	B-UNK
of	O
acetylcholine	B-CHEMICAL
(	O
ACh	O
)	O
,	O
is	O
an	O
important	B-UNK
factor	B-UNK
in	O
the	O
treatment	B-UNK
of	O
Alzheimer'	O
s	O
disease	B-DISEASE
(	O
AD	O
)	O
.	O
Methanolic	O
extracts	O
from	O
Pueraria	B-UNK
thunbergiana	B-UNK
exhibited	B-UNK
an	O
activation	B-UNK
effect	B-UNK
(	O
46	B-DISEASE
%	O
)	O
on	O
ChAT	O
in	O
vitro	B-UNK
.	O
Via	O
the	O
sequential	O
isolation	O
of	O
Pueraria	B-UNK
thunbergiana	B-UNK
,	O
the	O
active	B-UNK
component	B-UNK
was	O
ultimately	O
identified	B-UNK
as	O
daidzein	B-CHEMICAL
(	O
4',7-dihydroxy	O
-	O
isoflavone	O
)	O
.	O
In	O
order	O
to	O
investigate	O
the	O
effects	B-UNK
of	O
daidzein	B-CHEMICAL
from	O
Pueraria	B-UNK
thunbergiana	B-UNK
on	O
scopolamine	B-CHEMICAL
-	O
induced	B-UNK
impairments	B-UNK
of	O
learning	B-UNK
and	O
memory	B-UNK
,	O
we	O
conducted	O
a	O
series	B-UNK
of	O
in	O
vivo	B-UNK
tests	B-UNK
.	O
Administration	B-UNK
of	O
daidzein	B-CHEMICAL
(	O
4.5	B-UNK
mg	B-UNK
/	O
kg	B-UNK
body	B-DISEASE
weight	I-DISEASE
)	O
to	O
mice	B-UNK
was	O
shown	B-UNK
significantly	B-UNK
to	O
reverse	B-UNK
scopolamine	B-CHEMICAL
-	O
induced	B-UNK
amnesia	B-DISEASE
,	O
according	B-UNK
to	O
the	O
results	B-UNK
of	O
a	O
Y	O
-	O
maze	B-UNK
test	B-UNK
.	O
Injections	O
of	O
scopolamine	B-CHEMICAL
into	O
mice	B-UNK
resulted	B-UNK
in	O
impaired	B-UNK
performance	B-UNK
on	O
Y	O
-	O
maze	B-UNK
tests	B-UNK
(	O
a	O
37	O
%	O
decreases	B-UNK
in	O
alternation	O
behavior	B-UNK
)	O
.	O
By	O
way	O
of	O
contrast	B-UNK
,	O
mice	B-UNK
treated	B-UNK
with	O
daidzein	B-CHEMICAL
prior	B-UNK
to	O
the	O
scopolamine	B-CHEMICAL
injections	B-UNK
were	O
noticeably	O
protected	O
from	O
this	O
performance	B-UNK
impairment	B-UNK
(	O
an	O
approximately	B-UNK
12%-21	O
%	O
decrease	B-UNK
in	O
alternation	O
behavior	B-UNK
)	O
.	O
These	O
results	B-UNK
indicate	B-UNK
that	O
daidzein	B-CHEMICAL
might	O
play	B-UNK
a	O
role	B-UNK
in	O
acetylcholine	B-CHEMICAL
biosynthesis	O
as	O
a	O
ChAT	O
activator	B-UNK
,	O
and	O
that	O
it	O
also	O
ameliorates	O
scopolamine	B-CHEMICAL
-	O
induced	B-UNK
amnesia	B-DISEASE
.	O

Possible	O
azithromycin	B-CHEMICAL
-	O
associated	B-UNK
hiccups	B-DISEASE
.	O

OBJECTIVE	O
:	O
To	O
report	B-UNK
a	O
case	B-UNK
of	O
persistent	O
hiccups	B-DISEASE
associated	B-UNK
by	O
azithromycin	B-CHEMICAL
therapy	B-UNK
.	O
CASE	B-UNK
SUMMARY	B-UNK
:	O
A	O
76-year	O
-	O
old	B-UNK
man	B-UNK
presented	B-UNK
with	O
persistent	O
hiccups	B-DISEASE
after	O
beginning	B-UNK
azithromycin	B-CHEMICAL
for	O
the	O
treatment	B-UNK
of	O
pharyngitis	B-DISEASE
.	O
Hiccups	O
were	O
persistent	O
and	O
exhausting	O
.	O
Discontinuation	O
of	O
azithromycin	B-CHEMICAL
and	O
therapy	B-UNK
with	O
baclofen	B-CHEMICAL
finally	O
resolved	B-UNK
hiccups	B-DISEASE
.	O
No	O
organic	O
cause	B-UNK
of	O
hiccups	B-DISEASE
was	O
identified	B-UNK
despite	B-UNK
extensive	B-UNK
investigation	O
.	O
DISCUSSION	O
:	O
Pharmacotherapeutic	O
agents	B-UNK
have	O
been	O
uncommonly	O
associated	B-UNK
with	O
hiccups	B-DISEASE
.	O
Corticosteroids	O
(	O
dexamethasone	B-CHEMICAL
and	O
methylprednisolone	B-CHEMICAL
)	O
,	O
benzodiazepines	B-CHEMICAL
(	O
midazolam	B-CHEMICAL
)	O
and	O
general	B-UNK
anaesthesia	B-UNK
have	O
been	O
the	O
specific	B-UNK
agents	B-UNK
mentioned	B-UNK
most	O
frequently	B-UNK
in	O
the	O
literature	B-UNK
as	O
being	O
associated	B-UNK
with	O
the	O
development	B-UNK
of	O
hiccups	B-DISEASE
.	O
Few	O
cases	B-UNK
of	O
drug	B-UNK
-	O
induced	B-UNK
hiccups	B-DISEASE
have	O
been	O
reported	B-UNK
related	B-UNK
to	O
macrolide	B-UNK
antimicrobials	O
.	O
Using	O
the	O
Naranjo	B-UNK
adverse	B-UNK
effect	B-UNK
reaction	B-UNK
probability	B-UNK
scale	B-UNK
this	O
event	B-UNK
could	O
be	O
classified	O
as	O
possible	B-UNK
(	O
score	B-UNK
5	O
points	B-UNK
)	O
,	O
mostly	O
because	O
of	O
the	O
close	O
temporal	B-UNK
sequence	O
,	O
previous	B-UNK
reports	B-UNK
on	O
this	O
reaction	B-UNK
with	O
other	O
macrolides	B-CHEMICAL
and	O
the	O
absence	B-UNK
of	O
any	O
alternative	B-UNK
explanation	B-UNK
for	O
hiccups	B-DISEASE
.	O
Our	O
hypothesis	O
is	O
that	O
a	O
vagal	O
mechanism	B-UNK
mediated	B-UNK
by	O
azithromycin	B-CHEMICAL
could	O
be	O
the	O
pathogenesis	O
of	O
hiccups	B-DISEASE
in	O
our	O
patient	B-UNK
.	O
CONCLUSIONS	O
:	O
Diagnosis	O
of	O
drug	B-UNK
-	O
induced	B-UNK
hiccups	B-DISEASE
is	O
difficult	O
and	O
often	O
achieved	B-UNK
only	O
by	O
a	O
process	B-UNK
of	O
elimination	O
.	O
However	O
,	O
macrolide	B-UNK
antimicrobials	O
have	O
been	O
reported	B-UNK
to	O
be	O
associated	B-UNK
with	O
hiccups	B-DISEASE
and	O
vagal	O
mechanism	B-UNK
could	O
explain	O
the	O
development	B-UNK
of	O
this	O
side	O
-	O
effect	B-UNK
.	O

Time	O
trends	O
in	O
warfarin	B-CHEMICAL
-	O
associated	B-UNK
hemorrhage	B-DISEASE
.	O

The	O
annual	O
incidence	B-UNK
of	O
warfarin	B-CHEMICAL
-	O
related	B-UNK
bleeding	O
at	B-DISEASE
Brigham	O
and	O
Women'	O
s	O
Hospital	O
increased	B-UNK
from	O
0.97/1,000	O
patient	B-UNK
admissions	O
in	O
the	O
first	O
time	B-UNK
period	B-UNK
(	O
January	O
1995	O
to	O
October	O
1998	O
)	O
to	O
1.19/1,000	O
patient	B-UNK
admissions	O
in	O
the	O
second	B-UNK
time	B-UNK
period	B-UNK
(	O
November	O
1998	O
to	O
August	O
2002	O
)	O
of	O
this	O
study	B-UNK
.	O
The	O
proportion	B-UNK
of	O
patients	B-UNK
with	O
major	B-UNK
and	O
intracranial	O
bleeding	O
increased	B-UNK
from	O
20.2	O
%	O
and	O
1.9	O
%	O
,	O
respectively	O
,	O
in	O
the	O
first	O
time	B-UNK
period	B-UNK
,	O
to	O
33.3	O
%	O
and	O
7.8	O
%	O
,	O
respectively	O
,	O
in	O
the	O
second	B-UNK
.	O

Fatal	B-UNK
haemorrhagic	O
myocarditis	B-DISEASE
secondary	B-UNK
to	O
cyclophosphamide	B-CHEMICAL
therapy	B-UNK
.	O

Haemorrhagic	O
myocarditis	B-DISEASE
is	O
a	O
rare	B-UNK
but	O
important	B-UNK
complication	B-UNK
of	O
cyclophosphamide	B-CHEMICAL
therapy	B-UNK
.	O
Echocardiographic	O
identification	B-UNK
of	O
the	O
disorder	B-UNK
can	O
be	O
made	O
.	O
We	O
believe	O
that	O
the	O
ultrasound	B-UNK
features	B-UNK
of	O
this	O
disorder	B-UNK
have	O
not	O
been	O
previously	B-UNK
reported	B-UNK
.	O

Glyceryl	O
trinitrate	B-UNK
induces	B-UNK
attacks	B-UNK
of	O
migraine	B-DISEASE
without	I-DISEASE
aura	I-DISEASE
in	O
sufferers	O
of	O
migraine	B-DISEASE
with	I-DISEASE
aura	I-DISEASE
.	O

Migraine	O
with	O
aura	O
and	O
migraine	B-DISEASE
without	I-DISEASE
aura	I-DISEASE
have	O
the	O
same	O
pain	B-UNK
phase	B-UNK
,	O
thus	O
indicating	O
that	O
migraine	B-DISEASE
with	I-DISEASE
aura	I-DISEASE
and	O
migraine	B-DISEASE
without	I-DISEASE
aura	I-DISEASE
share	O
a	O
common	B-UNK
pathway	B-UNK
of	O
nociception	O
.	O
In	O
recent	B-UNK
years	B-UNK
,	O
increasing	B-UNK
evidence	B-UNK
has	O
suggested	B-UNK
that	O
the	O
messenger	B-UNK
molecule	O
nitric	B-CHEMICAL
oxide	I-CHEMICAL
(	O
NO	O
)	O
is	O
involved	B-UNK
in	O
pain	B-DISEASE
mechanisms	B-UNK
of	O
migraine	B-DISEASE
without	I-DISEASE
aura	I-DISEASE
.	O
In	O
order	O
to	O
clarify	O
whether	O
the	O
same	O
is	O
true	O
for	O
migraine	B-DISEASE
with	I-DISEASE
aura	I-DISEASE
,	O
in	O
the	O
present	B-UNK
study	B-UNK
we	O
examined	B-UNK
the	O
headache	B-DISEASE
response	B-UNK
to	O
intravenous	B-UNK
infusion	I-UNK
of	O
glyceryl	B-UNK
trinitrate	B-UNK
(	O
GTN	O
)	O
(	O
0.5	B-UNK
microg	B-UNK
/	O
kg	B-UNK
/	O
min	B-UNK
for	O
20	O
min	B-UNK
)	O
in	O
12	O
sufferers	O
of	O
migraine	B-DISEASE
with	I-DISEASE
aura	I-DISEASE
.	O
The	O
specific	B-UNK
aim	O
was	O
to	O
elucidate	O
whether	O
an	O
aura	O
and	O
/	O
or	O
an	O
attack	O
of	O
migraine	B-DISEASE
without	I-DISEASE
aura	I-DISEASE
could	O
be	O
induced	B-UNK
.	O
Fourteen	O
healthy	B-UNK
subjects	B-UNK
served	O
as	O
controls	B-UNK
.	O
Aura	O
symptoms	B-UNK
were	O
not	O
elicited	B-UNK
in	O
any	O
subject	B-UNK
.	O
Headache	O
was	O
more	O
severe	B-UNK
in	O
migraineurs	O
than	O
in	O
the	O
controls	B-UNK
during	O
and	O
immediately	B-UNK
after	O
GTN	O
infusion	B-UNK
(	O
p=0.037	O
)	O
as	O
well	O
as	O
during	O
the	O
following	B-UNK
11	O
h	B-UNK
(	O
p	B-UNK
=	I-UNK
0.008	O
)	O
.	O
In	O
the	O
controls	B-UNK
,	O
the	O
GTN	O
-	O
induced	B-UNK
headache	B-DISEASE
gradually	B-UNK
disappeared	B-UNK
,	O
whereas	O
in	O
migraineurs	O
peak	B-UNK
headache	B-DISEASE
intensity	B-UNK
occurred	B-UNK
at	B-DISEASE
a	O
mean	B-UNK
time	B-UNK
of	O
240	O
min	B-UNK
post-infusion	O
.	O
At	O
this	O
time	B-UNK
the	O
induced	B-UNK
headache	B-DISEASE
in	O
6	O
of	O
12	O
migraineurs	O
fulfilled	O
the	O
diagnostic	B-UNK
criteria	B-UNK
for	O
migraine	B-DISEASE
without	I-DISEASE
aura	I-DISEASE
of	O
the	O
International	O
Headache	O
Society	O
.	O
The	O
results	B-UNK
therefore	O
suggest	B-UNK
that	O
NO	O
is	O
involved	B-UNK
in	O
the	O
pain	B-UNK
mechanisms	B-UNK
of	O
migraine	B-DISEASE
with	I-DISEASE
aura	I-DISEASE
.	O
Since	O
cortical	B-UNK
spreading	O
depression	B-DISEASE
has	O
been	O
shown	B-UNK
to	O
liberate	O
NO	O
in	O
animals	B-UNK
,	O
this	O
finding	O
may	O
help	O
our	O
understanding	O
of	O
the	O
coupling	O
between	O
cortical	B-UNK
spreading	O
depression	B-DISEASE
and	O
headache	B-DISEASE
in	O
migraine	B-DISEASE
with	I-DISEASE
aura	I-DISEASE
.	O

Stroke	O
and	O
cocaine	B-CHEMICAL
or	O
amphetamine	B-CHEMICAL
use	B-UNK
.	O

The	O
association	B-UNK
of	O
cocaine	B-CHEMICAL
and	O
amphetamine	B-CHEMICAL
use	B-UNK
with	O
hemorrhagic	B-UNK
and	O
ischemic	B-DISEASE
stroke	I-DISEASE
is	O
based	B-UNK
almost	O
solely	O
on	O
data	B-UNK
from	O
case	B-UNK
series	B-UNK
.	O
The	O
limited	O
number	B-UNK
of	O
epidemiologic	B-UNK
studies	B-UNK
of	O
stroke	B-DISEASE
and	O
use	B-UNK
of	O
cocaine	B-CHEMICAL
and	O
/	O
or	O
amphetamine	B-CHEMICAL
have	O
been	O
done	O
in	O
settings	O
that	O
serve	O
mostly	O
the	O
poor	B-UNK
and	O
/	O
or	O
minorities	O
.	O
This	O
case	B-UNK
-	O
control	B-UNK
study	B-UNK
was	O
conducted	O
in	O
the	O
defined	O
population	B-UNK
comprising	B-UNK
members	O
of	O
Kaiser	O
Permanente	O
of	O
Northern	O
and	O
Southern	O
California	O
.	O
We	O
attempted	O
to	O
identify	B-UNK
all	O
incident	O
strokes	B-UNK
in	O
women	B-UNK
ages	O
15	O
-	O
44	O
years	B-UNK
during	O
a	O
3-year	O
period	B-UNK
using	O
hospital	B-UNK
admission	O
and	O
discharge	B-UNK
records	B-UNK
,	O
emergency	B-UNK
department	B-UNK
logs	O
,	O
and	O
payment	O
requests	O
for	O
out	O
-	O
of	O
-	O
plan	B-UNK
hospitalizations	O
.	O
We	O
selected	O
controls	B-UNK
,	O
matched	B-UNK
on	O
age	B-UNK
and	O
facility	O
of	O
usual	B-UNK
care	B-UNK
,	O
at	B-DISEASE
random	O
from	O
healthy	B-UNK
members	O
of	O
the	O
health	O
plan	B-UNK
.	O
We	O
obtained	B-UNK
information	B-UNK
in	O
face	O
-	O
to	O
-	O
face	O
interviews	O
.	O
There	O
were	O
347	O
confirmed	B-UNK
stroke	B-DISEASE
cases	B-UNK
and	O
1,021	O
controls	B-UNK
.	O
The	O
univariate	O
matched	B-UNK
odds	B-UNK
ratio	B-UNK
for	O
stroke	B-DISEASE
in	O
women	B-UNK
who	O
admitted	O
to	O
using	O
cocaine	B-CHEMICAL
and	O
/	O
or	O
amphetamine	B-CHEMICAL
was	O
8.5	O
(	O
95	O
%	O
confidence	B-UNK
interval	I-UNK
=	O
3.6	B-UNK
-	O
20.0	O
)	O
.	O
After	O
further	O
adjustment	O
for	O
potential	B-UNK
confounders	O
,	O
the	O
odds	B-UNK
ratio	B-UNK
in	O
women	B-UNK
who	O
reported	B-UNK
using	O
cocaine	B-CHEMICAL
and	O
/	O
or	O
amphetamine	B-CHEMICAL
was	O
7.0	B-UNK
(	O
95	O
%	O
confidence	B-UNK
interval	I-UNK
=	O
2.8	O
-	O
17.9	O
)	O
.	O
The	O
use	B-UNK
of	O
cocaine	B-CHEMICAL
and	O
/	O
or	O
amphetamine	B-CHEMICAL
is	O
a	O
strong	B-UNK
risk	B-UNK
factor	B-UNK
for	O
stroke	B-UNK
in	O
this	O
socioeconomically	O
heterogeneous	O
,	O
insured	O
urban	O
population	B-UNK
.	O

Prevention	O
of	O
breast	B-DISEASE
cancer	I-DISEASE
with	O
tamoxifen	B-CHEMICAL
:	O
preliminary	B-UNK
findings	B-UNK
from	O
the	O
Italian	O
randomised	B-UNK
trial	B-UNK
among	O
hysterectomised	O
women	B-UNK
.	O
Italian	O
Tamoxifen	O
Prevention	O
Study	B-UNK
.	O

BACKGROUND	O
:	O
Tamoxifen	O
is	O
a	O
candidate	O
chemopreventive	O
agent	B-UNK
in	O
breast	B-DISEASE
cancer	I-DISEASE
,	O
although	O
the	O
drug	B-UNK
may	O
be	O
associated	B-UNK
with	O
the	O
development	B-UNK
of	O
endometrial	B-DISEASE
cancer	I-DISEASE
.	O
Therefore	O
we	O
did	O
a	O
trial	B-UNK
in	O
hysterectomised	O
women	B-UNK
of	O
tamoxifen	B-CHEMICAL
as	O
a	O
chemopreventive	O
.	O
METHODS	O
:	O
In	O
October	O
,	O
1992	O
,	O
we	O
started	B-UNK
a	O
double-blind	B-UNK
placebo	B-UNK
-	O
controlled	B-UNK
,	O
randomised	B-UNK
trial	B-UNK
of	O
tamoxifen	B-CHEMICAL
in	O
women	B-UNK
(	O
mainly	B-UNK
in	O
Italy	O
)	O
who	O
did	O
not	O
have	O
breast	B-DISEASE
cancer	I-DISEASE
and	O
who	O
had	O
had	O
a	O
hysterectomy	O
.	O
Women	O
were	O
randomised	B-UNK
to	O
receive	B-UNK
tamoxifen	B-CHEMICAL
20	O
mg	B-UNK
per	O
day	B-UNK
or	O
placebo	B-UNK
,	O
both	O
orally	B-UNK
for	O
5	O
years	B-UNK
.	O
The	O
original	B-UNK
plan	B-UNK
was	O
to	O
follow	B-UNK
the	O
intervention	O
phase	B-UNK
by	O
5	O
years	B-UNK
'	O
follow	B-UNK
-	O
up	O
.	O
In	O
June	O
,	O
1997	O
,	O
the	O
trialists	O
and	O
the	O
data	B-UNK
-	O
monitoring	B-UNK
committee	O
decided	O
to	O
end	B-UNK
recruitment	O
primarily	B-UNK
because	O
of	O
the	O
number	B-UNK
of	O
women	B-UNK
dropping	O
out	O
of	O
the	O
study	B-UNK
.	O
Recruitment	O
ended	O
on	O
July	O
11	O
,	O
1997	O
,	O
and	O
the	O
study	B-UNK
will	O
continue	O
as	O
planned	O
.	O
The	O
primary	B-UNK
endpoints	O
are	O
the	O
occurrence	O
of	O
and	O
deaths	O
from	O
breast	B-DISEASE
cancer	I-DISEASE
.	O
This	O
preliminary	B-UNK
interim	O
analysis	B-UNK
is	O
based	B-UNK
on	O
intention	O
-	O
to	O
-	O
treat	O
.	O
FINDINGS	O
:	O
5408	O
women	B-UNK
were	O
randomised	B-UNK
;	O
participating	O
women	B-UNK
have	O
a	O
median	B-UNK
follow	B-UNK
-	O
up	O
of	O
46	B-DISEASE
months	B-UNK
for	O
major	B-UNK
endpoints	O
.	O
41	O
cases	B-UNK
of	O
breast	B-DISEASE
cancer	I-DISEASE
occurred	B-UNK
so	O
far	O
;	O
there	O
have	O
been	O
no	O
deaths	O
from	O
breast	B-DISEASE
cancer	I-DISEASE
.	O
There	O
is	O
no	O
difference	B-UNK
in	O
breast	O
-	O
cancer	B-UNK
frequency	B-UNK
between	O
the	O
placebo	B-UNK
(	O
22	O
cases	B-UNK
)	O
and	O
tamoxifen	B-CHEMICAL
(	O
19	O
)	O
arms	B-DISEASE
.	O
There	O
is	O
a	O
statistically	B-UNK
significant	I-UNK
reduction	B-UNK
of	O
breast	B-DISEASE
cancer	I-DISEASE
among	O
women	B-UNK
receiving	B-UNK
tamoxifen	B-CHEMICAL
who	O
also	O
used	O
hormone	B-UNK
-	O
replacement	O
therapy	B-UNK
during	O
the	O
trial	B-UNK
:	O
among	O
390	O
women	B-UNK
on	O
such	O
therapy	B-UNK
and	O
allocated	B-UNK
to	O
placebo	B-UNK
,	O
we	O
found	B-UNK
eight	O
cases	B-UNK
of	O
breast	B-DISEASE
cancer	I-DISEASE
compared	B-UNK
with	O
one	O
case	B-UNK
among	O
362	O
women	B-UNK
allocated	B-UNK
to	O
tamoxifen	B-CHEMICAL
.	O
Compared	O
with	O
the	O
placebo	B-UNK
group	B-UNK
,	O
there	O
was	O
a	O
significantly	B-UNK
increased	B-UNK
risk	I-UNK
of	O
vascular	B-UNK
events	B-UNK
and	O
hypertriglyceridaemia	O
among	O
women	B-UNK
on	O
tamoxifen	B-CHEMICAL
.	O
INTERPRETATION	O
:	O
Although	O
this	O
preliminary	B-UNK
analysis	B-UNK
has	O
low	B-UNK
power	B-UNK
,	O
in	O
this	O
cohort	B-UNK
of	O
women	B-UNK
at	B-DISEASE
low	B-UNK
-	O
to	O
-	O
normal	B-UNK
risk	B-UNK
of	O
breast	B-DISEASE
cancer	I-DISEASE
,	O
the	O
postulated	O
protective	B-UNK
effects	B-UNK
of	O
tamoxifen	B-CHEMICAL
are	O
not	O
yet	O
apparent	O
.	O
Women	O
using	O
hormone	B-UNK
-	O
replacement	O
therapy	B-UNK
appear	O
to	O
have	O
benefited	O
from	O
use	B-UNK
of	O
tamoxifen	B-CHEMICAL
.	O
There	O
were	O
no	O
deaths	O
from	O
breast	B-DISEASE
cancer	I-DISEASE
recorded	B-UNK
in	O
women	B-UNK
in	O
the	O
study	B-UNK
.	O
It	O
is	O
essential	O
to	O
continue	O
follow	B-UNK
-	O
up	O
to	O
quantify	O
the	O
long	B-UNK
-	O
term	B-UNK
risks	O
and	O
benefits	O
of	O
tamoxifen	B-CHEMICAL
therapy	B-UNK
.	O

A	O
measure	B-UNK
of	O
pupillary	O
oscillation	O
as	O
a	O
marker	B-UNK
of	O
cocaine	B-CHEMICAL
-	O
induced	B-UNK
paranoia	O
.	O

Cocaine	O
-	O
induced	B-UNK
paranoia	O
(	O
CIP	O
)	O
remains	B-UNK
an	O
important	B-UNK
drug	B-UNK
-	O
induced	B-UNK
model	B-UNK
of	O
idiopathic	B-UNK
paranoia	O
for	O
which	O
no	O
psychophysiologic	O
marker	B-UNK
has	O
yet	O
emerged	B-UNK
.	O
Measures	O
of	O
pupillary	O
oscillation	O
were	O
able	O
to	O
significantly	B-UNK
distinguish	O
a	O
group	B-UNK
of	O
abstinent	O
crack	B-CHEMICAL
cocaine	I-CHEMICAL
abusers	O
endorsing	O
past	B-UNK
CIP	O
(	O
n	B-UNK
=	O
32	O
)	O
from	O
another	O
group	B-UNK
of	O
crack	O
addicts	O
who	O
denied	O
past	B-UNK
CIP	O
(	O
n	B-UNK
=	O
29	O
)	O
.	O

Seizures	O
induced	B-UNK
by	O
combined	B-UNK
levomepromazine	O
-	O
fluvoxamine	B-CHEMICAL
treatment	B-UNK
.	O

We	O
report	B-UNK
a	O
case	B-UNK
of	O
combined	B-UNK
levomepromazine	O
-	O
fluvoxamine	B-CHEMICAL
treatment	B-UNK
-	O
induced	B-UNK
seizures	B-DISEASE
.	O
It	O
seems	O
that	O
combined	B-UNK
treatment	B-UNK
of	O
fluvoxamine	B-CHEMICAL
with	O
phenothiazines	B-CHEMICAL
may	O
possess	O
proconvulsive	O
activity	B-UNK
.	O

Why	O
may	O
epsilon	O
-	O
aminocaproic	B-CHEMICAL
acid	I-CHEMICAL
(	O
EACA	O
)	O
induce	B-UNK
myopathy	B-DISEASE
in	O
man	B-UNK
?	O
Report	O
of	O
a	O
case	B-UNK
and	O
literature	B-UNK
review	B-UNK
.	O

A	O
case	B-UNK
of	O
necrotizing	B-UNK
myopathy	B-DISEASE
due	O
to	O
a	O
short	B-UNK
epsilon	O
-	O
aminocaproic	B-CHEMICAL
acid	I-CHEMICAL
(	O
EACA	O
)	O
treatment	B-UNK
in	O
a	O
72	O
year	B-UNK
-	O
old	B-UNK
patient	B-UNK
with	O
subarachnoid	O
haemorrhage	B-UNK
(	O
SAH	O
)	O
is	O
described	B-UNK
.	O
Pathogenetic	O
hypotheses	O
are	O
discussed	O
.	O

Comparison	O
of	O
the	O
effectiveness	O
of	O
ranitidine	B-CHEMICAL
and	O
cimetidine	B-CHEMICAL
in	O
inhibiting	O
acid	B-UNK
secretion	B-UNK
in	O
patients	B-UNK
with	O
gastric	B-UNK
hypersecretory	O
states	B-UNK
.	O

The	O
H2-histamine	O
receptor	B-UNK
antagonists	B-UNK
ranitidine	B-CHEMICAL
and	O
cimetidine	B-CHEMICAL
were	O
compared	B-UNK
for	O
their	O
abilities	O
to	O
control	B-UNK
gastric	B-UNK
acid	B-UNK
hypersecretion	O
on	O
a	O
short-	O
and	O
long	B-UNK
-	O
term	B-UNK
basis	B-UNK
in	O
22	O
patients	B-UNK
with	O
gastric	B-UNK
acid	B-UNK
hypersecretory	O
states	B-UNK
.	O
Nineteen	O
patients	B-UNK
had	O
Zollinger	O
-	O
Ellison	O
syndrome	B-UNK
,	O
one	O
patient	B-UNK
had	O
systemic	B-DISEASE
mastocytosis	I-DISEASE
,	O
and	O
two	O
patients	B-UNK
had	O
idiopathic	B-UNK
hypersecretion	O
.	O
The	O
rates	B-UNK
of	O
onset	B-UNK
of	O
the	O
action	B-UNK
of	O
cimetidine	B-CHEMICAL
and	O
ranitidine	B-CHEMICAL
were	O
the	O
same	O
.	O
The	O
actions	B-UNK
of	O
both	O
drugs	B-UNK
were	O
increased	B-UNK
by	O
anticholinergic	B-UNK
agents	B-UNK
,	O
and	O
there	O
was	O
a	O
close	O
correlation	B-UNK
between	O
the	O
daily	B-UNK
maintenance	B-UNK
dose	B-UNK
of	O
each	O
drug	B-UNK
needed	B-UNK
to	O
control	B-UNK
acid	B-UNK
secretion	B-UNK
.	O
However	O
,	O
ranitidine	B-CHEMICAL
was	O
threefold	O
more	O
potent	B-UNK
than	O
cimetidine	B-CHEMICAL
both	O
in	O
acute	B-UNK
inhibition	B-UNK
studies	B-UNK
and	O
in	O
the	O
median	B-UNK
maintenance	B-UNK
dose	B-UNK
needed	B-UNK
(	O
1.2	O
g	B-UNK
per	O
day	B-UNK
for	O
ranitidine	B-CHEMICAL
and	O
3.6	B-UNK
g	B-UNK
per	O
day	B-UNK
for	O
cimetidine	B-CHEMICAL
)	O
.	O
Sixty	O
percent	O
of	O
the	O
males	O
developed	B-UNK
breast	O
changes	B-UNK
or	O
impotence	B-DISEASE
while	O
taking	B-UNK
cimetidine	B-CHEMICAL
and	O
in	O
all	O
cases	B-UNK
these	O
changes	B-UNK
disappeared	B-UNK
when	O
cimetidine	B-CHEMICAL
was	O
replaced	O
by	O
ranitidine	B-CHEMICAL
.	O
Treatment	O
with	O
high	B-UNK
doses	B-UNK
of	O
cimetidine	B-CHEMICAL
(	O
one	O
to	O
60	O
months	B-UNK
;	O
median	B-UNK
,	O
11	O
months	B-UNK
)	O
or	O
ranitidine	B-CHEMICAL
(	O
two	O
to	O
31	O
months	B-UNK
;	O
median	B-UNK
,	O
14	O
months	B-UNK
)	O
was	O
not	O
associated	B-UNK
with	O
hepatic	B-UNK
or	O
hematologic	B-UNK
toxicity	B-UNK
or	O
alterations	B-UNK
of	O
serum	B-UNK
gastrin	O
concentrations	B-UNK
,	O
but	O
ranitidine	B-CHEMICAL
therapy	B-UNK
was	O
associated	B-UNK
with	O
a	O
significantly	B-UNK
lower	B-UNK
serum	B-UNK
creatinine	B-CHEMICAL
level	B-UNK
than	O
seen	B-UNK
with	O
cimetidine	B-CHEMICAL
therapy	B-UNK
.	O
The	O
results	B-UNK
show	O
that	O
both	O
drugs	B-UNK
can	O
adequately	O
inhibit	O
acid	B-UNK
secretion	B-UNK
in	O
patients	B-UNK
with	O
gastric	B-UNK
hypersecretory	O
states	B-UNK
.	O
Both	O
are	O
safe	B-UNK
at	B-DISEASE
high	B-UNK
doses	B-UNK
,	O
but	O
ranitidine	B-CHEMICAL
is	O
threefold	O
more	O
potent	B-UNK
and	O
does	O
not	O
cause	B-UNK
the	O
antiandrogen	O
side	O
effects	B-UNK
frequently	B-UNK
seen	B-UNK
with	O
high	B-UNK
doses	B-UNK
of	O
cimetidine	B-CHEMICAL
.	O

A	O
catch	O
in	O
the	O
Reye	O
.	O

Twenty	O
-	O
six	O
cases	B-UNK
of	O
Reye	O
syndrome	B-DISEASE
from	O
The	O
Children'	O
s	O
Hospital	O
,	O
Camperdown	O
,	O
Australia	O
,	O
occurring	B-UNK
between	O
1973	O
and	O
1982	O
were	O
reviewed	B-UNK
.	O
Of	O
these	O
,	O
20	O
cases	B-UNK
met	O
the	O
US	O
Public	O
Health	B-UNK
Service	O
Centers	O
for	O
Disease	B-UNK
Control	B-UNK
criteria	B-UNK
for	O
the	O
diagnosis	B-UNK
of	O
Reye	O
syndrome	B-UNK
.	O
Aspirin	O
or	O
salicylate	O
ingestion	B-UNK
had	O
occurred	B-UNK
in	O
only	O
one	O
of	O
the	O
20	O
cases	B-UNK
(	O
5	O
%	O
)	O
,	O
and	O
paracetamol	B-UNK
(	O
acetaminophen	B-CHEMICAL
)	O
had	O
been	O
administered	B-UNK
in	O
only	O
six	O
of	O
the	O
cases	B-UNK
(	O
30	O
%	O
)	O
.	O
Pathologic	O
confirmation	O
of	O
the	O
diagnosis	B-UNK
of	O
Reye	O
syndrome	B-UNK
was	O
accomplished	O
in	O
90	O
%	O
of	O
the	O
cases	B-UNK
.	O
The	O
incidence	B-UNK
of	O
Reye	O
syndrome	B-UNK
in	O
New	B-UNK
South	O
Wales	O
,	O
Australia	O
,	O
is	O
estimated	B-UNK
from	O
this	O
study	B-UNK
to	O
be	O
approximately	B-UNK
nine	O
cases	B-UNK
per	O
1	O
million	B-UNK
children	B-UNK
compared	B-UNK
with	O
recent	B-UNK
US	O
data	B-UNK
of	O
ten	B-DISEASE
to	O
20	O
cases	B-UNK
per	O
1	O
million	B-UNK
children	B-UNK
and	O
three	O
to	O
seven	O
cases	B-UNK
per	O
1	O
million	B-UNK
children	B-UNK
in	O
Great	O
Britain	O
.	O
The	O
mortality	B-UNK
for	O
these	O
Reye	O
syndrome	B-UNK
cases	B-UNK
in	O
Australia	O
was	O
45	O
%	O
as	O
compared	B-UNK
with	O
a	O
32	O
%	O
case	B-UNK
-	O
fatality	O
rate	B-UNK
in	O
the	O
United	B-UNK
States	B-UNK
.	O
In	O
Australia	O
,	O
the	O
pediatric	B-UNK
usage	B-UNK
of	O
aspirin	B-CHEMICAL
has	O
been	O
extremely	O
low	B-UNK
for	O
the	O
past	B-UNK
25	O
years	B-UNK
(	O
less	O
than	O
1	O
%	O
of	O
total	B-UNK
dosage	B-UNK
units	B-UNK
sold	O
)	O
,	O
with	O
paracetamol	B-UNK
(	O
acetaminophen	B-CHEMICAL
)	O
dominating	O
the	O
pediatric	B-UNK
analgesic	B-UNK
and	O
antipyretic	O
market	O
.	O
Reye	O
syndrome	B-UNK
may	O
be	O
disappearing	O
from	O
Australia	O
despite	B-UNK
a	O
total	B-UNK
lack	O
of	O
association	B-UNK
with	O
salicylates	B-CHEMICAL
or	O
aspirin	B-CHEMICAL
ingestion	B-UNK
,	O
since	O
there	O
were	O
no	O
cases	B-UNK
found	B-UNK
at	B-DISEASE
The	O
Children'	O
s	O
Hospital	O
in	O
1983	O
,	O
1984	O
,	O
or	O
1985	O
.	O

St.	B-UNK
Anthony'	O
s	O
fire	O
,	O
then	O
and	O
now	O
:	O
a	O
case	B-UNK
report	B-UNK
and	O
historical	O
review	B-UNK
.	O

A	O
rare	B-UNK
case	B-UNK
of	O
morbid	O
vasospasm	B-DISEASE
,	O
together	O
with	O
striking	B-UNK
angiographic	B-UNK
findings	B-UNK
,	O
is	O
described	B-UNK
secondary	B-UNK
to	O
the	O
ingestion	B-UNK
of	O
methysergide	B-CHEMICAL
by	O
a	O
48-year	O
-	O
old	B-UNK
woman	B-UNK
.	O
A	O
brief	B-DISEASE
review	B-UNK
of	O
the	O
literature	B-UNK
on	O
similar	B-UNK
cases	B-UNK
is	O
presented	B-UNK
.	O
A	O
discussion	O
of	O
the	O
history	B-UNK
of	O
ergot	O
includes	O
its	O
original	B-UNK
discovery	O
,	O
the	O
epidemics	O
of	O
gangrene	B-DISEASE
that	O
it	O
has	O
caused	B-UNK
through	O
the	O
ages	O
and	O
its	O
past	B-UNK
and	O
present	B-UNK
role	B-UNK
in	O
the	O
management	B-UNK
of	O
migraine	B-DISEASE
headache	B-DISEASE
.	O
Despite	B-UNK
the	O
advent	O
of	O
calcium	B-CHEMICAL
channel	I-CHEMICAL
blockers	I-CHEMICAL
and	O
beta-adrenergic	B-UNK
antagonists	B-UNK
,	O
ergot	O
preparations	B-UNK
continue	O
to	O
play	B-UNK
a	O
major	B-UNK
role	B-UNK
in	O
migraine	B-DISEASE
therapy	B-UNK
,	O
so	O
that	O
the	O
danger	O
of	O
St.	B-UNK
Anthony'	O
s	O
fire	O
persists	O
.	O

Beta-2-adrenoceptor	O
-	O
mediated	B-UNK
hypokalemia	B-DISEASE
and	O
its	O
abolishment	O
by	O
oxprenolol	B-CHEMICAL
.	O

The	O
time	B-UNK
course	B-UNK
and	O
concentration	B-UNK
-	O
effect	B-UNK
relationship	B-UNK
of	O
terbutaline	B-CHEMICAL
-	O
induced	B-UNK
hypokalemia	B-DISEASE
was	O
studied	B-UNK
,	O
using	O
computer	O
-	O
aided	O
pharmacokinetic	B-UNK
-	O
dynamic	B-UNK
modeling	O
.	O
Subsequently	O
we	O
investigated	B-UNK
the	O
efficacy	B-UNK
of	O
oxprenolol	B-CHEMICAL
in	O
antagonizing	O
such	O
hypokalemia	B-DISEASE
,	O
together	O
with	O
the	O
pharmacokinetic	B-UNK
interaction	B-UNK
between	O
both	O
drugs	B-UNK
.	O
Six	O
healthy	B-UNK
subjects	B-UNK
were	O
given	B-UNK
a	O
0.5	B-UNK
mg	I-UNK
subcutaneous	B-UNK
dose	B-UNK
of	O
terbutaline	B-CHEMICAL
on	O
two	O
occasions	B-UNK
:	O
1	O
hour	O
after	O
oral	B-UNK
administration	B-UNK
of	O
a	O
placebo	B-UNK
and	O
1	O
hour	O
after	O
80	O
mg	B-UNK
oxprenolol	B-CHEMICAL
orally	B-UNK
.	O
In	O
the	O
7-hour	O
period	B-UNK
after	O
terbutaline	B-CHEMICAL
administration	B-UNK
,	O
plasma	B-UNK
samples	B-UNK
were	O
taken	O
for	O
determination	O
of	O
plasma	B-UNK
potassium	B-CHEMICAL
levels	B-UNK
and	O
drug	B-UNK
concentrations	B-UNK
.	O
The	O
sigmoid	O
Emax	O
model	B-UNK
offered	O
a	O
good	B-UNK
description	O
of	O
the	O
relation	O
between	O
terbutaline	B-CHEMICAL
concentrations	B-UNK
and	O
potassium	B-CHEMICAL
effects	B-UNK
.	O
Oxprenolol	O
caused	B-UNK
decreases	B-UNK
of	O
65	O
%	O
and	O
56	O
%	O
of	O
terbutaline	B-CHEMICAL
volume	B-UNK
of	O
distribution	O
and	O
clearance	B-UNK
,	O
respectively	O
,	O
and	O
an	O
increase	B-UNK
of	O
130	O
%	O
of	O
its	O
AUC	B-UNK
.	O
In	O
spite	O
of	O
higher	B-UNK
terbutaline	B-CHEMICAL
concentrations	B-UNK
after	O
oxprenolol	B-CHEMICAL
pretreatment	B-UNK
,	O
the	O
hypokalemia	B-DISEASE
was	O
almost	O
completely	B-UNK
antagonized	B-UNK
by	O
the	O
beta	B-UNK
2-blocking	O
action	B-UNK
.	O

Midline	O
B3	B-UNK
serotonin	B-CHEMICAL
nerves	B-UNK
in	O
rat	B-UNK
medulla	B-UNK
are	O
involved	B-UNK
in	O
hypotensive	B-UNK
effect	B-UNK
of	O
methyldopa	B-CHEMICAL
.	O

Previous	B-UNK
experiments	B-UNK
in	O
this	O
laboratory	B-UNK
have	O
shown	B-UNK
that	O
microinjection	B-UNK
of	O
methyldopa	B-CHEMICAL
onto	O
the	O
ventrolateral	B-UNK
cells	B-UNK
of	O
the	O
B3	B-UNK
serotonin	B-CHEMICAL
neurons	B-UNK
in	O
the	O
medulla	B-UNK
elicits	O
a	O
hypotensive	B-UNK
response	B-UNK
mediated	B-UNK
by	O
a	O
projection	O
descending	O
into	O
the	O
spinal	B-UNK
cord	O
.	O
The	O
present	B-UNK
experiments	B-UNK
were	O
designed	O
to	O
investigate	O
the	O
role	B-UNK
of	O
the	O
midline	B-UNK
cells	B-UNK
of	O
the	O
B3	B-UNK
serotonin	B-CHEMICAL
neurons	B-UNK
in	O
the	O
medulla	B-UNK
,	O
coinciding	O
with	O
the	O
raphe	O
magnus	O
.	O
In	O
spontaneously	B-UNK
hypertensive	B-UNK
,	O
stroke	B-DISEASE
-	O
prone	O
rats	B-UNK
,	O
microinjection	B-UNK
of	O
methyldopa	B-CHEMICAL
into	O
the	O
area	B-UNK
of	O
the	O
midline	B-UNK
B3	B-UNK
serotonin	B-CHEMICAL
cell	B-UNK
group	B-UNK
in	O
the	O
ventral	B-UNK
medulla	B-UNK
caused	B-UNK
a	O
potent	B-UNK
hypotension	B-DISEASE
of	O
30	O
-	O
40	O
mm	B-UNK
Hg	B-UNK
,	O
which	O
was	O
maximal	O
2	B-DISEASE
-	O
3	O
h	B-UNK
after	O
administration	B-UNK
and	O
was	O
abolished	B-UNK
by	O
the	O
serotonin	B-CHEMICAL
neurotoxin	O
5,7-dihydroxytryptamine	B-CHEMICAL
(	O
5,7-DHT	O
)	O
injected	B-UNK
intracerebroventricularly	O
.	O
However	O
,	O
intraspinal	O
injection	B-UNK
of	O
5,7-DHT	O
to	O
produce	B-UNK
a	O
more	O
selective	B-UNK
lesion	B-UNK
of	O
only	O
descending	O
serotonin	B-CHEMICAL
projections	O
in	O
the	O
spinal	B-UNK
cord	O
did	O
not	O
affect	B-UNK
this	O
hypotension	B-DISEASE
.	O
Further	O
,	O
5,7-DHT	O
lesion	B-UNK
of	O
serotonin	B-CHEMICAL
nerves	B-UNK
travelling	O
in	O
the	O
median	B-UNK
forebrain	O
bundle	B-UNK
,	O
one	O
of	O
the	O
main	B-UNK
ascending	O
pathways	B-UNK
from	O
the	O
B3	B-UNK
serotonin	B-CHEMICAL
cells	B-UNK
,	O
did	O
not	O
affect	B-UNK
the	O
fall	O
in	O
blood	B-UNK
pressure	B-UNK
associated	B-UNK
with	O
a	O
midline	B-UNK
B3	B-UNK
serotonin	B-CHEMICAL
methyldopa	B-CHEMICAL
injection	B-UNK
.	O
It	O
is	O
concluded	O
therefore	O
that	O
,	O
unlike	O
the	O
ventrolateral	B-UNK
B3	B-UNK
cells	B-UNK
which	O
mediate	O
a	O
methyldopa	B-CHEMICAL
-	O
induced	B-UNK
hypotension	B-DISEASE
via	O
descending	O
projections	O
,	O
the	O
midline	B-UNK
serotonin	B-CHEMICAL
B3	B-UNK
cells	B-UNK
in	O
the	O
medulla	B-UNK
contribute	O
to	O
the	O
hypotensive	B-UNK
action	B-UNK
of	O
methyldopa	B-CHEMICAL
,	O
either	O
by	O
way	O
of	O
an	O
ascending	O
projection	O
which	O
does	O
not	O
pass	O
through	O
the	O
median	B-UNK
forebrain	O
bundle	B-UNK
,	O
or	O
through	O
a	O
projection	O
restricted	B-UNK
to	O
the	O
caudal	B-UNK
brainstem	B-UNK
.	O

Yohimbine	O
treatment	B-UNK
of	O
sexual	B-UNK
side	O
effects	B-UNK
induced	B-UNK
by	O
serotonin	B-CHEMICAL
reuptake	B-UNK
blockers	B-UNK
.	O

BACKGROUND	O
:	O
Preclinical	O
and	O
clinical	B-UNK
studies	B-UNK
suggest	B-UNK
that	O
yohimbine	B-CHEMICAL
facilitates	O
sexual	B-UNK
behavior	B-UNK
and	O
may	O
be	O
helpful	O
in	O
the	O
treatment	B-UNK
of	O
male	B-UNK
impotence	B-DISEASE
.	O
A	O
single	B-UNK
case	B-UNK
report	B-UNK
suggests	B-UNK
that	O
yohimbine	B-CHEMICAL
may	O
be	O
used	O
to	O
treat	O
the	O
sexual	B-UNK
side	O
effects	B-UNK
of	O
clomipramine	B-CHEMICAL
.	O
This	O
study	B-UNK
evaluated	B-UNK
yohimbine	B-CHEMICAL
as	O
a	O
treatment	B-UNK
for	O
the	O
sexual	B-UNK
side	O
effects	B-UNK
caused	B-UNK
by	O
serotonin	B-CHEMICAL
reuptake	B-UNK
blockers	B-UNK
.	O
METHOD	O
:	O
Six	O
patients	B-UNK
with	O
either	O
obsessive	O
compulsive	O
disorder	B-UNK
,	O
trichotillomania	B-DISEASE
,	O
anxiety	B-DISEASE
,	O
or	O
affective	B-DISEASE
disorders	I-DISEASE
who	O
suffered	O
sexual	B-UNK
side	O
effects	B-UNK
after	O
treatment	B-UNK
with	O
serotonin	B-CHEMICAL
reuptake	B-UNK
blockers	B-UNK
were	O
given	B-UNK
yohimbine	B-CHEMICAL
on	O
a	O
p.r.n	O
.	O
basis	B-UNK
in	O
an	O
open	B-UNK
clinical	B-UNK
trial	B-UNK
.	O
Various	O
doses	B-UNK
of	O
yohimbine	B-CHEMICAL
were	O
used	O
to	O
determine	B-UNK
the	O
ideal	O
dose	B-UNK
for	O
each	O
patient	B-UNK
.	O
RESULTS	B-UNK
:	O
Five	O
of	O
the	O
six	O
patients	B-UNK
experienced	B-UNK
improved	B-UNK
sexual	B-UNK
functioning	B-UNK
after	O
taking	B-UNK
yohimbine	B-CHEMICAL
.	O
One	O
patient	B-UNK
who	O
failed	B-UNK
to	O
comply	O
with	O
yohimbine	B-CHEMICAL
treatment	B-UNK
had	O
no	O
therapeutic	B-UNK
effects	B-UNK
.	O
Side	O
effects	B-UNK
of	O
yohimbine	B-CHEMICAL
included	B-UNK
excessive	B-UNK
sweating	B-DISEASE
,	O
increased	B-UNK
anxiety	B-DISEASE
,	O
and	O
a	O
wound	O
-	O
up	O
feeling	O
in	O
some	O
patients	B-UNK
.	O
CONCLUSION	O
:	O
The	O
results	B-UNK
of	O
this	O
study	B-UNK
indicate	B-UNK
that	O
yohimbine	B-CHEMICAL
may	O
be	O
an	O
effective	B-UNK
treatment	B-UNK
for	O
the	O
sexual	B-UNK
side	O
effects	B-UNK
caused	B-UNK
by	O
serotonin	B-CHEMICAL
reuptake	B-UNK
blockers	B-UNK
.	O
Future	O
controlled	B-UNK
studies	B-UNK
are	O
needed	B-UNK
to	O
further	O
investigate	O
the	O
effectiveness	O
and	O
safety	B-UNK
of	O
yohimbine	B-CHEMICAL
for	O
this	O
indication	O
.	O

Hypersensitivity	O
immune	B-UNK
reaction	B-UNK
as	O
a	O
mechanism	B-UNK
for	O
dilevalol	B-UNK
-	O
associated	B-UNK
hepatitis	B-DISEASE
.	O

OBJECTIVE	O
:	O
To	O
assess	B-UNK
lymphocyte	B-UNK
reactivity	O
to	O
dilevalol	B-UNK
and	O
to	O
serum	B-UNK
containing	B-UNK
putative	B-UNK
ex	B-UNK
vivo	B-UNK
dilevalol	B-UNK
antigens	B-CHEMICAL
or	O
metabolites	B-UNK
in	O
a	O
case	B-UNK
of	O
dilevalol	B-UNK
-	O
induced	B-UNK
liver	B-DISEASE
injury	B-UNK
.	O
PATIENT	O
:	O
A	O
58-year	O
-	O
old	B-UNK
woman	B-UNK
with	O
a	O
clinical	B-UNK
diagnosis	B-UNK
of	O
dilevalol	B-UNK
-	O
induced	B-UNK
liver	B-DISEASE
injury	B-UNK
.	O
METHODS	O
:	O
Peripheral	O
blood	B-UNK
mononuclear	O
cells	B-UNK
collected	B-UNK
from	O
the	O
patient	B-UNK
were	O
cultured	O
in	O
the	O
presence	O
of	O
a	O
solution	B-UNK
of	O
dilevalol	B-UNK
and	O
also	O
with	O
sera	O
collected	B-UNK
from	O
a	O
volunteer	O
before	O
and	O
after	O
dilevalol	B-UNK
intake	B-UNK
.	O
A	O
similar	B-UNK
protocol	B-UNK
was	O
performed	B-UNK
with	O
lymphocytes	B-UNK
from	O
a	O
healthy	B-UNK
subject	B-UNK
.	O
RESULTS	B-UNK
:	O
No	O
lymphocyte	B-UNK
proliferation	B-UNK
was	O
observed	B-UNK
either	O
in	O
the	O
patient	B-UNK
or	O
in	O
the	O
healthy	B-UNK
volunteer	O
in	O
the	O
presence	O
of	O
dilevalol	B-UNK
solutions	O
.	O
A	O
significant	B-UNK
proliferative	O
response	B-UNK
to	O
serum	B-UNK
collected	B-UNK
after	O
dilevalol	B-UNK
intake	B-UNK
was	O
observed	B-UNK
in	O
the	O
case	B-UNK
of	O
the	O
patient	B-UNK
compared	B-UNK
with	O
the	O
proliferative	O
response	B-UNK
to	O
the	O
serum	B-UNK
collected	B-UNK
before	O
the	O
drug	B-UNK
intake	B-UNK
.	O
No	O
reactivity	O
was	O
found	B-UNK
when	O
lymphocytes	B-UNK
from	O
the	O
healthy	B-UNK
subject	B-UNK
were	O
tested	B-UNK
under	O
similar	B-UNK
conditions	B-UNK
.	O
CONCLUSIONS	O
:	O
The	O
methodology	O
used	O
allowed	O
the	O
detection	O
of	O
lymphocyte	B-UNK
sensitization	B-UNK
to	O
sera	O
containing	B-UNK
ex	B-UNK
vivo	B-UNK
-	O
prepared	O
dilevalol	B-UNK
antigens	B-CHEMICAL
,	O
suggesting	B-UNK
the	O
involvement	B-UNK
of	O
an	O
immunologic	O
mechanism	B-UNK
in	O
dilevalol	B-UNK
-	O
induced	B-UNK
liver	B-DISEASE
injury	B-UNK
.	O

Reversible	O
myocardial	B-UNK
hypertrophy	B-DISEASE
induced	B-UNK
by	O
tacrolimus	B-CHEMICAL
in	O
a	O
pediatric	B-UNK
heart	B-UNK
transplant	B-UNK
recipient	O
:	O
case	B-UNK
report	B-UNK
.	O

Tacrolimus	O
is	O
a	O
potent	B-UNK
immunosuppressant	O
that	O
is	O
frequently	B-UNK
used	O
in	O
organ	O
transplantation	B-UNK
.	O
However	O
,	O
adverse	B-UNK
effects	B-UNK
include	B-UNK
cardiac	B-UNK
toxicity	B-UNK
.	O
Herein	O
we	O
describe	O
transient	B-UNK
myocardial	B-UNK
hypertrophy	B-DISEASE
induced	B-UNK
by	O
tacrolimus	B-CHEMICAL
after	O
heart	B-UNK
transplantation	B-UNK
.	O
The	O
hypertrophy	B-DISEASE
caused	B-UNK
no	O
clinical	B-UNK
symptoms	B-UNK
but	O
was	O
noted	O
because	O
of	O
elevation	B-UNK
of	O
plasma	B-UNK
brain	B-UNK
natriuretic	O
peptide	O
concentration	B-UNK
and	O
confirmed	B-UNK
at	B-DISEASE
echocardiography	O
.	O
Initially	O
,	O
allograft	O
rejection	B-UNK
was	O
feared	O
;	O
however	O
,	O
myocardial	B-UNK
biopsy	B-UNK
samples	B-UNK
revealed	B-UNK
only	O
interstitial	O
edema	B-DISEASE
and	O
mild	B-UNK
myocardial	B-UNK
hypertrophy	B-DISEASE
;	O
neither	O
cellular	B-UNK
nor	O
humoral	O
rejection	B-UNK
was	O
detected	B-UNK
.	O
The	O
blood	B-UNK
tacrolimus	B-CHEMICAL
concentration	B-UNK
was	O
higher	B-UNK
than	O
usual	B-UNK
at	B-DISEASE
that	O
time	B-UNK
;	O
thus	O
,	O
tacrolimus	B-CHEMICAL
dosage	B-UNK
was	O
reduced	B-UNK
.	O
Myocardial	O
hypertrophy	B-DISEASE
completely	B-UNK
resolved	B-UNK
upon	O
reducing	B-UNK
the	O
target	O
concentration	B-UNK
of	O
tacrolimus	B-CHEMICAL
and	O
did	O
not	O
recur	O
,	O
as	O
confirmed	B-UNK
at	B-DISEASE
echocardiography	O
and	O
myocardial	B-UNK
biopsy	B-UNK
.	O
Thus	O
,	O
we	O
conclude	O
that	O
tacrolimus	B-CHEMICAL
induces	B-UNK
reversible	B-UNK
myocardial	B-UNK
hypertrophy	B-DISEASE
.	O
In	O
patients	B-UNK
receiving	B-UNK
tacrolimus	B-CHEMICAL
therapy	B-UNK
,	O
blood	B-UNK
concentration	B-UNK
should	O
be	O
carefully	O
controlled	B-UNK
and	O
extreme	O
attention	B-UNK
paid	O
to	O
cardiac	B-UNK
involvement	B-UNK
.	O

Comparison	O
of	O
unilateral	B-UNK
pallidotomy	B-UNK
and	O
subthalamotomy	O
findings	B-UNK
in	O
advanced	B-UNK
idiopathic	B-UNK
Parkinson'	O
s	O
disease	B-DISEASE
.	O

A	O
prospective	B-UNK
,	O
randomized	B-UNK
,	O
double-blind	B-UNK
pilot	O
study	B-UNK
to	O
compare	O
the	O
results	B-UNK
of	O
stereotactic	O
unilateral	B-UNK
pallidotomy	B-UNK
and	O
subthalamotomy	O
in	O
advanced	B-UNK
idiopathic	B-UNK
Parkinson'	O
s	O
disease	B-DISEASE
(	O
PD	O
)	O
refractory	B-UNK
to	O
medical	B-UNK
treatment	B-UNK
was	O
designed	O
.	O
Ten	O
consecutive	B-UNK
patients	B-UNK
(	O
mean	B-UNK
age	B-UNK
,	O
58.4	O
+	O
/-	O
6.8	O
years	B-UNK
;	O
7	O
men	O
,	O
3	O
women	B-UNK
)	O
with	O
similar	B-UNK
characteristics	B-UNK
at	B-DISEASE
the	O
duration	B-UNK
of	O
disease	B-DISEASE
(	O
mean	B-UNK
disease	B-DISEASE
time	B-UNK
,	O
8.4	O
+	O
/-	O
3.5	B-UNK
years	B-UNK
)	O
,	O
disabling	B-UNK
motor	B-UNK
fluctuations	B-UNK
(	O
Hoehn	O
_	O
Yahr	O
stage	B-UNK
3	O
-	O
5	O
in	O
off	O
-	O
drug	B-UNK
phases	B-UNK
)	O
and	O
levodopa	B-CHEMICAL
-	O
induced	B-UNK
dyskinesias	B-DISEASE
were	O
selected	O
.	O
All	O
patients	B-UNK
had	O
bilateral	B-UNK
symptoms	B-UNK
and	O
their	O
levodopa	B-CHEMICAL
equivalent	B-UNK
dosing	B-UNK
were	O
analysed	O
.	O
Six	O
patients	B-UNK
were	O
operated	O
on	O
in	O
the	O
globus	B-UNK
pallidus	B-UNK
interna	O
(	O
GPi	O
)	O
and	O
four	O
in	O
the	O
subthalamic	O
nucleus	B-UNK
(	O
STN	O
)	O
.	O
Clinical	B-UNK
evaluation	B-UNK
included	B-UNK
the	O
use	B-UNK
of	O
the	O
Unified	O
Parkinson'	O
s	O
Disease	B-UNK
Rating	B-UNK
Scale	I-UNK
(	O
UPDRS	O
)	O
,	O
Hoehn_Yahr	O
score	B-UNK
and	O
Schwab	O
England	O
activities	B-UNK
of	O
daily	B-UNK
living	B-UNK
(	O
ADL	O
)	O
score	B-UNK
in	O
'	O
on'-	O
and	O
'	O
off'-drug	O
conditions	B-UNK
before	O
surgery	B-UNK
and	O
6	O
months	B-UNK
after	O
surgery	B-UNK
.	O
There	O
was	O
statistically	B-UNK
significant	I-UNK
improvement	B-UNK
in	O
all	O
contralateral	B-UNK
major	B-UNK
parkinsonian	B-UNK
motor	B-UNK
signs	B-UNK
in	O
all	O
patients	B-UNK
followed	B-UNK
for	O
6	O
months	B-UNK
.	O
Levodopa	O
equivalent	B-UNK
daily	B-UNK
intake	B-UNK
was	O
significantly	B-UNK
reduced	B-UNK
in	O
the	O
STN	O
group	B-UNK
.	O
Changes	O
in	O
UPDRS	O
,	O
Hoehn	O
_	O
Yahr	O
and	O
Schwab	O
England	O
ADL	O
scores	B-UNK
were	O
similar	B-UNK
in	O
both	O
groups	B-UNK
.	O
Cognitive	B-UNK
functions	B-UNK
were	O
unchanged	B-UNK
in	O
both	O
groups	B-UNK
.	O
Complications	O
were	O
observed	B-UNK
in	O
two	O
patients	B-UNK
:	O
one	O
had	O
a	O
left	B-UNK
homonymous	O
hemianopsia	B-DISEASE
after	O
pallidotomy	B-UNK
and	O
another	O
one	O
developed	B-UNK
left	B-UNK
hemiballistic	O
movements	B-UNK
3	O
days	B-UNK
after	O
subthalamotomy	O
which	O
partly	O
improved	B-UNK
within	O
1	O
month	O
with	O
Valproate	O
1000	O
mg	B-UNK
/	O
day	B-UNK
.	O
The	O
findings	B-UNK
of	O
this	O
study	B-UNK
suggest	B-UNK
that	O
lesions	B-UNK
of	O
the	O
unilateral	B-UNK
STN	O
and	O
GPi	O
are	O
equally	O
effective	B-UNK
treatment	B-UNK
for	O
patients	B-UNK
with	O
advanced	B-UNK
PD	O
refractory	B-UNK
to	O
medical	B-UNK
treatment	B-UNK
.	O

Protective	B-UNK
effects	B-UNK
of	O
antithrombin	B-DISEASE
on	O
puromycin	B-CHEMICAL
aminonucleoside	I-CHEMICAL
nephrosis	B-DISEASE
in	O
rats	B-UNK
.	O

We	O
investigated	B-UNK
the	O
effects	B-UNK
of	O
antithrombin	B-DISEASE
,	O
a	O
plasma	B-UNK
inhibitor	B-UNK
of	O
coagulation	O
factors	B-UNK
,	O
in	O
rats	B-UNK
with	O
puromycin	B-CHEMICAL
aminonucleoside	I-CHEMICAL
-	O
induced	B-UNK
nephrosis	B-DISEASE
,	O
which	O
is	O
an	O
experimental	B-UNK
model	B-UNK
of	O
human	B-UNK
nephrotic	B-DISEASE
syndrome	I-DISEASE
.	O
Antithrombin	O
(	O
50	O
or	O
500	O
IU	O
/	O
kg	B-UNK
/	O
i.v	B-UNK
.	O
)	O
was	O
administered	B-UNK
to	O
rats	B-UNK
once	O
a	O
day	B-UNK
for	O
10	O
days	B-UNK
immediately	B-UNK
after	O
the	O
injection	B-UNK
of	O
puromycin	B-CHEMICAL
aminonucleoside	I-CHEMICAL
(	O
50	O
mg	B-UNK
/	O
kg	B-UNK
/	O
i.v	B-UNK
.	O
)	O
.	O
Treatment	O
with	O
antithrombin	B-DISEASE
attenuated	B-UNK
the	O
puromycin	B-CHEMICAL
aminonucleoside	I-CHEMICAL
-	O
induced	B-UNK
hematological	O
abnormalities	B-DISEASE
.	O
Puromycin	O
aminonucleoside	O
-	O
induced	B-UNK
renal	B-DISEASE
dysfunction	B-UNK
and	O
hyperlipidemia	B-DISEASE
were	O
also	O
suppressed	B-UNK
.	O
Histopathological	O
examination	B-UNK
revealed	B-UNK
severe	B-UNK
renal	B-UNK
damage	B-UNK
such	O
as	O
proteinaceous	O
casts	O
in	O
tubuli	O
and	O
tubular	B-UNK
expansion	O
in	O
the	O
kidney	B-UNK
of	O
control	B-UNK
rats	B-UNK
,	O
while	O
an	O
improvement	B-UNK
of	O
the	O
damage	B-UNK
was	O
seen	B-UNK
in	O
antithrombin	B-DISEASE
-	O
treated	B-UNK
rats	B-UNK
.	O
In	O
addition	O
,	O
antithrombin	B-DISEASE
treatment	B-UNK
markedly	B-UNK
suppressed	B-UNK
puromycin	B-CHEMICAL
aminonucleoside	I-CHEMICAL
-	O
induced	B-UNK
apoptosis	B-UNK
of	O
renal	B-UNK
tubular	B-UNK
epithelial	B-UNK
cells	B-UNK
.	O
Furthermore	O
,	O
puromycin	B-CHEMICAL
aminonucleoside	I-CHEMICAL
-	O
induced	B-UNK
increases	B-UNK
in	O
renal	B-DISEASE
cytokine	B-UNK
content	B-UNK
were	O
also	O
decreased	B-UNK
.	O
These	O
findings	B-UNK
suggest	B-UNK
that	O
thrombin	B-CHEMICAL
plays	O
an	O
important	B-UNK
role	B-UNK
in	O
the	O
pathogenesis	O
of	O
puromycin	B-CHEMICAL
aminonucleoside	I-CHEMICAL
-	O
induced	B-UNK
nephrotic	B-DISEASE
syndrome	I-DISEASE
.	O
Treatment	O
with	O
antithrombin	B-DISEASE
may	O
be	O
clinically	B-UNK
effective	B-UNK
in	O
patients	B-UNK
with	O
nephrotic	B-DISEASE
syndrome	I-DISEASE
.	O

Reverse	O
or	O
inverted	O
left	B-UNK
ventricular	I-UNK
apical	B-DISEASE
ballooning	I-DISEASE
syndrome	I-DISEASE
(	O
reverse	B-UNK
Takotsubo	O
cardiomyopathy	B-DISEASE
)	O
in	O
a	O
young	B-UNK
woman	B-UNK
in	O
the	O
setting	B-UNK
of	O
amphetamine	B-CHEMICAL
use	B-UNK
.	O

Transient	O
left	B-UNK
ventricular	I-UNK
apical	B-DISEASE
ballooning	I-DISEASE
syndrome	I-DISEASE
was	O
first	O
described	B-UNK
in	O
Japan	O
as	O
"	O
Takotsubo	O
cardiomyopathy	B-DISEASE
.	O
"	O
This	O
syndrome	B-UNK
has	O
been	O
identified	B-UNK
in	O
many	O
other	O
countries	O
.	O
Many	O
variations	O
of	O
this	O
syndrome	B-UNK
have	O
been	O
recently	B-UNK
described	B-UNK
in	O
the	O
literature	B-UNK
.	O
One	O
of	O
the	O
rarest	O
is	O
the	O
reverse	B-UNK
type	B-UNK
of	O
this	O
syndrome	B-UNK
,	O
with	O
hyperdynamic	O
apex	O
and	O
complete	B-UNK
akinesia	O
of	O
the	O
base	O
(	O
as	O
opposed	O
to	O
the	O
classic	B-UNK
apical	B-UNK
ballooning	O
)	O
.	O
In	O
this	O
article	O
,	O
we	O
report	B-UNK
an	O
interesting	O
case	B-UNK
of	O
a	O
young	B-UNK
woman	B-UNK
who	O
presented	B-UNK
with	O
this	O
rare	B-UNK
type	B-UNK
of	O
reverse	B-UNK
apical	B-DISEASE
ballooning	I-DISEASE
syndrome	I-DISEASE
occurring	B-UNK
after	O
amphetamine	B-CHEMICAL
use	B-UNK
.	O
This	O
report	B-UNK
is	O
followed	B-UNK
by	O
review	B-UNK
of	O
the	O
literature	B-UNK
.	O

Attenuated	O
disruption	B-UNK
of	O
prepulse	B-UNK
inhibition	B-UNK
by	O
dopaminergic	B-UNK
stimulation	B-UNK
after	O
maternal	B-UNK
deprivation	B-UNK
and	O
adolescent	O
corticosterone	B-CHEMICAL
treatment	B-UNK
in	O
rats	B-UNK
.	O

The	O
development	B-UNK
of	O
schizophrenia	B-DISEASE
may	O
include	B-UNK
an	O
early	B-UNK
neurodevelopmental	O
stress	B-UNK
component	B-UNK
which	O
increases	B-UNK
vulnerability	O
to	O
later	B-UNK
stressful	O
life	B-UNK
events	B-UNK
,	O
in	O
combination	B-UNK
leading	B-UNK
to	O
overt	O
disease	B-DISEASE
.	O
We	O
investigated	B-UNK
the	O
effect	B-UNK
of	O
an	O
early	B-UNK
stress	B-UNK
,	O
in	O
the	O
form	B-UNK
of	O
maternal	B-UNK
deprivation	B-UNK
,	O
combined	B-UNK
with	O
a	O
later	B-UNK
stress	B-UNK
,	O
simulated	O
by	O
chronic	B-UNK
periadolescent	O
corticosterone	B-CHEMICAL
treatment	B-UNK
,	O
on	O
behaviour	B-UNK
in	O
rats	B-UNK
.	O
Acute	B-UNK
treatment	B-UNK
with	O
apomorphine	B-CHEMICAL
caused	B-UNK
disruption	B-UNK
of	O
prepulse	B-UNK
inhibition	B-UNK
(	O
PPI	O
)	O
in	O
controls	B-UNK
and	O
in	O
rats	B-UNK
that	O
had	O
undergone	B-UNK
either	O
maternal	B-UNK
deprivation	B-UNK
or	O
corticosterone	B-CHEMICAL
treatment	B-UNK
,	O
but	O
was	O
surprisingly	O
absent	O
in	O
rats	B-UNK
that	O
had	O
undergone	B-UNK
the	O
combined	B-UNK
early	B-UNK
and	O
late	B-UNK
stress	B-UNK
.	O
Amphetamine	O
treatment	B-UNK
significantly	I-UNK
disrupted	O
PPI	O
in	O
both	O
non-deprived	O
groups	B-UNK
,	O
but	O
was	O
absent	O
in	O
both	O
maternally	O
deprived	O
groups	B-UNK
.	O
The	O
serotonin-1A	O
receptor	B-UNK
agonist	B-UNK
,	O
8-OH	O
-	O
DPAT	O
,	O
induced	B-UNK
a	O
significant	B-UNK
disruption	B-UNK
of	O
PPI	O
in	O
all	O
groups	B-UNK
.	O
Amphetamine	O
-	O
induced	B-UNK
locomotor	B-UNK
hyperactivity	B-UNK
was	O
similar	B-UNK
in	O
all	O
groups	B-UNK
.	O
These	O
results	B-UNK
show	O
an	O
inhibitory	B-UNK
interaction	B-UNK
of	O
early	B-UNK
stress	B-UNK
,	O
caused	B-UNK
by	O
maternal	B-UNK
deprivation	B-UNK
,	O
combined	B-UNK
with	O
'	O
adolescent	O
'	O
stress	B-UNK
,	O
simulated	O
by	O
corticosterone	B-CHEMICAL
treatment	B-UNK
,	O
on	O
dopaminergic	B-UNK
regulation	O
of	O
PPI	O
.	O
The	O
altered	B-UNK
effects	B-UNK
of	O
apomorphine	B-CHEMICAL
and	O
amphetamine	B-CHEMICAL
could	O
indicate	B-UNK
differential	B-UNK
changes	B-UNK
in	O
dopamine	B-CHEMICAL
receptor	B-UNK
signalling	O
leading	B-UNK
to	O
functional	B-UNK
desensitisation	O
,	O
or	O
altered	B-UNK
modulation	O
of	O
sensory	B-UNK
gating	O
in	O
the	O
nucleus	B-UNK
accumbens	B-UNK
by	O
limbic	O
structures	B-UNK
such	O
as	O
the	O
hippocampus	B-UNK
.	O

Peripheral	O
iron	B-CHEMICAL
dextran	B-UNK
induced	B-UNK
degeneration	B-UNK
of	O
dopaminergic	B-UNK
neurons	B-UNK
in	O
rat	B-UNK
substantia	B-UNK
nigra	B-UNK
.	O

Iron	O
accumulation	B-UNK
is	O
considered	B-UNK
to	O
be	O
involved	B-UNK
in	O
the	O
pathogenesis	O
of	O
Parkinson'	O
s	O
disease	B-DISEASE
.	O
To	O
demonstrate	B-UNK
the	O
relationship	B-UNK
between	O
peripheral	B-UNK
iron	B-DISEASE
overload	I-DISEASE
and	O
dopaminergic	B-UNK
neuron	O
loss	B-UNK
in	O
rat	B-UNK
substantia	B-UNK
nigra	B-UNK
(	O
SN	O
)	O
,	O
in	O
the	O
present	B-UNK
study	B-UNK
we	O
used	O
fast	O
cyclic	O
voltammetry	O
,	O
tyrosine	B-CHEMICAL
hydroxylase	O
(	O
TH	O
)	O
immunohistochemistry	O
,	O
Perls	O
'	O
iron	B-CHEMICAL
staining	B-UNK
,	O
and	O
high	B-UNK
performance	B-UNK
liquid	B-UNK
chromatography	O
-	O
electrochemical	O
detection	O
to	O
study	B-UNK
the	O
degeneration	B-UNK
of	O
dopaminergic	B-UNK
neurons	B-UNK
and	O
increased	B-UNK
iron	B-CHEMICAL
content	B-UNK
in	O
the	O
SN	O
of	O
iron	B-CHEMICAL
dextran	B-UNK
overloaded	O
animals	B-UNK
.	O
The	O
findings	B-UNK
showed	B-UNK
that	O
peripheral	B-UNK
iron	B-CHEMICAL
dextran	B-UNK
overload	O
increased	B-UNK
the	O
iron	B-CHEMICAL
staining	B-UNK
positive	B-UNK
cells	B-UNK
and	O
reduced	B-UNK
the	O
number	B-UNK
of	O
TH	O
-	O
immunoreactive	O
neurons	B-UNK
in	O
the	O
SN	O
.	O
As	O
a	O
result	B-UNK
,	O
dopamine	B-CHEMICAL
release	B-UNK
and	O
content	B-UNK
,	O
as	O
well	O
as	O
its	O
metabolites	B-UNK
contents	O
were	O
decreased	B-UNK
in	O
caudate	O
putamen	O
.	O
Even	O
more	O
dramatic	B-UNK
changes	B-UNK
were	O
found	B-UNK
in	O
chronic	B-UNK
overload	O
group	B-UNK
.	O
These	O
results	B-UNK
suggest	B-UNK
that	O
peripheral	B-UNK
iron	B-CHEMICAL
dextran	B-UNK
can	O
increase	B-UNK
the	O
iron	B-CHEMICAL
level	B-UNK
in	O
the	O
SN	O
,	O
where	O
excessive	B-UNK
iron	B-CHEMICAL
causes	B-UNK
the	O
degeneration	B-UNK
of	O
dopaminergic	B-UNK
neurons	B-UNK
.	O
The	O
chronic	B-UNK
iron	B-DISEASE
overload	I-DISEASE
may	O
be	O
more	O
destructive	O
to	O
dopaminergic	B-UNK
neurons	B-UNK
than	O
the	O
acute	B-UNK
iron	B-DISEASE
overload	I-DISEASE
.	O

Warfarin	O
-	O
induced	B-UNK
leukocytoclastic	O
vasculitis	B-DISEASE
.	O

Skin	B-UNK
reactions	B-UNK
associated	B-UNK
with	O
oral	B-UNK
coumarin	B-CHEMICAL
-	O
derived	O
anticoagulants	B-CHEMICAL
are	O
an	O
uncommon	O
occurrence	O
.	O
Leukocytoclastic	O
vasculitis	B-DISEASE
(	O
LV	O
)	O
is	O
primarily	B-UNK
a	O
cutaneous	B-UNK
small	B-UNK
vessel	O
vasculitis	B-DISEASE
,	O
though	O
systemic	B-UNK
involvement	B-UNK
may	O
be	O
encountered	B-UNK
.	O
We	O
report	B-UNK
4	O
patients	B-UNK
with	O
late	B-UNK
-	O
onset	B-UNK
LV	O
probably	B-UNK
due	O
to	O
warfarin	B-CHEMICAL
.	O
All	O
4	O
patients	B-UNK
presented	B-UNK
with	O
skin	B-DISEASE
eruptions	O
that	O
developed	B-UNK
after	O
receiving	B-UNK
warfarin	B-CHEMICAL
for	O
several	O
years	B-UNK
.	O
The	O
results	B-UNK
of	O
skin	B-DISEASE
lesion	B-UNK
biopsies	B-UNK
were	O
available	B-UNK
in	O
3	O
patients	B-UNK
,	O
confirming	O
LV	O
Cutaneous	O
lesions	B-UNK
resolved	B-UNK
in	O
all	O
patients	B-UNK
after	O
warfarin	B-CHEMICAL
was	O
discontinued	O
.	O
In	O
2	B-DISEASE
of	O
the	O
4	O
patients	B-UNK
,	O
rechallenge	O
with	O
warfarin	B-CHEMICAL
led	B-UNK
to	O
recurrence	B-DISEASE
of	O
the	O
lesions	B-UNK
.	O
LV	O
may	O
be	O
a	O
late	B-UNK
-	O
onset	B-UNK
adverse	B-UNK
reaction	B-UNK
associated	B-UNK
with	O
warfarin	B-CHEMICAL
therapy	B-UNK
.	O

The	O
activation	B-UNK
of	O
spinal	B-UNK
N	B-UNK
-	O
methyl	O
-	O
D	B-UNK
-	O
aspartate	B-UNK
receptors	B-UNK
may	O
contribute	O
to	O
degeneration	B-UNK
of	O
spinal	B-UNK
motor	B-UNK
neurons	B-UNK
induced	B-UNK
by	O
neuraxial	B-UNK
morphine	B-CHEMICAL
after	O
a	O
noninjurious	O
interval	B-UNK
of	O
spinal	B-DISEASE
cord	I-DISEASE
ischemia	I-DISEASE
.	O

We	O
investigated	B-UNK
the	O
relationship	B-UNK
between	O
the	O
degeneration	B-UNK
of	O
spinal	B-UNK
motor	B-UNK
neurons	B-UNK
and	O
activation	B-UNK
of	O
N	B-UNK
-	O
methyl	O
-	O
d	B-UNK
-	O
aspartate	B-UNK
(	O
NMDA	O
)	O
receptors	B-UNK
after	O
neuraxial	B-UNK
morphine	B-CHEMICAL
following	B-UNK
a	O
noninjurious	O
interval	B-UNK
of	O
aortic	B-UNK
occlusion	B-UNK
in	O
rats	B-UNK
.	O
Spinal	O
cord	O
ischemia	B-DISEASE
was	O
induced	B-UNK
by	O
aortic	B-UNK
occlusion	B-UNK
for	O
6	O
min	B-UNK
with	O
a	O
balloon	O
catheter	B-UNK
.	O
In	O
a	O
microdialysis	O
study	B-UNK
,	O
10	O
muL	O
of	O
saline	B-UNK
(	O
group	B-UNK
C	B-UNK
;	O
n	B-UNK
=	O
8)	B-UNK
or	O
30	O
mug	O
of	O
morphine	B-CHEMICAL
(	O
group	B-UNK
M	O
;	O
n	B-UNK
=	O
8)	B-UNK
was	O
injected	B-UNK
intrathecally	O
(	O
IT	O
)	O
0.5	B-UNK
h	B-UNK
after	O
reflow	O
,	O
and	O
30	O
mug	O
of	O
morphine	B-CHEMICAL
(	O
group	B-UNK
SM	O
;	O
n	B-UNK
=	O
8)	B-UNK
or	O
10	O
muL	O
of	O
saline	B-UNK
(	O
group	B-UNK
SC	O
;	O
n	B-UNK
=	O
8)	B-UNK
was	O
injected	B-UNK
IT	O
0.5	B-UNK
h	B-UNK
after	O
sham	O
operation	O
.	O
Microdialysis	O
samples	B-UNK
were	O
collected	B-UNK
preischemia	O
,	O
before	O
IT	O
injection	B-UNK
,	O
and	O
at	B-DISEASE
2	B-DISEASE
,	O
4	O
,	O
8	O
,	O
24	O
,	O
and	O
48	O
h	B-UNK
of	O
reperfusion	O
(	O
after	O
IT	O
injection	B-UNK
)	O
.	O
Second	O
,	O
we	O
investigated	B-UNK
the	O
effect	B-UNK
of	O
IT	O
MK-801	O
(	O
30	O
mug	O
)	O
on	O
the	O
histopathologic	O
changes	B-UNK
in	O
the	O
spinal	B-UNK
cord	O
after	O
morphine	B-CHEMICAL
-	O
induced	B-UNK
spastic	O
paraparesis	B-DISEASE
.	O
After	O
IT	O
morphine	B-CHEMICAL
,	O
the	O
cerebrospinal	B-UNK
fluid	B-UNK
(	O
CSF	O
)	O
glutamate	B-UNK
concentration	B-UNK
was	O
increased	B-UNK
in	O
group	B-UNK
M	O
relative	B-UNK
to	O
both	O
baseline	B-UNK
and	O
group	B-UNK
C	B-UNK
(	O
P	B-UNK
<	I-UNK
0.05	O
)	O
.	O
This	O
increase	B-UNK
persisted	B-UNK
for	O
8	O
hrs	O
.	O
IT	O
MK-801	O
significantly	B-UNK
reduced	B-UNK
the	O
number	B-UNK
of	O
dark	O
-	O
stained	B-UNK
alpha	B-UNK
-	O
motoneurons	O
after	O
morphine	B-CHEMICAL
-	O
induced	B-UNK
spastic	O
paraparesis	B-DISEASE
compared	B-UNK
with	O
the	O
saline	B-UNK
group	B-UNK
.	O
These	O
data	B-UNK
indicate	B-UNK
that	O
IT	O
morphine	B-CHEMICAL
induces	B-UNK
spastic	O
paraparesis	B-DISEASE
with	O
a	O
concomitant	B-UNK
increase	B-UNK
in	O
CSF	O
glutamate	B-UNK
,	O
which	O
is	O
involved	B-UNK
in	O
NMDA	O
receptor	B-UNK
activation	B-UNK
.	O
We	O
suggest	B-UNK
that	O
opioids	O
may	O
be	O
neurotoxic	B-UNK
in	O
the	O
setting	B-UNK
of	O
spinal	B-DISEASE
cord	I-DISEASE
ischemia	I-DISEASE
via	O
NMDA	O
receptor	B-UNK
activation	B-UNK
.	O

Reduced	O
sodium	B-CHEMICAL
channel	B-UNK
density	B-UNK
,	O
altered	B-UNK
voltage	O
dependence	B-DISEASE
of	O
inactivation	O
,	O
and	O
increased	B-UNK
susceptibility	B-UNK
to	O
seizures	B-DISEASE
in	O
mice	B-UNK
lacking	O
sodium	B-CHEMICAL
channel	B-UNK
beta	B-UNK
2-subunits	O
.	O

Sodium	O
channel	B-UNK
beta-subunits	O
modulate	O
channel	B-UNK
gating	O
,	O
assembly	O
,	O
and	O
cell	B-UNK
surface	O
expression	B-UNK
in	O
heterologous	O
cell	B-UNK
systems	B-UNK
.	O
We	O
generated	B-UNK
beta2(-/-	O
)	O
mice	B-UNK
to	O
investigate	O
the	O
role	B-UNK
of	O
beta2	O
in	O
control	B-UNK
of	O
sodium	B-CHEMICAL
channel	B-UNK
density	B-UNK
,	O
localization	O
,	O
and	O
function	B-UNK
in	O
neurons	B-UNK
in	O
vivo	B-UNK
.	O
Measurements	O
of	O
[	O
(	O
3)H]saxitoxin	O
(	O
STX	O
)	O
binding	B-UNK
showed	B-UNK
a	O
significant	B-UNK
reduction	B-UNK
in	O
the	O
level	B-UNK
of	O
plasma	B-UNK
membrane	O
sodium	B-CHEMICAL
channels	O
in	O
beta2(-/-	O
)	O
neurons	B-UNK
.	O
The	O
loss	B-UNK
of	O
beta2	O
resulted	B-UNK
in	O
negative	B-UNK
shifts	O
in	O
the	O
voltage	O
dependence	B-DISEASE
of	O
inactivation	O
as	O
well	O
as	O
significant	B-UNK
decreases	B-UNK
in	O
sodium	B-CHEMICAL
current	B-UNK
density	B-UNK
in	O
acutely	B-UNK
dissociated	O
hippocampal	B-UNK
neurons	B-UNK
.	O
The	O
integral	O
of	O
the	O
compound	B-UNK
action	B-UNK
potential	B-UNK
in	O
optic	B-UNK
nerve	I-UNK
was	O
significantly	B-UNK
reduced	B-UNK
,	O
and	O
the	O
threshold	B-UNK
for	O
action	B-UNK
potential	B-UNK
generation	B-UNK
was	O
increased	B-UNK
,	O
indicating	O
a	O
reduction	B-UNK
in	O
the	O
level	B-UNK
of	O
functional	B-UNK
plasma	B-UNK
membrane	O
sodium	B-CHEMICAL
channels	O
.	O
In	O
contrast	B-UNK
,	O
the	O
conduction	B-UNK
velocity	B-UNK
,	O
the	O
number	B-UNK
and	O
size	O
of	O
axons	O
in	O
the	O
optic	B-UNK
nerve	I-UNK
,	O
and	O
the	O
specific	B-UNK
localization	O
of	O
Na(v)1.6	O
channels	O
in	O
the	O
nodes	O
of	O
Ranvier	O
were	O
unchanged	B-UNK
.	O
beta2(-/-	O
)	O
mice	B-UNK
displayed	O
increased	B-UNK
susceptibility	B-UNK
to	O
seizures	B-DISEASE
,	O
as	O
indicated	B-UNK
by	O
reduced	B-UNK
latency	O
and	O
threshold	B-UNK
for	O
pilocarpine	B-CHEMICAL
-	O
induced	B-UNK
seizures	B-DISEASE
,	O
but	O
seemed	O
normal	B-UNK
in	O
other	O
neurological	B-UNK
tests	B-UNK
.	O
Our	O
observations	B-UNK
show	O
that	O
beta2-subunits	O
play	B-UNK
an	O
important	B-UNK
role	B-UNK
in	O
the	O
regulation	O
of	O
sodium	B-CHEMICAL
channel	B-UNK
density	B-UNK
and	O
function	B-UNK
in	O
neurons	B-UNK
in	O
vivo	B-UNK
and	O
are	O
required	B-UNK
for	O
normal	B-UNK
action	B-UNK
potential	B-UNK
generation	B-UNK
and	O
control	B-UNK
of	O
excitability	B-UNK
.	O

Screening	O
for	O
stimulant	B-UNK
use	B-UNK
in	O
adult	B-UNK
emergency	B-UNK
department	B-UNK
seizure	B-DISEASE
patients	B-UNK
.	O

OBJECTIVE	O
:	O
The	O
objective	B-UNK
of	O
this	O
study	B-UNK
was	O
to	O
determine	B-UNK
the	O
prevalence	O
of	O
positive	B-UNK
plasma	B-UNK
drug	B-UNK
screening	B-UNK
for	O
cocaine	B-CHEMICAL
or	O
amphetamine	B-CHEMICAL
in	O
adult	B-UNK
emergency	B-UNK
department	B-UNK
seizure	B-DISEASE
patients	B-UNK
.	O
METHODS	O
:	O
This	O
prospective	B-UNK
study	B-UNK
evaluated	B-UNK
consecutive	B-UNK
eligible	O
seizure	B-UNK
patients	B-UNK
who	O
had	O
a	O
plasma	B-UNK
sample	O
collected	B-UNK
as	O
part	O
of	O
their	O
clinical	B-UNK
evaluation	B-UNK
.	O
Plasma	B-UNK
was	O
tested	B-UNK
for	O
amphetamine	B-CHEMICAL
and	O
the	O
cocaine	B-CHEMICAL
metabolite	B-UNK
benzoylecgonine	B-CHEMICAL
using	O
enzyme	B-UNK
-	O
mediated	B-UNK
immunoassay	B-UNK
methodology	O
.	O
Plasma	B-UNK
samples	B-UNK
with	O
benzoylecgonine	B-CHEMICAL
greater	B-UNK
than	O
150	O
ng	B-UNK
/	O
mL	O
or	O
an	O
amphetamine	B-CHEMICAL
greater	B-UNK
than	O
500	O
ng	B-UNK
/	O
mL	O
were	O
defined	O
as	O
positive	B-UNK
.	O
Patient	O
demographics	O
,	O
history	B-UNK
of	O
underlying	B-UNK
drug	B-UNK
or	O
alcohol	B-UNK
-	O
related	B-UNK
seizure	B-DISEASE
disorder	I-DISEASE
,	O
estimated	B-UNK
time	B-UNK
from	O
seizure	B-DISEASE
to	O
sample	O
collection	O
,	O
history	B-UNK
or	O
suspicion	O
of	O
cocaine	B-CHEMICAL
or	O
amphetamine	B-CHEMICAL
abuse	B-UNK
,	O
results	B-UNK
of	O
clinical	B-UNK
urine	B-DISEASE
testing	B-UNK
for	O
drugs	B-UNK
of	O
abuse	B-UNK
,	O
and	O
assay	B-UNK
results	B-UNK
were	O
recorded	B-UNK
without	O
patient	B-UNK
identifiers	O
.	O
RESULTS	B-UNK
:	O
Fourteen	O
of	O
248	O
(	O
5.6	O
%	O
,	O
95	O
%	O
CI	B-UNK
2.7%-8.5	O
%	O
)	O
plasma	B-UNK
samples	B-UNK
were	O
positive	B-UNK
by	O
immunoassay	B-UNK
testing	B-UNK
for	O
benzoylecgonine	B-CHEMICAL
and	O
no	O
samples	B-UNK
(	O
0	O
%	O
,	O
95	O
%	O
CI	B-UNK
0	O
-	O
1.2	O
%	O
)	O
were	O
positive	B-UNK
for	O
amphetamine	B-CHEMICAL
.	O
Positive	O
test	B-UNK
results	B-UNK
were	O
more	O
common	B-UNK
in	O
patient	B-UNK
visits	O
where	O
there	O
was	O
a	O
history	B-UNK
or	O
suspicion	O
of	O
cocaine	B-CHEMICAL
or	O
amphetamine	B-CHEMICAL
abuse	B-UNK
(	O
p	B-UNK
<	I-UNK
0.0005	O
)	O
.	O
CONCLUSIONS	O
:	O
During	O
this	O
study	B-UNK
period	B-UNK
,	O
routine	B-UNK
plasma	B-UNK
screening	B-UNK
for	O
cocaine	B-CHEMICAL
and	O
amphetamines	B-CHEMICAL
in	O
adult	B-UNK
seizure	B-UNK
patients	B-UNK
had	O
a	O
low	B-UNK
yield	O
.	O
As	O
a	O
result	B-UNK
,	O
routine	B-UNK
plasma	B-UNK
screening	B-UNK
would	O
yield	O
few	O
cases	B-UNK
of	O
stimulant	B-UNK
drug	B-UNK
in	O
which	O
there	O
was	O
neither	O
a	O
history	B-UNK
nor	O
suspicion	O
of	O
drug	B-UNK
abuse	B-UNK
in	O
this	O
population	B-UNK
.	O

Evidence	O
of	O
functional	B-UNK
somatotopy	O
in	O
GPi	O
from	O
results	B-UNK
of	O
pallidotomy	B-UNK
.	O

The	O
objective	B-UNK
of	O
this	O
study	B-UNK
was	O
to	O
explore	O
the	O
functional	B-UNK
anatomy	O
of	O
the	O
globus	B-UNK
pallidus	B-UNK
internus	O
(	O
GPi	O
)	O
by	O
studying	O
the	O
effects	B-UNK
of	O
unilateral	B-UNK
pallidotomy	B-UNK
on	O
parkinsonian	B-UNK
'	O
off	O
'	O
signs	B-UNK
and	O
levodopa	B-CHEMICAL
-	O
induced	B-UNK
dyskinesias	B-DISEASE
(	O
LID	B-UNK
)	O
.	O
We	O
found	B-UNK
significant	B-UNK
positive	B-UNK
correlations	O
between	O
the	O
preoperative	B-UNK
levodopa	B-CHEMICAL
responsiveness	O
of	O
motor	B-UNK
signs	B-UNK
and	O
the	O
levodopa	B-CHEMICAL
responsiveness	O
of	O
scores	B-UNK
in	O
timed	O
tests	B-UNK
(	O
Core	O
Assessment	B-UNK
Program	O
for	O
Intracerebral	O
Transplantations	O
)	O
in	O
the	O
contralateral	B-UNK
limbs	B-UNK
and	O
the	O
improvement	B-UNK
in	O
these	O
scores	B-UNK
after	O
surgery	B-UNK
,	O
whereas	O
there	O
was	O
no	O
correlation	B-UNK
with	O
the	O
improvement	B-UNK
in	O
LID	B-UNK
.	O
We	O
also	O
found	B-UNK
a	O
highly	B-UNK
significant	B-UNK
correlation	B-UNK
(	O
P	B-UNK
:	O
<	B-UNK
0.0001	I-UNK
,	O
r	B-UNK
=	I-UNK
0.8	B-UNK
)	O
between	O
the	O
volume	B-UNK
of	O
the	O
ventral	B-UNK
lesion	B-UNK
in	O
the	O
GPi	O
and	O
the	O
improvement	B-UNK
in	O
LID	B-UNK
in	O
the	O
contralateral	B-UNK
limbs	B-UNK
,	O
whereas	O
there	O
was	O
no	O
correlation	B-UNK
between	O
the	O
ventral	B-UNK
volume	B-UNK
and	O
the	O
improvement	B-UNK
in	O
parkinsonian	B-UNK
'	O
off	O
'	O
signs	B-UNK
.	O
The	O
volumes	O
of	O
the	O
total	B-UNK
lesion	B-UNK
cylinder	O
and	O
the	O
dorsal	B-UNK
lesion	B-UNK
did	O
not	O
correlate	O
with	O
the	O
outcome	B-UNK
of	O
either	O
dyskinesias	B-DISEASE
or	O
parkinsonian	B-UNK
'	O
off	O
'	O
signs	B-UNK
.	O
The	O
differential	B-UNK
predictive	B-UNK
value	B-UNK
of	O
levodopa	B-CHEMICAL
responsiveness	O
for	O
the	O
outcome	B-UNK
of	O
parkinsonian	B-UNK
'	O
off	O
'	O
signs	B-UNK
and	O
LID	B-UNK
and	O
the	O
different	B-UNK
correlations	O
of	O
ventral	B-UNK
lesion	B-UNK
volume	B-UNK
with	O
dyskinesias	B-DISEASE
and	O
parkinsonian	B-UNK
'	O
off	O
'	O
signs	B-UNK
indicate	B-UNK
that	O
different	B-UNK
anatomical	O
or	O
pathophysiological	O
substrates	O
may	O
be	O
responsible	O
for	O
the	O
generation	B-UNK
of	O
parkinsonian	B-UNK
'	O
off	O
'	O
signs	B-UNK
and	O
dyskinesias	B-DISEASE
.	O
Whereas	O
cells	B-UNK
in	O
a	O
wider	O
area	B-UNK
of	O
the	O
GPi	O
may	O
be	O
implicated	B-UNK
in	O
parkinsonism	B-DISEASE
,	O
the	O
ventral	B-UNK
GPi	O
seems	O
to	O
be	O
crucial	O
for	O
the	O
manifestation	B-UNK
of	O
LID	B-UNK
.	O
We	O
suggest	B-UNK
that	O
our	O
observations	B-UNK
are	O
additional	B-UNK
proof	O
of	O
the	O
functional	B-UNK
somatotopy	O
of	O
the	O
systems	B-UNK
within	O
the	O
GPi	O
that	O
mediate	O
parkinsonism	B-DISEASE
and	O
dyskinesias	B-DISEASE
,	O
especially	B-UNK
along	O
the	O
dorsoventral	O
trajectory	O
used	O
in	O
pallidotomy	B-UNK
.	O
The	O
outcome	B-UNK
of	O
pallidotomy	B-UNK
in	O
which	O
the	O
lesion	B-UNK
involves	B-UNK
the	O
ventral	B-UNK
and	O
dorsal	B-UNK
GPi	O
could	O
be	O
the	O
net	O
effect	B-UNK
of	O
alteration	O
in	O
the	O
activity	B-UNK
of	O
pathways	B-UNK
which	O
mediate	O
different	B-UNK
symptoms	B-UNK
,	O
and	O
hence	O
could	O
be	O
variable	B-UNK
.	O

Pain	O
responses	B-UNK
in	O
methadone	B-CHEMICAL
-	O
maintained	O
opioid	B-UNK
abusers	O
.	O

Providing	O
pain	B-DISEASE
management	B-UNK
for	O
known	B-UNK
opioid	B-UNK
abusers	O
is	O
a	O
challenging	O
clinical	B-UNK
task	B-UNK
,	O
in	O
part	O
because	O
little	B-UNK
is	O
known	B-UNK
about	O
their	O
pain	B-UNK
experience	B-UNK
and	O
analgesic	B-UNK
requirements	O
.	O
This	O
study	B-UNK
was	O
designed	O
to	O
describe	O
pain	B-DISEASE
tolerance	B-UNK
and	O
analgesic	B-UNK
response	B-UNK
in	O
a	O
sample	O
of	O
opioid	B-UNK
addicts	O
stabilized	O
in	O
methadone	B-CHEMICAL
-	O
maintenance	B-UNK
(	O
MM	O
)	O
treatment	B-UNK
(	O
n	B-UNK
=	O
60	O
)	O
in	O
comparison	O
to	O
matched	B-UNK
nondependent	O
control	B-UNK
subjects	B-UNK
(	O
n	B-UNK
=	O
60	O
)	O
.	O
By	O
using	O
a	O
placebo	B-UNK
-	O
controlled	B-UNK
,	O
two	O
-	O
way	O
factorial	O
design	O
,	O
tolerance	B-UNK
to	O
cold	B-DISEASE
-	O
pressor	B-UNK
(	O
CP	O
)	O
pain	B-UNK
was	O
examined	B-UNK
,	O
both	O
before	O
and	O
after	O
oral	B-UNK
administration	B-UNK
of	O
therapeutic	B-UNK
doses	B-UNK
of	O
common	B-UNK
opioid	B-UNK
(	O
hydromorphone	B-CHEMICAL
2	B-DISEASE
mg	B-UNK
)	O
and	O
nonsteroidal	B-UNK
anti-inflammatory	I-UNK
(	O
ketorolac	B-CHEMICAL
10	O
mg	B-UNK
)	O
analgesic	B-UNK
agents	B-UNK
.	O
Results	O
showed	B-UNK
that	O
MM	O
individuals	B-UNK
were	O
significantly	B-UNK
less	O
tolerant	O
of	O
CP	O
pain	B-UNK
than	O
control	B-UNK
subjects	B-UNK
,	O
replicating	O
previous	B-UNK
work	B-UNK
.	O
Analgesic	O
effects	B-UNK
were	O
significant	B-UNK
neither	O
for	O
medication	B-UNK
nor	O
group	B-UNK
.	O
These	O
data	B-UNK
indicate	B-UNK
that	O
MM	O
opioid	B-UNK
abusers	O
represent	B-UNK
a	O
pain	B-UNK
-	O
intolerant	O
subset	O
of	O
clinical	B-UNK
patients	B-UNK
.	O
Their	O
complaints	O
of	O
pain	B-UNK
should	O
be	O
evaluated	B-UNK
seriously	O
and	O
managed	B-UNK
aggressively	O
.	O

Urine	B-UNK
N	B-UNK
-	O
acetyl	O
-	O
beta	B-UNK
-	O
D	B-UNK
-	O
glucosaminidase	O
--	O
a	O
marker	B-UNK
of	O
tubular	B-UNK
damage	B-UNK
?	O

BACKGROUND	O
:	O
Although	O
an	O
indicator	O
of	O
renal	B-DISEASE
tubular	B-UNK
dysfunction	B-UNK
,	O
an	O
increased	B-UNK
urinary	B-UNK
N	B-UNK
-	O
acetyl	O
-	O
beta	B-UNK
-	O
D	B-UNK
-	O
glucosaminidase	O
(	O
NAG	B-UNK
)	O
activity	B-UNK
might	O
reflect	O
increased	B-UNK
lysosomal	B-UNK
activity	B-UNK
in	O
renal	B-DISEASE
tubular	B-UNK
cells	B-UNK
.	O
METHODS	O
:	O
Puromycin	O
aminonucleoside	O
(	O
PAN	O
)	O
was	O
administered	B-UNK
to	O
Sprague	B-UNK
Dawley	B-UNK
rats	B-UNK
to	O
induce	B-UNK
proteinuria	B-UNK
.	O
Total	O
protein	B-UNK
,	O
albumin	O
,	O
NAG	B-UNK
activity	B-UNK
and	O
protein	B-UNK
electrophoretic	O
pattern	B-UNK
were	O
assessed	B-UNK
in	O
daily	B-UNK
urine	B-DISEASE
samples	B-UNK
for	O
33	O
days	B-UNK
.	O
The	O
morphological	O
appearance	O
of	O
the	O
kidneys	B-UNK
was	O
examined	B-UNK
on	O
days	B-UNK
three	O
,	O
four	O
,	O
six	O
,	O
eight	O
and	O
thirty	B-UNK
three	O
and	O
the	O
NAG	B-UNK
isoenzyme	O
patterns	B-UNK
on	O
days	B-UNK
zero	O
,	O
four	O
,	O
eight	O
and	O
thirty	B-UNK
three	O
.	O
RESULTS	B-UNK
:	O
Following	O
intravenous	B-UNK
PAN	O
urine	B-DISEASE
volume	B-UNK
and	O
urine	B-DISEASE
NAG	B-UNK
activity	B-UNK
increased	B-UNK
significantly	B-UNK
by	O
day	B-UNK
two	O
,	O
but	O
returned	B-UNK
to	O
normal	B-UNK
by	O
day	B-UNK
four	O
.	O
After	O
day	B-UNK
four	O
all	O
treated	B-UNK
animals	B-UNK
exhibited	B-UNK
a	O
marked	B-UNK
rise	B-UNK
in	O
urine	B-DISEASE
albumin	O
,	O
total	B-UNK
protein	B-UNK
excretion	B-UNK
and	O
NAG	B-UNK
activity	B-UNK
.	O
Electrophoresis	O
showed	B-UNK
a	O
generalised	O
increase	B-UNK
in	O
middle	B-UNK
and	O
high	B-UNK
molecular	B-UNK
weight	B-UNK
urine	B-DISEASE
proteins	B-UNK
from	O
day	B-UNK
four	O
onwards	O
.	O
Protein	O
droplets	O
first	O
appeared	B-UNK
prominent	O
in	O
tubular	B-UNK
cells	B-UNK
on	O
day	B-UNK
four	O
.	O
Peak	O
urine	B-DISEASE
NAG	B-UNK
activity	B-UNK
and	O
a	O
change	B-UNK
in	O
NAG	B-UNK
isoenzyme	O
pattern	B-UNK
coincided	O
with	O
both	O
the	O
peak	B-UNK
proteinuria	B-UNK
and	O
the	O
reduction	B-UNK
in	O
intracellular	B-UNK
protein	B-UNK
and	O
NAG	B-UNK
droplets	O
(	O
day	B-UNK
six	O
onwards	O
)	O
.	O
CONCLUSIONS	O
:	O
This	O
animal	B-UNK
model	B-UNK
demonstrates	B-UNK
that	O
an	O
increase	B-UNK
in	O
lysosomal	B-UNK
turnover	O
and	O
hence	O
urine	B-DISEASE
NAG	B-UNK
activity	B-UNK
,	O
occurs	B-UNK
when	O
increased	B-UNK
protein	B-UNK
is	O
presented	B-UNK
to	O
the	O
tubular	B-UNK
cells	B-UNK
.	O
Urine	B-UNK
NAG	B-UNK
activity	B-UNK
is	O
thus	O
a	O
measure	B-UNK
of	O
altered	B-UNK
function	B-UNK
in	O
the	O
renal	B-UNK
tubules	O
and	O
not	O
simply	O
an	O
indicator	O
of	O
damage	B-UNK
.	O

Over	O
expression	B-UNK
of	O
vascular	B-UNK
endothelial	B-UNK
growth	B-UNK
factor	B-UNK
and	O
its	O
receptor	B-UNK
during	O
the	O
development	B-UNK
of	O
estrogen	B-UNK
-	O
induced	B-UNK
rat	B-UNK
pituitary	B-DISEASE
tumors	I-DISEASE
may	O
mediate	O
estrogen	B-UNK
-	O
initiated	O
tumor	B-DISEASE
angiogenesis	O
.	O

Estrogens	O
,	O
which	O
have	O
been	O
associated	B-UNK
with	O
several	O
types	O
of	O
human	B-UNK
and	O
animal	B-UNK
cancers	O
,	O
can	O
induce	B-UNK
tumor	B-DISEASE
angiogenesis	O
in	O
the	O
pituitary	O
of	O
Fischer	O
344	O
rats	B-UNK
.	O
The	O
mechanistic	O
details	O
of	O
tumor	B-DISEASE
angiogenesis	O
induction	B-UNK
,	O
during	O
estrogen	B-UNK
carcinogenesis	B-DISEASE
,	O
are	O
still	O
unknown	B-UNK
.	O
To	O
elucidate	O
the	O
role	B-UNK
of	O
estrogen	B-UNK
in	O
the	O
regulation	O
of	O
tumor	B-DISEASE
angiogenesis	O
in	O
the	O
pituitary	O
of	O
female	B-UNK
rats	B-UNK
,	O
the	O
density	B-UNK
of	O
blood	B-UNK
vessels	O
was	O
analysed	O
using	O
factor	B-UNK
VIII	O
related	B-UNK
antigen	B-UNK
(	O
FVIIIRAg	O
)	O
immunohistochemistry	O
and	O
the	O
expression	B-UNK
of	O
vascular	B-UNK
endothelial	B-UNK
growth	B-UNK
factor	B-UNK
/	O
vascular	B-UNK
permeability	O
factor	B-UNK
(	O
VEGF	O
/	O
VPF	O
)	O
was	O
examined	B-UNK
by	O
Western	B-UNK
blot	B-UNK
and	O
immunohistochemical	O
analysis	B-UNK
.	O
The	O
expression	B-UNK
of	O
VEGF	O
receptor	B-UNK
(	O
VEGFR-2	O
/	O
Flk-1	O
/	O
KDR	O
)	O
was	O
also	O
examined	B-UNK
by	O
immunohistochemistry	O
.	O
The	O
results	B-UNK
demonstrated	B-UNK
that	O
17beta	O
-	O
estradiol	B-CHEMICAL
(	O
E2	B-UNK
)	O
induces	B-UNK
neovascularization	B-DISEASE
,	O
as	O
well	O
as	O
the	O
growth	B-UNK
and	O
enlargement	B-UNK
of	O
blood	B-UNK
vessels	O
after	O
7	O
days	B-UNK
of	O
exposure	B-UNK
.	O
The	O
high	B-UNK
tumor	B-DISEASE
angiogenic	O
potential	B-UNK
was	O
associated	B-UNK
with	O
an	O
elevated	B-UNK
VEGF	O
/	O
VPF	O
protein	B-UNK
expression	B-UNK
in	O
the	O
E2	B-UNK
exposed	B-UNK
pituitary	O
of	O
ovariectomized	O
(	O
OVEX	O
)	O
rats	B-UNK
.	O
VEGF	O
/	O
VPF	O
and	O
FVIIIRAg	O
immunohistochemistry	O
and	O
endothelial	B-UNK
specific	B-UNK
lectin	O
(	O
UEA1	O
)	O
binding	B-UNK
studies	B-UNK
,	O
indicate	B-UNK
that	O
the	O
elevation	B-UNK
of	O
VEGF	O
protein	B-UNK
expression	B-UNK
initially	B-UNK
occurred	B-UNK
in	O
both	O
blood	B-UNK
vessels	O
and	O
non-endothelial	O
cells	B-UNK
.	O
After	O
15	O
days	B-UNK
of	O
E2	B-UNK
exposure	B-UNK
,	O
VEGF	O
/	O
VPF	O
protein	B-UNK
expression	B-UNK
,	O
in	O
the	O
non-endothelial	O
cell	B-UNK
population	B-UNK
,	O
sharply	O
declined	O
and	O
was	O
restricted	B-UNK
to	O
the	O
blood	B-UNK
vessels	O
.	O
The	O
function	B-UNK
of	O
non-endothelial-derived	O
VEGF	O
is	O
not	O
clear	B-UNK
.	O
Furthermore	O
,	O
immunohistochemical	O
studies	B-UNK
demonstrated	I-UNK
that	O
VEGFR-2	O
(	O
flk-1	O
/	O
KDR	O
)	O
,	O
expression	B-UNK
was	O
elevated	B-UNK
significantly	B-UNK
in	O
the	O
endothelial	B-UNK
cells	B-UNK
of	O
microblood	O
vessels	O
after	O
7	O
days	B-UNK
of	O
E2	B-UNK
exposure	B-UNK
.	O
These	O
findings	B-UNK
suggest	B-UNK
that	O
over	O
expression	B-UNK
of	O
VEGF	O
and	O
its	O
receptor	B-UNK
(	O
VEGFR-2	O
)	O
may	O
play	B-UNK
an	O
important	B-UNK
role	B-UNK
in	O
the	O
initial	B-UNK
step	O
of	O
the	O
regulation	O
of	O
estrogen	B-UNK
induced	B-UNK
tumor	B-DISEASE
angiogenesis	O
in	O
the	O
rat	B-UNK
pituitary	O
.	O

Pravastatin	O
-	O
associated	B-UNK
myopathy	B-DISEASE
.	O
Report	O
of	O
a	O
case	B-UNK
.	O

A	O
case	B-UNK
of	O
acute	B-UNK
inflammatory	B-UNK
myopathy	B-DISEASE
associated	B-UNK
with	O
the	O
use	B-UNK
of	O
pravastatin	B-CHEMICAL
,	O
a	O
new	B-UNK
hydrophilic	O
3-hydroxy-3	O
methylglutaril	O
coenzyme	O
A	O
reductase	B-UNK
inhibitor	B-UNK
,	O
is	O
reported	B-UNK
.	O
The	O
patient	B-UNK
,	O
a	O
69-year	O
-	O
old	B-UNK
man	B-UNK
was	O
affected	B-UNK
by	O
non-insulin-dependent	O
diabetes	B-DISEASE
mellitus	I-DISEASE
and	O
hypertension	B-DISEASE
.	O
He	O
assumed	O
pravastatin	B-CHEMICAL
(	O
20	O
mg	B-UNK
/	O
day	B-UNK
)	O
because	O
of	O
hypercholesterolemia	B-DISEASE
.	O
He	O
was	O
admitted	O
with	O
acute	B-UNK
myopathy	B-DISEASE
of	O
the	O
lower	B-UNK
limbs	B-UNK
which	O
resolved	B-UNK
in	O
a	O
few	O
days	B-UNK
after	O
pravastatin	B-CHEMICAL
discontinuation	B-UNK
.	O
A	O
previously	B-UNK
unknown	B-UNK
hypothyroidism	B-DISEASE
,	O
probably	B-UNK
due	O
to	O
chronic	B-UNK
autoimmune	O
thyroiditis	B-DISEASE
,	O
was	O
evidenced	O
.	O
Muscle	B-UNK
biopsy	B-UNK
(	O
left	B-UNK
gastrocnemius	B-UNK
)	O
revealed	B-UNK
a	O
perimysial	O
and	O
endomysial	O
inflammatory	B-UNK
infiltrate	O
with	O
a	O
prevalence	O
of	O
CD4	B-UNK
+	O
lymphocytes	B-UNK
.	O
While	O
lovastatin	B-CHEMICAL
and	O
simvastatin	B-CHEMICAL
have	O
been	O
associated	B-UNK
with	O
toxic	B-UNK
myopathy	B-DISEASE
,	O
pravastatin	B-CHEMICAL
-	O
associated	B-UNK
myopathy	B-DISEASE
could	O
represent	B-UNK
a	O
distinct	O
,	O
inflammatory	B-UNK
entity	O
.	O

Dose	B-UNK
-	O
effect	B-UNK
and	O
structure	B-UNK
-	O
function	B-UNK
relationships	O
in	O
doxorubicin	B-CHEMICAL
cardiomyopathy	B-DISEASE
.	O

The	O
cardiomyopathy	B-DISEASE
(	O
CM	O
)	O
produced	B-UNK
by	O
the	O
anticancer	O
drug	B-UNK
doxorubicin	B-CHEMICAL
(	O
DXR	B-UNK
)	O
(	O
Adriamycin	O
)	O
provides	B-UNK
a	O
unique	B-UNK
opportunity	O
to	O
analyze	O
dose	B-UNK
-	O
effect	B-UNK
and	O
structure	B-UNK
-	O
function	B-UNK
relationships	O
during	O
development	B-UNK
of	O
myocardial	B-UNK
disease	B-DISEASE
.	O
We	O
measured	B-UNK
the	O
degree	B-UNK
of	O
morphologic	B-UNK
damage	B-UNK
by	O
ultrastructural	O
examination	B-UNK
of	O
endomyocardial	O
biopsy	B-UNK
and	O
the	O
degree	B-UNK
of	O
performance	B-UNK
abnormally	O
by	O
right	B-UNK
heart	B-UNK
catheterization	O
in	O
patients	B-UNK
receiving	B-UNK
DXR	B-UNK
.	O
Morphologic	O
damage	B-UNK
was	O
variable	B-UNK
but	O
was	O
proportional	O
to	O
the	O
total	B-UNK
cumulative	B-UNK
DXR	B-UNK
dose	B-UNK
between	O
100	O
and	O
600	O
mg	B-UNK
/	O
m2	O
.	O
Performance	O
abnormalities	B-DISEASE
correlated	B-UNK
weakly	O
with	O
dose	B-UNK
,	O
exhibited	B-UNK
a	O
curvilinear	O
relationship	B-UNK
,	O
and	O
had	O
a	O
"	O
threshold	B-UNK
"	O
for	O
expression	B-UNK
.	O
Catheterization	O
abnormalities	B-DISEASE
correlated	B-UNK
well	O
with	O
morphologic	B-UNK
damage	B-UNK
(	O
r	B-UNK
=	I-UNK
0.57	O
to	O
0.78	O
)	O
in	O
a	O
subgroup	O
of	O
patients	B-UNK
in	O
whom	O
exercise	B-UNK
hemodynamics	O
were	O
measured	B-UNK
,	O
and	O
this	O
relationship	B-UNK
also	O
exhibited	B-UNK
a	O
curvilinear	O
,	O
threshold	B-UNK
configuration	O
.	O
In	O
DXR	B-UNK
-	O
CM	O
myocardial	B-UNK
damage	B-UNK
is	O
proportional	O
to	O
the	O
degree	B-UNK
of	O
cytotoxic	B-UNK
insult	O
(	O
DXR	B-UNK
dose	B-UNK
)	O
while	O
myocardial	B-UNK
function	B-UNK
is	O
preserved	O
until	O
a	O
critical	B-UNK
dose	B-UNK
or	O
degree	B-UNK
of	O
damage	B-UNK
is	O
reached	B-UNK
,	O
after	O
which	O
myocardial	B-UNK
performance	B-UNK
deteriorates	O
rapidly	B-UNK
.	O

Fatal	B-UNK
aplastic	B-DISEASE
anemia	I-DISEASE
following	B-UNK
topical	B-UNK
administration	B-UNK
of	O
ophthalmic	B-UNK
chloramphenicol	B-CHEMICAL
.	O

A	O
73-year	O
-	O
old	B-UNK
woman	B-UNK
died	B-UNK
of	O
aplastic	B-DISEASE
anemia	I-DISEASE
less	O
than	O
two	O
months	B-UNK
after	O
undergoing	B-UNK
cataract	B-DISEASE
extraction	O
and	O
beginning	B-UNK
topical	B-UNK
therapy	B-UNK
with	O
chloramphenicol	B-CHEMICAL
.	O
The	O
first	O
signs	B-UNK
of	O
pancytopenia	B-DISEASE
began	B-UNK
within	O
one	O
month	O
of	O
the	O
surgery	B-UNK
.	O
The	O
pattern	B-UNK
of	O
the	O
aplastic	B-DISEASE
anemia	I-DISEASE
was	O
associated	B-UNK
with	O
an	O
idiosyncratic	O
response	B-UNK
to	O
chloramphenicol	B-CHEMICAL
.	O
This	O
was	O
the	O
second	B-UNK
report	B-UNK
of	O
fatal	B-UNK
aplastic	B-DISEASE
anemia	I-DISEASE
after	O
topical	B-UNK
treatment	B-UNK
with	O
chloramphenicol	B-CHEMICAL
for	O
ocular	B-UNK
conditions	B-UNK
,	O
although	O
two	O
cases	B-UNK
of	O
reversible	B-UNK
bone	B-UNK
marrow	B-UNK
hypoplasia	O
have	O
also	O
been	O
reported	B-UNK
.	O
Any	O
other	O
suspected	O
cases	B-UNK
of	O
ocular	B-UNK
toxicity	B-UNK
associated	B-UNK
with	O
topically	O
applied	O
chloramphenicol	B-CHEMICAL
should	O
be	O
reported	B-UNK
to	O
the	O
National	B-UNK
Registry	O
of	O
Drug	B-UNK
-	O
Induced	O
Ocular	O
Side	O
Effects	O
,	O
Oregon	O
Health	B-UNK
Sciences	O
University	B-UNK
,	O
Portland	O
,	O
OR	O
97201	O
.	O

Bradycardia	O
due	O
to	O
trihexyphenidyl	B-CHEMICAL
hydrochloride	B-UNK
.	O

A	O
chronic	B-UNK
schizophrenic	B-UNK
patient	B-UNK
was	O
treated	B-UNK
with	O
an	O
anticholinergic	B-UNK
drug	B-UNK
,	O
trihexyphenidyl	B-CHEMICAL
hydrochloride	B-UNK
.	O
The	O
patient	B-UNK
developed	I-UNK
,	O
paradoxically	O
,	O
sinus	B-UNK
bradycardia	B-DISEASE
.	O
The	O
reaction	B-UNK
was	O
specific	B-UNK
to	O
trihexyphenidyl	B-CHEMICAL
and	O
not	O
to	O
other	O
anticholinergic	B-UNK
drugs	B-UNK
.	O
This	O
antidyskinetic	O
drug	B-UNK
is	O
widely	B-UNK
used	O
in	O
clinical	B-UNK
psychiatric	B-UNK
practice	O
and	O
physicians	O
should	O
be	O
aware	O
of	O
this	O
side	O
effect	B-UNK
.	O

Experimental	O
cyclosporine	B-CHEMICAL
nephrotoxicity	B-UNK
:	O
risk	B-UNK
of	O
concomitant	B-UNK
chemotherapy	B-UNK
.	O

The	O
role	B-UNK
of	O
cyclosporine	B-CHEMICAL
(	O
CSA	O
)	O
alone	O
or	O
in	O
combination	B-UNK
with	O
various	O
chemotherapeutics	O
in	O
the	O
development	B-UNK
of	O
renal	B-UNK
toxicity	B-UNK
was	O
evaluated	B-UNK
in	O
rats	B-UNK
.	O
Administration	B-UNK
of	O
20	O
mg	B-UNK
/	O
kg	B-UNK
/	O
day	B-UNK
CSA	O
for	O
4	O
weeks	B-UNK
caused	B-UNK
renal	B-DISEASE
functional	B-UNK
and	O
structural	B-UNK
changes	B-UNK
similar	B-UNK
to	O
those	O
reported	B-UNK
in	O
man	B-UNK
.	O
The	O
combined	B-UNK
administration	B-UNK
of	O
CSA	O
and	O
various	O
chemotherapeutic	B-UNK
drugs	B-UNK
with	O
a	O
nephrotoxic	B-UNK
potential	B-UNK
,	O
such	O
as	O
gentamicin	B-UNK
(	O
at	B-DISEASE
therapeutic	B-UNK
doses	B-UNK
)	O
,	O
amphothericin	O
B	B-UNK
and	O
ketoconazole	B-CHEMICAL
,	O
which	O
are	O
frequently	B-UNK
used	O
in	O
immunosuppressed	O
patients	B-UNK
,	O
did	O
not	O
aggravate	O
the	O
CSA	O
induced	B-UNK
toxicity	B-UNK
in	O
the	O
rat	B-UNK
model	B-UNK
.	O
Gentamicin	O
at	B-DISEASE
toxic	B-UNK
doses	B-UNK
,	O
however	O
,	O
increased	B-UNK
CSA	O
nephrotoxicity	B-UNK
.	O
Thus	O
,	O
the	O
nephrotoxicity	B-UNK
induced	B-UNK
by	O
CSA	O
has	O
a	O
different	B-UNK
pathogenetic	O
mechanism	B-UNK
.	O

Receptor	O
mechanisms	B-UNK
of	O
nicotine	B-CHEMICAL
-	O
induced	B-UNK
locomotor	B-UNK
hyperactivity	B-UNK
in	O
chronic	B-UNK
nicotine	B-CHEMICAL
-	O
treated	B-UNK
rats	B-UNK
.	O

Rats	O
were	O
pretreated	B-UNK
with	O
saline	B-UNK
or	O
nicotine	B-CHEMICAL
(	O
1.5	B-UNK
mg	B-UNK
/	O
kg	B-UNK
per	O
day	B-UNK
)	O
by	O
subcutaneously	O
implanting	O
each	O
animal	B-UNK
with	O
an	O
Alzet	O
osmotic	B-UNK
mini-pump	O
which	O
continuously	B-UNK
released	O
saline	B-UNK
or	O
nicotine	B-CHEMICAL
for	O
1	O
,	O
5	O
and	O
14	O
days	B-UNK
.	O
At	O
the	O
end	B-UNK
of	O
each	O
pretreatment	B-UNK
period	B-UNK
,	O
animals	B-UNK
were	O
used	O
for	O
(	O
i	O
)	O
determining	O
their	O
locomotor	B-UNK
response	B-UNK
to	O
acutely	B-UNK
injected	B-UNK
nicotine	B-CHEMICAL
(	O
0.2	B-UNK
mg	B-UNK
/	O
kg	B-UNK
,	O
s.c	B-UNK
.	O
)	O
and	O
(	O
ii	B-UNK
)	O
measuring	B-UNK
the	O
density	B-UNK
of	O
L-[3H]nicotine	B-UNK
and	O
[	O
3H]spiperone	B-UNK
binding	I-UNK
sites	O
in	O
the	O
striatum	O
.	O
We	O
observed	B-UNK
no	O
changes	B-UNK
in	O
nicotine	B-CHEMICAL
-	O
induced	B-UNK
locomotor	B-UNK
response	B-UNK
,	O
striatal	B-UNK
L-[3H]nicotine	B-UNK
and	O
[	O
3H]spiperone	B-UNK
binding	I-UNK
in	O
the	O
animals	B-UNK
pretreated	B-UNK
with	O
nicotine	B-CHEMICAL
for	O
1	O
day	B-UNK
.	O
In	O
rats	B-UNK
which	O
were	O
pretreated	B-UNK
with	O
nicotine	B-CHEMICAL
for	O
5	O
days	B-UNK
,	O
there	O
was	O
a	O
significant	B-UNK
increase	B-UNK
in	O
the	O
nicotine	B-CHEMICAL
-	O
stimulated	O
locomotor	B-UNK
response	B-UNK
which	O
was	O
associated	B-UNK
with	O
an	O
increase	B-UNK
in	O
the	O
number	B-UNK
of	O
L-[3H]nicotine	B-UNK
binding	B-UNK
sites	I-UNK
and	O
also	O
with	O
an	O
elevated	B-UNK
dopamine	B-CHEMICAL
(	O
DA	B-UNK
)	O
level	B-UNK
in	O
the	O
striatum	O
.	O
The	O
number	B-UNK
of	O
striatal	B-UNK
[	O
3H]spiperone	B-UNK
binding	I-UNK
sites	O
was	O
not	O
affected	B-UNK
.	O
In	O
animals	B-UNK
pretreated	B-UNK
with	O
nicotine	B-CHEMICAL
for	O
14	O
days	B-UNK
,	O
the	O
nicotine	B-CHEMICAL
-	O
induced	B-UNK
locomotor	B-UNK
response	B-UNK
remained	B-UNK
to	O
be	O
potentiated	B-UNK
.	O
However	O
,	O
this	O
response	B-UNK
was	O
correlated	B-UNK
with	O
an	O
elevated	B-UNK
number	B-UNK
of	O
striatal	B-UNK
[	O
3H]spiperone	B-UNK
binding	I-UNK
sites	O
,	O
whereas	O
the	O
number	B-UNK
of	O
striatal	B-UNK
L-[3H]nicotine	B-UNK
binding	B-UNK
sites	I-UNK
and	O
the	O
striatal	B-UNK
DA	B-UNK
level	B-UNK
were	O
normal	B-UNK
.	O
These	O
results	B-UNK
suggest	B-UNK
that	O
chronic	B-UNK
nicotine	B-CHEMICAL
-	O
treated	B-UNK
rats	B-UNK
develop	B-UNK
locomotor	B-UNK
hyperactivity	B-UNK
in	O
response	B-UNK
to	O
nicotine	B-CHEMICAL
initially	B-UNK
due	O
to	O
increases	B-UNK
of	O
both	O
the	O
density	B-UNK
of	O
nicotinic	O
receptors	B-UNK
and	O
DA	B-UNK
concentration	B-UNK
,	O
followed	B-UNK
by	O
inducing	B-UNK
DA	B-UNK
receptor	B-UNK
supersensitivity	O
in	O
the	O
striatum	O
.	O

Hydrocortisone	O
-	O
induced	B-UNK
hypertension	B-DISEASE
in	O
humans	O
:	O
pressor	B-UNK
responsiveness	O
and	O
sympathetic	B-UNK
function	B-UNK
.	O

Oral	O
hydrocortisone	B-CHEMICAL
increases	B-UNK
blood	B-UNK
pressure	B-UNK
and	O
enhances	O
pressor	B-UNK
responsiveness	O
in	O
normal	B-UNK
human	B-UNK
subjects	B-UNK
.	O
We	O
studied	B-UNK
the	O
effects	B-UNK
of	O
1	O
week	B-UNK
of	O
oral	B-UNK
hydrocortisone	B-CHEMICAL
(	O
200	O
mg	B-UNK
/	O
day	B-UNK
)	O
on	O
blood	B-UNK
pressure	B-UNK
,	O
cardiac	B-DISEASE
output	I-DISEASE
,	O
total	B-UNK
peripheral	B-UNK
resistance	B-UNK
,	O
forearm	O
vascular	B-UNK
resistance	B-UNK
,	O
and	O
norepinephrine	B-CHEMICAL
spillover	O
to	O
plasma	B-UNK
in	O
eight	O
healthy	B-UNK
male	B-UNK
volunteers	O
.	O
Although	O
diastolic	B-UNK
blood	B-UNK
pressure	B-UNK
remained	B-UNK
unchanged	B-UNK
,	O
systolic	B-UNK
blood	B-UNK
pressure	B-UNK
increased	B-UNK
from	O
119	O
to	O
135	O
mm	B-UNK
Hg	B-UNK
(	O
SED	B-UNK
+	O
/-	O
3.4	B-UNK
,	O
p	B-UNK
less	O
than	O
0.01	B-UNK
)	O
,	O
associated	B-UNK
with	O
an	O
increased	B-UNK
cardiac	B-DISEASE
output	I-DISEASE
(	O
5.85	O
-	O
7.73	O
l	B-UNK
/	O
min	B-UNK
,	O
SED	B-UNK
+	O
/-	O
0.46	O
,	O
p	B-UNK
less	O
than	O
0.01	B-UNK
)	O
.	O
Total	O
peripheral	B-UNK
vascular	B-UNK
resistance	B-UNK
fell	O
from	O
15.1	O
to	O
12.2	O
mm	B-UNK
Hg	B-UNK
/	O
l	B-UNK
/	O
min	B-UNK
(	O
SED	B-UNK
+	O
/-	O
1.03	O
,	O
p	B-UNK
less	O
than	O
0.05	O
)	O
.	O
Resting	O
forearm	O
vascular	B-UNK
resistance	B-UNK
remained	B-UNK
unchanged	B-UNK
,	O
but	O
the	O
reflex	B-DISEASE
response	B-UNK
to	O
the	O
cold	B-DISEASE
pressor	B-UNK
test	B-UNK
was	O
accentuated	O
,	O
the	O
rise	B-UNK
in	O
resistance	B-UNK
increasing	B-UNK
from	O
10.5	O
mm	B-UNK
Hg	B-UNK
/	O
ml/100	O
ml	B-UNK
/	O
min	B-UNK
(	O
R	B-UNK
units	I-UNK
)	O
before	O
treatment	B-UNK
to	O
32.6	O
R	B-UNK
units	I-UNK
after	O
treatment	B-UNK
(	O
SED	B-UNK
+	O
/-	O
6.4	O
,	O
p	B-UNK
less	O
than	O
0.025	O
)	O
.	O
The	O
rise	B-UNK
in	O
forearm	O
vascular	B-UNK
resistance	B-UNK
accompanying	O
intra-arterial	B-UNK
norepinephrine	B-CHEMICAL
(	O
25	O
,	O
50	O
,	O
and	O
100	O
ng	B-UNK
/	O
min	B-UNK
)	O
was	O
also	O
significantly	B-UNK
greater	B-UNK
after	O
hydrocortisone	B-CHEMICAL
,	O
increasing	B-UNK
from	O
an	O
average	B-UNK
of	O
14.9	O
+	O
/-	O
2.4	B-UNK
R	B-UNK
units	I-UNK
before	O
treatment	B-UNK
to	O
35.1	O
+	O
/-	O
5.5	O
R	B-UNK
units	I-UNK
after	O
hydrocortisone	B-CHEMICAL
(	O
SED	B-UNK
+	O
/-	O
6.0	O
,	O
p	B-UNK
less	O
than	O
0.05	O
)	O
.	O
A	O
shift	O
to	O
the	O
left	B-UNK
in	O
the	O
dose	B-UNK
-	O
response	B-UNK
relation	O
and	O
fall	O
in	O
threshold	B-UNK
suggested	B-UNK
increased	B-UNK
sensitivity	B-UNK
to	O
norepinephrine	B-CHEMICAL
after	O
treatment	B-UNK
.	O
Measurement	O
of	O
resting	B-UNK
norepinephrine	B-CHEMICAL
spillover	O
rate	B-UNK
to	O
plasma	B-UNK
and	O
norepinephrine	B-CHEMICAL
uptake	B-UNK
indicated	B-UNK
that	O
overall	B-UNK
resting	B-UNK
sympathetic	B-UNK
nervous	B-UNK
system	I-UNK
activity	B-UNK
was	O
not	O
increased	B-UNK
.	O
The	O
rise	B-UNK
in	O
resting	B-UNK
blood	B-UNK
pressure	B-UNK
with	O
hydrocortisone	B-CHEMICAL
is	O
associated	B-UNK
with	O
an	O
increased	B-UNK
cardiac	B-DISEASE
output	I-DISEASE
(	O
presumably	O
due	O
to	O
increased	B-UNK
blood	B-UNK
volume).(ABSTRACT	O
TRUNCATED	B-UNK
AT	O
250	O
WORDS	O
)	O

Effects	O
of	O
suprofen	B-CHEMICAL
on	O
the	O
isolated	B-UNK
perfused	B-UNK
rat	B-UNK
kidney	B-UNK
.	O

Although	O
suprofen	B-CHEMICAL
has	O
been	O
associated	B-UNK
with	O
the	O
development	B-UNK
of	O
acute	B-DISEASE
renal	I-DISEASE
failure	I-DISEASE
in	O
greater	B-UNK
than	O
100	O
subjects	B-UNK
,	O
the	O
mechanism	B-UNK
of	O
damage	B-UNK
remains	B-UNK
unclear	O
.	O
The	O
direct	B-UNK
nephrotoxic	B-UNK
effects	B-UNK
of	O
a	O
single	B-UNK
dose	B-UNK
of	O
15	O
mg	B-UNK
of	O
suprofen	B-CHEMICAL
were	O
compared	B-UNK
in	O
the	O
recirculating	O
isolated	B-UNK
rat	B-UNK
kidney	B-UNK
perfused	B-UNK
with	O
cell	B-UNK
-	O
free	B-UNK
buffer	O
with	O
or	O
without	O
the	O
addition	O
of	O
5	O
mg	B-UNK
/	O
dL	O
of	O
uric	B-CHEMICAL
acid	I-CHEMICAL
.	O
There	O
were	O
no	O
significant	B-UNK
differences	B-UNK
in	O
renal	B-UNK
sodium	B-CHEMICAL
excretion	B-UNK
,	O
oxygen	B-CHEMICAL
consumption	B-UNK
,	O
or	O
urinary	B-UNK
flow	B-UNK
rates	B-UNK
in	O
kidneys	B-UNK
perfused	B-UNK
with	O
suprofen	B-CHEMICAL
compared	B-UNK
with	O
the	O
drug	B-UNK
-	O
free	B-UNK
control	B-UNK
groups	B-UNK
.	O
In	O
contrast	B-UNK
,	O
a	O
significant	B-UNK
decline	O
in	O
glomerular	B-UNK
filtration	I-UNK
rate	B-UNK
was	O
found	B-UNK
after	O
the	O
introduction	O
of	O
suprofen	B-CHEMICAL
to	O
the	O
kidney	B-UNK
perfused	B-UNK
with	O
uric	B-CHEMICAL
acid	I-CHEMICAL
;	O
no	O
changes	B-UNK
were	O
found	B-UNK
with	O
suprofen	B-CHEMICAL
in	O
the	O
absence	B-UNK
of	O
uric	B-CHEMICAL
acid	I-CHEMICAL
.	O
A	O
significant	B-UNK
decrease	B-UNK
in	O
the	O
baseline	B-UNK
excretion	B-UNK
rate	B-UNK
of	O
uric	B-CHEMICAL
acid	I-CHEMICAL
was	O
found	B-UNK
in	O
rats	B-UNK
given	I-UNK
suprofen	B-CHEMICAL
,	O
compared	B-UNK
with	O
drug	B-UNK
-	O
free	B-UNK
controls	B-UNK
.	O
However	O
,	O
the	O
fractional	B-UNK
excretion	B-UNK
of	O
uric	B-CHEMICAL
acid	I-CHEMICAL
was	O
unchanged	B-UNK
between	O
the	O
groups	B-UNK
over	O
the	O
experimental	B-UNK
period	B-UNK
.	O
In	O
summary	B-UNK
,	O
suprofen	B-CHEMICAL
causes	B-UNK
acute	B-UNK
declines	O
in	O
renal	B-DISEASE
function	B-UNK
,	O
most	O
likely	B-UNK
by	O
directly	B-UNK
altering	O
the	O
intrarenal	O
distribution	O
of	O
uric	B-CHEMICAL
acid	I-CHEMICAL
.	O

Cocaine	O
-	O
induced	B-UNK
brainstem	B-UNK
seizures	B-DISEASE
and	O
behavior	B-UNK
.	O

A	O
variety	O
of	O
abnormal	B-UNK
sensory	B-UNK
/	O
motor	B-UNK
behaviors	B-UNK
associated	B-UNK
with	O
electrical	B-UNK
discharges	B-UNK
recorded	B-UNK
from	O
the	O
bilateral	B-UNK
brainstem	B-UNK
were	O
induced	B-UNK
in	O
adult	B-UNK
WKY	O
rats	B-UNK
by	O
mechanical	B-UNK
(	O
electrode	B-UNK
implants	O
)	O
and	O
DC	O
electrical	B-UNK
current	B-UNK
stimulations	O
and	O
by	O
acute	B-UNK
and	O
chronic	B-UNK
administration	B-UNK
of	O
cocaine	B-CHEMICAL
.	O
The	O
electrode	B-UNK
implant	B-UNK
implicated	B-UNK
one	O
side	O
or	O
the	O
other	O
of	O
the	O
reticular	O
system	B-UNK
of	O
the	O
brainstem	B-UNK
but	O
subjects	B-UNK
were	O
not	O
incapacitated	O
by	O
the	O
stimulations	O
.	O
Cocaine	O
(	O
40	O
mg	B-UNK
/	O
kg	B-UNK
)	O
was	O
injected	B-UNK
subcutaneously	O
for	O
an	O
acute	B-UNK
experiment	B-UNK
and	O
subsequent	B-UNK
20	O
mg	B-UNK
/	O
kg	B-UNK
doses	B-UNK
twice	B-UNK
daily	B-UNK
for	O
3	O
days	B-UNK
in	O
a	O
chronic	B-UNK
study	B-UNK
.	O
Cocaine	O
generated	B-UNK
more	O
abnormal	B-UNK
behaviors	B-UNK
in	O
the	O
brainstem	B-UNK
perturbation	O
group	B-UNK
,	O
especially	B-UNK
the	O
electrically	O
perturbated	O
subjects	B-UNK
.	O
The	O
abnormal	B-UNK
behaviors	B-UNK
were	O
yawning	O
,	O
retrocollis	O
,	O
hyperactivity	B-UNK
,	O
hypersensitivity	B-DISEASE
,	O
"	O
beating	O
drum	O
"	O
behavior	B-UNK
,	O
squealing	O
,	O
head	B-UNK
bobbing	O
,	O
circling	O
,	O
sniffing	O
,	O
abnormal	B-UNK
posturing	O
,	O
and	O
facial	B-UNK
twitching	O
.	O
Shifts	O
in	O
the	O
power	B-UNK
frequency	B-UNK
spectra	O
of	O
the	O
discharge	B-UNK
patterns	B-UNK
were	O
noted	O
between	O
quiet	O
and	O
pacing	B-UNK
behavioral	B-UNK
states	B-UNK
.	O
Hypersensitivity	O
to	O
various	O
auditory	B-UNK
,	O
tactile	O
,	O
and	O
visual	B-UNK
stimulation	B-UNK
was	O
present	B-UNK
and	O
shifts	O
in	O
the	O
brainstem	B-UNK
ambient	O
power	B-UNK
spectral	B-UNK
frequency	B-UNK
occurred	B-UNK
in	O
response	B-UNK
to	O
tactile	O
stimulation	B-UNK
.	O
These	O
findings	B-UNK
suggest	B-UNK
that	O
the	O
brainstem	B-UNK
generates	O
and	O
propagates	O
pathological	B-UNK
discharges	B-UNK
that	O
can	O
be	O
elicited	B-UNK
by	O
mechanical	B-UNK
and	O
DC	O
electrical	B-UNK
perturbation	O
.	O
Cocaine	O
was	O
found	B-UNK
to	O
activate	B-UNK
the	O
discharge	B-UNK
system	B-UNK
and	O
thus	O
induce	B-UNK
abnormal	B-UNK
behaviors	B-UNK
that	O
are	O
generated	B-UNK
at	B-DISEASE
the	O
discharge	B-UNK
site	B-UNK
and	O
at	B-DISEASE
distant	O
sites	O
to	O
which	O
the	O
discharge	B-UNK
propagates	O
.	O
Cognitive	B-UNK
functions	B-UNK
may	O
also	O
be	O
involved	B-UNK
since	O
dopaminergic	B-UNK
and	O
serotonergic	B-UNK
cellular	B-UNK
elements	B-CHEMICAL
at	B-DISEASE
the	O
brainstem	B-UNK
level	B-UNK
are	O
also	O
implicated	B-UNK
.	O

Increased	B-UNK
sulfation	O
and	O
decreased	B-UNK
7alpha	O
-	O
hydroxylation	O
of	O
deoxycholic	B-CHEMICAL
acid	I-CHEMICAL
in	O
ethinyl	B-CHEMICAL
estradiol	I-CHEMICAL
-	O
induced	B-UNK
cholestasis	B-DISEASE
in	O
rats	B-UNK
.	O

Deoxycholic	O
acid	B-UNK
conjugation	O
,	O
transport	B-UNK
capacity	B-UNK
,	O
and	O
metabolism	B-DISEASE
were	O
compared	B-UNK
in	O
control	B-UNK
and	O
ethinyl	B-CHEMICAL
estradiol	I-CHEMICAL
-	O
treated	B-UNK
rats	B-UNK
.	O
Control	B-UNK
rats	B-UNK
were	O
found	B-UNK
to	O
have	O
a	O
lower	B-UNK
capacity	B-UNK
to	O
transport	B-UNK
deoxycholic	B-CHEMICAL
acid	I-CHEMICAL
than	O
taurodeoxycholic	B-CHEMICAL
acid	I-CHEMICAL
,	O
and	O
both	O
were	O
decreased	B-UNK
by	O
ethinyl	B-CHEMICAL
estradiol	I-CHEMICAL
treatment	B-UNK
.	O
During	O
[	O
24	O
-	O
14C]sodium	O
deoxycholate	O
infusion	B-UNK
,	O
[	O
14C]biliary	O
bile	B-UNK
acid	B-UNK
secretion	B-UNK
increased	B-UNK
,	O
but	O
bile	B-UNK
flow	B-UNK
did	O
not	O
change	B-UNK
significantly	B-UNK
in	O
either	O
control	B-UNK
or	O
ethinyl	B-CHEMICAL
estradiol	I-CHEMICAL
-	O
treated	B-UNK
rats	B-UNK
.	O
Ethinyl	O
estradiol	B-CHEMICAL
-	O
treated	B-UNK
animals	B-UNK
excreted	O
significantly	B-UNK
less	O
14C	O
as	O
taurocholic	B-CHEMICAL
acid	I-CHEMICAL
than	O
did	O
control	B-UNK
animals	B-UNK
,	O
consistent	B-UNK
with	O
an	O
impairment	B-UNK
of	O
7alpha	O
-	O
hydroxylation	O
of	O
taurodeoxycholic	B-CHEMICAL
acid	I-CHEMICAL
.	O
Ethinyl	O
estradiol	B-CHEMICAL
treatment	B-UNK
did	O
not	O
impair	O
conjugation	O
of	O
deoxycholic	B-CHEMICAL
acid	I-CHEMICAL
,	O
but	O
did	O
result	B-UNK
in	O
an	O
increase	B-UNK
in	O
sulfation	O
of	O
taurodeoxycholic	B-CHEMICAL
acid	I-CHEMICAL
from	O
1.5	B-UNK
%	O
in	O
controls	B-UNK
to	O
nearly	B-UNK
4.0	B-UNK
%	O
(	O
P	B-UNK
less	O
than	O
0.01	B-UNK
)	O
.	O
These	O
results	B-UNK
are	O
consistent	B-UNK
with	O
the	O
hypothesis	O
that	O
the	O
rat	B-UNK
has	O
a	O
poorer	B-UNK
tolerance	B-UNK
for	O
deoxycholic	B-CHEMICAL
acid	I-CHEMICAL
than	O
do	O
certain	B-UNK
other	O
species	O
.	O
Furthermore	O
,	O
the	O
rat	B-UNK
converts	O
deoxycholic	B-CHEMICAL
acid	I-CHEMICAL
,	O
a	O
poor	B-UNK
choleretic	O
,	O
to	O
taurocholic	B-CHEMICAL
acid	I-CHEMICAL
,	O
a	O
good	B-UNK
choleretic	O
.	O
When	O
this	O
conversion	B-UNK
is	O
impaired	B-UNK
with	O
ethinyl	B-CHEMICAL
estradiol	I-CHEMICAL
treatment	B-UNK
,	O
sulfation	O
may	O
be	O
an	O
important	B-UNK
alternate	B-UNK
pathway	B-UNK
for	O
excretion	B-UNK
of	O
this	O
potentially	B-UNK
harmful	O
bile	B-UNK
acid	B-UNK
.	O

Effects	O
of	O
ouabain	B-CHEMICAL
on	O
myocardial	B-UNK
oxygen	B-CHEMICAL
supply	O
and	O
demand	O
in	O
patients	B-UNK
with	O
chronic	B-UNK
coronary	B-DISEASE
artery	I-DISEASE
disease	I-DISEASE
.	O
A	O
hemodynamic	B-UNK
,	O
volumetric	O
,	O
and	O
metabolic	B-UNK
study	B-UNK
in	O
patients	B-UNK
without	O
heart	B-DISEASE
failure	I-DISEASE
.	O

The	O
effects	B-UNK
of	O
digitalis	B-CHEMICAL
glycosides	I-CHEMICAL
on	O
myocardial	B-UNK
oxygen	B-CHEMICAL
supply	O
and	O
demand	O
are	O
of	O
particular	B-UNK
interest	O
in	O
the	O
presence	O
of	O
obstructive	O
coronary	B-DISEASE
artery	I-DISEASE
disease	I-DISEASE
,	O
but	O
have	O
not	O
been	O
measured	B-UNK
previously	B-UNK
in	O
man	B-UNK
.	O
We	O
assessed	B-UNK
the	O
effects	B-UNK
of	O
ouabain	B-CHEMICAL
(	O
0.015	O
mg	B-UNK
/	O
kg	B-UNK
body	B-DISEASE
weight	I-DISEASE
)	O
on	O
hemodynamic	B-UNK
,	O
volumetric	O
,	O
and	O
metabolic	B-UNK
parameters	B-UNK
in	O
11	O
patients	B-UNK
with	O
severe	B-UNK
chronic	B-UNK
coronary	B-DISEASE
artery	I-DISEASE
disease	I-DISEASE
without	O
clinical	B-UNK
congestive	B-DISEASE
heart	I-DISEASE
failure	I-DISEASE
.	O
Because	O
the	O
protocol	B-UNK
was	O
long	B-UNK
and	O
involved	B-UNK
interventions	O
which	O
might	O
affect	B-UNK
the	O
determinations	O
,	O
we	O
also	O
studied	B-UNK
in	O
nine	O
patients	B-UNK
using	O
an	O
identical	B-UNK
protocol	B-UNK
except	O
that	O
ouabain	B-CHEMICAL
administration	B-UNK
was	O
omitted	O
.	O
Left	O
ventricular	B-UNK
end	B-UNK
-	O
diastolic	B-UNK
pressure	B-UNK
and	O
left	B-UNK
ventricular	I-UNK
end	B-UNK
-	O
diastolic	B-UNK
volume	B-UNK
fell	O
in	O
each	O
patient	B-UNK
given	B-UNK
ouabain	B-CHEMICAL
,	O
even	O
though	O
they	O
were	O
initially	B-UNK
elevated	B-UNK
in	O
only	O
two	O
patients	B-UNK
.	O
Left	O
ventricular	B-UNK
end	B-UNK
-	O
diastolic	B-UNK
pressure	B-UNK
fell	O
from	O
11.5+/-1.4	O
(	O
mean+/-SE	O
)	O
to	O
5.6+/-0.9	O
mm	B-UNK
Hg	B-UNK
(	O
P	B-UNK
less	O
than	O
0.001	B-UNK
)	O
and	O
left	B-UNK
ventricular	I-UNK
end	B-UNK
-	O
diastolic	B-UNK
volume	B-UNK
fell	O
from	O
100+/-17	O
to	O
82+/-12	O
ml	B-UNK
/	O
m2	O
(	O
P	B-UNK
less	O
than	O
0.01	B-UNK
)	O
1	O
h	B-UNK
after	O
ouabain	B-CHEMICAL
infusion	B-UNK
was	O
completed	O
.	O
The	O
maximum	B-UNK
velocity	B-UNK
of	O
contractile	B-UNK
element	B-UNK
shortening	O
increased	B-UNK
from	O
1.68+/-0.11	O
ml	B-UNK
/	O
s	O
to	O
2.18+/-0.21	O
muscle	B-UNK
-	O
lengths	O
/	O
s	O
(	O
P	B-UNK
less	O
than	O
0.05	O
)	O
and	O
is	O
consistent	B-UNK
with	O
an	O
increase	B-UNK
in	O
contractility	O
.	O
No	O
significant	B-UNK
change	B-UNK
in	O
these	O
parameters	B-UNK
occurred	B-UNK
in	O
the	O
control	B-UNK
patients	B-UNK
.	O
No	O
significant	B-UNK
change	B-UNK
in	O
myocardial	B-UNK
oxygen	B-CHEMICAL
consumption	B-UNK
occurred	B-UNK
after	O
ouabain	B-CHEMICAL
administration	B-UNK
but	O
this	O
may	O
be	O
related	B-UNK
to	O
a	O
greater	B-UNK
decrease	B-UNK
in	O
mean	B-UNK
arterial	B-UNK
pressure	I-UNK
in	O
the	O
ouabain	B-CHEMICAL
patients	B-UNK
than	O
in	O
the	O
control	B-UNK
patients	B-UNK
.	O
We	O
conclude	O
that	O
in	O
patients	B-UNK
with	O
chronic	B-UNK
coronary	B-DISEASE
artery	I-DISEASE
disease	I-DISEASE
who	O
are	O
not	O
in	O
clinical	B-UNK
congestive	B-DISEASE
heart	I-DISEASE
failure	I-DISEASE
left	B-UNK
ventricular	I-UNK
end	B-UNK
-	O
diastolic	B-UNK
volume	B-UNK
falls	O
after	O
ouabain	B-CHEMICAL
administration	B-UNK
even	O
when	O
it	O
is	O
initially	B-UNK
normal	B-UNK
.	O
Though	O
this	O
fall	O
would	O
be	O
associated	B-UNK
with	O
a	O
decrease	B-UNK
in	O
wall	B-UNK
tension	O
,	O
and	O
,	O
therefore	O
,	O
of	O
myocardial	B-UNK
oxygen	B-CHEMICAL
consumption	B-UNK
,	O
it	O
may	O
not	O
be	O
of	O
sufficient	O
magnitude	O
to	O
prevent	B-UNK
a	O
net	O
increase	B-UNK
in	O
myocardial	B-UNK
oxygen	B-CHEMICAL
consumption	B-UNK
.	O
Nevertheless	O
,	O
compensatory	B-UNK
mechanisms	B-UNK
prevent	B-UNK
a	O
deterioration	B-UNK
of	O
resting	B-UNK
myocardial	B-UNK
metabolism	B-DISEASE
.	O

Prolongation	O
of	O
the	O
QT	B-UNK
interval	B-UNK
related	B-UNK
to	O
cisapride	B-CHEMICAL
-	O
diltiazem	B-CHEMICAL
interaction	B-UNK
.	O

Cisapride	O
,	O
a	O
cytochrome	B-UNK
P450	B-UNK
3A4	O
(	O
CYP3A4	O
)	O
substrate	B-UNK
,	O
is	O
widely	B-UNK
prescribed	B-UNK
for	O
the	O
treatment	B-UNK
of	O
gastrointestinal	B-UNK
motility	B-UNK
disorders	B-UNK
.	O
Prolongation	O
of	O
QT	B-UNK
interval	B-UNK
,	O
torsades	B-DISEASE
de	I-DISEASE
pointes	I-DISEASE
,	O
and	O
sudden	B-UNK
cardiac	B-UNK
death	B-DISEASE
have	O
been	O
reported	B-UNK
after	O
concomitant	B-UNK
administration	B-UNK
with	O
erythromycin	B-CHEMICAL
or	O
azole	O
antifungal	B-CHEMICAL
agents	I-CHEMICAL
,	O
but	O
not	O
with	O
other	O
CYP3A4	O
inhibitors	B-UNK
.	O
A	O
possible	B-UNK
drug	B-UNK
interaction	B-UNK
occurred	B-UNK
in	O
a	O
45-year	O
-	O
old	B-UNK
woman	B-UNK
who	O
was	O
taking	B-UNK
cisapride	B-CHEMICAL
for	O
gastroesophageal	B-DISEASE
reflux	I-DISEASE
disorder	B-UNK
and	O
diltiazem	B-CHEMICAL
,	O
an	O
agent	B-UNK
that	O
has	O
inhibitory	B-UNK
effect	B-UNK
on	O
CYP3A4	O
,	O
for	O
hypertension	B-DISEASE
.	O
The	O
patient	B-UNK
was	O
in	O
near	O
syncope	B-DISEASE
and	O
had	O
QT	B-UNK
-	O
interval	B-UNK
prolongation	B-UNK
.	O
After	O
discontinuing	O
cisapride	B-CHEMICAL
,	O
the	O
QT	B-UNK
interval	B-UNK
returned	B-UNK
to	O
normal	B-UNK
and	O
symptoms	B-UNK
did	O
not	O
recur	O
.	O
We	O
suggest	B-UNK
that	O
caution	B-UNK
be	O
taken	O
when	O
cisapride	B-CHEMICAL
is	O
prescribed	B-UNK
with	O
any	O
potent	B-UNK
inhibitor	B-UNK
of	O
CYP3A4	O
,	O
including	B-UNK
diltiazem	B-CHEMICAL
.	O

Paclitaxel	O
combined	B-UNK
with	O
carboplatin	B-CHEMICAL
in	O
the	O
first	O
-	O
line	B-UNK
treatment	B-UNK
of	O
advanced	B-UNK
ovarian	B-DISEASE
cancer	I-DISEASE
.	O

In	O
a	O
phase	B-UNK
I	O
study	B-UNK
to	O
determine	B-UNK
the	O
maximum	B-UNK
tolerated	B-UNK
dose	B-UNK
of	O
paclitaxel	B-CHEMICAL
(	O
Taxol	O
;	O
Bristol	O
-	O
Myers	O
Squibb	O
Company	B-UNK
,	O
Princeton	O
,	O
NJ	O
)	O
given	B-UNK
as	O
a	O
3-hour	O
infusion	B-UNK
in	O
combination	B-UNK
with	O
carboplatin	B-CHEMICAL
administered	B-UNK
every	O
21	O
days	B-UNK
to	O
women	B-UNK
with	O
advanced	B-UNK
ovarian	B-DISEASE
cancer	I-DISEASE
,	O
paclitaxel	B-CHEMICAL
doses	B-UNK
were	O
escalated	O
as	O
follows	O
:	O
level	B-UNK
1	O
,	O
135	O
mg	B-UNK
/	O
m2	O
;	O
level	B-UNK
2	B-DISEASE
,	O
160	O
mg	B-UNK
/	O
m2	O
;	O
level	B-UNK
3	O
,	O
185	O
mg	B-UNK
/	O
m2	O
;	O
and	O
level	B-UNK
4,210	O
mg	B-UNK
/	O
m2	O
.	O
The	O
fixed	B-UNK
dose	B-UNK
of	O
carboplatin	B-CHEMICAL
at	B-DISEASE
levels	B-UNK
1	O
through	O
4	O
was	O
given	B-UNK
to	O
achieve	O
an	O
area	B-UNK
under	O
the	O
concentration	B-UNK
-	O
time	B-UNK
curve	O
(	O
AUC	B-UNK
)	O
of	O
5	O
using	O
the	O
Calvert	O
formula	O
.	O
In	O
levels	B-UNK
5	O
and	O
6	O
the	O
carboplatin	B-CHEMICAL
dose	B-UNK
was	O
targeted	O
at	B-DISEASE
AUCs	O
of	O
6	O
and	O
7.5	B-UNK
,	O
respectively	O
,	O
combined	B-UNK
with	O
a	O
fixed	B-UNK
paclitaxel	B-CHEMICAL
dose	B-UNK
of	O
185	O
mg	B-UNK
/	O
m2	O
.	O
To	O
date	O
,	O
30	O
previously	B-UNK
untreated	B-UNK
patients	B-UNK
,	O
all	O
with	O
a	O
good	B-UNK
performance	B-UNK
status	B-UNK
(	O
Eastern	O
Cooperative	O
Oncology	O
Group	B-UNK
0	O
to	O
2	B-DISEASE
)	O
have	O
been	O
entered	O
into	O
this	O
ongoing	O
study	B-UNK
.	O
The	O
dose	B-UNK
-	O
limiting	B-UNK
toxicity	B-UNK
of	O
the	O
combination	B-UNK
was	O
myelosuppression	O
(	O
leukopenia	B-DISEASE
,	O
granulocytopenia	O
,	O
and	O
thrombocytopenia	B-DISEASE
)	O
.	O
Neurotoxicity	O
was	O
largely	O
moderate	B-UNK
.	O
So	O
far	O
,	O
14	O
patients	B-UNK
are	O
evaluable	O
for	O
response	B-UNK
;	O
of	O
these	O
,	O
eight	O
(	O
57	O
%	O
)	O
showed	B-UNK
objective	B-UNK
(	O
complete	B-UNK
or	O
partial	B-UNK
)	O
response	B-UNK
and	O
disease	B-DISEASE
stabilized	O
in	O
six	O
patients	B-UNK
.	O
No	O
patient	B-UNK
had	O
disease	B-DISEASE
progression	I-DISEASE
.	O
We	O
conclude	O
that	O
the	O
combination	B-UNK
of	O
paclitaxel	B-CHEMICAL
185	O
mg	B-UNK
/	O
m2	O
administered	B-UNK
as	O
a	O
3-hour	O
infusion	B-UNK
followed	B-UNK
immediately	B-UNK
by	O
a	O
1-hour	O
infusion	B-UNK
of	O
carboplatin	B-CHEMICAL
at	B-DISEASE
an	O
AUC	B-UNK
of	O
6	O
can	O
be	O
administered	B-UNK
safely	O
in	O
a	O
21-day	O
schedule	B-UNK
in	O
the	O
outpatient	B-UNK
setting	B-UNK
.	O
The	O
recommended	B-UNK
dose	B-UNK
for	O
phase	B-UNK
III	B-UNK
studies	B-UNK
is	O
paclitaxel	B-CHEMICAL
185	O
mg	B-UNK
/	O
m2	O
and	O
carboplatin	B-CHEMICAL
AUC	B-UNK
6	O
.	O

Treatment	O
of	O
tacrolimus	B-CHEMICAL
-	O
related	B-UNK
adverse	B-UNK
effects	B-UNK
by	O
conversion	B-UNK
to	O
cyclosporine	B-CHEMICAL
in	O
liver	B-DISEASE
transplant	B-UNK
recipients	B-UNK
.	O

When	O
tacrolimus	B-CHEMICAL
side	O
effects	B-UNK
persist	O
despite	B-UNK
dose	B-UNK
reduction	B-UNK
,	O
conversion	B-UNK
to	O
cyclosporine	B-CHEMICAL
-	O
based	B-UNK
immunosuppression	B-UNK
(	O
CyA	O
)	O
is	O
necessary	O
.	O
We	O
characterized	B-UNK
tacrolimus	B-CHEMICAL
side	O
effects	B-UNK
that	O
warranted	O
discontinuation	B-UNK
of	O
the	O
drug	B-UNK
,	O
and	O
outcomes	B-UNK
after	O
conversion	B-UNK
.	O
Of	O
388	O
liver	B-DISEASE
recipients	B-UNK
who	O
received	B-UNK
tacrolimus	B-CHEMICAL
as	O
primary	B-UNK
immunosuppression	B-UNK
,	O
70	O
required	B-UNK
conversion	B-UNK
to	O
CyA.	O
We	O
recorded	B-UNK
indication	O
for	O
conversion	B-UNK
,	O
whether	O
conversion	B-UNK
was	O
early	B-UNK
or	O
late	B-UNK
after	O
transplantation	B-UNK
,	O
tacrolimus	B-CHEMICAL
dose	B-UNK
and	O
trough	O
blood	B-UNK
level	B-UNK
at	B-DISEASE
conversion	B-UNK
,	O
and	O
incidence	B-UNK
of	O
rejection	B-UNK
after	O
conversion	B-UNK
.	O
Conversion	O
was	O
early	B-UNK
in	O
29	O
patients	B-UNK
(	O
41.4	O
%	O
)	O
and	O
late	B-UNK
in	O
41	O
(	O
58.6	O
%	O
)	O
.	O
Indications	O
for	O
early	B-UNK
conversion	B-UNK
were	O
neurotoxicity	B-UNK
(	O
20	O
)	O
,	O
(	O
insulin	B-CHEMICAL
-	O
dependent	B-UNK
)	O
diabetes	B-DISEASE
mellitus	I-DISEASE
(	O
IDDM	O
)	O
(	O
5	O
)	O
,	O
nephrotoxicity	B-UNK
(	O
3	O
)	O
,	O
gastrointestinal	B-UNK
(	O
GI	B-UNK
)	O
toxicity	B-UNK
(	O
6	O
)	O
,	O
and	O
cardiomyopathy	B-DISEASE
(	O
1	O
)	O
,	O
and	O
for	O
late	B-UNK
conversion	B-UNK
were	O
neurotoxicity	B-UNK
(	O
15	O
)	O
,	O
IDDM	O
(	O
12	O
)	O
,	O
nephrotoxicity	B-UNK
(	O
3	O
)	O
,	O
GI	B-UNK
toxicity	B-UNK
(	O
5	O
)	O
,	O
hepatotoxicity	O
(	O
6	O
)	O
,	O
post-transplant	O
lmphoproliferate	O
disease	B-DISEASE
(	O
PTLD	O
)	O
(	O
2	B-DISEASE
)	O
,	O
cardiomyopathy	B-DISEASE
(	O
1	O
)	O
,	O
hemolytic	B-DISEASE
anemia	I-DISEASE
(	O
1	O
)	O
,	O
and	O
pruritus	B-DISEASE
(	O
1	O
)	O
.	O
All	O
early	B-UNK
-	O
conversion	B-UNK
patients	B-UNK
showed	B-UNK
improvement	B-UNK
/	O
resolution	B-UNK
of	O
symptoms	B-UNK
.	O
Among	O
late	B-UNK
-	O
conversion	B-UNK
patients	B-UNK
,	O
37	O
(	O
90.2	O
%	O
)	O
had	O
improvement	B-UNK
/	O
resolution	B-UNK
;	O
in	O
4	O
(	O
9.8	O
%	O
)	O
,	O
adverse	B-UNK
effects	B-UNK
persisted	B-UNK
.	O
The	O
overall	B-UNK
rejection	B-UNK
rate	B-UNK
was	O
30	O
%	O
.	O
Sixty	O
-	O
two	O
patients	B-UNK
(	O
88.6	O
%	O
)	O
are	O
alive	O
with	O
functioning	B-UNK
grafts	O
686	O
+	O
/-	O
362	O
days	B-UNK
(	O
range	B-UNK
,	O
154	O
-	O
1433	O
days	B-UNK
)	O
after	O
conversion	B-UNK
.	O
When	O
tacrolimus	B-CHEMICAL
side	O
effects	B-UNK
are	O
unresponsive	O
to	O
dose	B-UNK
reduction	B-UNK
,	O
conversion	B-UNK
to	O
CyA	O
can	O
be	O
accomplished	O
safely	O
,	O
with	O
no	O
increased	B-UNK
risk	I-UNK
of	O
rejection	B-UNK
and	O
excellent	O
long	B-UNK
-	O
term	B-UNK
outcome	B-UNK
.	O

Relative	O
efficacy	B-UNK
and	O
toxicity	B-UNK
of	O
netilmicin	B-CHEMICAL
and	O
tobramycin	B-CHEMICAL
in	O
oncology	O
patients	B-UNK
.	O

We	O
prospectively	B-UNK
compared	B-UNK
the	O
efficacy	B-UNK
and	O
safety	B-UNK
of	O
netilmicin	B-CHEMICAL
sulfate	O
or	O
tobramycin	B-CHEMICAL
sulfate	O
in	O
conjunction	O
with	O
piperacillin	B-CHEMICAL
sodium	B-CHEMICAL
in	O
118	O
immunocompromised	B-UNK
patients	B-UNK
with	O
presumed	O
severe	B-UNK
infections	B-DISEASE
.	O
The	O
two	O
treatment	B-UNK
regimens	B-UNK
were	O
equally	O
efficacious	B-UNK
.	O
Nephrotoxicity	O
occurred	B-UNK
in	O
a	O
similar	B-UNK
proportion	B-UNK
in	O
patients	B-UNK
treated	B-UNK
with	O
netilmicin	B-CHEMICAL
and	O
tobramycin	B-CHEMICAL
(	O
17	B-DISEASE
%	O
vs	B-UNK
11	O
%	O
)	O
.	O
Ototoxicity	O
occurred	B-UNK
in	O
four	O
(	O
9.5	O
%	O
)	O
of	O
42	O
netilmicin	B-CHEMICAL
and	O
piperacillin	B-CHEMICAL
and	O
in	O
12	O
(	O
22	O
%	O
)	O
of	O
54	O
tobramycin	B-CHEMICAL
and	O
piperacillin	B-CHEMICAL
-	O
treated	B-UNK
patients	B-UNK
.	O
Of	O
those	O
evaluated	B-UNK
with	O
posttherapy	O
audiograms	B-UNK
,	O
three	O
of	O
four	O
netilmicin	B-CHEMICAL
and	O
piperacillin	B-CHEMICAL
-	O
treated	B-UNK
patients	B-UNK
had	O
auditory	B-UNK
thresholds	B-UNK
return	B-UNK
to	O
baseline	B-UNK
compared	B-UNK
with	O
one	O
of	O
nine	O
tobramycin	B-CHEMICAL
and	O
piperacillin	B-CHEMICAL
-	O
treated	B-UNK
patients	B-UNK
.	O
The	O
number	B-UNK
of	O
greater	B-UNK
than	O
or	O
equal	O
to	O
15-dB	O
increases	B-UNK
in	O
auditory	B-UNK
threshold	B-UNK
as	O
a	O
proportion	B-UNK
of	O
total	B-UNK
greater	B-UNK
than	O
or	O
equal	O
to	O
15-dB	O
changes	B-UNK
(	O
increases	B-UNK
and	O
decreases	B-UNK
)	O
was	O
significantly	B-UNK
lower	B-UNK
in	O
netilmicin	B-CHEMICAL
and	O
piperacillin-	O
vs	B-UNK
tobramycin	B-CHEMICAL
and	O
piperacillin	B-CHEMICAL
-	O
treated	B-UNK
patients	B-UNK
(	O
18	O
of	O
78	O
vs	B-UNK
67	O
of	O
115	O
)	O
.	O
We	O
conclude	O
that	O
aminoglycoside	O
-	O
associated	B-UNK
ototoxicity	B-DISEASE
was	O
less	O
severe	B-UNK
and	O
more	O
often	O
reversible	B-UNK
with	O
netilmicin	B-CHEMICAL
than	O
with	O
tobramycin	B-CHEMICAL
.	O

Effect	O
of	O
prostaglandin	B-UNK
synthetase	O
inhibitors	B-UNK
on	O
experimentally	B-UNK
induced	B-UNK
convulsions	B-DISEASE
in	O
rats	B-UNK
.	O

To	O
investigate	O
the	O
relationship	B-UNK
of	O
prostaglandins	B-CHEMICAL
(	O
PGs	O
)	O
to	O
seizure	B-DISEASE
induction	B-UNK
,	O
the	O
effects	B-UNK
of	O
six	O
PG	O
synthetase	O
inhibitors	B-UNK
on	O
convulsions	B-DISEASE
induced	B-UNK
by	O
flurothyl	B-CHEMICAL
,	O
picrotoxin	B-CHEMICAL
,	O
pentetrazol	O
(	O
PTZ	O
)	O
,	O
electroshock	O
or	O
bicuculline	B-CHEMICAL
were	O
evaluated	B-UNK
.	O
Ibuprofen	O
,	O
sulindac	B-CHEMICAL
,	O
mefenamic	B-CHEMICAL
acid	I-CHEMICAL
,	O
and	O
low	B-UNK
dose	B-UNK
meclofenamic	B-CHEMICAL
acid	I-CHEMICAL
increased	B-UNK
the	O
latency	O
-	O
to	O
-	O
onset	B-UNK
in	O
the	O
flurothyl	B-CHEMICAL
and	O
/	O
or	O
PTZ	O
models	B-UNK
;	O
the	O
electroshock	O
,	O
picrotoxin	B-CHEMICAL
and	O
bicuculline	B-CHEMICAL
models	B-UNK
were	O
not	O
significantly	B-UNK
affected	B-UNK
by	O
any	O
of	O
the	O
pretreatment	B-UNK
agents	B-UNK
.	O
These	O
results	B-UNK
suggest	B-UNK
that	O
PGs	O
are	O
involved	B-UNK
in	O
the	O
mechanism(s	O
)	O
underlying	B-UNK
fluorthyl-	O
and	O
PTZ	O
-	O
induced	B-UNK
convulsions	B-DISEASE
,	O
but	O
not	O
picrotoxin-	O
,	O
electroshock-	O
,	O
or	O
bicuculline	B-CHEMICAL
-	O
induced	B-UNK
convulsions	B-DISEASE
.	O

Angiotensin	O
-	O
converting	B-UNK
enzyme	B-UNK
(	O
ACE	O
)	O
inhibitor	B-UNK
-	O
associated	B-UNK
angioedema	B-DISEASE
of	O
the	O
stomach	O
and	O
small	B-UNK
intestine	O
:	O
a	O
case	B-UNK
report	B-UNK
.	O

This	O
is	O
a	O
case	B-UNK
report	B-UNK
on	O
a	O
45-year	O
old	B-UNK
African	B-UNK
-	O
American	B-UNK
female	B-UNK
with	O
newly	B-UNK
diagnosed	B-UNK
hypertension	B-DISEASE
,	O
who	O
was	O
started	B-UNK
on	O
a	O
combination	B-UNK
pill	O
of	O
amlodipine	B-CHEMICAL
/	O
benazapril	O
10/5	O
mg	B-UNK
.	O
The	O
very	O
next	O
day	B-UNK
,	O
she	O
presented	B-UNK
at	B-DISEASE
the	O
emergency	B-UNK
room	B-UNK
(	O
ER	O
)	O
with	O
abdominal	B-DISEASE
pain	I-DISEASE
,	O
nausea	B-DISEASE
and	O
vomiting	B-DISEASE
.	O
Physical	O
exam	O
,	O
complete	B-UNK
metabolic	B-UNK
panel	O
,	O
and	O
hemogram	O
were	O
in	O
the	O
normal	B-UNK
range	B-UNK
.	O
She	O
was	O
discharged	O
from	O
the	O
ER	O
after	O
a	O
few	O
hours	B-UNK
of	O
treatment	B-UNK
with	O
fluid	B-UNK
and	O
analgesics	B-CHEMICAL
.	O
However	O
,	O
she	O
returned	B-UNK
to	O
the	O
ER	O
the	O
next	O
day	B-UNK
with	O
the	O
same	O
complaints	O
.	O
This	O
time	B-UNK
the	O
physical	B-UNK
exam	O
was	O
significant	B-UNK
for	O
a	O
distended	O
abdomen	B-DISEASE
with	O
dullness	O
to	O
percussion	O
.	O
CT	B-UNK
scan	O
of	O
the	O
abdomen	B-DISEASE
revealed	B-UNK
markedly	B-UNK
thickened	B-UNK
antrum	O
of	O
the	O
stomach	O
,	O
duodenum	O
and	O
jejunum	O
,	O
along	O
with	O
fluid	B-UNK
in	O
the	O
abdominal	B-UNK
and	O
pelvic	B-UNK
cavity	O
.	O
Angiotensin	O
-	O
converting	B-UNK
enzyme	B-UNK
inhibitor	B-UNK
(	O
ACEI)-induced	O
angioedema	B-DISEASE
was	O
suspected	O
,	O
and	O
anti-hypertensive	O
medications	B-UNK
were	O
discontinued	O
.	O
Her	O
symptoms	B-UNK
improved	B-UNK
within	O
the	O
next	O
24	O
hours	B-UNK
,	O
and	O
repeat	B-UNK
CT	B-UNK
after	O
72	O
hours	B-UNK
revealed	B-UNK
marked	B-UNK
improvement	B-UNK
in	O
stomach	O
and	O
small	B-UNK
bowel	B-UNK
thickening	O
and	O
resolution	B-UNK
of	O
ascites	B-DISEASE
.	O
The	O
recognition	O
of	O
angiotensin	B-UNK
-	O
converting	B-UNK
enzyme	B-UNK
(	O
ACE	O
)	O
and	O
angiotensin	B-UNK
receptor	B-UNK
blocker	B-UNK
(	O
ARB	O
)	O
intestinal	O
angioedema	B-DISEASE
constitutes	O
a	O
challenge	B-UNK
to	O
primary	B-UNK
care	B-UNK
physicians	O
,	O
internists	O
,	O
emergency	B-UNK
room	B-UNK
personal	O
and	O
surgeons	O
.	O

Valproic	O
acid	B-UNK
I	O
:	O
time	B-UNK
course	B-UNK
of	O
lipid	B-UNK
peroxidation	B-UNK
biomarkers	B-CHEMICAL
,	O
liver	B-DISEASE
toxicity	B-UNK
,	O
and	O
valproic	B-CHEMICAL
acid	I-CHEMICAL
metabolite	B-UNK
levels	B-UNK
in	O
rats	B-UNK
.	O

A	O
single	B-UNK
dose	B-UNK
of	O
valproic	B-CHEMICAL
acid	I-CHEMICAL
(	O
VPA	B-UNK
)	O
,	O
which	O
is	O
a	O
widely	B-UNK
used	O
antiepileptic	B-UNK
drug	I-UNK
,	O
is	O
associated	B-UNK
with	O
oxidative	B-UNK
stress	B-UNK
in	O
rats	B-UNK
,	O
as	O
recently	B-UNK
demonstrated	B-UNK
by	O
elevated	B-UNK
levels	B-UNK
of	O
15-F(2t)-isoprostane	O
(	O
15-F(2t)-IsoP	O
)	O
.	O
To	O
determine	B-UNK
whether	O
there	O
was	O
a	O
temporal	B-UNK
relationship	B-UNK
between	O
VPA	B-UNK
-	O
associated	B-UNK
oxidative	B-UNK
stress	B-UNK
and	O
hepatotoxicity	O
,	O
adult	B-UNK
male	B-UNK
Sprague	B-UNK
-	O
Dawley	B-UNK
rats	B-UNK
were	O
treated	B-UNK
ip	O
with	O
VPA	B-UNK
(	O
500	O
mg	B-UNK
/	O
kg	B-UNK
)	O
or	O
0.9	O
%	O
saline	B-UNK
(	O
vehicle	B-UNK
)	O
once	O
daily	B-UNK
for	O
2	B-DISEASE
,	O
4	O
,	O
7	O
,	O
10	O
,	O
or	O
14	O
days	B-UNK
.	O
Oxidative	O
stress	B-UNK
was	O
assessed	B-UNK
by	O
determining	O
plasma	B-UNK
and	O
liver	B-DISEASE
levels	B-UNK
of	O
15-F(2t)-IsoP	O
,	O
lipid	B-UNK
hydroperoxides	O
(	O
LPO	O
)	O
,	O
and	O
thiobarbituric	B-CHEMICAL
acid	I-CHEMICAL
reactive	I-CHEMICAL
substances	I-CHEMICAL
(	O
TBARs	O
)	O
.	O
Plasma	B-UNK
and	O
liver	B-DISEASE
15-F(2t)-IsoP	O
were	O
elevated	B-UNK
and	O
reached	B-UNK
a	O
plateau	O
after	O
day	B-UNK
2	B-DISEASE
of	O
VPA	B-UNK
treatment	B-UNK
compared	B-UNK
to	O
control	B-UNK
.	O
Liver	B-UNK
LPO	O
levels	B-UNK
were	O
not	O
elevated	B-UNK
until	O
day	B-UNK
7	O
of	O
treatment	B-UNK
(	O
1.8-fold	O
versus	B-UNK
control	B-UNK
,	O
p	B-UNK
<	I-UNK
0.05	O
)	O
.	O
Liver	B-UNK
and	O
plasma	B-UNK
TBARs	O
were	O
not	O
increased	B-UNK
until	O
14	O
days	B-UNK
(	O
2-fold	O
vs	B-UNK
.	O
control	B-UNK
,	O
p	B-UNK
<	I-UNK
0.05	O
)	O
.	O
Liver	B-UNK
toxicity	B-UNK
was	O
evaluated	B-UNK
based	B-UNK
on	O
serum	B-UNK
levels	B-UNK
of	O
alpha	B-UNK
-	O
glutathione	B-CHEMICAL
S	O
-	O
transferase	O
(	O
alpha	B-UNK
-	O
GST	O
)	O
and	O
by	O
histology	O
.	O
Serum	B-UNK
alpha	B-UNK
-	O
GST	O
levels	B-UNK
were	O
significantly	B-UNK
elevated	B-UNK
by	O
day	B-UNK
4	O
,	O
which	O
corresponded	O
to	O
hepatotoxicity	O
as	O
shown	B-UNK
by	O
the	O
increasing	B-UNK
incidence	B-UNK
of	O
inflammation	B-DISEASE
of	O
the	O
liver	B-DISEASE
capsule	O
,	O
necrosis	B-DISEASE
,	O
and	O
steatosis	O
throughout	O
the	O
study	B-UNK
.	O
The	O
liver	B-DISEASE
levels	B-UNK
of	O
beta-oxidation	O
metabolites	B-UNK
of	O
VPA	B-UNK
were	O
decreased	B-UNK
by	O
day	B-UNK
14	O
,	O
while	O
the	O
levels	B-UNK
of	O
4-ene	O
-	O
VPA	B-UNK
and	O
(	O
E)-2,4-diene	O
-	O
VPA	B-UNK
were	O
not	O
elevated	B-UNK
throughout	O
the	O
study	B-UNK
.	O
Overall	O
,	O
these	O
findings	B-UNK
indicate	B-UNK
that	O
VPA	B-UNK
treatment	B-UNK
results	B-UNK
in	O
oxidative	B-UNK
stress	B-UNK
,	O
as	O
measured	B-UNK
by	O
levels	B-UNK
of	O
15-F(2t)-IsoP	O
,	O
which	O
precedes	O
the	O
onset	B-UNK
of	O
necrosis	B-DISEASE
,	O
steatosis	O
,	O
and	O
elevated	B-UNK
levels	B-UNK
of	O
serum	B-UNK
alpha	B-UNK
-	O
GST	O
.	O

Pheochromocytoma	O
unmasked	O
by	O
amisulpride	B-CHEMICAL
and	O
tiapride	O
.	O

OBJECTIVE	O
:	O
To	O
describe	O
the	O
unmasking	O
of	O
pheochromocytoma	B-DISEASE
in	O
a	O
patient	B-UNK
treated	B-UNK
with	O
amisulpride	B-CHEMICAL
and	O
tiapride	O
.	O
CASE	B-UNK
SUMMARY	B-UNK
:	O
A	O
42-year	O
-	O
old	B-UNK
white	B-UNK
man	B-UNK
developed	B-UNK
acute	B-UNK
hypertension	B-DISEASE
with	O
severe	B-UNK
headache	B-DISEASE
and	O
vomiting	B-DISEASE
2	B-DISEASE
hours	B-UNK
after	O
the	O
first	O
doses	B-UNK
of	O
amisulpride	B-CHEMICAL
100	O
mg	B-UNK
and	O
tiapride	O
100	O
mg	B-UNK
.	O
Both	O
drugs	B-UNK
were	O
immediately	B-UNK
discontinued	O
,	O
and	O
the	O
patient	B-UNK
recovered	O
after	O
subsequent	B-UNK
nicardipine	B-CHEMICAL
and	O
verapamil	B-CHEMICAL
treatment	B-UNK
.	O
Abdominal	O
ultrasound	B-UNK
showed	B-UNK
an	O
adrenal	B-DISEASE
mass	I-DISEASE
,	O
and	O
postoperative	B-UNK
histologic	B-UNK
examination	B-UNK
confirmed	B-UNK
the	O
diagnosis	B-UNK
of	O
pheochromocytoma	B-DISEASE
.	O
DISCUSSION	O
:	O
Drug	B-UNK
-	O
induced	B-UNK
symptoms	B-UNK
of	O
pheochromocytoma	B-DISEASE
are	O
often	O
associated	B-UNK
with	O
the	O
use	B-UNK
of	O
substituted	O
benzamide	B-CHEMICAL
drugs	B-UNK
,	O
but	O
the	O
underlying	B-UNK
mechanism	B-UNK
is	O
unknown	B-UNK
.	O
In	O
our	O
case	B-UNK
,	O
use	B-UNK
of	O
the	O
Naranjo	B-UNK
probability	B-UNK
scale	B-UNK
indicated	B-UNK
a	O
possible	B-UNK
relationship	B-UNK
between	O
the	O
hypertensive	B-UNK
crisis	O
and	O
amisulpride	B-CHEMICAL
and	O
tiapride	O
therapy	B-UNK
.	O
CONCLUSIONS	O
:	O
As	O
of	O
March	O
24	O
,	O
2005	O
,	O
this	O
is	O
the	O
first	O
reported	B-UNK
case	B-UNK
of	O
amisulpride-	O
and	O
tiapride	O
-	O
induced	B-UNK
hypertensive	B-UNK
crisis	O
in	O
a	O
patient	B-UNK
with	O
pheochromocytoma	B-DISEASE
.	O
Physicians	O
and	O
other	O
healthcare	O
professionals	O
should	O
be	O
aware	O
of	O
this	O
potential	B-UNK
adverse	B-UNK
effect	B-UNK
of	O
tiapride	O
and	O
amisulpride	B-CHEMICAL
.	O

Quantitative	O
drug	B-UNK
levels	B-UNK
in	O
stimulant	B-UNK
psychosis	B-UNK
:	O
relationship	B-UNK
to	O
symptom	O
severity	B-UNK
,	O
catecholamines	B-CHEMICAL
and	O
hyperkinesia	O
.	O

To	O
examine	O
the	O
relationship	B-UNK
between	O
quantitative	B-UNK
stimulant	B-UNK
drug	B-UNK
levels	B-UNK
,	O
catecholamines	B-CHEMICAL
,	O
and	O
psychotic	O
symptoms	B-UNK
,	O
nineteen	O
patients	B-UNK
in	O
a	O
psychiatric	B-UNK
emergency	B-UNK
service	O
with	O
a	O
diagnosis	B-UNK
of	O
amphetamine-	O
or	O
cocaine	B-CHEMICAL
-	O
induced	B-UNK
psychosis	B-UNK
were	O
interviewed	O
,	O
and	O
plasma	B-UNK
and	O
urine	B-DISEASE
were	O
collected	B-UNK
for	O
quantitative	B-UNK
assays	O
of	O
stimulant	B-UNK
drug	B-UNK
and	O
catecholamine	B-UNK
metabolite	B-UNK
levels	B-UNK
.	O
Methamphetamine	O
or	O
amphetamine	B-CHEMICAL
levels	B-UNK
were	O
related	B-UNK
to	O
several	O
psychopathology	O
scores	B-UNK
and	O
the	O
global	O
hyperkinesia	O
rating	O
.	O
HVA	O
levels	B-UNK
were	O
related	B-UNK
to	O
global	O
hyperkinesia	O
but	O
not	O
to	O
psychopathology	O
ratings	B-UNK
.	O
Although	O
many	O
other	O
factors	B-UNK
such	O
as	O
sensitization	B-UNK
may	O
play	B-UNK
a	O
role	B-UNK
,	O
intensity	B-UNK
of	O
stimulant	B-UNK
-	O
induced	B-UNK
psychotic	O
symptoms	B-UNK
and	O
stereotypies	O
appears	B-UNK
to	O
be	O
at	B-DISEASE
least	O
in	O
part	O
dose	B-UNK
-	O
related	B-UNK
.	O

Delayed	B-UNK
asystolic	O
cardiac	B-DISEASE
arrest	I-DISEASE
after	O
diltiazem	B-CHEMICAL
overdose	B-UNK
;	O
resuscitation	O
with	O
high	B-UNK
dose	B-UNK
intravenous	B-UNK
calcium	B-CHEMICAL
.	O

A	O
51	O
year	B-UNK
old	B-UNK
man	B-UNK
took	O
a	O
mixed	B-UNK
overdose	B-UNK
including	B-UNK
1.8	O
-	O
3.6	B-UNK
g	B-UNK
of	O
diltiazem	B-CHEMICAL
,	O
paracetamol	B-UNK
,	O
aspirin	B-CHEMICAL
,	O
isosorbide	B-CHEMICAL
nitrate	O
,	O
and	O
alcohol	B-UNK
.	O
He	O
initially	B-UNK
presented	B-UNK
to	O
hospital	B-UNK
after	O
six	O
hours	B-UNK
with	O
mild	B-UNK
hypotension	B-DISEASE
and	O
was	O
treated	B-UNK
with	O
activated	B-UNK
charcoal	B-CHEMICAL
and	O
intravenous	B-UNK
fluids	O
.	O
Eighteen	O
hours	B-UNK
after	O
the	O
overdose	B-UNK
he	O
had	O
two	O
generalised	O
tonic	B-DISEASE
-	O
clonic	O
seizures	B-DISEASE
.	O
The	O
patient	B-UNK
remained	B-UNK
unresponsive	O
with	O
junctional	O
bradycardia	B-DISEASE
,	O
unrecordable	O
blood	B-UNK
pressure	B-UNK
,	O
and	O
then	O
became	O
asystolic	O
.	O
He	O
was	O
resuscitated	O
with	O
high	B-UNK
dose	B-UNK
(	O
13.5	O
g	B-UNK
)	O
intravenous	B-UNK
calcium	B-CHEMICAL
and	O
adrenaline	O
(	O
epinephrine	B-CHEMICAL
)	O
.	O
He	O
required	B-UNK
inotropic	O
support	B-UNK
and	O
temporary	O
pacing	B-UNK
over	O
the	O
next	O
48	O
hours	B-UNK
.	O
This	O
case	B-UNK
suggests	B-UNK
there	O
is	O
a	O
role	B-UNK
for	O
aggressive	B-UNK
high	B-UNK
dose	B-UNK
intravenous	B-UNK
calcium	B-CHEMICAL
therapy	B-UNK
in	O
severe	B-UNK
diltiazem	B-CHEMICAL
overdose	B-UNK
,	O
particularly	O
with	O
the	O
onset	B-UNK
of	O
asystole	O
.	O
It	O
should	O
be	O
considered	B-UNK
early	B-UNK
in	O
cases	B-UNK
of	O
cardiac	B-DISEASE
arrest	I-DISEASE
after	O
diltiazem	B-CHEMICAL
overdose	B-UNK
.	O
The	O
case	B-UNK
also	O
highlights	O
the	O
problems	O
with	O
delayed	B-UNK
toxicity	B-UNK
when	O
whole	O
bowel	B-UNK
irrigation	B-UNK
is	O
not	O
administered	B-UNK
.	O

Renal	B-UNK
papillary	B-UNK
necrosis	B-DISEASE
due	O
to	O
naproxen	B-CHEMICAL
.	O

A	O
31-year	O
-	O
old	B-UNK
man	B-UNK
with	O
rheumatoid	B-DISEASE
arthritis	I-DISEASE
,	O
who	O
had	O
previously	B-UNK
been	O
treated	B-UNK
with	O
sulindac	B-CHEMICAL
,	O
fenoprofen	B-CHEMICAL
calcium	B-CHEMICAL
,	O
high	B-UNK
dose	B-UNK
salicylates	B-CHEMICAL
and	O
gold	B-CHEMICAL
salts	B-CHEMICAL
,	O
developed	B-UNK
renal	B-UNK
papillary	B-UNK
necrosis	B-DISEASE
(	O
RPN	O
)	O
4	O
months	B-UNK
after	O
institution	O
of	O
naproxen	B-CHEMICAL
therapy	B-UNK
.	O
No	O
other	O
factor	B-UNK
predisposing	O
to	O
RPN	O
could	O
be	O
discovered	O
.	O
Sulindac	O
was	O
substituted	O
for	O
naproxen	B-CHEMICAL
and	O
no	O
further	O
adverse	B-UNK
renal	B-DISEASE
effects	B-UNK
occurred	B-UNK
over	O
the	O
next	O
12	O
months	B-UNK
.	O
We	O
review	B-UNK
previous	B-UNK
reports	B-UNK
linking	O
RPN	O
to	O
antiinflammatory	B-UNK
drug	B-UNK
use	B-UNK
and	O
discuss	O
possible	B-UNK
advantages	O
of	O
sulindac	B-CHEMICAL
in	O
patients	B-UNK
who	O
have	O
experienced	B-UNK
renal	B-UNK
toxicity	B-UNK
from	O
other	O
antiinflammatory	B-UNK
agents	B-UNK
.	O

Adverse	B-UNK
interaction	B-UNK
between	O
beta-adrenergic	B-UNK
blocking	B-UNK
drugs	B-UNK
and	O
verapamil	B-CHEMICAL
--	O
report	B-UNK
of	O
three	O
cases	B-UNK
.	O

Three	O
patients	B-UNK
with	O
ischaemic	B-UNK
heart	B-DISEASE
disease	I-DISEASE
developed	B-UNK
profound	B-UNK
cardiac	B-UNK
failure	B-UNK
,	O
hypotension	B-DISEASE
and	O
bradycardia	B-DISEASE
during	O
combined	B-UNK
therapy	B-UNK
with	O
verapamil	B-CHEMICAL
and	O
beta-adrenergic	B-UNK
blocking	B-UNK
drugs	B-UNK
.	O
This	O
clinical	B-UNK
picture	O
resolved	B-UNK
completely	B-UNK
with	O
cessation	B-UNK
of	O
the	O
combined	B-UNK
therapy	B-UNK
.	O
Baseline	O
left	B-UNK
ventricular	I-UNK
function	B-UNK
,	O
assessed	B-UNK
by	O
cardiac	B-UNK
catheterisation	O
or	O
nuclear	B-UNK
angiography	B-UNK
,	O
was	O
normal	B-UNK
in	O
two	O
patients	B-UNK
and	O
only	O
mildly	O
reduced	B-UNK
in	O
the	O
other	O
.	O
Simultaneously	O
administration	B-UNK
of	O
beta-adrenergic	B-UNK
blocking	B-UNK
drugs	B-UNK
and	O
verapamil	B-CHEMICAL
may	O
result	B-UNK
in	O
profound	B-UNK
adverse	B-UNK
interactions	B-UNK
and	O
should	O
only	O
be	O
administered	B-UNK
with	O
great	O
caution	B-UNK
.	O

Adverse	B-UNK
reactions	B-UNK
to	O
bendrofluazide	B-UNK
and	O
propranolol	B-CHEMICAL
for	O
the	O
treatment	B-UNK
of	O
mild	B-UNK
hypertension	B-DISEASE
.	O
Report	O
of	O
Medical	B-UNK
Research	O
Council	O
Working	O
Party	O
on	O
Mild	O
to	O
Moderate	O
Hypertension	O
.	O

Participants	O
in	O
the	O
Medical	B-UNK
Research	O
Council	O
treatment	B-UNK
trial	B-UNK
for	O
mild	B-UNK
hypertension	B-DISEASE
are	O
randomly	B-UNK
allocated	B-UNK
to	O
one	O
of	O
four	O
treatment	B-UNK
groups	B-UNK
:	O
bendrofluazide	B-UNK
,	O
propranolol	B-CHEMICAL
,	O
or	O
a	O
placebo	B-UNK
for	O
either	O
of	O
these	O
drugs	B-UNK
.	O
The	O
trial	B-UNK
is	O
single	B-UNK
-	O
blind	B-UNK
.	O
23	O
582	O
patient	B-UNK
-	O
years	B-UNK
of	O
observation	B-UNK
have	O
been	O
completed	O
so	O
far	O
,	O
10	O
684	O
on	O
active	B-UNK
drugs	B-UNK
and	O
12	O
898	O
on	O
placebos	O
.	O
The	O
results	B-UNK
show	O
an	O
association	B-UNK
between	O
bendrofluazide	B-UNK
treatment	B-UNK
and	O
impotence	B-DISEASE
,	O
and	O
impotence	B-DISEASE
also	O
occurred	B-UNK
more	O
frequently	B-UNK
in	O
patients	B-UNK
taking	B-UNK
propranolol	B-CHEMICAL
than	O
in	O
those	O
taking	B-UNK
placebos	O
.	O
Other	O
adverse	B-UNK
reactions	B-UNK
significantly	B-UNK
linked	B-UNK
with	O
active	B-UNK
drugs	B-UNK
include	B-UNK
impaired	B-DISEASE
glucose	I-DISEASE
tolerance	I-DISEASE
in	O
men	O
and	O
women	B-UNK
and	O
gout	B-DISEASE
in	O
men	O
,	O
associated	B-UNK
with	O
bendrofluazide	B-UNK
treatment	B-UNK
,	O
and	O
Raynaud'	O
s	O
phenomenon	B-UNK
and	O
dyspnoea	O
in	O
men	O
and	O
women	B-UNK
taking	B-UNK
propranolol	B-CHEMICAL
.	O
No	O
corneal	O
disease	B-DISEASE
is	O
known	B-UNK
to	O
have	O
occurred	B-UNK
in	O
the	O
propranolol	B-CHEMICAL
group	B-UNK
.	O
Mean	O
serum	B-UNK
potassium	B-CHEMICAL
level	B-UNK
fell	O
,	O
and	O
urea	B-CHEMICAL
and	O
uric	B-CHEMICAL
acid	I-CHEMICAL
levels	B-UNK
rose	B-UNK
,	O
in	O
men	O
and	O
women	B-UNK
taking	B-UNK
bendrofluazide	B-UNK
.	O
In	O
the	O
propranolol	B-CHEMICAL
group	B-UNK
,	O
serum	B-UNK
potassium	B-CHEMICAL
and	O
uric	B-CHEMICAL
acid	I-CHEMICAL
levels	B-UNK
rose	B-UNK
in	O
both	O
sexes	O
,	O
but	O
the	O
urea	B-CHEMICAL
level	B-UNK
rose	B-UNK
significantly	B-UNK
in	O
women	B-UNK
only	O
.	O

Dexmedetomidine	O
and	O
cardiac	B-UNK
protection	B-UNK
for	O
non-cardiac	O
surgery	B-UNK
:	O
a	O
meta-analysis	O
of	O
randomised	B-UNK
controlled	B-UNK
trials	B-UNK
.	O

We	O
conducted	O
a	O
systematic	O
review	B-UNK
of	O
the	O
effects	B-UNK
of	O
dexmedetomidine	B-CHEMICAL
on	O
cardiac	B-UNK
outcomes	B-UNK
following	B-UNK
non-cardiac	O
surgery	B-UNK
.	O
We	O
included	B-UNK
prospective	B-UNK
,	O
randomised	B-UNK
peri	O
-	O
operative	O
studies	B-UNK
of	O
dexmedetomidine	B-CHEMICAL
that	O
reported	B-UNK
mortality	B-UNK
,	O
cardiac	B-UNK
morbidity	O
or	O
adverse	B-UNK
drug	I-UNK
events	B-UNK
.	O
A	O
PubMed	O
Central	B-UNK
and	O
EMBASE	O
search	O
was	O
conducted	O
up	O
to	O
July	O
2007	O
.	O
The	O
reference	B-UNK
lists	O
of	O
identified	B-UNK
papers	O
were	O
examined	B-UNK
for	O
further	O
trials	B-UNK
.	O
Of	O
425	O
studies	B-UNK
identified	B-UNK
,	O
20	O
were	O
included	B-UNK
in	O
the	O
meta-analysis	O
(	O
840	O
patients	B-UNK
)	O
.	O
Dexmedetomidine	O
was	O
associated	B-UNK
with	O
a	O
trend	B-UNK
towards	O
improved	B-UNK
cardiac	B-UNK
outcomes	B-UNK
;	O
all	O
-	O
cause	B-UNK
mortality	B-UNK
(	O
OR	O
0.27	O
,	O
95	O
%	O
CI	B-UNK
0.01	B-UNK
-	O
7.13	O
,	O
p	B-UNK
=	I-UNK
0.44	O
)	O
,	O
non-fatal	O
myocardial	B-DISEASE
infarction	I-DISEASE
(	O
OR	O
0.26	O
,	O
95	O
%	O
CI	B-UNK
0.04	O
-	O
1.60	O
,	O
p	B-UNK
=	I-UNK
0.14	O
)	O
,	O
and	O
myocardial	B-UNK
ischaemia	O
(	O
OR	O
0.65	O
,	O
95	O
%	O
CI	B-UNK
0.26	O
-	O
1.63	O
,	O
p	B-UNK
=	I-UNK
0.36	O
)	O
.	O
Peri	O
-	O
operative	O
hypotension	B-DISEASE
(	O
26	O
%	O
,	O
OR	O
3.80	O
,	O
95	O
%	O
CI	B-UNK
1.91	O
-	O
7.54	O
,	O
p	B-UNK
=	I-UNK
0.0001	O
)	O
and	O
bradycardia	B-DISEASE
(	O
17	B-DISEASE
%	O
,	O
OR	O
5.45	O
,	O
95	O
%	O
CI	B-UNK
2.98	O
-	O
9.95	O
,	O
p	B-UNK
<	I-UNK
0.00001	O
)	O
were	O
significantly	B-UNK
increased	B-UNK
.	O
An	O
anticholinergic	B-UNK
did	O
not	O
reduce	B-UNK
the	O
incidence	B-UNK
of	O
bradycardia	B-DISEASE
(	O
p	B-UNK
=	I-UNK
0.43	O
)	O
.	O
A	O
randomised	B-UNK
placebo	B-UNK
-	O
controlled	B-UNK
trial	B-UNK
of	O
dexmedetomidine	B-CHEMICAL
is	O
warranted	O
.	O

Differential	O
diagnosis	B-UNK
of	O
high	B-UNK
serum	B-UNK
creatine	B-CHEMICAL
kinase	B-UNK
levels	B-UNK
in	O
systemic	B-DISEASE
lupus	I-DISEASE
erythematosus	I-DISEASE
.	O

We	O
report	B-UNK
the	O
clinical	B-UNK
and	O
bioptic	O
findings	B-UNK
for	O
a	O
57-year	O
-	O
old	B-UNK
woman	B-UNK
with	O
severe	B-UNK
chloroquine	B-CHEMICAL
-	O
induced	B-UNK
myopathy	B-DISEASE
.	O
Since	O
1989	O
,	O
she	O
had	O
been	O
suffering	O
from	O
systemic	B-DISEASE
lupus	I-DISEASE
erythematosus	I-DISEASE
(	O
SLE	O
)	O
with	O
renal	B-UNK
involvement	B-UNK
and	O
undergone	B-UNK
periods	B-UNK
of	O
treatment	B-UNK
with	O
azathioprine	B-CHEMICAL
and	O
cyclophosphamide	B-CHEMICAL
.	O
Additional	O
therapy	B-UNK
with	O
chloroquine	B-CHEMICAL
(	O
CQ	O
)	O
was	O
started	B-UNK
because	O
of	O
arthralgia	B-DISEASE
.	O
At	O
the	O
same	O
time	B-UNK
,	O
slightly	O
increased	B-UNK
creatine	B-CHEMICAL
kinase	B-UNK
(	O
CK	O
)	O
levels	B-UNK
were	O
noted	O
.	O
Myositis	O
was	O
suspected	O
,	O
and	O
the	O
patient	B-UNK
was	O
treated	B-UNK
with	O
steroids	B-CHEMICAL
.	O
The	O
CK	O
increase	B-UNK
persisted	B-UNK
,	O
however	O
,	O
and	O
she	O
developed	B-UNK
progressive	B-UNK
muscular	B-UNK
weakness	B-UNK
and	O
muscular	B-DISEASE
atrophy	I-DISEASE
.	O
Routine	O
controls	B-UNK
revealed	B-UNK
markedly	B-UNK
elevated	B-UNK
CK	O
levels	B-UNK
of	O
1,700	O
U	B-UNK
/	O
l.	O
The	O
neurological	B-UNK
and	O
electrophysiological	B-UNK
findings	B-UNK
were	O
not	O
typical	O
of	O
myositis	B-DISEASE
.	O
Thus	O
,	O
muscle	B-UNK
biopsy	B-UNK
of	O
the	O
deltoid	O
muscle	B-UNK
was	O
performed	B-UNK
in	O
order	O
to	O
exclude	O
polymyositis	B-DISEASE
or	O
toxic	B-UNK
myopathy	B-DISEASE
.	O
As	O
it	O
revealed	B-UNK
chloroquine	B-CHEMICAL
-	O
induced	B-UNK
myopathy	B-DISEASE
,	O
medication	B-UNK
was	O
stopped	O
.	O
Discriminating	O
between	O
primary	B-UNK
SLE	O
-	O
induced	B-UNK
affection	O
of	O
the	O
musculoskeletal	O
system	B-UNK
and	O
drug	B-UNK
-	O
induced	B-UNK
side	O
effects	B-UNK
is	O
important	B-UNK
for	O
appropriate	B-UNK
treatment	B-UNK
of	O
SLE	O
patients	B-UNK
.	O

Intravenous	B-UNK
ribavirin	B-CHEMICAL
treatment	B-UNK
for	O
severe	B-UNK
adenovirus	B-UNK
disease	B-DISEASE
in	O
immunocompromised	B-UNK
children	B-UNK
.	O

BACKGROUND	O
:	O
Adenovirus	O
is	O
an	O
important	B-UNK
cause	B-UNK
of	O
morbidity	O
and	O
mortality	B-UNK
in	O
the	O
immunocompromised	B-UNK
host	O
.	O
The	O
incidence	B-UNK
of	O
severe	B-UNK
adenovirus	B-UNK
disease	B-DISEASE
in	O
pediatrics	O
is	O
increasing	B-UNK
in	O
association	B-UNK
with	O
growing	O
numbers	O
of	O
immunocompromised	B-UNK
children	B-UNK
,	O
where	O
case	B-UNK
fatality	O
rates	B-UNK
as	O
high	B-UNK
as	O
50	O
%	O
to	O
80	O
%	O
have	O
been	O
reported	B-UNK
.	O
There	O
are	O
no	O
approved	O
antiviral	B-CHEMICAL
agents	I-CHEMICAL
with	O
proven	B-UNK
efficacy	B-UNK
for	O
the	O
treatment	B-UNK
of	O
severe	B-UNK
adenovirus	B-UNK
disease	B-DISEASE
,	O
nor	O
are	O
there	O
any	O
prospective	B-UNK
randomized	B-UNK
,	O
controlled	B-UNK
trials	B-UNK
of	O
potentially	B-UNK
useful	B-UNK
anti-adenovirus	O
therapies	B-UNK
.	O
Apparent	O
clinical	B-UNK
success	O
in	O
the	O
treatment	B-UNK
of	O
severe	B-UNK
adenovirus	B-UNK
disease	B-DISEASE
is	O
limited	O
to	O
a	O
few	O
case	B-UNK
reports	B-UNK
and	O
small	B-UNK
series	B-UNK
.	O
Experience	O
is	O
greatest	O
with	O
intravenous	B-UNK
ribavirin	B-CHEMICAL
and	O
cidofovir	B-CHEMICAL
.	O
Ribavirin	O
,	O
a	O
guanosine	B-CHEMICAL
analogue	B-UNK
,	O
has	O
broad	O
antiviral	B-UNK
activity	B-UNK
against	O
both	O
RNA	B-UNK
and	O
DNA	B-UNK
viruses	O
,	O
including	B-UNK
documented	B-UNK
activity	B-UNK
against	O
adenovirus	B-UNK
in	O
vitro	B-UNK
.	O
Ribavirin	O
is	O
licensed	O
in	O
aerosol	O
form	B-UNK
for	O
the	O
treatment	B-UNK
of	O
respiratory	B-UNK
syncytial	O
virus	B-UNK
infection	B-UNK
,	O
and	O
orally	B-UNK
in	O
combination	B-UNK
with	O
interferon	O
to	O
treat	O
hepatitis	B-DISEASE
C.	O
Intravenous	B-UNK
ribavirin	B-CHEMICAL
is	O
the	O
treatment	B-UNK
of	O
choice	O
for	O
infection	B-UNK
with	O
hemorrhagic	B-DISEASE
fever	I-DISEASE
viruses	O
.	O
The	O
most	O
common	B-UNK
adverse	B-UNK
effect	B-UNK
of	O
intravenous	B-UNK
ribavirin	B-CHEMICAL
is	O
reversible	B-UNK
mild	B-UNK
anemia	B-DISEASE
.	O
The	O
use	B-UNK
of	O
cidofovir	B-CHEMICAL
in	O
severe	B-UNK
adenovirus	B-UNK
infection	B-UNK
has	O
been	O
limited	O
by	O
adverse	B-UNK
effects	B-UNK
,	O
the	O
most	O
significant	B-UNK
of	O
which	O
is	O
nephrotoxicity	B-UNK
.	O
OBJECTIVE	O
:	O
We	O
report	B-UNK
our	O
experience	B-UNK
with	O
intravenous	B-UNK
ribavirin	B-CHEMICAL
therapy	B-UNK
for	O
severe	B-UNK
adenovirus	B-UNK
disease	B-DISEASE
in	O
a	O
series	B-UNK
of	O
immunocompromised	B-UNK
children	B-UNK
and	O
review	B-UNK
the	O
literature	B-UNK
.	O
DESIGN	B-UNK
/	O
METHODS	O
:	O
We	O
retrospectively	B-UNK
reviewed	B-UNK
the	O
medical	B-UNK
records	B-UNK
of	O
5	O
children	B-UNK
treated	B-UNK
with	O
intravenous	B-UNK
ribavirin	B-CHEMICAL
for	O
documented	B-UNK
severe	B-UNK
adenovirus	B-UNK
disease	B-DISEASE
.	O
Two	O
patients	B-UNK
developed	B-UNK
adenovirus	B-UNK
hemorrhagic	B-UNK
cystitis	B-DISEASE
after	O
cardiac	B-UNK
and	O
bone	B-UNK
marrow	B-UNK
transplants	O
,	O
respectively	O
.	O
The	O
bone	B-UNK
marrow	B-UNK
transplant	B-UNK
patient	B-UNK
also	O
received	B-UNK
intravenous	B-UNK
cidofovir	B-CHEMICAL
for	O
progressive	B-UNK
disseminated	O
disease	B-DISEASE
.	O
An	O
additional	B-UNK
3	O
children	B-UNK
developed	B-UNK
adenovirus	B-UNK
pneumonia	B-DISEASE
;	O
2	B-DISEASE
were	O
neonates	O
,	O
1	O
of	O
whom	O
had	O
partial	B-UNK
DiGeorge	O
syndrome	B-UNK
.	O
The	O
remaining	B-UNK
infant	B-DISEASE
had	O
recently	B-UNK
undergone	B-UNK
a	O
cardiac	B-UNK
transplant	B-UNK
.	O
Intravenous	B-UNK
ribavirin	B-CHEMICAL
was	O
administered	B-UNK
on	O
a	O
compassionate	O
-	O
use	B-UNK
protocol	B-UNK
.	O
RESULTS	B-UNK
:	O
Complete	O
clinical	B-UNK
recovery	B-UNK
followed	B-UNK
later	B-UNK
by	O
viral	O
clearance	B-UNK
was	O
observed	B-UNK
in	O
2	B-DISEASE
children	B-UNK
:	O
the	O
cardiac	B-UNK
transplant	B-UNK
recipient	O
with	O
adenovirus	B-UNK
hemorrhagic	B-UNK
cystitis	B-DISEASE
and	O
the	O
immunocompetent	O
neonate	O
with	O
adenovirus	B-UNK
pneumonia	B-DISEASE
.	O
The	O
remaining	B-UNK
3	O
children	B-UNK
died	B-UNK
of	O
adenovirus	B-UNK
disease	B-DISEASE
.	O
Intravenous	B-UNK
ribavirin	B-CHEMICAL
therapy	B-UNK
was	O
well	O
tolerated	B-UNK
.	O
Use	O
of	O
cidofovir	B-CHEMICAL
in	O
1	O
child	B-UNK
was	O
associated	B-UNK
with	O
progressive	B-UNK
renal	B-DISEASE
failure	I-DISEASE
and	O
neutropenia	B-DISEASE
.	O
DISCUSSION	O
:	O
Our	O
series	B-UNK
of	O
patients	B-UNK
is	O
representative	O
of	O
the	O
spectrum	O
of	O
immunocompromised	B-UNK
children	B-UNK
at	B-DISEASE
greatest	O
risk	B-UNK
for	O
severe	B-UNK
adenovirus	B-UNK
disease	B-DISEASE
,	O
namely	O
solid	O
-	O
organ	O
and	O
bone	B-UNK
marrow	B-UNK
transplant	B-UNK
recipients	B-UNK
,	O
neonates	O
,	O
and	O
children	B-UNK
with	O
immunodeficiency	B-DISEASE
.	O
Although	O
intravenous	B-UNK
ribavirin	B-CHEMICAL
was	O
not	O
effective	B-UNK
for	O
all	O
children	B-UNK
with	O
severe	B-UNK
adenovirus	B-UNK
disease	B-DISEASE
in	O
this	O
series	B-UNK
or	O
in	O
the	O
literature	B-UNK
,	O
therapy	B-UNK
is	O
unlikely	O
to	O
be	O
of	O
benefit	B-UNK
if	O
begun	O
late	B-UNK
in	O
the	O
course	B-UNK
of	O
the	O
infection	B-UNK
.	O
Early	O
identification	B-UNK
,	O
eg	O
by	O
polymerase	B-UNK
chain	I-UNK
reaction	B-UNK
of	O
those	O
patients	B-UNK
at	B-DISEASE
risk	B-UNK
of	O
disseminated	O
adenovirus	B-UNK
disease	B-DISEASE
may	O
permit	O
earlier	B-UNK
antiviral	B-UNK
treatment	B-UNK
and	O
better	B-UNK
evaluation	B-UNK
of	O
therapeutic	B-UNK
response	B-UNK
.	O
CONCLUSIONS	O
:	O
Two	O
of	O
5	O
children	B-UNK
with	O
severe	B-UNK
adenovirus	B-UNK
disease	B-DISEASE
treated	B-UNK
with	O
intravenous	B-UNK
ribavirin	B-CHEMICAL
recovered	O
.	O
The	O
availability	O
of	O
newer	O
rapid	B-UNK
diagnostic	B-UNK
techniques	O
,	O
such	O
as	O
polymerase	B-UNK
chain	I-UNK
reaction	B-UNK
,	O
may	O
make	O
earlier	B-UNK
,	O
more	O
effective	B-UNK
treatment	B-UNK
of	O
adenovirus	B-UNK
infection	B-UNK
possible	B-UNK
.	O
Given	O
the	O
seriousness	O
and	O
increasing	B-UNK
prevalence	O
of	O
adenovirus	B-UNK
disease	B-DISEASE
in	O
certain	B-UNK
hosts	O
,	O
especially	B-UNK
children	B-UNK
,	O
a	O
large	B-UNK
,	O
multicenter	O
clinical	B-UNK
trial	B-UNK
of	O
potentially	B-UNK
useful	B-UNK
anti-adenoviral	O
therapies	B-UNK
,	O
such	O
as	O
intravenous	B-UNK
ribavirin	B-CHEMICAL
,	O
is	O
clearly	B-UNK
required	B-UNK
to	O
demonstrate	B-UNK
the	O
most	O
effective	B-UNK
and	O
least	O
toxic	B-UNK
therapy	B-UNK
.	O

Hepatotoxicity	O
of	O
amiodarone	B-CHEMICAL
.	O

Amiodarone	O
has	O
proved	O
very	O
effective	B-UNK
in	O
the	O
treatment	B-UNK
of	O
otherwise	O
resistant	B-UNK
cardiac	B-UNK
tachyarrhythmias	O
.	O
The	O
use	B-UNK
of	O
amiodarone	B-CHEMICAL
has	O
,	O
however	O
,	O
been	O
limited	O
due	O
to	O
its	O
serious	O
side	O
-	O
effects	B-UNK
.	O
A	O
patient	B-UNK
with	O
cholestatic	B-UNK
hepatitis	B-DISEASE
due	O
to	O
amiodarone	B-CHEMICAL
treatment	B-UNK
is	O
presented	B-UNK
below	O
and	O
a	O
review	B-UNK
of	O
the	O
hepatotoxicity	O
of	O
amiodarone	B-CHEMICAL
is	O
given	B-UNK
.	O
It	O
is	O
concluded	O
that	O
solid	O
evidence	B-UNK
exists	B-UNK
of	O
hepatic	B-UNK
injury	B-UNK
due	O
to	O
amiodarone	B-CHEMICAL
treatment	B-UNK
,	O
including	B-UNK
steatosis	O
,	O
alterations	B-UNK
resembling	O
alcoholic	B-DISEASE
hepatitis	I-DISEASE
,	O
cholestatic	B-UNK
hepatitis	B-DISEASE
and	O
micronodular	O
cirrhosis	B-DISEASE
of	O
the	O
liver	B-DISEASE
.	O
Patients	B-UNK
receiving	B-UNK
amiodarone	B-CHEMICAL
should	O
be	O
regularly	O
screened	O
with	O
respect	O
to	O
hepatic	B-UNK
enzyme	B-UNK
levels	B-UNK
.	O
Therapy	O
should	O
be	O
discontinued	O
on	O
the	O
suspicion	O
of	O
cholestatic	B-UNK
injury	B-UNK
or	O
hepatomegaly	B-DISEASE
.	O

Catalepsy	O
induced	B-UNK
by	O
combinations	B-UNK
of	O
ketamine	B-CHEMICAL
and	O
morphine	B-CHEMICAL
:	O
potentiation	B-UNK
,	O
antagonism	B-UNK
,	O
tolerance	B-UNK
and	O
cross-tolerance	O
in	O
the	O
rat	B-UNK
.	O

Previous	B-UNK
studies	B-UNK
demonstrated	I-UNK
that	O
both	O
ketamine	B-CHEMICAL
and	O
morphine	B-CHEMICAL
induced	B-UNK
analgesia	O
and	O
catalepsy	B-DISEASE
in	O
the	O
rat	B-UNK
.	O
Pre	O
-	O
treatment	B-UNK
with	O
ketamine	B-CHEMICAL
produced	B-UNK
cross-tolerance	O
to	O
morphine	B-CHEMICAL
,	O
whereas	O
pretreatment	B-UNK
with	O
morphine	B-CHEMICAL
did	O
not	O
induce	B-UNK
cross-tolerance	O
to	O
ketamine	B-CHEMICAL
but	O
rather	O
augmented	O
the	O
cataleptic	O
response	B-UNK
;	O
this	O
augmentation	O
was	O
attributed	B-UNK
to	O
residual	O
morphine	B-CHEMICAL
in	O
the	O
brain	B-UNK
.	O
The	O
present	B-UNK
studies	B-UNK
explored	O
the	O
duration	B-UNK
of	O
the	O
loss	B-UNK
of	O
righting	O
reflex	B-DISEASE
induced	B-UNK
by	O
sub-effective	O
doses	B-UNK
of	O
ketamine	B-CHEMICAL
and	O
morphine	B-CHEMICAL
,	O
administered	B-UNK
simultaneously	B-UNK
.	O
There	O
was	O
mutual	O
potentiation	B-UNK
between	O
sub-effective	O
doses	B-UNK
of	O
ketamine	B-CHEMICAL
and	O
morphine	B-CHEMICAL
,	O
but	O
sub-effective	O
doses	B-UNK
of	O
ketamine	B-CHEMICAL
partly	O
antagonized	B-UNK
fully	B-UNK
-	O
effective	B-UNK
doses	B-UNK
of	O
morphine	B-CHEMICAL
.	O
Latency	O
to	O
the	O
loss	B-UNK
of	O
righting	O
reflex	B-DISEASE
,	O
rigidity	B-UNK
and	O
behavior	B-UNK
on	O
recovery	B-UNK
,	O
reflected	O
the	O
relative	B-UNK
predominance	O
of	O
ketamine	B-CHEMICAL
or	O
morphine	B-CHEMICAL
in	O
each	O
combination	B-UNK
.	O
Naloxone	O
inhibited	B-UNK
the	O
induced	B-UNK
cataleptic	O
effects	B-UNK
.	O
The	O
degree	B-UNK
and	O
time	B-UNK
course	B-UNK
of	O
development	B-UNK
of	O
tolerance	B-UNK
to	O
daily	B-UNK
administration	B-UNK
of	O
sub-effective	O
dose	B-UNK
combinations	B-UNK
of	O
ketamine	B-CHEMICAL
and	O
morphine	B-CHEMICAL
were	O
similar	B-UNK
.	O
Rats	O
,	O
tolerant	O
to	O
ketamine	B-CHEMICAL
-	O
dominant	O
combinations	B-UNK
,	O
were	O
cross-tolerant	O
to	O
both	O
drugs	B-UNK
,	O
while	O
those	O
tolerant	O
to	O
morphine	B-CHEMICAL
-	O
dominant	O
combinations	B-UNK
were	O
cross-tolerant	O
to	O
morphine	B-CHEMICAL
but	O
showed	B-UNK
either	O
no	O
cross-tolerance	O
or	O
an	O
augmented	O
response	B-UNK
to	O
ketamine	B-CHEMICAL
.	O
While	O
the	O
mutual	O
potentiation	B-UNK
,	O
antagonism	B-UNK
and	O
tolerance	B-UNK
suggest	B-UNK
common	B-UNK
mechanisms	B-UNK
for	O
the	O
induced	B-UNK
catalepsy	B-DISEASE
,	O
differences	B-UNK
in	O
latency	O
,	O
rigidity	B-UNK
and	O
behavior	B-UNK
,	O
asymmetry	O
of	O
cross-tolerance	O
and	O
a	O
widely	B-UNK
-	O
different	B-UNK
ID50	O
for	O
naloxone	B-CHEMICAL
would	O
argue	O
against	O
an	O
action	B-UNK
at	B-DISEASE
a	O
single	B-UNK
opioid	B-UNK
site	B-UNK
.	O

Acute	B-UNK
renal	B-DISEASE
failure	I-DISEASE
in	O
patients	B-UNK
with	O
AIDS	O
on	O
tenofovir	B-CHEMICAL
while	O
receiving	B-UNK
prolonged	B-UNK
vancomycin	B-CHEMICAL
course	B-UNK
for	O
osteomyelitis	B-DISEASE
.	O

Renal	B-UNK
failure	B-UNK
developed	B-UNK
after	O
a	O
prolonged	B-UNK
course	B-UNK
of	O
vancomycin	B-CHEMICAL
therapy	B-UNK
in	O
2	B-DISEASE
patients	B-UNK
who	O
were	O
receiving	B-UNK
tenofovir	B-CHEMICAL
disoproxil	O
fumarate	O
as	O
part	O
of	O
an	O
antiretroviral	B-UNK
regimen	B-UNK
.	O
Tenofovir	O
has	O
been	O
implicated	B-UNK
in	O
the	O
development	B-UNK
of	O
Fanconi	O
syndrome	B-UNK
and	O
renal	B-DISEASE
insufficiency	I-DISEASE
because	O
of	O
its	O
effects	B-UNK
on	O
the	O
proximal	B-UNK
renal	B-UNK
tubule	B-UNK
.	O
Vancomycin	O
nephrotoxicity	B-UNK
is	O
infrequent	O
but	O
may	O
result	B-UNK
from	O
coadministration	O
with	O
a	O
nephrotoxic	B-UNK
agent	B-UNK
.	O
Clinicians	O
should	O
be	O
aware	O
that	O
tenofovir	B-CHEMICAL
may	O
raise	O
the	O
risk	B-UNK
of	O
renal	B-DISEASE
failure	I-DISEASE
during	O
prolonged	B-UNK
administration	B-UNK
of	O
vancomycin	B-CHEMICAL
.	O

Delayed	B-UNK
leukoencephalopathy	B-DISEASE
with	O
stroke	B-UNK
-	O
like	B-UNK
presentation	O
in	O
chemotherapy	B-UNK
recipients	B-UNK
.	O

BACKGROUND	O
:	O
A	O
transient	B-UNK
leukoencephalopathy	B-DISEASE
mimicking	O
cerebrovascular	B-DISEASE
accident	I-DISEASE
has	O
been	O
described	B-UNK
as	O
a	O
complication	B-UNK
of	O
chemotherapy	B-UNK
,	O
most	O
commonly	B-UNK
in	O
recipients	B-UNK
of	O
intrathecal	O
methotrexate	B-CHEMICAL
for	O
childhood	O
leukaemia	O
.	O
Recently	O
published	B-UNK
neuroimaging	O
data	B-UNK
suggest	B-UNK
a	O
common	B-UNK
pathophysiology	O
associated	B-UNK
with	O
a	O
variety	O
of	O
chemotherapy	B-UNK
agents	B-UNK
and	O
modes	O
of	O
administration	B-UNK
.	O
METHODS	O
:	O
We	O
reviewed	B-UNK
the	O
medical	B-UNK
literature	B-UNK
for	O
single	B-UNK
reports	B-UNK
and	O
case	B-UNK
series	B-UNK
of	O
patients	B-UNK
presenting	O
with	O
stroke	B-DISEASE
-	O
like	B-UNK
episodes	B-UNK
while	O
receiving	B-UNK
systemic	B-UNK
or	O
intrathecal	O
chemotherapy	B-UNK
.	O
We	O
only	O
included	B-UNK
studies	B-UNK
providing	O
detailed	B-UNK
neuroimaging	O
data	B-UNK
.	O
Patients	B-UNK
with	O
cerebrovascular	O
accidents	O
were	O
excluded	O
.	O
RESULTS	B-UNK
:	O
We	O
identified	B-UNK
27	O
reports	B-UNK
of	O
toxic	B-UNK
leukoencephalopathy	B-DISEASE
in	O
patients	B-UNK
treated	B-UNK
with	O
methotrexate	B-CHEMICAL
(	O
intrathecal	O
,	O
systemic	B-UNK
)	O
,	O
5-fluorouracil	B-UNK
and	O
its	O
derivative	B-UNK
carmofur	B-CHEMICAL
,	O
and	O
capecitabine	B-CHEMICAL
.	O
Diffusion	O
weighted	O
imaging	B-UNK
(	O
DWI	O
)	O
of	O
all	O
patients	B-UNK
revealed	B-UNK
well	O
demarcated	O
hyperintense	O
lesions	B-UNK
within	O
the	O
subcortical	O
white	B-UNK
matter	I-UNK
of	O
the	O
cerebral	B-UNK
hemispheres	O
and	O
the	O
corpus	B-DISEASE
callosum	I-DISEASE
,	O
corresponding	B-UNK
to	O
areas	B-UNK
of	O
decreased	B-UNK
proton	O
diffusion	O
on	O
apparent	O
diffusion	O
coefficient	O
(	O
ADC	O
)	O
maps	O
(	O
available	B-UNK
in	O
21/27	O
patients	B-UNK
)	O
.	O
Lesions	O
exceeded	O
the	O
confines	O
of	O
adjacent	O
vascular	B-UNK
territories	O
.	O
Complete	O
resolution	B-UNK
of	O
symptoms	B-UNK
within	O
1	O
-	O
4	O
days	B-UNK
was	O
accompanied	O
by	O
normalisation	O
of	O
ADC	O
abnormalities	B-DISEASE
.	O
However	O
,	O
fluid	B-UNK
attenuated	B-UNK
inversion	O
recovery	B-UNK
(	O
FLAIR	O
)	O
sequences	O
frequently	B-UNK
revealed	B-UNK
persistent	O
white	B-UNK
matter	I-UNK
abnormalities	B-DISEASE
.	O
CONCLUSIONS	O
:	O
Several	O
pathophysiological	O
models	B-UNK
of	O
delayed	B-UNK
leukoencephalopathy	B-DISEASE
after	O
exposure	B-UNK
to	O
intrathecal	O
or	O
systemic	B-UNK
chemotherapy	B-UNK
have	O
been	O
proposed	O
.	O
DWI	O
findings	B-UNK
in	O
this	O
cohort	B-UNK
are	O
indicative	O
of	O
cytotoxic	B-UNK
oedema	O
within	O
cerebral	B-UNK
white	B-UNK
matter	I-UNK
and	O
lend	O
support	B-UNK
to	O
an	O
at	B-DISEASE
least	O
partially	O
reversible	B-UNK
metabolic	B-UNK
derangement	O
as	O
the	O
basis	B-UNK
for	O
this	O
syndrome	B-UNK
.	O

Down	O
-	O
regulation	O
of	O
norepinephrine	B-CHEMICAL
transporter	O
function	B-UNK
induced	B-UNK
by	O
chronic	B-UNK
administration	B-UNK
of	O
desipramine	B-CHEMICAL
linking	O
to	O
the	O
alteration	O
of	O
sensitivity	B-UNK
of	O
local	B-UNK
-	O
anesthetics	B-CHEMICAL
-	O
induced	B-UNK
convulsions	B-DISEASE
and	O
the	O
counteraction	O
by	O
co-administration	O
with	O
local	B-UNK
anesthetics	B-CHEMICAL
.	O

Alterations	O
of	O
norepinephrine	B-CHEMICAL
transporter	O
(	O
NET	O
)	O
function	B-UNK
by	O
chronic	B-UNK
inhibition	B-UNK
of	O
NET	O
in	O
relation	O
to	O
sensitization	B-UNK
to	O
seizures	B-DISEASE
induce	B-UNK
by	O
cocaine	B-CHEMICAL
and	O
local	B-UNK
anesthetics	B-CHEMICAL
were	O
studied	B-UNK
in	O
mice	B-UNK
.	O
Daily	B-UNK
administration	B-UNK
of	O
desipramine	B-CHEMICAL
,	O
an	O
inhibitor	B-UNK
of	O
the	O
NET	O
,	O
for	O
5	O
days	B-UNK
decreased	B-UNK
[	O
(	O
3)H]norepinephrine	O
uptake	B-UNK
in	O
the	O
P2	O
fractions	O
of	O
hippocampus	B-UNK
but	O
not	O
cortex	B-UNK
,	O
striatum	O
or	O
amygdalae	O
.	O
Co-administration	O
of	O
lidocaine	B-CHEMICAL
,	O
bupivacaine	B-CHEMICAL
or	O
tricaine	B-CHEMICAL
with	O
desipramine	B-CHEMICAL
reversed	B-UNK
this	O
effect	B-UNK
.	O
Daily	B-UNK
treatment	B-UNK
of	O
cocaine	B-CHEMICAL
increased	B-UNK
[	O
(	O
3)H]norepinephrine	O
uptake	B-UNK
into	O
the	O
hippocampus	B-UNK
.	O
Daily	B-UNK
administration	B-UNK
of	O
desipramine	B-CHEMICAL
increased	B-UNK
the	O
incidence	B-UNK
of	O
appearance	O
of	O
lidocaine	B-CHEMICAL
-	O
induced	B-UNK
convulsions	B-DISEASE
and	O
decreased	B-UNK
that	O
of	O
cocaine	B-CHEMICAL
-	O
induced	B-UNK
convulsions	B-DISEASE
.	O
Co-administration	O
of	O
lidocaine	B-CHEMICAL
with	O
desipramine	B-CHEMICAL
reversed	B-UNK
the	O
changes	B-UNK
of	O
convulsive	B-UNK
activity	B-UNK
of	O
lidocaine	B-CHEMICAL
and	O
cocaine	B-CHEMICAL
induced	B-UNK
by	O
repeated	B-UNK
administration	B-UNK
of	O
desipramine	B-CHEMICAL
.	O
These	O
results	B-UNK
suggest	B-UNK
that	O
down	O
-	O
regulation	O
of	O
hippocampal	B-UNK
NET	O
induced	B-UNK
by	O
chronic	B-UNK
administration	B-UNK
of	O
desipramine	B-CHEMICAL
may	O
be	O
relevant	B-UNK
to	O
desipramine	B-CHEMICAL
-	O
induced	B-UNK
sensitization	B-UNK
of	O
lidocaine	B-CHEMICAL
convulsions	B-DISEASE
.	O
Inhibition	O
of	O
Na(+	O
)	O
channels	O
by	O
local	B-UNK
anesthetics	B-CHEMICAL
may	O
regulate	O
desipramine	B-CHEMICAL
-	O
induced	B-UNK
down	O
-	O
regulation	O
of	O
NET	O
function	B-UNK
.	O
Repeated	O
administration	B-UNK
of	O
cocaine	B-CHEMICAL
induces	B-UNK
up	O
-	O
regulation	O
of	O
hippocampal	B-UNK
NET	O
function	B-UNK
.	O
Desipramine	O
-	O
induced	B-UNK
sensitization	B-UNK
of	O
lidocaine	B-CHEMICAL
seizures	B-DISEASE
may	O
have	O
a	O
mechanism	B-UNK
distinct	O
from	O
kindling	O
resulting	B-UNK
from	O
repeated	B-UNK
administration	B-UNK
of	O
cocaine	B-CHEMICAL
.	O

Definition	O
and	O
management	B-UNK
of	O
anemia	B-DISEASE
in	O
patients	B-UNK
infected	B-UNK
with	O
hepatitis	B-DISEASE
C	B-UNK
virus	B-UNK
.	O

Chronic	B-UNK
infection	B-UNK
with	O
hepatitis	B-DISEASE
C	B-UNK
virus	B-UNK
(	O
HCV	O
)	O
can	O
progress	O
to	O
cirrhosis	B-DISEASE
,	O
hepatocellular	B-DISEASE
carcinoma	I-DISEASE
,	O
and	O
end	B-UNK
-	O
stage	B-UNK
liver	B-DISEASE
disease	I-DISEASE
.	O
The	O
current	B-UNK
best	B-UNK
treatment	B-UNK
for	O
HCV	O
infection	B-UNK
is	O
combination	B-UNK
therapy	B-UNK
with	O
pegylated	B-UNK
interferon	I-UNK
and	O
ribavirin	B-CHEMICAL
.	O
Although	O
this	O
regimen	B-UNK
produces	B-UNK
sustained	B-UNK
virologic	O
responses	B-UNK
(	O
SVRs	O
)	O
in	O
approximately	B-UNK
50	O
%	O
of	O
patients	B-UNK
,	O
it	O
can	O
be	O
associated	B-UNK
with	O
a	O
potentially	B-UNK
dose	B-UNK
-	O
limiting	B-UNK
hemolytic	B-DISEASE
anemia	I-DISEASE
.	O
Hemoglobin	O
concentrations	B-UNK
decrease	B-UNK
mainly	B-UNK
as	O
a	O
result	B-UNK
of	O
ribavirin	B-CHEMICAL
-	O
induced	B-UNK
hemolysis	B-DISEASE
,	O
and	O
this	O
anemia	B-DISEASE
can	O
be	O
problematic	O
in	O
patients	B-UNK
with	O
HCV	O
infection	B-UNK
,	O
especially	B-UNK
those	O
who	O
have	O
comorbid	O
renal	B-UNK
or	O
cardiovascular	B-UNK
disorders	B-UNK
.	O
In	O
general	B-UNK
,	O
anemia	B-DISEASE
can	O
increase	B-UNK
the	O
risk	B-UNK
of	O
morbidity	O
and	O
mortality	B-UNK
,	O
and	O
may	O
have	O
negative	B-UNK
effects	B-UNK
on	O
cerebral	B-UNK
function	B-UNK
and	O
quality	O
of	O
life	B-UNK
.	O
Although	O
ribavirin	B-CHEMICAL
-	O
associated	B-UNK
anemia	B-DISEASE
can	O
be	O
reversed	B-UNK
by	O
dose	B-UNK
reduction	B-UNK
or	O
discontinuation	B-UNK
,	O
this	O
approach	B-UNK
compromises	O
outcomes	B-UNK
by	O
significantly	B-UNK
decreasing	B-UNK
SVR	O
rates	B-UNK
.	O
Recombinant	O
human	B-UNK
erythropoietin	B-CHEMICAL
has	O
been	O
used	O
to	O
manage	O
ribavirin	B-CHEMICAL
-	O
associated	B-UNK
anemia	B-DISEASE
but	O
has	O
other	O
potential	B-UNK
disadvantages	O
.	O
Viramidine	O
,	O
a	O
liver	B-DISEASE
-	O
targeting	B-UNK
prodrug	O
of	O
ribavirin	B-CHEMICAL
,	O
has	O
the	O
potential	B-UNK
to	O
maintain	O
the	O
virologic	O
efficacy	B-UNK
of	O
ribavirin	B-CHEMICAL
while	O
decreasing	B-UNK
the	O
risk	B-UNK
of	O
hemolytic	B-DISEASE
anemia	I-DISEASE
in	O
patients	B-UNK
with	O
chronic	B-UNK
hepatitis	B-DISEASE
C.	O

Calcium	B-UNK
carbonate	O
toxicity	B-UNK
:	O
the	O
updated	O
milk	O
-	O
alkali	O
syndrome	B-UNK
;	O
report	B-UNK
of	O
3	O
cases	B-UNK
and	O
review	B-UNK
of	O
the	O
literature	B-UNK
.	O

OBJECTIVE	O
:	O
To	O
describe	O
3	O
patients	B-UNK
with	O
calcium	B-CHEMICAL
carbonate	I-CHEMICAL
-	O
induced	B-UNK
hypercalcemia	B-DISEASE
and	O
gain	O
insights	O
into	O
the	O
cause	B-UNK
and	O
management	B-UNK
of	O
the	O
milk	O
-	O
alkali	O
syndrome	B-DISEASE
.	O
METHODS	O
:	O
We	O
report	B-UNK
the	O
clinical	B-UNK
and	O
laboratory	B-UNK
data	B-UNK
in	O
3	O
patients	B-UNK
who	O
presented	B-UNK
with	O
severe	B-UNK
hypercalcemia	B-DISEASE
(	O
corrected	O
serum	B-UNK
calcium	B-CHEMICAL
>	O
or	O
=	O
14	O
mg	B-UNK
/	O
dL	O
)	O
and	O
review	B-UNK
the	O
pertinent	O
literature	B-UNK
on	O
milk	O
-	O
alkali	O
syndrome	B-DISEASE
.	O
RESULTS	B-UNK
:	O
The	O
3	O
patients	B-UNK
had	O
acute	B-UNK
renal	B-DISEASE
insufficiency	I-DISEASE
,	O
relative	B-UNK
metabolic	B-UNK
alkalosis	B-DISEASE
,	O
and	O
low	B-UNK
parathyroid	B-CHEMICAL
hormone	I-CHEMICAL
(	O
PTH	B-UNK
)	O
,	O
PTH	B-UNK
-	O
related	B-UNK
peptide	O
,	O
and	O
1,25-dihydroxyvitamin	O
D	B-UNK
concentrations	B-UNK
.	O
No	O
malignant	B-UNK
lesion	B-UNK
was	O
found	B-UNK
.	O
Treatment	O
included	B-UNK
aggressive	B-UNK
hydration	B-UNK
and	O
varied	O
amounts	B-UNK
of	O
furosemide	B-CHEMICAL
.	O
The	O
2	B-DISEASE
patients	B-UNK
with	O
the	O
higher	B-UNK
serum	B-UNK
calcium	B-CHEMICAL
concentrations	B-UNK
received	B-UNK
pamidronate	B-CHEMICAL
intravenously	B-UNK
(	O
60	O
and	O
30	O
mg	B-UNK
,	O
respectively	O
)	O
,	O
which	O
caused	B-UNK
severe	B-UNK
hypocalcemia	B-DISEASE
.	O
Of	O
the	O
3	O
patients	B-UNK
,	O
2	B-DISEASE
were	O
ingesting	O
acceptable	O
doses	B-UNK
of	O
elemental	O
calcium	B-CHEMICAL
(	O
1	O
g	B-UNK
and	O
2	B-DISEASE
g	B-UNK
daily	B-UNK
,	O
respectively	O
)	O
in	O
the	O
form	B-UNK
of	O
calcium	B-CHEMICAL
carbonate	I-CHEMICAL
.	O
In	O
addition	O
to	O
our	O
highlighted	O
cases	B-UNK
,	O
we	O
review	B-UNK
the	O
history	B-UNK
,	O
classification	O
,	O
pathophysiologic	O
features	B-UNK
,	O
and	O
treatment	B-UNK
of	O
milk	O
-	O
alkali	O
syndrome	B-DISEASE
and	O
summarize	O
the	O
cases	B-UNK
reported	B-UNK
from	O
early	B-UNK
1995	O
to	O
November	O
2003	O
.	O
CONCLUSION	O
:	O
Milk	O
-	O
alkali	O
syndrome	B-UNK
may	O
be	O
a	O
common	B-UNK
cause	B-UNK
of	O
unexplained	O
hypercalcemia	B-DISEASE
and	O
can	O
be	O
precipitated	O
by	O
small	B-UNK
amounts	B-UNK
of	O
orally	B-UNK
ingested	O
calcium	B-CHEMICAL
carbonate	I-CHEMICAL
in	O
susceptible	B-UNK
persons	B-UNK
.	O
Treatment	O
with	O
hydration	B-UNK
,	O
furosemide	B-CHEMICAL
,	O
and	O
discontinuation	B-UNK
of	O
the	O
calcium	B-CHEMICAL
and	O
vitamin	B-UNK
D	B-UNK
source	B-UNK
is	O
adequate	B-UNK
.	O
Pamidronate	O
treatment	B-UNK
is	O
associated	B-UNK
with	O
considerable	O
risk	B-UNK
for	O
hypocalcemia	B-DISEASE
,	O
even	O
in	O
cases	B-UNK
of	O
initially	B-UNK
severe	B-UNK
hypercalcemia	B-DISEASE
.	O

Management	O
strategies	O
for	O
ribavirin	B-CHEMICAL
-	O
induced	B-UNK
hemolytic	B-DISEASE
anemia	I-DISEASE
in	O
the	O
treatment	B-UNK
of	O
hepatitis	B-DISEASE
C	B-UNK
:	O
clinical	B-UNK
and	O
economic	O
implications	O
.	O

OBJECTIVES	O
:	O
Recently	O
published	B-UNK
studies	B-UNK
have	O
demonstrated	B-UNK
increased	B-UNK
efficacy	B-UNK
and	O
cost	B-UNK
-	O
effectiveness	O
of	O
combination	B-UNK
therapy	B-UNK
with	O
interferon	O
and	O
alpha-2b	O
/	O
ribavirin	B-CHEMICAL
compared	B-UNK
with	O
interferon	B-CHEMICAL
-	I-CHEMICAL
alpha	I-CHEMICAL
monotherapy	B-UNK
in	O
the	O
treatment	B-UNK
of	O
chronic	B-UNK
hepatitis	B-DISEASE
C	B-UNK
(	O
CHC	O
)	O
.	O
Combination	O
therapy	B-UNK
is	O
associated	B-UNK
with	O
a	O
clinically	B-UNK
important	B-UNK
adverse	B-UNK
effect	B-UNK
:	O
ribavirin	B-CHEMICAL
-	O
induced	B-UNK
hemolytic	B-DISEASE
anemia	I-DISEASE
(	O
RIHA	B-UNK
)	O
.	O
The	O
objective	B-UNK
of	O
this	O
study	B-UNK
was	O
to	O
evaluate	B-UNK
the	O
direct	B-UNK
health	O
-	O
care	B-UNK
costs	O
and	O
management	B-UNK
of	O
RIHA	B-UNK
during	O
treatment	B-UNK
of	O
CHC	O
in	O
a	O
clinical	B-UNK
trial	B-UNK
setting	B-UNK
.	O
METHODS	O
:	O
A	O
systematic	O
literature	B-UNK
review	B-UNK
was	O
conducted	O
to	O
synthesize	O
information	B-UNK
on	O
the	O
incidence	B-UNK
and	O
management	B-UNK
of	O
RIHA	B-UNK
.	O
Decision	O
-	O
analytic	O
techniques	O
were	O
used	O
to	O
estimate	O
the	O
cost	B-UNK
of	O
treating	B-UNK
RIHA	B-UNK
.	O
Uncertainty	O
was	O
evaluated	B-UNK
using	O
sensitivity	B-UNK
analyses	B-UNK
.	O
RESULTS	B-UNK
:	O
RIHA	B-UNK
,	O
defined	O
as	O
a	O
reduction	B-UNK
in	O
hemoglobin	B-UNK
to	O
less	O
than	O
100	O
g	B-UNK
/	O
L	B-UNK
,	O
occurs	B-UNK
in	O
approximately	B-UNK
7	O
%	O
to	O
9	O
%	O
of	O
patients	B-UNK
treated	B-UNK
with	O
combination	B-UNK
therapy	B-UNK
.	O
The	O
standard	B-UNK
of	O
care	B-UNK
for	O
management	B-UNK
of	O
RIHA	B-UNK
is	O
reduction	B-UNK
or	O
discontinuation	B-UNK
of	O
the	O
ribavirin	B-CHEMICAL
dosage	B-UNK
.	O
We	O
estimated	B-UNK
the	O
direct	B-UNK
cost	B-UNK
of	O
treating	B-UNK
clinically	B-UNK
significant	I-UNK
RIHA	B-UNK
to	O
be	O
 	O
170	O
per	O
patient	B-UNK
receiving	B-UNK
combination	B-UNK
therapy	B-UNK
per	O
48-week	O
treatment	B-UNK
course	B-UNK
(	O
range	B-UNK
 	O
68-	O
692	O
)	O
.	O
The	O
results	B-UNK
of	O
the	O
one	O
-	O
way	O
sensitivity	B-UNK
analyses	B-UNK
ranged	B-UNK
from	O
 	O
57	O
to	O
 	O
317	O
.	O
In	O
comparison	O
,	O
the	O
cost	B-UNK
of	O
48	O
weeks	B-UNK
of	O
combination	B-UNK
therapy	B-UNK
is	O
 	O
16,459	O
.	O
CONCLUSIONS	O
:	O
The	O
direct	B-UNK
cost	B-UNK
of	O
treating	B-UNK
clinically	B-UNK
significant	I-UNK
RIHA	B-UNK
is	O
1	O
%	O
(	O
170/	O
16,459	O
)	O
of	O
drug	B-UNK
treatment	B-UNK
costs	O
.	O
Questions	O
remain	B-UNK
about	O
the	O
optimal	B-UNK
dose	B-UNK
of	O
ribavirin	B-CHEMICAL
and	O
the	O
incidence	B-UNK
of	O
RIHA	B-UNK
in	O
a	O
real	O
-	O
world	O
population	B-UNK
.	O
Despite	B-UNK
these	O
uncertainties	O
,	O
this	O
initial	B-UNK
evaluation	B-UNK
of	O
the	O
direct	B-UNK
cost	B-UNK
of	O
treating	B-UNK
RIHA	B-UNK
provides	B-UNK
an	O
estimate	O
of	O
the	O
cost	B-UNK
and	O
management	B-UNK
implications	O
of	O
this	O
clinically	B-UNK
important	B-UNK
adverse	B-UNK
effect	B-UNK
.	O

Effects	O
of	O
amine	O
pretreatment	B-UNK
on	O
ketamine	B-CHEMICAL
catatonia	B-DISEASE
in	O
pinealectomized	O
or	O
hypophysectomized	O
animals	B-UNK
.	O

The	O
present	B-UNK
studies	B-UNK
were	O
designed	O
to	O
clarify	O
the	O
role	B-UNK
of	O
catecholamines	B-CHEMICAL
and	O
pineal	B-UNK
idolamines	O
on	O
ketamine	B-CHEMICAL
-	O
induced	B-UNK
catatonia	B-DISEASE
in	O
the	O
intact	B-UNK
,	O
pinealectomized	O
or	O
hypophysectomized	O
chick	B-UNK
and	O
rat	B-UNK
.	O
In	O
the	O
pinealectomized	O
chick	B-UNK
,	O
pretreatment	B-UNK
with	O
dopamine	B-CHEMICAL
increased	B-UNK
the	O
duration	B-UNK
of	O
catatonia	B-DISEASE
(	O
DOC	O
)	O
after	O
ketamine	B-CHEMICAL
,	O
but	O
pretreatment	B-UNK
with	O
norepinephrine	B-CHEMICAL
did	O
not	O
.	O
The	O
pineal	B-UNK
indolamines	O
exhibited	B-UNK
mixed	B-UNK
actions	B-UNK
.	O
Serotonin	O
and	O
N	B-UNK
-	O
acetyl	O
serotonin	B-CHEMICAL
which	O
augmented	O
ketamine	B-CHEMICAL
DOC	O
,	O
did	O
not	O
do	O
so	O
in	O
the	O
absence	B-UNK
of	O
the	O
pineal	B-UNK
gland	O
,	O
whereas	O
melatonin	B-CHEMICAL
potentiated	B-UNK
the	O
ketamine	B-CHEMICAL
DOC	O
in	O
both	O
the	O
intact	B-UNK
and	O
pinealectomized	O
chick	B-UNK
.	O
Ketamine	B-UNK
was	O
more	O
potent	B-UNK
in	O
the	O
hypophysectomized	O
chick	B-UNK
and	O
the	O
circadian	O
rhythm	B-UNK
noted	O
in	O
the	O
intact	B-UNK
chick	B-UNK
was	O
absent	O
;	O
furthermore	O
,	O
melatonin	B-CHEMICAL
did	O
not	O
augment	O
the	O
ketamine	B-CHEMICAL
DOC	O
whereas	O
dopamine	B-CHEMICAL
continued	B-UNK
to	O
do	O
so	O
.	O
This	O
study	B-UNK
did	O
not	O
demonstrate	B-UNK
a	O
species	O
difference	B-UNK
regarding	O
the	O
role	B-UNK
of	O
the	O
amines	B-CHEMICAL
on	O
the	O
pineal	B-UNK
in	O
spite	O
of	O
the	O
immature	O
blood	B-UNK
-	O
brain	B-UNK
barrier	B-UNK
in	O
the	O
young	B-UNK
chick	B-UNK
and	O
the	O
intact	B-UNK
barrier	B-UNK
in	O
the	O
rat	B-UNK
.	O
In	O
addition	O
,	O
these	O
data	B-UNK
indicate	B-UNK
a	O
direct	B-UNK
role	B-UNK
of	O
the	O
pituitary	O
in	O
the	O
augmentation	O
of	O
ketamine	B-CHEMICAL
DOC	O
induced	B-UNK
by	O
melatonin	B-CHEMICAL
.	O
Furthermore	O
,	O
dopamine	B-CHEMICAL
appeared	B-UNK
to	O
act	O
on	O
systems	B-UNK
more	O
closely	O
involved	B-UNK
with	O
the	O
induction	B-UNK
of	O
ketamine	B-CHEMICAL
catatonia	B-DISEASE
rather	O
than	O
directly	B-UNK
on	O
the	O
pituitary	O
.	O

Multicenter	O
,	O
double-blind	B-UNK
,	O
multiple	B-UNK
-	O
dose	B-UNK
,	O
parallel	O
-	O
groups	B-UNK
efficacy	B-UNK
and	O
safety	B-UNK
trial	B-UNK
of	O
azelastine	B-CHEMICAL
,	O
chlorpheniramine	B-CHEMICAL
,	O
and	O
placebo	B-UNK
in	O
the	O
treatment	B-UNK
of	O
spring	O
allergic	B-DISEASE
rhinitis	I-DISEASE
.	O

Azelastine	O
,	O
a	O
novel	B-UNK
antiallergic	O
medication	B-UNK
,	O
was	O
compared	B-UNK
with	O
chlorpheniramine	B-CHEMICAL
maleate	O
and	O
placebo	B-UNK
for	O
efficacy	B-UNK
and	O
safety	B-UNK
in	O
the	O
treatment	B-UNK
of	O
spring	O
allergic	B-DISEASE
rhinitis	I-DISEASE
in	O
a	O
multicenter	O
,	O
double-blind	B-UNK
,	O
multiple	B-UNK
-	O
dose	B-UNK
,	O
parallel	O
-	O
groups	B-UNK
study	B-UNK
.	O
One	O
hundred	O
fifty	O
-	O
five	O
subjects	B-UNK
participated	O
.	O
Subjects	O
ranged	B-UNK
in	O
age	B-UNK
from	O
18	O
to	O
60	O
years	B-UNK
of	O
age	B-UNK
and	O
had	O
at	B-DISEASE
least	O
a	O
2-year	O
history	B-UNK
of	O
spring	O
allergic	B-DISEASE
rhinitis	I-DISEASE
,	O
confirmed	B-UNK
by	O
positive	B-UNK
skin	B-DISEASE
test	B-UNK
to	O
spring	O
aeroallergens	O
.	O
Medications	O
were	O
given	B-UNK
four	O
times	B-UNK
daily	B-UNK
;	O
the	O
azelastine	B-CHEMICAL
groups	B-UNK
received	B-UNK
0.5	B-UNK
,	O
1.0	B-UNK
,	O
or	O
2.0	B-UNK
mg	B-UNK
in	O
the	O
morning	O
and	O
evening	O
with	O
placebo	B-UNK
in	O
the	O
early	B-UNK
and	O
late	B-UNK
afternoon	O
;	O
the	O
chlorpheniramine	B-CHEMICAL
group	B-UNK
received	B-UNK
4.0	B-UNK
mg	B-UNK
four	O
times	B-UNK
daily	B-UNK
.	O
Daily	B-UNK
subject	B-UNK
symptom	O
cards	O
were	O
completed	O
during	O
a	O
screening	B-UNK
period	B-UNK
to	O
assess	B-UNK
pretreatment	B-UNK
symptoms	B-UNK
and	O
during	O
a	O
4-week	O
treatment	B-UNK
period	B-UNK
while	O
subjects	B-UNK
received	B-UNK
study	B-UNK
medications	B-UNK
.	O
Individual	O
symptoms	B-UNK
,	O
total	B-UNK
symptoms	B-UNK
,	O
and	O
major	B-UNK
symptoms	B-UNK
were	O
compared	B-UNK
to	O
determine	B-UNK
efficacy	B-UNK
of	O
medication	B-UNK
.	O
Elicited	O
,	O
volunteered	O
,	O
and	O
observed	B-UNK
adverse	B-UNK
experiences	O
were	O
recorded	B-UNK
for	O
each	O
subject	B-UNK
and	O
compared	B-UNK
among	O
groups	B-UNK
.	O
Vital	O
signs	B-UNK
,	O
body	B-UNK
weights	B-UNK
,	O
serum	B-UNK
chemistry	O
values	B-UNK
,	O
complete	B-UNK
blood	B-UNK
cell	B-UNK
counts	B-UNK
,	O
urine	B-DISEASE
studies	B-UNK
,	O
and	O
electrocardiograms	O
were	O
obtained	B-UNK
for	O
each	O
subject	B-UNK
and	O
compared	B-UNK
among	O
groups	B-UNK
.	O
Symptoms	O
relief	O
in	O
the	O
group	B-UNK
receiving	B-UNK
the	O
highest	B-UNK
concentration	B-UNK
of	O
azelastine	B-CHEMICAL
(	O
2.0	B-UNK
mg	B-UNK
twice	B-UNK
daily	B-UNK
)	O
was	O
statistically	B-UNK
greater	B-UNK
than	O
in	O
the	O
placebo	B-UNK
group	B-UNK
during	O
all	O
weeks	B-UNK
of	O
the	O
study	B-UNK
.	O
Lower	O
doses	B-UNK
of	O
azelastine	B-CHEMICAL
were	O
statistically	B-UNK
more	O
effective	B-UNK
than	O
placebo	B-UNK
only	O
during	O
portions	O
of	O
the	O
first	O
3	O
weeks	B-UNK
of	O
the	O
study	B-UNK
.	O
In	O
contrast	B-UNK
,	O
although	O
the	O
chlorpheniramine	B-CHEMICAL
group	B-UNK
did	O
have	O
fewer	B-UNK
symptoms	B-UNK
than	O
the	O
placebo	B-UNK
group	B-UNK
during	O
the	O
study	B-UNK
,	O
the	O
difference	B-UNK
never	O
reached	B-UNK
statistical	B-UNK
significance	I-UNK
during	O
any	O
week	B-UNK
of	O
the	O
study	B-UNK
.	O
There	O
were	O
no	O
serious	O
side	O
effects	B-UNK
in	O
any	O
of	O
the	O
treatment	B-UNK
groups	B-UNK
.	O
Drowsiness	O
and	O
altered	B-UNK
taste	O
perception	B-UNK
were	O
increased	B-UNK
significantly	B-UNK
over	O
placebo	B-UNK
only	O
in	O
the	O
high	B-UNK
-	O
dose	B-UNK
azelastine	B-CHEMICAL
group	B-UNK
.	O
Azelastine	O
appears	B-UNK
to	O
be	O
a	O
safe	B-UNK
,	O
efficacious	B-UNK
medication	B-UNK
for	O
seasonal	O
allergic	B-DISEASE
rhinitis	I-DISEASE
.	O

Obsolete	O
but	O
dangerous	O
antacid	O
preparations	B-UNK
.	O

One	O
case	B-UNK
of	O
acute	B-UNK
hypercalcaemia	O
and	O
two	O
of	O
recurrent	B-UNK
nephrolithiasis	B-DISEASE
are	O
reported	B-UNK
in	O
patients	B-UNK
who	O
had	O
regularly	O
consumed	O
large	B-UNK
amounts	B-UNK
of	O
calcium	B-CHEMICAL
carbon	B-CHEMICAL
-	O
ate	O
-	O
sodium	B-CHEMICAL
bicarbonate	I-CHEMICAL
powders	O
for	O
more	O
than	O
20	O
years	B-UNK
.	O
The	O
powders	O
had	O
been	O
obtained	B-UNK
from	O
pharmacists	O
unknown	B-UNK
to	O
the	O
patients	B-UNK
'	O
medical	B-UNK
practitioners	O
.	O
It	O
is	O
suggested	B-UNK
that	O
these	O
preparations	B-UNK
were	O
responsible	O
for	O
the	O
patient'	O
s	O
problems	O
,	O
and	O
that	O
such	O
powders	O
should	O
no	O
longer	B-UNK
be	O
freely	O
obtainable	O
.	O

Prolonged	O
paralysis	B-DISEASE
due	O
to	O
nondepolarizing	O
neuromuscular	B-CHEMICAL
blocking	I-CHEMICAL
agents	I-CHEMICAL
and	O
corticosteroids	O
.	O

The	O
long	B-UNK
-	O
term	B-UNK
use	B-UNK
of	O
nondepolarizing	O
neuromuscular	B-CHEMICAL
blocking	I-CHEMICAL
agents	I-CHEMICAL
(	O
ND	O
-	O
NMBA	O
)	O
has	O
recently	B-UNK
been	O
implicated	B-UNK
as	O
a	O
cause	B-UNK
of	O
prolonged	B-UNK
muscle	B-DISEASE
weakness	I-DISEASE
,	O
although	O
the	O
site	B-UNK
of	O
the	O
lesion	B-UNK
and	O
the	O
predisposing	O
factors	B-UNK
have	O
been	O
unclear	O
.	O
We	O
report	B-UNK
3	O
patients	B-UNK
(	O
age	B-UNK
37	O
-	O
52	O
years	B-UNK
)	O
with	O
acute	B-UNK
respiratory	B-DISEASE
insufficiency	I-DISEASE
who	O
developed	B-UNK
prolonged	B-UNK
weakness	B-UNK
following	B-UNK
the	O
discontinuation	B-UNK
of	O
ND	O
-	O
NMBAs	O
.	O
Two	O
patients	B-UNK
also	O
received	B-UNK
intravenous	B-UNK
corticosteroids	O
.	O
Renal	B-UNK
function	B-UNK
was	O
normal	B-UNK
but	O
hepatic	B-UNK
function	B-UNK
was	O
impaired	B-UNK
in	O
all	O
patients	B-UNK
,	O
and	O
all	O
had	O
acidosis	B-DISEASE
.	O
Electrophysiologic	O
studies	B-UNK
revealed	B-UNK
low	B-UNK
amplitude	B-UNK
compound	B-UNK
motor	B-UNK
action	B-UNK
potentials	O
,	O
normal	B-UNK
sensory	B-UNK
studies	B-UNK
,	O
and	O
fibrillations	O
.	O
Repetitive	O
stimulation	B-UNK
at	B-DISEASE
2	B-DISEASE
Hz	O
showed	B-UNK
a	O
decremental	O
response	B-UNK
in	O
2	B-DISEASE
patients	B-UNK
.	O
The	O
serum	B-UNK
vecuronium	O
level	B-UNK
measured	B-UNK
in	O
1	O
patient	B-UNK
14	O
days	B-UNK
after	O
the	O
drug	B-UNK
had	O
been	O
discontinued	O
was	O
172	O
ng	B-UNK
/	O
mL.	O
A	O
muscle	B-UNK
biopsy	B-UNK
in	O
this	O
patient	B-UNK
showed	B-UNK
loss	B-UNK
of	O
thick	O
,	O
myosin	O
filaments	O
.	O
The	O
weakness	B-UNK
in	O
these	O
patients	B-UNK
is	O
due	O
to	O
pathology	O
at	B-DISEASE
both	O
the	O
neuromuscular	B-UNK
junction	O
(	O
most	O
likely	B-UNK
due	O
to	O
ND	O
-	O
NMBA	O
)	O
and	O
muscle	B-UNK
(	O
most	O
likely	B-UNK
due	O
to	O
corticosteroids	O
)	O
.	O
Hepatic	B-UNK
dysfunction	B-UNK
and	O
acidosis	B-DISEASE
are	O
contributing	B-UNK
risk	B-UNK
factors	I-UNK
.	O

Prostaglandin	B-UNK
E2-induced	B-UNK
bladder	B-UNK
hyperactivity	B-UNK
in	O
normal	B-UNK
,	O
conscious	B-UNK
rats	B-UNK
:	O
involvement	B-UNK
of	O
tachykinins	B-CHEMICAL
?	O

In	O
normal	B-UNK
conscious	B-UNK
rats	B-UNK
investigated	B-UNK
by	O
continuous	B-UNK
cystometry	O
,	O
intravesically	B-UNK
instilled	O
prostaglandin	B-UNK
(	O
PG	O
)	O
E2	B-UNK
facilitated	O
micturition	B-UNK
and	O
increased	B-UNK
basal	B-UNK
intravesical	B-UNK
pressure	B-UNK
.	O
The	O
effect	B-UNK
was	O
attenuated	B-UNK
by	O
both	O
the	O
NK1	O
receptor	B-UNK
selective	B-UNK
antagonist	B-UNK
RP	O
67,580	O
and	O
the	O
NK2	O
receptor	B-UNK
selective	B-UNK
antagonist	B-UNK
SR	O
48,968	O
,	O
given	B-UNK
intra-arterially	O
,	O
suggesting	B-UNK
that	O
it	O
was	O
mediated	B-UNK
by	O
stimulation	B-UNK
of	O
both	O
NK1	O
and	O
NK2	O
receptors	B-UNK
.	O
Intra-arterially	O
given	B-UNK
PGE2	B-UNK
produced	B-UNK
a	O
distinct	O
increase	B-UNK
in	O
bladder	B-UNK
pressure	B-UNK
before	O
initiating	O
a	O
micturition	B-UNK
reflex	B-DISEASE
,	O
indicating	O
that	O
the	O
PG	O
had	O
a	O
direct	B-UNK
contractant	O
effect	B-UNK
on	O
the	O
detrusor	O
smooth	B-UNK
muscle	I-UNK
.	O
The	O
effect	B-UNK
of	O
intra-arterial	B-UNK
PGE2	B-UNK
could	O
not	O
be	O
blocked	B-UNK
by	O
intra-arterial	B-UNK
RP	O
67,580	O
or	O
SR	O
48,968	O
,	O
which	O
opens	O
the	O
possibility	O
that	O
the	O
micturition	B-UNK
reflex	B-DISEASE
elicited	B-UNK
by	O
intra-arterial	B-UNK
PGE2	B-UNK
was	O
mediated	B-UNK
by	O
pathways	B-UNK
other	O
than	O
the	O
reflex	B-DISEASE
initiated	O
when	O
the	O
PG	O
was	O
given	B-UNK
intravesically	B-UNK
.	O
The	O
present	B-UNK
results	B-UNK
thus	O
suggest	B-UNK
that	O
intra-arterial	B-UNK
PGE2	B-UNK
,	O
given	B-UNK
near	O
the	O
bladder	B-UNK
,	O
may	O
initiate	O
micturition	B-UNK
in	O
the	O
normal	B-UNK
rat	B-UNK
chiefly	O
by	O
directly	B-UNK
contracting	O
the	O
smooth	B-UNK
muscle	I-UNK
of	O
the	O
detrusor	O
.	O
However	O
,	O
when	O
given	B-UNK
intravesically	B-UNK
,	O
PGE2	B-UNK
may	O
stimulate	O
micturition	B-UNK
by	O
releasing	B-UNK
tachykinins	B-CHEMICAL
from	O
nerves	B-UNK
in	O
and	O
/	O
or	O
immediately	B-UNK
below	O
the	O
urothelium	O
.	O
These	O
tachykinins	B-CHEMICAL
,	O
in	O
turn	O
,	O
initiate	O
a	O
micturition	B-UNK
reflex	B-DISEASE
by	O
stimulating	B-UNK
NK1	O
and	O
NK2	O
receptors	B-UNK
.	O
Prostanoids	O
may	O
,	O
via	O
release	B-UNK
of	O
tachykinins	B-CHEMICAL
,	O
contribute	O
to	O
both	O
urge	O
and	O
bladder	B-UNK
hyperactivity	B-UNK
seen	B-UNK
in	O
inflammatory	B-UNK
conditions	B-UNK
of	O
the	O
lower	B-UNK
urinary	B-UNK
tract	O
.	O

Thiazide	O
diuretics	B-CHEMICAL
,	O
hypokalemia	B-DISEASE
and	O
cardiac	B-UNK
arrhythmias	B-DISEASE
.	O

Thiazide	O
diuretics	B-CHEMICAL
are	O
widely	B-UNK
accepted	O
as	O
the	O
cornerstone	O
of	O
antihypertensive	O
treatment	B-UNK
programs	O
.	O
Hypokalemia	O
is	O
a	O
commonly	B-UNK
encountered	B-UNK
metabolic	B-UNK
consequence	O
of	O
chronic	B-UNK
thiazide	O
therapy	B-UNK
.	O
We	O
treated	B-UNK
38	O
patients	B-UNK
(	O
22	O
low	B-UNK
renin	O
,	O
16	O
normal	B-UNK
renin	O
)	O
with	O
moderate	B-UNK
diastolic	B-UNK
hypertension	B-DISEASE
with	O
hydrochlorothiazide	B-CHEMICAL
(	O
HCTC	O
)	O
administered	B-UNK
on	O
a	O
twice	B-UNK
daily	B-UNK
schedule	B-UNK
.	O
Initial	O
dose	B-UNK
was	O
50	O
mg	B-UNK
and	O
the	O
dose	B-UNK
was	O
increased	B-UNK
at	B-DISEASE
monthly	O
intervals	B-UNK
to	O
100	O
mg	B-UNK
,	O
150	O
mg	B-UNK
and	O
200	O
mg	B-UNK
daily	B-UNK
until	O
blood	B-UNK
pressure	B-UNK
normalized	B-UNK
.	O
The	O
serum	B-UNK
K	O
during	O
the	O
control	B-UNK
period	B-UNK
was	O
4.5	B-UNK
+	O
/-	O
0.2	B-UNK
mEq	B-UNK
/	O
l	B-UNK
an	O
on	O
50	O
,	O
100	O
,	O
150	O
and	O
200	O
mg	B-UNK
HCTZ	O
daily	B-UNK
3.9	B-UNK
+	O
/-	O
0.3	B-UNK
,	O
3.4	B-UNK
+	O
/-	O
0.2	B-UNK
,	O
2.9	O
+	O
/-	O
0.2	B-UNK
,	O
and	O
2.4	B-UNK
+	O
/-	O
0.3	B-UNK
mEq	B-UNK
/	O
l	B-UNK
,	O
respectively	O
.	O
Corresponding	O
figures	B-UNK
for	O
whole	O
body	B-UNK
K	O
were	O
4107	O
+	O
/-	O
208	O
,	O
3722	O
+	O
/-	O
319	O
,	O
3628	O
+	O
/-	O
257	O
,	O
3551	O
+	O
/-	O
336	O
,	O
and	O
3269	O
+	O
/-	O
380	O
mEq	B-UNK
,	O
respectively	O
.	O
In	O
13	O
patients	B-UNK
we	O
observed	B-UNK
the	O
effects	B-UNK
of	O
HCTZ	O
therapy	B-UNK
(	O
100	O
mg	B-UNK
daily	B-UNK
)	O
on	O
the	O
occurrence	O
of	O
PVC'	O
s	O
during	O
rest	O
as	O
well	O
as	O
during	O
static	O
and	O
dynamic	B-UNK
exercise	B-UNK
.	O
During	O
rest	O
we	O
observed	B-UNK
0.6	B-UNK
+	O
/-	O
0.08	O
PVC	O
beats	B-UNK
/	O
min	B-UNK
+	O
/-	O
SEM	O
and	O
during	O
static	O
and	O
dynamic	B-UNK
exercise	B-UNK
0.6	B-UNK
+	O
/-	O
0.06	O
and	O
0.8	B-UNK
+	O
/-	O
0.15	O
,	O
respectively	O
.	O
Corresponding	O
figures	B-UNK
during	O
HCTZ	O
therapy	B-UNK
100	O
mg	B-UNK
daily	B-UNK
were	O
1.4	O
+	O
/-	O
0.1	B-UNK
,	O
3.6	B-UNK
+	O
/-	O
0.7	O
and	O
5.7	O
4/-	O
0.8	B-UNK
,	O
respectively	O
.	O
The	O
occurrence	O
of	O
PVC'	O
s	O
correlated	B-UNK
significantly	B-UNK
with	O
the	O
fall	O
in	O
serum	B-UNK
K+	O
observed	B-UNK
r	B-UNK
=	I-UNK
0.72	O
,	O
p	B-UNK
less	O
than	O
0.001	B-UNK
.	O
In	O
conclusion	O
we	O
found	B-UNK
that	O
thiazide	O
diuretics	B-CHEMICAL
cause	B-UNK
hypokalemia	B-DISEASE
and	O
depletion	O
of	O
body	B-UNK
potassium	B-CHEMICAL
.	O
The	O
more	O
profound	B-UNK
hypokalemia	B-DISEASE
,	O
the	O
greater	B-UNK
the	O
propensity	O
for	O
the	O
occurrence	O
of	O
PVC'	O
s.	O

Diuretics	O
,	O
potassium	B-CHEMICAL
and	O
arrhythmias	B-DISEASE
in	O
hypertensive	B-UNK
coronary	B-DISEASE
disease	I-DISEASE
.	O

It	O
has	O
been	O
proposed	O
that	O
modest	O
changes	B-UNK
in	O
plasma	B-UNK
potassium	B-CHEMICAL
can	O
alter	B-UNK
the	O
tendency	O
towards	O
cardiac	B-UNK
arrhythmias	B-DISEASE
.	O
If	O
this	O
were	O
so	O
,	O
patients	B-UNK
with	O
coronary	B-DISEASE
artery	I-DISEASE
disease	I-DISEASE
might	O
be	O
especially	B-UNK
susceptible	B-UNK
.	O
Thus	O
,	O
myocardial	B-UNK
electrical	B-UNK
excitability	B-UNK
was	O
measured	B-UNK
in	O
patients	B-UNK
with	O
mild	B-UNK
essential	B-DISEASE
hypertension	I-DISEASE
and	O
known	B-UNK
coronary	B-DISEASE
artery	I-DISEASE
disease	I-DISEASE
after	O
8	O
weeks	B-UNK
of	O
treatment	B-UNK
with	O
a	O
potassium	B-CHEMICAL
-	O
conserving	O
diuretic	B-UNK
(	O
amiloride	B-CHEMICAL
)	O
and	O
a	O
similar	B-UNK
period	B-UNK
on	O
a	O
potassium	B-CHEMICAL
-	O
losing	O
diuretic	B-UNK
(	O
chlorthalidone	B-CHEMICAL
)	O
in	O
a	O
randomised	B-UNK
study	B-UNK
.	O
Plasma	B-UNK
potassium	B-CHEMICAL
concentrations	B-UNK
were	O
on	O
average	B-UNK
1	O
mmol	B-UNK
/	O
L	B-UNK
lower	B-UNK
during	O
the	O
chlorthalidone	B-CHEMICAL
phase	B-UNK
compared	B-UNK
to	O
amiloride	B-CHEMICAL
therapy	B-UNK
.	O
Blood	O
pressure	B-UNK
and	O
volume	B-UNK
states	B-UNK
as	O
assessed	B-UNK
by	O
bodyweight	O
,	O
plasma	B-UNK
renin	O
and	O
noradrenaline	O
(	O
norepinephrine	B-CHEMICAL
)	O
concentrations	B-UNK
were	O
similar	B-UNK
on	O
the	O
2	B-DISEASE
regimens	B-UNK
.	O
Compared	O
to	O
amiloride	B-CHEMICAL
treatment	B-UNK
,	O
the	O
chlorthalidone	B-CHEMICAL
phase	B-UNK
was	O
associated	B-UNK
with	O
an	O
increased	B-UNK
frequency	B-UNK
of	O
ventricular	B-UNK
ectopic	O
beats	B-UNK
(	O
24-hour	B-UNK
Holter	O
monitoring	B-UNK
)	O
and	O
a	O
higher	B-UNK
Lown	O
grading	O
,	O
increased	B-UNK
upslope	O
and	O
duration	B-UNK
of	O
the	O
monophasic	O
action	B-UNK
potential	B-UNK
,	O
prolonged	B-UNK
ventricular	B-UNK
effective	B-UNK
refractory	B-UNK
period	B-UNK
,	O
and	O
increased	B-UNK
electrical	B-UNK
instability	O
during	O
programmed	O
ventricular	B-UNK
stimulation	B-UNK
.	O
The	O
above	O
results	B-UNK
indicate	B-UNK
that	O
because	O
potassium	B-CHEMICAL
-	O
losing	O
diuretic	B-UNK
therapy	B-UNK
can	O
increase	B-UNK
myocardial	B-UNK
electrical	B-UNK
excitability	B-UNK
in	O
patients	B-UNK
with	O
ischaemic	B-UNK
heart	B-DISEASE
disease	I-DISEASE
,	O
even	O
minor	B-UNK
falls	O
in	O
plasma	B-UNK
potassium	B-CHEMICAL
concentrations	B-UNK
are	O
probably	B-UNK
best	B-UNK
avoided	O
in	O
such	O
patients	B-UNK
.	O

GABA	O
involvement	B-UNK
in	O
naloxone	B-CHEMICAL
induced	B-UNK
reversal	B-UNK
of	O
respiratory	B-DISEASE
paralysis	I-DISEASE
produced	B-UNK
by	O
thiopental	B-CHEMICAL
.	O

No	O
agent	B-UNK
is	O
yet	O
available	B-UNK
to	O
reverse	B-UNK
respiratory	B-DISEASE
paralysis	I-DISEASE
produced	B-UNK
by	O
CNS	O
depressants	O
,	O
such	O
as	O
general	B-UNK
anesthetics	B-CHEMICAL
.	O
In	O
this	O
study	B-UNK
naloxone	B-CHEMICAL
reversed	B-UNK
respiratory	B-DISEASE
paralysis	I-DISEASE
induced	B-UNK
by	O
thiopental	B-CHEMICAL
in	O
rats	B-UNK
.	O
25	O
mg	B-UNK
/	O
kg	B-UNK
,	O
i.v	B-UNK
.	O
thiopental	B-CHEMICAL
produced	B-UNK
anesthesia	B-UNK
without	O
altering	O
respiratory	B-UNK
rate	B-UNK
,	O
increased	B-UNK
GABA	O
,	O
decreased	B-UNK
glutamate	B-UNK
,	O
and	O
had	O
no	O
effect	B-UNK
on	O
aspartate	B-UNK
or	O
glycine	B-CHEMICAL
levels	B-UNK
compared	B-UNK
to	O
controls	B-UNK
in	O
rat	B-UNK
cortex	B-UNK
and	O
brain	B-UNK
stem	B-UNK
.	O
Pretreatment	O
of	O
rats	B-UNK
with	O
thiosemicarbazide	B-CHEMICAL
for	O
30	O
minutes	B-UNK
abolished	B-UNK
the	O
anesthetic	B-UNK
action	B-UNK
as	O
well	O
as	O
the	O
respiratory	B-UNK
depressant	B-UNK
action	B-UNK
of	O
thiopental	B-CHEMICAL
.	O
50	O
mg	B-UNK
/	O
kg	B-UNK
,	O
i.v	B-UNK
.	O
thiopental	B-CHEMICAL
produced	B-UNK
respiratory	B-UNK
arrest	B-UNK
with	O
further	O
increase	B-UNK
in	O
GABA	O
and	O
decrease	B-UNK
in	O
glutamate	B-UNK
again	O
in	O
cortex	B-UNK
and	O
brain	B-UNK
stem	B-UNK
without	O
affecting	O
any	O
of	O
the	O
amino	B-CHEMICAL
acids	I-CHEMICAL
studied	B-UNK
in	O
four	O
regions	B-UNK
of	O
rat	B-UNK
brain	B-UNK
.	O
Naloxone	O
(	O
2.5	B-UNK
mg	B-UNK
/	O
kg	B-UNK
,	O
i.v	B-UNK
.	O
)	O
reversed	B-UNK
respiratory	B-DISEASE
paralysis	I-DISEASE
,	O
glutamate	B-UNK
and	O
GABA	O
levels	B-UNK
to	O
control	B-UNK
values	B-UNK
in	O
brain	B-UNK
stem	B-UNK
and	O
cortex	B-UNK
with	O
no	O
changes	B-UNK
in	O
caudate	O
or	O
cerebellum	O
.	O
These	O
data	B-UNK
suggest	B-UNK
naloxone	B-CHEMICAL
reverses	B-UNK
respiratory	B-DISEASE
paralysis	I-DISEASE
produced	B-UNK
by	O
thiopental	B-CHEMICAL
and	O
involves	B-UNK
GABA	O
in	O
its	O
action	B-UNK
.	O

National	B-UNK
project	O
on	O
the	O
prevention	O
of	O
mother	O
-	O
to	O
-	O
infant	B-DISEASE
infection	B-UNK
by	O
hepatitis	B-DISEASE
B	B-UNK
virus	B-UNK
in	O
Japan	O
.	O

In	O
Japan	O
,	O
a	O
nationwide	O
prevention	O
program	O
against	O
mother	O
-	O
to	O
-	O
infant	B-DISEASE
infection	B-UNK
by	O
hepatitis	B-DISEASE
B	B-UNK
virus	B-UNK
(	O
HBV	B-UNK
)	O
started	B-UNK
in	O
1985	O
.	O
This	O
program	O
consists	B-UNK
of	O
double	B-UNK
screenings	O
of	O
pregnant	B-UNK
women	B-UNK
and	O
prophylactic	B-UNK
treatment	B-UNK
to	O
the	O
infants	B-UNK
born	O
to	O
both	O
hepatitis	B-DISEASE
B	B-UNK
surface	I-UNK
antigen	B-UNK
(	O
HBsAg	O
)	O
and	O
hepatitis	B-DISEASE
B	B-UNK
e	B-UNK
antigen	B-UNK
(	O
HBeAg	O
)	O
positive	B-UNK
mothers	B-UNK
.	O
These	O
infants	B-UNK
are	O
treated	B-UNK
with	O
two	O
injections	B-UNK
of	O
hepatitis	B-DISEASE
B	B-UNK
immune	B-UNK
globulin	B-UNK
(	O
HBIG	O
)	O
and	O
at	B-DISEASE
least	O
three	O
injections	B-UNK
of	O
plasma	B-UNK
derived	O
hepatitis	B-DISEASE
B	B-UNK
vaccine	B-UNK
.	O
We	O
sent	O
questionnaires	O
about	O
the	O
numbers	O
of	O
each	O
procedure	B-UNK
or	O
examination	B-UNK
during	O
nine	O
months	B-UNK
of	O
investigation	O
period	B-UNK
to	O
each	O
local	B-UNK
government	O
in	O
1986	O
and	O
1987	O
.	O
93.4	O
%	O
pregnant	B-UNK
women	B-UNK
had	O
the	O
chance	O
to	O
be	O
examined	B-UNK
for	O
HBsAg	O
,	O
and	O
the	O
positive	B-UNK
rate	B-UNK
was	O
1.4	O
to	O
1.5	B-UNK
%	O
.	O
The	O
HBeAg	O
positive	B-UNK
rate	B-UNK
in	O
HBsAg	O
positive	B-UNK
was	O
23	O
to	O
26	O
%	O
.	O
The	O
HBsAg	O
positive	B-UNK
rate	B-UNK
in	O
neonates	O
and	O
in	O
infants	B-UNK
before	O
two	O
months	B-UNK
were	O
3	O
%	O
and	O
2	B-DISEASE
%	O
respectively	O
.	O
Some	O
problems	O
may	O
arise	O
,	O
because	O
27	O
to	O
30	O
%	O
of	O
infants	B-UNK
need	B-UNK
the	O
fourth	B-UNK
vaccination	O
in	O
some	O
restricted	B-UNK
areas	B-UNK
.	O

Nociceptive	O
effects	B-UNK
induced	B-UNK
by	O
intrathecal	O
administration	B-UNK
of	O
prostaglandin	B-UNK
D2	B-UNK
,	O
E2	B-UNK
,	O
or	O
F2	O
alpha	B-UNK
to	O
conscious	B-UNK
mice	B-UNK
.	O

The	O
effects	B-UNK
of	O
intrathecal	O
administration	B-UNK
of	O
prostaglandins	B-CHEMICAL
on	O
pain	B-UNK
responses	B-UNK
in	O
conscious	B-UNK
mice	B-UNK
were	O
evaluated	B-UNK
by	O
using	O
hot	B-UNK
plate	O
and	O
acetic	B-CHEMICAL
acid	I-CHEMICAL
writhing	B-UNK
tests	B-UNK
.	O
Prostaglandin	B-UNK
D2	B-UNK
(	O
0.5	B-UNK
-	O
3	O
ng	B-UNK
/	O
mouse	B-UNK
)	O
had	O
a	O
hyperalgesic	O
action	B-UNK
on	O
the	O
response	B-UNK
to	O
a	O
hot	B-UNK
plate	O
during	O
a	O
3	O
-	O
60	O
min	B-UNK
period	B-UNK
after	O
injection	B-UNK
.	O
Prostaglandin	B-UNK
E2	B-UNK
showed	B-UNK
a	O
hyperalgesic	O
effect	B-UNK
at	B-DISEASE
doses	B-UNK
of	O
1	O
pg	O
to	O
10	O
ng	B-UNK
/	O
mouse	B-UNK
,	O
but	O
the	O
effect	B-UNK
lasted	B-UNK
shorter	O
(	O
3	O
-	O
30	O
min	B-UNK
)	O
than	O
that	O
of	O
prostaglandin	B-UNK
D2	B-UNK
.	O
Similar	B-UNK
results	B-UNK
were	O
obtained	B-UNK
by	O
acetic	B-CHEMICAL
acid	I-CHEMICAL
writhing	B-UNK
tests	B-UNK
.	O
The	O
hyperalgesic	O
effect	B-UNK
of	O
prostaglandin	B-UNK
D2	B-UNK
was	O
blocked	B-UNK
by	O
simultaneous	O
injection	B-UNK
of	O
a	O
substance	B-UNK
P	B-UNK
antagonist	B-UNK
(	O
greater	B-UNK
than	O
or	O
equal	O
to	O
100	O
ng	B-UNK
)	O
but	O
not	O
by	O
AH6809	O
,	O
a	O
prostanoid	O
EP1-receptor	O
antagonist	B-UNK
.	O
Conversely	O
,	O
prostaglandin	B-UNK
E2-induced	B-UNK
hyperalgesia	B-DISEASE
was	O
blocked	B-UNK
by	O
AH6809	O
(	O
greater	B-UNK
than	O
or	O
equal	O
to	O
500	O
ng	B-UNK
)	O
but	O
not	O
by	O
the	O
substance	B-UNK
P	B-UNK
antagonist	B-UNK
.	O
Prostaglandin	B-UNK
F2	O
alpha	B-UNK
had	O
little	B-UNK
effect	B-UNK
on	O
pain	B-UNK
responses	B-UNK
.	O
These	O
results	B-UNK
demonstrate	B-UNK
that	O
both	O
prostaglandin	B-UNK
D2	B-UNK
and	O
prostaglandin	B-UNK
E2	B-UNK
exert	O
hyperalgesia	B-DISEASE
in	O
the	O
spinal	B-UNK
cord	O
,	O
but	O
in	O
different	B-UNK
ways	O
.	O

Swallowing	O
-	O
induced	B-UNK
atrial	B-UNK
tachyarrhythmia	O
triggered	O
by	O
salbutamol	O
:	O
case	B-UNK
report	B-UNK
and	O
review	B-UNK
of	O
the	O
literature	B-UNK
.	O

CASE	B-UNK
:	O
A	O
49-year	O
-	O
old	B-UNK
patient	B-UNK
experienced	B-UNK
chest	B-UNK
discomfort	O
while	O
swallowing	O
.	O
On	O
electrocardiogram	O
,	O
episodes	B-UNK
of	O
atrial	B-UNK
tachyarrhythmia	O
were	O
recorded	B-UNK
immediately	B-UNK
after	O
swallowing	O
;	O
24-hour	B-UNK
Holter	O
monitoring	B-UNK
recorded	B-UNK
several	O
events	B-UNK
.	O
The	O
arrhythmia	B-DISEASE
resolved	B-UNK
after	O
therapy	B-UNK
with	O
atenolol	B-CHEMICAL
,	O
but	O
recurred	O
a	O
year	B-UNK
later	B-UNK
.	O
The	O
patient	B-UNK
noticed	O
that	O
before	O
these	O
episodes	B-UNK
he	O
had	O
been	O
using	O
an	O
inhalator	O
of	O
salbutamol	O
.	O
After	O
stopping	O
the	O
beta-agonist	O
,	O
and	O
after	O
a	O
week	B-UNK
with	O
the	O
atenolol	B-CHEMICAL
,	O
the	O
arrhythmia	B-DISEASE
disappeared	B-UNK
.	O
DISCUSSION	O
:	O
Swallowing	O
-	O
induced	B-UNK
atrial	B-UNK
tachyarrhythmia	O
(	O
SIAT	O
)	O
is	O
a	O
rare	B-UNK
phenomenon	B-UNK
.	O
Fewer	O
than	O
50	O
cases	B-UNK
of	O
SIAT	O
have	O
been	O
described	B-UNK
in	O
the	O
literature	B-UNK
.	O
This	O
article	O
summarizes	O
all	O
the	O
cases	B-UNK
published	B-UNK
,	O
creating	O
a	O
comprehensive	O
review	B-UNK
of	O
the	O
current	B-UNK
knowledge	O
and	O
approach	B-UNK
to	O
SIAT	O
.	O
It	O
discusses	O
demographics	O
,	O
clinical	B-UNK
characteristics	B-UNK
and	O
types	O
of	O
arrhythmia	B-DISEASE
,	O
postulated	O
mechanisms	B-UNK
of	O
SIAT	O
,	O
and	O
different	B-UNK
treatment	B-UNK
possibilities	O
such	O
as	O
medications	B-UNK
,	O
surgery	B-UNK
,	O
and	O
radiofrequency	O
catheter	B-UNK
ablation	O
(	O
RFCA	O
)	O
.	O
CONCLUSION	O
:	O
Salbutamol	O
is	O
presented	B-UNK
here	O
as	O
a	O
possible	B-UNK
trigger	O
for	O
SIAT	O
.	O
Although	O
it	O
is	O
difficult	O
to	O
define	B-UNK
causality	B-UNK
in	O
a	O
case	B-UNK
report	B-UNK
,	O
it	O
is	O
logical	O
to	O
think	O
that	O
a	O
beta-agonist	O
like	B-UNK
salbutamol	O
(	O
known	B-UNK
to	O
induce	B-UNK
tachycardia	B-DISEASE
)	O
may	O
be	O
the	O
trigger	O
of	O
adrenergic	B-UNK
reflexes	B-UNK
originating	O
in	O
the	O
esophagus	O
while	O
swallowing	O
and	O
that	O
a	O
beta-blocker	B-UNK
such	O
as	O
atenolol	B-CHEMICAL
(	O
that	O
blocks	O
the	O
adrenergic	B-UNK
activity	B-UNK
)	O
may	O
relieve	O
it	O
.	O

Coenzyme	B-UNK
Q10	I-UNK
treatment	B-UNK
ameliorates	O
acute	B-UNK
cisplatin	B-CHEMICAL
nephrotoxicity	B-UNK
in	O
mice	B-UNK
.	O

The	O
nephroprotective	O
effect	B-UNK
of	O
coenzyme	B-UNK
Q10	I-UNK
was	O
investigated	B-UNK
in	O
mice	B-UNK
with	O
acute	B-UNK
renal	B-UNK
injury	B-UNK
induced	B-UNK
by	O
a	O
single	B-UNK
i.p	B-UNK
.	O
injection	B-UNK
of	O
cisplatin	B-CHEMICAL
(	O
5	O
mg	B-UNK
/	O
kg	B-UNK
)	O
.	O
Coenzyme	B-UNK
Q10	I-UNK
treatment	B-UNK
(	O
10	O
mg	B-UNK
/	O
kg	B-UNK
/	O
day	B-UNK
,	O
i.p	B-UNK
.	O
)	O
was	O
applied	O
for	O
6	O
consecutive	B-UNK
days	B-UNK
,	O
starting	B-UNK
1	O
day	B-UNK
before	O
cisplatin	B-CHEMICAL
administration	B-UNK
.	O
Coenzyme	B-UNK
Q10	I-UNK
significantly	B-UNK
reduced	B-UNK
blood	B-UNK
urea	B-CHEMICAL
nitrogen	B-CHEMICAL
and	O
serum	B-UNK
creatinine	B-CHEMICAL
levels	B-UNK
which	O
were	O
increased	B-UNK
by	O
cisplatin	B-CHEMICAL
.	O
Coenzyme	B-UNK
Q10	I-UNK
significantly	B-UNK
compensated	O
deficits	B-UNK
in	O
the	O
antioxidant	B-UNK
defense	O
mechanisms	B-UNK
(	O
reduced	B-UNK
glutathione	B-CHEMICAL
level	B-UNK
and	O
superoxide	B-UNK
dismutase	O
activity	B-UNK
)	O
,	O
suppressed	B-UNK
lipid	B-UNK
peroxidation	B-UNK
,	O
decreased	B-UNK
the	O
elevations	O
of	O
tumor	B-CHEMICAL
necrosis	I-CHEMICAL
factor	I-CHEMICAL
-	I-CHEMICAL
alpha	I-CHEMICAL
,	O
nitric	B-CHEMICAL
oxide	I-CHEMICAL
and	O
platinum	B-CHEMICAL
ion	O
concentration	B-UNK
,	O
and	O
attenuated	B-UNK
the	O
reductions	O
of	O
selenium	B-CHEMICAL
and	O
zinc	B-CHEMICAL
ions	B-CHEMICAL
in	O
renal	B-UNK
tissue	B-UNK
resulted	B-UNK
from	O
cisplatin	B-CHEMICAL
administration	B-UNK
.	O
Also	O
,	O
histopathological	O
renal	B-UNK
tissue	B-UNK
damage	B-UNK
mediated	B-UNK
by	O
cisplatin	B-CHEMICAL
was	O
ameliorated	O
by	O
coenzyme	B-UNK
Q10	I-UNK
treatment	B-UNK
.	O
Immunohistochemical	O
analysis	B-UNK
revealed	B-UNK
that	O
coenzyme	B-UNK
Q10	I-UNK
significantly	B-UNK
decreased	B-UNK
the	O
cisplatin	B-CHEMICAL
-	O
induced	B-UNK
overexpression	O
of	O
inducible	B-UNK
nitric	B-CHEMICAL
oxide	I-CHEMICAL
synthase	B-UNK
,	O
nuclear	B-UNK
factor	B-UNK
-	O
kappaB	O
,	O
caspase-3	O
and	O
p53	O
in	O
renal	B-UNK
tissue	B-UNK
.	O
It	O
was	O
concluded	O
that	O
coenzyme	B-UNK
Q10	I-UNK
represents	O
a	O
potential	B-UNK
therapeutic	B-UNK
option	O
to	O
protect	B-UNK
against	O
acute	B-UNK
cisplatin	B-CHEMICAL
nephrotoxicity	B-UNK
commonly	B-UNK
encountered	B-UNK
in	O
clinical	B-UNK
practice	O
.	O

Metformin	B-UNK
prevents	B-UNK
experimental	B-UNK
gentamicin	B-UNK
-	O
induced	B-UNK
nephropathy	B-DISEASE
by	O
a	O
mitochondria	O
-	O
dependent	B-UNK
pathway	B-UNK
.	O

The	O
antidiabetic	O
drug	B-UNK
metformin	B-CHEMICAL
can	O
diminish	O
apoptosis	B-UNK
induced	B-UNK
by	O
oxidative	B-UNK
stress	B-UNK
in	O
endothelial	B-UNK
cells	B-UNK
and	O
prevent	B-UNK
vascular	B-UNK
dysfunction	B-UNK
even	O
in	O
nondiabetic	O
patients	B-UNK
.	O
Here	O
we	O
tested	B-UNK
whether	O
it	O
has	O
a	O
beneficial	B-UNK
effect	B-UNK
in	O
a	O
rat	B-UNK
model	B-UNK
of	O
gentamicin	B-UNK
toxicity	B-UNK
.	O
Mitochondrial	O
analysis	B-UNK
,	O
respiration	O
intensity	B-UNK
,	O
levels	B-UNK
of	O
reactive	B-CHEMICAL
oxygen	I-CHEMICAL
species	I-CHEMICAL
,	O
permeability	O
transition	B-UNK
,	O
and	O
cytochrome	B-UNK
c	B-UNK
release	B-UNK
were	O
assessed	B-UNK
3	O
and	O
6	O
days	B-UNK
after	O
gentamicin	B-UNK
administration	B-UNK
.	O
Metformin	B-UNK
treatment	B-UNK
fully	B-UNK
blocked	B-UNK
gentamicin	B-UNK
-	O
mediated	B-UNK
acute	B-DISEASE
renal	I-DISEASE
failure	I-DISEASE
.	O
This	O
was	O
accompanied	O
by	O
a	O
lower	B-UNK
activity	B-UNK
of	O
N	B-UNK
-	O
acetyl	O
-	O
beta	B-UNK
-	O
D	B-UNK
-	O
glucosaminidase	O
,	O
together	O
with	O
a	O
decrease	B-UNK
of	O
lipid	B-UNK
peroxidation	B-UNK
and	O
increase	B-UNK
of	O
antioxidant	B-UNK
systems	B-UNK
.	O
Metformin	B-UNK
also	O
protected	O
the	O
kidney	B-UNK
from	O
histological	B-UNK
damage	B-UNK
6	O
days	B-UNK
after	O
gentamicin	B-UNK
administration	B-UNK
.	O
These	O
in	O
vivo	B-UNK
markers	B-UNK
of	O
kidney	B-UNK
dysfunction	B-UNK
and	O
their	O
correction	O
by	O
metformin	B-CHEMICAL
were	O
complemented	O
by	O
in	O
vitro	B-UNK
studies	B-UNK
of	O
mitochondrial	B-UNK
function	B-UNK
.	O
We	O
found	B-UNK
that	O
gentamicin	B-UNK
treatment	B-UNK
depleted	B-UNK
respiratory	B-UNK
components	B-UNK
(	O
cytochrome	B-UNK
c	B-UNK
,	O
NADH	O
)	O
,	O
probably	B-UNK
due	O
to	O
the	O
opening	O
of	O
mitochondrial	B-UNK
transition	B-UNK
pores	O
.	O
These	O
injuries	O
,	O
partly	O
mediated	B-UNK
by	O
a	O
rise	B-UNK
in	O
reactive	B-CHEMICAL
oxygen	I-CHEMICAL
species	I-CHEMICAL
from	O
the	O
electron	B-UNK
transfer	O
chain	O
,	O
were	O
significantly	B-UNK
decreased	B-UNK
by	O
metformin	B-CHEMICAL
.	O
Thus	O
,	O
our	O
study	B-UNK
suggests	B-UNK
that	O
pleiotropic	O
effects	B-UNK
of	O
metformin	B-CHEMICAL
can	O
lessen	O
gentamicin	B-UNK
nephrotoxicity	B-UNK
and	O
improve	O
mitochondrial	B-UNK
homeostasis	O
.	O

Sedation	B-UNK
depth	B-UNK
during	O
spinal	B-UNK
anesthesia	B-UNK
and	O
the	O
development	B-UNK
of	O
postoperative	B-UNK
delirium	B-DISEASE
in	O
elderly	B-UNK
patients	B-UNK
undergoing	B-UNK
hip	B-DISEASE
fracture	I-DISEASE
repair	O
.	O

OBJECTIVE	O
:	O
To	O
determine	B-UNK
whether	O
limiting	B-UNK
intraoperative	O
sedation	B-UNK
depth	B-UNK
during	O
spinal	B-UNK
anesthesia	B-UNK
for	O
hip	B-DISEASE
fracture	I-DISEASE
repair	O
in	O
elderly	B-UNK
patients	B-UNK
can	O
decrease	B-UNK
the	O
prevalence	O
of	O
postoperative	B-UNK
delirium	B-DISEASE
.	O
PATIENTS	O
AND	O
METHODS	O
:	O
We	O
performed	B-UNK
a	O
double-blind	B-UNK
,	O
randomized	B-UNK
controlled	B-UNK
trial	B-UNK
at	B-DISEASE
an	O
academic	O
medical	B-UNK
center	B-UNK
of	O
elderly	B-UNK
patients	B-UNK
(	O
>	O
or=65	O
years	B-UNK
)	O
without	O
preoperative	B-UNK
delirium	B-DISEASE
or	O
severe	B-UNK
dementia	B-DISEASE
who	O
underwent	B-UNK
hip	B-DISEASE
fracture	I-DISEASE
repair	O
under	O
spinal	B-UNK
anesthesia	B-UNK
with	O
propofol	B-CHEMICAL
sedation	B-UNK
.	O
Sedation	B-UNK
depth	B-UNK
was	O
titrated	B-UNK
using	O
processed	O
electroencephalography	O
with	O
the	O
bispectral	O
index	B-UNK
(	O
BIS	O
)	O
,	O
and	O
patients	B-UNK
were	O
randomized	B-UNK
to	O
receive	B-UNK
either	O
deep	B-UNK
(	O
BIS	O
,	O
approximately	B-UNK
50	O
)	O
or	O
light	B-UNK
(	O
BIS	O
,	O
>	O
or=80	O
)	O
sedation	B-UNK
.	O
Postoperative	O
delirium	B-DISEASE
was	O
assessed	B-UNK
as	O
defined	O
by	O
Diagnostic	O
and	O
Statistical	O
Manual	O
of	O
Mental	O
Disorders	B-UNK
(	O
Third	O
Edition	O
Revised	O
)	O
criteria	B-UNK
using	O
the	O
Confusion	O
Assessment	B-UNK
Method	O
beginning	B-UNK
at	B-DISEASE
any	O
time	B-UNK
from	O
the	O
second	B-UNK
day	B-UNK
after	O
surgery	B-UNK
.	O
RESULTS	B-UNK
:	O
From	O
April	O
2	B-DISEASE
,	O
2005	O
,	O
through	O
October	O
30	O
,	O
2008	O
,	O
a	O
total	B-UNK
of	O
114	O
patients	B-UNK
were	O
randomized	B-UNK
.	O
The	O
prevalence	O
of	O
postoperative	B-UNK
delirium	B-DISEASE
was	O
significantly	B-UNK
lower	B-UNK
in	O
the	O
light	B-UNK
sedation	B-UNK
group	B-UNK
(	O
11/57	O
[	O
19	O
%	O
]	O
vs	B-UNK
23/57	O
[	O
40	O
%	O
]	O
in	O
the	O
deep	B-UNK
sedation	B-UNK
group	B-UNK
;	O
P=.02	O
)	O
,	O
indicating	O
that	O
1	O
incident	O
of	O
delirium	B-DISEASE
will	O
be	O
prevented	B-UNK
for	O
every	O
4.7	O
patients	B-UNK
treated	B-UNK
with	O
light	B-UNK
sedation	B-UNK
.	O
The	O
mean	B-UNK
+	O
/-	O
SD	B-UNK
number	B-UNK
of	O
days	B-UNK
of	O
delirium	B-DISEASE
during	O
hospitalization	O
was	O
lower	B-UNK
in	O
the	O
light	B-UNK
sedation	B-UNK
group	B-UNK
than	O
in	O
the	O
deep	B-UNK
sedation	B-UNK
group	B-UNK
(	O
0.5+/-1.5	O
days	B-UNK
vs	B-UNK
1.4+/-4.0	O
days	B-UNK
;	O
P=.01	O
)	O
.	O
CONCLUSION	O
:	O
The	O
use	B-UNK
of	O
light	B-UNK
propofol	B-CHEMICAL
sedation	B-UNK
decreased	B-UNK
the	O
prevalence	O
of	O
postoperative	B-UNK
delirium	B-DISEASE
by	O
50	O
%	O
compared	B-UNK
with	O
deep	B-UNK
sedation	B-UNK
.	O
Limiting	O
depth	B-UNK
of	O
sedation	B-UNK
during	O
spinal	B-UNK
anesthesia	B-UNK
is	O
a	O
simple	O
,	O
safe	B-UNK
,	O
and	O
cost	B-UNK
-	O
effective	B-UNK
intervention	O
for	O
preventing	B-UNK
postoperative	B-UNK
delirium	B-DISEASE
in	O
elderly	B-UNK
patients	B-UNK
that	O
could	O
be	O
widely	B-UNK
and	O
readily	O
adopted	O
.	O

Sorafenib	O
-	O
induced	B-UNK
acute	B-UNK
myocardial	B-DISEASE
infarction	I-DISEASE
due	O
to	O
coronary	B-UNK
artery	I-UNK
spasm	B-DISEASE
.	O

A	O
65-year	O
-	O
old	B-UNK
man	B-UNK
with	O
advanced	B-UNK
renal	B-UNK
cell	B-UNK
carcinoma	B-DISEASE
was	O
admitted	O
due	O
to	O
continuing	O
chest	B-DISEASE
pain	I-DISEASE
at	B-DISEASE
rest	O
.	O
Two	O
weeks	B-UNK
before	O
his	O
admission	O
,	O
sorafenib	B-CHEMICAL
had	O
been	O
started	B-UNK
.	O
He	O
was	O
diagnosed	B-UNK
with	O
non-ST-elevation	O
myocardial	B-DISEASE
infarction	I-DISEASE
by	O
laboratory	B-UNK
data	B-UNK
and	O
electrocardiogram	O
.	O
Enhanced	O
heart	B-UNK
magnetic	B-UNK
resonance	I-UNK
imaging	B-UNK
also	O
showed	B-UNK
subendocardial	O
infarction	B-DISEASE
.	O
However	O
,	O
there	O
was	O
no	O
stenosis	B-DISEASE
in	O
coronary	B-UNK
arteries	B-UNK
on	O
angiography	B-UNK
.	O
Coronary	O
artery	B-UNK
spasm	B-DISEASE
was	O
induced	B-UNK
by	O
a	O
provocative	O
test	B-UNK
.	O
Cessation	O
of	O
sorafenib	B-CHEMICAL
and	O
administration	B-UNK
of	O
Ca	O
-	O
channel	B-UNK
blocker	B-UNK
and	O
nitrates	B-CHEMICAL
ameliorated	O
his	O
symptoms	B-UNK
,	O
but	O
relapse	O
occurred	B-UNK
after	O
resumption	O
of	O
sorafenib	B-CHEMICAL
.	O
Addition	O
of	O
oral	B-UNK
nicorandil	B-CHEMICAL
reduced	B-UNK
his	O
symptoms	B-UNK
and	O
maintained	O
stable	B-UNK
angina	B-DISEASE
status	B-UNK
.	O
We	O
report	B-UNK
the	O
first	O
case	B-UNK
of	O
sorafenib	B-CHEMICAL
-	O
induced	B-UNK
coronary	B-UNK
artery	I-UNK
spasm	B-DISEASE
.	O
Sorafenib	O
is	O
a	O
multikinase	O
inhibitor	B-UNK
that	O
targets	O
signaling	O
pathways	B-UNK
necessary	O
for	O
cellular	B-UNK
proliferation	B-UNK
and	O
survival	B-UNK
.	O
On	O
the	O
other	O
hand	B-DISEASE
,	O
the	O
Rho	O
/	O
ROCK	O
pathway	B-UNK
has	O
an	O
important	B-UNK
role	B-UNK
in	O
the	O
pathogenesis	O
of	O
coronary	B-UNK
artery	I-UNK
spasm	B-DISEASE
.	O
Our	O
report	B-UNK
may	O
show	O
an	O
adverse	B-UNK
effect	B-UNK
on	O
the	O
Rho	O
/	O
ROCK	O
pathway	B-UNK
by	O
sorafenib	B-CHEMICAL
use	B-UNK
.	O

Anxiogenic	O
potential	B-UNK
of	O
ciprofloxacin	B-CHEMICAL
and	O
norfloxacin	B-CHEMICAL
in	O
rats	B-UNK
.	O

INTRODUCTION	O
:	O
The	O
possible	B-UNK
anxiogenic	B-UNK
effects	B-UNK
of	O
fluoroquinolones	B-CHEMICAL
,	O
namely	O
ciprofloxacin	B-CHEMICAL
and	O
norfloxacin	B-CHEMICAL
,	O
were	O
investigated	B-UNK
in	O
adult	B-UNK
Charles	O
Foster	O
albino	B-UNK
rats	B-UNK
of	O
either	O
sex	O
,	O
weighing	O
150	O
-	O
200	O
g.	O
METHODS	O
:	O
The	O
drugs	B-UNK
were	O
given	B-UNK
orally	B-UNK
,	O
in	O
doses	B-UNK
of	O
50	O
mg	B-UNK
/	O
kg	B-UNK
for	O
five	O
consecutive	B-UNK
days	B-UNK
and	O
the	O
experiments	B-UNK
were	O
performed	B-UNK
on	O
the	O
fifth	O
day	B-UNK
.	O
The	O
tests	B-UNK
included	B-UNK
open	B-UNK
-	O
field	B-UNK
exploratory	O
behaviour	B-UNK
,	O
elevated	B-UNK
plus	B-UNK
maze	B-UNK
and	O
elevated	B-UNK
zero	O
maze	B-UNK
,	O
social	O
interaction	B-UNK
and	O
novelty	O
-	O
suppressed	B-UNK
feeding	B-UNK
latency	O
behaviour	B-UNK
.	O
RESULTS	B-UNK
:	O
The	O
results	B-UNK
indicate	B-UNK
that	O
ciprofloxacin-	O
and	O
norfloxacin	B-CHEMICAL
-	O
treated	B-UNK
rats	B-UNK
showed	B-UNK
anxious	O
behaviour	B-UNK
in	O
comparison	O
to	O
control	B-UNK
rats	B-UNK
in	O
all	O
the	O
parameters	B-UNK
studied	B-UNK
.	O
However	O
,	O
ciprofloxacin-	O
and	O
norfloxacin	B-CHEMICAL
-	O
treated	B-UNK
rats	B-UNK
did	O
not	O
differ	B-UNK
significantly	B-UNK
from	O
each	O
other	O
in	O
various	O
behavioural	B-UNK
parameters	B-UNK
.	O
CONCLUSION	O
:	O
The	O
present	B-UNK
experimental	B-UNK
findings	B-UNK
substantiate	O
the	O
clinically	B-UNK
observed	B-UNK
anxiogenic	B-UNK
potential	B-UNK
of	O
ciprofloxacin	B-CHEMICAL
and	O
norfloxacin	B-CHEMICAL
.	O

Myocardial	O
Fas	B-UNK
ligand	B-UNK
expression	B-UNK
increases	B-UNK
susceptibility	B-UNK
to	O
AZT	B-UNK
-	O
induced	B-UNK
cardiomyopathy	B-DISEASE
.	O

BACKGROUND	O
:	O
Dilated	O
cardiomyopathy	B-DISEASE
(	O
DCM	O
)	O
and	O
myocarditis	B-DISEASE
occur	O
in	O
many	O
HIV	O
-	O
infected	B-UNK
individuals	B-UNK
,	O
resulting	B-UNK
in	O
symptomatic	B-UNK
heart	B-DISEASE
failure	I-DISEASE
in	O
up	O
to	O
5	O
%	O
of	O
patients	B-UNK
.	O
Highly	O
active	B-UNK
antiretroviral	B-UNK
therapy	B-UNK
(	O
HAART	O
)	O
has	O
significantly	B-UNK
reduced	B-UNK
morbidity	O
and	O
mortality	B-UNK
of	O
acquired	B-DISEASE
immunodeficiency	I-DISEASE
syndrome	I-DISEASE
(	O
AIDS	O
)	O
,	O
but	O
has	O
resulted	B-UNK
in	O
an	O
increase	B-UNK
in	O
cardiac	B-UNK
and	O
skeletal	O
myopathies	B-DISEASE
.	O
METHODS	O
AND	O
RESULTS	B-UNK
:	O
In	O
order	O
to	O
investigate	O
whether	O
the	O
HAART	O
component	B-UNK
zidovudine	B-CHEMICAL
(	O
3'-azido-2',3'-deoxythymidine	O
;	O
AZT	B-UNK
)	O
triggers	O
the	O
Fas	B-UNK
-	O
dependent	B-UNK
cell	B-UNK
-	O
death	B-DISEASE
pathway	B-UNK
and	O
cause	B-UNK
cytoskeletal	O
disruption	B-UNK
in	O
a	O
murine	B-UNK
model	B-UNK
of	O
DCM	O
,	O
8-week	O
-	O
old	B-UNK
transgenic	B-UNK
(	O
expressing	O
Fas	B-UNK
ligand	B-UNK
in	O
the	O
myocardium	B-UNK
:	O
FasL	B-UNK
Tg	B-UNK
)	O
and	O
non-transgenic	O
(	O
NTg	O
)	O
mice	B-UNK
received	B-UNK
water	B-CHEMICAL
ad	O
libitum	O
containing	B-UNK
different	B-UNK
concentrations	B-UNK
of	O
AZT	B-UNK
(	O
0	O
,	O
0.07	O
,	O
0.2	B-UNK
,	O
and	O
0.7	O
mg	B-UNK
/	O
ml	B-UNK
)	O
.	O
After	O
6	O
weeks	B-UNK
,	O
cardiac	B-UNK
function	B-UNK
was	O
assessed	B-UNK
by	O
echocardiography	O
and	O
morphology	O
was	O
assessed	B-UNK
by	O
histopathologic	O
and	O
immunohistochemical	O
methods	B-UNK
.	O
NTg	O
and	O
untreated	B-UNK
FasL	B-UNK
Tg	B-UNK
mice	B-UNK
showed	B-UNK
little	B-UNK
or	O
no	O
change	B-UNK
in	O
cardiac	B-UNK
structure	B-UNK
or	O
function	B-UNK
.	O
In	O
contrast	B-UNK
,	O
AZT	B-UNK
-	O
treated	B-UNK
FasL	B-UNK
Tg	B-UNK
mice	B-UNK
developed	B-UNK
cardiac	B-UNK
dilation	O
and	O
depressed	B-UNK
cardiac	B-UNK
function	B-UNK
in	O
a	O
dose	B-UNK
-	O
dependent	B-UNK
manner	B-UNK
,	O
with	O
concomitant	B-UNK
inflammatory	B-UNK
infiltration	O
of	O
both	O
ventricles	O
.	O
These	O
changes	B-UNK
were	O
associated	B-UNK
with	O
an	O
increased	B-UNK
sarcolemmal	B-UNK
expression	B-UNK
of	O
Fas	B-UNK
and	O
FasL	B-UNK
,	O
as	O
well	O
as	O
increased	B-UNK
activation	B-UNK
of	O
caspase	O
3	O
,	O
translocation	B-DISEASE
of	O
calpain	O
1	O
to	O
the	O
sarcolemma	O
and	O
sarcomere	O
,	O
and	O
increased	B-UNK
numbers	O
of	O
cells	B-UNK
undergoing	B-UNK
apoptosis	B-UNK
.	O
These	O
were	O
associated	B-UNK
with	O
changes	B-UNK
in	O
dystrophin	O
and	O
cardiac	B-UNK
troponin	O
I	O
localization	O
,	O
as	O
well	O
as	O
loss	B-UNK
of	O
sarcolemmal	B-UNK
integrity	B-UNK
.	O
CONCLUSIONS	O
:	O
The	O
expression	B-UNK
of	O
Fas	B-UNK
ligand	B-UNK
in	O
the	O
myocardium	B-UNK
,	O
as	O
identified	B-UNK
in	O
HIV	O
-	O
positive	B-UNK
patients	B-UNK
,	O
might	O
increase	B-UNK
the	O
susceptibility	B-UNK
to	O
HAART	O
-	O
induced	B-UNK
cardiomyopathy	B-DISEASE
due	O
to	O
activation	B-UNK
of	O
apoptotic	B-UNK
pathways	B-UNK
,	O
resulting	B-UNK
in	O
cardiac	B-UNK
dilation	O
and	O
dysfunction	B-UNK
.	O

Valproate	O
-	O
induced	B-UNK
chorea	B-DISEASE
and	O
encephalopathy	B-DISEASE
in	O
atypical	B-UNK
nonketotic	O
hyperglycinemia	B-DISEASE
.	O

Nonketotic	O
hyperglycinemia	B-DISEASE
is	O
a	O
disorder	B-UNK
of	O
amino	B-DISEASE
acid	I-DISEASE
metabolism	I-DISEASE
in	O
which	O
a	O
defect	B-UNK
in	O
the	O
glycine	B-CHEMICAL
cleavage	B-UNK
system	B-UNK
leads	O
to	O
an	O
accumulation	B-UNK
of	O
glycine	B-CHEMICAL
in	O
the	O
brain	B-UNK
and	O
other	O
body	B-UNK
compartments	O
.	O
In	O
the	O
classical	O
form	B-UNK
it	O
presents	O
as	O
neonatal	O
apnea	B-DISEASE
,	O
intractable	B-UNK
seizures	B-DISEASE
,	O
and	O
hypotonia	B-DISEASE
,	O
followed	B-UNK
by	O
significant	B-UNK
psychomotor	B-UNK
retardation	B-UNK
.	O
An	O
important	B-UNK
subset	O
of	O
children	B-UNK
with	O
nonketotic	O
hyperglycinemia	B-DISEASE
are	O
atypical	B-UNK
variants	B-UNK
who	O
present	B-UNK
in	O
a	O
heterogeneous	O
manner	B-UNK
.	O
This	O
report	B-UNK
describes	B-UNK
a	O
patient	B-UNK
with	O
mild	B-UNK
language	O
delay	B-UNK
and	O
mental	B-DISEASE
retardation	I-DISEASE
,	O
who	O
was	O
found	B-UNK
to	O
have	O
nonketotic	O
hyperglycinemia	B-DISEASE
following	B-UNK
her	O
presentation	O
with	O
acute	B-UNK
encephalopathy	B-DISEASE
and	O
chorea	B-DISEASE
shortly	B-UNK
after	O
initiation	O
of	O
valproate	O
therapy	B-UNK
.	O

Microinjection	O
of	O
ritanserin	B-CHEMICAL
into	O
the	O
CA1	B-UNK
region	B-UNK
of	O
hippocampus	B-UNK
improves	B-UNK
scopolamine	B-CHEMICAL
-	O
induced	B-UNK
amnesia	B-DISEASE
in	O
adult	B-UNK
male	B-UNK
rats	B-UNK
.	O

The	O
effect	B-UNK
of	O
ritanserin	B-CHEMICAL
(	O
5-HT2	O
antagonist	B-UNK
)	O
on	O
scopolamine	B-CHEMICAL
(	O
muscarinic	O
cholinergic	B-UNK
antagonist)-induced	O
amnesia	B-DISEASE
in	O
Morris	O
water	B-CHEMICAL
maze	B-UNK
(	O
MWM	O
)	O
was	O
investigated	B-UNK
.	O
Rats	O
were	O
divided	O
into	O
eight	O
groups	B-UNK
and	O
bilaterally	B-UNK
cannulated	O
into	O
CA1	B-UNK
region	B-UNK
of	O
the	O
hippocampus	B-UNK
.	O
One	O
week	B-UNK
later	B-UNK
,	O
they	O
received	B-UNK
repeatedly	B-UNK
vehicles	O
(	O
saline	B-UNK
,	O
DMSO	O
,	O
saline+DMSO	O
)	O
,	O
scopolamine	B-CHEMICAL
(	O
2	B-DISEASE
microg/0.5	B-UNK
microl	I-UNK
saline	B-UNK
/	O
side	O
;	O
30	O
min	B-UNK
before	O
training	O
)	O
,	O
ritanserin	B-CHEMICAL
(	O
2	B-DISEASE
,	O
4	O
and	O
8	O
microg/0.5	B-UNK
microl	I-UNK
DMSO	O
/	O
side	O
;	O
20	O
min	B-UNK
before	O
training	O
)	O
and	O
scopolamine	B-CHEMICAL
(	O
2	B-DISEASE
microg/0.5	B-UNK
microl	I-UNK
;	O
30	O
min	B-UNK
before	O
ritanserin	B-CHEMICAL
injection)+ritanserin	O
(	O
4	O
microg/0.5	B-UNK
microl	I-UNK
DMSO	O
)	O
through	O
cannulae	O
each	O
day	B-UNK
.	O
Animals	O
were	O
tested	B-UNK
for	O
four	O
consecutive	B-UNK
days	B-UNK
(	O
4	O
trial	B-UNK
/	O
day	B-UNK
)	O
in	O
MWM	O
during	O
which	O
the	O
position	O
of	O
hidden	O
platform	B-UNK
was	O
unchanged	B-UNK
.	O
In	O
the	O
fifth	O
day	B-UNK
,	O
the	O
platform	B-UNK
was	O
elevated	B-UNK
above	O
the	O
water	B-CHEMICAL
surface	O
in	O
another	O
position	O
to	O
evaluate	B-UNK
the	O
function	B-UNK
of	O
motor	B-UNK
,	O
motivational	O
and	O
visual	B-UNK
systems	B-UNK
.	O
The	O
results	B-UNK
showed	B-UNK
a	O
significant	B-UNK
increase	B-UNK
in	O
escape	B-UNK
latencies	O
and	O
traveled	O
distances	O
to	O
find	O
platform	B-UNK
in	O
scopolamine	B-CHEMICAL
-	O
treated	B-UNK
group	B-UNK
as	O
compared	B-UNK
to	O
saline	B-UNK
group	B-UNK
.	O
Ritanserin	O
-	O
treated	B-UNK
rats	B-UNK
(	O
4	O
microg/0.5	B-UNK
microl	I-UNK
/	O
side	O
)	O
showed	B-UNK
a	O
significant	B-UNK
decrease	B-UNK
in	O
the	O
mentioned	B-UNK
parameters	B-UNK
as	O
compared	B-UNK
to	O
DMSO	O
-	O
treated	B-UNK
group	B-UNK
.	O
However	O
,	O
scopolamine	B-CHEMICAL
and	O
ritanserin	B-CHEMICAL
co-administration	O
resulted	B-UNK
in	O
a	O
significant	B-UNK
decrease	B-UNK
in	O
escape	B-UNK
latencies	O
and	O
traveled	O
distances	O
as	O
compared	B-UNK
to	O
the	O
scopolamine	B-CHEMICAL
-	O
treated	B-UNK
rats	B-UNK
.	O
Our	O
findings	B-UNK
show	O
that	O
microinjection	B-UNK
of	O
ritanserin	B-CHEMICAL
into	O
the	O
CA1	B-UNK
region	B-UNK
of	O
the	O
hippocampus	B-UNK
improves	B-UNK
the	O
scopolamine	B-CHEMICAL
-	O
induced	B-UNK
amnesia	B-DISEASE
.	O

Hypoxia	O
in	O
renal	B-DISEASE
disease	B-DISEASE
with	O
proteinuria	B-DISEASE
and	O
/	O
or	O
glomerular	B-UNK
hypertension	B-DISEASE
.	O

Despite	B-UNK
the	O
increasing	B-UNK
need	B-UNK
to	O
identify	B-UNK
and	O
quantify	O
tissue	B-UNK
oxygenation	O
at	B-DISEASE
the	O
cellular	B-UNK
level	B-UNK
,	O
relatively	B-UNK
few	O
methods	B-UNK
have	O
been	O
available	B-UNK
.	O
In	O
this	O
study	B-UNK
,	O
we	O
developed	B-UNK
a	O
new	B-UNK
hypoxia	B-DISEASE
-	O
responsive	B-UNK
reporter	O
vector	O
using	O
a	O
hypoxia	B-DISEASE
-	O
responsive	B-UNK
element	B-UNK
of	O
the	O
5	O
'	O
vascular	B-UNK
endothelial	B-UNK
growth	B-UNK
factor	B-UNK
untranslated	O
region	B-UNK
and	O
generated	B-UNK
a	O
novel	B-UNK
hypoxia	B-DISEASE
-	O
sensing	O
transgenic	B-UNK
rat	B-UNK
.	O
We	O
then	O
applied	O
this	O
animal	B-UNK
model	B-UNK
to	O
the	O
detection	O
of	O
tubulointerstitial	B-UNK
hypoxia	B-DISEASE
in	O
the	O
diseased	O
kidney	B-UNK
.	O
With	O
this	O
model	B-UNK
,	O
we	O
were	O
able	O
to	O
identify	B-UNK
diffuse	B-UNK
cortical	B-UNK
hypoxia	B-DISEASE
in	O
the	O
puromycin	B-CHEMICAL
aminonucleoside	I-CHEMICAL
-	O
induced	B-UNK
nephrotic	B-DISEASE
syndrome	I-DISEASE
and	O
focal	B-UNK
and	O
segmental	O
hypoxia	B-DISEASE
in	O
the	O
remnant	B-UNK
kidney	I-UNK
model	B-UNK
.	O
Expression	O
of	O
the	O
hypoxia	B-DISEASE
-	O
responsive	B-UNK
transgene	O
increased	B-UNK
throughout	O
the	O
observation	B-UNK
period	B-UNK
,	O
reaching	O
2.2-fold	O
at	B-DISEASE
2	B-DISEASE
weeks	B-UNK
in	O
the	O
puromycin	B-CHEMICAL
aminonucleoside	I-CHEMICAL
model	B-UNK
and	O
2.6-fold	O
at	B-DISEASE
4	O
weeks	B-UNK
in	O
the	O
remnant	B-UNK
kidney	I-UNK
model	B-UNK
,	O
whereas	O
that	O
of	O
vascular	B-UNK
endothelial	B-UNK
growth	B-UNK
factor	B-UNK
showed	B-UNK
a	O
mild	B-UNK
decrease	B-UNK
,	O
reflecting	B-UNK
distinct	O
behaviors	B-UNK
of	O
the	O
two	O
genes	B-UNK
.	O
The	O
degree	B-UNK
of	O
hypoxia	B-DISEASE
showed	B-UNK
a	O
positive	B-UNK
correlation	B-UNK
with	O
microscopic	B-UNK
tubulointerstitial	B-UNK
injury	B-UNK
in	O
both	O
models	B-UNK
.	O
Finally	O
,	O
we	O
identified	B-UNK
the	O
localization	O
of	O
proliferating	B-CHEMICAL
cell	I-CHEMICAL
nuclear	I-CHEMICAL
antigen	I-CHEMICAL
-	O
positive	B-UNK
,	O
ED-1-positive	B-UNK
,	O
and	O
terminal	B-UNK
dUTP	O
nick	O
-	O
end	B-UNK
labeled	B-UNK
-	O
positive	B-UNK
cells	B-UNK
in	O
the	O
hypoxic	O
cortical	B-UNK
area	B-UNK
in	O
the	O
remnant	B-UNK
kidney	I-UNK
model	B-UNK
.	O
We	O
propose	O
here	O
a	O
possible	B-UNK
pathological	B-UNK
tie	O
between	O
chronic	B-UNK
tubulointerstitial	B-UNK
hypoxia	B-DISEASE
and	O
progressive	B-UNK
glomerular	B-UNK
diseases	B-DISEASE
.	O

Consensus	O
statement	O
concerning	B-UNK
cardiotoxicity	B-DISEASE
occurring	B-UNK
during	O
haematopoietic	O
stem	B-UNK
cell	I-UNK
transplantation	I-UNK
in	O
the	O
treatment	B-UNK
of	O
autoimmune	B-DISEASE
diseases	I-DISEASE
,	O
with	O
special	O
reference	B-UNK
to	O
systemic	B-DISEASE
sclerosis	I-DISEASE
and	O
multiple	B-DISEASE
sclerosis	I-DISEASE
.	O

Autologous	O
haematopoietic	O
stem	B-UNK
cell	I-UNK
transplantation	I-UNK
is	O
now	O
a	O
feasible	O
and	O
effective	B-UNK
treatment	B-UNK
for	O
selected	O
patients	B-UNK
with	O
severe	B-UNK
autoimmune	B-DISEASE
diseases	I-DISEASE
.	O
Worldwide	O
,	O
over	O
650	O
patients	B-UNK
have	O
been	O
transplanted	O
in	O
the	O
context	O
of	O
phase	B-UNK
I	O
and	O
II	B-UNK
clinical	B-UNK
trials	B-UNK
.	O
The	O
results	B-UNK
are	O
encouraging	O
enough	O
to	O
begin	O
randomised	B-UNK
phase	B-UNK
III	B-UNK
trials	B-UNK
.	O
However	O
,	O
as	O
predicted	O
,	O
significant	B-UNK
transplant	B-UNK
-	O
related	B-UNK
morbidity	O
and	O
mortality	B-UNK
have	O
been	O
observed	B-UNK
.	O
This	O
is	O
primarily	B-UNK
due	O
to	O
complications	B-UNK
related	B-UNK
to	O
either	O
the	O
stage	B-UNK
of	O
the	O
disease	B-DISEASE
at	B-DISEASE
transplant	B-UNK
or	O
due	O
to	O
infections	B-DISEASE
.	O
The	O
number	B-UNK
of	O
deaths	O
related	B-UNK
to	O
cardiac	B-UNK
toxicity	B-UNK
is	O
low	B-UNK
.	O
However	O
,	O
caution	B-UNK
is	O
required	B-UNK
when	O
cyclophosphamide	B-CHEMICAL
or	O
anthracyclines	B-CHEMICAL
such	O
as	O
mitoxantrone	B-CHEMICAL
are	O
used	O
in	O
patients	B-UNK
with	O
a	O
possible	B-UNK
underlying	B-UNK
heart	B-UNK
damage	B-UNK
,	O
for	O
example	O
,	O
systemic	B-DISEASE
sclerosis	I-DISEASE
patients	B-UNK
.	O
In	O
November	O
2002	O
,	O
a	O
meeting	O
was	O
held	O
in	O
Florence	O
,	O
bringing	O
together	O
a	O
number	B-UNK
of	O
experts	O
in	O
various	O
fields	B-UNK
,	O
including	B-UNK
rheumatology	O
,	O
cardiology	O
,	O
neurology	O
,	O
pharmacology	O
and	O
transplantation	B-UNK
medicine	O
.	O
The	O
object	B-UNK
of	O
the	O
meeting	O
was	O
to	O
analyse	O
existing	B-UNK
data	B-UNK
,	O
both	O
published	B-UNK
or	O
available	B-UNK
,	O
in	O
the	O
European	O
Group	B-UNK
for	O
Blood	O
and	O
Marrow	O
Transplantation	O
autoimmune	B-DISEASE
disease	I-DISEASE
database	B-UNK
,	O
and	O
to	O
propose	O
a	O
safe	B-UNK
approach	B-UNK
to	O
such	O
patients	B-UNK
.	O
A	O
full	O
cardiological	O
assessment	B-UNK
before	O
and	O
during	O
the	O
transplant	B-UNK
emerged	B-UNK
as	O
the	O
major	B-UNK
recommendation	O
.	O

Immunohistochemical	O
study	B-UNK
on	O
inducible	B-UNK
type	B-UNK
of	O
nitric	B-CHEMICAL
oxide	I-CHEMICAL
(	O
iNOS	O
)	O
,	O
basic	B-UNK
fibroblast	O
growth	B-UNK
factor	B-UNK
(	O
bFGF	O
)	O
and	O
tumor	B-DISEASE
growth	B-UNK
factor	B-UNK
-	O
beta1	O
(	O
TGF	O
-	O
beta1	O
)	O
in	O
arteritis	B-DISEASE
induced	B-UNK
in	O
rats	B-UNK
by	O
fenoldopam	B-CHEMICAL
and	O
theophylline	B-CHEMICAL
,	O
vasodilators	O
.	O

Arteritis	O
induced	B-UNK
in	O
rats	B-UNK
by	O
vasodilators	O
,	O
fenoldopam	B-CHEMICAL
and	O
theophylline	B-CHEMICAL
,	O
was	O
examined	B-UNK
immunohistochemically	O
for	O
expressions	O
of	O
inducible	B-UNK
type	B-UNK
of	O
nitric	B-CHEMICAL
oxide	I-CHEMICAL
synthase	B-UNK
(	O
iNOS	O
)	O
,	O
basic	B-UNK
fibroblast	O
growth	B-UNK
factor	B-UNK
(	O
bFGF	O
)	O
and	O
tumor	B-DISEASE
growth	B-UNK
factor	B-UNK
-	O
beta1	O
(	O
TGF	O
-	O
beta1	O
)	O
.	O
Rats	O
were	O
administered	B-UNK
fenoldopam	B-CHEMICAL
for	O
24	O
hours	B-UNK
by	O
intravenous	B-UNK
infusion	I-UNK
with	O
or	O
without	O
following	B-UNK
repeated	B-UNK
daily	B-UNK
oral	B-UNK
administrations	O
of	O
theophylline	B-CHEMICAL
.	O
Irrespective	O
of	O
theophylline	B-CHEMICAL
administration	B-UNK
,	O
iNOS	O
antigens	B-CHEMICAL
were	O
remarkably	B-UNK
abundant	B-UNK
in	O
ED-1-positive	B-UNK
cells	B-UNK
on	O
day	B-UNK
5	O
and	O
8	O
post-fenoldopam-infusion	O
(	O
DPI	O
)	O
;	O
bFGF	O
antigens	B-CHEMICAL
were	O
remarkably	B-UNK
abundant	B-UNK
in	O
ED-1-positive	B-UNK
cells	B-UNK
on	O
1	O
and	O
3	O
DPI	O
;	O
TGF	O
-	O
beta1	O
antigens	B-CHEMICAL
were	O
observed	B-UNK
in	O
ED-1-positive	B-UNK
cells	B-UNK
on	O
and	O
after	O
5	O
DPI	O
.	O
These	O
results	B-UNK
suggest	B-UNK
that	O
the	O
peak	B-UNK
expression	B-UNK
of	O
iNOS	O
antigen	B-UNK
was	O
followed	B-UNK
by	O
that	O
of	O
bFGF	O
antigen	B-UNK
,	O
and	O
bFGF	O
may	O
have	O
a	O
suppressive	O
effect	B-UNK
on	O
iNOS	O
expression	B-UNK
in	O
these	O
rat	B-UNK
arteritis	B-DISEASE
models	B-UNK
.	O
On	O
the	O
other	O
hand	B-DISEASE
,	O
TGF	O
-	O
beta1	O
was	O
not	O
considered	B-UNK
to	O
have	O
a	O
suppressive	O
effect	B-UNK
on	O
iNOS	O
expression	B-UNK
in	O
these	O
models	B-UNK
.	O

Low	O
-	O
molecular	B-UNK
-	O
weight	B-UNK
heparin	B-CHEMICAL
for	O
the	O
treatment	B-UNK
of	O
patients	B-UNK
with	O
mechanical	B-UNK
heart	B-UNK
valves	O
.	O

BACKGROUND	O
:	O
The	O
interruption	O
of	O
oral	B-UNK
anticoagulant	O
(	O
OAC	O
)	O
administration	B-UNK
is	O
sometimes	O
indicated	B-UNK
in	O
patients	B-UNK
with	O
mechanical	B-UNK
heart	B-UNK
valves	O
,	O
mainly	B-UNK
before	O
noncardiac	O
surgery	B-UNK
,	O
non-surgical	O
interventions	O
,	O
and	O
pregnancy	B-DISEASE
.	O
Unfractionated	O
heparin	B-CHEMICAL
(	O
UH	O
)	O
is	O
currently	B-UNK
the	O
substitute	O
for	O
selected	O
patients	B-UNK
.	O
Low	O
-	O
molecular	B-UNK
-	O
weight	B-UNK
heparin	B-CHEMICAL
(	O
LMWH	B-UNK
)	O
offers	O
theoretical	O
advantages	O
over	O
UH	O
,	O
but	O
is	O
not	O
currently	B-UNK
considered	B-UNK
in	O
clinical	B-UNK
guidelines	O
as	O
an	O
alternative	B-UNK
to	O
UH	O
in	O
patients	B-UNK
with	O
prosthetic	O
valves	O
.	O
HYPOTHESIS	O
:	O
The	O
aim	O
of	O
the	O
present	B-UNK
study	B-UNK
was	O
to	O
review	B-UNK
the	O
data	B-UNK
accumulated	O
so	O
far	O
on	O
the	O
use	B-UNK
of	O
LMWH	B-UNK
in	O
this	O
patient	B-UNK
population	B-UNK
and	O
to	O
discuss	O
its	O
applicability	O
in	O
common	B-UNK
practice	O
.	O
METHODS	O
:	O
For	O
this	O
paper	O
,	O
the	O
current	B-UNK
medical	B-UNK
literature	B-UNK
on	O
LMWH	B-UNK
in	O
patients	B-UNK
with	O
mechanical	B-UNK
heart	B-UNK
valves	O
was	O
extensively	O
reviewed	B-UNK
.	O
RESULTS	B-UNK
:	O
There	O
were	O
eight	O
series	B-UNK
and	O
six	O
case	B-UNK
reports	B-UNK
.	O
None	O
of	O
the	O
studies	B-UNK
was	O
randomized	B-UNK
,	O
and	O
only	O
one	O
was	O
prospective	B-UNK
.	O
Data	O
to	O
establish	O
the	O
thromboembolic	B-UNK
risk	B-UNK
were	O
incomplete	O
.	O
After	O
excluding	O
case	B-UNK
reports	B-UNK
,	O
the	O
following	B-UNK
groups	B-UNK
were	O
constructed	O
:	O
(	O
a	O
)	O
short	B-UNK
-	O
term	B-UNK
administration	B-UNK
,	O
after	O
valve	B-UNK
insertion	B-UNK
(	O
n	B-UNK
=	O
212	O
)	O
;	O
(	O
b	B-UNK
)	O
short	B-UNK
-	O
term	B-UNK
,	O
perioperative	O
(	O
noncardiac)/periprocedural	O
(	O
n	B-UNK
=	O
114	O
)	O
;	O
(	O
c	B-UNK
)	O
long	B-UNK
-	O
term	B-UNK
,	O
due	O
to	O
intolerance	O
to	O
OAC	O
(	O
n	B-UNK
=	O
16	O
)	O
;	O
(	O
d	B-UNK
)	O
long	B-UNK
-	O
term	B-UNK
,	O
in	O
pregnancy	B-DISEASE
(	O
n	B-UNK
=	O
10	O
)	O
.	O
The	O
incidence	B-UNK
rate	B-UNK
of	O
thromboembolism	B-DISEASE
was	O
0.9	O
%	O
for	O
all	O
the	O
studies	B-UNK
and	O
0.5	B-UNK
,	O
0	O
,	O
20	O
,	O
and	O
0	O
%	O
in	O
groups	B-UNK
a	O
,	O
b	B-UNK
,	O
c	B-UNK
,	O
and	O
d	B-UNK
,	O
respectively	O
;	O
for	O
hemorrhage	B-DISEASE
,	O
the	O
overall	B-UNK
rate	B-UNK
was	O
3.4	B-UNK
%	O
(	O
3.8	O
,	O
2.6	O
,	O
10	O
,	O
and	O
0	O
%	O
for	O
the	O
respective	B-UNK
groups	B-UNK
)	O
.	O
CONCLUSIONS	O
:	O
In	O
patients	B-UNK
with	O
mechanical	B-UNK
heart	B-UNK
valves	O
,	O
short	B-UNK
-	O
term	B-UNK
LMWH	B-UNK
therapy	B-UNK
compares	O
favorably	O
with	O
UH	O
.	O
Data	O
on	O
mid-	O
and	O
long	B-UNK
-	O
term	B-UNK
LMWH	B-UNK
administration	B-UNK
in	O
these	O
patients	B-UNK
are	O
sparse	O
.	O
Further	O
randomized	B-UNK
studies	B-UNK
are	O
needed	B-UNK
to	O
confirm	B-UNK
the	O
safety	B-UNK
and	O
precise	O
indications	O
for	O
the	O
use	B-UNK
of	O
LMWH	B-UNK
in	O
patients	B-UNK
with	O
mechanical	B-UNK
heart	B-UNK
valves	O
.	O

Topiramate	O
-	O
induced	B-UNK
nephrolithiasis	B-DISEASE
.	O

Topiramate	O
is	O
a	O
recently	B-UNK
developed	B-UNK
antiepileptic	B-UNK
medication	B-UNK
that	O
is	O
becoming	O
more	O
widely	B-UNK
prescribed	B-UNK
because	O
of	O
its	O
efficacy	B-UNK
in	O
treating	B-UNK
refractory	B-UNK
seizures	B-DISEASE
.	O
Urologists	O
should	O
be	O
aware	O
that	O
this	O
medication	B-UNK
can	O
cause	B-UNK
metabolic	B-UNK
acidosis	B-DISEASE
in	O
patients	B-UNK
secondary	B-UNK
to	O
inhibition	B-UNK
of	O
carbonic	O
anhydrase	O
.	O
In	O
addition	O
,	O
a	O
distal	B-UNK
tubular	B-UNK
acidification	O
defect	B-UNK
may	O
result	B-UNK
,	O
thus	O
impairing	O
the	O
normal	B-UNK
compensatory	B-UNK
drop	O
in	O
urine	B-DISEASE
pH.	O
These	O
factors	B-UNK
can	O
lead	B-CHEMICAL
to	O
the	O
development	B-UNK
of	O
calcium	B-CHEMICAL
phosphate	I-CHEMICAL
nephrolithiasis	B-DISEASE
.	O
We	O
report	B-UNK
the	O
first	O
two	O
cases	B-UNK
of	O
topiramate	B-CHEMICAL
-	O
induced	B-UNK
nephrolithiasis	B-DISEASE
in	O
the	O
urologic	O
literature	B-UNK
.	O

Spironolactone	O
:	O
is	O
it	O
a	O
novel	B-UNK
drug	B-UNK
for	O
the	O
prevention	O
of	O
amphotericin	B-UNK
B	B-UNK
-	O
related	B-UNK
hypokalemia	B-DISEASE
in	O
cancer	B-UNK
patients	B-UNK
?	O

OBJECTIVE	O
:	O
Nephrotoxicity	O
is	O
the	O
major	B-UNK
adverse	B-UNK
effect	B-UNK
of	O
amphotericin	B-UNK
B	B-UNK
(	O
AmB	B-UNK
)	O
,	O
often	O
limiting	B-UNK
administration	B-UNK
of	O
full	O
dosage	B-UNK
.	O
Selective	O
distal	B-UNK
tubular	B-UNK
epithelial	B-UNK
toxicity	B-UNK
seems	O
to	O
be	O
responsible	O
for	O
the	O
profound	B-UNK
potassium	B-CHEMICAL
wasting	O
that	O
is	O
a	O
major	B-UNK
clinical	B-UNK
side	O
effect	B-UNK
of	O
treatment	B-UNK
with	O
AmB.	O
Potassium	O
depletion	O
also	O
potentiates	B-UNK
the	O
tubular	B-UNK
toxicity	B-UNK
of	O
AmB.	O
This	O
study	B-UNK
was	O
designed	O
to	O
assess	B-UNK
the	O
ability	B-UNK
of	O
spironolactone	B-CHEMICAL
to	O
reduce	B-UNK
potassium	B-CHEMICAL
requirements	O
and	O
to	O
prevent	B-UNK
hypokalemia	B-DISEASE
in	O
neutropenic	O
patients	B-UNK
on	O
AmB	B-UNK
treatment	B-UNK
.	O
METHODS	O
:	O
In	O
this	O
study	B-UNK
26	O
patients	B-UNK
with	O
various	O
hematological	O
disorders	B-UNK
were	O
randomized	B-UNK
to	O
receive	B-UNK
either	O
intravenous	B-UNK
AmB	B-UNK
alone	O
or	O
AmB	B-UNK
and	O
oral	B-UNK
spironolactone	B-CHEMICAL
100	O
mg	B-UNK
twice	B-UNK
daily	B-UNK
when	O
developing	O
a	O
proven	B-UNK
or	O
suspected	O
fungal	B-DISEASE
infection	I-DISEASE
.	O
RESULTS	B-UNK
:	O
Patients	B-UNK
receiving	B-UNK
concomitant	B-UNK
AmB	B-UNK
and	O
spironolactone	B-CHEMICAL
had	O
significantly	B-UNK
higher	B-UNK
plasma	B-UNK
potassium	B-CHEMICAL
levels	B-UNK
than	O
those	O
receiving	B-UNK
AmB	B-UNK
alone	O
(	O
P	B-UNK
=	I-UNK
0.0027	O
)	O
.	O
Those	O
patients	B-UNK
receiving	B-UNK
AmB	B-UNK
and	O
spironolactone	B-CHEMICAL
required	B-UNK
significantly	B-UNK
less	O
potassium	B-CHEMICAL
supplementation	B-UNK
to	O
maintain	O
their	O
plasma	B-UNK
potassium	B-CHEMICAL
within	O
the	O
normal	B-UNK
range	B-UNK
(	O
P	B-UNK
=	I-UNK
0.022	O
)	O
.	O
Moreover	O
,	O
urinary	B-UNK
potassium	B-CHEMICAL
losses	O
were	O
significantly	B-UNK
less	O
in	O
patients	B-UNK
receiving	B-UNK
AmB	B-UNK
and	O
spironolactone	B-CHEMICAL
than	O
those	O
receiving	B-UNK
AmB	B-UNK
alone	O
(	O
P	B-UNK
=	I-UNK
0.040	O
)	O
.	O
CONCLUSION	O
:	O
This	O
study	B-UNK
showed	B-UNK
that	O
spironolactone	B-CHEMICAL
can	O
reduce	B-UNK
potassium	B-CHEMICAL
requirements	O
and	O
prevent	B-UNK
hypokalemia	B-DISEASE
by	O
reducing	B-UNK
urinary	B-UNK
potassium	B-CHEMICAL
loss	B-UNK
in	O
neutropenic	O
patients	B-UNK
on	O
AmB	B-UNK
treatment	B-UNK
.	O

Dopamine	O
D2	B-UNK
receptor	B-UNK
signaling	O
controls	B-UNK
neuronal	B-UNK
cell	B-UNK
death	B-DISEASE
induced	B-UNK
by	O
muscarinic	O
and	O
glutamatergic	B-UNK
drugs	B-UNK
.	O

Dopamine	O
(	O
DA	B-UNK
)	O
,	O
through	O
D1	O
/	O
D2	B-UNK
receptor	B-UNK
-	O
mediated	B-UNK
signaling	O
,	O
plays	O
a	O
major	B-UNK
role	B-UNK
in	O
the	O
control	B-UNK
of	O
epileptic	B-UNK
seizures	B-DISEASE
arising	O
in	O
the	O
limbic	O
system	B-UNK
.	O
Excitotoxicity	O
leading	B-UNK
to	O
neuronal	B-UNK
cell	B-UNK
death	B-DISEASE
in	O
the	O
affected	B-UNK
areas	B-UNK
is	O
a	O
major	B-UNK
consequence	O
of	O
seizures	B-DISEASE
at	B-DISEASE
the	O
cellular	B-UNK
level	B-UNK
.	O
In	O
this	O
respect	O
,	O
little	B-UNK
is	O
known	B-UNK
about	O
the	O
role	B-UNK
of	O
DA	B-UNK
receptors	B-UNK
in	O
the	O
occurrence	O
of	O
epilepsy	B-DISEASE
-	O
induced	B-UNK
neuronal	B-UNK
cell	B-UNK
death	B-DISEASE
.	O
Here	O
we	O
analyze	O
the	O
occurrence	O
of	O
seizures	B-DISEASE
and	O
neurotoxicity	B-UNK
in	O
D2R	O
-/-	O
mice	B-UNK
treated	B-UNK
with	O
the	O
cholinergic	B-UNK
agonist	B-UNK
pilocarpine	B-CHEMICAL
.	O
We	O
compared	B-UNK
these	O
results	B-UNK
with	O
those	O
previously	B-UNK
obtained	B-UNK
with	O
kainic	B-CHEMICAL
acid	I-CHEMICAL
(	O
KA	O
)	O
,	O
a	O
potent	B-UNK
glutamate	B-UNK
agonist	B-UNK
.	O
Importantly	O
,	O
D2R	O
-/-	O
mice	B-UNK
develop	B-UNK
seizures	B-DISEASE
at	B-DISEASE
doses	B-UNK
of	O
both	O
drugs	B-UNK
that	O
are	O
not	O
epileptogenic	O
for	O
WT	O
littermates	O
and	O
show	O
greater	B-UNK
neurotoxicity	B-UNK
.	O
However	O
,	O
pilocarpine	B-CHEMICAL
-	O
induced	B-UNK
seizures	B-DISEASE
result	B-UNK
in	O
a	O
more	O
widespread	O
neuronal	B-UNK
death	B-DISEASE
in	O
both	O
WT	O
and	O
D2R	O
-/-	O
brains	O
in	O
comparison	O
to	O
KA	O
.	O
Thus	O
,	O
the	O
absence	B-UNK
of	O
D2R	O
lowers	O
the	O
threshold	B-UNK
for	O
seizures	B-DISEASE
induced	B-UNK
by	O
both	O
glutamate	B-UNK
and	O
acetylcholine	B-CHEMICAL
.	O
Moreover	O
,	O
the	O
dopaminergic	B-UNK
control	B-UNK
of	O
epilepsy	B-DISEASE
-	O
induced	B-UNK
neurodegeneration	O
seems	O
to	O
be	O
mediated	B-UNK
by	O
distinct	O
interactions	B-UNK
of	O
D2R	O
signaling	O
with	O
these	O
two	O
neurotransmitters	B-UNK
.	O

Treatment	O
of	O
risperidone	B-CHEMICAL
-	O
induced	B-UNK
hyperprolactinemia	B-DISEASE
with	O
a	O
dopamine	B-CHEMICAL
agonist	B-UNK
in	O
children	B-UNK
.	O

BACKGROUND	O
:	O
Risperidone	O
,	O
a	O
potent	B-UNK
antagonist	B-UNK
of	O
both	O
serotonergic	B-UNK
(	O
5HT2A	O
)	O
and	O
dopaminergic	B-UNK
D2	B-UNK
receptors	B-UNK
is	O
associated	B-UNK
with	O
hyperprolactinemia	B-DISEASE
in	O
adults	O
and	O
children	B-UNK
.	O
Chronically	O
elevated	B-UNK
prolactin	B-CHEMICAL
levels	B-UNK
in	O
children	B-UNK
with	O
prolactinomas	O
may	O
be	O
associated	B-UNK
with	O
arrested	O
growth	B-UNK
and	O
development	B-UNK
resulting	B-UNK
in	O
either	O
delayed	B-UNK
puberty	B-DISEASE
or	O
short	B-DISEASE
stature	I-DISEASE
.	O
These	O
possibilities	O
stress	B-UNK
the	O
importance	O
of	O
developing	O
a	O
safe	B-UNK
and	O
effective	B-UNK
approach	B-UNK
to	O
drug	B-UNK
-	O
induced	B-UNK
hyperprolactinemia	B-DISEASE
in	O
youth	O
.	O
We	O
report	B-UNK
the	O
successful	B-UNK
treatment	B-UNK
of	O
risperidone	B-CHEMICAL
-	O
induced	B-UNK
hyperprolactinemia	B-DISEASE
with	O
cabergoline	B-CHEMICAL
in	O
youth	O
.	O
METHODS	O
:	O
We	O
undertook	O
a	O
retrospective	O
case	B-UNK
review	B-UNK
of	O
four	O
children	B-UNK
with	O
risperidone	B-CHEMICAL
-	O
induced	B-UNK
hyperprolactinemia	B-DISEASE
treated	B-UNK
with	O
cabergoline	B-CHEMICAL
.	O
RESULTS	B-UNK
:	O
Four	O
males	O
(	O
age	B-UNK
6	O
-	O
11	O
years	B-UNK
)	O
with	O
Diagnostic	O
and	O
Statistical	O
Manual	O
of	O
Mental	O
Disorders	B-UNK
(	O
fourth	B-UNK
edition	O
)	O
bipolar	B-DISEASE
disorder	I-DISEASE
or	O
psychoses	B-DISEASE
,	O
with	O
risperidone	B-CHEMICAL
-	O
induced	B-UNK
elevations	O
in	O
serum	B-UNK
prolactin	B-CHEMICAL
levels	B-UNK
(	O
57.5	O
-	O
129	O
ng	B-UNK
/	O
mL	O
,	O
normal	B-UNK
5	O
-	O
15	O
ng	B-UNK
/	O
mL	O
)	O
,	O
were	O
treated	B-UNK
with	O
cabergoline	B-CHEMICAL
(	O
mean	B-UNK
dose	B-UNK
2.13	O
+	O
/-	O
0.09	O
mg	B-UNK
/	O
week	B-UNK
)	O
.	O
When	O
serum	B-UNK
prolactin	B-CHEMICAL
levels	B-UNK
normalized	B-UNK
in	O
all	O
four	O
subjects	B-UNK
(	O
mean	B-UNK
11.2	O
+	O
/-	O
10.9	O
ng	B-UNK
/	O
mL	O
)	O
,	O
the	O
cabergoline	B-CHEMICAL
dose	B-UNK
was	O
reduced	B-UNK
to	O
1	O
mg	B-UNK
/	O
week	B-UNK
in	O
three	O
of	O
four	O
subjects	B-UNK
.	O
The	O
mean	B-UNK
duration	B-UNK
of	O
therapy	B-UNK
with	O
cabergoline	B-CHEMICAL
was	O
523.5	O
+	O
/-	O
129.7	O
days	B-UNK
,	O
and	O
the	O
mean	B-UNK
duration	B-UNK
of	O
therapy	B-UNK
with	O
risperidone	B-CHEMICAL
was	O
788.5	O
+	O
/-	O
162.5	O
days	B-UNK
.	O
Cabergoline	O
was	O
well	O
tolerated	B-UNK
without	O
adverse	B-UNK
effects	B-UNK
.	O
CONCLUSIONS	O
:	O
Cabergoline	O
may	O
be	O
useful	B-UNK
for	O
the	O
treatment	B-UNK
of	O
risperidone	B-CHEMICAL
-	O
induced	B-UNK
hyperprolactinemia	B-DISEASE
in	O
youth	O
;	O
however	O
,	O
further	O
research	B-UNK
is	O
needed	B-UNK
.	O

Cholestatic	O
jaundice	B-DISEASE
associated	B-UNK
with	O
the	O
use	B-UNK
of	O
metformin	B-CHEMICAL
.	O

We	O
report	B-UNK
a	O
patient	B-UNK
who	O
developed	B-UNK
cholestatic	B-UNK
jaundice	B-DISEASE
shortly	B-UNK
after	O
initiation	O
of	O
treatment	B-UNK
with	O
metformin	B-CHEMICAL
hydrochloride	B-UNK
.	O
Ultrasound	O
of	O
the	O
liver	B-DISEASE
and	O
abdominal	B-UNK
CT	B-UNK
were	O
normal	B-UNK
.	O
An	O
ERCP	O
showed	B-UNK
normal	B-UNK
biliary	O
anatomy	O
.	O
A	O
percutaneous	B-UNK
liver	B-DISEASE
biopsy	B-UNK
was	O
obtained	B-UNK
showing	B-UNK
marked	B-UNK
cholestasis	B-DISEASE
,	O
with	O
portal	O
edema	B-DISEASE
,	O
ductular	O
proliferation	B-UNK
,	O
and	O
acute	B-UNK
inflammation	B-DISEASE
.	O
Metformin	B-UNK
hydrochloride	B-UNK
was	O
discontinued	O
,	O
and	O
the	O
patient'	O
s	O
jaundice	B-DISEASE
resolved	B-UNK
slowly	O
over	O
a	O
period	B-UNK
of	O
several	O
months	B-UNK
.	O
Given	O
the	O
onset	B-UNK
of	O
his	O
jaundice	B-DISEASE
2	B-DISEASE
wk	O
after	O
the	O
initiation	O
of	O
metformin	B-CHEMICAL
,	O
we	O
believe	O
that	O
this	O
case	B-UNK
represents	O
an	O
example	O
of	O
metformin	B-CHEMICAL
-	O
associated	B-UNK
hepatotoxicity	O
,	O
the	O
first	O
such	O
case	B-UNK
reported	B-UNK
.	O

Electro-oculography	O
,	O
electroretinography	O
,	O
visual	B-UNK
evoked	I-UNK
potentials	O
,	O
and	O
multifocal	O
electroretinography	O
in	O
patients	B-UNK
with	O
vigabatrin	B-CHEMICAL
-	O
attributed	B-UNK
visual	B-UNK
field	I-UNK
constriction	B-DISEASE
.	O

PURPOSE	O
:	O
Symptomatic	O
visual	B-UNK
field	I-UNK
constriction	B-DISEASE
thought	O
to	O
be	O
associated	B-UNK
with	O
vigabatrin	B-CHEMICAL
has	O
been	O
reported	B-UNK
.	O
The	O
current	B-UNK
study	B-UNK
investigated	B-UNK
the	O
visual	B-UNK
fields	B-UNK
and	O
visual	B-UNK
electrophysiology	O
of	O
eight	O
patients	B-UNK
with	O
known	B-UNK
vigabatrin	B-CHEMICAL
-	O
attributed	B-UNK
visual	B-UNK
field	I-UNK
loss	B-UNK
,	O
three	O
of	O
whom	O
were	O
reported	B-UNK
previously	B-UNK
.	O
Six	O
of	O
the	O
patients	B-UNK
were	O
no	O
longer	B-UNK
receiving	B-UNK
vigabatrin	B-CHEMICAL
.	O
METHODS	O
:	O
The	O
central	B-UNK
and	O
peripheral	B-UNK
fields	B-UNK
were	O
examined	B-UNK
with	O
the	O
Humphrey	O
Visual	B-UNK
Field	O
Analyzer	O
.	O
Full	O
visual	B-UNK
electrophysiology	O
,	O
including	B-UNK
flash	O
electroretinography	O
(	O
ERG	O
)	O
,	O
pattern	B-UNK
electroretinography	O
,	O
multifocal	O
ERG	O
using	O
the	O
VERIS	O
system	B-UNK
,	O
electro-oculography	O
,	O
and	O
flash	O
and	O
pattern	B-UNK
visual	B-UNK
evoked	I-UNK
potentials	O
,	O
was	O
undertaken	O
.	O
RESULTS	B-UNK
:	O
Seven	O
patients	B-UNK
showed	B-UNK
marked	B-UNK
visual	B-UNK
field	I-UNK
constriction	B-DISEASE
with	O
some	O
sparing	O
of	O
the	O
temporal	B-UNK
visual	B-UNK
field	I-UNK
.	O
The	O
eighth	O
exhibited	B-UNK
concentric	O
constriction	B-DISEASE
.	O
Most	O
electrophysiological	B-UNK
responses	B-UNK
were	O
usually	B-UNK
just	O
within	O
normal	B-UNK
limits	B-UNK
;	O
two	O
patients	B-UNK
had	O
subnormal	O
Arden	O
electro-oculography	O
indices	O
;	O
and	O
one	O
patient	B-UNK
showed	B-UNK
an	O
abnormally	O
delayed	B-UNK
photopic	O
b	B-UNK
wave	O
.	O
However	O
,	O
five	O
patients	B-UNK
showed	B-UNK
delayed	B-UNK
30-Hz	O
flicker	O
b	B-UNK
waves	O
,	O
and	O
seven	O
patients	B-UNK
showed	B-UNK
delayed	B-UNK
oscillatory	O
potentials	O
.	O
Multifocal	O
ERG	O
showed	B-UNK
abnormalities	B-DISEASE
that	O
sometimes	O
correlated	B-UNK
with	O
the	O
visual	B-UNK
field	I-UNK
appearance	O
and	O
confirmed	B-UNK
that	O
the	O
deficit	B-UNK
occurs	B-UNK
at	B-DISEASE
the	O
retinal	O
level	B-UNK
.	O
CONCLUSION	O
:	O
Marked	O
visual	B-UNK
field	I-UNK
constriction	B-DISEASE
appears	B-UNK
to	O
be	O
associated	B-UNK
with	O
vigabatrin	B-CHEMICAL
therapy	B-UNK
.	O
The	O
field	B-UNK
defects	B-UNK
and	O
some	O
electrophysiological	B-UNK
abnormalities	B-DISEASE
persist	O
when	O
vigabatrin	B-CHEMICAL
therapy	B-UNK
is	O
withdrawn	O
.	O

Conversion	O
to	O
rapamycin	B-UNK
immunosuppression	B-UNK
in	O
renal	B-DISEASE
transplant	B-UNK
recipients	B-UNK
:	O
report	B-UNK
of	O
an	O
initial	B-UNK
experience	B-UNK
.	O

BACKGROUND	O
:	O
The	O
aim	O
of	O
this	O
study	B-UNK
is	O
to	O
evaluate	B-UNK
the	O
effects	B-UNK
of	O
RAPA	O
conversion	B-UNK
in	O
patients	B-UNK
undergoing	B-UNK
cyclosporine	B-CHEMICAL
(	O
CsA	O
)	O
or	O
tacrolimus	B-CHEMICAL
(	O
Tac	O
)	O
toxicity	B-UNK
.	O
METHODS	O
:	O
Twenty	O
renal	B-DISEASE
transplant	B-UNK
recipients	B-UNK
were	O
switched	O
to	O
fixed	B-UNK
dose	B-UNK
rapamycin	B-UNK
(	O
RAPA	O
)	O
(	O
5	O
mg	B-UNK
/	O
day	B-UNK
)	O
0	O
to	O
204	O
months	B-UNK
posttransplant	O
.	O
Drug	B-UNK
monitoring	B-UNK
was	O
not	O
initially	B-UNK
used	O
to	O
adjust	O
doses	B-UNK
.	O
The	O
indications	O
for	O
switch	O
were	O
chronic	B-UNK
CsA	O
or	O
Tac	O
nephrotoxicity	B-UNK
(	O
12	O
)	O
,	O
acute	B-UNK
CsA	O
or	O
Tac	O
toxicity	B-UNK
(	O
3	O
)	O
,	O
severe	B-UNK
facial	B-DISEASE
dysmorphism	I-DISEASE
(	O
2	B-DISEASE
)	O
,	O
posttransplant	O
lymphoproliferative	O
disorder	B-UNK
(	O
PTLD	O
)	O
in	O
remission	B-DISEASE
(	O
2	B-DISEASE
)	O
,	O
and	O
hepatotoxicity	O
in	O
1	O
.	O
Follow	O
-	O
up	O
is	O
7	O
to	O
24	O
months	B-UNK
.	O
RESULTS	B-UNK
:	O
In	O
the	O
12	O
patients	B-UNK
switched	O
because	O
of	O
chronic	B-UNK
nephrotoxicity	B-UNK
there	O
was	O
a	O
significant	B-UNK
decrease	B-UNK
in	O
serum	B-UNK
creatinine	B-CHEMICAL
[	O
233+/-34	O
to	O
210+/-56	O
micromol	B-UNK
/	O
liter	O
(	O
P<0.05	O
)	O
at	B-DISEASE
6	O
months].	O
Facial	O
dysmorphism	O
improved	B-UNK
in	O
two	O
patients	B-UNK
.	O
No	O
relapse	O
of	O
PTLD	O
was	O
observed	B-UNK
.	O
Five	O
patients	B-UNK
developed	B-UNK
pneumonia	B-DISEASE
(	O
two	O
Pneumocystis	O
carinii	O
pneumonia	B-DISEASE
,	O
one	O
infectious	B-DISEASE
mononucleosis	I-DISEASE
with	O
polyclonal	O
PTLD	O
lung	B-DISEASE
infiltrate	O
)	O
and	O
two	O
had	O
bronchiolitis	B-DISEASE
obliterans	I-DISEASE
.	O
There	O
were	O
no	O
deaths	O
.	O
RAPA	O
was	O
discontinued	O
in	O
four	O
patients	B-UNK
,	O
because	O
of	O
pneumonia	B-DISEASE
in	O
two	O
,	O
PTLD	O
in	O
one	O
,	O
and	O
oral	B-UNK
aphtous	O
ulcers	O
in	O
one	O
.	O
RAPA	O
levels	B-UNK
were	O
high	B-UNK
(	O
>	O
15	O
ng	B-UNK
/	O
ml	B-UNK
)	O
in	O
7	O
of	O
13	O
(	O
54	O
%	O
)	O
patients	B-UNK
.	O
CONCLUSIONS	O
:	O
RAPA	O
conversion	B-UNK
provides	B-UNK
adequate	B-UNK
immunosuppression	B-UNK
to	O
enable	O
CsA	O
withdrawal	B-UNK
.	O
However	O
,	O
when	O
converting	B-UNK
patients	B-UNK
to	O
RAPA	O
drug	B-UNK
levels	B-UNK
should	O
be	O
monitored	B-UNK
to	O
avoid	B-UNK
over	O
-	O
immunosuppression	B-UNK
and	O
adequate	B-UNK
antiviral	B-UNK
and	O
Pneumocystis	O
carinii	O
pneumonia	B-DISEASE
prophylaxis	B-UNK
should	O
be	O
given	B-UNK
.	O

Worsening	O
of	O
levodopa	B-CHEMICAL
-	O
induced	B-UNK
dyskinesias	B-DISEASE
by	O
motor	B-UNK
and	O
mental	B-UNK
tasks	O
.	O

Ten	O
patients	B-UNK
who	O
had	O
Parkinson'	O
s	O
disease	B-DISEASE
with	O
disabling	B-UNK
dyskinesia	B-DISEASE
were	O
included	B-UNK
in	O
this	O
study	B-UNK
to	O
evaluate	B-UNK
the	O
role	B-UNK
of	O
mental	B-UNK
(	O
mental	B-UNK
calculation	O
)	O
and	O
motor	B-UNK
(	O
flexion	O
/	O
extension	O
of	O
right	B-UNK
fingers	O
,	O
flexion	O
/	O
extension	O
of	O
left	B-UNK
fingers	O
,	O
flexion	O
/	O
extension	O
of	O
the	O
neck	O
,	O
speaking	B-UNK
aloud	B-UNK
)	O
tasks	O
on	O
the	O
worsening	O
of	O
peak	B-UNK
-	O
dose	B-UNK
dyskinesia	B-DISEASE
following	B-UNK
administration	B-UNK
of	O
an	O
effective	B-UNK
single	B-UNK
dose	B-UNK
of	O
apomorphine	B-CHEMICAL
.	O
Compared	O
with	O
the	O
score	B-UNK
at	B-DISEASE
rest	O
(	O
1.3+/-0.3	O
)	O
,	O
a	O
significant	B-UNK
aggravation	O
of	O
the	O
dyskinesia	B-DISEASE
score	B-UNK
was	O
observed	B-UNK
during	O
speaking	B-UNK
aloud	B-UNK
(	O
5.2+/-1.1	O
,	O
p<0.05	O
)	O
,	O
movements	B-UNK
of	O
right	B-UNK
(	O
4.5+/-1.0	O
,	O
p<0.05	O
)	O
and	O
left	B-UNK
(	O
3.7+/-0.8	O
,	O
p<0.05	O
)	O
fingers	O
,	O
movements	B-UNK
of	O
the	O
neck	O
(	O
5.1+/-1.0	O
,	O
p<0.05	O
)	O
,	O
and	O
mental	B-UNK
calculation	O
(	O
3.1+/-1.0	O
,	O
p<0.05	O
)	O
.	O
These	O
results	B-UNK
suggest	B-UNK
that	O
activation	B-UNK
tasks	O
such	O
as	O
"	O
speaking	B-UNK
aloud	B-UNK
"	O
could	O
be	O
used	O
for	O
objective	B-UNK
assessment	B-UNK
of	O
dyskinesia	B-DISEASE
severity	B-UNK
.	O

Structural	O
and	O
functional	B-UNK
impairment	B-UNK
of	O
mitochondria	O
in	O
adriamycin	O
-	O
induced	B-UNK
cardiomyopathy	B-DISEASE
in	O
mice	B-UNK
:	O
suppression	B-UNK
of	O
cytochrome	B-UNK
c	B-UNK
oxidase	B-UNK
II	B-UNK
gene	B-UNK
expression	B-UNK
.	O

The	O
use	B-UNK
of	O
adriamycin	O
(	O
ADR	B-UNK
)	O
in	O
cancer	B-UNK
chemotherapy	B-UNK
has	O
been	O
limited	O
due	O
to	O
its	O
cumulative	B-UNK
cardiovascular	B-UNK
toxicity	B-UNK
.	O
Earlier	O
observations	B-UNK
that	O
ADR	B-UNK
interacts	O
with	O
mitochondrial	B-UNK
cytochrome	B-UNK
c	B-UNK
oxidase	B-UNK
(	O
COX	B-UNK
)	O
and	O
suppresses	O
its	O
enzyme	B-UNK
activity	B-UNK
led	B-UNK
us	O
to	O
investigate	O
ADR'	O
s	O
action	B-UNK
on	O
the	O
cardiovascular	B-UNK
functions	B-UNK
and	O
heart	B-UNK
mitochondrial	B-UNK
morphology	O
in	O
Balb	O
-	O
c	B-UNK
mice	B-UNK
i.p	B-UNK
.	O
treated	B-UNK
with	O
ADR	B-UNK
for	O
several	O
weeks	B-UNK
.	O
At	O
various	O
times	B-UNK
during	O
treatment	B-UNK
,	O
the	O
animals	B-UNK
were	O
assessed	B-UNK
for	O
cardiovascular	B-UNK
functions	B-UNK
by	O
electrocardiography	O
and	O
for	O
heart	B-UNK
tissue	B-UNK
damage	B-UNK
by	O
electron	B-UNK
microscopy	B-UNK
.	O
In	O
parallel	O
,	O
total	B-UNK
RNA	B-UNK
was	O
extracted	O
from	O
samples	B-UNK
of	O
dissected	O
heart	B-UNK
and	O
analyzed	B-UNK
by	O
Northern	O
blot	B-UNK
hybridization	B-UNK
to	O
determine	B-UNK
the	O
steady	O
-	O
state	B-UNK
level	B-UNK
of	O
three	O
RNA	B-UNK
transcripts	O
encoded	B-UNK
by	O
the	O
COXII	O
,	O
COXIII	O
,	O
and	O
COXIV	O
genes	B-UNK
.	O
Similarly	O
,	O
samples	B-UNK
obtained	B-UNK
from	O
the	O
liver	B-DISEASE
of	O
the	O
same	O
animals	B-UNK
were	O
analyzed	B-UNK
for	O
comparative	O
studies	B-UNK
.	O
Our	O
results	B-UNK
indicated	B-UNK
that	O
1	O
)	O
treatment	B-UNK
of	O
mice	B-UNK
with	O
ADR	B-UNK
caused	B-UNK
cardiovascular	B-UNK
arrhythmias	B-DISEASE
characterized	B-UNK
by	O
bradycardia	B-DISEASE
,	O
extension	O
of	O
ventricular	B-UNK
depolarization	O
time	B-UNK
(	O
tQRS	O
)	O
,	O
and	O
failure	B-UNK
of	O
QRS	O
at	B-DISEASE
high	B-UNK
concentrations	B-UNK
(	O
10	O
-	O
14	O
mg	B-UNK
/	O
kg	B-UNK
body	B-DISEASE
weight	I-DISEASE
cumulative	B-UNK
dose	B-UNK
)	O
;	O
2	B-DISEASE
)	O
the	O
heart	B-UNK
mitochondria	O
underwent	B-UNK
swelling	B-DISEASE
,	O
fusion	O
,	O
dissolution	O
,	O
and	O
/	O
or	O
disruption	B-UNK
of	O
mitochondrial	B-UNK
cristae	O
after	O
several	O
weeks	B-UNK
of	O
treatment	B-UNK
.	O
Such	O
abnormalities	B-DISEASE
were	O
not	O
observed	B-UNK
in	O
the	O
mitochondria	O
of	O
liver	B-DISEASE
tissue	B-UNK
;	O
and	O
3	O
)	O
among	O
the	O
three	O
genes	B-UNK
of	O
COX	B-UNK
enzyme	B-UNK
examined	B-UNK
,	O
only	O
COXII	O
gene	B-UNK
expression	B-UNK
was	O
suppressed	B-UNK
by	O
ADR	B-UNK
treatment	B-UNK
,	O
mainly	B-UNK
after	O
8	O
weeks	B-UNK
in	O
both	O
heart	B-UNK
and	O
liver	B-DISEASE
.	O
Knowing	O
that	O
heart	B-UNK
mitochondria	O
represent	B-UNK
almost	O
40	O
%	O
of	O
heart	B-UNK
muscle	B-UNK
by	O
weight	B-UNK
,	O
we	O
conclude	O
that	O
the	O
deteriorating	B-UNK
effects	B-UNK
of	O
ADR	B-UNK
on	O
cardiovascular	B-UNK
function	B-UNK
involve	B-UNK
mitochondrial	B-UNK
structural	B-UNK
and	O
functional	B-UNK
impairment	B-UNK
.	O

Enhanced	O
bradycardia	B-DISEASE
induced	B-UNK
by	O
beta-adrenoceptor	B-UNK
antagonists	B-UNK
in	O
rats	B-UNK
pretreated	B-UNK
with	O
isoniazid	B-CHEMICAL
.	O

High	B-UNK
doses	B-UNK
of	O
isoniazid	B-CHEMICAL
increase	B-UNK
hypotension	B-DISEASE
induced	B-UNK
by	O
vasodilators	O
and	O
change	B-UNK
the	O
accompanying	O
reflex	B-DISEASE
tachycardia	B-DISEASE
to	O
bradycardia	B-DISEASE
,	O
an	O
interaction	B-UNK
attributed	B-UNK
to	O
decreased	B-UNK
synthesis	O
of	O
brain	B-UNK
gamma	B-CHEMICAL
-	I-CHEMICAL
aminobutyric	I-CHEMICAL
acid	I-CHEMICAL
(	O
GABA	O
)	O
.	O
In	O
the	O
present	B-UNK
study	B-UNK
,	O
the	O
possible	B-UNK
enhancement	O
by	O
isoniazid	B-CHEMICAL
of	O
bradycardia	B-DISEASE
induced	B-UNK
by	O
beta-adrenoceptor	B-UNK
antagonists	B-UNK
was	O
determined	O
in	O
rats	B-UNK
anaesthetised	O
with	O
chloralose	B-CHEMICAL
-	O
urethane	B-CHEMICAL
.	O
Isoniazid	O
significantly	B-UNK
increased	B-UNK
bradycardia	B-DISEASE
after	O
propranolol	B-CHEMICAL
,	O
pindolol	B-CHEMICAL
,	O
labetalol	B-CHEMICAL
and	O
atenolol	B-CHEMICAL
,	O
as	O
well	O
as	O
after	O
clonidine	B-CHEMICAL
,	O
but	O
not	O
after	O
hexamethonium	B-CHEMICAL
or	O
carbachol	B-CHEMICAL
.	O
Enhancement	O
was	O
not	O
observed	B-UNK
in	O
rats	B-UNK
pretreated	B-UNK
with	O
methylatropine	B-CHEMICAL
or	O
previously	B-UNK
vagotomised	O
.	O
These	O
results	B-UNK
are	O
compatible	O
with	O
interference	O
by	O
isoniazid	B-CHEMICAL
with	O
GABAergic	B-UNK
inhibition	B-UNK
of	O
cardiac	B-UNK
parasympathetic	O
tone	B-UNK
.	O
Such	O
interference	O
could	O
be	O
exerted	O
centrally	O
,	O
possibly	B-UNK
at	B-DISEASE
the	O
nucleus	B-UNK
ambiguus	O
,	O
or	O
peripherally	O
at	B-DISEASE
the	O
sinus	B-UNK
node	B-UNK
.	O

Epileptogenic	O
activity	B-UNK
of	O
folic	B-CHEMICAL
acid	I-CHEMICAL
after	O
drug	B-UNK
induces	B-UNK
SLE	O
(	O
folic	B-CHEMICAL
acid	I-CHEMICAL
and	O
epilepsy	B-DISEASE
)	O

OBJECTIVE	O
:	O
To	O
study	B-UNK
the	O
effect	B-UNK
of	O
folic	B-CHEMICAL
acid	I-CHEMICAL
-	O
containing	B-UNK
multivitamin	B-UNK
supplementation	B-UNK
in	O
epileptic	B-UNK
women	B-UNK
before	O
and	O
during	O
pregnancy	B-DISEASE
in	O
order	O
to	O
determine	B-UNK
the	O
rate	B-UNK
of	O
structural	B-UNK
birth	B-UNK
defects	B-UNK
and	O
epilepsy	B-DISEASE
-	O
related	B-UNK
side	O
effects	B-UNK
.	O
STUDY	B-UNK
DESIGN	B-UNK
:	O
First	O
a	O
randomised	B-UNK
trial	B-UNK
,	O
later	B-UNK
periconception	O
care	B-UNK
including	B-UNK
in	O
total	B-UNK
12225	O
females	O
.	O
RESULTS	B-UNK
:	O
Of	O
60	O
epileptic	B-UNK
women	B-UNK
with	O
periconceptional	O
folic	B-CHEMICAL
acid	I-CHEMICAL
(	O
0.8	B-UNK
mg)-containing	O
multivitamin	B-UNK
supplementation	B-UNK
,	O
no	O
one	O
developed	B-UNK
epilepsy	B-DISEASE
-	O
related	B-UNK
side	O
effects	B-UNK
during	O
the	O
periconception	O
period	B-UNK
.	O
One	O
epileptic	B-UNK
woman	B-UNK
delivered	O
a	O
newborn	O
with	O
cleft	B-DISEASE
lip	I-DISEASE
and	O
palate	O
.	O
Another	O
patient	B-UNK
exhibited	B-UNK
with	O
a	O
cluster	O
of	O
seizures	B-DISEASE
after	O
the	O
periconception	O
period	B-UNK
using	O
another	O
multivitamin	B-UNK
.	O
This	O
22-year	O
-	O
old	B-UNK
epileptic	B-UNK
woman	B-UNK
was	O
treated	B-UNK
continuously	B-UNK
by	O
carbamazepine	B-CHEMICAL
and	O
a	O
folic	B-CHEMICAL
acid	I-CHEMICAL
(	O
1	O
mg)-containing	O
multivitamin	B-UNK
from	O
the	O
20th	O
week	B-UNK
of	O
gestation	O
.	O
She	O
developed	B-UNK
status	B-DISEASE
epilepticus	I-DISEASE
and	O
later	B-UNK
symptoms	B-UNK
of	O
systemic	B-UNK
lupus	B-DISEASE
erythematodes	O
.	O
Her	O
pregnancy	B-DISEASE
ended	O
with	O
stillbirth	B-DISEASE
.	O
CONCLUSIONS	O
:	O
The	O
epileptic	B-UNK
pregnant	B-UNK
patient'	O
s	O
autoimmune	B-DISEASE
disease	I-DISEASE
(	O
probably	B-UNK
drug	B-UNK
-	O
induced	B-UNK
lupus	B-DISEASE
)	O
could	O
damage	B-UNK
the	O
blood	B-UNK
-	O
brain	B-UNK
barrier	B-UNK
,	O
therefore	O
the	O
therapeutic	B-UNK
dose	B-UNK
(	O
>	O
or	O
=	O
1	O
mg	B-UNK
)	O
of	O
folic	B-CHEMICAL
acid	I-CHEMICAL
triggered	O
a	O
cluster	O
of	O
seizures	B-DISEASE
.	O
Physiological	O
dose	B-UNK
(	O
<	O
1	O
mg	B-UNK
)	O
of	O
folic	B-CHEMICAL
acid	I-CHEMICAL
both	O
in	O
healthy	B-UNK
and	O
60	O
epileptic	B-UNK
women	B-UNK
,	O
all	O
without	O
any	O
autoimmune	B-DISEASE
disease	I-DISEASE
,	O
did	O
not	O
increase	B-UNK
the	O
risk	B-UNK
for	O
epileptic	B-UNK
seizures	B-DISEASE
.	O

Effects	O
of	O
cisapride	B-CHEMICAL
on	O
symptoms	B-UNK
and	O
postcibal	O
small	B-UNK
-	O
bowel	B-UNK
motor	B-UNK
function	B-UNK
in	O
patients	B-UNK
with	O
irritable	B-DISEASE
bowel	I-DISEASE
syndrome	I-DISEASE
.	O

BACKGROUND	O
:	O
Irritable	O
bowel	B-UNK
syndrome	B-UNK
is	O
a	O
common	B-UNK
cause	B-UNK
of	O
abdominal	B-DISEASE
pain	I-DISEASE
and	O
discomfort	O
and	O
may	O
be	O
related	B-UNK
to	O
disordered	O
gastrointestinal	B-UNK
motility	B-UNK
.	O
Our	O
aim	O
was	O
to	O
assess	B-UNK
the	O
effects	B-UNK
of	O
long	B-UNK
-	O
term	B-UNK
treatment	B-UNK
with	O
a	O
prokinetic	O
agent	B-UNK
,	O
cisapride	B-CHEMICAL
,	O
on	O
postprandial	O
jejunal	B-UNK
motility	B-UNK
and	O
symptoms	B-UNK
in	O
the	O
irritable	B-DISEASE
bowel	I-DISEASE
syndrome	I-DISEASE
(	O
IBS	O
)	O
.	O
METHODS	O
:	O
Thirty	O
-	O
eight	O
patients	B-UNK
with	O
IBS	O
(	O
constipation	B-DISEASE
-	O
predominant	B-UNK
,	O
n	B-UNK
=	O
17	B-DISEASE
;	O
diarrhoea	O
-	O
predominant	B-UNK
,	O
n	B-UNK
=	O
21	O
)	O
underwent	B-UNK
24-h	O
ambulatory	B-UNK
jejunal	B-UNK
manometry	O
before	O
and	O
after	O
12	O
week'	O
s	O
treatment	B-UNK
[	O
cisapride	B-CHEMICAL
,	O
5	O
mg	B-UNK
three	O
times	B-UNK
daily	B-UNK
(	O
n	B-UNK
=	O
19	O
)	O
or	O
placebo	B-UNK
(	O
n	B-UNK
=	O
19)].	O
RESULTS	B-UNK
:	O
In	O
diarrhoea	O
-	O
predominant	B-UNK
patients	B-UNK
significant	B-UNK
differences	B-UNK
in	O
contraction	B-UNK
characteristics	B-UNK
were	O
observed	B-UNK
between	O
the	O
cisapride	B-CHEMICAL
and	O
placebo	B-UNK
groups	B-UNK
.	O
In	O
cisapride	B-CHEMICAL
-	O
treated	B-UNK
diarrhoea	O
-	O
predominant	B-UNK
patients	B-UNK
the	O
mean	B-UNK
contraction	B-UNK
amplitude	B-UNK
was	O
higher	B-UNK
(	O
29.3	O
+	O
/-	O
3.2	O
versus	B-UNK
24.9	O
+	O
/-	O
2.6	O
mm	B-UNK
Hg	B-UNK
,	O
cisapride	B-CHEMICAL
versus	B-UNK
placebo	B-UNK
(	O
P	B-UNK
<	I-UNK
0.001	B-UNK
)	O
;	O
pretreatment	B-UNK
,	O
25.7	O
+	O
/-	O
6.0	O
mm	B-UNK
Hg	B-UNK
)	O
,	O
the	O
mean	B-UNK
contraction	B-UNK
duration	B-UNK
longer	B-UNK
(	O
3.4	B-UNK
+	O
/-	O
0.2	B-UNK
versus	B-UNK
3.0	O
+	O
/-	O
0.2	B-UNK
sec	O
,	O
cisapride	B-CHEMICAL
versus	B-UNK
placebo	B-UNK
(	O
P	B-UNK
<	I-UNK
0.001	B-UNK
)	O
;	O
pretreatment	B-UNK
,	O
3.1	O
+	O
/-	O
0.5	B-UNK
sec	O
)	O
,	O
and	O
the	O
mean	B-UNK
contraction	B-UNK
frequency	B-UNK
lower	B-UNK
(	O
2.0	B-UNK
+	O
/-	O
0.2	B-UNK
versus	B-UNK
2.5	B-UNK
+	O
/-	O
0.4	O
cont./min	O
,	O
cisapride	B-CHEMICAL
versus	B-UNK
placebo	B-UNK
(	O
P	B-UNK
<	I-UNK
0.001	B-UNK
)	O
;	O
pretreatment	B-UNK
,	O
2.5	B-UNK
+	O
/-	O
1.1	B-UNK
cont./min	O
]	O
than	O
patients	B-UNK
treated	B-UNK
with	O
placebo	B-UNK
.	O
No	O
significant	B-UNK
differences	B-UNK
in	O
jejunal	B-UNK
motility	B-UNK
were	O
found	B-UNK
in	O
the	O
constipation	B-DISEASE
-	O
predominant	B-UNK
IBS	O
group	B-UNK
.	O
Symptoms	O
were	O
assessed	B-UNK
by	O
using	O
a	O
visual	B-UNK
analogue	B-UNK
scale	B-UNK
before	O
and	O
after	O
treatment	B-UNK
.	O
Symptom	O
scores	B-UNK
relating	O
to	O
the	O
severity	B-UNK
of	O
constipation	B-DISEASE
were	O
lower	B-UNK
in	O
cisapride	B-CHEMICAL
-	O
treated	B-UNK
constipation	B-DISEASE
-	O
predominant	B-UNK
IBS	O
patients	B-UNK
[	O
score	B-UNK
,	O
54	O
+	O
/-	O
5	O
versus	B-UNK
67	O
+	O
/-	O
14	O
mm	B-UNK
,	O
cisapride	B-CHEMICAL
versus	B-UNK
placebo	B-UNK
(	O
P	B-UNK
<	I-UNK
0.05	O
)	O
;	O
pretreatment	B-UNK
,	O
62	O
+	O
/-	O
19	O
mm].	O
Diarrhoea	O
-	O
predominant	B-UNK
IBS	O
patients	B-UNK
had	O
a	O
higher	B-UNK
pain	B-UNK
score	B-UNK
after	O
cisapride	B-CHEMICAL
therapy	B-UNK
[	O
score	B-UNK
,	O
55	O
+	O
/-	O
15	O
versus	B-UNK
34	O
+	O
/-	O
12	O
mm	B-UNK
,	O
cisapride	B-CHEMICAL
versus	B-UNK
placebo	B-UNK
(	O
P	B-UNK
<	I-UNK
0.05	O
)	O
;	O
pretreatment	B-UNK
,	O
67	O
+	O
/-	O
19	O
mm].	O
CONCLUSION	O
:	O
Cisapride	O
affects	B-UNK
jejunal	B-UNK
contraction	B-UNK
characteristics	B-UNK
and	O
some	O
symptoms	B-UNK
in	O
IBS	O
.	O

Clarithromycin	O
-	O
induced	B-UNK
ventricular	B-DISEASE
tachycardia	I-DISEASE
.	O

Clarithromycin	O
is	O
a	O
relatively	B-UNK
new	B-UNK
macrolide	B-UNK
antibiotic	B-UNK
that	O
offers	O
twice	B-UNK
-	O
daily	B-UNK
dosing	B-UNK
.	O
It	O
differs	O
from	O
erythromycin	B-CHEMICAL
only	O
in	O
the	O
methylation	O
of	O
the	O
hydroxyl	O
group	B-UNK
at	B-DISEASE
position	O
6	O
.	O
Although	O
the	O
side	O
-	O
effect	B-UNK
profile	B-UNK
of	O
erythromycin	B-CHEMICAL
is	O
established	B-UNK
,	O
including	B-UNK
gastroenteritis	B-DISEASE
and	O
interactions	B-UNK
with	O
other	O
drugs	B-UNK
subject	B-UNK
to	O
hepatic	B-UNK
mixed	B-UNK
-	O
function	B-UNK
oxidase	B-UNK
metabolism	B-DISEASE
,	O
experience	B-UNK
with	O
the	O
newer	O
macrolides	B-CHEMICAL
is	O
still	O
being	O
recorded	B-UNK
.	O
Cardiotoxicity	O
has	O
been	O
demonstrated	B-UNK
after	O
both	O
intravenous	B-UNK
and	O
oral	B-UNK
administration	B-UNK
of	O
erythromycin	B-CHEMICAL
but	O
has	O
never	O
been	O
reported	B-UNK
with	O
the	O
newer	O
macrolides	B-CHEMICAL
.	O
We	O
report	B-UNK
a	O
case	B-UNK
of	O
ventricular	B-UNK
dysrhythmias	B-DISEASE
that	O
occurred	B-UNK
after	O
six	O
therapeutic	B-UNK
doses	B-UNK
of	O
clarithromycin	B-CHEMICAL
.	O
The	O
dysrhythmias	B-DISEASE
resolved	B-UNK
after	O
discontinuation	B-UNK
of	O
the	O
drug	B-UNK
.	O

Persistent	O
nephrogenic	O
diabetes	B-DISEASE
insipidus	I-DISEASE
following	B-UNK
lithium	B-CHEMICAL
therapy	B-UNK
.	O

We	O
report	B-UNK
the	O
case	B-UNK
of	O
a	O
patient	B-UNK
who	O
developed	B-UNK
severe	B-UNK
hypernatraemic	O
dehydration	B-DISEASE
following	B-UNK
a	O
head	B-UNK
injury	B-UNK
.	O
Ten	O
years	B-UNK
previously	B-UNK
he	O
had	O
been	O
diagnosed	B-UNK
to	O
have	O
lithium	B-CHEMICAL
-	O
induced	B-UNK
nephrogenic	O
diabetes	B-DISEASE
insipidus	I-DISEASE
,	O
and	O
lithium	B-CHEMICAL
therapy	B-UNK
had	O
been	O
discontinued	O
.	O
He	O
remained	B-UNK
thirsty	O
and	O
polyuric	O
despite	B-UNK
cessation	B-UNK
of	O
lithium	B-CHEMICAL
and	O
investigations	B-UNK
on	O
admission	O
showed	B-UNK
him	O
to	O
have	O
normal	B-UNK
osmoregulated	O
thirst	O
and	O
vasopressin	O
secretion	B-UNK
,	O
with	O
clear	B-UNK
evidence	B-UNK
of	O
nephrogenic	O
diabetes	B-DISEASE
insipidus	I-DISEASE
.	O
Lithium	O
induced	B-UNK
nephrogenic	O
diabetes	B-DISEASE
insipidus	I-DISEASE
is	O
considered	B-UNK
to	O
be	O
reversible	B-UNK
on	O
cessation	B-UNK
of	O
therapy	B-UNK
but	O
polyuria	B-DISEASE
persisted	B-UNK
in	O
this	O
patient	B-UNK
for	O
ten	B-DISEASE
years	B-UNK
after	O
lithium	B-CHEMICAL
was	O
stopped	O
.	O
We	O
discuss	O
the	O
possible	B-UNK
renal	B-UNK
mechanisms	B-UNK
and	O
the	O
implications	O
for	O
management	B-UNK
of	O
patients	B-UNK
with	O
lithium	B-CHEMICAL
-	O
induced	B-UNK
nephrogenic	O
diabetes	B-DISEASE
insipidus	I-DISEASE
.	O

Late	O
cardiotoxicity	B-DISEASE
after	O
treatment	B-UNK
for	O
a	O
malignant	B-UNK
bone	B-UNK
tumor	B-DISEASE
.	O

Cardiac	B-UNK
function	B-UNK
was	O
assessed	B-UNK
in	O
long	B-UNK
-	O
term	B-UNK
survivors	B-UNK
of	O
malignant	B-UNK
bone	B-UNK
tumors	B-UNK
who	O
were	O
treated	B-UNK
according	B-UNK
to	O
Rosen'	O
s	O
T5	O
or	O
T10	O
protocol	B-UNK
,	O
both	O
including	B-UNK
doxorubicin	B-CHEMICAL
.	O
Thirty	O
-	O
one	O
patients	B-UNK
,	O
age	B-UNK
10	O
-	O
45	O
years	B-UNK
(	O
median	B-UNK
age	B-UNK
17.8	O
years	B-UNK
)	O
were	O
evaluated	B-UNK
2.3	O
-	O
14.1	O
years	B-UNK
(	O
median	B-UNK
8.9	O
years	B-UNK
)	O
following	B-UNK
completion	O
of	O
treatment	B-UNK
.	O
Cumulative	O
doses	B-UNK
of	O
doxorubicin	B-CHEMICAL
were	O
225	O
-	O
550	O
mg	B-UNK
/	O
m2	O
(	O
median	B-UNK
dose	B-UNK
360	O
)	O
.	O
The	O
evaluation	B-UNK
consisted	B-UNK
of	O
a	O
history	B-UNK
,	O
physical	B-UNK
examination	B-UNK
,	O
electrocardiogram	O
(	O
ECG	B-UNK
)	O
,	O
signal	O
averaged	O
ECG	B-UNK
,	O
24-hour	B-UNK
ambulatory	B-UNK
ECG	I-UNK
,	O
echocardiography	O
and	O
radionuclide	O
angiography	B-UNK
.	O
Eighteen	O
of	O
31	O
(	O
58	O
%	O
)	O
patients	B-UNK
showed	B-UNK
cardiac	B-UNK
toxicity	B-UNK
,	O
defined	O
as	O
having	B-UNK
one	O
or	O
more	O
of	O
the	O
following	B-UNK
abnormalities	B-DISEASE
:	O
late	B-UNK
potentials	O
,	O
complex	B-UNK
ventricular	B-UNK
arrhythmias	B-DISEASE
,	O
left	B-UNK
ventricular	I-UNK
dilation	O
,	O
decreased	B-UNK
shortening	O
fraction	B-UNK
,	O
or	O
decreased	B-UNK
ejection	B-UNK
fraction	I-UNK
.	O
The	O
incidence	B-UNK
of	O
cardiac	B-UNK
abnormalities	B-DISEASE
increased	B-UNK
with	O
length	O
of	O
follow	B-UNK
-	O
up	O
(	O
P	B-UNK
<	I-UNK
or	O
=	O
.05	O
)	O
.	O
No	O
correlation	B-UNK
could	O
be	O
demonstrated	B-UNK
between	O
cumulative	B-UNK
dose	B-UNK
of	O
doxorubicin	B-CHEMICAL
and	O
cardiac	B-UNK
status	B-UNK
,	O
except	O
for	O
heart	B-UNK
rate	I-UNK
variability	O
.	O
When	O
adjusted	B-UNK
to	O
body	B-UNK
surface	O
area	B-UNK
,	O
the	O
left	B-UNK
ventricular	I-UNK
posterior	B-UNK
wall	B-UNK
thickness	B-UNK
(	O
LVPW	O
index	B-UNK
)	O
was	O
decreased	B-UNK
in	O
all	O
patients	B-UNK
.	O
The	O
incidence	B-UNK
of	O
doxorubicin	B-CHEMICAL
-	O
induced	B-UNK
cardiotoxicity	B-DISEASE
is	O
high	B-UNK
and	O
increases	B-UNK
with	O
follow	B-UNK
-	O
up	O
,	O
irrespective	O
of	O
cumulative	B-UNK
dose	B-UNK
.	O
Life	O
-	O
long	B-UNK
cardiac	B-UNK
follow	B-UNK
-	O
up	O
in	O
these	O
patients	B-UNK
is	O
warranted	O
.	O
The	O
results	B-UNK
of	O
our	O
study	B-UNK
suggest	B-UNK
that	O
heart	B-UNK
rate	I-UNK
variability	O
and	O
LVPW	O
index	B-UNK
could	O
be	O
sensitive	B-UNK
indicators	O
for	O
cardiotoxicity	B-DISEASE
.	O

Venous	O
complications	B-UNK
of	O
midazolam	B-CHEMICAL
versus	B-UNK
diazepam	B-CHEMICAL
.	O

Although	O
some	O
studies	B-UNK
have	O
suggested	B-UNK
fewer	B-UNK
venous	B-UNK
complications	B-UNK
are	O
associated	B-UNK
with	O
midazolam	B-CHEMICAL
than	O
with	O
diazepam	B-CHEMICAL
for	O
endoscopic	O
procedures	B-UNK
,	O
this	O
variable	B-UNK
has	O
not	O
been	O
well	O
documented	B-UNK
.	O
We	O
prospectively	B-UNK
evaluated	B-UNK
the	O
incidence	B-UNK
of	O
venous	B-UNK
complications	B-UNK
after	O
intravenous	B-UNK
injection	B-UNK
of	O
diazepam	B-CHEMICAL
or	O
midazolam	B-CHEMICAL
in	O
122	O
consecutive	B-UNK
patients	B-UNK
undergoing	B-UNK
colonoscopy	O
and	O
esophagogastroduodenoscopy	O
.	O
Overall	O
,	O
venous	B-UNK
complications	B-UNK
were	O
more	O
frequent	B-UNK
with	O
diazepam	B-CHEMICAL
(	O
22	O
of	O
62	O
patients	B-UNK
)	O
than	O
with	O
midazolam	B-CHEMICAL
(	O
4	O
of	O
60	O
patients	B-UNK
)	O
(	O
p	B-UNK
<	I-UNK
0.001	B-UNK
)	O
.	O
A	O
palpable	B-UNK
venous	B-UNK
cord	O
was	O
present	B-UNK
in	O
23	O
%	O
(	O
14	O
of	O
62	O
)	O
of	O
patients	B-UNK
in	O
the	O
diazepam	B-CHEMICAL
group	B-UNK
,	O
compared	B-UNK
with	O
2	B-DISEASE
%	O
(	O
1	O
of	O
60	O
patients	B-UNK
)	O
in	O
the	O
midazolam	B-CHEMICAL
group	B-UNK
(	O
p	B-UNK
<	I-UNK
0.002	O
)	O
.	O
Pain	O
at	B-DISEASE
the	O
injection	B-UNK
site	B-UNK
occurred	B-UNK
in	O
35	O
%	O
(	O
22	O
of	O
62	O
)	O
of	O
patients	B-UNK
in	O
the	O
diazepam	B-CHEMICAL
group	B-UNK
compared	B-UNK
with	O
7	O
%	O
(	O
4	O
of	O
60	O
patients	B-UNK
)	O
in	O
the	O
midazolam	B-CHEMICAL
group	B-UNK
(	O
p	B-UNK
<	I-UNK
0.001	B-UNK
)	O
.	O
Swelling	O
and	O
warmth	O
at	B-DISEASE
the	O
injection	B-UNK
site	B-UNK
were	O
not	O
significantly	B-UNK
different	B-UNK
between	O
the	O
two	O
groups	B-UNK
.	O
Smoking	O
,	O
nonsteroidal	B-UNK
anti-inflammatory	I-UNK
drug	B-UNK
use	B-UNK
,	O
intravenous	B-UNK
catheter	B-UNK
site	B-UNK
,	O
dwell	O
time	B-UNK
of	O
the	O
needle	O
,	O
alcohol	B-UNK
use	B-UNK
,	O
and	O
pain	B-UNK
during	O
the	O
injection	B-UNK
had	O
no	O
effect	B-UNK
on	O
the	O
incidence	B-UNK
of	O
venous	B-UNK
complications	B-UNK
.	O

Tetany	O
and	O
rhabdomyolysis	B-DISEASE
due	O
to	O
surreptitious	O
furosemide	B-CHEMICAL
--	O
importance	O
of	O
magnesium	B-CHEMICAL
supplementation	B-UNK
.	O

Diuretics	O
may	O
induce	B-UNK
hypokalemia	B-DISEASE
,	O
hypocalcemia	B-DISEASE
and	O
hypomagnesemia	B-DISEASE
.	O
While	O
severe	B-UNK
hypokalemia	B-DISEASE
may	O
cause	B-UNK
muscle	B-DISEASE
weakness	I-DISEASE
,	O
severe	B-UNK
hypomagnesemia	B-DISEASE
is	O
associated	B-UNK
with	O
muscle	B-UNK
spasms	B-DISEASE
and	O
tetany	B-DISEASE
which	O
cannot	O
be	O
corrected	O
by	O
potassium	B-CHEMICAL
and	O
calcium	B-CHEMICAL
supplementation	B-UNK
alone	O
(	O
1,2	O
)	O
.	O
Surreptitious	O
diuretic	B-UNK
ingestion	B-UNK
has	O
been	O
described	B-UNK
,	O
mainly	B-UNK
in	O
women	B-UNK
who	O
are	O
concerned	O
that	O
they	O
are	O
obese	O
or	O
edematous	O
.	O
Symptomatic	O
hypokalemia	B-DISEASE
has	O
been	O
reported	B-UNK
in	O
such	O
patients	B-UNK
(	O
3	O
-	O
7	O
)	O
and	O
in	O
one	O
case	B-UNK
hypocalcemia	B-DISEASE
was	O
observed	B-UNK
(	O
8)	B-UNK
,	O
but	O
the	O
effects	B-UNK
of	O
magnesium	B-CHEMICAL
depletion	O
were	O
not	O
noted	O
in	O
these	O
patients	B-UNK
.	O

Loss	O
of	O
glutamate	B-UNK
decarboxylase	O
mRNA	B-UNK
-	O
containing	B-UNK
neurons	B-UNK
in	O
the	O
rat	B-UNK
dentate	B-UNK
gyrus	B-UNK
following	B-UNK
pilocarpine	B-CHEMICAL
-	O
induced	B-UNK
seizures	B-DISEASE
.	O

In	O
situ	O
hybridization	B-UNK
methods	B-UNK
were	O
used	O
to	O
determine	B-UNK
if	O
glutamic	B-CHEMICAL
acid	I-CHEMICAL
decarboxylase	O
(	O
GAD	B-UNK
)	O
mRNA	B-UNK
-	O
containing	B-UNK
neurons	B-UNK
within	O
the	O
hilus	O
of	O
the	O
dentate	B-UNK
gyrus	B-UNK
are	O
vulnerable	O
to	O
seizure	B-DISEASE
-	O
induced	B-UNK
damage	B-UNK
in	O
a	O
model	B-UNK
of	O
chronic	B-UNK
seizures	B-DISEASE
.	O
Sprague	B-UNK
-	O
Dawley	B-UNK
rats	B-UNK
were	O
injected	B-UNK
intraperitoneally	B-UNK
with	O
pilocarpine	B-CHEMICAL
,	O
and	O
the	O
hippocampal	B-UNK
formation	B-UNK
was	O
studied	B-UNK
histologically	O
at	B-DISEASE
1	O
,	O
2	B-DISEASE
,	O
4	O
,	O
and	O
8	O
week	B-UNK
intervals	B-UNK
after	O
pilocarpine	B-CHEMICAL
-	O
induced	B-UNK
seizures	B-DISEASE
.	O
In	O
situ	O
hybridization	B-UNK
histochemistry	O
,	O
using	O
a	O
digoxigenin	B-CHEMICAL
-	O
labeled	B-UNK
GAD	B-UNK
cRNA	O
probe	O
,	O
demonstrated	B-UNK
a	O
substantial	O
decrease	B-UNK
in	O
the	O
number	B-UNK
of	O
GAD	B-UNK
mRNA	B-UNK
-	O
containing	B-UNK
neurons	B-UNK
in	O
the	O
hilus	O
of	O
the	O
dentate	B-UNK
gyrus	B-UNK
in	O
the	O
pilocarpine	B-CHEMICAL
-	O
treated	B-UNK
rats	B-UNK
as	O
compared	B-UNK
to	O
controls	B-UNK
at	B-DISEASE
all	O
time	B-UNK
intervals	B-UNK
.	O
Additional	O
neuronanatomical	O
studies	B-UNK
,	O
including	B-UNK
cresyl	B-CHEMICAL
violet	I-CHEMICAL
staining	B-UNK
,	O
neuronal	B-UNK
degeneration	B-UNK
methods	B-UNK
,	O
and	O
histochemical	B-UNK
localization	O
of	O
glial	O
fibrillary	O
acidic	O
protein	B-UNK
,	O
suggested	B-UNK
that	O
the	O
decrease	B-UNK
in	O
the	O
number	B-UNK
of	O
GAD	B-UNK
mRNA	B-UNK
-	O
containing	B-UNK
neurons	B-UNK
was	O
related	B-UNK
to	O
neuronal	B-UNK
loss	B-UNK
rather	O
than	O
to	O
a	O
decrease	B-UNK
in	O
GAD	B-UNK
mRNA	B-UNK
levels	B-UNK
.	O
The	O
loss	B-UNK
of	O
GAD	B-UNK
mRNA	B-UNK
-	O
containing	B-UNK
neurons	B-UNK
in	O
the	O
hilus	O
contrasted	O
with	O
the	O
relative	B-UNK
preservation	O
of	O
labeled	B-UNK
putative	B-UNK
basket	O
cells	B-UNK
along	O
the	O
inner	B-UNK
margin	O
of	O
the	O
granule	B-UNK
cell	B-UNK
layer	B-UNK
.	O
Quantitative	O
analyses	B-UNK
of	O
labeled	B-UNK
neurons	B-UNK
in	O
three	O
regions	B-UNK
of	O
the	O
dentate	B-UNK
gyrus	B-UNK
in	O
the	O
1	O
and	O
2	B-DISEASE
week	B-UNK
groups	B-UNK
showed	B-UNK
statistically	B-UNK
significant	I-UNK
decreases	B-UNK
in	O
the	O
mean	B-UNK
number	B-UNK
of	O
GAD	B-UNK
mRNA	B-UNK
-	O
containing	B-UNK
neurons	B-UNK
in	O
the	O
hilus	O
of	O
both	O
groups	B-UNK
of	O
experimental	B-UNK
animals	B-UNK
.	O
No	O
significant	B-UNK
differences	B-UNK
were	O
found	B-UNK
in	O
the	O
molecular	B-UNK
layer	B-UNK
or	O
the	O
granule	B-UNK
cell	B-UNK
layer	B-UNK
,	O
which	O
included	B-UNK
labeled	B-UNK
neurons	B-UNK
along	O
the	O
lower	B-UNK
margin	O
of	O
the	O
granule	B-UNK
cell	B-UNK
layer	B-UNK
.	O
The	O
results	B-UNK
indicate	B-UNK
that	O
,	O
in	O
this	O
model	B-UNK
,	O
a	O
subpopulation	O
of	O
GAD	B-UNK
mRNA	B-UNK
-	O
containing	B-UNK
neurons	B-UNK
within	O
the	O
dentate	B-UNK
gyrus	B-UNK
is	O
selectively	B-UNK
vulnerable	O
to	O
seizure	B-UNK
-	O
induced	B-UNK
damage	B-UNK
.	O
Such	O
differential	B-UNK
vulnerability	O
appears	B-UNK
to	O
be	O
another	O
indication	O
of	O
the	O
heterogeneity	O
of	O
GABA	O
neurons	B-UNK
.	O

Protective	B-UNK
effect	B-UNK
of	O
misoprostol	B-CHEMICAL
on	O
indomethacin	B-CHEMICAL
induced	B-UNK
renal	B-UNK
dysfunction	B-UNK
in	O
elderly	B-UNK
patients	B-UNK
.	O

OBJECTIVE	O
:	O
To	O
evaluate	B-UNK
the	O
possible	B-UNK
protective	B-UNK
effects	B-UNK
of	O
misoprostol	B-CHEMICAL
on	O
renal	B-UNK
function	B-UNK
in	O
hospitalized	O
elderly	B-UNK
patients	B-UNK
treated	B-UNK
with	O
indomethacin	B-CHEMICAL
.	O
METHODS	O
:	O
Forty	O
-	O
five	O
hospitalized	O
elderly	B-UNK
patients	B-UNK
(	O
>	O
65	O
years	B-UNK
old	B-UNK
)	O
who	O
required	B-UNK
therapy	B-UNK
with	O
nonsteroidal	B-UNK
antiinflammatory	I-UNK
drugs	B-UNK
(	O
NSAID	O
)	O
were	O
randomly	B-UNK
assigned	B-UNK
to	O
receive	B-UNK
either	O
indomethacin	B-CHEMICAL
,	O
150	O
mg	B-UNK
/	O
day	B-UNK
(	O
Group	B-UNK
A	O
)	O
,	O
or	O
indomethacin	B-CHEMICAL
150	O
mg	B-UNK
/	O
day	B-UNK
plus	B-UNK
misoprostol	B-CHEMICAL
at	B-DISEASE
0.6	B-UNK
mg	B-UNK
/	O
day	B-UNK
(	O
Group	B-UNK
B	B-UNK
)	O
.	O
Laboratory	B-UNK
variables	B-UNK
of	O
renal	B-DISEASE
function	B-UNK
[	O
serum	B-UNK
creatinine	B-CHEMICAL
,	O
blood	B-UNK
urea	B-CHEMICAL
nitrogen	B-CHEMICAL
(	O
BUN	O
)	O
and	O
electrolytes	B-CHEMICAL
]	O
were	O
evaluated	B-UNK
before	O
initiation	O
of	O
therapy	B-UNK
and	O
every	O
2	B-DISEASE
days	B-UNK
,	O
until	O
termination	O
of	O
the	O
study	B-UNK
(	O
a	O
period	B-UNK
of	O
at	B-DISEASE
least	O
6	O
days	B-UNK
)	O
.	O
Response	O
to	O
treatment	B-UNK
was	O
estimated	B-UNK
by	O
the	O
visual	B-UNK
analog	B-UNK
scale	B-UNK
for	O
severity	B-UNK
of	O
pain	B-DISEASE
.	O
RESULTS	B-UNK
:	O
Forty	O
-	O
two	O
patients	B-UNK
completed	O
the	O
study	B-UNK
,	O
22	O
in	O
Group	B-UNK
A	O
and	O
20	O
in	O
Group	B-UNK
B.	O
BUN	O
and	O
creatinine	B-CHEMICAL
increased	B-UNK
by	O
>	O
50	O
%	O
of	O
baseline	B-UNK
levels	B-UNK
in	O
54	O
and	O
45	O
%	O
of	O
Group	B-UNK
A	O
patients	B-UNK
,	O
respectively	O
,	O
compared	B-UNK
to	O
only	O
20	O
and	O
10	O
%	O
of	O
Group	B-UNK
B	B-UNK
patients	B-UNK
(	O
p	B-UNK
<	I-UNK
0.05	O
)	O
.	O
Potassium	O
(	O
K	O
)	O
increment	O
of	O
0.6	B-UNK
mEq	B-UNK
/	O
l	B-UNK
or	O
more	O
was	O
observed	B-UNK
in	O
50	O
%	O
of	O
Group	B-UNK
A	O
,	O
but	O
in	O
only	O
15	O
%	O
of	O
Group	B-UNK
B	B-UNK
patients	B-UNK
(	O
p	B-UNK
<	I-UNK
0.05	O
)	O
.	O
The	O
mean	B-UNK
increments	O
in	O
BUN	O
,	O
creatinine	B-CHEMICAL
,	O
and	O
K	O
were	O
reduced	B-UNK
by	O
63	O
,	O
80	O
,	O
and	O
42	O
%	O
,	O
respectively	O
,	O
in	O
Group	B-UNK
B	B-UNK
patients	B-UNK
compared	B-UNK
to	O
Group	B-UNK
A.	O
Response	O
to	O
treatment	B-UNK
did	O
not	O
differ	B-UNK
significantly	B-UNK
between	O
the	O
2	B-DISEASE
groups	B-UNK
.	O
CONCLUSION	O
:	O
Hospitalized	O
elderly	B-UNK
patients	B-UNK
are	O
at	B-DISEASE
risk	B-UNK
for	O
developing	O
indomethacin	B-CHEMICAL
related	B-UNK
renal	B-UNK
dysfunction	B-UNK
.	O
Addition	O
of	O
misoprostol	B-CHEMICAL
can	O
minimize	O
this	O
renal	B-UNK
impairment	B-UNK
without	O
affecting	O
pain	B-UNK
control	B-UNK
.	O

Nephrotoxic	O
effects	B-UNK
of	O
aminoglycoside	O
treatment	B-UNK
on	O
renal	B-UNK
protein	B-UNK
reabsorption	O
and	O
accumulation	B-UNK
.	O

To	O
quantify	O
the	O
effects	B-UNK
of	O
gentamicin	B-UNK
,	O
kanamycin	B-CHEMICAL
and	O
netilmicin	B-CHEMICAL
on	O
renal	B-UNK
protein	B-UNK
reabsorption	O
and	O
accumulation	B-UNK
,	O
these	O
drugs	B-UNK
were	O
administered	B-UNK
to	O
rats	B-UNK
intraperitoneally	B-UNK
(	O
30	O
mg	B-UNK
/	O
kg	B-UNK
/	O
day	B-UNK
)	O
for	O
7	O
,	O
14	O
or	O
21	O
days	B-UNK
.	O
Scanning	O
electron	B-UNK
microscopy	B-UNK
of	O
the	O
glomerular	B-UNK
endothelia	O
,	O
urinary	B-UNK
measurements	B-UNK
of	O
sodium	B-CHEMICAL
,	O
potassium	B-CHEMICAL
,	O
endogenous	B-UNK
lysozyme	B-UNK
,	O
N	B-UNK
-	O
acetyl	O
-	O
beta	B-UNK
-	O
D	B-UNK
-	O
glucosaminidase	O
(	O
NAG	B-UNK
)	O
as	O
well	O
as	O
clearance	B-UNK
and	O
accumulation	B-UNK
experiments	B-UNK
after	O
i.v	B-UNK
.	O
administration	B-UNK
of	O
egg	O
-	O
white	B-UNK
lysozyme	B-UNK
and	O
measurements	B-UNK
of	O
inulin	B-CHEMICAL
clearance	B-UNK
(	O
GFR	O
)	O
were	O
done	O
in	O
each	O
treatment	B-UNK
group	B-UNK
.	O
Gentamicin	O
administration	B-UNK
decreased	B-UNK
diameter	B-UNK
,	O
density	B-UNK
and	O
shape	O
of	O
endothelial	B-UNK
fenestrae	O
.	O
Kanamycin	O
and	O
netilmicin	B-CHEMICAL
appeared	B-UNK
to	O
have	O
no	O
effect	B-UNK
at	B-DISEASE
the	O
dose	B-UNK
used	O
.	O
All	O
three	O
aminoglycosides	B-CHEMICAL
decreased	B-UNK
GFR	O
and	O
increased	B-UNK
urinary	B-UNK
excretion	B-UNK
of	O
sodium	B-CHEMICAL
and	O
potassium	B-CHEMICAL
.	O
While	O
gentamicin	B-UNK
and	O
kanamycin	B-CHEMICAL
decreased	B-UNK
the	O
percentage	B-UNK
reabsorption	O
and	O
accumulation	B-UNK
of	O
lysozyme	B-UNK
after	O
i.v	B-UNK
.	O
administration	B-UNK
of	O
egg	O
-	O
white	B-UNK
lysozyme	B-UNK
netilmicin	B-CHEMICAL
had	O
no	O
effect	B-UNK
.	O
Daily	B-UNK
excretion	B-UNK
of	O
total	B-UNK
protein	B-UNK
,	O
endogenous	B-UNK
lysozyme	B-UNK
and	O
NAG	B-UNK
increased	B-UNK
only	O
after	O
treatment	B-UNK
with	O
kanamycin	B-CHEMICAL
and	O
gentamicin	B-UNK
.	O
Thus	O
,	O
aminoglycosides	B-CHEMICAL
may	O
act	O
as	O
nephrotoxicants	O
at	B-DISEASE
glomerular	B-UNK
and	O
/	O
or	O
tubular	B-UNK
level	B-UNK
inducing	B-UNK
impairment	B-UNK
of	O
renal	B-UNK
reabsorption	O
and	O
accumulation	B-UNK
of	O
proteins	B-UNK
.	O

Pharmacology	O
of	O
GYKI-41	O
099	O
(	O
chlorpropanol	O
,	O
Tobanum	O
)	O
a	O
new	B-UNK
potent	B-UNK
beta-adrenergic	B-UNK
antagonist	B-UNK
.	O

The	O
compound	B-UNK
GYKI-41	O
099	O
,	O
as	O
a	O
beta-adrenergic	B-UNK
antagonist	B-UNK
,	O
is	O
3	O
-	O
8	O
times	B-UNK
more	O
potent	B-UNK
than	O
propranolol	B-CHEMICAL
in	O
vitro	B-UNK
and	O
in	O
vivo	B-UNK
.	O
Its	O
antiarrhythmic	B-UNK
effectiveness	O
surpasses	O
that	O
of	O
propranolol	B-CHEMICAL
and	O
pindolol	B-CHEMICAL
inhibiting	O
the	O
ouabain	B-CHEMICAL
arrhythmia	B-DISEASE
in	O
dogs	B-UNK
and	O
cats	O
.	O
GYKI-41	O
900	O
has	O
a	O
negligible	O
cardiodepressant	O
activity	B-UNK
;	O
it	O
is	O
not	O
cardioselective	O
.	O
The	O
compound	B-UNK
shows	B-UNK
a	O
rapid	B-UNK
and	O
long	B-UNK
lasting	B-UNK
effect	B-UNK
.	O
There	O
was	O
a	O
prolonged	B-UNK
elimination	O
of	O
the	O
radioactivity	O
after	O
the	O
injection	B-UNK
of	O
14C-41	O
099	O
to	O
rats	B-UNK
and	O
dogs	B-UNK
.	O
The	O
half	O
life	B-UNK
of	O
the	O
unlabeled	O
substance	B-UNK
in	O
humans	O
was	O
more	O
than	O
10	O
hours	B-UNK
.	O

Chorea	O
associated	B-UNK
with	O
oral	B-UNK
contraception	O
.	O

Three	O
patients	B-UNK
developed	B-UNK
chorea	B-DISEASE
while	O
receiving	B-UNK
oral	B-UNK
contraceptives	O
.	O
Two	O
were	O
young	B-UNK
patients	B-UNK
whose	O
chorea	B-DISEASE
developed	B-UNK
long	B-UNK
after	O
treatment	B-UNK
had	O
been	O
started	B-UNK
and	O
disappeared	B-UNK
soon	O
after	O
it	O
had	O
been	O
discontinued	O
.	O
The	O
third	O
patient	B-UNK
had	O
acute	B-UNK
amphetamine	B-CHEMICAL
-	O
induced	B-UNK
chorea	B-DISEASE
after	O
prolonged	B-UNK
oral	B-UNK
contraception	O
.	O
Prolonged	O
administration	B-UNK
of	O
female	B-UNK
sex	O
hormones	B-CHEMICAL
is	O
a	O
possible	B-UNK
cause	B-UNK
of	O
chorea	B-DISEASE
in	O
women	B-UNK
who	O
have	O
not	O
previously	B-UNK
had	O
chorea	B-DISEASE
or	O
rheumatic	B-DISEASE
fever	I-DISEASE
.	O

Reversal	O
of	O
ammonia	B-CHEMICAL
coma	B-DISEASE
in	O
rats	B-UNK
by	O
L	B-UNK
-	O
dopa	O
:	O
a	O
peripheral	B-UNK
effect	B-UNK
.	O

Ammonia	O
coma	B-DISEASE
was	O
produced	B-UNK
in	O
rats	B-UNK
within	O
10	O
to	O
15	O
minutes	B-UNK
of	O
an	O
intraperitonealinjection	O
of	O
1.7	O
mmol	B-UNK
NH4CL	O
.	O
This	O
coma	B-DISEASE
was	O
prevented	B-UNK
with	O
1.68	O
mmol	B-UNK
L	B-UNK
-	O
dopa	O
given	B-UNK
by	O
gastric	B-UNK
intubation	O
15	O
minutes	B-UNK
before	O
the	O
ammonium	O
salt	B-UNK
injection	B-UNK
.	O
The	O
effect	B-UNK
of	O
L	B-UNK
-	O
dopa	O
was	O
correlated	B-UNK
with	O
a	O
decrease	B-UNK
in	O
blood	B-UNK
and	O
brain	B-UNK
ammonia	B-CHEMICAL
,	O
an	O
increase	B-UNK
in	O
brain	B-UNK
dopamine	B-CHEMICAL
,	O
and	O
an	O
increase	B-UNK
in	O
renal	B-UNK
excretion	B-UNK
of	O
ammonia	B-CHEMICAL
and	O
urea	B-CHEMICAL
.	O
Intraventricular	O
infusion	B-UNK
of	O
dopamine	B-CHEMICAL
sufficient	O
to	O
raise	O
the	O
brain	B-UNK
dopamine	B-CHEMICAL
to	O
the	O
same	O
extent	B-UNK
did	O
not	O
prevent	B-UNK
the	O
ammonia	B-CHEMICAL
coma	B-DISEASE
nor	O
affect	B-UNK
the	O
blood	B-UNK
and	O
brain	B-UNK
ammonia	B-CHEMICAL
concentrations	B-UNK
.	O
Bilateral	O
nephrectomy	O
eliminated	O
the	O
beneficial	B-UNK
effect	B-UNK
of	O
L	B-UNK
-	O
dopa	O
on	O
blood	B-UNK
and	O
brain	B-UNK
ammonia	B-CHEMICAL
and	O
the	O
ammonia	B-CHEMICAL
coma	B-DISEASE
was	O
not	O
prevented	B-UNK
.	O
Thus	O
,	O
the	O
reduction	B-UNK
in	O
blood	B-UNK
and	O
brain	B-UNK
ammonia	B-CHEMICAL
and	O
the	O
prevention	O
of	O
ammonia	B-CHEMICAL
coma	B-DISEASE
after	O
L	B-UNK
-	O
dopa	O
,	O
can	O
be	O
accounted	O
for	O
by	O
the	O
peripheral	B-UNK
effect	B-UNK
of	O
dopamine	B-CHEMICAL
on	O
renal	B-UNK
function	B-UNK
rather	O
than	O
its	O
central	B-UNK
action	B-UNK
.	O
These	O
results	B-UNK
provide	B-UNK
a	O
reasonable	O
explanation	B-UNK
for	O
the	O
beneficial	B-UNK
effects	B-UNK
observed	B-UNK
in	O
some	O
encephalopathic	O
patients	B-UNK
receiving	B-UNK
L	B-UNK
-	O
dopa	O
.	O

Heparin	O
-	O
induced	B-UNK
thrombocytopenia	B-DISEASE
after	O
liver	B-DISEASE
transplantation	B-UNK
.	O

BACKGROUND	O
:	O
Unfractionated	O
heparin	B-CHEMICAL
sodium	B-CHEMICAL
(	O
UFH	O
)	O
or	O
low	B-UNK
-	O
molecular	B-UNK
weight	B-UNK
heparin	B-CHEMICAL
(	O
LMWH	B-UNK
)	O
is	O
used	O
in	O
anticoagulant	O
protocols	B-UNK
at	B-DISEASE
several	O
institutions	O
to	O
prevent	B-UNK
thrombosis	B-DISEASE
after	O
liver	B-DISEASE
transplantation	B-UNK
.	O
Heparin	O
-	O
induced	B-UNK
thrombocytopenia	B-DISEASE
(	O
HIT	B-UNK
)	O
is	O
an	O
adverse	B-UNK
immune	B-UNK
-	O
mediated	B-UNK
reaction	B-UNK
to	O
heparin	B-CHEMICAL
,	O
resulting	B-UNK
in	O
platelet	B-UNK
count	I-UNK
decreases	B-UNK
of	O
more	O
than	O
50	O
%	O
.	O
The	O
frequencies	O
of	O
HIT	B-UNK
after	O
liver	B-DISEASE
transplantation	B-UNK
and	O
platelet	B-CHEMICAL
factor	I-CHEMICAL
4	I-CHEMICAL
/	O
heparin	B-CHEMICAL
-	O
reactive	B-UNK
antibody	B-UNK
(	O
HIT	B-UNK
antibody	B-UNK
)	O
positivity	O
in	O
liver	B-DISEASE
transplantation	B-UNK
patients	B-UNK
,	O
however	O
,	O
are	O
unknown	B-UNK
.	O
PATIENTS	O
AND	O
METHODS	O
:	O
The	O
32	O
men	O
and	O
20	O
women	B-UNK
underwent	B-UNK
living	B-UNK
donor	B-UNK
liver	B-DISEASE
transplantation	B-UNK
.	O
We	O
started	B-UNK
LMWH	B-UNK
(	O
25	O
IU	O
/	O
kg	B-UNK
/	O
h	B-UNK
)	O
on	O
postoperative	B-UNK
day	B-UNK
(	O
POD	O
)	O
1	O
,	O
switching	O
to	O
UFH	O
(	O
5000	O
U	B-UNK
/	O
d	B-UNK
)	O
on	O
POD	O
2	B-DISEASE
or	O
3	O
.	O
The	O
dose	B-UNK
of	O
UFH	O
was	O
changed	B-UNK
according	B-UNK
to	O
the	O
activated	B-UNK
clotting	O
time	B-UNK
level	B-UNK
.	O
HIT	B-UNK
antibody	B-UNK
levels	B-UNK
were	O
measured	B-UNK
the	O
day	B-UNK
before	O
surgery	B-UNK
and	O
on	O
POD	O
7	O
and	O
14	O
.	O
Platelet	B-UNK
count	B-UNK
was	O
measured	B-UNK
daily	B-UNK
for	O
3	O
weeks	B-UNK
.	O
RESULTS	B-UNK
:	O
The	O
average	B-UNK
platelet	B-UNK
counts	B-UNK
preoperatively	O
,	O
and	O
on	O
POD	O
7	O
,	O
14	O
,	O
and	O
21	O
were	O
65	O
,	O
88	O
,	O
149	O
,	O
and	O
169	O
x	B-UNK
10(9)/L	O
,	O
respectively	O
.	O
Two	O
patients	B-UNK
developed	B-UNK
hepatic	B-UNK
artery	B-UNK
thrombosis	B-DISEASE
on	O
POD	O
11	O
and	O
19	O
,	O
respectively	O
,	O
although	O
they	O
were	O
HIT	B-UNK
antibody	B-UNK
-	O
negative	B-UNK
and	O
their	O
platelet	B-UNK
counts	B-UNK
were	O
stable	B-UNK
.	O
In	O
2	B-DISEASE
other	O
patients	B-UNK
,	O
the	O
platelet	B-UNK
count	I-UNK
decreased	B-UNK
suddenly	O
from	O
107	O
x	B-UNK
10(9)/L	O
on	O
POD	O
4	O
to	O
65	O
x	B-UNK
10(9)/L	O
on	O
POD	O
6	O
and	O
from	O
76	O
x	B-UNK
10(9)/L	O
on	O
POD	O
7	O
to	O
33	O
x	B-UNK
10(9)/L	O
on	O
POD	O
9	O
,	O
respectively	O
.	O
The	O
heparin	B-CHEMICAL
-	O
induced	B-UNK
platelet	B-DISEASE
aggregation	I-DISEASE
test	B-UNK
was	O
negative	B-UNK
in	O
these	O
patients	B-UNK
.	O
The	O
percentage	B-UNK
of	O
HIT	B-UNK
antibody	B-UNK
-	O
positive	B-UNK
patients	B-UNK
was	O
0.5	B-UNK
%	O
preoperatively	O
,	O
5.6	O
%	O
on	O
POD	O
7	O
,	O
and	O
5.6	O
%	O
on	O
POD	O
14	O
.	O
None	O
of	O
the	O
subjects	B-UNK
/	O
patients	B-UNK
developed	B-UNK
UFH	O
-	O
related	B-UNK
HIT	B-UNK
.	O
CONCLUSIONS	O
:	O
In	O
our	O
series	B-UNK
,	O
the	O
occurrence	O
of	O
HIT	B-UNK
after	O
liver	B-DISEASE
transplantation	B-UNK
was	O
uncommon	O
.	O

PTU	O
-	O
associated	B-UNK
vasculitis	B-DISEASE
in	O
a	O
girl	O
with	O
Turner	O
Syndrome	B-UNK
and	O
Graves	O
'	O
disease	B-DISEASE
.	O

Palpable	O
purpura	B-DISEASE
is	O
a	O
concerning	B-UNK
clinical	B-UNK
finding	O
in	O
pediatric	B-UNK
patients	B-UNK
and	O
can	O
have	O
many	O
causes	B-UNK
,	O
including	B-UNK
infectious	O
and	O
autoimmune	O
processes	B-UNK
.	O
A	O
rare	B-UNK
cause	B-UNK
,	O
drug	B-UNK
-	O
induced	B-UNK
vasculitis	B-DISEASE
,	O
may	O
result	B-UNK
from	O
the	O
production	B-UNK
of	O
antineutrophil	O
cytoplasmic	B-UNK
antibodies	B-UNK
(	O
ANCAs	O
)	O
in	O
response	B-UNK
to	O
a	O
medication	B-UNK
.	O
We	O
report	B-UNK
a	O
girl	O
with	O
Turner	O
syndrome	B-UNK
and	O
Graves	O
'	O
disease	B-DISEASE
who	O
presented	B-UNK
with	O
palpable	B-UNK
purpuric	O
lesions	B-UNK
.	O
The	O
diagnosis	B-UNK
of	O
propylthiouracil	B-CHEMICAL
(	O
PTU)-associated	O
vasculitis	B-DISEASE
was	O
made	O
by	O
observation	B-UNK
of	O
consistent	B-UNK
clinical	B-UNK
features	B-UNK
,	O
the	O
detection	O
of	O
elevated	B-UNK
ANA	O
and	O
ANCA	O
in	O
the	O
blood	B-UNK
,	O
and	O
the	O
observed	B-UNK
clinical	B-UNK
resolution	B-UNK
of	O
symptoms	B-UNK
following	B-UNK
withdrawal	B-UNK
of	O
PTU	O
.	O
Subsequent	B-UNK
treatment	B-UNK
of	O
persistent	O
hyperthyroidism	B-DISEASE
with	O
radioablation	O
did	O
not	O
result	B-UNK
in	O
an	O
exacerbation	O
of	O
the	O
vasculitis	B-DISEASE
,	O
a	O
complication	B-UNK
described	B-UNK
in	O
prior	B-UNK
case	B-UNK
reports	B-UNK
.	O

Succinylcholine	O
-	O
induced	B-UNK
masseter	O
muscle	B-DISEASE
rigidity	I-DISEASE
during	O
bronchoscopic	O
removal	O
of	O
a	O
tracheal	B-UNK
foreign	O
body	B-UNK
.	O

Masseter	O
muscle	B-DISEASE
rigidity	I-DISEASE
during	O
general	B-UNK
anesthesia	B-UNK
is	O
considered	B-UNK
an	O
early	B-UNK
warning	O
sign	O
of	O
a	O
possible	B-UNK
episode	O
of	O
malignant	B-DISEASE
hyperthermia	I-DISEASE
.	O
The	O
decision	O
whether	O
to	O
continue	O
or	O
discontinue	O
the	O
procedure	B-UNK
depends	O
on	O
the	O
urgency	O
of	O
the	O
surgery	B-UNK
and	O
severity	B-UNK
of	O
masseter	O
muscle	B-DISEASE
rigidity	I-DISEASE
.	O
Here	O
,	O
we	O
describe	O
a	O
case	B-UNK
of	O
severe	B-UNK
masseter	O
muscle	B-DISEASE
rigidity	I-DISEASE
(	O
jaw	B-DISEASE
of	O
steel	B-CHEMICAL
)	O
after	O
succinylcholine	B-CHEMICAL
(	O
Sch	O
)	O
administration	B-UNK
during	O
general	B-UNK
anesthetic	B-UNK
management	B-UNK
for	O
rigid	O
bronchoscopic	O
removal	O
of	O
a	O
tracheal	B-UNK
foreign	O
body	B-UNK
.	O
Anesthesia	O
was	O
continued	B-UNK
uneventfully	O
with	O
propofol	B-CHEMICAL
infusion	B-UNK
while	O
all	O
facilities	O
were	O
available	B-UNK
to	O
detect	B-UNK
and	O
treat	O
malignant	B-DISEASE
hyperthermia	I-DISEASE
.	O

Minor	O
neurological	B-UNK
dysfunction	B-UNK
,	O
cognitive	B-UNK
development	B-UNK
,	O
and	O
somatic	O
development	B-UNK
at	B-DISEASE
the	O
age	B-UNK
of	O
3	O
to	O
7	O
years	B-UNK
after	O
dexamethasone	B-CHEMICAL
treatment	B-UNK
in	O
very	O
-	O
low	B-UNK
birth	B-UNK
-	O
weight	B-UNK
infants	B-UNK
.	O

The	O
objective	B-UNK
of	O
this	O
study	B-UNK
was	O
to	O
assess	B-UNK
minor	B-UNK
neurological	I-UNK
dysfunction	B-UNK
,	O
cognitive	B-UNK
development	B-UNK
,	O
and	O
somatic	O
development	B-UNK
after	O
dexamethasone	B-CHEMICAL
therapy	B-UNK
in	O
very	O
-	O
low	B-UNK
-	O
birthweight	O
infants	B-UNK
.	O
Thirty	O
-	O
three	O
children	B-UNK
after	O
dexamethasone	B-CHEMICAL
treatment	B-UNK
were	O
matched	B-UNK
to	O
33	O
children	B-UNK
without	O
dexamethasone	B-CHEMICAL
treatment	B-UNK
.	O
Data	O
were	O
assessed	B-UNK
at	B-DISEASE
the	O
age	B-UNK
of	O
3	O
-	O
7	O
years	B-UNK
.	O
Dexamethasone	O
was	O
started	B-UNK
between	O
the	O
7th	O
and	O
the	O
28th	O
day	B-UNK
of	O
life	B-UNK
over	O
7	O
days	B-UNK
with	O
a	O
total	B-UNK
dose	B-UNK
of	O
2.35	O
mg	B-UNK
/	O
kg	B-UNK
/	O
day	B-UNK
.	O
Exclusion	O
criteria	B-UNK
were	O
asphyxia	B-DISEASE
,	O
malformations	O
,	O
major	B-UNK
surgical	B-UNK
interventions	O
,	O
small	B-UNK
for	O
gestational	O
age	B-UNK
,	O
intraventricular	O
haemorrhage	B-UNK
grades	O
III	B-UNK
and	O
IV	B-UNK
,	O
periventricular	O
leukomalacia	B-DISEASE
,	O
and	O
severe	B-UNK
psychomotor	B-UNK
retardation	B-UNK
.	O
Each	O
child	B-UNK
was	O
examined	B-UNK
by	O
a	O
neuropediatrician	O
for	O
minor	B-UNK
neurological	I-UNK
dysfunctions	O
and	O
tested	B-UNK
by	O
a	O
psychologist	O
for	O
cognitive	B-UNK
development	B-UNK
with	O
a	O
Kaufman	O
Assessment	B-UNK
Battery	O
for	O
Children	O
and	O
a	O
Draw	O
-	O
a	O
-	O
Man	O
Test	O
.	O
There	O
were	O
no	O
differences	B-UNK
in	O
demographic	O
data	B-UNK
,	O
growth	B-UNK
,	O
and	O
socio-economic	O
status	B-UNK
between	O
the	O
two	O
groups	B-UNK
.	O
Fine	O
motor	B-UNK
skills	O
and	O
gross	B-UNK
motor	B-UNK
function	B-UNK
were	O
significantly	B-UNK
better	B-UNK
in	O
the	O
control	B-UNK
group	B-UNK
(	O
p<0.01	O
)	O
.	O
In	O
the	O
Draw	O
-	O
a	O
-	O
Man	O
Test	O
,	O
the	O
control	B-UNK
group	B-UNK
showed	B-UNK
better	B-UNK
results	B-UNK
(	O
p<0.001	O
)	O
.	O
There	O
were	O
no	O
differences	B-UNK
in	O
development	B-UNK
of	O
speech	O
,	O
social	O
development	B-UNK
,	O
and	O
the	O
Kaufman	O
Assessment	B-UNK
Battery	O
for	O
Children	O
.	O
After	O
dexamethasone	B-CHEMICAL
treatment	B-UNK
,	O
children	B-UNK
showed	B-UNK
a	O
higher	B-UNK
rate	B-UNK
of	O
minor	B-UNK
neurological	I-UNK
dysfunctions	O
.	O
Neurological	O
development	B-UNK
was	O
affected	B-UNK
even	O
without	O
neurological	B-UNK
diagnosis	B-UNK
.	O
Further	O
long	B-UNK
-	O
term	B-UNK
follow	B-UNK
-	O
up	O
studies	B-UNK
will	O
be	O
necessary	O
to	O
fully	B-UNK
evaluate	B-UNK
the	O
impact	B-UNK
of	O
dexamethasone	B-CHEMICAL
on	O
neurological	B-UNK
and	O
cognitive	B-UNK
development	B-UNK
.	O

Force	O
overflow	B-UNK
and	O
levodopa	B-CHEMICAL
-	O
induced	B-UNK
dyskinesias	B-DISEASE
in	O
Parkinson'	O
s	O
disease	B-DISEASE
.	O

We	O
assessed	B-UNK
force	B-UNK
coordination	O
of	O
the	O
hand	B-DISEASE
in	O
Parkinson'	O
s	O
disease	B-DISEASE
and	O
its	O
relationship	B-UNK
to	O
motor	B-UNK
complications	B-UNK
of	O
levodopa	B-CHEMICAL
therapy	B-UNK
,	O
particularly	O
to	O
levodopa	B-CHEMICAL
-	O
induced	B-UNK
dyskinesias	B-DISEASE
(	O
LID	B-UNK
)	O
.	O
We	O
studied	B-UNK
two	O
groups	B-UNK
of	O
Parkinson'	O
s	O
disease	B-DISEASE
patients	B-UNK
with	O
(	O
Parkinson'	O
s	O
disease	B-DISEASE
+	O
LID	B-UNK
,	O
n	B-UNK
=	O
23	O
)	O
and	O
without	O
levodopa	B-CHEMICAL
-	O
induced	B-UNK
dyskinesias	B-DISEASE
(	O
Parkinson'	O
s	O
disease	B-DISEASE
-	O
LID	B-UNK
,	O
n	B-UNK
=	O
10	O
)	O
,	O
and	O
age	B-UNK
-	O
matched	B-UNK
healthy	B-UNK
controls	B-UNK
.	O
The	O
motor	B-UNK
score	B-UNK
of	O
the	O
Unified	O
Parkinson'	O
s	O
Disease	B-UNK
Rating	B-UNK
Scale	I-UNK
,	O
a	O
dyskinesia	B-DISEASE
score	B-UNK
and	O
force	B-UNK
in	O
a	O
grip	O
-	O
lift	O
paradigm	B-UNK
were	O
assessed	B-UNK
ON	O
and	O
OFF	O
levodopa	B-CHEMICAL
.	O
A	O
pathological	B-UNK
increase	B-UNK
of	O
forces	O
was	O
seen	B-UNK
in	O
ON	O
-	O
state	B-UNK
in	O
Parkinson'	O
s	O
disease	B-DISEASE
+	O
LID	B-UNK
only	O
.	O
In	O
Parkinson'	O
s	O
disease	B-DISEASE
+	O
LID	B-UNK
,	O
the	O
force	B-UNK
involved	B-UNK
in	O
pressing	O
down	O
the	O
object	B-UNK
before	O
lifting	O
was	O
significantly	B-UNK
increased	B-UNK
by	O
levodopa	B-CHEMICAL
(	O
by	O
61	O
%	O
,	O
P	B-UNK
<	I-UNK
0.05	O
)	O
.	O
An	O
overshooting	O
of	O
peak	B-UNK
grip	B-UNK
force	I-UNK
by	O
51	O
%	O
(	O
P	B-UNK
<	I-UNK
0.05	O
)	O
and	O
of	O
static	O
grip	B-UNK
force	I-UNK
by	O
45	O
%	O
(	O
P	B-UNK
<	I-UNK
0.01	B-UNK
)	O
was	O
observed	B-UNK
in	O
the	O
ON-	O
compared	B-UNK
with	O
the	O
OFF	O
-	O
drug	B-UNK
condition	B-UNK
.	O
In	O
contrast	B-UNK
,	O
no	O
excessive	B-UNK
force	B-UNK
was	O
found	B-UNK
in	O
Parkinson'	O
s	O
disease	B-DISEASE
-	O
LID	B-UNK
.	O
Peak	O
grip	B-UNK
force	I-UNK
in	O
ON	O
-	O
state	B-UNK
was	O
140	O
%	O
(	O
P	B-UNK
<	I-UNK
0.05	O
)	O
higher	B-UNK
in	O
Parkinson'	O
s	O
disease	B-DISEASE
+	O
LID	B-UNK
than	O
in	O
Parkinson'	O
s	O
disease	B-DISEASE
-	O
LID	B-UNK
,	O
while	O
static	O
grip	B-UNK
force	I-UNK
was	O
increased	B-UNK
by	O
138	O
%	O
(	O
P	B-UNK
<	I-UNK
0.01	B-UNK
)	O
between	O
groups	B-UNK
.	O
Severity	O
of	O
peak	B-UNK
-	O
dose	B-UNK
dyskinesias	B-DISEASE
was	O
strongly	B-UNK
correlated	B-UNK
with	O
grip	B-UNK
force	I-UNK
in	O
ON	O
-	O
state	B-UNK
(	O
r	B-UNK
=	I-UNK
0.79	O
with	O
peak	B-UNK
force	B-UNK
,	O
P	B-UNK
<	I-UNK
0.01	B-UNK
)	O
.	O
No	O
correlation	B-UNK
was	O
observed	B-UNK
between	O
forces	O
and	O
the	O
motor	B-UNK
score	B-UNK
as	O
well	O
as	O
with	O
the	O
daily	B-UNK
dose	B-UNK
of	O
dopaminergic	B-UNK
medication	B-UNK
.	O
Force	O
excess	B-UNK
was	O
only	O
observed	B-UNK
in	O
patients	B-UNK
with	O
LID	B-UNK
and	O
motor	B-UNK
fluctuations	B-UNK
.	O
A	O
close	O
relationship	B-UNK
was	O
seen	B-UNK
between	O
the	O
overshooting	O
of	O
forces	O
and	O
dyskinesias	B-DISEASE
in	O
the	O
ON	O
-	O
drug	B-UNK
condition	B-UNK
.	O
We	O
postulate	O
that	O
both	O
LID	B-UNK
and	O
grip	B-UNK
force	I-UNK
excess	B-UNK
share	O
common	B-UNK
pathophysiological	O
mechanisms	B-UNK
related	B-UNK
to	O
motor	B-UNK
fluctuations	B-UNK
.	O

Postinfarction	O
ventricular	B-UNK
septal	B-DISEASE
defect	I-DISEASE
associated	B-UNK
with	O
long	B-UNK
-	O
term	B-UNK
steroid	B-UNK
therapy	B-UNK
.	O

Two	O
cases	B-UNK
of	O
postinfarction	O
ventricular	B-DISEASE
septal	I-DISEASE
rupture	I-DISEASE
in	O
patients	B-UNK
on	O
long	B-UNK
-	O
term	B-UNK
steroid	B-UNK
therapy	B-UNK
are	O
presented	B-UNK
and	O
the	O
favourable	O
outcome	B-UNK
in	O
both	O
cases	B-UNK
described	B-UNK
.	O
A	O
possible	B-UNK
association	B-UNK
between	O
steroid	B-UNK
therapy	B-UNK
and	O
subsequent	B-UNK
postinfarction	O
septal	O
rupture	B-DISEASE
is	O
discussed	O
.	O

Angioedema	O
associated	B-UNK
with	O
droperidol	B-CHEMICAL
administration	B-UNK
.	O

Angioedema	O
,	O
also	O
known	B-UNK
as	O
angioneurotic	O
edema	B-DISEASE
or	O
Quincke'	O
s	O
disease	B-DISEASE
,	O
is	O
a	O
well	O
-	O
demarcated	O
,	O
localized	O
edema	B-DISEASE
involving	B-UNK
the	O
subcutaneous	B-UNK
tissues	B-UNK
that	O
may	O
cause	B-UNK
upper	B-UNK
-	O
airway	B-DISEASE
obstruction	I-DISEASE
.	O
We	O
report	B-UNK
the	O
case	B-UNK
of	O
a	O
previously	B-UNK
healthy	B-UNK
19-year	O
-	O
old	B-UNK
man	B-UNK
with	O
no	O
known	B-UNK
drug	B-UNK
allergies	B-DISEASE
in	O
whom	O
angioedema	B-DISEASE
with	O
significant	B-UNK
tongue	B-DISEASE
swelling	B-DISEASE
and	O
protrusion	O
developed	B-UNK
within	O
10	O
minutes	B-UNK
of	O
the	O
administration	B-UNK
of	O
a	O
single	B-UNK
IV	B-UNK
dose	B-UNK
of	O
droperidol	B-CHEMICAL
.	O

Clarithromycin	O
-	O
associated	B-UNK
visual	B-UNK
hallucinations	B-DISEASE
in	O
a	O
patient	B-UNK
with	O
chronic	B-DISEASE
renal	I-DISEASE
failure	I-DISEASE
on	O
continuous	B-UNK
ambulatory	B-UNK
peritoneal	O
dialysis	O
.	O

Visual	B-UNK
hallucinations	B-DISEASE
are	O
a	O
rare	B-UNK
event	B-UNK
in	O
chronic	B-DISEASE
renal	I-DISEASE
failure	I-DISEASE
and	O
not	O
related	B-UNK
to	O
uremia	B-DISEASE
per	O
se	O
.	O
Unreported	O
in	O
the	O
literature	B-UNK
is	O
visual	B-UNK
hallucinations	B-DISEASE
occurring	B-UNK
in	O
association	B-UNK
with	O
the	O
new	B-UNK
macrolide	B-UNK
antibiotic	B-UNK
,	O
clarithromycin	B-CHEMICAL
.	O
We	O
describe	O
such	O
a	O
case	B-UNK
in	O
a	O
patient	B-UNK
with	O
end	B-DISEASE
-	I-DISEASE
stage	I-DISEASE
renal	I-DISEASE
disease	I-DISEASE
(	O
ESRD	O
)	O
maintained	O
on	O
continuous	B-UNK
ambulatory	B-UNK
peritoneal	O
dialysis	O
(	O
CAPD	O
)	O
.	O
The	O
combination	B-UNK
of	O
a	O
relatively	B-UNK
high	B-UNK
dose	B-UNK
of	O
clarithromycin	B-CHEMICAL
in	O
face	O
of	O
chronic	B-DISEASE
renal	I-DISEASE
failure	I-DISEASE
in	O
a	O
functionally	O
anephric	O
patient	B-UNK
,	O
with	O
underlying	B-UNK
aluminum	B-CHEMICAL
intoxication	O
,	O
may	O
have	O
facilitated	O
the	O
appearance	O
of	O
this	O
neurotoxic	B-UNK
side	O
effect	B-UNK
.	O
It	O
is	O
important	B-UNK
to	O
understand	O
the	O
pharmacokinetics	O
of	O
medications	B-UNK
in	O
face	O
of	O
chronic	B-DISEASE
renal	I-DISEASE
failure	I-DISEASE
,	O
the	O
possibility	O
of	O
drug	B-UNK
interactions	B-UNK
,	O
and	O
how	O
these	O
factors	B-UNK
should	O
help	O
guide	O
medication	B-UNK
therapy	B-UNK
in	O
the	O
ESRD	O
patient	B-UNK
.	O

Acute	B-UNK
renal	B-DISEASE
toxicity	B-UNK
of	O
doxorubicin	B-CHEMICAL
(	O
adriamycin)-loaded	O
cyanoacrylate	O
nanoparticles	B-UNK
.	O

Acute	B-UNK
doxorubicin	B-CHEMICAL
-	O
loaded	B-UNK
nanoparticle	O
(	O
DXNP	O
)	O
renal	B-UNK
toxicity	B-UNK
was	O
explored	O
in	O
both	O
normal	B-UNK
rats	B-UNK
and	O
rats	B-UNK
with	O
experimental	B-UNK
glomerulonephritis	B-DISEASE
.	O
In	O
normal	B-UNK
rats	B-UNK
,	O
2/6	O
rats	B-UNK
given	I-UNK
free	B-UNK
doxorubicin	B-CHEMICAL
(	O
DX	B-UNK
)	O
(	O
5	O
mg	B-UNK
/	O
kg	B-UNK
)	O
died	B-UNK
within	O
one	O
week	B-UNK
,	O
whereas	O
all	O
control	B-UNK
animals	B-UNK
and	O
all	O
rats	B-UNK
having	B-UNK
received	B-UNK
free	B-UNK
NP	B-UNK
or	O
DXNP	O
survived	O
.	O
A	O
3	O
times	B-UNK
higher	B-UNK
proteinuria	B-UNK
appeared	B-UNK
in	O
animals	B-UNK
treated	B-UNK
with	O
DXNP	O
than	O
in	O
those	O
treated	B-UNK
with	O
DX	B-UNK
.	O
Free	O
NP	B-UNK
did	O
not	O
provoke	O
any	O
proteinuria	B-DISEASE
.	O
Two	O
hr	B-UNK
post-injection	O
,	O
DXNP	O
was	O
2.7	B-UNK
times	B-UNK
more	O
concentrated	O
in	O
kidneys	B-UNK
than	O
free	B-UNK
DX	B-UNK
(	O
p	B-UNK
<	I-UNK
0.025	O
)	O
.	O
In	O
rats	B-UNK
with	O
immune	B-UNK
experimental	B-UNK
glomerulonephritis	B-DISEASE
,	O
5/6	O
rats	B-UNK
given	I-UNK
DX	B-UNK
died	B-UNK
within	O
7	O
days	B-UNK
,	O
in	O
contrast	B-UNK
to	O
animals	B-UNK
treated	B-UNK
by	O
DXNP	O
,	O
NP	B-UNK
,	O
or	O
untreated	B-UNK
,	O
which	O
all	O
survived	O
.	O
Proteinuria	O
appeared	B-UNK
in	O
all	O
series	B-UNK
,	O
but	O
was	O
2	B-DISEASE
-	O
5	O
times	B-UNK
more	O
intense	O
(	O
p	B-UNK
>	O
0.001	B-UNK
)	O
and	O
prolonged	B-UNK
after	O
doxorubicin	B-CHEMICAL
treatment	B-UNK
(	O
400	O
-	O
700	O
mg	B-UNK
/	O
day	B-UNK
)	O
,	O
without	O
significant	B-UNK
difference	B-UNK
between	O
DXNP	O
and	O
DX	B-UNK
.	O
Rats	O
treated	B-UNK
by	O
unloaded	O
NP	B-UNK
behaved	O
as	O
controls	B-UNK
.	O
These	O
results	B-UNK
demonstrate	B-UNK
that	O
,	O
in	O
these	O
experimental	B-UNK
conditions	B-UNK
,	O
DXNP	O
killed	O
less	O
animals	B-UNK
than	O
free	B-UNK
DX	B-UNK
,	O
despite	B-UNK
of	O
an	O
enhanced	B-UNK
renal	B-UNK
toxicity	B-UNK
of	O
the	O
former	O
.	O
Both	O
effects	B-UNK
(	O
better	B-UNK
survival	B-UNK
and	O
nephrosis	B-DISEASE
)	O
are	O
most	O
probably	B-UNK
related	B-UNK
to	O
an	O
enhanced	B-UNK
capture	O
of	O
DXNP	O
by	O
cells	B-UNK
of	O
the	O
mononuclear	O
phagocyte	O
system	B-UNK
,	O
including	B-UNK
mesangial	B-UNK
cells	B-UNK
.	O

Etoposide	O
-	O
related	B-UNK
myocardial	B-DISEASE
infarction	I-DISEASE
.	O

The	O
occurrence	O
of	O
a	O
myocardial	B-DISEASE
infarction	I-DISEASE
is	O
reported	B-UNK
after	O
chemotherapy	B-UNK
containing	B-UNK
etoposide	B-CHEMICAL
,	O
in	O
a	O
man	B-UNK
with	O
no	O
risk	B-UNK
factors	I-UNK
for	O
coronary	B-UNK
heart	B-DISEASE
disease	I-DISEASE
.	O
Possible	O
causal	O
mechanisms	B-UNK
are	O
discussed	O
.	O

Subjective	O
assessment	B-UNK
of	O
sexual	B-DISEASE
dysfunction	I-DISEASE
of	O
patients	B-UNK
on	O
long	B-UNK
-	O
term	B-UNK
administration	B-UNK
of	O
digoxin	B-CHEMICAL
.	O

Various	O
data	B-UNK
suggest	B-UNK
that	O
male	B-UNK
patients	B-UNK
who	O
have	O
received	B-UNK
digoxin	B-CHEMICAL
on	O
a	O
longterm	O
basis	B-UNK
have	O
increased	B-UNK
levels	B-UNK
of	O
serum	B-UNK
estrogen	B-UNK
and	O
decreased	B-UNK
levels	B-UNK
of	O
plasma	B-UNK
testosterone	B-CHEMICAL
and	O
luteinizing	B-CHEMICAL
hormone	I-CHEMICAL
(	O
LH	O
)	O
.	O
This	O
study	B-UNK
was	O
undertaken	O
to	O
investigate	O
the	O
links	O
between	O
the	O
long	B-UNK
-	O
term	B-UNK
administration	B-UNK
of	O
digoxin	B-CHEMICAL
therapy	B-UNK
and	O
sexual	B-UNK
behavior	B-UNK
,	O
and	O
the	O
effect	B-UNK
of	O
digoxin	B-CHEMICAL
on	O
plasma	B-UNK
levels	B-UNK
of	O
estradiol	B-CHEMICAL
,	O
testosterone	B-CHEMICAL
,	O
and	O
LH	O
.	O
The	O
patients	B-UNK
of	O
the	O
study	B-UNK
and	O
control	B-UNK
group	B-UNK
(	O
without	O
digoxin	B-CHEMICAL
)	O
were	O
of	O
similar	B-UNK
cardiac	B-UNK
functional	B-UNK
capacity	B-UNK
and	O
age	B-UNK
(	O
25	O
-	O
40	O
years	B-UNK
)	O
and	O
were	O
randomly	B-UNK
selected	O
from	O
the	O
rheumatic	B-DISEASE
heart	I-DISEASE
disease	I-DISEASE
patients	B-UNK
.	O
A	O
subjective	B-UNK
assessment	B-UNK
of	O
sexual	B-UNK
behavior	B-UNK
in	O
the	O
study	B-UNK
and	O
control	B-UNK
groups	B-UNK
was	O
carried	O
out	O
,	O
using	O
parameters	B-UNK
such	O
as	O
sexual	B-UNK
desire	B-UNK
,	O
sexual	B-UNK
excitement	O
,	O
and	O
frequency	B-UNK
of	O
sexual	B-UNK
relations	O
.	O
Personal	O
interviews	O
and	O
a	O
questionnaire	O
were	O
also	O
used	O
for	O
the	O
evaluation	B-UNK
of	O
sexual	B-UNK
behavior	B-UNK
.	O
The	O
findings	B-UNK
support	B-UNK
the	O
reports	B-UNK
concerning	B-UNK
digoxin	B-CHEMICAL
effect	B-UNK
on	O
plasma	B-UNK
estradiol	B-CHEMICAL
,	O
testosterone	B-CHEMICAL
,	O
and	O
LH	O
.	O
The	O
differences	B-UNK
in	O
the	O
means	O
were	O
significant	B-UNK
.	O
Tests	O
used	O
to	O
evaluate	B-UNK
the	O
changes	B-UNK
in	O
sexual	B-UNK
behavior	B-UNK
showed	B-UNK
a	O
significant	B-UNK
decrease	B-UNK
in	O
sexual	B-UNK
desire	B-UNK
,	O
sexual	B-UNK
excitement	O
phase	B-UNK
(	O
erection	O
)	O
,	O
and	O
frequency	B-UNK
of	O
sexual	B-UNK
relations	O
in	O
the	O
study	B-UNK
group	B-UNK
.	O

Fatal	B-UNK
aplastic	B-DISEASE
anemia	I-DISEASE
due	O
to	O
indomethacin	B-CHEMICAL
--	O
lymphocyte	B-UNK
transformation	O
tests	B-UNK
in	O
vitro	B-UNK
.	O

Although	O
indomethacin	B-CHEMICAL
has	O
been	O
implicated	B-UNK
as	O
a	O
possible	B-UNK
cause	B-UNK
of	O
aplastic	B-DISEASE
anemia	I-DISEASE
on	O
the	O
basis	B-UNK
of	O
a	O
few	O
clinical	B-UNK
observations	B-UNK
,	O
its	O
role	B-UNK
has	O
not	O
been	O
definitely	O
established	B-UNK
.	O
A	O
case	B-UNK
of	O
fatal	B-UNK
aplastic	B-DISEASE
anemia	I-DISEASE
is	O
described	B-UNK
in	O
which	O
no	O
drugs	B-UNK
other	O
than	O
allopurinol	B-CHEMICAL
and	O
indomethacin	B-CHEMICAL
were	O
given	B-UNK
.	O
Indomethacin	O
was	O
first	O
given	B-UNK
four	O
weeks	B-UNK
prior	B-UNK
to	O
the	O
onset	B-UNK
of	O
symptoms	B-UNK
.	O
A	O
positive	B-UNK
lymphocyte	B-UNK
transformation	O
test	B-UNK
with	O
indomethacin	B-CHEMICAL
in	O
vitro	B-UNK
further	O
substantiates	O
the	O
potential	B-UNK
role	B-UNK
of	O
this	O
drug	B-UNK
in	O
causing	B-UNK
aplastic	B-DISEASE
anemia	I-DISEASE
in	O
a	O
susceptible	B-UNK
patient	B-UNK
.	O
Fortunately	O
,	O
this	O
seems	O
to	O
be	O
a	O
very	O
rare	B-UNK
complication	B-UNK
.	O

Plasma	B-UNK
and	O
urinary	B-UNK
lipids	B-CHEMICAL
and	O
lipoproteins	O
during	O
the	O
development	B-UNK
of	O
nephrotic	B-DISEASE
syndrome	I-DISEASE
induced	B-UNK
in	O
the	O
rat	B-UNK
by	O
puromycin	B-CHEMICAL
aminonucleoside	I-CHEMICAL
.	O

This	O
study	B-UNK
was	O
undertaken	O
to	O
ascertain	O
whether	O
the	O
alterations	B-UNK
of	O
plasma	B-UNK
lipoproteins	O
found	B-UNK
in	O
nephrotic	B-DISEASE
syndrome	I-DISEASE
induced	B-UNK
by	O
puromycin	B-CHEMICAL
aminonucleoside	I-CHEMICAL
were	O
due	O
to	O
nephrotic	B-DISEASE
syndrome	I-DISEASE
per	O
se	O
,	O
or	O
,	O
at	B-DISEASE
least	O
in	O
part	O
,	O
to	O
the	O
aminonucleoside	O
.	O
The	O
purpose	O
of	O
the	O
present	B-UNK
study	B-UNK
was	O
to	O
investigate	O
the	O
changes	B-UNK
in	O
plasma	B-UNK
and	O
urinary	B-UNK
lipoproteins	O
during	O
the	O
administration	B-UNK
of	O
puromycin	B-CHEMICAL
aminonucleoside	I-CHEMICAL
(	O
20	O
mg	B-UNK
/	O
kg	B-UNK
for	O
7	O
days	B-UNK
)	O
and	O
the	O
subsequent	B-UNK
development	B-UNK
of	O
nephrotic	B-DISEASE
syndrome	I-DISEASE
.	O
Since	O
massive	O
albuminuria	B-DISEASE
occurred	B-UNK
after	O
6	O
days	B-UNK
of	O
treatment	B-UNK
,	O
the	O
time	B-UNK
-	O
course	B-UNK
study	B-UNK
was	O
divided	O
into	O
two	O
stages	O
:	O
pre	B-UNK
-	O
nephrotic	B-UNK
stage	B-UNK
(	O
day	B-UNK
1	O
-	O
5	O
)	O
and	O
nephrotic	B-UNK
stage	B-UNK
(	O
day	B-UNK
6	O
-	O
11	O
)	O
.	O
In	O
pre	B-UNK
-	O
nephrotic	B-UNK
stage	B-UNK
the	O
plasma	B-UNK
level	B-UNK
of	O
fatty	B-CHEMICAL
acids	I-CHEMICAL
,	O
triacylglycerol	O
and	O
VLDL	O
decreased	B-UNK
while	O
that	O
of	O
phospholipid	O
,	O
cholesteryl	B-UNK
esters	B-CHEMICAL
and	O
HDL	O
remained	B-UNK
constant	O
.	O
Plasma	B-UNK
apolipoprotein	O
A	O
-	O
I	O
tended	B-UNK
to	O
increase	B-UNK
(	O
40	O
%	O
increase	B-UNK
at	B-DISEASE
day	B-UNK
5	O
)	O
.	O
At	O
the	O
beginning	B-UNK
of	O
nephrotic	B-UNK
stage	B-UNK
(	O
day	B-UNK
6	O
)	O
the	O
concentration	B-UNK
of	O
plasma	B-UNK
albumin	O
dropped	O
to	O
a	O
very	O
low	B-UNK
level	B-UNK
,	O
while	O
that	O
of	O
apolipoprotein	O
A	O
-	O
I	O
increased	B-UNK
abruptly	O
(	O
4-fold	O
increase	B-UNK
)	O
and	O
continued	B-UNK
to	O
rise	B-UNK
,	O
although	O
less	O
steeply	O
,	O
in	O
the	O
following	B-UNK
days	B-UNK
.	O
The	O
plasma	B-UNK
concentration	B-UNK
of	O
HDL	O
followed	B-UNK
the	O
same	O
pattern	B-UNK
.	O
Plasma	B-UNK
VLDL	O
and	O
LDL	O
increased	B-UNK
at	B-DISEASE
a	O
later	B-UNK
stage	B-UNK
(	O
day	B-UNK
9	O
)	O
.	O
Plasma	B-UNK
apolipoprotein	O
A	O
-	O
I	O
was	O
found	B-UNK
not	O
only	O
in	O
HDL	O
(	O
1.063	O
-	O
1.210	O
g	B-UNK
/	O
ml	B-UNK
)	O
but	O
also	O
in	O
the	O
LDL	O
density	B-UNK
class	O
(	O
1.025	O
-	O
1.050	O
g	B-UNK
/	O
ml	B-UNK
)	O
.	O
In	O
the	O
pre	B-UNK
-	O
nephrotic	B-UNK
stage	B-UNK
lipoproteinuria	O
was	O
negligible	O
,	O
while	O
in	O
the	O
early	B-UNK
nephrotic	B-UNK
stage	B-UNK
the	O
urinary	B-UNK
loss	B-UNK
of	O
plasma	B-UNK
lipoproteins	O
consisted	B-UNK
mainly	B-UNK
of	O
HDL	O
.	O
These	O
observations	B-UNK
indicate	B-UNK
that	O
puromycin	B-CHEMICAL
aminonucleoside	I-CHEMICAL
alters	O
plasma	B-UNK
lipoproteins	O
by	O
lowering	B-UNK
VLDL	O
and	O
increasing	B-UNK
HDL	O
.	O
It	O
is	O
likely	B-UNK
that	O
the	O
early	B-UNK
and	O
striking	B-UNK
increase	B-UNK
of	O
plasma	B-UNK
HDL	O
found	B-UNK
in	O
nephrotic	B-UNK
rats	B-UNK
is	O
related	B-UNK
to	O
a	O
direct	B-UNK
effect	B-UNK
of	O
the	O
drug	B-UNK
on	O
HDL	O
metabolism	B-DISEASE
.	O

Circulating	O
lysosomal	B-UNK
enzymes	B-UNK
and	O
acute	B-UNK
hepatic	B-UNK
necrosis	B-DISEASE
.	O

The	O
activities	B-UNK
of	O
the	O
lysosomal	B-UNK
enzymes	B-UNK
acid	B-UNK
and	O
neutral	O
protease	B-UNK
,	O
N	B-UNK
-	O
acetylglucosaminidase	O
,	O
and	O
acid	B-UNK
phosphatase	B-UNK
were	O
measured	B-UNK
in	O
the	O
serum	B-UNK
of	O
patients	B-UNK
with	O
fulminant	B-UNK
hepatic	B-UNK
failure	B-UNK
.	O
Acid	O
protease	B-UNK
(	O
cathepsin	O
D	B-UNK
)	O
activity	B-UNK
was	O
increased	B-UNK
about	O
tenfold	O
in	O
patients	B-UNK
who	O
died	B-UNK
and	O
nearly	B-UNK
fourfold	O
in	O
those	O
who	O
survived	O
fulminant	B-UNK
hepatic	B-UNK
failure	B-UNK
after	O
paracetamol	B-UNK
overdose	B-UNK
,	O
whereas	O
activities	B-UNK
were	O
increased	B-UNK
equally	O
in	O
patients	B-UNK
with	O
fulminant	B-UNK
hepatic	B-UNK
failure	B-UNK
due	O
to	O
viral	O
hepatitis	B-DISEASE
whether	O
or	O
not	O
they	O
survived	O
.	O
A	O
correlation	B-UNK
was	O
found	B-UNK
between	O
serum	B-UNK
acid	B-UNK
protease	B-UNK
activity	B-UNK
and	O
prothrombin	B-CHEMICAL
time	B-UNK
,	O
and	O
the	O
increase	B-UNK
in	O
cathepsin	O
D	B-UNK
activity	B-UNK
was	O
sustained	B-UNK
over	O
several	O
days	B-UNK
compared	B-UNK
with	O
aspartate	B-UNK
aminotransferase	B-UNK
,	O
which	O
showed	B-UNK
a	O
sharp	O
early	B-UNK
peak	B-UNK
and	O
then	O
a	O
fall	O
.	O
Circulating	O
lysosomal	B-UNK
proteases	O
can	O
damage	B-UNK
other	O
organs	O
,	O
and	O
measurement	B-UNK
of	O
their	O
activity	B-UNK
may	O
therefore	O
be	O
of	O
added	O
value	B-UNK
in	O
assessing	O
prognosis	B-UNK
in	O
this	O
condition	B-UNK
.	O

Transketolase	O
abnormality	B-UNK
in	O
tolazamide	B-CHEMICAL
-	O
induced	B-UNK
Wernicke'	O
s	O
encephalopathy	B-DISEASE
.	O

We	O
studied	B-UNK
a	O
thiamine	B-CHEMICAL
-	O
dependent	B-UNK
enzyme	B-UNK
,	O
transketolase	B-UNK
,	O
from	O
fibroblasts	O
of	O
a	O
diabetic	B-UNK
patient	B-UNK
who	O
developed	B-UNK
Wernicke'	O
s	O
encephalopathy	B-DISEASE
when	O
treated	B-UNK
with	O
tolazamide	B-CHEMICAL
,	O
in	O
order	O
to	O
delineate	O
if	O
this	O
patient	B-UNK
also	O
had	O
transketolase	B-UNK
abnormality	B-UNK
[	O
high	B-UNK
Km	O
for	O
thiamine	B-CHEMICAL
pyrophosphate	I-CHEMICAL
(	O
TPP	O
)	O
]	O
,	O
as	O
previously	B-UNK
reported	B-UNK
in	O
postalcoholic	O
Wernicke	O
-	O
Korsakoff	O
syndrome	B-DISEASE
.	O
In	O
addition	O
to	O
this	O
patient	B-UNK
,	O
we	O
also	O
studied	B-UNK
this	O
enzyme	B-UNK
from	O
three	O
diabetic	B-UNK
kindreds	O
without	O
any	O
history	B-UNK
of	O
Wernicke'	O
s	O
encephalopathy	B-DISEASE
and	O
from	O
four	O
normal	B-UNK
controls	B-UNK
.	O
We	O
found	B-UNK
that	O
the	O
above	O
-	O
mentioned	B-UNK
patient	B-UNK
and	O
one	O
of	O
the	O
diabetic	B-UNK
kindreds	O
with	O
no	O
history	B-UNK
of	O
Wernicke'	O
s	O
encephalopathy	B-DISEASE
had	O
abnormal	B-UNK
transketolase	B-UNK
as	O
determined	O
by	O
its	O
Km	O
for	O
TPP	O
.	O
These	O
data	B-UNK
suggest	B-UNK
a	O
similarity	O
between	O
postalcoholic	O
Wernicke	O
-	O
Korsakoff	O
syndrome	B-UNK
and	O
the	O
patient	B-UNK
with	O
tolazamide	B-CHEMICAL
-	O
induced	B-UNK
Wernicke'	O
s	O
encephalopathy	B-DISEASE
from	O
the	O
standpoint	O
of	O
transketolase	B-UNK
abnormality	B-UNK
.	O

Mechanisms	O
of	O
myocardial	B-DISEASE
ischemia	I-DISEASE
induced	B-UNK
by	O
epinephrine	B-CHEMICAL
:	O
comparison	O
with	O
exercise	B-UNK
-	O
induced	B-UNK
ischemia	B-DISEASE
.	O

The	O
role	B-UNK
of	O
epinephrine	B-CHEMICAL
in	O
eliciting	O
myocardial	B-DISEASE
ischemia	I-DISEASE
was	O
examined	B-UNK
in	O
patients	B-UNK
with	O
coronary	B-DISEASE
artery	I-DISEASE
disease	I-DISEASE
.	O
Objective	O
signs	B-UNK
of	O
ischemia	B-DISEASE
and	O
factors	B-UNK
increasing	B-UNK
myocardial	B-UNK
oxygen	B-CHEMICAL
consumption	B-UNK
were	O
compared	B-UNK
during	O
epinephrine	B-CHEMICAL
infusion	B-UNK
and	O
supine	O
bicycle	O
exercise	B-UNK
.	O
Both	O
epinephrine	B-CHEMICAL
and	O
exercise	B-UNK
produced	B-UNK
myocardial	B-DISEASE
ischemia	I-DISEASE
as	O
evidenced	O
by	O
ST	B-UNK
segment	B-UNK
depression	B-DISEASE
and	O
angina	B-DISEASE
.	O
However	O
,	O
the	O
mechanisms	B-UNK
of	O
myocardial	B-DISEASE
ischemia	I-DISEASE
induced	B-UNK
by	O
epinephrine	B-CHEMICAL
were	O
significantly	B-UNK
different	B-UNK
from	O
those	O
of	O
exercise	B-UNK
.	O
Exercise	O
-	O
induced	B-UNK
myocardial	B-DISEASE
ischemia	I-DISEASE
was	O
marked	B-UNK
predominantly	B-UNK
by	O
increased	B-UNK
heart	B-UNK
rate	I-UNK
and	O
rate	B-UNK
-	O
pressure	B-UNK
product	B-UNK
with	O
a	O
minor	B-UNK
contribution	O
of	O
end	B-UNK
-	O
diastolic	B-UNK
volume	B-UNK
,	O
while	O
epinephrine	B-CHEMICAL
-	O
induced	B-UNK
ischemia	B-DISEASE
was	O
characterized	B-UNK
by	O
a	O
marked	B-UNK
increase	B-UNK
in	O
contractility	O
and	O
a	O
less	O
pronounced	O
increase	B-UNK
in	O
heart	B-UNK
rate	I-UNK
and	O
rate	B-UNK
-	O
pressure	B-UNK
product	B-UNK
.	O
These	O
findings	B-UNK
indicate	B-UNK
that	O
ischemia	B-DISEASE
produced	B-UNK
by	O
epinephrine	B-CHEMICAL
,	O
as	O
may	O
occur	O
during	O
states	B-UNK
of	O
emotional	O
distress	O
,	O
has	O
a	O
mechanism	B-UNK
distinct	O
from	O
that	O
due	O
to	O
physical	B-UNK
exertion	O
.	O

Transient	O
contralateral	B-UNK
rotation	B-UNK
following	B-UNK
unilateral	B-UNK
substantia	B-UNK
nigra	B-UNK
lesion	B-UNK
reflects	O
susceptibility	B-UNK
of	O
the	O
nigrostriatal	B-UNK
system	B-UNK
to	O
exhaustion	O
by	O
amphetamine	B-CHEMICAL
.	O

Following	O
unilateral	B-UNK
6-OHDA	O
induced	B-UNK
SN	O
lesion	B-UNK
,	O
a	O
transient	B-UNK
period	B-UNK
of	O
contralateral	B-UNK
rotation	B-UNK
has	O
been	O
reported	B-UNK
to	O
precede	O
the	O
predominant	B-UNK
ipsilateral	O
circling	O
.	O
In	O
order	O
to	O
clarify	O
the	O
nature	O
of	O
this	O
initial	B-UNK
contralateral	B-UNK
rotation	B-UNK
we	O
examined	B-UNK
the	O
effect	B-UNK
of	O
the	O
duration	B-UNK
of	O
recovery	B-UNK
period	B-UNK
after	O
the	O
lesion	B-UNK
,	O
on	O
amphetamine	B-CHEMICAL
-	O
induced	B-UNK
rotational	O
behavior	B-UNK
.	O
Three	O
days	B-UNK
post	O
lesion	B-UNK
,	O
most	O
rats	B-UNK
circled	O
predominantly	B-UNK
contralaterally	O
to	O
the	O
lesion	B-UNK
.	O
Such	O
contralateral	B-UNK
rotation	B-UNK
may	O
result	B-UNK
from	O
either	O
degeneration	B-UNK
-	O
induced	B-UNK
breakdown	O
of	O
the	O
DA	B-UNK
pool	O
,	O
or	O
lesion	B-UNK
-	O
induced	B-UNK
increase	B-UNK
of	O
DA	B-UNK
turnover	O
in	O
the	O
spared	O
neurons	B-UNK
.	O
A	O
substantial	O
degree	B-UNK
of	O
contralateral	B-UNK
preference	B-UNK
was	O
still	O
evident	O
when	O
amphetamine	B-CHEMICAL
was	O
administered	B-UNK
for	O
the	O
first	O
time	B-UNK
24	O
days	B-UNK
after	O
lesioning	O
,	O
indicating	O
involvement	B-UNK
of	O
spared	O
cells	B-UNK
in	O
the	O
contralateral	B-UNK
rotation	B-UNK
.	O
However	O
,	O
regardless	O
of	O
the	O
duration	B-UNK
of	O
recovery	B-UNK
(	O
and	O
irrespective	O
of	O
either	O
lesion	B-UNK
volume	B-UNK
,	O
amphetamine	B-CHEMICAL
dose	B-UNK
,	O
or	O
post-lesion	O
motor	B-UNK
exercise	B-UNK
)	O
,	O
amphetamine	B-CHEMICAL
-	O
induced	B-UNK
rotation	B-UNK
tended	B-UNK
to	O
become	O
gradually	B-UNK
more	O
ipsilateral	O
as	O
the	O
observation	B-UNK
session	O
progressed	O
,	O
and	O
all	O
rats	B-UNK
circled	O
ipsilaterally	O
to	O
the	O
lesion	B-UNK
in	O
response	B-UNK
to	O
further	O
amphetamine	B-CHEMICAL
injections	B-UNK
.	O
These	O
findings	B-UNK
suggest	B-UNK
that	O
amphetamine	B-CHEMICAL
has	O
an	O
irreversible	B-UNK
effect	B-UNK
on	O
the	O
post-lesion	O
DA	B-UNK
pool	O
contributing	B-UNK
to	O
contralateral	B-UNK
rotation	B-UNK
.	O

Thyroid	O
function	B-UNK
and	O
urine	B-DISEASE
-	O
concentrating	O
ability	B-UNK
during	O
lithium	B-CHEMICAL
treatment	B-UNK
.	O

It	O
has	O
been	O
suggested	B-UNK
that	O
adenylate	O
cyclase	O
inhibition	B-UNK
may	O
be	O
important	B-UNK
in	O
the	O
development	B-UNK
of	O
both	O
nephrogenic	O
diabetes	B-DISEASE
insipidus	I-DISEASE
and	O
hypothyroidism	B-DISEASE
during	O
lithium	B-CHEMICAL
treatment	B-UNK
.	O
We	O
measured	B-UNK
serum	B-UNK
thyroxine	B-CHEMICAL
and	O
urine	B-DISEASE
-	O
concentrating	O
ability	B-UNK
(	O
Umax	O
)	O
in	O
response	B-UNK
to	O
desmopressin	O
(	O
DDAVP	O
)	O
in	O
85	O
patients	B-UNK
receiving	B-UNK
lithium	B-CHEMICAL
.	O
Hypothyroidism	O
developed	B-UNK
in	O
eight	O
patients	B-UNK
while	O
they	O
were	O
taking	B-UNK
lithium	B-CHEMICAL
.	O
Impaired	O
Umax	O
was	O
found	B-UNK
in	O
both	O
euthyroid	O
and	O
hypothyroid	O
patients	B-UNK
while	O
some	O
hypothyroid	O
patients	B-UNK
concentrated	O
their	O
urine	B-DISEASE
well	O
.	O
It	O
is	O
concluded	O
that	O
the	O
dominant	O
mechanisms	B-UNK
by	O
which	O
lithium	B-CHEMICAL
exerts	B-UNK
these	O
two	O
effects	B-UNK
are	O
different	B-UNK
.	O

Sensitivity	O
of	O
erythroid	O
progenitor	B-UNK
colonies	O
to	O
erythropoietin	B-CHEMICAL
in	O
azidothymidine	O
treated	B-UNK
immunodeficient	O
mice	B-UNK
.	O

The	O
anaemia	B-UNK
induced	B-UNK
by	O
3'-azido-3'dideoxythymidine	O
(	O
AZT	B-UNK
)	O
is	O
poorly	B-UNK
understood	B-UNK
.	O
We	O
have	O
used	O
a	O
murine	B-UNK
model	B-UNK
of	O
AIDS	O
,	O
infection	B-UNK
of	O
female	B-UNK
C57BL/6	O
mice	B-UNK
with	O
LP	O
-	O
BM5	O
murine	B-UNK
leukaemia	O
(	O
MuLV	O
)	O
virus	B-UNK
,	O
to	O
determine	B-UNK
if	O
AZT	B-UNK
-	O
induced	B-UNK
anaemia	B-UNK
is	O
due	O
,	O
in	O
part	O
,	O
to	O
decreased	B-UNK
responsiveness	O
of	O
erythropoietic	O
precursors	O
(	O
BFU	O
-	O
e	B-UNK
)	O
to	O
erythropoietin	B-CHEMICAL
(	O
EPO	O
)	O
.	O
Mice	O
in	O
the	O
early	B-UNK
stage	B-UNK
of	O
LP	O
-	O
BM5	O
MuLV	O
disease	B-DISEASE
were	O
given	B-UNK
AZT	B-UNK
in	O
their	O
drinking	B-CHEMICAL
water	I-CHEMICAL
at	B-DISEASE
1.0	B-UNK
and	O
2.5	B-UNK
mg	B-UNK
/	O
ml	B-UNK
.	O
AZT	B-UNK
produced	B-UNK
anaemia	B-UNK
in	O
both	O
groups	B-UNK
,	O
in	O
a	O
dose	B-UNK
-	O
dependent	B-UNK
fashion	B-UNK
.	O
Despite	B-UNK
the	O
anaemia	B-UNK
,	O
the	O
number	B-UNK
of	O
splenic	O
and	O
bone	B-UNK
marrow	B-UNK
BFU	O
-	O
e	B-UNK
in	O
AZT	B-UNK
treated	B-UNK
mice	B-UNK
increased	B-UNK
up	O
to	O
five	O
-	O
fold	O
over	O
levels	B-UNK
observed	B-UNK
in	O
infected	B-UNK
untreated	B-UNK
animals	B-UNK
after	O
15	O
d	B-UNK
of	O
treatment	B-UNK
.	O
Colony	O
formation	B-UNK
by	O
splenic	O
and	O
bone	B-UNK
marrow	B-UNK
BFUe	O
was	O
stimulated	O
at	B-DISEASE
lower	B-UNK
concentrations	B-UNK
of	O
EPO	O
in	O
mice	B-UNK
receiving	B-UNK
AZT	B-UNK
for	O
15	O
d	B-UNK
than	O
for	O
infected	B-UNK
,	O
untreated	B-UNK
mice	B-UNK
.	O
By	O
day	B-UNK
30	O
,	O
sensitivity	B-UNK
of	O
both	O
splenic	O
and	O
bone	B-UNK
marrow	B-UNK
BFU	O
-	O
e	B-UNK
of	O
treated	B-UNK
animals	B-UNK
returned	B-UNK
to	O
that	O
observed	B-UNK
from	O
cells	B-UNK
of	O
infected	B-UNK
untreated	B-UNK
animals	B-UNK
.	O
The	O
mean	B-UNK
plasma	B-UNK
levels	B-UNK
of	O
EPO	O
observed	B-UNK
in	O
AZT	B-UNK
treated	B-UNK
mice	B-UNK
were	O
appropriate	B-UNK
for	O
the	O
degree	B-UNK
of	O
anaemia	B-UNK
observed	B-UNK
when	O
compared	B-UNK
with	O
phenylhydrazine	B-CHEMICAL
(	O
PHZ	O
)	O
treated	B-UNK
mice	B-UNK
.	O
The	O
numbers	O
of	O
BFU	O
-	O
e	B-UNK
and	O
the	O
percentage	B-UNK
of	O
bone	B-UNK
marrow	B-UNK
erythroblasts	O
observed	B-UNK
were	O
comparable	B-UNK
in	O
AZT	B-UNK
and	O
PHZ	O
treated	B-UNK
mice	B-UNK
with	O
similar	B-UNK
degrees	O
of	O
anaemia	B-UNK
.	O
However	O
,	O
reticulocytosis	B-DISEASE
was	O
inappropriate	O
for	O
the	O
degree	B-UNK
of	O
anaemia	B-UNK
observed	B-UNK
in	O
AZT	B-UNK
treated	B-UNK
infected	B-UNK
mice	B-UNK
.	O
AZT	B-UNK
-	O
induced	B-UNK
peripheral	B-UNK
anaemia	B-UNK
in	O
the	O
face	O
of	O
increased	B-UNK
numbers	O
of	O
BFU	O
-	O
e	B-UNK
and	O
increased	B-UNK
levels	B-UNK
of	O
plasma	B-UNK
EPO	O
suggest	B-UNK
a	O
lesion	B-UNK
in	O
terminal	B-UNK
differentiation	B-UNK
.	O

Detection	O
of	O
abnormal	B-UNK
cardiac	B-UNK
adrenergic	B-UNK
neuron	I-UNK
activity	B-UNK
in	O
adriamycin	O
-	O
induced	B-UNK
cardiomyopathy	B-DISEASE
with	O
iodine-125-metaiodobenzylguanidine	O
.	O

Radiolabeled	O
metaiodobenzylguanidine	O
(	O
MIBG	B-UNK
)	O
,	O
an	O
analog	B-UNK
of	O
norepinephrine	B-CHEMICAL
(	O
NE	O
)	O
,	O
serves	O
as	O
an	O
index	B-UNK
of	O
adrenergic	B-UNK
neuron	I-UNK
integrity	B-UNK
and	O
function	B-UNK
.	O
Using	O
a	O
rat	B-UNK
model	B-UNK
of	O
adriamycin	O
-	O
induced	B-UNK
cardiomyopathy	B-DISEASE
,	O
we	O
tested	B-UNK
the	O
hypothesis	O
that	O
abnormal	B-UNK
cardiac	B-UNK
adrenergic	B-UNK
neuron	I-UNK
activity	B-UNK
may	O
appear	O
and	O
be	O
exacerbated	B-UNK
dose	B-UNK
-	O
dependently	B-UNK
in	O
adriamycin	O
cardiomyopathy	B-DISEASE
.	O
The	O
degree	B-UNK
of	O
vacuolar	O
degeneration	B-UNK
of	O
myocardial	B-UNK
cells	B-UNK
was	O
analyzed	B-UNK
in	O
relation	O
to	O
the	O
duration	B-UNK
of	O
adriamycin	O
treatment	B-UNK
(	O
2	B-DISEASE
mg	B-UNK
/	O
kg	B-UNK
,	O
once	O
a	O
week	B-UNK
)	O
.	O
There	O
were	O
no	O
abnormalities	B-DISEASE
or	O
only	O
isolated	B-UNK
degeneration	B-UNK
in	O
the	O
1-	O
or	O
2-wk	O
treatment	B-UNK
groups	B-UNK
,	O
isolated	B-UNK
or	O
scattered	O
degeneration	B-UNK
in	O
half	O
of	O
the	O
3-wk	O
group	B-UNK
,	O
frequent	B-UNK
scattered	O
degeneration	B-UNK
in	O
the	O
4-wk	O
group	B-UNK
,	O
scattered	O
or	O
focal	B-UNK
degeneration	B-UNK
in	O
the	O
5-wk	O
group	B-UNK
,	O
and	O
extensive	B-UNK
degeneration	B-UNK
in	O
the	O
8-wk	O
group	B-UNK
.	O
Myocardial	O
accumulation	B-UNK
of	O
[	O
125I]MIBG	O
4	O
hr	B-UNK
after	O
intravenous	B-UNK
injection	B-UNK
did	O
not	O
differ	B-UNK
between	O
the	O
controls	B-UNK
and	O
the	O
groups	B-UNK
treated	B-UNK
3	O
wk	O
or	O
less	O
.	O
However	O
,	O
the	O
4-wk	O
group	B-UNK
had	O
a	O
slightly	O
lower	B-UNK
accumulation	B-UNK
in	O
the	O
right	B-UNK
ventricular	B-UNK
wall	B-UNK
(	O
82	O
%	O
of	O
the	O
control	B-UNK
)	O
and	O
significantly	B-UNK
lower	B-UNK
accumulation	B-UNK
in	O
the	O
left	B-UNK
ventricular	I-UNK
wall	B-UNK
(	O
about	O
66	O
%	O
of	O
the	O
control	B-UNK
:	O
p	B-UNK
less	O
than	O
0.05	O
)	O
.	O
In	O
the	O
5-wk	O
group	B-UNK
,	O
MIBG	B-UNK
accumulation	B-UNK
in	O
the	O
right	B-UNK
and	O
left	B-UNK
ventricular	I-UNK
wall	B-UNK
was	O
35	O
%	O
and	O
27	O
%	O
of	O
that	O
in	O
controls	B-UNK
,	O
respectively	O
(	O
p	B-UNK
less	O
than	O
0.001	B-UNK
)	O
.	O
In	O
the	O
8-wk	O
group	B-UNK
,	O
MIBG	B-UNK
accumulation	B-UNK
in	O
the	O
right	B-UNK
and	O
left	B-UNK
ventricular	I-UNK
wall	B-UNK
was	O
18	O
%	O
and	O
14	O
%	O
of	O
that	O
in	O
controls	B-UNK
,	O
respectively	O
(	O
p	B-UNK
less	O
than	O
0.001	B-UNK
)	O
.	O
Thus	O
,	O
MIBG	B-UNK
accumulation	B-UNK
in	O
the	O
myocardium	B-UNK
decreased	B-UNK
in	O
an	O
adriamycin	O
dose	B-UNK
-	O
dependent	B-UNK
manner	B-UNK
.	O
The	O
appearance	O
of	O
impaired	B-UNK
cardiac	B-UNK
adrenergic	B-UNK
neuron	I-UNK
activity	B-UNK
in	O
the	O
presence	O
of	O
slight	O
myocardial	B-UNK
impairment	B-UNK
(	O
scattered	O
or	O
focal	B-UNK
vacuolar	O
degeneration	B-UNK
)	O
indicates	B-UNK
that	O
MIBG	B-UNK
scintigraphy	O
may	O
be	O
a	O
useful	B-UNK
method	B-UNK
for	O
detection	O
of	O
adriamycin	O
-	O
induced	B-UNK
cardiomyopathy	B-DISEASE
.	O

Amnestic	O
syndrome	B-DISEASE
associated	B-UNK
with	O
propranolol	B-CHEMICAL
toxicity	B-UNK
:	O
a	O
case	B-UNK
report	B-UNK
.	O

An	O
elderly	B-UNK
woman	B-UNK
developed	B-UNK
an	O
Alzheimer	O
-	O
like	B-UNK
subacute	O
dementia	B-DISEASE
as	O
a	O
result	B-UNK
of	O
propranolol	B-CHEMICAL
toxicity	B-UNK
.	O
Analysis	O
of	O
the	O
manifestations	B-UNK
showed	B-UNK
that	O
severe	B-UNK
impairment	B-UNK
of	O
memory	B-UNK
accounted	O
for	O
virtually	O
all	O
of	O
the	O
abnormalities	B-DISEASE
.	O
There	O
is	O
evidence	B-UNK
that	O
cerebral	B-UNK
reactions	B-UNK
to	O
drug	B-UNK
toxicity	B-UNK
can	O
exhibit	B-UNK
patterns	B-UNK
that	O
suggest	B-UNK
highly	B-UNK
selective	B-UNK
involvement	B-UNK
of	O
functional	B-UNK
subdivisions	O
of	O
the	O
brain	B-UNK
.	O

Biphasic	O
response	B-UNK
of	O
the	O
SA	B-UNK
node	B-UNK
of	O
the	O
dog	O
heart	B-UNK
in	O
vivo	B-UNK
to	O
selective	B-UNK
administration	B-UNK
of	O
ketamine	B-CHEMICAL
.	O

Effect	O
of	O
ketamine	B-CHEMICAL
on	O
the	O
SA	B-UNK
node	B-UNK
of	O
the	O
dog	O
heart	B-UNK
was	O
studied	B-UNK
in	O
vivo	B-UNK
using	O
a	O
selective	B-UNK
perfusion	B-UNK
technique	B-UNK
of	O
the	O
SA	B-UNK
node	B-UNK
artery	B-UNK
.	O
Injections	O
of	O
ketamine	B-CHEMICAL
in	O
doses	B-UNK
from	O
100	O
microgram	O
to	O
3	O
mg	B-UNK
into	O
the	O
artery	B-UNK
produced	B-UNK
a	O
depression	B-DISEASE
of	O
the	O
SA	B-UNK
nodal	O
activity	B-UNK
by	O
a	O
direct	B-UNK
action	B-UNK
.	O
This	O
depression	B-DISEASE
was	O
followed	B-UNK
by	O
the	O
sudden	B-UNK
appearance	O
of	O
a	O
stimulatory	O
phase	B-UNK
.	O
Bilateral	O
vagotomy	O
and	O
sympathectomy	O
or	O
prior	B-UNK
administration	B-UNK
of	O
a	O
ganglion	O
blocker	B-UNK
failed	B-UNK
to	O
inhibit	O
the	O
occurrence	O
of	O
the	O
ketamine	B-CHEMICAL
-	O
induced	B-UNK
tachycardia	B-DISEASE
,	O
while	O
it	O
was	O
completely	B-UNK
abolished	B-UNK
in	O
the	O
reserpinized	O
dogs	B-UNK
or	O
by	O
a	O
prior	B-UNK
injection	B-UNK
of	O
a	O
beta-blocking	O
agent	B-UNK
into	O
the	O
SA	B-UNK
node	B-UNK
artery	B-UNK
.	O
This	O
may	O
indicate	B-UNK
that	O
an	O
activation	B-UNK
of	O
the	O
peripheral	B-UNK
adrenergic	B-UNK
mechanism	B-UNK
plays	O
an	O
important	B-UNK
role	B-UNK
in	O
the	O
induction	B-UNK
of	O
the	O
excitatory	B-UNK
effect	B-UNK
of	O
ketamine	B-CHEMICAL
injected	B-UNK
in	O
the	O
SA	B-UNK
node	B-UNK
artery	B-UNK
.	O

The	O
use	B-UNK
of	O
serum	B-UNK
cholinesterase	B-UNK
in	O
succinylcholine	B-CHEMICAL
apnoea	O
.	O

Fifteen	O
patients	B-UNK
demonstrating	O
unexpected	O
prolonged	B-UNK
apnoea	O
lasting	B-UNK
several	O
hours	B-UNK
after	O
succinylcholine	B-CHEMICAL
have	O
been	O
treated	B-UNK
by	O
a	O
new	B-UNK
preparation	O
of	O
human	B-UNK
serum	B-UNK
cholinesterase	B-UNK
.	O
Adequate	O
spontaneous	B-UNK
respiration	O
was	O
re-established	O
in	O
an	O
average	B-UNK
period	B-UNK
of	O
ten	B-DISEASE
minutes	B-UNK
after	O
the	O
injection	B-UNK
.	O
In	O
12	O
patients	B-UNK
biochemical	B-UNK
genetic	B-UNK
examinations	B-UNK
confirmed	B-UNK
the	O
presence	O
of	O
an	O
atypical	B-UNK
serum	B-UNK
cholinesterase	B-UNK
.	O
In	O
three	O
patients	B-UNK
none	O
of	O
the	O
usual	B-UNK
variants	B-UNK
were	O
found	B-UNK
.	O
It	O
is	O
therefore	O
supposed	O
that	O
other	O
unknown	B-UNK
variants	B-UNK
of	O
serum	B-UNK
cholinesterase	B-UNK
exist	O
which	O
cannot	O
hydrolyze	O
succinylcholine	B-CHEMICAL
.	O
The	O
use	B-UNK
of	O
serum	B-UNK
cholinesterase	B-UNK
in	O
succinylcholine	B-CHEMICAL
apnoea	O
provided	B-UNK
considerable	O
relief	O
to	O
both	O
patient	B-UNK
and	O
anaesthetist	O
.	O

Orthostatic	O
hypotension	B-DISEASE
occurs	B-UNK
following	B-UNK
alpha	B-UNK
2-adrenoceptor	O
blockade	B-UNK
in	O
chronic	B-UNK
prazosin	B-CHEMICAL
-	O
pretreated	B-UNK
conscious	B-UNK
spontaneously	B-UNK
hypertensive	B-UNK
rats	B-UNK
.	O

Coexistence	O
of	O
cerebral	B-UNK
venous	B-UNK
sinus	B-UNK
and	O
internal	B-DISEASE
carotid	I-DISEASE
artery	I-DISEASE
thrombosis	B-DISEASE
associated	B-UNK
with	O
exogenous	B-UNK
sex	O
hormones	B-CHEMICAL
.	O
A	O
case	B-UNK
report	B-UNK
.	O

A	O
forty	O
-	O
six	O
year	B-UNK
-	O
old	B-UNK
premenopausal	O
woman	B-UNK
developed	B-UNK
headache	B-DISEASE
,	O
nausea	B-DISEASE
and	O
vomiting	B-DISEASE
,	O
left	B-UNK
hemiparesis	O
and	O
seizure	B-UNK
two	O
days	B-UNK
after	O
parenteral	O
use	B-UNK
of	O
progesterone	B-CHEMICAL
and	O
estradiol	B-CHEMICAL
.	O
Diabetes	O
mellitus	O
(	O
DM	B-UNK
)	O
was	O
found	B-UNK
during	O
admission	O
.	O
Computed	O
tomography	B-UNK
showed	B-UNK
a	O
hemorrhagic	B-UNK
infarct	O
in	O
the	O
right	B-UNK
frontal	B-UNK
lobe	I-UNK
and	O
increased	B-UNK
density	B-UNK
in	O
the	O
superior	B-UNK
sagittal	B-UNK
sinus	B-UNK
(	O
SSS	O
)	O
.	O
Left	O
carotid	B-UNK
angiography	B-UNK
found	B-UNK
occlusion	B-UNK
of	O
the	O
left	B-UNK
internal	B-DISEASE
carotid	I-DISEASE
artery	I-DISEASE
(	O
ICA	O
)	O
.	O
Right	O
carotid	B-UNK
angiograms	O
failed	B-UNK
to	O
show	O
the	O
SSS	O
and	O
inferior	B-UNK
sagittal	B-UNK
sinus	B-UNK
,	O
suggestive	O
of	O
venous	B-UNK
sinus	B-DISEASE
thrombosis	I-DISEASE
.	O
Coexistence	O
of	O
the	O
cerebral	B-UNK
artery	B-UNK
and	O
the	O
venous	B-UNK
sinus	B-UNK
occlusion	B-UNK
has	O
been	O
described	B-UNK
infrequently	O
.	O
In	O
this	O
case	B-UNK
,	O
the	O
authors	B-UNK
postulate	O
that	O
the	O
use	B-UNK
of	O
estradiol	B-CHEMICAL
and	O
progesterone	B-CHEMICAL
and	O
the	O
underlying	B-UNK
DM	B-UNK
increased	B-UNK
vascular	B-UNK
thrombogenicity	O
,	O
which	O
provided	B-UNK
a	O
common	B-UNK
denominator	O
for	O
thrombosis	B-DISEASE
of	O
both	O
the	O
ICA	O
and	O
the	O
venous	B-UNK
sinus	B-UNK
.	O

Chloroquine	O
related	B-UNK
complete	B-UNK
heart	B-DISEASE
block	I-DISEASE
with	O
blindness	B-DISEASE
:	O
case	B-UNK
report	B-UNK
.	O

A	O
27-year	O
old	B-UNK
African	B-UNK
woman	B-UNK
with	O
history	B-UNK
of	O
regular	B-UNK
chloroquine	B-CHEMICAL
ingestion	B-UNK
presented	B-UNK
with	O
progressive	B-UNK
deterioration	B-UNK
of	O
vision	B-DISEASE
,	O
easy	O
fatiguability	O
,	O
dyspnoea	O
,	O
dizziness	B-DISEASE
progressing	O
to	O
syncopal	B-UNK
attacks	B-UNK
.	O
Ophthalmological	O
assessment	B-UNK
revealed	B-UNK
features	B-UNK
of	O
chloroquine	B-CHEMICAL
retinopathy	B-DISEASE
,	O
cardiac	B-UNK
assessment	B-UNK
revealed	B-UNK
features	B-UNK
of	O
heart	B-DISEASE
failure	I-DISEASE
and	O
a	O
complete	B-UNK
heart	B-DISEASE
block	I-DISEASE
with	O
right	B-UNK
bundle	B-DISEASE
branch	I-DISEASE
block	I-DISEASE
pattern	B-UNK
.	O
The	O
heart	B-DISEASE
block	I-DISEASE
was	O
treated	B-UNK
by	O
pacemaker	O
insertion	B-UNK
and	O
the	O
heart	B-DISEASE
failure	I-DISEASE
resolved	B-UNK
spontaneously	B-UNK
following	B-UNK
chloroquine	B-CHEMICAL
discontinuation	B-UNK
.	O
She	O
however	O
remains	B-UNK
blind	B-UNK
.	O

Systemic	B-UNK
toxicity	B-UNK
and	O
resuscitation	O
in	O
bupivacaine-	O
,	O
levobupivacaine-	O
,	O
or	O
ropivacaine	B-CHEMICAL
-	O
infused	O
rats	B-UNK
.	O

We	O
compared	B-UNK
the	O
systemic	B-UNK
toxicity	B-UNK
of	O
bupivacaine	B-CHEMICAL
,	O
levobupivacaine	B-CHEMICAL
,	O
and	O
ropivacaine	B-CHEMICAL
in	O
anesthetized	B-UNK
rats	B-UNK
.	O
We	O
also	O
compared	B-UNK
the	O
ability	B-UNK
to	O
resuscitate	O
rats	B-UNK
after	O
lethal	B-UNK
doses	B-UNK
of	O
these	O
local	B-UNK
anesthetics	B-CHEMICAL
.	O
Bupivacaine	O
,	O
levobupivacaine	B-CHEMICAL
,	O
or	O
ropivacaine	B-CHEMICAL
was	O
infused	O
at	B-DISEASE
a	O
rate	B-UNK
of	O
2	B-DISEASE
mg	B-UNK
.	O
kg(-1	B-UNK
)	O
.	O
min(-1	O
)	O
while	O
electrocardiogram	O
,	O
electroencephalogram	O
,	O
and	O
arterial	B-UNK
pressure	I-UNK
were	O
continuously	B-UNK
monitored	B-UNK
.	O
When	O
asystole	O
was	O
recorded	B-UNK
,	O
drug	B-UNK
infusion	B-UNK
was	O
stopped	O
and	O
a	O
resuscitation	O
sequence	O
was	O
begun	O
.	O
Epinephrine	O
0.01	B-UNK
mg	B-UNK
/	O
kg	B-UNK
was	O
administered	B-UNK
at	B-DISEASE
1-min	O
intervals	B-UNK
while	O
external	O
cardiac	B-UNK
compressions	O
were	O
applied	O
.	O
Resuscitation	O
was	O
considered	B-UNK
successful	B-UNK
when	O
a	O
systolic	B-UNK
arterial	B-UNK
pressure	I-UNK
>	O
or	O
=	O
100	O
mm	B-UNK
Hg	B-UNK
was	O
achieved	B-UNK
within	O
5	O
min	B-UNK
.	O
The	O
cumulative	B-UNK
doses	B-UNK
of	O
levobupivacaine	B-CHEMICAL
and	O
ropivacaine	B-CHEMICAL
that	O
produced	B-UNK
seizures	B-DISEASE
were	O
similar	B-UNK
and	O
were	O
larger	B-UNK
than	O
those	O
of	O
bupivacaine	B-CHEMICAL
.	O
The	O
cumulative	B-UNK
doses	B-UNK
of	O
levobupivacaine	B-CHEMICAL
that	O
produced	B-UNK
dysrhythmias	B-DISEASE
and	O
asystole	O
were	O
smaller	B-UNK
than	O
the	O
corresponding	B-UNK
doses	B-UNK
of	O
ropivacaine	B-CHEMICAL
,	O
but	O
they	O
were	O
larger	B-UNK
than	O
those	O
of	O
bupivacaine	B-CHEMICAL
.	O
The	O
number	B-UNK
of	O
successful	B-UNK
resuscitations	O
did	O
not	O
differ	B-UNK
among	O
groups	B-UNK
.	O
However	O
,	O
a	O
smaller	B-UNK
dose	B-UNK
of	O
epinephrine	B-CHEMICAL
was	O
required	B-UNK
in	O
the	O
Ropivacaine	O
group	B-UNK
than	O
in	O
the	O
other	O
groups	B-UNK
.	O
We	O
conclude	O
that	O
the	O
systemic	B-UNK
toxicity	B-UNK
of	O
levobupivacaine	B-CHEMICAL
is	O
intermediate	O
between	O
that	O
of	O
ropivacaine	B-CHEMICAL
and	O
bupivacaine	B-CHEMICAL
when	O
administered	B-UNK
at	B-DISEASE
the	O
same	O
rate	B-UNK
and	O
that	O
ropivacaine	B-CHEMICAL
-	O
induced	B-UNK
cardiac	B-DISEASE
arrest	I-DISEASE
appears	B-UNK
to	O
be	O
more	O
susceptible	B-UNK
to	O
treatment	B-UNK
than	O
that	O
induced	B-UNK
by	O
bupivacaine	B-CHEMICAL
or	O
levobupivacaine	B-CHEMICAL
.	O

BACKGROUND	O
:	O
Calcitriol	O
therapy	B-UNK
suppresses	O
serum	B-UNK
levels	B-UNK
of	O
parathyroid	B-CHEMICAL
hormone	I-CHEMICAL
(	O
PTH	B-UNK
)	O
in	O
patients	B-UNK
with	O
renal	B-DISEASE
failure	I-DISEASE
but	O
has	O
several	O
drawbacks	O
,	O
including	B-UNK
hypercalcemia	B-DISEASE
and	O
/	O
or	O
marked	B-UNK
suppression	B-UNK
of	O
bone	B-UNK
turnover	O
,	O
which	O
may	O
lead	B-CHEMICAL
to	O
adynamic	O
bone	B-UNK
disease	B-DISEASE
.	O
A	O
new	B-UNK
vitamin	B-UNK
D	B-UNK
analogue	B-UNK
,	O
22-oxacalcitriol	O
(	O
OCT	B-UNK
)	O
,	O
has	O
been	O
shown	B-UNK
to	O
have	O
promising	B-UNK
characteristics	B-UNK
.	O
This	O
study	B-UNK
was	O
undertaken	O
to	O
determine	B-UNK
the	O
effects	B-UNK
of	O
OCT	B-UNK
on	O
serum	B-UNK
PTH	B-UNK
levels	B-UNK
and	O
bone	B-UNK
turnover	O
in	O
states	B-UNK
of	O
normal	B-UNK
or	O
impaired	B-UNK
renal	B-DISEASE
function	B-UNK
.	O
METHODS	O
:	O
Sixty	O
dogs	B-UNK
were	O
either	O
nephrectomized	O
(	O
Nx	O
,	O
N	B-UNK
=	O
38	O
)	O
or	O
sham	O
-	O
operated	O
(	O
Sham	O
,	O
N	B-UNK
=	O
22	O
)	O
.	O
The	O
animals	B-UNK
received	B-UNK
supplemental	O
phosphate	B-UNK
to	O
enhance	B-UNK
PTH	B-UNK
secretion	B-UNK
.	O
Fourteen	O
weeks	B-UNK
after	O
the	O
start	O
of	O
phosphate	B-UNK
supplementation	B-UNK
,	O
half	O
of	O
the	O
Nx	O
and	O
Sham	O
dogs	B-UNK
received	B-UNK
doses	B-UNK
of	O
OCT	B-UNK
(	O
three	O
times	B-UNK
per	O
week	B-UNK
)	O
;	O
the	O
other	O
half	O
were	O
given	B-UNK
vehicle	B-UNK
for	O
60	O
weeks	B-UNK
.	O
Thereafter	O
,	O
the	O
treatment	B-UNK
modalities	O
for	O
a	O
subset	O
of	O
animals	B-UNK
were	O
crossed	O
over	O
for	O
an	O
additional	B-UNK
eight	O
months	B-UNK
.	O
Biochemical	O
and	O
hormonal	O
indices	O
of	O
calcium	B-CHEMICAL
and	O
bone	B-UNK
metabolism	B-DISEASE
were	O
measured	B-UNK
throughout	O
the	O
study	B-UNK
,	O
and	O
bone	B-UNK
biopsies	B-UNK
were	O
done	O
at	B-DISEASE
baseline	B-UNK
,	O
60	O
weeks	B-UNK
after	O
OCT	B-UNK
or	O
vehicle	B-UNK
treatment	B-UNK
,	O
and	O
at	B-DISEASE
the	O
end	B-UNK
of	O
the	O
crossover	B-UNK
period	B-UNK
.	O
RESULTS	B-UNK
:	O
In	O
Nx	O
dogs	B-UNK
,	O
OCT	B-UNK
significantly	B-UNK
decreased	B-UNK
serum	B-UNK
PTH	B-UNK
levels	B-UNK
soon	O
after	O
the	O
induction	B-UNK
of	O
renal	B-DISEASE
insufficiency	I-DISEASE
.	O
In	O
long	B-UNK
-	O
standing	O
secondary	B-UNK
hyperparathyroidism	B-DISEASE
,	O
OCT	B-UNK
(	O
0.03	B-UNK
microg	B-UNK
/	O
kg	B-UNK
)	O
stabilized	O
serum	B-UNK
PTH	B-UNK
levels	B-UNK
during	O
the	O
first	O
months	B-UNK
.	O
Serum	B-UNK
PTH	B-UNK
levels	B-UNK
rose	B-UNK
thereafter	O
,	O
but	O
the	O
rise	B-UNK
was	O
less	O
pronounced	O
compared	B-UNK
with	O
baseline	B-UNK
than	O
the	O
rise	B-UNK
seen	B-UNK
in	O
Nx	O
control	B-UNK
.	O
These	O
effects	B-UNK
were	O
accompanied	O
by	O
episodes	B-UNK
of	O
hypercalcemia	B-DISEASE
and	O
hyperphosphatemia	B-DISEASE
.	O
In	O
animals	B-UNK
with	O
normal	B-UNK
renal	B-UNK
function	B-UNK
,	O
OCT	B-UNK
induced	B-UNK
a	O
transient	B-UNK
decrease	B-UNK
in	O
serum	B-UNK
PTH	B-UNK
levels	B-UNK
at	B-DISEASE
a	O
dose	B-UNK
of	O
0.1	B-UNK
microg	B-UNK
/	O
kg	B-UNK
,	O
which	O
was	O
not	O
sustained	B-UNK
with	O
lowering	B-UNK
of	O
the	O
doses	B-UNK
.	O
In	O
Nx	O
dogs	B-UNK
,	O
OCT	B-UNK
reversed	B-UNK
abnormal	B-UNK
bone	B-UNK
formation	B-UNK
,	O
such	O
as	O
woven	O
osteoid	O
and	O
fibrosis	B-DISEASE
,	O
but	O
did	O
not	O
significantly	B-UNK
alter	B-UNK
the	O
level	B-UNK
of	O
bone	B-UNK
turnover	O
.	O
In	O
addition	O
,	O
OCT	B-UNK
improved	B-UNK
mineralization	O
lag	O
time	B-UNK
,	O
(	O
that	O
is	O
,	O
the	O
rate	B-UNK
at	B-DISEASE
which	O
osteoid	O
mineralizes	O
)	O
in	O
both	O
Nx	O
and	O
Sham	O
dogs	B-UNK
.	O
CONCLUSIONS	O
:	O
These	O
results	B-UNK
indicate	B-UNK
that	O
even	O
though	O
OCT	B-UNK
does	O
not	O
completely	B-UNK
prevent	B-UNK
the	O
occurrence	O
of	O
hypercalcemia	B-DISEASE
in	O
experimental	B-UNK
dogs	B-UNK
with	O
renal	B-DISEASE
insufficiency	I-DISEASE
,	O
it	O
may	O
be	O
of	O
use	B-UNK
in	O
the	O
management	B-UNK
of	O
secondary	B-UNK
hyperparathyroidism	B-DISEASE
because	O
it	O
does	O
not	O
induce	B-UNK
low	B-UNK
bone	B-UNK
turnover	O
and	O
,	O
therefore	O
,	O
does	O
not	O
increase	B-UNK
the	O
risk	B-UNK
of	O
adynamic	O
bone	B-UNK
disease	B-DISEASE
.	O

Chemotherapy	O
of	O
advanced	B-UNK
inoperable	O
non-small	O
cell	B-UNK
lung	B-DISEASE
cancer	I-DISEASE
with	O
paclitaxel	B-CHEMICAL
:	O
a	O
phase	B-UNK
II	B-UNK
trial	B-UNK
.	O

Paclitaxel	O
(	O
Taxol	O
;	O
Bristol	O
-	O
Myers	O
Squibb	O
Company	B-UNK
,	O
Princeton	O
,	O
NJ	O
)	O
has	O
demonstrated	B-UNK
significant	B-UNK
antineoplastic	O
activity	B-UNK
against	O
different	B-UNK
tumor	B-DISEASE
types	O
,	O
notably	O
ovarian	B-UNK
and	O
breast	O
carcinoma	B-DISEASE
.	O
Two	O
phase	B-UNK
II	B-UNK
trials	B-UNK
of	O
24-hour	B-UNK
paclitaxel	B-CHEMICAL
infusions	O
in	O
chemotherapy	B-UNK
-	O
naive	O
patients	B-UNK
with	O
stage	B-UNK
IIIB	O
or	O
IV	B-UNK
non-small	O
cell	B-UNK
lung	B-DISEASE
cancer	I-DISEASE
(	O
NSCLC	O
)	O
reported	B-UNK
response	B-UNK
rates	B-UNK
of	O
21	O
%	O
and	O
24	O
%	O
.	O
Leukopenia	O
was	O
dose	B-UNK
limiting	B-UNK
:	O
as	O
many	O
as	O
62.5	O
%	O
of	O
patients	B-UNK
experienced	B-UNK
grade	B-UNK
4	O
leukopenia	B-DISEASE
.	O
We	O
investigated	B-UNK
the	O
efficacy	B-UNK
and	O
toxicity	B-UNK
of	O
a	O
3-hour	O
paclitaxel	B-CHEMICAL
infusion	B-UNK
in	O
a	O
phase	B-UNK
II	B-UNK
trial	B-UNK
in	O
patients	B-UNK
with	O
inoperable	O
stage	B-UNK
IIIB	O
or	O
IV	B-UNK
NSCLC	O
.	O
The	O
58	O
patients	B-UNK
treated	B-UNK
(	O
41	O
men	O
and	O
17	B-DISEASE
women	B-UNK
)	O
had	O
a	O
median	B-UNK
age	B-UNK
of	O
59	O
years	B-UNK
(	O
age	B-UNK
range	B-UNK
,	O
25	O
to	O
75	O
)	O
and	O
a	O
performance	B-UNK
status	B-UNK
of	O
0	O
through	O
2	B-DISEASE
.	O
Most	O
patients	B-UNK
(	O
72.4	O
%	O
)	O
had	O
stage	B-UNK
IV	B-UNK
NSCLC	O
.	O
Paclitaxel	O
225	O
mg	B-UNK
/	O
m2	O
was	O
infused	O
over	O
3	O
hours	B-UNK
every	O
3	O
weeks	B-UNK
with	O
standard	B-UNK
prophylactic	B-UNK
premedication	O
.	O
Of	O
50	O
patients	B-UNK
evaluable	O
for	O
response	B-UNK
,	O
12	O
(	O
24	O
%	O
)	O
had	O
partial	B-UNK
remission	B-DISEASE
,	O
26	O
(	O
52	O
%	O
)	O
had	O
no	O
change	B-UNK
,	O
and	O
12	O
had	O
disease	B-DISEASE
progression	I-DISEASE
(	O
24	O
%	O
)	O
.	O
Hematologic	O
toxicities	B-UNK
were	O
mild	B-UNK
:	O
only	O
one	O
patient	B-UNK
(	O
2	B-DISEASE
%	O
)	O
developed	B-UNK
grade	B-UNK
3	O
or	O
4	O
neutropenia	B-DISEASE
,	O
while	O
29	O
%	O
had	O
grade	B-UNK
1	O
or	O
2	B-DISEASE
.	O
Grade	O
1	O
or	O
2	B-DISEASE
polyneuropathy	B-DISEASE
affected	B-UNK
56	O
%	O
of	O
patients	B-UNK
while	O
only	O
one	O
(	O
2	B-DISEASE
%	O
)	O
experienced	B-UNK
severe	B-UNK
polyneuropathy	B-DISEASE
.	O
Similarly	O
,	O
grade	B-UNK
1	O
or	O
2	B-DISEASE
myalgia	B-DISEASE
/	O
arthralgia	B-DISEASE
was	O
observed	B-UNK
in	O
63.2	O
%	O
of	O
patients	B-UNK
,	O
but	O
only	O
14.3	O
%	O
experienced	B-UNK
grade	B-UNK
3	O
or	O
4	O
.	O
Nausea	O
and	O
vomiting	B-DISEASE
were	O
infrequent	O
,	O
with	O
14	O
%	O
of	O
patients	B-UNK
experiencing	O
grade	B-UNK
1	O
or	O
2	B-DISEASE
and	O
only	O
2	B-DISEASE
%	O
experiencing	O
grade	B-UNK
3	O
or	O
4	O
.	O
Paclitaxel	O
is	O
thus	O
an	O
active	B-UNK
single	B-UNK
agent	B-UNK
in	O
this	O
patient	B-UNK
population	B-UNK
,	O
with	O
a	O
3-hour	O
infusion	B-UNK
proving	O
comparably	O
effective	B-UNK
to	O
a	O
24-hour	B-UNK
infusion	B-UNK
and	O
superior	B-UNK
in	O
terms	O
of	O
the	O
incidence	B-UNK
of	O
hematologic	B-UNK
and	O
nonhematologic	O
toxicity	B-UNK
.	O
Further	O
phase	B-UNK
II	B-UNK
studies	B-UNK
with	O
paclitaxel	B-CHEMICAL
combined	B-UNK
with	O
other	O
drugs	B-UNK
active	B-UNK
against	O
NSCLC	O
are	O
indicated	B-UNK
,	O
and	O
phase	B-UNK
III	B-UNK
studies	B-UNK
comparing	O
paclitaxel	B-CHEMICAL
with	O
standard	B-UNK
chemotherapy	B-UNK
remain	B-UNK
to	O
be	O
completed	O
.	O

Cerebral	O
hemorrhage	B-DISEASE
associated	B-UNK
with	O
phenylpropanolamine	B-CHEMICAL
in	O
combination	B-UNK
with	O
caffeine	B-CHEMICAL
.	O

Phenylpropanolamine	O
(	O
PPA	O
)	O
is	O
a	O
drug	B-UNK
that	O
has	O
been	O
associated	B-UNK
with	O
serious	O
side	O
effects	B-UNK
including	B-UNK
stroke	B-UNK
.	O
It	O
is	O
often	O
combined	B-UNK
with	O
caffeine	B-CHEMICAL
in	O
diet	B-UNK
preparations	B-UNK
and	O
"	O
look	O
-	O
alike	O
"	O
pills	O
.	O
In	O
order	O
to	O
determine	B-UNK
if	O
PPA	O
/	O
caffeine	B-CHEMICAL
can	O
lead	B-CHEMICAL
to	O
stroke	B-UNK
in	O
normotensive	O
and	O
/	O
or	O
hypertensive	B-UNK
rats	B-UNK
,	O
we	O
administered	B-UNK
the	O
combination	B-UNK
in	O
six	O
times	B-UNK
the	O
allowed	O
human	B-UNK
dose	B-UNK
calculated	O
on	O
a	O
per	O
weight	B-UNK
basis	B-UNK
for	O
the	O
rats	B-UNK
two	O
times	B-UNK
per	O
day	B-UNK
for	O
five	O
days	B-UNK
.	O
Subarachnoid	O
and	O
cerebral	B-DISEASE
hemorrhage	I-DISEASE
was	O
noted	O
in	O
18	O
%	O
of	O
the	O
hypertensive	B-UNK
rats	B-UNK
.	O
A	O
single	B-UNK
PPA	O
/	O
caffeine	B-CHEMICAL
administration	B-UNK
(	O
same	O
dose	B-UNK
)	O
lead	B-CHEMICAL
to	O
acute	B-UNK
hypertension	B-DISEASE
in	O
both	O
the	O
normotensive	O
and	O
hypertensive	B-UNK
animals	B-UNK
.	O
These	O
results	B-UNK
suggest	B-UNK
that	O
PPA	O
/	O
caffeine	B-CHEMICAL
can	O
lead	B-CHEMICAL
to	O
cerebral	B-DISEASE
hemorrhage	I-DISEASE
in	O
previously	B-UNK
hypertensive	B-UNK
animals	B-UNK
when	O
administered	B-UNK
in	O
greater	B-UNK
than	O
the	O
allowed	O
dosage	B-UNK
.	O
An	O
acute	B-UNK
elevation	B-UNK
in	O
blood	B-UNK
pressure	B-UNK
may	O
be	O
a	O
contributing	B-UNK
factor	B-UNK
.	O

Long	O
-	O
term	B-UNK
efficacy	B-UNK
and	O
toxicity	B-UNK
of	O
high	B-UNK
-	O
dose	B-UNK
amiodarone	B-CHEMICAL
therapy	B-UNK
for	O
ventricular	B-DISEASE
tachycardia	I-DISEASE
or	O
ventricular	B-DISEASE
fibrillation	I-DISEASE
.	O

Amiodarone	O
was	O
administered	B-UNK
to	O
154	O
patients	B-UNK
who	O
had	O
sustained	B-UNK
,	O
symptomatic	B-UNK
ventricular	B-DISEASE
tachycardia	I-DISEASE
(	O
VT	O
)	O
(	O
n	B-UNK
=	O
118	O
)	O
or	O
a	O
cardiac	B-DISEASE
arrest	I-DISEASE
(	O
n	B-UNK
=	O
36	O
)	O
and	O
who	O
were	O
refractory	B-UNK
to	O
conventional	B-UNK
antiarrhythmic	B-UNK
drugs	B-UNK
.	O
The	O
loading	B-UNK
dose	I-UNK
was	O
800	O
mg	B-UNK
/	O
day	B-UNK
for	O
6	O
weeks	B-UNK
and	O
the	O
maintenance	B-UNK
dose	B-UNK
was	O
600	O
mg	B-UNK
/	O
day	B-UNK
.	O
Sixty	O
-	O
nine	O
percent	O
of	O
patients	B-UNK
continued	B-UNK
treatment	B-UNK
with	O
amiodarone	B-CHEMICAL
and	O
had	O
no	O
recurrence	B-DISEASE
of	O
symptomatic	B-UNK
VT	O
or	O
ventricular	B-DISEASE
fibrillation	I-DISEASE
(	O
VF	O
)	O
over	O
a	O
follow	B-UNK
-	O
up	O
of	O
6	O
to	O
52	O
months	B-UNK
(	O
mean	B-UNK
+	O
/-	O
standard	B-UNK
deviation	B-UNK
14.2	O
+	O
/-	O
8.2	O
)	O
.	O
Six	O
percent	O
of	O
the	O
patients	B-UNK
had	O
a	O
nonfatal	O
recurrence	B-DISEASE
of	O
VT	O
and	O
were	O
successfully	B-UNK
managed	B-UNK
by	O
continuing	O
amiodarone	B-CHEMICAL
at	B-DISEASE
a	O
higher	B-UNK
dose	B-UNK
or	O
by	O
the	O
addition	O
of	O
a	O
conventional	B-UNK
antiarrhythmic	B-UNK
drug	B-UNK
.	O
One	O
or	O
more	O
adverse	B-UNK
drug	I-UNK
reactions	B-UNK
occurred	B-UNK
in	O
51	O
%	O
of	O
patients	B-UNK
.	O
Adverse	B-UNK
effects	B-UNK
forced	B-UNK
a	O
reduction	B-UNK
in	O
the	O
dose	B-UNK
of	O
amiodarone	B-CHEMICAL
in	O
41	O
%	O
and	O
discontinuation	B-UNK
of	O
amiodarone	B-CHEMICAL
in	O
10	O
%	O
of	O
patients	B-UNK
.	O
The	O
most	O
common	B-UNK
symptomatic	B-UNK
adverse	B-UNK
reactions	B-UNK
were	O
tremor	B-DISEASE
or	O
ataxia	B-DISEASE
(	O
35	O
%	O
)	O
,	O
nausea	B-DISEASE
and	O
anorexia	B-DISEASE
(	O
8	O
%	O
)	O
,	O
visual	B-UNK
halos	O
or	O
blurring	O
(	O
6	O
%	O
)	O
,	O
thyroid	B-DISEASE
function	B-UNK
abnormalities	B-DISEASE
(	O
6	O
%	O
)	O
and	O
pulmonary	B-UNK
interstitial	O
infiltrates	O
(	O
5	O
%	O
)	O
.	O
Although	O
large	B-UNK
-	O
dose	B-UNK
amiodarone	B-CHEMICAL
is	O
highly	B-UNK
effective	B-UNK
in	O
the	O
long	B-UNK
-	O
term	B-UNK
treatment	B-UNK
of	O
VT	O
or	O
VF	O
refractory	B-UNK
to	O
conventional	B-UNK
antiarrhythmic	B-UNK
drugs	B-UNK
,	O
it	O
causes	B-UNK
significant	B-UNK
toxicity	B-UNK
in	O
approximately	B-UNK
50	O
%	O
of	O
patients	B-UNK
.	O
However	O
,	O
when	O
the	O
dose	B-UNK
is	O
adjusted	B-UNK
based	B-UNK
on	O
clinical	B-UNK
response	B-UNK
or	O
the	O
development	B-UNK
of	O
adverse	B-UNK
effects	B-UNK
,	O
75	O
%	O
of	O
patients	B-UNK
with	O
VT	O
or	O
VF	O
can	O
be	O
successfully	B-UNK
managed	B-UNK
with	O
amiodarone	B-CHEMICAL
.	O

Effect	O
of	O
calcium	B-CHEMICAL
chloride	I-CHEMICAL
and	O
4-aminopyridine	B-CHEMICAL
therapy	B-UNK
on	O
desipramine	B-CHEMICAL
toxicity	B-UNK
in	O
rats	B-UNK
.	O

BACKGROUND	O
:	O
Hypotension	O
is	O
a	O
major	B-UNK
contributor	O
to	O
mortality	B-UNK
in	O
tricyclic	B-UNK
antidepressant	I-UNK
overdose	B-UNK
.	O
Recent	B-UNK
data	B-UNK
suggest	B-UNK
that	O
tricyclic	B-UNK
antidepressants	B-UNK
inhibit	O
calcium	B-CHEMICAL
influx	O
in	O
some	O
tissues	B-UNK
.	O
This	O
study	B-UNK
addressed	O
the	O
potential	B-UNK
role	B-UNK
of	O
calcium	B-CHEMICAL
channel	B-UNK
blockade	B-UNK
in	O
tricyclic	B-UNK
antidepressant	I-UNK
-	O
induced	B-UNK
hypotension	B-DISEASE
.	O
METHODS	O
:	O
Two	O
interventions	O
were	O
studied	B-UNK
that	O
have	O
been	O
shown	B-UNK
previously	B-UNK
to	O
improve	O
blood	B-UNK
pressure	B-UNK
with	O
calcium	B-CHEMICAL
channel	B-UNK
blocker	B-UNK
overdose	B-UNK
.	O
CaCl2	O
and	O
4-aminopyridine	B-CHEMICAL
.	O
Anesthetized	O
rats	B-UNK
received	I-UNK
the	O
tricyclic	B-UNK
antidepressant	I-UNK
desipramine	B-CHEMICAL
IP	O
to	O
produce	B-UNK
hypotension	B-DISEASE
,	O
QRS	O
prolongation	B-UNK
,	O
and	O
bradycardia	B-DISEASE
.	O
Fifteen	O
min	B-UNK
later	B-UNK
,	O
animals	B-UNK
received	B-UNK
CaCl2	O
,	O
NaHCO3	O
,	O
or	O
saline	B-UNK
.	O
In	O
a	O
second	B-UNK
experiment	B-UNK
,	O
rats	B-UNK
received	I-UNK
tricyclic	B-UNK
antidepressant	I-UNK
desipramine	B-CHEMICAL
IP	O
followed	B-UNK
in	O
15	O
min	B-UNK
by	O
4-aminopyridine	B-CHEMICAL
or	O
saline	B-UNK
.	O
RESULTS	B-UNK
:	O
NaHCO3	O
briefly	B-UNK
(	O
5	O
min	B-UNK
)	O
reversed	B-UNK
hypotension	B-DISEASE
and	O
QRS	O
prolongation	B-UNK
.	O
CaCl2	O
and	O
4-aminopyridine	B-CHEMICAL
failed	B-UNK
to	O
improve	O
blood	B-UNK
pressure	B-UNK
.	O
The	O
incidence	B-UNK
of	O
ventricular	B-UNK
arrhythmias	B-DISEASE
(	O
p	B-UNK
=	I-UNK
0.004	O
)	O
and	O
seizures	B-DISEASE
(	O
p	B-UNK
=	I-UNK
0.03	B-UNK
)	O
in	O
the	O
CaCl2	O
group	B-UNK
was	O
higher	B-UNK
than	O
the	O
other	O
groups	B-UNK
.	O
CONCLUSION	O
:	O
The	O
administration	B-UNK
of	O
CaCl2	O
or	O
4-aminopyridine	B-CHEMICAL
did	O
not	O
reverse	B-UNK
tricyclic	B-UNK
antidepressant	I-UNK
-	O
induced	B-UNK
hypotension	B-DISEASE
in	O
rats	B-UNK
.	O
CaCl2	O
therapy	B-UNK
may	O
possibly	B-UNK
worsen	O
both	O
cardiovascular	B-UNK
and	O
central	B-UNK
nervous	I-UNK
system	B-UNK
toxicity	B-UNK
.	O
These	O
findings	B-UNK
do	O
not	O
support	B-UNK
a	O
role	B-UNK
for	O
calcium	B-CHEMICAL
channel	B-UNK
inhibition	B-UNK
in	O
the	O
pathogenesis	O
of	O
tricyclic	B-UNK
antidepressant	I-UNK
-	O
induced	B-UNK
hypotension	B-DISEASE
.	O

Phase	O
I	O
trial	B-UNK
of	O
13-cis	O
-	O
retinoic	O
acid	B-UNK
in	O
children	B-UNK
with	O
neuroblastoma	B-DISEASE
following	B-UNK
bone	B-UNK
marrow	B-UNK
transplantation	B-UNK
.	O

PURPOSE	O
:	O
Treatment	O
of	O
neuroblastoma	B-DISEASE
cell	B-UNK
lines	O
with	O
13-cis	O
-	O
retinoic	O
acid	B-UNK
(	O
cis	O
-	O
RA	B-UNK
)	O
can	O
cause	B-UNK
sustained	B-UNK
inhibition	B-UNK
of	O
proliferation	B-UNK
.	O
Since	O
cis	O
-	O
RA	B-UNK
has	O
demonstrated	B-UNK
clinical	B-UNK
responses	B-UNK
in	O
neuroblastoma	B-DISEASE
patients	B-UNK
,	O
it	O
may	O
be	O
effective	B-UNK
in	O
preventing	B-UNK
relapse	O
after	O
cytotoxic	B-UNK
therapy	B-UNK
.	O
This	O
phase	B-UNK
I	O
trial	B-UNK
was	O
designed	O
to	O
determine	B-UNK
the	O
maximal	O
-	O
tolerated	B-UNK
dosage	B-UNK
(	O
MTD	O
)	O
,	O
toxicities	B-UNK
,	O
and	O
pharmacokinetics	O
of	O
cis	O
-	O
RA	B-UNK
administered	B-UNK
on	O
an	O
intermittent	B-UNK
schedule	B-UNK
in	O
children	B-UNK
with	O
neuroblastoma	B-DISEASE
following	B-UNK
bone	B-UNK
marrow	B-UNK
transplantation	B-UNK
(	O
BMT	O
)	O
.	O
PATIENTS	O
AND	O
METHODS	O
:	O
Fifty	O
-	O
one	O
assessable	O
patients	B-UNK
,	O
2	B-DISEASE
to	O
12	O
years	B-UNK
of	O
age	B-UNK
,	O
were	O
treated	B-UNK
with	O
oral	B-UNK
cis	O
-	O
RA	B-UNK
administered	B-UNK
in	O
two	O
equally	O
divided	O
doses	B-UNK
daily	B-UNK
for	O
2	B-DISEASE
weeks	B-UNK
,	O
followed	B-UNK
by	O
a	O
2-week	O
rest	O
period	B-UNK
,	O
for	O
up	O
to	O
12	O
courses	O
.	O
The	O
dose	B-UNK
was	O
escalated	O
from	O
100	O
to	O
200	O
mg	B-UNK
/	O
m2	O
/	O
d	B-UNK
until	O
dose	B-UNK
-	O
limiting	B-UNK
toxicity	B-UNK
(	O
DLT	O
)	O
was	O
observed	B-UNK
.	O
A	O
single	B-UNK
intrapatient	O
dose	B-UNK
escalation	B-UNK
was	O
permitted	O
.	O
RESULTS	B-UNK
:	O
The	O
MTD	O
of	O
cis	O
-	O
RA	B-UNK
was	O
160	O
mg	B-UNK
/	O
m2	O
/	O
d.	B-UNK
Dose	B-UNK
-	O
limiting	B-UNK
toxicities	B-UNK
in	O
six	O
of	O
nine	O
patients	B-UNK
at	B-DISEASE
200	O
mg	B-UNK
/	O
m2	O
/	O
d	B-UNK
included	B-UNK
hypercalcemia	B-DISEASE
(	O
n	B-UNK
=	O
3	O
)	O
,	O
rash	B-DISEASE
(	O
n	B-UNK
=	O
2	B-DISEASE
)	O
,	O
and	O
anemia	B-DISEASE
/	O
thrombocytopenia	B-DISEASE
/	O
emesis	O
/	O
rash	B-DISEASE
(	O
n	B-UNK
=	O
1	O
)	O
.	O
All	O
toxicities	B-UNK
resolved	B-UNK
after	O
cis	O
-	O
RA	B-UNK
was	O
discontinued	O
.	O
Three	O
complete	B-UNK
responses	B-UNK
were	O
observed	B-UNK
in	O
marrow	B-UNK
metastases	O
.	O
Serum	B-UNK
levels	B-UNK
of	O
7.4	B-UNK
+	O
/-	O
3.0	O
mumol	B-UNK
/	O
L	B-UNK
(	O
peak	B-UNK
)	O
and	O
4.0	B-UNK
+	O
/-	O
2.8	O
mumol	B-UNK
/	O
L	B-UNK
(	O
trough	O
)	O
at	B-DISEASE
the	O
MTD	O
were	O
maintained	O
during	O
14	O
days	B-UNK
of	O
therapy	B-UNK
.	O
The	O
DLT	O
correlated	B-UNK
with	O
serum	B-UNK
levels	B-UNK
>	O
or	O
=	O
10	O
mumol	B-UNK
/	O
L.	B-UNK
CONCLUSION	O
:	O
The	O
MTD	O
of	O
cis	O
-	O
RA	B-UNK
given	B-UNK
on	O
this	O
intermittent	B-UNK
schedule	B-UNK
was	O
160	O
mg	B-UNK
/	O
m2	O
/	O
d.	B-UNK
Serum	B-UNK
levels	B-UNK
known	B-UNK
to	O
be	O
effective	B-UNK
against	O
neuroblastoma	B-DISEASE
in	O
vitro	B-UNK
were	O
achieved	B-UNK
at	B-DISEASE
this	O
dose	B-UNK
.	O
The	O
DLT	O
included	B-UNK
hypercalcemia	B-DISEASE
,	O
and	O
may	O
be	O
predicted	O
by	O
serum	B-UNK
cis	O
-	O
RA	B-UNK
levels	B-UNK
.	O
Monitoring	O
of	O
serum	B-UNK
calcium	B-CHEMICAL
and	O
cis	O
-	O
RA	B-UNK
levels	B-UNK
is	O
indicated	B-UNK
in	O
future	B-UNK
trials	B-UNK
.	O

Effect	O
of	O
calcium	B-CHEMICAL
chloride	I-CHEMICAL
on	O
gross	B-UNK
behavioural	B-UNK
changes	B-UNK
produced	B-UNK
by	O
carbachol	B-CHEMICAL
and	O
eserine	O
in	O
cats	O
.	O

The	O
effect	B-UNK
of	O
calcium	B-CHEMICAL
chloride	I-CHEMICAL
injected	B-UNK
into	O
the	O
cerebral	B-UNK
ventricles	O
of	O
group	B-UNK
-	O
housed	O
unanaesthetized	O
cats	O
upon	O
vocalization	O
(	O
rage	O
,	O
hissing	O
and	O
snarling	O
)	O
,	O
fighting	O
(	O
attack	O
with	O
paws	O
and	O
claws	O
,	O
defense	O
with	O
paws	O
and	O
claws	O
and	O
biting	O
)	O
,	O
mydriasis	B-DISEASE
,	O
tremor	B-DISEASE
and	O
clonic	O
-	O
tonic	B-DISEASE
convulsions	B-DISEASE
produced	B-UNK
by	O
carbachol	B-CHEMICAL
and	O
eserine	O
injected	B-UNK
similarly	O
was	O
investigated	B-UNK
.	O
Calcium	B-UNK
chloride	B-UNK
depressed	B-UNK
or	O
almost	O
completely	B-UNK
abolished	B-UNK
the	O
vocalization	O
and	O
fighting	O
due	O
to	O
carbachol	B-CHEMICAL
and	O
eserine	O
.	O
On	O
the	O
other	O
hand	B-DISEASE
,	O
mydriasis	B-DISEASE
,	O
tremor	B-DISEASE
and	O
clonic	O
-	O
tonic	B-DISEASE
convulsions	B-DISEASE
evoked	O
by	O
carbachol	B-CHEMICAL
and	O
eserine	O
were	O
not	O
significantly	B-UNK
changed	B-UNK
by	O
calcium	B-CHEMICAL
chloride	I-CHEMICAL
.	O
It	O
is	O
apparent	O
that	O
calcium	B-CHEMICAL
chloride	I-CHEMICAL
can	O
"	O
dissociate	O
"	O
vocalization	O
and	O
fighting	O
from	O
autonomic	B-UNK
and	O
motor	B-UNK
phenomena	O
such	O
as	O
mydriasis	B-DISEASE
,	O
tremor	B-DISEASE
and	O
clonic	O
-	O
tonic	B-DISEASE
convulsions	B-DISEASE
caused	B-UNK
by	O
carbachol	B-CHEMICAL
and	O
eserine	O
.	O
Calcium	B-UNK
chloride	B-UNK
inhibited	B-UNK
the	O
vocalization	O
and	O
fighting	O
produced	B-UNK
by	O
carbachol	B-CHEMICAL
and	O
eserine	O
most	O
probably	B-UNK
by	O
a	O
nonspecific	O
stabilizing	O
action	B-UNK
on	O
central	B-UNK
muscarinic	O
cholinoceptive	O
sites	O
.	O
These	O
results	B-UNK
further	O
support	B-UNK
the	O
view	O
that	O
calcium	B-CHEMICAL
ions	B-CHEMICAL
in	O
excess	B-UNK
have	O
an	O
atropine	B-CHEMICAL
-	O
like	B-UNK
action	B-UNK
also	O
in	O
the	O
central	B-UNK
nervous	I-UNK
system	B-UNK
.	O

Multiple	O
side	O
effects	B-UNK
of	O
penicillamine	B-CHEMICAL
therapy	B-UNK
in	O
one	O
patient	B-UNK
with	O
rheumatoid	B-DISEASE
arthritis	I-DISEASE
.	O

Skin	B-UNK
rashes	O
,	O
proteinuria	B-UNK
,	O
systemic	B-DISEASE
lupus	I-DISEASE
erythematosus	I-DISEASE
,	O
polymyositis	B-DISEASE
and	O
myasthenia	B-DISEASE
gravis	I-DISEASE
have	O
all	O
been	O
recorded	B-UNK
as	O
complications	B-UNK
of	O
penicillamine	B-CHEMICAL
therapy	B-UNK
in	O
patients	B-UNK
with	O
rheumatoid	B-DISEASE
arthritis	I-DISEASE
.	O
A	O
patient	B-UNK
who	O
had	O
developed	B-UNK
all	O
5	O
is	O
now	O
described	B-UNK
.	O
The	O
skin	B-DISEASE
lesion	B-UNK
resembled	O
elastosis	B-DISEASE
perforans	I-DISEASE
serpiginosa	I-DISEASE
,	O
which	O
has	O
been	O
reported	B-UNK
as	O
a	O
rare	B-UNK
side	O
effect	B-UNK
in	O
patients	B-UNK
with	O
Wilson'	O
s	O
disease	B-DISEASE
but	O
not	O
in	O
patients	B-UNK
with	O
rheumatoid	B-DISEASE
arthritis	I-DISEASE
treated	B-UNK
with	O
penicillamine	B-CHEMICAL
.	O

Electrocardiographic	O
changes	B-UNK
and	O
cardiac	B-UNK
arrhythmias	B-DISEASE
in	O
patients	B-UNK
receiving	B-UNK
psychotropic	B-CHEMICAL
drugs	I-CHEMICAL
.	O

Eight	O
patients	B-UNK
had	O
cardiac	B-UNK
manifestations	B-UNK
that	O
were	O
life	B-UNK
-	O
threatening	O
in	O
five	O
while	O
taking	B-UNK
psychotropic	B-CHEMICAL
drugs	I-CHEMICAL
,	O
either	O
phenothiazines	B-CHEMICAL
or	O
tricyclic	B-UNK
antidepressants	B-UNK
.	O
Although	O
most	O
patients	B-UNK
were	O
receiving	B-UNK
several	O
drugs	B-UNK
,	O
Mellaril	O
(	O
thioridazine	B-CHEMICAL
)	O
appeared	B-UNK
to	O
be	O
responsible	O
for	O
five	O
cases	B-UNK
of	O
ventricular	B-DISEASE
tachycardia	I-DISEASE
,	O
one	O
of	O
which	O
was	O
fatal	B-UNK
in	O
a	O
35	O
year	B-UNK
old	B-UNK
woman	B-UNK
.	O
Supraventricular	O
tachycardia	B-DISEASE
developed	B-UNK
in	O
one	O
patient	B-UNK
receiving	B-UNK
Thorazine	O
(	O
chlorpromazine	B-CHEMICAL
)	O
.	O
Aventyl	O
(	O
nortriptyline	B-CHEMICAL
)	O
and	O
Elavil	O
(	O
amitriptyline	B-CHEMICAL
)	O
each	O
produced	B-UNK
left	B-UNK
bundle	B-DISEASE
branch	I-DISEASE
block	I-DISEASE
in	O
a	O
73	O
year	B-UNK
old	B-UNK
woman	B-UNK
.	O
Electrocardiographic	O
T	B-UNK
and	O
U	B-UNK
wave	O
abnormalities	B-DISEASE
were	O
present	B-UNK
in	O
most	O
patients	B-UNK
.	O
The	O
ventricular	B-UNK
arrhythmias	B-DISEASE
responded	O
to	O
intravenous	B-UNK
administration	B-UNK
of	O
lidocaine	B-CHEMICAL
and	O
to	O
direct	B-UNK
current	B-UNK
electric	O
shock	B-DISEASE
;	O
ventricular	B-UNK
pacing	B-UNK
was	O
required	B-UNK
in	O
some	O
instances	O
and	O
intravenous	B-UNK
administration	B-UNK
of	O
propranolol	B-CHEMICAL
combined	B-UNK
with	O
ventricular	B-UNK
pacing	B-UNK
in	O
one	O
.	O
The	O
tachyarrhythmias	O
generally	B-UNK
subsided	O
within	O
48	O
hours	B-UNK
after	O
administration	B-UNK
of	O
the	O
drugs	B-UNK
was	O
stopped	O
.	O
Five	O
of	O
the	O
eight	O
patients	B-UNK
were	O
50	O
years	B-UNK
of	O
age	B-UNK
or	O
younger	O
;	O
only	O
one	O
clearly	B-UNK
had	O
antecedent	O
heart	B-DISEASE
disease	I-DISEASE
.	O
Major	O
cardiac	B-UNK
arrhythmias	B-DISEASE
are	O
a	O
potential	B-UNK
hazard	B-UNK
in	O
patients	B-UNK
without	O
heart	B-DISEASE
disease	I-DISEASE
who	O
are	O
receiving	B-UNK
customary	O
therapeutic	B-UNK
doses	B-UNK
of	O
psychotropic	B-CHEMICAL
drugs	I-CHEMICAL
.	O
A	O
prospective	B-UNK
clinical	B-UNK
trial	B-UNK
is	O
suggested	B-UNK
to	O
quantify	O
the	O
risk	B-UNK
of	O
cardiac	B-UNK
complications	B-UNK
to	O
patients	B-UNK
receiving	B-UNK
phenothiazines	B-CHEMICAL
or	O
tricyclic	B-UNK
antidepressant	I-UNK
drugs	B-UNK
.	O

Serotonergic	O
drugs	B-UNK
,	O
benzodiazepines	B-CHEMICAL
and	O
baclofen	B-CHEMICAL
block	B-UNK
muscimol	B-CHEMICAL
-	O
induced	B-UNK
myoclonic	B-UNK
jerks	B-UNK
in	O
a	O
strain	B-UNK
of	O
mice	B-UNK
.	O

In	O
male	B-UNK
Swiss	B-UNK
mice	B-UNK
,	O
muscimol	B-CHEMICAL
produced	B-UNK
myoclonic	B-UNK
jerks	B-UNK
.	O
A	O
3	O
mg	B-UNK
/	O
kg	B-UNK
(	O
i.p	B-UNK
.	O
)	O
dose	B-UNK
induced	B-UNK
this	O
response	B-UNK
in	O
all	O
of	O
the	O
mice	B-UNK
tested	B-UNK
and	O
the	O
peak	B-UNK
response	B-UNK
of	O
73	O
jerks	B-UNK
per	O
min	B-UNK
was	O
observed	B-UNK
between	O
27	O
and	O
45	O
min	B-UNK
.	O
Increasing	O
the	O
brain	B-UNK
serotonin	B-CHEMICAL
levels	B-UNK
by	O
the	O
administration	B-UNK
of	O
5-hydroxytryptophan	B-CHEMICAL
(	O
80	O
-	O
160	O
mg	B-UNK
/	O
kg	B-UNK
)	O
in	O
combination	B-UNK
with	O
a	O
peripheral	B-UNK
decarboxylase	O
inhibitor	B-UNK
resulted	B-UNK
in	O
an	O
inhibition	B-UNK
of	O
the	O
muscimol	B-CHEMICAL
effect	B-UNK
.	O
However	O
,	O
in	O
a	O
similar	B-UNK
experiment	B-UNK
l	B-UNK
-	O
dopa	O
(	O
80	O
-	O
160	O
mg	B-UNK
/	O
kg	B-UNK
)	O
was	O
without	O
effect	B-UNK
.	O
In	O
doses	B-UNK
of	O
3	O
-	O
10	O
mg	B-UNK
/	O
kg	B-UNK
,	O
the	O
serotonin	B-CHEMICAL
receptor	B-UNK
agonist	B-UNK
MK-212	O
caused	B-UNK
a	O
dose	B-UNK
-	O
dependent	B-UNK
blockade	B-UNK
of	O
the	O
response	B-UNK
of	O
muscimol	B-CHEMICAL
.	O
Of	O
the	O
benzodiazepines	B-CHEMICAL
,	O
clonazepam	B-CHEMICAL
(	O
0.1	B-UNK
-	O
0.3	B-UNK
mg	B-UNK
/	O
kg	B-UNK
)	O
was	O
found	B-UNK
to	O
be	O
several	O
fold	O
more	O
potent	B-UNK
than	O
diazepam	B-CHEMICAL
(	O
0.3	B-UNK
-	O
3	O
mg	B-UNK
/	O
kg	B-UNK
)	O
in	O
blocking	B-UNK
the	O
myoclonic	B-UNK
jerks	B-UNK
.	O
While	O
(	O
-)-baclofen	O
(	O
1	O
-	O
3	O
mg	B-UNK
/	O
kg	B-UNK
)	O
proved	O
to	O
be	O
an	O
effective	B-UNK
antagonist	B-UNK
of	O
muscimol	B-CHEMICAL
,	O
its	O
(	O
+	O
)	O
-isomer	O
(	O
5	O
-	O
20	O
mg	B-UNK
/	O
kg	B-UNK
)	O
lacked	O
this	O
property	O
.	O
Considering	O
the	O
fact	O
that	O
5-HTP	O
and	O
the	O
benzodiazepines	B-CHEMICAL
have	O
been	O
found	B-UNK
to	O
be	O
beneficial	B-UNK
in	O
the	O
management	B-UNK
of	O
clinical	B-UNK
myoclonus	B-DISEASE
,	O
the	O
muscimol	B-CHEMICAL
-	O
induced	B-UNK
myoclonus	B-DISEASE
seems	O
to	O
be	O
a	O
satisfactory	O
animal	B-UNK
model	B-UNK
that	O
may	O
prove	O
useful	B-UNK
for	O
the	O
development	B-UNK
of	O
new	B-UNK
drug	B-UNK
treatments	B-UNK
for	O
this	O
condition	B-UNK
.	O
Our	O
present	B-UNK
study	B-UNK
indicated	B-UNK
the	O
possible	B-UNK
value	B-UNK
of	O
MK-212	O
and	O
(	O
-)-baclofen	O
in	O
the	O
management	B-UNK
of	O
clinical	B-UNK
myoclonus	B-DISEASE
.	O

Hyperglycemic	O
acidotic	O
coma	B-DISEASE
and	O
death	B-DISEASE
in	O
Kearns	O
-	O
Sayre	O
syndrome	B-DISEASE
.	O

This	O
paper	O
presents	O
the	O
clinical	B-UNK
and	O
metabolic	B-UNK
findings	B-UNK
in	O
two	O
young	B-UNK
boys	O
with	O
long	B-UNK
-	O
standing	O
Kearns	O
-	O
Sayre	O
syndrome	B-UNK
.	O
Following	O
short	B-UNK
exposure	B-UNK
to	O
oral	B-UNK
prednisone	B-CHEMICAL
,	O
both	O
boys	O
developed	B-UNK
lethargy	B-DISEASE
,	O
increasing	B-UNK
somnolence	O
,	O
polydipsia	B-DISEASE
,	O
polyphagia	O
,	O
and	O
polyuria	B-DISEASE
.	O
Both	O
presented	B-UNK
in	O
the	O
emergency	B-UNK
room	B-UNK
with	O
profound	B-UNK
coma	B-DISEASE
,	O
hypotension	B-DISEASE
,	O
severe	B-UNK
hyperglycemia	B-DISEASE
,	O
and	O
acidosis	B-DISEASE
.	O
Nonketotic	O
lactic	B-DISEASE
acidosis	I-DISEASE
was	O
present	B-UNK
in	O
one	O
and	O
ketosis	B-DISEASE
without	O
a	O
known	B-UNK
serum	B-UNK
lactate	B-UNK
level	B-UNK
was	O
present	B-UNK
in	O
the	O
other	O
.	O
Respiratory	O
failure	B-UNK
rapidly	B-UNK
ensued	O
and	O
both	O
patients	B-UNK
expired	O
in	O
spite	O
of	O
efforts	O
at	B-DISEASE
resuscitation	O
.	O
We	O
believe	O
these	O
two	O
cases	B-UNK
represent	B-UNK
a	O
newly	B-UNK
described	B-UNK
and	O
catastrophic	O
metabolic	B-UNK
-	O
endocrine	B-UNK
failure	B-UNK
in	O
the	O
Kearns	O
-	O
Sayre	O
syndrome	B-UNK
.	O

Effects	O
of	O
active	B-UNK
constituents	O
of	O
Crocus	O
sativus	O
L.	B-UNK
,	O
crocin	B-CHEMICAL
on	O
streptozocin	B-CHEMICAL
-	O
induced	B-UNK
model	B-UNK
of	O
sporadic	B-UNK
Alzheimer'	O
s	O
disease	B-DISEASE
in	O
male	B-UNK
rats	B-UNK
.	O

BACKGROUND	O
:	O
The	O
involvement	B-UNK
of	O
water	B-CHEMICAL
-	O
soluble	B-UNK
carotenoids	B-CHEMICAL
,	O
crocins	O
,	O
as	O
the	O
main	B-UNK
and	O
active	B-UNK
components	B-UNK
of	O
Crocus	O
sativus	O
L.	B-UNK
extract	B-UNK
in	O
learning	B-UNK
and	O
memory	B-UNK
processes	B-UNK
has	O
been	O
proposed	O
.	O
In	O
the	O
present	B-UNK
study	B-UNK
,	O
the	O
effect	B-UNK
of	O
crocins	O
on	O
sporadic	B-UNK
Alzheimer'	O
s	O
disease	B-DISEASE
induced	B-UNK
by	O
intracerebroventricular	O
(	O
icv	O
)	O
streptozocin	B-CHEMICAL
(	O
STZ	B-UNK
)	O
in	O
male	B-UNK
rats	B-UNK
was	O
investigated	B-UNK
.	O
METHODS	O
:	O
Male	B-UNK
adult	B-UNK
Wistar	B-UNK
rats	I-UNK
(	O
n	B-UNK
=	O
90	O
and	O
260	O
-	O
290	O
g	B-UNK
)	O
were	O
divided	O
into	O
1	O
,	O
control	B-UNK
;	O
2	B-DISEASE
and	O
3	O
,	O
crocins	O
(	O
15	O
and	O
30	O
mg	B-UNK
/	O
kg	B-UNK
)	O
;	O
4	O
,	O
STZ	B-UNK
;	O
5	O
and	O
6	O
,	O
STZ	B-UNK
+	O
crocins	O
(	O
15	O
and	O
30	O
mg	B-UNK
/	O
kg	B-UNK
)	O
groups	B-UNK
.	O
In	O
Alzheimer'	O
s	O
disease	B-DISEASE
groups	B-UNK
,	O
rats	B-UNK
were	O
injected	B-UNK
with	O
STZ	B-UNK
-	O
icv	O
bilaterally	B-UNK
(	O
3	O
mg	B-UNK
/	O
kg	B-UNK
)	O
in	O
first	O
day	B-UNK
and	O
3	O
days	B-UNK
later	B-UNK
,	O
a	O
similar	B-UNK
STZ	B-UNK
-	O
icv	O
application	B-UNK
was	O
repeated	B-UNK
.	O
In	O
STZ	B-UNK
+	O
crocin	B-CHEMICAL
animal	B-UNK
groups	B-UNK
,	O
crocin	B-CHEMICAL
was	O
applied	O
in	O
doses	B-UNK
of	O
15	O
and	O
30	O
mg	B-UNK
/	O
kg	B-UNK
,	O
i.p	B-UNK
.	O
,	O
one	O
day	B-UNK
pre	B-UNK
-	O
surgery	B-UNK
and	O
continued	B-UNK
for	O
three	O
weeks	B-UNK
.	O
Prescription	O
of	O
crocin	B-CHEMICAL
in	O
each	O
dose	B-UNK
was	O
repeated	B-UNK
once	O
for	O
two	O
days	B-UNK
.	O
However	O
,	O
the	O
learning	B-UNK
and	O
memory	B-UNK
performance	B-UNK
was	O
assessed	B-UNK
using	O
passive	B-UNK
avoidance	B-UNK
paradigm	B-UNK
,	O
and	O
for	O
spatial	B-UNK
cognition	O
evaluation	B-UNK
,	O
Y	O
-	O
maze	B-UNK
task	B-UNK
was	O
used	O
.	O
RESULTS	B-UNK
:	O
It	O
was	O
found	B-UNK
out	O
that	O
crocin	B-CHEMICAL
(	O
30	O
mg	B-UNK
/	O
kg)-treated	O
STZ	B-UNK
-	O
injected	B-UNK
rats	B-UNK
show	O
higher	B-UNK
correct	O
choices	O
and	O
lower	B-UNK
errors	O
in	O
Y	O
-	O
maze	B-UNK
than	O
vehicle	B-UNK
-	O
treated	B-UNK
STZ	B-UNK
-	O
injected	B-UNK
rats	B-UNK
.	O
In	O
addition	O
,	O
crocin	B-CHEMICAL
in	O
the	O
mentioned	B-UNK
dose	B-UNK
could	O
significantly	B-UNK
attenuated	B-UNK
learning	B-UNK
and	O
memory	B-UNK
impairment	B-UNK
in	O
treated	B-UNK
STZ	B-UNK
-	O
injected	B-UNK
group	B-UNK
in	O
passive	B-UNK
avoidance	B-UNK
test	B-UNK
.	O
CONCLUSION	O
:	O
Therefore	O
,	O
these	O
results	B-UNK
demonstrate	B-UNK
the	O
effectiveness	O
of	O
crocin	B-CHEMICAL
(	O
30	O
mg	B-UNK
/	O
kg	B-UNK
)	O
in	O
antagonizing	O
the	O
cognitive	B-UNK
deficits	B-UNK
caused	B-UNK
by	O
STZ	B-UNK
-	O
icv	O
in	O
rats	B-UNK
and	O
its	O
potential	B-UNK
in	O
the	O
treatment	B-UNK
of	O
neurodegenerative	B-DISEASE
diseases	I-DISEASE
such	O
as	O
Alzheimer'	O
s	O
disease	B-DISEASE
.	O

Rosaceiform	O
dermatitis	B-DISEASE
associated	B-UNK
with	O
topical	B-UNK
tacrolimus	B-CHEMICAL
treatment	B-UNK
.	O

We	O
describe	O
herein	O
3	O
patients	B-UNK
who	O
developed	B-UNK
rosacea	B-DISEASE
-	O
like	B-UNK
dermatitis	B-DISEASE
eruptions	O
while	O
using	O
0.03	B-UNK
%	O
or	O
0.1	B-UNK
%	O
tacrolimus	B-CHEMICAL
ointment	O
for	O
facial	B-UNK
dermatitis	B-DISEASE
.	O
Skin	B-UNK
biopsy	B-UNK
specimens	O
showed	B-UNK
telangiectasia	B-DISEASE
and	O
noncaseating	O
epithelioid	O
granulomatous	O
tissue	B-UNK
formation	B-UNK
in	O
the	O
papillary	B-UNK
to	O
mid	O
dermis	O
.	O
Continuous	B-UNK
topical	B-UNK
use	B-UNK
of	O
immunomodulators	O
such	O
as	O
tacrolimus	B-CHEMICAL
or	O
pimecrolimus	B-CHEMICAL
should	O
be	O
regarded	O
as	O
a	O
potential	B-UNK
cause	B-UNK
of	O
rosaceiform	O
dermatitis	B-DISEASE
,	O
although	O
many	O
cases	B-UNK
have	O
not	O
been	O
reported	B-UNK
.	O

A	O
novel	B-UNK
animal	B-UNK
model	B-UNK
to	O
evaluate	B-UNK
the	O
ability	B-UNK
of	O
a	O
drug	B-UNK
delivery	B-UNK
system	B-UNK
to	O
promote	B-UNK
the	O
passage	O
through	O
the	O
BBB	O
.	O

The	O
purpose	O
of	O
this	O
investigation	O
was	O
to	O
explore	O
the	O
potentiality	O
of	O
a	O
novel	B-UNK
animal	B-UNK
model	B-UNK
to	O
be	O
used	O
for	O
the	O
in	O
vivo	B-UNK
evaluation	B-UNK
of	O
the	O
ability	B-UNK
of	O
a	O
drug	B-UNK
delivery	B-UNK
system	B-UNK
to	O
promote	B-UNK
the	O
passage	O
through	O
the	O
blood	B-UNK
-	O
brain	B-UNK
barrier	B-UNK
(	O
BBB	O
)	O
and	O
/	O
or	O
to	O
improve	O
the	O
brain	B-UNK
localization	O
of	O
a	O
bioactive	O
compound	B-UNK
.	O
A	O
Tween	O
80-coated	O
poly	O
-	O
L	B-UNK
-	O
lactid	O
acid	B-UNK
nanoparticles	B-UNK
was	O
used	O
as	O
a	O
model	B-UNK
of	O
colloidal	O
drug	B-UNK
delivery	B-UNK
system	B-UNK
,	O
able	O
to	O
trespass	O
the	O
BBB	O
.	O
Tacrine	O
,	O
administered	B-UNK
in	O
LiCl	O
pre	B-UNK
-	O
treated	B-UNK
rats	B-UNK
,	O
induces	B-UNK
electrocorticographic	O
seizures	B-DISEASE
and	O
delayed	B-UNK
hippocampal	B-UNK
damage	B-UNK
.	O
The	O
toxic	B-UNK
effects	B-UNK
of	O
tacrine	B-CHEMICAL
-	O
loaded	B-UNK
poly	O
-	O
L	B-UNK
-	O
lactid	O
acid	B-UNK
nanoparticles	B-UNK
(	O
5mg	O
/	O
kg	B-UNK
)	O
,	O
a	O
saline	B-UNK
solution	B-UNK
of	O
tacrine	B-CHEMICAL
(	O
5mg	O
/	O
kg	B-UNK
)	O
and	O
an	O
empty	O
colloidal	O
nanoparticle	O
suspension	O
were	O
compared	B-UNK
following	B-UNK
i.p	B-UNK
.	O
administration	B-UNK
in	O
LiCl	O
-	O
pre	B-UNK
-	O
treated	B-UNK
Wistar	B-UNK
rats	I-UNK
.	O
All	O
the	O
animals	B-UNK
treated	B-UNK
with	O
tacrine	B-CHEMICAL
-	O
loaded	B-UNK
nanoparticles	B-UNK
showed	B-UNK
an	O
earlier	B-UNK
outcome	B-UNK
of	O
CNS	O
adverse	B-UNK
symptoms	B-UNK
,	O
i.e	O
.	O
epileptic	B-UNK
onset	B-UNK
,	O
with	O
respect	O
to	O
those	O
animals	B-UNK
treated	B-UNK
with	O
the	O
free	B-UNK
compound	B-UNK
(	O
10	O
min	B-UNK
vs	B-UNK
.	O
22	O
min	B-UNK
respectively	O
)	O
.	O
In	O
addition	O
,	O
tacrine	B-CHEMICAL
-	O
loaded	B-UNK
nanoparticles	B-UNK
administration	B-UNK
induced	B-UNK
damage	B-UNK
of	O
neuronal	B-UNK
cells	B-UNK
in	O
CA1	B-UNK
field	B-UNK
of	O
the	O
hippocampus	B-UNK
in	O
all	O
treated	B-UNK
animals	B-UNK
,	O
while	O
the	O
saline	B-UNK
solution	B-UNK
of	O
tacrine	B-CHEMICAL
only	O
in	O
60	O
%	O
of	O
animals	B-UNK
.	O
Empty	O
nanoparticles	B-UNK
provided	B-UNK
similar	B-UNK
results	B-UNK
to	O
control	B-UNK
(	O
saline	B-UNK
-	O
treated	B-UNK
)	O
group	B-UNK
of	O
animals	B-UNK
.	O
In	O
conclusion	O
,	O
the	O
evaluation	B-UNK
of	O
time	B-UNK
-	O
to	O
-	O
onset	B-UNK
of	O
symptoms	B-UNK
and	O
the	O
severity	B-UNK
of	O
neurodegenerative	O
processes	B-UNK
induced	B-UNK
by	O
the	O
tacrine	B-CHEMICAL
-	O
lithium	B-CHEMICAL
model	B-UNK
of	O
epilepsy	B-DISEASE
in	O
the	O
rat	B-UNK
,	O
could	O
be	O
used	O
to	O
evaluate	B-UNK
preliminarily	O
the	O
capability	O
of	O
a	O
drug	B-UNK
delivery	B-UNK
system	B-UNK
to	O
trespass	O
(	O
or	O
not	O
)	O
the	O
BBB	O
in	O
vivo	B-UNK
.	O

The	O
antiarrhythmic	B-UNK
effect	B-UNK
and	O
possible	B-UNK
ionic	O
mechanisms	B-UNK
of	O
pilocarpine	B-CHEMICAL
on	O
animal	B-UNK
models	B-UNK
.	O

This	O
study	B-UNK
was	O
designed	O
to	O
evaluate	B-UNK
the	O
effects	B-UNK
of	O
pilocarpine	B-CHEMICAL
and	O
explore	O
the	O
underlying	B-UNK
ionic	O
mechanism	B-UNK
,	O
using	O
both	O
aconitine	B-CHEMICAL
-	O
induced	B-UNK
rat	B-UNK
and	O
ouabain	B-CHEMICAL
-	O
induced	B-UNK
guinea	B-UNK
pig	I-UNK
arrhythmia	B-DISEASE
models	B-UNK
.	O
Confocal	O
microscopy	B-UNK
was	O
used	O
to	O
measure	B-UNK
intracellular	B-UNK
free	B-UNK
-	O
calcium	B-CHEMICAL
concentrations	B-UNK
(	O
[	O
Ca(2+)](i	O
)	O
)	O
in	O
isolated	B-UNK
myocytes	O
.	O
The	O
current	B-UNK
data	B-UNK
showed	B-UNK
that	O
pilocarpine	B-CHEMICAL
significantly	B-UNK
delayed	B-UNK
onset	B-UNK
of	O
arrhythmias	B-DISEASE
,	O
decreased	B-UNK
the	O
time	B-UNK
course	B-UNK
of	O
ventricular	B-DISEASE
tachycardia	I-DISEASE
and	O
fibrillation	B-UNK
,	O
reduced	B-UNK
arrhythmia	B-DISEASE
score	B-UNK
,	O
and	O
increased	B-UNK
the	O
survival	B-UNK
time	B-UNK
of	O
arrhythmic	O
rats	B-UNK
and	O
guinea	B-UNK
pigs	B-UNK
.	O
[	O
Ca(2+)](i	O
)	O
overload	O
induced	B-UNK
by	O
aconitine	B-CHEMICAL
or	O
ouabain	B-CHEMICAL
was	O
reduced	B-UNK
in	O
isolated	B-UNK
myocytes	O
pretreated	B-UNK
with	O
pilocarpine	B-CHEMICAL
.	O
Moreover	O
,	O
M(3)-muscarinic	O
acetylcholine	B-CHEMICAL
receptor	B-UNK
(	O
mAChR	O
)	O
antagonist	B-UNK
4-DAMP	O
(	O
4-diphenylacetoxy	O
-	O
N	B-UNK
-	O
methylpiperidine	O
-	O
methiodide	O
)	O
partially	O
abolished	B-UNK
the	O
beneficial	B-UNK
effects	B-UNK
of	O
pilocarpine	B-CHEMICAL
.	O
These	O
data	B-UNK
suggest	B-UNK
that	O
pilocarpine	B-CHEMICAL
produced	B-UNK
antiarrhythmic	B-UNK
actions	B-UNK
on	O
arrhythmic	O
rat	B-UNK
and	O
guinea	B-UNK
pig	I-UNK
models	B-UNK
induced	B-UNK
by	O
aconitine	B-CHEMICAL
or	O
ouabain	B-CHEMICAL
via	O
stimulating	B-UNK
the	O
cardiac	B-UNK
M(3)-mAChR.	O
The	O
mechanism	B-UNK
may	O
be	O
related	B-UNK
to	O
the	O
improvement	B-UNK
of	O
Ca(2	B-UNK
+	O
)	O
handling	O
.	O

Disulfiram	O
-	O
induced	B-UNK
transient	B-UNK
optic	B-UNK
and	O
peripheral	B-DISEASE
neuropathy	I-DISEASE
:	O
a	O
case	B-UNK
report	B-UNK
.	O

AIM	O
:	O
To	O
report	B-UNK
a	O
case	B-UNK
of	O
optic	B-UNK
and	O
peripheral	B-DISEASE
neuropathy	I-DISEASE
after	O
chronic	B-UNK
use	B-UNK
of	O
disulfiram	B-CHEMICAL
for	O
alcohol	B-UNK
dependence	B-DISEASE
management	B-UNK
.	O
MATERIALS	O
AND	O
METHODS	O
:	O
A	O
case	B-UNK
report	B-UNK
.	O
RESULTS	B-UNK
:	O
A	O
57-year	O
-	O
old	B-UNK
male	B-UNK
presented	B-UNK
with	O
gradual	O
loss	B-UNK
of	O
vision	B-DISEASE
in	O
both	O
eyes	B-UNK
with	O
intermittent	B-UNK
headaches	O
for	O
2	B-DISEASE
months	B-UNK
.	O
He	O
also	O
complained	O
of	O
paraesthesia	O
with	O
numbness	O
in	O
both	O
feet	O
.	O
His	O
vision	B-DISEASE
was	O
6/15	O
and	O
2/60	O
in	O
the	O
right	B-UNK
and	O
left	B-UNK
eyes	B-UNK
,	O
respectively	O
.	O
Fundoscopy	O
revealed	B-UNK
bilaterally	B-UNK
swollen	O
optic	B-UNK
nerve	I-UNK
heads	O
.	O
Visual	B-UNK
field	B-UNK
testing	B-UNK
confirmed	B-UNK
bilateral	B-UNK
central	B-UNK
-	O
caecal	O
scotomata	O
.	O
He	O
had	O
been	O
taking	B-UNK
disulfiram	B-CHEMICAL
for	O
alcohol	B-UNK
dependence	B-DISEASE
for	O
the	O
preceding	O
3	O
years	B-UNK
.	O
Disulfiram	O
discontinuation	B-UNK
lead	B-CHEMICAL
to	O
an	O
immediate	B-UNK
symptomatic	B-UNK
improvement	B-UNK
.	O
CONCLUSION	O
:	O
Physicians	O
initiating	O
long	B-UNK
-	O
term	B-UNK
disulfiram	B-CHEMICAL
therapy	B-UNK
should	O
be	O
aware	O
of	O
these	O
adverse	B-UNK
effects	B-UNK
.	O
They	O
should	O
recommend	B-UNK
annual	O
ophthalmic	B-UNK
reviews	O
with	O
visual	B-UNK
field	I-UNK
testing	B-UNK
.	O
Patients	B-UNK
should	O
be	O
reassured	O
with	O
respect	O
to	O
the	O
reversibility	O
of	O
these	O
adverse	B-UNK
effects	B-UNK
.	O

Sustained	O
clinical	B-UNK
improvement	B-UNK
of	O
a	O
patient	B-UNK
with	O
decompensated	O
hepatitis	B-DISEASE
B	B-UNK
virus	B-UNK
-	O
related	B-UNK
cirrhosis	B-DISEASE
after	O
treatment	B-UNK
with	O
lamivudine	B-CHEMICAL
monotherapy	B-UNK
.	O

Hepatitis	B-UNK
B	I-UNK
virus	B-UNK
(	O
HBV	B-UNK
)	O
infection	B-UNK
,	O
which	O
causes	B-UNK
liver	B-DISEASE
cirrhosis	I-DISEASE
and	O
hepatocellular	B-DISEASE
carcinoma	I-DISEASE
,	O
remains	B-UNK
a	O
major	B-UNK
health	O
problem	B-UNK
in	O
Asian	O
countries	O
.	O
Recent	B-UNK
development	B-UNK
of	O
vaccine	B-UNK
for	O
prevention	O
is	O
reported	B-UNK
to	O
be	O
successful	B-UNK
in	O
reducing	B-UNK
the	O
size	O
of	O
chronically	B-UNK
infected	B-UNK
carriers	O
,	O
although	O
the	O
standard	B-UNK
medical	B-UNK
therapies	B-UNK
have	O
not	O
been	O
established	B-UNK
up	O
to	O
now	O
.	O
In	O
this	O
report	B-UNK
,	O
we	O
encountered	B-UNK
a	O
patient	B-UNK
with	O
decompensated	O
HBV	B-UNK
-	O
related	B-UNK
cirrhosis	B-DISEASE
who	O
exhibited	B-UNK
the	O
dramatic	B-UNK
improvements	B-UNK
after	O
antiviral	B-UNK
therapy	B-UNK
.	O
The	O
patient	B-UNK
was	O
a	O
50-year	O
-	O
old	B-UNK
woman	B-UNK
.	O
Previous	B-UNK
conventional	B-UNK
medical	B-UNK
treatments	B-UNK
were	O
not	O
effective	B-UNK
for	O
this	O
patient	B-UNK
,	O
thus	O
this	O
patient	B-UNK
had	O
been	O
referred	O
to	O
our	O
hospital	B-UNK
.	O
However	O
,	O
the	O
administration	B-UNK
of	O
lamivudine	B-CHEMICAL
,	O
a	O
reverse	B-UNK
transcriptase	O
inhibitor	B-UNK
,	O
for	O
23	O
months	B-UNK
dramatically	O
improved	B-UNK
her	O
liver	B-DISEASE
severity	B-UNK
.	O
During	O
this	O
period	B-UNK
,	O
no	O
drug	B-UNK
resistant	B-UNK
mutant	O
HBV	B-UNK
emerged	B-UNK
,	O
and	O
the	O
serum	B-UNK
HBV	B-UNK
-	O
DNA	B-UNK
level	B-UNK
was	O
continuously	B-UNK
suppressed	B-UNK
.	O
These	O
virological	O
responses	B-UNK
were	O
also	O
maintained	O
even	O
after	O
the	O
antiviral	B-UNK
therapy	B-UNK
was	O
discontinued	O
.	O
Moreover	O
,	O
both	O
hepatitis	B-DISEASE
B	B-UNK
surface	I-UNK
antigen	B-UNK
and	O
e	B-UNK
antigen	B-UNK
were	O
observed	B-UNK
to	O
have	O
disappeared	B-UNK
in	O
this	O
patient	B-UNK
.	O
The	O
administration	B-UNK
of	O
lamivudine	B-CHEMICAL
to	O
patients	B-UNK
with	O
HBV	B-UNK
-	O
related	B-UNK
cirrhosis	B-DISEASE
,	O
like	B-UNK
our	O
present	B-UNK
case	B-UNK
,	O
should	O
be	O
considered	B-UNK
as	O
an	O
initial	B-UNK
medical	B-UNK
therapeutic	B-UNK
option	O
,	O
especially	B-UNK
in	O
countries	O
where	O
liver	B-DISEASE
transplantation	B-UNK
is	O
not	O
reliably	B-UNK
available	B-UNK
.	O

Dual	O
effects	B-UNK
of	O
melatonin	B-CHEMICAL
on	O
barbiturate	O
-	O
induced	B-UNK
narcosis	B-UNK
in	O
rats	B-UNK
.	O

Melatonin	O
affects	B-UNK
the	O
circadian	O
sleep	O
/	O
wake	O
cycle	B-UNK
,	O
but	O
it	O
is	O
not	O
clear	B-UNK
whether	O
it	O
may	O
influence	B-UNK
drug	B-UNK
-	O
induced	B-UNK
narcosis	B-UNK
.	O
Sodium	O
thiopenthal	O
was	O
administered	B-UNK
intraperitoneally	B-UNK
into	O
male	B-UNK
rats	B-UNK
pre	B-UNK
-	O
treated	B-UNK
with	O
melatonin	B-CHEMICAL
(	O
0.05	O
,	O
0.5	B-UNK
,	O
5	O
and	O
50	O
mg	B-UNK
/	O
kg	B-UNK
)	O
.	O
Melatonin	O
pre	B-UNK
-	O
treatment	B-UNK
affected	B-UNK
in	O
a	O
dual	B-UNK
manner	B-UNK
barbiturate	O
narcosis	B-UNK
,	O
however	O
,	O
no	O
dose	B-UNK
-	O
effect	B-UNK
correlation	B-UNK
was	O
found	B-UNK
.	O
In	O
particular	B-UNK
,	O
low	B-UNK
doses	B-UNK
reduced	B-UNK
the	O
latency	O
to	O
and	O
prolonged	B-UNK
the	O
duration	B-UNK
of	O
barbiturate	O
narcosis	B-UNK
.	O
In	O
contrast	B-UNK
,	O
the	O
highest	B-UNK
dose	B-UNK
of	O
melatonin	B-CHEMICAL
(	O
50	O
mg	B-UNK
/	O
kg	B-UNK
)	O
caused	B-UNK
a	O
paradoxical	O
increase	B-UNK
in	O
the	O
latency	O
and	O
produced	B-UNK
a	O
sustained	B-UNK
reduction	B-UNK
of	O
the	O
duration	B-UNK
of	O
narcosis	B-UNK
,	O
and	O
a	O
reduction	B-UNK
in	O
mortality	B-UNK
rate	B-UNK
.	O
Melatonin	O
0.5	B-UNK
and	O
5	O
mg	B-UNK
/	O
kg	B-UNK
influenced	O
the	O
duration	B-UNK
but	O
not	O
the	O
latency	O
of	O
ketamine-	O
or	O
diazepam	B-CHEMICAL
-	O
induced	B-UNK
narcosis	B-UNK
.	O
Thus	O
,	O
the	O
dual	B-UNK
action	B-UNK
of	O
melatonin	B-CHEMICAL
on	O
pharmacological	B-UNK
narcosis	B-UNK
seems	O
to	O
be	O
specific	B-UNK
for	O
the	O
barbiturate	O
mechanism	B-UNK
of	O
action	B-UNK
.	O

Effects	O
of	O
NIK-247	O
on	O
cholinesterase	B-UNK
and	O
scopolamine	B-CHEMICAL
-	O
induced	B-UNK
amnesia	B-DISEASE
.	O

The	O
effects	B-UNK
of	O
NIK-247	O
on	O
cholinesterase	B-UNK
,	O
scopolamine	B-CHEMICAL
-	O
induced	B-UNK
amnesia	B-DISEASE
and	O
spontaneous	B-UNK
movement	B-UNK
were	O
examined	B-UNK
and	O
compared	B-UNK
with	O
those	O
of	O
the	O
well	O
-	O
known	B-UNK
cholinesterase	B-CHEMICAL
inhibitors	I-CHEMICAL
tacrine	B-CHEMICAL
and	O
E-2020	O
.	O
NIK-247	O
,	O
tacrine	B-CHEMICAL
and	O
E-2020	O
all	O
strongly	B-UNK
inhibited	B-UNK
acetylcholinesterase	O
(	O
AChE	O
)	O
in	O
human	B-UNK
red	O
blood	B-UNK
cells	B-UNK
(	O
IC50s	O
=	O
1.0	B-UNK
x	B-UNK
10(-6	O
)	O
,	O
2.9	O
x	B-UNK
10(-7	O
)	O
and	O
3.7	O
x	B-UNK
10(-8	O
)	O
M	O
,	O
respectively	O
)	O
.	O
In	O
addition	O
,	O
NIK-247	O
and	O
tacrine	B-CHEMICAL
,	O
but	O
not	O
E-2020	O
,	O
strongly	B-UNK
inhibited	B-UNK
butyrylcholinestrase	O
(	O
BuChE	O
)	O
in	O
human	B-UNK
serum	B-UNK
.	O
All	O
three	O
drugs	B-UNK
produced	B-UNK
mixed	B-UNK
inhibition	B-UNK
of	O
AChE	O
activity	B-UNK
.	O
Moreover	O
,	O
the	O
inhibitory	B-UNK
effect	B-UNK
of	O
NIK-247	O
on	O
AChE	O
was	O
reversible	B-UNK
.	O
All	O
compounds	B-UNK
at	B-DISEASE
0.1	B-UNK
-	O
1	O
mg	B-UNK
/	O
kg	B-UNK
p.o	B-UNK
.	O
significantly	B-UNK
improved	B-UNK
the	O
amnesia	B-DISEASE
induced	B-UNK
by	O
scopolamine	B-CHEMICAL
(	O
0.5	B-UNK
mg	I-UNK
/	O
kg	B-UNK
s.c	B-UNK
.	O
)	O
in	O
rats	B-UNK
performing	O
a	O
passive	B-UNK
avoidance	B-UNK
task	B-UNK
.	O
The	O
three	O
compounds	B-UNK
at	B-DISEASE
1	O
and	O
3	O
mg	B-UNK
/	O
kg	B-UNK
p.o	B-UNK
.	O
did	O
not	O
significantly	B-UNK
decrease	B-UNK
spontaneous	B-UNK
movement	B-UNK
by	O
rats	B-UNK
.	O
These	O
findings	B-UNK
suggest	B-UNK
that	O
NIK-247	O
at	B-DISEASE
a	O
low	B-UNK
dose	B-UNK
(	O
0.1	B-UNK
-	O
1	O
mg	B-UNK
/	O
kg	B-UNK
p.o	B-UNK
.	O
)	O
improves	B-UNK
scopolamine	B-CHEMICAL
-	O
induced	B-UNK
amnesia	B-DISEASE
but	O
does	O
not	O
affect	B-UNK
spontaneous	B-UNK
movement	B-UNK
.	O
The	O
findings	B-UNK
suggest	B-UNK
that	O
NIK-247	O
may	O
be	O
a	O
useful	B-UNK
drug	B-UNK
for	O
the	O
treatment	B-UNK
of	O
Alzheimer'	O
s	O
disease	B-DISEASE
.	O

Nightmares	O
and	O
hallucinations	B-DISEASE
after	O
long	B-UNK
-	O
term	B-UNK
intake	B-UNK
of	O
tramadol	B-CHEMICAL
combined	B-UNK
with	O
antidepressants	B-UNK
.	O

Tramadol	O
is	O
a	O
weak	O
opioid	B-UNK
with	O
effects	B-UNK
on	O
adrenergic	B-UNK
and	O
serotonergic	B-UNK
neurotransmission	B-UNK
that	O
is	O
used	O
to	O
treat	O
cancer	B-DISEASE
pain	I-DISEASE
and	O
chronic	B-UNK
non	O
malignant	B-UNK
pain	B-UNK
.	O
This	O
drug	B-UNK
was	O
initiated	O
in	O
association	B-UNK
with	O
paroxetine	B-CHEMICAL
and	O
dosulepine	O
hydrochloride	B-UNK
in	O
a	O
tetraparetic	O
patient	B-UNK
with	O
chronic	B-DISEASE
pain	I-DISEASE
.	O
Fifty	O
-	O
six	O
days	B-UNK
after	O
initiation	O
of	O
the	O
treatment	B-UNK
the	O
patient	B-UNK
presented	B-UNK
hallucinations	B-DISEASE
that	O
only	O
stopped	O
after	O
the	O
withdrawal	B-UNK
of	O
psycho	O
-	O
active	B-UNK
drugs	B-UNK
and	O
tramadol	B-CHEMICAL
.	O
The	O
case	B-UNK
report	B-UNK
questions	O
the	O
long	B-UNK
term	B-UNK
use	B-UNK
of	O
pain	B-UNK
killers	O
combined	B-UNK
with	O
psycho	O
-	O
active	B-UNK
drugs	B-UNK
in	O
chronic	B-UNK
non	O
malignant	B-UNK
pain	B-DISEASE
,	O
especially	B-UNK
if	O
pain	B-UNK
is	O
under	O
control	B-UNK
.	O

Apparent	O
cure	O
of	O
rheumatoid	B-DISEASE
arthritis	I-DISEASE
by	O
bone	B-UNK
marrow	B-UNK
transplantation	B-UNK
.	O

We	O
describe	O
the	O
induction	B-UNK
of	O
sustained	B-UNK
remissions	O
and	O
possible	B-UNK
cure	O
of	O
severe	B-UNK
erosive	O
rheumatoid	B-DISEASE
arthritis	I-DISEASE
(	O
RA	B-UNK
)	O
by	O
bone	B-UNK
marrow	B-UNK
transplantation	B-UNK
(	O
BMT	O
)	O
in	O
2	B-DISEASE
patients	B-UNK
.	O
BMT	O
was	O
used	O
to	O
treat	O
severe	B-UNK
aplastic	B-DISEASE
anemia	I-DISEASE
which	O
was	O
caused	B-UNK
by	O
gold	B-CHEMICAL
in	O
one	O
case	B-UNK
and	O
D	B-UNK
-	O
penicillamine	B-CHEMICAL
in	O
the	O
other	O
.	O
In	O
the	O
8	O
and	O
6	O
years	B-UNK
since	O
the	O
transplants	O
(	O
representing	O
8	O
and	O
4	O
years	B-UNK
since	O
cessation	B-UNK
of	O
all	O
immunosuppressive	B-UNK
therapy	B-UNK
,	O
respectively	O
)	O
,	O
the	O
RA	B-UNK
in	O
each	O
case	B-UNK
has	O
been	O
completely	B-UNK
quiescent	O
.	O
Although	O
short	B-UNK
term	B-UNK
remission	B-DISEASE
of	O
severe	B-UNK
RA	B-UNK
following	B-UNK
BMT	O
has	O
been	O
reported	B-UNK
,	O
these	O
are	O
the	O
first	O
cases	B-UNK
for	O
which	O
prolonged	B-UNK
followup	O
has	O
been	O
available	B-UNK
.	O
This	O
experience	B-UNK
raises	O
the	O
question	O
of	O
the	O
role	B-UNK
of	O
BMT	O
itself	O
as	O
a	O
therapeutic	B-UNK
option	O
for	O
patients	B-UNK
with	O
uncontrolled	B-UNK
destructive	O
synovitis	B-DISEASE
.	O

Urinary	B-UNK
enzymes	B-UNK
and	O
protein	B-UNK
patterns	B-UNK
as	O
indicators	O
of	O
injury	B-UNK
to	O
different	B-UNK
regions	B-UNK
of	O
the	O
kidney	B-UNK
.	O

Acute	B-UNK
experimental	B-UNK
models	B-UNK
of	O
renal	B-UNK
damage	B-UNK
to	O
the	O
proximal	B-UNK
tubular	B-UNK
,	O
glomerular	B-UNK
,	O
and	O
papillary	B-UNK
regions	B-UNK
of	O
the	O
rat	B-UNK
were	O
produced	B-UNK
by	O
administration	B-UNK
of	O
hexachloro-1:3-butadiene	O
(	O
HCBD	O
)	O
,	O
puromycin	B-CHEMICAL
aminonucleoside	I-CHEMICAL
(	O
PAN	O
)	O
,	O
and	O
2-bromoethylamine	B-CHEMICAL
(	O
BEA	O
)	O
,	O
respectively	O
.	O
Several	O
routine	B-UNK
indicators	O
of	O
nephrotoxicity	B-UNK
,	O
the	O
enzymes	B-UNK
alkaline	B-UNK
phosphatase	B-UNK
and	O
N	B-UNK
-	O
acetyl	O
-	O
beta	B-UNK
-	O
glucosaminidase	O
,	O
and	O
the	O
molecular	B-UNK
weight	B-UNK
of	O
protein	B-UNK
excretion	B-UNK
were	O
determined	O
on	O
urine	B-DISEASE
samples	B-UNK
.	O
Tubular	O
damage	B-UNK
produced	B-UNK
by	O
HCBD	O
or	O
BEA	O
was	O
discriminated	O
both	O
quantitatively	O
and	O
qualitatively	O
from	O
glomerular	B-UNK
damage	B-UNK
produced	B-UNK
by	O
PAN	O
.	O
The	O
latter	O
was	O
characterized	B-UNK
by	O
a	O
pronounced	O
increase	B-UNK
in	O
protein	B-UNK
excretion	B-UNK
,	O
especially	B-UNK
proteins	B-UNK
with	O
molecular	B-UNK
weight	B-UNK
greater	B-UNK
than	O
40,000	O
Da	O
.	O
In	O
contrast	B-UNK
,	O
protein	B-UNK
excretion	B-UNK
in	O
tubular	B-UNK
damage	B-UNK
was	O
raised	O
only	O
slightly	O
and	O
characterized	B-UNK
by	O
excretion	B-UNK
of	O
proteins	B-UNK
of	O
a	O
wide	B-UNK
range	B-UNK
of	O
molecular	B-UNK
weights	B-UNK
.	O
Proximal	O
tubular	B-UNK
damage	B-UNK
caused	B-UNK
by	O
HCBD	O
and	O
papillary	B-UNK
damage	B-UNK
caused	B-UNK
by	O
BEA	O
were	O
distinguished	O
both	O
by	O
conventional	B-UNK
urinalysis	O
(	O
volume	B-UNK
and	O
specific	B-UNK
gravity	O
)	O
and	O
by	O
measurement	B-UNK
of	O
the	O
two	O
urinary	B-UNK
enzymes	B-UNK
.	O
Alkaline	O
phosphatase	B-UNK
and	O
glucose	B-CHEMICAL
were	O
markedly	B-UNK
and	O
transiently	O
elevated	B-UNK
in	O
proximal	B-UNK
tubular	B-UNK
damage	B-UNK
and	O
N	B-UNK
-	O
acetyl	O
-	O
beta	B-UNK
-	O
glucosaminidase	O
showed	B-UNK
a	O
sustained	B-UNK
elevation	B-UNK
in	O
papillary	B-UNK
damage	B-UNK
.	O
It	O
is	O
concluded	O
that	O
both	O
selective	B-UNK
urinary	B-UNK
enzymes	B-UNK
and	O
the	O
molecular	B-UNK
weight	B-UNK
pattern	B-UNK
of	O
urinary	B-UNK
proteins	B-UNK
can	O
be	O
used	O
to	O
provide	B-UNK
diagnostic	B-UNK
information	B-UNK
about	O
the	O
possible	B-UNK
site	B-UNK
of	O
renal	B-UNK
damage	B-UNK
.	O

Neuromuscular	O
blockade	B-UNK
with	O
magnesium	B-CHEMICAL
sulfate	I-CHEMICAL
and	O
nifedipine	B-CHEMICAL
.	O

A	O
patient	B-UNK
who	O
received	B-UNK
tocolysis	O
with	O
nifedipine	B-CHEMICAL
developed	B-UNK
neuromuscular	B-UNK
blockade	B-UNK
after	O
500	O
mg	B-UNK
of	O
magnesium	B-CHEMICAL
sulfate	I-CHEMICAL
was	O
administered	B-UNK
.	O
This	O
reaction	B-UNK
demonstrates	B-UNK
that	O
nifedipine	B-CHEMICAL
can	O
seriously	O
potentiate	O
the	O
toxicity	B-UNK
of	O
magnesium	B-CHEMICAL
.	O
Caution	O
should	O
be	O
exercised	O
when	O
these	O
two	O
tocolytics	O
are	O
combined	B-UNK
.	O

Ifosfamide	O
continuous	B-UNK
infusion	B-UNK
without	O
mesna	B-CHEMICAL
.	O
A	O
phase	B-UNK
I	O
trial	B-UNK
of	O
a	O
14-day	O
cycle	B-UNK
.	O

Twenty	O
patients	B-UNK
received	B-UNK
27	O
courses	O
of	O
ifosfamide	B-CHEMICAL
administered	B-UNK
as	O
a	O
24-hour	B-UNK
continuous	B-UNK
infusion	B-UNK
for	O
14	O
days	B-UNK
without	O
Mesna	O
.	O
The	O
goal	O
of	O
the	O
study	B-UNK
was	O
to	O
deliver	O
a	O
dose	B-UNK
rate	B-UNK
and	O
total	B-UNK
cumulative	B-UNK
dose	B-UNK
of	O
ifosfamide	B-CHEMICAL
that	O
would	O
be	O
comparable	B-UNK
to	O
standard	B-UNK
bolus	B-UNK
or	O
short	B-UNK
-	O
term	B-UNK
infusions	O
administered	B-UNK
with	O
Mesna	O
.	O
Dose	B-UNK
escalations	O
proceeded	O
from	O
200	O
to	O
300	O
,	O
400	O
,	O
450	O
,	O
500	O
,	O
and	O
550	O
mg	B-UNK
/	O
m2	O
/	O
d.	B-UNK
Four	O
patients	B-UNK
developed	B-UNK
transient	B-UNK
microscopic	B-DISEASE
hematuria	I-DISEASE
at	B-DISEASE
400	O
,	O
450	O
,	O
and	O
500	O
mg	B-UNK
/	O
m2	O
/	O
d.	B-UNK
There	O
were	O
no	O
instances	O
of	O
macroscopic	O
hematuria	B-DISEASE
.	O
At	O
550	O
mg	B-UNK
/	O
m2	O
/	O
d	B-UNK
,	O
three	O
patients	B-UNK
experienced	B-UNK
nonurologic	O
toxicity	B-UNK
;	O
confusion	B-DISEASE
(	O
1	O
)	O
,	O
nausea	B-DISEASE
(	O
1	O
)	O
,	O
and	O
Grade	O
2	B-DISEASE
leukopenia	B-DISEASE
(	O
1	O
)	O
.	O
The	O
recommended	B-UNK
dose	B-UNK
of	O
500	O
mg	B-UNK
/	O
m2	O
/	O
d	B-UNK
delivers	O
a	O
total	B-UNK
dose	B-UNK
of	O
7	O
g	B-UNK
/	O
m2	O
per	O
cycle	B-UNK
,	O
which	O
is	O
comparable	B-UNK
to	O
that	O
delivered	O
in	O
clinical	B-UNK
practice	O
for	O
bolus	B-UNK
or	O
short	B-UNK
-	O
term	B-UNK
infusion	B-UNK
.	O
Because	O
few	O
patients	B-UNK
received	B-UNK
multiple	B-UNK
courses	O
over	O
time	B-UNK
,	O
the	O
cumulative	B-UNK
effects	B-UNK
are	O
indeterminate	O
in	O
the	O
present	B-UNK
trial	B-UNK
.	O
The	O
frequency	B-UNK
and	O
predictability	O
of	O
hematuria	B-DISEASE
are	O
not	O
precise	O
,	O
and	O
at	B-DISEASE
least	O
daily	B-UNK
monitoring	B-UNK
by	O
urine	B-DISEASE
Hematest	O
is	O
essential	O
,	O
adding	O
Mesna	O
to	O
the	O
infusate	O
in	O
patients	B-UNK
with	O
persistent	O
hematuria	B-DISEASE
.	O
The	O
protracted	O
infusion	B-UNK
schedule	B-UNK
for	O
ifosfamide	B-CHEMICAL
permits	O
convenient	O
outpatient	B-UNK
administration	B-UNK
without	O
Mesna	O
and	O
reduces	B-UNK
the	O
drug	B-UNK
cost	B-UNK
of	O
clinical	B-UNK
usage	B-UNK
of	O
this	O
agent	B-UNK
by	O
up	O
to	O
 	O
890	O
per	O
cycle	B-UNK
.	O
Clinical	B-UNK
activity	B-UNK
was	O
demonstrated	B-UNK
in	O
a	O
single	B-UNK
patient	B-UNK
,	O
but	O
a	O
comparative	O
trial	B-UNK
of	O
standard	B-UNK
bolus	B-UNK
schedules	B-UNK
with	O
the	O
protracted	O
infusion	B-UNK
schedule	B-UNK
will	O
be	O
necessary	O
to	O
determine	B-UNK
if	O
the	O
clinical	B-UNK
effectiveness	O
of	O
the	O
drug	B-UNK
is	O
maintained	O
.	O

Myocardial	O
infarction	B-DISEASE
in	O
pregnancy	B-DISEASE
associated	B-UNK
with	O
clomiphene	B-CHEMICAL
citrate	O
for	O
ovulation	O
induction	B-UNK
:	O
a	O
case	B-UNK
report	B-UNK
.	O

BACKGROUND	O
:	O
Clomiphene	O
citrate	O
(	O
CC	O
)	O
is	O
commonly	B-UNK
prescribed	B-UNK
for	O
ovulation	O
induction	B-UNK
.	O
It	O
is	O
considered	B-UNK
safe	B-UNK
,	O
with	O
minimal	O
side	O
effects	B-UNK
.	O
Thromboembolism	O
is	O
a	O
rare	B-UNK
but	O
life	B-UNK
-	O
threatening	O
complication	B-UNK
that	O
has	O
been	O
reported	B-UNK
after	O
ovulation	O
induction	B-UNK
with	O
CC	O
.	O
Spontaneous	O
coronary	B-DISEASE
thrombosis	I-DISEASE
or	O
thromboembolism	B-DISEASE
with	O
subsequent	B-UNK
clot	O
lysis	O
has	O
been	O
suggested	B-UNK
as	O
one	O
of	O
the	O
most	O
common	B-UNK
causes	B-UNK
of	O
myocardial	B-DISEASE
infarction	I-DISEASE
(	O
MI	B-UNK
)	O
during	O
pregnancy	B-DISEASE
,	O
with	O
a	O
subsequently	B-UNK
normal	B-UNK
coronary	B-UNK
angiogram	O
.	O
CASE	B-UNK
:	O
A	O
33-year	O
-	O
old	B-UNK
woman	B-UNK
with	O
a	O
5-week	O
gestation	O
had	O
recently	B-UNK
received	B-UNK
CC	O
for	O
ovulation	O
induction	B-UNK
and	O
presented	B-UNK
with	O
chest	B-DISEASE
pain	I-DISEASE
.	O
An	O
electrocardiogram	O
showed	B-UNK
a	O
lateral	B-UNK
and	O
anterior	B-DISEASE
wall	I-DISEASE
myocardial	I-DISEASE
infarction	I-DISEASE
.	O
Cardiac	B-UNK
enzymes	B-UNK
showed	B-UNK
a	O
peak	B-UNK
rise	B-UNK
in	O
troponin	O
I	O
to	O
9.10	O
ng	B-UNK
/	O
mL.	O
An	O
initial	B-UNK
exercise	B-UNK
stress	B-UNK
test	B-UNK
was	O
normal	B-UNK
.	O
At	O
the	O
time	B-UNK
of	O
admission	O
,	O
the	O
patient	B-UNK
was	O
at	B-DISEASE
high	B-UNK
risk	B-UNK
of	O
radiation	O
injury	B-UNK
to	O
the	O
fetus	O
,	O
so	O
a	O
coronary	B-UNK
angiogram	O
was	O
postponed	O
until	O
the	O
second	B-UNK
trimester	O
.	O
It	O
showed	B-UNK
normal	B-UNK
coronary	B-UNK
vessels	O
.	O
CONCLUSION	O
:	O
This	O
appears	B-UNK
to	O
be	O
the	O
first	O
reported	B-UNK
case	B-UNK
documenting	O
a	O
possible	B-UNK
association	B-UNK
between	O
CC	O
and	O
myocardial	B-DISEASE
infarction	I-DISEASE
.	O
Thrombosis	O
might	O
be	O
a	O
rare	B-UNK
but	O
hazardous	O
complication	B-UNK
of	O
CC	O
.	O
Given	O
this	O
life	B-UNK
-	O
threatening	O
complication	B-UNK
,	O
appropriate	B-UNK
prophylactic	B-UNK
measures	B-UNK
should	O
be	O
used	O
in	O
high	B-UNK
-	O
risk	B-UNK
woman	B-UNK
undergoing	B-UNK
ovarian	B-UNK
stimulation	B-UNK
.	O

Hepatonecrosis	O
and	O
cholangitis	B-DISEASE
related	B-UNK
to	O
long	B-UNK
-	O
term	B-UNK
phenobarbital	B-CHEMICAL
therapy	B-UNK
:	O
an	O
autopsy	O
report	B-UNK
of	O
two	O
patients	B-UNK
.	O

Phenobarbital	O
(	O
PB	O
)	O
has	O
a	O
reputation	O
for	O
safety	B-UNK
,	O
and	O
it	O
is	O
commonly	B-UNK
believed	O
that	O
PB	O
-	O
related	B-UNK
increases	B-UNK
in	O
serum	B-UNK
aminotransferase	B-UNK
levels	B-UNK
do	O
not	O
indicate	B-UNK
or	O
predict	O
the	O
development	B-UNK
of	O
significant	B-UNK
chronic	B-UNK
liver	B-DISEASE
disease	I-DISEASE
.	O
Here	O
we	O
report	B-UNK
of	O
two	O
adult	B-UNK
patients	B-UNK
with	O
a	O
long	B-UNK
history	B-UNK
of	O
epilepsy	B-DISEASE
treated	B-UNK
with	O
PB	O
who	O
died	B-UNK
suddenly	O
:	O
one	O
as	O
consequence	O
of	O
cardiac	B-DISEASE
arrest	I-DISEASE
,	O
the	O
other	O
of	O
acute	B-UNK
bronchopneumonia	B-DISEASE
.	O
At	O
autopsy	O
,	O
analysis	B-UNK
of	O
liver	B-DISEASE
parenchyma	O
revealed	B-UNK
rich	O
portal	O
inflammatory	B-UNK
infiltrate	O
,	O
which	O
consisted	B-UNK
of	O
mixed	B-UNK
eosinophil	O
and	O
monocyte	O
cells	B-UNK
,	O
associated	B-UNK
with	O
several	O
foci	O
of	O
necrosis	B-DISEASE
surrounded	O
by	O
a	O
hard	O
ring	O
of	O
non-specific	O
granulomatous	O
tissue	B-UNK
.	O
Inflammatory	O
reactions	B-UNK
of	O
internal	B-UNK
and	O
external	O
hepatic	B-UNK
biliary	O
ducts	O
were	O
also	O
seen	B-UNK
.	O
Our	O
findings	B-UNK
illustrate	O
that	O
PB	O
may	O
be	O
associated	B-UNK
with	O
chronic	B-UNK
liver	B-DISEASE
damage	B-UNK
,	O
which	O
may	O
lead	B-CHEMICAL
to	O
more	O
serious	O
and	O
deleterious	O
consequences	B-UNK
.	O
For	O
this	O
reason	O
,	O
each	O
clinician	O
should	O
recognize	O
this	O
entity	O
in	O
the	O
differential	B-UNK
diagnosis	B-UNK
of	O
PB	O
-	O
related	B-UNK
asymptomatic	B-UNK
chronic	B-UNK
hepatic	B-UNK
enzyme	B-UNK
dysfunction	B-UNK
.	O

Ethambutol	O
-	O
associated	B-UNK
optic	B-DISEASE
neuropathy	I-DISEASE
.	O

INTRODUCTION	O
:	O
Ethambutol	O
is	O
used	O
in	O
the	O
treatment	B-UNK
of	O
tuberculosis	B-DISEASE
,	O
which	O
is	O
still	O
prevalent	O
in	O
Southeast	O
Asia	O
,	O
and	O
can	O
be	O
associated	B-UNK
with	O
permanent	B-UNK
visual	B-UNK
loss	B-UNK
.	O
We	O
report	B-UNK
3	O
cases	B-UNK
which	O
presented	B-UNK
with	O
bitemporal	B-UNK
hemianopia	O
.	O
CLINICAL	O
PICTURE	O
:	O
Three	O
patients	B-UNK
with	O
ethambutol	B-CHEMICAL
-	O
associated	B-UNK
toxic	B-DISEASE
optic	I-DISEASE
neuropathy	I-DISEASE
are	O
described	B-UNK
.	O
All	O
3	O
patients	B-UNK
had	O
loss	B-UNK
of	O
central	B-UNK
visual	B-UNK
acuity	B-UNK
,	O
colour	O
vision	B-DISEASE
(	O
Ishihara	O
)	O
and	O
visual	B-UNK
field	I-UNK
.	O
The	O
visual	B-UNK
field	I-UNK
loss	B-UNK
had	O
a	O
bitemporal	B-UNK
flavour	O
,	O
suggesting	B-UNK
involvement	B-UNK
of	O
the	O
optic	B-UNK
chiasm	O
.	O
TREATMENT	O
:	O
Despite	B-UNK
stopping	O
ethambutol	B-CHEMICAL
on	O
diagnosis	B-UNK
,	O
visual	B-UNK
function	B-UNK
continued	B-UNK
to	O
deteriorate	O
for	O
a	O
few	O
months	B-UNK
.	O
Subsequent	B-UNK
improvement	B-UNK
was	O
mild	B-UNK
in	O
2	B-DISEASE
cases	B-UNK
.	O
In	O
the	O
third	O
case	B-UNK
,	O
visual	B-UNK
acuity	B-UNK
and	O
colour	O
vision	B-DISEASE
normalised	O
but	O
the	O
optic	B-UNK
discs	O
were	O
pale	O
.	O
OUTCOME	B-UNK
:	O
All	O
3	O
patients	B-UNK
had	O
some	O
permanent	B-UNK
loss	B-UNK
of	O
visual	B-UNK
function	B-UNK
.	O
CONCLUSIONS	O
:	O
Ethambutol	O
usage	B-UNK
is	O
associated	B-UNK
with	O
permanent	B-UNK
visual	B-UNK
loss	B-UNK
and	O
should	O
be	O
avoided	O
if	O
possible	B-UNK
or	O
used	O
with	O
caution	B-UNK
and	O
proper	B-UNK
ophthalmological	O
follow	B-UNK
-	O
up	O
.	O
The	O
author	O
postulates	O
that	O
in	O
cases	B-UNK
of	O
ethambutol	B-CHEMICAL
associated	B-UNK
chiasmopathy	O
,	O
ethambutol	B-CHEMICAL
may	O
initially	B-UNK
affect	B-UNK
the	O
optic	B-UNK
nerves	B-UNK
and	O
subsequently	B-UNK
progress	O
to	O
involve	B-UNK
the	O
optic	B-UNK
chiasm	O
.	O

Tolerability	O
of	O
nimesulide	B-CHEMICAL
and	O
paracetamol	B-UNK
in	O
patients	B-UNK
with	O
NSAID	O
-	O
induced	B-UNK
urticaria	B-DISEASE
/	O
angioedema	B-DISEASE
.	O

Previous	B-UNK
studies	B-UNK
evaluated	B-UNK
the	O
tolerance	B-UNK
of	O
nimesulide	B-CHEMICAL
and	O
paracetamol	B-UNK
in	O
subjects	B-UNK
with	O
cutaneous	B-UNK
,	O
respiratory	B-UNK
and	O
anaphylactoid	O
reactions	B-UNK
induced	B-UNK
by	O
nonsteroidal	B-UNK
anti-inflammatory	I-UNK
drugs	B-UNK
(	O
NSAIDs	B-UNK
)	O
.	O
In	O
this	O
study	B-UNK
we	O
investigated	B-UNK
tolerability	B-UNK
and	O
reliability	O
of	O
nimesulide	B-CHEMICAL
and	O
paracetamol	B-UNK
in	O
a	O
very	O
large	B-UNK
number	B-UNK
of	O
patients	B-UNK
with	O
an	O
exclusive	O
well	O
-	O
documented	B-UNK
history	B-UNK
of	O
NSAID	O
-	O
induced	B-UNK
urticaria	B-DISEASE
/	O
angioedema	B-DISEASE
.	O
Furthermore	O
,	O
we	O
evaluated	B-UNK
whether	O
some	O
factors	B-UNK
have	O
the	O
potential	B-UNK
to	O
increase	B-UNK
the	O
risk	B-UNK
of	O
reaction	B-UNK
to	O
paracetamol	B-UNK
and	O
nimesulide	B-CHEMICAL
.	O
A	O
single	B-UNK
-	O
placebo	B-UNK
-	O
controlled	B-UNK
oral	B-UNK
challenge	B-UNK
procedure	B-UNK
with	O
nimesulide	B-CHEMICAL
or	O
paracetamol	B-UNK
was	O
applied	O
to	O
829	O
patients	B-UNK
with	O
a	O
history	B-UNK
of	O
NSAID	O
-	O
induced	B-UNK
urticaria	B-DISEASE
/	O
angioedema	B-DISEASE
.	O
A	O
total	B-UNK
of	O
75/829	O
(	O
9.4	O
%	O
)	O
patients	B-UNK
experienced	B-UNK
reactions	B-UNK
to	O
nimesulide	B-CHEMICAL
or	O
paracetamol	B-UNK
.	O
Of	O
the	O
715	O
patients	B-UNK
tested	B-UNK
with	O
nimesulide	B-CHEMICAL
62	O
(	O
8.6	O
%	O
)	O
showed	B-UNK
a	O
positive	B-UNK
test	B-UNK
,	O
while	O
of	O
114	O
subjects	B-UNK
submitted	O
to	O
the	O
challenge	B-UNK
with	O
paracetamol	B-UNK
,	O
13	O
(	O
9.6	O
%	O
)	O
did	O
not	O
tolerate	O
this	O
drug	B-UNK
.	O
Furthermore	O
,	O
18.28	O
%	O
of	O
patients	B-UNK
with	O
a	O
history	B-UNK
of	O
chronic	B-DISEASE
urticaria	I-DISEASE
and	O
11.8	O
%	O
of	O
subjects	B-UNK
with	O
an	O
history	B-UNK
of	O
NSAID	O
-	O
induced	B-UNK
urticaria	B-DISEASE
/	O
angioedema	B-DISEASE
or	O
angioedema	B-DISEASE
alone	O
(	O
with	O
or	O
without	O
chronic	B-DISEASE
urticaria	I-DISEASE
)	O
resulted	B-UNK
to	O
be	O
intolerant	O
to	O
alternative	B-UNK
drugs	B-UNK
.	O
Taken	O
together	O
,	O
our	O
results	B-UNK
confirm	B-UNK
the	O
good	B-UNK
tolerability	B-UNK
of	O
nimesulide	B-CHEMICAL
and	O
paracetamol	B-UNK
in	O
patients	B-UNK
who	O
experienced	B-UNK
urticaria	B-DISEASE
/	O
angioedema	B-DISEASE
caused	B-UNK
by	O
NSAIDs	B-UNK
.	O
However	O
,	O
the	O
risk	B-UNK
of	O
reaction	B-UNK
to	O
these	O
alternative	B-UNK
study	B-UNK
drugs	B-UNK
is	O
statistically	B-UNK
increased	B-UNK
by	O
a	O
history	B-UNK
of	O
chronic	B-DISEASE
urticaria	I-DISEASE
and	O
,	O
above	O
all	O
,	O
by	O
a	O
history	B-UNK
of	O
NSAID	O
-	O
induced	B-UNK
angioedema	B-DISEASE
.	O

Effects	O
of	O
verapamil	B-CHEMICAL
on	O
atrial	B-DISEASE
fibrillation	I-DISEASE
and	O
its	O
electrophysiological	B-UNK
determinants	O
in	O
dogs	B-UNK
.	O

BACKGROUND	O
:	O
Atrial	O
tachycardia	B-DISEASE
-	O
induced	B-UNK
remodeling	O
promotes	O
the	O
occurrence	O
and	O
maintenance	B-UNK
of	O
atrial	B-DISEASE
fibrillation	I-DISEASE
(	O
AF	B-UNK
)	O
and	O
decreases	B-UNK
L	B-UNK
-	O
type	B-UNK
Ca(2	B-UNK
+	O
)	O
current	B-UNK
.	O
There	O
is	O
also	O
a	O
clinical	B-UNK
suggestion	O
that	O
acute	B-UNK
L	B-UNK
-	O
type	B-UNK
Ca(2	B-UNK
)	O
channel	B-UNK
blockade	B-UNK
can	O
promote	B-UNK
AF	B-UNK
,	O
consistent	B-UNK
with	O
an	O
AF	B-UNK
promoting	O
effect	B-UNK
of	O
Ca(2	B-UNK
+	O
)	O
channel	B-UNK
inhibition	B-UNK
.	O
METHODS	O
:	O
To	O
evaluate	B-UNK
the	O
potential	B-UNK
mechanisms	B-UNK
of	O
AF	B-UNK
promotion	O
by	O
Ca(2	B-UNK
+	O
)	O
channel	B-UNK
blockers	B-UNK
,	O
we	O
administered	B-UNK
verapamil	B-CHEMICAL
to	O
morphine	B-CHEMICAL
-	O
chloralose	B-CHEMICAL
anesthetized	B-UNK
dogs	B-UNK
.	O
Diltiazem	O
was	O
used	O
as	O
a	O
comparison	O
drug	B-UNK
and	O
autonomic	B-UNK
blockade	B-UNK
with	O
atropine	B-CHEMICAL
and	O
nadolol	B-CHEMICAL
was	O
applied	O
in	O
some	O
experiments	B-UNK
.	O
Epicardial	O
mapping	B-UNK
with	O
240	O
epicardial	O
electrodes	B-UNK
was	O
used	O
to	O
evaluate	B-UNK
activation	B-UNK
during	O
AF	B-UNK
.	O
RESULTS	B-UNK
:	O
Verapamil	O
caused	B-UNK
AF	B-UNK
promotion	O
in	O
six	O
dogs	B-UNK
,	O
increasing	B-UNK
mean	B-UNK
duration	B-UNK
of	O
AF	B-UNK
induced	B-UNK
by	O
burst	O
pacing	B-UNK
,	O
from	O
8+/-4	O
s	O
(	O
mean+/-S.E.	O
)	O
to	O
95+/-39	O
s	O
(	O
P<0.01	O
vs	B-UNK
.	O
control	B-UNK
)	O
at	B-DISEASE
a	O
loading	B-UNK
dose	I-UNK
of	O
0.1	B-UNK
mg	B-UNK
/	O
kg	B-UNK
and	O
228+/-101	O
s	O
(	O
P<0.0005	O
vs	B-UNK
.	O
control	B-UNK
)	O
at	B-DISEASE
a	O
dose	B-UNK
of	O
0.2	B-UNK
mg	B-UNK
/	O
kg	B-UNK
.	O
Underlying	O
electrophysiological	B-UNK
mechanisms	B-UNK
were	O
studied	B-UNK
in	O
detail	O
in	O
five	O
additional	B-UNK
dogs	B-UNK
under	O
control	B-UNK
conditions	B-UNK
and	O
in	O
the	O
presence	O
of	O
the	O
higher	B-UNK
dose	B-UNK
of	O
verapamil	B-CHEMICAL
.	O
In	O
these	O
experiments	B-UNK
,	O
verapamil	B-CHEMICAL
shortened	O
mean	B-UNK
effective	B-UNK
refractory	B-UNK
period	B-UNK
(	O
ERP	O
)	O
from	O
122+/-5	O
to	O
114+/-4	O
ms	B-DISEASE
(	O
P<0.02	O
)	O
at	B-DISEASE
a	O
cycle	B-UNK
length	O
of	O
300	O
ms	B-DISEASE
,	O
decreased	B-UNK
ERP	O
heterogeneity	O
(	O
from	O
15+/-1	O
to	O
10+/-1	O
%	O
,	O
P<0.05	O
)	O
,	O
heterogeneously	O
accelerated	O
atrial	B-UNK
conduction	B-UNK
and	O
decreased	B-UNK
the	O
cycle	B-UNK
length	O
of	O
AF	B-UNK
(	O
94+/-4	O
to	O
84+/-3	O
ms	B-DISEASE
,	O
P<0.005	O
)	O
.	O
Diltiazem	O
did	O
not	O
affect	B-UNK
ERP	O
,	O
AF	B-UNK
cycle	B-UNK
length	O
or	O
AF	B-UNK
duration	B-UNK
,	O
but	O
produced	B-UNK
conduction	B-UNK
acceleration	O
similar	B-UNK
to	O
that	O
caused	B-UNK
by	O
verapamil	B-CHEMICAL
(	O
n=5	O
)	O
.	O
In	O
the	O
presence	O
of	O
autonomic	B-UNK
blockade	B-UNK
,	O
verapamil	B-CHEMICAL
failed	B-UNK
to	O
promote	B-UNK
AF	B-UNK
and	O
increased	B-UNK
,	O
rather	O
than	O
decreasing	B-UNK
,	O
refractoriness	O
.	O
Neither	O
verapamil	B-CHEMICAL
nor	O
diltiazem	B-CHEMICAL
affected	B-UNK
atrial	B-UNK
conduction	B-UNK
in	O
the	O
presence	O
of	O
autonomic	B-UNK
blockade	B-UNK
.	O
Epicardial	O
mapping	B-UNK
suggested	B-UNK
that	O
verapamil	B-CHEMICAL
promoted	O
AF	B-UNK
by	O
increasing	B-UNK
the	O
number	B-UNK
of	O
simultaneous	O
wavefronts	O
reflected	O
by	O
separate	B-UNK
zones	O
of	O
reactivation	O
in	O
each	O
cycle	B-UNK
.	O
CONCLUSIONS	O
:	O
Verapamil	O
promotes	O
AF	B-UNK
in	O
normal	B-UNK
dogs	B-UNK
by	O
promoting	O
multiple	B-UNK
circuit	O
reentry	O
,	O
an	O
effect	B-UNK
dependent	B-UNK
on	O
intact	B-UNK
autonomic	B-UNK
tone	B-UNK
and	O
not	O
shared	O
by	O
diltiazem	B-CHEMICAL
.	O

Hypotension	O
,	O
bradycardia	B-DISEASE
,	O
and	O
asystole	O
after	O
high	B-UNK
-	O
dose	B-UNK
intravenous	B-UNK
methylprednisolone	B-CHEMICAL
in	O
a	O
monitored	B-UNK
patient	B-UNK
.	O

We	O
report	B-UNK
a	O
case	B-UNK
of	O
hypotension	B-DISEASE
,	O
bradycardia	B-DISEASE
,	O
and	O
asystole	O
after	O
intravenous	B-UNK
administration	B-UNK
of	O
high	B-UNK
-	O
dose	B-UNK
methylprednisolone	B-CHEMICAL
in	O
a	O
73-year	O
-	O
old	B-UNK
patient	B-UNK
who	O
underwent	B-UNK
electrocardiographic	B-UNK
(	O
ECG	B-UNK
)	O
monitoring	B-UNK
throughout	O
the	O
episode	O
.	O
There	O
was	O
a	O
history	B-UNK
of	O
ischemic	B-UNK
cardiac	B-UNK
disease	B-DISEASE
9	O
years	B-UNK
earlier	B-UNK
.	O
The	O
patient	B-UNK
was	O
admitted	O
with	O
a	O
pulmonary	B-UNK
-	O
renal	B-DISEASE
syndrome	B-UNK
with	O
hemoptysis	B-DISEASE
,	O
rapidly	B-UNK
progressive	B-UNK
renal	B-DISEASE
failure	I-DISEASE
,	O
and	O
hypoxemia	O
that	O
required	B-UNK
mechanical	B-UNK
ventilation	O
in	O
the	O
intensive	B-UNK
care	B-UNK
unit	O
.	O
After	O
receiving	B-UNK
advanced	B-UNK
cardiopulmonary	B-UNK
resuscitation	O
,	O
the	O
patient	B-UNK
recovered	O
cardiac	B-UNK
rhythm	B-UNK
.	O
The	O
ECG	B-UNK
showed	B-UNK
a	O
junctional	O
rhythm	B-UNK
without	O
ventricular	B-UNK
arrhythmia	B-DISEASE
.	O
This	O
study	B-UNK
reviews	O
the	O
current	B-UNK
proposed	O
mechanisms	B-UNK
of	O
sudden	B-UNK
death	B-DISEASE
after	O
a	O
high	B-UNK
dose	B-UNK
of	O
intravenous	B-UNK
methylprednisolone	B-CHEMICAL
(	O
IVMP	O
)	O
.	O
These	O
mechanisms	B-UNK
are	O
not	O
well	O
understood	B-UNK
because	O
,	O
in	O
most	O
cases	B-UNK
,	O
the	O
patients	B-UNK
were	O
not	O
monitored	B-UNK
at	B-DISEASE
the	O
moment	O
of	O
the	O
event	B-UNK
.	O
Rapid	O
infusion	B-UNK
and	O
underlying	B-UNK
cardiac	B-UNK
disease	B-DISEASE
were	O
important	B-UNK
risk	B-UNK
factors	I-UNK
in	O
the	O
case	B-UNK
reported	B-UNK
here	O
,	O
and	O
the	O
authors	B-UNK
discount	O
ventricular	B-UNK
arrhythmia	B-DISEASE
as	O
the	O
main	B-UNK
mechanism	B-UNK
.	O

Lifetime	O
treatment	B-UNK
of	O
mice	B-UNK
with	O
azidothymidine	O
(	O
AZT	B-UNK
)	O
produces	B-UNK
myelodysplasia	B-DISEASE
.	O

AZT	B-UNK
has	O
induced	B-UNK
a	O
macrocytic	O
anemia	B-DISEASE
in	O
AIDS	O
patients	B-UNK
on	O
long	B-UNK
term	B-UNK
AZT	B-UNK
therapy	B-UNK
.	O
It	O
is	O
generally	B-UNK
assumed	O
that	O
DNA	B-UNK
elongation	O
is	O
stopped	O
by	O
the	O
insertion	B-UNK
of	O
AZT	B-UNK
into	O
the	O
chain	O
in	O
place	O
of	O
thymidine	B-CHEMICAL
thus	O
preventing	B-UNK
the	O
phosphate	B-UNK
hydroxyl	O
linkages	O
and	O
therefore	O
suppresses	O
hemopoietic	O
progenitor	B-UNK
cell	B-UNK
proliferation	B-UNK
in	O
an	O
early	B-UNK
stage	B-UNK
of	O
differentiation	B-UNK
.	O
CBA	O
/	O
Ca	O
male	B-UNK
mice	B-UNK
started	B-UNK
on	O
AZT	B-UNK
0.75	O
mg	B-UNK
/	O
ml	B-UNK
H2O	O
at	B-DISEASE
84	O
days	B-UNK
of	O
age	B-UNK
and	O
kept	O
on	O
it	O
for	O
687	O
days	B-UNK
when	O
dosage	B-UNK
reduced	B-UNK
to	O
0.5	B-UNK
mg	I-UNK
/	O
ml	B-UNK
H2O	O
for	O
a	O
group	B-UNK
,	O
another	O
group	B-UNK
removed	O
from	O
AZT	B-UNK
to	O
see	O
recovery	B-UNK
,	O
and	O
third	O
group	B-UNK
remained	B-UNK
on	O
0.75	O
mg	B-UNK
.	O
At	O
687	O
days	B-UNK
mice	B-UNK
that	O
had	O
been	O
on	O
0.75	O
mg	B-UNK
had	O
average	B-UNK
platelet	B-UNK
counts	B-UNK
of	O
2.5	B-UNK
x	B-UNK
10(6	O
)	O
.	O
Histological	O
examination	B-UNK
on	O
9	O
of	O
10	O
mice	B-UNK
with	O
such	O
thrombocytopenia	B-DISEASE
showed	B-UNK
changes	B-UNK
compatible	O
with	O
myelodysplastic	O
syndrome	B-UNK
(	O
MDS	O
)	O
.	O
A	O
variety	O
of	O
histological	B-UNK
patterns	B-UNK
was	O
observed	B-UNK
.	O
There	O
were	O
two	O
cases	B-UNK
of	O
hypocellular	O
myelodysplasia	B-DISEASE
,	O
two	O
cases	B-UNK
of	O
hypersegmented	O
myelodysplastic	O
granulocytosis	O
,	O
two	O
cases	B-UNK
of	O
hypercellular	O
marrow	B-UNK
with	O
abnormal	B-UNK
megakaryocytes	O
with	O
bizarre	O
nuclei	B-UNK
,	O
one	O
case	B-UNK
of	O
megakaryocytic	O
myelosis	O
associated	B-UNK
with	O
a	O
hyperplastic	B-UNK
marrow	B-UNK
,	O
dysmyelopoiesis	O
and	O
a	O
hypocellular	O
marrow	B-UNK
and	O
two	O
cases	B-UNK
of	O
myelodysplasia	B-DISEASE
with	O
dyserythropoiesis	B-DISEASE
,	O
hemosiderosis	B-DISEASE
and	O
a	O
hypocellular	O
marrow	B-UNK
.	O
Above	O
mentioned	B-UNK
AZT	B-UNK
incorporation	O
may	O
have	O
induced	B-UNK
an	O
ineffective	O
hemopoiesis	O
in	O
the	O
primitive	O
hemopoietic	O
progenitor	B-UNK
cells	B-UNK
,	O
which	O
is	O
known	B-UNK
to	O
be	O
seen	B-UNK
commonly	B-UNK
in	O
the	O
myelodysplastic	O
syndrome	B-UNK
.	O

Influence	O
of	O
diet	B-UNK
free	B-UNK
of	O
NAD	O
-	O
precursors	O
on	O
acetaminophen	B-CHEMICAL
hepatotoxicity	O
in	O
mice	B-UNK
.	O

Recently	O
,	O
we	O
demonstrated	B-UNK
the	O
hepatoprotective	O
effects	B-UNK
of	O
nicotinic	O
acid	B-UNK
amide	O
,	O
a	O
selective	B-UNK
inhibitor	B-UNK
of	O
poly(ADP	O
-	O
ribose	B-CHEMICAL
)	O
polymerase	O
(	O
PARP	B-UNK
;	O
EC	O
2.4.2.30	O
)	O
on	O
mice	B-UNK
suffering	O
from	O
acetaminophen	B-CHEMICAL
(	O
AAP)-hepatitis	O
,	O
suggesting	B-UNK
that	O
the	O
AAP	O
-	O
induced	B-UNK
liver	B-DISEASE
injury	B-UNK
involves	B-UNK
a	O
step	O
which	O
depends	O
on	O
adenoribosylation	O
.	O
The	O
present	B-UNK
study	B-UNK
investigates	O
the	O
effects	B-UNK
of	O
a	O
diet	B-UNK
free	B-UNK
of	O
precursors	O
of	O
NAD	O
,	O
the	O
substrate	B-UNK
on	O
which	O
PARP	B-UNK
acts	B-UNK
,	O
in	O
female	B-UNK
NMRI	O
mice	B-UNK
with	O
AAP	O
hepatitis	B-DISEASE
and	O
evaluates	O
the	O
influence	B-UNK
of	O
simultaneous	O
ethanol	B-CHEMICAL
consumption	B-UNK
in	O
these	O
animals	B-UNK
.	O
Liver	B-UNK
injuries	O
were	O
quantified	O
as	O
serum	B-UNK
activities	B-UNK
of	O
glutamate	B-UNK
-	O
oxaloacetate	O
transaminase	B-UNK
(	O
GOT	O
)	O
and	O
glutamate	B-UNK
-	O
pyruvate	O
transaminase	B-UNK
(	O
GPT	O
)	O
.	O
While	O
AAP	O
caused	B-UNK
a	O
117-fold	O
elevation	B-UNK
of	O
serum	B-UNK
transaminase	B-UNK
activities	B-UNK
in	O
mice	B-UNK
kept	O
on	O
a	O
standard	B-UNK
laboratory	B-UNK
diet	B-UNK
,	O
which	O
was	O
significantly	B-UNK
exacerbated	B-UNK
by	O
ethanol	B-CHEMICAL
and	O
inhibited	B-UNK
by	O
nicotinic	O
acid	B-UNK
amide	O
(	O
NAA	O
)	O
,	O
adverse	B-UNK
effects	B-UNK
were	O
noted	O
in	O
animals	B-UNK
fed	B-UNK
a	O
diet	B-UNK
free	B-UNK
of	O
precursors	O
of	O
NAD	O
.	O
In	O
these	O
animals	B-UNK
,	O
only	O
minor	B-UNK
increases	B-UNK
of	O
serum	B-UNK
transaminase	B-UNK
activities	B-UNK
were	O
measured	B-UNK
in	O
the	O
presence	O
of	O
AAP	O
,	O
and	O
unlike	O
the	O
exacerbation	O
caused	B-UNK
by	O
ethanol	B-CHEMICAL
in	O
mice	B-UNK
on	O
a	O
standard	B-UNK
diet	B-UNK
,	O
the	O
liver	B-DISEASE
damage	B-UNK
was	O
inhibited	B-UNK
by	O
50	O
%	O
by	O
ethanol	B-CHEMICAL
.	O
A	O
further	O
64	O
%	O
reduction	B-UNK
of	O
hepatitis	B-DISEASE
was	O
observed	B-UNK
,	O
when	O
NAA	O
was	O
given	B-UNK
to	O
ethanol	B-CHEMICAL
/	O
AAP	O
-	O
mice	B-UNK
.	O
Our	O
results	B-UNK
provide	B-UNK
evidence	B-UNK
that	O
the	O
AAP	O
-	O
induced	B-UNK
hepatitis	B-DISEASE
and	O
its	O
exacerbation	O
by	O
ethanol	B-CHEMICAL
can	O
either	O
be	O
reduced	B-UNK
by	O
end	B-UNK
-	O
product	B-UNK
inhibition	B-UNK
of	O
PARP	B-UNK
by	O
NAA	O
or	O
by	O
dietary	O
depletion	O
of	O
the	O
enzyme'	O
s	O
substrate	B-UNK
NAD	O
.	O
We	O
see	O
the	O
main	B-UNK
application	B-UNK
of	O
NAA	O
as	O
for	O
the	O
combinational	O
use	B-UNK
in	O
pharmaceutical	O
preparations	B-UNK
of	O
acetaminophen	B-CHEMICAL
in	O
order	O
to	O
avoid	B-UNK
hepatic	B-UNK
damage	B-UNK
in	O
patients	B-UNK
treated	B-UNK
with	O
this	O
widely	B-UNK
used	O
analgesic	B-UNK
.	O

Antiarrhythmic	O
plasma	B-UNK
concentrations	B-UNK
of	O
cibenzoline	O
on	O
canine	O
ventricular	B-UNK
arrhythmias	B-DISEASE
.	O

Using	O
two	O
-	O
stage	B-UNK
coronary	B-UNK
ligation-	O
,	O
digitalis-	O
,	O
and	O
adrenaline	O
-	O
induced	B-UNK
canine	O
ventricular	B-UNK
arrhythmias	B-DISEASE
,	O
antiarrhythmic	B-UNK
effects	B-UNK
of	O
cibenzoline	O
were	O
examined	B-UNK
and	O
the	O
minimum	O
effective	B-UNK
plasma	B-UNK
concentration	B-UNK
for	O
each	O
arrhythmia	B-DISEASE
model	B-UNK
was	O
determined	O
.	O
Cibenzoline	O
suppressed	B-UNK
all	O
the	O
arrhythmias	B-DISEASE
,	O
and	O
the	O
minimum	O
effective	B-UNK
plasma	B-UNK
concentrations	B-UNK
for	O
arrhythmias	B-DISEASE
induced	B-UNK
by	O
24-h	O
coronary	B-UNK
ligation	O
,	O
48-h	O
coronary	B-UNK
ligation	O
,	O
digitalis	O
,	O
and	O
adrenaline	O
were	O
1.9	O
+	O
/-	O
0.9	O
(	O
by	O
8	O
mg	B-UNK
/	O
kg	B-UNK
i.v	B-UNK
.	O
)	O
,	O
1.6	O
+	O
/-	O
0.5	B-UNK
(	O
by	O
8	O
mg	B-UNK
/	O
kg	B-UNK
i.v	B-UNK
.	O
)	O
,	O
0.6	B-UNK
+	O
/-	O
0.2	B-UNK
(	O
by	O
2	B-DISEASE
mg	B-UNK
/	O
kg	B-UNK
i.v	B-UNK
.	O
)	O
,	O
and	O
3.5	B-UNK
+	O
/-	O
1.3	O
(	O
by	O
5	O
mg	B-UNK
/	O
kg	B-UNK
i.v	B-UNK
.	O
)	O
micrograms	B-UNK
/	O
ml	B-UNK
,	O
respectively	O
(	O
mean	B-UNK
+	O
/-	O
SDM	O
,	O
n	B-UNK
=	O
6	O
-	O
7	O
)	O
.	O
The	O
concentration	B-UNK
for	O
adrenaline	O
-	O
induced	B-UNK
arrhythmia	B-DISEASE
was	O
significantly	B-UNK
higher	B-UNK
than	O
those	O
for	O
the	O
other	O
types	O
of	O
arrhythmias	B-DISEASE
.	O
This	O
pharmacological	B-UNK
profile	B-UNK
is	O
similar	B-UNK
to	O
those	O
of	O
mexiletine	B-CHEMICAL
and	O
tocainide	B-CHEMICAL
,	O
and	O
all	O
three	O
drugs	B-UNK
have	O
central	B-UNK
nervous	I-UNK
system	B-UNK
(	O
CNS	O
)	O
stimulant	B-UNK
action	B-UNK
.	O
Because	O
cibenzoline	O
had	O
only	O
weak	O
hypotensive	B-UNK
and	O
sinus	B-UNK
node	B-UNK
depressive	O
effects	B-UNK
and	O
was	O
found	B-UNK
to	O
be	O
orally	B-UNK
active	B-UNK
when	O
given	B-UNK
to	O
coronary	B-UNK
ligation	O
arrhythmia	B-DISEASE
dogs	B-UNK
,	O
its	O
clinical	B-UNK
usefulness	O
is	O
expected	O
.	O

Immunopathology	O
of	O
penicillamine	B-CHEMICAL
-	O
induced	B-UNK
glomerular	B-UNK
disease	B-DISEASE
.	O

Four	O
patients	B-UNK
with	O
rheumatoid	B-DISEASE
arthritis	I-DISEASE
developed	B-UNK
heavy	B-UNK
proteinuria	B-UNK
after	O
five	O
to	O
12	O
months	B-UNK
of	O
treatment	B-UNK
with	O
D	B-UNK
-	O
penicillamine	B-CHEMICAL
.	O
Light	B-UNK
microscopy	B-UNK
of	O
renal	B-UNK
biopsy	B-UNK
samples	B-UNK
showed	B-UNK
minimal	O
glomerular	B-UNK
capillary	B-UNK
wall	B-UNK
thickening	O
and	O
mesangial	B-UNK
matrix	B-UNK
increase	B-UNK
,	O
or	O
no	O
departure	O
from	O
normal	B-UNK
.	O
Electron	O
microscopy	B-UNK
,	O
however	O
,	O
revealed	B-UNK
subepithelial	O
electron	B-UNK
-	O
dense	O
deposits	B-UNK
,	O
fusion	O
of	O
epithelial	B-UNK
cell	B-UNK
foot	B-UNK
processes	B-UNK
,	O
and	O
evidence	B-UNK
of	O
mesangial	B-UNK
cell	B-UNK
hyperactivity	B-UNK
.	O
Immunofluorescence	O
microscopy	B-UNK
demonstrated	B-UNK
granular	O
capillary	B-UNK
wall	B-UNK
deposits	B-UNK
of	O
IgG	O
and	O
C3	O
.	O
The	O
findings	B-UNK
were	O
similar	B-UNK
to	O
those	O
in	O
early	B-UNK
membranous	O
glomerulonephritis	B-DISEASE
,	O
differences	B-UNK
being	O
observed	B-UNK
however	O
in	O
the	O
results	B-UNK
of	O
staining	B-UNK
for	O
the	O
early	B-UNK
-	O
acting	B-UNK
complement	B-UNK
components	B-UNK
C1q	O
and	O
C4	O
.	O
It	O
is	O
tentatively	O
concluded	O
that	O
complement	B-UNK
was	O
activated	B-UNK
by	O
the	O
classical	O
pathway	B-UNK
.	O

Ventricular	B-UNK
fibrillation	B-UNK
from	O
diatrizoate	B-CHEMICAL
with	O
and	O
without	O
chelating	B-CHEMICAL
agents	I-CHEMICAL
.	O

The	O
toxicity	B-UNK
of	O
Renografin	O
76	O
%	O
was	O
compared	B-UNK
with	O
that	O
of	O
Hypaque	O
76	O
%	O
by	O
selective	B-UNK
injection	B-UNK
of	O
each	O
into	O
the	O
right	B-UNK
coronary	I-UNK
artery	B-UNK
of	O
dogs	B-UNK
.	O
Renografin	O
contains	O
the	O
chelating	B-CHEMICAL
agents	I-CHEMICAL
sodium	B-CHEMICAL
citrate	I-CHEMICAL
and	O
disodium	O
edetate	O
,	O
while	O
Hypaque	O
contains	O
calcium	B-CHEMICAL
disodium	O
edetate	O
and	O
no	O
sodium	B-CHEMICAL
citrate	I-CHEMICAL
.	O
Ventricular	B-UNK
fibrillation	B-UNK
occurred	B-UNK
significantly	B-UNK
more	O
often	O
with	O
Renografin	O
,	O
suggesting	B-UNK
that	O
chelating	B-CHEMICAL
agents	I-CHEMICAL
contribute	O
to	O
toxicity	B-UNK
in	O
coronary	B-UNK
angiography	B-UNK
.	O

Rapid	O
reversal	B-UNK
of	O
anticoagulation	B-UNK
reduces	B-UNK
hemorrhage	B-DISEASE
volume	B-UNK
in	O
a	O
mouse	B-UNK
model	B-UNK
of	O
warfarin	B-CHEMICAL
-	O
associated	B-UNK
intracerebral	O
hemorrhage	B-DISEASE
.	O

Warfarin	O
-	O
associated	B-UNK
intracerebral	O
hemorrhage	B-DISEASE
(	O
W	O
-	O
ICH	O
)	O
is	O
a	O
severe	B-UNK
type	B-UNK
of	O
stroke	B-UNK
.	O
There	O
is	O
no	O
consensus	O
on	O
the	O
optimal	B-UNK
treatment	B-UNK
for	O
W	O
-	O
ICH	O
.	O
Using	O
a	O
mouse	B-UNK
model	B-UNK
,	O
we	O
tested	B-UNK
whether	O
the	O
rapid	B-UNK
reversal	B-UNK
of	O
anticoagulation	B-UNK
using	O
human	B-UNK
prothrombin	B-CHEMICAL
complex	B-UNK
concentrate	O
(	O
PCC	O
)	O
can	O
reduce	B-UNK
hemorrhagic	B-UNK
blood	B-UNK
volume	B-UNK
.	O
Male	B-UNK
CD-1	O
mice	B-UNK
were	O
treated	B-UNK
with	O
warfarin	B-CHEMICAL
(	O
2	B-DISEASE
mg	B-UNK
/	O
kg	B-UNK
over	O
24	O
h	B-UNK
)	O
,	O
resulting	B-UNK
in	O
a	O
mean	B-UNK
(	O
+	O
/-s.d	O
.	O
)	O
International	O
Normalized	O
Ratio	O
of	O
3.5+/-0.9	O
.	O
First	O
,	O
we	O
showed	B-UNK
that	O
an	O
intravenous	B-UNK
administration	B-UNK
of	O
human	B-UNK
PCC	O
rapidly	B-UNK
reversed	B-UNK
anticoagulation	B-UNK
in	O
mice	B-UNK
.	O
Second	O
,	O
a	O
stereotactic	O
injection	B-UNK
of	O
collagenase	O
was	O
administered	B-UNK
to	O
induce	B-UNK
hemorrhage	B-DISEASE
in	O
the	O
right	B-UNK
striatum	O
.	O
Forty	O
-	O
five	O
minutes	B-UNK
later	B-UNK
,	O
the	O
animals	B-UNK
were	O
randomly	B-UNK
treated	B-UNK
with	O
PCC	O
(	O
100	O
U	B-UNK
/	O
kg	B-UNK
)	O
or	O
saline	B-UNK
i.v	B-UNK
.	O
(	O
n=12	O
per	O
group	B-UNK
)	O
.	O
Twenty	O
-	O
four	O
hours	B-UNK
after	O
hemorrhage	B-DISEASE
induction	B-UNK
,	O
hemorrhagic	B-UNK
blood	B-UNK
volume	B-UNK
was	O
quantified	O
using	O
a	O
photometric	O
hemoglobin	B-UNK
assay	B-UNK
.	O
The	O
mean	B-UNK
hemorrhagic	B-UNK
blood	B-UNK
volume	B-UNK
was	O
reduced	B-UNK
in	O
PCC	O
-	O
treated	B-UNK
animals	B-UNK
(	O
6.5+/-3.1	O
microL	O
)	O
compared	B-UNK
with	O
saline	B-UNK
controls	B-UNK
(	O
15.3+/-11.2	O
microL	O
,	O
P=0.015	O
)	O
.	O
In	O
the	O
saline	B-UNK
group	B-UNK
,	O
45	O
%	O
of	O
the	O
mice	B-UNK
developed	B-UNK
large	B-UNK
hematomas	O
(	O
i.e	O
.	O
,	O
>	O
15	O
microL	O
)	O
.	O
In	O
contrast	B-UNK
,	O
such	O
extensive	B-UNK
lesions	B-UNK
were	O
never	O
found	B-UNK
in	O
the	O
PCC	O
group	B-UNK
.	O
We	O
provide	B-UNK
experimental	B-UNK
data	B-UNK
suggesting	B-UNK
PCC	O
to	O
be	O
an	O
effective	B-UNK
acute	B-UNK
treatment	B-UNK
for	O
W	O
-	O
ICH	O
in	O
terms	O
of	O
reducing	B-UNK
hemorrhagic	B-UNK
blood	B-UNK
volume	B-UNK
.	O
Future	O
studies	B-UNK
are	O
needed	B-UNK
to	O
assess	B-UNK
the	O
therapeutic	B-UNK
potential	B-UNK
emerging	O
from	O
our	O
finding	O
for	O
human	B-UNK
W	O
-	O
ICH	O
.	O

Impact	O
of	O
alcohol	B-UNK
exposure	B-UNK
after	O
pregnancy	B-DISEASE
recognition	O
on	O
ultrasonographic	O
fetal	B-UNK
growth	B-UNK
measures	B-UNK
.	O

BACKGROUND	O
:	O
More	O
than	O
3	O
decades	O
after	O
Jones	O
and	O
Smith	O
(	O
1973	O
)	O
reported	B-UNK
on	O
the	O
devastation	O
caused	B-UNK
by	O
alcohol	B-UNK
exposure	B-UNK
on	O
fetal	B-UNK
development	B-UNK
,	O
the	O
rates	B-UNK
of	O
heavy	B-UNK
drinking	B-UNK
during	O
pregnancy	B-DISEASE
remain	B-UNK
relatively	B-UNK
unchanged	B-UNK
.	O
Early	O
identification	B-UNK
of	O
fetal	B-UNK
alcohol	B-UNK
exposure	B-UNK
and	O
maternal	B-UNK
abstinence	B-UNK
led	B-UNK
to	O
better	B-UNK
infant	B-DISEASE
outcomes	B-UNK
.	O
This	O
study	B-UNK
examined	B-UNK
the	O
utility	O
of	O
biometry	O
for	O
detecting	O
alcohol	B-UNK
-	O
related	B-UNK
fetal	B-UNK
growth	B-UNK
impairment	B-UNK
.	O
METHODS	O
:	O
We	O
obtained	B-UNK
fetal	B-UNK
ultrasound	B-UNK
measures	B-UNK
from	O
routine	B-UNK
ultrasound	B-UNK
examinations	B-UNK
for	O
167	O
pregnant	B-UNK
hazardous	O
drinkers	B-UNK
who	O
were	O
enrolled	O
in	O
a	O
brief	B-DISEASE
alcohol	B-UNK
intervention	O
study	B-UNK
.	O
The	O
fetal	B-UNK
measures	B-UNK
for	O
women	B-UNK
who	O
quit	O
after	O
learning	B-UNK
of	O
their	O
pregnancies	O
were	O
compared	B-UNK
with	O
measures	B-UNK
for	O
women	B-UNK
who	O
continued	B-UNK
some	O
drinking	B-UNK
throughout	O
the	O
course	B-UNK
of	O
their	O
pregnancies	O
.	O
Because	O
intensity	B-UNK
of	O
alcohol	B-UNK
consumption	B-UNK
is	O
associated	B-UNK
with	O
poorer	B-UNK
fetal	B-UNK
outcomes	B-UNK
,	O
separate	B-UNK
analyses	B-UNK
were	O
conducted	O
for	O
the	O
heavy	B-UNK
(	O
average	B-UNK
of	O
>	O
or=5	O
drinks	O
per	O
drinking	B-UNK
day	B-UNK
)	O
alcohol	B-UNK
consumers	O
.	O
Fetal	O
measures	B-UNK
from	O
the	O
heavy	B-UNK
-	O
exposed	B-UNK
fetuses	O
were	O
also	O
compared	B-UNK
with	O
measures	B-UNK
from	O
a	O
nondrinking	O
group	B-UNK
that	O
was	O
representative	O
of	O
normal	B-UNK
,	O
uncomplicated	O
pregnancies	O
from	O
our	O
clinics	O
.	O
Analyses	O
of	O
covariance	O
were	O
used	O
to	O
determine	B-UNK
whether	O
there	O
were	O
differences	B-UNK
between	O
groups	B-UNK
after	O
controlling	O
for	O
influences	O
of	O
gestational	O
age	B-UNK
and	O
drug	B-UNK
abuse	B-UNK
.	O
RESULTS	B-UNK
:	O
Nearly	O
half	O
of	O
the	O
pregnant	B-UNK
drinkers	B-UNK
abstained	O
after	O
learning	B-UNK
of	O
their	O
pregnancies	O
.	O
When	O
women	B-UNK
reportedly	O
quit	O
drinking	B-UNK
early	B-UNK
in	O
their	O
pregnancies	O
,	O
fetal	B-UNK
growth	B-UNK
measures	B-UNK
were	O
not	O
significantly	B-UNK
different	B-UNK
from	O
a	O
non-alcohol-exposed	O
group	B-UNK
,	O
regardless	O
of	O
prior	B-UNK
drinking	B-UNK
patterns	B-UNK
.	O
Any	O
alcohol	B-UNK
consumption	B-UNK
postpregnancy	O
recognition	O
among	O
the	O
heavy	B-UNK
drinkers	B-UNK
resulted	B-UNK
in	O
reduced	B-UNK
cerebellar	B-UNK
growth	B-UNK
as	O
well	O
as	O
decreased	B-UNK
cranial	B-UNK
to	O
body	B-UNK
growth	B-UNK
in	O
comparison	O
with	O
women	B-UNK
who	O
either	O
quit	O
drinking	B-UNK
or	O
who	O
were	O
nondrinkers	O
.	O
Amphetamine	O
abuse	B-UNK
was	O
predictive	B-UNK
of	O
larger	B-UNK
cranial	B-UNK
to	O
body	B-UNK
growth	B-UNK
ratios	O
.	O
CONCLUSIONS	O
:	O
Alterations	O
in	O
fetal	B-UNK
biometric	O
measurements	B-UNK
were	O
observed	B-UNK
among	O
the	O
heavy	B-UNK
drinkers	B-UNK
only	O
when	O
they	O
continued	B-UNK
drinking	B-UNK
after	O
becoming	O
aware	O
of	O
their	O
pregnancies	O
.	O
Although	O
the	O
reliance	O
on	O
self	O
-	O
reported	B-UNK
drinking	B-UNK
is	O
a	O
limitation	O
in	O
this	O
study	B-UNK
,	O
these	O
findings	B-UNK
support	B-UNK
the	O
benefits	O
of	O
early	B-UNK
abstinence	B-UNK
and	O
the	O
potential	B-UNK
for	O
ultrasound	B-UNK
examinations	B-UNK
in	O
the	O
detection	O
of	O
fetal	B-UNK
alcohol	B-UNK
effects	B-UNK
.	O

Urinary	B-UNK
symptoms	B-UNK
and	O
quality	O
of	O
life	B-UNK
changes	B-UNK
in	O
Thai	O
women	B-UNK
with	O
overactive	B-DISEASE
bladder	I-DISEASE
after	O
tolterodine	O
treatment	B-UNK
.	O

OBJECTIVES	O
:	O
To	O
study	B-UNK
the	O
urinary	B-UNK
symptoms	B-UNK
and	O
quality	O
of	O
life	B-UNK
changes	B-UNK
in	O
Thai	O
women	B-UNK
with	O
overactive	B-DISEASE
bladder	I-DISEASE
(	O
OAB	B-UNK
)	O
after	O
tolterodine	O
treatment	B-UNK
.	O
MATERIAL	O
AND	O
METHOD	O
:	O
Thirty	O
women	B-UNK
(	O
aged	B-UNK
30	O
-	O
77	O
years	B-UNK
)	O
diagnosed	B-UNK
as	O
having	B-UNK
OAB	B-UNK
at	B-DISEASE
the	O
Gynecology	O
Clinic	B-UNK
,	O
King	O
Chulalongkorn	O
Memorial	O
Hospital	O
from	O
January	O
to	O
April	O
2004	O
were	O
included	B-UNK
in	O
the	O
present	B-UNK
study	B-UNK
.	O
Tolterodine	O
2	B-DISEASE
mg	B-UNK
,	O
twice	B-UNK
daily	B-UNK
was	O
given	B-UNK
.	O
After	O
8	O
weeks	B-UNK
treatment	B-UNK
,	O
changes	B-UNK
in	O
micturition	B-UNK
diary	O
variables	B-UNK
and	O
tolerability	B-UNK
were	O
determined	O
.	O
Short	O
form	B-UNK
36	O
(	O
SF36	O
)	O
questionaires	O
(	O
Thai	O
version	B-UNK
)	O
were	O
given	B-UNK
before	O
and	O
after	O
8	O
weeks	B-UNK
of	O
treatment	B-UNK
.	O
RESULTS	B-UNK
:	O
At	O
8	O
weeks	B-UNK
,	O
all	O
micturition	B-UNK
per	O
day	B-UNK
decreased	B-UNK
from	O
16	O
.	O
7	O
+	O
/-	O
5	O
.	O
3	O
to	O
6	O
.	O
7	O
+	O
/-	O
2.4	B-UNK
times	B-UNK
per	O
day	B-UNK
.	O
The	O
number	B-UNK
of	O
nocturia	B-DISEASE
episodes	B-UNK
decreased	B-UNK
from	O
5.4	O
+	O
/-	O
4.2	O
to	O
1.1	B-UNK
+	O
/-	O
1.0	B-UNK
times	B-UNK
per	O
night	O
.	O
The	O
most	O
common	B-UNK
side	O
effect	B-UNK
was	O
dry	O
month	O
in	O
5	O
cases	B-UNK
(	O
16.7	O
%	O
)	O
with	O
2	B-DISEASE
cases	B-UNK
reporting	B-UNK
a	O
moderate	B-UNK
degree	B-UNK
and	O
1	O
case	B-UNK
with	O
severe	B-UNK
degree	B-UNK
.	O
Only	O
one	O
case	B-UNK
(	O
3.3	O
%	O
)	O
withdrew	O
from	O
the	O
present	B-UNK
study	B-UNK
due	O
to	O
a	O
severe	B-UNK
dry	B-DISEASE
mouth	I-DISEASE
.	O
The	O
SF-36	O
scores	B-UNK
changed	B-UNK
significantly	B-UNK
in	O
the	O
domains	O
of	O
physical	B-UNK
functioning	B-UNK
,	O
role	B-UNK
function	B-UNK
emotional	O
,	O
social	O
function	B-UNK
and	O
mental	B-UNK
heath	O
.	O
CONCLUSION	O
:	O
Tolterodine	O
was	O
well	O
tolerated	B-UNK
and	O
its	O
effects	B-UNK
improved	B-UNK
the	O
quality	O
of	O
life	B-UNK
in	O
Thai	O
women	B-UNK
with	O
OAB	B-UNK
.	O

Absence	O
of	O
acute	B-UNK
cerebral	B-UNK
vasoconstriction	O
after	O
cocaine	B-CHEMICAL
-	O
associated	B-UNK
subarachnoid	B-DISEASE
hemorrhage	I-DISEASE
.	O

INTRODUCTION	O
:	O
Cocaine	O
use	B-UNK
has	O
been	O
associated	B-UNK
with	O
neurovascular	O
complications	B-UNK
,	O
including	B-UNK
arterial	B-UNK
vasoconstriction	O
and	O
vasculitis	B-DISEASE
.	O
However	O
,	O
there	O
are	O
few	O
studies	B-UNK
of	O
angiographic	B-UNK
effects	B-UNK
of	O
cocaine	B-CHEMICAL
on	O
human	B-UNK
cerebral	B-UNK
arteries	B-UNK
.	O
Information	O
on	O
these	O
effects	B-UNK
could	O
be	O
obtained	B-UNK
from	O
angiograms	O
of	O
patients	B-UNK
with	O
cocaine	B-CHEMICAL
-	O
associated	B-UNK
subarachnoid	B-DISEASE
hemorrhage	I-DISEASE
(	O
SAH	O
)	O
who	O
underwent	B-UNK
angiography	B-UNK
shortly	B-UNK
after	O
cocaine	B-CHEMICAL
use	B-UNK
.	O
METHODS	O
:	O
We	O
screened	O
patients	B-UNK
with	O
SAH	O
retrospectively	B-UNK
and	O
identified	B-UNK
those	O
with	O
positive	B-UNK
urine	B-DISEASE
toxicology	O
for	O
cocaine	B-CHEMICAL
or	O
its	O
metabolites	B-UNK
.	O
Quantitative	O
arterial	B-UNK
diameter	B-UNK
measurements	B-UNK
from	O
angiograms	O
of	O
these	O
patients	B-UNK
were	O
compared	B-UNK
to	O
measurements	B-UNK
from	O
control	B-UNK
patients	B-UNK
with	O
SAH	O
who	O
were	O
matched	B-UNK
for	O
factors	B-UNK
known	B-UNK
to	O
influence	B-UNK
arterial	B-UNK
diameter	B-UNK
.	O
Qualitative	O
comparisons	O
of	O
small	B-UNK
artery	B-UNK
changes	B-UNK
also	O
were	O
made	O
.	O
RESULTS	B-UNK
:	O
Thirteen	O
patients	B-UNK
with	O
positive	B-UNK
cocaine	B-CHEMICAL
toxicology	O
were	O
compared	B-UNK
to	O
26	O
controls	B-UNK
.	O
There	O
were	O
no	O
significant	B-UNK
differences	B-UNK
between	O
groups	B-UNK
in	O
the	O
mean	B-UNK
diameters	O
of	O
the	O
intradural	O
internal	B-UNK
carotid	B-UNK
,	O
sphenoidal	O
segment	B-UNK
of	O
the	O
middle	B-UNK
cerebral	B-UNK
,	O
precommunicating	O
segment	B-UNK
of	O
the	O
anterior	B-UNK
cerebral	B-UNK
,	O
or	O
basilar	O
arteries	B-UNK
(	O
p	B-UNK
greater	B-UNK
than	O
0.05	O
for	O
all	O
comparisons	O
,	O
unpaired	O
t	B-UNK
-	O
tests	B-UNK
)	O
.	O
There	O
also	O
were	O
no	O
significant	B-UNK
differences	B-UNK
between	O
groups	B-UNK
when	O
expressing	O
diameters	O
as	O
the	O
sum	O
of	O
the	O
precommunicating	O
segment	B-UNK
of	O
the	O
anterior	B-UNK
cerebral	B-UNK
+	O
sphenoidal	O
segment	B-UNK
of	O
the	O
middle	B-UNK
cerebral	B-UNK
+	O
supraclinoid	O
internal	B-DISEASE
carotid	I-DISEASE
artery	I-DISEASE
+	O
basilar	O
artery	B-UNK
divided	O
by	O
the	O
diameter	B-UNK
of	O
the	O
petrous	O
internal	B-DISEASE
carotid	I-DISEASE
artery	I-DISEASE
(	O
p	B-UNK
greater	B-UNK
than	O
0.05	O
,	O
unpaired	O
t	B-UNK
-	O
tests	B-UNK
)	O
.	O
Qualitative	O
assessments	O
showed	B-UNK
two	O
arterial	B-UNK
irregularities	O
in	O
the	O
distal	B-UNK
vasculature	O
in	O
each	O
group	B-UNK
.	O
CONCLUSION	O
:	O
No	O
quantitative	B-UNK
evidence	B-UNK
for	O
narrowing	O
of	O
large	B-UNK
cerebral	B-UNK
arteries	B-UNK
or	O
qualitative	O
angiographic	B-UNK
evidence	B-UNK
for	O
distal	B-UNK
narrowing	O
or	O
vasculitis	B-DISEASE
could	O
be	O
found	B-UNK
in	O
patients	B-UNK
who	O
underwent	B-UNK
angiography	B-UNK
after	O
aneurysmal	O
SAH	O
associated	B-UNK
with	O
cocaine	B-CHEMICAL
use	B-UNK
.	O

Atrial	O
fibrillation	B-UNK
following	B-UNK
chemotherapy	B-UNK
for	O
stage	B-UNK
IIIE	O
diffuse	B-UNK
large	B-UNK
B	B-UNK
-	O
cell	B-UNK
gastric	B-UNK
lymphoma	B-DISEASE
in	O
a	O
patient	B-UNK
with	O
myotonic	B-DISEASE
dystrophy	I-DISEASE
(	O
Steinert'	O
s	O
disease	B-DISEASE
)	O
.	O

The	O
authors	B-UNK
describe	O
the	O
unusual	O
association	B-UNK
between	O
diffuse	B-UNK
B	B-UNK
-	O
cell	B-UNK
gastric	B-UNK
lymphoma	B-DISEASE
and	O
myotonic	B-DISEASE
dystrophy	I-DISEASE
,	O
the	O
most	O
common	B-UNK
form	B-UNK
of	O
adult	B-UNK
muscular	B-DISEASE
dystrophy	I-DISEASE
,	O
and	O
sudden	B-UNK
atrial	B-DISEASE
fibrillation	I-DISEASE
following	B-UNK
one	O
cycle	B-UNK
of	O
doxorubicin	B-CHEMICAL
-	O
based	B-UNK
chemotherapy	B-UNK
in	O
the	O
same	O
patient	B-UNK
.	O
Atrial	O
fibrillation	B-UNK
or	O
other	O
cardiac	B-UNK
arrhythmias	B-DISEASE
are	O
unusual	O
complications	B-UNK
in	O
patients	B-UNK
treated	B-UNK
with	O
chemotherapy	B-UNK
.	O
The	O
cardiac	B-UNK
toxicity	B-UNK
intrinsically	O
associated	B-UNK
with	O
the	O
aggressive	B-UNK
chemotherapy	B-UNK
employed	B-UNK
could	O
function	B-UNK
as	O
a	O
triggering	O
factor	B-UNK
for	O
the	O
arrhythmia	B-DISEASE
in	O
the	O
predisposed	O
myocardium	B-UNK
of	O
this	O
patient	B-UNK
.	O

A	O
phase	B-UNK
II	B-UNK
study	B-UNK
of	O
thalidomide	B-CHEMICAL
in	O
advanced	B-UNK
metastatic	B-UNK
renal	B-UNK
cell	B-UNK
carcinoma	B-DISEASE
.	O

OBJECTIVES	O
:	O
To	O
evaluate	B-UNK
the	O
toxicity	B-UNK
and	O
activity	B-UNK
of	O
thalidomide	B-CHEMICAL
in	O
patients	B-UNK
with	O
advanced	B-UNK
metastatic	B-UNK
renal	B-UNK
cell	B-UNK
cancer	B-DISEASE
and	O
to	O
measure	B-UNK
changes	B-UNK
of	O
one	O
angiogenic	O
factor	B-UNK
,	O
vascular	B-UNK
endothelial	B-UNK
growth	B-UNK
factor	B-UNK
(	O
VEGF)165	O
,	O
with	O
therapy	B-UNK
.	O
PATIENTS	O
AND	O
METHODS	O
:	O
29	O
patients	B-UNK
were	O
enrolled	O
on	O
a	O
study	B-UNK
of	O
thalidomide	B-CHEMICAL
using	O
an	O
intra-patient	O
dose	B-UNK
escalation	B-UNK
schedule	B-UNK
.	O
Patients	B-UNK
began	B-UNK
thalidomide	B-CHEMICAL
at	B-DISEASE
400	O
mg	B-UNK
/	O
d	B-UNK
and	O
escalated	O
as	O
tolerated	B-UNK
to	O
1200	O
mg	B-UNK
/	O
d	B-UNK
by	O
day	B-UNK
54	O
.	O
Fifty	O
-	O
nine	O
per	O
cent	O
of	O
patients	B-UNK
had	O
had	O
previous	B-UNK
therapy	B-UNK
with	O
IL-2	O
and	O
52	O
%	O
were	O
performance	B-UNK
status	B-UNK
2	B-DISEASE
or	O
3	O
.	O
Systemic	B-UNK
plasma	B-UNK
VEGF165	O
levels	B-UNK
were	O
measured	B-UNK
by	O
dual	B-UNK
monoclonal	O
ELISA	O
in	O
8	O
patients	B-UNK
.	O
RESULTS	B-UNK
:	O
24	O
patients	B-UNK
were	O
evaluable	O
for	O
response	B-UNK
with	O
one	O
partial	B-UNK
response	B-UNK
of	O
11	O
months	B-UNK
duration	B-UNK
of	O
a	O
patient	B-UNK
with	O
hepatic	B-UNK
and	O
pulmonary	B-UNK
metastases	O
(	O
4	O
%	O
)	O
,	O
one	O
minor	B-UNK
response	B-UNK
,	O
and	O
2	B-DISEASE
patients	B-UNK
stable	B-UNK
for	O
over	O
6	O
months	B-UNK
.	O
Somnolence	O
and	O
constipation	B-DISEASE
were	O
prominent	O
toxicities	B-UNK
and	O
most	O
patients	B-UNK
could	O
not	O
tolerate	O
the	O
1200	O
mg	B-UNK
/	O
day	B-UNK
dose	B-UNK
level	B-UNK
.	O
Systemic	B-UNK
plasma	B-UNK
VEGF165	O
levels	B-UNK
did	O
not	O
change	B-UNK
with	O
therapy	B-UNK
.	O
CONCLUSION	O
:	O
These	O
results	B-UNK
are	O
consistent	B-UNK
with	O
a	O
low	B-UNK
level	B-UNK
of	O
activity	B-UNK
of	O
thalidomide	B-CHEMICAL
in	O
renal	B-DISEASE
cell	B-UNK
carcinoma	B-DISEASE
.	O
Administration	B-UNK
of	O
doses	B-UNK
over	O
800	O
mg	B-UNK
/	O
day	B-UNK
was	O
difficult	O
to	O
achieve	O
in	O
this	O
patient	B-UNK
population	B-UNK
,	O
however	O
lower	B-UNK
doses	B-UNK
were	O
practical	O
.	O
The	O
dose	B-UNK
-	O
response	B-UNK
relationship	B-UNK
,	O
if	O
any	O
,	O
of	O
thalidomide	B-CHEMICAL
for	O
renal	B-UNK
cell	B-UNK
carcinoma	B-DISEASE
is	O
unclear	O
.	O

The	O
striatum	O
as	O
a	O
target	O
for	O
anti-rigor	O
effects	B-UNK
of	O
an	O
antagonist	B-UNK
of	O
mGluR1	O
,	O
but	O
not	O
an	O
agonist	B-UNK
of	O
group	B-UNK
II	B-UNK
metabotropic	O
glutamate	B-UNK
receptors	B-UNK
.	O

The	O
aim	O
of	O
the	O
present	B-UNK
study	B-UNK
was	O
to	O
find	O
out	O
whether	O
the	O
metabotropic	O
receptor	B-UNK
1	O
(	O
mGluR1	O
)	O
and	O
group	B-UNK
II	B-UNK
mGluRs	O
,	O
localized	O
in	O
the	O
striatum	O
,	O
are	O
involved	B-UNK
in	O
antiparkinsonian	B-UNK
-	O
like	B-UNK
effects	B-UNK
in	O
rats	B-UNK
.	O
Haloperidol	O
(	O
1	O
mg	B-UNK
/	O
kg	B-UNK
ip	O
)	O
induced	B-UNK
parkinsonian	B-UNK
-	O
like	B-UNK
muscle	B-DISEASE
rigidity	I-DISEASE
,	O
measured	B-UNK
as	O
an	O
increased	B-UNK
resistance	B-UNK
of	O
a	O
rat'	O
s	O
hind	O
foot	B-UNK
to	O
passive	B-UNK
flexion	O
and	O
extension	O
at	B-DISEASE
the	O
ankle	O
joint	O
.	O
(	O
RS)-1-aminoindan-1,5-dicarboxylic	O
acid	B-UNK
(	O
AIDA	O
;	O
0.5	B-UNK
-	O
15	O
microg/0.5	B-UNK
microl	I-UNK
)	O
,	O
a	O
potent	B-UNK
and	O
selective	B-UNK
mGluR1	O
antagonist	B-UNK
,	O
or	O
(	O
2R,4R)-4-aminopyrrolidine-2,4-dicarboxylate	O
(	O
2R,4R	O
-	O
APDC	O
;	O
7.5	B-UNK
-	O
15	O
microg/0.5	B-UNK
microl	I-UNK
)	O
,	O
a	O
selective	B-UNK
group	B-UNK
II	B-UNK
agonist	B-UNK
,	O
was	O
injected	B-UNK
bilaterally	B-UNK
into	O
the	O
striatum	O
of	O
haloperidol	B-CHEMICAL
-	O
treated	B-UNK
animals	B-UNK
.	O
AIDA	O
in	O
doses	B-UNK
of	O
7.5	B-UNK
-	O
15	O
microg/0.5	B-UNK
microl	I-UNK
diminished	B-UNK
the	O
haloperidol	B-CHEMICAL
-	O
induced	B-UNK
muscle	B-DISEASE
rigidity	I-DISEASE
.	O
In	O
contrast	B-UNK
,	O
2R,4R	O
-	O
APDC	O
injections	B-UNK
were	O
ineffective	O
.	O
The	O
present	B-UNK
results	B-UNK
may	O
suggest	B-UNK
that	O
the	O
blockade	B-UNK
of	O
striatal	B-UNK
mGluR1	O
,	O
but	O
not	O
the	O
stimulation	B-UNK
of	O
group	B-UNK
II	B-UNK
mGluRs	O
,	O
may	O
ameliorate	O
parkinsonian	B-UNK
muscle	B-DISEASE
rigidity	I-DISEASE
.	O

Acute	B-UNK
cholestatic	B-UNK
hepatitis	B-DISEASE
after	O
exposure	B-UNK
to	O
isoflurane	B-CHEMICAL
.	O

OBJECTIVE	O
:	O
To	O
report	B-UNK
a	O
case	B-UNK
of	O
acute	B-UNK
cholestatic	B-UNK
hepatitis	B-DISEASE
following	B-UNK
exposure	B-UNK
to	O
the	O
inhalational	O
anesthetic	B-UNK
isoflurane	B-CHEMICAL
.	O
CASE	B-UNK
SUMMARY	B-UNK
:	O
A	O
70-year	O
-	O
old	B-UNK
healthy	B-UNK
woman	B-UNK
from	O
Iraq	O
developed	B-UNK
acute	B-UNK
cholestatic	B-UNK
hepatitis	B-DISEASE
3	O
weeks	B-UNK
following	B-UNK
repair	O
of	O
the	O
right	B-UNK
rotator	O
cuff	O
under	O
general	B-UNK
anesthesia	B-UNK
.	O
There	O
was	O
no	O
evidence	B-UNK
for	O
viral	O
,	O
autoimmune	O
,	O
or	O
metabolic	B-UNK
causes	B-UNK
of	O
hepatitis	B-DISEASE
.	O
No	O
other	O
medications	B-UNK
were	O
involved	B-UNK
except	O
for	O
dipyrone	B-CHEMICAL
for	O
analgesia	O
.	O
The	O
alanine	B-CHEMICAL
aminotransferase	B-UNK
was	O
elevated	B-UNK
to	O
a	O
peak	B-UNK
concentration	B-UNK
of	O
1533	O
U	B-UNK
/	O
L	B-UNK
and	O
the	O
serum	B-UNK
bilirubin	B-CHEMICAL
reached	B-UNK
a	O
peak	B-UNK
of	O
17.0	O
mg	B-UNK
/	O
dL.	O
There	O
was	O
slow	O
improvement	B-UNK
over	O
4	O
months	B-UNK
.	O
Accidental	O
reexposure	O
by	O
the	O
patient	B-UNK
to	O
dipyrone	B-CHEMICAL
was	O
uneventful	O
.	O
DISCUSSION	O
:	O
The	O
clinical	B-UNK
and	O
histologic	B-UNK
picture	O
of	O
this	O
case	B-UNK
resembles	O
halothane	B-DISEASE
hepatitis	I-DISEASE
,	O
which	O
has	O
a	O
significant	B-UNK
mortality	B-UNK
rate	B-UNK
.	O
CONCLUSIONS	O
:	O
Isoflurane	O
,	O
a	O
common	B-UNK
anesthetic	B-UNK
agent	B-UNK
,	O
can	O
cause	B-UNK
severe	B-UNK
cholestatic	B-UNK
hepatitis	B-DISEASE
.	O

Calcitonin	O
gene	B-UNK
-	O
related	B-UNK
peptide	O
levels	B-UNK
during	O
nitric	B-CHEMICAL
oxide	I-CHEMICAL
-	O
induced	B-UNK
headache	B-DISEASE
in	O
patients	B-UNK
with	O
chronic	B-UNK
tension	B-DISEASE
-	I-DISEASE
type	I-DISEASE
headache	I-DISEASE
.	O

It	O
has	O
been	O
proposed	O
that	O
nitric	B-CHEMICAL
oxide	I-CHEMICAL
(	O
NO	O
)	O
induced	B-UNK
headache	B-DISEASE
in	O
primary	B-UNK
headaches	O
may	O
be	O
associated	B-UNK
with	O
release	B-UNK
of	O
calcitonin	B-CHEMICAL
gene	I-CHEMICAL
-	I-CHEMICAL
related	I-CHEMICAL
peptide	I-CHEMICAL
(	O
CGRP	O
)	O
.	O
In	O
the	O
present	B-UNK
study	B-UNK
we	O
aimed	O
to	O
investigate	O
plasma	B-UNK
levels	B-UNK
of	O
CGRP	O
during	O
headache	B-DISEASE
induced	B-UNK
by	O
the	O
NO	O
donor	B-UNK
glyceryl	B-UNK
trinitrate	B-UNK
(	O
GTN	O
)	O
in	O
16	O
patients	B-UNK
with	O
chronic	B-UNK
tension	B-DISEASE
-	I-DISEASE
type	I-DISEASE
headache	I-DISEASE
and	O
16	O
healthy	B-UNK
controls	B-UNK
.	O
The	O
subjects	B-UNK
were	O
randomly	B-UNK
allocated	B-UNK
to	O
receive	B-UNK
0.5	B-UNK
microg	B-UNK
/	O
kg	B-UNK
/	O
min	B-UNK
GTN	O
or	O
placebo	B-UNK
over	O
20	O
min	B-UNK
on	O
two	O
headache	B-DISEASE
-	O
free	B-UNK
days	B-UNK
.	O
Blood	O
samples	B-UNK
were	O
collected	B-UNK
at	B-DISEASE
baseline	B-UNK
,	O
10	O
,	O
20	O
and	O
60	O
min	B-UNK
after	O
start	O
of	O
infusion	B-UNK
.	O
Both	O
patients	B-UNK
and	O
controls	B-UNK
developed	B-UNK
significantly	B-UNK
stronger	B-UNK
immediate	B-UNK
headache	B-DISEASE
on	O
the	O
GTN	O
day	B-UNK
than	O
on	O
the	O
placebo	B-UNK
day	B-UNK
and	O
the	O
headache	B-DISEASE
was	O
significantly	B-UNK
more	O
pronounced	O
in	O
patients	B-UNK
than	O
in	O
controls	B-UNK
.	O
There	O
was	O
no	O
difference	B-UNK
between	O
the	O
area	B-UNK
under	O
the	O
CGRP	O
curve	O
(	O
AUCCGRP	O
)	O
on	O
GTN	O
vs	B-UNK
.	O
placebo	B-UNK
day	B-UNK
in	O
either	O
patients	B-UNK
(	O
P=0.65	O
)	O
or	O
controls	B-UNK
(	O
P=0.48	O
)	O
.	O
The	O
AUCCGRP	O
recorded	B-UNK
on	O
the	O
GTN	O
day	B-UNK
did	O
not	O
differ	B-UNK
between	O
patients	B-UNK
and	O
controls	B-UNK
(	O
P=0.36	O
)	O
.	O
Both	O
in	O
patients	B-UNK
and	O
controls	B-UNK
,	O
CGRP	O
levels	B-UNK
changed	B-UNK
significantly	B-UNK
over	O
time	B-UNK
,	O
on	O
both	O
the	O
GTN	O
and	O
placebo	B-UNK
days	B-UNK
(	O
P	B-UNK
<	I-UNK
0.05	O
)	O
.	O
The	O
present	B-UNK
study	B-UNK
indicates	B-UNK
that	O
NO	O
-	O
induced	B-UNK
immediate	B-UNK
headache	B-DISEASE
is	O
not	O
associated	B-UNK
with	O
release	B-UNK
of	O
CGRP	O
.	O

Myocardial	O
ischemia	B-DISEASE
due	O
to	O
coronary	B-UNK
artery	I-UNK
spasm	B-DISEASE
during	O
dobutamine	B-CHEMICAL
stress	B-UNK
echocardiography	O
.	O

Dobutamine	O
stress	B-UNK
echocardiography	O
(	O
DSE	O
)	O
is	O
a	O
useful	B-UNK
and	O
safe	B-UNK
provocation	B-UNK
test	B-UNK
for	O
myocardial	B-DISEASE
ischemia	I-DISEASE
.	O
Until	O
now	O
,	O
the	O
test	B-UNK
has	O
been	O
focused	O
only	O
on	O
the	O
organic	O
lesion	B-UNK
in	O
the	O
coronary	B-UNK
artery	I-UNK
,	O
and	O
positive	B-UNK
DSE	O
has	O
indicated	B-UNK
the	O
presence	O
of	O
significant	B-UNK
fixed	B-UNK
coronary	B-UNK
artery	I-UNK
stenosis	B-DISEASE
.	O
The	O
aim	O
of	O
the	O
present	B-UNK
study	B-UNK
is	O
to	O
examine	O
whether	O
myocardial	B-DISEASE
ischemia	I-DISEASE
due	O
to	O
coronary	B-UNK
spasm	B-DISEASE
is	O
induced	B-UNK
by	O
dobutamine	B-CHEMICAL
.	O
We	O
performed	B-UNK
DSE	O
on	O
51	O
patients	B-UNK
with	O
coronary	B-UNK
spastic	O
angina	B-DISEASE
but	O
without	O
significant	B-UNK
fixed	B-UNK
coronary	B-UNK
artery	I-UNK
stenosis	B-DISEASE
.	O
All	O
patients	B-UNK
had	O
anginal	O
attacks	B-UNK
at	B-DISEASE
rest	O
with	O
ST	B-UNK
elevation	B-UNK
on	O
the	O
electrocardiogram	O
(	O
variant	O
angina	B-DISEASE
)	O
.	O
Coronary	O
spasm	B-DISEASE
was	O
induced	B-UNK
by	O
intracoronary	O
injection	B-UNK
of	O
acetylcholine	B-CHEMICAL
,	O
and	O
no	O
fixed	B-UNK
coronary	B-UNK
artery	I-UNK
stenosis	B-DISEASE
was	O
documented	B-UNK
on	O
angiograms	O
in	O
all	O
patients	B-UNK
.	O
DSE	O
was	O
performed	B-UNK
with	O
intravenous	B-UNK
dobutamine	B-CHEMICAL
infusion	B-UNK
with	O
an	O
incremental	O
doses	B-UNK
of	O
5	O
,	O
10	O
,	O
20	O
,	O
30	O
,	O
and	O
40	O
microg	B-UNK
/	O
kg	B-UNK
/	O
min	B-UNK
every	O
5	O
minutes	B-UNK
.	O
Of	O
the	O
51	O
patients	B-UNK
,	O
7	O
patients	B-UNK
showed	B-UNK
asynergy	O
with	O
ST	B-UNK
elevation	B-UNK
.	O
All	O
7	O
patients	B-UNK
(	O
13.7	O
%	O
)	O
had	O
chest	B-DISEASE
pain	I-DISEASE
during	O
asynergy	O
,	O
and	O
both	O
chest	B-DISEASE
pain	I-DISEASE
and	O
electrocardiographic	B-UNK
changes	B-UNK
were	O
preceded	O
by	O
asynergy	O
.	O
These	O
findings	B-UNK
indicate	B-UNK
that	O
dobutamine	B-CHEMICAL
can	O
provoke	O
coronary	B-UNK
spasm	B-DISEASE
in	O
some	O
patients	B-UNK
with	O
coronary	B-UNK
spastic	O
angina	B-DISEASE
.	O
When	O
DSE	O
is	O
performed	B-UNK
to	O
evaluate	B-UNK
coronary	B-DISEASE
artery	I-DISEASE
disease	I-DISEASE
,	O
not	O
only	O
fixed	B-UNK
coronary	B-DISEASE
stenosis	I-DISEASE
,	O
but	O
also	O
coronary	B-UNK
spasm	B-DISEASE
should	O
be	O
considered	B-UNK
as	O
a	O
genesis	O
of	O
asynergy	O
.	O

Nitric	O
oxide	O
synthase	B-UNK
expression	B-UNK
in	O
the	O
course	B-UNK
of	O
lead	B-CHEMICAL
-	O
induced	B-UNK
hypertension	B-DISEASE
.	O

We	O
recently	B-UNK
showed	B-UNK
elevated	B-UNK
reactive	B-CHEMICAL
oxygen	I-CHEMICAL
species	I-CHEMICAL
(	O
ROS	O
)	O
,	O
reduced	B-UNK
urinary	B-UNK
excretion	B-UNK
of	O
NO	O
metabolites	B-UNK
(	O
NOx	O
)	O
,	O
and	O
increased	B-UNK
NO	O
sequestration	O
as	O
nitrotyrosine	O
in	O
various	O
tissues	B-UNK
in	O
rats	B-UNK
with	O
lead	B-CHEMICAL
-	O
induced	B-UNK
hypertension	B-DISEASE
.	O
This	O
study	B-UNK
was	O
designed	O
to	O
discern	O
whether	O
the	O
reduction	B-UNK
in	O
urinary	B-UNK
NOx	I-UNK
in	O
lead	B-CHEMICAL
-	O
induced	B-UNK
hypertension	B-DISEASE
is	O
,	O
in	O
part	O
,	O
due	O
to	O
depressed	B-UNK
NO	O
synthase	B-UNK
(	O
NOS	O
)	O
expression	B-UNK
.	O
Male	B-UNK
Sprague	B-UNK
-	O
Dawley	B-UNK
rats	B-UNK
were	O
randomly	B-UNK
assigned	B-UNK
to	O
a	O
lead	B-CHEMICAL
-	O
treated	B-UNK
group	B-UNK
(	O
given	B-UNK
lead	B-CHEMICAL
acetate	I-CHEMICAL
,	O
100	O
ppm	O
,	O
in	O
drinking	B-CHEMICAL
water	I-CHEMICAL
and	O
regular	B-UNK
rat	B-UNK
chow	O
)	O
,	O
a	O
group	B-UNK
given	B-UNK
lead	B-CHEMICAL
and	O
vitamin	B-UNK
E-fortified	O
chow	O
,	O
or	O
a	O
normal	B-UNK
control	B-UNK
group	B-UNK
given	B-UNK
either	O
regular	B-UNK
food	B-UNK
and	O
water	B-CHEMICAL
or	O
vitamin	B-UNK
E-fortified	O
food	B-UNK
for	O
12	O
weeks	B-UNK
.	O
Tail	O
blood	B-UNK
pressure	B-UNK
,	O
urinary	B-UNK
NOx	I-UNK
excretion	B-UNK
,	O
plasma	B-UNK
malondialdehyde	B-CHEMICAL
(	O
MDA	O
)	O
,	O
and	O
endothelial	B-UNK
and	O
inducible	B-UNK
NOS	O
(	O
eNOS	O
and	O
iNOS	O
)	O
isotypes	O
in	O
the	O
aorta	O
and	O
kidney	B-UNK
were	O
measured	B-UNK
.	O
The	O
lead	B-CHEMICAL
-	O
treated	B-UNK
group	B-UNK
exhibited	B-UNK
a	O
rise	B-UNK
in	O
blood	B-UNK
pressure	B-UNK
and	O
plasma	B-UNK
MDA	O
concentration	B-UNK
,	O
a	O
fall	O
in	O
urinary	B-UNK
NOx	I-UNK
excretion	B-UNK
,	O
and	O
a	O
paradoxical	O
rise	B-UNK
in	O
vascular	B-UNK
and	O
renal	B-UNK
tissue	B-UNK
eNOS	O
and	O
iNOS	O
expression	B-UNK
.	O
Vitamin	B-UNK
E	B-UNK
supplementation	B-UNK
ameliorated	O
hypertension	B-DISEASE
,	O
lowered	O
plasma	B-UNK
MDA	O
concentration	B-UNK
,	O
and	O
raised	O
urinary	B-UNK
NOx	I-UNK
excretion	B-UNK
while	O
significantly	B-UNK
lowering	B-UNK
vascular	B-UNK
,	O
but	O
not	O
renal	B-UNK
,	O
tissue	B-UNK
eNOS	O
and	O
iNOS	O
expression	B-UNK
.	O
Vitamin	B-UNK
E	B-UNK
supplementation	B-UNK
had	O
no	O
effect	B-UNK
on	O
either	O
blood	B-UNK
pressure	B-UNK
,	O
plasma	B-UNK
MDA	O
,	O
or	O
NOS	O
expression	B-UNK
in	O
the	O
control	B-UNK
group	B-UNK
.	O
The	O
study	B-UNK
also	O
revealed	B-UNK
significant	B-UNK
inhibition	B-UNK
of	O
NOS	O
enzymatic	O
activity	B-UNK
by	O
lead	B-CHEMICAL
in	O
cell	B-UNK
-	O
free	B-UNK
preparations	B-UNK
.	O
In	O
conclusion	O
,	O
lead	B-CHEMICAL
-	O
induced	B-UNK
hypertension	B-DISEASE
in	O
this	O
model	B-UNK
was	O
associated	B-UNK
with	O
a	O
compensatory	B-UNK
upregulation	O
of	O
renal	B-DISEASE
and	O
vascular	B-UNK
eNOS	O
and	O
iNOS	O
expression	B-UNK
.	O
This	O
is	O
,	O
in	O
part	O
,	O
due	O
to	O
ROS	O
-	O
mediated	B-UNK
NO	O
inactivation	O
,	O
lead	B-CHEMICAL
-	O
associated	B-UNK
inhibition	B-UNK
of	O
NOS	O
activity	B-UNK
,	O
and	O
perhaps	O
stimulatory	O
actions	B-UNK
of	O
increased	B-UNK
shear	O
stress	B-UNK
associated	B-UNK
with	O
hypertension	B-DISEASE
.	O

Risk	O
for	O
valvular	B-DISEASE
heart	I-DISEASE
disease	I-DISEASE
among	O
users	B-UNK
of	O
fenfluramine	B-CHEMICAL
and	O
dexfenfluramine	B-CHEMICAL
who	O
underwent	B-UNK
echocardiography	O
before	O
use	B-UNK
of	O
medication	B-UNK
.	O

BACKGROUND	O
:	O
Because	O
uncontrolled	B-UNK
echocardiographic	O
surveys	O
suggested	B-UNK
that	O
up	O
to	O
30	O
%	O
to	O
38	O
%	O
of	O
users	B-UNK
of	O
fenfluramine	B-CHEMICAL
and	O
dexfenfluramine	B-CHEMICAL
had	O
valvular	O
disease	B-DISEASE
,	O
these	O
drugs	B-UNK
were	O
withdrawn	O
from	O
the	O
market	O
.	O
OBJECTIVE	O
:	O
To	O
determine	B-UNK
the	O
risk	B-UNK
for	O
new	B-UNK
or	O
worsening	O
valvular	O
abnormalities	B-DISEASE
among	O
users	B-UNK
of	O
fenfluramine	B-CHEMICAL
or	O
dexfenfluramine	B-CHEMICAL
who	O
underwent	B-UNK
echocardiography	O
before	O
they	O
began	B-UNK
to	O
take	O
these	O
medications	B-UNK
.	O
DESIGN	B-UNK
:	O
Cohort	O
study	B-UNK
.	O
SETTING	O
:	O
Academic	O
primary	B-UNK
care	B-UNK
practices	O
.	O
PATIENTS	O
:	O
46	B-DISEASE
patients	B-UNK
who	O
used	O
fenfluramine	B-CHEMICAL
or	O
dexfenfluramine	B-CHEMICAL
for	O
14	O
days	B-UNK
or	O
more	O
and	O
had	O
echocardiograms	O
obtained	B-UNK
before	O
therapy	B-UNK
.	O
MEASUREMENTS	O
:	O
Follow	O
-	O
up	O
echocardiography	O
.	O
The	O
primary	B-UNK
outcome	B-UNK
was	O
new	B-UNK
or	O
worsening	O
valvulopathy	O
,	O
defined	O
as	O
progression	B-UNK
of	O
either	O
aortic	B-UNK
or	O
mitral	O
regurgitation	B-DISEASE
by	O
at	B-DISEASE
least	O
one	O
degree	B-UNK
of	O
severity	B-UNK
and	O
disease	B-DISEASE
that	O
met	O
U.S.	O
Food	O
and	O
Drug	B-UNK
Administration	B-UNK
criteria	B-UNK
(	O
at	B-DISEASE
least	O
mild	B-UNK
aortic	B-UNK
regurgitation	B-DISEASE
or	O
moderate	B-UNK
mitral	O
regurgitation	B-DISEASE
)	O
.	O
RESULTS	B-UNK
:	O
Two	O
patients	B-UNK
(	O
4.3	O
%	O
[	O
95	O
%	O
CI	B-UNK
,	O
0.6	B-UNK
%	O
to	O
14.8	O
%	O
]	O
)	O
receiving	B-UNK
fenfluramine	B-CHEMICAL
-	O
phentermine	B-CHEMICAL
developed	B-UNK
valvular	B-DISEASE
heart	I-DISEASE
disease	I-DISEASE
.	O
One	O
had	O
baseline	B-UNK
bicuspid	B-DISEASE
aortic	I-DISEASE
valve	I-DISEASE
and	O
mild	B-UNK
aortic	B-UNK
regurgitation	B-DISEASE
that	O
progressed	O
to	O
moderate	B-UNK
regurgitation	B-DISEASE
.	O
The	O
second	B-UNK
patient	B-UNK
developed	I-UNK
new	B-UNK
moderate	B-UNK
aortic	B-UNK
insufficiency	O
.	O
CONCLUSION	O
:	O
Users	O
of	O
diet	B-UNK
medications	B-UNK
are	O
at	B-DISEASE
risk	B-UNK
for	O
valvular	B-DISEASE
heart	I-DISEASE
disease	I-DISEASE
.	O
However	O
,	O
the	O
incidence	B-UNK
may	O
be	O
lower	B-UNK
than	O
that	O
reported	B-UNK
previously	B-UNK
.	O

Carboplatin	O
toxic	B-UNK
effects	B-UNK
on	O
the	O
peripheral	B-UNK
nervous	B-UNK
system	I-UNK
of	O
the	O
rat	B-UNK
.	O

BACKGROUND	O
:	O
The	O
most	O
striking	B-UNK
of	O
carboplatin'	O
s	O
advantages	O
(	O
CBDCA	O
)	O
over	O
cisplatin	B-CHEMICAL
(	O
CDDP	O
)	O
is	O
its	O
markedly	B-UNK
reduced	B-UNK
rate	B-UNK
of	O
neurotoxic	B-UNK
effects	B-UNK
.	O
However	O
,	O
the	O
use	B-UNK
of	O
CBDCA	O
higher	B-UNK
-	O
intensity	B-UNK
schedules	B-UNK
and	O
the	O
association	B-UNK
with	O
other	O
neurotoxic	B-UNK
drugs	B-UNK
in	O
polychemotherapy	O
may	O
cause	B-UNK
some	O
concern	O
about	O
its	O
safety	B-UNK
with	O
respect	O
to	O
peripheral	B-UNK
nervous	B-UNK
system	I-UNK
damage	B-UNK
.	O
MATERIALS	O
AND	O
METHODS	O
:	O
Two	O
different	B-UNK
schedules	B-UNK
of	O
CBDCA	O
administration	B-UNK
(	O
10	O
mg	B-UNK
/	O
kg	B-UNK
and	O
15	O
mg	B-UNK
/	O
kg	B-UNK
i.p	B-UNK
.	O
twice	B-UNK
a	O
week	B-UNK
for	O
nine	O
times	B-UNK
)	O
were	O
evaluated	B-UNK
in	O
Wistar	B-UNK
rats	I-UNK
.	O
Neurotoxicity	O
was	O
assessed	B-UNK
for	O
behavioral	B-UNK
(	O
tail	O
-	O
flick	O
test	B-UNK
)	O
,	O
neurophysiological	O
(	O
nerve	B-UNK
conduction	B-UNK
velocity	B-UNK
in	O
the	O
tail	O
nerve	B-UNK
)	O
,	O
morphological	O
,	O
morphometrical	O
and	O
analytical	O
effects	B-UNK
.	O
RESULTS	B-UNK
:	O
CBDCA	O
administration	B-UNK
induced	B-UNK
dose	B-UNK
-	O
dependent	B-UNK
peripheral	B-UNK
neurotoxicity	B-UNK
.	O
Pain	O
perception	B-UNK
and	O
nerve	B-UNK
conduction	B-UNK
velocity	B-UNK
in	O
the	O
tail	O
were	O
significantly	B-UNK
impaired	B-UNK
,	O
particularly	O
after	O
the	O
high	B-UNK
-	O
dose	B-UNK
treatment	B-UNK
.	O
The	O
dorsal	B-UNK
root	B-UNK
ganglia	B-UNK
sensory	B-UNK
neurons	B-UNK
and	O
,	O
to	O
a	O
lesser	B-UNK
extent	B-UNK
,	O
satellite	O
cells	B-UNK
showed	B-UNK
the	O
same	O
changes	B-UNK
as	O
those	O
induced	B-UNK
by	O
CDDP	O
,	O
mainly	B-UNK
affecting	O
the	O
nucleus	B-UNK
and	O
nucleolus	O
of	O
ganglionic	B-UNK
sensory	B-UNK
neurons	B-UNK
.	O
Moreover	O
,	O
significant	B-UNK
amounts	B-UNK
of	O
platinum	B-CHEMICAL
were	O
detected	B-UNK
in	O
the	O
dorsal	B-UNK
root	B-UNK
ganglia	B-UNK
and	O
kidney	B-UNK
after	O
CBDCA	O
treatment	B-UNK
.	O
CONCLUSIONS	O
:	O
CBDCA	O
is	O
neurotoxic	B-UNK
in	O
our	O
model	B-UNK
,	O
and	O
the	O
type	B-UNK
of	O
pathological	B-UNK
changes	B-UNK
it	O
induces	B-UNK
are	O
so	O
closely	O
similar	B-UNK
to	O
those	O
caused	B-UNK
by	O
CDDP	O
that	O
it	O
is	O
probable	B-UNK
that	O
neurotoxicity	B-UNK
is	O
induced	B-UNK
in	O
the	O
two	O
drugs	B-UNK
by	O
the	O
same	O
mechanism	B-UNK
.	O
This	O
model	B-UNK
can	O
be	O
used	O
alone	O
or	O
in	O
combination	B-UNK
with	O
other	O
drugs	B-UNK
to	O
explore	O
the	O
effect	B-UNK
of	O
CBDCA	O
on	O
the	O
peripheral	B-UNK
nervous	B-UNK
system	I-UNK
.	O

Iatrogenic	O
risks	O
of	O
endometrial	B-UNK
carcinoma	B-DISEASE
after	O
treatment	B-UNK
for	O
breast	B-DISEASE
cancer	I-DISEASE
in	O
a	O
large	B-UNK
French	O
case	B-UNK
-	O
control	B-UNK
study	B-UNK
.	O
F	O
 	O
d	B-UNK
 	O
ration	O
Nationale	O
des	O
Centres	O
de	B-UNK
Lutte	O
Contre	O
le	O
Cancer	O
(	O
FNCLCC	O
)	O
.	O

Since	O
tamoxifen	B-CHEMICAL
is	O
widely	B-UNK
used	O
in	O
breast	B-DISEASE
cancer	I-DISEASE
treatment	B-UNK
and	O
has	O
been	O
proposed	O
for	O
the	O
prevention	O
of	O
breast	B-DISEASE
cancer	I-DISEASE
,	O
its	O
endometrial	B-UNK
iatrogenic	O
effects	B-UNK
must	O
be	O
carefully	O
examined	B-UNK
.	O
We	O
have	O
investigated	B-UNK
the	O
association	B-UNK
between	O
endometrial	B-DISEASE
cancer	I-DISEASE
and	O
tamoxifen	B-CHEMICAL
use	B-UNK
or	O
other	O
treatments	B-UNK
in	O
women	B-UNK
treated	B-UNK
for	O
breast	B-DISEASE
cancer	I-DISEASE
in	O
a	O
case	B-UNK
-	O
control	B-UNK
study	B-UNK
.	O
Cases	O
of	O
endometrial	B-DISEASE
cancer	I-DISEASE
diagnosed	B-UNK
after	O
breast	B-DISEASE
cancer	I-DISEASE
(	O
n	B-UNK
=	O
135	O
)	O
and	O
467	O
controls	B-UNK
matched	B-UNK
for	O
age	B-UNK
,	O
year	B-UNK
of	O
diagnosis	B-UNK
of	O
breast	B-DISEASE
cancer	I-DISEASE
and	O
hospital	B-UNK
and	O
survival	B-UNK
time	B-UNK
with	O
an	O
intact	B-UNK
uterus	O
were	O
included	B-UNK
.	O
Women	O
who	O
had	O
received	B-UNK
tamoxifen	B-CHEMICAL
were	O
significantly	B-UNK
more	O
likely	B-UNK
to	O
have	O
endometrial	B-DISEASE
cancer	I-DISEASE
diagnosed	B-UNK
than	O
those	O
who	O
had	O
not	O
(	O
crude	O
relative	B-UNK
risk	B-UNK
=	O
4.9	O
,	O
p	B-UNK
=	I-UNK
0.0001	O
)	O
.	O
Univariate	O
and	O
adjusted	B-UNK
analyses	B-UNK
showed	B-UNK
that	O
the	O
risk	B-UNK
increased	B-UNK
with	O
the	O
length	O
of	O
treatment	B-UNK
(	O
p	B-UNK
=	I-UNK
0.0001	O
)	O
or	O
the	O
cumulative	B-UNK
dose	B-UNK
of	O
tamoxifen	B-CHEMICAL
received	B-UNK
(	O
p	B-UNK
=	I-UNK
0.0001	O
)	O
,	O
irrespective	O
of	O
the	O
daily	B-UNK
dose	B-UNK
.	O
Women	O
who	O
had	O
undergone	B-UNK
pelvic	B-UNK
radiotherapy	B-UNK
also	O
had	O
a	O
higher	B-UNK
risk	B-UNK
(	O
crude	O
relative	B-UNK
risk	B-UNK
=	O
7.8	O
,	O
p	B-UNK
=	I-UNK
0.0001	O
)	O
.	O
After	O
adjusting	O
for	O
confounding	O
factors	B-UNK
,	O
the	O
risk	B-UNK
was	O
higher	B-UNK
for	O
tamoxifen	B-CHEMICAL
users	B-UNK
(	O
p	B-UNK
=	I-UNK
0.0012	O
)	O
,	O
treatment	B-UNK
for	O
more	O
than	O
3	O
years	B-UNK
(	O
all	O
p	B-UNK
<	I-UNK
0.03	B-UNK
)	O
and	O
pelvic	B-UNK
radiotherapy	B-UNK
(	O
p	B-UNK
=	I-UNK
0.012	O
)	O
.	O
Women	O
who	O
had	O
endometrial	B-DISEASE
cancer	I-DISEASE
and	O
had	O
received	B-UNK
tamoxifen	B-CHEMICAL
had	O
more	O
advanced	B-UNK
disease	B-DISEASE
and	O
poorer	B-UNK
prognosis	B-UNK
than	O
those	O
with	O
endometrial	B-DISEASE
cancer	I-DISEASE
who	O
had	O
not	O
received	B-UNK
this	O
treatment	B-UNK
.	O
Our	O
results	B-UNK
suggest	B-UNK
a	O
causal	O
role	B-UNK
of	O
tamoxifen	B-CHEMICAL
in	O
endometrial	B-DISEASE
cancer	I-DISEASE
,	O
particularly	O
when	O
used	O
as	O
currently	B-UNK
proposed	O
for	O
breast	B-DISEASE
cancer	I-DISEASE
prevention	O
.	O
Pelvic	O
radiotherapy	B-UNK
may	O
be	O
an	O
additional	B-UNK
iatrogenic	O
factor	B-UNK
for	O
women	B-UNK
with	O
breast	B-DISEASE
cancer	I-DISEASE
.	O
Endometrial	O
cancers	O
diagnosed	B-UNK
in	O
women	B-UNK
treated	B-UNK
with	O
tamoxifen	B-CHEMICAL
have	O
poorer	B-UNK
prognosis	B-UNK
.	O
Women	O
who	O
receive	B-UNK
tamoxifen	B-CHEMICAL
for	O
breast	B-DISEASE
cancer	I-DISEASE
should	O
be	O
offered	O
gynaecological	O
surveillance	B-UNK
during	O
and	O
after	O
treatment	B-UNK
.	O
A	O
long	B-UNK
-	O
term	B-UNK
evaluation	B-UNK
of	O
the	O
risk	B-UNK
-	O
benefit	B-UNK
ratio	B-UNK
of	O
tamoxifen	B-CHEMICAL
as	O
a	O
preventive	O
treatment	B-UNK
for	O
breast	B-DISEASE
cancer	I-DISEASE
is	O
clearly	B-UNK
warranted	O
.	O

Granulosa	O
cell	B-UNK
tumor	B-DISEASE
of	O
the	O
ovary	O
associated	B-UNK
with	O
antecedent	O
tamoxifen	B-CHEMICAL
use	B-UNK
.	O

BACKGROUND	O
:	O
Increased	B-UNK
attention	B-UNK
has	O
been	O
focused	O
recently	B-UNK
on	O
the	O
estrogenic	O
effects	B-UNK
of	O
tamoxifen	B-CHEMICAL
.	O
Review	O
of	O
the	O
literature	B-UNK
reveals	O
an	O
association	B-UNK
between	O
tamoxifen	B-CHEMICAL
use	B-UNK
and	O
gynecologic	B-UNK
tumors	B-UNK
.	O
CASE	B-UNK
:	O
A	O
52-year	O
-	O
old	B-UNK
postmenopausal	B-UNK
woman	B-UNK
was	O
treated	B-UNK
with	O
tamoxifen	B-CHEMICAL
for	O
stage	B-UNK
II	B-UNK
estrogen	B-UNK
receptor	B-UNK
-	O
positive	B-UNK
breast	O
carcinoma	B-DISEASE
.	O
Her	O
aspartate	B-UNK
transaminase	B-UNK
and	O
alanine	B-CHEMICAL
transaminase	B-UNK
levels	B-UNK
increase	B-UNK
markedly	B-UNK
after	O
6	O
months	B-UNK
of	O
tamoxifen	B-CHEMICAL
use	B-UNK
.	O
After	O
an	O
additional	B-UNK
17	B-DISEASE
months	B-UNK
of	O
elevated	B-UNK
serum	B-UNK
transaminases	O
,	O
the	O
patient	B-UNK
was	O
found	B-UNK
to	O
have	O
a	O
stage	B-UNK
Ic	O
granulosa	B-DISEASE
cell	I-DISEASE
tumor	I-DISEASE
of	I-DISEASE
the	I-DISEASE
ovary	I-DISEASE
.	O
CONCLUSION	O
:	O
Patients	B-UNK
with	O
tamoxifen	B-CHEMICAL
-	O
induced	B-UNK
liver	B-DISEASE
dysfunction	B-UNK
may	O
be	O
at	B-DISEASE
increased	B-UNK
risk	I-UNK
for	O
granulosa	O
cell	B-UNK
tumors	B-UNK
because	O
of	O
alterations	B-UNK
in	O
tamoxifen	B-CHEMICAL
metabolism	B-DISEASE
.	O

A	O
murine	B-UNK
model	B-UNK
of	O
adenomyosis	B-DISEASE
:	O
the	O
effects	B-UNK
of	O
hyperprolactinemia	B-DISEASE
induced	B-UNK
by	O
fluoxetine	B-CHEMICAL
hydrochloride	B-UNK
,	O
a	O
selective	B-UNK
serotonin	B-CHEMICAL
reuptake	B-UNK
inhibitor	B-UNK
,	O
on	O
adenomyosis	B-DISEASE
induction	B-UNK
in	O
Wistar	B-UNK
albino	B-UNK
rats	B-UNK
.	O

OBJECTIVE	O
:	O
The	O
aim	O
of	O
this	O
study	B-UNK
was	O
to	O
investigate	O
whether	O
fluoxetine	B-CHEMICAL
given	B-UNK
to	O
castrated	O
and	O
noncastrated	B-UNK
rats	B-UNK
caused	B-UNK
hyperprolactinemia	B-DISEASE
and	O
its	O
effects	B-UNK
with	O
respect	O
to	O
adenomyosis	B-DISEASE
.	O
DESIGN	B-UNK
:	O
Fluoxetine	O
,	O
a	O
serotonin	B-CHEMICAL
reuptake	B-UNK
inhibitor	B-UNK
,	O
was	O
given	B-UNK
to	O
Wistar	B-UNK
Albino	O
rats	B-UNK
for	O
98	O
days	B-UNK
to	O
produce	B-UNK
hyperprolactinemia	B-DISEASE
.	O
The	O
drug	B-UNK
was	O
given	B-UNK
to	O
two	O
groups	B-UNK
consisting	O
of	O
castrated	O
and	O
noncastrated	B-UNK
rats	B-UNK
and	O
compared	B-UNK
to	O
two	O
groups	B-UNK
of	O
castrated	O
and	O
noncastrated	B-UNK
controls	B-UNK
.	O
Prolactin	O
levels	B-UNK
were	O
measured	B-UNK
and	O
the	O
uteri	O
of	O
the	O
rats	B-UNK
were	O
removed	O
for	O
histopathological	O
analysis	B-UNK
at	B-DISEASE
the	O
end	B-UNK
of	O
98	O
days	B-UNK
.	O
SETTING	O
:	O
Marmara	O
University	B-UNK
School	O
of	O
Medicine	O
,	O
Department	O
of	O
Histology	O
and	O
Embryology	O
,	O
Zeynep	O
Kamil	O
Women	O
and	O
Children'	O
s	O
Hospital	O
.	O
MAIN	B-UNK
OUTCOME	B-UNK
MEASURES	B-UNK
:	O
Serum	B-UNK
prolactin	B-CHEMICAL
levels	B-UNK
,	O
uterine	O
histopathology	O
.	O
RESULTS	B-UNK
:	O
The	O
prolactin	B-CHEMICAL
levels	B-UNK
of	O
castrated	O
and	O
noncastrated	B-UNK
groups	B-UNK
treated	B-UNK
with	O
fluoxetine	B-CHEMICAL
were	O
statistically	B-UNK
significantly	B-UNK
higher	B-UNK
when	O
compared	B-UNK
to	O
their	O
respective	B-UNK
control	B-UNK
groups	B-UNK
.	O
Histological	O
studies	B-UNK
revealed	B-UNK
11	O
cases	B-UNK
of	O
adenomyosis	B-DISEASE
,	O
all	O
within	O
the	O
noncastrated	B-UNK
group	B-UNK
receiving	B-UNK
fluoxetine	B-CHEMICAL
.	O
CONCLUSION	O
:	O
It	O
was	O
suggested	B-UNK
that	O
high	B-UNK
serum	B-UNK
prolactin	B-CHEMICAL
levels	B-UNK
cause	B-UNK
degeneration	B-UNK
of	O
myometrial	O
cells	B-UNK
in	O
the	O
presence	O
of	O
ovarian	B-UNK
steroids	B-CHEMICAL
that	O
results	B-UNK
in	O
a	O
myometrial	O
invasion	O
by	O
endometrial	B-UNK
stroma	O
.	O
This	O
invasion	O
eventually	O
progresses	O
to	O
adenomyosis	B-DISEASE
.	O

Effects	O
of	O
deliberate	O
hypotension	B-DISEASE
induced	B-UNK
by	O
labetalol	B-CHEMICAL
with	O
isoflurane	B-CHEMICAL
on	O
neuropsychological	B-UNK
function	B-UNK
.	O

The	O
effect	B-UNK
of	O
deliberate	O
hypotension	B-DISEASE
on	O
brain	B-UNK
function	B-UNK
measured	B-UNK
by	O
neuropsychological	B-UNK
tests	B-UNK
was	O
studied	B-UNK
in	O
41	O
adult	B-UNK
patients	B-UNK
.	O
Twenty	O
-	O
four	O
patients	B-UNK
were	O
anaesthetized	O
for	O
middle	B-UNK
-	O
ear	B-UNK
surgery	B-UNK
with	O
deliberate	O
hypotension	B-DISEASE
induced	B-UNK
by	O
labetalol	B-CHEMICAL
with	O
isoflurane	B-CHEMICAL
(	O
hypotensive	B-UNK
group	B-UNK
)	O
.	O
Seventeen	O
patients	B-UNK
without	O
hypotension	B-DISEASE
served	O
as	O
a	O
control	B-UNK
group	B-UNK
.	O
The	O
mean	B-UNK
arterial	B-UNK
pressure	I-UNK
was	O
77	O
+	O
/-	O
2	B-DISEASE
mmHg	B-UNK
(	O
10.3	O
+	O
/-	O
0.3	B-UNK
kPa	B-UNK
)	O
before	O
hypotension	B-DISEASE
and	O
50	O
+	O
/-	O
0	O
mmHg	B-UNK
(	O
6.7	O
+	O
/-	O
0.0	O
kPa	B-UNK
)	O
during	O
hypotension	B-DISEASE
in	O
the	O
hypotensive	B-UNK
group	B-UNK
,	O
and	O
86	O
+	O
/-	O
2	B-DISEASE
mmHg	B-UNK
(	O
11.5	O
+	O
/-	O
0.3	B-UNK
kPa	B-UNK
)	O
during	O
anaesthesia	B-UNK
in	O
the	O
control	B-UNK
group	B-UNK
.	O
The	O
following	B-UNK
psychological	O
tests	B-UNK
were	O
performed	B-UNK
:	O
four	O
subtests	O
of	O
the	O
Wechsler	O
Adult	O
Intelligence	O
Scale	B-UNK
(	O
similarities	O
,	O
digit	O
span	O
,	O
vocabulary	O
and	O
digit	O
symbol	O
)	O
,	O
Trail	O
-	O
Making	O
tests	B-UNK
A	O
and	O
B	B-UNK
,	O
Zung	O
tests	B-UNK
(	O
self	O
-	O
rating	O
anxiety	B-DISEASE
scale	B-UNK
and	O
self	O
-	O
rating	O
depression	B-DISEASE
scale	B-UNK
)	O
and	O
two	O
-	O
part	O
memory	B-UNK
test	B-UNK
battery	O
with	O
immediate	B-UNK
and	O
delayed	B-UNK
recall	B-UNK
.	O
The	O
tests	B-UNK
were	O
performed	B-UNK
preoperatively	O
and	O
2	B-DISEASE
days	B-UNK
postoperatively	O
.	O
There	O
were	O
no	O
statistically	B-UNK
significant	I-UNK
differences	B-UNK
between	O
the	O
groups	B-UNK
in	O
any	O
of	O
the	O
tests	B-UNK
in	O
the	O
changes	B-UNK
from	O
preoperative	B-UNK
value	B-UNK
to	O
postoperative	B-UNK
value	B-UNK
.	O
The	O
results	B-UNK
indicate	B-UNK
that	O
hypotension	B-DISEASE
induced	B-UNK
by	O
labetalol	B-CHEMICAL
with	O
isoflurane	B-CHEMICAL
has	O
no	O
significant	B-UNK
harmful	O
effects	B-UNK
on	O
mental	B-UNK
functions	B-UNK
compared	B-UNK
to	O
normotensive	O
anaesthesia	B-UNK
.	O

Auditory	O
disturbance	O
associated	B-UNK
with	O
interscalene	O
brachial	B-UNK
plexus	O
block	B-UNK
.	O

We	O
performed	B-UNK
an	O
audiometric	O
study	B-UNK
in	O
20	O
patients	B-UNK
who	O
underwent	B-UNK
surgery	B-UNK
of	O
the	O
shoulder	O
region	B-UNK
under	O
an	O
interscalene	O
brachial	B-UNK
plexus	O
block	B-UNK
(	O
IBPB	O
)	O
.	O
Bupivacaine	O
0.75	O
%	O
with	O
adrenaline	O
was	O
given	B-UNK
followed	B-UNK
by	O
a	O
24-hr	O
continuous	B-UNK
infusion	B-UNK
of	O
0.25	B-UNK
%	O
bupivacaine	B-CHEMICAL
.	O
Three	O
audiometric	O
threshold	B-UNK
measurements	B-UNK
(	O
0.25	B-UNK
-	O
18	O
kHz	O
)	O
were	O
made	O
:	O
the	O
first	O
before	O
IBPB	O
,	O
the	O
second	B-UNK
2	B-DISEASE
-	O
6	O
h	B-UNK
after	O
surgery	B-UNK
and	O
the	O
third	O
on	O
the	O
first	O
day	B-UNK
after	O
operation	O
.	O
In	O
four	O
patients	B-UNK
hearing	O
impairment	B-UNK
on	O
the	O
side	O
of	O
the	O
block	B-UNK
was	O
demonstrated	B-UNK
after	O
operation	O
,	O
in	O
three	O
measurements	B-UNK
on	O
the	O
day	B-UNK
of	O
surgery	B-UNK
and	O
in	O
one	O
on	O
the	O
following	B-UNK
day	B-UNK
.	O
The	O
frequencies	O
at	B-DISEASE
which	O
the	O
impairment	B-UNK
occurred	B-UNK
varied	O
between	O
patients	B-UNK
;	O
in	O
one	O
only	O
low	B-UNK
frequencies	O
(	O
0.25	B-UNK
-	O
0.5	B-UNK
kHz	O
)	O
were	O
involved	B-UNK
.	O
The	O
maximum	B-UNK
change	B-UNK
in	O
threshold	B-UNK
was	O
35	O
dB	B-UNK
at	B-DISEASE
6	O
kHz	O
measured	B-UNK
at	B-DISEASE
the	O
end	B-UNK
of	O
the	O
continuous	B-UNK
infusion	B-UNK
of	O
bupivacaine	B-CHEMICAL
.	O
This	O
patient	B-UNK
had	O
hearing	O
threshold	B-UNK
changes	B-UNK
(	O
15	O
-	O
20	O
dB	B-UNK
)	O
at	B-DISEASE
6	O
-	O
10	O
kHz	O
on	O
the	O
opposite	O
side	O
also	O
.	O
IBPB	O
may	O
cause	B-UNK
transient	B-UNK
auditory	B-UNK
dysfunction	B-UNK
in	O
the	O
ipsilateral	O
ear	B-UNK
,	O
possibly	B-UNK
via	O
an	O
effect	B-UNK
on	O
sympathetic	B-UNK
innervation	O
.	O

Midazolam	O
compared	B-UNK
with	O
thiopentone	O
as	O
an	O
induction	B-UNK
agent	B-UNK
.	O

In	O
patients	B-UNK
premedicated	O
with	O
scopolamine	B-CHEMICAL
+	O
morphine	B-CHEMICAL
(	O
+5	O
mg	B-UNK
nitrazepam	B-CHEMICAL
the	O
evening	O
before	O
surgery	B-UNK
)	O
,	O
the	O
sleep	O
-	O
inducing	B-UNK
effect	B-UNK
of	O
midazolam	B-CHEMICAL
0.15	O
mg	B-UNK
/	O
kg	B-UNK
i.v	B-UNK
.	O
was	O
clearly	B-UNK
slower	O
in	O
onset	B-UNK
than	O
that	O
of	O
thiopentone	O
4.67	O
mg	B-UNK
/	O
kg	B-UNK
i.v	B-UNK
.	O
Somewhat	O
fewer	B-UNK
cardiovascular	B-UNK
and	O
local	B-UNK
sequelae	O
were	O
found	B-UNK
in	O
the	O
midazolam	B-CHEMICAL
group	B-UNK
,	O
but	O
,	O
although	O
apnoea	O
occurred	B-UNK
less	O
often	O
in	O
the	O
midazolam	B-CHEMICAL
group	B-UNK
it	O
lasted	B-UNK
longer	B-UNK
.	O
On	O
the	O
whole	O
,	O
the	O
differences	B-UNK
between	O
midazolam	B-CHEMICAL
and	O
thiopentone	O
had	O
no	O
apparent	O
clinical	B-UNK
consequences	B-UNK
.	O
Midazolam	O
is	O
a	O
new	B-UNK
alternative	B-UNK
agent	B-UNK
for	O
induction	B-UNK
in	O
combination	B-UNK
anaesthesia	B-UNK
.	O

Cardiotoxic	O
and	O
possible	B-UNK
leukemogenic	O
effects	B-UNK
of	O
adriamycin	O
in	O
nonhuman	O
primates	O
.	O

Doxorubicin	B-UNK
cardiomyopathy	B-DISEASE
in	O
children	B-UNK
with	O
left	B-UNK
-	O
sided	O
Wilms	O
tumor	B-DISEASE
.	O

Two	O
children	B-UNK
with	O
Wilms	O
tumor	B-DISEASE
of	O
the	O
left	B-UNK
kidney	B-UNK
experienced	B-UNK
severe	B-UNK
anthracycline	O
cardiomyopathy	B-DISEASE
after	O
irradiation	O
to	O
the	O
tumor	B-DISEASE
bed	O
and	O
conventional	B-UNK
dosage	B-UNK
of	O
doxorubicin	B-CHEMICAL
.	O
The	O
cardiomyopathy	B-DISEASE
is	O
attributed	B-UNK
1	O
)	O
to	O
the	O
fact	O
that	O
radiation	O
fields	B-UNK
for	O
left	B-UNK
Wilms	O
tumor	B-DISEASE
include	B-UNK
the	O
lower	B-UNK
portion	O
of	O
the	O
heart	B-UNK
and	O
2	B-DISEASE
)	O
to	O
the	O
interaction	B-UNK
of	O
doxorubicin	B-CHEMICAL
and	O
irradiation	O
on	O
cardiac	B-UNK
muscle	B-UNK
.	O
It	O
is	O
recommended	B-UNK
that	O
doxorubicin	B-CHEMICAL
dosage	B-UNK
be	O
sharply	O
restricted	B-UNK
in	O
children	B-UNK
with	O
Wilms	O
tumor	B-DISEASE
of	O
the	O
left	B-UNK
kidney	B-UNK
who	O
receive	B-UNK
postoperative	B-UNK
irradiation	O
.	O

Promotional	O
effects	B-UNK
of	O
testosterone	B-CHEMICAL
and	O
dietary	O
fat	O
on	O
prostate	O
carcinogenesis	B-DISEASE
in	O
genetically	B-UNK
susceptible	B-UNK
rats	B-UNK
.	O

Germfree	O
(	O
GF	O
)	O
Lobund	O
strain	B-UNK
Wistar	B-UNK
(	O
LW	O
)	O
rats	B-UNK
,	O
fed	B-UNK
vegetable	O
diet	B-UNK
L-485	O
,	O
have	O
developed	B-UNK
prostate	O
adenocarcinomas	O
spontaneously	B-UNK
(	O
10	O
%	O
incidence	B-UNK
)	O
at	B-DISEASE
average	B-UNK
age	B-UNK
34	O
months	B-UNK
.	O
Conventional	O
LW	O
rats	B-UNK
,	O
implanted	B-UNK
with	O
testosterone	B-CHEMICAL
at	B-DISEASE
age	B-UNK
4	O
months	B-UNK
,	O
developed	B-UNK
a	O
higher	B-UNK
incidence	B-UNK
of	O
prostate	B-DISEASE
cancer	I-DISEASE
after	O
an	O
average	B-UNK
interval	B-UNK
of	O
14	O
months	B-UNK
:	O
24	O
%	O
had	O
developed	B-UNK
gross	B-UNK
tumors	B-UNK
,	O
and	O
40	O
%	O
when	O
it	O
included	B-UNK
microscopic	B-UNK
tumors	B-UNK
.	O
Preliminary	B-UNK
results	B-UNK
indicate	B-UNK
that	O
testosterone	B-CHEMICAL
-	O
treated	B-UNK
LW	O
rats	B-UNK
that	O
were	O
fed	B-UNK
the	O
same	O
diet	B-UNK
,	O
which	O
was	O
supplemented	O
with	O
corn	B-CHEMICAL
oil	I-CHEMICAL
up	O
to	O
20	O
%	O
fat	O
,	O
developed	B-UNK
prostate	B-DISEASE
cancer	I-DISEASE
after	O
intervals	B-UNK
of	O
6	O
-	O
12	O
months	B-UNK
.	O
Aged	O
GF	O
Sprague	B-UNK
-	O
Dawley	B-UNK
(	O
SD	B-UNK
)	O
rats	B-UNK
have	O
not	O
developed	B-UNK
prostate	B-DISEASE
cancer	I-DISEASE
spontaneously	B-UNK
.	O
Conventional	O
SD	B-UNK
rats	B-UNK
fed	B-UNK
diet	B-UNK
L-485	O
and	O
treated	B-UNK
with	O
testosterone	B-CHEMICAL
developed	B-UNK
only	O
prostatitis	B-DISEASE
.	O
Experimental	O
designs	O
should	O
consider	O
genetic	B-UNK
susceptibility	B-UNK
as	O
a	O
basic	B-UNK
prerequisite	O
for	O
studies	B-UNK
on	O
experimental	B-UNK
prostate	B-DISEASE
cancer	I-DISEASE
.	O

Mitomycin	O
C	B-UNK
associated	B-UNK
hemolytic	B-UNK
uremic	B-UNK
syndrome	B-DISEASE
.	O

Mitomycin	O
C	B-UNK
associated	B-UNK
Hemolytic	O
Uremic	O
Syndrome	B-UNK
(	O
HUS	O
)	O
is	O
a	O
potentially	B-UNK
fatal	B-UNK
but	O
uncommon	O
condition	B-UNK
that	O
is	O
not	O
yet	O
widely	B-UNK
recognised	O
.	O
It	O
consists	B-UNK
of	O
microangiopathic	O
hemolytic	B-DISEASE
anemia	I-DISEASE
,	O
thrombocytopenia	B-DISEASE
and	O
progressive	B-UNK
renal	B-DISEASE
failure	I-DISEASE
associated	B-UNK
with	O
mitomycin	B-CHEMICAL
C	B-UNK
treatment	B-UNK
and	O
affects	B-UNK
about	O
10	O
%	O
of	O
patients	B-UNK
treated	B-UNK
with	O
this	O
agent	B-UNK
.	O
The	O
renal	B-DISEASE
failure	I-DISEASE
usually	B-UNK
develops	O
about	O
8	O
-	O
10	O
mth	O
after	O
start	O
of	O
mitomycin	B-CHEMICAL
C	B-UNK
treatment	B-UNK
and	O
the	O
mortality	B-UNK
is	O
approximately	B-UNK
60	O
%	O
from	O
renal	B-DISEASE
failure	I-DISEASE
or	O
pulmonary	B-DISEASE
edema	I-DISEASE
.	O
Renal	B-UNK
lesions	B-UNK
are	O
similar	B-UNK
to	O
those	O
seen	B-UNK
in	O
idiopathic	B-UNK
HUS	O
and	O
include	B-UNK
arteriolar	O
fibrin	O
thrombi	O
,	O
expanded	O
subendothelial	O
zones	O
in	O
glomerular	B-UNK
capillary	B-UNK
walls	O
,	O
ischemic	B-UNK
wrinkling	O
of	O
glomerular	B-UNK
basement	O
membranes	O
and	O
mesangiolysis	O
.	O
The	O
mechanism	B-UNK
of	O
action	B-UNK
is	O
postulated	O
as	O
mitomycin	B-CHEMICAL
C	B-UNK
-	O
induced	B-UNK
endothelial	B-UNK
cell	B-UNK
damage	B-UNK
.	O
We	O
describe	O
the	O
clinical	B-UNK
course	B-UNK
and	O
pathological	B-UNK
findings	B-UNK
in	O
a	O
65	O
yr	O
-	O
old	B-UNK
man	B-UNK
with	O
gastric	B-UNK
adenocarcinoma	B-DISEASE
who	O
developed	B-UNK
renal	B-DISEASE
failure	I-DISEASE
and	O
thrombocytopenia	B-DISEASE
while	O
on	O
treatment	B-UNK
with	O
mitomycin	B-CHEMICAL
C	B-UNK
and	O
died	B-UNK
in	O
pulmonary	B-DISEASE
edema	I-DISEASE
.	O

Continuous	B-UNK
ambulatory	B-UNK
ECG	I-UNK
monitoring	B-UNK
during	O
fluorouracil	B-CHEMICAL
therapy	B-UNK
:	O
a	O
prospective	B-UNK
study	B-UNK
.	O

Although	O
there	O
have	O
been	O
anecdotal	O
reports	B-UNK
of	O
cardiac	B-UNK
toxicity	B-UNK
associated	B-UNK
with	O
fluorouracil	B-CHEMICAL
(	O
5-FU	O
)	O
therapy	B-UNK
,	O
this	O
phenomenon	B-UNK
has	O
not	O
been	O
studied	B-UNK
in	O
a	O
systematic	O
fashion	B-UNK
.	O
We	O
prospectively	B-UNK
performed	B-UNK
continuous	B-UNK
ambulatory	B-UNK
ECG	I-UNK
monitoring	B-UNK
on	O
25	O
patients	B-UNK
undergoing	B-UNK
5-FU	O
infusion	B-UNK
for	O
treatment	B-UNK
of	O
solid	O
tumors	B-UNK
in	O
order	O
to	O
assess	B-UNK
the	O
incidence	B-UNK
of	O
ischemic	B-UNK
ST	B-UNK
changes	B-UNK
.	O
Patients	B-UNK
were	O
monitored	B-UNK
for	O
23	O
+	O
/-	O
4	O
hours	B-UNK
before	O
5-FU	O
infusion	B-UNK
,	O
and	O
98	O
+	O
/-	O
9	O
hours	B-UNK
during	O
5-FU	O
infusion	B-UNK
.	O
Anginal	O
episodes	B-UNK
were	O
rare	B-UNK
:	O
only	O
one	O
patient	B-UNK
had	O
angina	B-DISEASE
(	O
during	O
5-FU	O
infusion	B-UNK
)	O
.	O
However	O
,	O
asymptomatic	B-UNK
ST	B-UNK
changes	B-UNK
(	O
greater	B-UNK
than	O
or	O
equal	O
to	O
1	O
mm	B-UNK
ST	B-UNK
deviation	B-UNK
)	O
were	O
common	B-UNK
:	O
six	O
of	O
25	O
patients	B-UNK
(	O
24	O
%	O
)	O
had	O
ST	B-UNK
changes	B-UNK
before	O
5-FU	O
infusion	B-UNK
v	O
17	B-DISEASE
(	O
68	O
%	O
)	O
during	O
5-FU	O
infusion	B-UNK
(	O
P	B-UNK
less	O
than	O
.002	O
)	O
.	O
The	O
incidence	B-UNK
of	O
ischemic	B-UNK
episodes	B-UNK
per	O
patient	B-UNK
per	O
hour	O
was	O
0.05	O
+	O
/-	O
0.02	O
prior	B-UNK
to	O
5-FU	O
infusion	B-UNK
v	O
0.13	O
+	O
/-	O
0.03	B-UNK
during	O
5-FU	O
infusion	B-UNK
(	O
P	B-UNK
less	O
than	O
.001	O
)	O
;	O
the	O
duration	B-UNK
of	O
ECG	B-UNK
changes	B-UNK
was	O
0.6	B-UNK
+	O
/-	O
0.3	B-UNK
minutes	B-UNK
per	O
patient	B-UNK
per	O
hour	O
before	O
5-FU	O
v	O
1.9	O
+	O
/-	O
0.5	B-UNK
minutes	B-UNK
per	O
patient	B-UNK
per	O
hour	O
during	O
5-FU	O
(	O
P	B-UNK
less	O
than	O
.01	B-UNK
)	O
.	O
ECG	B-UNK
changes	B-UNK
were	O
more	O
common	B-UNK
among	O
patients	B-UNK
with	O
known	B-UNK
coronary	B-DISEASE
artery	I-DISEASE
disease	I-DISEASE
.	O
There	O
were	O
two	O
cases	B-UNK
of	O
sudden	B-UNK
death	B-DISEASE
,	O
both	O
of	O
which	O
occurred	B-UNK
at	B-DISEASE
the	O
end	B-UNK
of	O
the	O
chemotherapy	B-UNK
course	B-UNK
.	O
We	O
conclude	O
that	O
5-FU	O
infusion	B-UNK
is	O
associated	B-UNK
with	O
a	O
significant	B-UNK
increase	B-UNK
in	O
silent	O
ST	B-UNK
segment	B-UNK
deviation	B-UNK
suggestive	O
of	O
ischemia	B-DISEASE
,	O
particularly	O
among	O
patients	B-UNK
with	O
coronary	B-DISEASE
artery	I-DISEASE
disease	I-DISEASE
.	O
The	O
mechanism	B-UNK
and	O
clinical	B-UNK
significance	O
of	O
these	O
ECG	B-UNK
changes	B-UNK
remain	B-UNK
to	O
be	O
determined	O
.	O

Lethal	O
anuria	B-DISEASE
complicating	O
high	B-UNK
dose	B-UNK
ifosfamide	B-CHEMICAL
chemotherapy	B-UNK
in	O
a	O
breast	B-DISEASE
cancer	I-DISEASE
patient	B-UNK
with	O
an	O
impaired	B-UNK
renal	B-DISEASE
function	B-UNK
.	O

A	O
sixty	O
-	O
year	B-UNK
-	O
old	B-UNK
woman	B-UNK
with	O
advanced	B-UNK
breast	B-DISEASE
cancer	I-DISEASE
,	O
previously	B-UNK
treated	B-UNK
with	O
cisplatin	B-CHEMICAL
,	O
developed	B-UNK
an	O
irreversible	B-UNK
lethal	B-UNK
renal	B-DISEASE
failure	I-DISEASE
with	O
anuria	B-DISEASE
,	O
the	O
day	B-UNK
after	O
5	O
g	B-UNK
/	O
m2	O
bolus	B-UNK
ifosfamide	B-CHEMICAL
.	O
Postrenal	O
failure	B-UNK
was	O
excluded	O
by	O
echography	O
.	O
A	O
prerenal	O
component	B-UNK
could	O
have	O
contributed	O
to	O
renal	B-DISEASE
failure	I-DISEASE
because	O
of	O
a	O
transient	B-UNK
hypotension	B-DISEASE
,	O
due	O
to	O
an	O
increasing	B-UNK
ascitis	O
,	O
occurring	B-UNK
just	O
before	O
anuria	B-DISEASE
.	O
However	O
,	O
correction	O
of	O
the	O
hemodynamic	B-UNK
parameters	B-UNK
did	O
not	O
improve	O
renal	B-DISEASE
function	B-UNK
.	O
Ifosfamide	O
is	O
a	O
known	B-UNK
nephrotoxic	B-UNK
drug	B-UNK
with	O
demonstrated	B-UNK
tubulopathies	O
.	O
We	O
strongly	B-UNK
suspect	O
that	O
this	O
lethal	B-UNK
anuria	B-DISEASE
was	O
mainly	B-UNK
due	O
to	O
ifosfamide	B-CHEMICAL
,	O
occurring	B-UNK
in	O
a	O
patient	B-UNK
having	B-UNK
received	B-UNK
previous	B-UNK
cisplatin	B-CHEMICAL
chemotherapy	B-UNK
and	O
with	O
poor	B-UNK
kidney	B-UNK
perfusion	B-UNK
due	O
to	O
transient	B-UNK
hypotension	B-DISEASE
.	O
We	O
recommend	B-UNK
careful	O
use	B-UNK
of	O
ifosfamide	B-CHEMICAL
in	O
patients	B-UNK
pretreated	B-UNK
with	O
nephrotoxic	B-UNK
chemotherapy	B-UNK
and	O
inadequate	O
renal	B-UNK
perfusion	B-UNK
.	O

Central	B-UNK
vein	O
thrombosis	B-DISEASE
and	O
topical	B-UNK
dipivalyl	O
epinephrine	B-CHEMICAL
.	O

A	O
report	B-UNK
is	O
given	B-UNK
on	O
an	O
83-year	O
-	O
old	B-UNK
female	B-UNK
who	O
acquired	B-UNK
central	B-UNK
vein	O
thrombosis	B-DISEASE
in	O
her	O
seeing	O
eye	B-UNK
one	O
day	B-UNK
after	O
having	B-UNK
started	B-UNK
topical	B-UNK
medication	B-UNK
with	O
dipivalyl	O
epinephrine	B-CHEMICAL
for	O
advanced	B-UNK
glaucoma	B-DISEASE
discovered	O
in	O
the	O
other	O
eye	B-UNK
.	O
From	O
present	B-UNK
knowledge	O
about	O
the	O
effects	B-UNK
of	O
adrenergic	B-UNK
eye	B-UNK
drops	B-UNK
on	O
ocular	B-UNK
blood	B-UNK
circulation	O
,	O
it	O
is	O
difficult	O
to	O
suggest	B-UNK
an	O
association	B-UNK
between	O
the	O
two	O
events	B-UNK
,	O
which	O
may	O
be	O
coincidental	O
only	O
.	O

Amelioration	O
of	O
bendrofluazide	B-UNK
-	O
induced	B-UNK
hypokalemia	B-DISEASE
by	O
timolol	B-CHEMICAL
.	O

The	O
beta	B-UNK
adrenergic	B-UNK
blocking	B-UNK
drug	B-UNK
,	O
timolol	B-CHEMICAL
,	O
tended	B-UNK
to	O
correct	O
the	O
hypokalemia	B-DISEASE
of	O
short	B-UNK
-	O
term	B-UNK
bendrofluazide	B-UNK
treatment	B-UNK
in	O
6	O
healthy	B-UNK
male	B-UNK
subjects	B-UNK
and	O
although	O
the	O
effect	B-UNK
was	O
small	B-UNK
it	O
was	O
significant	B-UNK
.	O
Timolol	O
also	O
reduced	B-UNK
the	O
rise	B-UNK
in	O
plasma	B-UNK
aldosterone	B-CHEMICAL
and	O
urine	B-DISEASE
potassium	B-CHEMICAL
excretion	B-UNK
following	B-UNK
bendrofluazide	B-UNK
and	O
increased	B-UNK
the	O
urine	B-DISEASE
sodium	B-CHEMICAL
/	O
potassium	B-CHEMICAL
ratio	B-UNK
.	O
There	O
was	O
no	O
evidence	B-UNK
of	O
a	O
shift	O
of	O
potassium	B-CHEMICAL
from	O
the	O
intracellular	B-UNK
to	O
the	O
extracellular	B-UNK
space	B-UNK
.	O

A	O
cross-sectional	O
evaluation	B-UNK
of	O
the	O
effect	B-UNK
of	O
risperidone	B-CHEMICAL
and	O
selective	B-UNK
serotonin	B-CHEMICAL
reuptake	B-UNK
inhibitors	B-UNK
on	O
bone	B-UNK
mineral	O
density	B-UNK
in	O
boys	O
.	O

OBJECTIVE	O
:	O
The	O
aim	O
of	O
the	O
present	B-UNK
study	B-UNK
was	O
to	O
investigate	O
the	O
effect	B-UNK
of	O
risperidone	B-CHEMICAL
-	O
induced	B-UNK
hyperprolactinemia	B-DISEASE
on	O
trabecular	B-UNK
bone	B-UNK
mineral	O
density	B-UNK
(	O
BMD	B-UNK
)	O
in	O
children	B-UNK
and	O
adolescents	O
.	O
METHOD	O
:	O
Medically	O
healthy	B-UNK
7-	O
to	O
17-year	O
-	O
old	B-UNK
males	O
chronically	B-UNK
treated	B-UNK
,	O
in	O
a	O
naturalistic	O
setting	B-UNK
,	O
with	O
risperidone	B-CHEMICAL
were	O
recruited	O
for	O
this	O
cross-sectional	O
study	B-UNK
through	O
child	B-UNK
psychiatry	B-UNK
outpatient	B-UNK
clinics	O
between	O
November	O
2005	O
and	O
June	O
2007	O
.	O
Anthropometric	O
measurements	B-UNK
and	O
laboratory	B-UNK
testing	B-UNK
were	O
conducted	O
.	O
The	O
clinical	B-UNK
diagnoses	O
were	O
based	B-UNK
on	O
chart	O
review	B-UNK
,	O
and	O
developmental	B-UNK
and	O
treatment	B-UNK
history	B-UNK
was	O
obtained	B-UNK
from	O
the	O
medical	B-UNK
record	O
.	O
Volumetric	O
BMD	B-UNK
of	O
the	O
ultradistal	O
radius	O
was	O
measured	B-UNK
using	O
peripheral	B-UNK
quantitative	B-UNK
computed	O
tomography	B-UNK
,	O
and	O
areal	O
BMD	B-UNK
of	O
the	O
lumbar	B-UNK
spine	O
was	O
estimated	B-UNK
using	O
dual	B-UNK
-	O
energy	O
x	B-UNK
-	O
ray	O
absorptiometry	O
.	O
RESULTS	B-UNK
:	O
Hyperprolactinemia	O
was	O
present	B-UNK
in	O
49	B-DISEASE
%	O
of	O
83	O
boys	O
(	O
n	B-UNK
=	O
41	O
)	O
treated	B-UNK
with	O
risperidone	B-CHEMICAL
for	O
a	O
mean	B-UNK
of	O
2.9	O
years	B-UNK
.	O
Serum	B-UNK
testosterone	B-CHEMICAL
concentration	B-UNK
increased	B-UNK
with	O
pubertal	B-UNK
status	B-UNK
but	O
was	O
not	O
affected	B-UNK
by	O
hyperprolactinemia	B-DISEASE
.	O
As	O
expected	O
,	O
bone	B-UNK
mineral	O
content	B-UNK
and	O
BMD	B-UNK
increased	B-UNK
with	O
sexual	B-UNK
maturity	O
.	O
After	O
adjusting	O
for	O
the	O
stage	B-UNK
of	O
sexual	B-UNK
development	B-UNK
and	O
height	O
and	O
BMI	O
z	O
scores	B-UNK
,	O
serum	B-UNK
prolactin	B-CHEMICAL
was	O
negatively	O
associated	B-UNK
with	O
trabecular	B-UNK
volumetric	O
BMD	B-UNK
at	B-DISEASE
the	O
ultradistal	O
radius	O
(	O
P	B-UNK
<	I-UNK
.03	O
)	O
.	O
Controlling	O
for	O
relevant	B-UNK
covariates	O
,	O
we	O
also	O
found	B-UNK
treatment	B-UNK
with	O
selective	B-UNK
serotonin	B-CHEMICAL
reuptake	B-UNK
inhibitors	B-UNK
(	O
SSRIs	O
)	O
to	O
be	O
associated	B-UNK
with	O
lower	B-UNK
trabecular	B-UNK
BMD	B-UNK
at	B-DISEASE
the	O
radius	O
(	O
P	B-UNK
=	I-UNK
.03	O
)	O
and	O
BMD	B-UNK
z	O
score	B-UNK
at	B-DISEASE
the	O
lumbar	B-UNK
spine	O
(	O
P	B-UNK
<	I-UNK
.05	O
)	O
.	O
These	O
findings	B-UNK
became	O
more	O
marked	B-UNK
when	O
the	O
analysis	B-UNK
was	O
restricted	B-UNK
to	O
non-Hispanic	O
white	B-UNK
patients	B-UNK
.	O
Of	O
13	O
documented	B-UNK
fractures	B-DISEASE
,	O
3	O
occurred	B-UNK
after	O
risperidone	B-CHEMICAL
and	O
SSRIs	O
were	O
started	B-UNK
,	O
and	O
none	O
occurred	B-UNK
in	O
patients	B-UNK
with	O
hyperprolactinemia	B-DISEASE
.	O
CONCLUSIONS	O
:	O
This	O
is	O
the	O
first	O
study	B-UNK
to	O
link	O
risperidone	B-CHEMICAL
-	O
induced	B-UNK
hyperprolactinemia	B-DISEASE
and	O
SSRI	O
treatment	B-UNK
to	O
lower	B-UNK
BMD	B-UNK
in	O
children	B-UNK
and	O
adolescents	O
.	O
Future	O
research	B-UNK
should	O
evaluate	B-UNK
the	O
longitudinal	O
course	B-UNK
of	O
this	O
adverse	B-UNK
event	B-UNK
to	O
determine	B-UNK
its	O
temporal	B-UNK
stability	B-UNK
and	O
whether	O
a	O
higher	B-UNK
fracture	B-DISEASE
rate	B-UNK
ensues	O
.	O

Seizures	O
associated	B-UNK
with	O
levofloxacin	B-CHEMICAL
:	O
case	B-UNK
presentation	O
and	O
literature	B-UNK
review	B-UNK
.	O

PURPOSE	O
:	O
We	O
present	B-UNK
a	O
case	B-UNK
of	O
a	O
patient	B-UNK
who	O
developed	B-UNK
seizures	B-DISEASE
shortly	B-UNK
after	O
initiating	O
treatment	B-UNK
with	O
levofloxacin	B-CHEMICAL
and	O
to	O
discuss	O
the	O
potential	B-UNK
drug	B-UNK
-	O
drug	B-UNK
interactions	B-UNK
related	B-UNK
to	O
the	O
inhibition	B-UNK
of	O
cytochrome	B-UNK
P450	B-UNK
(	O
CYP	B-UNK
)	O
1A2	O
in	O
this	O
case	B-UNK
,	O
as	O
well	O
as	O
in	O
other	O
cases	B-UNK
,	O
of	O
levofloxacin	B-CHEMICAL
-	O
induced	B-UNK
seizures	B-DISEASE
.	O
METHODS	O
:	O
Several	O
biomedical	O
databases	O
were	O
searched	O
including	B-UNK
MEDLINE	O
,	O
Cochrane	B-UNK
and	O
Ovid	O
.	O
The	O
main	B-UNK
search	O
terms	O
utilized	O
were	O
case	B-UNK
report	B-UNK
and	O
levofloxacin	B-CHEMICAL
.	O
The	O
search	O
was	O
limited	O
to	O
studies	B-UNK
published	B-UNK
in	O
English	O
.	O
RESULTS	B-UNK
:	O
Six	O
cases	B-UNK
of	O
levofloxacin	B-CHEMICAL
-	O
induced	B-UNK
seizures	B-DISEASE
have	O
been	O
reported	B-UNK
in	O
the	O
literature	B-UNK
.	O
Drug	B-UNK
-	O
drug	B-UNK
interactions	B-UNK
related	B-UNK
to	O
the	O
inhibition	B-UNK
of	O
CYP1A2	O
by	O
levofloxacin	B-CHEMICAL
are	O
likely	B-UNK
involved	B-UNK
in	O
the	O
clinical	B-UNK
outcome	B-UNK
of	O
these	O
cases	B-UNK
.	O
CONCLUSIONS	O
:	O
Clinicians	O
are	O
exhorted	O
to	O
pay	O
close	O
attention	B-UNK
when	O
initiating	O
levofloxacin	B-CHEMICAL
therapy	B-UNK
in	O
patients	B-UNK
taking	B-UNK
medications	B-UNK
with	O
epileptogenic	O
properties	B-UNK
that	O
are	O
CYP1A2	O
substrates	O
.	O

Mice	O
lacking	O
mPGES-1	O
are	O
resistant	B-UNK
to	O
lithium	B-CHEMICAL
-	O
induced	B-UNK
polyuria	B-DISEASE
.	O

Cyclooxygenase-2	O
activity	B-UNK
is	O
required	B-UNK
for	O
the	O
development	B-UNK
of	O
lithium	B-CHEMICAL
-	O
induced	B-UNK
polyuria	B-DISEASE
.	O
However	O
,	O
the	O
involvement	B-UNK
of	O
a	O
specific	B-UNK
,	O
terminal	B-UNK
prostaglandin	B-UNK
(	O
PG	O
)	O
isomerase	O
has	O
not	O
been	O
evaluated	B-UNK
.	O
The	O
present	B-UNK
study	B-UNK
was	O
undertaken	O
to	O
assess	B-UNK
lithium	B-CHEMICAL
-	O
induced	B-UNK
polyuria	B-DISEASE
in	O
mice	B-UNK
deficient	O
in	O
microsomal	O
prostaglandin	B-UNK
E	B-UNK
synthase-1	O
(	O
mPGES-1	O
)	O
.	O
A	O
2-wk	O
administration	B-UNK
of	O
LiCl	O
(	O
4	O
mmol.kg(-1).day(-1	O
)	O
ip	O
)	O
in	O
mPGES-1	O
+	O
/+	B-UNK
mice	I-UNK
led	B-UNK
to	O
a	O
marked	B-UNK
polyuria	B-DISEASE
with	O
hyposmotic	O
urine	B-DISEASE
.	O
This	O
was	O
associated	B-UNK
with	O
elevated	B-UNK
renal	B-UNK
mPGES-1	O
protein	B-UNK
expression	B-UNK
and	O
increased	B-UNK
urine	B-DISEASE
PGE(2	O
)	O
excretion	B-UNK
.	O
In	O
contrast	B-UNK
,	O
mPGES-1	O
-/-	O
mice	B-UNK
were	O
largely	O
resistant	B-UNK
to	O
lithium	B-CHEMICAL
-	O
induced	B-UNK
polyuria	B-DISEASE
and	O
a	O
urine	B-DISEASE
concentrating	O
defect	B-UNK
,	O
accompanied	O
by	O
nearly	B-UNK
complete	B-UNK
blockade	B-UNK
of	O
high	B-UNK
urine	B-DISEASE
PGE(2	O
)	O
and	O
cAMP	B-UNK
output	B-UNK
.	O
Immunoblotting	O
,	O
immunohistochemistry	O
,	O
and	O
quantitative	B-UNK
(	O
q	O
)	O
RT	O
-	O
PCR	O
consistently	O
detected	B-UNK
a	O
significant	B-UNK
decrease	B-UNK
in	O
aquaporin-2	O
(	O
AQP2	O
)	O
protein	B-UNK
expression	B-UNK
in	O
both	O
the	O
renal	B-UNK
cortex	B-UNK
and	O
medulla	B-UNK
of	O
lithium	B-CHEMICAL
-	O
treated	B-UNK
+	O
/+	B-UNK
mice	I-UNK
.	O
This	O
decrease	B-UNK
was	O
significantly	B-UNK
attenuated	B-UNK
in	O
the	O
-/-	O
mice	B-UNK
.	O
qRT	O
-	O
PCR	O
detected	B-UNK
similar	B-UNK
patterns	B-UNK
of	O
changes	B-UNK
in	O
AQP2	O
mRNA	B-UNK
in	O
the	O
medulla	B-UNK
but	O
not	O
in	O
the	O
cortex	B-UNK
.	O
Similarly	O
,	O
the	O
total	B-UNK
protein	B-UNK
abundance	O
of	O
the	O
Na	O
-	O
K-2Cl	O
cotransporter	O
(	O
NKCC2	O
)	O
in	O
the	O
medulla	B-UNK
but	O
not	O
in	O
the	O
cortex	B-UNK
of	O
the	O
+	O
/+	B-UNK
mice	I-UNK
was	O
significantly	B-UNK
reduced	B-UNK
by	O
lithium	B-CHEMICAL
treatment	B-UNK
.	O
In	O
contrast	B-UNK
,	O
the	O
dowregulation	O
of	O
renal	B-UNK
medullary	O
NKCC2	O
expression	B-UNK
was	O
significantly	B-UNK
attenuated	B-UNK
in	O
the	O
-/-	O
mice	B-UNK
.	O
We	O
conclude	O
that	O
mPGES-1-derived	O
PGE(2	O
)	O
mediates	O
lithium	B-CHEMICAL
-	O
induced	B-UNK
polyuria	B-DISEASE
likely	B-UNK
via	O
inhibition	B-UNK
of	O
AQP2	O
and	O
NKCC2	O
expression	B-UNK
.	O

Identification	O
of	O
a	O
simple	O
and	O
sensitive	B-UNK
microplate	O
method	B-UNK
for	O
the	O
detection	O
of	O
oversulfated	O
chondroitin	B-CHEMICAL
sulfate	O
in	O
heparin	B-CHEMICAL
products	O
.	O

Heparin	O
is	O
a	O
commonly	B-UNK
implemented	O
anticoagulant	O
used	O
to	O
treat	O
critically	O
ill	O
patients	B-UNK
.	O
Recently	O
,	O
a	O
number	B-UNK
of	O
commercial	O
lots	O
of	O
heparin	B-CHEMICAL
products	O
were	O
found	B-UNK
to	O
be	O
contaminated	O
with	O
an	O
oversulfated	O
chondroitin	B-CHEMICAL
sulfate	O
(	O
OSCS	O
)	O
derivative	B-UNK
that	O
could	O
elicit	O
a	O
hypotensive	B-UNK
response	B-UNK
in	O
pigs	B-UNK
following	B-UNK
a	O
single	B-UNK
high	B-UNK
-	O
dose	B-UNK
infusion	B-UNK
.	O
Using	O
both	O
contaminated	O
heparin	B-CHEMICAL
products	O
and	O
the	O
synthetically	O
produced	B-UNK
derivative	B-UNK
,	O
we	O
showed	B-UNK
that	O
the	O
OSCS	O
produces	B-UNK
dose	B-UNK
-	O
dependent	B-UNK
hypotension	B-DISEASE
in	O
pigs	B-UNK
.	O
The	O
no	O
observed	B-UNK
effect	B-UNK
level	B-UNK
(	O
NOEL	O
)	O
for	O
this	O
contaminant	O
appears	B-UNK
to	O
be	O
approximately	B-UNK
1mg	O
/	O
kg	B-UNK
,	O
corresponding	B-UNK
to	O
a	O
contamination	O
level	B-UNK
of	O
approximately	B-UNK
3	O
%	O
.	O
We	O
also	O
demonstrated	B-UNK
that	O
OSCS	O
can	O
be	O
identified	B-UNK
in	O
heparin	B-CHEMICAL
products	O
using	O
a	O
simple	O
,	O
inexpensive	O
,	O
commercially	O
available	B-UNK
heparin	B-CHEMICAL
enzyme	B-UNK
immunoassay	B-UNK
(	O
EIA	O
)	O
kit	O
that	O
has	O
a	O
limit	B-UNK
of	O
detection	O
of	O
approximately	B-UNK
0.1	B-UNK
%	O
,	O
well	O
below	O
the	O
NOEL	O
.	O
This	O
kit	O
may	O
provide	B-UNK
a	O
useful	B-UNK
method	B-UNK
to	O
test	B-UNK
heparin	B-CHEMICAL
products	O
for	O
contamination	O
with	O
oversulfated	O
GAG	O
derivatives	O
.	O

Doxorubicin	B-UNK
cardiomyopathy	B-DISEASE
-	O
induced	B-UNK
inflammation	B-DISEASE
and	O
apoptosis	B-UNK
are	O
attenuated	B-UNK
by	O
gene	B-UNK
deletion	B-UNK
of	O
the	O
kinin	O
B1	O
receptor	B-UNK
.	O

Clinical	B-UNK
use	B-UNK
of	O
the	O
anthracycline	O
doxorubicin	B-CHEMICAL
(	O
DOX	O
)	O
is	O
limited	O
by	O
its	O
cardiotoxic	B-UNK
effects	B-UNK
,	O
which	O
are	O
attributed	B-UNK
to	O
the	O
induction	B-UNK
of	O
apoptosis	B-UNK
.	O
To	O
elucidate	O
the	O
possible	B-UNK
role	B-UNK
of	O
the	O
kinin	O
B1	O
receptor	B-UNK
(	O
B1R	O
)	O
during	O
the	O
development	B-UNK
of	O
DOX	O
cardiomyopathy	B-DISEASE
,	O
we	O
studied	B-UNK
B1R	O
knockout	B-UNK
mice	B-UNK
(	O
B1R(-/-	O
)	O
)	O
by	O
investigating	O
cardiac	B-UNK
inflammation	B-DISEASE
and	O
apoptosis	B-UNK
after	O
induction	B-UNK
of	O
DOX	O
-	O
induced	B-UNK
cardiomyopathy	B-DISEASE
.	O
DOX	O
control	B-UNK
mice	B-UNK
showed	B-UNK
cardiac	B-UNK
dysfunction	B-UNK
measured	B-UNK
by	O
pressure	B-UNK
-	O
volume	B-UNK
loops	O
in	O
vivo	B-UNK
.	O
This	O
was	O
associated	B-UNK
with	O
a	O
reduced	B-UNK
activation	B-UNK
state	B-UNK
of	O
AKT	O
,	O
as	O
well	O
as	O
an	O
increased	B-UNK
bax	O
/	O
bcl2	O
ratio	B-UNK
in	O
Western	B-UNK
blots	O
,	O
indicating	O
cardiac	B-UNK
apoptosis	B-UNK
.	O
Furthermore	O
,	O
mRNA	B-UNK
levels	B-UNK
of	O
the	O
proinflammatory	O
cytokine	B-UNK
interleukin	O
6	O
were	O
increased	B-UNK
in	O
the	O
cardiac	B-UNK
tissue	B-UNK
.	O
In	O
DOX	O
B1R(-/-	O
)	O
mice	B-UNK
,	O
cardiac	B-UNK
dysfunction	B-UNK
was	O
improved	B-UNK
compared	B-UNK
to	O
DOX	O
control	B-UNK
mice	B-UNK
,	O
which	O
was	O
associated	B-UNK
with	O
normalization	O
of	O
the	O
bax	O
/	O
bcl-2	O
ratio	B-UNK
and	O
interleukin	O
6	O
,	O
as	O
well	O
as	O
AKT	O
activation	B-UNK
state	B-UNK
.	O
These	O
findings	B-UNK
suggest	B-UNK
that	O
B1R	O
is	O
detrimental	O
in	O
DOX	O
cardiomyopathy	B-DISEASE
in	O
that	O
it	O
mediates	O
the	O
inflammatory	B-UNK
response	B-UNK
and	O
apoptosis	B-UNK
.	O
These	O
insights	O
might	O
have	O
useful	B-UNK
implications	O
for	O
future	B-UNK
studies	B-UNK
utilizing	O
B1R	O
antagonists	B-UNK
for	O
treatment	B-UNK
of	O
human	B-UNK
DOX	O
cardiomyopathy	B-DISEASE
.	O

Hepatotoxicity	O
associated	B-UNK
with	O
sulfasalazine	B-CHEMICAL
in	O
inflammatory	B-UNK
arthritis	B-DISEASE
:	O
A	O
case	B-UNK
series	B-UNK
from	O
a	O
local	B-UNK
surveillance	B-UNK
of	O
serious	O
adverse	B-UNK
events	B-UNK
.	O

BACKGROUND	O
:	O
Spontaneous	O
reporting	B-UNK
systems	B-UNK
for	O
adverse	B-UNK
drug	I-UNK
reactions	B-UNK
(	O
ADRs	O
)	O
are	O
handicapped	O
by	O
under	O
-	O
reporting	B-UNK
and	O
limited	O
detail	O
on	O
individual	O
cases	B-UNK
.	O
We	O
report	B-UNK
an	O
investigation	O
from	O
a	O
local	B-UNK
surveillance	B-UNK
for	O
serious	O
adverse	B-UNK
drug	I-UNK
reactions	B-UNK
associated	B-UNK
with	O
disease	B-DISEASE
modifying	O
anti-rheumatic	O
drugs	B-UNK
that	O
was	O
triggered	O
by	O
the	O
occurrence	O
of	O
liver	B-DISEASE
failure	I-DISEASE
in	O
two	O
of	O
our	O
patients	B-UNK
.	O
METHODS	O
:	O
Serious	O
ADR	B-UNK
reports	B-UNK
have	O
been	O
solicited	O
from	O
local	B-UNK
clinicians	O
by	O
regular	B-UNK
postcards	O
over	O
the	O
past	B-UNK
seven	O
years	B-UNK
.	O
Patients	B-UNK
'	O
,	O
who	O
had	O
hepatotoxicity	O
on	O
sulfasalazine	B-CHEMICAL
and	O
met	O
a	O
definition	O
of	O
a	O
serious	O
ADR	B-UNK
,	O
were	O
identified	B-UNK
.	O
Two	O
clinicians	O
reviewed	B-UNK
structured	O
case	B-UNK
reports	B-UNK
and	O
assessed	B-UNK
causality	B-UNK
by	O
consensus	O
and	O
by	O
using	O
a	O
causality	B-UNK
assessment	B-UNK
instrument	O
.	O
The	O
likely	B-UNK
frequency	B-UNK
of	O
hepatotoxicity	O
with	O
sulfasalazine	B-CHEMICAL
was	O
estimated	B-UNK
by	O
making	O
a	O
series	B-UNK
of	O
conservative	O
assumptions	O
.	O
RESULTS	B-UNK
:	O
Ten	O
cases	B-UNK
were	O
identified	B-UNK
:	O
eight	O
occurred	B-UNK
during	O
surveillance	B-UNK
.	O
Eight	O
patients	B-UNK
were	O
hospitalised	O
,	O
two	O
in	O
hepatic	B-UNK
failure	B-UNK
-	O
one	O
died	B-UNK
after	O
a	O
liver	B-DISEASE
transplant	B-UNK
.	O
All	O
but	O
one	O
event	B-UNK
occurred	B-UNK
within	O
6	O
weeks	B-UNK
of	O
treatment	B-UNK
.	O
Seven	O
patients	B-UNK
had	O
a	O
skin	B-DISEASE
rash	B-DISEASE
,	O
three	O
eosinophilia	B-DISEASE
and	O
one	O
interstitial	B-DISEASE
nephritis	I-DISEASE
.	O
Five	O
patients	B-UNK
were	O
of	O
Black	O
British	O
of	O
African	B-UNK
or	O
Caribbean	O
descent	O
.	O
Liver	B-UNK
enzymes	B-UNK
showed	B-UNK
a	O
hepatocellular	O
pattern	B-UNK
in	O
four	O
cases	B-UNK
and	O
a	O
mixed	B-UNK
pattern	B-UNK
in	O
six	O
.	O
Drug	B-UNK
-	O
related	B-UNK
hepatotoxicity	O
was	O
judged	O
probable	B-UNK
or	O
highly	B-UNK
probable	B-UNK
in	O
8	O
patients	B-UNK
.	O
The	O
likely	B-UNK
frequency	B-UNK
of	O
serious	O
hepatotoxicity	O
with	O
sulfasalazine	B-CHEMICAL
was	O
estimated	B-UNK
at	B-DISEASE
0.4	O
%	O
of	O
treated	B-UNK
patients	B-UNK
.	O
CONCLUSION	O
:	O
Serious	O
hepatotoxicity	O
associated	B-UNK
with	O
sulfasalazine	B-CHEMICAL
appears	B-UNK
to	O
be	O
under	O
-	O
appreciated	O
and	O
intensive	B-UNK
monitoring	B-UNK
and	O
vigilance	O
in	O
the	O
first	O
6	O
weeks	B-UNK
of	O
treatment	B-UNK
is	O
especially	B-UNK
important	B-UNK
.	O

An	O
evaluation	B-UNK
of	O
amikacin	B-CHEMICAL
nephrotoxicity	B-UNK
in	O
the	O
hematology	O
/	O
oncology	O
population	B-UNK
.	O

Amikacin	O
is	O
an	O
aminoglycoside	O
commonly	B-UNK
used	O
to	O
provide	B-UNK
empirical	O
double	B-UNK
gram	O
-	O
negative	B-UNK
treatment	B-UNK
for	O
febrile	B-DISEASE
neutropenia	I-DISEASE
and	O
other	O
suspected	O
infections	B-DISEASE
.	O
Strategies	O
of	O
extended	O
-	O
interval	B-UNK
and	O
conventional	B-UNK
dosing	B-UNK
have	O
been	O
utilized	O
extensively	O
in	O
the	O
general	B-UNK
medical	B-UNK
population	B-UNK
;	O
however	O
,	O
data	B-UNK
are	O
lacking	O
to	O
support	B-UNK
a	O
dosing	B-UNK
strategy	O
in	O
the	O
hematology	O
/	O
oncology	O
population	B-UNK
.	O
To	O
evaluate	B-UNK
amikacin	B-CHEMICAL
-	O
associated	B-UNK
nephrotoxicity	B-UNK
in	O
an	O
adult	B-UNK
hematology	O
/	O
oncology	O
population	B-UNK
,	O
a	O
prospective	B-UNK
,	O
randomized	B-UNK
,	O
open	B-UNK
-	O
label	O
trial	B-UNK
was	O
conducted	O
at	B-DISEASE
a	O
university	O
-	O
affiliated	O
medical	B-UNK
center	B-UNK
.	O
Forty	O
patients	B-UNK
with	O
a	O
diagnosis	B-UNK
consistent	B-UNK
with	O
a	O
hematologic	B-UNK
/	O
oncologic	O
disorder	B-UNK
that	O
required	B-UNK
treatment	B-UNK
with	O
an	O
aminoglycoside	O
were	O
randomized	B-UNK
to	O
either	O
conventional	B-UNK
or	O
extended	O
-	O
interval	B-UNK
amikacin	B-CHEMICAL
.	O
The	O
occurrence	O
of	O
nephrotoxicity	B-UNK
by	O
means	O
of	O
an	O
increase	B-UNK
in	O
serum	B-UNK
creatinine	B-CHEMICAL
and	O
evaluation	B-UNK
of	O
efficacy	B-UNK
via	O
amikacin	B-CHEMICAL
serum	B-UNK
concentrations	B-UNK
with	O
respective	B-UNK
pathogens	O
were	O
assessed	B-UNK
.	O
The	O
occurrence	O
of	O
nephrotoxicity	B-UNK
was	O
similar	B-UNK
between	O
the	O
conventional	B-UNK
and	O
extended	O
-	O
interval	B-UNK
groups	B-UNK
,	O
at	B-DISEASE
10	O
%	O
and	O
5	O
%	O
,	O
respectively	O
(	O
P	B-UNK
=	I-UNK
1.00	O
)	O
.	O
Six	O
patients	B-UNK
in	O
the	O
conventional	B-UNK
group	B-UNK
had	O
a	O
positive	B-UNK
culture	O
,	O
compared	B-UNK
with	O
none	O
in	O
the	O
extended	O
-	O
interval	B-UNK
group	B-UNK
(	O
P	B-UNK
=	I-UNK
0.002	O
)	O
.	O
The	O
occurrence	O
of	O
nephrotoxicity	B-UNK
was	O
similar	B-UNK
between	O
the	O
two	O
dosing	B-UNK
regimens	B-UNK
,	O
but	O
the	O
distribution	O
of	O
risk	B-UNK
factors	I-UNK
was	O
variable	B-UNK
between	O
the	O
two	O
groups	B-UNK
.	O
Efficacy	O
could	O
not	O
be	O
assessed	B-UNK
.	O

Memory	O
function	B-UNK
and	O
serotonin	B-CHEMICAL
transporter	O
promoter	B-UNK
gene	B-UNK
polymorphism	O
in	O
ecstasy	O
(	O
MDMA	B-UNK
)	O
users	B-UNK
.	O

Although	O
3,4-methylenedioxymethamphetamine	O
(	O
MDMA	B-UNK
or	O
ecstasy	O
)	O
has	O
been	O
shown	B-UNK
to	O
damage	B-UNK
brain	B-UNK
serotonin	B-CHEMICAL
(	O
5-HT	B-UNK
)	O
neurons	B-UNK
in	O
animals	B-UNK
and	O
possibly	B-UNK
humans	O
,	O
little	B-UNK
is	O
known	B-UNK
about	O
the	O
long	B-UNK
-	O
term	B-UNK
consequences	B-UNK
of	O
MDMA	B-UNK
-	O
induced	B-UNK
5-HT	B-UNK
neurotoxic	B-UNK
lesions	B-UNK
on	O
functions	B-UNK
in	O
which	O
5-HT	B-UNK
is	O
involved	B-UNK
,	O
such	O
as	O
cognitive	B-UNK
function	B-UNK
.	O
Because	O
5-HT	B-UNK
transporters	O
play	B-UNK
a	O
key	O
element	B-UNK
in	O
the	O
regulation	O
of	O
synaptic	O
5-HT	B-UNK
transmission	B-UNK
it	O
may	O
be	O
important	B-UNK
to	O
control	B-UNK
for	O
the	O
potential	B-UNK
covariance	O
effect	B-UNK
of	O
a	O
polymorphism	O
in	O
the	O
5-HT	B-UNK
transporter	O
promoter	B-UNK
gene	B-UNK
region	B-UNK
(	O
5-HTTLPR	O
)	O
when	O
studying	O
the	O
effects	B-UNK
of	O
MDMA	B-UNK
as	O
well	O
as	O
cognitive	B-UNK
functioning	B-UNK
.	O
The	O
aim	O
of	O
the	O
study	B-UNK
was	O
to	O
investigate	O
the	O
effects	B-UNK
of	O
moderate	B-UNK
and	O
heavy	B-UNK
MDMA	B-UNK
use	B-UNK
on	O
cognitive	B-UNK
function	B-UNK
,	O
as	O
well	O
as	O
the	O
effects	B-UNK
of	O
long	B-UNK
-	O
term	B-UNK
abstention	O
from	O
MDMA	B-UNK
,	O
in	O
subjects	B-UNK
genotyped	O
for	O
5-HTTLPR	O
.	O
A	O
second	B-UNK
aim	O
of	O
the	O
study	B-UNK
was	O
to	O
determine	B-UNK
whether	O
these	O
effects	B-UNK
differ	B-UNK
for	O
females	O
and	O
males	O
.	O
Fifteen	O
moderate	B-UNK
MDMA	B-UNK
users	B-UNK
(	O
<	O
55	O
lifetime	O
tablets	B-UNK
)	O
,	O
22	O
heavy	B-UNK
MDMA+	B-UNK
users	B-UNK
(	O
>	O
55	O
lifetime	O
tablets	B-UNK
)	O
,	O
16	O
ex	B-UNK
-	O
MDMA+	B-UNK
users	B-UNK
(	O
last	O
tablet	O
>	O
1	O
year	B-UNK
ago	O
)	O
and	O
13	O
controls	B-UNK
were	O
compared	B-UNK
on	O
a	O
battery	O
of	O
neuropsychological	B-UNK
tests	B-UNK
.	O
DNA	B-UNK
from	O
peripheral	B-UNK
nuclear	B-UNK
blood	B-UNK
cells	B-UNK
was	O
genotyped	O
for	O
5-HTTLPR	O
using	O
standard	B-UNK
polymerase	B-UNK
chain	I-UNK
reaction	B-UNK
methods	B-UNK
.	O
A	O
significant	B-UNK
group	B-UNK
effect	B-UNK
was	O
observed	B-UNK
only	O
on	O
memory	B-UNK
function	B-UNK
tasks	O
(	O
p	B-UNK
=	I-UNK
0.04	O
)	O
but	O
not	O
on	O
reaction	B-UNK
times	B-UNK
(	O
p	B-UNK
=	I-UNK
0.61	O
)	O
or	O
attention	B-UNK
/	O
executive	O
functioning	B-UNK
(	O
p	B-UNK
=	I-UNK
0.59	O
)	O
.	O
Heavy	O
and	O
ex	B-UNK
-	O
MDMA+	B-UNK
users	B-UNK
performed	B-UNK
significantly	B-UNK
poorer	B-UNK
on	O
memory	B-UNK
tasks	O
than	O
controls	B-UNK
.	O
In	O
contrast	B-UNK
,	O
no	O
evidence	B-UNK
of	O
memory	B-UNK
impairment	B-UNK
was	O
observed	B-UNK
in	O
moderate	B-UNK
MDMA	B-UNK
users	B-UNK
.	O
No	O
significant	B-UNK
effect	B-UNK
of	O
5-HTTLPR	O
or	O
gender	O
was	O
observed	B-UNK
.	O
While	O
the	O
use	B-UNK
of	O
MDMA	B-UNK
in	O
quantities	O
that	O
may	O
be	O
considered	B-UNK
"	O
moderate	B-UNK
"	O
is	O
not	O
associated	B-UNK
with	O
impaired	B-UNK
memory	B-UNK
functioning	B-UNK
,	O
heavy	B-UNK
use	B-UNK
of	O
MDMA	B-UNK
use	B-UNK
may	O
lead	B-CHEMICAL
to	O
long	B-UNK
lasting	B-UNK
memory	B-UNK
impairments	B-UNK
.	O
No	O
effect	B-UNK
of	O
5-HTTLPR	O
or	O
gender	O
on	O
memory	B-UNK
function	B-UNK
or	O
MDMA	B-UNK
use	B-UNK
was	O
observed	B-UNK
.	O

Aging	O
process	B-UNK
of	O
epithelial	B-UNK
cells	B-UNK
of	O
the	O
rat	B-UNK
prostate	O
lateral	B-UNK
lobe	O
in	O
experimental	B-UNK
hyperprolactinemia	B-DISEASE
induced	B-UNK
by	O
haloperidol	B-CHEMICAL
.	O

The	O
aim	O
of	O
the	O
study	B-UNK
was	O
to	O
examine	O
the	O
influence	B-UNK
of	O
hyperprolactinemia	B-DISEASE
,	O
induced	B-UNK
by	O
haloperidol	B-CHEMICAL
(	O
HAL	O
)	O
on	O
age	B-UNK
related	B-UNK
morphology	O
and	O
function	B-UNK
changes	B-UNK
of	O
epithelial	B-UNK
cells	B-UNK
in	O
rat	B-UNK
prostate	O
lateral	B-UNK
lobe	O
.	O
The	O
study	B-UNK
was	O
performed	B-UNK
on	O
sexually	O
mature	O
male	B-UNK
rats	B-UNK
.	O
Serum	B-UNK
concentrations	B-UNK
of	O
prolactin	B-CHEMICAL
(	O
PRL	O
)	O
and	O
testosterone	B-CHEMICAL
(	O
T	B-UNK
)	O
were	O
measured	B-UNK
.	O
Tissue	O
sections	O
were	O
evaluated	B-UNK
with	O
light	B-UNK
and	O
electron	B-UNK
microscopy	B-UNK
.	O
Immunohistochemical	O
reactions	B-UNK
for	O
Anti-Proliferating	O
Cell	O
Nuclear	O
Antigen	O
(	O
PCNA	O
)	O
were	O
performed	B-UNK
.	O
In	O
rats	B-UNK
of	O
the	O
experimental	B-UNK
group	B-UNK
,	O
the	O
mean	B-UNK
concentration	B-UNK
of	O
:	O
PRL	O
was	O
more	O
than	O
twice	B-UNK
higher	B-UNK
,	O
whereas	O
T	B-UNK
concentration	B-UNK
was	O
almost	O
twice	B-UNK
lower	B-UNK
than	O
that	O
in	O
the	O
control	B-UNK
group	B-UNK
.	O
Light	B-UNK
microscopy	B-UNK
visualized	O
the	O
following	B-UNK
:	O
hypertrophy	B-DISEASE
and	O
epithelium	B-UNK
hyperplasia	B-DISEASE
of	O
the	O
glandular	O
ducts	O
,	O
associated	B-UNK
with	O
increased	B-UNK
PCNA	O
expression	B-UNK
.	O
Electron	O
microscopy	B-UNK
revealed	B-UNK
changes	B-UNK
in	O
columnar	O
epithelial	B-UNK
cells	B-UNK
,	O
concerning	B-UNK
organelles	O
,	O
engaged	O
in	O
protein	B-UNK
synthesis	O
and	O
secretion	B-UNK
.	O

Does	O
supplemental	O
vitamin	B-UNK
C	B-UNK
increase	B-UNK
cardiovascular	B-DISEASE
disease	I-DISEASE
risk	B-UNK
in	O
women	B-UNK
with	O
diabetes	B-DISEASE
?	O

BACKGROUND	O
:	O
Vitamin	B-UNK
C	B-UNK
acts	B-UNK
as	O
a	O
potent	B-UNK
antioxidant	B-UNK
;	O
however	O
,	O
it	O
can	O
also	O
be	O
a	O
prooxidant	O
and	O
glycate	O
protein	B-UNK
under	O
certain	B-UNK
circumstances	O
in	O
vitro	B-UNK
.	O
These	O
observations	B-UNK
led	B-UNK
us	O
to	O
hypothesize	O
that	O
a	O
high	B-UNK
intake	B-UNK
of	O
vitamin	B-UNK
C	B-UNK
in	O
diabetic	B-UNK
persons	B-UNK
might	O
promote	B-UNK
atherosclerosis	B-DISEASE
.	O
OBJECTIVE	O
:	O
The	O
objective	B-UNK
was	O
to	O
examine	O
the	O
relation	O
between	O
vitamin	B-UNK
C	B-UNK
intake	B-UNK
and	O
mortality	B-UNK
from	O
cardiovascular	B-DISEASE
disease	I-DISEASE
.	O
DESIGN	B-UNK
:	O
We	O
studied	B-UNK
the	O
relation	O
between	O
vitamin	B-UNK
C	B-UNK
intake	B-UNK
and	O
mortality	B-UNK
from	O
total	B-UNK
cardiovascular	B-DISEASE
disease	I-DISEASE
(	O
n	B-UNK
=	O
281	O
)	O
,	O
coronary	B-DISEASE
artery	I-DISEASE
disease	I-DISEASE
(	O
n	B-UNK
=	O
175	O
)	O
,	O
and	O
stroke	B-UNK
(	O
n	B-UNK
=	O
57	O
)	O
in	O
1923	O
postmenopausal	B-UNK
women	B-UNK
who	O
reported	B-UNK
being	O
diabetic	B-UNK
at	B-DISEASE
baseline	B-UNK
.	O
Diet	O
was	O
assessed	B-UNK
with	O
a	O
food	B-UNK
-	O
frequency	B-UNK
questionnaire	O
at	B-DISEASE
baseline	B-UNK
,	O
and	O
subjects	B-UNK
initially	B-UNK
free	B-UNK
of	O
coronary	B-DISEASE
artery	I-DISEASE
disease	I-DISEASE
were	O
prospectively	B-UNK
followed	B-UNK
for	O
15	O
y.	O
RESULTS	B-UNK
:	O
After	O
adjustment	O
for	O
cardiovascular	B-DISEASE
disease	I-DISEASE
risk	B-UNK
factors	I-UNK
,	O
type	B-UNK
of	O
diabetes	B-DISEASE
medication	B-UNK
used	O
,	O
duration	B-UNK
of	O
diabetes	B-DISEASE
,	O
and	O
intakes	O
of	O
folate	B-UNK
,	O
vitamin	B-UNK
E	B-UNK
,	O
and	O
beta-carotene	O
,	O
the	O
adjusted	B-UNK
relative	B-UNK
risks	O
of	O
total	B-UNK
cardiovascular	B-DISEASE
disease	I-DISEASE
mortality	B-UNK
were	O
1.0	B-UNK
,	O
0.97	O
,	O
1.11	O
,	O
1.47	O
,	O
and	O
1.84	O
(	O
P	B-UNK
for	O
trend	B-UNK
<	B-UNK
0.01	I-UNK
)	O
across	O
quintiles	O
of	O
total	B-UNK
vitamin	B-UNK
C	B-UNK
intake	B-UNK
from	O
food	B-UNK
and	O
supplements	O
.	O
Adjusted	O
relative	B-UNK
risks	O
of	O
coronary	B-DISEASE
artery	I-DISEASE
disease	I-DISEASE
were	O
1.0	B-UNK
,	O
0.81	O
,	O
0.99	O
,	O
1.26	O
,	O
and	O
1.91	O
(	O
P	B-UNK
for	O
trend	B-UNK
=	O
0.01	B-UNK
)	O
and	O
of	O
stroke	B-UNK
were	O
1.0	B-UNK
,	O
0.52	O
,	O
1.23	O
,	O
2.22	O
,	O
and	O
2.57	O
(	O
P	B-UNK
for	O
trend	B-UNK
<	B-UNK
0.01	I-UNK
)	O
.	O
When	O
dietary	O
and	O
supplemental	O
vitamin	B-UNK
C	B-UNK
were	O
analyzed	B-UNK
separately	O
,	O
only	O
supplemental	O
vitamin	B-UNK
C	B-UNK
showed	B-UNK
a	O
positive	B-UNK
association	B-UNK
with	O
mortality	B-UNK
endpoints	O
.	O
Vitamin	B-UNK
C	B-UNK
intake	B-UNK
was	O
unrelated	O
to	O
mortality	B-UNK
from	O
cardiovascular	B-DISEASE
disease	I-DISEASE
in	O
the	O
nondiabetic	O
subjects	B-UNK
at	B-DISEASE
baseline	B-UNK
.	O
CONCLUSION	O
:	O
A	O
high	B-UNK
vitamin	B-UNK
C	B-UNK
intake	B-UNK
from	O
supplements	O
is	O
associated	B-UNK
with	O
an	O
increased	B-UNK
risk	I-UNK
of	O
cardiovascular	B-DISEASE
disease	I-DISEASE
mortality	B-UNK
in	O
postmenopausal	B-UNK
women	B-UNK
with	O
diabetes	B-DISEASE
.	O

Absolute	O
and	O
attributable	O
risk	B-UNK
of	O
venous	B-DISEASE
thromboembolism	I-DISEASE
in	O
women	B-UNK
on	O
combined	B-UNK
cyproterone	B-CHEMICAL
acetate	I-CHEMICAL
and	O
ethinylestradiol	O
.	O

OBJECTIVE	O
:	O
To	O
achieve	O
absolute	B-UNK
risk	B-UNK
estimates	O
of	O
venous	B-DISEASE
thromboembolism	I-DISEASE
(	O
VTE	O
)	O
among	O
women	B-UNK
on	O
cyproterone	B-CHEMICAL
acetate	I-CHEMICAL
plus	B-UNK
ethinylestradiol	O
(	O
CPA	O
/	O
EE	O
)	O
,	O
and	O
among	O
women	B-UNK
on	O
combined	B-UNK
oral	B-UNK
contraceptives	O
(	O
COCs	O
)	O
.	O
METHODS	O
:	O
From	O
the	O
Danish	B-UNK
National	B-UNK
Register	B-UNK
of	O
Patients	B-UNK
(	O
NRP	O
)	O
,	O
1996	O
to	O
1998	O
,	O
the	O
records	B-UNK
of	O
1.1	B-UNK
million	B-UNK
Danish	B-UNK
women	B-UNK
,	O
ages	O
15	O
to	O
44	O
years	B-UNK
,	O
were	O
searched	O
for	O
evidence	B-UNK
of	O
VTE	O
.	O
COC	O
use	B-UNK
was	O
ascertained	O
through	O
mailed	O
questionnaires	O
.	O
Sales	O
statistics	O
of	O
COCs	O
and	O
CPA	O
/	O
EE	O
were	O
provided	B-UNK
through	O
Danish	B-UNK
Drug	B-UNK
Statistics	O
.	O
RESULTS	B-UNK
:	O
During	O
the	O
time	B-UNK
frame	O
of	O
the	O
study	B-UNK
,	O
330	O
women	B-UNK
were	O
found	B-UNK
to	O
have	O
had	O
VTE	O
while	O
on	O
COCs	O
.	O
Of	O
these	O
women	B-UNK
,	O
67	O
were	O
on	O
levonorgestrel	B-CHEMICAL
-	O
containing	B-UNK
COCs	O
.	O
Eleven	O
were	O
on	O
CPA	O
/	O
EE	O
.	O
The	O
corresponding	B-UNK
absolute	B-UNK
risk	B-UNK
of	O
VTE	O
was	O
3.4	B-UNK
(	O
range	B-UNK
,	O
3.1	O
-	O
3.8	O
)	O
per	O
10	O
000	O
women	B-UNK
years	B-UNK
among	O
the	O
women	B-UNK
on	O
COCs	O
,	O
4.2	O
(	O
range	B-UNK
,	O
3.2	O
-	O
5.2	O
)	O
per	O
10	O
000	O
women	B-UNK
years	B-UNK
among	O
women	B-UNK
on	O
levonorgestrel	B-CHEMICAL
-	O
containing	B-UNK
COCs	O
,	O
and	O
3.1	O
(	O
range	B-UNK
,	O
1.3	O
-	O
4.9	O
)	O
per	O
10	O
000	O
women	B-UNK
years	B-UNK
among	O
the	O
women	B-UNK
on	O
CPA	O
/	O
EE	O
.	O
CONCLUSION	O
:	O
Our	O
results	B-UNK
suggest	B-UNK
the	O
absolute	B-UNK
risk	B-UNK
of	O
VTE	O
among	O
Danish	B-UNK
women	B-UNK
on	O
COCs	O
is	O
similar	B-UNK
to	O
that	O
among	O
women	B-UNK
taking	B-UNK
CPA	O
/	O
EE	O
.	O

Effect	O
of	O
lindane	O
on	O
hepatic	B-UNK
and	O
brain	B-UNK
cytochrome	B-UNK
P450s	O
and	O
influence	B-UNK
of	O
P450	B-UNK
modulation	O
in	O
lindane	O
induced	B-UNK
neurotoxicity	B-UNK
.	O

Oral	O
administration	B-UNK
of	O
lindane	O
(	O
2.5	B-UNK
,	O
5	O
,	O
10	O
and	O
15	O
mg	B-UNK
/	O
kg	B-UNK
,	O
body	B-DISEASE
weight	I-DISEASE
)	O
for	O
5	O
days	B-UNK
was	O
found	B-UNK
to	O
produce	B-UNK
a	O
dose	B-UNK
-	O
dependent	B-UNK
increase	B-UNK
in	O
the	O
activity	B-UNK
of	O
P450	B-UNK
dependent	B-UNK
7-ethoxyresorufin	O
-	O
O	O
-	O
deethylase	O
(	O
EROD	O
)	O
,	O
7-pentoxyresorufin	O
-	O
O	O
-	O
dealkylase	O
(	O
PROD	O
)	O
and	O
N	B-UNK
-	O
nitrosodimethylamine	O
demethylase	O
(	O
NDMA	O
-	O
d	B-UNK
)	O
in	O
rat	B-UNK
brain	B-UNK
and	O
liver	B-DISEASE
.	O
A	O
significant	B-UNK
increase	B-UNK
in	O
the	O
hepatic	B-UNK
and	O
brain	B-UNK
P450	B-UNK
monooxygenases	O
was	O
also	O
observed	B-UNK
when	O
the	O
duration	B-UNK
of	O
exposure	B-UNK
of	O
low	B-UNK
dose	B-UNK
(	O
2.5	B-UNK
mg	B-UNK
/	O
kg	B-UNK
)	O
of	O
lindane	O
was	O
increased	B-UNK
from	O
5	O
days	B-UNK
to	O
15	O
or	O
21	O
days	B-UNK
.	O
As	O
observed	B-UNK
with	O
different	B-UNK
doses	B-UNK
,	O
the	O
magnitude	O
of	O
induction	B-UNK
in	O
the	O
activity	B-UNK
of	O
P450	B-UNK
monooxygenases	O
was	O
several	O
fold	O
higher	B-UNK
in	O
liver	B-DISEASE
microsomes	O
when	O
compared	B-UNK
with	O
the	O
brain	B-UNK
.	O
Western	B-UNK
blotting	O
studies	B-UNK
have	O
indicated	B-UNK
that	O
the	O
increase	B-UNK
in	O
the	O
P450	B-UNK
enzymes	B-UNK
could	O
be	O
due	O
to	O
the	O
increase	B-UNK
in	O
the	O
expression	B-UNK
of	O
P450	B-UNK
1A1/1A2	O
,	O
2B1/2B2	O
and	O
2E1	B-UNK
isoenzymes	B-UNK
.	O
In	O
vitro	B-UNK
studies	B-UNK
using	O
organic	O
inhibitors	B-UNK
specific	B-UNK
for	O
individual	O
P450	B-UNK
isoenzymes	B-UNK
and	O
antibody	B-UNK
inhibition	B-UNK
experiments	B-UNK
have	O
further	O
demonstrated	B-UNK
that	O
the	O
increase	B-UNK
in	O
the	O
activity	B-UNK
of	O
PROD	O
,	O
EROD	O
and	O
NDMA	O
-	O
d	B-UNK
are	O
due	O
to	O
the	O
increase	B-UNK
in	O
the	O
levels	B-UNK
of	O
P450	B-UNK
2B1/2B2	O
,	O
1A1/1A2	O
and	O
2E1	B-UNK
isoenzymes	B-UNK
,	O
respectively	O
.	O
Induction	O
studies	B-UNK
have	O
further	O
shown	B-UNK
that	O
while	O
pretreatment	B-UNK
of	O
3-methylcholanthrene	O
(	O
MC	O
)	O
,	O
an	O
inducer	O
of	O
P4501A1/1A2	O
,	O
did	O
not	O
produce	B-UNK
any	O
significant	B-UNK
effect	B-UNK
in	O
the	O
incidence	B-UNK
of	O
lindane	O
induced	B-UNK
convulsions	B-DISEASE
,	O
pretreatment	B-UNK
with	O
phenobarbital	B-CHEMICAL
(	O
PB	O
)	O
,	O
an	O
inducer	O
of	O
P450	B-UNK
2B1/2B2	O
or	O
ethanol	B-CHEMICAL
,	O
an	O
inducer	O
of	O
P450	B-UNK
2E1	B-UNK
catalysed	O
reactions	B-UNK
,	O
significantly	B-UNK
increased	B-UNK
the	O
incidence	B-UNK
of	O
lindane	O
induced	B-UNK
convulsions	B-DISEASE
.	O
Similarly	O
,	O
when	O
the	O
P450-mediated	O
metabolism	B-DISEASE
of	O
lindane	O
was	O
blocked	B-UNK
by	O
cobalt	B-CHEMICAL
chloride	B-UNK
incidence	B-UNK
of	O
convulsions	B-DISEASE
was	O
increased	B-UNK
in	O
animals	B-UNK
treated	B-UNK
with	O
lindane	O
indicating	O
that	O
lindane	O
per	O
se	O
or	O
its	O
metabolites	B-UNK
formed	B-UNK
by	O
PB	O
or	O
ethanol	B-CHEMICAL
inducible	B-UNK
P450	B-UNK
isoenzymes	B-UNK
are	O
involved	B-UNK
in	O
its	O
neurobehavioral	O
toxicity	B-UNK
.	O

Seizure	O
associated	B-UNK
with	O
sleep	B-DISEASE
deprivation	I-DISEASE
and	O
sustained	B-UNK
-	O
release	B-UNK
bupropion	B-CHEMICAL
.	O

This	O
case	B-UNK
report	B-UNK
describes	B-UNK
a	O
generalized	B-UNK
seizure	B-UNK
associated	B-UNK
with	O
sustained	B-UNK
-	O
release	B-UNK
bupropion	B-CHEMICAL
use	B-UNK
and	O
sleep	B-DISEASE
deprivation	I-DISEASE
.	O
The	O
subject	B-UNK
,	O
a	O
31-year	O
-	O
old	B-UNK
female	B-UNK
smoker	O
,	O
was	O
participating	O
in	O
a	O
clinical	B-UNK
trial	B-UNK
evaluating	O
an	O
investigational	O
medication	B-UNK
for	O
smoking	O
cessation	B-UNK
that	O
used	O
sustained	B-UNK
-	O
release	B-UNK
bupropion	B-CHEMICAL
as	O
an	O
active	B-UNK
control	B-UNK
.	O
After	O
5	O
weeks	B-UNK
of	O
bupropion	B-CHEMICAL
use	B-UNK
,	O
the	O
subject	B-UNK
experienced	B-UNK
a	O
generalized	B-UNK
tonic	B-DISEASE
clonic	O
seizure	B-DISEASE
after	O
staying	O
up	O
nearly	B-UNK
all	O
night	O
packing	O
and	O
moving	O
to	O
a	O
new	B-UNK
residence	O
.	O
The	O
patient	B-UNK
had	O
no	O
other	O
risk	B-UNK
factors	I-UNK
for	O
seizures	B-DISEASE
.	O
We	O
suggest	B-UNK
that	O
sleep	B-DISEASE
deprivation	I-DISEASE
may	O
add	O
to	O
the	O
risk	B-UNK
of	O
bupropion	B-CHEMICAL
-	O
associated	B-UNK
seizures	B-DISEASE
.	O

Nephrotoxic	O
effects	B-UNK
in	O
high	B-UNK
-	O
risk	B-UNK
patients	B-UNK
undergoing	B-UNK
angiography	B-UNK
.	O

BACKGROUND	O
:	O
The	O
use	B-UNK
of	O
iodinated	O
contrast	B-UNK
medium	B-UNK
can	O
result	B-UNK
in	O
nephropathy	B-DISEASE
.	O
Whether	O
iso	O
-	O
osmolar	O
contrast	B-UNK
medium	B-UNK
is	O
less	O
nephrotoxic	B-UNK
than	O
low	B-UNK
-	O
osmolar	O
contrast	B-UNK
medium	B-UNK
in	O
high	B-UNK
-	O
risk	B-UNK
patients	B-UNK
is	O
uncertain	O
.	O
METHODS	O
:	O
We	O
conducted	O
a	O
randomized	B-UNK
,	O
double-blind	B-UNK
,	O
prospective	B-UNK
,	O
multicenter	O
study	B-UNK
comparing	O
the	O
nephrotoxic	B-UNK
effects	B-UNK
of	O
an	O
iso	O
-	O
osmolar	O
,	O
dimeric	O
,	O
nonionic	O
contrast	B-UNK
medium	B-UNK
,	O
iodixanol	B-CHEMICAL
,	O
with	O
those	O
of	O
a	O
low	B-UNK
-	O
osmolar	O
,	O
nonionic	O
,	O
monomeric	O
contrast	B-UNK
medium	B-UNK
,	O
iohexol	B-CHEMICAL
.	O
The	O
study	B-UNK
involved	B-UNK
129	O
patients	B-UNK
with	O
diabetes	B-DISEASE
with	O
serum	B-UNK
creatinine	B-CHEMICAL
concentrations	B-UNK
of	O
1.5	B-UNK
to	O
3.5	B-UNK
mg	B-UNK
per	O
deciliter	O
who	O
underwent	B-UNK
coronary	B-UNK
or	O
aortofemoral	O
angiography	B-UNK
.	O
The	O
primary	B-UNK
end	B-UNK
point	O
was	O
the	O
peak	B-UNK
increase	B-UNK
from	O
base	O
line	B-UNK
in	O
the	O
creatinine	B-CHEMICAL
concentration	B-UNK
during	O
the	O
three	O
days	B-UNK
after	O
angiography	B-UNK
.	O
Other	O
end	B-UNK
points	B-UNK
were	O
an	O
increase	B-UNK
in	O
the	O
creatinine	B-CHEMICAL
concentration	B-UNK
of	O
0.5	B-UNK
mg	I-UNK
per	O
deciliter	O
or	O
more	O
,	O
an	O
increase	B-UNK
of	O
1.0	B-UNK
mg	B-UNK
per	O
deciliter	O
or	O
more	O
,	O
and	O
a	O
change	B-UNK
in	O
the	O
creatinine	B-CHEMICAL
concentration	B-UNK
from	O
day	B-UNK
0	O
to	O
day	B-UNK
7	O
.	O
RESULTS	B-UNK
:	O
The	O
creatinine	B-CHEMICAL
concentration	B-UNK
increased	B-UNK
significantly	B-UNK
less	O
in	O
patients	B-UNK
who	O
received	B-UNK
iodixanol	B-CHEMICAL
.	O
From	O
day	B-UNK
0	O
to	O
day	B-UNK
3	O
,	O
the	O
mean	B-UNK
peak	B-UNK
increase	B-UNK
in	O
creatinine	B-CHEMICAL
was	O
0.13	O
mg	B-UNK
per	O
deciliter	O
in	O
the	O
iodixanol	B-CHEMICAL
group	B-UNK
and	O
0.55	O
mg	B-UNK
per	O
deciliter	O
in	O
the	O
iohexol	B-CHEMICAL
group	B-UNK
(	O
P=0.001	O
;	O
the	O
increase	B-UNK
with	O
iodixanol	B-CHEMICAL
minus	O
the	O
increase	B-UNK
with	O
iohexol	B-CHEMICAL
,	O
-0.42	O
mg	B-UNK
per	O
deciliter	O
[	O
95	O
percent	B-UNK
confidence	I-UNK
interval	B-UNK
,	O
-0.73	O
to	O
-0.22	O
]	O
)	O
.	O
Two	O
of	O
the	O
64	O
patients	B-UNK
in	O
the	O
iodixanol	B-CHEMICAL
group	B-UNK
(	O
3	O
percent	O
)	O
had	O
an	O
increase	B-UNK
in	O
the	O
creatinine	B-CHEMICAL
concentration	B-UNK
of	O
0.5	B-UNK
mg	I-UNK
per	O
deciliter	O
or	O
more	O
,	O
as	O
compared	B-UNK
with	O
17	B-DISEASE
of	O
the	O
65	O
patients	B-UNK
in	O
the	O
iohexol	B-CHEMICAL
group	B-UNK
(	O
26	O
percent	O
)	O
(	O
P=0.002	O
;	O
odds	B-UNK
ratio	B-UNK
for	O
such	O
an	O
increase	B-UNK
in	O
the	O
iodixanol	B-CHEMICAL
group	B-UNK
,	O
0.09	O
[	O
95	O
percent	B-UNK
confidence	I-UNK
interval	B-UNK
,	O
0.02	O
to	O
0.41	O
]	O
)	O
.	O
No	O
patient	B-UNK
receiving	B-UNK
iodixanol	B-CHEMICAL
had	O
an	O
increase	B-UNK
of	O
1.0	B-UNK
mg	B-UNK
per	O
deciliter	O
or	O
more	O
,	O
but	O
10	O
patients	B-UNK
in	O
the	O
iohexol	B-CHEMICAL
group	B-UNK
(	O
15	O
percent	O
)	O
did	O
.	O
The	O
mean	B-UNK
change	B-UNK
in	O
the	O
creatinine	B-CHEMICAL
concentration	B-UNK
from	O
day	B-UNK
0	O
to	O
day	B-UNK
7	O
was	O
0.07	O
mg	B-UNK
per	O
deciliter	O
in	O
the	O
iodixanol	B-CHEMICAL
group	B-UNK
and	O
0.24	O
mg	B-UNK
per	O
deciliter	O
in	O
the	O
iohexol	B-CHEMICAL
group	B-UNK
(	O
P=0.003	O
;	O
value	B-UNK
in	O
the	O
iodixanol	B-CHEMICAL
group	B-UNK
minus	O
the	O
value	B-UNK
in	O
the	O
iohexol	B-CHEMICAL
group	B-UNK
,	O
-0.17	O
mg	B-UNK
per	O
deciliter	O
[	O
95	O
percent	B-UNK
confidence	I-UNK
interval	B-UNK
,	O
-0.34	O
to	O
-0.07	O
]	O
)	O
.	O
CONCLUSIONS	O
:	O
Nephropathy	O
induced	B-UNK
by	O
contrast	B-UNK
medium	B-UNK
may	O
be	O
less	O
likely	B-UNK
to	O
develop	B-UNK
in	O
high	B-UNK
-	O
risk	B-UNK
patients	B-UNK
when	O
iodixanol	B-CHEMICAL
is	O
used	O
rather	O
than	O
a	O
low	B-UNK
-	O
osmolar	O
,	O
nonionic	O
contrast	B-UNK
medium	B-UNK
.	O

Experimental	O
cranial	B-UNK
pain	B-DISEASE
elicited	B-UNK
by	O
capsaicin	B-CHEMICAL
:	O
a	O
PET	O
study	B-UNK
.	O

Using	O
a	O
positron	O
emission	B-UNK
tomography	B-UNK
(	O
PET	O
)	O
study	B-UNK
it	O
was	O
shown	B-UNK
recently	B-UNK
that	O
in	O
migraine	B-DISEASE
without	I-DISEASE
aura	I-DISEASE
certain	B-UNK
areas	B-UNK
in	O
the	O
brain	B-UNK
stem	B-UNK
were	O
activated	B-UNK
during	O
the	O
headache	B-DISEASE
state	B-UNK
,	O
but	O
not	O
in	O
the	O
headache	B-DISEASE
free	B-UNK
interval	B-UNK
.	O
It	O
was	O
suggested	B-UNK
that	O
this	O
brain	B-UNK
stem	B-UNK
activation	B-UNK
is	O
inherent	O
to	O
the	O
migraine	B-DISEASE
attack	O
itself	O
and	O
represents	O
the	O
so	O
called	O
'	O
migraine	B-DISEASE
generator	O
'	O
.	O
To	O
test	B-UNK
this	O
hypothesis	O
we	O
performed	B-UNK
an	O
experimental	B-UNK
pain	B-UNK
study	B-UNK
in	O
seven	O
healthy	B-UNK
volunteers	O
,	O
using	O
the	O
same	O
positioning	O
in	O
the	O
PET	O
scanner	O
as	O
in	O
the	O
migraine	B-DISEASE
patients	B-UNK
.	O
A	O
small	B-UNK
amount	O
of	O
capsaicin	B-CHEMICAL
was	O
administered	B-UNK
subcutaneously	O
in	O
the	O
right	B-UNK
forehead	O
to	O
evoke	O
a	O
burning	O
painful	B-UNK
sensation	O
in	O
the	O
first	O
division	O
of	O
the	O
trigeminal	O
nerve	B-UNK
.	O
Increases	O
of	O
regional	B-UNK
cerebral	B-UNK
blood	B-UNK
flow	B-UNK
(	O
rCBF	O
)	O
were	O
found	B-UNK
bilaterally	B-UNK
in	O
the	O
insula	O
,	O
in	O
the	O
anterior	B-UNK
cingulate	O
cortex	B-UNK
,	O
the	O
cavernous	B-UNK
sinus	B-UNK
and	O
the	O
cerebellum	O
.	O
Using	O
the	O
same	O
stereotactic	O
space	B-UNK
limits	B-UNK
as	O
in	O
the	O
above	O
mentioned	B-UNK
migraine	B-DISEASE
study	B-UNK
no	O
brain	B-UNK
stem	B-UNK
activation	B-UNK
was	O
found	B-UNK
in	O
the	O
acute	B-DISEASE
pain	I-DISEASE
state	B-UNK
compared	B-UNK
to	O
the	O
pain	B-DISEASE
free	B-UNK
state	B-UNK
.	O
The	O
increase	B-UNK
of	O
activation	B-UNK
in	O
the	O
region	B-UNK
of	O
the	O
cavernous	B-UNK
sinus	B-UNK
however	O
,	O
suggests	B-UNK
that	O
this	O
structure	B-UNK
is	O
more	O
likely	B-UNK
to	O
be	O
involved	B-UNK
in	O
trigeminal	O
transmitted	O
pain	B-UNK
as	O
such	O
,	O
rather	O
than	O
in	O
a	O
specific	B-UNK
type	B-UNK
of	O
headache	B-DISEASE
as	O
was	O
suggested	B-UNK
for	O
cluster	B-DISEASE
headache	I-DISEASE
.	O

Neuroleptic	B-UNK
malignant	B-UNK
syndrome	B-DISEASE
with	O
risperidone	B-CHEMICAL
.	O

Neuroleptic	B-UNK
malignant	B-UNK
syndrome	B-UNK
is	O
thought	O
to	O
be	O
a	O
result	B-UNK
of	O
dopamine	B-CHEMICAL
D2	B-UNK
receptor	B-UNK
blockade	B-UNK
in	O
the	O
striatum	O
of	O
the	O
basal	B-UNK
ganglia	B-UNK
.	O
Risperidone	O
,	O
a	O
benzisoxazole	O
derivative	B-UNK
antipsychotic	B-UNK
,	O
has	O
high	B-UNK
serotonin	B-CHEMICAL
5-HT2	O
receptor	B-UNK
blockade	B-UNK
and	O
dose	B-UNK
-	O
related	B-UNK
D2	B-UNK
receptor	B-UNK
blockade	B-UNK
.	O
The	O
high	B-UNK
ratio	B-UNK
is	O
believed	O
to	O
impart	O
the	O
low	B-UNK
frequency	B-UNK
of	O
extrapyramidal	B-UNK
symptoms	B-UNK
with	O
risperidone	B-CHEMICAL
at	B-DISEASE
low	B-UNK
dosages	O
.	O
With	O
this	O
low	B-UNK
frequency	B-UNK
of	O
extrapyramidal	B-UNK
symptoms	B-UNK
,	O
it	O
was	O
thought	O
the	O
frequency	B-UNK
of	O
neuroleptic	B-DISEASE
malignant	I-DISEASE
syndrome	I-DISEASE
might	O
also	O
be	O
lowered	O
.	O
A	O
73-year	O
-	O
old	B-UNK
woman	B-UNK
developed	B-UNK
neuroleptic	B-DISEASE
malignant	I-DISEASE
syndrome	I-DISEASE
after	O
monotherapy	B-UNK
with	O
risperidone	B-CHEMICAL
.	O
The	O
syndrome	B-UNK
reversed	B-UNK
after	O
discontinuing	O
risperidone	B-CHEMICAL
and	O
starting	B-UNK
treatment	B-UNK
with	O
dantrolene	B-CHEMICAL
and	O
bromocriptine	B-CHEMICAL
.	O
It	O
appears	B-UNK
that	O
the	O
protection	B-UNK
from	O
extrapyramidal	B-UNK
side	O
effects	B-UNK
observed	B-UNK
with	O
risperidone	B-CHEMICAL
does	O
not	O
ensure	O
protection	B-UNK
from	O
neuroleptic	B-DISEASE
malignant	I-DISEASE
syndrome	I-DISEASE
.	O

Hepatic	B-UNK
and	O
extrahepatic	B-UNK
angiotensinogen	B-CHEMICAL
gene	B-UNK
expression	B-UNK
in	O
rats	B-UNK
with	O
acute	B-UNK
nephrotic	B-DISEASE
syndrome	I-DISEASE
.	O

Plasma	B-UNK
concentration	B-UNK
and	O
urine	B-DISEASE
excretion	B-UNK
of	O
the	O
renin	O
-	O
angiotensin	B-UNK
system	B-UNK
proteins	B-UNK
are	O
altered	B-UNK
in	O
rats	B-UNK
with	O
nephrotic	B-DISEASE
syndrome	I-DISEASE
(	O
NS	O
)	O
.	O
In	O
this	O
work	B-UNK
the	O
messenger	B-UNK
ribonucleic	O
acid	B-UNK
(	O
mRNA	B-UNK
)	O
levels	B-UNK
of	O
angiotensinogen	B-CHEMICAL
(	O
Ao	B-UNK
)	O
were	O
analyzed	B-UNK
with	O
the	O
slot	O
-	O
blot	B-UNK
hybridization	B-UNK
technique	B-UNK
in	O
liver	B-DISEASE
and	O
other	O
extrahepatic	B-UNK
tissues	B-UNK
:	O
kidney	B-UNK
,	O
heart	B-UNK
,	O
brain	B-UNK
,	O
and	O
adrenal	O
gland	O
from	O
control	B-UNK
,	O
nephrotic	B-UNK
,	O
and	O
pair	O
-	O
fed	B-UNK
(	O
PF	O
)	O
rats	B-UNK
.	O
NS	O
was	O
induced	B-UNK
by	O
a	O
single	B-UNK
injection	B-UNK
of	O
puromycin	B-CHEMICAL
amino	O
-	O
nucleoside	O
(	O
PAN	O
)	O
.	O
Although	O
a	O
great	O
urinary	B-UNK
excretion	B-UNK
and	O
half	O
-	O
normal	B-UNK
plasma	B-UNK
levels	B-UNK
of	O
Ao	B-UNK
were	O
observed	B-UNK
on	O
day	B-UNK
6	O
after	O
PAN	O
injection	B-UNK
,	O
when	O
NS	O
was	O
clearly	B-UNK
established	B-UNK
,	O
hepatic	B-UNK
Ao	B-UNK
mRNA	B-UNK
levels	B-UNK
did	O
not	O
change	B-UNK
.	O
Furthermore	O
,	O
the	O
Ao	B-UNK
mRNA	B-UNK
levels	B-UNK
did	O
not	O
change	B-UNK
in	O
any	O
of	O
the	O
extrahepatic	B-UNK
tissues	B-UNK
studied	B-UNK
on	O
day	B-UNK
6	O
,	O
nor	O
did	O
its	O
hepatic	B-UNK
levels	B-UNK
at	B-DISEASE
days	B-UNK
1	O
,	O
3	O
,	O
5	O
,	O
or	O
7	O
after	O
PAN	O
injection	B-UNK
.	O
These	O
data	B-UNK
suggest	B-UNK
that	O
the	O
hepatic	B-UNK
and	O
extrahepatic	B-UNK
Ao	B-UNK
mRNA	B-UNK
levels	B-UNK
are	O
unaltered	O
during	O
the	O
development	B-UNK
of	O
the	O
acute	B-UNK
NS	O
induced	B-UNK
by	O
PAN	O
.	O

Cyclophosphamide	O
associated	B-UNK
bladder	B-DISEASE
cancer	I-DISEASE
--	O
a	O
highly	B-UNK
aggressive	B-UNK
disease	B-DISEASE
:	O
analysis	B-UNK
of	O
12	O
cases	B-UNK
.	O

PURPOSE	O
:	O
We	O
gained	O
knowledge	O
of	O
the	O
etiology	O
,	O
treatment	B-UNK
and	O
prevention	O
of	O
cyclophosphamide	B-CHEMICAL
associated	B-UNK
urothelial	O
cancer	B-UNK
.	O
MATERIALS	O
AND	O
METHODS	O
:	O
The	O
medical	B-UNK
records	B-UNK
of	O
6	O
men	O
and	O
6	O
women	B-UNK
(	O
mean	B-UNK
age	B-UNK
55	O
years	B-UNK
)	O
with	O
cyclophosphamide	B-CHEMICAL
associated	B-UNK
bladder	B-DISEASE
cancer	I-DISEASE
were	O
reviewed	B-UNK
.	O
RESULTS	B-UNK
:	O
All	O
tumors	B-UNK
were	O
grade	B-UNK
3	O
or	O
4	O
transitional	O
cell	B-UNK
carcinoma	B-DISEASE
.	O
Of	O
the	O
5	O
patients	B-UNK
initially	B-UNK
treated	B-UNK
with	O
endoscopic	O
resection	O
alone	O
only	O
1	O
is	O
alive	O
without	O
disease	B-DISEASE
.	O
Of	O
the	O
6	O
patients	B-UNK
who	O
underwent	B-UNK
early	B-UNK
cystectomy	O
4	O
were	O
alive	O
at	B-DISEASE
24	O
to	O
111	O
months	B-UNK
.	O
The	O
remaining	B-UNK
patient	B-UNK
with	O
extensive	B-UNK
cancer	B-DISEASE
underwent	B-UNK
partial	B-UNK
cystectomy	O
for	O
palliation	O
and	O
died	B-UNK
3	O
months	B-UNK
later	B-UNK
.	O
CONCLUSIONS	O
:	O
Cyclophosphamide	O
associated	B-UNK
bladder	B-UNK
tumor	B-DISEASE
is	O
an	O
aggressive	B-UNK
disease	B-DISEASE
.	O
However	O
,	O
long	B-UNK
-	O
term	B-UNK
survival	B-UNK
is	O
possible	B-UNK
when	O
radical	B-UNK
cystectomy	O
is	O
performed	B-UNK
for	O
bladder	B-UNK
tumors	B-UNK
with	O
any	O
sign	O
of	O
invasion	O
and	O
for	O
recurrent	B-UNK
high	B-UNK
grade	B-UNK
disease	B-DISEASE
,	O
even	O
when	O
noninvasive	O
.	O

Leg	O
and	O
back	B-DISEASE
pain	I-DISEASE
after	O
spinal	B-UNK
anaesthesia	B-UNK
involving	B-UNK
hyperbaric	O
5	O
%	O
lignocaine	O
.	O

Fifty	O
-	O
four	O
patients	B-UNK
,	O
aged	B-UNK
27	O
-	O
90	O
years	B-UNK
,	O
who	O
were	O
given	B-UNK
lignocaine	O
5	O
%	O
in	O
6.8	O
%	O
glucose	B-CHEMICAL
solution	B-UNK
for	O
spinal	B-UNK
anaesthesia	B-UNK
were	O
studied	B-UNK
.	O
Thirteen	O
of	O
these	O
patients	B-UNK
experienced	B-UNK
pain	B-DISEASE
in	O
the	O
legs	O
and	O
/	O
or	O
back	O
after	O
recovery	B-UNK
from	O
anaesthesia	B-UNK
.	O
The	O
patients	B-UNK
affected	B-UNK
were	O
younger	O
(	O
p	B-UNK
<	I-UNK
0.05	O
)	O
and	O
the	O
site	B-UNK
of	O
the	O
dural	O
puncture	O
was	O
higher	B-UNK
(	O
p	B-UNK
<	I-UNK
0.01	B-UNK
)	O
than	O
those	O
individuals	B-UNK
without	O
pain	B-UNK
.	O
Five	O
of	O
the	O
13	O
patients	B-UNK
(	O
38	O
%	O
)	O
with	O
pain	B-UNK
and	O
seven	O
of	O
the	O
41	O
patients	B-UNK
(	O
17	B-DISEASE
%	O
)	O
without	O
pain	B-UNK
admitted	O
to	O
a	O
high	B-UNK
alcohol	B-UNK
intake	B-UNK
,	O
which	O
might	O
be	O
a	O
contributing	B-UNK
factor	B-UNK
.	O
Leg	O
and	O
/	O
or	O
back	B-DISEASE
pain	I-DISEASE
is	O
associated	B-UNK
with	O
the	O
intrathecal	O
use	B-UNK
of	O
hyperbaric	O
5	O
%	O
lignocaine	O
.	O

Acute	B-UNK
blood	B-UNK
pressure	B-UNK
elevations	O
with	O
caffeine	B-CHEMICAL
in	O
men	O
with	O
borderline	B-UNK
systemic	B-UNK
hypertension	B-DISEASE
.	O

Whether	O
the	O
vasoconstrictive	O
actions	B-UNK
of	O
caffeine	B-CHEMICAL
are	O
enhanced	B-UNK
in	O
hypertensive	B-UNK
persons	B-UNK
has	O
not	O
been	O
demonstrated	B-UNK
.	O
Thus	O
,	O
caffeine	B-CHEMICAL
(	O
3.3	O
mg	B-UNK
/	O
kg	B-UNK
)	O
versus	B-UNK
placebo	B-UNK
was	O
tested	B-UNK
in	O
48	O
healthy	B-UNK
men	O
(	O
aged	B-UNK
20	O
to	O
35	O
years	B-UNK
)	O
selected	O
after	O
screening	B-UNK
on	O
2	B-DISEASE
separate	B-UNK
occasions	B-UNK
.	O
Borderline	O
hypertensive	B-UNK
men	O
(	O
n	B-UNK
=	O
24	O
)	O
were	O
selected	O
with	O
screening	B-UNK
systolic	B-UNK
blood	B-UNK
pressure	B-UNK
(	O
BP	B-UNK
)	O
of	O
140	O
to	O
160	O
mm	B-UNK
Hg	B-UNK
and	O
/	O
or	O
diastolic	B-UNK
BP	B-UNK
90	O
to	O
99	O
mm	B-UNK
Hg	B-UNK
.	O
Low	O
-	O
risk	B-UNK
controls	B-UNK
(	O
n	B-UNK
=	O
24	O
)	O
reported	B-UNK
no	O
parental	O
history	B-UNK
of	O
hypertension	B-DISEASE
and	O
had	O
screening	B-UNK
BP	B-UNK
<	O
130/85	O
mm	B-UNK
Hg	B-UNK
.	O
Participants	O
were	O
then	O
tested	B-UNK
on	O
2	B-DISEASE
occasions	B-UNK
after	O
12-hour	O
abstinence	B-UNK
from	O
caffeine	B-CHEMICAL
in	O
each	O
of	O
2	B-DISEASE
protocols	B-UNK
;	O
this	O
required	B-UNK
a	O
total	B-UNK
of	O
4	O
laboratory	B-UNK
visits	O
.	O
Caffeine	O
-	O
induced	B-UNK
changes	B-UNK
in	O
diastolic	B-UNK
BP	B-UNK
were	O
2	B-DISEASE
to	O
3	O
times	B-UNK
larger	B-UNK
in	O
borderline	B-UNK
subjects	B-UNK
than	O
in	O
controls	B-UNK
(	O
+8.4	O
vs	B-UNK
+3.8	O
mm	B-UNK
Hg	B-UNK
,	O
p	B-UNK
<	I-UNK
0.0001	O
)	O
,	O
and	O
were	O
attributable	O
to	O
larger	B-UNK
changes	B-UNK
in	O
impedance	O
-	O
derived	O
measures	B-UNK
of	O
systemic	B-UNK
vascular	B-UNK
resistance	B-UNK
(	O
+135	O
vs	B-UNK
+45	O
dynes.s.cm-5	O
,	O
p	B-UNK
<	I-UNK
0.004	O
)	O
.	O
These	O
findings	B-UNK
were	O
consistent	B-UNK
and	O
reached	B-UNK
significance	O
in	O
both	O
protocols	B-UNK
.	O
The	O
percentage	B-UNK
of	O
borderline	B-UNK
subjects	B-UNK
in	O
whom	O
diastolic	B-UNK
BP	B-UNK
changes	B-UNK
exceeded	O
the	O
median	B-UNK
control	B-UNK
response	B-UNK
was	O
96	O
%	O
.	O
Consequently	O
,	O
whereas	O
all	O
participants	O
exhibited	B-UNK
normotensive	O
levels	B-UNK
during	O
the	O
resting	B-UNK
predrug	O
baseline	B-UNK
,	O
33	O
%	O
of	O
borderline	B-UNK
subjects	B-UNK
achieved	B-UNK
hypertensive	B-UNK
BP	B-UNK
levels	B-UNK
after	O
caffeine	B-CHEMICAL
ingestion	B-UNK
.	O
Thus	O
,	O
in	O
borderline	B-UNK
hypertensive	B-UNK
men	O
,	O
exaggerated	O
responses	B-UNK
to	O
caffeine	B-CHEMICAL
were	O
:	O
selective	B-UNK
for	O
diastolic	B-UNK
BP	B-UNK
,	O
consistent	B-UNK
with	O
greater	B-UNK
vasoconstriction	O
,	O
replicated	O
in	O
2	B-DISEASE
protocols	B-UNK
,	O
and	O
representative	O
of	O
nearly	B-UNK
all	O
borderline	B-UNK
hypertensives	O
.	O
We	O
suspect	O
that	O
the	O
potential	B-UNK
for	O
caffeine	B-CHEMICAL
to	O
stabilize	O
high	B-UNK
resistance	B-UNK
states	B-UNK
in	O
susceptible	B-UNK
persons	B-UNK
suggests	B-UNK
that	O
its	O
use	B-UNK
may	O
facilitate	O
their	O
disease	B-DISEASE
progression	I-DISEASE
,	O
as	O
well	O
as	O
hinder	O
accurate	O
diagnosis	B-UNK
and	O
treatment	B-UNK
.	O

Hallucinations	O
and	O
ifosfamide	B-CHEMICAL
-	O
induced	B-UNK
neurotoxicity	B-UNK
.	O

BACKGROUND	O
:	O
Hallucinations	O
as	O
a	O
symptom	O
of	O
central	B-UNK
neurotoxicity	B-UNK
are	O
a	O
known	B-UNK
but	O
poorly	B-UNK
described	B-UNK
side	O
effect	B-UNK
of	O
ifosfamide	B-CHEMICAL
.	O
Most	O
cases	B-UNK
of	O
ifosfamide	B-CHEMICAL
-	O
induced	B-UNK
hallucinations	B-DISEASE
have	O
been	O
reported	B-UNK
with	O
other	O
mental	B-UNK
status	I-UNK
changes	B-UNK
.	O
METHODS	O
:	O
The	O
authors	B-UNK
interviewed	O
six	O
persons	B-UNK
with	O
ifosfamide	B-CHEMICAL
-	O
induced	B-UNK
hallucinations	B-DISEASE
in	O
the	O
presence	O
of	O
a	O
clear	B-UNK
sensorium	O
.	O
All	O
patients	B-UNK
were	O
receiving	B-UNK
high	B-UNK
-	O
dose	B-UNK
ifosfamide	B-CHEMICAL
as	O
part	O
of	O
their	O
bone	B-UNK
marrow	B-UNK
transplant	B-UNK
procedure	B-UNK
.	O
RESULTS	B-UNK
:	O
Hallucinations	O
occurred	B-UNK
only	O
when	O
the	O
patient'	O
s	O
eyes	B-UNK
were	O
closed	O
and	O
,	O
in	O
all	O
but	O
one	O
case	B-UNK
,	O
were	O
reported	B-UNK
as	O
disturbing	O
or	O
frightening	O
.	O
Underreporting	O
of	O
these	O
hallucinations	B-DISEASE
by	O
patients	B-UNK
is	O
likely	B-UNK
.	O
CONCLUSIONS	O
:	O
Hallucinations	O
may	O
be	O
the	O
sole	B-UNK
or	O
first	O
manifestation	B-UNK
of	O
neurotoxicity	B-UNK
.	O
The	O
incidence	B-UNK
may	O
be	O
dose	B-UNK
and	O
infusion	B-UNK
-	O
time	B-UNK
related	B-UNK
.	O
The	O
clinician	O
should	O
be	O
alerted	O
for	O
possible	B-UNK
ifosfamide	B-CHEMICAL
-	O
induced	B-UNK
hallucinations	B-DISEASE
,	O
which	O
may	O
occur	O
without	O
other	O
signs	B-UNK
of	O
neurotoxicity	B-UNK
.	O
"	O
Eyes	O
-	O
closed	O
"	O
hallucinatory	O
experiences	O
appear	O
to	O
be	O
an	O
unusual	O
feature	O
of	O
this	O
presentation	O
.	O
Patients	B-UNK
anxious	O
about	O
this	O
experience	B-UNK
respond	O
well	O
to	O
support	B-UNK
and	O
education	O
about	O
this	O
occurrence	O
.	O
Optimal	O
pharmacologic	O
management	B-UNK
of	O
disturbed	O
patients	B-UNK
is	O
unclear	O
.	O
If	O
agitation	O
becomes	O
marked	B-UNK
,	O
high	B-UNK
-	O
potency	B-UNK
neuroleptics	O
(	O
i.e	O
.	O
,	O
haloperidol	B-CHEMICAL
)	O
may	O
be	O
effective	B-UNK
.	O

Chlorpropamide	O
-	O
induced	B-UNK
optic	B-DISEASE
neuropathy	I-DISEASE
.	O

A	O
65-year	O
-	O
old	B-UNK
woman	B-UNK
with	O
adult	B-UNK
-	O
onset	B-UNK
diabetes	B-DISEASE
treated	B-UNK
with	O
chlorpropamide	B-CHEMICAL
(	O
Diabenese	O
)	O
had	O
a	O
toxic	B-DISEASE
optic	I-DISEASE
neuropathy	I-DISEASE
that	O
resolved	B-UNK
with	O
discontinuation	B-UNK
of	O
chlorpropamide	B-CHEMICAL
therapy	B-UNK
.	O
Visual	B-UNK
loss	B-UNK
occurs	B-UNK
in	O
diabetics	O
for	O
a	O
variety	O
of	O
reasons	O
,	O
and	O
accurate	O
diagnosis	B-UNK
is	O
necessary	O
to	O
institute	O
appropriate	B-UNK
therapy	B-UNK
.	O
The	O
possibility	O
of	O
a	O
drug	B-UNK
-	O
induced	B-UNK
optic	B-DISEASE
neuropathy	I-DISEASE
should	O
be	O
considered	B-UNK
in	O
the	O
differential	B-UNK
diagnosis	B-UNK
of	O
visual	B-UNK
loss	B-UNK
in	O
diabetics	O
.	O

Levodopa	O
-	O
induced	B-UNK
dyskinesia	B-DISEASE
and	O
thalamotomy	O
.	O

Levodopa	O
-	O
induced	B-UNK
dyskinesia	B-DISEASE
of	O
the	O
limbs	B-UNK
in	O
thirteen	O
cases	B-UNK
of	O
Parkinsonism	O
,	O
which	O
was	O
choreic	O
,	O
ballistic	O
or	O
dystonic	O
in	O
type	B-UNK
,	O
was	O
alleviated	O
almost	O
completely	B-UNK
by	O
stereotaxic	O
surgery	B-UNK
using	O
a	O
microelectrode	O
technique	B-UNK
for	O
the	O
ventralis	B-UNK
oralis	O
anterior	B-UNK
and	O
posterior	B-UNK
nuclei	B-UNK
of	O
the	O
thalamus	O
,	O
but	O
much	O
less	O
by	O
the	O
ventralis	B-UNK
intermedius	O
nucleus	B-UNK
.	O
Control	B-UNK
of	O
levodopa	B-CHEMICAL
-	O
induced	B-UNK
dyskinesias	B-DISEASE
by	O
thalamic	O
lesions	B-UNK
in	O
the	O
course	B-UNK
of	O
routine	B-UNK
treatment	B-UNK
of	O
Parkinsonism	O
is	O
discussed	O
.	O

Factors	O
associated	B-UNK
with	O
nephrotoxicity	B-UNK
and	O
clinical	B-UNK
outcome	B-UNK
in	O
patients	B-UNK
receiving	B-UNK
amikacin	B-CHEMICAL
.	O

Data	O
from	O
60	O
patients	B-UNK
treated	B-UNK
with	O
amikacin	B-CHEMICAL
were	O
analyzed	B-UNK
for	O
factors	B-UNK
associated	B-UNK
with	O
nephrotoxicity	B-UNK
.	O
In	O
42	O
of	O
these	O
patients	B-UNK
,	O
data	B-UNK
were	O
examined	B-UNK
for	O
factors	B-UNK
associated	B-UNK
with	O
clinical	B-UNK
outcome	B-UNK
.	O
Variables	O
evaluated	B-UNK
included	B-UNK
patient	B-UNK
weight	B-UNK
,	O
age	B-UNK
,	O
sex	O
,	O
serum	B-UNK
creatinine	B-CHEMICAL
level	B-UNK
,	O
creatinine	B-CHEMICAL
clearance	B-UNK
,	O
duration	B-UNK
of	O
therapy	B-UNK
,	O
total	B-UNK
dose	B-UNK
,	O
mean	B-UNK
daily	B-UNK
dose	B-UNK
,	O
organism	O
minimum	O
inhibitory	B-UNK
concentration	B-UNK
(	O
MIC	O
)	O
,	O
mean	B-UNK
peak	B-UNK
levels	B-UNK
,	O
mean	B-UNK
trough	O
levels	B-UNK
,	O
mean	B-UNK
area	B-UNK
under	O
the	O
serum	B-UNK
concentration	B-UNK
-	O
time	B-UNK
curve	O
(	O
AUC	B-UNK
)	O
,	O
total	B-UNK
AUC	B-UNK
,	O
mean	B-UNK
AUC	B-UNK
greater	B-UNK
than	O
MIC	O
,	O
total	B-UNK
AUC	B-UNK
greater	B-UNK
than	O
MIC	O
,	O
mean	B-UNK
Schumacher'	O
s	O
intensity	B-UNK
factor	B-UNK
(	O
IF	O
)	O
,	O
total	B-UNK
IF	O
,	O
In	O
(	O
mean	B-UNK
maximum	B-UNK
concentration	B-UNK
[	O
Cmax]/MIC	O
)	O
.	O
Model	O
-	O
dependent	B-UNK
pharmacokinetic	B-UNK
parameters	B-UNK
were	O
calculated	O
by	O
computer	O
based	B-UNK
on	O
a	O
one	O
-	O
compartment	O
model	B-UNK
.	O
When	O
the	O
parameters	B-UNK
were	O
examined	B-UNK
individually	O
,	O
duration	B-UNK
of	O
therapy	B-UNK
and	O
total	B-UNK
AUC	B-UNK
correlated	B-UNK
significantly	B-UNK
(	O
P	B-UNK
less	O
than	O
.05	O
)	O
with	O
nephrotoxicity	B-UNK
.	O
In	O
contrast	B-UNK
,	O
a	O
stepwise	O
discriminant	O
function	B-UNK
analysis	B-UNK
identified	B-UNK
only	O
duration	B-UNK
of	O
therapy	B-UNK
(	O
P	B-UNK
less	O
than	O
.001	O
)	O
as	O
an	O
important	B-UNK
factor	B-UNK
.	O
Based	O
on	O
this	O
model	B-UNK
and	O
on	O
Bayes	O
'	O
theorem	O
,	O
the	O
predictive	B-UNK
accuracy	B-UNK
of	O
identifying	O
"	O
nephrotoxic	B-UNK
"	O
patients	B-UNK
increased	B-UNK
from	O
0.17	O
to	O
0.39	O
.	O
When	O
examined	B-UNK
individually	O
,	O
mean	B-UNK
IF	O
,	O
MIC	O
,	O
total	B-UNK
dose	B-UNK
,	O
mean	B-UNK
daily	B-UNK
dose	B-UNK
,	O
and	O
ln	O
(	O
mean	B-UNK
Cmax	O
/	O
MIC	O
)	O
correlated	B-UNK
significantly	B-UNK
(	O
P	B-UNK
less	O
than	O
.05	O
)	O
with	O
cure	O
.	O
In	O
contrast	B-UNK
,	O
a	O
simultaneous	O
multivariable	O
analysis	B-UNK
identified	B-UNK
IF	O
,	O
MIC	O
,	O
and	O
total	B-UNK
dose	B-UNK
according	B-UNK
to	O
one	O
model	B-UNK
and	O
ln	O
(	O
mean	B-UNK
Cmax	O
/	O
MIC	O
)	O
according	B-UNK
to	O
a	O
second	B-UNK
statistical	O
model	B-UNK
of	O
parameters	B-UNK
selected	O
to	O
have	O
the	O
greatest	O
prospective	B-UNK
value	B-UNK
.	O
Based	O
on	O
Bayes	O
'	O
theorem	O
and	O
the	O
first	O
model	B-UNK
,	O
the	O
predictive	B-UNK
accuracy	B-UNK
of	O
identifying	O
patients	B-UNK
not	O
cured	O
increased	B-UNK
from	O
0.19	O
to	O
0.83	O
.	O
For	O
the	O
second	B-UNK
model	B-UNK
,	O
the	O
predictive	B-UNK
accuracy	B-UNK
increased	B-UNK
from	O
0.19	O
to	O
0.50.(ABSTRACT	O
TRUNCATED	B-UNK
AT	O
250	O
WORDS	O
)	O

Cardiac	B-UNK
transplantation	B-UNK
:	O
improved	B-UNK
quality	O
of	O
survival	B-UNK
with	O
a	O
modified	B-UNK
immunosuppressive	B-UNK
protocol	B-UNK
.	O

The	O
effects	B-UNK
on	O
renal	B-UNK
function	B-UNK
on	O
two	O
different	B-UNK
immunosuppressive	B-UNK
protocols	B-UNK
were	O
evaluated	B-UNK
retrospectively	B-UNK
in	O
two	O
subsequent	B-UNK
groups	B-UNK
of	O
heart	B-UNK
transplant	B-UNK
recipients	B-UNK
.	O
In	O
group	B-UNK
I	O
,	O
cyclosporine	B-CHEMICAL
was	O
given	B-UNK
before	O
the	O
procedure	B-UNK
at	B-DISEASE
a	O
loading	B-UNK
dose	I-UNK
of	O
17.5	O
mg	B-UNK
/	O
kg	B-UNK
and	O
then	O
continued	B-UNK
after	O
the	O
procedure	B-UNK
to	O
keep	O
a	O
whole	O
blood	B-UNK
level	B-UNK
about	O
1000	O
ng	B-UNK
/	O
ml	B-UNK
.	O
In	O
group	B-UNK
II	B-UNK
,	O
cyclosporine	B-CHEMICAL
was	O
started	B-UNK
only	O
after	O
the	O
procedure	B-UNK
at	B-DISEASE
a	O
lower	B-UNK
dosage	B-UNK
and	O
was	O
complemented	O
by	O
azathioprine	B-CHEMICAL
,	O
which	O
was	O
used	O
for	O
the	O
first	O
postoperative	B-UNK
week	B-UNK
.	O
Group	B-UNK
II	B-UNK
showed	B-UNK
a	O
better	B-UNK
perioperative	O
renal	B-UNK
function	B-UNK
as	O
determined	O
by	O
serum	B-UNK
blood	B-UNK
urea	B-CHEMICAL
nitrogen	B-CHEMICAL
and	O
serum	B-UNK
creatinine	B-CHEMICAL
levels	B-UNK
.	O
Group	B-UNK
II	B-UNK
also	O
showed	B-UNK
a	O
significant	B-UNK
decrease	B-UNK
of	O
chronic	B-UNK
nephrotoxicity	B-UNK
secondary	B-UNK
to	O
long	B-UNK
-	O
term	B-UNK
therapy	B-UNK
with	O
cyclosporine	B-CHEMICAL
.	O
Despite	B-UNK
this	O
improvement	B-UNK
in	O
late	B-UNK
renal	B-UNK
function	B-UNK
,	O
group	B-UNK
II	B-UNK
still	O
shows	B-UNK
a	O
slow	O
rise	B-UNK
in	O
serum	B-UNK
creatinine	B-CHEMICAL
.	O
We	O
think	O
that	O
even	O
these	O
lower	B-UNK
dosages	O
of	O
cyclosporine	B-CHEMICAL
can	O
cause	B-UNK
chronic	B-UNK
nephrotoxicity	B-UNK
and	O
that	O
further	O
modification	O
of	O
the	O
immunosuppressive	B-UNK
regimen	B-UNK
is	O
required	B-UNK
to	O
completely	B-UNK
abolish	O
this	O
toxic	B-UNK
side	O
effect	B-UNK
.	O

Reversible	O
cholestasis	B-DISEASE
with	O
bile	B-UNK
duct	B-UNK
injury	B-UNK
following	B-UNK
azathioprine	B-CHEMICAL
therapy	B-UNK
.	O
A	O
case	B-UNK
report	B-UNK
.	O

A	O
67-year	O
-	O
old	B-UNK
patient	B-UNK
,	O
with	O
primary	B-UNK
polymyositis	B-DISEASE
and	O
without	O
previous	B-UNK
evidence	B-UNK
of	O
liver	B-DISEASE
disease	I-DISEASE
,	O
developed	B-UNK
clinical	B-UNK
and	O
biochemical	B-UNK
features	B-UNK
of	O
severe	B-UNK
cholestasis	B-DISEASE
3	O
months	B-UNK
after	O
initiation	O
of	O
azathioprine	B-CHEMICAL
therapy	B-UNK
.	O
Liver	B-UNK
biopsy	I-UNK
showed	B-UNK
cholestasis	B-DISEASE
with	O
both	O
cytological	O
and	O
architectural	O
alterations	B-UNK
of	O
interlobular	O
bile	B-UNK
ducts	O
.	O
Azathioprine	O
withdrawal	B-UNK
resulted	B-UNK
after	O
7	O
weeks	B-UNK
in	O
the	O
resolution	B-UNK
of	O
clinical	B-UNK
and	O
biochemical	B-UNK
abnormalities	B-DISEASE
.	O
It	O
is	O
believed	O
that	O
this	O
is	O
the	O
first	O
reported	B-UNK
case	B-UNK
of	O
reversible	B-UNK
azathioprine	B-CHEMICAL
-	O
induced	B-UNK
cholestasis	B-DISEASE
associated	B-UNK
with	O
histological	B-UNK
evidence	B-UNK
of	O
bile	B-UNK
duct	B-UNK
injury	B-UNK
.	O

Renal	B-UNK
function	B-UNK
and	O
hemodynamics	O
during	O
prolonged	B-UNK
isoflurane	B-CHEMICAL
-	O
induced	B-UNK
hypotension	B-DISEASE
in	O
humans	O
.	O

The	O
effect	B-UNK
of	O
isoflurane	B-CHEMICAL
-	O
induced	B-UNK
hypotension	B-DISEASE
on	O
glomerular	B-UNK
function	B-UNK
and	O
renal	B-DISEASE
blood	B-UNK
flow	B-UNK
was	O
investigated	B-UNK
in	O
20	O
human	B-UNK
subjects	B-UNK
.	O
Glomerular	O
filtration	B-UNK
rate	I-UNK
(	O
GFR	O
)	O
and	O
effective	B-UNK
renal	B-DISEASE
plasma	B-UNK
flow	B-UNK
(	O
ERPF	O
)	O
were	O
measured	B-UNK
by	O
inulin	B-CHEMICAL
and	O
para	O
-	O
aminohippurate	O
(	O
PAH	O
)	O
clearance	B-UNK
,	O
respectively	O
.	O
Anesthesia	O
was	O
maintained	O
with	O
fentanyl	B-CHEMICAL
,	O
nitrous	B-CHEMICAL
oxide	I-CHEMICAL
,	O
oxygen	B-CHEMICAL
,	O
and	O
isoflurane	B-CHEMICAL
.	O
Hypotension	O
was	O
induced	B-UNK
for	O
236.9	O
+	O
/-	O
15.1	O
min	B-UNK
by	O
increasing	B-UNK
the	O
isoflurane	B-CHEMICAL
inspired	O
concentration	B-UNK
to	O
maintain	O
a	O
mean	B-UNK
arterial	B-UNK
pressure	I-UNK
of	O
59.8	O
+	O
/-	O
0.4	O
mmHg	B-UNK
.	O
GFR	O
and	O
ERPF	O
decreased	B-UNK
with	O
the	O
induction	B-UNK
of	O
anesthesia	B-UNK
but	O
not	O
significantly	B-UNK
more	O
during	O
hypotension	B-DISEASE
.	O
Postoperatively	O
,	O
ERPF	O
returned	B-UNK
to	O
preoperative	B-UNK
values	B-UNK
,	O
whereas	O
GFR	O
was	O
higher	B-UNK
than	O
preoperative	B-UNK
values	B-UNK
.	O
Renal	B-UNK
vascular	B-UNK
resistance	B-UNK
increased	B-UNK
during	O
anesthesia	B-UNK
but	O
decreased	B-UNK
when	O
hypotension	B-DISEASE
was	O
induced	B-UNK
,	O
allowing	O
the	O
maintenance	B-UNK
of	O
renal	B-UNK
blood	B-UNK
flow	B-UNK
.	O
We	O
conclude	O
that	O
renal	B-UNK
compensatory	B-UNK
mechanisms	B-UNK
are	O
preserved	O
during	O
isoflurane	B-CHEMICAL
-	O
induced	B-UNK
hypotension	B-DISEASE
and	O
that	O
renal	B-UNK
function	B-UNK
and	O
hemodynamics	O
quickly	O
return	B-UNK
to	O
normal	B-UNK
when	O
normotension	O
is	O
resumed	O
.	O

Debrisoquine	O
phenotype	O
and	O
the	O
pharmacokinetics	O
and	O
beta-2	O
receptor	B-UNK
pharmacodynamics	O
of	O
metoprolol	B-CHEMICAL
and	O
its	O
enantiomers	O
.	O

The	O
metabolism	B-DISEASE
of	O
the	O
cardioselective	O
beta-blocker	B-UNK
metoprolol	B-CHEMICAL
is	O
under	O
genetic	B-UNK
control	B-UNK
of	O
the	O
debrisoquine	O
/	O
sparteine	B-CHEMICAL
type	B-UNK
.	O
The	O
two	O
metabolic	B-UNK
phenotypes	O
,	O
extensive	B-UNK
(	O
EM	O
)	O
and	O
poor	B-UNK
metabolizers	O
(	O
PM	O
)	O
,	O
show	O
different	B-UNK
stereoselective	O
metabolism	B-DISEASE
,	O
resulting	B-UNK
in	O
apparently	O
higher	B-UNK
beta-1	O
adrenoceptor	B-UNK
antagonistic	B-UNK
potency	B-UNK
of	O
racemic	O
metoprolol	B-CHEMICAL
in	O
EMs	O
.	O
We	O
investigated	B-UNK
if	O
the	O
latter	O
also	O
applies	O
to	O
the	O
beta-2	O
adrenoceptor	B-UNK
antagonism	B-UNK
by	O
metoprolol	B-CHEMICAL
.	O
The	O
drug	B-UNK
effect	B-UNK
studied	B-UNK
was	O
the	O
antagonism	B-UNK
by	O
metoprolol	B-CHEMICAL
of	O
terbutaline	B-CHEMICAL
-	O
induced	B-UNK
hypokalemia	B-DISEASE
.	O
By	O
using	O
pharmacokinetic	B-UNK
pharmacodynamic	O
modeling	O
the	O
pharmacodynamics	O
of	O
racemic	O
metoprolol	B-CHEMICAL
and	O
the	O
active	B-UNK
S	O
-	O
isomer	O
,	O
were	O
quantitated	O
in	O
EMs	O
and	O
PMs	O
in	O
terms	O
of	O
IC50	O
values	B-UNK
,	O
representing	O
metoprolol	B-CHEMICAL
plasma	B-UNK
concentrations	B-UNK
resulting	B-UNK
in	O
half	O
-	O
maximum	B-UNK
receptor	B-UNK
occupancy	B-UNK
.	O
Six	O
EMs	O
received	B-UNK
0.5	B-UNK
mg	I-UNK
of	O
terbutaline	B-CHEMICAL
s.c	B-UNK
.	O
on	O
two	O
different	B-UNK
occasions	B-UNK
:	O
1	O
)	O
1	O
hr	B-UNK
after	O
administration	B-UNK
of	O
a	O
placebo	B-UNK
and	O
2	B-DISEASE
)	O
1	O
hr	B-UNK
after	O
150	O
mg	B-UNK
of	O
metoprolol	B-CHEMICAL
p.o	B-UNK
.	O
Five	O
PMs	O
were	O
studied	B-UNK
according	B-UNK
to	O
the	O
same	O
protocol	B-UNK
,	O
except	O
for	O
a	O
higher	B-UNK
terbutaline	B-CHEMICAL
dose	B-UNK
(	O
0.75	O
mg	B-UNK
)	O
on	O
day	B-UNK
2	B-DISEASE
.	O
Blood	O
samples	B-UNK
for	O
the	O
analysis	B-UNK
of	O
plasma	B-UNK
potassium	B-CHEMICAL
,	O
terbutaline	B-CHEMICAL
,	O
metoprolol	B-CHEMICAL
(	O
racemic	O
,	O
R-	O
and	O
S	O
-	O
isomer	O
)	O
,	O
and	O
alpha	B-CHEMICAL
-	I-CHEMICAL
hydroxymetoprolol	I-CHEMICAL
concentrations	B-UNK
were	O
taken	O
at	B-DISEASE
regular	B-UNK
time	B-UNK
intervals	B-UNK
,	O
during	O
8	O
hr	B-UNK
after	O
metoprolol	B-CHEMICAL
.	O
In	O
PMs	O
,	O
metoprolol	B-CHEMICAL
increased	B-UNK
the	O
terbutaline	B-CHEMICAL
area	B-UNK
under	O
the	O
plasma	B-UNK
concentration	B-UNK
vs	B-UNK
.	O
time	B-UNK
curve	O
(	O
+67	O
%	O
)	O
.	O
Higher	O
metoprolol	B-CHEMICAL
/	O
alpha	B-CHEMICAL
-	I-CHEMICAL
hydroxymetoprolol	I-CHEMICAL
ratios	O
in	O
PMs	O
were	O
predictive	B-UNK
for	O
higher	B-UNK
R-/S	O
-	O
isomer	O
ratios	O
of	O
unchanged	B-UNK
drug	B-UNK
.	O
There	O
was	O
a	O
difference	B-UNK
in	O
metoprolol	B-CHEMICAL
potency	B-UNK
with	O
higher	B-UNK
racemic	O
metoprolol	B-CHEMICAL
IC50	O
values	B-UNK
in	O
PMs	O
(	O
72	O
+	O
/-	O
7	O
ng.ml-1	O
)	O
than	O
EMs	O
(	O
42	O
+	O
/-	O
8	O
ng.ml-1	O
,	O
P	B-UNK
less	O
than	O
.001).(ABSTRACT	O
TRUNCATED	B-UNK
AT	O
250	O
WORDS	O
)	O

Cefotetan	O
-	O
induced	B-UNK
immune	B-UNK
hemolytic	B-DISEASE
anemia	I-DISEASE
.	O

Immune	O
hemolytic	B-DISEASE
anemia	I-DISEASE
due	O
to	O
a	O
drug	B-UNK
-	O
adsorption	O
mechanism	B-UNK
has	O
been	O
described	B-UNK
primarily	B-UNK
in	O
patients	B-UNK
receiving	B-UNK
penicillins	B-CHEMICAL
and	O
first	O
-	O
generation	B-UNK
cephalosporins	B-CHEMICAL
.	O
We	O
describe	O
a	O
patient	B-UNK
who	O
developed	B-UNK
anemia	B-DISEASE
while	O
receiving	B-UNK
intravenous	B-UNK
cefotetan	B-CHEMICAL
.	O
Cefotetan	O
-	O
dependent	B-UNK
antibodies	B-UNK
were	O
detected	B-UNK
in	O
the	O
patient'	O
s	O
serum	B-UNK
and	O
in	O
an	O
eluate	O
prepared	O
from	O
his	O
red	O
blood	B-UNK
cells	B-UNK
.	O
The	O
eluate	O
also	O
reacted	O
weakly	O
with	O
red	O
blood	B-UNK
cells	B-UNK
in	O
the	O
absence	B-UNK
of	O
cefotetan	B-CHEMICAL
,	O
suggesting	B-UNK
the	O
concomitant	B-UNK
formation	B-UNK
of	O
warm	O
-	O
reactive	B-UNK
autoantibodies	O
.	O
These	O
observations	B-UNK
,	O
in	O
conjunction	O
with	O
clinical	B-UNK
and	O
laboratory	B-UNK
evidence	B-UNK
of	O
extravascular	O
hemolysis	B-DISEASE
,	O
are	O
consistent	B-UNK
with	O
drug	B-UNK
-	O
induced	B-UNK
hemolytic	B-DISEASE
anemia	I-DISEASE
,	O
possibly	B-UNK
involving	B-UNK
both	O
drug	B-UNK
-	O
adsorption	O
and	O
autoantibody	O
formation	B-UNK
mechanisms	B-UNK
.	O
This	O
case	B-UNK
emphasizes	O
the	O
need	B-UNK
for	O
increased	B-UNK
awareness	O
of	O
hemolytic	B-UNK
reactions	B-UNK
to	O
all	O
cephalosporins	B-CHEMICAL
.	O

Acute	B-UNK
renal	B-DISEASE
failure	I-DISEASE
subsequent	B-UNK
to	O
the	O
administration	B-UNK
of	O
rifampicin	O
.	O
A	O
follow	B-UNK
-	O
up	O
study	B-UNK
of	O
cases	B-UNK
reported	B-UNK
earlier	B-UNK
.	O

A	O
clinical	B-UNK
presentation	O
is	O
made	O
of	O
a	O
2	B-DISEASE
-	O
3	O
year	B-UNK
follow	B-UNK
-	O
up	O
of	O
six	O
cases	B-UNK
of	O
acute	B-DISEASE
renal	I-DISEASE
failure	I-DISEASE
that	O
have	O
been	O
reported	B-UNK
earlier	B-UNK
.	O
The	O
patients	B-UNK
had	O
developed	B-UNK
transient	B-UNK
renal	B-DISEASE
failure	I-DISEASE
after	O
the	O
intermittent	B-UNK
administration	B-UNK
of	O
rifampicin	O
.	O
The	O
stage	B-UNK
of	O
olig	O
-	O
anuria	B-DISEASE
lasted	B-UNK
for	O
1	O
-	O
3	O
weeks	B-UNK
,	O
and	O
five	O
of	O
the	O
patients	B-UNK
were	O
treated	B-UNK
by	O
hemodialysis	O
.	O
Two	O
of	O
the	O
patients	B-UNK
died	B-UNK
due	O
to	O
unrelated	O
causes	B-UNK
during	O
the	O
follow	B-UNK
-	O
up	O
period	B-UNK
.	O
The	O
four	O
patients	B-UNK
re-examined	O
were	O
clinically	B-UNK
cured	O
.	O
Pathologic	O
findings	B-UNK
by	O
light	B-UNK
microscopy	B-UNK
and	O
immunofluorescence	O
at	B-DISEASE
biopsy	B-UNK
were	O
scarce	O
.	O
Nothing	O
abnormal	B-UNK
was	O
seen	B-UNK
by	O
electron	B-UNK
microscopy	B-UNK
in	O
two	O
of	O
the	O
cases	B-UNK
studied	B-UNK
.	O
Renal	B-UNK
function	B-UNK
was	O
normal	B-UNK
.	O
In	O
three	O
cases	B-UNK
the	O
excretion	B-UNK
at	B-DISEASE
131I	O
-	O
hippuran	O
renography	O
was	O
slightly	O
slowed	O
.	O
Although	O
in	O
the	O
acute	B-UNK
stage	B-UNK
the	O
renal	B-DISEASE
lesions	B-UNK
histologically	O
appeared	B-UNK
toxic	B-UNK
,	O
evidence	B-UNK
suggestive	O
of	O
an	O
immunological	O
mechanism	B-UNK
cannot	O
be	O
excluded	O
.	O

Type	O
B	B-UNK
hepatitis	B-DISEASE
after	O
needle	O
-	O
stick	O
exposure	B-UNK
:	O
prevention	O
with	O
hepatitis	B-DISEASE
B	B-UNK
immune	B-UNK
globulin	B-UNK
.	O
Final	O
report	B-UNK
of	O
the	O
Veterans	O
Administration	B-UNK
Cooperative	O
Study	B-UNK
.	O

Hepatitis	B-UNK
B	I-UNK
immune	B-UNK
globulin	B-UNK
(	O
HBIG	O
)	O
and	O
immune	B-UNK
serum	B-UNK
globulin	B-UNK
(	O
ISG	O
)	O
were	O
examined	B-UNK
in	O
a	O
randomized	B-UNK
,	O
double-blind	B-UNK
trial	B-UNK
to	O
assess	B-UNK
their	O
relative	B-UNK
efficacies	O
in	O
preventing	B-UNK
type	B-UNK
B	B-UNK
hepatitis	B-DISEASE
after	O
needle	O
-	O
stick	O
exposure	B-UNK
to	O
hepatitis	B-DISEASE
B	B-UNK
surface	I-UNK
antigen	B-UNK
(	O
HBsAG)-positive	O
donors	O
.	O
Clinical	B-UNK
hepatitis	B-DISEASE
developed	B-UNK
in	O
1.4	O
%	O
of	O
HBIG	O
and	O
in	O
5.9	B-UNK
%	O
of	O
ISG	O
recipients	B-UNK
(	O
P	B-UNK
=	I-UNK
0.016	O
)	O
,	O
and	O
seroconversion	O
(	O
anti-HBs	O
)	O
occurred	B-UNK
in	O
5.6	O
%	O
and	O
20.7	O
%	O
of	O
them	O
respectively	O
(	O
P	B-UNK
less	O
than	O
0.001	B-UNK
)	O
.	O
Mild	O
and	O
transient	B-UNK
side	O
-	O
effects	B-UNK
were	O
noted	O
in	O
3.0	O
%	O
of	O
ISG	O
and	O
in	O
3.2	O
%	O
of	O
HBIG	O
recipients	B-UNK
.	O
Available	O
donor	B-UNK
sera	O
were	O
examined	B-UNK
for	O
DNA	B-UNK
polymerase	O
(	O
DNAP	O
)	O
and	O
e	B-UNK
antigen	B-UNK
and	O
antibody	B-UNK
(	O
HBeAg	O
;	O
anti-HBE	O
)	O
.	O
Both	O
DNAP	O
and	O
HBeAg	O
showed	B-UNK
a	O
highly	B-UNK
statistically	B-UNK
significant	I-UNK
correlation	B-UNK
with	O
the	O
infectivity	O
of	O
HBsAg	O
-	O
positive	B-UNK
donors	O
.	O
Hepatitis	B-UNK
B	I-UNK
immune	B-UNK
globulin	B-UNK
remained	B-UNK
significantly	B-UNK
superior	B-UNK
to	O
ISG	O
in	O
preventing	B-UNK
type	B-UNK
B	B-UNK
hepatitis	B-DISEASE
even	O
when	O
the	O
analysis	B-UNK
was	O
confined	O
to	O
these	O
two	O
high	B-UNK
-	O
risk	B-UNK
subgroups	O
.	O
The	O
efficacy	B-UNK
of	O
ISG	O
in	O
preventing	B-UNK
type	B-UNK
B	B-UNK
hepatitis	B-DISEASE
cannot	O
be	O
ascertained	O
because	O
a	O
true	O
placebo	B-UNK
group	B-UNK
was	O
not	O
included	B-UNK
.	O

Serotonin	O
syndrome	B-DISEASE
from	O
venlafaxine	O
-	O
tranylcypromine	B-CHEMICAL
interaction	B-UNK
.	O

Excessive	O
stimulation	B-UNK
of	O
serotonin	B-CHEMICAL
5HT1A	O
receptors	B-UNK
causes	B-UNK
a	O
syndrome	B-UNK
of	O
serotonin	B-CHEMICAL
excess	B-UNK
that	O
consists	B-UNK
of	O
shivering	O
,	O
muscle	B-DISEASE
rigidity	I-DISEASE
,	O
salivation	O
,	O
confusion	B-DISEASE
,	O
agitation	O
and	O
hyperthermia	B-DISEASE
.	O
The	O
most	O
common	B-UNK
cause	B-UNK
of	O
this	O
syndrome	B-UNK
is	O
an	O
interaction	B-UNK
between	O
a	O
monoamine	O
oxidase	B-UNK
inhibitor	B-UNK
(	O
MAOI	O
)	O
and	O
a	O
specific	B-UNK
serotonin	B-CHEMICAL
reuptake	B-UNK
inhibitor	B-UNK
.	O
Venlafaxine	O
is	O
a	O
new	B-UNK
antidepressant	B-UNK
agent	B-UNK
that	O
inhibits	O
the	O
reuptake	B-UNK
of	O
serotonin	B-CHEMICAL
and	O
norepinephrine	B-CHEMICAL
.	O
We	O
report	B-UNK
a	O
venlafaxine	O
-	O
MAOI	O
interaction	B-UNK
that	O
resulted	B-UNK
in	O
the	O
serotonin	B-DISEASE
syndrome	I-DISEASE
in	O
a	O
23-y	O
-	O
old	B-UNK
male	B-UNK
who	O
was	O
taking	B-UNK
tranylcypromine	B-CHEMICAL
for	O
depression	B-DISEASE
.	O
He	O
had	O
been	O
well	O
until	O
the	O
morning	O
of	O
presentation	O
when	O
he	O
took	O
1/2	O
tab	O
of	O
venlafaxine	O
.	O
Within	O
2	B-DISEASE
h	B-UNK
he	O
became	O
confused	O
with	O
jerking	O
movements	B-UNK
of	O
his	O
extremities	O
,	O
tremors	O
and	O
rigidity	B-UNK
.	O
He	O
was	O
brought	O
directly	B-UNK
to	O
a	O
hospital	B-UNK
where	O
he	O
was	O
found	B-UNK
to	O
be	O
agitated	O
and	O
confused	O
with	O
shivering	O
,	O
myoclonic	B-UNK
jerks	B-UNK
,	O
rigidity	B-UNK
,	O
salivation	O
and	O
diaphoresis	O
.	O
His	O
pupils	O
were	O
7	O
mm	B-UNK
and	O
sluggishly	O
reactive	B-UNK
to	O
light	B-UNK
.	O
Vital	O
signs	B-UNK
were	O
:	O
blood	B-UNK
pressure	B-UNK
120/67	O
mm	B-UNK
Hg	B-UNK
,	O
heart	B-UNK
rate	I-UNK
127	O
/	O
min	B-UNK
,	O
respiratory	B-UNK
rate	B-UNK
28	O
/	O
min	B-UNK
,	O
and	O
temperature	B-UNK
97	O
F.	O
After	O
180	O
mg	B-UNK
of	O
diazepam	B-CHEMICAL
i.v	B-UNK
.	O
he	O
remained	B-UNK
tremulous	O
with	O
muscle	B-DISEASE
rigidity	I-DISEASE
and	O
clenched	O
jaws	O
.	O
He	O
was	O
intubated	O
for	O
airway	B-UNK
protection	B-UNK
and	O
because	O
of	O
hypoventilation	B-DISEASE
,	O
and	O
was	O
paralyzed	O
to	O
control	B-UNK
muscle	B-DISEASE
rigidity	I-DISEASE
.	O
His	O
subsequent	B-UNK
course	B-UNK
was	O
remarkable	O
for	O
non-immune	O
thrombocytopenia	B-DISEASE
which	O
resolved	B-UNK
.	O
The	O
patient'	O
s	O
maximal	O
temperature	B-UNK
was	O
101.2	O
F	O
and	O
his	O
CPK	O
remained	B-UNK
<	O
500	O
units	B-UNK
/	O
L	B-UNK
with	O
no	O
other	O
evidence	B-UNK
of	O
rhabdomyolysis	B-DISEASE
.	O
His	O
mental	B-UNK
status	I-UNK
normalized	B-UNK
and	O
he	O
was	O
transferred	O
to	O
a	O
psychiatry	B-UNK
ward	O
.	O
This	O
patient	B-UNK
survived	O
without	O
sequelae	O
due	O
to	O
the	O
aggressive	B-UNK
sedation	B-UNK
and	O
neuromuscular	B-UNK
paralysis	B-DISEASE
.	O

Effect	O
of	O
nondopaminergic	O
drugs	B-UNK
on	O
L	B-UNK
-	O
dopa	O
-	O
induced	B-UNK
dyskinesias	B-DISEASE
in	O
MPTP	O
-	O
treated	B-UNK
monkeys	O
.	O

A	O
group	B-UNK
of	O
four	O
monkeys	O
was	O
rendered	O
parkinsonian	B-UNK
with	O
the	O
toxin	O
MPTP	O
.	O
They	O
were	O
then	O
treated	B-UNK
chronically	B-UNK
with	O
L	B-UNK
-	O
DOPA	O
/	O
benserazide	B-CHEMICAL
50/12.5	O
mg	B-UNK
/	O
kg	B-UNK
given	B-UNK
orally	B-UNK
daily	B-UNK
for	O
2	B-DISEASE
months	B-UNK
.	O
This	O
dose	B-UNK
produced	B-UNK
a	O
striking	B-UNK
antiparkinsonian	B-UNK
effect	B-UNK
,	O
but	O
all	O
animals	B-UNK
manifested	O
dyskinesia	B-DISEASE
.	O
A	O
series	B-UNK
of	O
agents	B-UNK
acting	B-UNK
primarily	B-UNK
on	O
neurotransmitters	B-UNK
other	O
than	O
dopamine	B-CHEMICAL
were	O
then	O
tested	B-UNK
in	O
combination	B-UNK
with	O
L	B-UNK
-	O
DOPA	O
to	O
see	O
if	O
the	O
dyskinetic	B-UNK
movements	B-UNK
would	O
be	O
modified	B-UNK
.	O
Several	O
drugs	B-UNK
,	O
including	B-UNK
clonidine	B-CHEMICAL
,	O
physostigmine	B-CHEMICAL
,	O
methysergide	B-CHEMICAL
,	O
5-MDOT	O
,	O
propranolol	B-CHEMICAL
,	O
and	O
MK-801	O
,	O
markedly	B-UNK
reduced	B-UNK
the	O
dyskinetic	B-UNK
movements	B-UNK
but	O
at	B-DISEASE
the	O
cost	B-UNK
of	O
a	O
return	B-UNK
of	O
parkinsonian	B-UNK
symptomatology	O
.	O
However	O
,	O
yohimbine	B-CHEMICAL
and	O
meperidine	B-CHEMICAL
reduced	B-UNK
predominantly	B-UNK
the	O
dyskinetic	B-UNK
movements	B-UNK
.	O
Baclofen	O
was	O
also	O
useful	B-UNK
in	O
one	O
monkey	O
against	O
a	O
more	O
dystonic	O
form	B-UNK
of	O
dyskinesia	B-DISEASE
.	O
Atropine	O
converted	O
the	O
dystonic	O
movements	B-UNK
into	O
chorea	B-DISEASE
.	O

CCNU	O
(	O
lomustine	B-CHEMICAL
)	O
toxicity	B-UNK
in	O
dogs	B-UNK
:	O
a	O
retrospective	O
study	B-UNK
(	O
2002	O
-	O
07	O
)	O
.	O

OBJECTIVE	O
:	O
To	O
describe	O
the	O
incidence	B-UNK
of	O
haematological	O
,	O
renal	B-UNK
,	O
hepatic	B-UNK
and	O
gastrointestinal	B-UNK
toxicities	B-UNK
in	O
tumour	O
-	O
bearing	O
dogs	B-UNK
receiving	B-UNK
1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea	O
(	O
CCNU	O
)	O
.	O
DESIGN	B-UNK
:	O
The	O
medical	B-UNK
records	B-UNK
of	O
206	O
dogs	B-UNK
that	O
were	O
treated	B-UNK
with	O
CCNU	O
at	B-DISEASE
the	O
Melbourne	O
Veterinary	O
Specialist	O
Centre	O
between	O
February	O
2002	O
and	O
December	O
2007	O
were	O
retrospectively	B-UNK
evaluated	B-UNK
.	O
RESULTS	B-UNK
:	O
Of	O
the	O
206	O
dogs	B-UNK
treated	B-UNK
with	O
CCNU	O
,	O
185	O
met	O
the	O
inclusion	O
criteria	B-UNK
for	O
at	B-DISEASE
least	O
one	O
class	O
of	O
toxicity	B-UNK
.	O
CCNU	O
was	O
used	O
most	O
commonly	B-UNK
in	O
the	O
treatment	B-UNK
of	O
lymphoma	B-DISEASE
,	O
mast	O
cell	B-UNK
tumour	O
,	O
brain	B-UNK
tumour	O
,	O
histiocytic	O
tumours	O
and	O
epitheliotropic	O
lymphoma	B-DISEASE
.	O
Throughout	O
treatment	B-UNK
,	O
56.9	O
%	O
of	O
dogs	B-UNK
experienced	B-UNK
neutropenia	B-DISEASE
,	O
34.2	O
%	O
experienced	B-UNK
anaemia	B-UNK
and	O
14.2	O
%	O
experienced	B-UNK
thrombocytopenia	B-DISEASE
.	O
Gastrointestinal	O
toxicosis	O
was	O
detected	B-UNK
in	O
37.8	O
%	O
of	O
dogs	B-UNK
,	O
the	O
most	O
common	B-UNK
sign	O
of	O
which	O
was	O
vomiting	B-DISEASE
(	O
24.3	O
%	O
)	O
.	O
Potential	O
renal	B-UNK
toxicity	B-UNK
and	O
elevated	B-UNK
alanine	B-CHEMICAL
transaminase	B-UNK
(	O
ALT	O
)	O
concentration	B-UNK
were	O
reported	B-UNK
in	O
12.2	O
%	O
and	O
48.8	O
%	O
of	O
dogs	B-UNK
,	O
respectively	O
.	O
The	O
incidence	B-UNK
of	O
hepatic	B-UNK
failure	B-UNK
was	O
1.2	O
%	O
.	O
CONCLUSIONS	O
:	O
CCNU	O
-	O
associated	B-UNK
toxicity	B-UNK
in	O
dogs	B-UNK
is	O
common	B-UNK
,	O
but	O
is	O
usually	B-UNK
not	O
life	B-UNK
threatening	O
.	O

Neuroactive	O
steroids	B-CHEMICAL
protect	B-UNK
against	O
pilocarpine-	O
and	O
kainic	B-CHEMICAL
acid	I-CHEMICAL
-	O
induced	B-UNK
limbic	O
seizures	B-DISEASE
and	O
status	B-DISEASE
epilepticus	I-DISEASE
in	O
mice	B-UNK
.	O

Several	O
structurally	O
related	B-UNK
metabolites	B-UNK
of	O
progesterone	B-CHEMICAL
(	O
3	O
alpha	B-UNK
-	O
hydroxy	O
pregnane-20-ones	O
)	O
and	O
deoxycorticosterone	O
(	O
3	O
alpha	B-UNK
-	O
hydroxy	O
pregnane-21-diol-20-ones	O
)	O
and	O
their	O
3	O
beta-epimers	O
were	O
evaluated	B-UNK
for	O
protective	B-UNK
activity	B-UNK
against	O
pilocarpine-	O
,	O
kainic	O
acid-	O
and	O
N	B-UNK
-	O
methyl	O
-	O
D	B-UNK
-	O
aspartate	B-UNK
(	O
NMDA)-induced	O
seizures	B-DISEASE
in	O
mice	B-UNK
.	O
Steroids	O
with	O
the	O
3-hydroxy	O
group	B-UNK
in	O
the	O
alpha	B-UNK
-	O
position	O
and	O
5-H	O
in	O
the	O
alpha-	O
or	O
beta-configurations	O
were	O
highly	B-UNK
effective	B-UNK
in	O
protecting	O
against	O
pilocarpine	B-CHEMICAL
(	O
416	O
mg	B-UNK
/	O
kg	B-UNK
,	O
s.c.)-induced	O
limbic	O
motor	B-UNK
seizures	B-DISEASE
and	O
status	B-DISEASE
epilepticus	I-DISEASE
(	O
ED50	O
values	B-UNK
,	O
7.0	B-UNK
-	O
18.7	O
mg	B-UNK
/	O
kg	B-UNK
,	O
i.p	B-UNK
.	O
)	O
.	O
The	O
corresponding	B-UNK
epimers	O
with	O
the	O
3-hydroxy	O
group	B-UNK
in	O
the	O
beta-position	O
were	O
also	O
effective	B-UNK
but	O
less	O
potent	B-UNK
(	O
ED50	O
values	B-UNK
,	O
33.8	O
-	O
63.5	O
,	O
i.p	B-UNK
.	O
)	O
.	O
Although	O
the	O
neuroactive	O
steroids	B-CHEMICAL
were	O
considerably	B-UNK
less	O
potent	B-UNK
than	O
the	O
benzodiazepine	O
clonazepam	B-CHEMICAL
in	O
protecting	O
against	O
pilocarpine	B-CHEMICAL
seizures	B-DISEASE
,	O
steroids	B-CHEMICAL
with	O
the	O
5	O
alpha,3	O
alpha	B-UNK
-	O
configuration	O
had	O
comparable	B-UNK
or	O
higher	B-UNK
protective	B-UNK
index	B-UNK
values	B-UNK
(	O
TD50	O
for	O
motor	B-UNK
impairment	B-UNK
divided	O
by	O
ED50	O
for	O
seizure	B-UNK
protection	B-UNK
)	O
than	O
clonazepam	B-CHEMICAL
,	O
indicating	O
that	O
some	O
neuroactive	O
steroids	B-CHEMICAL
may	O
have	O
lower	B-UNK
relative	B-UNK
toxicity	B-UNK
.	O
Steroids	O
with	O
the	O
5	O
alpha,3	O
alpha-	O
or	O
5	O
beta,3	O
alpha	B-UNK
-	O
configurations	O
also	O
produced	B-UNK
a	O
dose	B-UNK
-	O
dependent	B-UNK
delay	B-UNK
in	O
the	O
onset	B-UNK
of	O
limbic	O
seizures	B-DISEASE
induced	B-UNK
by	O
kainic	B-CHEMICAL
acid	I-CHEMICAL
(	O
32	O
mg	B-UNK
/	O
kg	B-UNK
,	O
s.c	B-UNK
.	O
)	O
,	O
but	O
did	O
not	O
completely	B-UNK
protect	B-UNK
against	O
the	O
seizures	B-DISEASE
.	O
However	O
,	O
when	O
a	O
second	B-UNK
dose	B-UNK
of	O
the	O
steroid	B-UNK
was	O
administered	B-UNK
1	O
hr	B-UNK
after	O
the	O
first	O
dose	B-UNK
,	O
complete	B-UNK
protection	B-UNK
from	O
the	O
kainic	B-CHEMICAL
acid	I-CHEMICAL
-	O
induced	B-UNK
limbic	O
seizures	B-DISEASE
and	O
status	B-DISEASE
epilepticus	I-DISEASE
was	O
obtained	B-UNK
.	O
The	O
steroids	B-CHEMICAL
also	O
caused	B-UNK
a	O
dose	B-UNK
-	O
dependent	B-UNK
delay	B-UNK
in	O
NMDA	O
(	O
257	O
mg	B-UNK
/	O
kg	B-UNK
,	O
s.c.)-induced	O
lethality	B-UNK
,	O
but	O
did	O
not	O
completely	B-UNK
protect	B-UNK
against	O
NMDA	O
seizures	B-DISEASE
or	O
lethality	B-UNK
.	O
We	O
conclude	O
that	O
neuroactive	O
steroids	B-CHEMICAL
are	O
highly	B-UNK
effective	B-UNK
in	O
protecting	O
against	O
pilocarpine-	O
and	O
kainic	B-CHEMICAL
acid	I-CHEMICAL
-	O
induced	B-UNK
seizures	B-DISEASE
and	O
status	B-DISEASE
epilepticus	I-DISEASE
in	O
mice	B-UNK
,	O
and	O
may	O
be	O
of	O
utility	O
in	O
the	O
treatment	B-UNK
of	O
some	O
forms	O
of	O
status	B-DISEASE
epilepticus	I-DISEASE
in	O
humans	O
.	O

The	O
safety	B-UNK
and	O
efficacy	B-UNK
of	O
combination	B-UNK
N	B-UNK
-	O
butyl	O
-	O
deoxynojirimycin	O
(	O
SC-48334	O
)	O
and	O
zidovudine	B-CHEMICAL
in	O
patients	B-UNK
with	O
HIV-1	O
infection	B-UNK
and	O
200	O
-	O
500	O
CD4	B-UNK
cells	B-UNK
/	O
mm3	O
.	O

We	O
conducted	O
a	O
double-blind	B-UNK
,	O
randomized	B-UNK
phase	B-UNK
II	B-UNK
study	B-UNK
to	O
evaluate	B-UNK
the	O
safety	B-UNK
and	O
activity	B-UNK
of	O
combination	B-UNK
therapy	B-UNK
with	O
N	B-UNK
-	O
butyl	O
-	O
deoxynojirimycin	O
(	O
SC-48334	O
)	O
(	O
an	O
alpha	B-UNK
-	O
glucosidase	O
I	O
inhibitor	B-UNK
)	O
and	O
zidovudine	B-CHEMICAL
versus	B-UNK
zidovudine	B-CHEMICAL
alone	O
.	O
Patients	B-UNK
with	O
200	O
to	O
500	O
CD4	B-UNK
cells	B-UNK
/	O
mm3	O
who	O
tolerated	B-UNK
<	O
or	O
=	O
12	O
weeks	B-UNK
of	O
prior	B-UNK
zidovudine	B-CHEMICAL
therapy	B-UNK
received	B-UNK
SC-48334	O
(	O
1000	O
mg	B-UNK
every	O
8	O
h	B-UNK
)	O
and	O
zidovudine	B-CHEMICAL
(	O
100	O
mg	B-UNK
every	O
8	O
h	B-UNK
)	O
or	O
zidovudine	B-CHEMICAL
and	O
placebo	B-UNK
.	O
Sixty	O
patients	B-UNK
received	B-UNK
combination	B-UNK
therapy	B-UNK
and	O
58	O
,	O
zidovudine	B-CHEMICAL
and	O
placebo	B-UNK
.	O
Twenty	O
-	O
three	O
patients	B-UNK
(	O
38	O
%	O
)	O
and	O
15	O
(	O
26	O
%	O
)	O
,	O
in	O
the	O
combination	B-UNK
and	O
zidovudine	B-CHEMICAL
groups	B-UNK
,	O
respectively	O
,	O
discontinued	O
therapy	B-UNK
(	O
p	B-UNK
=	I-UNK
0.15	O
)	O
.	O
The	O
mean	B-UNK
SC-48334	O
steady	O
-	O
state	B-UNK
trough	O
level	B-UNK
(	O
4.04	O
+	O
/-	O
0.99	O
micrograms	B-UNK
/	O
ml	B-UNK
)	O
was	O
below	O
the	O
in	O
vitro	B-UNK
inhibitory	B-UNK
concentration	B-UNK
for	O
human	B-DISEASE
immunodeficiency	I-DISEASE
virus	I-DISEASE
(	O
HIV	O
)	O
.	O
The	O
mean	B-UNK
increase	B-UNK
in	O
CD4	B-UNK
cells	B-UNK
at	B-DISEASE
week	B-UNK
4	O
was	O
73.8	O
cells	B-UNK
/	O
mm3	O
and	O
52.4	O
cells	B-UNK
/	O
mm3	O
for	O
the	O
combination	B-UNK
and	O
zidovudine	B-CHEMICAL
groups	B-UNK
,	O
respectively	O
(	O
p	B-UNK
>	O
0.36	O
)	O
.	O
For	O
patients	B-UNK
with	O
prior	B-UNK
zidovudine	B-CHEMICAL
therapy	B-UNK
,	O
the	O
mean	B-UNK
change	B-UNK
in	O
CD4	B-UNK
cells	B-UNK
in	O
the	O
combination	B-UNK
and	O
zidovudine	B-CHEMICAL
groups	B-UNK
was	O
63.7	O
cells	B-UNK
/	O
mm3	O
and	O
4.9	O
cells	B-UNK
/	O
mm3	O
at	B-DISEASE
week	B-UNK
8	O
and	O
6.8	O
cells	B-UNK
/	O
mm3	O
and	O
-45.1	O
cells	B-UNK
/	O
mm3	O
at	B-DISEASE
week	B-UNK
16	O
,	O
respectively	O
.	O
The	O
number	B-UNK
of	O
patients	B-UNK
with	O
suppression	B-UNK
of	O
HIV	O
p24	O
antigenemia	O
in	O
the	O
combination	B-UNK
and	O
zidovudine	B-CHEMICAL
groups	B-UNK
was	O
six	O
(	O
40	O
%	O
)	O
and	O
two	O
(	O
11	O
%	O
)	O
at	B-DISEASE
week	B-UNK
4	O
(	O
p	B-UNK
=	I-UNK
0.10	O
)	O
and	O
five	O
(	O
45	O
%	O
)	O
and	O
two	O
(	O
14	O
%	O
)	O
at	B-DISEASE
week	B-UNK
24	O
(	O
p	B-UNK
=	I-UNK
0.08	O
)	O
,	O
respectively	O
.	O
Diarrhea	O
,	O
flatulence	B-DISEASE
,	O
abdominal	B-DISEASE
pain	I-DISEASE
,	O
and	O
weight	B-DISEASE
loss	I-DISEASE
were	O
common	B-UNK
for	O
combination	B-UNK
recipients.(ABSTRACT	O
TRUNCATED	B-UNK
AT	O
250	O
WORDS	O
)	O

Recent	B-UNK
preclinical	O
and	O
clinical	B-UNK
studies	B-UNK
with	O
the	O
thymidylate	O
synthase	B-UNK
inhibitor	B-UNK
N10-propargyl-5,8-dideazafolic	O
acid	B-UNK
(	O
CB	O
3717	O
)	O
.	O

CB	O
3717	O
,	O
N10-propargyl-5,8-dideazafolic	O
acid	B-UNK
,	O
is	O
a	O
tight	B-UNK
-	O
binding	B-UNK
inhibitor	B-UNK
of	O
thymidylate	O
synthase	B-UNK
(	O
TS	O
)	O
whose	O
cytotoxicity	O
is	O
mediated	B-UNK
solely	O
through	O
the	O
inhibition	B-UNK
of	O
this	O
enzyme	B-UNK
.	O
Recent	B-UNK
preclinical	O
studies	B-UNK
have	O
focused	O
on	O
the	O
intracellular	B-UNK
formation	B-UNK
of	O
CB	O
3717	O
polyglutamates	O
.	O
Following	O
a	O
12-hour	O
exposure	B-UNK
of	O
L1210	O
cells	B-UNK
to	O
50	O
microM	O
[	O
3H]CB	O
3717	O
,	O
30	O
%	O
of	O
the	O
extractable	O
radioactivity	O
could	O
be	O
accounted	O
for	O
as	O
CB	O
3717	O
tetra-	O
and	O
pentaglutamate	O
,	O
as	O
determined	O
by	O
high	B-UNK
-	O
pressure	B-UNK
liquid	B-UNK
chromatography	O
(	O
HPLC	O
)	O
analyses	B-UNK
.	O
As	O
inhibitors	B-UNK
of	O
isolated	B-UNK
L1210	O
TS	O
,	O
CB	O
3717	O
di-	O
,	O
tri-	O
,	O
tetra-	O
and	O
pentaglutamate	O
are	O
26-	O
,	O
87-	O
,	O
119-	O
and	O
114-fold	O
more	O
potent	B-UNK
than	O
CB	O
3717	O
,	O
respectively	O
,	O
and	O
their	O
formation	B-UNK
may	O
,	O
therefore	O
,	O
be	O
an	O
important	B-UNK
determinant	O
of	O
CB	O
3717	O
cytotoxicity	O
.	O
In	O
early	B-UNK
clinical	B-UNK
studies	B-UNK
with	O
CB	O
3717	O
,	O
activity	B-UNK
has	O
been	O
seen	B-UNK
in	O
breast	B-DISEASE
cancer	I-DISEASE
,	O
ovarian	B-DISEASE
cancer	I-DISEASE
,	O
hepatoma	O
,	O
and	O
mesothelioma	B-DISEASE
.	O
Toxicities	O
included	B-UNK
hepatotoxicity	O
,	O
malaise	O
,	O
and	O
dose	B-UNK
-	O
limiting	B-UNK
nephrotoxicity	B-UNK
.	O
This	O
latter	O
effect	B-UNK
is	O
thought	O
to	O
be	O
due	O
to	O
drug	B-UNK
precipitation	O
within	O
the	O
renal	B-UNK
tubule	B-UNK
as	O
a	O
result	B-UNK
of	O
the	O
poor	B-UNK
solubility	O
of	O
CB	O
3717	O
under	O
acidic	O
conditions	B-UNK
.	O
In	O
an	O
attempt	O
to	O
overcome	O
this	O
problem	B-UNK
,	O
a	O
clinical	B-UNK
trial	B-UNK
of	O
CB	O
3717	O
administered	B-UNK
with	O
alkaline	B-UNK
diuresis	B-UNK
is	O
under	O
way	O
.	O
Preliminary	B-UNK
results	B-UNK
at	B-DISEASE
400	O
and	O
500	O
mg	B-UNK
/	O
m2	O
suggest	B-UNK
that	O
a	O
reduction	B-UNK
in	O
nephrotoxicity	B-UNK
may	O
have	O
been	O
achieved	B-UNK
with	O
only	O
1	O
instance	O
of	O
renal	B-UNK
toxicity	B-UNK
in	O
10	O
patients	B-UNK
.	O
Hepatotoxicity	O
and	O
malaise	O
are	O
again	O
the	O
most	O
frequent	B-UNK
side	O
effects	B-UNK
.	O
Evidence	O
of	O
antitumor	B-UNK
activity	B-UNK
has	O
been	O
seen	B-UNK
in	O
3	O
patients	B-UNK
.	O
Pharmacokinetic	O
investigations	B-UNK
have	O
shown	B-UNK
that	O
alkaline	B-UNK
diuresis	B-UNK
does	O
not	O
alter	B-UNK
CB	O
3717	O
plasma	B-UNK
levels	B-UNK
or	O
urinary	B-UNK
excretion	B-UNK
and	O
that	O
satisfactory	O
urinary	B-UNK
alkalinization	O
can	O
be	O
readily	O
achieved	B-UNK
.	O

Ethopropazine	O
and	O
benztropine	B-CHEMICAL
in	O
neuroleptic	B-UNK
-	O
induced	B-UNK
parkinsonism	B-DISEASE
.	O

In	O
a	O
12-week	O
controlled	B-UNK
study	B-UNK
ethopropazine	O
was	O
compared	B-UNK
to	O
benztropine	B-CHEMICAL
in	O
the	O
treatment	B-UNK
of	O
parkinsonism	B-DISEASE
induced	B-UNK
by	O
fluphenazine	B-CHEMICAL
enanthate	I-CHEMICAL
in	O
60	O
schizophrenic	B-UNK
outpatients	O
.	O
Ethopropazine	O
and	O
benztropine	B-CHEMICAL
were	O
found	B-UNK
to	O
be	O
equally	O
effective	B-UNK
in	O
controlling	O
parkinsonian	B-UNK
symptoms	B-UNK
and	O
were	O
as	O
efficacious	B-UNK
as	O
procyclidine	B-CHEMICAL
,	O
their	O
previous	B-UNK
antiparkinsonian	B-UNK
drug	B-UNK
.	O
However	O
,	O
benztropine	B-CHEMICAL
treated	B-UNK
patients	B-UNK
had	O
a	O
significant	B-UNK
increase	B-UNK
in	O
tardive	B-DISEASE
dyskinesia	I-DISEASE
compared	B-UNK
to	O
their	O
condition	B-UNK
during	O
procyclindine	O
treatment	B-UNK
,	O
and	O
significantly	B-UNK
more	O
anxiety	B-DISEASE
and	O
depression	B-DISEASE
than	O
ethopropazine	O
treated	B-UNK
patients	B-UNK
.	O
This	O
suggests	B-UNK
that	O
benztropine	B-CHEMICAL
is	O
not	O
the	O
anticholinergic	B-UNK
drug	B-UNK
of	O
choice	O
in	O
the	O
treatment	B-UNK
of	O
neuroleptic	B-UNK
-	O
induced	B-UNK
parkinsonian	B-UNK
symptoms	B-UNK
,	O
because	O
of	O
its	O
more	O
toxic	B-UNK
central	B-UNK
and	O
peripheral	B-UNK
atropinic	O
effect	B-UNK
.	O

Effect	O
of	O
alpha	B-CHEMICAL
-	I-CHEMICAL
tocopherol	I-CHEMICAL
and	O
deferoxamine	B-CHEMICAL
on	O
methamphetamine	B-CHEMICAL
-	O
induced	B-UNK
neurotoxicity	B-UNK
.	O

Methamphetamine	O
(	O
MA)-induced	O
dopaminergic	B-UNK
neurotoxicity	B-UNK
is	O
believed	O
to	O
be	O
associated	B-UNK
with	O
the	O
increased	B-UNK
formation	B-UNK
of	O
free	B-CHEMICAL
radicals	I-CHEMICAL
.	O
This	O
study	B-UNK
examined	B-UNK
the	O
effect	B-UNK
of	O
alpha	B-CHEMICAL
-	I-CHEMICAL
tocopherol	I-CHEMICAL
(	O
alpha	B-UNK
-	O
TC	O
)	O
,	O
a	O
scavenger	O
of	O
reactive	B-CHEMICAL
oxygen	I-CHEMICAL
species	I-CHEMICAL
,	O
and	O
deferoxamine	B-CHEMICAL
(	O
DFO	B-UNK
)	O
,	O
an	O
iron	B-CHEMICAL
chelator	O
,	O
on	O
the	O
MA	O
-	O
induced	B-UNK
neurotoxicity	B-UNK
.	O
Male	B-UNK
rats	B-UNK
were	O
treated	B-UNK
with	O
MA	O
(	O
10	O
mg	B-UNK
/	O
kg	B-UNK
,	O
every	O
2	B-DISEASE
h	B-UNK
for	O
four	O
injections	B-UNK
)	O
.	O
The	O
rat	B-UNK
received	B-UNK
either	O
alpha	B-UNK
-	O
TC	O
(	O
20	O
mg	B-UNK
/	O
kg	B-UNK
)	O
intraperitoneally	B-UNK
for	O
3	O
days	B-UNK
and	O
30	O
min	B-UNK
prior	B-UNK
to	O
MA	O
administration	B-UNK
or	O
DFO	B-UNK
(	O
50	O
mg	B-UNK
/	O
kg	B-UNK
)	O
subcutaneously	O
30	O
min	B-UNK
before	O
MA	O
administration	B-UNK
.	O
The	O
concentrations	B-UNK
of	O
dopamine	B-CHEMICAL
(	O
DA	B-UNK
)	O
,	O
serotonin	B-CHEMICAL
and	O
their	O
metabolites	B-UNK
decreased	B-UNK
significantly	B-UNK
after	O
MA	O
administration	B-UNK
,	O
which	O
was	O
inhibited	B-UNK
by	O
the	O
alpha	B-UNK
-	O
TC	O
and	O
DFO	B-UNK
pretreatment	B-UNK
.	O
alpha	B-UNK
-	O
TC	O
and	O
DFO	B-UNK
attenuated	B-UNK
the	O
MA	O
-	O
induced	B-UNK
hyperthermia	B-DISEASE
as	O
well	O
as	O
the	O
alterations	B-UNK
in	O
the	O
locomotor	B-UNK
activity	B-UNK
.	O
The	O
level	B-UNK
of	O
lipid	B-UNK
peroxidation	B-UNK
was	O
higher	B-UNK
and	O
the	O
reduced	B-UNK
glutathione	B-CHEMICAL
concentration	B-UNK
was	O
lower	B-UNK
in	O
the	O
MA	O
-	O
treated	B-UNK
rats	B-UNK
.	O
These	O
changes	B-UNK
were	O
significantly	B-UNK
attenuated	B-UNK
by	O
alpha	B-UNK
-	O
TC	O
and	O
DFO	B-UNK
.	O
This	O
suggests	B-UNK
that	O
alpha	B-UNK
-	O
TC	O
and	O
DFO	B-UNK
ameliorate	O
the	O
MA	O
-	O
induced	B-UNK
neuronal	B-UNK
damage	B-UNK
by	O
decreasing	B-UNK
the	O
level	B-UNK
of	O
oxidative	B-UNK
stress	B-UNK
.	O

Use	O
of	O
dexamethasone	B-CHEMICAL
with	O
mesna	B-CHEMICAL
for	O
the	O
prevention	O
of	O
ifosfamide	B-CHEMICAL
-	O
induced	B-UNK
hemorrhagic	B-UNK
cystitis	B-DISEASE
.	O

AIM	O
:	O
Hemorrhagic	O
cystitis	B-DISEASE
(	O
HC	O
)	O
is	O
a	O
limiting	B-UNK
side	O
-	O
effect	B-UNK
of	O
chemotherapy	B-UNK
with	O
ifosfamide	B-CHEMICAL
(	O
IFS	O
)	O
.	O
In	O
the	O
study	B-UNK
presented	B-UNK
here	O
,	O
we	O
investigated	B-UNK
the	O
use	B-UNK
of	O
dexamethasone	B-CHEMICAL
in	O
combination	B-UNK
with	O
mesna	B-CHEMICAL
for	O
the	O
prevention	O
of	O
IFS	O
-	O
induced	B-UNK
HC	O
.	O
METHODS	O
:	O
Male	B-UNK
Wistar	I-UNK
rats	B-UNK
(	O
150	O
-	O
200	O
g	B-UNK
;	O
6	O
rats	B-UNK
per	O
group	B-UNK
)	O
were	O
treated	B-UNK
with	O
saline	B-UNK
or	O
mesna	B-CHEMICAL
5	O
min	B-UNK
(	O
i.p	B-UNK
.	O
)	O
before	O
and	O
2	B-DISEASE
and	O
6	O
h	B-UNK
after	O
(	O
v.o	O
.	O
)	O
administration	B-UNK
of	O
IFS	O
.	O
One	O
,	O
two	O
or	O
three	O
doses	B-UNK
of	O
mesna	B-CHEMICAL
were	O
replaced	O
with	O
dexamethasone	B-CHEMICAL
alone	O
or	O
with	O
dexamethasone	B-CHEMICAL
plus	B-UNK
mesna	B-CHEMICAL
.	O
Cystitis	O
was	O
evaluated	B-UNK
24	O
h	B-UNK
after	O
its	O
induction	B-UNK
by	O
the	O
changes	B-UNK
in	O
bladder	B-UNK
wet	O
weight	B-UNK
and	O
by	O
macroscopic	O
and	O
microscopic	B-UNK
analysis	B-UNK
.	O
RESULTS	B-UNK
:	O
The	O
replacement	O
of	O
the	O
last	O
dose	B-UNK
or	O
the	O
last	O
two	O
doses	B-UNK
of	O
mesna	B-CHEMICAL
with	O
dexamethasone	B-CHEMICAL
reduced	B-UNK
the	O
increase	B-UNK
in	O
bladder	B-UNK
wet	O
weight	B-UNK
induced	B-UNK
by	O
IFS	O
by	O
84.79	O
%	O
and	O
89.13	O
%	O
,	O
respectively	O
.	O
In	O
addition	O
,	O
it	O
almost	O
abolished	B-UNK
the	O
macroscopic	O
and	O
microscopic	B-UNK
alterations	B-UNK
induced	B-UNK
by	O
IFS	O
.	O
Moreover	O
,	O
the	O
addition	O
of	O
dexamethasone	B-CHEMICAL
to	O
the	O
last	O
two	O
doses	B-UNK
of	O
mesna	B-CHEMICAL
was	O
more	O
efficient	O
than	O
three	O
doses	B-UNK
of	O
mesna	B-CHEMICAL
alone	O
when	O
evaluated	B-UNK
microscopically	O
.	O
CONCLUSION	O
:	O
Dexamethasone	O
in	O
combination	B-UNK
with	O
mesna	B-CHEMICAL
was	O
efficient	O
in	O
blocking	B-UNK
IFS	O
-	O
induced	B-UNK
HC	O
.	O
However	O
,	O
the	O
replacement	O
of	O
last	O
two	O
doses	B-UNK
of	O
mesna	B-CHEMICAL
with	O
saline	B-UNK
or	O
all	O
of	O
the	O
mesna	B-CHEMICAL
doses	B-UNK
with	O
dexamethasone	B-CHEMICAL
did	O
not	O
prevent	B-UNK
HC	O
.	O

Behavioral	B-UNK
effects	B-UNK
of	O
MK-801	O
on	O
reserpine	B-CHEMICAL
-	O
treated	B-UNK
mice	B-UNK
.	O

The	O
effects	B-UNK
of	O
dizocilpine	O
(	O
MK-801	O
)	O
,	O
a	O
noncompetitive	O
N	B-UNK
-	O
methyl	O
-	O
D	B-UNK
-	O
aspartate	B-UNK
(	O
NMDA	O
)	O
receptor	B-UNK
antagonist	I-UNK
,	O
were	O
studied	B-UNK
on	O
dopamine	B-CHEMICAL
-	O
related	B-UNK
behaviors	B-UNK
induced	B-UNK
by	O
reserpine	B-CHEMICAL
treatments	B-UNK
.	O
This	O
study	B-UNK
focuses	O
on	O
behavioral	B-UNK
syndromes	O
that	O
may	O
used	O
as	O
models	B-UNK
for	O
Parkinson'	O
s	O
disease	B-DISEASE
,	O
or	O
tardive	B-DISEASE
dyskinesia	I-DISEASE
,	O
and	O
its	O
response	B-UNK
after	O
glutamatergic	B-UNK
blockage	O
.	O
Reserpine	O
(	O
1	O
mg	B-UNK
/	O
kg	B-UNK
)	O
,	O
administered	B-UNK
once	O
every	O
other	O
day	B-UNK
for	O
4	O
days	B-UNK
,	O
produced	B-UNK
increases	B-UNK
in	O
orofacial	B-UNK
dyskinesia	B-DISEASE
,	O
tongue	B-DISEASE
protrusion	O
and	O
vacuous	B-UNK
chewing	B-UNK
in	O
mice	B-UNK
,	O
which	O
are	O
signs	B-UNK
indicative	O
of	O
tardive	B-DISEASE
dyskinesia	I-DISEASE
.	O
Reserpine	O
also	O
produced	B-UNK
tremor	B-DISEASE
and	O
catalepsy	B-DISEASE
,	O
which	O
are	O
signs	B-UNK
suggestive	O
of	O
Parkinson'	O
s	O
disease	B-DISEASE
.	O
MK-801	O
(	O
0.1	B-UNK
mg	B-UNK
/	O
kg	B-UNK
)	O
,	O
administered	B-UNK
30	O
min	B-UNK
before	O
the	O
observation	B-UNK
test	B-UNK
,	O
prevented	B-UNK
the	O
vacuous	B-UNK
chewing	B-UNK
movements	B-UNK
,	O
tongue	B-DISEASE
protrusions	O
and	O
catalepsy	B-DISEASE
induced	B-UNK
by	O
reserpine	B-CHEMICAL
.	O
However	O
,	O
MK-801	O
injection	B-UNK
produced	B-UNK
a	O
significant	B-UNK
increase	B-UNK
of	O
tremor	B-DISEASE
in	O
reserpine	B-CHEMICAL
-	O
treated	B-UNK
mice	B-UNK
.	O
Reserpine	O
(	O
1	O
mg	B-UNK
/	O
kg	B-UNK
)	O
,	O
administered	B-UNK
90	O
min	B-UNK
before	O
the	O
test	B-UNK
and	O
followed	B-UNK
by	O
apomophine	O
injection	B-UNK
(	O
0.1	B-UNK
mg	B-UNK
/	O
kg	B-UNK
)	O
5	O
min	B-UNK
before	O
the	O
test	B-UNK
,	O
did	O
not	O
produce	B-UNK
oral	B-UNK
dyskinesia	B-DISEASE
in	O
mice	B-UNK
.	O
On	O
the	O
other	O
hand	B-DISEASE
,	O
reserpine	B-CHEMICAL
induced	B-UNK
increases	B-UNK
in	O
tremor	B-DISEASE
and	O
catalepsy	B-DISEASE
compared	B-UNK
to	O
control	B-UNK
mice	B-UNK
.	O
MK-801	O
(	O
0.1	B-UNK
mg	B-UNK
/	O
kg	B-UNK
)	O
administration	B-UNK
attenuated	B-UNK
the	O
catalepsy	B-DISEASE
and	O
tremor	B-DISEASE
induced	B-UNK
by	O
reserpine	B-CHEMICAL
.	O
Pretreatment	O
with	O
reserpine	B-CHEMICAL
(	O
1	O
mg	B-UNK
/	O
kg	B-UNK
)	O
24	O
h	B-UNK
before	O
the	O
observation	B-UNK
test	B-UNK
produced	B-UNK
increases	B-UNK
in	O
vacuous	B-UNK
chewing	B-UNK
movements	B-UNK
and	O
tongue	B-DISEASE
protrusion	O
,	O
as	O
well	O
as	O
increases	B-UNK
in	O
tremor	B-DISEASE
and	O
catalepsy	B-DISEASE
,	O
whereas	O
MK-801	O
(	O
0.1	B-UNK
mg	B-UNK
/	O
kg	B-UNK
)	O
injection	B-UNK
90	O
min	B-UNK
before	O
the	O
test	B-UNK
reversed	B-UNK
the	O
effects	B-UNK
of	O
reserpine	B-CHEMICAL
.	O
These	O
results	B-UNK
show	O
that	O
reserpine	B-CHEMICAL
produces	B-UNK
different	B-UNK
and	O
abnormal	B-UNK
movements	B-UNK
,	O
which	O
are	O
related	B-UNK
to	O
dose	B-UNK
and	O
schedule	B-UNK
employed	B-UNK
and	O
can	O
be	O
considered	B-UNK
as	O
parkinsonian	B-UNK
-	O
like	B-UNK
and	O
tardive	O
dsykinesia	O
signs	B-UNK
.	O
The	O
glutamatergic	B-UNK
blockage	O
produced	B-UNK
by	O
NMDA	O
can	O
restore	O
these	O
signs	B-UNK
,	O
such	O
as	O
vacuous	B-UNK
chewing	B-UNK
movements	B-UNK
,	O
tongue	B-DISEASE
protrusions	O
,	O
catalepsy	B-DISEASE
and	O
tremor	B-DISEASE
according	B-UNK
to	O
the	O
employed	B-UNK
model	B-UNK
.	O

Effect	O
of	O
glyceryl	B-UNK
trinitrate	B-UNK
on	O
the	O
sphincter	O
of	O
Oddi	O
spasm	B-DISEASE
evoked	O
by	O
prostigmine	O
-	O
morphine	B-CHEMICAL
administration	B-UNK
.	O

OBJECTIVE	O
:	O
In	O
this	O
study	B-UNK
the	O
effect	B-UNK
of	O
glyceryl	B-UNK
trinitrate	B-UNK
on	O
the	O
prostigmine	O
-	O
morphine	B-CHEMICAL
-	O
induced	B-UNK
sphincter	O
of	O
Oddi	O
spasm	B-DISEASE
was	O
evaluated	B-UNK
in	O
nine	O
female	B-UNK
patients	B-UNK
with	O
sphincter	O
of	O
Oddi	O
dyskinesia	B-DISEASE
.	O
METHOD	O
:	O
Sphincter	O
of	O
Oddi	O
spasm	B-DISEASE
was	O
induced	B-UNK
by	O
prostigmine	O
-	O
morphine	B-CHEMICAL
administration	B-UNK
(	O
0.5	B-UNK
mg	I-UNK
prostigmine	O
intramuscularly	O
and	O
10	O
mg	B-UNK
morphine	B-CHEMICAL
subcutaneously	O
)	O
and	O
visualized	O
by	O
quantitative	B-UNK
hepatobiliary	O
scintigraphy	O
.	O
The	O
entire	B-UNK
procedure	B-UNK
was	O
repeated	B-UNK
during	O
glyceryl	B-UNK
trinitrate	B-UNK
infusion	B-UNK
(	O
Nitrolingual	O
1	O
microg	B-UNK
/	O
kg	B-UNK
/	O
min	B-UNK
for	O
120	O
min	B-UNK
)	O
.	O
RESULTS	B-UNK
:	O
Prostigmine	O
-	O
morphine	B-CHEMICAL
provocation	B-UNK
caused	B-UNK
significant	B-UNK
increases	B-UNK
in	O
the	O
time	B-UNK
to	O
peak	B-UNK
activity	B-UNK
(	O
Tmax	O
)	O
over	O
the	O
hepatic	B-UNK
hilum	O
(	O
HH	O
:	O
34.33	O
+	O
/-	O
5.05	O
vs	B-UNK
.	O
22.77	O
+	O
/-	O
3.26	O
)	O
and	O
the	O
common	B-UNK
bile	B-UNK
duct	B-UNK
(	O
CBD	O
:	O
60.44	O
+	O
/-	O
5.99	O
vs	B-UNK
.	O
40.0	O
+	O
/-	O
2.88	O
)	O
and	O
in	O
the	O
half	O
-	O
time	B-UNK
of	O
excretion	B-UNK
(	O
T1/2	O
)	O
over	O
the	O
liver	B-DISEASE
parenchyma	O
(	O
LP	O
:	O
120.04	O
+	O
/-	O
16.01	O
vs	B-UNK
.	O
27.37	O
+	O
/-	O
2.19	O
)	O
,	O
HH	O
(	O
117.61	O
+	O
/-	O
14.71	O
vs	B-UNK
.	O
31.85	O
+	O
/-	O
3.99	O
)	O
and	O
CBD	O
(	O
158.11	O
+	O
/-	O
9.18	O
vs	B-UNK
.	O
40.1	O
+	O
/-	O
6.24	O
)	O
,	O
indicating	O
a	O
complete	B-UNK
spasm	B-DISEASE
at	B-DISEASE
the	O
level	B-UNK
of	O
the	O
sphincter	O
of	O
Oddi	O
.	O
Glyceryl	O
trinitrate	B-UNK
infusion	B-UNK
completely	B-UNK
normalized	B-UNK
the	O
prostigmine	O
-	O
morphine	B-CHEMICAL
-	O
induced	B-UNK
alterations	B-UNK
in	O
these	O
quantitative	B-UNK
parameters	B-UNK
(	O
TmaX	O
over	O
the	O
LP	O
:	O
11.33	O
+	O
/-	O
1.13	O
;	O
over	O
the	O
HH	O
:	O
18.88	O
+	O
/-	O
1.48	O
;	O
and	O
over	O
the	O
CBD	O
:	O
36.22	O
+	O
/-	O
1.92	O
;	O
and	O
T1/2	O
over	O
the	O
LP	O
:	O
28.21	O
+	O
/-	O
1.83	O
;	O
over	O
the	O
HH	O
:	O
33.42	O
+	O
/-	O
3.10	O
;	O
and	O
over	O
the	O
CBD	O
:	O
41.66	O
+	O
/-	O
6.33	O
)	O
,	O
suggesting	B-UNK
an	O
effective	B-UNK
sphincter	O
-	O
relaxing	O
effect	B-UNK
of	O
glyceryl	B-UNK
trinitrate	B-UNK
.	O
CONCLUSION	O
:	O
These	O
results	B-UNK
provide	B-UNK
the	O
first	O
evidence	B-UNK
of	O
the	O
effectiveness	O
of	O
glyceryl	B-UNK
trinitrate	B-UNK
on	O
the	O
morphine	B-CHEMICAL
-	O
induced	B-UNK
sphincter	O
of	O
Oddi	O
spasm	B-DISEASE
in	O
humans	O
.	O
Since	O
glyceryl	B-UNK
trinitrate	B-UNK
is	O
able	O
to	O
overcome	O
even	O
the	O
drastic	O
effect	B-UNK
of	O
morphine	B-CHEMICAL
,	O
it	O
might	O
be	O
of	O
relevance	O
in	O
the	O
treatment	B-UNK
of	O
sphincter	O
of	O
Oddi	O
dyskinesia	B-DISEASE
.	O

Effects	O
of	O
acute	B-UNK
steroid	B-UNK
administration	B-UNK
on	O
ventilatory	O
and	O
peripheral	B-UNK
muscles	B-UNK
in	O
rats	B-UNK
.	O

Occasional	O
case	B-UNK
reports	B-UNK
have	O
shown	B-UNK
that	O
acute	B-UNK
myopathy	B-DISEASE
may	O
occur	O
in	O
patients	B-UNK
treated	B-UNK
with	O
massive	O
doses	B-UNK
of	O
corticosteroids	O
.	O
The	O
mechanism	B-UNK
of	O
this	O
myopathy	B-DISEASE
is	O
poorly	B-UNK
understood	B-UNK
.	O
Therefore	O
,	O
60	O
male	B-UNK
rats	B-UNK
were	O
randomly	B-UNK
assigned	B-UNK
to	O
receive	B-UNK
daily	B-UNK
injection	B-UNK
of	O
saline	B-UNK
(	O
C	B-UNK
)	O
,	O
methylprednisolone	B-CHEMICAL
(	O
M	O
)	O
,	O
or	O
triamcinolone	B-CHEMICAL
(	O
T	B-UNK
)	O
80	O
mg	B-UNK
/	O
kg	B-UNK
/	O
d	B-UNK
for	O
5	O
d.	B-UNK
Nutritional	O
intake	B-UNK
,	O
measured	B-UNK
daily	B-UNK
in	O
15	O
animals	B-UNK
,	O
showed	B-UNK
a	O
significant	B-UNK
reduction	B-UNK
of	O
food	B-UNK
intake	B-UNK
in	O
the	O
steroid	B-UNK
-	O
treated	B-UNK
groups	B-UNK
(	O
-50	O
and	O
-79	O
%	O
in	O
M	O
and	O
T	B-UNK
,	O
respectively	O
)	O
.	O
This	O
was	O
associated	B-UNK
with	O
a	O
similar	B-UNK
loss	B-UNK
in	O
body	B-DISEASE
weight	I-DISEASE
.	O
In	O
the	O
45	O
remaining	B-UNK
animals	B-UNK
,	O
diaphragm	B-DISEASE
contractility	O
and	O
histopathologic	O
features	B-UNK
of	O
several	O
muscles	B-UNK
were	O
studied	B-UNK
.	O
Weights	O
of	O
respiratory	B-UNK
and	O
peripheral	B-UNK
muscles	B-UNK
were	O
similarly	O
decreased	B-UNK
after	O
steroid	B-UNK
treatment	B-UNK
.	O
Maximal	O
twitches	O
of	O
the	O
diaphragm	B-DISEASE
were	O
lower	B-UNK
in	O
the	O
C	B-UNK
group	B-UNK
(	O
653	O
+	O
/-	O
174	O
g	B-UNK
/	O
cm(2	O
)	O
)	O
than	O
in	O
the	O
M	O
group	B-UNK
(	O
837	O
+	O
/-	O
171	O
g	B-UNK
/	O
cm(2	O
)	O
;	O
p	B-UNK
<	I-UNK
0.05	O
)	O
and	O
the	O
T	B-UNK
group	B-UNK
(	O
765	O
+	O
/-	O
145	O
g	B-UNK
/	O
cm(2	O
)	O
,	O
NS	O
)	O
.	O
Half	O
-	O
relaxation	O
time	B-UNK
was	O
prolonged	B-UNK
in	O
both	O
steroid	B-UNK
groups	B-UNK
,	O
and	O
time	B-UNK
to	O
peak	B-UNK
tension	O
was	O
longer	B-UNK
with	O
M	O
,	O
whereas	O
tetanic	B-UNK
tensions	B-UNK
were	O
similar	B-UNK
.	O
Steroid	B-UNK
treatment	B-UNK
also	O
induced	B-UNK
a	O
leftward	O
shift	O
of	O
the	O
force	B-UNK
-	O
frequency	B-UNK
curve	O
at	B-DISEASE
25	O
and	O
50	O
Hz	O
when	O
compared	B-UNK
with	O
saline	B-UNK
treatment	B-UNK
(	O
p	B-UNK
<	I-UNK
0.05	O
)	O
.	O
ATPase	O
staining	B-UNK
of	O
the	O
diaphragm	B-DISEASE
,	O
scalenus	O
medius	O
,	O
and	O
gastrocnemius	B-UNK
showed	B-UNK
type	B-UNK
IIb	B-UNK
fiber	O
atrophy	B-DISEASE
in	O
the	O
steroid	B-UNK
groups	B-UNK
and	O
also	O
diaphragmatic	O
type	B-UNK
IIa	O
atrophy	B-DISEASE
with	O
T	B-UNK
,	O
whereas	O
histologic	B-UNK
examinations	B-UNK
revealed	B-UNK
a	O
normal	B-UNK
muscular	B-UNK
pattern	B-UNK
with	O
absence	B-UNK
of	O
necrosis	B-DISEASE
.	O
Finally	O
,	O
a	O
pair	O
-	O
fed	B-UNK
(	O
PF	O
)	O
study	B-UNK
,	O
performed	B-UNK
in	O
18	O
rats	B-UNK
(	O
C	B-UNK
,	O
T	B-UNK
,	O
and	O
PF	O
)	O
,	O
showed	B-UNK
that	O
muscle	B-UNK
atrophy	B-DISEASE
was	O
considerably	B-UNK
less	O
pronounced	O
in	O
PF	O
animals	B-UNK
than	O
in	O
T	B-UNK
-	O
treated	B-UNK
animals	B-UNK
.	O
We	O
conclude	O
that	O
(	O
1	O
)	O
short	B-UNK
-	O
term	B-UNK
treatment	B-UNK
with	O
massive	O
doses	B-UNK
of	O
steroids	B-CHEMICAL
induced	B-UNK
severe	B-UNK
respiratory	B-UNK
and	O
limb	B-UNK
muscle	B-UNK
wasting	O
;	O
(	O
2	B-DISEASE
)	O
both	O
types	O
of	O
steroids	B-CHEMICAL
induced	B-UNK
predominantly	B-UNK
type	B-UNK
IIb	B-UNK
atrophy	B-DISEASE
,	O
resulting	B-UNK
in	O
the	O
expected	O
alterations	B-UNK
in	O
diaphragm	B-DISEASE
contractile	B-UNK
properties	B-UNK
;	O
(	O
3	O
)	O
neither	O
steroid	B-UNK
caused	B-UNK
muscle	B-UNK
necrosis	B-DISEASE
;	O
(	O
4	O
)	O
type	B-UNK
IIb	B-UNK
atrophy	B-DISEASE
was	O
not	O
caused	B-UNK
by	O
acute	B-UNK
nutritional	O
deprivation	B-UNK
alone	O
.	O

Refractory	O
cardiogenic	B-DISEASE
shock	I-DISEASE
and	O
complete	B-UNK
heart	B-DISEASE
block	I-DISEASE
after	O
verapamil	B-CHEMICAL
SR	O
and	O
metoprolol	B-CHEMICAL
treatment	B-UNK
.	O
A	O
case	B-UNK
report	B-UNK
.	O

A	O
seventy	O
-	O
eight	O
-	O
year	B-UNK
-	O
old	B-UNK
woman	B-UNK
presented	B-UNK
with	O
complete	B-UNK
heart	B-DISEASE
block	I-DISEASE
and	O
refractory	B-UNK
hypotension	B-DISEASE
two	O
days	B-UNK
after	O
a	O
therapeutic	B-UNK
dose	B-UNK
of	O
sustained	B-UNK
-	O
release	B-UNK
verapamil	B-CHEMICAL
with	O
concomitant	B-UNK
use	B-UNK
of	O
metoprolol	B-CHEMICAL
.	O
The	O
patient	B-UNK
continued	B-UNK
to	O
remain	B-UNK
hypotensive	B-UNK
with	O
complete	B-UNK
heart	B-DISEASE
block	I-DISEASE
,	O
even	O
with	O
multiple	B-UNK
uses	O
of	O
intravenous	B-UNK
atropine	B-CHEMICAL
as	O
well	O
as	O
high	B-UNK
doses	B-UNK
of	O
pressor	B-UNK
agents	B-UNK
such	O
as	O
dopamine	B-CHEMICAL
and	O
dobutamine	B-CHEMICAL
.	O
However	O
,	O
shortly	B-UNK
after	O
the	O
use	B-UNK
of	O
intravenous	B-UNK
calcium	B-CHEMICAL
chloride	I-CHEMICAL
,	O
the	O
refractory	B-UNK
hypotension	B-DISEASE
and	O
complete	B-UNK
heart	B-DISEASE
block	I-DISEASE
resolved	B-UNK
.	O

A	O
phase	B-UNK
I	O
clinical	B-UNK
study	B-UNK
of	O
the	O
antipurine	O
antifolate	O
lometrexol	B-CHEMICAL
(	O
DDATHF	O
)	O
given	B-UNK
with	O
oral	B-UNK
folic	B-CHEMICAL
acid	I-CHEMICAL
.	O

Lometrexol	O
is	O
an	O
antifolate	O
which	O
inhibits	O
glycinamide	B-CHEMICAL
ribonucleotide	I-CHEMICAL
formyltransferase	O
(	O
GARFT	O
)	O
,	O
an	O
enzyme	B-UNK
essential	O
for	O
de	B-UNK
novo	B-UNK
purine	B-CHEMICAL
synthesis	O
.	O
Extensive	O
experimental	B-UNK
and	O
limited	O
clinical	B-UNK
data	B-UNK
have	O
shown	B-UNK
that	O
lometrexol	B-CHEMICAL
has	O
activity	B-UNK
against	O
tumours	O
which	O
are	O
refractory	B-UNK
to	O
other	O
drugs	B-UNK
,	O
notably	O
methotrexate	B-CHEMICAL
.	O
However	O
,	O
the	O
initial	B-UNK
clinical	B-UNK
development	B-UNK
of	O
lometrexol	B-CHEMICAL
was	O
curtailed	O
because	O
of	O
severe	B-UNK
and	O
cumulative	B-UNK
antiproliferative	O
toxicities	B-UNK
.	O
Preclinical	O
murine	B-UNK
studies	B-UNK
demonstrated	I-UNK
that	O
the	O
toxicity	B-UNK
of	O
lometrexol	B-CHEMICAL
can	O
be	O
prevented	B-UNK
by	O
low	B-UNK
dose	B-UNK
folic	B-CHEMICAL
acid	I-CHEMICAL
administration	B-UNK
,	O
i.e	O
.	O
for	O
7	O
days	B-UNK
prior	B-UNK
to	O
and	O
7	O
days	B-UNK
following	B-UNK
a	O
single	B-UNK
bolus	B-UNK
dose	B-UNK
.	O
This	O
observation	B-UNK
prompted	O
a	O
Phase	O
I	O
clinical	B-UNK
study	B-UNK
of	O
lometrexol	B-CHEMICAL
given	B-UNK
with	O
folic	B-CHEMICAL
acid	I-CHEMICAL
supplementation	B-UNK
which	O
has	O
confirmed	B-UNK
that	O
the	O
toxicity	B-UNK
of	O
lometrexol	B-CHEMICAL
can	O
be	O
markedly	B-UNK
reduced	B-UNK
by	O
folic	B-CHEMICAL
acid	I-CHEMICAL
supplementation	B-UNK
.	O
Thrombocytopenia	O
and	O
mucositis	B-DISEASE
were	O
the	O
major	B-UNK
toxicities	B-UNK
.	O
There	O
was	O
no	O
clear	B-UNK
relationship	B-UNK
between	O
clinical	B-UNK
toxicity	B-UNK
and	O
the	O
extent	B-UNK
of	O
plasma	B-UNK
folate	B-UNK
elevation	B-UNK
.	O
Associated	O
studies	B-UNK
demonstrated	I-UNK
that	O
lometrexol	B-CHEMICAL
plasma	B-UNK
pharmacokinetics	O
were	O
not	O
altered	B-UNK
by	O
folic	B-CHEMICAL
acid	I-CHEMICAL
administration	B-UNK
indicating	O
that	O
supplementation	B-UNK
is	O
unlikely	O
to	O
reduce	B-UNK
toxicity	B-UNK
by	O
enhancing	B-UNK
lometrexol	B-CHEMICAL
plasma	B-UNK
clearance	B-UNK
.	O
The	O
work	B-UNK
described	B-UNK
in	O
this	O
report	B-UNK
has	O
identified	B-UNK
for	O
the	O
first	O
time	B-UNK
a	O
clinically	B-UNK
acceptable	O
schedule	B-UNK
for	O
the	O
administration	B-UNK
of	O
a	O
GARFT	O
inhibitor	B-UNK
.	O
This	O
information	B-UNK
will	O
facilitate	O
the	O
future	B-UNK
evaluation	B-UNK
of	O
this	O
class	O
of	O
compounds	B-UNK
in	O
cancer	B-UNK
therapy	B-UNK
.	O

Involvement	O
of	O
the	O
mu	O
-	O
opiate	B-UNK
receptor	B-UNK
in	O
peripheral	B-UNK
analgesia	O
.	O

The	O
intradermal	O
injection	B-UNK
of	O
mu	O
(	O
morphine	B-CHEMICAL
,	O
Tyr	O
-	O
D	B-UNK
-	O
Ala	O
-	O
Gly	O
-	O
NMe	O
-	O
Phe	O
-	O
Gly	O
-	O
ol	O
and	O
morphiceptin	B-CHEMICAL
)	O
,	O
kappa	O
(	O
trans-3,4-dichloro	O
-	O
N	B-UNK
-	O
methyl	O
-	O
N[2-(1-pyrrolidinyl	O
)	O
cyclohexyl]benzeneactemide	O
)	O
and	O
delta	O
(	O
[	O
D	B-UNK
-	O
Pen2.5]-enkephalin	O
and	O
[	O
D	B-UNK
-	O
Ser2]-[Leu]enkephalin	O
-	O
Thr	O
)	O
selective	B-UNK
opioid	B-UNK
-	O
agonists	O
,	O
by	O
themselves	O
,	O
did	O
not	O
significantly	B-UNK
affect	B-UNK
the	O
mechanical	B-UNK
nociceptive	O
threshold	B-UNK
in	O
the	O
hindpaw	O
of	O
the	O
rat	B-UNK
.	O
Intradermal	O
injection	B-UNK
of	O
mu	O
,	O
but	O
not	O
delta	O
or	O
kappa	O
opioid	B-UNK
-	O
agonists	O
,	O
however	O
,	O
produced	B-UNK
dose	B-UNK
-	O
dependent	B-UNK
inhibition	B-UNK
of	O
prostaglandin	B-UNK
E2-induced	B-UNK
hyperalgesia	B-DISEASE
.	O
The	O
analgesic	B-UNK
effect	B-UNK
of	O
the	O
mu	O
-	O
agonist	B-UNK
morphine	B-CHEMICAL
was	O
dose	B-UNK
-	O
dependently	B-UNK
antagonized	B-UNK
by	O
naloxone	B-CHEMICAL
and	O
prevented	B-UNK
by	O
co-injection	O
of	O
pertussis	B-CHEMICAL
toxin	I-CHEMICAL
.	O
Morphine	O
did	O
not	O
,	O
however	O
,	O
alter	B-UNK
the	O
hyperalgesia	B-DISEASE
induced	B-UNK
by	O
8-bromo	B-CHEMICAL
cyclic	I-CHEMICAL
adenosine	I-CHEMICAL
monophosphate	I-CHEMICAL
.	O
We	O
conclude	O
that	O
the	O
analgesic	B-UNK
action	B-UNK
of	O
opioids	O
on	O
the	O
peripheral	B-UNK
terminals	O
of	O
primary	B-UNK
afferents	O
is	O
via	O
a	O
binding	B-UNK
site	B-UNK
with	O
characteristics	B-UNK
of	O
the	O
mu	O
-	O
opioid	B-UNK
receptor	B-UNK
and	O
that	O
this	O
action	B-UNK
is	O
mediated	B-UNK
by	O
inhibition	B-UNK
of	O
the	O
cyclic	O
adenosine	B-CHEMICAL
monophosphate	I-CHEMICAL
second	B-UNK
messenger	B-UNK
system	B-UNK
.	O

Adequate	O
timing	O
of	O
ribavirin	B-CHEMICAL
reduction	B-UNK
in	O
patients	B-UNK
with	O
hemolysis	B-DISEASE
during	O
combination	B-UNK
therapy	B-UNK
of	O
interferon	O
and	O
ribavirin	B-CHEMICAL
for	O
chronic	B-UNK
hepatitis	B-DISEASE
C.	O

BACKGROUND	O
:	O
Hemolytic	O
anemia	B-DISEASE
is	O
one	O
of	O
the	O
major	B-UNK
adverse	B-UNK
events	B-UNK
of	O
the	O
combination	B-UNK
therapy	B-UNK
of	O
interferon	O
and	O
ribavirin	B-CHEMICAL
.	O
Because	O
of	O
ribavirin	B-CHEMICAL
-	O
related	B-UNK
hemolytic	B-DISEASE
anemia	I-DISEASE
,	O
dose	B-UNK
reduction	B-UNK
is	O
a	O
common	B-UNK
event	B-UNK
in	O
this	O
therapy	B-UNK
.	O
In	O
this	O
clinical	B-UNK
retrospective	O
cohort	B-UNK
study	B-UNK
we	O
have	O
examined	B-UNK
the	O
suitable	B-UNK
timing	O
of	O
ribavirin	B-CHEMICAL
reduction	B-UNK
in	O
patients	B-UNK
with	O
hemolysis	B-DISEASE
during	O
combination	B-UNK
therapy	B-UNK
.	O
METHODS	O
:	O
Thirty	O
-	O
seven	O
of	O
160	O
patients	B-UNK
who	O
had	O
HCV	O
-	O
genotype	O
1b	O
,	O
had	O
high	B-UNK
virus	B-UNK
load	O
,	O
and	O
received	B-UNK
24-week	O
combination	B-UNK
therapy	B-UNK
developed	B-UNK
anemia	B-DISEASE
with	O
hemoglobin	B-UNK
level	B-UNK
<	O
10	O
g	B-UNK
/	O
dl	O
or	O
anemia	B-DISEASE
-	O
related	B-UNK
signs	B-UNK
during	O
therapy	B-UNK
.	O
After	O
that	O
,	O
these	O
37	O
patients	B-UNK
were	O
reduced	B-UNK
one	O
tablet	O
of	O
ribavirin	B-CHEMICAL
(	O
200	O
mg	B-UNK
)	O
per	O
day	B-UNK
.	O
After	O
reduction	B-UNK
of	O
ribavirin	B-CHEMICAL
,	O
27	O
of	O
37	O
patients	B-UNK
could	O
continue	O
combination	B-UNK
therapy	B-UNK
for	O
a	O
total	B-UNK
of	O
24	O
weeks	B-UNK
(	O
group	B-UNK
A	O
)	O
.	O
However	O
,	O
10	O
of	O
37	O
patients	B-UNK
with	O
reduction	B-UNK
of	O
ribavirin	B-CHEMICAL
could	O
not	O
continue	O
combination	B-UNK
therapy	B-UNK
because	O
their	O
<	O
8.5	O
g	B-UNK
/	O
dl	O
hemoglobin	B-UNK
values	B-UNK
decreased	B-UNK
to	O
or	O
anemia	B-DISEASE
-	O
related	B-UNK
severe	B-UNK
side	O
effects	B-UNK
occurred	B-UNK
(	O
group	B-UNK
B	B-UNK
)	O
.	O
We	O
assessed	B-UNK
the	O
final	O
efficacy	B-UNK
and	O
safety	B-UNK
after	O
reduction	B-UNK
of	O
ribavirin	B-CHEMICAL
in	O
groups	B-UNK
A	O
and	O
B.	O
RESULTS	B-UNK
:	O
A	O
sustained	B-UNK
virological	O
response	B-UNK
(	O
SVR	O
)	O
was	O
29.6	O
%	O
(	O
8/27	O
)	O
in	O
group	B-UNK
A	O
and	O
10	O
%	O
(	O
1/10	O
)	O
in	O
group	B-UNK
B	B-UNK
,	O
respectively	O
.	O
A	O
34.4	O
%	O
(	O
12/27	O
)	O
of	O
SVR	O
+	O
biological	O
response	B-UNK
in	O
group	B-UNK
A	O
was	O
higher	B-UNK
than	O
10	O
%	O
(	O
1/10	O
)	O
in	O
group	B-UNK
B	B-UNK
(	O
P	B-UNK
=	I-UNK
0.051	O
)	O
,	O
with	O
slight	O
significance	O
.	O
With	O
respect	O
to	O
hemoglobin	B-UNK
level	B-UNK
at	B-DISEASE
the	O
time	B-UNK
of	O
ribavirin	B-CHEMICAL
reduction	B-UNK
,	O
a	O
rate	B-UNK
of	O
continuation	O
of	O
therapy	B-UNK
in	O
patients	B-UNK
with	O
>	O
or	O
=	O
10	O
g	B-UNK
/	O
dl	O
hemoglobin	B-UNK
was	O
higher	B-UNK
than	O
that	O
in	O
patients	B-UNK
with	O
<	O
10	O
g	B-UNK
/	O
dl	O
(	O
P	B-UNK
=	I-UNK
0.036	O
)	O
.	O
CONCLUSIONS	O
:	O
Reduction	O
of	O
ribavirin	B-CHEMICAL
at	B-DISEASE
hemoglobin	B-UNK
level	B-UNK
>	O
or	O
=	O
10	O
g	B-UNK
/	O
dl	O
is	O
suitable	B-UNK
in	O
terms	O
of	O
efficacy	B-UNK
and	O
side	O
effects	B-UNK
.	O

Increased	B-UNK
expression	B-UNK
and	O
apical	B-UNK
targeting	B-UNK
of	O
renal	B-UNK
ENaC	B-UNK
subunits	B-UNK
in	O
puromycin	B-CHEMICAL
aminonucleoside	I-CHEMICAL
-	O
induced	B-UNK
nephrotic	B-DISEASE
syndrome	I-DISEASE
in	O
rats	B-UNK
.	O

Nephrotic	O
syndrome	B-UNK
is	O
often	O
accompanied	O
by	O
sodium	B-CHEMICAL
retention	B-UNK
and	O
generalized	B-UNK
edema	B-DISEASE
.	O
However	O
,	O
the	O
molecular	B-UNK
basis	B-UNK
for	O
the	O
decreased	B-UNK
renal	B-UNK
sodium	B-CHEMICAL
excretion	B-UNK
remains	B-UNK
undefined	O
.	O
We	O
hypothesized	O
that	O
epithelial	B-UNK
Na	O
channel	B-UNK
(	O
ENaC	B-UNK
)	O
subunit	B-UNK
dysregulation	O
may	O
be	O
responsible	O
for	O
the	O
increased	B-UNK
sodium	B-CHEMICAL
retention	B-UNK
.	O
An	O
experimental	B-UNK
group	B-UNK
of	O
rats	B-UNK
was	O
treated	B-UNK
with	O
puromycin	B-CHEMICAL
aminonucleoside	I-CHEMICAL
(	O
PAN	O
;	O
180	O
mg	B-UNK
/	O
kg	B-UNK
iv	B-UNK
)	O
,	O
whereas	O
the	O
control	B-UNK
group	B-UNK
received	B-UNK
only	O
vehicle	B-UNK
.	O
After	O
7	O
days	B-UNK
,	O
PAN	O
treatment	B-UNK
induced	B-UNK
significant	B-UNK
proteinuria	B-UNK
,	O
hypoalbuminemia	B-DISEASE
,	O
decreased	B-UNK
urinary	B-UNK
sodium	B-CHEMICAL
excretion	B-UNK
,	O
and	O
extensive	B-UNK
ascites	B-DISEASE
.	O
The	O
protein	B-UNK
abundance	O
of	O
alpha	B-UNK
-	O
ENaC	B-UNK
and	O
beta-ENaC	O
was	O
increased	B-UNK
in	O
the	O
inner	B-UNK
stripe	O
of	O
the	O
outer	O
medulla	B-UNK
(	O
ISOM	O
)	O
and	O
in	O
the	O
inner	B-UNK
medulla	B-UNK
(	O
IM	O
)	O
but	O
was	O
not	O
altered	B-UNK
in	O
the	O
cortex	B-UNK
.	O
gamma	O
-	O
ENaC	B-UNK
abundance	O
was	O
increased	B-UNK
in	O
the	O
cortex	B-UNK
,	O
ISOM	O
,	O
and	O
IM	O
.	O
Immunoperoxidase	O
brightfield-	O
and	O
laser	B-UNK
-	O
scanning	B-UNK
confocal	O
fluorescence	O
microscopy	B-UNK
demonstrated	B-UNK
increased	B-UNK
targeting	B-UNK
of	O
alpha	B-UNK
-	O
ENaC	B-UNK
,	O
beta-ENaC	O
,	O
and	O
gamma	O
-	O
ENaC	B-UNK
subunits	B-UNK
to	O
the	O
apical	B-UNK
plasma	B-UNK
membrane	O
in	O
the	O
distal	B-UNK
convoluted	O
tubule	B-UNK
(	O
DCT2	O
)	O
,	O
connecting	O
tubule	B-UNK
,	O
and	O
cortical	B-UNK
and	O
medullary	O
collecting	B-UNK
duct	B-UNK
segments	O
.	O
Immunoelectron	O
microscopy	B-UNK
further	O
revealed	B-UNK
an	O
increased	B-UNK
labeling	O
of	O
alpha	B-UNK
-	O
ENaC	B-UNK
in	O
the	O
apical	B-UNK
plasma	B-UNK
membrane	O
of	O
cortical	B-UNK
collecting	B-UNK
duct	B-UNK
principal	O
cells	B-UNK
of	O
PAN	O
-	O
treated	B-UNK
rats	B-UNK
,	O
indicating	O
enhanced	B-UNK
apical	B-UNK
targeting	B-UNK
of	O
alpha	B-UNK
-	O
ENaC	B-UNK
subunits	B-UNK
.	O
In	O
contrast	B-UNK
,	O
the	O
protein	B-UNK
abundances	O
of	O
Na(+)/H(+	O
)	O
exchanger	O
type	B-UNK
3	O
(	O
NHE3	O
)	O
,	O
Na(+)-K(+)-2Cl(-	O
)	O
cotransporter	O
(	O
BSC-1	O
)	O
,	O
and	O
thiazide	O
-	O
sensitive	B-UNK
Na(+)-Cl(-	O
)	O
cotransporter	O
(	O
TSC	O
)	O
were	O
decreased	B-UNK
.	O
Moreover	O
,	O
the	O
abundance	O
of	O
the	O
alpha(1)-subunit	O
of	O
the	O
Na	O
-	O
K	O
-	O
ATPase	O
was	O
decreased	B-UNK
in	O
the	O
cortex	B-UNK
and	O
ISOM	O
,	O
but	O
it	O
remained	B-UNK
unchanged	B-UNK
in	O
the	O
IM	O
.	O
In	O
conclusion	O
,	O
the	O
increased	B-UNK
or	O
sustained	B-UNK
expression	B-UNK
of	O
ENaC	B-UNK
subunits	B-UNK
combined	B-UNK
with	O
increased	B-UNK
apical	B-UNK
targeting	B-UNK
in	O
the	O
DCT2	O
,	O
connecting	O
tubule	B-UNK
,	O
and	O
collecting	B-UNK
duct	B-UNK
are	O
likely	B-UNK
to	O
play	B-UNK
a	O
role	B-UNK
in	O
the	O
sodium	B-CHEMICAL
retention	B-UNK
associated	B-UNK
with	O
PAN	O
-	O
induced	B-UNK
nephrotic	B-DISEASE
syndrome	I-DISEASE
.	O
The	O
decreased	B-UNK
abundance	O
of	O
NHE3	O
,	O
BSC-1	O
,	O
TSC	O
,	O
and	O
Na	O
-	O
K	O
-	O
ATPase	O
may	O
play	B-UNK
a	O
compensatory	B-UNK
role	B-UNK
to	O
promote	B-UNK
sodium	B-CHEMICAL
excretion	B-UNK
.	O

Does	O
hormone	B-UNK
therapy	B-UNK
for	O
the	O
treatment	B-UNK
of	O
breast	B-DISEASE
cancer	I-DISEASE
have	O
a	O
detrimental	O
effect	B-UNK
on	O
memory	B-UNK
and	O
cognition	O
?	O
A	O
pilot	O
study	B-UNK
.	O

This	O
pilot	O
study	B-UNK
examines	O
whether	O
hormone	B-UNK
therapy	B-UNK
for	O
breast	B-DISEASE
cancer	I-DISEASE
affects	B-UNK
cognition	O
.	O
Patients	B-UNK
participating	O
in	O
a	O
randomised	B-UNK
trial	B-UNK
of	O
anastrozole	B-CHEMICAL
,	O
tamoxifen	B-CHEMICAL
alone	O
or	O
combined	B-UNK
(	O
ATAC	O
)	O
(	O
n=94	O
)	O
and	O
a	O
group	B-UNK
of	O
women	B-UNK
without	O
breast	B-DISEASE
cancer	I-DISEASE
(	O
n=35	O
)	O
completed	O
a	O
battery	O
of	O
neuropsychological	B-UNK
measures	B-UNK
.	O
Compared	O
with	O
the	O
control	B-UNK
group	B-UNK
,	O
the	O
patients	B-UNK
were	O
impaired	B-UNK
on	O
a	O
processing	O
speed	O
task	B-UNK
(	O
p=0.032	O
)	O
and	O
on	O
a	O
measure	B-UNK
of	O
immediate	B-UNK
verbal	O
memory	B-UNK
(	O
p=0.026	O
)	O
after	O
controlling	O
for	O
the	O
use	B-UNK
of	O
hormone	B-UNK
replacement	O
therapy	B-UNK
in	O
both	O
groups	B-UNK
.	O
Patient	O
group	B-UNK
performance	B-UNK
was	O
not	O
significantly	B-UNK
related	B-UNK
to	O
length	O
of	O
treatment	B-UNK
or	O
measures	B-UNK
of	O
psychological	O
morbidity	O
.	O
The	O
results	B-UNK
showed	B-UNK
specific	B-UNK
impairments	B-UNK
in	O
processing	O
speed	O
and	O
verbal	O
memory	B-UNK
in	O
women	B-UNK
receiving	B-UNK
hormonal	O
therapy	B-UNK
for	O
the	O
treatment	B-UNK
of	O
breast	B-DISEASE
cancer	I-DISEASE
.	O
Verbal	O
memory	B-UNK
may	O
be	O
especially	B-UNK
sensitive	B-UNK
to	O
changes	B-UNK
in	O
oestrogen	O
levels	B-UNK
,	O
a	O
finding	O
commonly	B-UNK
reported	B-UNK
in	O
studies	B-UNK
of	O
hormone	B-UNK
replacement	O
therapy	B-UNK
in	O
healthy	B-UNK
women	B-UNK
.	O
In	O
view	O
of	O
the	O
increased	B-UNK
use	B-UNK
of	O
hormone	B-UNK
therapies	B-UNK
in	O
an	O
adjuvant	O
and	O
preventative	O
setting	B-UNK
their	O
impact	B-UNK
on	O
cognitive	B-UNK
functioning	B-UNK
should	O
be	O
investigated	B-UNK
more	O
thoroughly	O
.	O

Association	O
of	O
nitric	B-CHEMICAL
oxide	I-CHEMICAL
production	B-UNK
and	O
apoptosis	B-UNK
in	O
a	O
model	B-UNK
of	O
experimental	B-UNK
nephropathy	B-DISEASE
.	O

BACKGROUND	O
:	O
In	O
recent	B-UNK
studies	B-UNK
increased	B-UNK
amounts	B-UNK
of	O
nitric	B-CHEMICAL
oxide	I-CHEMICAL
(	O
NO	O
)	O
and	O
apoptosis	B-UNK
have	O
been	O
implicated	B-UNK
in	O
various	O
pathological	B-DISEASE
conditions	I-DISEASE
in	O
the	O
kidney	B-UNK
.	O
We	O
have	O
studied	B-UNK
the	O
role	B-UNK
of	O
NO	O
and	O
its	O
association	B-UNK
with	O
apoptosis	B-UNK
in	O
an	O
experimental	B-UNK
model	B-UNK
of	O
nephrotic	B-DISEASE
syndrome	I-DISEASE
induced	B-UNK
by	O
a	O
single	B-UNK
injection	B-UNK
of	O
adriamycin	O
(	O
ADR	B-UNK
)	O
.	O
METHODS	O
:	O
The	O
alteration	O
in	O
the	O
NO	O
pathway	B-UNK
was	O
assessed	B-UNK
by	O
measuring	B-UNK
nitrite	O
levels	B-UNK
in	O
serum	B-UNK
/	O
urine	B-DISEASE
and	O
by	O
evaluating	O
the	O
changes	B-UNK
in	O
vascular	B-UNK
reactivity	O
of	O
the	O
isolated	B-UNK
perfused	B-UNK
rat	B-UNK
kidney	B-UNK
(	O
IPRK	O
)	O
system	B-UNK
.	O
Rats	O
were	O
stratified	O
into	O
control	B-UNK
groups	B-UNK
and	O
ADR	B-UNK
-	O
induced	B-UNK
nephropathy	B-DISEASE
groups	B-UNK
.	O
These	O
two	O
groups	B-UNK
were	O
then	O
divided	O
into	O
:	O
group	B-UNK
1	O
,	O
animals	B-UNK
receiving	B-UNK
saline	B-UNK
;	O
and	O
group	B-UNK
2	B-DISEASE
,	O
animals	B-UNK
receiving	B-UNK
aminoguanidine	O
(	O
AG	O
)	O
which	O
is	O
a	O
specific	B-UNK
inhibitor	B-UNK
of	O
inducible	B-UNK
-	O
NO	O
synthase	B-UNK
.	O
On	O
day	B-UNK
21	O
,	O
rats	B-UNK
were	O
sacrificed	O
after	O
obtaining	O
material	O
for	O
biochemical	B-UNK
analysis	B-UNK
.	O
RESULTS	B-UNK
:	O
Histopathological	O
examination	B-UNK
of	O
the	O
kidneys	B-UNK
of	O
rats	B-UNK
treated	B-UNK
with	O
ADR	B-UNK
revealed	B-UNK
focal	B-UNK
areas	B-UNK
of	O
mesangial	B-UNK
proliferation	B-UNK
and	O
mild	B-UNK
tubulointerstitial	B-UNK
inflammation	B-DISEASE
.	O
They	O
also	O
had	O
significantly	B-UNK
higher	B-UNK
levels	B-UNK
of	O
proteinuria	B-DISEASE
compared	B-UNK
with	O
control	B-UNK
and	O
treatment	B-UNK
groups	B-UNK
(	O
P	B-UNK
<	I-UNK
0.05	O
)	O
.	O
Urine	B-UNK
nitrite	O
levels	B-UNK
were	O
significantly	B-UNK
increased	B-UNK
in	O
the	O
ADR	B-UNK
-	O
nephropathy	B-DISEASE
group	B-UNK
(	O
P	B-UNK
<	I-UNK
0.05	O
)	O
.	O
In	O
the	O
IPRK	O
phenylephrine	B-CHEMICAL
and	O
acetylcholine	B-CHEMICAL
related	B-UNK
responses	B-UNK
were	O
significantly	B-UNK
impaired	B-UNK
in	O
the	O
ADR	B-UNK
-	O
nephropathy	B-DISEASE
group	B-UNK
.	O
Apoptosis	O
was	O
not	O
detected	B-UNK
in	O
controls	B-UNK
.	O
However	O
,	O
in	O
the	O
ADR	B-UNK
-	O
nephropathy	B-DISEASE
group	B-UNK
,	O
numerous	O
apoptotic	B-UNK
cells	B-UNK
were	O
identified	B-UNK
in	O
the	O
tubulointerstitial	B-UNK
areas	B-UNK
.	O
Double	O
staining	B-UNK
revealed	B-UNK
numerous	O
interstitial	O
apoptotic	B-UNK
cells	B-UNK
to	O
stain	O
for	O
ED1	O
,	O
a	O
marker	B-UNK
for	O
monocytes	O
/	O
macrophages	O
.	O
Treatment	O
with	O
AG	O
prevented	B-UNK
the	O
impairment	B-UNK
of	O
renal	B-DISEASE
vascular	B-UNK
bed	O
responses	B-UNK
and	O
reduced	B-UNK
both	O
urine	B-DISEASE
nitrite	O
levels	B-UNK
and	O
apoptosis	B-UNK
to	O
control	B-UNK
levels	B-UNK
.	O
CONCLUSION	O
:	O
We	O
suggest	B-UNK
that	O
interactions	B-UNK
between	O
NO	O
and	O
apoptosis	B-UNK
are	O
important	B-UNK
in	O
the	O
pathogenesis	O
of	O
the	O
ADR	B-UNK
-	O
induced	B-UNK
nephrosis	B-DISEASE
.	O

The	O
attenuating	B-UNK
effect	B-UNK
of	O
carteolol	B-CHEMICAL
hydrochloride	B-UNK
,	O
a	O
beta-adrenoceptor	B-UNK
antagonist	B-UNK
,	O
on	O
neuroleptic	B-UNK
-	O
induced	B-UNK
catalepsy	B-DISEASE
in	O
rats	B-UNK
.	O

It	O
is	O
known	B-UNK
that	O
beta-adrenoceptor	B-UNK
antagonists	B-UNK
are	O
effective	B-UNK
in	O
the	O
treatment	B-UNK
of	O
akathisia	B-DISEASE
,	O
one	O
of	O
the	O
extrapyramidal	B-UNK
side	O
effects	B-UNK
that	O
occur	O
during	O
neuroleptic	B-UNK
treatment	B-UNK
.	O
Neuroleptic	B-UNK
-	O
induced	B-UNK
catalepsy	B-DISEASE
,	O
a	O
model	B-UNK
of	O
neuroleptic	B-UNK
-	O
induced	B-UNK
extrapyramidal	B-UNK
side	O
effects	B-UNK
,	O
was	O
considered	B-UNK
suitable	B-UNK
as	O
a	O
model	B-UNK
for	O
predicting	O
neuroleptic	B-UNK
-	O
induced	B-UNK
akathisia	B-DISEASE
in	O
humans	O
,	O
although	O
neuroleptic	B-UNK
-	O
induced	B-UNK
catalepsy	B-DISEASE
was	O
not	O
considered	B-UNK
a	O
specific	B-UNK
test	B-UNK
for	O
neuroleptic	B-UNK
-	O
induced	B-UNK
akathisia	B-DISEASE
.	O
Therefore	O
,	O
the	O
effects	B-UNK
of	O
carteolol	B-CHEMICAL
,	O
a	O
beta-adrenoceptor	B-UNK
antagonist	B-UNK
,	O
on	O
haloperidol	B-CHEMICAL
-	O
induced	B-UNK
catalepsy	B-DISEASE
in	O
rats	B-UNK
were	O
behaviorally	O
studied	B-UNK
and	O
compared	B-UNK
with	O
those	O
of	O
propranolol	B-CHEMICAL
and	O
biperiden	B-CHEMICAL
,	O
a	O
muscarinic	O
receptor	B-UNK
antagonist	I-UNK
.	O
Carteolol	O
,	O
as	O
well	O
as	O
propranolol	B-CHEMICAL
and	O
biperiden	B-CHEMICAL
,	O
inhibited	B-UNK
the	O
haloperidol	B-CHEMICAL
-	O
induced	B-UNK
catalepsy	B-DISEASE
.	O
The	O
inhibitory	B-UNK
effect	B-UNK
of	O
carteolol	B-CHEMICAL
was	O
almost	O
comparable	B-UNK
to	O
that	O
of	O
propranolol	B-CHEMICAL
,	O
but	O
was	O
weaker	O
than	O
that	O
of	O
biperiden	B-CHEMICAL
.	O
Carteolol	O
did	O
not	O
evoke	O
postsynaptic	O
dopamine	B-CHEMICAL
receptor	B-UNK
-	O
stimulating	B-UNK
behavioral	B-UNK
signs	B-UNK
such	O
as	O
stereotypy	O
and	O
hyperlocomotion	O
in	O
rats	B-UNK
.	O
Carteolol	O
did	O
not	O
antagonize	O
the	O
inhibitory	B-UNK
effects	B-UNK
of	O
haloperidol	B-CHEMICAL
on	O
apomorphine	B-CHEMICAL
-	O
induced	B-UNK
stereotypy	O
and	O
locomotor	B-UNK
activity	B-UNK
in	O
rats	B-UNK
.	O
In	O
addition	O
,	O
carteolol	B-CHEMICAL
did	O
not	O
evoke	O
5-HT1A	O
receptor	B-UNK
-	O
stimulating	B-UNK
behavioral	B-UNK
signs	B-UNK
such	O
as	O
flat	O
body	B-UNK
posture	O
and	O
forepaw	O
treading	O
and	O
did	O
not	O
inhibit	O
5-hydroxytryptophan	B-CHEMICAL
-	O
induced	B-UNK
head	B-UNK
twitch	O
in	O
rats	B-UNK
.	O
Finally	O
,	O
carteolol	B-CHEMICAL
did	O
not	O
inhibit	O
physostigmine	B-CHEMICAL
-	O
induced	B-UNK
lethality	B-UNK
in	O
rats	B-UNK
.	O
These	O
results	B-UNK
strongly	B-UNK
suggest	B-UNK
that	O
carteolol	B-CHEMICAL
improves	B-UNK
haloperidol	B-CHEMICAL
-	O
induced	B-UNK
catalepsy	B-DISEASE
via	O
its	O
beta-adrenoceptor	B-UNK
antagonistic	B-UNK
activity	B-UNK
and	O
is	O
expected	O
to	O
be	O
effective	B-UNK
in	O
the	O
treatment	B-UNK
of	O
akathisia	B-DISEASE
without	O
attenuating	B-UNK
neuroleptic	B-UNK
-	O
induced	B-UNK
antipsychotic	B-UNK
effects	B-UNK
due	O
to	O
its	O
postsynaptic	O
dopamine	B-CHEMICAL
receptor	B-UNK
antagonistic	B-UNK
activity	B-UNK
.	O

Penicillamine	O
-	O
induced	B-UNK
rapidly	B-UNK
progressive	B-UNK
glomerulonephritis	B-DISEASE
in	O
a	O
patient	B-UNK
with	O
rheumatoid	B-DISEASE
arthritis	I-DISEASE
.	O

A	O
67-year	O
-	O
old	B-UNK
woman	B-UNK
with	O
rheumatoid	B-DISEASE
arthritis	I-DISEASE
presented	B-UNK
rapidly	B-UNK
progressive	B-UNK
glomerulonephritis	B-DISEASE
(	O
RPGN	O
)	O
after	O
5	O
months	B-UNK
of	O
D	B-UNK
-	O
penicillamine	B-CHEMICAL
(	O
250	O
mg	B-UNK
/	O
day	B-UNK
)	O
treatment	B-UNK
.	O
Light	B-UNK
microscopy	B-UNK
study	B-UNK
showed	B-UNK
severe	B-UNK
glomerulonephritis	B-DISEASE
with	O
crescent	O
formation	B-UNK
in	O
60	O
%	O
of	O
the	O
glomeruli	B-UNK
and	O
infiltration	O
of	O
inflammatory	B-UNK
cells	B-UNK
in	O
the	O
wall	B-UNK
of	O
an	O
arteriole	O
.	O
Immunofluorescence	O
revealed	B-UNK
scanty	O
granular	O
IgG	O
,	O
IgA	O
and	O
C3	O
deposits	B-UNK
along	O
the	O
capillary	B-UNK
walls	O
and	O
mesangium	O
.	O
The	O
patient	B-UNK
was	O
treated	B-UNK
with	O
steroid	B-UNK
pulse	B-UNK
,	O
plasmapheresis	O
,	O
cyclophosphamide	B-CHEMICAL
and	O
antiplatelet	O
agents	B-UNK
.	O
A	O
complete	B-UNK
recovery	B-UNK
of	O
renal	B-DISEASE
function	B-UNK
was	O
achieved	B-UNK
in	O
a	O
few	O
weeks	B-UNK
.	O
This	O
new	B-UNK
case	B-UNK
of	O
RPGN	O
in	O
the	O
course	B-UNK
of	O
D	B-UNK
-	O
penicillamine	B-CHEMICAL
treatment	B-UNK
emphasizes	O
the	O
need	B-UNK
for	O
frequent	B-UNK
monitoring	B-UNK
of	O
renal	B-UNK
function	B-UNK
and	O
evaluation	B-UNK
of	O
urinary	B-UNK
sediment	O
and	O
proteinuria	B-DISEASE
in	O
these	O
patients	B-UNK
.	O
The	O
prompt	B-UNK
discontinuation	B-UNK
of	O
D	B-UNK
-	O
penicillamine	B-CHEMICAL
and	O
vigorous	O
treatment	B-UNK
measures	B-UNK
could	O
allow	O
for	O
a	O
good	B-UNK
prognosis	B-UNK
as	O
in	O
this	O
case	B-UNK
.	O

Nature	O
,	O
time	B-UNK
course	B-UNK
and	O
dose	B-UNK
dependence	B-DISEASE
of	O
zidovudine	B-CHEMICAL
-	O
related	B-UNK
side	O
effects	B-UNK
:	O
results	B-UNK
from	O
the	O
Multicenter	O
Canadian	O
Azidothymidine	O
Trial	O
.	O

To	O
characterize	O
the	O
nature	O
,	O
time	B-UNK
course	B-UNK
and	O
dose	B-UNK
dependency	B-UNK
of	O
zidovudine	B-CHEMICAL
-	O
related	B-UNK
side	O
effects	B-UNK
,	O
we	O
undertook	O
a	O
multicenter	O
,	O
prospective	B-UNK
,	O
dose	B-UNK
-	O
range	B-UNK
finding	O
study	B-UNK
.	O
Our	O
study	B-UNK
group	B-UNK
consisted	B-UNK
of	O
74	O
HIV	O
-	O
positive	B-UNK
homosexual	O
men	O
belonging	O
to	O
groups	B-UNK
II	B-UNK
B	B-UNK
,	O
III	B-UNK
and	O
IV	B-UNK
C2	O
from	O
the	O
Centers	O
for	O
Disease	B-UNK
Control	B-UNK
(	O
CDC	O
)	O
classification	O
of	O
HIV	O
disease	B-DISEASE
.	O
Following	O
a	O
3-week	O
observation	B-UNK
period	B-UNK
,	O
volunteers	O
were	O
treated	B-UNK
with	O
zidovudine	B-CHEMICAL
600	O
mg	B-UNK
/	O
day	B-UNK
for	O
18	O
weeks	B-UNK
,	O
900	O
mg	B-UNK
/	O
day	B-UNK
for	O
9	O
weeks	B-UNK
and	O
1200	O
mg	B-UNK
/	O
day	B-UNK
for	O
9	O
weeks	B-UNK
,	O
followed	B-UNK
by	O
a	O
washout	O
period	B-UNK
of	O
6	O
weeks	B-UNK
after	O
which	O
they	O
were	O
re-started	O
on	O
1200	O
mg	B-UNK
/	O
day	B-UNK
or	O
the	O
highest	B-UNK
tolerated	B-UNK
dose	B-UNK
at	B-DISEASE
8-hourly	O
intervals	B-UNK
.	O
Subjects	O
were	O
randomly	B-UNK
assigned	B-UNK
to	O
4-hourly	O
or	O
8-hourly	O
regimens	B-UNK
within	O
CDC	O
groups	B-UNK
while	O
taking	B-UNK
600	O
and	O
1200	O
mg	B-UNK
/	O
day	B-UNK
.	O
Clinical	B-UNK
and	O
laboratory	B-UNK
evaluations	O
were	O
performed	B-UNK
at	B-DISEASE
3-week	O
intervals	B-UNK
.	O
Symptomatic	O
adverse	B-UNK
effects	B-UNK
were	O
present	B-UNK
in	O
96	O
%	O
of	O
subjects	B-UNK
,	O
most	O
commonly	B-UNK
nausea	B-DISEASE
(	O
64	O
%	O
)	O
,	O
fatigue	B-DISEASE
(	O
55	O
%	O
)	O
and	O
headache	B-DISEASE
(	O
49	B-DISEASE
%	O
)	O
.	O
These	O
were	O
generally	B-UNK
self	O
-	O
limited	O
,	O
reappearing	O
briefly	B-UNK
at	B-DISEASE
each	O
dose	B-UNK
increment	O
.	O
A	O
decrease	B-UNK
in	O
hemoglobin	B-UNK
occurred	B-UNK
shortly	B-UNK
after	O
initiation	O
of	O
therapy	B-UNK
.	O
This	O
was	O
not	O
dose	B-UNK
dependent	B-UNK
and	O
reversed	B-UNK
rapidly	B-UNK
upon	O
discontinuation	B-UNK
of	O
treatment	B-UNK
.	O
A	O
red	O
blood	B-UNK
cell	B-UNK
count	B-UNK
decrease	B-UNK
,	O
a	O
mean	B-UNK
cell	B-UNK
volume	B-UNK
increase	B-UNK
and	O
a	O
granulocyte	O
count	B-UNK
decrease	B-UNK
developed	B-UNK
early	B-UNK
in	O
a	O
dose	B-UNK
-	O
independent	B-UNK
fashion	B-UNK
,	O
reverting	O
at	B-DISEASE
least	O
partially	O
during	O
the	O
washout	O
phase	B-UNK
.	O
The	O
decrease	B-UNK
in	O
reticulocyte	O
count	B-UNK
was	O
dose	B-UNK
related	B-UNK
between	O
600	O
and	O
900	O
mg	B-UNK
/	O
day	B-UNK
with	O
no	O
further	O
change	B-UNK
when	O
the	O
dose	B-UNK
was	O
escalated	O
to	O
1200	O
mg	B-UNK
/	O
day	B-UNK
.	O
Bone	O
marrow	B-UNK
changes	B-UNK
occurred	B-UNK
rapidly	B-UNK
as	O
demonstrated	B-UNK
by	O
megaloblastosis	O
in	O
95	O
%	O
of	O
65	O
specimens	O
at	B-DISEASE
week	B-UNK
18.(ABSTRACT	O
TRUNCATED	B-UNK
AT	O
250	O
WORDS	O
)	O

Bilateral	O
optic	B-DISEASE
neuropathy	I-DISEASE
due	O
to	O
combined	B-UNK
ethambutol	B-CHEMICAL
and	O
isoniazid	B-CHEMICAL
treatment	B-UNK
.	O

The	O
case	B-UNK
of	O
a	O
40-year	O
-	O
old	B-UNK
patient	B-UNK
who	O
underwent	B-UNK
an	O
unsuccessful	O
cadaver	B-DISEASE
kidney	B-UNK
transplantation	B-UNK
and	O
was	O
treated	B-UNK
with	O
ethambutol	B-CHEMICAL
and	O
isoniazid	B-CHEMICAL
is	O
reported	B-UNK
.	O
A	O
bilateral	B-UNK
retrobulbar	O
neuropathy	B-DISEASE
with	O
an	O
unusual	O
central	B-UNK
bitemporal	B-UNK
hemianopic	O
scotoma	B-DISEASE
was	O
found	B-UNK
.	O
Ethambutol	O
was	O
stopped	O
and	O
only	O
small	B-UNK
improvement	B-UNK
of	O
the	O
visual	B-UNK
acuity	B-UNK
followed	B-UNK
.	O
Isoniazid	O
was	O
discontinued	O
later	B-UNK
,	O
followed	B-UNK
by	O
a	O
dramatic	B-UNK
improvement	B-UNK
in	O
the	O
visual	B-UNK
acuity	B-UNK
.	O
The	O
hazards	O
of	O
optic	B-UNK
nerve	I-UNK
toxicity	B-UNK
due	O
to	O
ethambutol	B-CHEMICAL
are	O
known	B-UNK
.	O
We	O
emphasize	O
the	O
potential	B-UNK
danger	O
in	O
the	O
use	B-UNK
of	O
ethambutol	B-CHEMICAL
and	O
isoniazid	B-CHEMICAL
.	O

Progestational	O
agents	B-UNK
and	O
blood	B-UNK
coagulation	O
.	O
VII	O
.	O
Thromboembolic	O
and	O
other	O
complications	B-UNK
of	O
oral	B-UNK
contraceptive	O
therapy	B-UNK
in	O
relationship	B-UNK
to	O
pretreatment	B-UNK
levels	B-UNK
of	O
blood	B-CHEMICAL
coagulation	I-CHEMICAL
factors	I-CHEMICAL
:	O
summary	B-UNK
report	B-UNK
of	O
a	O
ten	B-DISEASE
-	O
year	B-UNK
study	B-UNK
.	O

During	O
a	O
ten	B-DISEASE
-	O
year	B-UNK
period	B-UNK
,	O
348	O
women	B-UNK
were	O
studied	B-UNK
for	O
a	O
total	B-UNK
of	O
5,877	O
patient	B-UNK
months	B-UNK
in	O
four	O
separate	B-UNK
studies	B-UNK
relating	O
oral	B-UNK
contraceptives	O
to	O
changes	B-UNK
in	O
hematologic	B-UNK
parameters	B-UNK
.	O
Significant	B-UNK
increases	B-UNK
in	O
certain	B-UNK
factors	B-UNK
of	O
the	O
blood	B-UNK
coagulation	O
and	O
fibrinolysin	O
systems	B-UNK
(	O
factors	B-UNK
I	O
,	O
II	B-UNK
,	O
VII	O
,	O
VIII	O
,	O
IX	O
,	O
and	O
X	O
and	O
plasminogen	O
)	O
were	O
observed	B-UNK
in	O
the	O
treated	B-UNK
groups	B-UNK
.	O
Severe	B-UNK
complications	B-UNK
developed	B-UNK
in	O
four	O
patients	B-UNK
.	O
All	O
four	O
had	O
an	O
abnormal	B-UNK
blood	B-UNK
coagulation	O
profile	B-UNK
,	O
suggesting	B-UNK
"	O
hypercoagulability	O
"	O
before	O
initiation	O
of	O
therapy	B-UNK
.	O
Some	O
of	O
these	O
findings	B-UNK
represented	O
the	O
most	O
extreme	O
abnormalities	B-DISEASE
seen	B-UNK
in	O
the	O
entire	B-UNK
group	B-UNK
of	O
patients	B-UNK
;	O
some	O
increased	B-UNK
further	O
during	O
therapy	B-UNK
.	O
One	O
of	O
these	O
patients	B-UNK
developed	B-UNK
a	O
myocardial	B-DISEASE
infarction	I-DISEASE
before	O
receiving	B-UNK
any	O
medication	B-UNK
,	O
shortly	B-UNK
after	O
the	O
base	O
-	O
line	B-UNK
values	B-UNK
were	O
obtained	B-UNK
.	O
One	O
patient	B-UNK
developed	I-UNK
retinopathy	B-DISEASE
19	O
months	B-UNK
after	O
she	O
began	B-UNK
therapy	B-UNK
,	O
and	O
another	O
developed	B-UNK
thrombophlebitis	B-DISEASE
after	O
27	O
months	B-UNK
of	O
therapy	B-UNK
.	O
The	O
fourth	B-UNK
patient	B-UNK
developed	I-UNK
thrombophlebitis	B-DISEASE
14	O
days	B-UNK
after	O
initiation	O
of	O
contraceptive	O
therapy	B-UNK
.	O
All	O
four	O
patients	B-UNK
were	O
of	O
the	O
A	O
or	O
AB	O
blood	B-UNK
group	B-UNK
.	O
Previous	B-UNK
studies	B-UNK
suggested	B-UNK
the	O
possiblility	O
of	O
increased	B-UNK
propensity	O
for	O
thromboembolic	B-UNK
episodes	B-UNK
in	O
patients	B-UNK
possessing	O
the	O
A	O
antigen	B-UNK
.	O
It	O
appears	B-UNK
from	O
these	O
data	B-UNK
that	O
hematologic	B-UNK
work	B-UNK
-	O
ups	O
may	O
be	O
useful	B-UNK
in	O
women	B-UNK
who	O
are	O
about	O
to	O
start	O
long	B-UNK
-	O
term	B-UNK
oral	B-UNK
contraceptive	O
therapy	B-UNK
.	O

Cardiac	B-UNK
arrest	B-UNK
in	O
a	O
child	B-UNK
with	O
cerebral	B-DISEASE
palsy	I-DISEASE
undergoing	B-UNK
sevoflurane	B-CHEMICAL
induction	B-UNK
of	O
anesthesia	B-UNK
after	O
preoperative	B-UNK
clonidine	B-CHEMICAL
.	O

Clonidine	O
is	O
a	O
frequently	B-UNK
administered	B-UNK
alpha2-adrenergic	O
agonist	B-UNK
which	O
can	O
decrease	B-UNK
heart	B-UNK
rate	I-UNK
and	O
blood	B-UNK
pressure	B-UNK
.	O
We	O
present	B-UNK
a	O
case	B-UNK
of	O
a	O
5-year	O
-	O
old	B-UNK
child	B-UNK
with	O
cerebral	B-DISEASE
palsy	I-DISEASE
and	O
seizure	B-DISEASE
disorder	I-DISEASE
,	O
receiving	B-UNK
clonidine	B-CHEMICAL
for	O
restlessness	O
,	O
who	O
presented	B-UNK
for	O
placement	O
of	O
a	O
baclofen	B-CHEMICAL
pump	O
.	O
Without	O
the	O
knowledge	O
of	O
the	O
medical	B-UNK
personnel	O
,	O
the	O
patient'	O
s	O
mother	O
administered	B-UNK
three	O
doses	B-UNK
of	O
clonidine	B-CHEMICAL
during	O
the	O
evening	O
before	O
and	O
morning	O
of	O
surgery	B-UNK
to	O
reduce	B-UNK
anxiety	B-DISEASE
.	O
During	O
induction	B-UNK
of	O
anesthesia	B-UNK
,	O
the	O
patient	B-UNK
developed	I-UNK
bradycardia	B-DISEASE
and	O
hypotension	B-DISEASE
requiring	O
cardiac	B-UNK
resuscitation	O
.	O
There	O
are	O
no	O
previous	B-UNK
reports	B-UNK
of	O
clonidine	B-CHEMICAL
-	O
associated	B-UNK
cardiac	B-DISEASE
arrest	I-DISEASE
in	O
a	O
child	B-UNK
undergoing	B-UNK
induction	B-UNK
of	O
anesthesia	B-UNK
.	O

Effects	O
of	O
UMB24	O
and	O
(	O
+	O
/-)-SM	B-UNK
21	O
,	O
putative	B-UNK
sigma2-preferring	O
antagonists	B-UNK
,	O
on	O
behavioral	B-UNK
toxic	B-UNK
and	O
stimulant	B-UNK
effects	B-UNK
of	O
cocaine	B-CHEMICAL
in	O
mice	B-UNK
.	O

Earlier	O
studies	B-UNK
have	O
demonstrated	B-UNK
that	O
antagonism	B-UNK
of	O
sigma1	B-UNK
receptors	B-UNK
attenuates	O
the	O
convulsive	B-UNK
,	O
lethal	B-UNK
,	O
locomotor	B-UNK
stimulatory	O
and	O
rewarding	O
actions	B-UNK
of	O
cocaine	B-CHEMICAL
in	O
mice	B-UNK
.	O
In	O
contrast	B-UNK
,	O
the	O
contribution	O
of	O
sigma2	O
receptors	B-UNK
is	O
unclear	O
because	O
experimental	B-UNK
tools	O
to	O
selectively	B-UNK
target	O
this	O
subtype	O
are	O
unavailable	O
.	O
To	O
begin	O
addressing	O
this	O
need	B-UNK
,	O
we	O
characterized	B-UNK
UMB24	O
(	O
1-(2-phenethyl)-4-(2-pyridyl)-piperazine	O
)	O
and	O
(	O
+	O
/-)-SM	B-UNK
21	O
(	O
3alpha	O
-	O
tropanyl-2-(4-chorophenoxy)butyrate	O
)	O
in	O
receptor	B-UNK
binding	B-UNK
and	O
behavioral	B-UNK
studies	B-UNK
.	O
Receptor	O
binding	B-UNK
studies	B-UNK
confirmed	B-UNK
that	O
UMB24	O
and	O
(	O
+	O
/-)-SM	B-UNK
21	O
display	O
preferential	O
affinity	B-UNK
for	O
sigma2	O
over	O
sigma1	B-UNK
receptors	B-UNK
.	O
In	O
behavioral	B-UNK
studies	B-UNK
,	O
pretreatment	B-UNK
of	O
Swiss	B-UNK
Webster	O
mice	B-UNK
with	O
UMB24	O
or	O
(	O
+	O
/-)-SM	B-UNK
21	O
significantly	B-UNK
attenuated	B-UNK
cocaine	B-CHEMICAL
-	O
induced	B-UNK
convulsions	B-DISEASE
and	O
locomotor	B-UNK
activity	B-UNK
,	O
but	O
not	O
lethality	B-UNK
.	O
When	O
administered	B-UNK
alone	O
,	O
(	O
+	O
/-)-SM	B-UNK
21	O
produced	B-UNK
no	O
significant	B-UNK
effects	B-UNK
compared	B-UNK
to	O
control	B-UNK
injections	B-UNK
of	O
saline	B-UNK
,	O
but	O
UMB24	O
had	O
locomotor	B-UNK
depressant	B-UNK
actions	B-UNK
.	O
Together	O
,	O
the	O
data	B-UNK
suggest	B-UNK
that	O
sigma2	O
receptor	B-UNK
antagonists	B-UNK
have	O
the	O
potential	B-UNK
to	O
attenuate	O
some	O
of	O
the	O
behavioral	B-UNK
effects	B-UNK
of	O
cocaine	B-CHEMICAL
,	O
and	O
further	O
development	B-UNK
of	O
more	O
selective	B-UNK
,	O
high	B-UNK
affinity	B-UNK
ligands	O
are	O
warranted	O
.	O

Methimazole	O
-	O
induced	B-UNK
cholestatic	B-UNK
jaundice	B-DISEASE
.	O

Methimazole	O
is	O
a	O
widely	B-UNK
used	O
and	O
generally	B-UNK
well	O
-	O
tolerated	B-UNK
antithyroid	O
agent	B-UNK
.	O
A	O
43-year	O
-	O
old	B-UNK
woman	B-UNK
had	O
severe	B-UNK
jaundice	B-DISEASE
and	O
itching	O
1	O
month	O
after	O
receiving	B-UNK
methimazole	B-CHEMICAL
(	O
10	O
mg	B-UNK
tid	O
)	O
and	O
propranolol	B-CHEMICAL
(	O
20	O
mg	B-UNK
tid	O
)	O
for	O
treatment	B-UNK
of	O
hyperthyroidism	B-DISEASE
.	O
The	O
patient	B-UNK
continued	B-UNK
treatment	B-UNK
for	O
another	O
4	O
days	B-UNK
after	O
the	O
appearance	O
of	O
jaundice	B-DISEASE
until	O
she	O
finished	O
both	O
medications	B-UNK
.	O
When	O
seen	B-UNK
at	B-DISEASE
the	O
emergency	B-UNK
department	B-UNK
2	B-DISEASE
weeks	B-UNK
later	B-UNK
,	O
she	O
still	O
had	O
severe	B-UNK
icterus	O
,	O
pruritus	B-DISEASE
,	O
and	O
hyperbilirubinemia	B-DISEASE
,	O
formed	B-UNK
mainly	B-UNK
of	O
the	O
conjugated	O
fraction	B-UNK
.	O
Methimazole	O
-	O
induced	B-UNK
cholestasis	B-DISEASE
was	O
diagnosed	B-UNK
,	O
and	O
propranolol	B-CHEMICAL
therapy	B-UNK
was	O
resumed	O
.	O
Over	O
the	O
following	B-UNK
9	O
days	B-UNK
,	O
the	O
symptoms	B-UNK
improved	B-UNK
and	O
plasma	B-UNK
bilirubin	B-CHEMICAL
levels	B-UNK
were	O
normal	B-UNK
after	O
12	O
weeks	B-UNK
without	O
methimazole	B-CHEMICAL
.	O
In	O
rare	B-UNK
cases	B-UNK
within	O
the	O
first	O
few	O
weeks	B-UNK
of	O
therapy	B-UNK
,	O
this	O
drug	B-UNK
can	O
cause	B-UNK
severe	B-UNK
and	O
reversible	B-UNK
cholestatic	B-UNK
jaundice	B-DISEASE
.	O
Physicians	O
and	O
patients	B-UNK
should	O
be	O
aware	O
of	O
this	O
adverse	B-UNK
effect	B-UNK
so	O
that	O
,	O
upon	O
occurrence	O
,	O
they	O
can	O
discontinue	O
methimazole	B-CHEMICAL
therapy	B-UNK
and	O
avoid	B-UNK
unnecessary	O
invasive	O
procedures	B-UNK
.	O

Ciprofloxacin	O
-	O
induced	B-UNK
acute	B-UNK
interstitial	B-DISEASE
nephritis	I-DISEASE
and	O
autoimmune	O
hemolytic	B-DISEASE
anemia	I-DISEASE
.	O

Ciprofloxacin	O
has	O
been	O
associated	B-UNK
with	O
several	O
side	O
effects	B-UNK
including	B-UNK
interstitial	B-DISEASE
nephritis	I-DISEASE
and	O
hemolytic	B-DISEASE
anemia	I-DISEASE
.	O
The	O
combination	B-UNK
of	O
both	O
side	O
effects	B-UNK
is	O
extremely	O
rare	B-UNK
.	O
In	O
this	O
report	B-UNK
,	O
we	O
describe	O
a	O
case	B-UNK
of	O
ciprofloxacin	B-CHEMICAL
-	O
induced	B-UNK
interstitial	B-DISEASE
nephritis	I-DISEASE
and	O
autoimmune	O
hemolytic	B-DISEASE
anemia	I-DISEASE
.	O
Hemolytic	O
anemia	B-DISEASE
improved	B-UNK
after	O
stopping	O
the	O
drug	B-UNK
and	O
initiation	O
of	O
steroid	B-UNK
therapy	B-UNK
.	O
Unfortunately	O
,	O
acute	B-UNK
interstitial	B-DISEASE
nephritis	I-DISEASE
was	O
irreversible	B-UNK
and	O
the	O
patient	B-UNK
developed	I-UNK
end	B-DISEASE
-	I-DISEASE
stage	I-DISEASE
renal	I-DISEASE
disease	I-DISEASE
.	O

Contribution	O
of	O
sodium	B-CHEMICAL
valproate	O
to	O
the	O
syndrome	B-UNK
of	O
inappropriate	O
secretion	B-UNK
of	O
antidiuretic	O
hormone	B-UNK
.	O

We	O
report	B-UNK
the	O
case	B-UNK
of	O
a	O
62-year	O
-	O
old	B-UNK
man	B-UNK
who	O
was	O
administered	B-UNK
sodium	B-CHEMICAL
valproate	O
(	O
VPA	B-UNK
)	O
and	O
who	O
subsequently	B-UNK
developed	B-UNK
the	O
syndrome	B-UNK
of	O
inappropriate	O
secretion	B-UNK
of	O
antidiuretic	O
hormone	B-UNK
(	O
SIADH	O
)	O
.	O
He	O
had	O
been	O
taking	B-UNK
VPA	B-UNK
for	O
treatment	B-UNK
of	O
idiopathic	B-UNK
generalized	B-UNK
tonic	B-DISEASE
-	O
clonic	O
convulsions	B-DISEASE
since	O
he	O
was	O
56	O
years	B-UNK
old	B-UNK
.	O
After	O
substituting	O
VPA	B-UNK
with	O
zonisamide	B-CHEMICAL
,	O
the	O
serum	B-UNK
sodium	B-CHEMICAL
level	B-UNK
returned	B-UNK
to	O
normal	B-UNK
.	O
We	O
consider	O
this	O
episode	O
of	O
SIADH	O
to	O
be	O
the	O
result	B-UNK
of	O
a	O
combination	B-UNK
of	O
factors	B-UNK
including	B-UNK
a	O
weakness	B-UNK
of	O
the	O
central	B-UNK
nervous	I-UNK
system	B-UNK
and	O
the	O
long	B-UNK
-	O
term	B-UNK
administration	B-UNK
of	O
VPA	B-UNK
.	O

Vasopressin	O
in	O
the	O
treatment	B-UNK
of	O
milrinone	B-CHEMICAL
-	O
induced	B-UNK
hypotension	B-DISEASE
in	O
severe	B-UNK
heart	B-DISEASE
failure	I-DISEASE
.	O

The	O
use	B-UNK
of	O
phosphodiesterase	B-CHEMICAL
inhibitors	I-CHEMICAL
such	O
as	O
milrinone	B-CHEMICAL
in	O
the	O
treatment	B-UNK
of	O
severe	B-UNK
heart	B-DISEASE
failure	I-DISEASE
is	O
frequently	B-UNK
restricted	B-UNK
because	O
they	O
cause	B-UNK
vasodilation	O
and	O
hypotension	B-DISEASE
.	O
In	O
patients	B-UNK
with	O
decompensated	O
heart	B-DISEASE
failure	I-DISEASE
with	O
hypotension	B-DISEASE
after	O
treatment	B-UNK
with	O
milrinone	B-CHEMICAL
,	O
low	B-UNK
doses	B-UNK
of	O
vasopressin	O
restored	B-UNK
blood	B-UNK
pressure	B-UNK
without	O
inhibiting	O
the	O
inotropic	O
effect	B-UNK
of	O
milrinone	B-CHEMICAL
.	O

Halogenated	O
anesthetics	B-CHEMICAL
form	B-UNK
liver	B-DISEASE
adducts	O
and	O
antigens	B-CHEMICAL
that	O
cross-react	O
with	O
halothane	B-CHEMICAL
-	O
induced	B-UNK
antibodies	B-UNK
.	O

Two	O
halogenated	O
anesthetics	B-CHEMICAL
,	O
enflurane	B-CHEMICAL
and	O
isoflurane	B-CHEMICAL
,	O
have	O
been	O
associated	B-UNK
with	O
an	O
allergic	O
-	O
type	B-UNK
hepatic	B-UNK
injury	B-UNK
both	O
alone	O
and	O
following	B-UNK
previous	B-UNK
exposure	B-UNK
to	O
halothane	B-CHEMICAL
.	O
Halothane	O
hepatitis	B-DISEASE
appears	B-UNK
to	O
involve	B-UNK
an	O
aberrant	B-UNK
immune	B-UNK
response	B-UNK
.	O
An	O
antibody	B-UNK
response	B-UNK
to	O
a	O
protein	B-UNK
-	O
bound	O
biotransformation	O
product	B-UNK
(	O
trifluoroacetyl	O
adduct	O
)	O
has	O
been	O
detected	B-UNK
on	O
halothane	B-CHEMICAL
hepatitis	I-CHEMICAL
patients	B-UNK
.	O
This	O
study	B-UNK
was	O
performed	B-UNK
to	O
determine	B-UNK
cross-reactivity	O
between	O
enflurane	B-CHEMICAL
and	O
isoflurane	B-CHEMICAL
with	O
the	O
hypersensitivity	B-DISEASE
induced	B-UNK
by	O
halothane	B-CHEMICAL
.	O
The	O
subcellular	O
and	O
lobular	O
production	B-UNK
of	O
hepatic	B-UNK
neoantigens	O
recognized	B-UNK
by	O
halothane	B-CHEMICAL
-	O
induced	B-UNK
antibodies	B-UNK
following	B-UNK
enflurane	B-CHEMICAL
and	O
isoflurane	B-CHEMICAL
,	O
and	O
the	O
biochemical	B-UNK
nature	O
of	O
these	O
neoantigens	O
was	O
investigated	B-UNK
in	O
two	O
animal	B-UNK
models	B-UNK
.	O
Enflurane	O
administration	B-UNK
resulted	B-UNK
in	O
neoantigens	O
detected	B-UNK
in	O
both	O
the	O
microsomal	O
and	O
cytosolic	O
fraction	B-UNK
of	O
liver	B-DISEASE
homogenates	O
and	O
in	O
the	O
centrilobular	O
region	B-UNK
of	O
the	O
liver	B-DISEASE
.	O
In	O
the	O
same	O
liver	B-DISEASE
,	O
biochemical	B-UNK
analysis	B-UNK
detected	B-UNK
fluorinated	O
liver	B-DISEASE
adducts	O
that	O
were	O
up	O
to	O
20-fold	O
greater	B-UNK
in	O
guinea	B-UNK
pigs	B-UNK
than	O
in	O
rats	B-UNK
.	O
This	O
supports	O
and	O
extends	O
previous	B-UNK
evidence	B-UNK
for	O
a	O
mechanism	B-UNK
by	O
which	O
enflurane	B-CHEMICAL
and	O
/	O
or	O
isoflurane	B-CHEMICAL
could	O
produce	B-UNK
a	O
hypersensitivity	B-DISEASE
condition	B-UNK
similar	B-UNK
to	O
that	O
of	O
halothane	B-CHEMICAL
hepatitis	I-CHEMICAL
either	O
alone	O
or	O
subsequent	B-UNK
to	O
halothane	B-CHEMICAL
administration	B-UNK
.	O
The	O
guinea	B-UNK
pig	I-UNK
would	O
appear	O
to	O
be	O
a	O
useful	B-UNK
model	B-UNK
for	O
further	O
investigations	B-UNK
of	O
the	O
immunological	O
response	B-UNK
to	O
these	O
antigens	B-CHEMICAL
.	O

Induction	O
by	O
paracetamol	B-UNK
of	O
bladder	B-UNK
and	O
liver	B-DISEASE
tumours	O
in	O
the	O
rat	B-UNK
.	O
Effects	O
on	O
hepatocyte	B-UNK
fine	O
structure	B-UNK
.	O

Groups	B-UNK
of	O
male	B-UNK
and	O
female	B-UNK
inbred	B-UNK
Leeds	O
strain	B-UNK
rats	B-UNK
were	O
fed	B-UNK
diets	B-UNK
containing	B-UNK
either	O
0.5	B-UNK
%	O
or	O
1.0	B-UNK
%	O
paracetamol	B-UNK
by	O
weight	B-UNK
for	O
up	O
to	O
18	O
months	B-UNK
.	O
At	O
the	O
1.0	B-UNK
%	O
dosage	B-UNK
level	B-UNK
,	O
20	O
%	O
of	O
rats	B-UNK
of	O
both	O
sexes	O
developed	B-UNK
neoplastic	O
nodules	B-UNK
of	O
the	O
liver	B-DISEASE
,	O
a	O
statistically	B-UNK
significant	I-UNK
incidence	B-UNK
.	O
These	O
rats	B-UNK
also	O
showed	B-UNK
gross	B-UNK
enlargement	B-UNK
of	O
their	O
livers	O
and	O
an	O
increase	B-UNK
in	O
foci	O
of	O
cellular	B-UNK
alteration	O
,	O
the	O
latter	O
also	O
being	O
observed	B-UNK
in	O
the	O
low	B-UNK
dosage	B-UNK
male	B-UNK
rats	B-UNK
.	O
Papillomas	O
of	O
the	O
transitional	O
epithelium	B-UNK
of	O
the	O
bladder	B-UNK
developed	B-UNK
in	O
all	O
paracetamol	B-UNK
-	O
treated	B-UNK
groups	B-UNK
,	O
and	O
three	O
rats	B-UNK
bore	O
bladder	B-UNK
carcinomas	O
.	O
However	O
,	O
significant	B-UNK
yields	O
of	O
bladder	B-UNK
tumours	O
were	O
only	O
obtained	B-UNK
from	O
low	B-UNK
dosage	B-UNK
females	O
and	O
high	B-UNK
dosage	B-UNK
males	O
.	O
Additionally	O
,	O
20	O
to	O
25	O
%	O
of	O
paracetamol	B-UNK
-	O
treated	B-UNK
rats	B-UNK
developed	B-UNK
hyperplasia	B-DISEASE
of	O
the	O
bladder	B-UNK
epithelium	B-UNK
,	O
which	O
was	O
not	O
coincident	O
with	O
the	O
presence	O
of	O
bladder	B-DISEASE
calculi	I-DISEASE
.	O
A	O
low	B-UNK
yield	O
of	O
tumours	O
at	B-DISEASE
various	O
other	O
sites	O
also	O
arose	O
following	B-UNK
paracetamol	B-UNK
feeding	B-UNK
.	O
An	O
electron	B-UNK
microscope	O
study	B-UNK
of	O
the	O
livers	O
of	O
paracetamol	B-UNK
-	O
treated	B-UNK
rats	B-UNK
revealed	B-UNK
ultrastructural	O
changes	B-UNK
in	O
the	O
hepatocytes	O
that	O
resemble	O
those	O
that	O
result	B-UNK
from	O
exposure	B-UNK
to	O
a	O
variety	O
of	O
known	B-UNK
hepatocarcinogens	O
.	O

Rat	O
extraocular	B-UNK
muscle	B-UNK
regeneration	O
.	O
Repair	O
of	O
local	B-UNK
anesthetic	B-UNK
-	O
induced	B-UNK
damage	B-UNK
.	O

Local	O
anesthetics	B-CHEMICAL
that	O
are	O
commonly	B-UNK
used	O
in	O
ophthalmic	B-UNK
surgery	B-UNK
(	O
0.75	O
%	O
bupivacaine	B-CHEMICAL
hydrochloride	B-UNK
,	O
2.0	B-UNK
%	O
mepivacaine	B-CHEMICAL
hydrochloride	B-UNK
,	O
and	O
2.0	B-UNK
%	O
lidocaine	B-CHEMICAL
hydrochloride	B-UNK
plus	B-UNK
1:100,000	O
epinephrine	B-CHEMICAL
)	O
were	O
injected	B-UNK
into	O
the	O
retrobulbar	O
area	B-UNK
of	O
rat	B-UNK
eyes	B-UNK
.	O
Controls	O
were	O
injected	B-UNK
with	O
physiological	O
saline	B-UNK
.	O
All	O
three	O
anesthetics	B-CHEMICAL
produced	B-UNK
massive	O
degeneration	B-UNK
of	O
the	O
extraocular	B-UNK
muscles	B-UNK
.	O
Muscle	B-UNK
degeneration	B-UNK
is	O
followed	B-UNK
by	O
regeneration	O
of	O
the	O
damaged	O
muscle	B-UNK
fibers	B-UNK
.	O
In	O
addition	O
to	O
muscle	B-UNK
damage	B-UNK
,	O
severe	B-UNK
damage	B-UNK
was	O
also	O
seen	B-UNK
in	O
harderian	O
glands	O
,	O
especially	B-UNK
after	O
exposure	B-UNK
to	O
mepivacaine	B-CHEMICAL
and	O
lidocaine	B-CHEMICAL
plus	B-UNK
epinephrine	B-CHEMICAL
.	O
With	O
these	O
findings	B-UNK
in	O
rats	B-UNK
,	O
it	O
is	O
hypothesized	O
that	O
the	O
temporary	O
diplopia	B-DISEASE
sometimes	O
seen	B-UNK
in	O
patients	B-UNK
after	O
ophthalmic	B-UNK
surgery	B-UNK
might	O
be	O
due	O
to	O
anesthetic	B-UNK
-	O
induced	B-UNK
damage	B-UNK
to	O
the	O
extraocular	B-UNK
muscles	B-UNK
.	O

Reversal	O
of	O
neuroleptic	B-UNK
-	O
induced	B-UNK
catalepsy	B-DISEASE
by	O
novel	B-UNK
aryl	O
-	O
piperazine	B-CHEMICAL
anxiolytic	O
drugs	B-UNK
.	O

The	O
novel	B-UNK
anxiolytic	O
drug	B-UNK
,	O
buspirone	B-CHEMICAL
,	O
reverses	B-UNK
catalepsy	B-DISEASE
induced	B-UNK
by	O
haloperidol	B-CHEMICAL
.	O
A	O
series	B-UNK
of	O
aryl	O
-	O
piperazine	B-CHEMICAL
analogues	O
of	O
buspirone	B-CHEMICAL
and	O
other	O
5-hydroxytryptaminergic	O
agonists	O
were	O
tested	B-UNK
for	O
their	O
ability	B-UNK
to	O
reverse	B-UNK
haloperidol	B-CHEMICAL
induced	B-UNK
catalepsy	B-DISEASE
.	O
Those	O
drugs	B-UNK
with	O
strong	B-UNK
affinity	B-UNK
for	O
5-hydroxytryptamine1a	O
receptors	B-UNK
were	O
able	O
to	O
reverse	B-UNK
catalepsy	B-DISEASE
.	O
Drugs	O
with	O
affinity	B-UNK
for	O
other	O
5-HT	B-UNK
receptors	B-UNK
or	O
weak	O
affinity	B-UNK
were	O
ineffective	O
.	O
However	O
,	O
inhibition	B-UNK
of	O
postsynaptic	O
5-HT	B-UNK
receptors	B-UNK
neither	O
inhibited	B-UNK
nor	O
potentiated	B-UNK
reversal	B-UNK
of	O
catalepsy	B-DISEASE
and	O
leaves	O
open	B-UNK
the	O
question	O
as	O
to	O
the	O
site	B-UNK
or	O
mechanism	B-UNK
for	O
this	O
effect	B-UNK
.	O

Diazepam	O
facilitates	O
reflex	B-DISEASE
bradycardia	B-DISEASE
in	O
conscious	B-UNK
rats	B-UNK
.	O

The	O
effects	B-UNK
of	O
diazepam	B-CHEMICAL
on	O
cardiovascular	B-UNK
function	B-UNK
were	O
assessed	B-UNK
in	O
conscious	B-UNK
rats	B-UNK
.	O
Intravenous	B-UNK
administration	B-UNK
of	O
diazepam	B-CHEMICAL
(	O
1	O
-	O
30	O
mg	B-UNK
kg-1	O
)	O
produced	B-UNK
a	O
dose	B-UNK
-	O
dependent	B-UNK
decrease	B-UNK
in	O
both	O
the	O
mean	B-UNK
arterial	B-UNK
pressure	I-UNK
and	O
the	O
heart	B-UNK
rate	I-UNK
.	O
Also	O
,	O
reflex	B-DISEASE
bradycardia	B-DISEASE
was	O
produced	B-UNK
in	O
rats	B-UNK
by	O
intravenous	B-UNK
infusion	I-UNK
of	O
adrenaline	O
(	O
1.25	O
-	O
2.5	B-UNK
micrograms	B-UNK
kg-1	I-UNK
)	O
.	O
Intravenous	B-UNK
pretreatment	B-UNK
of	O
the	O
rats	B-UNK
with	O
diazepam	B-CHEMICAL
,	O
although	O
causing	B-UNK
no	O
change	B-UNK
in	O
the	O
adrenaline	O
-	O
induced	B-UNK
pressor	B-UNK
effect	B-UNK
,	O
did	O
enhance	B-UNK
the	O
adrenaline	O
-	O
induced	B-UNK
reflex	B-DISEASE
bradycardia	B-DISEASE
.	O
However	O
,	O
the	O
diazepam	B-CHEMICAL
enhancement	O
of	O
adrenaline	O
-	O
induced	B-UNK
reflex	B-DISEASE
bradycardia	B-DISEASE
was	O
antagonized	B-UNK
by	O
pretreatment	B-UNK
of	O
rats	B-UNK
with	O
an	O
intravenous	B-UNK
dose	B-UNK
of	O
picrotoxin	B-CHEMICAL
(	O
an	O
agent	B-UNK
blocks	O
chloride	B-UNK
channels	O
by	O
binding	B-UNK
to	O
sites	O
associated	B-UNK
with	O
the	O
benzodiazepine	O
-	O
GABA	O
-	O
chloride	B-UNK
channel	B-UNK
macromolecular	O
complex	B-UNK
)	O
.	O
The	O
data	B-UNK
indicate	B-UNK
that	O
diazepam	B-CHEMICAL
acts	B-UNK
through	O
the	O
benzodiazepine	O
-	O
GABA	O
-	O
chloride	B-UNK
channel	B-UNK
macromolecular	O
complex	B-UNK
within	O
the	O
central	B-UNK
nervous	I-UNK
system	B-UNK
to	O
facilitate	O
reflex	B-DISEASE
bradycardia	B-DISEASE
mediated	B-UNK
through	O
baroreceptor	O
reflexes	B-UNK
in	O
response	B-UNK
to	O
an	O
acute	B-UNK
increase	B-UNK
in	O
arterial	B-UNK
pressure	I-UNK
.	O

Chronic	B-UNK
carbamazepine	B-CHEMICAL
inhibits	O
the	O
development	B-UNK
of	O
local	B-UNK
anesthetic	B-UNK
seizures	B-DISEASE
kindled	O
by	O
cocaine	B-CHEMICAL
and	O
lidocaine	B-CHEMICAL
.	O

The	O
effects	B-UNK
of	O
carbamazepine	B-CHEMICAL
(	O
CBZ	B-UNK
)	O
treatment	B-UNK
on	O
local	B-UNK
anesthetic	B-UNK
-	O
kindled	O
seizures	B-DISEASE
and	O
lethality	B-UNK
were	O
evaluated	B-UNK
in	O
different	B-UNK
stages	O
of	O
the	O
kindling	O
process	B-UNK
and	O
under	O
different	B-UNK
methods	B-UNK
of	O
CBZ	B-UNK
administration	B-UNK
.	O
Chronic	B-UNK
oral	B-UNK
CBZ	B-UNK
inhibited	B-UNK
the	O
development	B-UNK
of	O
both	O
lidocaine-	O
and	O
cocaine	B-CHEMICAL
-	O
induced	B-UNK
seizures	B-DISEASE
,	O
but	O
had	O
little	B-UNK
effect	B-UNK
on	O
the	O
fully	B-UNK
developed	B-UNK
local	B-UNK
anesthetic	B-UNK
seizures	B-DISEASE
.	O
Chronic	B-UNK
CBZ	B-UNK
also	O
decreased	B-UNK
the	O
incidence	B-UNK
of	O
seizure	B-UNK
-	O
related	B-UNK
mortality	B-UNK
in	O
the	O
cocaine	B-CHEMICAL
-	O
injected	B-UNK
rats	B-UNK
.	O
Acute	B-UNK
CBZ	B-UNK
over	O
a	O
range	B-UNK
of	O
doses	B-UNK
(	O
15	O
-	O
50	O
mg	B-UNK
/	O
kg	B-UNK
)	O
had	O
no	O
effect	B-UNK
on	O
completed	O
lidocaine	B-CHEMICAL
-	O
kindled	O
or	O
acute	B-UNK
cocaine	B-CHEMICAL
-	O
induced	B-UNK
seizures	B-DISEASE
.	O
Repeated	O
i.p	B-UNK
.	O
injection	B-UNK
of	O
CBZ	B-UNK
(	O
15	O
mg	B-UNK
/	O
kg	B-UNK
)	O
also	O
was	O
without	O
effect	B-UNK
on	O
the	O
development	B-UNK
of	O
lidocaine-	O
or	O
cocaine	B-CHEMICAL
-	O
kindled	O
seizures	B-DISEASE
.	O
The	O
differential	B-UNK
effects	B-UNK
of	O
CBZ	B-UNK
depending	O
upon	O
stage	B-UNK
of	O
seizure	B-UNK
development	B-UNK
suggest	B-UNK
that	O
distinct	O
mechanisms	B-UNK
underlie	O
the	O
development	B-UNK
versus	B-UNK
maintenance	B-UNK
of	O
local	B-UNK
anesthetic	B-UNK
-	O
kindled	O
seizures	B-DISEASE
.	O
The	O
effectiveness	O
of	O
chronic	B-UNK
but	O
not	O
repeated	B-UNK
,	O
intermittent	B-UNK
injections	B-UNK
of	O
CBZ	B-UNK
suggests	B-UNK
that	O
different	B-UNK
biochemical	B-UNK
consequences	B-UNK
result	B-UNK
from	O
the	O
different	B-UNK
treatment	B-UNK
regimens	B-UNK
.	O
The	O
possible	B-UNK
utility	O
of	O
chronic	B-UNK
CBZ	B-UNK
in	O
preventing	B-UNK
the	O
development	B-UNK
of	O
toxic	B-UNK
side	O
effects	B-UNK
in	O
human	B-UNK
cocaine	B-CHEMICAL
users	B-UNK
is	O
suggested	B-UNK
by	O
these	O
data	B-UNK
,	O
but	O
remains	B-UNK
to	O
be	O
directly	B-UNK
evaluated	B-UNK
.	O

D	B-UNK
-	O
penicillamine	B-CHEMICAL
in	O
the	O
treatment	B-UNK
of	O
localized	B-DISEASE
scleroderma	I-DISEASE
.	O

Localized	O
scleroderma	B-DISEASE
has	O
no	O
recognized	B-UNK
internal	B-UNK
organ	O
involvement	B-UNK
but	O
may	O
be	O
disfiguring	O
and	O
disabling	B-UNK
when	O
the	O
cutaneous	B-UNK
lesions	B-UNK
are	O
extensive	B-UNK
or	O
affect	B-UNK
children	B-UNK
.	O
There	O
is	O
no	O
accepted	O
or	O
proven	B-UNK
treatment	B-UNK
for	O
localized	B-DISEASE
scleroderma	I-DISEASE
.	O
Case	B-UNK
reports	B-UNK
of	O
11	O
patients	B-UNK
with	O
severe	B-UNK
,	O
extensive	B-UNK
localized	B-DISEASE
scleroderma	I-DISEASE
who	O
were	O
treated	B-UNK
with	O
D	B-UNK
-	O
penicillamine	B-CHEMICAL
are	O
summarized	O
in	O
this	O
article	O
.	O
This	O
drug	B-UNK
was	O
judged	O
to	O
have	O
a	O
favorable	O
effect	B-UNK
on	O
the	O
disease	B-DISEASE
course	B-UNK
in	O
7	O
(	O
64	O
%	O
)	O
of	O
11	O
patients	B-UNK
.	O
Improvement	O
began	B-UNK
within	O
3	O
to	O
6	O
months	B-UNK
and	O
consisted	B-UNK
of	O
cessation	B-UNK
of	O
active	B-UNK
cutaneous	B-UNK
lesions	B-UNK
in	O
all	O
7	O
patients	B-UNK
,	O
skin	B-DISEASE
softening	O
in	O
5	O
,	O
and	O
more	O
normal	B-UNK
growth	B-UNK
of	O
the	O
affected	B-UNK
limb	B-UNK
in	O
2	B-DISEASE
of	O
3	O
children	B-UNK
.	O
Joint	O
stiffness	O
and	O
contractures	B-DISEASE
also	O
improved	B-UNK
.	O
The	O
dose	B-UNK
of	O
D	B-UNK
-	O
penicillamine	B-CHEMICAL
associated	B-UNK
with	O
a	O
favorable	O
response	B-UNK
was	O
as	O
low	B-UNK
as	O
2	B-DISEASE
to	O
5	O
mg	B-UNK
/	O
kg	B-UNK
per	O
day	B-UNK
given	B-UNK
over	O
a	O
period	B-UNK
ranging	O
from	O
15	O
to	O
53	O
months	B-UNK
.	O
D	B-UNK
-	O
Penicillamine	O
caused	B-UNK
nephrotic	B-DISEASE
syndrome	I-DISEASE
in	O
1	O
patient	B-UNK
and	O
milder	O
reversible	B-UNK
proteinuria	B-UNK
in	O
3	O
other	O
patients	B-UNK
;	O
none	O
developed	B-UNK
renal	B-DISEASE
insufficiency	I-DISEASE
.	O
These	O
data	B-UNK
suggest	B-UNK
that	O
D	B-UNK
-	O
penicillamine	B-CHEMICAL
may	O
be	O
effective	B-UNK
in	O
severe	B-UNK
cases	B-UNK
of	O
localized	B-DISEASE
scleroderma	I-DISEASE
.	O

Preservation	O
of	O
renal	B-DISEASE
blood	B-UNK
flow	B-UNK
during	O
hypotension	B-DISEASE
induced	B-UNK
with	O
fenoldopam	B-CHEMICAL
in	O
dogs	B-UNK
.	O

The	O
introduction	O
of	O
drugs	B-UNK
that	O
could	O
induce	B-UNK
hypotension	B-DISEASE
with	O
different	B-UNK
pharmacological	B-UNK
actions	B-UNK
would	O
be	O
advantageous	O
because	O
side	O
effects	B-UNK
unique	B-UNK
to	O
a	O
specific	B-UNK
drug	B-UNK
could	O
be	O
minimized	O
by	O
selecting	O
appropriate	B-UNK
therapy	B-UNK
.	O
Specific	O
dopamine-1	O
,	O
(	O
DA1	O
)	O
and	O
dopamine-2	O
(	O
DA2	O
)	O
receptor	B-UNK
agonists	O
are	O
now	O
under	O
clinical	B-UNK
investigation	O
.	O
Fenoldopam	O
mesylate	O
is	O
a	O
specific	B-UNK
DA1	O
receptor	B-UNK
agonist	B-UNK
that	O
lowers	O
blood	B-UNK
pressure	B-UNK
by	O
vasodilatation	O
.	O
The	O
hypothesis	O
that	O
fenoldopam	B-CHEMICAL
could	O
be	O
used	O
to	O
induce	B-UNK
hypotension	B-DISEASE
and	O
preserve	O
blood	B-UNK
flow	B-UNK
to	O
the	O
kidney	B-UNK
was	O
tested	B-UNK
.	O
Systemic	B-UNK
aortic	B-UNK
blood	B-UNK
pressure	B-UNK
and	O
renal	B-UNK
blood	B-UNK
flow	B-UNK
were	O
measured	B-UNK
continuously	B-UNK
with	O
a	O
carotid	B-UNK
arterial	B-UNK
catheter	B-UNK
and	O
an	O
electromagnetic	O
flow	B-UNK
probe	O
respectively	O
,	O
in	O
order	O
to	O
compare	O
the	O
cardiovascular	B-UNK
and	O
renal	B-UNK
vascular	B-UNK
effects	B-UNK
of	O
fenoldopam	B-CHEMICAL
and	O
sodium	B-CHEMICAL
nitroprusside	B-CHEMICAL
in	O
ten	B-DISEASE
dogs	B-UNK
under	O
halothane	B-CHEMICAL
general	B-UNK
anaesthesia	B-UNK
.	O
Mean	O
arterial	B-UNK
pressure	I-UNK
was	O
decreased	B-UNK
30	O
+	O
/-	O
8	O
per	O
cent	O
from	O
control	B-UNK
with	O
infusion	B-UNK
of	O
fenoldopam	B-CHEMICAL
(	O
3.4	B-UNK
+	O
/-	O
2.0	B-UNK
micrograms.kg-1.min-1	O
)	O
and	O
34	O
+	O
/-	O
4	O
per	O
cent	O
with	O
infusion	B-UNK
of	O
sodium	B-CHEMICAL
nitroprusside	B-CHEMICAL
(	O
5.9	B-UNK
micrograms.kg-1.min-1	O
)	O
(	O
NS	O
)	O
.	O
Renal	B-UNK
blood	B-UNK
flow	B-UNK
(	O
RBF	O
)	O
increased	B-UNK
during	O
fenoldopam	B-CHEMICAL
-	O
induced	B-UNK
hypotension	B-DISEASE
11	O
+	O
/-	O
7	O
per	O
cent	O
and	O
decreased	B-UNK
21	O
+	O
/-	O
8	O
per	O
cent	O
during	O
sodium	B-CHEMICAL
nitroprusside	B-CHEMICAL
-	O
induced	B-UNK
hypotension	B-DISEASE
(	O
P	B-UNK
less	O
than	O
0.01	B-UNK
)	O
.	O
Sodium	O
nitroprusside	B-CHEMICAL
is	O
a	O
non-selective	O
arteriolar	O
and	O
venous	B-UNK
vasodilator	O
that	O
can	O
produce	B-UNK
redistribution	O
of	O
blood	B-UNK
flow	B-UNK
away	O
from	O
the	O
kidney	B-UNK
during	O
induced	B-UNK
hypotension	B-DISEASE
.	O
Fenoldopam	O
is	O
a	O
selective	B-UNK
dopamine-1	O
(	O
DA1	O
)	O
receptor	B-UNK
agonist	B-UNK
that	O
causes	B-UNK
vasodilatation	O
to	O
the	O
kidney	B-UNK
and	O
other	O
organs	O
with	O
DA1	O
receptors	B-UNK
and	O
preserves	O
blood	B-UNK
flow	B-UNK
to	O
the	O
kidney	B-UNK
during	O
induced	B-UNK
hypotension	B-DISEASE
.	O

Antiarrhythmic	O
effects	B-UNK
of	O
optical	B-UNK
isomers	O
of	O
cibenzoline	O
on	O
canine	O
ventricular	B-UNK
arrhythmias	B-DISEASE
.	O

Antiarrhythmic	O
effects	B-UNK
of	O
(	O
+	O
)	O
-cibenzoline	O
and	O
(	O
-)-cibenzoline	O
were	O
examined	B-UNK
using	O
two	O
canine	O
ventricular	B-UNK
arrhythmia	B-DISEASE
models	B-UNK
.	O
Digitalis	O
arrhythmia	B-DISEASE
,	O
which	O
is	O
suppressed	B-UNK
by	O
Na	O
channel	B-UNK
blockers	B-UNK
,	O
was	O
induced	B-UNK
by	O
intermittent	B-UNK
intravenous	B-UNK
(	O
i.v	B-UNK
.	O
)	O
injection	B-UNK
of	O
ouabain	B-CHEMICAL
in	O
pentobarbital	B-CHEMICAL
-	O
anesthetized	B-UNK
dogs	B-UNK
.	O
Adrenaline	O
arrhythmia	B-DISEASE
,	O
which	O
is	O
suppressed	B-UNK
by	O
Ca	O
channel	B-UNK
blockers	B-UNK
,	O
was	O
induced	B-UNK
by	O
adrenaline	O
infusion	B-UNK
in	O
halothane	B-CHEMICAL
-	O
anesthetized	B-UNK
dogs	B-UNK
.	O
Ten	O
and	O
5	O
mg	B-UNK
/	O
kg	B-UNK
i.v	B-UNK
.	O
(	O
+	O
)	O
-cibenzoline	O
suppressed	B-UNK
digitalis-	O
and	O
adrenaline	O
-	O
induced	B-UNK
arrhythmias	B-DISEASE
,	O
respectively	O
.	O
The	O
minimum	O
effective	B-UNK
plasma	B-UNK
concentrations	B-UNK
of	O
(	O
+	O
)	O
-cibenzoline	O
for	O
digitalis-	O
and	O
adrenaline	O
-	O
induced	B-UNK
arrhythmias	B-DISEASE
were	O
1.4	O
+	O
/-	O
0.4	O
and	O
2.0	B-UNK
+	O
/-	O
0.6	B-UNK
micrograms	B-UNK
/	O
ml	B-UNK
,	O
respectively	O
(	O
mean	B-UNK
+	O
/-	O
SD	B-UNK
,	O
n	B-UNK
=	O
6	O
)	O
.	O
A	O
lower	B-UNK
dose	B-UNK
of	O
1	O
mg	B-UNK
/	O
kg	B-UNK
i.v	B-UNK
.	O
of	O
(	O
-)-cibenzoline	O
suppressed	B-UNK
the	O
digitalis	O
-	O
induced	B-UNK
arrhythmia	B-DISEASE
,	O
whereas	O
5	O
mg	B-UNK
/	O
kg	B-UNK
i.v	B-UNK
.	O
was	O
needed	B-UNK
to	O
suppress	O
adrenaline	O
-	O
induced	B-UNK
arrhythmias	B-DISEASE
.	O
The	O
minimum	O
effective	B-UNK
plasma	B-UNK
concentrations	B-UNK
of	O
(	O
-)-cibenzoline	O
for	O
digitalis-	O
and	O
adrenaline	O
-	O
induced	B-UNK
arrhythmia	B-DISEASE
were	O
0.06	O
+	O
/-	O
0.04	O
and	O
0.7	O
+	O
/-	O
0.1	B-UNK
micrograms	B-UNK
/	O
ml	B-UNK
,	O
respectively	O
(	O
mean	B-UNK
+	O
/-	O
SD	B-UNK
,	O
n	B-UNK
=	O
6	O
)	O
.	O
The	O
stronger	B-UNK
antiarrhythmic	B-UNK
effect	B-UNK
of	O
(	O
-)-cibenzoline	O
indicates	B-UNK
that	O
(	O
-)-isomer	O
may	O
have	O
an	O
effect	B-UNK
nearly	B-UNK
5	O
-	O
20	O
times	B-UNK
stronger	B-UNK
in	O
suppressing	O
Na	O
channels	O
,	O
but	O
effects	B-UNK
of	O
both	O
drugs	B-UNK
on	O
Ca	O
channels	O
may	O
be	O
almost	O
equipotent	O
.	O

Effect	O
of	O
Hibiscus	B-UNK
rosa	I-UNK
sinensis	O
on	O
reserpine	B-CHEMICAL
-	O
induced	B-UNK
neurobehavioral	O
and	O
biochemical	B-UNK
alterations	B-UNK
in	O
rats	B-UNK
.	O

Effect	O
of	O
methanolic	O
extract	B-UNK
of	O
Hibiscus	B-UNK
rosa	I-UNK
sinensis	O
(	O
100	O
-	O
300	O
mg	B-UNK
/	O
kg	B-UNK
)	O
was	O
studied	B-UNK
on	O
reserpine	B-CHEMICAL
-	O
induced	B-UNK
orofacial	B-UNK
dyskinesia	B-DISEASE
and	O
neurochemical	B-UNK
alterations	B-UNK
.	O
The	O
rats	B-UNK
were	O
treated	B-UNK
with	O
intraperitoneal	O
reserpine	B-CHEMICAL
(	O
1	O
mg	B-UNK
/	O
kg	B-UNK
,	O
ip	O
)	O
for	O
3	O
days	B-UNK
every	O
other	O
day	B-UNK
.	O
On	O
day	B-UNK
5	O
,	O
vacuous	B-UNK
chewing	B-UNK
movements	B-UNK
and	O
tongue	B-DISEASE
protrusions	O
were	O
counted	O
for	O
5	O
min	B-UNK
.	O
Reserpine	O
treated	B-UNK
rats	B-UNK
significantly	B-UNK
developed	B-UNK
vacuous	B-UNK
chewing	B-UNK
movements	B-UNK
and	O
tongue	B-DISEASE
protrusions	O
however	O
,	O
coadministration	O
of	O
Hibiscus	B-UNK
rosa	I-UNK
sinensis	O
roots	O
extract	B-UNK
(	O
100	O
,	O
200	O
and	O
300	O
mg	B-UNK
/	O
kg	B-UNK
,	O
per	O
orally	B-UNK
)	O
attenuated	B-UNK
the	O
effects	B-UNK
.	O
Biochemical	O
analysis	B-UNK
of	O
brain	B-UNK
revealed	B-UNK
that	O
the	O
reserpine	B-CHEMICAL
treatment	B-UNK
significantly	I-UNK
increased	B-UNK
lipid	B-UNK
peroxidation	B-UNK
and	O
decreased	B-UNK
levels	B-UNK
of	O
superoxide	B-UNK
dismutase	O
(	O
SOD	O
)	O
,	O
catalase	O
(	O
CAT	O
)	O
and	O
glutathione	B-DISEASE
reductase	I-DISEASE
(	O
GSH	O
)	O
,	O
an	O
index	B-UNK
of	O
oxidative	B-UNK
stress	B-UNK
process	B-UNK
.	O
Coadministration	O
of	O
extract	B-UNK
significantly	B-UNK
reduced	B-UNK
the	O
lipid	B-UNK
peroxidation	B-UNK
and	O
reversed	B-UNK
the	O
decrease	B-UNK
in	O
brain	B-UNK
SOD	O
,	O
CAT	O
and	O
GSH	O
levels	B-UNK
.	O
The	O
results	B-UNK
of	O
the	O
present	B-UNK
study	B-UNK
suggested	B-UNK
that	O
Hibiscus	B-UNK
rosa	I-UNK
sinensis	O
had	O
a	O
protective	B-UNK
role	B-UNK
against	O
reserpine	B-CHEMICAL
-	O
induced	B-UNK
orofacial	B-UNK
dyskinesia	B-DISEASE
and	O
oxidative	B-UNK
stress	B-UNK
.	O

Comparison	O
of	O
aqueous	B-UNK
and	O
gellan	B-UNK
ophthalmic	B-UNK
timolol	B-CHEMICAL
with	O
placebo	B-UNK
on	O
the	O
24-hour	B-UNK
heart	B-UNK
rate	I-UNK
response	B-UNK
in	O
patients	B-UNK
on	O
treatment	B-UNK
for	O
glaucoma	B-DISEASE
.	O

PURPOSE	O
:	O
Topical	O
beta-blocker	B-UNK
treatment	B-UNK
is	O
routine	B-UNK
therapy	B-UNK
in	O
the	O
management	B-UNK
of	O
patients	B-UNK
with	O
glaucoma	B-DISEASE
.	O
Therapy	O
results	B-UNK
in	O
systemic	B-UNK
absorption	O
,	O
however	O
,	O
the	O
degree	B-UNK
of	O
reduction	B-UNK
of	O
resting	B-UNK
and	O
peak	B-UNK
heart	B-UNK
rate	I-UNK
has	O
not	O
been	O
quantified	O
.	O
DESIGN	B-UNK
:	O
This	O
trial	B-UNK
evaluated	B-UNK
the	O
effect	B-UNK
of	O
placebo	B-UNK
,	O
0.5	B-UNK
%	O
aqueous	B-UNK
timolol	B-CHEMICAL
(	O
timolol	B-CHEMICAL
solution	B-UNK
)	O
and	O
a	O
0.5	B-UNK
%	O
timolol	B-CHEMICAL
suspension	O
that	O
forms	O
a	O
gel	O
on	O
application	B-UNK
to	O
the	O
conjunctiva	O
(	O
timolol	B-CHEMICAL
gellan	B-UNK
)	O
on	O
the	O
24-hour	B-UNK
heart	B-UNK
rate	I-UNK
in	O
patients	B-UNK
currently	B-UNK
being	O
treated	B-UNK
for	O
glaucoma	B-DISEASE
to	O
quantify	O
the	O
reduction	B-UNK
in	O
mean	B-UNK
heart	B-UNK
rate	I-UNK
.	O
METHODS	O
:	O
Forty	O
-	O
three	O
Caucasian	O
patients	B-UNK
with	O
primary	B-UNK
open	B-UNK
-	O
angle	O
glaucoma	B-DISEASE
or	O
ocular	B-DISEASE
hypertension	I-DISEASE
with	O
a	O
mean	B-UNK
(	O
+	O
/-SD	O
)	O
age	B-UNK
of	O
63	O
(	O
+	O
/-8	O
)	O
years	B-UNK
were	O
randomized	B-UNK
and	O
crossed	O
over	O
in	O
a	O
double-masked	O
manner	B-UNK
to	O
14	O
days	B-UNK
of	O
treatment	B-UNK
with	O
placebo	B-UNK
(	O
morning	O
and	O
evening	O
in	O
both	O
eyes	B-UNK
)	O
,	O
timolol	B-CHEMICAL
solution	B-UNK
(	O
morning	O
and	O
evening	O
in	O
both	O
eyes	B-UNK
)	O
,	O
or	O
timolol	B-CHEMICAL
gellan	B-UNK
(	O
morning	O
in	O
both	O
eyes	B-UNK
with	O
placebo	B-UNK
in	O
the	O
evening	O
)	O
.	O
On	O
the	O
13th	O
day	B-UNK
of	O
each	O
period	B-UNK
,	O
heart	B-UNK
rate	I-UNK
was	O
recorded	B-UNK
continuously	B-UNK
during	O
a	O
typical	O
,	O
ambulant	O
24-hour	B-UNK
period	B-UNK
.	O
RESULTS	B-UNK
:	O
Both	O
timolol	B-CHEMICAL
solution	B-UNK
and	O
timolol	B-CHEMICAL
gellan	B-UNK
reduced	B-UNK
the	O
mean	B-UNK
24-hour	B-UNK
heart	B-UNK
rate	I-UNK
compared	B-UNK
with	O
placebo	B-UNK
(	O
P	B-UNK
<	I-UNK
or	O
=	O
.001	O
)	O
,	O
and	O
this	O
reduction	B-UNK
was	O
most	O
pronounced	O
during	O
the	O
daytime	O
(	O
-7.5	O
%	O
change	B-UNK
in	O
mean	B-UNK
heart	B-UNK
rate	I-UNK
,	O
-5.7	O
beats	B-UNK
/	O
min	B-UNK
)	O
.	O
Timolol	O
gellan	B-UNK
showed	B-UNK
a	O
numerically	O
but	O
not	O
significantly	B-UNK
smaller	B-UNK
reduction	B-UNK
in	O
24-hour	B-UNK
heart	B-UNK
rate	I-UNK
,	O
compared	B-UNK
with	O
timolol	B-CHEMICAL
solution	B-UNK
.	O
During	O
the	O
night	O
,	O
the	O
mean	B-UNK
12-hour	O
heart	B-UNK
rate	I-UNK
on	O
placebo	B-UNK
and	O
timolol	B-CHEMICAL
gellan	B-UNK
were	O
both	O
significantly	B-UNK
less	O
than	O
on	O
timolol	B-CHEMICAL
solution	B-UNK
;	O
the	O
difference	B-UNK
between	O
solution	B-UNK
and	O
gellan	B-UNK
treatments	B-UNK
was	O
statistically	B-UNK
significant	I-UNK
(	O
P	B-UNK
=	I-UNK
.01	B-UNK
)	O
.	O
CONCLUSIONS	O
:	O
Both	O
timolol	B-CHEMICAL
solution	B-UNK
and	O
timolol	B-CHEMICAL
gellan	B-UNK
decrease	B-UNK
the	O
mean	B-UNK
24-hour	B-UNK
heart	B-UNK
rate	I-UNK
compared	B-UNK
with	O
placebo	B-UNK
.	O
This	O
response	B-UNK
was	O
most	O
pronounced	O
during	O
the	O
active	B-UNK
daytime	O
period	B-UNK
.	O
These	O
data	B-UNK
quantify	O
the	O
modest	O
bradycardia	B-DISEASE
associated	B-UNK
with	O
ophthalmic	B-UNK
beta-blocker	B-UNK
therapy	B-UNK
in	O
a	O
typical	O
patient	B-UNK
population	B-UNK
on	O
therapy	B-UNK
for	O
glaucoma	B-DISEASE
.	O
Although	O
exercise	B-UNK
performance	B-UNK
was	O
not	O
assessed	B-UNK
in	O
this	O
trial	B-UNK
,	O
reductions	O
of	O
this	O
magnitude	O
should	O
not	O
have	O
substantial	O
clinical	B-UNK
consequences	B-UNK
.	O

The	O
apical	B-DISEASE
ballooning	I-DISEASE
syndrome	I-DISEASE
(	O
ABS	O
)	O
is	O
a	O
recently	B-UNK
described	B-UNK
stress	B-UNK
-	O
mediated	B-UNK
acute	B-UNK
cardiac	B-UNK
syndrome	B-UNK
characterized	B-UNK
by	O
transient	B-UNK
wall	B-UNK
-	O
motion	O
abnormalities	B-DISEASE
involving	B-UNK
the	O
apex	O
and	O
midventricle	O
with	O
hyperkinesis	B-DISEASE
of	O
the	O
basal	B-UNK
left	B-UNK
ventricular	I-UNK
(	O
LV	O
)	O
segments	O
without	O
obstructive	O
epicardial	O
coronary	B-DISEASE
disease	I-DISEASE
.	O
Cardiotoxicity	O
is	O
not	O
an	O
uncommon	O
adverse	B-UNK
effect	B-UNK
of	O
chemotherapeutic	B-UNK
agents	B-UNK
.	O
However	O
,	O
there	O
are	O
no	O
reports	B-UNK
of	O
ABS	O
secondary	B-UNK
to	O
chemotherapeutic	B-UNK
agents	B-UNK
.	O
We	O
describe	O
the	O
case	B-UNK
of	O
a	O
woman	B-UNK
who	O
developed	B-UNK
the	O
syndrome	B-UNK
after	O
chemotherapy	B-UNK
for	O
metastatic	B-UNK
cancer	B-UNK
.	O
A	O
79-year	O
-	O
old	B-UNK
woman	B-UNK
presented	B-UNK
with	O
typical	O
ischemic	B-UNK
chest	B-DISEASE
pain	I-DISEASE
,	O
elevated	B-UNK
cardiac	B-UNK
enzymes	B-UNK
with	O
significant	B-UNK
ST	B-UNK
-	O
segment	B-UNK
abnormalities	B-DISEASE
on	O
her	O
electrocardiogram	O
.	O
She	O
underwent	B-UNK
recent	B-UNK
chemotherapy	B-UNK
with	O
fluorouracil	B-CHEMICAL
for	O
metastatic	B-UNK
colorectal	B-DISEASE
cancer	I-DISEASE
.	O
Echocardiography	O
revealed	B-UNK
a	O
wall	B-UNK
-	O
motion	O
abnormality	B-UNK
involving	B-UNK
the	O
apical	B-UNK
and	O
periapical	O
segments	O
which	O
appeared	B-UNK
akinetic	O
.	O
Coronary	O
angiography	B-UNK
revealed	B-UNK
no	O
obstructive	O
coronary	B-UNK
lesions	B-UNK
.	O
The	O
patient	B-UNK
was	O
stabilized	O
with	O
medical	B-UNK
therapy	B-UNK
.	O
Four	O
weeks	B-UNK
later	B-UNK
she	O
remained	B-UNK
completely	B-UNK
asymptomatic	B-UNK
.	O
Echocardiogram	O
revealed	B-UNK
a	O
normal	B-UNK
ejection	B-UNK
fraction	I-UNK
and	O
a	O
resolution	B-UNK
of	O
the	O
apical	B-UNK
akinesis	O
.	O
Pathogenetic	O
mechanisms	B-UNK
of	O
cardiac	B-UNK
complications	B-UNK
in	O
cancer	B-DISEASE
patients	B-UNK
undergoing	B-UNK
chemotherapy	B-UNK
include	B-UNK
coronary	B-DISEASE
vasospasm	I-DISEASE
,	O
endothelial	B-UNK
damage	B-UNK
and	O
consequent	O
thrombus	O
formation	B-UNK
.	O
In	O
our	O
patient	B-UNK
,	O
both	O
supraphysiologic	O
levels	B-UNK
of	O
plasma	B-UNK
catecholamines	B-CHEMICAL
and	O
stress	B-UNK
related	B-UNK
neuropeptides	B-CHEMICAL
caused	B-UNK
by	O
cancer	B-UNK
diagnosis	B-UNK
as	O
well	O
as	O
chemotherapy	B-UNK
may	O
have	O
contributed	O
the	O
development	B-UNK
of	O
ABS	O
.	O

Reduction	O
of	O
pain	B-DISEASE
during	O
induction	B-UNK
with	O
target	O
-	O
controlled	B-UNK
propofol	B-CHEMICAL
and	O
remifentanil	B-CHEMICAL
.	O

BACKGROUND	O
:	O
Pain	O
on	O
injection	B-UNK
of	O
propofol	B-CHEMICAL
is	O
unpleasant	O
.	O
We	O
hypothesized	O
that	O
propofol	B-CHEMICAL
infusion	B-UNK
pain	B-UNK
might	O
be	O
prevented	B-UNK
by	O
infusing	O
remifentanil	B-CHEMICAL
before	O
starting	B-UNK
the	O
propofol	B-CHEMICAL
infusion	B-UNK
in	O
a	O
clinical	B-UNK
setting	B-UNK
where	O
target	O
-	O
controlled	B-UNK
infusions	O
(	O
TCI	O
)	O
of	O
both	O
drugs	B-UNK
were	O
used	O
.	O
A	O
prospective	B-UNK
,	O
randomized	B-UNK
,	O
double-blind	B-UNK
,	O
placebo	B-UNK
-	O
controlled	B-UNK
trial	B-UNK
was	O
performed	B-UNK
to	O
determine	B-UNK
the	O
effect	B-UNK
-	O
site	B-UNK
concentration	B-UNK
(	O
Ce	O
)	O
of	O
remifentanil	B-CHEMICAL
to	O
prevent	B-UNK
the	O
pain	B-DISEASE
without	O
producing	O
complications	B-UNK
.	O
METHODS	O
:	O
A	O
total	B-UNK
of	O
128	O
patients	B-UNK
undergoing	B-UNK
general	B-UNK
surgery	B-UNK
were	O
randomly	B-UNK
allocated	B-UNK
to	O
receive	B-UNK
normal	B-UNK
saline	B-UNK
(	O
control	B-UNK
)	O
or	O
remifentanil	B-CHEMICAL
to	O
a	O
target	O
Ce	O
of	O
2	B-DISEASE
ng	B-UNK
ml(-1	B-UNK
)	O
(	O
R2	O
)	O
,	O
4	O
ng	B-UNK
ml(-1	B-UNK
)	O
(	O
R4	B-UNK
)	O
,	O
or	O
6	O
ng	B-UNK
ml(-1	B-UNK
)	O
(	O
R6	O
)	O
administered	B-UNK
via	O
TCI	O
.	O
After	O
the	O
target	O
Ce	O
was	O
achieved	B-UNK
,	O
the	O
infusion	B-UNK
of	O
propofol	B-CHEMICAL
was	O
started	B-UNK
.	O
Remifentanil	O
-	O
related	B-UNK
complications	B-UNK
were	O
assessed	B-UNK
during	O
the	O
remifentanil	B-CHEMICAL
infusion	B-UNK
,	O
and	O
pain	B-UNK
caused	B-UNK
by	O
propofol	B-CHEMICAL
was	O
evaluated	B-UNK
using	O
a	O
four	O
-	O
point	O
scale	B-UNK
during	O
the	O
propofol	B-CHEMICAL
infusion	B-UNK
.	O
RESULTS	B-UNK
:	O
The	O
incidence	B-UNK
of	O
pain	B-UNK
was	O
significantly	B-UNK
lower	B-UNK
in	O
Groups	B-UNK
R4	B-UNK
and	O
R6	O
than	O
in	O
the	O
control	B-UNK
and	O
R2	O
groups	B-UNK
(	O
12/32	O
and	O
6/31	O
vs	B-UNK
26/31	O
and	O
25/32	O
,	O
respectively	O
,	O
P<0.001	O
)	O
.	O
Pain	O
was	O
less	O
severe	B-UNK
in	O
Groups	B-UNK
R4	B-UNK
and	O
R6	O
than	O
in	O
the	O
control	B-UNK
and	O
R2	O
groups	B-UNK
(	O
P<0.001	O
)	O
.	O
However	O
,	O
both	O
incidence	B-UNK
and	O
severity	B-UNK
of	O
pain	B-UNK
were	O
not	O
different	B-UNK
between	O
Groups	B-UNK
R4	B-UNK
and	O
R6	O
.	O
No	O
significant	B-UNK
complications	B-UNK
were	O
observed	B-UNK
during	O
the	O
study	B-UNK
.	O
CONCLUSIONS	O
:	O
During	O
induction	B-UNK
of	O
anaesthesia	B-UNK
with	O
TCI	O
of	O
propofol	B-CHEMICAL
and	O
remifentanil	B-CHEMICAL
,	O
a	O
significant	B-UNK
reduction	B-UNK
in	O
propofol	B-CHEMICAL
infusion	B-UNK
pain	B-UNK
was	O
achieved	B-UNK
without	O
significant	B-UNK
complications	B-UNK
by	O
prior	B-UNK
administration	B-UNK
of	O
remifentanil	B-CHEMICAL
at	B-DISEASE
a	O
target	O
Ce	O
of	O
4	O
ng	B-UNK
ml(-1	B-UNK
)	O
.	O

Prenatal	O
exposure	B-UNK
to	O
fluoxetine	B-CHEMICAL
induces	B-UNK
fetal	B-UNK
pulmonary	B-DISEASE
hypertension	I-DISEASE
in	O
the	O
rat	B-UNK
.	O

RATIONALE	O
:	O
Fluoxetine	O
is	O
a	O
selective	B-UNK
serotonin	B-CHEMICAL
reuptake	B-UNK
inhibitor	B-UNK
antidepressant	B-UNK
widely	B-UNK
used	O
by	O
pregnant	B-UNK
women	B-UNK
.	O
Epidemiological	O
data	B-UNK
suggest	B-UNK
that	O
fluoxetine	B-CHEMICAL
exposure	B-UNK
prenatally	O
increases	B-UNK
the	O
prevalence	O
of	O
persistent	O
pulmonary	B-DISEASE
hypertension	I-DISEASE
syndrome	B-UNK
of	O
the	O
newborn	O
.	O
The	O
mechanism	B-UNK
responsible	O
for	O
this	O
effect	B-UNK
is	O
unclear	O
and	O
paradoxical	O
,	O
considering	O
the	O
current	B-UNK
evidence	B-UNK
of	O
a	O
pulmonary	B-DISEASE
hypertension	I-DISEASE
protective	B-UNK
fluoxetine	B-CHEMICAL
effect	B-UNK
in	O
adult	B-UNK
rodents	O
.	O
OBJECTIVES	O
:	O
To	O
evaluate	B-UNK
the	O
fluoxetine	B-CHEMICAL
effect	B-UNK
on	O
fetal	B-UNK
rat	B-UNK
pulmonary	B-UNK
vascular	B-UNK
smooth	B-UNK
muscle	I-UNK
mechanical	B-UNK
properties	B-UNK
and	O
cell	B-UNK
proliferation	B-UNK
rate	B-UNK
.	O
METHODS	O
:	O
Pregnant	O
rats	B-UNK
were	O
treated	B-UNK
with	O
fluoxetine	B-CHEMICAL
(	O
10	O
mg	B-UNK
/	O
kg	B-UNK
)	O
from	O
Day	O
11	O
through	O
Day	O
21	O
of	O
gestation	O
.	O
MEASUREMENTS	O
AND	O
MAIN	B-UNK
RESULTS	B-UNK
:	O
Fetuses	O
were	O
delivered	O
by	O
cesarean	B-UNK
section	O
.	O
As	O
compared	B-UNK
with	O
controls	B-UNK
,	O
fluoxetine	B-CHEMICAL
exposure	B-UNK
resulted	B-UNK
in	O
fetal	B-UNK
pulmonary	B-DISEASE
hypertension	I-DISEASE
as	O
evidenced	O
by	O
an	O
increase	B-UNK
in	O
the	O
weight	B-UNK
ratio	B-UNK
of	O
the	O
right	B-UNK
ventricle	O
to	O
the	O
left	B-UNK
ventricle	O
plus	B-UNK
septum	O
(	O
P	B-UNK
=	I-UNK
0.02	O
)	O
and	O
by	O
an	O
increase	B-UNK
in	O
pulmonary	B-UNK
arterial	B-UNK
medial	B-UNK
thickness	B-UNK
(	O
P	B-UNK
<	I-UNK
0.01	B-UNK
)	O
.	O
Postnatal	O
mortality	B-UNK
was	O
increased	B-UNK
among	O
experimental	B-UNK
animals	B-UNK
,	O
and	O
arterial	B-UNK
oxygen	B-CHEMICAL
saturation	O
was	O
96	O
+	O
/-	O
1	O
%	O
in	O
1-day	O
-	O
old	B-UNK
control	B-UNK
animals	B-UNK
and	O
significantly	B-UNK
lower	B-UNK
(	O
P	B-UNK
<	I-UNK
0.01	B-UNK
)	O
in	O
fluoxetine	B-CHEMICAL
-	O
exposed	B-UNK
pups	O
(	O
79	O
+	O
/-	O
2	B-DISEASE
%	O
)	O
.	O
In	O
vitro	B-UNK
,	O
fluoxetine	B-CHEMICAL
induced	B-UNK
pulmonary	B-UNK
arterial	B-UNK
muscle	B-UNK
contraction	B-UNK
in	O
fetal	B-UNK
,	O
but	O
not	O
adult	B-UNK
,	O
animals	B-UNK
(	O
P	B-UNK
<	I-UNK
0.01	B-UNK
)	O
and	O
reduced	B-UNK
serotonin	B-CHEMICAL
-	O
induced	B-UNK
contraction	B-UNK
at	B-DISEASE
both	O
ages	O
(	O
P	B-UNK
<	I-UNK
0.01	B-UNK
)	O
.	O
After	O
in	O
utero	O
exposure	B-UNK
to	O
a	O
low	B-UNK
fluoxetine	B-CHEMICAL
concentration	B-UNK
the	O
pulmonary	B-UNK
arterial	B-UNK
smooth	B-UNK
muscle	I-UNK
cell	B-UNK
proliferation	B-UNK
rate	B-UNK
was	O
significantly	B-UNK
increased	B-UNK
in	O
fetal	B-UNK
,	O
but	O
not	O
adult	B-UNK
,	O
cells	B-UNK
(	O
P	B-UNK
<	I-UNK
0.01	B-UNK
)	O
.	O
CONCLUSIONS	O
:	O
In	O
contrast	B-UNK
to	O
the	O
adult	B-UNK
,	O
fluoxetine	B-CHEMICAL
exposure	B-UNK
in	O
utero	O
induces	B-UNK
pulmonary	B-DISEASE
hypertension	I-DISEASE
in	O
the	O
fetal	B-UNK
rat	B-UNK
as	O
a	O
result	B-UNK
of	O
a	O
developmentally	O
regulated	O
increase	B-UNK
in	O
pulmonary	B-UNK
vascular	B-UNK
smooth	B-UNK
muscle	I-UNK
proliferation	B-UNK
.	O

Syncope	O
and	O
QT	B-UNK
prolongation	B-UNK
among	O
patients	B-UNK
treated	B-UNK
with	O
methadone	B-CHEMICAL
for	O
heroin	B-DISEASE
dependence	I-DISEASE
in	O
the	O
city	O
of	O
Copenhagen	O
.	O

BACKGROUND	O
:	O
Methadone	O
is	O
prescribed	B-UNK
to	O
heroin	B-CHEMICAL
addicts	O
to	O
decrease	B-UNK
illicit	O
opioid	B-UNK
use	B-UNK
.	O
Prolongation	O
of	O
the	O
QT	B-UNK
interval	B-UNK
in	O
the	O
ECG	B-UNK
of	O
patients	B-UNK
with	O
torsade	B-UNK
de	B-UNK
pointes	O
(	O
TdP	O
)	O
has	O
been	O
reported	B-UNK
in	O
methadone	B-CHEMICAL
users	B-UNK
.	O
As	O
heroin	B-CHEMICAL
addicts	O
sometimes	O
faint	O
while	O
using	O
illicit	O
drugs	B-UNK
,	O
doctors	O
might	O
attribute	O
too	O
many	O
episodes	B-UNK
of	O
syncope	B-DISEASE
to	O
illicit	O
drug	B-UNK
use	B-UNK
and	O
thereby	O
underestimate	O
the	O
incidence	B-UNK
of	O
TdP	O
in	O
this	O
special	O
population	B-UNK
,	O
and	O
the	O
high	B-UNK
mortality	B-UNK
in	O
this	O
population	B-UNK
may	O
,	O
in	O
part	O
,	O
be	O
caused	B-UNK
by	O
the	O
proarrhythmic	O
effect	B-UNK
of	O
methadone	B-CHEMICAL
.	O
METHODS	O
:	O
In	O
this	O
cross-sectional	O
study	B-UNK
interview	O
,	O
ECGs	O
and	O
blood	B-UNK
samples	B-UNK
were	O
collected	B-UNK
in	O
a	O
population	B-UNK
of	O
adult	B-UNK
heroin	B-CHEMICAL
addicts	O
treated	B-UNK
with	O
methadone	B-CHEMICAL
or	O
buprenorphine	B-CHEMICAL
on	O
a	O
daily	B-UNK
basis	B-UNK
.	O
Of	O
the	O
patients	B-UNK
at	B-DISEASE
the	O
Drug	B-UNK
Addiction	O
Service	O
in	O
the	O
municipal	O
of	O
Copenhagen	O
,	O
450	O
(	O
approximately	B-UNK
52	O
%	O
)	O
were	O
included	B-UNK
.	O
The	O
QT	B-UNK
interval	B-UNK
was	O
estimated	B-UNK
from	O
12	O
lead	B-CHEMICAL
ECGs	O
.	O
All	O
participants	O
were	O
interviewed	O
about	O
any	O
experience	B-UNK
of	O
syncope	B-DISEASE
.	O
The	O
association	B-UNK
between	O
opioid	B-UNK
dose	B-UNK
and	O
QT	B-UNK
,	O
and	O
methadone	B-CHEMICAL
dose	B-UNK
and	O
reporting	B-UNK
of	O
syncope	B-DISEASE
was	O
assessed	B-UNK
using	O
multivariate	B-UNK
linear	O
regression	B-UNK
and	O
logistic	O
regression	B-UNK
,	O
respectively	O
.	O
RESULTS	B-UNK
:	O
Methadone	O
dose	B-UNK
was	O
associated	B-UNK
with	O
longer	B-UNK
QT	B-UNK
interval	B-UNK
of	O
0.140	O
ms	B-DISEASE
/	O
mg	B-UNK
(	O
p	B-UNK
=	I-UNK
0.002	O
)	O
.	O
No	O
association	B-UNK
between	O
buprenorphine	B-CHEMICAL
and	O
QTc	B-UNK
was	O
found	B-UNK
.	O
Among	O
the	O
subjects	B-UNK
treated	B-UNK
with	O
methadone	B-CHEMICAL
,	O
28	O
%	O
men	O
and	O
32	O
%	O
women	B-UNK
had	O
prolonged	B-UNK
QTc	B-UNK
interval	B-UNK
.	O
None	O
of	O
the	O
subjects	B-UNK
treated	B-UNK
with	O
buprenorphine	B-CHEMICAL
had	O
QTc	B-UNK
interval	B-UNK
>	O
0.440	O
s((1/2	O
)	O
)	O
.	O
A	O
50	O
mg	B-UNK
higher	B-UNK
methadone	B-CHEMICAL
dose	B-UNK
was	O
associated	B-UNK
with	O
a	O
1.2	O
(	O
95	O
%	O
CI	B-UNK
1.1	B-UNK
to	O
1.4	O
)	O
times	B-UNK
higher	B-UNK
odds	B-UNK
for	O
syncope	B-DISEASE
.	O
CONCLUSIONS	O
:	O
Methadone	O
is	O
associated	B-UNK
with	O
QT	B-UNK
prolongation	B-UNK
and	O
higher	B-UNK
reporting	B-UNK
of	O
syncope	B-DISEASE
in	O
a	O
population	B-UNK
of	O
heroin	B-CHEMICAL
addicts	O
.	O

Peripheral	O
neuropathy	B-DISEASE
caused	B-UNK
by	O
high	B-UNK
-	O
dose	B-UNK
cytosine	B-CHEMICAL
arabinoside	O
treatment	B-UNK
in	O
a	O
patient	B-UNK
with	O
acute	B-UNK
myeloid	O
leukemia	B-DISEASE
.	O

The	O
central	B-UNK
nervous	I-UNK
system	B-UNK
toxicity	B-UNK
of	O
high	B-UNK
-	O
dose	B-UNK
cytosine	B-CHEMICAL
arabinoside	O
is	O
well	O
recognized	B-UNK
,	O
but	O
the	O
toxicity	B-UNK
of	O
cytosine	B-CHEMICAL
arabinoside	O
in	O
the	O
peripheral	B-UNK
nervous	B-UNK
system	I-UNK
has	O
been	O
infrequently	O
reported	B-UNK
.	O
A	O
49-year	O
-	O
old	B-UNK
Japanese	O
man	B-UNK
was	O
diagnosed	B-UNK
with	O
acute	B-UNK
myeloid	O
leukemia	B-DISEASE
.	O
After	O
he	O
achieved	B-UNK
complete	B-UNK
remission	B-DISEASE
,	O
he	O
received	B-UNK
high	B-UNK
-	O
dose	B-UNK
cytosine	B-CHEMICAL
arabinoside	O
treatment	B-UNK
(	O
2	B-DISEASE
g	B-UNK
/	O
m2	O
twice	B-UNK
a	O
day	B-UNK
for	O
5	O
days	B-UNK
;	O
total	B-UNK
,	O
20	O
g	B-UNK
/	O
m2	O
)	O
as	O
consolidation	O
therapy	B-UNK
.	O
The	O
first	O
course	B-UNK
of	O
high	B-UNK
-	O
dose	B-UNK
cytosine	B-CHEMICAL
arabinoside	O
resulted	B-UNK
in	O
no	O
unusual	O
symptoms	B-UNK
,	O
but	O
on	O
day	B-UNK
21	O
of	O
the	O
second	B-UNK
course	B-UNK
of	O
treatment	B-UNK
,	O
the	O
patient	B-UNK
complained	O
of	O
numbness	O
in	O
his	O
right	B-UNK
foot	B-UNK
.	O
Electromyogram	O
and	O
nerve	B-UNK
-	O
conduction	B-UNK
studies	B-UNK
showed	B-UNK
peripheral	B-DISEASE
neuropathy	I-DISEASE
in	O
both	O
peroneal	O
nerves	B-UNK
.	O
This	O
neuropathy	B-DISEASE
was	O
gradually	B-UNK
resolving	O
;	O
however	O
,	O
after	O
the	O
patient	B-UNK
received	B-UNK
allogeneic	O
bone	B-UNK
marrow	B-UNK
transplantation	B-UNK
,	O
the	O
symptoms	B-UNK
worsened	O
,	O
with	O
the	O
development	B-UNK
of	O
graft	O
-	O
versus	B-UNK
-	O
host	O
disease	B-DISEASE
,	O
and	O
the	O
symptoms	B-UNK
subsequently	B-UNK
responded	O
to	O
methylprednisolone	B-CHEMICAL
.	O
Although	O
the	O
mechanisms	B-UNK
of	O
peripheral	B-DISEASE
neuropathy	I-DISEASE
are	O
still	O
unclear	O
,	O
high	B-UNK
-	O
dose	B-UNK
cytosine	B-CHEMICAL
arabinoside	O
is	O
a	O
therapy	B-UNK
that	O
is	O
potentially	B-UNK
toxic	B-UNK
to	O
the	O
peripheral	B-UNK
nervous	B-UNK
system	I-UNK
,	O
and	O
auto	O
/	O
alloimmunity	O
may	O
play	B-UNK
an	O
important	B-UNK
role	B-UNK
in	O
these	O
mechanisms	B-UNK
.	O

Atorvastatin	O
prevented	B-UNK
and	O
reversed	B-UNK
dexamethasone	B-CHEMICAL
-	O
induced	B-UNK
hypertension	B-DISEASE
in	O
the	O
rat	B-UNK
.	O

To	O
assess	B-UNK
the	O
antioxidant	B-UNK
effects	B-UNK
of	O
atorvastatin	B-CHEMICAL
(	O
atorva	O
)	O
on	O
dexamethasone	B-CHEMICAL
(	O
dex)-induced	O
hypertension	B-DISEASE
,	O
60	O
male	B-UNK
Sprague	B-UNK
-	O
Dawley	B-UNK
rats	B-UNK
were	O
treated	B-UNK
with	O
atorva	O
30	O
mg	B-UNK
/	O
kg	B-UNK
/	O
day	B-UNK
or	O
tap	O
water	B-CHEMICAL
for	O
15	O
days	B-UNK
.	O
Dex	O
increased	B-UNK
systolic	B-UNK
blood	B-UNK
pressure	B-UNK
(	O
SBP	O
)	O
from	O
109	O
+	O
/-	O
1.8	O
to	O
135	O
+	O
/-	O
0.6	B-UNK
mmHg	B-UNK
and	O
plasma	B-UNK
superoxide	B-UNK
(	O
5711	O
+	O
/-	O
284.9	O
saline	B-UNK
,	O
7931	O
+	O
/-	O
392.8	O
U	B-UNK
/	O
ml	B-UNK
dex	B-UNK
,	O
P	B-UNK
<	I-UNK
0.001	B-UNK
)	O
.	O
In	O
this	O
prevention	O
study	B-UNK
,	O
SBP	O
in	O
the	O
atorva	O
+	O
dex	B-UNK
group	B-UNK
was	O
increased	B-UNK
from	O
115	O
+	O
/-	O
0.4	O
to	O
124	O
+	O
/-	O
1.5	B-UNK
mmHg	B-UNK
,	O
but	O
this	O
was	O
significantly	B-UNK
lower	B-UNK
than	O
in	O
the	O
dex	B-UNK
-	O
only	O
group	B-UNK
(	O
P	B-UNK
'	O
<	B-UNK
0.05	I-UNK
)	O
.	O
Atorva	O
reversed	B-UNK
dex	B-UNK
-	O
induced	B-UNK
hypertension	B-DISEASE
(	O
129	O
+	O
/-	O
0.6	B-UNK
mmHg	B-UNK
,	O
vs	B-UNK
.	O
135	O
+	O
/-	O
0.6	B-UNK
mmHg	B-UNK
P	B-UNK
'	O
<	B-UNK
0.05	I-UNK
)	O
and	O
decreased	B-UNK
plasma	B-UNK
superoxide	B-UNK
(	O
7931	O
+	O
/-	O
392.8	O
dex	B-UNK
,	O
1187	O
+	O
/-	O
441.2	O
atorva	O
+	O
dex	B-UNK
,	O
P	B-UNK
<	I-UNK
0.0001	O
)	O
.	O
Plasma	B-UNK
nitrate	O
/	O
nitrite	O
(	O
NOx	O
)	O
was	O
decreased	B-UNK
in	O
dex	B-UNK
-	O
treated	B-UNK
rats	B-UNK
compared	B-UNK
to	O
saline	B-UNK
-	O
treated	B-UNK
rats	B-UNK
(	O
11.2	O
+	O
/-	O
1.08	O
microm	B-UNK
,	O
15.3	O
+	O
/-	O
1.17	O
microm	B-UNK
,	O
respectively	O
,	O
P	B-UNK
<	I-UNK
0.05	O
)	O
.	O
Atorva	O
affected	B-UNK
neither	O
plasma	B-UNK
NOx	O
nor	O
thymus	O
weight	B-UNK
.	O
Thus	O
,	O
atorvastatin	B-CHEMICAL
prevented	B-UNK
and	O
reversed	B-UNK
dexamethasone	B-CHEMICAL
-	O
induced	B-UNK
hypertension	B-DISEASE
in	O
the	O
rat	B-UNK
.	O

Two	O
prodrugs	O
of	O
potent	B-UNK
and	O
selective	B-UNK
GluR5	O
kainate	O
receptor	B-UNK
antagonists	B-UNK
actives	O
in	O
three	O
animal	B-UNK
models	B-UNK
of	O
pain	B-UNK
.	O

Amino	O
acids	B-CHEMICAL
5	O
and	O
7	O
,	O
two	O
potent	B-UNK
and	O
selective	B-UNK
competitive	O
GluR5	O
KA	O
receptor	B-UNK
antagonists	B-UNK
,	O
exhibited	B-UNK
high	B-UNK
GluR5	O
receptor	B-UNK
affinity	B-UNK
over	O
other	O
glutamate	B-UNK
receptors	B-UNK
.	O
Their	O
ester	B-UNK
prodrugs	O
6	O
and	O
8	O
were	O
orally	B-UNK
active	B-UNK
in	O
three	O
models	B-UNK
of	O
pain	B-UNK
:	O
reversal	B-UNK
of	O
formalin	O
-	O
induced	B-UNK
paw	O
licking	O
,	O
carrageenan	B-CHEMICAL
-	O
induced	B-UNK
thermal	O
hyperalgesia	B-DISEASE
,	O
and	O
capsaicin	B-CHEMICAL
-	O
induced	B-UNK
mechanical	B-UNK
hyperalgesia	B-DISEASE
.	O

Sirolimus	O
and	O
mycophenolate	O
mofetil	O
for	O
calcineurin	B-UNK
-	O
free	B-UNK
immunosuppression	B-UNK
in	O
renal	B-UNK
transplant	B-UNK
recipients	B-UNK
.	O

Calcineurin	O
inhibitors	B-UNK
,	O
such	O
as	O
cyclosporine	B-CHEMICAL
and	O
tacrolimus	B-CHEMICAL
,	O
have	O
been	O
available	B-UNK
for	O
almost	O
20	O
years	B-UNK
.	O
Although	O
these	O
drugs	B-UNK
are	O
highly	B-UNK
effective	B-UNK
and	O
represent	B-UNK
the	O
mainstay	O
of	O
transplant	B-UNK
immunosuppression	B-UNK
,	O
they	O
are	O
associated	B-UNK
with	O
acute	B-UNK
and	O
chronic	B-UNK
nephrotoxicity	B-UNK
.	O
Acute	B-UNK
nephrotoxicity	B-UNK
,	O
which	O
occurs	B-UNK
in	O
the	O
early	B-UNK
period	B-UNK
after	O
transplantation	B-UNK
,	O
leads	O
to	O
a	O
higher	B-UNK
rate	B-UNK
of	O
dialysis	O
,	O
and	O
chronic	B-UNK
nephrotoxicity	B-UNK
may	O
eventually	O
result	B-UNK
in	O
graft	O
loss	B-UNK
.	O
Acute	B-UNK
and	O
chronic	B-UNK
nephrotoxicity	B-UNK
is	O
becoming	O
more	O
common	B-UNK
as	O
the	O
use	B-UNK
of	O
marginal	O
kidneys	B-UNK
for	O
transplantation	B-UNK
increases	B-UNK
.	O
Two	O
recently	B-UNK
available	B-UNK
immunosuppressive	B-CHEMICAL
agents	I-CHEMICAL
,	O
mycophenolate	O
mofetil	O
and	O
sirolimus	B-CHEMICAL
(	O
rapamycin	B-UNK
)	O
,	O
have	O
no	O
nephrotoxicity	B-UNK
.	O
The	O
use	B-UNK
of	O
these	O
drugs	B-UNK
in	O
combination	B-UNK
with	O
other	O
agents	B-UNK
has	O
led	B-UNK
to	O
the	O
development	B-UNK
of	O
new	B-UNK
paradigms	O
of	O
immunosuppressive	B-UNK
therapy	B-UNK
.	O
This	O
paper	O
reviews	O
the	O
results	B-UNK
of	O
clinical	B-UNK
trials	B-UNK
that	O
have	O
investigated	B-UNK
these	O
new	B-UNK
approaches	O
to	O
immunosuppression	B-UNK
in	O
renal	B-UNK
transplant	B-UNK
recipients	B-UNK
.	O

Erythropoietin	O
restores	O
the	O
anemia	B-DISEASE
-	O
induced	B-UNK
reduction	B-UNK
in	O
cyclophosphamide	B-CHEMICAL
cytotoxicity	O
in	O
rat	B-UNK
tumors	B-UNK
.	O

The	O
aim	O
of	O
this	O
study	B-UNK
was	O
to	O
examine	O
the	O
impact	B-UNK
of	O
anemia	B-DISEASE
prevention	O
by	O
recombinant	O
human	B-UNK
erythropoietin	B-CHEMICAL
(	O
rHuEPO	B-UNK
)	O
treatment	B-UNK
on	O
the	O
cytotoxicity	O
of	O
cyclophosphamide	B-CHEMICAL
in	O
solid	O
experimental	B-UNK
tumors	B-UNK
.	O
Anemia	O
was	O
induced	B-UNK
using	O
a	O
single	B-UNK
dose	B-UNK
of	O
carboplatin	B-CHEMICAL
(	O
50	O
mg	B-UNK
/	O
kg	B-UNK
i.v	B-UNK
.	O
)	O
resulting	B-UNK
in	O
a	O
long	B-UNK
-	O
lasting	B-UNK
reduction	B-UNK
(	O
30	O
%	O
)	O
of	O
the	O
hemoglobin	B-UNK
concentration	B-UNK
.	O
In	O
a	O
second	B-UNK
group	B-UNK
,	O
the	O
development	B-UNK
of	O
anemia	B-DISEASE
was	O
prevented	B-UNK
by	O
rHuEPO	B-UNK
(	O
1000	O
IU	O
/	O
kg	B-UNK
)	O
administered	B-UNK
s.c	B-UNK
.	O
three	O
times	B-UNK
/	O
week	B-UNK
starting	B-UNK
7	O
days	B-UNK
before	O
carboplatin	B-CHEMICAL
application	B-UNK
.	O
Four	O
days	B-UNK
after	O
carboplatin	B-CHEMICAL
treatment	B-UNK
,	O
tumors	B-UNK
(	O
DS	O
-	O
sarcoma	B-DISEASE
of	O
the	O
rat	B-UNK
)	O
were	O
implanted	B-UNK
s.c	B-UNK
.	O
onto	O
the	O
hind	O
food	B-UNK
dorsum	O
.	O
Neither	O
carboplatin	B-CHEMICAL
nor	O
rHuEPO	B-UNK
treatment	B-UNK
influenced	O
tumor	B-DISEASE
growth	B-UNK
rate	B-UNK
per	O
se	O
.	O
When	O
tumors	B-UNK
were	O
treated	B-UNK
with	O
a	O
single	B-UNK
dose	B-UNK
of	O
cyclophosphamide	B-CHEMICAL
(	O
60	O
mg	B-UNK
/	O
kg	B-UNK
i.p	B-UNK
.	O
)	O
5	O
days	B-UNK
after	O
implantation	O
,	O
a	O
growth	B-UNK
delay	B-UNK
with	O
a	O
subsequent	B-UNK
regrowth	O
of	O
the	O
tumors	B-UNK
was	O
observed	B-UNK
.	O
In	O
the	O
anemia	B-DISEASE
group	B-UNK
,	O
the	O
growth	B-UNK
delay	B-UNK
was	O
significantly	B-UNK
shorter	O
compared	B-UNK
with	O
nonanemic	O
controls	B-UNK
(	O
13.3	O
days	B-UNK
versus	B-UNK
8.6	O
days	B-UNK
)	O
.	O
In	O
the	O
group	B-UNK
where	O
anemia	B-DISEASE
was	O
prevented	B-UNK
by	O
rHuEPO	B-UNK
treatment	B-UNK
,	O
growth	B-UNK
delay	B-UNK
was	O
comparable	B-UNK
with	O
that	O
of	O
nonanemic	O
controls	B-UNK
(	O
13.3	O
days	B-UNK
)	O
.	O
These	O
results	B-UNK
suggest	B-UNK
that	O
chemotherapy	B-UNK
-	O
induced	B-UNK
anemia	B-DISEASE
reduces	B-UNK
cytotoxicity	O
of	O
cyclophosphamide	B-CHEMICAL
in	O
tumors	B-UNK
,	O
whereas	O
correction	O
of	O
anemia	B-DISEASE
by	O
rHuEPO	B-UNK
treatment	B-UNK
(	O
epoetin	O
alpha	B-UNK
)	O
increases	B-UNK
the	O
sensitivity	B-UNK
,	O
probably	B-UNK
as	O
a	O
result	B-UNK
of	O
an	O
improved	B-UNK
oxygen	B-CHEMICAL
supply	O
to	O
tumor	B-DISEASE
tissue	B-UNK
.	O

The	O
role	B-UNK
of	O
nitrergic	O
system	B-UNK
in	O
lidocaine	B-CHEMICAL
-	O
induced	B-UNK
convulsion	O
in	O
the	O
mouse	B-UNK
.	O

The	O
effects	B-UNK
of	O
N	B-UNK
-	O
nitro	O
-	O
L	B-UNK
-	O
arginine	B-CHEMICAL
-	O
methyl	O
ester	B-UNK
(	O
L	B-UNK
-	O
NAME	O
)	O
a	O
nitric	B-CHEMICAL
oxide	I-CHEMICAL
(	O
NO	O
)	O
synthase	B-UNK
inhibitor	B-UNK
and	O
L	B-UNK
-	O
arginine	B-CHEMICAL
,	O
a	O
NO	O
precursor	O
,	O
were	O
investigated	B-UNK
on	O
lidocaine	B-CHEMICAL
-	O
induced	B-UNK
convulsions	B-DISEASE
.	O
In	O
the	O
first	O
experiment	B-UNK
,	O
four	O
groups	B-UNK
of	O
mice	B-UNK
received	B-UNK
physiological	O
saline	B-UNK
(	O
0.9	O
%	O
)	O
,	O
L	B-UNK
-	O
arginine	B-CHEMICAL
(	O
300	O
mg	B-UNK
/	O
kg	B-UNK
,	O
i.p	B-UNK
.	O
)	O
,	O
L	B-UNK
-	O
NAME	O
(	O
100	O
mg	B-UNK
/	O
kg	B-UNK
,	O
i.p	B-UNK
.	O
)	O
and	O
diazepam	B-CHEMICAL
(	O
2	B-DISEASE
mg	B-UNK
/	O
kg	B-UNK
)	O
,	O
respectively	O
.	O
Thirty	O
minutes	B-UNK
after	O
these	O
injections	B-UNK
,	O
all	O
mice	B-UNK
received	B-UNK
lidocaine	B-CHEMICAL
(	O
50	O
mg	B-UNK
/	O
kg	B-UNK
,	O
i.p	B-UNK
.	O
)	O
.	O
In	O
the	O
second	B-UNK
experiment	B-UNK
,	O
four	O
groups	B-UNK
of	O
mice	B-UNK
received	B-UNK
similar	B-UNK
treatment	B-UNK
in	O
the	O
first	O
experiment	B-UNK
,	O
and	O
30	O
min	B-UNK
after	O
these	O
injections	B-UNK
,	O
all	O
mice	B-UNK
received	B-UNK
a	O
higher	B-UNK
dose	B-UNK
of	O
lidocaine	B-CHEMICAL
(	O
80	O
mg	B-UNK
/	O
kg	B-UNK
)	O
.	O
L	B-UNK
-	O
NAME	O
(	O
100	O
mg	B-UNK
/	O
kg	B-UNK
,	O
i.p	B-UNK
.	O
)	O
and	O
diazepam	B-CHEMICAL
(	O
2	B-DISEASE
mg	B-UNK
/	O
kg	B-UNK
)	O
significantly	B-UNK
decreased	B-UNK
the	O
incidence	B-UNK
of	O
lidocaine	B-CHEMICAL
(	O
50	O
mg	B-UNK
/	O
kg)-induced	O
convulsions	B-DISEASE
.	O
In	O
contrast	B-UNK
,	O
the	O
L	B-UNK
-	O
arginine	B-CHEMICAL
treatment	B-UNK
increased	B-UNK
the	O
incidence	B-UNK
of	O
lidocaine	B-CHEMICAL
(	O
80	O
mg	B-UNK
/	O
kg	B-UNK
,	O
i.p.)-induced	O
convulsions	B-DISEASE
significantly	B-UNK
.	O
These	O
results	B-UNK
may	O
suggest	B-UNK
that	O
NO	O
is	O
a	O
proconvulsant	O
mediator	B-UNK
in	O
lidocaine	B-CHEMICAL
-	O
induced	B-UNK
convulsions	B-DISEASE
.	O

Effect	O
of	O
intravenous	B-UNK
metoprolol	B-CHEMICAL
or	O
intravenous	B-UNK
metoprolol	B-CHEMICAL
plus	B-UNK
glucagon	B-CHEMICAL
on	O
dobutamine	B-CHEMICAL
-	O
induced	B-UNK
myocardial	B-DISEASE
ischemia	I-DISEASE
.	O

STUDY	B-UNK
OBJECTIVE	O
:	O
To	O
determine	B-UNK
the	O
effect	B-UNK
of	O
metoprolol	B-CHEMICAL
on	O
dobutamine	B-CHEMICAL
stress	B-UNK
testing	B-UNK
with	O
technetium-99	B-CHEMICAL
m	O
sestamibi	O
single	B-UNK
-	O
photon	B-UNK
emission	B-UNK
computed	O
tomography	B-UNK
imaging	B-UNK
and	O
ST	B-UNK
-	O
segment	B-UNK
monitoring	B-UNK
,	O
and	O
to	O
assess	B-UNK
the	O
impact	B-UNK
of	O
intravenous	B-UNK
glucagon	B-CHEMICAL
on	O
metoprolol'	O
s	O
effects	B-UNK
.	O
DESIGN	B-UNK
:	O
Randomized	O
,	O
double-blind	B-UNK
,	O
placebo	B-UNK
-	O
controlled	B-UNK
trial	B-UNK
.	O
SETTING	O
:	O
Community	O
hospital	B-UNK
.	O
PATIENTS	O
:	O
Twenty	O
-	O
two	O
patients	B-UNK
with	O
known	B-UNK
reversible	B-UNK
perfusion	B-UNK
defects	B-UNK
.	O
INTERVENTION	O
:	O
Patients	B-UNK
underwent	B-UNK
dobutamine	B-CHEMICAL
stress	B-UNK
tests	B-UNK
per	O
standard	B-UNK
protocol	B-UNK
.	O
Before	O
dobutamine	B-CHEMICAL
was	O
begun	O
,	O
no	O
therapy	B-UNK
was	O
given	B-UNK
during	O
the	O
first	O
visit	O
,	O
and	O
patients	B-UNK
were	O
randomized	B-UNK
on	O
subsequent	B-UNK
visits	O
to	O
receive	B-UNK
metoprolol	B-CHEMICAL
or	O
metoprolol	B-CHEMICAL
plus	B-UNK
glucagon	B-CHEMICAL
1	O
mg	B-UNK
.	O
Metoprolol	O
was	O
dosed	O
to	O
achieve	O
a	O
resting	B-UNK
predobutamine	O
heart	B-UNK
rate	I-UNK
below	O
65	O
beats	B-UNK
/	O
minute	O
or	O
a	O
total	B-UNK
intravenous	B-UNK
dose	B-UNK
of	O
20	O
mg	B-UNK
.	O
MEASUREMENTS	O
AND	O
MAIN	B-UNK
RESULTS	B-UNK
:	O
Metoprolol	O
reduced	B-UNK
maximum	B-UNK
heart	B-UNK
rate	I-UNK
31	O
%	O
,	O
summed	O
stress	B-UNK
scores	B-UNK
29	O
%	O
,	O
and	O
summed	O
difference	B-UNK
scores	B-UNK
43	O
%	O
versus	B-UNK
control	B-UNK
.	O
Metoprolol	O
plus	B-UNK
glucagon	B-CHEMICAL
also	O
reduced	B-UNK
the	O
maximum	B-UNK
heart	B-UNK
rate	I-UNK
29	O
%	O
versus	B-UNK
control	B-UNK
.	O
Summed	O
stress	B-UNK
and	O
summed	O
difference	B-UNK
scores	B-UNK
were	O
not	O
significantly	B-UNK
reduced	B-UNK
,	O
although	O
they	O
were	O
18	O
%	O
and	O
30	O
%	O
lower	B-UNK
,	O
respectively	O
,	O
than	O
control	B-UNK
.	O
No	O
significant	B-UNK
differences	B-UNK
were	O
found	B-UNK
in	O
any	O
parameter	O
between	O
metoprolol	B-CHEMICAL
and	O
metoprolol	B-CHEMICAL
-	O
glucagon	B-CHEMICAL
.	O
CONCLUSION	O
:	O
During	O
dobutamine	B-CHEMICAL
stress	B-UNK
testing	B-UNK
,	O
metoprolol	B-CHEMICAL
attenuates	O
or	O
eliminates	O
evidence	B-UNK
of	O
myocardial	B-DISEASE
ischemia	I-DISEASE
.	O
Glucagon	O
1	O
mg	B-UNK
,	O
although	O
somewhat	O
effective	B-UNK
,	O
does	O
not	O
correct	O
this	O
effect	B-UNK
to	O
the	O
extent	B-UNK
that	O
it	O
can	O
be	O
administered	B-UNK
clinically	B-UNK
.	O

Prednisolone	O
-	O
induced	B-UNK
muscle	B-UNK
dysfunction	B-UNK
is	O
caused	B-UNK
more	O
by	O
atrophy	B-DISEASE
than	O
by	O
altered	B-UNK
acetylcholine	B-CHEMICAL
receptor	B-UNK
expression	B-UNK
.	O

Large	O
doses	B-UNK
of	O
glucocorticoids	B-CHEMICAL
can	O
alter	B-UNK
muscle	B-UNK
physiology	O
and	O
susceptibility	B-UNK
to	O
neuromuscular	B-UNK
blocking	B-UNK
drugs	B-UNK
by	O
mechanisms	B-UNK
not	O
clearly	B-UNK
understood	B-UNK
.	O
We	O
investigated	B-UNK
the	O
effects	B-UNK
of	O
moderate	B-UNK
and	O
large	B-UNK
doses	B-UNK
of	O
prednisolone	B-CHEMICAL
on	O
muscle	B-UNK
function	B-UNK
and	O
pharmacology	O
,	O
and	O
their	O
relationship	B-UNK
to	O
changes	B-UNK
in	O
muscle	B-UNK
size	O
and	O
acetylcholine	B-CHEMICAL
receptor	B-UNK
(	O
AChR	O
)	O
expression	B-UNK
.	O
With	O
institutional	O
approval	O
,	O
35	O
Sprague	B-UNK
-	O
Dawley	B-UNK
rats	B-UNK
were	O
randomly	B-UNK
allocated	B-UNK
to	O
receive	B-UNK
daily	B-UNK
subcutaneous	B-UNK
doses	B-UNK
of	O
10	O
mg	B-UNK
/	O
kg	B-UNK
prednisolone	B-CHEMICAL
(	O
P10	O
group	B-UNK
)	O
,	O
100	O
mg	B-UNK
/	O
kg	B-UNK
prednisolone	B-CHEMICAL
(	O
P100	O
group	B-UNK
)	O
,	O
or	O
an	O
equal	O
volume	B-UNK
of	O
saline	B-UNK
(	O
S	O
group	B-UNK
)	O
for	O
7	O
days	B-UNK
.	O
A	O
fourth	B-UNK
group	B-UNK
of	O
rats	B-UNK
was	O
pair	O
fed	B-UNK
(	O
food	B-UNK
restricted	B-UNK
)	O
with	O
the	O
P100	O
rats	B-UNK
for	O
7	O
days	B-UNK
(	O
FR	O
group	B-UNK
)	O
.	O
On	O
Day	O
8	O
,	O
the	O
nerve	B-UNK
-	O
evoked	O
peak	B-UNK
twitch	O
tensions	B-UNK
,	O
tetanic	B-UNK
tensions	B-UNK
,	O
and	O
fatigability	O
,	O
and	O
the	O
dose	B-UNK
-	O
response	B-UNK
curves	O
of	O
d	B-UNK
-	O
tubocurarine	B-CHEMICAL
in	O
the	O
tibialis	O
cranialis	O
muscle	B-UNK
were	O
measured	B-UNK
in	O
vivo	B-UNK
and	O
related	B-UNK
to	O
muscle	B-UNK
mass	B-UNK
or	O
expression	B-UNK
of	O
AChRs	O
.	O
Rate	O
of	O
body	B-DISEASE
weight	I-DISEASE
gain	O
was	O
depressed	B-UNK
in	O
the	O
P100	O
,	O
FR	O
,	O
and	O
P10	O
groups	B-UNK
compared	B-UNK
with	O
the	O
S	O
group	B-UNK
.	O
Tibialis	O
muscle	B-UNK
mass	B-UNK
was	O
smaller	B-UNK
in	O
the	O
P100	O
group	B-UNK
than	O
in	O
the	O
P10	O
or	O
S	O
groups	B-UNK
.	O
The	O
evoked	O
peak	B-UNK
twitch	O
and	O
tetanic	B-UNK
tensions	B-UNK
were	O
less	O
in	O
the	O
P100	O
group	B-UNK
than	O
in	O
the	O
P10	O
or	O
S	O
groups	B-UNK
,	O
however	O
,	O
tension	O
per	O
milligram	O
of	O
muscle	B-UNK
mass	B-UNK
was	O
greater	B-UNK
in	O
the	O
P100	O
group	B-UNK
than	O
in	O
the	O
S	O
group	B-UNK
.	O
The	O
50	O
%	O
effective	B-UNK
dose	B-UNK
of	O
d	B-UNK
-	O
tubocurarine	B-CHEMICAL
(	O
microg	B-UNK
/	O
kg	B-UNK
)	O
in	O
the	O
tibialis	O
muscle	B-UNK
was	O
smaller	B-UNK
in	O
the	O
P10	O
(	O
33.6	O
+	O
/-	O
5.4	O
)	O
than	O
in	O
the	O
S	O
(	O
61.9	O
+	O
/-	O
5.0	B-UNK
)	O
or	O
the	O
P100	O
(	O
71.3	O
+	O
/-	O
9.6	O
)	O
groups	B-UNK
.	O
AChR	O
expression	B-UNK
was	O
less	O
in	O
the	O
P10	O
group	B-UNK
than	O
in	O
the	O
S	O
group	B-UNK
.	O
The	O
evoked	O
tensions	B-UNK
correlated	B-UNK
with	O
muscle	B-UNK
mass	B-UNK
(	O
r(2	O
)	O
=	O
0.32	O
,	O
P	B-UNK
<	I-UNK
0.001	B-UNK
)	O
,	O
however	O
,	O
not	O
with	O
expression	B-UNK
of	O
AChR.	O
The	O
50	O
%	O
effective	B-UNK
dose	B-UNK
of	O
d	B-UNK
-	O
tubocurarine	B-CHEMICAL
did	O
not	O
correlate	O
with	O
muscle	B-UNK
mass	B-UNK
or	O
AChR	O
expression	B-UNK
.	O
Our	O
results	B-UNK
suggest	B-UNK
that	O
the	O
neuromuscular	B-UNK
dysfunction	B-UNK
after	O
prednisolone	B-CHEMICAL
is	O
dose	B-UNK
-	O
dependent	B-UNK
,	O
and	O
derives	O
primarily	B-UNK
from	O
muscle	B-UNK
atrophy	B-DISEASE
and	O
derives	O
less	O
so	O
from	O
changes	B-UNK
in	O
AChR	O
expression	B-UNK
.	O
IMPLICATIONS	O
:	O
The	O
mechanisms	B-UNK
by	O
which	O
chronic	B-UNK
glucocorticoid	O
therapy	B-UNK
alters	O
neuromuscular	B-UNK
physiology	O
and	O
pharmacology	O
are	O
unclear	O
.	O
We	O
suggest	B-UNK
that	O
the	O
observed	B-UNK
effects	B-UNK
are	O
dose	B-UNK
-	O
dependent	B-UNK
and	O
derive	O
primarily	B-UNK
from	O
muscle	B-UNK
atrophy	B-DISEASE
and	O
derive	O
less	O
from	O
changes	B-UNK
in	O
acetylcholine	B-CHEMICAL
receptor	B-UNK
expression	B-UNK
.	O

Rapid	O
reversal	B-UNK
of	O
life	B-UNK
-	O
threatening	O
diltiazem	B-CHEMICAL
-	O
induced	B-UNK
tetany	B-DISEASE
with	O
calcium	B-CHEMICAL
chloride	I-CHEMICAL
.	O

We	O
describe	O
a	O
patient	B-UNK
who	O
developed	B-UNK
tetany	B-DISEASE
with	O
sudden	B-UNK
respiratory	B-UNK
arrest	B-UNK
after	O
the	O
infusion	B-UNK
of	O
intravenous	B-UNK
diltiazem	B-CHEMICAL
.	O
The	O
administration	B-UNK
of	O
calcium	B-CHEMICAL
chloride	I-CHEMICAL
rapidly	B-UNK
resolved	B-UNK
the	O
patient'	O
s	O
tetany	B-DISEASE
with	O
prompt	B-UNK
recovery	B-UNK
of	O
respiratory	B-UNK
function	B-UNK
,	O
averting	O
the	O
need	B-UNK
for	O
more	O
aggressive	B-UNK
airway	B-UNK
management	B-UNK
and	O
ventilatory	O
support	B-UNK
.	O
The	O
emergency	B-UNK
physician	O
should	O
be	O
aware	O
that	O
life	B-UNK
-	O
threatening	O
tetany	B-DISEASE
may	O
accompany	O
the	O
administration	B-UNK
of	O
intravenous	B-UNK
diltiazem	B-CHEMICAL
and	O
that	O
calcium	B-CHEMICAL
chloride	I-CHEMICAL
may	O
be	O
a	O
rapid	B-UNK
and	O
effective	B-UNK
remedy	O
.	O

Effects	O
of	O
nonsteroidal	B-UNK
anti-inflammatory	I-UNK
drugs	B-UNK
on	O
hemostasis	O
in	O
patients	B-UNK
with	O
aneurysmal	O
subarachnoid	B-DISEASE
hemorrhage	I-DISEASE
.	O

Platelet	B-UNK
function	B-UNK
is	O
impaired	B-UNK
by	O
nonsteroidal	B-UNK
anti-inflammatory	I-UNK
drugs	B-UNK
(	O
NSAIDs	B-UNK
)	O
with	O
prominent	O
anti-inflammatory	O
properties	B-UNK
.	O
Their	O
safety	B-UNK
in	O
patients	B-UNK
undergoing	B-UNK
intracranial	O
surgery	B-UNK
is	O
under	O
debate	O
.	O
Patients	B-UNK
with	O
aneurysmal	O
subarachnoid	B-DISEASE
hemorrhage	I-DISEASE
(	O
SAH	O
)	O
were	O
randomized	B-UNK
to	O
receive	B-UNK
either	O
ketoprofen	B-CHEMICAL
,	O
100	O
mg	B-UNK
,	O
three	O
times	B-UNK
a	O
day	B-UNK
(	O
ketoprofen	B-CHEMICAL
group	B-UNK
,	O
n	B-UNK
=	O
9	O
)	O
or	O
a	O
weak	O
NSAID	O
,	O
acetaminophen	B-CHEMICAL
,	O
1	O
g	B-UNK
,	O
three	O
times	B-UNK
a	O
day	B-UNK
(	O
acetaminophen	B-CHEMICAL
group	B-UNK
,	O
n	B-UNK
=	O
9	O
)	O
starting	B-UNK
immediately	B-UNK
after	O
the	O
diagnosis	B-UNK
of	O
aneurysmal	O
SAH	O
.	O
Treatment	O
was	O
continued	B-UNK
for	O
3	O
days	B-UNK
postoperatively	O
.	O
Test	O
blood	B-UNK
samples	B-UNK
were	O
taken	O
before	O
treatment	B-UNK
and	O
surgery	B-UNK
as	O
well	O
as	O
on	O
the	O
first	O
,	O
third	O
,	O
and	O
fifth	O
postoperative	B-UNK
mornings	O
.	O
Maximal	O
platelet	B-DISEASE
aggregation	I-DISEASE
induced	B-UNK
by	O
6	O
microM	O
of	O
adenosine	B-CHEMICAL
diphosphate	I-CHEMICAL
decreased	B-UNK
after	O
administration	B-UNK
of	O
ketoprofen	B-CHEMICAL
.	O
Aggregation	O
was	O
lower	B-UNK
(	O
P	B-UNK
<	I-UNK
.05	O
)	O
in	O
the	O
ketoprofen	B-CHEMICAL
group	B-UNK
than	O
in	O
the	O
acetaminophen	B-CHEMICAL
group	B-UNK
just	O
before	O
surgery	B-UNK
and	O
on	O
the	O
third	O
postoperative	B-UNK
day	B-UNK
.	O
In	O
contrast	B-UNK
,	O
maximal	O
platelet	B-DISEASE
aggregation	I-DISEASE
increased	B-UNK
in	O
the	O
acetaminophen	B-CHEMICAL
group	B-UNK
on	O
the	O
third	O
postoperative	B-UNK
day	B-UNK
as	O
compared	B-UNK
with	O
the	O
pretreatment	B-UNK
platelet	B-DISEASE
aggregation	I-DISEASE
results	B-UNK
(	O
P	B-UNK
<	I-UNK
.05	O
)	O
.	O
One	O
patient	B-UNK
in	O
the	O
ketoprofen	B-CHEMICAL
group	B-UNK
developed	B-UNK
a	O
postoperative	B-UNK
intracranial	B-DISEASE
hematoma	I-DISEASE
.	O
Coagulation	O
(	O
prothrombin	B-CHEMICAL
time	B-UNK
[	O
PT	O
]	O
,	O
activated	B-UNK
partial	B-UNK
thromboplastin	B-CHEMICAL
time	B-UNK
[	O
APPT	O
]	O
,	O
fibrinogen	B-CHEMICAL
concentration	B-UNK
,	O
and	O
antithrombin	B-DISEASE
III	B-UNK
[	O
AT	O
III	B-UNK
]	O
)	O
was	O
comparable	B-UNK
between	O
the	O
two	O
groups	B-UNK
.	O
Ketoprofen	O
but	O
not	O
acetaminophen	B-CHEMICAL
impaired	B-UNK
platelet	B-UNK
function	B-UNK
in	O
patients	B-UNK
with	O
SAH	O
.	O
If	O
ketoprofen	B-CHEMICAL
is	O
used	O
before	O
surgery	B-UNK
on	O
cerebral	B-UNK
artery	B-UNK
aneurysms	B-DISEASE
,	O
it	O
may	O
pose	O
an	O
additional	B-UNK
risk	B-UNK
factor	B-UNK
for	O
hemorrhage	B-DISEASE
.	O

Value	O
of	O
methylprednisolone	B-CHEMICAL
in	O
prevention	O
of	O
the	O
arthralgia	B-DISEASE
-	O
myalgia	B-DISEASE
syndrome	B-UNK
associated	B-UNK
with	O
the	O
total	B-UNK
dose	B-UNK
infusion	B-UNK
of	O
iron	B-CHEMICAL
dextran	B-UNK
:	O
a	O
double	B-UNK
blind	B-UNK
randomized	B-UNK
trial	B-UNK
.	O

The	O
safety	B-UNK
and	O
efficacy	B-UNK
of	O
total	B-UNK
dose	B-UNK
infusion	B-UNK
(	O
TDI	O
)	O
of	O
iron	B-CHEMICAL
dextran	B-UNK
has	O
been	O
well	O
documented	B-UNK
.	O
In	O
40	O
%	O
of	O
treated	B-UNK
patients	B-UNK
,	O
an	O
arthralgia	B-DISEASE
-	O
myalgia	B-DISEASE
syndrome	B-UNK
develops	O
.	O
The	O
purpose	O
of	O
this	O
randomized	B-UNK
,	O
double-blind	B-UNK
,	O
prospective	B-UNK
study	B-UNK
was	O
to	O
investigate	O
whether	O
intravenous	B-UNK
(	O
i.v	B-UNK
.	O
)	O
administration	B-UNK
of	O
methylprednisolone	B-CHEMICAL
(	O
MP	O
)	O
prevents	B-UNK
this	O
complication	B-UNK
.	O
Sixty	O
-	O
five	O
patients	B-UNK
,	O
34	O
women	B-UNK
and	O
31	O
men	O
,	O
ages	O
36	O
to	O
80	O
years	B-UNK
,	O
received	B-UNK
either	O
normal	B-UNK
saline	B-UNK
before	O
and	O
after	O
TDI	O
(	O
group	B-UNK
1	O
)	O
,	O
125	O
mg	B-UNK
i.v	B-UNK
.	O
MP	O
before	O
and	O
saline	B-UNK
after	O
TDI	O
(	O
group	B-UNK
2	B-DISEASE
)	O
,	O
or	O
125	O
mg	B-UNK
i.v	B-UNK
.	O
MP	O
before	O
and	O
after	O
TDI	O
(	O
group	B-UNK
3	O
)	O
.	O
Patients	B-UNK
were	O
observed	B-UNK
for	O
72	O
hours	B-UNK
and	O
reactions	B-UNK
were	O
recorded	B-UNK
and	O
graded	O
according	B-UNK
to	O
severity	B-UNK
.	O
Fifty	O
-	O
eight	O
percent	O
of	O
group	B-UNK
1	O
patients	B-UNK
,	O
33	O
%	O
of	O
group	B-UNK
2	B-DISEASE
,	O
and	O
26	O
%	O
of	O
group	B-UNK
3	O
had	O
reactions	B-UNK
to	O
TDI	O
.	O
The	O
severity	B-UNK
of	O
reactions	B-UNK
(	O
minimal	O
,	O
mild	B-UNK
,	O
and	O
moderate	B-UNK
,	O
respectively	O
)	O
was	O
as	O
follows	O
:	O
group	B-UNK
1	O
-	O
-6	O
,	O
6	O
,	O
and	O
2	B-DISEASE
;	O
group	B-UNK
2	B-DISEASE
-	O
-1	O
,	O
5	O
,	O
and	O
0	O
;	O
group	B-UNK
3	O
-	O
-5	O
,	O
1	O
,	O
and	O
0	O
.	O
Data	O
were	O
analyzed	B-UNK
by	O
the	O
two	O
-	O
sided	O
Fisher'	O
s	O
exact	O
test	B-UNK
using	O
95	O
%	O
confidence	B-UNK
intervals	B-UNK
with	O
the	O
approximation	O
of	O
Woolf	O
.	O
These	O
data	B-UNK
demonstrate	B-UNK
that	O
administration	B-UNK
of	O
MP	O
before	O
and	O
after	O
TDI	O
reduces	B-UNK
the	O
frequency	B-UNK
and	O
severity	B-UNK
of	O
the	O
arthralgia	B-DISEASE
-	O
myalgia	B-DISEASE
syndrome	B-UNK
.	O
We	O
conclude	O
that	O
125	O
mg	B-UNK
i.v	B-UNK
.	O
MP	O
should	O
be	O
given	B-UNK
routinely	O
before	O
and	O
after	O
TDI	O
of	O
iron	B-CHEMICAL
dextran	B-UNK
.	O

Long	O
-	O
term	B-UNK
effects	B-UNK
of	O
vincristine	B-CHEMICAL
on	O
the	O
peripheral	B-UNK
nervous	B-UNK
system	I-UNK
.	O

Forty	O
patients	B-UNK
with	O
Non-Hodgkin's	O
Lymphoma	O
treated	B-UNK
with	O
vincristine	B-CHEMICAL
between	O
1984	O
and	O
1990	O
(	O
cumulative	B-UNK
dose	B-UNK
12	O
mg	B-UNK
in	O
18	O
-	O
24	O
weeks	B-UNK
)	O
were	O
investigated	B-UNK
in	O
order	O
to	O
evaluate	B-UNK
the	O
long	B-UNK
term	B-UNK
effects	B-UNK
of	O
vincristine	B-CHEMICAL
on	O
the	O
peripheral	B-UNK
nervous	B-UNK
system	I-UNK
.	O
The	O
patients	B-UNK
were	O
interviewed	O
with	O
emphasis	O
on	O
neuropathic	O
symptoms	B-UNK
.	O
Physical	O
and	O
quantitative	B-UNK
sensory	B-UNK
examination	B-UNK
with	O
determination	O
of	O
vibratory	O
perception	B-UNK
and	O
thermal	O
discrimination	B-UNK
thresholds	B-UNK
were	O
performed	B-UNK
,	O
four	O
to	O
77	O
months	B-UNK
(	O
median	B-UNK
34	O
months	B-UNK
)	O
after	O
vincristine	B-CHEMICAL
treatment	B-UNK
.	O
Twenty	O
-	O
seven	O
patients	B-UNK
reported	B-UNK
neuropathic	O
symptoms	B-UNK
.	O
In	O
13	O
of	O
these	O
27	O
patients	B-UNK
symptoms	B-UNK
were	O
still	O
present	B-UNK
at	B-DISEASE
the	O
time	B-UNK
of	O
examination	B-UNK
.	O
In	O
these	O
patients	B-UNK
sensory	B-UNK
signs	B-DISEASE
and	I-DISEASE
symptoms	I-DISEASE
predominated	O
.	O
In	O
the	O
other	O
14	O
patients	B-UNK
symptoms	B-UNK
had	O
been	O
present	B-UNK
in	O
the	O
past	B-UNK
.	O
Symptoms	O
persisted	B-UNK
maximally	O
40	O
months	B-UNK
since	O
cessation	B-UNK
of	O
therapy	B-UNK
.	O
There	O
was	O
no	O
age	B-UNK
difference	B-UNK
between	O
patients	B-UNK
with	O
and	O
without	O
complaints	O
at	B-DISEASE
the	O
time	B-UNK
of	O
examination	B-UNK
.	O
Normal	O
reflexes	B-UNK
were	O
found	B-UNK
in	O
two	O
third	O
of	O
patients	B-UNK
.	O
Neuropathic	O
complaints	O
were	O
not	O
very	O
troublesome	O
on	O
the	O
long	B-UNK
term	B-UNK
.	O
It	O
is	O
concluded	O
that	O
with	O
the	O
above	O
mentioned	B-UNK
vincristine	B-CHEMICAL
dose	B-UNK
schedule	B-UNK
signs	B-DISEASE
and	I-DISEASE
symptoms	I-DISEASE
of	O
vincristine	B-CHEMICAL
neuropathy	B-DISEASE
are	O
reversible	B-UNK
for	O
a	O
great	O
deal	O
and	O
prognosis	B-UNK
is	O
fairly	O
good	B-UNK
.	O

A	O
case	B-UNK
of	O
polymyositis	B-DISEASE
in	O
a	O
patient	B-UNK
with	O
primary	B-DISEASE
biliary	I-DISEASE
cirrhosis	I-DISEASE
treated	B-UNK
with	O
D	B-UNK
-	O
penicillamine	B-CHEMICAL
.	O

Although	O
D	B-UNK
-	O
penicillamine	B-CHEMICAL
has	O
been	O
used	O
for	O
many	O
rheumatologic	O
diseases	B-DISEASE
,	O
toxicity	B-UNK
limits	B-UNK
its	O
usefulness	O
in	O
many	O
patients	B-UNK
.	O
Polymyositis	O
/	O
dermatomyositis	B-DISEASE
can	O
develop	B-UNK
as	O
one	O
of	O
the	O
autoimmune	O
complications	B-UNK
of	O
D	B-UNK
-	O
penicillamine	B-CHEMICAL
treatment	B-UNK
,	O
but	O
its	O
exact	O
pathogenesis	O
remains	B-UNK
unclear	O
.	O
We	O
report	B-UNK
a	O
patient	B-UNK
with	O
primary	B-DISEASE
biliary	I-DISEASE
cirrhosis	I-DISEASE
,	O
who	O
developed	B-UNK
polymyositis	B-DISEASE
while	O
receiving	B-UNK
D	B-UNK
-	O
penicillamine	B-CHEMICAL
therapy	B-UNK
.	O
We	O
described	B-UNK
the	O
special	O
clinical	B-UNK
course	B-UNK
of	O
the	O
patient	B-UNK
.	O
Patients	B-UNK
receiving	B-UNK
D	B-UNK
-	O
penicillamine	B-CHEMICAL
therapy	B-UNK
should	O
be	O
followed	B-UNK
carefully	O
for	O
the	O
development	B-UNK
of	O
autoimmune	O
complications	B-UNK
like	B-UNK
polymyositis	B-DISEASE
/	O
dermatomyositis	B-DISEASE
.	O

Photodistributed	O
nifedipine	B-CHEMICAL
-	O
induced	B-UNK
facial	B-UNK
telangiectasia	B-DISEASE
.	O

Five	O
months	B-UNK
after	O
starting	B-UNK
nifedipine	B-CHEMICAL
(	O
Adalat	O
)	O
,	O
two	O
patients	B-UNK
developed	B-UNK
photodistributed	O
facial	B-UNK
telangiectasia	B-DISEASE
,	O
which	O
became	O
more	O
noticeable	O
with	O
time	B-UNK
.	O
Neither	O
patient	B-UNK
complained	O
of	O
photosensitivity	O
or	O
flushing	B-DISEASE
.	O
Both	O
patients	B-UNK
reported	B-UNK
a	O
significant	B-UNK
cosmetic	O
improvement	B-UNK
after	O
discontinuing	O
the	O
drug	B-UNK
.	O
One	O
commenced	O
the	O
closely	O
related	B-UNK
drug	B-UNK
amlodipine	B-CHEMICAL
3	O
years	B-UNK
later	B-UNK
,	O
with	O
recurrence	B-DISEASE
of	O
telangiectasia	B-DISEASE
.	O
The	O
photodistribution	O
of	O
the	O
telangiectasia	B-DISEASE
suggests	B-UNK
a	O
significant	B-UNK
drug	B-UNK
/	O
light	B-UNK
interaction	B-UNK
.	O

Nephrotoxicity	O
of	O
cyclosporin	O
A	O
and	O
FK506	O
:	O
inhibition	B-UNK
of	O
calcineurin	B-UNK
phosphatase	B-UNK
.	O

Cyclosporin	O
A	O
(	O
CsA	O
;	O
50	O
mg	B-UNK
/	O
kg	B-UNK
)	O
and	O
Fujimycine	O
(	O
FK506	O
;	O
5	O
mg	B-UNK
/	O
kg	B-UNK
)	O
,	O
but	O
not	O
the	O
related	B-UNK
macrolide	B-UNK
immunosuppressant	O
rapamycin	B-UNK
(	O
5	O
mg	B-UNK
/	O
kg	B-UNK
)	O
,	O
caused	B-UNK
a	O
reduction	B-UNK
of	O
glomerular	B-UNK
filtration	I-UNK
rate	B-UNK
,	O
degenerative	O
changes	B-UNK
of	O
proximal	B-UNK
tubular	B-UNK
epithelium	B-UNK
,	O
and	O
hypertrophy	B-DISEASE
of	O
the	O
juxtaglomerular	O
apparatus	O
in	O
male	B-UNK
Wistar	B-UNK
rats	I-UNK
when	O
given	B-UNK
for	O
10	O
days	B-UNK
.	O
The	O
molecular	B-UNK
mechanisms	B-UNK
of	O
CsA	O
and	O
FK506	O
toxicity	B-UNK
were	O
investigated	B-UNK
.	O
Cyclophilin	O
A	O
and	O
FK506-binding	O
protein	B-UNK
,	O
the	O
main	B-UNK
intracytoplasmic	O
receptors	B-UNK
for	O
CsA	O
and	O
FK506	O
,	O
respectively	O
,	O
were	O
each	O
detected	B-UNK
in	O
renal	B-UNK
tissue	B-UNK
extract	B-UNK
.	O
In	O
the	O
kidney	B-UNK
,	O
high	B-UNK
levels	B-UNK
of	O
immunoreactive	O
and	O
enzymatically	O
active	B-UNK
calcineurin	B-UNK
were	O
found	B-UNK
which	O
were	O
inhibited	B-UNK
by	O
the	O
immunosuppressants	O
CsA	O
and	O
FK506	O
,	O
but	O
not	O
by	O
rapamycin	B-UNK
.	O
Finally	O
,	O
specific	B-UNK
immunophilin	O
-	O
drug	B-UNK
-	O
calcineurin	B-UNK
complexes	O
formed	B-UNK
only	O
in	O
the	O
presence	O
of	O
CsA	O
and	O
FK506	O
,	O
but	O
not	O
rapamycin	B-UNK
.	O
These	O
results	B-UNK
suggest	B-UNK
that	O
the	O
nephrotoxic	B-UNK
effects	B-UNK
of	O
CsA	O
and	O
FK506	O
is	O
likely	B-UNK
mediated	B-UNK
through	O
binding	B-UNK
to	O
renal	B-DISEASE
immunophilin	O
and	O
inhibiting	O
calcineurin	B-UNK
phosphatase	B-UNK
.	O

Massive	O
cerebral	B-UNK
edema	B-DISEASE
associated	B-UNK
with	O
fulminant	B-UNK
hepatic	B-UNK
failure	B-UNK
in	O
acetaminophen	B-CHEMICAL
overdose	B-UNK
:	O
possible	B-UNK
role	B-UNK
of	O
cranial	B-UNK
decompression	B-UNK
.	O

Cerebral	O
edema	B-DISEASE
may	O
complicate	O
the	O
course	B-UNK
of	O
fulminant	B-UNK
hepatic	B-UNK
failure	B-UNK
.	O
Response	O
to	O
conventional	B-UNK
therapy	B-UNK
has	O
been	O
disappointing	O
.	O
We	O
present	B-UNK
a	O
patient	B-UNK
with	O
fatal	B-UNK
acetaminophen	B-CHEMICAL
-	O
induced	B-UNK
fulminant	B-UNK
hepatic	B-UNK
failure	B-UNK
,	O
with	O
signs	B-DISEASE
and	I-DISEASE
symptoms	I-DISEASE
of	O
cerebral	B-UNK
edema	B-DISEASE
,	O
unresponsive	O
to	O
conventional	B-UNK
medical	B-UNK
therapy	B-UNK
.	O
Cranial	O
decompression	B-UNK
was	O
carried	O
out	O
.	O
A	O
justification	O
of	O
the	O
need	B-UNK
for	O
further	O
evaluation	B-UNK
of	O
cranial	B-UNK
decompression	B-UNK
in	O
such	O
patients	B-UNK
is	O
presented	B-UNK
.	O

Gentamicin	O
nephropathy	B-DISEASE
in	O
a	O
neonate	O
.	O

The	O
clinical	B-UNK
and	O
autopsy	O
findings	B-UNK
in	O
a	O
premature	O
baby	O
who	O
died	B-UNK
of	O
acute	B-DISEASE
renal	I-DISEASE
failure	I-DISEASE
after	O
therapy	B-UNK
with	O
gentamicin	B-UNK
(	O
5	O
mg	B-UNK
/	O
kg	B-UNK
/	O
day	B-UNK
)	O
and	O
penicillin	O
are	O
presented	B-UNK
.	O
The	O
serum	B-UNK
gentamicin	B-UNK
concentration	B-UNK
had	O
reached	B-UNK
toxic	B-UNK
levels	B-UNK
when	O
anuria	B-DISEASE
developed	B-UNK
.	O
Numerous	O
periodic	B-CHEMICAL
acid	I-CHEMICAL
Schiff	O
(	O
PAS	O
)	O
positive	B-UNK
,	O
diastase	O
resistant	B-UNK
cytoplasmic	B-UNK
inclusion	O
bodies	O
which	O
appeared	B-UNK
as	O
myelin	O
figures	B-UNK
in	O
cytosegresomes	O
under	O
the	O
electron	B-UNK
microscope	O
were	O
identified	B-UNK
in	O
the	O
proximal	B-UNK
convoluted	O
tubules	O
.	O
The	O
pathological	B-UNK
changes	B-UNK
induced	B-UNK
by	O
gentamicin	B-UNK
in	O
the	O
human	B-UNK
neonatal	O
kidneys	B-UNK
have	O
not	O
been	O
previously	B-UNK
reported	B-UNK
.	O

Anti-carcinogenic	O
action	B-UNK
of	O
phenobarbital	B-CHEMICAL
given	B-UNK
simultaneously	B-UNK
with	O
diethylnitrosamine	B-CHEMICAL
in	O
the	O
rat	B-UNK
.	O

The	O
present	B-UNK
work	B-UNK
has	O
been	O
planned	O
in	O
order	O
to	O
elucidate	O
the	O
effect	B-UNK
of	O
phenobarbital	B-CHEMICAL
(	O
PB	O
:	O
15	O
mg	B-UNK
per	O
rat	B-UNK
of	O
ingested	O
dose	B-UNK
)	O
on	O
carcinogenesis	B-DISEASE
when	O
it	O
is	O
administered	B-UNK
simultaneously	B-UNK
with	O
diethylnitrosamine	B-CHEMICAL
(	O
DEN	O
:	O
10	O
mg	B-UNK
/	O
kg	B-UNK
/	O
day	B-UNK
)	O
.	O
Wistar	B-UNK
rats	I-UNK
(	O
180	O
g	B-UNK
)	O
were	O
treated	B-UNK
by	O
DEN	O
alone	O
or	O
by	O
DEN	B-UNK
+	I-UNK
PB	O
during	O
2	B-DISEASE
,	O
4	O
and	O
6	O
weeks	B-UNK
according	B-UNK
to	O
our	O
schedule	B-UNK
for	O
hepatocarcinogenesis	O
.	O
After	O
the	O
end	B-UNK
of	O
the	O
treatment	B-UNK
,	O
the	O
number	B-UNK
and	O
the	O
size	O
of	O
induced	B-UNK
PAS	O
positive	B-UNK
preneoplastic	B-UNK
foci	O
was	O
significantly	B-UNK
reduced	B-UNK
when	O
PB	O
was	O
given	B-UNK
simultaneously	B-UNK
with	O
DEN	O
for	O
4	O
and	O
6	O
weeks	B-UNK
.	O
The	O
mitotic	O
inhibition	B-UNK
and	O
the	O
production	B-UNK
of	O
micronuclei	B-DISEASE
normally	O
observed	B-UNK
after	O
partial	B-UNK
hepatectomy	O
in	O
DEN	O
treated	B-UNK
rats	B-UNK
were	O
also	O
significantly	B-UNK
decreased	B-UNK
in	O
DEN	B-UNK
+	I-UNK
PB	O
treated	B-UNK
rats	B-UNK
.	O
When	O
the	O
treatment	B-UNK
last	O
only	O
2	B-DISEASE
weeks	B-UNK
,	O
the	O
presence	O
of	O
PB	O
did	O
not	O
change	B-UNK
significantly	B-UNK
the	O
last	O
parameters	B-UNK
.	O
In	O
DEN	B-UNK
+	I-UNK
PB	O
treated	B-UNK
rats	B-UNK
,	O
the	O
survival	B-UNK
was	O
prolonged	B-UNK
and	O
the	O
tumor	B-DISEASE
incidence	B-UNK
decreased	B-UNK
as	O
compared	B-UNK
with	O
the	O
results	B-UNK
obtained	B-UNK
by	O
DEN	O
alone	O
.	O
It	O
is	O
concluded	O
that	O
PB	O
,	O
which	O
promotes	O
carcinogenesis	B-DISEASE
when	O
administered	B-UNK
after	O
the	O
DEN	O
treatment	B-UNK
,	O
reduces	B-UNK
the	O
carcinogen	O
effect	B-UNK
when	O
given	B-UNK
simultaneously	B-UNK
with	O
DEN	O
.	O
This	O
'	O
anti-carcinogen	O
'	O
effect	B-UNK
acts	B-UNK
on	O
the	O
initiation	O
as	O
well	O
as	O
on	O
the	O
promotion	O
of	O
the	O
precancerous	O
lesions	B-UNK
.	O
Biochemical	O
investigations	B-UNK
are	O
in	O
progress	O
to	O
obtain	O
more	O
information	B-UNK
about	O
this	O
'	O
paradoxical	O
'	O
PB	O
effect	B-UNK
.	O

Post-operative	O
rigidity	B-UNK
after	O
fentanyl	B-CHEMICAL
administration	B-UNK
.	O

A	O
case	B-UNK
of	O
thoraco	O
-	O
abdominal	B-UNK
rigidity	B-UNK
leading	B-UNK
to	O
respiratory	B-UNK
failure	B-UNK
is	O
described	B-UNK
in	O
the	O
post-operative	O
period	B-UNK
in	O
an	O
elderly	B-UNK
patient	B-UNK
who	O
received	B-UNK
a	O
moderate	B-UNK
dose	B-UNK
of	O
fentanyl	B-CHEMICAL
.	O
This	O
was	O
successfully	B-UNK
reversed	B-UNK
by	O
naloxone	B-CHEMICAL
.	O
The	O
mechanisms	B-UNK
possibly	B-UNK
implicated	B-UNK
in	O
this	O
accident	O
are	O
discussed	O
.	O

Postpartum	O
psychosis	B-UNK
induced	B-UNK
by	O
bromocriptine	B-CHEMICAL
.	O

Two	O
multigravida	O
patients	B-UNK
with	O
no	O
prior	B-UNK
psychiatric	B-UNK
history	B-UNK
were	O
seen	B-UNK
with	O
postpartum	O
psychosis	B-UNK
,	O
having	B-UNK
received	B-UNK
bromocriptine	B-CHEMICAL
for	O
inhibition	B-UNK
of	O
lactation	O
.	O
Bromocriptine	O
given	B-UNK
in	O
high	B-UNK
doses	B-UNK
has	O
been	O
associated	B-UNK
with	O
psychosis	B-UNK
in	O
patients	B-UNK
receiving	B-UNK
the	O
drug	B-UNK
for	O
Parkinson'	O
s	O
disease	B-DISEASE
.	O
These	O
cases	B-UNK
demonstrate	B-UNK
that	O
bromocriptine	B-CHEMICAL
may	O
cause	B-UNK
psychosis	B-UNK
even	O
when	O
given	B-UNK
in	O
low	B-UNK
doses	B-UNK
.	O

A	O
prospective	B-UNK
study	B-UNK
on	O
the	O
dose	B-UNK
dependency	B-UNK
of	O
cardiotoxicity	B-DISEASE
induced	B-UNK
by	O
mitomycin	B-CHEMICAL
C.	O

Since	O
1975	O
mitomycin	B-CHEMICAL
C	B-UNK
(	O
MMC	O
)	O
has	O
been	O
suggested	B-UNK
to	O
be	O
cardiotoxic	B-UNK
,	O
especially	B-UNK
when	O
combined	B-UNK
with	O
or	O
given	B-UNK
following	B-UNK
doxorubicin	B-CHEMICAL
.	O
Data	O
on	O
dose	B-UNK
dependency	B-UNK
or	O
incidence	B-UNK
concerning	B-UNK
this	O
side	O
effect	B-UNK
were	O
not	O
known	B-UNK
.	O
We	O
have	O
initiated	O
a	O
prospective	B-UNK
study	B-UNK
to	O
obtain	O
some	O
more	O
data	B-UNK
on	O
these	O
subjects	B-UNK
.	O
Forty	O
-	O
four	O
MMC	O
-	O
treated	B-UNK
patients	B-UNK
were	O
studied	B-UNK
,	O
37	O
of	O
them	O
could	O
be	O
evaluated	B-UNK
.	O
All	O
patients	B-UNK
were	O
studied	B-UNK
by	O
repeated	B-UNK
physical	B-UNK
examinations	B-UNK
,	O
chest	B-UNK
X	O
-	O
rays	O
,	O
electro-	O
and	O
echocardiography	O
and	O
radionuclide	O
left	B-UNK
ventricular	I-UNK
ejection	B-UNK
fraction	I-UNK
(	O
EF	O
)	O
determinations	O
.	O
The	O
results	B-UNK
were	O
evaluated	B-UNK
per	O
cumulative	B-UNK
dose	B-UNK
level	B-UNK
.	O
One	O
of	O
the	O
patients	B-UNK
developed	B-UNK
cardiac	B-UNK
failure	B-UNK
after	O
30	O
mg	B-UNK
m-2	O
MMC	O
and	O
only	O
150	O
mg	B-UNK
m-2	O
doxorubicin	B-CHEMICAL
.	O
The	O
cardiac	B-UNK
failure	B-UNK
was	O
predicted	O
by	O
a	O
drop	O
in	O
EF	O
determined	O
during	O
a	O
cold	B-DISEASE
pressor	B-UNK
test	B-UNK
.	O
None	O
of	O
the	O
other	O
patients	B-UNK
developed	B-UNK
clinical	B-UNK
cardiotoxicity	B-DISEASE
,	O
nor	O
did	O
the	O
studied	B-UNK
parameters	B-UNK
change	B-UNK
.	O
The	O
literature	B-UNK
on	O
this	O
subject	B-UNK
was	O
also	O
reviewed	B-UNK
.	O
Based	O
on	O
the	O
combined	B-UNK
data	B-UNK
from	O
the	O
present	B-UNK
study	B-UNK
and	O
the	O
literature	B-UNK
,	O
we	O
suggest	B-UNK
that	O
MMC	O
-	O
related	B-UNK
cardiotoxicity	B-DISEASE
is	O
dose	B-UNK
dependent	B-UNK
,	O
occurring	B-UNK
at	B-DISEASE
cumulative	B-UNK
dose	B-UNK
levels	B-UNK
of	O
30	O
mg	B-UNK
m-2	O
or	O
more	O
,	O
mainly	B-UNK
in	O
patients	B-UNK
also	O
(	O
previously	B-UNK
or	O
simultaneously	B-UNK
)	O
treated	B-UNK
with	O
doxorubicin	B-CHEMICAL
.	O
The	O
incidence	B-UNK
is	O
likely	B-UNK
to	O
be	O
less	O
than	O
10	O
%	O
even	O
for	O
this	O
risk	B-UNK
group	B-UNK
.	O

Phlorizin	O
-	O
induced	B-UNK
glycosuria	B-DISEASE
does	O
not	O
prevent	B-UNK
gentamicin	B-UNK
nephrotoxicity	B-UNK
in	O
rats	B-UNK
.	O

Because	O
rats	B-UNK
with	O
streptozotocin	O
-	O
induced	B-UNK
diabetes	B-DISEASE
mellitus	I-DISEASE
(	O
DM	B-UNK
)	O
have	O
a	O
high	B-UNK
solute	O
diuresis	B-UNK
(	O
glycosuria	B-DISEASE
of	O
10	O
to	O
12	O
g	B-UNK
/	O
day	B-UNK
)	O
,	O
we	O
have	O
suggested	B-UNK
that	O
this	O
may	O
in	O
part	O
be	O
responsible	O
for	O
their	O
resistance	B-UNK
to	O
gentamicin	B-UNK
-	O
induced	B-UNK
acute	B-DISEASE
renal	I-DISEASE
failure	I-DISEASE
(	O
ARF	O
)	O
.	O
The	O
protection	B-UNK
from	O
gentamicin	B-UNK
nephrotoxicity	B-UNK
was	O
studied	B-UNK
in	O
non-diabetic	O
rats	B-UNK
with	O
chronic	B-UNK
solute	O
diuresis	B-UNK
induced	B-UNK
by	O
blockage	O
of	O
tubular	B-UNK
glucose	B-CHEMICAL
reabsorption	O
with	O
phlorizin	O
(	O
P	B-UNK
)	O
.	O
DM	B-UNK
rats	B-UNK
with	O
mild	B-UNK
glycosuria	B-DISEASE
(	O
similar	B-UNK
in	O
degree	B-UNK
to	O
that	O
of	O
the	O
P	B-UNK
treated	B-UNK
animals	B-UNK
)	O
were	O
also	O
studied	B-UNK
.	O
Unanesthetized	O
adult	B-UNK
female	B-UNK
,	O
Sprague	B-UNK
-	O
Dawley	B-UNK
rats	B-UNK
were	O
divided	O
in	O
four	O
groups	B-UNK
and	O
studied	B-UNK
for	O
15	O
days	B-UNK
.	O
Group	B-UNK
1	O
(	O
P	B-UNK
alone	O
)	O
received	B-UNK
P	B-UNK
,	O
360	O
mg	B-UNK
/	O
day	B-UNK
,	O
for	O
15	O
days	B-UNK
;	O
Group	B-UNK
II	B-UNK
(	O
P	B-UNK
+	O
gentamicin	B-UNK
)	O
;	O
Group	B-UNK
III	B-UNK
(	O
gentamicin	B-UNK
alone	O
)	O
and	O
Group	B-UNK
IV	B-UNK
(	O
mild	B-UNK
DM	B-UNK
+	O
gentamicin	B-UNK
)	O
.	O
Nephrotoxic	O
doses	B-UNK
(	O
40	O
mg	B-UNK
/	O
kg	B-UNK
body	B-UNK
wt	O
/	O
day	B-UNK
)	O
of	O
gentamicin	B-UNK
were	O
injected	B-UNK
during	O
the	O
last	O
nine	O
days	B-UNK
of	O
study	B-UNK
to	O
the	O
animals	B-UNK
of	O
groups	B-UNK
II	B-UNK
to	O
IV	B-UNK
.	O
In	O
Group	B-UNK
I	O
,	O
P	B-UNK
induced	B-UNK
a	O
moderate	B-UNK
and	O
stable	B-UNK
glycosuria	B-DISEASE
(	O
3.9	B-UNK
+	O
/-	O
0.1	B-UNK
g	B-UNK
/	O
day	B-UNK
,	O
SE	O
)	O
,	O
and	O
no	O
functional	B-UNK
or	O
morphologic	B-UNK
evidence	B-UNK
of	O
renal	B-UNK
dysfunction	B-UNK
(	O
baseline	B-UNK
CCr	O
2.1	O
+	O
/-	O
0.1	B-UNK
ml	B-UNK
/	O
min	B-UNK
,	O
undetectable	O
lysozymuria	O
)	O
or	O
damage	B-UNK
(	O
tubular	B-UNK
necrosis	B-DISEASE
score	B-UNK
[	O
maximum	B-UNK
4	O
]	O
,	O
zero	O
)	O
.	O
In	O
Group	B-UNK
II	B-UNK
,	O
P	B-UNK
did	O
not	O
prevent	B-UNK
gentamicin	B-UNK
-	O
ARF	O
(	O
maximal	O
decrease	B-UNK
in	O
CCr	O
at	B-DISEASE
day	B-UNK
9.89	O
%	O
,	O
P	B-UNK
less	O
than	O
0.001	B-UNK
;	O
peak	B-UNK
lysozymuria	O
,	O
1863	O
+	O
/-	O
321	O
micrograms	B-UNK
/	O
day	B-UNK
;	O
and	O
tubular	B-UNK
necrosis	B-DISEASE
score	B-UNK
,	O
3.9	B-UNK
+	O
/-	O
0.1	B-UNK
)	O
.	O
These	O
values	B-UNK
were	O
not	O
different	B-UNK
from	O
those	O
of	O
Group	B-UNK
III	B-UNK
:	O
maximal	O
decrease	B-UNK
in	O
CCr	O
73	O
%	O
(	O
P	B-UNK
less	O
than	O
0.001	B-UNK
)	O
;	O
lysozymuria	O
,	O
2147	O
+	O
/-	O
701	O
micrograms	B-UNK
/	O
day	B-UNK
;	O
tubular	B-UNK
necrosis	B-DISEASE
score	B-UNK
,	O
3.8	O
+	O
/-	O
0.1.(ABSTRACT	O
TRUNCATED	B-UNK
AT	O
250	O
WORDS	O
)	O

Tiapride	O
in	O
levodopa	B-CHEMICAL
-	O
induced	B-UNK
involuntary	B-UNK
movements	B-UNK
.	O

Tiapride	O
,	O
a	O
substituted	O
benzamide	B-CHEMICAL
derivative	B-UNK
closely	O
related	B-UNK
to	O
metoclopramide	B-CHEMICAL
,	O
reduced	B-UNK
levodopa	B-CHEMICAL
-	O
induced	B-UNK
peak	B-UNK
dose	B-UNK
involuntary	B-UNK
movements	B-UNK
in	O
16	O
patients	B-UNK
with	O
idiopathic	B-UNK
Parkinson'	O
s	O
disease	B-DISEASE
.	O
However	O
,	O
an	O
unacceptable	O
increase	B-UNK
in	O
disability	O
from	O
Parkinsonism	O
with	O
aggravation	O
of	O
end	B-UNK
-	O
of	O
-	O
dose	B-UNK
akinesia	O
led	B-UNK
to	O
its	O
cessation	B-UNK
in	O
14	O
patients	B-UNK
.	O
Tiapride	O
had	O
no	O
effect	B-UNK
on	O
levodopa	B-CHEMICAL
-	O
induced	B-UNK
early	B-UNK
morning	O
of	O
"	O
off	O
-	O
period	B-UNK
"	O
segmental	O
dystonia	B-DISEASE
.	O
These	O
results	B-UNK
fail	O
to	O
support	B-UNK
the	O
notion	O
that	O
levodopa	B-CHEMICAL
-	O
induced	B-UNK
dyskinesias	B-DISEASE
are	O
caused	B-UNK
by	O
overstimulation	O
of	O
a	O
separate	B-UNK
group	B-UNK
of	O
dopamine	B-CHEMICAL
receptors	B-UNK
.	O

Effects	O
of	O
the	O
hippocampal	B-UNK
deep	B-UNK
brain	B-UNK
stimulation	B-UNK
on	O
cortical	B-UNK
epileptic	I-UNK
discharges	B-UNK
in	O
penicillin	O
-	O
induced	B-UNK
epilepsy	B-DISEASE
model	B-UNK
in	O
rats	B-UNK
.	O

AIM	O
:	O
Experimental	O
and	O
clinical	B-UNK
studies	B-UNK
have	O
revealed	B-UNK
that	O
hippocampal	B-UNK
DBS	B-UNK
can	O
control	B-UNK
epileptic	B-UNK
activity	I-UNK
,	O
but	O
the	O
mechanism	B-UNK
of	O
action	B-UNK
is	O
obscure	O
and	O
optimal	B-UNK
stimulation	B-UNK
parameters	B-UNK
are	O
not	O
clearly	B-UNK
defined	O
.	O
The	O
aim	O
was	O
to	O
evaluate	B-UNK
the	O
effects	B-UNK
of	O
high	B-UNK
frequency	B-UNK
hippocampal	B-UNK
stimulation	B-UNK
on	O
cortical	B-UNK
epileptic	I-UNK
activity	B-UNK
in	O
penicillin	O
-	O
induced	B-UNK
epilepsy	B-DISEASE
model	B-UNK
.	O
MATERIAL	O
AND	O
METHODS	O
:	O
Twenty	O
-	O
five	O
Sprague	B-UNK
-	O
Dawley	B-UNK
rats	B-UNK
were	O
implanted	B-UNK
DBS	B-UNK
electrodes	B-UNK
.	O
In	O
group-1	O
(	O
n=10	O
)	O
hippocampal	B-UNK
DBS	B-UNK
was	O
off	O
and	O
in	O
the	O
group-2	O
(	O
n=10	O
)	O
hippocampal	B-UNK
DBS	B-UNK
was	O
on	O
(	O
185	O
Hz	O
,	O
0.5V	O
,	O
1V	O
,	O
2V	O
,	O
and	O
5V	O
for	O
60	O
sec	O
)	O
following	B-UNK
penicillin	O
G	O
injection	B-UNK
intracortically	O
.	O
In	O
the	O
control	B-UNK
group	B-UNK
hippocampal	B-UNK
DBS	B-UNK
was	O
on	O
following	B-UNK
8	O
 	O
l	B-UNK
saline	B-UNK
injection	B-UNK
intracortically	O
.	O
EEG	O
recordings	O
were	O
obtained	B-UNK
before	O
and	O
15	O
minutes	B-UNK
following	B-UNK
penicillin	O
-	O
G	O
injection	B-UNK
,	O
and	O
at	B-DISEASE
10th	O
minutes	B-UNK
following	B-UNK
each	O
stimulus	O
for	O
analysis	B-UNK
in	O
terms	O
of	O
frequency	B-UNK
,	O
amplitude	B-UNK
,	O
and	O
power	B-UNK
spectrum	O
.	O
RESULTS	B-UNK
:	O
High	B-UNK
frequency	B-UNK
hippocampal	B-UNK
DBS	B-UNK
suppressed	B-UNK
the	O
acute	B-UNK
penicillin	O
-	O
induced	B-UNK
cortical	B-UNK
epileptic	I-UNK
activity	B-UNK
independent	B-UNK
from	O
stimulus	O
intensity	B-UNK
.	O
In	O
the	O
control	B-UNK
group	B-UNK
,	O
hippocampal	B-UNK
stimulation	B-UNK
alone	O
lead	B-CHEMICAL
only	O
to	O
diffuse	B-UNK
slowing	B-UNK
of	O
cerebral	B-UNK
bioelectrical	O
activity	B-UNK
at	B-DISEASE
5V	O
stimulation	B-UNK
.	O
CONCLUSION	O
:	O
Our	O
results	B-UNK
revealed	B-UNK
that	O
continuous	B-UNK
high	B-UNK
frequency	B-UNK
stimulation	B-UNK
of	O
the	O
hippocampus	B-UNK
suppressed	B-UNK
acute	B-UNK
cortical	B-UNK
epileptic	I-UNK
activity	B-UNK
effectively	O
without	O
causing	B-UNK
secondary	B-UNK
epileptic	B-UNK
discharges	B-UNK
.	O
These	O
results	B-UNK
are	O
important	B-UNK
in	O
terms	O
of	O
defining	O
the	O
optimal	B-UNK
parameters	B-UNK
of	O
hippocampal	B-UNK
DBS	B-UNK
in	O
patients	B-UNK
with	O
epilepsy	B-DISEASE
.	O

Neural	O
correlates	O
of	O
S	O
-	O
ketamine	B-CHEMICAL
induced	B-UNK
psychosis	B-UNK
during	O
overt	O
continuous	B-UNK
verbal	B-UNK
fluency	I-UNK
.	O

The	O
glutamatergic	B-UNK
N	B-UNK
-	O
methyl	O
-	O
D	B-UNK
-	O
aspartate	B-UNK
(	O
NMDA	O
)	O
receptor	B-UNK
has	O
been	O
implicated	B-UNK
in	O
the	O
pathophysiology	O
of	O
schizophrenia	B-DISEASE
.	O
Administered	O
to	O
healthy	B-UNK
volunteers	O
,	O
a	O
subanesthetic	O
dose	B-UNK
of	O
the	O
non-competitive	B-UNK
NMDA	O
receptor	B-UNK
antagonist	I-UNK
ketamine	B-CHEMICAL
leads	O
to	O
psychopathological	O
symptoms	B-UNK
similar	B-UNK
to	O
those	O
observed	B-UNK
in	O
schizophrenia	B-DISEASE
.	O
In	O
patients	B-UNK
with	O
schizophrenia	B-DISEASE
,	O
ketamine	B-CHEMICAL
exacerbates	O
the	O
core	O
symptoms	B-UNK
of	O
illness	O
,	O
supporting	O
the	O
hypothesis	O
of	O
a	O
glutamatergic	B-UNK
dysfunction	B-UNK
.	O
In	O
a	O
counterbalanced	O
,	O
placebo	B-UNK
-	O
controlled	B-UNK
,	O
double-blind	B-UNK
study	B-UNK
design	O
,	O
healthy	B-UNK
subjects	B-UNK
were	O
administered	B-UNK
a	O
continuous	B-UNK
subanesthetic	O
S	O
-	O
ketamine	B-CHEMICAL
infusion	B-UNK
while	O
differences	B-UNK
in	O
BOLD	O
responses	B-UNK
measured	B-UNK
with	O
fMRI	O
were	O
detected	B-UNK
.	O
During	O
the	O
scanning	B-UNK
period	B-UNK
,	O
subjects	B-UNK
performed	B-UNK
continuous	B-UNK
overt	O
verbal	B-UNK
fluency	I-UNK
tasks	O
(	O
phonological	O
,	O
lexical	O
and	O
semantic	O
)	O
.	O
Ketamine	B-UNK
-	O
induced	B-UNK
psychopathological	O
symptoms	B-UNK
were	O
assessed	B-UNK
with	O
the	O
Positive	O
and	O
Negative	O
Syndrome	B-UNK
Scale	B-UNK
(	O
PANSS	O
)	O
.	O
Ketamine	B-UNK
elicited	B-UNK
psychosis	B-UNK
like	B-UNK
psychopathology	O
.	O
Post-hoc	O
t	B-UNK
-	O
tests	B-UNK
revealed	B-UNK
significant	B-UNK
differences	B-UNK
between	O
placebo	B-UNK
and	O
ketamine	B-CHEMICAL
for	O
the	O
amounts	B-UNK
of	O
words	B-UNK
generated	B-UNK
during	O
lexical	O
and	O
semantic	O
verbal	B-UNK
fluency	I-UNK
,	O
while	O
the	O
phonological	O
domain	O
remained	B-UNK
unaffected	B-UNK
.	O
Ketamine	B-UNK
led	B-UNK
to	O
enhanced	B-UNK
cortical	B-UNK
activations	O
in	O
supramarginal	O
and	O
frontal	B-UNK
brain	B-UNK
regions	B-UNK
for	O
phonological	O
and	O
lexical	O
verbal	B-UNK
fluency	I-UNK
,	O
but	O
not	O
for	O
semantic	O
verbal	B-UNK
fluency	I-UNK
.	O
Ketamine	B-UNK
induces	B-UNK
activation	B-UNK
changes	B-UNK
in	O
healthy	B-UNK
subjects	B-UNK
similar	B-UNK
to	O
those	O
observed	B-UNK
in	O
patients	B-UNK
with	O
schizophrenia	B-DISEASE
,	O
particularly	O
in	O
frontal	B-UNK
and	O
temporal	B-UNK
brain	B-UNK
regions	B-UNK
.	O
Our	O
results	B-UNK
provide	B-UNK
further	O
support	B-UNK
for	O
the	O
hypothesis	O
of	O
an	O
NMDA	O
receptor	B-UNK
dysfunction	B-UNK
in	O
the	O
pathophysiology	O
of	O
schizophrenia	B-DISEASE
.	O

Dopamine	O
is	O
not	O
essential	O
for	O
the	O
development	B-UNK
of	O
methamphetamine	B-CHEMICAL
-	O
induced	B-UNK
neurotoxicity	B-UNK
.	O

It	O
is	O
widely	B-UNK
believed	O
that	O
dopamine	B-CHEMICAL
(	O
DA	B-UNK
)	O
mediates	O
methamphetamine	B-CHEMICAL
(	O
METH)-induced	O
toxicity	B-UNK
to	O
brain	B-UNK
dopaminergic	B-UNK
neurons	B-UNK
,	O
because	O
drugs	B-UNK
that	O
interfere	O
with	O
DA	B-UNK
neurotransmission	B-UNK
decrease	B-UNK
toxicity	B-UNK
,	O
whereas	O
drugs	B-UNK
that	O
increase	B-UNK
DA	B-UNK
neurotransmission	B-UNK
enhance	B-UNK
toxicity	B-UNK
.	O
However	O
,	O
temperature	B-UNK
effects	B-UNK
of	O
drugs	B-UNK
that	O
have	O
been	O
used	O
to	O
manipulate	O
brain	B-UNK
DA	B-UNK
neurotransmission	B-UNK
confound	O
interpretation	O
of	O
the	O
data	B-UNK
.	O
Here	O
we	O
show	O
that	O
the	O
recently	B-UNK
reported	B-UNK
ability	B-UNK
of	O
L	B-UNK
-	O
dihydroxyphenylalanine	B-CHEMICAL
to	O
reverse	B-UNK
the	O
protective	B-UNK
effect	B-UNK
of	O
alpha	B-UNK
-	O
methyl	O
-	O
para	O
-	O
tyrosine	B-CHEMICAL
on	O
METH	B-UNK
-	O
induced	B-UNK
DA	B-UNK
neurotoxicity	B-UNK
is	O
also	O
confounded	O
by	O
drug	B-UNK
effects	B-UNK
on	O
body	B-UNK
temperature	B-UNK
.	O
Further	O
,	O
we	O
show	O
that	O
mice	B-UNK
genetically	B-UNK
engineered	O
to	O
be	O
deficient	O
in	O
brain	B-UNK
DA	B-UNK
develop	B-UNK
METH	B-UNK
neurotoxicity	B-UNK
,	O
as	O
long	B-UNK
as	O
the	O
thermic	O
effects	B-UNK
of	O
METH	B-UNK
are	O
preserved	O
.	O
In	O
addition	O
,	O
we	O
demonstrate	B-UNK
that	O
mice	B-UNK
genetically	B-UNK
engineered	O
to	O
have	O
unilateral	B-UNK
brain	B-UNK
DA	B-UNK
deficits	B-UNK
develop	B-UNK
METH	B-UNK
-	O
induced	B-UNK
dopaminergic	B-UNK
deficits	B-UNK
that	O
are	O
of	O
comparable	B-UNK
magnitude	O
on	O
both	O
sides	O
of	O
the	O
brain	B-UNK
.	O
Taken	O
together	O
,	O
these	O
findings	B-UNK
demonstrate	B-UNK
that	O
DA	B-UNK
is	O
not	O
essential	O
for	O
the	O
development	B-UNK
of	O
METH	B-UNK
-	O
induced	B-UNK
dopaminergic	B-UNK
neurotoxicity	B-UNK
and	O
suggest	B-UNK
that	O
mechanisms	B-UNK
independent	B-UNK
of	O
DA	B-UNK
warrant	O
more	O
intense	O
investigation	O
.	O

Brainstem	O
dysgenesis	O
in	O
an	O
infant	B-DISEASE
prenatally	O
exposed	B-UNK
to	O
cocaine	B-CHEMICAL
.	O

Many	O
authors	B-UNK
described	B-UNK
the	O
effects	B-UNK
on	O
the	O
fetus	O
of	O
maternal	B-UNK
cocaine	B-CHEMICAL
abuse	B-UNK
during	O
pregnancy	B-DISEASE
.	O
Vasoconstriction	O
appears	B-UNK
to	O
be	O
the	O
common	B-UNK
mechanism	B-UNK
of	O
action	B-UNK
leading	B-UNK
to	O
a	O
wide	B-UNK
range	B-UNK
of	O
fetal	B-UNK
anomalies	B-UNK
.	O
We	O
report	B-UNK
on	O
an	O
infant	B-DISEASE
with	O
multiple	B-UNK
cranial	B-UNK
-	O
nerve	B-UNK
involvement	B-UNK
attributable	O
to	O
brainstem	B-UNK
dysgenesis	O
,	O
born	O
to	O
a	O
cocaine	B-CHEMICAL
-	O
addicted	O
mother	O
.	O

The	O
protective	B-UNK
role	B-UNK
of	O
Nrf2	O
in	O
streptozotocin	O
-	O
induced	B-UNK
diabetic	B-UNK
nephropathy	B-DISEASE
.	O

OBJECTIVE	O
:	O
Diabetic	O
nephropathy	B-DISEASE
is	O
one	O
of	O
the	O
major	B-UNK
causes	B-UNK
of	O
renal	B-DISEASE
failure	I-DISEASE
,	O
which	O
is	O
accompanied	O
by	O
the	O
production	B-UNK
of	O
reactive	B-CHEMICAL
oxygen	I-CHEMICAL
species	I-CHEMICAL
(	O
ROS	O
)	O
.	O
Nrf2	O
is	O
the	O
primary	B-UNK
transcription	O
factor	B-UNK
that	O
controls	B-UNK
the	O
antioxidant	B-UNK
response	B-UNK
essential	O
for	O
maintaining	O
cellular	B-UNK
redox	O
homeostasis	O
.	O
Here	O
,	O
we	O
report	B-UNK
our	O
findings	B-UNK
demonstrating	O
a	O
protective	B-UNK
role	B-UNK
of	O
Nrf2	O
against	O
diabetic	B-UNK
nephropathy	B-DISEASE
.	O
RESEARCH	O
DESIGN	B-UNK
AND	O
METHODS	O
:	O
We	O
explore	O
the	O
protective	B-UNK
role	B-UNK
of	O
Nrf2	O
against	O
diabetic	B-UNK
nephropathy	B-DISEASE
using	O
human	B-UNK
kidney	B-UNK
biopsy	B-UNK
tissues	B-UNK
from	O
diabetic	B-UNK
nephropathy	B-DISEASE
patients	B-UNK
,	O
a	O
streptozotocin	O
-	O
induced	B-UNK
diabetic	B-UNK
nephropathy	B-DISEASE
model	B-UNK
in	O
Nrf2(-/-	O
)	O
mice	B-UNK
,	O
and	O
cultured	O
human	B-UNK
mesangial	B-UNK
cells	B-UNK
.	O
RESULTS	B-UNK
:	O
The	O
glomeruli	B-UNK
of	O
human	B-UNK
diabetic	B-UNK
nephropathy	B-DISEASE
patients	B-UNK
were	O
under	O
oxidative	B-UNK
stress	B-UNK
and	O
had	O
elevated	B-UNK
Nrf2	O
levels	B-UNK
.	O
In	O
the	O
animal	B-UNK
study	B-UNK
,	O
Nrf2	O
was	O
demonstrated	B-UNK
to	O
be	O
crucial	O
in	O
ameliorating	O
streptozotocin	O
-	O
induced	B-UNK
renal	B-DISEASE
damage	B-UNK
.	O
This	O
is	O
evident	O
by	O
Nrf2(-/-	O
)	O
mice	B-UNK
having	B-UNK
higher	B-UNK
ROS	O
production	B-UNK
and	O
suffering	O
from	O
greater	B-UNK
oxidative	B-UNK
DNA	B-UNK
damage	B-UNK
and	O
renal	B-UNK
injury	B-UNK
compared	B-UNK
with	O
Nrf2(+/+	O
)	O
mice	B-UNK
.	O
Mechanistic	O
studies	B-UNK
in	O
both	O
in	O
vivo	B-UNK
and	O
in	O
vitro	B-UNK
systems	B-UNK
showed	B-UNK
that	O
the	O
Nrf2-mediated	O
protection	B-UNK
against	O
diabetic	B-UNK
nephropathy	B-DISEASE
is	O
,	O
at	B-DISEASE
least	O
,	O
partially	O
through	O
inhibition	B-UNK
of	O
transforming	O
growth	B-UNK
factor	B-UNK
-	O
beta1	O
(	O
TGF	O
-	O
beta1	O
)	O
and	O
reduction	B-UNK
of	O
extracellular	B-UNK
matrix	B-UNK
production	B-UNK
.	O
In	O
human	B-UNK
renal	B-UNK
mesangial	B-UNK
cells	B-UNK
,	O
high	B-UNK
glucose	B-CHEMICAL
induced	B-UNK
ROS	O
production	B-UNK
and	O
activated	B-UNK
expression	B-UNK
of	O
Nrf2	O
and	O
its	O
downstream	O
genes	B-UNK
.	O
Furthermore	O
,	O
activation	B-UNK
or	O
overexpression	O
of	O
Nrf2	O
inhibited	B-UNK
the	O
promoter	B-UNK
activity	B-UNK
of	O
TGF	O
-	O
beta1	O
in	O
a	O
dose	B-UNK
-	O
dependent	B-UNK
manner	B-UNK
,	O
whereas	O
knockdown	O
of	O
Nrf2	O
by	O
siRNA	O
enhanced	B-UNK
TGF	O
-	O
beta1	O
transcription	O
and	O
fibronectin	O
production	B-UNK
.	O
CONCLUSIONS	O
:	O
This	O
work	B-UNK
clearly	B-UNK
indicates	B-UNK
a	O
protective	B-UNK
role	B-UNK
of	O
Nrf2	O
in	O
diabetic	B-UNK
nephropathy	B-DISEASE
,	O
suggesting	B-UNK
that	O
dietary	O
or	O
therapeutic	B-UNK
activation	B-UNK
of	O
Nrf2	O
could	O
be	O
used	O
as	O
a	O
strategy	O
to	O
prevent	B-UNK
or	O
slow	O
down	O
the	O
progression	B-UNK
of	O
diabetic	B-UNK
nephropathy	B-DISEASE
.	O

High	B-UNK
-	O
dose	B-UNK
tranexamic	O
Acid	O
is	O
associated	B-UNK
with	O
nonischemic	O
clinical	B-UNK
seizures	B-DISEASE
in	O
cardiac	B-UNK
surgical	B-UNK
patients	B-UNK
.	O

BACKGROUND	O
:	O
In	O
2	B-DISEASE
separate	B-UNK
centers	O
,	O
we	O
observed	B-UNK
a	O
notable	O
increase	B-UNK
in	O
the	O
incidence	B-UNK
of	O
postoperative	B-UNK
convulsive	B-UNK
seizures	B-DISEASE
from	O
1.3	O
%	O
to	O
3.8	O
%	O
in	O
patients	B-UNK
having	B-UNK
undergone	B-UNK
major	B-UNK
cardiac	B-UNK
surgical	B-UNK
procedures	B-UNK
.	O
These	O
events	B-UNK
were	O
temporally	O
coincident	O
with	O
the	O
initial	B-UNK
use	B-UNK
of	O
high	B-UNK
-	O
dose	B-UNK
tranexamic	B-CHEMICAL
acid	I-CHEMICAL
(	O
TXA	B-UNK
)	O
therapy	B-UNK
after	O
withdrawal	B-UNK
of	O
aprotinin	O
from	O
general	B-UNK
clinical	B-UNK
usage	B-UNK
.	O
The	O
purpose	O
of	O
this	O
review	B-UNK
was	O
to	O
perform	O
a	O
retrospective	O
analysis	B-UNK
to	O
examine	O
whether	O
there	O
was	O
a	O
relation	O
between	O
TXA	B-UNK
usage	B-UNK
and	O
seizures	B-DISEASE
after	O
cardiac	B-UNK
surgery	B-UNK
.	O
METHODS	O
:	O
An	O
in	O
-	O
depth	B-UNK
chart	O
review	B-UNK
was	O
undertaken	O
in	O
all	O
24	O
patients	B-UNK
who	O
developed	B-UNK
perioperative	O
seizures	B-DISEASE
.	O
Electroencephalographic	O
activity	B-UNK
was	O
recorded	B-UNK
in	O
11	O
of	O
these	O
patients	B-UNK
,	O
and	O
all	O
patients	B-UNK
had	O
a	O
formal	O
neurological	B-UNK
evaluation	B-UNK
and	O
brain	B-UNK
imaging	B-UNK
studies	B-UNK
.	O
RESULTS	B-UNK
:	O
Twenty	O
-	O
one	O
of	O
the	O
24	O
patients	B-UNK
did	O
not	O
have	O
evidence	B-UNK
of	O
new	B-UNK
cerebral	B-UNK
ischemic	B-UNK
injury	B-UNK
,	O
but	O
seizures	B-DISEASE
were	O
likely	B-UNK
due	O
to	O
ischemic	B-UNK
brain	B-DISEASE
injury	I-DISEASE
in	O
3	O
patients	B-UNK
.	O
All	O
patients	B-UNK
with	O
seizures	B-DISEASE
did	O
not	O
have	O
permanent	B-UNK
neurological	B-UNK
abnormalities	B-DISEASE
.	O
All	O
24	O
patients	B-UNK
with	O
seizures	B-DISEASE
received	B-UNK
high	B-UNK
doses	B-UNK
of	O
TXA	B-UNK
intraoperatively	O
ranging	O
from	O
61	O
to	O
259	O
mg	B-UNK
/	O
kg	B-UNK
,	O
had	O
a	O
mean	B-UNK
age	B-UNK
of	O
69.9	O
years	B-UNK
,	O
and	O
21	O
of	O
24	O
had	O
undergone	B-UNK
open	B-UNK
chamber	O
rather	O
than	O
coronary	B-UNK
bypass	B-UNK
procedures	B-UNK
.	O
All	O
but	O
one	O
patient	B-UNK
were	O
managed	B-UNK
using	O
cardiopulmonary	B-UNK
bypass	B-UNK
.	O
No	O
evidence	B-UNK
of	O
brain	B-UNK
ischemic	B-UNK
,	O
metabolic	B-UNK
,	O
or	O
hyperthermia	B-DISEASE
-	O
induced	B-UNK
causes	B-UNK
for	O
their	O
seizures	B-DISEASE
was	O
apparent	O
.	O
CONCLUSION	O
:	O
Our	O
results	B-UNK
suggest	B-UNK
that	O
use	B-UNK
of	O
high	B-UNK
-	O
dose	B-UNK
TXA	B-UNK
in	O
older	O
patients	B-UNK
in	O
conjunction	O
with	O
cardiopulmonary	B-UNK
bypass	B-UNK
and	O
open	B-UNK
-	O
chamber	O
cardiac	B-UNK
surgery	B-UNK
is	O
associated	B-UNK
with	O
clinical	B-UNK
seizures	B-DISEASE
in	O
susceptible	B-UNK
patients	B-UNK
.	O

Recurrent	O
dysosmia	O
induced	B-UNK
by	O
pyrazinamide	B-CHEMICAL
.	O

Pyrazinamide	O
can	O
have	O
adverse	B-UNK
effects	B-UNK
such	O
as	O
hepatic	B-UNK
toxicity	B-UNK
,	O
hyperuricemia	B-DISEASE
or	O
digestive	O
disorders	B-UNK
.	O
In	O
rare	B-UNK
cases	B-UNK
,	O
alterations	B-UNK
in	O
taste	O
and	O
smell	O
function	B-UNK
have	O
been	O
reported	B-UNK
for	O
pyrazinamide	B-CHEMICAL
when	O
combined	B-UNK
with	O
other	O
drugs	B-UNK
.	O
We	O
report	B-UNK
a	O
case	B-UNK
of	O
reversible	B-UNK
olfactory	O
disorder	B-UNK
related	B-UNK
to	O
pyrazinamide	B-CHEMICAL
in	O
a	O
woman	B-UNK
,	O
with	O
a	O
positive	B-UNK
rechallenge	O
.	O
The	O
patient	B-UNK
presented	B-UNK
every	O
day	B-UNK
a	O
sensation	O
of	O
smelling	O
something	O
burning	O
15	O
min	B-UNK
after	O
drug	B-UNK
intake	B-UNK
.	O
Dysosmia	O
disappeared	B-UNK
completely	B-UNK
after	O
pyrazinamide	B-CHEMICAL
withdrawal	B-UNK
and	O
recurred	O
after	O
its	O
rechallenge	O
.	O
The	O
case	B-UNK
was	O
reported	B-UNK
to	O
the	O
Tunisian	O
Centre	O
of	O
Pharmacovigilance	O
.	O

Longitudinal	O
assessment	B-UNK
of	O
air	B-UNK
conduction	I-UNK
audiograms	B-UNK
in	O
a	O
phase	B-UNK
III	B-UNK
clinical	B-UNK
trial	B-UNK
of	O
difluoromethylornithine	O
and	O
sulindac	B-CHEMICAL
for	O
prevention	O
of	O
sporadic	B-UNK
colorectal	O
adenomas	O
.	O

A	O
phase	B-UNK
III	B-UNK
clinical	B-UNK
trial	B-UNK
assessed	B-UNK
the	O
recurrence	B-DISEASE
of	O
adenomatous	B-DISEASE
polyps	I-DISEASE
after	O
treatment	B-UNK
for	O
36	O
months	B-UNK
with	O
difluoromethylornithine	O
(	O
DFMO	O
)	O
plus	B-UNK
sulindac	B-CHEMICAL
or	O
matched	B-UNK
placebos	O
.	O
Temporary	O
hearing	B-DISEASE
loss	I-DISEASE
is	O
a	O
known	B-UNK
toxicity	B-UNK
of	O
treatment	B-UNK
with	O
DFMO	O
,	O
thus	O
a	O
comprehensive	O
approach	B-UNK
was	O
developed	B-UNK
to	O
analyze	O
serial	B-UNK
air	B-UNK
conduction	I-UNK
audiograms	B-UNK
.	O
The	O
generalized	B-UNK
estimating	O
equation	O
method	B-UNK
estimated	B-UNK
the	O
mean	B-UNK
difference	B-UNK
between	O
treatment	B-UNK
arms	B-DISEASE
with	O
regard	O
to	O
change	B-UNK
in	O
air	B-UNK
conduction	I-UNK
pure	O
tone	B-UNK
thresholds	B-UNK
while	O
accounting	O
for	O
within	O
-	O
subject	B-UNK
correlation	B-UNK
due	O
to	O
repeated	B-UNK
measurements	B-UNK
at	B-DISEASE
frequencies	O
.	O
Based	O
on	O
290	O
subjects	B-UNK
,	O
there	O
was	O
an	O
average	B-UNK
difference	B-UNK
of	O
0.50	B-UNK
dB	B-UNK
between	O
subjects	B-UNK
treated	B-UNK
with	O
DFMO	O
plus	B-UNK
sulindac	B-CHEMICAL
compared	B-UNK
with	O
those	O
treated	B-UNK
with	O
placebo	B-UNK
(	O
95	O
%	O
confidence	B-UNK
interval	I-UNK
,	O
-0.64	O
to	O
1.63	O
dB	B-UNK
;	O
P	B-UNK
=	I-UNK
0.39	O
)	O
,	O
adjusted	B-UNK
for	O
baseline	B-UNK
values	B-UNK
,	O
age	B-UNK
,	O
and	O
frequencies	O
.	O
In	O
the	O
normal	B-UNK
speech	O
range	B-UNK
of	O
500	O
to	O
3,000	O
Hz	O
,	O
an	O
estimated	B-UNK
difference	B-UNK
of	O
0.99	O
dB	B-UNK
(	O
-0.17	O
to	O
2.14	O
dB	B-UNK
;	O
P	B-UNK
=	I-UNK
0.09	O
)	O
was	O
detected	B-UNK
.	O
Dose	B-UNK
intensity	B-UNK
did	O
not	O
add	O
information	B-UNK
to	O
models	B-UNK
.	O
There	O
were	O
14	O
of	O
151	O
(	O
9.3	O
%	O
)	O
in	O
the	O
DFMO	O
plus	B-UNK
sulindac	B-CHEMICAL
group	B-UNK
and	O
4	O
of	O
139	O
(	O
2.9	O
%	O
)	O
in	O
the	O
placebo	B-UNK
group	B-UNK
who	O
experienced	B-UNK
at	B-DISEASE
least	O
15	O
dB	B-UNK
hearing	O
reduction	B-UNK
from	O
baseline	B-UNK
in	O
2	B-DISEASE
or	O
more	O
consecutive	B-UNK
frequencies	O
across	O
the	O
entire	B-UNK
range	B-UNK
tested	B-UNK
(	O
P	B-UNK
=	I-UNK
0.02	O
)	O
.	O
Follow	O
-	O
up	O
air	B-UNK
conduction	I-UNK
done	O
at	B-DISEASE
least	O
6	O
months	B-UNK
after	O
end	B-UNK
of	O
treatment	B-UNK
showed	B-UNK
an	O
adjusted	B-UNK
mean	B-UNK
difference	B-UNK
in	O
hearing	O
thresholds	B-UNK
of	O
1.08	O
dB	B-UNK
(	O
-0.81	O
to	O
2.96	O
dB	B-UNK
;	O
P	B-UNK
=	I-UNK
0.26	O
)	O
between	O
treatment	B-UNK
arms	B-DISEASE
.	O
There	O
was	O
no	O
significant	B-UNK
difference	B-UNK
in	O
the	O
proportion	B-UNK
of	O
subjects	B-UNK
in	O
the	O
DFMO	O
plus	B-UNK
sulindac	B-CHEMICAL
group	B-UNK
who	O
experienced	B-UNK
clinically	B-UNK
significant	I-UNK
hearing	B-DISEASE
loss	I-DISEASE
compared	B-UNK
with	O
the	O
placebo	B-UNK
group	B-UNK
.	O
The	O
estimated	B-UNK
attributable	O
risk	B-UNK
of	O
ototoxicity	B-DISEASE
from	O
exposure	B-UNK
to	O
the	O
drug	B-UNK
is	O
8.4	O
%	O
(	O
95	O
%	O
confidence	B-UNK
interval	I-UNK
,	O
-2.0	O
%	O
to	O
18.8	O
%	O
;	O
P	B-UNK
=	I-UNK
0.12	O
)	O
.	O
There	O
is	O
a	O
<	O
2	B-DISEASE
dB	B-UNK
difference	B-UNK
in	O
mean	B-UNK
threshold	B-UNK
for	O
patients	B-UNK
treated	B-UNK
with	O
DFMO	O
plus	B-UNK
sulindac	B-CHEMICAL
compared	B-UNK
with	O
those	O
treated	B-UNK
with	O
placebo	B-UNK
.	O

Increased	B-UNK
mental	B-UNK
slowing	B-UNK
associated	B-UNK
with	O
the	O
APOE	B-UNK
epsilon4	I-UNK
allele	O
after	O
trihexyphenidyl	B-CHEMICAL
oral	B-UNK
anticholinergic	B-UNK
challenge	B-UNK
in	O
healthy	B-UNK
elderly	B-UNK
.	O

OBJECTIVES	O
:	O
The	O
objectives	O
of	O
this	O
study	B-UNK
were	O
to	O
examine	O
the	O
relationship	B-UNK
between	O
APOE	B-UNK
epsilon4	I-UNK
and	O
subjective	B-UNK
effects	B-UNK
of	O
trihexyphenidyl	B-CHEMICAL
on	O
measures	B-UNK
reflecting	B-UNK
sedation	B-UNK
and	O
confusion	B-DISEASE
and	O
to	O
investigate	O
the	O
relationship	B-UNK
between	O
trihexyphenidyl	B-CHEMICAL
-	O
induced	B-UNK
subjective	B-UNK
effects	B-UNK
and	O
objective	B-UNK
memory	B-UNK
performance	B-UNK
.	O
METHODS	O
:	O
This	O
study	B-UNK
comprised	O
24	O
cognitively	O
intact	B-UNK
,	O
health	O
elderly	B-UNK
adults	O
(	O
12	O
APOE	B-UNK
epsilon4	I-UNK
carriers	O
)	O
at	B-DISEASE
an	O
outpatient	B-UNK
geriatric	O
psychiatry	B-UNK
research	B-UNK
clinic	O
.	O
This	O
was	O
a	O
randomized	B-UNK
,	O
double	B-UNK
blind	B-UNK
,	O
placebo	B-UNK
-	O
controlled	B-UNK
,	O
three	O
-	O
way	O
,	O
crossover	B-UNK
experimental	B-UNK
design	O
.	O
All	O
participants	O
received	B-UNK
1.0	B-UNK
mg	B-UNK
or	O
2.0	B-UNK
mg	B-UNK
trihexyphenidyl	B-CHEMICAL
or	O
placebo	B-UNK
administered	B-UNK
in	O
counterbalanced	O
sequences	O
over	O
a	O
period	B-UNK
of	O
three	O
consecutive	B-UNK
weeks	B-UNK
.	O
Bond	O
and	O
Lader'	O
s	O
visual	B-UNK
analog	B-UNK
scales	O
and	O
alternate	B-UNK
versions	O
of	O
the	O
Buschke	B-UNK
Selective	I-UNK
Reminding	I-UNK
Test	O
were	O
administered	B-UNK
in	O
a	O
repeated	B-UNK
measures	B-UNK
design	O
at	B-DISEASE
baseline	B-UNK
,	O
1	O
,	O
2.5	B-UNK
,	O
and	O
5	O
hours	B-UNK
postdrug	O
administration	B-UNK
.	O
RESULTS	B-UNK
:	O
A	O
2.0-mg	O
oral	B-UNK
dose	B-UNK
of	O
trihexyphenidyl	B-CHEMICAL
resulted	B-UNK
in	O
increased	B-UNK
subjective	B-UNK
ratings	B-UNK
of	O
mental	B-UNK
slowness	O
in	O
carriers	O
of	O
the	O
APOE	B-UNK
epsilon4	I-UNK
allele	O
only	O
.	O
Drug	B-UNK
effects	B-UNK
as	O
determined	O
by	O
difference	B-UNK
scores	B-UNK
between	O
2.0	B-UNK
mg	B-UNK
trihexyphenidyl	B-CHEMICAL
and	O
placebo	B-UNK
on	O
ratings	B-UNK
of	O
mental	B-UNK
slowness	O
significantly	B-UNK
correlated	B-UNK
with	O
total	B-UNK
and	O
delayed	B-UNK
recall	B-UNK
on	O
the	O
Buschke	B-UNK
Selective	I-UNK
Reminding	I-UNK
Test	O
in	O
carriers	O
of	O
the	O
APOE	B-UNK
epsilon4	I-UNK
allele	O
only	O
.	O
However	O
,	O
no	O
significant	B-UNK
effects	B-UNK
were	O
found	B-UNK
with	O
other	O
visual	B-UNK
analog	B-UNK
scales	O
reflecting	B-UNK
subjective	B-UNK
sedation	B-UNK
and	O
clear	B-UNK
-	O
headedness	O
.	O
CONCLUSION	O
:	O
The	O
epsilon4	B-UNK
allele	I-UNK
in	O
healthy	B-UNK
elderly	B-UNK
was	O
associated	B-UNK
with	O
increased	B-UNK
subjective	B-UNK
mental	B-UNK
slowing	B-UNK
after	O
trihexyphenidyl	B-CHEMICAL
anticholinergic	B-UNK
challenge	B-UNK
.	O

Behavioral	B-UNK
effects	B-UNK
of	O
pubertal	B-UNK
anabolic	O
androgenic	O
steroid	B-UNK
exposure	B-UNK
in	O
male	B-UNK
rats	B-UNK
with	O
low	B-UNK
serotonin	B-CHEMICAL
.	O

The	O
goal	O
of	O
this	O
study	B-UNK
was	O
to	O
assess	B-UNK
the	O
interactive	O
effects	B-UNK
of	O
chronic	B-UNK
anabolic	O
androgenic	O
steroid	B-UNK
(	O
AAS	O
)	O
exposure	B-UNK
and	O
brain	B-UNK
serotonin	B-CHEMICAL
(	O
5-hydroxytryptamine	O
,	O
5-HT	B-UNK
)	O
depletion	O
on	O
behavior	B-UNK
of	O
pubertal	B-UNK
male	B-UNK
rats	B-UNK
.	O
Serotonin	O
was	O
depleted	B-UNK
beginning	B-UNK
on	O
postnatal	O
day	B-UNK
26	O
with	O
parachlorophenylalanine	O
(	O
PCPA	O
100	O
mg	B-UNK
/	O
kg	B-UNK
,	O
every	O
other	O
day	B-UNK
)	O
;	O
controls	B-UNK
received	B-UNK
saline	B-UNK
.	O
At	O
puberty	B-DISEASE
(	O
P40	O
)	O
,	O
half	O
the	O
PCPA	O
-	O
treated	B-UNK
rats	B-UNK
and	O
half	O
the	O
saline	B-UNK
-	O
treated	B-UNK
rats	B-UNK
began	B-UNK
treatment	B-UNK
with	O
testosterone	B-CHEMICAL
(	O
T	B-UNK
,	O
5	O
mg	B-UNK
/	O
kg	B-UNK
,	O
5	O
days	B-UNK
/	O
week	B-UNK
)	O
.	O
Behavioral	B-UNK
measures	B-UNK
included	B-UNK
locomotion	B-UNK
,	O
irritability	O
,	O
copulation	O
,	O
partner	B-UNK
preference	B-UNK
,	O
and	O
aggression	O
.	O
Animals	O
were	O
tested	B-UNK
for	O
aggression	O
in	O
their	O
home	B-UNK
cage	O
,	O
both	O
with	O
and	O
without	O
physical	B-UNK
provocation	B-UNK
(	O
mild	B-UNK
tail	O
pinch	O
)	O
.	O
Brain	O
levels	B-UNK
of	O
5-HT	B-UNK
and	O
its	O
metabolite	B-UNK
,	O
5-hydroxyindoleacetic	O
acid	B-UNK
(	O
5-HIAA	O
)	O
,	O
were	O
determined	O
using	O
HPLC	O
.	O
PCPA	O
significantly	B-UNK
and	O
substantially	O
depleted	B-UNK
5-HT	B-UNK
and	O
5-HIAA	O
in	O
all	O
brain	B-UNK
regions	B-UNK
examined	B-UNK
.	O
Chronic	B-UNK
T	B-UNK
treatment	B-UNK
significantly	I-UNK
decreased	B-UNK
5-HT	B-UNK
and	O
5-HIAA	O
in	O
certain	B-UNK
brain	B-UNK
areas	B-UNK
,	O
but	O
to	O
a	O
much	O
lesser	B-UNK
extent	B-UNK
than	O
PCPA	O
.	O
Chronic	B-UNK
exposure	B-UNK
to	O
PCPA	O
alone	O
significantly	B-UNK
decreased	B-UNK
locomotor	B-UNK
activity	B-UNK
and	O
increased	B-UNK
irritability	O
but	O
had	O
no	O
effect	B-UNK
on	O
sexual	B-UNK
behavior	B-UNK
,	O
partner	B-UNK
preference	B-UNK
,	O
or	O
aggression	O
.	O
T	B-UNK
alone	O
had	O
no	O
effect	B-UNK
on	O
locomotion	B-UNK
,	O
irritability	O
,	O
or	O
sexual	B-UNK
behavior	B-UNK
but	O
increased	B-UNK
partner	B-UNK
preference	B-UNK
and	O
aggression	O
.	O
The	O
most	O
striking	B-UNK
effect	B-UNK
of	O
combining	O
T+PCPA	O
was	O
a	O
significant	B-UNK
increase	B-UNK
in	O
attack	O
frequency	B-UNK
as	O
well	O
as	O
a	O
significant	B-UNK
decrease	B-UNK
in	O
the	O
latency	O
to	O
attack	O
,	O
particularly	O
following	B-UNK
physical	B-UNK
provocation	B-UNK
.	O
Based	O
on	O
these	O
data	B-UNK
,	O
it	O
can	O
be	O
speculated	O
that	O
pubertal	B-UNK
AAS	O
users	B-UNK
with	O
low	B-UNK
central	B-UNK
5-HT	B-UNK
may	O
be	O
especially	B-UNK
prone	O
to	O
exhibit	B-UNK
aggressive	B-UNK
behavior	B-UNK
.	O

Intracavitary	O
chemotherapy	B-UNK
(	O
paclitaxel	B-CHEMICAL
/	O
carboplatin	B-CHEMICAL
liquid	B-UNK
crystalline	O
cubic	B-UNK
phases	B-UNK
)	O
for	O
recurrent	B-UNK
glioblastoma	B-DISEASE
--	O
clinical	B-UNK
observations	B-UNK
.	O

Human	O
malignant	B-UNK
brain	B-UNK
tumors	B-UNK
have	O
a	O
poor	B-UNK
prognosis	B-UNK
in	O
spite	O
of	O
surgery	B-UNK
and	O
radiation	O
therapy	B-UNK
.	O
Cubic	O
phases	B-UNK
consist	O
of	O
curved	O
biocontinuous	O
lipid	B-UNK
bilayers	O
,	O
separating	O
two	O
congruent	O
networks	O
of	O
water	B-CHEMICAL
channels	O
.	O
Used	O
as	O
a	O
host	O
for	O
cytotoxic	B-UNK
drugs	B-UNK
,	O
the	O
gel	O
-	O
like	B-UNK
matrix	B-UNK
can	O
easily	O
be	O
applied	O
to	O
the	O
walls	O
of	O
a	O
surgical	B-UNK
resection	O
cavity	O
.	O
For	O
human	B-UNK
glioblastoma	B-DISEASE
recurrences	O
,	O
the	O
feasibility	O
,	O
safety	B-UNK
,	O
and	O
short	B-UNK
-	O
term	B-UNK
effects	B-UNK
of	O
a	O
surgical	B-UNK
intracavitary	O
application	B-UNK
of	O
paclitaxel	B-CHEMICAL
and	O
carboplatin	B-CHEMICAL
encapsulated	O
by	O
liquid	B-UNK
crystalline	O
cubic	B-UNK
phases	B-UNK
are	O
examined	B-UNK
in	O
a	O
pilot	O
study	B-UNK
.	O
A	O
total	B-UNK
of	O
12	O
patients	B-UNK
with	O
a	O
recurrence	B-DISEASE
of	O
a	O
glioblastoma	B-DISEASE
multiforme	O
underwent	B-UNK
re-resection	O
and	O
received	B-UNK
an	O
intracavitary	O
application	B-UNK
of	O
paclitaxel	B-CHEMICAL
and	O
carboplatin	B-CHEMICAL
cubic	B-UNK
phases	B-UNK
in	O
different	B-UNK
dosages	O
.	O
Six	O
of	O
the	O
patients	B-UNK
received	B-UNK
more	O
than	O
15	O
mg	B-UNK
paclitaxel	B-CHEMICAL
and	O
suffered	O
from	O
moderate	B-UNK
to	O
severe	B-UNK
brain	B-DISEASE
edema	I-DISEASE
,	O
while	O
the	O
remaining	B-UNK
patients	B-UNK
received	B-UNK
only	O
a	O
total	B-UNK
of	O
15	O
mg	B-UNK
paclitaxel	B-CHEMICAL
.	O
In	O
the	O
latter	O
group	B-UNK
,	O
brain	B-DISEASE
edema	I-DISEASE
was	O
markedly	B-UNK
reduced	B-UNK
and	O
dealt	O
medically	O
.	O
Intracavitary	O
chemotherapy	B-UNK
in	O
recurrent	B-UNK
glioblastoma	B-DISEASE
using	O
cubic	B-UNK
phases	B-UNK
is	O
feasible	O
and	O
safe	B-UNK
,	O
yet	O
the	O
clinical	B-UNK
benefit	B-UNK
remains	B-UNK
to	O
be	O
examined	B-UNK
in	O
a	O
clinical	B-UNK
phase	B-UNK
II	B-UNK
study	B-UNK
.	O

Methylphenidate	O
-	O
induced	B-UNK
obsessive	O
-	O
compulsive	O
symptoms	B-UNK
in	O
an	O
elderly	B-UNK
man	B-UNK
.	O

An	O
82-year	O
-	O
old	B-UNK
man	B-UNK
with	O
treatment	B-UNK
-	O
resistant	B-UNK
depression	B-DISEASE
and	O
early	B-UNK
Alzheimer'	O
s	O
disease	B-DISEASE
was	O
started	B-UNK
on	O
methylphenidate	B-CHEMICAL
.	O
Significant	B-UNK
obsessive	O
-	O
compulsive	O
behavior	B-UNK
ensued	O
but	O
diminished	B-UNK
over	O
several	O
weeks	B-UNK
when	O
methylphenidate	B-CHEMICAL
was	O
replaced	O
by	O
fluvoxamine	B-CHEMICAL
.	O
The	O
patient	B-UNK
had	O
no	O
prior	B-UNK
psychiatric	B-UNK
history	B-UNK
,	O
but	O
he	O
had	O
a	O
sister	O
with	O
obsessive	B-DISEASE
-	I-DISEASE
compulsive	I-DISEASE
disorder	I-DISEASE
.	O
It	O
appears	B-UNK
that	O
methylphenidate	B-CHEMICAL
precipitated	O
the	O
patient'	O
s	O
pathological	B-UNK
behavior	B-UNK
.	O

Cardiac	B-UNK
arrest	B-UNK
after	O
intravenous	B-UNK
metoclopramide	B-CHEMICAL
-	O
a	O
case	B-UNK
of	O
five	O
repeated	B-UNK
injections	B-UNK
of	O
metoclopramide	B-CHEMICAL
causing	B-UNK
five	O
episodes	B-UNK
of	O
cardiac	B-DISEASE
arrest	I-DISEASE
.	O

We	O
describe	O
a	O
patient	B-UNK
where	O
intravenous	B-UNK
injection	B-UNK
of	O
metoclopramide	B-CHEMICAL
was	O
immediately	B-UNK
followed	B-UNK
by	O
asystole	O
repeatedly	B-UNK
.	O
The	O
patient	B-UNK
received	B-UNK
metoclopramide	B-CHEMICAL
10	O
mg	B-UNK
i.v	B-UNK
.	O
five	O
times	B-UNK
during	O
48	O
h.	O
After	O
interviewing	O
the	O
attending	O
nurses	O
and	O
reviewing	O
the	O
written	O
documentation	O
,	O
it	O
is	O
clear	B-UNK
that	O
every	O
administration	B-UNK
of	O
metoclopramide	B-CHEMICAL
was	O
immediately	B-UNK
(	O
within	O
s	O
)	O
followed	B-UNK
by	O
asystole	O
.	O
The	O
asystole	O
lasted	B-UNK
15	O
-	O
30	O
s	O
on	O
four	O
occasions	B-UNK
,	O
on	O
one	O
occasion	O
it	O
lasted	B-UNK
2	B-DISEASE
min	B-UNK
.	O
The	O
patient	B-UNK
received	B-UNK
atropine	B-CHEMICAL
0.5	B-UNK
-	O
1	O
mg	B-UNK
and	O
chest	B-UNK
compressions	O
,	O
before	O
sinus	B-UNK
rhythm	B-UNK
again	O
took	O
over	O
.	O
We	O
interpret	O
this	O
as	O
episodes	B-UNK
of	O
cardiac	B-DISEASE
arrest	I-DISEASE
caused	B-UNK
by	O
metoclopramide	B-CHEMICAL
.	O
The	O
rapid	B-UNK
injection	B-UNK
via	O
the	O
central	B-UNK
venous	B-UNK
route	B-UNK
and	O
the	O
concomitant	B-UNK
tapering	O
of	O
dopamine	B-CHEMICAL
infusion	B-UNK
might	O
have	O
contributed	O
in	O
precipitating	O
the	O
adverse	B-UNK
drug	I-UNK
reaction	B-UNK
.	O

Severe	B-UNK
immune	B-UNK
hemolytic	B-DISEASE
anemia	I-DISEASE
associated	B-UNK
with	O
prophylactic	B-UNK
use	B-UNK
of	O
cefotetan	B-CHEMICAL
in	O
obstetric	O
and	O
gynecologic	B-UNK
procedures	B-UNK
.	O

Second-	O
and	O
third	O
-	O
generation	B-UNK
cephalosporins	B-CHEMICAL
,	O
especially	B-UNK
cefotetan	B-CHEMICAL
,	O
are	O
increasingly	O
associated	B-UNK
with	O
severe	B-UNK
,	O
sometimes	O
fatal	B-UNK
immune	B-UNK
hemolytic	B-DISEASE
anemia	I-DISEASE
.	O
We	O
noticed	O
that	O
10	O
of	O
our	O
35	O
cases	B-UNK
of	O
cefotetan	B-CHEMICAL
-	O
induced	B-UNK
hemolytic	B-UNK
anemias	O
were	O
in	O
patients	B-UNK
who	O
had	O
received	B-UNK
cefotetan	B-CHEMICAL
prophylactically	O
for	O
obstetric	O
and	O
gynecologic	B-UNK
procedures	B-UNK
.	O
Eight	O
of	O
these	O
cases	B-UNK
of	O
severe	B-UNK
immune	B-UNK
hemolytic	B-DISEASE
anemia	I-DISEASE
are	O
described	B-UNK
.	O

Cauda	O
equina	O
syndrome	B-DISEASE
after	O
spinal	B-UNK
anaesthesia	B-UNK
with	O
hyperbaric	O
5	O
%	O
lignocaine	O
:	O
a	O
review	B-UNK
of	O
six	O
cases	B-UNK
of	O
cauda	B-DISEASE
equina	I-DISEASE
syndrome	I-DISEASE
reported	B-UNK
to	O
the	O
Swedish	B-UNK
Pharmaceutical	O
Insurance	O
1993	O
-	O
1997	O
.	O

Six	O
cases	B-UNK
of	O
cauda	B-DISEASE
equina	I-DISEASE
syndrome	I-DISEASE
with	O
varying	O
severity	B-UNK
were	O
reported	B-UNK
to	O
the	O
Swedish	B-UNK
Pharmaceutical	O
Insurance	O
during	O
the	O
period	B-UNK
1993	O
-	O
1997	O
.	O
All	O
were	O
associated	B-UNK
with	O
spinal	B-UNK
anaesthesia	B-UNK
using	O
hyperbaric	O
5	O
%	O
lignocaine	O
.	O
Five	O
cases	B-UNK
had	O
single	B-UNK
-	O
shot	O
spinal	B-UNK
anaesthesia	B-UNK
and	O
one	O
had	O
a	O
repeat	B-UNK
spinal	B-UNK
anaesthetic	O
due	O
to	O
inadequate	O
block	B-UNK
.	O
The	O
dose	B-UNK
of	O
hyperbaric	O
5	O
%	O
lignocaine	O
administered	B-UNK
ranged	B-UNK
from	O
60	O
to	O
120	O
mg	B-UNK
.	O
Three	O
of	O
the	O
cases	B-UNK
were	O
most	O
likely	B-UNK
caused	B-UNK
by	O
direct	B-UNK
neurotoxicity	B-UNK
of	O
hyperbaric	O
5	O
%	O
lignocaine	O
.	O
In	O
the	O
other	O
3	O
cases	B-UNK
,	O
direct	B-UNK
neurotoxicity	B-UNK
was	O
also	O
probable	B-UNK
,	O
but	O
unfortunately	O
radiological	O
investigations	B-UNK
were	O
not	O
done	O
to	O
definitely	O
exclude	O
a	O
compressive	O
aetiology	O
.	O
All	O
cases	B-UNK
sustained	B-UNK
permanent	B-UNK
neurological	B-UNK
deficits	B-UNK
.	O
We	O
recommend	B-UNK
that	O
hyperbaric	O
lignocaine	O
should	O
be	O
administered	B-UNK
in	O
concentrations	B-UNK
not	O
greater	B-UNK
than	O
2	B-DISEASE
%	O
and	O
at	B-DISEASE
a	O
total	B-UNK
dose	B-UNK
preferably	O
not	O
exceeding	O
60	O
mg	B-UNK
.	O

Cortical	O
motor	B-UNK
overactivation	O
in	O
parkinsonian	B-UNK
patients	B-UNK
with	O
L	B-UNK
-	O
dopa	O
-	O
induced	B-UNK
peak	B-UNK
-	O
dose	B-UNK
dyskinesia	B-DISEASE
.	O

We	O
have	O
studied	B-UNK
the	O
regional	B-UNK
cerebral	B-UNK
blood	B-UNK
flow	B-UNK
(	O
rCBF	O
)	O
changes	B-UNK
induced	B-UNK
by	O
the	O
execution	O
of	O
a	O
finger	O
-	O
to	O
-	O
thumb	B-DISEASE
opposition	O
motor	B-UNK
task	B-UNK
in	O
the	O
supplementary	O
and	O
primary	B-UNK
motor	B-UNK
cortex	B-UNK
of	O
two	O
groups	B-UNK
of	O
parkinsonian	B-UNK
patients	B-UNK
on	O
L	B-UNK
-	O
dopa	O
medication	B-UNK
,	O
the	O
first	O
one	O
without	O
L	B-UNK
-	O
dopa	O
induced	B-UNK
dyskinesia	B-DISEASE
(	O
n	B-UNK
=	O
23	O
)	O
and	O
the	O
other	O
with	O
moderate	B-UNK
peak	B-UNK
-	O
dose	B-UNK
dyskinesia	B-DISEASE
(	O
n	B-UNK
=	O
15	O
)	O
,	O
and	O
of	O
a	O
group	B-UNK
of	O
14	O
normal	B-UNK
subjects	B-UNK
.	O
Single	O
photon	B-UNK
emission	B-UNK
tomography	B-UNK
with	O
i.v	B-UNK
.	O
133Xe	O
was	O
used	O
to	O
measure	B-UNK
the	O
rCBF	O
changes	B-UNK
.	O
The	O
dyskinetic	B-UNK
parkinsonian	B-UNK
patients	B-UNK
exhibited	B-UNK
a	O
pattern	B-UNK
of	O
response	B-UNK
which	O
was	O
markedly	B-UNK
different	B-UNK
from	O
those	O
of	O
the	O
normal	B-UNK
subjects	B-UNK
and	O
non-dyskinetic	O
parkinsonian	B-UNK
patients	B-UNK
,	O
with	O
a	O
significant	B-UNK
overactivation	O
in	O
the	O
supplementary	B-UNK
motor	I-UNK
area	B-UNK
and	O
the	O
ipsi-	O
and	O
contralateral	B-UNK
primary	B-UNK
motor	B-UNK
areas	B-UNK
.	O
These	O
results	B-UNK
are	O
compatible	O
with	O
the	O
hypothesis	O
that	O
an	O
hyperkinetic	O
abnormal	B-UNK
involuntary	B-UNK
movement	B-UNK
,	O
like	B-UNK
L	B-UNK
-	O
dopa	O
-	O
induced	B-UNK
peak	B-UNK
dose	B-UNK
dyskinesia	B-DISEASE
,	O
is	O
due	O
to	O
a	O
disinhibition	O
of	O
the	O
primary	B-UNK
and	O
associated	B-UNK
motor	B-UNK
cortex	B-UNK
secondary	B-UNK
to	O
an	O
excessive	B-UNK
outflow	B-UNK
of	O
the	O
pallidothalamocortical	O
motor	B-UNK
loop	O
.	O

Dexamethasone	O
-	O
induced	B-UNK
ocular	B-DISEASE
hypertension	I-DISEASE
in	O
perfusion	B-UNK
-	O
cultured	O
human	B-UNK
eyes	B-UNK
.	O

PURPOSE	O
:	O
Glucocorticoid	O
administration	B-UNK
can	O
lead	B-CHEMICAL
to	O
the	O
development	B-UNK
of	O
ocular	B-DISEASE
hypertension	I-DISEASE
and	O
corticosteroid	O
glaucoma	B-DISEASE
in	O
a	O
subset	O
of	O
the	O
population	B-UNK
through	O
a	O
decrease	B-UNK
in	O
the	O
aqueous	B-UNK
humor	O
outflow	B-UNK
facility	O
.	O
The	O
purpose	O
of	O
this	O
study	B-UNK
was	O
to	O
determine	B-UNK
whether	O
glucocorticoid	O
treatment	B-UNK
can	O
directly	B-UNK
affect	B-UNK
the	O
outflow	B-UNK
facility	O
of	O
isolated	B-UNK
,	O
perfusion	B-UNK
-	O
cultured	O
human	B-UNK
eyes	B-UNK
.	O
METHODS	O
:	O
The	O
anterior	B-UNK
segments	O
of	O
human	B-UNK
donor	B-UNK
eyes	B-UNK
from	O
regional	B-UNK
eye	B-UNK
banks	O
were	O
placed	O
in	O
a	O
constant	O
flow	B-UNK
,	O
variable	B-UNK
pressure	B-UNK
perfusion	B-UNK
culture	O
system	B-UNK
.	O
Paired	O
eyes	B-UNK
were	O
perfused	B-UNK
in	O
serum	B-UNK
-	O
free	B-UNK
media	O
with	O
or	O
without	O
10(-7	O
)	O
M	O
dexamethasone	B-CHEMICAL
for	O
12	O
days	B-UNK
.	O
Intraocular	O
pressure	B-UNK
was	O
monitored	B-UNK
daily	B-UNK
.	O
After	O
incubation	O
,	O
the	O
eyes	B-UNK
were	O
morphologically	O
characterized	B-UNK
by	O
light	B-UNK
microscopy	B-UNK
,	O
transmission	B-UNK
and	O
scanning	B-UNK
electron	B-UNK
microscopy	B-UNK
,	O
and	O
scanning	B-UNK
laser	B-UNK
confocal	O
microscopy	B-UNK
.	O
RESULTS	B-UNK
:	O
A	O
significant	B-UNK
increase	B-UNK
in	O
intraocular	B-UNK
pressure	B-UNK
developed	B-UNK
in	O
13	O
of	O
the	O
44	O
pairs	O
of	O
eyes	B-UNK
perfused	B-UNK
with	O
dexamethasone	B-CHEMICAL
with	O
an	O
average	B-UNK
pressure	B-UNK
rise	B-UNK
of	O
17.5	O
+	O
/-	O
3.8	O
mm	B-UNK
Hg	B-UNK
after	O
12	O
days	B-UNK
of	O
dexamethasone	B-CHEMICAL
exposure	B-UNK
.	O
The	O
contralateral	B-UNK
control	B-UNK
eyes	B-UNK
,	O
which	O
did	O
not	O
receive	B-UNK
dexamethasone	B-CHEMICAL
,	O
maintained	O
a	O
stable	B-UNK
intraocular	B-UNK
pressure	B-UNK
during	O
the	O
same	O
period	B-UNK
.	O
The	O
outflow	B-UNK
pathway	B-UNK
of	O
the	O
untreated	B-UNK
eyes	B-UNK
appeared	B-UNK
morphologically	O
normal	B-UNK
.	O
In	O
contrast	B-UNK
,	O
the	O
dexamethasone	B-CHEMICAL
-	O
treated	B-UNK
hypertensive	B-UNK
eyes	B-UNK
had	O
thickened	B-UNK
trabecular	B-UNK
beams	O
,	O
decreased	B-UNK
intertrabecular	O
spaces	O
,	O
thickened	B-UNK
juxtacanalicular	O
tissue	B-UNK
,	O
activated	B-UNK
trabecular	B-UNK
meshwork	O
cells	B-UNK
,	O
and	O
increased	B-UNK
amounts	B-UNK
of	O
amorphogranular	O
extracellular	B-UNK
material	O
,	O
especially	B-UNK
in	O
the	O
juxtacanalicular	O
tissue	B-UNK
and	O
beneath	O
the	O
endothelial	B-UNK
lining	O
of	O
the	O
canal	O
of	O
Schlemm	O
.	O
The	O
dexamethasone	B-CHEMICAL
-	O
treated	B-UNK
nonresponder	O
eyes	B-UNK
appeared	B-UNK
to	O
be	O
morphologically	O
similar	B-UNK
to	O
the	O
untreated	B-UNK
eyes	B-UNK
,	O
although	O
several	O
subtle	O
dexamethasone	B-CHEMICAL
-	O
induced	B-UNK
morphologic	B-UNK
changes	B-UNK
were	O
evident	O
.	O
CONCLUSION	O
:	O
Dexamethasone	O
treatment	B-UNK
of	O
isolated	B-UNK
,	O
perfusion	B-UNK
-	O
cultured	O
human	B-UNK
eyes	B-UNK
led	B-UNK
to	O
the	O
generation	B-UNK
of	O
ocular	B-DISEASE
hypertension	I-DISEASE
in	O
approximately	B-UNK
30	O
%	O
of	O
the	O
dexamethasone	B-CHEMICAL
-	O
treated	B-UNK
eyes	B-UNK
.	O
Steroid	B-UNK
treatment	B-UNK
resulted	B-UNK
in	O
morphologic	B-UNK
changes	B-UNK
in	O
the	O
trabecular	B-UNK
meshwork	O
similar	B-UNK
to	O
those	O
reported	B-UNK
for	O
corticosteroid	O
glaucoma	B-DISEASE
and	O
open	B-UNK
angle	O
glaucoma	B-DISEASE
.	O
This	O
system	B-UNK
may	O
provide	B-UNK
an	O
acute	B-UNK
model	B-UNK
in	O
which	O
to	O
study	B-UNK
the	O
pathogenic	O
mechanisms	B-UNK
involved	B-UNK
in	O
steroid	B-UNK
glaucoma	B-DISEASE
and	O
primary	B-UNK
open	B-UNK
angle	O
glaucoma	B-DISEASE
.	O

Cognitive	B-UNK
deterioration	B-UNK
from	O
long	B-UNK
-	O
term	B-UNK
abuse	B-UNK
of	O
dextromethorphan	B-CHEMICAL
:	O
a	O
case	B-UNK
report	B-UNK
.	O

Dextromethorphan	O
(	O
DM	B-UNK
)	O
,	O
the	O
dextrorotatory	O
isomer	O
of	O
3-hydroxy	O
-	O
N	B-UNK
-	O
methylmorphinan	O
,	O
is	O
the	O
main	B-UNK
ingredient	O
in	O
a	O
number	B-UNK
of	O
widely	B-UNK
available	B-UNK
,	O
over	O
-	O
the	O
-	O
counter	O
antitussives	O
.	O
Initial	O
studies	B-UNK
(	O
Bornstein	O
1968	O
)	O
showed	B-UNK
that	O
it	O
possessed	O
no	O
respiratory	B-UNK
suppressant	O
effects	B-UNK
and	O
no	O
addiction	B-DISEASE
liability	O
.	O
Subsequently	O
,	O
however	O
,	O
several	O
articles	O
reporting	B-UNK
abuse	B-UNK
of	O
this	O
drug	B-UNK
have	O
appeared	B-UNK
in	O
the	O
literature	B-UNK
.	O
The	O
drug	B-UNK
is	O
known	B-UNK
to	O
cause	B-UNK
a	O
variety	O
of	O
acute	B-UNK
toxic	B-UNK
effects	B-UNK
,	O
ranging	O
from	O
nausea	B-DISEASE
,	O
restlessness	O
,	O
insomnia	B-DISEASE
,	O
ataxia	B-DISEASE
,	O
slurred	O
speech	O
and	O
nystagmus	B-DISEASE
to	O
mood	B-UNK
changes	B-UNK
,	O
perceptual	O
alterations	B-UNK
,	O
inattention	O
,	O
disorientation	O
and	O
aggressive	B-UNK
behavior	B-UNK
(	O
Rammer	O
et	O
al	O
1988	O
;	O
Katona	O
and	O
Watson	O
1986	O
;	O
Isbell	O
and	O
Fraser	O
1953	O
;	O
Devlin	O
et	O
al	O
1985	O
;	O
McCarthy	O
1971	O
;	O
Dodds	O
and	O
Revai	O
1967	O
;	O
Degkwitz	O
1964	O
;	O
Hildebrand	O
et	O
al	O
1989	O
)	O
.	O
There	O
have	O
also	O
been	O
two	O
reported	B-UNK
fatalities	O
from	O
DM	B-UNK
overdoses	O
(	O
Fleming	O
1986	O
)	O
.	O
However	O
,	O
there	O
are	O
no	O
reports	B-UNK
describing	O
the	O
effects	B-UNK
of	O
chronic	B-UNK
abuse	B-UNK
.	O
This	O
report	B-UNK
describes	B-UNK
a	O
case	B-UNK
of	O
cognitive	B-UNK
deterioration	B-UNK
resulting	B-UNK
from	O
prolonged	B-UNK
use	B-UNK
of	O
DM	B-UNK
.	O

Long	O
-	O
term	B-UNK
lithium	B-CHEMICAL
treatment	B-UNK
and	O
the	O
kidney	B-UNK
.	O
Interim	O
report	B-UNK
on	O
fifty	O
patients	B-UNK
.	O

This	O
is	O
a	O
report	B-UNK
on	O
the	O
first	O
part	O
of	O
our	O
study	B-UNK
of	O
the	O
effects	B-UNK
of	O
long	B-UNK
-	O
term	B-UNK
lithium	B-CHEMICAL
treatment	B-UNK
on	O
the	O
kidney	B-UNK
.	O
Creatinine	O
clearance	B-UNK
,	O
maximum	B-UNK
urinary	B-UNK
osmolality	O
and	O
24	O
hour	O
urine	B-DISEASE
volume	B-UNK
have	O
been	O
tested	B-UNK
in	O
50	O
affectively	O
ill	O
patients	B-UNK
who	O
have	O
been	O
on	O
long	B-UNK
-	O
term	B-UNK
lithium	B-CHEMICAL
for	O
more	O
than	O
one	O
year	B-UNK
.	O
These	O
findings	B-UNK
have	O
been	O
compared	B-UNK
with	O
norms	O
and	O
with	O
values	B-UNK
of	O
the	O
same	O
tests	B-UNK
from	O
screening	B-UNK
prior	B-UNK
to	O
lithium	B-CHEMICAL
,	O
available	B-UNK
for	O
most	O
of	O
our	O
patients	B-UNK
.	O
No	O
evidence	B-UNK
was	O
found	B-UNK
for	O
any	O
reduction	B-UNK
of	O
glomerular	B-UNK
filtration	I-UNK
during	O
lithium	B-CHEMICAL
treatment	B-UNK
.	O
Low	O
clearance	B-UNK
values	B-UNK
found	B-UNK
in	O
several	O
patients	B-UNK
could	O
be	O
accounted	O
for	O
by	O
their	O
age	B-UNK
and	O
their	O
pre	B-UNK
-	O
lithium	B-CHEMICAL
values	B-UNK
.	O
Urinary	B-UNK
concentration	B-UNK
defect	B-UNK
appeared	B-UNK
frequent	B-UNK
but	O
the	O
extent	B-UNK
of	O
the	O
impairment	B-UNK
is	O
difficult	O
to	O
assess	B-UNK
because	O
of	O
the	O
uncertainty	O
about	O
the	O
norms	O
applicable	O
to	O
this	O
group	B-UNK
of	O
patients	B-UNK
.	O
The	O
concentration	B-UNK
defect	B-UNK
appeared	B-UNK
reversible	B-UNK
,	O
at	B-DISEASE
least	O
in	O
part	O
.	O
Polyuria	O
above	O
3	O
litres/24	O
hours	B-UNK
was	O
found	B-UNK
in	O
10	O
%	O
of	O
patients	B-UNK
.	O
An	O
attempt	O
is	O
made	O
to	O
draw	O
practical	O
conclusions	O
from	O
the	O
preliminary	B-UNK
findings	B-UNK
.	O

Complete	O
heart	B-DISEASE
block	I-DISEASE
following	B-UNK
a	O
single	B-UNK
dose	B-UNK
of	O
trazodone	B-CHEMICAL
.	O

Forty	O
minutes	B-UNK
after	O
receiving	B-UNK
a	O
single	B-UNK
starting	B-UNK
dose	B-UNK
of	O
trazodone	B-CHEMICAL
,	O
a	O
patient	B-UNK
developed	I-UNK
complete	B-UNK
heart	B-DISEASE
block	I-DISEASE
.	O
The	O
case	B-UNK
illustrates	O
that	O
,	O
despite	B-UNK
the	O
results	B-UNK
of	O
earlier	B-UNK
studies	B-UNK
,	O
trazodone'	O
s	O
effect	B-UNK
on	O
cardiac	B-UNK
conduction	B-UNK
may	O
be	O
severe	B-UNK
in	O
individuals	B-UNK
at	B-DISEASE
risk	B-UNK
for	O
conduction	B-UNK
delay	B-UNK
.	O

Quinidine	O
phenylethylbarbiturate	O
-	O
induced	B-UNK
fulminant	B-UNK
hepatitis	B-DISEASE
in	O
a	O
pregnant	B-UNK
woman	B-UNK
.	O
A	O
case	B-UNK
report	B-UNK
.	O

We	O
report	B-UNK
the	O
case	B-UNK
of	O
a	O
19-year	O
-	O
old	B-UNK
Laotian	O
patient	B-UNK
affected	B-UNK
by	O
fulminant	B-UNK
hepatitis	B-DISEASE
during	O
the	O
third	O
trimester	O
of	O
her	O
pregnancy	B-DISEASE
after	O
a	O
1-month	O
administration	B-UNK
of	O
quinidine	B-CHEMICAL
phenylethylbarbiturate	O
.	O
After	O
delivery	B-UNK
,	O
the	O
patient	B-UNK
underwent	B-UNK
orthotopic	O
liver	B-DISEASE
transplantation	B-UNK
.	O
The	O
patient	B-UNK
was	O
in	O
good	B-UNK
condition	B-UNK
16	O
months	B-UNK
after	O
liver	B-DISEASE
transplantation	B-UNK
.	O
Quinidine	O
itself	O
or	O
phenylethylbarbiturate	O
may	O
be	O
responsible	O
for	O
fulminant	B-UNK
hepatitis	B-DISEASE
in	O
this	O
patient	B-UNK
.	O

The	O
epidemiology	O
of	O
the	O
acute	B-UNK
flank	B-DISEASE
pain	I-DISEASE
syndrome	B-UNK
from	O
suprofen	B-CHEMICAL
.	O

Suprofen	O
,	O
a	O
new	B-UNK
nonsteroidal	B-UNK
anti-inflammatory	I-UNK
drug	B-UNK
,	O
was	O
marketed	O
in	O
early	B-UNK
1986	O
as	O
an	O
analgesic	B-UNK
agent	B-UNK
.	O
Until	O
physicians	O
began	B-UNK
reporting	B-UNK
an	O
unusual	O
acute	B-UNK
flank	B-DISEASE
pain	I-DISEASE
syndrome	B-UNK
to	O
the	O
spontaneous	B-UNK
reporting	B-UNK
system	B-UNK
,	O
700,000	O
persons	B-UNK
used	O
the	O
drug	B-UNK
in	O
the	O
United	B-UNK
States	B-UNK
.	O
Through	O
August	O
1986	O
,	O
a	O
total	B-UNK
of	O
163	O
cases	B-UNK
of	O
this	O
syndrome	B-UNK
were	O
reported	B-UNK
.	O
To	O
elucidate	O
the	O
epidemiology	O
of	O
the	O
syndrome	B-DISEASE
,	O
a	O
case	B-UNK
-	O
control	B-UNK
study	B-UNK
was	O
performed	B-UNK
,	O
comparing	O
62	O
of	O
the	O
case	B-UNK
patients	B-UNK
who	O
had	O
been	O
reported	B-UNK
to	O
the	O
spontaneous	B-UNK
reporting	B-UNK
system	B-UNK
to	O
185	O
suprofen	B-CHEMICAL
-	O
exposed	B-UNK
control	B-UNK
subjects	B-UNK
who	O
did	O
not	O
have	O
the	O
syndrome	B-DISEASE
.	O
Case	B-UNK
patients	B-UNK
were	O
more	O
likely	B-UNK
to	O
be	O
men	O
(	O
odds	B-UNK
ratio	B-UNK
,	O
3.8	O
;	O
95	O
%	O
confidence	B-UNK
interval	I-UNK
,	O
1.2	O
-	O
12.1	O
)	O
,	O
suffer	O
from	O
hay	B-DISEASE
fever	I-DISEASE
and	O
asthma	B-DISEASE
(	O
odds	B-UNK
ratio	B-UNK
,	O
3.4	B-UNK
;	O
95	O
%	O
confidence	B-UNK
interval	I-UNK
,	O
1.0	B-UNK
-	O
11.9	O
)	O
;	O
to	O
participate	O
in	O
regular	B-UNK
exercise	B-UNK
(	O
odds	B-UNK
ratio	B-UNK
,	O
5.9	B-UNK
;	O
95	O
%	O
confidence	B-UNK
interval	I-UNK
,	O
1.1	B-UNK
-	O
30.7	O
)	O
,	O
especially	B-UNK
in	O
the	O
use	B-UNK
of	O
Nautilus	O
equipment	O
(	O
p	B-UNK
=	I-UNK
0.02	O
)	O
;	O
and	O
to	O
use	B-UNK
alcohol	B-UNK
(	O
odds	B-UNK
ratio	B-UNK
,	O
4.4	O
;	O
95	O
%	O
confidence	B-UNK
interval	I-UNK
,	O
1.1	B-UNK
-	O
17.5	O
)	O
.	O
Possible	O
risk	B-UNK
factors	I-UNK
included	B-UNK
young	B-UNK
age	B-UNK
,	O
concurrent	O
use	B-UNK
of	O
other	O
analgesic	B-UNK
agents	B-UNK
(	O
especially	B-UNK
ibuprofen	B-CHEMICAL
)	O
,	O
preexisting	O
renal	B-UNK
disease	B-DISEASE
,	O
a	O
history	B-UNK
of	O
kidney	B-DISEASE
stones	I-DISEASE
,	O
a	O
history	B-UNK
of	O
gout	B-DISEASE
,	O
a	O
recent	B-UNK
increase	B-UNK
in	O
activity	B-UNK
,	O
a	O
recent	B-UNK
increase	B-UNK
in	O
sun	O
exposure	B-UNK
,	O
and	O
residence	O
in	O
the	O
Sunbelt	O
.	O
These	O
were	O
findings	B-UNK
that	O
were	O
suggestive	O
but	O
did	O
not	O
reach	O
conventional	B-UNK
statistical	B-UNK
significance	I-UNK
.	O
These	O
findings	B-UNK
are	O
consistent	B-UNK
with	O
the	O
postulated	O
mechanism	B-UNK
for	O
this	O
unusual	O
syndrome	B-UNK
:	O
acute	B-UNK
diffuse	B-UNK
crystallization	O
of	O
uric	B-CHEMICAL
acid	I-CHEMICAL
in	O
renal	B-DISEASE
tubules	O
.	O

Hemolytic	O
-	O
uremic	B-UNK
syndrome	B-UNK
associated	B-UNK
with	O
ingestion	B-UNK
of	O
quinine	B-CHEMICAL
.	O

Hemolytic	O
-	O
uremic	B-UNK
syndrome	B-UNK
following	B-UNK
quinine	B-CHEMICAL
ingestion	B-UNK
is	O
a	O
newly	B-UNK
described	B-UNK
phenomenon	B-UNK
,	O
with	O
just	O
two	O
previous	B-UNK
descriptions	O
of	O
4	O
cases	B-UNK
in	O
the	O
literature	B-UNK
.	O
We	O
describe	O
a	O
5th	O
case	B-UNK
.	O
The	O
reaction	B-UNK
may	O
be	O
mediated	B-UNK
by	O
the	O
presence	O
of	O
antibodies	B-UNK
reactive	B-UNK
against	O
platelets	O
in	O
the	O
presence	O
of	O
quinine	B-CHEMICAL
.	O
Treatment	O
has	O
included	B-UNK
use	B-UNK
of	O
plasma	B-UNK
exchange	O
,	O
prednisone	B-CHEMICAL
,	O
aspirin	B-CHEMICAL
,	O
and	O
dipyridamole	B-CHEMICAL
.	O
The	O
patients	B-UNK
have	O
all	O
regained	O
some	O
degree	B-UNK
of	O
renal	B-UNK
function	B-UNK
.	O
However	O
,	O
it	O
is	O
unclear	O
whether	O
pharmacological	B-UNK
treatment	B-UNK
or	O
spontaneous	B-UNK
resolution	B-UNK
is	O
responsible	O
for	O
the	O
improvement	B-UNK
.	O
Quinine	O
-	O
associated	B-UNK
hemolytic	B-DISEASE
-	I-DISEASE
uremic	I-DISEASE
syndrome	I-DISEASE
probably	B-UNK
occurs	B-UNK
more	O
often	O
than	O
is	O
recognized	B-UNK
.	O
It	O
is	O
important	B-UNK
to	O
recognize	O
this	O
reaction	B-UNK
when	O
it	O
occurs	B-UNK
and	O
to	O
avoid	B-UNK
further	O
quinine	B-CHEMICAL
exposure	B-UNK
,	O
since	O
the	O
reaction	B-UNK
seems	O
to	O
be	O
recurrent	B-UNK
.	O

Pyeloureteral	O
filling	O
defects	B-UNK
associated	B-UNK
with	O
systemic	B-UNK
anticoagulation	B-UNK
:	O
a	O
case	B-UNK
report	B-UNK
.	O

The	O
etiology	O
of	O
pyeloureteritis	O
cystica	O
has	O
long	B-UNK
been	O
attributed	B-UNK
to	O
chronic	B-UNK
infection	B-UNK
and	O
inflammation	B-DISEASE
.	O
A	O
case	B-UNK
is	O
presented	B-UNK
that	O
is	O
unique	B-UNK
in	O
that	O
the	O
acute	B-UNK
onset	B-UNK
and	O
the	O
rapid	B-UNK
resolution	B-UNK
of	O
pyeloureteral	O
filling	O
defects	B-UNK
in	O
this	O
patient	B-UNK
were	O
documented	B-UNK
by	O
radiography	O
.	O
There	O
is	O
no	O
evidence	B-UNK
of	O
antecedent	O
or	O
concurrent	O
infection	B-UNK
in	O
this	O
patient	B-UNK
.	O
The	O
disease	B-DISEASE
occurred	B-UNK
subsequent	B-UNK
to	O
the	O
initiation	O
of	O
heparin	B-CHEMICAL
therapy	B-UNK
for	O
suspected	O
pelvic	B-UNK
thrombophlebitis	B-DISEASE
and	O
cleared	O
rapidly	B-UNK
subsequent	B-UNK
to	O
its	O
discontinuation	B-UNK
.	O
The	O
rate	B-UNK
of	O
resolution	B-UNK
of	O
the	O
radiographic	B-UNK
findings	B-UNK
may	O
be	O
helpful	O
in	O
distinguishing	O
between	O
true	O
pyeloureteritis	O
cystica	O
and	O
submucosal	O
hemorrhage	B-DISEASE
.	O

Changes	O
in	O
peroxisomes	O
in	O
preneoplastic	B-UNK
liver	B-DISEASE
and	O
hepatoma	O
of	O
mice	B-UNK
induced	B-UNK
by	O
alpha	B-UNK
-	O
benzene	B-CHEMICAL
hexachloride	O
.	O

Peroxisomes	O
in	O
hepatomas	O
and	O
hyperplastic	B-UNK
preneoplastic	B-UNK
liver	B-DISEASE
lesions	B-UNK
induced	B-UNK
in	O
mice	B-UNK
by	O
500	O
ppm	O
alpha	B-UNK
-	O
benzene	B-CHEMICAL
hexachloride	O
were	O
examined	B-UNK
histochemically	O
and	O
electron	B-UNK
microscopically	O
.	O
Although	O
most	O
of	O
the	O
hepatomas	O
were	O
well	O
-	O
differentiated	O
tumors	B-UNK
and	O
contained	B-UNK
a	O
considerable	O
number	B-UNK
of	O
peroxisomes	O
,	O
the	O
tumor	B-DISEASE
cells	B-UNK
did	O
not	O
respond	O
to	O
ethyl	O
-	O
alpha	B-UNK
-	O
p	B-UNK
-	O
chlorophenoxyisobutyrate	O
with	O
proliferation	B-UNK
of	O
peroxisomes	O
.	O
At	O
the	O
16th	O
week	B-UNK
of	O
carcinogen	O
feeding	B-UNK
,	O
hyperplastic	B-UNK
nodules	B-UNK
appeared	B-UNK
and	O
advanced	B-UNK
to	O
further	O
stages	O
.	O
A	O
majority	O
of	O
the	O
nodules	B-UNK
showed	B-UNK
a	O
considerable	O
number	B-UNK
of	O
peroxisomes	O
and	O
the	O
inductive	O
proliferation	B-UNK
of	O
peroxisomes	O
.	O
Within	O
the	O
nodules	B-UNK
,	O
foci	O
of	O
proliferation	B-UNK
of	O
the	O
cells	B-UNK
that	O
showed	B-UNK
no	O
inducibility	O
of	O
proliferation	B-UNK
of	O
peroxisomes	O
appeared	B-UNK
.	O
These	O
cells	B-UNK
proliferated	O
further	O
,	O
replacing	O
the	O
most	O
part	O
of	O
the	O
nodules	B-UNK
,	O
and	O
with	O
this	O
process	B-UNK
hepatomas	O
appeared	B-UNK
to	O
have	O
been	O
formed	B-UNK
.	O
No	O
abnormal	B-UNK
matrical	O
inclusions	O
of	O
peroxisomes	O
were	O
formed	B-UNK
in	O
the	O
cells	B-UNK
of	O
hyperplastic	B-UNK
nodules	B-UNK
by	O
ethyl	O
-	O
alpha	B-UNK
-	O
p	B-UNK
-	O
chlorophenoxyisobutyrate	O
unlike	O
in	O
the	O
case	B-UNK
of	O
rats	B-UNK
.	O

Quinidine	O
hepatitis	B-DISEASE
.	O

Long	O
-	O
term	B-UNK
administration	B-UNK
of	O
quinidine	B-CHEMICAL
was	O
associated	B-UNK
with	O
persistent	O
elevation	B-UNK
of	O
serum	B-UNK
concentrations	B-UNK
of	O
SGOT	O
,	O
lactic	B-CHEMICAL
acid	I-CHEMICAL
dehydrogenase	B-UNK
,	O
and	O
alkaline	B-UNK
phosphatase	B-UNK
.	O
Liver	B-UNK
biopsy	I-UNK
showed	B-UNK
active	B-UNK
hepatitis	B-DISEASE
.	O
Discontinuance	O
of	O
quinidine	B-CHEMICAL
therapy	B-UNK
led	B-UNK
to	O
normalization	O
of	O
liver	B-DISEASE
function	B-UNK
tests	B-UNK
.	O
A	O
challenge	B-UNK
dose	B-UNK
of	O
quinidine	B-CHEMICAL
caused	B-UNK
clinical	B-UNK
symptoms	B-UNK
and	O
abrupt	O
elevation	B-UNK
of	O
SGOT	O
,	O
alkaline	B-UNK
phosphatase	B-UNK
,	O
and	O
lactic	B-CHEMICAL
acid	I-CHEMICAL
dehydrogenase	B-UNK
values	B-UNK
.	O
We	O
concluded	O
that	O
this	O
patient	B-UNK
had	O
quinidine	B-CHEMICAL
hepatotoxicity	O
and	O
believe	O
that	O
this	O
is	O
the	O
first	O
case	B-UNK
reported	B-UNK
with	O
liver	B-DISEASE
biopsy	B-UNK
documentation	O
.	O
This	O
report	B-UNK
also	O
suggests	B-UNK
that	O
,	O
even	O
after	O
long	B-UNK
-	O
term	B-UNK
administration	B-UNK
,	O
the	O
hepatic	B-UNK
toxicity	B-UNK
is	O
reversible	B-UNK
.	O

Cholesteryl	O
hemisuccinate	O
treatment	B-UNK
protects	B-UNK
rodents	O
from	O
the	O
toxic	B-UNK
effects	B-UNK
of	O
acetaminophen	B-CHEMICAL
,	O
adriamycin	O
,	O
carbon	B-CHEMICAL
tetrachloride	I-CHEMICAL
,	O
chloroform	B-CHEMICAL
and	O
galactosamine	B-CHEMICAL
.	O

In	O
addition	O
to	O
its	O
use	B-UNK
as	O
a	O
stabilizer	O
/	O
rigidifier	O
of	O
membranes	O
,	O
cholesteryl	B-UNK
hemisuccinate	O
,	O
tris	O
salt	B-UNK
(	O
CS	B-UNK
)	O
administration	B-UNK
has	O
also	O
been	O
shown	B-UNK
to	O
protect	B-UNK
rats	B-UNK
from	O
the	O
hepatotoxic	B-UNK
effects	B-UNK
of	O
carbon	B-CHEMICAL
tetrachloride	I-CHEMICAL
(	O
CCl4	O
)	O
.	O
To	O
further	O
our	O
understanding	O
of	O
the	O
mechanism	B-UNK
of	O
CS	B-UNK
cytoprotection	O
,	O
we	O
examined	B-UNK
in	O
rats	B-UNK
and	O
mice	B-UNK
the	O
protective	B-UNK
abilities	O
of	O
CS	B-UNK
and	O
the	O
non-hydrolyzable	O
ether	B-CHEMICAL
form	B-UNK
of	O
CS	B-UNK
,	O
gamma	O
-	O
cholesteryloxybutyric	O
acid	B-UNK
,	O
tris	O
salt	B-UNK
(	O
CSE	O
)	O
against	O
acetaminophen-	O
,	O
adriamycin-	O
,	O
carbon	B-CHEMICAL
tetrachloride-	O
,	O
chloroform-	O
and	O
galactosamine	B-CHEMICAL
-	O
induced	B-UNK
toxicity	B-UNK
.	O
The	O
results	B-UNK
of	O
these	O
studies	B-UNK
demonstrated	I-UNK
that	O
CS	B-UNK
-	O
mediated	B-UNK
protection	B-UNK
is	O
not	O
selective	B-UNK
for	O
a	O
particular	B-UNK
species	O
,	O
organ	O
system	B-UNK
or	O
toxic	B-UNK
chemical	B-UNK
.	O
A	O
24-h	O
pretreatment	B-UNK
of	O
both	O
rats	B-UNK
and	O
mice	B-UNK
with	O
a	O
single	B-UNK
dose	B-UNK
of	O
CS	B-UNK
(	O
100mg	O
/	O
kg	B-UNK
,	O
i.p	B-UNK
.	O
)	O
,	O
resulted	B-UNK
in	O
significant	B-UNK
protection	B-UNK
against	O
the	O
hepatotoxic	B-UNK
effects	B-UNK
of	O
CCl4	O
,	O
CHCl3	O
,	O
acetaminophen	B-CHEMICAL
and	O
galactosamine	B-CHEMICAL
and	O
against	O
the	O
lethal	B-UNK
(	O
and	O
presumably	O
cardiotoxic	B-UNK
)	O
effect	B-UNK
of	O
adriamycin	O
administration	B-UNK
.	O
Maximal	O
CS	B-UNK
-	O
mediated	B-UNK
protection	B-UNK
was	O
observed	B-UNK
in	O
experimental	B-UNK
animals	B-UNK
pretreated	B-UNK
24	O
h	B-UNK
prior	B-UNK
to	O
the	O
toxic	B-UNK
insult	O
.	O
These	O
data	B-UNK
suggest	B-UNK
that	O
CS	B-UNK
intervenes	O
in	O
a	O
critical	B-UNK
cellular	B-UNK
event	B-UNK
that	O
is	O
an	O
important	B-UNK
common	B-UNK
pathway	B-UNK
to	O
toxic	B-UNK
cell	B-UNK
death	B-DISEASE
.	O
The	O
mechanism	B-UNK
of	O
CS	B-UNK
protection	B-UNK
does	O
not	O
appear	O
to	O
be	O
dependent	B-UNK
on	O
the	O
inhibition	B-UNK
of	O
chemical	B-UNK
bioactivation	O
to	O
a	O
toxic	B-UNK
reactive	B-UNK
intermediate	O
(	O
in	O
light	B-UNK
of	O
the	O
protection	B-UNK
observed	B-UNK
against	O
galactosamine	B-CHEMICAL
hepatotoxicity	O
)	O
.	O
However	O
,	O
based	B-UNK
on	O
the	O
data	B-UNK
presented	B-UNK
,	O
we	O
can	O
not	O
exclude	O
the	O
possibility	O
that	O
CS	B-UNK
administration	B-UNK
inhibits	O
chemical	B-UNK
bioactivation	O
.	O
Our	O
findings	B-UNK
do	O
suggest	B-UNK
that	O
CS	B-UNK
-	O
mediated	B-UNK
protection	B-UNK
is	O
dependent	B-UNK
on	O
the	O
action	B-UNK
of	O
the	O
intact	B-UNK
anionic	O
CS	B-UNK
molecule	O
(	O
non-hydrolyzable	O
CSE	O
was	O
as	O
protective	B-UNK
as	O
CS	B-UNK
)	O
,	O
whose	O
mechanism	B-UNK
has	O
yet	O
to	O
be	O
defined	O
.	O

DSMM	O
XI	O
study	B-UNK
:	O
dose	B-UNK
definition	O
for	O
intravenous	B-UNK
cyclophosphamide	B-CHEMICAL
in	O
combination	B-UNK
with	O
bortezomib	B-CHEMICAL
/	O
dexamethasone	B-CHEMICAL
for	O
remission	B-DISEASE
induction	B-UNK
in	O
patients	B-UNK
with	O
newly	B-UNK
diagnosed	B-UNK
myeloma	O
.	O

A	O
clinical	B-UNK
trial	B-UNK
was	O
initiated	O
to	O
evaluate	B-UNK
the	O
recommended	B-UNK
dose	B-UNK
of	O
cyclophosphamide	B-CHEMICAL
in	O
combination	B-UNK
with	O
bortezomib	B-CHEMICAL
and	O
dexamethasone	B-CHEMICAL
as	O
induction	B-UNK
treatment	B-UNK
before	O
stem	B-UNK
cell	I-UNK
transplantation	I-UNK
for	O
younger	O
patients	B-UNK
with	O
newly	B-UNK
diagnosed	B-UNK
multiple	B-DISEASE
myeloma	I-DISEASE
(	O
MM	O
)	O
.	O
Thirty	O
patients	B-UNK
were	O
treated	B-UNK
with	O
three	O
21-day	O
cycles	O
of	O
bortezomib	B-CHEMICAL
1.3	O
mg	B-UNK
/	O
m(2	O
)	O
on	O
days	B-UNK
1	O
,	O
4	O
,	O
8	O
,	O
and	O
11	O
plus	B-UNK
dexamethasone	B-CHEMICAL
40	O
mg	B-UNK
on	O
the	O
day	B-UNK
of	O
bortezomib	B-CHEMICAL
injection	B-UNK
and	O
the	O
day	B-UNK
after	O
plus	B-UNK
cyclophosphamide	B-CHEMICAL
at	B-DISEASE
900	O
,	O
1,200	O
,	O
or	O
1,500	O
mg	B-UNK
/	O
m(2	O
)	O
on	O
day	B-UNK
1	O
.	O
The	O
maximum	B-UNK
tolerated	B-UNK
dose	B-UNK
of	O
cyclophosphamide	B-CHEMICAL
was	O
defined	O
as	O
900	O
mg	B-UNK
/	O
m(2	O
)	O
.	O
At	O
this	O
dose	B-UNK
level	B-UNK
,	O
92	O
%	O
of	O
patients	B-UNK
achieved	B-UNK
at	B-DISEASE
least	O
a	O
partial	B-UNK
response	B-UNK
.	O
The	O
overall	B-UNK
response	B-UNK
rate	B-UNK
[	O
complete	B-UNK
response	B-UNK
(	O
CR	O
)	O
plus	B-UNK
partial	B-UNK
response	B-UNK
(	O
PR	B-UNK
)	O
]	O
across	O
all	O
dose	B-UNK
levels	B-UNK
was	O
77	O
%	O
,	O
with	O
a	O
10	O
%	O
CR	O
rate	B-UNK
.	O
No	O
patient	B-UNK
experienced	B-UNK
progressive	B-UNK
disease	B-DISEASE
.	O
The	O
most	O
frequent	B-UNK
adverse	B-UNK
events	B-UNK
were	O
hematological	O
and	O
gastrointestinal	B-UNK
toxicities	B-UNK
as	O
well	O
as	O
neuropathy	B-DISEASE
.	O
The	O
results	B-UNK
suggest	B-UNK
that	O
bortezomib	B-CHEMICAL
in	O
combination	B-UNK
with	O
cyclophosphamide	B-CHEMICAL
at	B-DISEASE
900	O
mg	B-UNK
/	O
m(2	O
)	O
and	O
dexamethasone	B-CHEMICAL
is	O
an	O
effective	B-UNK
induction	B-UNK
treatment	B-UNK
for	O
patients	B-UNK
with	O
newly	B-UNK
diagnosed	B-UNK
MM	O
that	O
warrants	O
further	O
investigation	O
.	O

Results	O
of	O
a	O
comparative	O
,	O
phase	B-UNK
III	B-UNK
,	O
12-week	O
,	O
multicenter	O
,	O
prospective	B-UNK
,	O
randomized	B-UNK
,	O
double-blind	B-UNK
assessment	B-UNK
of	O
the	O
efficacy	B-UNK
and	O
tolerability	B-UNK
of	O
a	O
fixed	B-UNK
-	O
dose	B-UNK
combination	B-UNK
of	O
telmisartan	B-CHEMICAL
and	O
amlodipine	B-CHEMICAL
versus	B-UNK
amlodipine	B-CHEMICAL
monotherapy	B-UNK
in	O
Indian	O
adults	O
with	O
stage	B-UNK
II	B-UNK
hypertension	B-DISEASE
.	O

OBJECTIVE	O
:	O
The	O
aim	O
of	O
this	O
study	B-UNK
was	O
to	O
evaluate	B-UNK
the	O
efficacy	B-UNK
and	O
tolerability	B-UNK
of	O
a	O
new	B-UNK
fixed	B-UNK
-	O
dose	B-UNK
combination	B-UNK
(	O
FDC	O
)	O
of	O
telmisartan	B-CHEMICAL
40	O
mg	B-UNK
+	O
amlodipine	B-CHEMICAL
5	O
mg	B-UNK
(	O
T+A	O
)	O
compared	B-UNK
with	O
amlodipine	B-CHEMICAL
5-mg	O
monotherapy	B-UNK
(	O
A	O
)	O
in	O
adult	B-UNK
Indian	O
patients	B-UNK
with	O
stage	B-UNK
II	B-UNK
hypertension	B-DISEASE
.	O
METHODS	O
:	O
This	O
comparative	O
,	O
Phase	O
III	B-UNK
,	O
12-week	O
,	O
multicenter	O
,	O
prospective	B-UNK
,	O
randomized	B-UNK
,	O
double-blind	B-UNK
study	B-UNK
was	O
conducted	O
in	O
Indian	O
patients	B-UNK
aged	B-UNK
18	O
to	O
65	O
years	B-UNK
with	O
established	B-UNK
stage	B-UNK
II	B-UNK
hypertension	B-DISEASE
.	O
Patients	B-UNK
were	O
treated	B-UNK
with	O
oral	B-UNK
FDC	O
of	O
T+A	O
or	O
A	O
QD	O
before	O
breakfast	O
for	O
12	O
weeks	B-UNK
;	O
blood	B-UNK
pressure	B-UNK
(	O
BP	B-UNK
)	O
and	O
heart	B-UNK
rate	I-UNK
were	O
measured	B-UNK
in	O
the	O
sitting	O
position	O
.	O
Primary	O
efficacy	B-UNK
end	B-UNK
points	B-UNK
were	O
reduction	B-UNK
in	O
clinical	B-UNK
systolic	B-UNK
BP	B-UNK
(	O
SBP)/	O
diastolic	B-UNK
BP	B-UNK
(	O
DBP	O
)	O
from	O
baseline	B-UNK
to	O
study	B-UNK
end	B-UNK
and	O
number	B-UNK
of	O
responders	O
(	O
ie	O
,	O
patients	B-UNK
who	O
achieved	B-UNK
target	O
SBP/	O
DBP	O
<	O
130/<80	O
mm	B-UNK
Hg	B-UNK
)	O
at	B-DISEASE
end	B-UNK
of	O
study	B-UNK
.	O
Tolerability	O
was	O
assessed	B-UNK
by	O
treatment	B-UNK
-	O
emergent	O
adverse	B-UNK
events	B-UNK
,	O
identified	B-UNK
using	O
physical	B-UNK
examination	B-UNK
,	O
laboratory	B-UNK
analysis	B-UNK
,	O
and	O
electrocardiography	O
.	O
RESULTS	B-UNK
:	O
A	O
total	B-UNK
of	O
210	O
patients	B-UNK
were	O
enrolled	O
in	O
the	O
study	B-UNK
;	O
203	O
patients	B-UNK
(	O
143	O
men	O
,	O
60	O
women	B-UNK
)	O
completed	O
the	O
study	B-UNK
while	O
7	O
were	O
lost	O
to	O
follow	B-UNK
-	O
up	O
(	O
4	O
patients	B-UNK
in	O
the	O
T+A	O
group	B-UNK
and	O
3	O
in	O
the	O
A	O
group	B-UNK
)	O
and	O
considered	B-UNK
with	O
-	O
drawn	O
.	O
At	O
study	B-UNK
end	B-UNK
,	O
statistically	B-UNK
significant	I-UNK
percentage	B-UNK
reductions	O
from	O
baseline	B-UNK
within	O
groups	B-UNK
and	O
between	O
groups	B-UNK
were	O
observed	B-UNK
in	O
SBP	O
(	O
T+A	O
[	O
-27.4	O
%	O
]	O
;	O
A	O
[	O
-16.6	O
%	O
]	O
)	O
and	O
DBP	O
(	O
T+A	O
[	O
-20.1	O
%	O
]	O
;	O
A	O
[	O
-13.3	O
%	O
]	O
)	O
(	O
all	O
,	O
P	B-UNK
<	I-UNK
0.05	O
)	O
.	O
Response	O
rates	B-UNK
were	O
87.3	O
%	O
(	O
89/102	O
)	O
in	O
the	O
T+A	O
group	B-UNK
and	O
69.3	O
%	O
(	O
70/101	O
)	O
in	O
the	O
A	O
group	B-UNK
(	O
P	B-UNK
<	I-UNK
0.05	O
)	O
.	O
The	O
prevalences	O
of	O
adverse	B-UNK
events	B-UNK
were	O
not	O
significantly	B-UNK
different	B-UNK
between	O
the	O
2	B-DISEASE
treatment	B-UNK
groups	B-UNK
(	O
T+A	O
,	O
16.0	O
%	O
[	O
17/106	O
]	O
;	O
A	O
,	O
15.4	O
%	O
[	O
16/104	O
]	O
)	O
.	O
Peripheral	O
edema	B-DISEASE
was	O
reported	B-UNK
in	O
8.5	O
%	O
patients	B-UNK
(	O
9/106	O
)	O
in	O
the	O
T+A	O
group	B-UNK
compared	B-UNK
with	O
13.5	O
%	O
(	O
14/104	O
)	O
in	O
the	O
A	O
group	B-UNK
,	O
and	O
cough	B-DISEASE
was	O
reported	B-UNK
in	O
3.8	O
%	O
patients	B-UNK
(	O
4/106	O
)	O
in	O
the	O
T+A	O
group	B-UNK
and	O
1.0	B-UNK
%	O
(	O
1/104	O
)	O
patients	B-UNK
in	O
the	O
A	O
group	B-UNK
;	O
these	O
differences	B-UNK
did	O
not	O
reach	O
statistical	B-UNK
significance	I-UNK
.	O
The	O
incidences	O
of	O
headache	B-DISEASE
,	O
dizziness	B-DISEASE
,	O
and	O
diarrhea	B-DISEASE
were	O
similar	B-UNK
between	O
the	O
2	B-DISEASE
groups	B-UNK
.	O
CONCLUSIONS	O
:	O
Among	O
these	O
Indian	O
patients	B-UNK
with	O
stage	B-UNK
II	B-UNK
hypertension	B-DISEASE
,	O
the	O
FDC	O
of	O
T+A	O
was	O
found	B-UNK
to	O
be	O
significantly	B-UNK
more	O
effective	B-UNK
,	O
with	O
regard	O
to	O
BP	B-UNK
reductions	O
,	O
than	O
A	O
,	O
and	O
both	O
treatments	B-UNK
were	O
well	O
tolerated	B-UNK
.	O

Cutaneous	O
leucocytoclastic	O
vasculitis	B-DISEASE
associated	B-UNK
with	O
oxacillin	B-CHEMICAL
.	O

A	O
67-year	O
-	O
old	B-UNK
man	B-UNK
who	O
was	O
treated	B-UNK
with	O
oxacillin	B-CHEMICAL
for	O
one	O
week	B-UNK
because	O
of	O
Staphylococcus	O
aureus	O
bacteremia	B-DISEASE
,	O
developed	B-UNK
renal	B-DISEASE
failure	I-DISEASE
and	O
diffuse	B-UNK
,	O
symmetric	O
,	O
palpable	B-UNK
purpuric	O
lesions	B-UNK
on	O
his	O
feet	O
.	O
Necrotic	O
blisters	O
were	O
noted	O
on	O
his	O
fingers	O
.	O
Skin	B-UNK
biopsies	B-UNK
showed	B-UNK
findings	B-UNK
diagnostic	B-UNK
of	O
leucocytoclastic	O
vasculitis	B-DISEASE
.	O
Oxacillin	O
was	O
discontinued	O
and	O
patient	B-UNK
was	O
treated	B-UNK
with	O
corticosteroids	O
.	O
The	O
rash	B-DISEASE
disappeared	B-UNK
after	O
three	O
weeks	B-UNK
and	O
renal	B-UNK
function	B-UNK
returned	B-UNK
to	O
normal	B-UNK
.	O
Leucocytoclastic	O
vasculitis	B-DISEASE
presents	O
as	O
palpable	B-UNK
purpura	B-DISEASE
of	O
the	O
lower	B-UNK
extremities	O
often	O
accompanied	O
by	O
abdominal	B-DISEASE
pain	I-DISEASE
,	O
arthralgia	B-DISEASE
,	O
and	O
renal	B-DISEASE
involvement	B-UNK
.	O
Etiologic	O
factors	B-UNK
or	O
associated	B-UNK
disorders	B-UNK
include	B-UNK
infections	B-DISEASE
,	O
medications	B-UNK
,	O
collagen	O
vascular	B-UNK
disease	B-DISEASE
and	O
neoplasia	O
.	O
However	O
,	O
in	O
half	O
of	O
the	O
cases	B-UNK
no	O
etiologic	O
factor	B-UNK
is	O
identified	B-UNK
.	O
Usually	O
it	O
is	O
a	O
self	O
-	O
limited	O
disorder	B-UNK
,	O
but	O
corticosteroid	O
therapy	B-UNK
may	O
be	O
needed	B-UNK
in	O
life	B-UNK
-	O
threatening	O
cases	B-UNK
since	O
early	B-UNK
treatment	B-UNK
with	O
corticosteroids	O
in	O
severe	B-UNK
cases	B-UNK
can	O
prevent	B-UNK
complications	B-UNK
.	O
Oxacillin	O
should	O
be	O
included	B-UNK
among	O
the	O
drugs	B-UNK
that	O
can	O
cause	B-UNK
leucocytoclastic	O
vasculitis	B-DISEASE
.	O

Naloxazone	O
pretreatment	B-UNK
modifies	O
cardiorespiratory	B-UNK
,	O
temperature	B-UNK
,	O
and	O
behavioral	B-UNK
effects	B-UNK
of	O
morphine	B-CHEMICAL
.	O

Behavioral	B-UNK
and	O
cardiorespiratory	B-UNK
responses	B-UNK
to	O
a	O
lethal	B-UNK
dose	B-UNK
of	O
morphine	B-CHEMICAL
were	O
evaluated	B-UNK
in	O
rats	B-UNK
pretreated	B-UNK
with	O
saline	B-UNK
or	O
naloxazone	B-CHEMICAL
,	O
an	O
antagonist	B-UNK
of	O
high	B-UNK
-	O
affinity	B-UNK
mu	O
1	O
opioid	B-UNK
receptors	B-UNK
.	O
Pretreatment	O
with	O
naloxazone	B-CHEMICAL
significantly	B-UNK
blocked	B-UNK
morphine	B-CHEMICAL
analgesia	O
,	O
catalepsy	B-DISEASE
and	O
hypothermia	B-DISEASE
at	B-DISEASE
a	O
dose	B-UNK
which	O
completely	B-UNK
eliminated	O
high	B-UNK
-	O
affinity	B-UNK
binding	B-UNK
in	O
brain	B-UNK
membranes	O
.	O
Moreover	O
,	O
naloxazone	B-CHEMICAL
significantly	B-UNK
attenuated	B-UNK
the	O
morphine	B-CHEMICAL
-	O
induced	B-UNK
hypotension	B-DISEASE
and	O
respiratory	B-UNK
depression	B-DISEASE
,	O
whereas	O
morphine	B-CHEMICAL
-	O
induced	B-UNK
bradycardia	B-DISEASE
was	O
less	O
affected	B-UNK
.	O
Results	O
indicate	B-UNK
that	O
subpopulations	O
of	O
mu	O
receptors	B-UNK
may	O
mediate	O
selective	B-UNK
behavioral	B-UNK
and	O
cardiorespiratory	B-UNK
responses	B-UNK
to	O
morphine	B-CHEMICAL
.	O

Dexrazoxane	O
protects	B-UNK
against	O
myelosuppression	O
from	O
the	O
DNA	B-UNK
cleavage	B-UNK
-	O
enhancing	B-UNK
drugs	B-UNK
etoposide	B-CHEMICAL
and	O
daunorubicin	B-CHEMICAL
but	O
not	O
doxorubicin	B-CHEMICAL
.	O

PURPOSE	O
:	O
The	O
anthracyclines	B-CHEMICAL
daunorubicin	B-CHEMICAL
and	O
doxorubicin	B-CHEMICAL
and	O
the	O
epipodophyllotoxin	O
etoposide	B-CHEMICAL
are	O
potent	B-UNK
DNA	B-UNK
cleavage	B-UNK
-	O
enhancing	B-UNK
drugs	B-UNK
that	O
are	O
widely	B-UNK
used	O
in	O
clinical	B-UNK
oncology	O
;	O
however	O
,	O
myelosuppression	O
and	O
cardiac	B-UNK
toxicity	B-UNK
limit	B-UNK
their	O
use	B-UNK
.	O
Dexrazoxane	O
(	O
ICRF-187	O
)	O
is	O
recommended	B-UNK
for	O
protection	B-UNK
against	O
anthracycline	O
-	O
induced	B-UNK
cardiotoxicity	B-DISEASE
.	O
EXPERIMENTAL	O
DESIGN	B-UNK
:	O
Because	O
of	O
their	O
widespread	O
use	B-UNK
,	O
the	O
hematologic	B-UNK
toxicity	B-UNK
following	B-UNK
coadministration	O
of	O
dexrazoxane	B-CHEMICAL
and	O
these	O
three	O
structurally	O
different	B-UNK
DNA	B-UNK
cleavage	B-UNK
enhancers	O
was	O
investigated	B-UNK
:	O
Sensitivity	O
of	O
human	B-UNK
and	O
murine	B-UNK
blood	B-UNK
progenitor	B-UNK
cells	B-UNK
to	O
etoposide	B-CHEMICAL
,	O
daunorubicin	B-CHEMICAL
,	O
and	O
doxorubicin	B-CHEMICAL
+	O
/-	O
dexrazoxane	B-CHEMICAL
was	O
determined	O
in	O
granulocyte	O
-	O
macrophage	O
colony	O
forming	O
assays	O
.	O
Likewise	O
,	O
in	O
vivo	B-UNK
,	O
B6D2F1	O
mice	B-UNK
were	O
treated	B-UNK
with	O
etoposide	B-CHEMICAL
,	O
daunorubicin	B-CHEMICAL
,	O
and	O
doxorubicin	B-CHEMICAL
,	O
with	O
or	O
without	O
dexrazoxane	B-CHEMICAL
over	O
a	O
wide	B-UNK
range	B-UNK
of	O
doses	B-UNK
:	O
posttreatment	O
,	O
a	O
full	O
hematologic	B-UNK
evaluation	B-UNK
was	O
done	O
.	O
RESULTS	B-UNK
:	O
Nontoxic	O
doses	B-UNK
of	O
dexrazoxane	B-CHEMICAL
reduced	B-UNK
myelosuppression	O
and	O
weight	B-DISEASE
loss	I-DISEASE
from	O
daunorubicin	B-CHEMICAL
and	O
etoposide	B-CHEMICAL
in	O
mice	B-UNK
and	O
antagonized	B-UNK
their	O
antiproliferative	O
effects	B-UNK
in	O
the	O
colony	O
assay	B-UNK
;	O
however	O
,	O
dexrazoxane	B-CHEMICAL
neither	O
reduced	B-UNK
myelosuppression	O
,	O
weight	B-DISEASE
loss	I-DISEASE
,	O
nor	O
the	O
in	O
vitro	B-UNK
cytotoxicity	O
from	O
doxorubicin	B-CHEMICAL
.	O
CONCLUSION	O
:	O
Although	O
our	O
findings	B-UNK
support	B-UNK
the	O
observation	B-UNK
that	O
dexrazoxane	B-CHEMICAL
reduces	B-UNK
neither	O
hematologic	B-UNK
activity	B-UNK
nor	O
antitumor	B-UNK
activity	B-UNK
from	O
doxorubicin	B-CHEMICAL
clinically	B-UNK
,	O
the	O
potent	B-UNK
antagonism	B-UNK
of	O
daunorubicin	B-CHEMICAL
activity	B-UNK
raises	O
concern	O
;	O
a	O
possible	B-UNK
interference	O
with	O
anticancer	O
efficacy	B-UNK
certainly	O
would	O
call	O
for	O
renewed	O
attention	B-UNK
.	O
Our	O
data	B-UNK
also	O
suggest	B-UNK
that	O
significant	B-UNK
etoposide	B-CHEMICAL
dose	B-UNK
escalation	B-UNK
is	O
perhaps	O
possible	B-UNK
by	O
the	O
use	B-UNK
of	O
dexrazoxane	B-CHEMICAL
.	O
Clinical	B-UNK
trials	B-UNK
in	O
patients	B-UNK
with	O
brain	B-DISEASE
metastases	I-DISEASE
combining	O
dexrazoxane	B-CHEMICAL
and	O
high	B-UNK
doses	B-UNK
of	O
etoposide	B-CHEMICAL
is	O
ongoing	O
with	O
the	O
aim	O
of	O
improving	O
efficacy	B-UNK
without	O
aggravating	O
hematologic	B-UNK
toxicity	B-UNK
.	O
If	O
successful	B-UNK
,	O
this	O
represents	O
an	O
exciting	O
mechanism	B-UNK
for	O
pharmacologic	O
regulation	O
of	O
side	O
effects	B-UNK
from	O
cytotoxic	B-UNK
chemotherapy	B-UNK
.	O

Effects	O
of	O
the	O
novel	B-UNK
compound	B-UNK
aniracetam	B-CHEMICAL
(	O
Ro	O
13	O
-	O
5057	O
)	O
upon	O
impaired	B-UNK
learning	B-UNK
and	O
memory	B-UNK
in	O
rodents	O
.	O

The	O
effect	B-UNK
of	O
aniracetam	B-CHEMICAL
(	O
Ro	O
13	O
-	O
5057	O
,	O
1-anisoyl-2-pyrrolidinone	O
)	O
was	O
studied	B-UNK
on	O
various	O
forms	O
of	O
experimentally	B-UNK
impaired	B-UNK
cognitive	B-UNK
functions	I-UNK
(	O
learning	B-UNK
and	O
memory	B-UNK
)	O
in	O
rodents	O
and	O
produced	B-UNK
the	O
following	B-UNK
effects	B-UNK
:	O
(	O
1	O
)	O
almost	O
complete	B-UNK
prevention	O
of	O
the	O
incapacity	O
to	O
learn	O
a	O
discrete	O
escape	B-UNK
response	B-UNK
in	O
rats	B-UNK
exposed	B-UNK
to	O
sublethal	O
hypercapnia	B-DISEASE
immediately	B-UNK
before	O
the	O
acquisition	O
session	O
;	O
(	O
2	B-DISEASE
)	O
partial	B-UNK
(	O
rats	B-UNK
)	O
or	O
complete	B-UNK
(	O
mice	B-UNK
)	O
prevention	O
of	O
the	O
scopolamine	B-CHEMICAL
-	O
induced	B-UNK
short	B-UNK
-	O
term	B-UNK
amnesia	B-DISEASE
for	O
a	O
passive	B-UNK
avoidance	B-UNK
task	B-UNK
;	O
(	O
3	O
)	O
complete	B-UNK
protection	B-UNK
against	O
amnesia	B-DISEASE
for	O
a	O
passive	B-UNK
avoidance	B-UNK
task	B-UNK
in	O
rats	B-UNK
submitted	O
to	O
electroconvulsive	B-UNK
shock	B-DISEASE
immediately	B-UNK
after	O
avoidance	B-UNK
acquisition	O
;	O
(	O
4	O
)	O
prevention	O
of	O
the	O
long	B-UNK
-	O
term	B-UNK
retention-	O
or	O
retrieval	B-UNK
-	O
deficit	B-UNK
for	O
a	O
passive	B-UNK
avoidance	B-UNK
task	B-UNK
induced	B-UNK
in	O
rats	B-UNK
and	O
mice	B-UNK
by	O
chloramphenicol	B-CHEMICAL
or	O
cycloheximide	B-CHEMICAL
administered	B-UNK
immediately	B-UNK
after	O
acquisition	O
;	O
(	O
5	O
)	O
reversal	B-UNK
,	O
when	O
administered	B-UNK
as	O
late	B-UNK
as	O
1	O
h	B-UNK
before	O
the	O
retention	B-UNK
test	B-UNK
,	O
of	O
the	O
deficit	B-UNK
in	O
retention	B-UNK
or	O
retrieval	B-UNK
of	O
a	O
passive	B-UNK
avoidance	B-UNK
task	B-UNK
induced	B-UNK
by	O
cycloheximide	B-CHEMICAL
injected	B-UNK
2	B-DISEASE
days	B-UNK
previously	B-UNK
;	O
(	O
6	O
)	O
prevention	O
of	O
the	O
deficit	B-UNK
in	O
the	O
retrieval	B-UNK
of	O
an	O
active	B-UNK
avoidance	B-UNK
task	B-UNK
induced	B-UNK
in	O
mice	B-UNK
by	O
subconvulsant	O
electroshock	O
or	O
hypercapnia	B-DISEASE
applied	O
immediately	B-UNK
before	O
retrieval	B-UNK
testing	B-UNK
(	O
24	O
h	B-UNK
after	O
acquisition	O
)	O
.	O
These	O
improvements	B-UNK
or	O
normalizations	O
of	O
impaired	B-UNK
cognitive	B-UNK
functions	I-UNK
were	O
seen	B-UNK
at	B-DISEASE
oral	B-UNK
aniracetam	B-CHEMICAL
doses	B-UNK
of	O
10	O
-	O
100	O
mg	B-UNK
/	O
kg	B-UNK
.	O
Generally	O
,	O
the	O
dose	B-UNK
-	O
response	B-UNK
curves	O
were	O
bell	O
-	O
shaped	O
.	O
The	O
mechanisms	B-UNK
underlying	B-UNK
the	O
activity	B-UNK
of	O
aniracetam	B-CHEMICAL
and	O
its	O
'	O
therapeutic	B-UNK
window	O
'	O
are	O
unknown	B-UNK
.	O
Piracetam	O
,	O
another	O
pyrrolidinone	O
derivative	B-UNK
was	O
used	O
for	O
comparison	O
.	O
It	O
was	O
active	B-UNK
only	O
in	O
six	O
of	O
nine	O
tests	B-UNK
and	O
had	O
about	O
one	O
-	O
tenth	O
the	O
potency	B-UNK
of	O
aniracetam	B-CHEMICAL
.	O
The	O
results	B-UNK
indicate	B-UNK
that	O
aniracetam	B-CHEMICAL
improves	B-UNK
cognitive	B-UNK
functions	I-UNK
which	O
are	O
impaired	B-UNK
by	O
different	B-UNK
procedure	B-UNK
and	O
in	O
different	B-UNK
phases	B-UNK
of	O
the	O
learning	B-UNK
and	O
memory	B-UNK
process	B-UNK
.	O

Nicotine	O
potentiation	B-UNK
of	O
morphine	B-CHEMICAL
-	O
induced	B-UNK
catalepsy	B-DISEASE
in	O
mice	B-UNK
.	O

In	O
the	O
present	B-UNK
study	B-UNK
,	O
effects	B-UNK
of	O
nicotine	B-CHEMICAL
on	O
catalepsy	B-DISEASE
induced	B-UNK
by	O
morphine	B-CHEMICAL
in	O
mice	B-UNK
have	O
been	O
investigated	B-UNK
.	O
Morphine	O
but	O
not	O
nicotine	B-CHEMICAL
induced	B-UNK
a	O
dose	B-UNK
-	O
dependent	B-UNK
catalepsy	B-DISEASE
.	O
The	O
response	B-UNK
of	O
morphine	B-CHEMICAL
was	O
potentiated	B-UNK
by	O
nicotine	B-CHEMICAL
.	O
Intraperitoneal	O
administration	B-UNK
of	O
atropine	B-CHEMICAL
,	O
naloxone	B-CHEMICAL
,	O
mecamylamine	B-CHEMICAL
,	O
and	O
hexamethonium	B-CHEMICAL
to	O
mice	B-UNK
reduced	B-UNK
catalepsy	B-DISEASE
induced	B-UNK
by	O
a	O
combination	B-UNK
of	O
morphine	B-CHEMICAL
with	O
nicotine	B-CHEMICAL
.	O
Intracerebroventricular	O
injection	B-UNK
of	O
atropine	B-CHEMICAL
,	O
hexamethonium	B-CHEMICAL
,	O
and	O
naloxone	B-CHEMICAL
also	O
decreased	B-UNK
catalepsy	B-DISEASE
induced	B-UNK
by	O
morphine	B-CHEMICAL
plus	B-UNK
nicotine	B-CHEMICAL
.	O
Intraperitoneal	O
administration	B-UNK
of	O
atropine	B-CHEMICAL
,	O
but	O
not	O
intraperitoneal	O
or	O
intracerebroventricular	O
injection	B-UNK
of	O
hexamethonium	B-CHEMICAL
,	O
decreased	B-UNK
the	O
effect	B-UNK
of	O
a	O
single	B-UNK
dose	B-UNK
of	O
morphine	B-CHEMICAL
.	O
It	O
was	O
concluded	O
that	O
morphine	B-CHEMICAL
catalepsy	B-DISEASE
can	O
be	O
elicited	B-UNK
by	O
opioid	B-UNK
and	O
cholinergic	B-UNK
receptors	B-UNK
,	O
and	O
the	O
potentiation	B-UNK
of	O
morphine	B-CHEMICAL
induced	B-UNK
by	O
nicotine	B-CHEMICAL
may	O
also	O
be	O
mediated	B-UNK
through	O
cholinergic	B-UNK
receptor	B-UNK
mechanisms	B-UNK
.	O

Reduced	O
cardiotoxicity	B-DISEASE
and	O
preserved	O
antitumor	B-UNK
efficacy	B-UNK
of	O
liposome	O
-	O
encapsulated	O
doxorubicin	B-CHEMICAL
and	O
cyclophosphamide	B-CHEMICAL
compared	B-UNK
with	O
conventional	B-UNK
doxorubicin	B-CHEMICAL
and	O
cyclophosphamide	B-CHEMICAL
in	O
a	O
randomized	B-UNK
,	O
multicenter	O
trial	B-UNK
of	O
metastatic	B-UNK
breast	B-DISEASE
cancer	I-DISEASE
.	O

PURPOSE	O
:	O
To	O
determine	B-UNK
whether	O
Myocet	O
(	O
liposome	O
-	O
encapsulated	O
doxorubicin	B-CHEMICAL
;	O
The	O
Liposome	O
Company	B-UNK
,	O
Elan	O
Corporation	O
,	O
Princeton	O
,	O
NJ	O
)	O
in	O
combination	B-UNK
with	O
cyclophosphamide	B-CHEMICAL
significantly	B-UNK
reduces	B-UNK
doxorubicin	B-CHEMICAL
cardiotoxicity	B-DISEASE
while	O
providing	O
comparable	B-UNK
antitumor	B-UNK
efficacy	B-UNK
in	O
first	O
-	O
line	B-UNK
treatment	B-UNK
of	O
metastatic	B-UNK
breast	B-DISEASE
cancer	I-DISEASE
(	O
MBC	O
)	O
.	O
PATIENTS	O
AND	O
METHODS	O
:	O
Two	O
hundred	O
ninety	O
-	O
seven	O
patients	B-UNK
with	O
MBC	O
and	O
no	O
prior	B-UNK
chemotherapy	B-UNK
for	O
metastatic	B-UNK
disease	B-DISEASE
were	O
randomized	B-UNK
to	O
receive	B-UNK
either	O
60	O
mg	B-UNK
/	O
m(2	O
)	O
of	O
Myocet	O
(	O
M	O
)	O
or	O
conventional	B-UNK
doxorubicin	B-CHEMICAL
(	O
A	O
)	O
,	O
in	O
combination	B-UNK
with	O
600	O
mg	B-UNK
/	O
m(2	O
)	O
of	O
cyclophosphamide	B-CHEMICAL
(	O
C	B-UNK
)	O
,	O
every	O
3	O
weeks	B-UNK
until	O
disease	B-DISEASE
progression	I-DISEASE
or	O
unacceptable	O
toxicity	B-UNK
.	O
Cardiotoxicity	O
was	O
defined	O
by	O
reductions	O
in	O
left	B-UNK
-	O
ventricular	B-UNK
ejection	B-UNK
fraction	I-UNK
,	O
assessed	B-UNK
by	O
serial	B-UNK
multigated	O
radionuclide	O
angiography	B-UNK
scans	B-UNK
,	O
or	O
congestive	B-DISEASE
heart	I-DISEASE
failure	I-DISEASE
(	O
CHF	O
)	O
.	O
Antitumor	O
efficacy	B-UNK
was	O
assessed	B-UNK
by	O
objective	B-UNK
tumor	B-DISEASE
response	B-UNK
rates	B-UNK
(	O
World	O
Health	B-UNK
Organization	O
criteria	B-UNK
)	O
,	O
time	B-UNK
to	O
progression	B-UNK
,	O
and	O
survival	B-UNK
.	O
RESULTS	B-UNK
:	O
Six	O
percent	O
of	O
MC	O
patients	B-UNK
versus	B-UNK
21	O
%	O
(	O
including	B-UNK
five	O
cases	B-UNK
of	O
CHF	O
)	O
of	O
AC	O
patients	B-UNK
developed	B-UNK
cardiotoxicity	B-DISEASE
(	O
P	B-UNK
=	I-UNK
.0002	O
)	O
.	O
Median	O
cumulative	B-UNK
doxorubicin	B-CHEMICAL
dose	B-UNK
at	B-DISEASE
onset	B-UNK
was	O
more	O
than	O
2,220	O
mg	B-UNK
/	O
m(2	O
)	O
for	O
MC	O
versus	B-UNK
480	O
mg	B-UNK
/	O
m(2	O
)	O
for	O
AC	O
(	O
P	B-UNK
=	I-UNK
.0001	O
,	O
hazard	B-UNK
ratio	B-UNK
,	O
5.04	O
)	O
.	O
MC	O
patients	B-UNK
also	O
experienced	B-UNK
less	O
grade	B-UNK
4	O
neutropenia	B-DISEASE
.	O
Antitumor	O
efficacy	B-UNK
of	O
MC	O
versus	B-UNK
AC	O
was	O
comparable	B-UNK
:	O
objective	B-UNK
response	B-UNK
rates	B-UNK
,	O
43	O
%	O
versus	B-UNK
43	O
%	O
;	O
median	B-UNK
time	B-UNK
to	O
progression	B-UNK
,	O
5.1	O
%	O
versus	B-UNK
5.5	O
months	B-UNK
;	O
median	B-UNK
time	B-UNK
to	O
treatment	B-UNK
failure	B-UNK
,	O
4.6	O
versus	B-UNK
4.4	O
months	B-UNK
;	O
and	O
median	B-UNK
survival	B-UNK
,	O
19	O
versus	B-UNK
16	O
months	B-UNK
.	O
CONCLUSION	O
:	O
Myocet	O
improves	B-UNK
the	O
therapeutic	B-UNK
index	B-UNK
of	O
doxorubicin	B-CHEMICAL
by	O
significantly	B-UNK
reducing	B-UNK
cardiotoxicity	B-DISEASE
and	O
grade	B-UNK
4	O
neutropenia	B-DISEASE
and	O
provides	B-UNK
comparable	B-UNK
antitumor	B-UNK
efficacy	B-UNK
,	O
when	O
used	O
in	O
combination	B-UNK
with	O
cyclophosphamide	B-CHEMICAL
as	O
first	O
-	O
line	B-UNK
therapy	B-UNK
for	O
MBC	O
.	O

Protective	B-UNK
effect	B-UNK
of	O
a	O
specific	B-UNK
platelet	B-UNK
-	O
activating	O
factor	B-UNK
antagonist	B-UNK
,	O
BN	O
52021	O
,	O
on	O
bupivacaine	B-CHEMICAL
-	O
induced	B-UNK
cardiovascular	B-UNK
impairments	B-UNK
in	O
rats	B-UNK
.	O

Administration	B-UNK
of	O
the	O
local	B-UNK
anaesthetic	O
bupivacaine	B-CHEMICAL
(	O
1.5	B-UNK
or	O
2	B-DISEASE
mg	B-UNK
/	O
kg	B-UNK
,	O
i.v	B-UNK
.	O
)	O
to	O
rats	B-UNK
elicited	B-UNK
a	O
marked	B-UNK
decrease	B-UNK
of	O
mean	B-UNK
arterial	B-UNK
blood	B-UNK
pressure	B-UNK
(	O
MBP	O
)	O
and	O
heart	B-UNK
rate	I-UNK
(	O
HR	O
)	O
leading	B-UNK
to	O
death	B-DISEASE
(	O
in	O
67	O
%	O
or	O
90	O
%	O
of	O
animals	B-UNK
respectively	O
)	O
.	O
Intravenous	B-UNK
injection	B-UNK
of	O
the	O
specific	B-UNK
platelet	B-UNK
-	O
activating	O
factor	B-UNK
(	O
PAF	O
)	O
antagonist	B-UNK
BN	O
52021	O
(	O
10	O
mg	B-UNK
/	O
kg	B-UNK
)	O
,	O
30	O
min	B-UNK
before	O
bupivacaine	B-CHEMICAL
administration	B-UNK
(	O
2	B-DISEASE
mg	B-UNK
/	O
kg	B-UNK
i.v	B-UNK
.	O
)	O
suppressed	B-UNK
both	O
the	O
decrease	B-UNK
of	O
MBP	O
and	O
HR	O
.	O
In	O
contrast	B-UNK
,	O
doses	B-UNK
of	O
1	O
mg	B-UNK
/	O
kg	B-UNK
BN	O
52021	O
given	B-UNK
30	O
min	B-UNK
before	O
or	O
10	O
mg	B-UNK
/	O
kg	B-UNK
administered	B-UNK
5	O
min	B-UNK
before	O
i.v	B-UNK
.	O
injection	B-UNK
of	O
bupivacaine	B-CHEMICAL
were	O
ineffective	O
.	O
When	O
BN	O
52021	O
(	O
20	O
mg	B-UNK
/	O
kg	B-UNK
i.v	B-UNK
.	O
)	O
was	O
injected	B-UNK
immediately	B-UNK
after	O
bupivacaine	B-CHEMICAL
(	O
2	B-DISEASE
mg	B-UNK
/	O
kg	B-UNK
)	O
,	O
a	O
partial	B-UNK
reversion	O
of	O
the	O
decrease	B-UNK
of	O
MBP	O
and	O
HR	O
was	O
observed	B-UNK
,	O
whereas	O
the	O
dose	B-UNK
of	O
10	O
mg	B-UNK
/	O
kg	B-UNK
was	O
ineffective	O
.	O
A	O
partial	B-UNK
recovery	B-UNK
of	O
bupivacaine	B-CHEMICAL
-	O
induced	B-UNK
ECG	B-UNK
alterations	B-UNK
was	O
observed	B-UNK
after	O
pretreatment	B-UNK
of	O
the	O
rats	B-UNK
with	O
BN	O
52021	O
.	O
Since	O
the	O
administration	B-UNK
of	O
BN	O
52021	O
,	O
at	B-DISEASE
all	O
doses	B-UNK
studied	B-UNK
,	O
did	O
not	O
alter	B-UNK
MBP	O
and	O
HR	O
at	B-DISEASE
the	O
doses	B-UNK
used	O
,	O
the	O
bulk	O
of	O
these	O
results	B-UNK
clearly	B-UNK
demonstrate	B-UNK
a	O
protective	B-UNK
action	B-UNK
of	O
BN	O
52021	O
,	O
a	O
specific	B-UNK
antagonist	B-UNK
of	O
PAF	O
,	O
against	O
bupivacaine	B-CHEMICAL
-	O
induced	B-UNK
cardiovascular	B-UNK
toxicity	B-UNK
.	O
Thus	O
,	O
consistent	B-UNK
with	O
its	O
direct	B-UNK
effect	B-UNK
on	O
heart	B-UNK
,	O
PAF	O
appears	B-UNK
to	O
be	O
implicated	B-UNK
in	O
bupivacaine	B-CHEMICAL
-	O
induced	B-UNK
cardiovascular	B-UNK
alterations	B-UNK
.	O

Benzylacyclouridine	O
reverses	B-UNK
azidothymidine	O
-	O
induced	B-UNK
marrow	B-UNK
suppression	B-UNK
without	O
impairment	B-UNK
of	O
anti-human	O
immunodeficiency	B-DISEASE
virus	B-UNK
activity	B-UNK
.	O

Increased	B-UNK
extracellular	B-UNK
concentrations	B-UNK
of	O
uridine	B-CHEMICAL
(	O
Urd	O
)	O
have	O
been	O
reported	B-UNK
to	O
reduce	B-UNK
,	O
in	O
vitro	B-UNK
,	O
azidothymidine	O
(	O
AZT)-induced	O
inhibition	B-UNK
of	O
human	B-UNK
granulocyte	O
-	O
macrophage	O
progenitor	B-UNK
cells	B-UNK
without	O
impairment	B-UNK
of	O
its	O
antihuman	O
immunodeficiency	B-DISEASE
virus	B-UNK
(	O
HIV	O
)	O
activity	B-UNK
.	O
Because	O
of	O
the	O
clinical	B-UNK
toxicities	B-UNK
associated	B-UNK
with	O
chronic	B-UNK
Urd	O
administration	B-UNK
,	O
the	O
ability	B-UNK
of	O
benzylacyclouridine	O
(	O
BAU	O
)	O
to	O
effect	B-UNK
,	O
in	O
vivo	B-UNK
,	O
AZT	B-UNK
-	O
induced	B-UNK
anemia	B-DISEASE
and	O
leukopenia	B-DISEASE
was	O
assessed	B-UNK
.	O
This	O
agent	B-UNK
inhibits	O
Urd	O
catabolism	O
and	O
,	O
in	O
vivo	B-UNK
,	O
increases	B-UNK
the	O
plasma	B-UNK
concentration	B-UNK
of	O
Urd	O
in	O
a	O
dose	B-UNK
-	O
dependent	B-UNK
manner	B-UNK
,	O
without	O
Urd	O
-	O
related	B-UNK
toxicity	B-UNK
.	O
In	O
mice	B-UNK
rendered	O
anemic	O
and	O
leukopenic	O
by	O
the	O
administration	B-UNK
of	O
AZT	B-UNK
for	O
28	O
days	B-UNK
in	O
drinking	B-CHEMICAL
water	I-CHEMICAL
(	O
1.5	B-UNK
mg	B-UNK
/	O
mL	O
)	O
,	O
the	O
continued	B-UNK
administration	B-UNK
of	O
AZT	B-UNK
plus	B-UNK
daily	B-UNK
BAU	O
(	O
300	O
mg	B-UNK
/	O
kg	B-UNK
,	O
orally	B-UNK
)	O
partially	O
reversed	B-UNK
AZT	B-UNK
-	O
induced	B-UNK
anemia	B-DISEASE
and	O
leukopenia	B-DISEASE
(	O
P	B-UNK
less	O
than	O
.05	O
)	O
,	O
increased	B-UNK
peripheral	B-UNK
reticulocytes	O
(	O
to	O
4.9	O
%	O
,	O
P	B-UNK
less	O
than	O
.01	B-UNK
)	O
,	O
increased	B-UNK
cellularity	O
in	O
the	O
marrow	B-UNK
,	O
and	O
improved	B-UNK
megaloblastosis	O
.	O
When	O
coadministered	O
with	O
AZT	B-UNK
from	O
the	O
onset	B-UNK
of	O
drug	B-UNK
administration	B-UNK
,	O
BAU	O
reduced	B-UNK
AZT	B-UNK
-	O
induced	B-UNK
marrow	B-UNK
toxicity	B-UNK
.	O
In	O
vitro	B-UNK
,	O
at	B-DISEASE
a	O
concentration	B-UNK
of	O
100	O
mumol	B-UNK
/	O
L	B-UNK
,	O
BAU	O
possesses	O
minimal	O
anti-HIV	O
activity	B-UNK
and	O
has	O
no	O
effect	B-UNK
on	O
the	O
ability	B-UNK
of	O
AZT	B-UNK
to	O
reverse	B-UNK
the	O
HIV	O
-	O
induced	B-UNK
cytopathic	O
effect	B-UNK
in	O
MT4	O
cells	B-UNK
.	O
The	O
clinical	B-UNK
and	O
biochemical	B-UNK
implications	O
of	O
these	O
findings	B-UNK
are	O
discussed	O
.	O

Cyclophosphamide	O
-	O
induced	B-UNK
cystitis	B-DISEASE
in	O
freely	O
-	O
moving	O
conscious	B-UNK
rats	B-UNK
:	O
behavioral	B-UNK
approach	B-UNK
to	O
a	O
new	B-UNK
model	B-UNK
of	O
visceral	B-DISEASE
pain	I-DISEASE
.	O

PURPOSE	O
:	O
To	O
develop	B-UNK
a	O
model	B-UNK
of	O
visceral	B-DISEASE
pain	I-DISEASE
in	O
rats	B-UNK
using	O
a	O
behavioral	B-UNK
approach	B-UNK
.	O
Cyclophosphamide	O
(	O
CP	O
)	O
,	O
an	O
antitumoral	O
agent	B-UNK
known	B-UNK
to	O
produce	B-UNK
toxic	B-UNK
effects	B-UNK
on	O
the	O
bladder	B-UNK
wall	B-UNK
through	O
its	O
main	B-UNK
toxic	B-UNK
metabolite	B-UNK
acrolein	B-CHEMICAL
,	O
was	O
used	O
to	O
induce	B-UNK
cystitis	B-DISEASE
.	O
MATERIALS	O
AND	O
METHODS	O
:	O
CP	O
was	O
administered	B-UNK
at	B-DISEASE
doses	B-UNK
of	O
50	O
,	O
100	O
and	O
200	O
mg./kg	O
.	O
i.p	B-UNK
.	O
to	O
male	B-UNK
rats	B-UNK
,	O
and	O
their	O
behavior	B-UNK
observed	B-UNK
and	O
scored	O
.	O
The	O
effects	B-UNK
of	O
morphine	B-CHEMICAL
(	O
0.5	B-UNK
to	O
4	O
mg./kg	O
.	O
i.v	B-UNK
.	O
)	O
on	O
CP	O
-	O
induced	B-UNK
behavioral	B-UNK
modifications	I-UNK
were	O
tested	B-UNK
administered	B-UNK
alone	O
and	O
after	O
naloxone	B-CHEMICAL
(	O
1	O
mg./kg	O
.	O
s.c	B-UNK
.	O
)	O
.	O
In	O
addition	O
,	O
90	O
minutes	B-UNK
after	O
CP	O
injection	B-UNK
,	O
that	O
is	O
,	O
at	B-DISEASE
the	O
time	B-UNK
of	O
administration	B-UNK
of	O
morphine	B-CHEMICAL
,	O
the	O
bladder	B-UNK
was	O
removed	O
in	O
some	O
rats	B-UNK
for	O
histological	B-UNK
examination	B-UNK
.	O
Finally	O
,	O
to	O
show	O
that	O
the	O
bladder	B-UNK
is	O
essential	O
for	O
the	O
CP	O
-	O
induced	B-UNK
behavioral	B-UNK
modifications	I-UNK
,	O
female	B-UNK
rats	B-UNK
also	O
received	B-UNK
CP	O
at	B-DISEASE
doses	B-UNK
of	O
200	O
mg./kg	O
.	O
i.p	B-UNK
.	O
and	O
of	O
20	O
mg	B-UNK
.	O
by	O
the	O
intravesical	B-UNK
route	B-UNK
,	O
and	O
acrolein	B-CHEMICAL
at	B-DISEASE
doses	B-UNK
of	O
0.5	B-UNK
mg	I-UNK
.	O
by	O
the	O
intravesical	B-UNK
route	B-UNK
and	O
of	O
5	O
mg./kg	O
.	O
i.v	B-UNK
.	O
RESULTS	B-UNK
:	O
CP	O
dose	B-UNK
-	O
relatedly	O
induced	B-UNK
marked	B-UNK
behavioral	B-UNK
modifications	I-UNK
in	O
male	B-UNK
rats	B-UNK
:	O
breathing	O
rate	B-UNK
decrease	B-UNK
,	O
closing	O
of	O
the	O
eyes	B-UNK
and	O
occurrence	O
of	O
specific	B-UNK
postures	O
.	O
Morphine	O
dose	B-UNK
-	O
dependently	B-UNK
reversed	B-UNK
these	O
behavioral	B-UNK
disorders	B-UNK
.	O
A	O
dose	B-UNK
of	O
0.5	B-UNK
mg./kg	O
.	O
produced	B-UNK
a	O
reduction	B-UNK
of	O
almost	O
50	O
%	O
of	O
the	O
behavioral	B-UNK
score	B-UNK
induced	B-UNK
by	O
CP	O
200	O
mg./kg	O
.	O
This	O
effect	B-UNK
was	O
completely	B-UNK
prevented	B-UNK
by	O
pretreatment	B-UNK
with	O
naloxone	B-CHEMICAL
.	O
At	O
the	O
time	B-UNK
of	O
administration	B-UNK
of	O
morphine	B-CHEMICAL
,	O
histological	B-UNK
modifications	B-UNK
of	O
the	O
bladder	B-UNK
wall	B-UNK
,	O
such	O
as	O
chorionic	O
and	O
muscle	B-UNK
layer	B-UNK
edema	B-DISEASE
,	O
were	O
observed	B-UNK
.	O
In	O
female	B-UNK
rats	B-UNK
,	O
CP	O
200	O
mg./kg	O
.	O
i.p	B-UNK
.	O
produced	B-UNK
the	O
same	O
marked	B-UNK
behavioral	B-UNK
modifications	I-UNK
as	O
those	O
observed	B-UNK
in	O
male	B-UNK
rats	B-UNK
.	O
Administered	O
at	B-DISEASE
the	O
dose	B-UNK
of	O
20	O
mg	B-UNK
.	O
intravesically	B-UNK
,	O
CP	O
did	O
not	O
produce	B-UNK
any	O
behavioral	B-UNK
effects	B-UNK
,	O
whereas	O
acrolein	B-CHEMICAL
at	B-DISEASE
0.5	B-UNK
mg	I-UNK
.	O
intravesically	B-UNK
induced	B-UNK
behavioral	B-UNK
modifications	I-UNK
identical	B-UNK
to	O
those	O
under	O
CP	O
200	O
mg./kg	O
.	O
i.p	B-UNK
.	O
,	O
with	O
the	O
same	O
maximal	O
levels	B-UNK
.	O
Conversely	O
,	O
acrolein	B-CHEMICAL
5	O
mg./kg	O
.	O
i.v	B-UNK
.	O
did	O
not	O
produce	B-UNK
any	O
behavioral	B-UNK
effects	B-UNK
at	B-DISEASE
all	O
.	O
CONCLUSIONS	O
:	O
Overall	O
,	O
these	O
results	B-UNK
indicate	B-UNK
that	O
this	O
experimental	B-UNK
model	B-UNK
of	O
CP	O
-	O
induced	B-UNK
cystitis	B-DISEASE
may	O
be	O
an	O
interesting	O
new	B-UNK
behavioral	B-UNK
model	B-UNK
of	O
inflammatory	B-UNK
visceral	B-DISEASE
pain	I-DISEASE
,	O
allowing	O
a	O
better	B-UNK
understanding	O
of	O
these	O
painful	B-UNK
syndromes	O
and	O
thus	O
a	O
better	B-UNK
therapeutic	B-UNK
approach	B-UNK
to	O
them	O
.	O

Hyperalgesia	O
and	O
myoclonus	B-DISEASE
in	O
terminal	B-UNK
cancer	B-DISEASE
patients	B-UNK
treated	B-UNK
with	O
continuous	B-UNK
intravenous	B-UNK
morphine	B-CHEMICAL
.	O

Eight	O
cancer	B-DISEASE
patients	B-UNK
in	O
the	O
terminal	B-UNK
stages	O
of	O
the	O
disease	B-DISEASE
treated	B-UNK
with	O
high	B-UNK
doses	B-UNK
of	O
intravenous	B-UNK
morphine	B-CHEMICAL
developed	B-UNK
hyperalgesia	B-DISEASE
.	O
All	O
cases	B-UNK
were	O
retrospectively	B-UNK
sampled	O
from	O
three	O
different	B-UNK
hospitals	B-UNK
in	O
Copenhagen	O
.	O
Five	O
patients	B-UNK
developed	B-UNK
universal	O
hyperalgesia	B-DISEASE
and	O
hyperesthesia	B-DISEASE
which	O
in	O
2	B-DISEASE
cases	B-UNK
were	O
accompanied	O
by	O
myoclonus	B-DISEASE
.	O
In	O
3	O
patients	B-UNK
a	O
pre	B-UNK
-	O
existing	B-UNK
neuralgia	B-DISEASE
increased	B-UNK
to	O
excruciating	O
intensity	B-UNK
and	O
in	O
2	B-DISEASE
of	O
these	O
cases	B-UNK
myoclonus	B-DISEASE
occurred	B-UNK
simultaneously	B-UNK
.	O
Although	O
only	O
few	O
clinical	B-UNK
descriptions	O
of	O
the	O
relationship	B-UNK
between	O
hyperalgesia	B-DISEASE
/	O
myoclonus	B-DISEASE
and	O
high	B-UNK
doses	B-UNK
of	O
morphine	B-CHEMICAL
are	O
available	B-UNK
,	O
experimental	B-UNK
support	B-UNK
from	O
animal	B-UNK
studies	B-UNK
indicates	B-UNK
that	O
morphine	B-CHEMICAL
,	O
or	O
its	O
metabolites	B-UNK
,	O
plays	O
a	O
causative	O
role	B-UNK
for	O
the	O
observed	B-UNK
behavioural	B-UNK
syndrome	B-DISEASE
.	O
The	O
possible	B-UNK
mechanisms	B-UNK
are	O
discussed	O
and	O
treatment	B-UNK
proposals	O
given	B-UNK
suggesting	B-UNK
the	O
use	B-UNK
of	O
more	O
efficacious	B-UNK
opioids	O
with	O
less	O
excitatory	B-UNK
potency	B-UNK
in	O
these	O
situations	O
.	O

A	O
prospective	B-UNK
study	B-UNK
of	O
adverse	B-UNK
reactions	B-UNK
associated	B-UNK
with	O
vancomycin	B-CHEMICAL
therapy	B-UNK
.	O

A	O
prospective	B-UNK
evaluation	B-UNK
of	O
the	O
efficacy	B-UNK
and	O
safety	B-UNK
of	O
vancomycin	B-CHEMICAL
was	O
conducted	O
in	O
54	O
consecutive	B-UNK
patients	B-UNK
over	O
a	O
16-month	O
period	B-UNK
.	O
Vancomycin	O
was	O
curative	O
in	O
95	O
%	O
of	O
43	O
patients	B-UNK
with	O
proven	B-UNK
infection	B-UNK
.	O
Drugs	O
were	O
ceased	O
in	O
six	O
patients	B-UNK
because	O
of	O
adverse	B-UNK
reactions	B-UNK
;	O
in	O
three	O
of	O
these	O
vancomycin	B-CHEMICAL
was	O
considered	B-UNK
the	O
likely	B-UNK
cause	B-UNK
.	O
Reactions	O
included	B-UNK
thrombophlebitis	B-DISEASE
(	O
20	O
of	O
54	O
patients	B-UNK
)	O
,	O
rash	B-DISEASE
(	O
4	O
of	O
54	O
)	O
,	O
nephrotoxicity	B-UNK
(	O
4	O
of	O
50	O
)	O
,	O
proteinuria	B-UNK
(	O
1	O
of	O
50	O
)	O
and	O
ototoxicity	B-DISEASE
(	O
1	O
of	O
11	O
patients	B-UNK
tested	B-UNK
by	O
audiometry	O
)	O
.	O
Thrombophlebitis	O
occurred	B-UNK
only	O
with	O
infusion	B-UNK
through	O
peripheral	B-UNK
cannulae	O
;	O
nephrotoxicity	B-UNK
and	O
ototoxicity	B-DISEASE
were	O
confined	O
to	O
patients	B-UNK
receiving	B-UNK
an	O
aminoglycoside	O
plus	B-UNK
vancomycin	B-CHEMICAL
.	O
We	O
conclude	O
that	O
vancomycin	B-CHEMICAL
,	O
administered	B-UNK
appropriately	O
,	O
constitutes	O
safe	B-UNK
,	O
effective	B-UNK
therapy	B-UNK
for	O
infections	B-DISEASE
caused	B-UNK
by	O
susceptible	B-UNK
bacteria	O
.	O

Blockade	O
of	O
both	O
D-1	O
and	O
D-2	O
dopamine	B-CHEMICAL
receptors	B-UNK
may	O
induce	B-UNK
catalepsy	B-DISEASE
in	O
mice	B-UNK
.	O

Dextran	O
-	O
etodolac	B-CHEMICAL
conjugates	O
:	O
synthesis	O
,	O
in	O
vitro	B-UNK
and	O
in	O
vivo	B-UNK
evaluation	B-UNK
.	O

Etodolac	O
(	O
E	B-UNK
)	O
,	O
is	O
a	O
non-narcotic	O
analgesic	B-UNK
and	O
antiinflammatory	B-UNK
drug	B-UNK
.	O
A	O
biodegradable	O
polymer	O
dextran	B-UNK
has	O
been	O
utilized	O
as	O
a	O
carrier	O
for	O
synthesis	O
of	O
etodolac	B-CHEMICAL
-	O
dextran	B-UNK
conjugates	O
(	O
ED	O
)	O
to	O
improve	O
its	O
aqueous	B-UNK
solubility	O
and	O
reduce	B-UNK
gastrointestinal	B-UNK
side	O
effects	B-UNK
.	O
An	O
activated	B-UNK
moiety	O
,	O
i.e	O
.	O
N	B-UNK
-	O
acylimidazole	O
derivative	B-UNK
of	O
etodolac	B-CHEMICAL
(	O
EAI	O
)	O
,	O
was	O
condensed	O
with	O
the	O
polysaccharide	B-DISEASE
polymer	O
dextran	B-UNK
of	O
different	B-UNK
molecular	B-UNK
weights	B-UNK
(	O
40000	O
,	O
60000	O
,	O
110000	O
and	O
200000	O
)	O
.	O
IR	O
spectral	B-UNK
data	B-UNK
confirmed	B-UNK
formation	B-UNK
of	O
ester	B-UNK
bonding	O
in	O
the	O
conjugates	O
.	O
Etodolac	O
contents	O
were	O
evaluated	B-UNK
by	O
UV	O
-	O
spectrophotometric	O
analysis	B-UNK
.	O
The	O
molecular	B-UNK
weights	B-UNK
were	O
determined	O
by	O
measuring	B-UNK
viscosity	O
using	O
the	O
Mark	O
-	O
Howink	O
-	O
Sakurada	O
equation	O
.	O
In	O
vitro	B-UNK
hydrolysis	O
of	O
ED	O
was	O
done	O
in	O
aqueous	B-UNK
buffers	O
(	O
pH	B-UNK
1.2	O
,	O
7.4	B-UNK
,	O
9	O
)	O
and	O
in	O
80	O
%	O
(	O
v	O
/	O
v	O
)	O
human	B-UNK
plasma	B-UNK
(	O
pH	B-UNK
7.4	B-UNK
)	O
.	O
At	O
pH	B-UNK
9	O
,	O
a	O
higher	B-UNK
rate	B-UNK
of	O
etodolac	B-CHEMICAL
release	B-UNK
from	O
ED	O
was	O
observed	B-UNK
as	O
compared	B-UNK
to	O
aqueous	B-UNK
buffer	O
of	O
pH	B-UNK
7.4	B-UNK
and	O
80	O
%	O
human	B-UNK
plasma	B-UNK
(	O
pH	B-UNK
7.4	B-UNK
)	O
,	O
following	B-UNK
first	O
-	O
order	O
kinetics	O
.	O
In	O
vivo	B-UNK
investigations	B-UNK
were	O
performed	B-UNK
in	O
animals	B-UNK
.	O
Acute	B-UNK
analgesic	B-UNK
and	O
antiinflammatory	B-UNK
activities	B-UNK
were	O
ascertained	O
using	O
acetic	B-CHEMICAL
acid	I-CHEMICAL
induced	B-UNK
writhing	B-UNK
model	B-UNK
(	O
mice	B-UNK
)	O
and	O
carrageenan	B-CHEMICAL
-	O
induced	B-UNK
rat	B-UNK
paw	O
edema	B-DISEASE
model	B-UNK
,	O
respectively	O
.	O
In	O
comparison	O
to	O
control	B-UNK
,	O
E	B-UNK
and	O
ED1-ED4	O
showed	B-UNK
highly	B-UNK
significant	B-UNK
analgesic	B-UNK
and	O
antiinflammatory	B-UNK
activities	B-UNK
(	O
p	B-UNK
<	I-UNK
0.001	B-UNK
)	O
.	O
Biological	O
evaluation	B-UNK
suggested	B-UNK
that	O
conjugates	O
(	O
ED1-ED4	O
)	O
retained	O
comparable	B-UNK
analgesic	B-UNK
and	O
antiinflammatory	B-UNK
activities	B-UNK
with	O
remarkably	B-UNK
reduced	B-UNK
ulcerogenicity	O
as	O
compared	B-UNK
to	O
their	O
parent	O
drug	B-UNK
--	O
etodolac	B-CHEMICAL
.	O

Hypersensitivity	O
myocarditis	B-DISEASE
complicating	O
hypertrophic	B-DISEASE
cardiomyopathy	I-DISEASE
heart	B-UNK
.	O

The	O
present	B-UNK
report	B-UNK
describes	B-UNK
a	O
case	B-UNK
of	O
eosinophilic	O
myocarditis	B-DISEASE
complicating	O
hypertrophic	B-DISEASE
cardiomyopathy	I-DISEASE
.	O
The	O
47-year	O
-	O
old	B-UNK
female	B-UNK
patient	B-UNK
,	O
known	B-UNK
to	O
have	O
hypertrophic	B-DISEASE
cardiomyopathy	I-DISEASE
,	O
was	O
admitted	O
with	O
biventricular	O
failure	B-UNK
and	O
managed	B-UNK
aggressively	O
with	O
dobutamine	B-CHEMICAL
infusion	B-UNK
and	O
other	O
drugs	B-UNK
while	O
being	O
assessed	B-UNK
for	O
heart	B-UNK
transplantation	B-UNK
.	O
On	O
transthoracic	O
echocardiogram	O
,	O
she	O
had	O
moderate	B-UNK
left	B-UNK
ventricular	I-UNK
dysfunction	B-UNK
with	O
regional	B-UNK
variability	O
and	O
moderate	B-UNK
mitral	O
regurgitation	B-DISEASE
.	O
The	O
recipient'	O
s	O
heart	B-UNK
showed	B-UNK
the	O
features	B-UNK
of	O
apical	B-UNK
hypertrophic	B-DISEASE
cardiomyopathy	I-DISEASE
and	O
myocarditis	B-DISEASE
with	O
abundant	B-UNK
eosinophils	O
.	O
Myocarditis	O
is	O
rare	B-UNK
and	O
eosinophilic	O
myocarditis	B-DISEASE
is	O
rarer	O
.	O
It	O
is	O
likely	B-UNK
that	O
the	O
hypersensitivity	B-DISEASE
(	O
eosinophilic	O
)	O
myocarditis	B-DISEASE
was	O
related	B-UNK
to	O
dobutamine	B-CHEMICAL
infusion	B-UNK
therapy	B-UNK
.	O
Eosinophilic	O
myocarditis	B-DISEASE
has	O
been	O
reported	B-UNK
with	O
an	O
incidence	B-UNK
of	O
2.4	B-UNK
%	O
to	O
7.2	O
%	O
in	O
explanted	O
hearts	O
and	O
may	O
be	O
related	B-UNK
to	O
multidrug	O
therapy	B-UNK
.	O

All-	O
trans-retinoic	O
acid	B-UNK
-	O
induced	B-UNK
erythema	B-DISEASE
nodosum	I-DISEASE
in	O
patients	B-UNK
with	O
acute	B-UNK
promyelocytic	O
leukemia	B-DISEASE
.	O

Erythema	O
nodosum	O
associated	B-UNK
with	O
all-	O
trans-retinoic	O
acid	B-UNK
(	O
ATRA	O
)	O
for	O
acute	B-UNK
promyelocytic	O
leukemia	B-DISEASE
(	O
APL	O
)	O
is	O
very	O
rare	B-UNK
.	O
We	O
describe	O
four	O
patients	B-UNK
with	O
classic	B-UNK
APL	O
who	O
developed	B-UNK
erythema	B-DISEASE
nodosum	I-DISEASE
during	O
ATRA	O
therapy	B-UNK
.	O
Fever	O
and	O
subsequent	B-UNK
multiple	B-UNK
painful	B-UNK
erythematous	O
nodules	B-UNK
over	O
extremities	O
developed	B-UNK
on	O
D11	O
,	O
D16	O
,	O
D17	O
,	O
and	O
D19	O
,	O
respectively	O
,	O
after	O
ATRA	O
therapy	B-UNK
.	O
The	O
skin	B-DISEASE
biopsy	B-UNK
taken	O
from	O
each	O
patient	B-UNK
was	O
consistent	B-UNK
with	O
erythema	B-DISEASE
nodosum	I-DISEASE
.	O
All	O
patients	B-UNK
received	B-UNK
short	B-UNK
course	B-UNK
of	O
steroids	B-CHEMICAL
.	O
Fever	O
subsided	O
rapidly	B-UNK
and	O
the	O
skin	B-DISEASE
lesions	B-UNK
regressed	O
completely	B-UNK
.	O
All	O
patients	B-UNK
achieved	B-UNK
complete	B-UNK
remission	B-DISEASE
without	O
withdrawal	B-UNK
of	O
ATRA	O
.	O
ATRA	O
seemed	O
to	O
be	O
the	O
most	O
possible	B-UNK
etiology	O
of	O
erythema	B-DISEASE
nodosum	I-DISEASE
in	O
our	O
patients	B-UNK
.	O
Short	O
-	O
term	B-UNK
use	B-UNK
of	O
steroid	B-UNK
is	O
very	O
effective	B-UNK
in	O
ATRA	O
-	O
induced	B-UNK
erythema	B-DISEASE
nodosum	I-DISEASE
.	O

Delayed	B-UNK
-	O
onset	B-UNK
heparin	B-CHEMICAL
-	O
induced	B-UNK
thrombocytopenia	B-DISEASE
.	O

BACKGROUND	O
:	O
Heparin	O
-	O
induced	B-UNK
thrombocytopenia	B-DISEASE
presents	O
5	O
to	O
12	O
days	B-UNK
after	O
heparin	B-CHEMICAL
exposure	B-UNK
,	O
with	O
or	O
without	O
arterial	B-UNK
or	O
venous	B-UNK
thromboemboli	O
.	O
Delayed	B-UNK
recognition	O
and	O
treatment	B-UNK
of	O
heparin	B-CHEMICAL
-	O
induced	B-UNK
thrombocytopenia	B-DISEASE
contribute	O
to	O
poor	B-UNK
patient	B-UNK
outcomes	B-UNK
.	O
OBJECTIVE	O
:	O
To	O
describe	O
and	O
increase	B-UNK
awareness	O
of	O
a	O
clinical	B-UNK
scenario	O
in	O
which	O
the	O
onset	B-UNK
or	O
manifestations	B-UNK
of	O
heparin	B-CHEMICAL
-	O
induced	B-UNK
thrombocytopenia	B-DISEASE
are	O
delayed	B-UNK
.	O
DESIGN	B-UNK
:	O
Retrospective	O
case	B-UNK
series	B-UNK
.	O
SETTING	O
:	O
Three	O
large	B-UNK
urban	O
hospitals	B-UNK
(	O
with	O
active	B-UNK
cardiovascular	B-UNK
surgery	B-UNK
programs	O
)	O
.	O
PATIENTS	O
:	O
14	O
patients	B-UNK
seen	B-UNK
over	O
a	O
3-year	O
period	B-UNK
in	O
whom	O
heparin	B-CHEMICAL
-	O
induced	B-UNK
thrombocytopenia	B-DISEASE
became	O
apparent	O
on	O
delayed	B-UNK
presentation	O
with	O
thromboembolic	B-UNK
complications	B-UNK
.	O
MEASUREMENTS	O
:	O
Platelet	B-UNK
counts	B-UNK
,	O
onset	B-UNK
of	O
objectively	O
determined	O
thromboembolism	B-DISEASE
,	O
results	B-UNK
of	O
heparin	B-CHEMICAL
-	O
induced	B-UNK
platelet	B-CHEMICAL
factor	I-CHEMICAL
4	I-CHEMICAL
antibody	B-UNK
tests	B-UNK
,	O
and	O
outcomes	B-UNK
.	O
RESULTS	B-UNK
:	O
Patients	B-UNK
went	O
home	B-UNK
after	O
hospitalizations	O
that	O
had	O
included	B-UNK
heparin	B-CHEMICAL
exposure	B-UNK
--	O
in	O
most	O
cases	B-UNK
,	O
with	O
no	O
thrombocytopenia	B-DISEASE
recognized	B-UNK
--	O
only	O
to	O
return	B-UNK
to	O
the	O
hospital	B-UNK
(	O
median	B-UNK
,	O
day	B-UNK
14	O
)	O
with	O
thromboembolic	B-UNK
complications	B-UNK
.	O
Thromboemboli	O
were	O
venous	B-UNK
(	O
12	O
patients	B-UNK
,	O
7	O
with	O
pulmonary	B-UNK
emboli	O
)	O
or	O
arterial	B-UNK
(	O
4	O
patients	B-UNK
)	O
or	O
both	O
.	O
Platelet	B-UNK
counts	B-UNK
were	O
mildly	O
decreased	B-UNK
in	O
all	O
but	O
2	B-DISEASE
patients	B-UNK
on	O
second	B-UNK
presentation	O
.	O
On	O
readmission	O
,	O
11	O
patients	B-UNK
received	B-UNK
therapeutic	B-UNK
heparin	B-CHEMICAL
,	O
which	O
worsened	O
the	O
patients	B-UNK
'	O
clinical	B-UNK
condition	B-UNK
and	O
,	O
in	O
all	O
11	O
cases	B-UNK
,	O
decreased	B-UNK
the	O
platelet	B-UNK
count	I-UNK
(	O
mean	B-UNK
at	B-DISEASE
readmission	O
,	O
143	O
x	B-UNK
10(9	O
)	O
cells	B-UNK
/	O
L	B-UNK
;	O
mean	B-UNK
nadir	O
after	O
heparin	B-CHEMICAL
re-exposure	O
,	O
39	O
x	B-UNK
10(9	O
)	O
cells	B-UNK
/	O
L	B-UNK
)	O
.	O
Results	O
of	O
serologic	O
tests	B-UNK
for	O
heparin	B-CHEMICAL
-	O
induced	B-UNK
antibodies	B-UNK
were	O
positive	B-UNK
in	O
all	O
patients	B-UNK
.	O
Subsequent	B-UNK
treatments	B-UNK
included	B-UNK
alternative	B-UNK
anticoagulants	B-CHEMICAL
(	O
11	O
patients	B-UNK
)	O
,	O
thrombolytic	O
drugs	B-UNK
(	O
3	O
patients	B-UNK
)	O
,	O
inferior	B-UNK
vena	O
cava	O
filters	O
(	O
3	O
patients	B-UNK
)	O
and	O
,	O
eventually	O
,	O
warfarin	B-CHEMICAL
(	O
11	O
patients	B-UNK
)	O
.	O
Three	O
patients	B-UNK
died	B-UNK
.	O
CONCLUSIONS	O
:	O
Delayed	B-UNK
-	O
onset	B-UNK
heparin	B-CHEMICAL
-	O
induced	B-UNK
thrombocytopenia	B-DISEASE
is	O
increasingly	O
being	O
recognized	B-UNK
.	O
To	O
avoid	B-UNK
disastrous	O
outcomes	B-UNK
,	O
physicians	O
must	O
consider	O
heparin	B-CHEMICAL
-	O
induced	B-UNK
thrombocytopenia	B-DISEASE
whenever	O
a	O
recently	B-UNK
hospitalized	O
patient	B-UNK
returns	O
with	O
thromboembolism	B-DISEASE
;	O
therapy	B-UNK
with	O
alternative	B-UNK
anticoagulants	B-CHEMICAL
,	O
not	O
heparin	B-CHEMICAL
,	O
should	O
be	O
initiated	O
.	O

Valsartan	O
,	O
a	O
new	B-UNK
angiotensin	B-UNK
II	B-UNK
antagonist	B-UNK
for	O
the	O
treatment	B-UNK
of	O
essential	B-DISEASE
hypertension	I-DISEASE
:	O
a	O
comparative	O
study	B-UNK
of	O
the	O
efficacy	B-UNK
and	O
safety	B-UNK
against	O
amlodipine	B-CHEMICAL
.	O

OBJECTIVE	O
:	O
To	O
compare	O
the	O
antihypertensive	O
efficacy	B-UNK
of	O
a	O
new	B-UNK
angiotensin	B-UNK
II	B-UNK
antagonist	B-UNK
,	O
valsartan	B-CHEMICAL
,	O
with	O
a	O
reference	B-UNK
therapy	B-UNK
,	O
amlodipine	B-CHEMICAL
.	O
METHODS	O
:	O
One	O
hundred	O
sixty	O
-	O
eight	O
adult	B-UNK
outpatients	O
with	O
mild	B-UNK
to	O
moderate	B-UNK
hypertension	B-DISEASE
were	O
randomly	B-UNK
allocated	B-UNK
in	O
double-blind	B-UNK
fashion	B-UNK
and	O
equal	O
number	B-UNK
to	O
receive	B-UNK
80	O
mg	B-UNK
valsartan	B-CHEMICAL
or	O
5	O
mg	B-UNK
amlodipine	B-CHEMICAL
for	O
12	O
weeks	B-UNK
.	O
After	O
8	O
weeks	B-UNK
of	O
therapy	B-UNK
,	O
in	O
patients	B-UNK
whose	O
blood	B-UNK
pressure	B-UNK
remained	B-UNK
uncontrolled	B-UNK
,	O
5	O
mg	B-UNK
amlodipine	B-CHEMICAL
was	O
added	O
to	O
the	O
initial	B-UNK
therapy	B-UNK
.	O
Patients	B-UNK
were	O
assessed	B-UNK
at	B-DISEASE
4	O
,	O
8	O
,	O
and	O
12	O
weeks	B-UNK
.	O
The	O
primary	B-UNK
efficacy	B-UNK
variable	B-UNK
was	O
change	B-UNK
from	O
baseline	B-UNK
in	O
mean	B-UNK
sitting	O
diastolic	B-UNK
blood	B-UNK
pressure	B-UNK
at	B-DISEASE
8	O
weeks	B-UNK
.	O
Secondary	O
variables	B-UNK
included	B-UNK
change	B-UNK
in	O
sitting	O
systolic	B-UNK
blood	B-UNK
pressure	B-UNK
and	O
responder	O
rates	B-UNK
.	O
RESULTS	B-UNK
:	O
Both	O
valsartan	B-CHEMICAL
and	O
amlodipine	B-CHEMICAL
were	O
effective	B-UNK
at	B-DISEASE
lowering	B-UNK
blood	B-UNK
pressure	B-UNK
at	B-DISEASE
4	O
,	O
8	O
,	O
and	O
12	O
weeks	B-UNK
.	O
Similar	B-UNK
decreases	B-UNK
were	O
observed	B-UNK
in	O
both	O
groups	B-UNK
,	O
with	O
no	O
statistically	B-UNK
significant	I-UNK
differences	B-UNK
between	O
the	O
groups	B-UNK
for	O
any	O
variable	B-UNK
analyzed	B-UNK
.	O
For	O
the	O
primary	B-UNK
variable	B-UNK
the	O
difference	B-UNK
was	O
0.5	B-UNK
mm	B-UNK
Hg	B-UNK
in	O
favor	O
of	O
valsartan	B-CHEMICAL
(	O
p	B-UNK
=	I-UNK
0.68	O
;	O
95	O
%	O
confidence	B-UNK
interval	I-UNK
,	O
-2.7	O
to	O
1.7	O
)	O
.	O
Responder	O
rates	B-UNK
at	B-DISEASE
8	O
weeks	B-UNK
were	O
66.7	O
%	O
for	O
valsartan	B-CHEMICAL
and	O
60.2	O
%	O
for	O
amlodipine	B-CHEMICAL
(	O
p	B-UNK
=	I-UNK
0.39	O
)	O
.	O
Both	O
treatments	B-UNK
were	O
well	O
tolerated	B-UNK
.	O
The	O
incidence	B-UNK
of	O
drug	B-UNK
-	O
related	B-UNK
dependent	B-UNK
edema	B-DISEASE
was	O
somewhat	O
higher	B-UNK
in	O
the	O
amlodipine	B-CHEMICAL
group	B-UNK
,	O
particularly	O
at	B-DISEASE
a	O
dose	B-UNK
of	O
10	O
mg	B-UNK
per	O
day	B-UNK
(	O
2.4	B-UNK
%	O
for	O
80	O
mg	B-UNK
valsartan	B-CHEMICAL
;	O
3.6	B-UNK
%	O
for	O
5	O
mg	B-UNK
amlodipine	B-CHEMICAL
;	O
0	O
%	O
for	O
valsartan	B-CHEMICAL
plus	B-UNK
5	O
mg	B-UNK
amlodipine	B-CHEMICAL
;	O
14.3	O
%	O
for	O
10	O
mg	B-UNK
amlodipine	B-CHEMICAL
)	O
.	O
CONCLUSIONS	O
:	O
The	O
data	B-UNK
show	O
that	O
valsartan	B-CHEMICAL
is	O
at	B-DISEASE
least	O
as	O
effective	B-UNK
as	O
amlodipine	B-CHEMICAL
in	O
the	O
treatment	B-UNK
of	O
mild	B-UNK
to	O
moderate	B-UNK
hypertension	B-DISEASE
.	O
The	O
results	B-UNK
also	O
show	O
valsartan	B-CHEMICAL
to	O
be	O
well	O
tolerated	B-UNK
and	O
suggest	B-UNK
that	O
it	O
is	O
not	O
associated	B-UNK
with	O
side	O
effects	B-UNK
characteristic	O
of	O
this	O
comparator	O
class	O
,	O
dihydropyridine	O
calcium	B-CHEMICAL
antagonists	B-UNK
.	O

KF17837	O
:	O
a	O
novel	B-UNK
selective	B-UNK
adenosine	B-CHEMICAL
A2A	O
receptor	B-UNK
antagonist	I-UNK
with	O
anticataleptic	B-UNK
activity	B-UNK
.	O

KF17837	O
is	O
a	O
novel	B-UNK
selective	B-UNK
adenosine	B-CHEMICAL
A2A	O
receptor	B-UNK
antagonist	I-UNK
.	O
Oral	O
administration	B-UNK
of	O
KF17837	O
(	O
2.5	B-UNK
,	O
10.0	O
and	O
30.0	O
mg	B-UNK
/	O
kg	B-UNK
)	O
significantly	B-UNK
ameliorated	O
the	O
cataleptic	O
responses	B-UNK
induced	B-UNK
by	O
intracerebroventricular	O
administration	B-UNK
of	O
an	O
adenosine	B-CHEMICAL
A2A	O
receptor	B-UNK
agonist	B-UNK
,	O
CGS	O
21680	O
(	O
10	O
micrograms	B-UNK
)	O
,	O
in	O
a	O
dose	B-UNK
-	O
dependent	B-UNK
manner	B-UNK
.	O
KF17837	O
also	O
reduced	B-UNK
the	O
catalepsy	B-DISEASE
induced	B-UNK
by	O
haloperidol	B-CHEMICAL
(	O
1	O
mg	B-UNK
/	O
kg	B-UNK
i.p	B-UNK
.	O
)	O
and	O
by	O
reserpine	B-CHEMICAL
(	O
5	O
mg	B-UNK
/	O
kg	B-UNK
i.p	B-UNK
.	O
)	O
.	O
These	O
anticataleptic	B-UNK
effects	B-UNK
were	O
exhibited	B-UNK
dose	B-UNK
dependently	B-UNK
at	B-DISEASE
doses	B-UNK
from	O
0.625	O
and	O
2.5	B-UNK
mg	B-UNK
/	O
kg	B-UNK
p.o	B-UNK
.	O
,	O
respectively	O
.	O
Moreover	O
,	O
KF17837	O
(	O
0.625	O
mg	B-UNK
/	O
kg	B-UNK
p.o	B-UNK
.	O
)	O
potentiated	B-UNK
the	O
anticataleptic	B-UNK
effects	B-UNK
of	O
a	O
subthreshold	O
dose	B-UNK
of	O
L-3,4-dihydroxyphenylalanine	O
(	O
L	B-UNK
-	O
DOPA	O
;	O
25	O
mg	B-UNK
/	O
kg	B-UNK
i.p	B-UNK
.	O
)	O
plus	B-UNK
benserazide	B-CHEMICAL
(	O
6.25	O
mg	B-UNK
/	O
kg	B-UNK
i.p	B-UNK
.	O
)	O
.	O
These	O
results	B-UNK
suggested	B-UNK
that	O
KF17837	O
is	O
a	O
centrally	O
active	B-UNK
adenosine	B-CHEMICAL
A2A	O
receptor	B-UNK
antagonist	I-UNK
and	O
that	O
the	O
dopaminergic	B-UNK
function	B-UNK
of	O
the	O
nigrostriatal	B-UNK
pathway	B-UNK
is	O
potentiated	B-UNK
by	O
adenosine	B-CHEMICAL
A2A	O
receptor	B-UNK
antagonists	B-UNK
.	O
Furthermore	O
,	O
KF17837	O
may	O
be	O
a	O
useful	B-UNK
drug	B-UNK
in	O
the	O
treatment	B-UNK
of	O
parkinsonism	B-DISEASE
.	O

Some	O
central	B-UNK
effects	B-UNK
of	O
repeated	B-UNK
treatment	B-UNK
with	O
fluvoxamine	B-CHEMICAL
.	O

We	O
investigated	B-UNK
the	O
effect	B-UNK
of	O
repeated	B-UNK
treatment	B-UNK
with	O
fluvoxamine	B-CHEMICAL
,	O
a	O
selective	B-UNK
serotonin	B-CHEMICAL
uptake	B-UNK
inhibitor	B-UNK
,	O
on	O
behavioral	B-UNK
effects	B-UNK
of	O
dopaminomimetics	O
and	O
methoxamine	B-CHEMICAL
and	O
on	O
the	O
animal	B-UNK
behavior	B-UNK
in	O
the	O
"	O
behavioral	B-UNK
despair	O
"	O
test	B-UNK
.	O
A	O
repeated	B-UNK
treatment	B-UNK
with	O
fluvoxamine	B-CHEMICAL
(	O
twice	B-UNK
daily	B-UNK
for	O
14	O
days	B-UNK
)	O
potentiated	B-UNK
in	O
mice	B-UNK
and	O
in	O
rats	B-UNK
(	O
weaker	O
)	O
the	O
amphetamine	B-CHEMICAL
-	O
induced	B-UNK
hyperactivity	B-UNK
.	O
The	O
hyperactivity	B-UNK
induced	B-UNK
by	O
nomifensine	B-CHEMICAL
in	O
mice	B-UNK
remained	B-UNK
unaffected	B-UNK
by	O
fluvoxamine	B-CHEMICAL
.	O
The	O
stimulation	B-UNK
of	O
locomotor	B-UNK
activity	B-UNK
by	O
intracerebroventricularly	O
administered	B-UNK
methoxamine	B-CHEMICAL
was	O
not	O
affected	B-UNK
by	O
repeated	B-UNK
treatment	B-UNK
with	O
fluvoxamine	B-CHEMICAL
.	O
Given	O
three	O
times	B-UNK
fluvoxamine	B-CHEMICAL
had	O
no	O
effect	B-UNK
on	O
the	O
immobilization	O
time	B-UNK
in	O
the	O
"	O
behavioral	B-UNK
despair	O
"	O
test	B-UNK
in	O
rats	B-UNK
.	O
The	O
results	B-UNK
indicate	B-UNK
that	O
fluvoxamine	B-CHEMICAL
given	B-UNK
repeatedly	B-UNK
acts	B-UNK
differently	O
than	O
citalopram	B-CHEMICAL
,	O
another	O
selective	B-UNK
serotonin	B-CHEMICAL
uptake	B-UNK
inhibitor	B-UNK
,	O
and	O
differs	O
also	O
from	O
other	O
antidepressant	B-UNK
drugs	B-UNK
.	O

Severe	B-UNK
congestive	B-DISEASE
heart	I-DISEASE
failure	I-DISEASE
patient	B-UNK
on	O
amiodarone	B-CHEMICAL
presenting	O
with	O
myxedemic	O
coma	B-DISEASE
:	O
a	O
case	B-UNK
report	B-UNK
.	O

This	O
is	O
a	O
case	B-UNK
report	B-UNK
of	O
myxedema	B-DISEASE
coma	B-DISEASE
secondary	B-UNK
to	O
amiodarone	B-CHEMICAL
-	O
induced	B-UNK
hypothyroidism	B-DISEASE
in	O
a	O
patient	B-UNK
with	O
severe	B-UNK
congestive	B-DISEASE
heart	I-DISEASE
failure	I-DISEASE
(	O
CHF	O
)	O
.	O
To	O
our	O
knowledge	O
and	O
after	O
reviewing	O
the	O
literature	B-UNK
there	O
is	O
one	O
case	B-UNK
report	B-UNK
of	O
myxedema	B-DISEASE
coma	B-DISEASE
during	O
long	B-UNK
term	B-UNK
amiodarone	B-CHEMICAL
therapy	B-UNK
.	O
Myxedema	O
coma	B-DISEASE
is	O
a	O
life	B-UNK
threatening	O
condition	B-UNK
that	O
carries	O
a	O
mortality	B-UNK
reaching	O
as	O
high	B-UNK
as	O
20	O
%	O
with	O
treatment	B-UNK
.	O
The	O
condition	B-UNK
is	O
treated	B-UNK
with	O
intravenous	B-UNK
thyroxine	B-CHEMICAL
(	O
T4	O
)	O
or	O
intravenous	B-UNK
tri-iodo-thyronine	O
(	O
T3	O
)	O
.	O
Patients	B-UNK
with	O
CHF	O
on	O
amiodarone	B-CHEMICAL
may	O
suffer	O
serious	O
morbidity	O
and	O
mortality	B-UNK
from	O
hypothyroidism	B-DISEASE
,	O
and	O
thus	O
may	O
deserve	O
closer	O
follow	B-UNK
up	O
for	O
thyroid	B-DISEASE
stimulating	B-UNK
hormone	B-UNK
(	O
TSH	O
)	O
levels	B-UNK
.	O
This	O
case	B-UNK
report	B-UNK
carries	O
an	O
important	B-UNK
clinical	B-UNK
application	B-UNK
given	B-UNK
the	O
frequent	B-UNK
usage	B-UNK
of	O
amiodarone	B-CHEMICAL
among	O
CHF	O
patients	B-UNK
.	O
The	O
myriad	O
clinical	B-UNK
presentation	O
of	O
myxedema	B-DISEASE
coma	B-DISEASE
and	O
its	O
serious	O
morbidity	O
and	O
mortality	B-UNK
stresses	O
the	O
need	B-UNK
to	O
suspect	O
this	O
clinical	B-UNK
syndrome	B-DISEASE
among	O
CHF	O
patients	B-UNK
presenting	O
with	O
hypotension	B-DISEASE
,	O
weakness	B-UNK
or	O
other	O
unexplained	O
symptoms	B-UNK
.	O

Fear	O
-	O
potentiated	B-UNK
startle	B-UNK
,	O
but	O
not	O
light	B-UNK
-	O
enhanced	B-UNK
startle	B-UNK
,	O
is	O
enhanced	B-UNK
by	O
anxiogenic	B-UNK
drugs	B-UNK
.	O

RATIONALE	O
AND	O
OBJECTIVES	O
:	O
The	O
light	B-UNK
-	O
enhanced	B-UNK
startle	B-UNK
paradigm	B-UNK
(	O
LES	O
)	O
is	O
suggested	B-UNK
to	O
model	B-UNK
anxiety	B-DISEASE
,	O
because	O
of	O
the	O
non-specific	O
cue	O
and	O
the	O
long	B-UNK
-	O
term	B-UNK
effect	B-UNK
.	O
In	O
contrast	B-UNK
,	O
the	O
fear	O
-	O
potentiated	B-UNK
startle	B-UNK
(	O
FPS	O
)	O
is	O
suggested	B-UNK
to	O
model	B-UNK
conditioned	O
fear	O
.	O
However	O
,	O
the	O
pharmacological	B-UNK
profiles	B-UNK
of	O
these	O
two	O
paradigms	O
are	O
very	O
similar	B-UNK
.	O
The	O
present	B-UNK
study	B-UNK
investigated	B-UNK
the	O
effects	B-UNK
of	O
putative	B-UNK
anxiogenic	B-UNK
drugs	B-UNK
on	O
LES	O
and	O
FPS	O
and	O
aimed	O
at	B-DISEASE
determining	O
the	O
sensitivity	B-UNK
of	O
LES	O
for	O
anxiogenic	B-UNK
drugs	B-UNK
and	O
to	O
potentially	B-UNK
showing	B-UNK
a	O
pharmacological	B-UNK
differentiation	B-UNK
between	O
these	O
two	O
paradigms	O
.	O
METHODS	O
:	O
Male	B-UNK
Wistar	I-UNK
rats	B-UNK
received	I-UNK
each	O
dose	B-UNK
of	O
the	O
alpha(2)-adrenoceptor	O
antagonist	B-UNK
yohimbine	B-CHEMICAL
(	O
0.25	B-UNK
-	O
1.0mg	O
/	O
kg	B-UNK
)	O
,	O
the	O
5-HT(2C	O
)	O
receptor	B-UNK
agonist	B-UNK
m	O
-	O
chlorophenylpiperazine	O
(	O
mCPP	O
,	O
0.5	B-UNK
-	O
2.0mg	O
/	O
kg	B-UNK
)	O
or	O
the	O
GABA(A	O
)	O
inverse	O
receptor	B-UNK
agonist	B-UNK
pentylenetetrazole	B-CHEMICAL
(	O
PTZ	O
,	O
3	O
-	O
30mg	O
/	O
kg	B-UNK
)	O
and	O
were	O
subsequently	B-UNK
tested	B-UNK
in	O
either	O
LES	O
or	O
FPS	O
.	O
RESULTS	B-UNK
:	O
None	O
of	O
the	O
drugs	B-UNK
enhanced	B-UNK
LES	O
,	O
whereas	O
mCPP	O
increased	B-UNK
percentage	B-UNK
FPS	O
and	O
yohimbine	B-CHEMICAL
increased	B-UNK
absolute	B-UNK
FPS	O
values	B-UNK
.	O
Furthermore	O
,	O
yohimbine	B-CHEMICAL
increased	B-UNK
baseline	B-UNK
startle	I-UNK
amplitude	B-UNK
in	O
the	O
LES	O
,	O
while	O
mCPP	O
suppressed	B-UNK
baseline	B-UNK
startle	I-UNK
in	O
both	O
the	O
LES	O
and	O
FPS	O
and	O
PTZ	O
suppressed	B-UNK
baseline	B-UNK
startle	I-UNK
in	O
the	O
FPS	O
.	O
CONCLUSIONS	O
:	O
In	O
contrast	B-UNK
to	O
findings	B-UNK
in	O
the	O
FPS	O
paradigm	B-UNK
,	O
none	O
of	O
the	O
drugs	B-UNK
were	O
able	O
to	O
exacerbate	O
the	O
LES	O
response	B-UNK
.	O
Thus	O
,	O
a	O
clear	B-UNK
pharmacological	B-UNK
differentiation	B-UNK
was	O
found	B-UNK
between	O
LES	O
and	O
FPS	O
.	O

Proteinase	O
3-antineutrophil	O
cytoplasmic	B-UNK
antibody-(PR3-ANCA	O
)	O
positive	B-UNK
necrotizing	B-UNK
glomerulonephritis	B-DISEASE
after	O
restarting	O
sulphasalazine	B-UNK
treatment	B-UNK
.	O

A	O
59-year	O
-	O
old	B-UNK
woman	B-UNK
with	O
ulcerative	B-DISEASE
colitis	I-DISEASE
developed	B-UNK
red	O
eyes	B-UNK
,	O
pleural	B-DISEASE
effusion	I-DISEASE
,	O
eosinophilia	B-DISEASE
and	O
urinary	B-UNK
abnormalities	B-DISEASE
after	O
restarting	O
of	O
sulphasalazine	B-UNK
treatment	B-UNK
.	O
Light	B-UNK
microscopy	B-UNK
of	O
a	O
kidney	B-UNK
biopsy	B-UNK
revealed	B-UNK
segmental	O
necrotizing	B-UNK
glomerulonephritis	B-DISEASE
without	O
deposition	O
of	O
immunoglobulin	O
or	O
complement	B-UNK
.	O
Proteinase	O
3-antineutrophil	O
cytoplasmic	B-UNK
antibody	B-UNK
(	O
PR3-ANCA	B-UNK
)	O
titer	B-UNK
was	O
elevated	B-UNK
at	B-DISEASE
183	O
ELISA	O
units	B-UNK
(	O
EU	O
)	O
in	O
sera	O
(	O
normal	B-UNK
range	B-UNK
less	O
than	O
10	O
EU	O
)	O
,	O
myeloperoxidase	O
-	O
ANCA	O
was	O
negative	B-UNK
.	O
PR3-ANCA	B-UNK
titer	B-UNK
was	O
250	O
and	O
1,070	O
EU	O
in	O
pleural	O
effusions	O
on	O
right	B-UNK
and	O
left	B-UNK
side	O
,	O
respectively	O
.	O
Although	O
cessation	B-UNK
of	O
sulphasalazine	B-UNK
treatment	B-UNK
resulted	B-UNK
in	O
improvements	B-UNK
in	O
fever	B-DISEASE
,	O
red	O
eyes	B-UNK
,	O
chest	B-DISEASE
pain	I-DISEASE
,	O
titer	B-UNK
of	O
C	B-UNK
-	O
reactive	B-UNK
protein	B-UNK
and	O
volume	B-UNK
of	O
the	O
pleural	O
effusions	O
,	O
we	O
initiated	O
steroid	B-UNK
therapy	B-UNK
,	O
because	O
PR3-ANCA	B-UNK
titer	B-UNK
rose	B-UNK
to	O
320	O
EU	O
,	O
eosinophil	O
count	B-UNK
increased	B-UNK
to	O
1,100	O
cells	B-UNK
/	O
microl	B-UNK
,	O
and	O
the	O
pleural	B-DISEASE
effusion	I-DISEASE
remained	B-UNK
.	O
One	O
month	O
after	O
steroid	B-UNK
therapy	B-UNK
,	O
the	O
pleural	B-DISEASE
effusion	I-DISEASE
disappeared	B-UNK
,	O
and	O
PR3-ANCA	B-UNK
titer	B-UNK
normalized	B-UNK
3	O
months	B-UNK
later	B-UNK
.	O
This	O
case	B-UNK
suggests	B-UNK
that	O
sulphasalazine	B-UNK
can	O
induce	B-UNK
PR3-ANCA	B-UNK
-	O
positive	B-UNK
necrotizing	B-UNK
glomerulonephritis	B-DISEASE
.	O

Is	O
phenytoin	B-CHEMICAL
administration	B-UNK
safe	B-UNK
in	O
a	O
hypothermic	O
child	B-UNK
?	O

A	O
male	B-UNK
neonate	O
with	O
a	O
Chiari	O
malformation	O
and	O
a	O
leaking	O
myelomeningocoele	O
underwent	B-UNK
ventriculoperitoneal	O
shunt	O
insertion	B-UNK
followed	B-UNK
by	O
repair	O
of	O
myelomeningocoele	O
.	O
During	O
anaesthesia	B-UNK
and	O
surgery	B-UNK
,	O
he	O
inadvertently	O
became	O
moderately	O
hypothermic	O
.	O
Intravenous	B-UNK
phenytoin	B-CHEMICAL
was	O
administered	B-UNK
during	O
the	O
later	B-UNK
part	O
of	O
the	O
surgery	B-UNK
for	O
seizure	B-UNK
prophylaxis	B-UNK
.	O
Following	O
phenytoin	B-CHEMICAL
administration	B-UNK
,	O
the	O
patient	B-UNK
developed	I-UNK
acute	B-UNK
severe	B-UNK
bradycardia	B-DISEASE
,	O
refractory	B-UNK
to	O
atropine	B-CHEMICAL
and	O
adrenaline	O
.	O
The	O
cardiac	B-UNK
depressant	B-UNK
actions	B-UNK
of	O
phenytoin	B-CHEMICAL
and	O
hypothermia	B-DISEASE
can	O
be	O
additive	O
.	O
Administration	B-UNK
of	O
phenytoin	B-CHEMICAL
in	O
the	O
presence	O
of	O
hypothermia	B-DISEASE
may	O
lead	B-CHEMICAL
to	O
an	O
adverse	B-UNK
cardiac	B-UNK
event	B-UNK
in	O
children	B-UNK
.	O
As	O
phenytoin	B-CHEMICAL
is	O
a	O
commonly	B-UNK
used	O
drug	B-UNK
,	O
clinicians	O
need	B-UNK
to	O
be	O
aware	O
of	O
this	O
interaction	B-UNK
.	O

Amisulpride	O
related	B-UNK
tic	O
-	O
like	B-UNK
symptoms	B-UNK
in	O
an	O
adolescent	O
schizophrenic	B-UNK
.	O

Tic	O
disorders	B-UNK
can	O
be	O
effectively	O
treated	B-UNK
by	O
atypical	B-UNK
antipsychotics	B-UNK
such	O
as	O
risperidone	B-CHEMICAL
,	O
olanzapine	B-CHEMICAL
and	O
ziprasidone	B-CHEMICAL
.	O
However	O
,	O
there	O
are	O
two	O
case	B-UNK
reports	B-UNK
that	O
show	O
tic	O
-	O
like	B-UNK
symptoms	B-UNK
,	O
including	B-UNK
motor	B-UNK
and	O
phonic	O
variants	B-UNK
,	O
occurring	B-UNK
during	O
treatment	B-UNK
with	O
quetiapine	B-UNK
or	O
clozapine	B-CHEMICAL
.	O
We	O
present	B-UNK
a	O
15-year	O
-	O
old	B-UNK
girl	O
schizophrenic	B-UNK
who	O
developed	B-UNK
frequent	B-UNK
involuntary	B-UNK
eye	B-UNK
-	O
blinking	O
movements	B-UNK
after	O
5	O
months	B-UNK
of	O
amisulpride	B-CHEMICAL
treatment	B-UNK
(	O
1000	O
mg	B-UNK
per	O
day	B-UNK
)	O
.	O
The	O
tic	O
-	O
like	B-UNK
symptoms	B-UNK
resolved	B-UNK
completely	B-UNK
after	O
we	O
reduced	B-UNK
the	O
dose	B-UNK
of	O
amisulpride	B-CHEMICAL
down	O
to	O
800	O
mg	B-UNK
per	O
day	B-UNK
.	O
However	O
,	O
her	O
psychosis	B-UNK
recurred	O
after	O
the	O
dose	B-UNK
reduction	B-UNK
.	O
We	O
then	O
placed	O
her	O
on	O
an	O
additional	B-UNK
100	O
mg	B-UNK
per	O
day	B-UNK
of	O
quetiapine	B-UNK
.	O
She	O
has	O
been	O
in	O
complete	B-UNK
remission	B-DISEASE
under	O
the	O
combined	B-UNK
medications	B-UNK
for	O
more	O
than	O
one	O
year	B-UNK
and	O
maintains	O
a	O
fair	O
role	B-UNK
function	B-UNK
.	O
No	O
more	O
tic	O
-	O
like	B-UNK
symptoms	B-UNK
or	O
other	O
side	O
effects	B-UNK
have	O
been	O
reported	B-UNK
.	O
Together	O
with	O
previously	B-UNK
reported	B-UNK
cases	B-UNK
,	O
our	O
patient	B-UNK
suggests	B-UNK
that	O
tic	O
-	O
like	B-UNK
symptoms	B-UNK
might	O
occur	O
in	O
certain	B-UNK
vulnerable	O
individuals	B-UNK
during	O
treatment	B-UNK
with	O
atypical	B-UNK
antipsychotics	B-UNK
such	O
as	O
quetiapine	B-UNK
,	O
clozapine	B-CHEMICAL
,	O
or	O
amisulpride	B-CHEMICAL
.	O

Comparison	O
of	O
developmental	B-UNK
toxicology	O
of	O
aspirin	B-CHEMICAL
(	O
acetylsalicylic	B-UNK
acid	B-UNK
)	O
in	O
rats	B-UNK
using	O
selected	O
dosing	B-UNK
paradigms	O
.	O

BACKGROUND	O
:	O
Analysis	O
of	O
the	O
literature	B-UNK
for	O
nonsteroidal	B-UNK
anti-inflammatory	I-UNK
drugs	B-UNK
(	O
NSAIDs	B-UNK
)	O
suggests	B-UNK
that	O
a	O
low	B-UNK
incidence	B-UNK
of	O
developmental	B-UNK
anomalies	B-UNK
occurs	B-UNK
in	O
rats	B-UNK
given	I-UNK
NSAIDs	B-UNK
on	O
specific	B-UNK
days	B-UNK
during	O
organogenesis	O
.	O
Aspirin	O
(	O
acetylsalicylic	B-UNK
acid	B-UNK
[	O
ASA	B-UNK
]	O
)	O
,	O
an	O
irreversible	B-UNK
cyclooxygenase	O
1	O
and	O
2	B-DISEASE
inhibitor	B-UNK
,	O
induces	B-UNK
developmental	B-UNK
anomalies	B-UNK
when	O
administered	B-UNK
to	O
Wistar	B-UNK
rats	I-UNK
on	O
gestational	O
day	B-UNK
(	O
GD	O
)	O
9	O
,	O
10	O
,	O
or	O
11	O
(	O
Kimmel	O
CA	O
,	O
Wilson	O
JG	O
,	O
Schumacher	O
HJ	O
.	O
Teratology	O
4:15	O
-	O
24	O
,	O
1971	O
)	O
.	O
There	O
are	O
no	O
published	B-UNK
ASA	B-UNK
studies	B-UNK
using	O
the	O
multiple	B-UNK
dosing	B-UNK
paradigm	B-UNK
of	O
GDs	O
6	O
to	O
17	B-DISEASE
.	O
Objectives	O
of	O
the	O
current	B-UNK
study	B-UNK
were	O
to	O
compare	O
results	B-UNK
between	O
Sprague	B-UNK
-	O
Dawley	B-UNK
(	O
SD	B-UNK
)	O
and	O
Wistar	B-UNK
strains	O
when	O
ASA	B-UNK
is	O
administered	B-UNK
on	O
GD	O
9	O
,	O
10	O
,	O
or	O
11	O
;	O
to	O
compare	O
the	O
malformation	O
patterns	B-UNK
following	B-UNK
single	B-UNK
and	O
multiple	B-UNK
dosings	O
during	O
organogenesis	O
in	O
SD	B-UNK
rats	B-UNK
;	O
and	O
to	O
test	B-UNK
the	O
hypothesis	O
that	O
maternal	B-UNK
gastrointestinal	B-UNK
toxicity	B-UNK
confounds	O
the	O
detection	O
of	O
low	B-UNK
incidence	B-UNK
malformations	O
with	O
ASA	B-UNK
when	O
a	O
multiple	B-UNK
dosing	B-UNK
paradigm	B-UNK
is	O
used	O
.	O
METHODS	O
:	O
ASA	B-UNK
was	O
administered	B-UNK
as	O
a	O
single	B-UNK
dose	B-UNK
on	O
GD	O
9	O
(	O
0	O
,	O
250	O
,	O
500	O
,	O
or	O
625	O
mg	B-UNK
/	O
kg	B-UNK
)	O
,	O
10	O
(	O
0	O
,	O
500	O
,	O
625	O
,	O
or	O
750	O
mg	B-UNK
/	O
kg	B-UNK
)	O
,	O
or	O
11	O
(	O
0	O
,	O
500	O
,	O
750	O
,	O
or	O
1000	O
mg	B-UNK
/	O
kg	B-UNK
)	O
and	O
from	O
GD	O
6	O
to	O
GD	O
17	B-DISEASE
(	O
0	O
,	O
50	O
,	O
125	O
,	O
or	O
250	O
mg	B-UNK
/	O
kg	B-UNK
a	O
day	B-UNK
)	O
in	O
the	O
multiple	B-UNK
dose	B-UNK
study	B-UNK
to	O
SD	B-UNK
rats	B-UNK
.	O
Animals	O
were	O
killed	O
on	O
GD	O
21	O
,	O
and	O
fetuses	O
were	O
examined	B-UNK
viscerally	O
.	O
RESULTS	B-UNK
:	O
The	O
literature	B-UNK
evaluation	B-UNK
suggested	B-UNK
that	O
NSAIDs	B-UNK
induce	B-UNK
ventricular	B-UNK
septal	O
defects	B-UNK
(	O
VSDs	O
)	O
and	O
midline	B-DISEASE
defects	I-DISEASE
(	O
MDs	O
)	O
in	O
rats	B-UNK
and	O
diaphragmatic	O
hernia	B-DISEASE
(	O
DH	O
)	O
,	O
MDs	O
,	O
and	O
VSDs	O
in	O
rabbits	O
(	O
Cook	O
JC	O
et	O
al	O
.	O
,	O
2003	O
)	O
;	O
hence	O
,	O
the	O
present	B-UNK
study	B-UNK
focused	O
on	O
these	O
malformations	O
,	O
even	O
though	O
ASA	B-UNK
induces	B-UNK
several	O
other	O
low	B-UNK
-	O
incidence	B-UNK
malformations	O
.	O
In	O
single	B-UNK
dose	B-UNK
studies	B-UNK
,	O
DH	O
,	O
MD	O
,	O
and	O
VSD	O
were	O
induced	B-UNK
on	O
GDs	O
9	O
and	O
10	O
.	O
VSD	O
also	O
was	O
noted	O
following	B-UNK
treatment	B-UNK
on	O
GD	O
11	O
.	O
In	O
contrast	B-UNK
,	O
DH	O
and	O
MD	O
were	O
noted	O
in	O
the	O
multiple	B-UNK
dose	B-UNK
study	B-UNK
design	O
only	O
in	O
the	O
high	B-UNK
-	O
dose	B-UNK
group	B-UNK
,	O
and	O
VSD	O
was	O
noted	O
across	O
all	O
dose	B-UNK
groups	B-UNK
.	O
CONCLUSIONS	O
:	O
High	B-UNK
concordance	O
in	O
major	B-UNK
developmental	B-UNK
anomalies	B-UNK
between	O
Wistar	B-UNK
and	O
SD	B-UNK
rats	B-UNK
were	O
noted	O
with	O
the	O
exception	O
of	O
VSD	O
in	O
the	O
SD	B-UNK
rats	B-UNK
and	O
hydrocephalus	B-DISEASE
in	O
the	O
Wistar	B-UNK
rats	I-UNK
.	O
Variations	O
and	O
malformations	O
were	O
similar	B-UNK
when	O
ASA	B-UNK
was	O
administered	B-UNK
as	O
a	O
single	B-UNK
dose	B-UNK
or	O
during	O
the	O
period	B-UNK
of	O
organogenesis	O
(	O
GDs	O
6	O
to	O
17	B-DISEASE
)	O
.	O
It	O
was	O
also	O
evident	O
that	O
,	O
by	O
titrating	O
the	O
dose	B-UNK
to	O
achieve	O
a	O
maximum	B-UNK
tolerated	B-UNK
dose	B-UNK
,	O
malformations	O
that	O
normally	O
occur	O
at	B-DISEASE
low	B-UNK
incidence	B-UNK
,	O
as	O
reported	B-UNK
from	O
previous	B-UNK
single	B-UNK
dose	B-UNK
studies	B-UNK
,	O
could	O
also	O
be	O
induced	B-UNK
with	O
ASA	B-UNK
given	B-UNK
at	B-DISEASE
multiple	B-UNK
doses	B-UNK
.	O

Torsade	O
de	B-UNK
pointes	O
induced	B-UNK
by	O
metoclopramide	B-CHEMICAL
in	O
an	O
elderly	B-UNK
woman	B-UNK
with	O
preexisting	O
complete	B-UNK
left	B-UNK
bundle	B-DISEASE
branch	I-DISEASE
block	I-DISEASE
.	O

There	O
is	O
a	O
growing	O
list	O
of	O
drugs	B-UNK
implicated	B-UNK
in	O
acquired	B-UNK
long	B-UNK
QT	B-UNK
syndrome	B-UNK
and	O
torsade	B-UNK
de	B-UNK
pointes	O
.	O
However	O
,	O
the	O
torsadogenic	O
potential	B-UNK
of	O
metoclopramide	B-CHEMICAL
,	O
a	O
commonly	B-UNK
used	O
antiemetic	O
and	O
prokinetic	O
drug	B-UNK
,	O
has	O
not	O
been	O
reported	B-UNK
in	O
the	O
literature	B-UNK
,	O
despite	B-UNK
its	O
chemical	B-UNK
similarity	O
to	O
procainamide	B-CHEMICAL
.	O
We	O
report	B-UNK
on	O
a	O
92-year	O
-	O
old	B-UNK
woman	B-UNK
with	O
preexisting	O
complete	B-UNK
left	B-UNK
bundle	B-DISEASE
branch	I-DISEASE
block	I-DISEASE
who	O
developed	B-UNK
torsade	B-UNK
de	B-UNK
pointes	O
after	O
intravenous	B-UNK
and	O
oral	B-UNK
administration	B-UNK
of	O
metoclopramide	B-CHEMICAL
.	O
This	O
patient	B-UNK
also	O
developed	B-UNK
torsade	B-UNK
de	B-UNK
pointes	O
when	O
cisapride	B-CHEMICAL
and	O
erythromycin	B-CHEMICAL
were	O
given	B-UNK
simultaneously	B-UNK
.	O
These	O
two	O
episodes	B-UNK
were	O
suppressed	B-UNK
successfully	B-UNK
after	O
discontinuing	O
the	O
offending	O
drugs	B-UNK
and	O
administering	O
class	O
IB	O
drugs	B-UNK
.	O
This	O
is	O
the	O
first	O
documentation	O
that	O
metoclopramide	B-CHEMICAL
provokes	O
torsade	B-UNK
de	B-UNK
pointes	O
clinically	B-UNK
.	O
Metoclopramide	O
should	O
be	O
used	O
cautiously	O
in	O
patients	B-UNK
with	O
a	O
risk	B-UNK
of	O
torsade	B-UNK
de	B-UNK
pointes	O
.	O

Apomorphine	O
:	O
an	O
underutilized	O
therapy	B-UNK
for	O
Parkinson'	O
s	O
disease	B-DISEASE
.	O

Apomorphine	O
was	O
the	O
first	O
dopaminergic	B-UNK
drug	B-UNK
ever	O
used	O
to	O
treat	O
symptoms	B-UNK
of	O
Parkinson'	O
s	O
disease	B-DISEASE
.	O
While	O
powerful	O
antiparkinsonian	B-UNK
effects	B-UNK
had	O
been	O
observed	B-UNK
as	O
early	B-UNK
as	O
1951	O
,	O
the	O
potential	B-UNK
of	O
treating	B-UNK
fluctuating	O
Parkinson'	O
s	O
disease	B-DISEASE
by	O
subcutaneous	B-UNK
administration	B-UNK
of	O
apomorphine	B-CHEMICAL
has	O
only	O
recently	B-UNK
become	O
the	O
subject	B-UNK
of	O
systematic	O
study	B-UNK
.	O
A	O
number	B-UNK
of	O
small	B-UNK
scale	B-UNK
clinical	B-UNK
trials	B-UNK
have	O
unequivocally	O
shown	B-UNK
that	O
intermittent	B-UNK
subcutaneous	B-UNK
apomorphine	B-CHEMICAL
injections	B-UNK
produce	B-UNK
antiparkinsonian	B-UNK
benefit	B-UNK
close	O
if	O
not	O
identical	B-UNK
to	O
that	O
seen	B-UNK
with	O
levodopa	B-CHEMICAL
and	O
that	O
apomorphine	B-CHEMICAL
rescue	O
injections	B-UNK
can	O
reliably	B-UNK
revert	O
off	O
-	O
periods	B-UNK
even	O
in	O
patients	B-UNK
with	O
complex	B-UNK
on	O
-	O
off	O
motor	B-UNK
swings	O
.	O
Continuous	B-UNK
subcutaneous	B-UNK
apomorphine	B-CHEMICAL
infusions	O
can	O
reduce	B-UNK
daily	B-UNK
off	O
-	O
time	B-UNK
by	O
more	O
than	O
50	O
%	O
in	O
this	O
group	B-UNK
of	O
patients	B-UNK
,	O
which	O
appears	B-UNK
to	O
be	O
a	O
stronger	B-UNK
effect	B-UNK
than	O
that	O
generally	B-UNK
seen	B-UNK
with	O
add	O
-on	O
therapy	B-UNK
with	O
oral	B-UNK
dopamine	B-CHEMICAL
agonists	I-CHEMICAL
or	O
COMT	O
inhibitors	B-UNK
.	O
Extended	O
follow	B-UNK
-	O
up	O
studies	B-UNK
of	O
up	O
to	O
8	O
years	B-UNK
have	O
demonstrated	B-UNK
long	B-UNK
-	O
term	B-UNK
persistence	O
of	O
apomorphine	B-CHEMICAL
efficacy	B-UNK
.	O
In	O
addition	O
,	O
there	O
is	O
convincing	O
clinical	B-UNK
evidence	B-UNK
that	O
monotherapy	B-UNK
with	O
continuous	B-UNK
subcutaneous	B-UNK
apomorphine	B-CHEMICAL
infusions	O
is	O
associated	B-UNK
with	O
marked	B-UNK
reductions	O
of	O
preexisting	O
levodopa	B-CHEMICAL
-	O
induced	B-UNK
dyskinesias	B-DISEASE
.	O
The	O
main	B-UNK
side	O
effects	B-UNK
of	O
subcutaneous	B-UNK
apomorphine	B-CHEMICAL
treatment	B-UNK
are	O
related	B-UNK
to	O
cutaneous	B-UNK
tolerability	B-UNK
problems	O
,	O
whereas	O
sedation	B-UNK
and	O
psychiatric	B-UNK
complications	B-UNK
play	B-UNK
a	O
lesser	B-UNK
role	B-UNK
.	O
Given	O
the	O
marked	B-UNK
degree	B-UNK
of	O
efficacy	B-UNK
of	O
subcutaneous	B-UNK
apomorphine	B-CHEMICAL
treatment	B-UNK
in	O
fluctuating	O
Parkinson'	O
s	O
disease	B-DISEASE
,	O
this	O
approach	B-UNK
seems	O
to	O
deserve	O
more	O
widespread	O
clinical	B-UNK
use	B-UNK
.	O

Fatal	B-UNK
excited	O
delirium	B-DISEASE
following	B-UNK
cocaine	B-CHEMICAL
use	B-UNK
:	O
epidemiologic	B-UNK
findings	B-UNK
provide	B-UNK
new	B-UNK
evidence	B-UNK
for	O
mechanisms	B-UNK
of	O
cocaine	B-CHEMICAL
toxicity	B-UNK
.	O

We	O
describe	O
an	O
outbreak	O
of	O
deaths	O
from	O
cocaine	B-CHEMICAL
-	O
induced	B-UNK
excited	O
delirium	B-DISEASE
(	O
EDDs	O
)	O
in	O
Dade	O
County	O
,	O
Florida	O
between	O
1979	O
and	O
1990	O
.	O
From	O
a	O
registry	O
of	O
all	O
cocaine	B-CHEMICAL
-	O
related	B-UNK
deaths	O
in	O
Dade	O
County	O
,	O
Florida	O
,	O
from	O
1969	O
-	O
1990	O
,	O
58	O
EDDs	O
were	O
compared	B-UNK
with	O
125	O
victims	O
of	O
accidental	O
cocaine	B-CHEMICAL
overdose	B-UNK
without	O
excited	O
delirium	B-DISEASE
.	O
Compared	O
with	O
controls	B-UNK
,	O
EDDs	O
were	O
more	O
frequently	B-UNK
black	O
,	O
male	B-UNK
,	O
and	O
younger	O
.	O
They	O
were	O
less	O
likely	B-UNK
to	O
have	O
a	O
low	B-UNK
body	B-UNK
mass	B-UNK
index	B-UNK
,	O
and	O
more	O
likely	B-UNK
to	O
have	O
died	B-UNK
in	O
police	O
custody	O
,	O
to	O
have	O
received	B-UNK
medical	B-UNK
treatment	B-UNK
immediately	B-UNK
before	O
death	B-DISEASE
,	O
to	O
have	O
survived	O
for	O
a	O
longer	B-UNK
period	B-UNK
,	O
to	O
have	O
developed	B-UNK
hyperthermia	B-DISEASE
,	O
and	O
to	O
have	O
died	B-UNK
in	O
summer	O
months	B-UNK
.	O
EDDs	O
had	O
concentrations	B-UNK
of	O
cocaine	B-CHEMICAL
and	O
benzoylecgonine	B-CHEMICAL
in	O
autopsy	O
blood	B-UNK
that	O
were	O
similar	B-UNK
to	O
those	O
for	O
controls	B-UNK
.	O
The	O
epidemiologic	B-UNK
findings	B-UNK
are	O
most	O
consistent	B-UNK
with	O
the	O
hypothesis	O
that	O
chronic	B-UNK
cocaine	B-CHEMICAL
use	B-UNK
disrupts	O
dopaminergic	B-UNK
function	B-UNK
and	O
,	O
when	O
coupled	O
with	O
recent	B-UNK
cocaine	B-CHEMICAL
use	B-UNK
,	O
may	O
precipitate	O
agitation	O
,	O
delirium	B-DISEASE
,	O
aberrant	B-UNK
thermoregulation	O
,	O
rhabdomyolysis	B-DISEASE
,	O
and	O
sudden	B-UNK
death	B-DISEASE
.	O

Heparin	O
-	O
induced	B-UNK
thrombocytopenia	B-DISEASE
,	O
thrombosis	B-DISEASE
,	O
and	O
hemorrhage	B-DISEASE
.	O

Sixty	O
-	O
two	O
patients	B-UNK
with	O
a	O
heparin	B-CHEMICAL
-	O
induced	B-UNK
thrombocytopenia	B-DISEASE
are	O
reported	B-UNK
.	O
Clinical	B-UNK
manifestations	B-UNK
of	O
this	O
disorder	B-UNK
include	B-UNK
hemorrhage	B-DISEASE
or	O
,	O
more	O
frequently	B-UNK
,	O
thromboembolic	B-UNK
events	B-UNK
in	O
patients	B-UNK
receiving	B-UNK
heparin	B-CHEMICAL
.	O
Laboratory	B-UNK
testing	B-UNK
has	O
revealed	B-UNK
a	O
falling	O
platelet	B-UNK
count	I-UNK
,	O
increased	B-UNK
resistance	B-UNK
to	O
heparin	B-CHEMICAL
,	O
and	O
aggregation	O
of	O
platelets	O
by	O
the	O
patient'	O
s	O
plasma	B-UNK
when	O
heparin	B-CHEMICAL
is	O
added	O
.	O
Immunologic	O
testing	B-UNK
has	O
demonstrated	B-UNK
the	O
presence	O
of	O
a	O
heparin	B-CHEMICAL
-	O
dependent	B-UNK
platelet	B-UNK
membrane	O
antibody	B-UNK
.	O
The	O
20	O
deaths	O
,	O
52	O
hemorrhagic	B-UNK
and	O
thromboembolic	B-UNK
complications	B-UNK
,	O
and	O
21	O
surgical	B-UNK
procedures	B-UNK
to	O
manage	O
the	O
complications	B-UNK
confirm	B-UNK
the	O
seriousness	O
of	O
the	O
disorder	B-UNK
.	O
Specific	O
risk	B-UNK
factors	I-UNK
have	O
not	O
been	O
identified	B-UNK
;	O
therefore	O
,	O
all	O
patients	B-UNK
receiving	B-UNK
heparin	B-CHEMICAL
should	O
be	O
monitored	B-UNK
.	O
If	O
the	O
platelet	B-UNK
count	I-UNK
falls	O
to	O
less	O
than	O
100,000	O
/	O
mm3	O
,	O
while	O
the	O
patient	B-UNK
is	O
receiving	B-UNK
heparin	B-CHEMICAL
,	O
platelet	B-DISEASE
aggregation	I-DISEASE
testing	B-UNK
,	O
using	O
the	O
patient'	O
s	O
plasma	B-UNK
,	O
is	O
indicated	B-UNK
.	O
Management	O
consists	B-UNK
of	O
cessation	B-UNK
of	O
heparin	B-CHEMICAL
,	O
platelet	B-UNK
anti-aggregating	O
agents	B-UNK
,	O
and	O
alternate	B-UNK
forms	O
of	O
anticoagulation	B-UNK
when	O
indicated	B-UNK
.	O

Cardiac	B-UNK
toxicity	B-UNK
of	O
5-fluorouracil	B-UNK
.	O
Report	O
of	O
a	O
case	B-UNK
of	O
spontaneous	B-UNK
angina	B-DISEASE
.	O

We	O
report	B-UNK
a	O
case	B-UNK
of	O
a	O
patient	B-UNK
with	O
colon	O
carcinoma	B-DISEASE
and	O
liver	B-DISEASE
metastasis	O
who	O
presented	B-UNK
chest	B-DISEASE
pain	I-DISEASE
after	O
5-fluorouracil	B-UNK
(	O
5-FU	O
)	O
administration	B-UNK
.	O
Clinical	B-UNK
electrocardiographic	B-UNK
evolution	O
was	O
similar	B-UNK
to	O
that	O
observed	B-UNK
in	O
Prinzmetal'	O
s	O
angina	B-DISEASE
,	O
and	O
chest	B-DISEASE
pain	I-DISEASE
promptly	B-UNK
resolved	B-UNK
with	O
nifedipine	B-CHEMICAL
.	O
These	O
data	B-UNK
suggest	B-UNK
that	O
coronary	B-UNK
spasm	B-DISEASE
may	O
be	O
the	O
cause	B-UNK
of	O
cardiotoxicity	B-DISEASE
due	O
to	O
5-FU	O
,	O
and	O
that	O
calcium	B-CHEMICAL
antagonists	B-UNK
may	O
probably	B-UNK
be	O
used	O
in	O
the	O
prevention	O
or	O
treatment	B-UNK
of	O
5-FU	O
cardiotoxicity	B-DISEASE
.	O

Toxicity	O
due	O
to	O
remission	B-DISEASE
inducing	B-UNK
drugs	B-UNK
in	O
rheumatoid	B-DISEASE
arthritis	I-DISEASE
.	O
Association	O
with	O
HLA	O
-	O
B35	O
and	O
Cw4	O
antigens	B-CHEMICAL
.	O

Twenty	O
-	O
five	O
patients	B-UNK
with	O
rheumatoid	B-DISEASE
arthritis	I-DISEASE
(	O
RA	B-UNK
)	O
who	O
developed	B-UNK
toxicity	B-UNK
while	O
taking	B-UNK
remission	B-DISEASE
inducing	B-UNK
drugs	B-UNK
and	O
30	O
without	O
toxicity	B-UNK
were	O
studied	B-UNK
for	O
possible	B-UNK
associations	O
with	O
class	O
I	O
and	O
II	B-UNK
HLA	O
antigens	B-CHEMICAL
.	O
A	O
strong	B-UNK
association	B-UNK
has	O
been	O
found	B-UNK
between	O
nephritis	B-DISEASE
and	O
dermatitis	B-DISEASE
due	O
to	O
Tiopronin	O
(	O
a	O
D	B-UNK
-	O
Penicillamine	O
like	B-UNK
compound	B-UNK
)	O
and	O
class	O
I	O
antigens	B-CHEMICAL
B35-Cw4	O
,	O
and	O
between	O
dermatitis	B-DISEASE
due	O
to	O
gold	B-CHEMICAL
thiosulphate	O
and	O
B35	O
.	O
Compared	O
to	O
healthy	B-UNK
controls	B-UNK
a	O
lower	B-UNK
DR5	O
frequency	B-UNK
was	O
observed	B-UNK
in	O
patients	B-UNK
with	O
RA	B-UNK
except	O
for	O
the	O
Tiopronin	O
related	B-UNK
nephritis	B-DISEASE
group	B-UNK
.	O

Transient	O
hemiparesis	O
:	O
a	O
rare	B-UNK
manifestation	B-UNK
of	O
diphenylhydantoin	B-DISEASE
toxicity	B-UNK
.	O
Report	O
of	O
two	O
cases	B-UNK
.	O

Among	O
the	O
common	B-UNK
side	O
effects	B-UNK
of	O
diphenylhydantoin	B-DISEASE
(	O
DPH	B-UNK
)	O
overdose	B-UNK
,	O
the	O
most	O
frequently	B-UNK
encountered	B-UNK
neurological	B-UNK
signs	B-UNK
are	O
those	O
of	O
cerebellar	B-UNK
dysfunction	B-UNK
.	O
Very	O
rarely	B-UNK
,	O
the	O
toxic	B-UNK
neurological	B-UNK
manifestations	B-UNK
of	O
this	O
drug	B-UNK
are	O
of	O
cerebral	B-UNK
origin	B-UNK
.	O
Two	O
patients	B-UNK
are	O
presented	B-UNK
who	O
suffered	O
progressive	B-UNK
hemiparesis	O
due	O
to	O
DPH	B-UNK
overdose	B-UNK
.	O
Both	O
had	O
brain	B-UNK
surgery	B-UNK
before	O
DPH	B-UNK
treatment	B-UNK
.	O
It	O
is	O
assumed	O
that	O
patients	B-UNK
with	O
some	O
cerebral	B-UNK
damage	B-UNK
are	O
liable	O
to	O
manifest	O
DPH	B-UNK
toxicity	B-UNK
as	O
focal	B-UNK
neurological	B-UNK
signs	B-UNK
.	O

Nerve	O
growth	B-UNK
factor	B-UNK
and	O
prostaglandins	B-CHEMICAL
in	O
the	O
urine	B-DISEASE
of	O
female	B-UNK
patients	B-UNK
with	O
overactive	B-DISEASE
bladder	I-DISEASE
.	O

PURPOSE	O
:	O
NGF	B-UNK
and	O
PGs	O
in	O
the	O
bladder	B-UNK
can	O
be	O
affected	B-UNK
by	O
pathological	B-UNK
changes	B-UNK
in	O
the	O
bladder	B-UNK
and	O
these	O
changes	B-UNK
can	O
be	O
detected	B-UNK
in	O
urine	B-DISEASE
.	O
We	O
investigated	B-UNK
changes	B-UNK
in	O
urinary	B-UNK
NGF	B-UNK
and	O
PGs	O
in	O
women	B-UNK
with	O
OAB	B-UNK
.	O
MATERIALS	O
AND	O
METHODS	O
:	O
The	O
study	B-UNK
groups	B-UNK
included	B-UNK
65	O
women	B-UNK
with	O
OAB	B-UNK
and	O
20	O
without	O
bladder	B-UNK
symptoms	B-UNK
who	O
served	O
as	O
controls	B-UNK
.	O
Evaluation	O
included	B-UNK
patient	B-UNK
history	B-UNK
,	O
urinalysis	O
,	O
a	O
voiding	O
diary	O
and	O
urodynamic	B-UNK
studies	B-UNK
.	O
Urine	B-UNK
samples	B-UNK
were	O
collected	B-UNK
.	O
NGF	B-UNK
,	O
PGE2	B-UNK
,	O
PGF2alpha	O
and	O
PGI2	O
were	O
measured	B-UNK
using	O
enzyme	B-UNK
-	O
linked	B-UNK
immunosorbent	O
assay	B-UNK
and	O
compared	B-UNK
between	O
the	O
groups	B-UNK
.	O
In	O
addition	O
,	O
correlations	O
between	O
urinary	B-UNK
NGF	B-UNK
and	O
PG	O
,	O
and	O
urodynamic	B-UNK
parameters	B-UNK
in	O
patients	B-UNK
with	O
OAB	B-UNK
were	O
examined	B-UNK
.	O
RESULTS	B-UNK
:	O
Urinary	B-UNK
NGF	B-UNK
,	O
PGE2	B-UNK
and	O
PGF2alpha	O
were	O
significantly	B-UNK
increased	B-UNK
in	O
patients	B-UNK
with	O
OAB	B-UNK
compared	B-UNK
with	O
controls	B-UNK
(	O
p	B-UNK
<	I-UNK
0.05	O
)	O
.	O
However	O
,	O
urinary	B-UNK
PGI2	O
was	O
not	O
different	B-UNK
between	O
controls	B-UNK
and	O
patients	B-UNK
with	O
OAB	B-UNK
.	O
In	O
patients	B-UNK
with	O
OAB	B-UNK
urinary	B-UNK
PGE2	B-UNK
positively	O
correlated	B-UNK
with	O
volume	B-UNK
at	B-DISEASE
first	O
desire	B-UNK
to	O
void	O
and	O
maximum	B-UNK
cystometric	O
capacity	B-UNK
(	O
p	B-UNK
<	I-UNK
0.05	O
)	O
.	O
Urinary	B-UNK
NGF	B-UNK
,	O
PGF2alpha	O
and	O
PGI2	O
did	O
not	O
correlate	O
with	O
urodynamic	B-UNK
parameters	B-UNK
in	O
patients	B-UNK
with	O
OAB	B-UNK
.	O
CONCLUSIONS	O
:	O
NGF	B-UNK
and	O
PGs	O
have	O
important	B-UNK
roles	O
in	O
the	O
development	B-UNK
of	O
OAB	B-UNK
symptoms	B-UNK
in	O
female	B-UNK
patients	B-UNK
.	O
Urinary	B-UNK
levels	B-UNK
of	O
these	O
factors	B-UNK
may	O
be	O
used	O
as	O
markers	B-UNK
to	O
evaluate	B-UNK
OAB	B-UNK
symptoms	B-UNK
.	O

Acute	B-UNK
low	B-DISEASE
back	I-DISEASE
pain	I-DISEASE
during	O
intravenous	B-UNK
administration	B-UNK
of	O
amiodarone	B-CHEMICAL
:	O
a	O
report	B-UNK
of	O
two	O
cases	B-UNK
.	O

Amiodarone	O
represents	O
an	O
effective	B-UNK
antiarrhythmic	B-UNK
drug	B-UNK
for	O
cardioversion	O
of	O
recent	B-UNK
-	O
onset	B-UNK
atrial	B-DISEASE
fibrillation	I-DISEASE
(	O
AF	B-UNK
)	O
and	O
maintenance	B-UNK
of	O
sinus	B-UNK
rhythm	B-UNK
.	O
We	O
briefly	B-UNK
describe	O
two	O
patients	B-UNK
suffering	O
from	O
recent	B-UNK
-	O
onset	B-UNK
atrial	B-DISEASE
fibrillation	I-DISEASE
,	O
who	O
experienced	B-UNK
an	O
acute	B-UNK
devastating	O
low	B-DISEASE
back	I-DISEASE
pain	I-DISEASE
a	O
few	O
minutes	B-UNK
after	O
initiation	O
of	O
intravenous	B-UNK
amiodarone	B-CHEMICAL
loading	B-UNK
.	O
Notably	O
,	O
this	O
side	O
effect	B-UNK
has	O
not	O
been	O
ever	O
reported	B-UNK
in	O
the	O
medical	B-UNK
literature	B-UNK
.	O
Clinicians	O
should	O
be	O
aware	O
of	O
this	O
reaction	B-UNK
since	O
prompt	B-UNK
termination	O
of	O
parenteral	O
administration	B-UNK
leads	O
to	O
complete	B-UNK
resolution	B-UNK
.	O

Postoperative	O
myalgia	B-DISEASE
after	O
succinylcholine	B-CHEMICAL
:	O
no	O
evidence	B-UNK
for	O
an	O
inflammatory	B-UNK
origin	B-UNK
.	O

A	O
common	B-UNK
side	O
effect	B-UNK
associated	B-UNK
with	O
succinylcholine	B-CHEMICAL
is	O
postoperative	B-UNK
myalgia	B-DISEASE
.	O
The	O
pathogenesis	O
of	O
this	O
myalgia	B-DISEASE
is	O
still	O
unclear	O
;	O
inflammation	B-DISEASE
has	O
been	O
suggested	B-UNK
but	O
without	O
convincing	O
evidence	B-UNK
.	O
We	O
designed	O
the	O
present	B-UNK
study	B-UNK
to	O
investigate	O
whether	O
an	O
inflammatory	B-UNK
reaction	B-UNK
contributes	B-UNK
to	O
this	O
myalgia	B-DISEASE
.	O
The	O
incidence	B-UNK
and	O
severity	B-UNK
of	O
succinylcholine	B-CHEMICAL
-	O
associated	B-UNK
myalgia	B-DISEASE
was	O
determined	O
in	O
64	O
patients	B-UNK
pretreated	B-UNK
with	O
saline	B-UNK
or	O
dexamethasone	B-CHEMICAL
before	O
succinylcholine	B-CHEMICAL
(	O
n	B-UNK
=	O
32	O
for	O
each	O
)	O
.	O
Incidence	O
and	O
severity	B-UNK
of	O
myalgia	B-DISEASE
did	O
not	O
differ	B-UNK
significantly	B-UNK
between	O
the	O
two	O
groups	B-UNK
:	O
15	O
patients	B-UNK
in	O
the	O
dexamethasone	B-CHEMICAL
group	B-UNK
complained	O
of	O
myalgia	B-DISEASE
compared	B-UNK
with	O
18	O
patients	B-UNK
in	O
the	O
saline	B-UNK
group	B-UNK
,	O
and	O
severe	B-UNK
myalgia	B-DISEASE
was	O
reported	B-UNK
by	O
five	O
patients	B-UNK
and	O
three	O
patients	B-UNK
,	O
respectively	O
(	O
not	O
significant	B-UNK
)	O
.	O
At	O
48	O
h	B-UNK
after	O
surgery	B-UNK
,	O
12	O
patients	B-UNK
in	O
both	O
groups	B-UNK
still	O
suffered	O
from	O
myalgia	B-DISEASE
(	O
not	O
significant	B-UNK
)	O
.	O
In	O
addition	O
,	O
interleukin-6	B-CHEMICAL
(	O
IL-6	O
)	O
as	O
an	O
early	B-UNK
marker	B-UNK
of	O
inflammation	B-DISEASE
was	O
assessed	B-UNK
in	O
a	O
subgroup	O
of	O
10	O
patients	B-UNK
pretreated	B-UNK
with	O
saline	B-UNK
.	O
We	O
found	B-UNK
an	O
increase	B-UNK
of	O
IL-6	O
for	O
only	O
three	O
patients	B-UNK
,	O
but	O
only	O
one	O
patient	B-UNK
reported	B-UNK
myalgia	B-DISEASE
;	O
no	O
relationship	B-UNK
between	O
myalgia	B-DISEASE
and	O
the	O
increase	B-UNK
of	O
IL-6	O
was	O
found	B-UNK
.	O
In	O
conclusion	O
,	O
there	O
is	O
no	O
evidence	B-UNK
for	O
an	O
inflammatory	B-UNK
origin	B-UNK
of	O
succinylcholine	B-CHEMICAL
-	O
associated	B-UNK
myalgia	B-DISEASE
.	O
IMPLICATIONS	O
:	O
Administration	B-UNK
of	O
dexamethasone	B-CHEMICAL
before	O
succinylcholine	B-CHEMICAL
was	O
not	O
effective	B-UNK
in	O
decreasing	B-UNK
the	O
incidence	B-UNK
or	O
the	O
severity	B-UNK
of	O
succinylcholine	B-CHEMICAL
-	O
induced	B-UNK
postoperative	B-UNK
myalgia	B-DISEASE
.	O
Furthermore	O
,	O
there	O
was	O
no	O
significant	B-UNK
relationship	B-UNK
between	O
postoperative	B-UNK
myalgia	B-DISEASE
and	O
time	B-UNK
course	B-UNK
of	O
interleukin-6	B-CHEMICAL
concentrations	B-UNK
,	O
a	O
marker	B-UNK
of	O
inflammation	B-DISEASE
.	O
Pretreatment	O
with	O
dexamethasone	B-CHEMICAL
is	O
not	O
justified	O
to	O
prevent	B-UNK
postoperative	B-UNK
myalgia	B-DISEASE
after	O
succinylcholine	B-CHEMICAL
.	O

Levodopa	O
-	O
induced	B-UNK
oromandibular	O
dystonia	B-DISEASE
in	O
progressive	B-DISEASE
supranuclear	I-DISEASE
palsy	I-DISEASE
.	O

Levodopa	O
-	O
induced	B-UNK
dyskinesias	B-DISEASE
have	O
been	O
reported	B-UNK
in	O
Parkinson'	O
s	O
disease	B-DISEASE
and	O
multiple	B-DISEASE
system	I-DISEASE
atrophy	I-DISEASE
.	O
Cranial	O
dystonias	O
are	O
rare	B-UNK
in	O
patients	B-UNK
with	O
progressive	B-DISEASE
supranuclear	I-DISEASE
palsy	I-DISEASE
(	O
PSP	O
)	O
.	O
In	O
this	O
report	B-UNK
we	O
describe	O
an	O
unusual	O
case	B-UNK
of	O
reversible	B-UNK
levodopa	B-CHEMICAL
-	O
induced	B-UNK
Oromandibular	O
dystonia	B-DISEASE
(	O
OMD	O
)	O
in	O
a	O
PSP	O
patient	B-UNK
to	O
highlight	O
the	O
importance	O
of	O
recognizing	O
this	O
drug	B-UNK
related	B-UNK
complication	B-UNK
in	O
the	O
management	B-UNK
of	O
PSP	O
,	O
and	O
discuss	O
the	O
possible	B-UNK
underlying	B-UNK
pathophysiology	O
.	O

Protective	B-UNK
effect	B-UNK
of	O
edaravone	B-CHEMICAL
against	O
streptomycin	B-CHEMICAL
-	O
induced	B-UNK
vestibulotoxicity	O
in	O
the	O
guinea	B-UNK
pig	I-UNK
.	O

This	O
study	B-UNK
investigated	B-UNK
alleviation	O
of	O
streptomycin	B-CHEMICAL
-	O
induced	B-UNK
vestibulotoxicity	O
by	O
edaravone	B-CHEMICAL
in	O
guinea	B-UNK
pigs	B-UNK
.	O
Edaravone	O
,	O
a	O
free	B-UNK
radical	B-UNK
scavenger	O
,	O
has	O
potent	B-UNK
free	B-UNK
radical	B-UNK
quenching	O
action	B-UNK
and	O
is	O
used	O
in	O
clinical	B-UNK
practice	O
to	O
treat	O
cerebral	B-DISEASE
infarction	I-DISEASE
.	O
Streptomycin	O
was	O
administered	B-UNK
to	O
the	O
inner	B-UNK
ear	B-UNK
by	O
osmotic	B-UNK
pump	O
for	O
24	O
h	B-UNK
,	O
and	O
edaravone	B-CHEMICAL
(	O
n=8	O
)	O
or	O
saline	B-UNK
(	O
n=6	O
)	O
was	O
intraperitoneally	B-UNK
injected	B-UNK
once	O
a	O
day	B-UNK
for	O
7	O
days	B-UNK
.	O
We	O
observed	B-UNK
horizontal	O
vestibulo	O
-	O
ocular	B-UNK
reflex	B-DISEASE
as	O
a	O
marker	B-UNK
of	O
postoperative	B-UNK
vestibular	O
function	B-UNK
.	O
Animals	O
injected	B-UNK
with	O
saline	B-UNK
showed	B-UNK
statistically	B-UNK
smaller	B-UNK
gains	O
than	O
those	O
injected	B-UNK
with	O
edaravone	B-CHEMICAL
.	O
These	O
results	B-UNK
suggest	B-UNK
that	O
edaravone	B-CHEMICAL
suppresses	O
streptomycin	B-CHEMICAL
-	O
induced	B-UNK
vestibulotoxicity	O
.	O

Ketamine	B-UNK
in	O
war	O
/	O
tropical	O
surgery	B-UNK
(	O
a	O
final	O
tribute	O
to	O
the	O
racemic	O
mixture	O
)	O
.	O

A	O
technique	B-UNK
of	O
continuous	B-UNK
intravenous	B-UNK
anaesthesia	B-UNK
with	O
ketamine	B-CHEMICAL
was	O
used	O
successfully	B-UNK
during	O
the	O
Somalia	O
civil	O
war	O
in	O
1994	O
and	O
in	O
north	O
Uganda	O
in	O
1999	O
for	O
64	O
operations	O
in	O
62	O
patients	B-UNK
,	O
aged	B-UNK
from	O
6	O
weeks	B-UNK
to	O
70	O
years	B-UNK
,	O
undergoing	B-UNK
limb	B-UNK
and	O
abdominal	B-UNK
surgery	B-UNK
including	B-UNK
caesarian	O
sections	O
and	O
interventions	O
in	O
neonates	O
.	O
Operations	O
lasting	B-UNK
up	O
to	O
2h	O
could	O
be	O
performed	B-UNK
in	O
the	O
absence	B-UNK
of	O
sophisticated	O
equipment	O
such	O
as	O
pulse	B-UNK
oximeters	O
or	O
ventilators	O
in	O
patients	B-UNK
on	O
spontaneous	B-UNK
ventilation	O
breathing	O
air	O
/	O
oxygen	B-CHEMICAL
only	O
.	O
After	O
premedication	O
with	O
diazepam	B-CHEMICAL
,	O
glycopyrrolate	B-CHEMICAL
and	O
local	B-UNK
anaesthesia	B-UNK
,	O
and	O
induction	B-UNK
with	O
standard	B-UNK
doses	B-UNK
of	O
ketamine	B-CHEMICAL
,	O
a	O
maintenance	B-UNK
dose	B-UNK
of	O
10	O
-	O
20	O
microg	B-UNK
/	O
kg	B-UNK
/	O
min	B-UNK
of	O
ketamine	B-CHEMICAL
proved	O
safe	B-UNK
and	O
effective	B-UNK
.	O
Emphasis	O
was	O
placed	O
on	O
bedside	O
clinical	B-UNK
monitoring	B-UNK
,	O
relying	O
heavily	O
on	O
the	O
heart	B-UNK
rate	I-UNK
.	O
Diazepam	O
,	O
unless	O
contraindicated	O
or	O
risky	O
,	O
remains	B-UNK
the	O
only	O
necessary	O
complementary	O
drug	B-UNK
to	O
ketamine	B-CHEMICAL
as	O
it	O
buffers	O
its	O
cardiovascular	B-UNK
response	B-UNK
and	O
decreases	B-UNK
the	O
duration	B-UNK
and	O
intensity	B-UNK
of	O
operative	O
and	O
postoperative	B-UNK
hallucinations	B-DISEASE
.	O
Local	O
anaesthetic	O
blocks	O
were	O
useful	B-UNK
in	O
decreasing	B-UNK
the	O
requirement	O
for	O
postoperative	B-UNK
analgesia	O
.	O
An	O
antisialogue	O
was	O
usually	B-UNK
unnecessary	O
in	O
operations	O
lasting	B-UNK
up	O
to	O
2	B-DISEASE
h	B-UNK
,	O
glycopyrrolate	B-CHEMICAL
being	O
the	O
best	B-UNK
choice	O
for	O
its	O
lowest	O
psychotropic	O
and	O
chronotropic	B-UNK
effects	B-UNK
,	O
especially	B-UNK
in	O
a	O
hot	B-UNK
climate	O
.	O
Experience	O
in	O
war	O
/	O
tropical	O
settings	O
suggests	B-UNK
this	O
technique	B-UNK
could	O
be	O
useful	B-UNK
in	O
civilian	O
contexts	O
such	O
as	O
outdoor	O
life	B-UNK
-	O
saving	O
emergency	B-UNK
surgery	B-UNK
or	O
in	O
mass	B-UNK
casualties	O
where	O
,	O
e.g	O
.	O
amputation	B-DISEASE
and	O
rapid	B-UNK
extrication	O
were	O
required	B-UNK
.	O

Steroid	B-UNK
structure	B-UNK
and	O
pharmacological	B-UNK
properties	B-UNK
determine	B-UNK
the	O
anti-amnesic	O
effects	B-UNK
of	O
pregnenolone	B-CHEMICAL
sulphate	B-UNK
in	O
the	O
passive	B-UNK
avoidance	B-UNK
task	B-UNK
in	O
rats	B-UNK
.	O

Pregnenolone	O
sulphate	B-UNK
(	O
PREGS	B-UNK
)	O
has	O
generated	B-UNK
interest	O
as	O
one	O
of	O
the	O
most	O
potent	B-UNK
memory	B-UNK
-	O
enhancing	B-UNK
neurosteroids	B-CHEMICAL
to	O
be	O
examined	B-UNK
in	O
rodent	O
learning	B-UNK
studies	B-UNK
,	O
with	O
particular	B-UNK
importance	O
in	O
the	O
ageing	O
process	B-UNK
.	O
The	O
mechanism	B-UNK
by	O
which	O
this	O
endogenous	B-UNK
steroid	B-UNK
enhances	O
memory	B-UNK
formation	B-UNK
is	O
hypothesized	O
to	O
involve	B-UNK
actions	B-UNK
on	O
glutamatergic	B-UNK
and	O
GABAergic	B-UNK
systems	B-UNK
.	O
This	O
hypothesis	O
stems	O
from	O
findings	B-UNK
that	O
PREGS	B-UNK
is	O
a	O
potent	B-UNK
positive	B-UNK
modulator	O
of	O
N	B-UNK
-	O
methyl	O
-	O
d	B-UNK
-	O
aspartate	B-UNK
receptors	B-UNK
(	O
NMDARs	O
)	O
and	O
a	O
negative	B-UNK
modulator	O
of	O
gamma	O
-	O
aminobutyric	O
acid(A	O
)	O
receptors	B-UNK
(	O
GABA(A)Rs	O
)	O
.	O
Moreover	O
,	O
PREGS	B-UNK
is	O
able	O
to	O
reverse	B-UNK
the	O
amnesic	O
-	O
like	B-UNK
effects	B-UNK
of	O
NMDAR	O
and	O
GABA(A)R	O
ligands	O
.	O
To	O
investigate	O
this	O
hypothesis	O
,	O
the	O
present	B-UNK
study	B-UNK
in	O
rats	B-UNK
examined	B-UNK
the	O
memory	B-UNK
-	O
altering	O
abilities	O
of	O
structural	B-UNK
analogs	O
of	O
PREGS	B-UNK
,	O
which	O
differ	B-UNK
in	O
their	O
modulation	O
of	O
NMDAR	O
and	O
/	O
or	O
GABA(A)R	O
function	B-UNK
.	O
The	O
analogs	O
tested	B-UNK
were	O
:	O
11-ketopregnenolone	O
sulphate	B-UNK
(	O
an	O
agent	B-UNK
that	O
is	O
inactive	O
at	B-DISEASE
GABA(A)Rs	O
and	O
NMDARs	O
)	O
,	O
epipregnanolone	O
(	O
[	O
3beta	O
-	O
hydroxy-5beta	O
-	O
pregnan-20-one	O
]	O
sulphate	B-UNK
,	O
an	O
inhibitor	B-UNK
of	O
both	O
GABA(A)Rs	O
and	O
NMDARs	O
)	O
,	O
and	O
a	O
newly	B-UNK
synthesized	O
(	O
-	O
)	O
PREGS	B-UNK
enantiomer	O
(	O
which	O
is	O
identical	B-UNK
to	O
PREGS	B-UNK
in	O
effects	B-UNK
on	O
GABA(A)Rs	O
and	O
NMDARs	O
)	O
.	O
The	O
memory	B-UNK
-	O
enhancing	B-UNK
effects	B-UNK
of	O
PREGS	B-UNK
and	O
its	O
analogs	O
were	O
tested	B-UNK
in	O
the	O
passive	B-UNK
avoidance	B-UNK
task	B-UNK
using	O
the	O
model	B-UNK
of	O
scopolamine	B-CHEMICAL
-	O
induced	B-UNK
amnesia	B-DISEASE
.	O
Both	O
PREGS	B-UNK
and	O
its	O
(	O
-	O
)	O
enantiomer	O
blocked	B-UNK
the	O
effects	B-UNK
of	O
scopolamine	B-CHEMICAL
.	O
The	O
results	B-UNK
show	O
that	O
,	O
unlike	O
PREGS	B-UNK
,	O
11-ketopregnenolone	O
sulphate	B-UNK
and	O
epipregnanolone	O
sulphate	B-UNK
failed	B-UNK
to	O
block	B-UNK
the	O
effect	B-UNK
of	O
scopolamine	B-CHEMICAL
,	O
suggesting	B-UNK
that	O
altering	O
the	O
modulation	O
of	O
NMDA	O
receptors	B-UNK
diminishes	O
the	O
memory	B-UNK
-	O
enhancing	B-UNK
effects	B-UNK
of	O
PREGS	B-UNK
.	O
Moreover	O
,	O
enantioselectivity	O
was	O
demonstrated	B-UNK
by	O
the	O
ability	B-UNK
of	O
natural	O
PREGS	B-UNK
to	O
be	O
an	O
order	O
of	O
magnitude	O
more	O
effective	B-UNK
than	O
its	O
synthetic	O
enantiomer	O
in	O
reversing	O
scopolamine	B-CHEMICAL
-	O
induced	B-UNK
amnesia	B-DISEASE
.	O
These	O
results	B-UNK
identify	B-UNK
a	O
novel	B-UNK
neuropharmacological	O
site	B-UNK
for	O
the	O
modulation	O
of	O
memory	B-UNK
processes	B-UNK
by	O
neuroactive	O
steroids	B-CHEMICAL
.	O

Preliminary	B-UNK
efficacy	B-UNK
assessment	B-UNK
of	O
intrathecal	O
injection	B-UNK
of	O
an	O
American	B-UNK
formulation	O
of	O
adenosine	B-CHEMICAL
in	O
humans	O
.	O

BACKGROUND	O
:	O
Preclinical	O
studies	B-UNK
of	O
intrathecal	O
adenosine	B-CHEMICAL
suggest	B-UNK
it	O
may	O
be	O
effective	B-UNK
in	O
the	O
treatment	B-UNK
of	O
acute	B-UNK
and	O
chronic	B-DISEASE
pain	I-DISEASE
in	O
humans	O
,	O
and	O
preliminary	B-UNK
studies	B-UNK
in	O
volunteers	O
and	O
patients	B-UNK
with	O
a	O
Swedish	B-UNK
formulation	O
of	O
adenosine	B-CHEMICAL
suggests	B-UNK
it	O
may	O
be	O
effective	B-UNK
in	O
hypersensitivity	B-DISEASE
states	B-UNK
but	O
not	O
with	O
acute	B-UNK
noxious	B-UNK
stimulation	B-UNK
.	O
The	O
purpose	O
of	O
this	O
study	B-UNK
was	O
to	O
screen	O
for	O
efficacy	B-UNK
of	O
a	O
different	B-UNK
formulation	O
of	O
adenosine	B-CHEMICAL
marketed	O
in	O
the	O
US	O
,	O
using	O
both	O
acute	B-UNK
noxious	B-UNK
stimulation	B-UNK
and	O
capsaicin	B-CHEMICAL
-	O
evoked	O
mechanical	B-UNK
hypersensitivity	B-DISEASE
.	O
METHODS	O
:	O
Following	O
Food	O
and	O
Drug	B-UNK
Administration	B-UNK
and	O
institutional	O
review	B-UNK
board	O
approval	O
and	O
written	O
informed	O
consent	O
,	O
65	O
volunteers	O
were	O
studied	B-UNK
in	O
two	O
trials	B-UNK
:	O
an	O
open	B-UNK
-	O
label	O
,	O
dose	B-UNK
-	O
escalating	O
trial	B-UNK
with	O
intrathecal	O
adenosine	B-CHEMICAL
doses	B-UNK
of	O
0.25	B-UNK
-	O
2.0	B-UNK
mg	B-UNK
and	O
a	O
double-blind	B-UNK
,	O
placebo	B-UNK
-	O
controlled	B-UNK
trial	B-UNK
of	O
adenosine	B-CHEMICAL
,	O
2	B-DISEASE
mg	B-UNK
.	O
Cerebrospinal	O
fluid	B-UNK
was	O
obtained	B-UNK
for	O
pharmacokinetic	B-UNK
analysis	B-UNK
,	O
and	O
pain	B-UNK
ratings	B-UNK
in	O
response	B-UNK
to	O
acute	B-UNK
heat	O
stimuli	O
and	O
areas	B-UNK
of	O
mechanical	B-UNK
hyperalgesia	B-DISEASE
and	O
allodynia	O
after	O
intradermal	O
capsaicin	B-CHEMICAL
injection	B-UNK
were	O
determined	O
.	O
RESULTS	B-UNK
:	O
Adenosine	O
produced	B-UNK
no	O
effect	B-UNK
on	O
pain	B-UNK
report	B-UNK
to	O
acute	B-UNK
noxious	B-UNK
thermal	O
or	O
chemical	B-UNK
stimulation	B-UNK
but	O
reduced	B-UNK
mechanical	B-UNK
hyperalgesia	B-DISEASE
and	O
allodynia	O
from	O
intradermal	O
capsaicin	B-CHEMICAL
injection	B-UNK
for	O
at	B-DISEASE
least	O
24	O
h.	O
In	O
contrast	B-UNK
,	O
residence	O
time	B-UNK
of	O
adenosine	B-CHEMICAL
in	O
cerebrospinal	B-UNK
fluid	B-UNK
was	O
short	B-UNK
(	O
<	O
4	O
h	B-UNK
)	O
.	O
CONCLUSIONS	O
:	O
These	O
results	B-UNK
show	O
selective	B-UNK
inhibition	B-UNK
by	O
intrathecal	O
adenosine	B-CHEMICAL
of	O
hypersensitivity	B-DISEASE
,	O
presumed	O
to	O
reflect	O
central	B-UNK
sensitization	I-UNK
in	O
humans	O
after	O
peripheral	B-UNK
capsaicin	B-CHEMICAL
injection	B-UNK
.	O
The	O
long	B-UNK
-	O
lasting	B-UNK
effect	B-UNK
is	O
consistent	B-UNK
with	O
that	O
observed	B-UNK
in	O
preliminary	B-UNK
reports	B-UNK
of	O
patients	B-UNK
with	O
chronic	B-UNK
neuropathic	O
pain	B-UNK
and	O
is	O
not	O
due	O
to	O
prolonged	B-UNK
residence	O
of	O
adenosine	B-CHEMICAL
in	O
cerebrospinal	B-UNK
fluid	B-UNK
.	O

Effect	O
of	O
lithium	B-CHEMICAL
maintenance	B-UNK
therapy	B-UNK
on	O
thyroid	B-DISEASE
and	O
parathyroid	O
function	B-UNK
.	O

OBJECTIVES	O
:	O
To	O
assess	B-UNK
changes	B-UNK
induced	B-UNK
by	O
lithium	B-CHEMICAL
maintenance	B-UNK
therapy	B-UNK
on	O
the	O
incidence	B-UNK
of	O
thyroid	B-DISEASE
,	O
parathyroid	O
and	O
ion	O
alterations	B-UNK
.	O
These	O
were	O
evaluated	B-UNK
with	O
respect	O
to	O
the	O
duration	B-UNK
of	O
lithium	B-CHEMICAL
therapy	B-UNK
,	O
age	B-UNK
,	O
sex	O
,	O
and	O
family	B-UNK
history	B-UNK
(	O
whether	O
or	O
not	O
the	O
patient	B-UNK
had	O
a	O
first	O
-	O
degree	B-UNK
relative	B-UNK
with	O
thyroid	B-DISEASE
disease	B-DISEASE
)	O
.	O
DESIGN	B-UNK
:	O
Prospective	O
study	B-UNK
.	O
SETTING	O
:	O
Affective	O
Disorders	B-UNK
Clinic	B-UNK
at	B-DISEASE
St.	B-UNK
Mary'	O
s	O
Hospital	O
,	O
Montreal	O
.	O
PATIENTS	O
:	O
One	O
hundred	O
and	O
one	O
patients	B-UNK
(	O
28	O
men	O
and	O
73	O
women	B-UNK
)	O
with	O
bipolar	B-DISEASE
disorder	I-DISEASE
receiving	B-UNK
lithium	B-CHEMICAL
maintenance	B-UNK
therapy	B-UNK
ranging	O
from	O
1	O
year'	O
s	O
to	O
32	O
years	B-UNK
'	O
duration	B-UNK
.	O
The	O
control	B-UNK
group	B-UNK
consisted	B-UNK
of	O
82	O
patients	B-UNK
with	O
no	O
psychiatric	B-UNK
or	O
endocrinological	O
diagnoses	O
from	O
the	O
hospital'	O
s	O
out	O
-	O
patient	B-UNK
clinics	O
.	O
OUTCOME	B-UNK
MEASURES	B-UNK
:	O
Laboratory	B-UNK
analyses	B-UNK
of	O
calcium	B-CHEMICAL
,	O
magnesium	B-CHEMICAL
and	O
thyroid	B-DISEASE
-	O
stimulating	B-UNK
hormone	B-UNK
levels	B-UNK
performed	B-UNK
before	O
beginning	B-UNK
lithium	B-CHEMICAL
therapy	B-UNK
and	O
at	B-DISEASE
biannual	O
follow	B-UNK
-	O
up	O
.	O
RESULTS	B-UNK
:	O
Hypothyroidism	O
developed	B-UNK
in	O
40	O
patients	B-UNK
,	O
excluding	O
8	O
patients	B-UNK
who	O
were	O
hypothyroid	O
at	B-DISEASE
baseline	B-UNK
.	O
All	O
patients	B-UNK
having	B-UNK
first	O
-	O
degree	B-UNK
relatives	O
affected	B-UNK
by	O
thyroid	B-DISEASE
illness	O
had	O
accelerated	O
onset	B-UNK
of	O
hypothyroidism	B-DISEASE
(	O
3.7	O
years	B-UNK
after	O
onset	B-UNK
of	O
lithium	B-CHEMICAL
therapy	B-UNK
)	O
compared	B-UNK
with	O
patients	B-UNK
without	O
a	O
family	B-UNK
history	B-UNK
(	O
8.6	O
years	B-UNK
after	O
onset	B-UNK
of	O
lithium	B-CHEMICAL
therapy	B-UNK
)	O
.	O
Women	O
over	O
60	O
years	B-UNK
of	O
age	B-UNK
were	O
more	O
often	O
affected	B-UNK
by	O
hypothyroidism	B-DISEASE
than	O
women	B-UNK
under	O
60	O
years	B-UNK
of	O
age	B-UNK
(	O
34.6	O
%	O
versus	B-UNK
31.9	O
%	O
)	O
.	O
Magnesium	O
levels	B-UNK
in	O
patients	B-UNK
on	O
lithium	B-CHEMICAL
treatment	B-UNK
were	O
unchanged	B-UNK
from	O
baseline	B-UNK
levels	B-UNK
.	O
After	O
lithium	B-CHEMICAL
treatment	B-UNK
,	O
calcium	B-CHEMICAL
levels	B-UNK
were	O
higher	B-UNK
than	O
either	O
baseline	B-UNK
levels	B-UNK
or	O
control	B-UNK
levels	B-UNK
.	O
Thus	O
,	O
lithium	B-CHEMICAL
treatment	B-UNK
counteracted	O
the	O
decrease	B-UNK
in	O
plasma	B-UNK
calcium	B-CHEMICAL
levels	B-UNK
associated	B-UNK
with	O
aging	B-DISEASE
.	O
CONCLUSIONS	O
:	O
Familial	O
thyroid	B-DISEASE
illness	O
is	O
a	O
risk	B-UNK
factor	B-UNK
for	O
hypothyroidism	B-DISEASE
and	O
hypercalcemia	B-DISEASE
during	O
lithium	B-CHEMICAL
therapy	B-UNK
.	O

Systemic	B-UNK
toxicity	B-UNK
following	B-UNK
administration	B-UNK
of	O
sirolimus	B-CHEMICAL
(	O
formerly	O
rapamycin	B-UNK
)	O
for	O
psoriasis	B-DISEASE
:	O
association	B-UNK
of	O
capillary	B-DISEASE
leak	I-DISEASE
syndrome	I-DISEASE
with	O
apoptosis	B-UNK
of	O
lesional	O
lymphocytes	B-UNK
.	O

BACKGROUND	O
:	O
Sirolimus	O
(	O
formerly	O
rapamycin	B-UNK
)	O
is	O
an	O
immunosuppressive	B-UNK
agent	B-UNK
that	O
interferes	O
with	O
T	B-UNK
-	O
cell	B-UNK
activation	B-UNK
.	O
After	O
2	B-DISEASE
individuals	B-UNK
with	O
psoriasis	B-DISEASE
developed	B-UNK
a	O
capillary	B-DISEASE
leak	I-DISEASE
syndrome	I-DISEASE
following	B-UNK
treatment	B-UNK
with	O
oral	B-UNK
sirolimus	B-CHEMICAL
lesional	O
skin	B-DISEASE
cells	B-UNK
and	O
activated	B-UNK
peripheral	B-UNK
blood	B-UNK
cells	B-UNK
were	O
analyzed	B-UNK
for	O
induction	B-UNK
of	O
apoptosis	B-UNK
.	O
OBSERVATIONS	O
:	O
A	O
keratome	O
skin	B-DISEASE
specimen	O
from	O
1	O
patient	B-UNK
with	O
sirolimus	B-CHEMICAL
-	O
induced	B-UNK
capillary	B-DISEASE
leak	I-DISEASE
syndrome	I-DISEASE
had	O
a	O
2.3-fold	O
increase	B-UNK
in	O
percentage	B-UNK
of	O
apoptotic	B-UNK
cells	B-UNK
(	O
to	O
48	O
%	O
)	O
compared	B-UNK
with	O
an	O
unaffected	B-UNK
sirolimus	B-CHEMICAL
-	O
treated	B-UNK
patient	B-UNK
with	O
psoriasis	B-DISEASE
(	O
21	O
%	O
)	O
.	O
Activated	O
peripheral	B-UNK
blood	B-UNK
T	B-UNK
cells	B-UNK
from	O
patients	B-UNK
with	O
psoriasis	B-DISEASE
tended	B-UNK
to	O
exhibit	B-UNK
greater	B-UNK
spontaneous	B-UNK
or	O
dexamethasone	B-CHEMICAL
-	O
induced	B-UNK
apoptosis	B-UNK
than	O
did	O
normal	B-UNK
T	B-UNK
cells	B-UNK
,	O
particularly	O
in	O
the	O
presence	O
of	O
sirolimus	B-CHEMICAL
.	O
CONCLUSIONS	O
:	O
Severe	B-UNK
adverse	B-UNK
effects	B-UNK
of	O
sirolimus	B-CHEMICAL
include	B-UNK
fever	B-DISEASE
,	O
anemia	B-DISEASE
,	O
and	O
capillary	B-DISEASE
leak	I-DISEASE
syndrome	I-DISEASE
.	O
These	O
symptoms	B-UNK
may	O
be	O
the	O
result	B-UNK
of	O
drug	B-UNK
-	O
induced	B-UNK
apoptosis	B-UNK
of	O
lesional	O
leukocytes	O
,	O
especially	B-UNK
activated	B-UNK
T	B-UNK
lymphocytes	B-UNK
,	O
and	O
possibly	B-UNK
release	B-UNK
of	O
inflammatory	B-UNK
mediators	B-UNK
.	O
Because	O
patients	B-UNK
with	O
severe	B-UNK
psoriasis	B-DISEASE
may	O
develop	B-UNK
capillary	B-UNK
leak	O
from	O
various	O
systemic	B-UNK
therapies	B-UNK
,	O
clinical	B-UNK
monitoring	B-UNK
is	O
advisable	O
for	O
patients	B-UNK
with	O
inflammatory	B-UNK
diseases	B-DISEASE
who	O
are	O
treated	B-UNK
with	O
immune	B-UNK
modulators	O
.	O

Contribution	O
of	O
the	O
glycine	B-CHEMICAL
site	B-UNK
of	O
NMDA	O
receptors	B-UNK
in	O
rostral	O
and	O
intermediate	O
-	O
caudal	B-UNK
parts	O
of	O
the	O
striatum	O
to	O
the	O
regulation	O
of	O
muscle	B-UNK
tone	B-UNK
in	O
rats	B-UNK
.	O

The	O
aim	O
of	O
the	O
present	B-UNK
study	B-UNK
was	O
to	O
assess	B-UNK
the	O
contribution	O
of	O
the	O
glycine	B-CHEMICAL
site	B-UNK
of	O
NMDA	O
receptors	B-UNK
in	O
the	O
striatum	O
to	O
the	O
regulation	O
of	O
muscle	B-UNK
tone	B-UNK
.	O
Muscle	B-UNK
tone	B-UNK
was	O
examined	B-UNK
using	O
a	O
combined	B-UNK
mechanoand	O
electromyographic	B-UNK
method	B-UNK
,	O
which	O
measured	B-UNK
simultaneously	B-UNK
the	O
muscle	B-UNK
resistance	B-UNK
(	O
MMG	O
)	O
of	O
the	O
rat'	O
s	O
hind	O
foot	B-UNK
to	O
passive	B-UNK
extension	O
and	O
flexion	O
in	O
the	O
ankle	O
joint	O
and	O
the	O
electromyographic	B-UNK
activity	I-UNK
(	O
EMG	O
)	O
of	O
the	O
antagonistic	B-UNK
muscles	B-UNK
of	O
that	O
joint	O
:	O
gastrocnemius	B-UNK
and	O
tibialis	O
anterior	B-UNK
.	O
Muscle	B-UNK
rigidity	B-UNK
was	O
induced	B-UNK
by	O
haloperidol	B-CHEMICAL
(	O
2.5	B-UNK
mg	B-UNK
/	O
kg	B-UNK
i.p	B-UNK
.	O
)	O
.	O
5,7-dichlorokynurenic	B-CHEMICAL
acid	I-CHEMICAL
(	O
5,7-DCKA	O
)	O
,	O
a	O
selective	B-UNK
glycine	B-CHEMICAL
site	B-UNK
antagonist	B-UNK
,	O
injected	B-UNK
in	O
doses	B-UNK
of	O
2.5	B-UNK
and	O
4.5	B-UNK
microg/0.5	B-UNK
microl	I-UNK
bilaterally	B-UNK
,	O
into	O
the	O
rostral	O
region	B-UNK
of	O
the	O
striatum	O
,	O
decreased	B-UNK
both	O
the	O
haloperidol	B-CHEMICAL
-	O
induced	B-UNK
muscle	B-DISEASE
rigidity	I-DISEASE
(	O
MMG	O
)	O
and	O
the	O
enhanced	B-UNK
electromyographic	B-UNK
activity	I-UNK
(	O
EMG	O
)	O
.	O
5,7-DCKA	O
injected	B-UNK
bilaterally	B-UNK
in	O
a	O
dose	B-UNK
of	O
4.5	B-UNK
microg/0.5	B-UNK
microl	I-UNK
into	O
the	O
intermediate	O
-	O
caudal	B-UNK
region	B-UNK
of	O
the	O
striatum	O
of	O
rats	B-UNK
not	O
pretreated	B-UNK
with	O
haloperidol	B-CHEMICAL
had	O
no	O
effect	B-UNK
on	O
the	O
muscle	B-UNK
tone	B-UNK
.	O
The	O
present	B-UNK
results	B-UNK
suggest	B-UNK
that	O
blockade	B-UNK
of	O
the	O
glycine	B-CHEMICAL
site	B-UNK
of	O
NMDA	O
receptors	B-UNK
in	O
the	O
rostral	O
part	O
of	O
the	O
striatum	O
may	O
be	O
mainly	B-UNK
responsible	O
for	O
the	O
antiparkinsonian	B-UNK
action	B-UNK
of	O
this	O
drug	B-UNK
.	O

Efficacy	O
and	O
tolerability	B-UNK
of	O
lovastatin	B-CHEMICAL
in	O
3390	O
women	B-UNK
with	O
moderate	B-UNK
hypercholesterolemia	B-DISEASE
.	O

OBJECTIVE	O
:	O
To	O
evaluate	B-UNK
the	O
efficacy	B-UNK
and	O
safety	B-UNK
of	O
lovastatin	B-CHEMICAL
in	O
women	B-UNK
with	O
moderate	B-UNK
hypercholesterolemia	B-DISEASE
.	O
DESIGN	B-UNK
:	O
The	O
Expanded	O
Clinical	B-UNK
Evaluation	O
of	O
Lovastatin	O
(	O
EXCEL	O
)	O
Study	B-UNK
,	O
a	O
multicenter	O
,	O
double-blind	B-UNK
,	O
diet-	O
and	O
placebo	B-UNK
-	O
controlled	B-UNK
trial	B-UNK
,	O
in	O
which	O
participants	O
were	O
randomly	B-UNK
assigned	B-UNK
to	O
receive	B-UNK
placebo	B-UNK
or	O
lovastatin	B-CHEMICAL
at	B-DISEASE
doses	B-UNK
of	O
20	O
or	O
40	O
mg	B-UNK
once	O
daily	B-UNK
,	O
or	O
20	O
or	O
40	O
mg	B-UNK
twice	B-UNK
daily	B-UNK
for	O
48	O
weeks	B-UNK
.	O
SETTING	O
:	O
Ambulatory	O
patients	B-UNK
recruited	O
by	O
362	O
participating	O
centers	O
throughout	O
the	O
United	B-UNK
States	B-UNK
.	O
PATIENTS	O
:	O
Women	O
(	O
n	B-UNK
=	O
3390	O
)	O
from	O
the	O
total	B-UNK
cohort	B-UNK
of	O
8245	O
volunteers	O
.	O
MEASUREMENTS	O
:	O
Plasma	B-UNK
total	B-UNK
,	O
low	B-UNK
-	O
density	B-UNK
lipoprotein	O
(	O
LDL	O
)	O
,	O
and	O
high	B-UNK
-	O
density	B-UNK
lipoprotein	O
(	O
HDL	O
)	O
cholesterol	B-CHEMICAL
,	O
and	O
triglycerides	B-CHEMICAL
;	O
and	O
laboratory	B-UNK
and	O
clinical	B-UNK
evidence	B-UNK
of	O
adverse	B-UNK
events	B-UNK
monitored	B-UNK
periodically	O
throughout	O
the	O
study	B-UNK
.	O
RESULTS	B-UNK
:	O
Among	O
women	B-UNK
,	O
lovastatin	B-CHEMICAL
(	O
20	O
to	O
80	O
mg	B-UNK
/	O
d	B-UNK
)	O
produced	B-UNK
sustained	B-UNK
(	O
12-	O
to	O
48-week	O
)	O
,	O
dose	B-UNK
-	O
related	B-UNK
changes	B-UNK
(	O
P	B-UNK
<	I-UNK
0.001	B-UNK
):	O
decreases	B-UNK
in	O
LDL	O
cholesterol	B-CHEMICAL
(	O
24	O
%	O
to	O
40	O
%	O
)	O
and	O
triglycerides	B-CHEMICAL
(	O
9	O
%	O
to	O
18	O
%	O
)	O
,	O
and	O
increases	B-UNK
in	O
HDL	O
cholesterol	B-CHEMICAL
(	O
6.7	O
%	O
to	O
8.6	O
%	O
)	O
.	O
Depending	O
on	O
the	O
dose	B-UNK
,	O
from	O
82	O
%	O
to	O
95	O
%	O
of	O
lovastatin	B-CHEMICAL
-	O
treated	B-UNK
women	B-UNK
achieved	B-UNK
the	O
National	B-UNK
Cholesterol	O
Education	O
Program	O
goal	O
of	O
LDL	O
cholesterol	B-CHEMICAL
levels	B-UNK
less	O
than	O
4.14	O
mmol	B-UNK
/	O
L	B-UNK
(	O
160	O
mg	B-UNK
/	O
dL	O
)	O
,	O
and	O
40	O
%	O
to	O
87	O
%	O
achieved	B-UNK
the	O
goal	O
of	O
3.36	O
mmol	B-UNK
/	O
L	B-UNK
(	O
130	O
mg	B-UNK
/	O
dL	O
)	O
.	O
Successive	O
transaminase	B-UNK
elevations	O
greater	B-UNK
than	O
three	O
times	B-UNK
the	O
upper	B-UNK
limit	B-UNK
of	O
normal	B-UNK
occurred	B-UNK
in	O
0.1	B-UNK
%	O
of	O
women	B-UNK
and	O
were	O
dose	B-UNK
dependent	B-UNK
above	O
the	O
20-mg	O
dose	B-UNK
.	O
Myopathy	O
,	O
defined	O
as	O
muscle	B-UNK
symptoms	B-UNK
with	O
creatine	B-CHEMICAL
kinase	B-UNK
elevations	O
greater	B-UNK
than	O
10	O
times	B-UNK
the	O
upper	B-UNK
limit	B-UNK
of	O
normal	B-UNK
,	O
was	O
rare	B-UNK
and	O
associated	B-UNK
with	O
the	O
highest	B-UNK
recommended	B-UNK
daily	B-UNK
dose	B-UNK
of	O
lovastatin	B-CHEMICAL
(	O
80	O
mg	B-UNK
)	O
.	O
Estrogen	O
-	O
replacement	O
therapy	B-UNK
appeared	B-UNK
to	O
have	O
no	O
effect	B-UNK
on	O
either	O
the	O
efficacy	B-UNK
or	O
safety	B-UNK
profile	B-UNK
of	O
lovastatin	B-CHEMICAL
.	O
CONCLUSION	O
:	O
Lovastatin	O
is	O
highly	B-UNK
effective	B-UNK
and	O
generally	B-UNK
well	O
tolerated	B-UNK
as	O
therapy	B-UNK
for	O
primary	B-UNK
hypercholesterolemia	B-DISEASE
in	O
women	B-UNK
.	O

REM	O
sleep	B-DISEASE
deprivation	I-DISEASE
changes	B-UNK
behavioral	B-UNK
response	B-UNK
to	O
catecholaminergic	O
and	O
serotonergic	B-UNK
receptor	B-UNK
activation	B-UNK
in	O
rats	B-UNK
.	O

The	O
effects	B-UNK
of	O
REM	O
sleep	B-DISEASE
deprivation	I-DISEASE
(	O
REMD	O
)	O
on	O
apomorphine	B-CHEMICAL
-	O
induced	B-UNK
aggressiveness	O
and	O
quipazine	B-CHEMICAL
-	O
induced	B-UNK
head	B-UNK
twitches	O
in	O
rats	B-UNK
were	O
determined	O
.	O
Forty	O
-	O
eight	O
hr	B-UNK
of	O
REMD	O
increased	B-UNK
apomorphine	B-CHEMICAL
-	O
induced	B-UNK
aggressiveness	O
,	O
and	O
reduced	B-UNK
(	O
immediately	B-UNK
after	O
completing	O
of	O
REMD	O
)	O
or	O
increased	B-UNK
(	O
96	O
hr	B-UNK
after	O
completing	O
of	O
REMD	O
)	O
quipazine	B-CHEMICAL
-	O
induced	B-UNK
head	B-UNK
twitches	O
.	O
Results	O
are	O
discussed	O
in	O
terms	O
of	O
similarity	O
to	O
pharmacological	B-UNK
effects	B-UNK
of	O
other	O
antidepressive	O
treatments	B-UNK
.	O

Extrapyramidal	O
side	O
effects	B-UNK
and	O
oral	B-UNK
haloperidol	B-CHEMICAL
:	O
an	O
analysis	B-UNK
of	O
explanatory	O
patient	B-UNK
and	O
treatment	B-UNK
characteristics	B-UNK
.	O

The	O
incidence	B-UNK
of	O
extrapyramidal	B-UNK
side	O
effects	B-UNK
(	O
EPS	O
)	O
was	O
evaluated	B-UNK
in	O
98	O
patients	B-UNK
treated	B-UNK
with	O
haloperidol	B-CHEMICAL
.	O
The	O
incidence	B-UNK
of	O
parkinsonism	B-DISEASE
was	O
higher	B-UNK
at	B-DISEASE
higher	B-UNK
doses	B-UNK
of	O
haloperidol	B-CHEMICAL
and	O
in	O
younger	O
patients	B-UNK
.	O
Prophylactic	O
antiparkinsonian	B-UNK
medication	B-UNK
was	O
effective	B-UNK
in	O
younger	O
but	O
not	O
in	O
older	O
patients	B-UNK
.	O
However	O
,	O
these	O
medications	B-UNK
were	O
more	O
effective	B-UNK
in	O
both	O
young	B-UNK
and	O
old	B-UNK
patients	B-UNK
when	O
given	B-UNK
after	O
parkinsonism	B-DISEASE
developed	B-UNK
.	O
Akathisia	O
was	O
controlled	B-UNK
by	O
the	O
benzodiazepine	O
lorazepam	B-CHEMICAL
in	O
14	O
out	O
of	O
16	O
patients	B-UNK
,	O
while	O
prophylactic	B-UNK
antiparkinsonians	O
were	O
ineffective	O
.	O
The	O
present	B-UNK
study	B-UNK
points	B-UNK
to	O
patient	B-UNK
characteristics	B-UNK
that	O
may	O
be	O
of	O
significance	O
in	O
the	O
development	B-UNK
of	O
EPS	O
due	O
to	O
haloperidol	B-CHEMICAL
.	O

Hepatic	B-UNK
veno	O
-	O
occlusive	O
disease	B-DISEASE
caused	B-UNK
by	O
6-thioguanine	O
.	O

Clinically	O
reversible	B-UNK
veno	O
-	O
occlusive	O
disease	B-DISEASE
of	O
the	O
liver	B-DISEASE
developed	B-UNK
in	O
a	O
23-year	O
-	O
old	B-UNK
man	B-UNK
with	O
acute	B-DISEASE
lymphocytic	I-DISEASE
leukemia	I-DISEASE
after	O
10	O
months	B-UNK
of	O
maintenance	B-UNK
therapy	B-UNK
with	O
6-thioguanine	O
.	O
Serial	O
liver	B-DISEASE
biopsies	B-UNK
showed	B-UNK
the	O
development	B-UNK
and	O
resolution	B-UNK
of	O
intense	O
sinusoidal	B-UNK
engorgement	O
.	O
Although	O
this	O
disease	B-DISEASE
was	O
clinically	B-UNK
reversible	B-UNK
,	O
some	O
subintimal	O
fibrosis	B-DISEASE
about	O
the	O
terminal	B-UNK
hepatic	B-UNK
veins	O
persisted	B-UNK
.	O
This	O
case	B-UNK
presented	B-UNK
a	O
unique	B-UNK
opportunity	O
to	O
observe	O
the	O
histologic	B-UNK
features	B-UNK
of	O
clinically	B-UNK
reversible	B-UNK
hepatic	B-DISEASE
veno	I-DISEASE
-	I-DISEASE
occlusive	I-DISEASE
disease	I-DISEASE
over	O
time	B-UNK
,	O
and	O
may	O
be	O
the	O
first	O
case	B-UNK
of	O
veno	O
-	O
occlusive	O
related	B-UNK
solely	O
to	O
6-thioguanine	O
.	O

Treatment	O
of	O
ifosfamide	B-CHEMICAL
-	O
induced	B-UNK
urothelial	O
toxicity	B-UNK
by	O
oral	B-UNK
administration	B-UNK
of	O
sodium	B-CHEMICAL
2-mercaptoethane	O
sulphonate	O
(	O
MESNA	O
)	O
to	O
patients	B-UNK
with	O
inoperable	O
lung	B-DISEASE
cancer	I-DISEASE
.	O

The	O
protective	B-UNK
effect	B-UNK
of	O
oral	B-UNK
administration	B-UNK
of	O
the	O
thiol	O
compound	B-UNK
sodium	B-CHEMICAL
2-mercaptoethane	O
sulphonate	O
(	O
MESNA	O
)	O
against	O
urothelial	O
toxicity	B-UNK
induced	B-UNK
by	O
ifosfamide	B-CHEMICAL
(	O
IF	O
)	O
was	O
tested	B-UNK
in	O
a	O
group	B-UNK
of	O
45	O
patients	B-UNK
with	O
inoperable	O
lung	B-DISEASE
cancer	I-DISEASE
under	O
treatment	B-UNK
with	O
IF	O
(	O
2250	O
mg	B-UNK
/	O
m2	O
on	O
days	B-UNK
2	B-DISEASE
-	O
5	O
)	O
as	O
part	O
of	O
a	O
polychemotherapy	O
regimen	B-UNK
repeated	B-UNK
in	O
a	O
4-week	O
cycle	B-UNK
.	O
MESNA	O
was	O
given	B-UNK
orally	B-UNK
on	O
the	O
days	B-UNK
of	O
treatment	B-UNK
with	O
IF	O
in	O
3	O
doses	B-UNK
of	O
840	O
mg	B-UNK
/	O
m2	O
,	O
each	O
administered	B-UNK
at	B-DISEASE
0	O
hr	B-UNK
(=	O
injection	B-UNK
of	O
IF	O
)	O
,	O
4	O
hr	B-UNK
and	O
8	O
hr	B-UNK
p.i	O
.	O
Out	O
of	O
a	O
total	B-UNK
of	O
88	O
courses	O
of	O
this	O
treatment	B-UNK
we	O
observed	B-UNK
10	O
episodes	B-UNK
of	O
asymptomatic	B-UNK
microscopic	B-UNK
haematuria	B-UNK
and	O
no	O
episodes	B-UNK
of	O
gross	B-UNK
haematuria	B-UNK
.	O
In	O
this	O
group	B-UNK
of	O
45	O
patients	B-UNK
under	O
protection	B-UNK
with	O
MESNA	O
there	O
were	O
5	O
complete	B-UNK
remissions	O
and	O
9	O
partial	B-UNK
remissions	O
(	O
total	B-UNK
31	O
%	O
)	O
.	O
A	O
further	O
group	B-UNK
of	O
25	O
patients	B-UNK
under	O
polychemotherapy	O
with	O
IF	O
were	O
treated	B-UNK
by	O
conventional	B-UNK
prophylactic	B-UNK
measures	B-UNK
(	O
raised	O
fluid	B-UNK
intake	B-UNK
and	O
forced	B-UNK
diuresis	B-UNK
)	O
.	O
In	O
this	O
group	B-UNK
there	O
were	O
1	O
complete	B-UNK
and	O
5	O
partial	B-UNK
remissions	O
(	O
total	B-UNK
24	O
%	O
)	O
,	O
but	O
nearly	B-UNK
all	O
patients	B-UNK
developed	B-UNK
either	O
gross	B-UNK
haematuria	B-UNK
and	O
/	O
or	O
symptoms	B-UNK
of	O
bladder	B-UNK
irritation	O
(	O
cystitis	B-DISEASE
and	O
pollakisuria	O
)	O
.	O
There	O
were	O
no	O
appreciable	O
differences	B-UNK
between	O
the	O
MESNA	O
series	B-UNK
and	O
the	O
conventional	B-UNK
prophylaxis	B-UNK
series	B-UNK
with	O
respect	O
to	O
either	O
haematological	O
or	O
systemic	B-UNK
toxicity	B-UNK
of	O
the	O
cytostatic	O
treatment	B-UNK
.	O
Our	O
results	B-UNK
support	B-UNK
the	O
view	O
that	O
MESNA	O
,	O
given	B-UNK
orally	B-UNK
in	O
conjunction	O
with	O
combined	B-UNK
cytostatic	O
regimens	B-UNK
which	O
include	B-UNK
IF	O
,	O
simplifies	O
the	O
treatment	B-UNK
and	O
provides	B-UNK
optimum	O
protection	B-UNK
for	O
the	O
urinary	B-UNK
epithelium	B-UNK
.	O
Protection	O
with	O
oral	B-UNK
MESNA	O
is	O
particularly	O
suitable	B-UNK
for	O
outpatients	O
.	O

Time	O
course	B-UNK
alterations	B-UNK
of	O
QTC	O
interval	B-UNK
due	O
to	O
hypaque	O
76	O
.	O

Sequential	O
measurement	B-UNK
of	O
QT	B-UNK
interval	B-UNK
during	O
left	B-UNK
ventricular	I-UNK
angiography	B-UNK
was	O
made	O
30	O
seconds	O
and	O
one	O
,	O
three	O
,	O
five	O
and	O
ten	B-DISEASE
minutes	B-UNK
after	O
injection	B-UNK
of	O
hypaque	O
76	O
.	O
The	O
subjects	B-UNK
were	O
ten	B-DISEASE
patients	B-UNK
found	B-UNK
to	O
have	O
normal	B-UNK
left	B-UNK
ventricles	O
and	O
coronary	B-UNK
arteries	B-UNK
.	O
Significant	B-UNK
QTC	O
prolongation	B-UNK
occurred	B-UNK
in	O
30	O
seconds	O
to	O
one	O
minute	O
in	O
association	B-UNK
with	O
marked	B-UNK
hypotension	B-DISEASE
and	O
elevation	B-UNK
of	O
cardiac	B-DISEASE
output	I-DISEASE
.	O

Production	O
of	O
autochthonous	O
prostate	B-DISEASE
cancer	I-DISEASE
in	O
Lobund	O
-	O
Wistar	B-UNK
rats	I-UNK
by	O
treatments	B-UNK
with	O
N	B-UNK
-	O
nitroso	O
-	O
N	B-UNK
-	O
methylurea	B-CHEMICAL
and	O
testosterone	B-CHEMICAL
.	O

More	O
than	O
50	O
%	O
of	O
Lobund	O
-	O
Wistar	B-UNK
(	O
L	B-UNK
-	O
W	O
)	O
strain	B-UNK
rats	B-UNK
developed	B-UNK
large	B-UNK
,	O
palpable	B-UNK
prostate	O
adenocarcinomas	O
(	O
PAs	O
)	O
following	B-UNK
treatments	B-UNK
with	O
N	B-UNK
-	O
nitroso	O
-	O
N	B-UNK
-	O
methylurea	B-CHEMICAL
(	O
CAS	O
:	O
684	O
-	O
93	O
-	O
5	O
)	O
and	O
testosterone	B-CHEMICAL
propionate	I-CHEMICAL
[	O
(	O
TP	O
)	O
CAS	O
:	O
57	O
-	O
85	O
-	O
2	B-DISEASE
]	O
,	O
and	O
most	O
of	O
the	O
tumor	B-DISEASE
-	O
bearing	O
rats	B-UNK
manifested	O
metastatic	B-UNK
lesions	B-UNK
.	O
The	O
incubation	O
periods	B-UNK
averaged	O
10.6	O
months	B-UNK
.	O
Within	O
the	O
same	O
timeframe	O
,	O
no	O
L	B-UNK
-	O
W	O
rat	B-UNK
developed	B-UNK
a	O
similar	B-UNK
palpable	B-UNK
PA	B-UNK
when	O
treated	B-UNK
only	O
with	O
TP	O
.	O
In	O
L	B-UNK
-	O
W	O
rats	B-UNK
,	O
TP	O
acted	O
as	O
a	O
tumor	B-DISEASE
enhancement	O
agent	B-UNK
,	O
with	O
primary	B-UNK
emphasis	O
on	O
the	O
development	B-UNK
of	O
prostate	B-DISEASE
cancer	I-DISEASE
.	O

A	O
dystonia	B-DISEASE
-	O
like	B-UNK
syndrome	B-DISEASE
after	O
neuropeptide	O
(	O
MSH	O
/	O
ACTH	O
)	O
stimulation	B-UNK
of	O
the	O
rat	B-UNK
locus	B-UNK
ceruleus	O
.	O

The	O
movement	B-UNK
disorder	B-UNK
investigated	B-UNK
in	O
these	O
studies	B-UNK
has	O
some	O
features	B-UNK
in	O
common	B-UNK
with	O
human	B-UNK
idiopathic	B-UNK
dystonia	B-DISEASE
,	O
and	O
information	B-UNK
obtained	B-UNK
in	O
these	O
studies	B-UNK
may	O
be	O
of	O
potential	B-UNK
clinical	B-UNK
benefit	B-UNK
.	O
The	O
present	B-UNK
experimental	B-UNK
results	B-UNK
indicated	B-UNK
that	O
peptidergic	O
stimulation	B-UNK
of	O
the	O
LC	O
resulted	B-UNK
in	O
a	O
NE	O
-	O
mediated	B-UNK
inhibition	B-UNK
of	O
cerebellar	B-UNK
Purkinje	O
cells	B-UNK
located	O
at	B-DISEASE
terminals	O
of	O
the	O
ceruleo	O
-	O
cerebellar	B-UNK
pathway	B-UNK
.	O
However	O
,	O
it	O
is	O
not	O
certain	B-UNK
as	O
to	O
the	O
following	B-UNK
:	O
(	O
a	O
)	O
what	O
receptors	B-UNK
were	O
stimulated	O
by	O
the	O
ACTH	O
N	B-UNK
-	O
terminal	B-UNK
fragments	O
at	B-DISEASE
the	O
LC	O
that	O
resulted	B-UNK
in	O
this	O
disorder	B-UNK
;	O
(	O
b	B-UNK
)	O
whether	O
NE	O
,	O
released	O
onto	O
Purkinje	O
cell	B-UNK
synapses	O
located	O
at	B-DISEASE
terminals	O
of	O
the	O
ceruleo	O
-	O
cerebellar	B-UNK
pathway	B-UNK
,	O
did	O
indeed	O
cause	B-UNK
the	O
long	B-UNK
-	O
term	B-UNK
depression	B-DISEASE
at	B-DISEASE
Purkinje	O
cell	B-UNK
synapses	O
(	O
previously	B-UNK
described	B-UNK
by	O
others	O
)	O
that	O
resulted	B-UNK
in	O
the	O
long	B-UNK
duration	B-UNK
of	O
the	O
movement	B-UNK
disorder	B-UNK
;	O
(	O
c	B-UNK
)	O
whether	O
the	O
inhibition	B-UNK
of	O
inhibitory	B-UNK
Purkinje	O
cells	B-UNK
resulted	B-UNK
in	O
disinhibition	O
or	O
increased	B-UNK
excitability	B-UNK
of	O
the	O
unilateral	B-UNK
cerebellar	B-UNK
fastigial	O
or	O
interpositus	O
nuclei	B-UNK
,	O
the	O
output	B-UNK
targets	O
of	O
the	O
Purkinje	O
cell	B-UNK
axons	O
,	O
that	O
may	O
have	O
been	O
an	O
important	B-UNK
contributing	B-UNK
factor	B-UNK
to	O
this	O
disorder	B-UNK
.	O
These	O
questions	O
are	O
currently	B-UNK
being	O
investigated	B-UNK
.	O

Dexmedetomidine	O
,	O
acting	B-UNK
through	O
central	B-UNK
alpha-2	B-UNK
adrenoceptors	O
,	O
prevents	B-UNK
opiate	B-UNK
-	O
induced	B-UNK
muscle	B-DISEASE
rigidity	I-DISEASE
in	O
the	O
rat	B-UNK
.	O

The	O
highly	B-UNK
-	O
selective	B-UNK
alpha-2	B-UNK
adrenergic	B-UNK
agonist	B-UNK
dexmedetomidine	B-CHEMICAL
(	O
D	B-UNK
-	O
MED	B-UNK
)	O
is	O
capable	O
of	O
inducing	B-UNK
muscle	B-UNK
flaccidity	O
and	O
anesthesia	B-UNK
in	O
rats	B-UNK
and	O
dogs	B-UNK
.	O
Intense	O
generalized	B-UNK
muscle	B-DISEASE
rigidity	I-DISEASE
is	O
an	O
undesirable	O
side	O
effect	B-UNK
of	O
potent	B-UNK
opiate	B-UNK
agonists	O
.	O
Although	O
the	O
neurochemistry	O
of	O
opiate	B-UNK
-	O
induced	B-UNK
rigidity	B-UNK
has	O
yet	O
to	O
be	O
fully	B-UNK
elucidated	O
,	O
recent	B-UNK
work	B-UNK
suggests	B-UNK
a	O
role	B-UNK
for	O
a	O
central	B-UNK
adrenergic	B-UNK
mechanism	B-UNK
.	O
In	O
the	O
present	B-UNK
study	B-UNK
,	O
the	O
authors	B-UNK
determined	O
if	O
treatment	B-UNK
with	O
D	B-UNK
-	O
MED	B-UNK
prevents	B-UNK
the	O
muscle	B-DISEASE
rigidity	I-DISEASE
caused	B-UNK
by	O
high	B-UNK
-	O
dose	B-UNK
alfentanil	B-CHEMICAL
anesthesia	B-UNK
in	O
the	O
rat	B-UNK
.	O
Animals	O
(	O
n	B-UNK
=	O
42	O
)	O
were	O
treated	B-UNK
intraperitoneally	B-UNK
with	O
one	O
of	O
the	O
following	B-UNK
six	O
regimens	B-UNK
:	O
1	O
)	O
L	B-UNK
-	O
MED	B-UNK
(	O
the	O
inactive	O
L	B-UNK
-	O
isomer	O
of	O
medetomidine	B-CHEMICAL
)	O
,	O
30	O
micrograms	B-UNK
/	O
kg	B-UNK
;	O
2	B-DISEASE
)	O
D	B-UNK
-	O
MED	B-UNK
,	O
10	O
micrograms	B-UNK
/	O
kg	B-UNK
;	O
3	O
)	O
D	B-UNK
-	O
MED	B-UNK
,	O
30	O
micrograms	B-UNK
/	O
kg	B-UNK
;	O
4	O
)	O
D	B-UNK
-	O
MED	B-UNK
[	O
30	O
micrograms	B-UNK
/	O
kg	B-UNK
]	O
and	O
the	O
central	B-UNK
-	O
acting	B-UNK
alpha-2	B-UNK
antagonist	B-UNK
,	O
idazoxan	B-CHEMICAL
[	O
10	O
mg	B-UNK
/	O
kg	B-UNK
]	O
;	O
5	O
)	O
D	B-UNK
-	O
MED	B-UNK
[	O
30	O
micrograms	B-UNK
/	O
kg	B-UNK
]	O
and	O
the	O
peripheral	B-UNK
-	O
acting	B-UNK
alpha-2	B-UNK
antagonist	B-UNK
DG-5128	O
[	O
10	O
mg	B-UNK
/	O
kg	B-UNK
]	O
,	O
or	O
;	O
6	O
)	O
saline	B-UNK
.	O
Baseline	O
electromyographic	B-UNK
activity	I-UNK
was	O
recorded	B-UNK
from	O
the	O
gastrocnemius	B-UNK
muscle	B-UNK
before	O
and	O
after	O
drug	B-UNK
treatment	B-UNK
.	O
Each	O
rat	B-UNK
was	O
then	O
injected	B-UNK
with	O
alfentanil	B-CHEMICAL
(	O
ALF	O
,	O
0.5	B-UNK
mg	I-UNK
/	O
kg	B-UNK
sc	O
)	O
.	O
ALF	O
injection	B-UNK
resulted	B-UNK
in	O
a	O
marked	B-UNK
increase	B-UNK
in	O
hindlimb	O
EMG	O
activity	B-UNK
in	O
the	O
L	B-UNK
-	O
MED	B-UNK
treatment	B-UNK
group	B-UNK
which	O
was	O
indistinguishable	O
from	O
that	O
seen	B-UNK
in	O
animals	B-UNK
treated	B-UNK
with	O
saline	B-UNK
.	O
In	O
contrast	B-UNK
,	O
D	B-UNK
-	O
MED	B-UNK
prevented	B-UNK
alfentanil	B-CHEMICAL
-	O
induced	B-UNK
muscle	B-DISEASE
rigidity	I-DISEASE
in	O
a	O
dose	B-UNK
-	O
dependent	B-UNK
fashion	B-UNK
.	O
The	O
small	B-UNK
EMG	O
values	B-UNK
obtained	B-UNK
in	O
the	O
high	B-UNK
-	O
dose	B-UNK
D	B-UNK
-	O
MED	B-UNK
group	B-UNK
were	O
comparable	B-UNK
with	O
those	O
recorded	B-UNK
in	O
earlier	B-UNK
studies	B-UNK
from	O
control	B-UNK
animals	B-UNK
not	O
given	B-UNK
any	O
opiate	B-UNK
.	O
The	O
high	B-UNK
-	O
dose	B-UNK
D	B-UNK
-	O
MED	B-UNK
animals	B-UNK
were	O
flaccid	O
,	O
akinetic	O
,	O
and	O
lacked	O
a	O
startle	B-UNK
response	B-UNK
during	O
the	O
entire	B-UNK
experimental	B-UNK
period.(ABSTRACT	O
TRUNCATED	B-UNK
AT	O
250	O
WORDS	O
)	O

Seizure	O
activity	B-UNK
with	O
imipenem	B-CHEMICAL
therapy	B-UNK
:	O
incidence	B-UNK
and	O
risk	B-UNK
factors	I-UNK
.	O

Two	O
elderly	B-UNK
patients	B-UNK
with	O
a	O
history	B-UNK
of	O
either	O
cerebral	B-UNK
vascular	B-UNK
accident	O
(	O
CVA	O
)	O
or	O
head	B-DISEASE
trauma	I-DISEASE
and	O
no	O
evidence	B-UNK
of	O
renal	B-UNK
disease	B-DISEASE
developed	B-UNK
seizures	B-DISEASE
while	O
receiving	B-UNK
maximum	B-UNK
doses	B-UNK
of	O
imipenem	B-CHEMICAL
/	O
cilastatin	B-CHEMICAL
.	O
Neither	O
patient	B-UNK
had	O
reported	B-UNK
previous	B-UNK
seizures	B-DISEASE
or	O
seizure	B-UNK
-	O
like	B-UNK
activity	B-UNK
nor	O
was	O
receiving	B-UNK
anticonvulsant	O
agents	B-UNK
.	O
All	O
seizures	B-DISEASE
were	O
controlled	B-UNK
with	O
therapeutic	B-UNK
doses	B-UNK
of	O
phenytoin	B-CHEMICAL
.	O
Both	O
patients	B-UNK
had	O
received	B-UNK
maximum	B-UNK
doses	B-UNK
of	O
other	O
beta-lactam	B-UNK
antibiotics	B-UNK
without	O
evidence	B-UNK
of	O
seizure	B-UNK
activity	B-UNK
.	O

The	O
ability	B-UNK
of	O
insulin	B-CHEMICAL
treatment	B-UNK
to	O
reverse	B-UNK
or	O
prevent	B-UNK
the	O
changes	B-UNK
in	O
urinary	B-DISEASE
bladder	I-DISEASE
function	B-UNK
caused	B-UNK
by	O
streptozotocin	O
-	O
induced	B-UNK
diabetes	B-DISEASE
mellitus	I-DISEASE
.	O

Delayed	B-UNK
institution	O
of	O
hypertension	B-DISEASE
during	O
focal	B-UNK
cerebral	B-UNK
ischemia	B-DISEASE
:	O
effect	B-UNK
on	O
brain	B-DISEASE
edema	I-DISEASE
.	O

The	O
effect	B-UNK
of	O
induced	B-UNK
hypertension	B-DISEASE
instituted	O
after	O
a	O
2-h	O
delay	B-UNK
following	B-UNK
middle	B-UNK
cerebral	B-UNK
artery	B-UNK
occlusion	B-UNK
(	O
MCAO	O
)	O
on	O
brain	B-DISEASE
edema	I-DISEASE
formation	B-UNK
and	O
histochemical	B-UNK
injury	B-UNK
was	O
studied	B-UNK
.	O
Under	O
isoflurane	B-CHEMICAL
anesthesia	B-UNK
,	O
the	O
MCA	O
of	O
14	O
spontaneously	B-UNK
hypertensive	B-UNK
rats	B-UNK
was	O
occluded	O
.	O
In	O
the	O
control	B-UNK
group	B-UNK
(	O
n	B-UNK
=	O
7	O
)	O
,	O
the	O
mean	B-UNK
arterial	B-UNK
pressure	I-UNK
(	O
MAP	O
)	O
was	O
not	O
manipulated	O
.	O
In	O
the	O
hypertensive	B-UNK
group	B-UNK
(	O
n	B-UNK
=	O
7	O
)	O
,	O
the	O
MAP	O
was	O
elevated	B-UNK
by	O
25	O
-	O
30	O
mm	B-UNK
Hg	B-UNK
beginning	B-UNK
2	B-DISEASE
h	B-UNK
after	O
MCAO	O
.	O
Four	O
hours	B-UNK
after	O
MCAO	O
,	O
the	O
rats	B-UNK
were	O
killed	O
and	O
the	O
brains	O
harvested	O
.	O
The	O
brains	O
were	O
sectioned	O
along	O
coronal	O
planes	O
spanning	O
the	O
distribution	O
of	O
ischemia	B-DISEASE
produced	B-UNK
by	O
MCAO	O
.	O
Specific	O
gravity	O
(	O
SG	O
)	O
was	O
determined	O
in	O
the	O
subcortex	O
and	O
in	O
two	O
sites	O
in	O
the	O
cortex	B-UNK
(	O
core	O
and	O
periphery	O
of	O
the	O
ischemic	B-UNK
territory	B-UNK
)	O
.	O
The	O
extent	B-UNK
of	O
neuronal	B-UNK
injury	B-UNK
was	O
determined	O
by	O
2,3,5-triphenyltetrazolium	O
staining	B-UNK
.	O
In	O
the	O
ischemic	B-UNK
core	O
,	O
there	O
was	O
no	O
difference	B-UNK
in	O
SG	O
in	O
the	O
subcortex	O
and	O
cortex	B-UNK
in	O
the	O
two	O
groups	B-UNK
.	O
In	O
the	O
periphery	O
of	O
the	O
ischemic	B-UNK
territory	B-UNK
,	O
SG	O
in	O
the	O
cortex	B-UNK
was	O
greater	B-UNK
(	O
less	O
edema	B-DISEASE
accumulation	B-UNK
)	O
in	O
the	O
hypertensive	B-UNK
group	B-UNK
(	O
1.041	O
+	O
/-	O
0.001	B-UNK
vs	B-UNK
1.039	O
+	O
/-	O
0.001	B-UNK
,	O
P	B-UNK
less	O
than	O
0.05	O
)	O
.	O
The	O
area	B-UNK
of	O
histochemical	B-UNK
injury	B-UNK
(	O
as	O
a	O
percent	O
of	O
the	O
cross-sectional	O
area	B-UNK
of	O
the	O
hemisphere	O
)	O
was	O
less	O
in	O
the	O
hypertensive	B-UNK
group	B-UNK
(	O
33	O
+	O
/-	O
3	O
%	O
vs	B-UNK
21	O
+	O
/-	O
2	B-DISEASE
%	O
,	O
P	B-UNK
less	O
than	O
0.05	O
)	O
.	O
The	O
data	B-UNK
indicate	B-UNK
that	O
phenylephrine	B-CHEMICAL
-	O
induced	B-UNK
hypertension	B-DISEASE
instituted	O
2	B-DISEASE
h	B-UNK
after	O
MCAO	O
does	O
not	O
aggravate	O
edema	B-DISEASE
in	O
the	O
ischemic	B-UNK
core	O
,	O
that	O
it	O
improves	B-UNK
edema	B-DISEASE
in	O
the	O
periphery	O
of	O
the	O
ischemic	B-UNK
territory	B-UNK
,	O
and	O
that	O
it	O
reduces	B-UNK
the	O
area	B-UNK
of	O
histochemical	B-UNK
neuronal	B-UNK
dysfunction	B-UNK
.	O

Amiodarone	O
pulmonary	B-UNK
toxicity	B-UNK
.	O

Amiodarone	O
is	O
an	O
effective	B-UNK
antiarrhythmic	B-UNK
agent	B-UNK
whose	O
utility	O
is	O
limited	O
by	O
many	O
side	O
-	O
effects	B-UNK
,	O
the	O
most	O
problematic	O
being	O
pneumonitis	B-DISEASE
.	O
The	O
pulmonary	B-UNK
toxicity	B-UNK
of	O
amiodarone	B-CHEMICAL
is	O
thought	O
to	O
result	B-UNK
from	O
direct	B-UNK
injury	B-UNK
related	B-UNK
to	O
the	O
intracellular	B-UNK
accumulation	B-UNK
of	O
phospholipid	O
and	O
T	B-UNK
cell	B-UNK
-	O
mediated	B-UNK
hypersensitivity	B-DISEASE
pneumonitis	B-DISEASE
.	O
The	O
clinical	B-UNK
and	O
radiographic	B-UNK
features	B-UNK
of	O
amiodarone	B-CHEMICAL
-	O
induced	B-UNK
pulmonary	B-UNK
toxicity	B-UNK
are	O
characteristic	O
but	O
nonspecific	O
.	O
The	O
diagnosis	B-UNK
depends	O
on	O
exclusion	O
of	O
other	O
entities	O
,	O
such	O
as	O
heart	B-DISEASE
failure	I-DISEASE
,	O
infection	B-UNK
,	O
and	O
malignancy	O
.	O
While	O
withdrawal	B-UNK
of	O
amiodarone	B-CHEMICAL
leads	O
to	O
clinical	B-UNK
improvement	B-UNK
in	O
majority	O
of	O
cases	B-UNK
,	O
this	O
is	O
not	O
always	O
possible	B-UNK
or	O
advisable	O
.	O
Dose	B-UNK
reduction	B-UNK
or	O
concomitant	B-UNK
steroid	B-UNK
therapy	B-UNK
may	O
have	O
a	O
role	B-UNK
in	O
selected	O
patients	B-UNK
.	O

Light	B-UNK
chain	O
proteinuria	B-DISEASE
and	O
cellular	B-UNK
mediated	B-UNK
immunity	O
in	O
rifampin	B-CHEMICAL
treated	B-UNK
patients	B-UNK
with	O
tuberculosis	B-DISEASE
.	O

Light	B-UNK
chain	O
proteinuria	B-UNK
was	O
found	B-UNK
in	O
9	O
of	O
17	B-DISEASE
tuberculosis	B-DISEASE
patients	B-UNK
treated	B-UNK
with	O
rifampin	B-CHEMICAL
.	O
Concomitant	O
assay	B-UNK
of	O
cellular	B-UNK
mediated	B-UNK
immunity	O
in	O
these	O
patients	B-UNK
using	O
skin	B-DISEASE
test	B-UNK
antigen	B-UNK
and	O
a	O
lymphokine	O
in	O
vitro	B-UNK
test	B-UNK
provided	B-UNK
results	B-UNK
that	O
were	O
different	B-UNK
.	O
Response	O
to	O
Varidase	O
skin	B-DISEASE
test	B-UNK
antigen	B-UNK
was	O
negative	B-UNK
for	O
all	O
eight	O
tuberculosis	B-DISEASE
patients	B-UNK
tested	B-UNK
,	O
but	O
there	O
occurred	B-UNK
a	O
hyper-responsiveness	O
of	O
the	O
lymphocytes	B-UNK
of	O
these	O
eight	O
patients	B-UNK
to	O
phytomitogen	O
(	O
PHA	O
-	O
P	B-UNK
)	O
.	O
as	O
well	O
as	O
of	O
those	O
of	O
seven	O
other	O
tuberculous	O
patients	B-UNK
.	O
This	O
last	O
finding	O
may	O
be	O
related	B-UNK
to	O
time	B-UNK
of	O
testing	B-UNK
and	O
/	O
or	O
endogenous	B-UNK
serum	B-UNK
binding	B-UNK
of	O
rifampin	B-CHEMICAL
which	O
could	O
have	O
inhibited	B-UNK
mitogen	O
activity	B-UNK
for	O
the	O
lymphocyte	B-UNK
.	O

Initial	O
potassium	B-CHEMICAL
loss	B-UNK
and	O
hypokalaemia	O
during	O
chlorthalidone	B-CHEMICAL
administration	B-UNK
in	O
patients	B-UNK
with	O
essential	B-DISEASE
hypertension	I-DISEASE
:	O
the	O
influence	B-UNK
of	O
dietary	O
sodium	B-CHEMICAL
restriction	O
.	O

To	O
investigate	O
the	O
initial	B-UNK
potassium	B-CHEMICAL
loss	B-UNK
and	O
development	B-UNK
of	O
hypokalaemia	O
during	O
the	O
administration	B-UNK
of	O
an	O
oral	B-UNK
diuretic	B-UNK
,	O
metabolic	B-UNK
balance	O
studies	B-UNK
were	O
performed	B-UNK
in	O
ten	B-DISEASE
patients	B-UNK
with	O
essential	B-DISEASE
hypertension	I-DISEASE
who	O
had	O
shown	B-UNK
hypokalaemia	O
under	O
prior	B-UNK
oral	B-UNK
diuretic	B-UNK
treatment	B-UNK
.	O
Chlorthalidone	O
(	O
50	O
mg	B-UNK
daily	B-UNK
)	O
was	O
given	B-UNK
for	O
14	O
days	B-UNK
.	O
Six	O
patients	B-UNK
received	B-UNK
a	O
normal	B-UNK
-	O
sodium	B-CHEMICAL
diet	B-UNK
and	O
four	O
a	O
low	B-UNK
-	O
sodium	B-CHEMICAL
(	O
17	B-DISEASE
mmol	B-UNK
/	O
day	B-UNK
)	O
diet	B-UNK
.	O
All	O
patients	B-UNK
had	O
a	O
normal	B-UNK
initial	B-UNK
total	B-UNK
body	B-UNK
potassium	B-CHEMICAL
(	O
40	O
K	O
)	O
.	O
The	O
electrolyte	B-UNK
balances	O
,	O
weight	B-UNK
,	O
bromide	O
space	B-UNK
,	O
plasma	B-UNK
renin	O
activity	B-UNK
,	O
and	O
aldosterone	B-CHEMICAL
secretion	B-UNK
rate	B-UNK
were	O
measured	B-UNK
.	O
In	O
both	O
groups	B-UNK
a	O
potassium	B-CHEMICAL
deficit	B-UNK
developed	B-UNK
,	O
with	O
proportionally	O
larger	B-UNK
losses	O
from	O
the	O
extracellular	B-UNK
than	O
from	O
the	O
intracellular	B-UNK
compartment	O
.	O
In	O
the	O
normal	B-UNK
-	O
sodium	B-CHEMICAL
group	B-UNK
the	O
highest	B-UNK
mean	B-UNK
potassium	B-CHEMICAL
deficit	B-UNK
was	O
176	O
mmol	B-UNK
on	O
day	B-UNK
9	O
,	O
after	O
which	O
some	O
potassium	B-CHEMICAL
was	O
regained	O
;	O
in	O
the	O
low	B-UNK
-	O
sodium	B-CHEMICAL
group	B-UNK
the	O
highest	B-UNK
deficit	B-UNK
was	O
276	O
mmol	B-UNK
on	O
day	B-UNK
13	O
.	O
The	O
normal	B-UNK
-	O
sodium	B-CHEMICAL
group	B-UNK
showed	B-UNK
an	O
immediate	B-UNK
but	O
temporary	O
rise	B-UNK
of	O
the	O
renin	O
and	O
aldosterone	B-CHEMICAL
levels	B-UNK
;	O
in	O
the	O
low	B-UNK
-	O
sodium	B-CHEMICAL
group	B-UNK
renin	O
and	O
aldosterone	B-CHEMICAL
increased	B-UNK
more	O
slowly	O
but	O
remained	B-UNK
elevated	B-UNK
.	O
It	O
is	O
concluded	O
that	O
dietary	O
sodium	B-CHEMICAL
restriction	O
increases	B-UNK
diuretic	B-UNK
-	O
induced	B-UNK
potassium	B-CHEMICAL
loss	B-UNK
,	O
presumably	O
by	O
an	O
increased	B-UNK
activity	B-UNK
of	O
the	O
renin	O
-	O
angiotensin	B-UNK
-	O
aldosterone	B-CHEMICAL
system	B-UNK
,	O
while	O
sodium	B-CHEMICAL
delivery	B-UNK
to	O
the	O
distal	B-UNK
renal	B-UNK
tubules	O
remains	B-UNK
sufficiently	O
high	B-UNK
to	O
allow	O
increased	B-UNK
potassium	B-CHEMICAL
secretion	B-UNK
.	O

Dynamic	O
response	B-UNK
of	O
blood	B-UNK
vessel	O
in	O
acute	B-DISEASE
renal	I-DISEASE
failure	I-DISEASE
.	O

In	O
this	O
study	B-UNK
we	O
postulated	O
that	O
during	O
acute	B-DISEASE
renal	I-DISEASE
failure	I-DISEASE
induced	B-UNK
by	O
gentamicin	B-UNK
the	O
transient	B-UNK
or	O
dynamic	B-UNK
response	B-UNK
of	O
blood	B-UNK
vessels	O
could	O
be	O
affected	B-UNK
,	O
and	O
that	O
antioxidants	B-CHEMICAL
can	O
prevent	B-UNK
the	O
changes	B-UNK
in	O
dynamic	B-UNK
responses	B-UNK
of	O
blood	B-UNK
vessels	O
.	O
The	O
new	B-UNK
approach	B-UNK
to	O
ex	B-UNK
vivo	B-UNK
blood	B-UNK
vessel	O
experiments	B-UNK
in	O
which	O
not	O
only	O
the	O
end	B-UNK
points	B-UNK
of	O
vessels	O
response	B-UNK
within	O
the	O
time	B-UNK
interval	B-UNK
is	O
considered	B-UNK
,	O
but	O
also	O
dynamics	O
of	O
this	O
response	B-UNK
,	O
was	O
used	O
in	O
this	O
paper	O
.	O
Our	O
results	B-UNK
confirm	B-UNK
the	O
alteration	O
in	O
dynamic	B-UNK
response	B-UNK
of	O
blood	B-UNK
vessels	O
during	O
the	O
change	B-UNK
of	O
pressure	B-UNK
in	O
gentamicin	B-UNK
-	O
treated	B-UNK
animals	B-UNK
.	O
The	O
beneficial	B-UNK
effects	B-UNK
of	O
vitamin	B-UNK
C	B-UNK
administration	B-UNK
to	O
gentamicin	B-UNK
-	O
treated	B-UNK
animals	B-UNK
are	O
also	O
confirmed	B-UNK
through	O
:	O
lower	B-UNK
level	B-UNK
of	O
blood	B-UNK
urea	B-CHEMICAL
and	O
creatinine	B-CHEMICAL
and	O
higher	B-UNK
level	B-UNK
of	O
potassium	B-CHEMICAL
.	O
The	O
pressure	B-UNK
dynamic	B-UNK
responses	B-UNK
of	O
isolated	B-UNK
blood	B-UNK
vessels	O
show	O
a	O
faster	O
pressure	B-UNK
change	B-UNK
in	O
gentamicin	B-UNK
-	O
treated	B-UNK
animals	B-UNK
(	O
8.07	O
+	O
/-	O
1.7	O
s	O
vs	B-UNK
.	O
5.64	O
+	O
/-	O
0.18	O
s	O
)	O
.	O
Vitamin	B-UNK
C	B-UNK
administration	B-UNK
induced	B-UNK
slowdown	O
of	O
pressure	B-UNK
change	B-UNK
back	O
to	O
the	O
control	B-UNK
values	B-UNK
.	O
The	O
pressure	B-UNK
dynamic	B-UNK
properties	B-UNK
,	O
quantitatively	O
defined	O
by	O
comparative	O
pressure	B-UNK
dynamic	B-UNK
and	O
total	B-UNK
pressure	B-UNK
dynamic	B-UNK
,	O
confirm	B-UNK
the	O
alteration	O
in	O
dynamic	B-UNK
response	B-UNK
of	O
blood	B-UNK
vessels	O
during	O
the	O
change	B-UNK
of	O
pressure	B-UNK
in	O
gentamicin	B-UNK
-	O
treated	B-UNK
animals	B-UNK
and	O
beneficial	B-UNK
effects	B-UNK
of	O
vitamin	B-UNK
C	B-UNK
administration	B-UNK
.	O

The	O
hemodynamics	O
of	O
oxytocin	B-CHEMICAL
and	O
other	O
vasoactive	O
agents	B-UNK
during	O
neuraxial	B-UNK
anesthesia	B-UNK
for	O
cesarean	B-UNK
delivery	B-UNK
:	O
findings	B-UNK
in	O
six	O
cases	B-UNK
.	O

Oxytocin	O
is	O
a	O
commonly	B-UNK
used	O
uterotonic	O
that	O
can	O
cause	B-UNK
significant	B-UNK
and	O
even	O
fatal	B-UNK
hypotension	B-DISEASE
,	O
particularly	O
when	O
given	B-UNK
as	O
a	O
bolus	B-UNK
.	O
The	O
resulting	B-UNK
hypotension	B-DISEASE
can	O
be	O
produced	B-UNK
by	O
a	O
decrease	B-UNK
in	O
systemic	B-UNK
vascular	B-UNK
resistance	B-UNK
or	O
cardiac	B-DISEASE
output	I-DISEASE
through	O
a	O
decrease	B-UNK
in	O
venous	B-UNK
return	B-UNK
.	O
Parturients	O
with	O
normal	B-UNK
volume	B-UNK
status	B-UNK
,	O
heart	B-UNK
valves	O
and	O
pulmonary	B-UNK
vasculature	O
most	O
often	O
respond	O
to	O
this	O
hypotension	B-DISEASE
with	O
a	O
compensatory	B-UNK
increase	B-UNK
in	O
heart	B-UNK
rate	I-UNK
and	O
stroke	B-UNK
volume	B-UNK
.	O
Oxytocin	O
-	O
induced	B-UNK
hypotension	B-DISEASE
at	B-DISEASE
cesarean	B-UNK
delivery	B-UNK
may	O
be	O
incorrectly	O
attributed	B-UNK
to	O
blood	B-DISEASE
loss	I-DISEASE
.	O
Pulse	B-UNK
power	B-UNK
analysis	B-UNK
(	O
also	O
called	O
"	O
pulse	B-UNK
contour	O
analysis	B-UNK
"	O
)	O
of	O
an	O
arterial	B-UNK
pressure	I-UNK
wave	O
form	B-UNK
allows	O
continuous	B-UNK
evaluation	B-UNK
of	O
systemic	B-UNK
vascular	B-UNK
resistance	B-UNK
and	O
cardiac	B-DISEASE
output	I-DISEASE
in	O
real	O
time	B-UNK
,	O
thereby	O
elucidating	O
the	O
causative	O
factors	B-UNK
behind	O
changes	B-UNK
in	O
blood	B-UNK
pressure	B-UNK
.	O
Pulse	B-UNK
power	B-UNK
analysis	B-UNK
was	O
conducted	O
in	O
six	O
cases	B-UNK
of	O
cesarean	B-UNK
delivery	B-UNK
performed	B-UNK
under	O
neuraxial	B-UNK
anesthesia	B-UNK
.	O
Hypotension	O
in	O
response	B-UNK
to	O
oxytocin	B-CHEMICAL
was	O
associated	B-UNK
with	O
a	O
decrease	B-UNK
in	O
systemic	B-UNK
vascular	B-UNK
resistance	B-UNK
and	O
a	O
compensatory	B-UNK
increase	B-UNK
in	O
stroke	B-UNK
volume	B-UNK
,	O
heart	B-UNK
rate	I-UNK
and	O
cardiac	B-DISEASE
output	I-DISEASE
.	O
Pulse	B-UNK
power	B-UNK
analysis	B-UNK
may	O
be	O
helpful	O
in	O
determining	O
the	O
etiology	O
of	O
and	O
treating	B-UNK
hypotension	B-DISEASE
during	O
cesarean	B-UNK
delivery	B-UNK
under	O
neuraxial	B-UNK
anesthesia	B-UNK
.	O

Exaggerated	O
expression	B-UNK
of	O
inflammatory	B-UNK
mediators	B-UNK
in	O
vasoactive	O
intestinal	O
polypeptide	O
knockout	B-UNK
(	O
VIP-/-	O
)	O
mice	B-UNK
with	O
cyclophosphamide	B-CHEMICAL
(	O
CYP)-induced	O
cystitis	B-DISEASE
.	O

Vasoactive	O
intestinal	O
polypeptide	O
(	O
VIP	O
)	O
is	O
an	O
immunomodulatory	O
neuropeptide	O
distributed	O
in	O
micturition	B-UNK
pathways	B-UNK
.	O
VIP(-/-	O
)	O
mice	B-UNK
exhibit	B-UNK
altered	B-UNK
bladder	B-UNK
function	B-UNK
and	O
neurochemical	B-UNK
properties	B-UNK
in	O
micturition	B-UNK
pathways	B-UNK
after	O
cyclophosphamide	B-CHEMICAL
(	O
CYP)-induced	O
cystitis	B-DISEASE
.	O
Given	O
VIP'	O
s	O
role	B-UNK
as	O
an	O
anti-inflammatory	O
mediator	B-UNK
,	O
we	O
hypothesized	O
that	O
VIP(-/-	O
)	O
mice	B-UNK
would	O
exhibit	B-UNK
enhanced	B-UNK
inflammatory	B-UNK
mediator	B-UNK
expression	B-UNK
after	O
cystitis	B-DISEASE
.	O
A	O
mouse	B-UNK
inflammatory	B-UNK
cytokine	B-UNK
and	O
receptor	B-UNK
RT2	O
profiler	O
array	O
was	O
used	O
to	O
determine	B-UNK
regulated	O
transcripts	O
in	O
the	O
urinary	B-DISEASE
bladder	I-DISEASE
of	O
wild	O
type	B-UNK
(	O
WT	O
)	O
and	O
VIP(-/-	O
)	O
mice	B-UNK
with	O
or	O
without	O
CYP	B-UNK
-	O
induced	B-UNK
cystitis	B-DISEASE
(	O
150	O
mg	B-UNK
/	O
kg	B-UNK
;	O
i.p	B-UNK
.	O
;	O
48	O
h	B-UNK
)	O
.	O
Four	O
binary	O
comparisons	O
were	O
made	O
:	O
WT	O
control	B-UNK
versus	B-UNK
CYP	B-UNK
treatment	I-UNK
(	O
48	O
h	B-UNK
)	O
,	O
VIP(-/-	O
)	O
control	B-UNK
versus	B-UNK
CYP	B-UNK
treatment	I-UNK
(	O
48	O
h	B-UNK
)	O
,	O
WT	O
control	B-UNK
versus	B-UNK
VIP(-/-	O
)	O
control	B-UNK
,	O
and	O
WT	O
with	O
CYP	B-UNK
treatment	I-UNK
(	O
48	O
h	B-UNK
)	O
versus	B-UNK
VIP(-/-	O
)	O
with	O
CYP	B-UNK
treatment	I-UNK
(	O
48	O
h	B-UNK
)	O
.	O
The	O
genes	B-UNK
presented	B-UNK
represent	B-UNK
(	O
1	O
)	O
greater	B-UNK
than	O
1.5-fold	O
change	B-UNK
in	O
either	O
direction	O
and	O
(	O
2	B-DISEASE
)	O
the	O
p	B-UNK
value	B-UNK
is	O
less	O
than	O
0.05	O
for	O
the	O
comparison	O
being	O
made	O
.	O
Several	O
regulated	O
genes	B-UNK
were	O
validated	O
using	O
enzyme	B-UNK
-	O
linked	B-UNK
immunoassays	O
including	B-UNK
IL-1beta	O
and	O
CXCL1	O
.	O
CYP	B-UNK
treatment	I-UNK
significantly	B-UNK
(	O
p	B-UNK
<	I-UNK
or	O
=	O
0.001	B-UNK
)	O
increased	B-UNK
expression	B-UNK
of	O
CXCL1	O
and	O
IL-1beta	O
in	O
the	O
urinary	B-DISEASE
bladder	I-DISEASE
of	O
WT	O
and	O
VIP(-/-	O
)	O
mice	B-UNK
,	O
but	O
expression	B-UNK
in	O
VIP(-/-	O
)	O
mice	B-UNK
with	O
CYP	B-UNK
treatment	I-UNK
was	O
significantly	B-UNK
(	O
p	B-UNK
<	I-UNK
or	O
=	O
0.001	B-UNK
)	O
greater	B-UNK
(	O
4.2-	O
to	O
13-fold	O
increase	B-UNK
)	O
than	O
that	O
observed	B-UNK
in	O
WT	O
urinary	B-DISEASE
bladder	I-DISEASE
(	O
3.6-	O
to	O
5-fold	O
increase	B-UNK
)	O
.	O
The	O
data	B-UNK
suggest	B-UNK
that	O
in	O
VIP(-/-	O
)	O
mice	B-UNK
with	O
bladder	B-DISEASE
inflammation	I-DISEASE
,	O
inflammatory	B-UNK
mediators	B-UNK
are	O
increased	B-UNK
above	O
that	O
observed	B-UNK
in	O
WT	O
with	O
CYP	B-UNK
.	O
This	O
shift	O
in	O
balance	O
may	O
contribute	O
to	O
increased	B-UNK
bladder	B-UNK
dysfunction	B-UNK
in	O
VIP(-/-	O
)	O
mice	B-UNK
with	O
bladder	B-DISEASE
inflammation	I-DISEASE
and	O
altered	B-UNK
neurochemical	B-UNK
expression	B-UNK
in	O
micturition	B-UNK
pathways	B-UNK
.	O

Intraocular	O
pressure	B-UNK
in	O
patients	B-UNK
with	O
uveitis	B-DISEASE
treated	B-UNK
with	O
fluocinolone	B-CHEMICAL
acetonide	I-CHEMICAL
implants	O
.	O

OBJECTIVE	O
:	O
To	O
report	B-UNK
the	O
incidence	B-UNK
and	O
management	B-UNK
of	O
elevated	B-UNK
intraocular	B-UNK
pressure	B-UNK
(	O
IOP	B-UNK
)	O
in	O
patients	B-UNK
with	O
uveitis	B-DISEASE
treated	B-UNK
with	O
the	O
fluocinolone	B-CHEMICAL
acetonide	I-CHEMICAL
(	O
FA	O
)	O
intravitreal	B-UNK
implant	B-UNK
.	O
DESIGN	B-UNK
:	O
Pooled	O
data	B-UNK
from	O
3	O
multicenter	O
,	O
double-masked	O
,	O
randomized	B-UNK
,	O
controlled	B-UNK
,	O
phase	B-UNK
2b/3	O
clinical	B-UNK
trials	B-UNK
evaluating	O
the	O
safety	B-UNK
and	O
efficacy	B-UNK
of	O
the	O
0.59-mg	O
or	O
2.1-mg	O
FA	O
intravitreal	B-UNK
implant	B-UNK
or	O
standard	B-UNK
therapy	B-UNK
were	O
analyzed	B-UNK
.	O
RESULTS	B-UNK
:	O
During	O
the	O
3-year	O
follow	B-UNK
-	O
up	O
,	O
71.0	O
%	O
of	O
implanted	B-UNK
eyes	B-UNK
had	O
an	O
IOP	B-UNK
increase	B-UNK
of	O
10	O
mm	B-UNK
Hg	B-UNK
or	O
more	O
than	O
baseline	B-UNK
and	O
55.1	O
%	O
,	O
24.7	O
%	O
,	O
and	O
6.2	O
%	O
of	O
eyes	B-UNK
reached	B-UNK
an	O
IOP	B-UNK
of	O
30	O
mm	B-UNK
Hg	B-UNK
or	O
more	O
,	O
40	O
mm	B-UNK
Hg	B-UNK
or	O
more	O
,	O
and	O
50	O
mm	B-UNK
Hg	B-UNK
or	O
more	O
,	O
respectively	O
.	O
Topical	O
IOP	B-UNK
-	O
lowering	B-UNK
medication	B-UNK
was	O
administered	B-UNK
in	O
74.8	O
%	O
of	O
implanted	B-UNK
eyes	B-UNK
,	O
and	O
IOP	B-UNK
-	O
lowering	B-UNK
surgeries	O
,	O
most	O
of	O
which	O
were	O
trabeculectomies	O
(	O
76.2	O
%	O
)	O
,	O
were	O
performed	B-UNK
on	O
36.6	O
%	O
of	O
implanted	B-UNK
eyes	B-UNK
.	O
Intraocular	O
pressure	B-UNK
-	O
lowering	B-UNK
surgeries	O
were	O
considered	B-UNK
a	O
success	O
(	O
postoperative	B-UNK
IOP	B-UNK
of	O
6	O
-	O
21	O
mm	B-UNK
Hg	B-UNK
with	O
or	O
without	O
additional	B-UNK
IOP	B-UNK
-	O
lowering	B-UNK
medication	B-UNK
)	O
in	O
85.1	O
%	O
of	O
eyes	B-UNK
at	B-DISEASE
1	O
year	B-UNK
.	O
The	O
rate	B-UNK
of	O
hypotony	O
(	O
IOP	B-UNK
<	O
/=	O
5	O
mm	B-UNK
Hg	B-UNK
)	O
following	B-UNK
IOP	B-UNK
-	O
lowering	B-UNK
surgery	B-UNK
(	O
42.5	O
%	O
)	O
was	O
not	O
different	B-UNK
from	O
that	O
of	O
implanted	B-UNK
eyes	B-UNK
not	O
subjected	O
to	O
surgery	B-UNK
(	O
35.4	O
%	O
)	O
(	O
P	B-UNK
=	I-UNK
.09	O
)	O
.	O
CONCLUSION	O
:	O
Elevated	O
IOP	B-UNK
is	O
a	O
significant	B-UNK
complication	B-UNK
with	O
the	O
FA	O
intravitreal	B-UNK
implant	B-UNK
but	O
may	O
be	O
controlled	B-UNK
with	O
medication	B-UNK
and	O
surgery	B-UNK
.	O

Pallidal	B-UNK
stimulation	B-UNK
:	O
an	O
alternative	B-UNK
to	O
pallidotomy	B-UNK
?	O

A	O
resurgence	O
of	O
interest	O
in	O
the	O
surgical	B-UNK
treatment	B-UNK
of	O
Parkinson'	O
s	O
disease	B-DISEASE
(	O
PD	O
)	O
came	O
with	O
the	O
rediscovery	O
of	O
posteroventral	O
pallidotomy	B-UNK
by	O
Laitinen	O
in	O
1985	O
.	O
Laitinen'	O
s	O
procedure	B-UNK
improved	B-UNK
most	O
symptoms	B-UNK
in	O
drug	B-UNK
-	O
resistant	B-UNK
PD	O
,	O
which	O
engendered	O
wide	B-UNK
interest	O
in	O
the	O
neurosurgical	O
community	O
.	O
Another	O
lesioning	O
procedure	B-UNK
,	O
ventrolateral	B-UNK
thalamotomy	O
,	O
has	O
become	O
a	O
powerful	O
alternative	B-UNK
to	O
stimulate	O
the	O
nucleus	B-UNK
ventralis	B-UNK
intermedius	O
,	O
producing	O
high	B-UNK
long	B-UNK
-	O
term	B-UNK
success	O
rates	B-UNK
and	O
low	B-UNK
morbidity	O
rates	B-UNK
.	O
Pallidal	B-UNK
stimulation	B-UNK
has	O
not	O
met	O
with	O
the	O
same	O
success	O
.	O
According	O
to	O
the	O
literature	B-UNK
pallidotomy	B-UNK
improves	B-UNK
the	O
"	O
on	O
"	O
symptoms	B-UNK
of	O
PD	O
,	O
such	O
as	O
dyskinesias	B-DISEASE
,	O
as	O
well	O
as	O
the	O
"	O
off	O
"	O
symptoms	B-UNK
,	O
such	O
as	O
rigidity	B-UNK
,	O
bradykinesia	O
,	O
and	O
on	O
-	O
off	O
fluctuations	B-UNK
.	O
Pallidal	B-UNK
stimulation	B-UNK
improves	B-UNK
bradykinesia	O
and	O
rigidity	B-UNK
to	O
a	O
minor	B-UNK
extent	B-UNK
;	O
however	O
,	O
its	O
strength	O
seems	O
to	O
be	O
in	O
improving	O
levodopa	B-CHEMICAL
-	O
induced	B-UNK
dyskinesias	B-DISEASE
.	O
Stimulation	O
often	O
produces	B-UNK
an	O
improvement	B-UNK
in	O
the	O
hyper-	O
or	O
dyskinetic	B-UNK
upper	B-UNK
limbs	B-UNK
,	O
but	O
increases	B-UNK
the	O
"	O
freezing	O
"	O
phenomenon	B-UNK
in	O
the	O
lower	B-UNK
limbs	B-UNK
at	B-DISEASE
the	O
same	O
time	B-UNK
.	O
Considering	O
the	O
small	B-UNK
increase	B-UNK
in	O
the	O
patient'	O
s	O
independence	O
,	O
the	O
high	B-UNK
costs	O
of	O
bilateral	B-UNK
implants	O
,	O
and	O
the	O
difficulty	O
most	O
patients	B-UNK
experience	B-UNK
in	O
handling	O
the	O
devices	O
,	O
the	O
question	O
arises	O
as	O
to	O
whether	O
bilateral	B-UNK
pallidal	O
stimulation	B-UNK
is	O
a	O
real	O
alternative	B-UNK
to	O
pallidotomy	B-UNK
.	O

Case	B-UNK
report	B-UNK
:	O
Dexatrim	O
(	O
Phenylpropanolamine	O
)	O
as	O
a	O
cause	B-UNK
of	O
myocardial	B-DISEASE
infarction	I-DISEASE
.	O

Phenylpropanolamine	O
(	O
PPA	O
)	O
is	O
a	O
sympathetic	B-UNK
amine	O
used	O
in	O
over	O
-	O
the	O
-	O
counter	O
cold	B-DISEASE
remedies	O
and	O
weight	B-UNK
-	O
control	B-UNK
preparations	B-UNK
worldwide	O
.	O
Its	O
use	B-UNK
has	O
been	O
associated	B-UNK
with	O
hypertensive	B-UNK
episodes	B-UNK
and	O
hemorrhagic	B-UNK
strokes	B-UNK
in	O
younger	O
women	B-UNK
.	O
Several	O
reports	B-UNK
have	O
linked	B-UNK
the	O
abuse	B-UNK
of	O
PPA	O
with	O
myocardial	B-UNK
injury	B-UNK
,	O
especially	B-UNK
when	O
overdose	B-UNK
is	O
involved	B-UNK
.	O
We	O
report	B-UNK
here	O
the	O
first	O
case	B-UNK
of	O
Dexatrim	O
(	O
PPA)-induced	O
myocardial	B-UNK
injury	B-UNK
in	O
a	O
young	B-UNK
woman	B-UNK
who	O
was	O
using	O
it	O
at	B-DISEASE
recommended	B-UNK
doses	B-UNK
for	O
weight	B-UNK
control	B-UNK
.	O
In	O
addition	O
,	O
we	O
review	B-UNK
the	O
7	O
other	O
cases	B-UNK
of	O
PPA	O
related	B-UNK
myocardial	B-UNK
injury	B-UNK
that	O
have	O
been	O
reported	B-UNK
so	O
far	O
.	O
Physicians	O
and	O
patients	B-UNK
should	O
be	O
alert	O
to	O
the	O
potential	B-UNK
cardiac	B-UNK
risk	B-UNK
associated	B-UNK
with	O
the	O
use	B-UNK
of	O
PPA	O
,	O
even	O
at	B-DISEASE
doses	B-UNK
generally	B-UNK
considered	B-UNK
to	O
be	O
safe	B-UNK
.	O

Risperidone	O
-	O
associated	B-UNK
,	O
benign	O
transient	B-UNK
visual	B-UNK
disturbances	B-UNK
in	O
schizophrenic	B-UNK
patients	B-UNK
with	O
a	O
past	B-UNK
history	B-UNK
of	O
LSD	B-UNK
abuse	B-UNK
.	O

Two	O
schizophrenic	B-UNK
patients	B-UNK
,	O
who	O
had	O
a	O
prior	B-UNK
history	B-UNK
of	O
LSD	B-UNK
abuse	B-UNK
and	O
who	O
had	O
previously	B-UNK
developed	B-UNK
EPS	O
with	O
classic	B-UNK
antipsychotics	B-UNK
,	O
were	O
successfully	B-UNK
treated	B-UNK
with	O
risperidone	B-CHEMICAL
.	O
They	O
both	O
reported	B-UNK
short	B-UNK
episodes	B-UNK
of	O
transient	B-UNK
visual	B-UNK
disturbances	B-UNK
,	O
which	O
appeared	B-UNK
immediately	B-UNK
after	O
starting	B-UNK
treatment	B-UNK
with	O
risperidone	B-CHEMICAL
.	O
This	O
imagery	O
resembled	O
visual	B-UNK
disturbances	B-UNK
previously	B-UNK
experienced	B-UNK
as	O
"	O
flashbacks	O
"	O
related	B-UNK
to	O
prior	B-UNK
LSD	B-UNK
consumption	B-UNK
.	O
Risperidone	O
administration	B-UNK
was	O
continued	B-UNK
and	O
the	O
visual	B-UNK
disturbances	B-UNK
gradually	B-UNK
wore	O
off	O
.	O
During	O
a	O
six	O
-	O
month	O
follow	B-UNK
-	O
up	O
period	B-UNK
,	O
there	O
was	O
no	O
recurrence	B-DISEASE
of	O
visual	B-UNK
disturbances	B-UNK
.	O
This	O
phenomenon	B-UNK
may	O
be	O
interpreted	O
as	O
a	O
benign	O
,	O
short	B-UNK
-	O
term	B-UNK
and	O
self	O
-	O
limiting	B-UNK
side	O
effect	B-UNK
which	O
does	O
not	O
contraindicate	O
the	O
use	B-UNK
of	O
risperidone	B-CHEMICAL
or	O
interfere	O
with	O
treatment	B-UNK
.	O
Conclusions	O
based	B-UNK
on	O
two	O
case	B-UNK
reports	B-UNK
should	O
be	O
taken	O
with	O
appropriate	B-UNK
caution	B-UNK
.	O

Activation	O
of	O
poly(ADP	O
-	O
ribose	B-CHEMICAL
)	O
polymerase	O
contributes	B-UNK
to	O
development	B-UNK
of	O
doxorubicin	B-CHEMICAL
-	O
induced	B-UNK
heart	B-DISEASE
failure	I-DISEASE
.	O

Activation	O
of	O
the	O
nuclear	B-UNK
enzyme	B-UNK
poly(ADP	O
-	O
ribose	B-CHEMICAL
)	O
polymerase	O
(	O
PARP	B-UNK
)	O
by	O
oxidant	O
-	O
mediated	B-UNK
DNA	B-UNK
damage	B-UNK
is	O
an	O
important	B-UNK
pathway	B-UNK
of	O
cell	B-UNK
dysfunction	B-UNK
and	O
tissue	B-UNK
injury	B-UNK
in	O
conditions	B-UNK
associated	B-UNK
with	O
oxidative	B-UNK
stress	B-UNK
.	O
Increased	B-UNK
oxidative	B-UNK
stress	B-UNK
is	O
a	O
major	B-UNK
factor	B-UNK
implicated	B-UNK
in	O
the	O
cardiotoxicity	B-DISEASE
of	O
doxorubicin	B-CHEMICAL
(	O
DOX	O
)	O
,	O
a	O
widely	B-UNK
used	O
antitumor	B-UNK
anthracycline	O
antibiotic	B-UNK
.	O
Thus	O
,	O
we	O
hypothesized	O
that	O
the	O
activation	B-UNK
of	O
PARP	B-UNK
may	O
contribute	O
to	O
the	O
DOX	O
-	O
induced	B-UNK
cardiotoxicity	B-DISEASE
.	O
Using	O
a	O
dual	B-UNK
approach	B-UNK
of	O
PARP-1	O
suppression	B-UNK
,	O
by	O
genetic	B-UNK
deletion	B-UNK
or	O
pharmacological	B-UNK
inhibition	B-UNK
with	O
the	O
phenanthridinone	O
PARP	B-UNK
inhibitor	B-UNK
PJ34	O
,	O
we	O
now	O
demonstrate	B-UNK
the	O
role	B-UNK
of	O
PARP	B-UNK
in	O
the	O
development	B-UNK
of	O
cardiac	B-UNK
dysfunction	B-UNK
induced	B-UNK
by	O
DOX	O
.	O
PARP-1+/+	O
and	O
PARP-1-/-	O
mice	B-UNK
received	B-UNK
a	O
single	B-UNK
injection	B-UNK
of	O
DOX	O
(	O
25	O
mg	B-UNK
/	O
kg	B-UNK
i.p	B-UNK
)	O
.	O
Five	O
days	B-UNK
after	O
DOX	O
administration	B-UNK
,	O
left	B-UNK
ventricular	I-UNK
performance	B-UNK
was	O
significantly	B-UNK
depressed	B-UNK
in	O
PARP-1+/+	O
mice	B-UNK
,	O
but	O
only	O
to	O
a	O
smaller	B-UNK
extent	B-UNK
in	O
PARP-1-/-	O
ones	O
.	O
Similar	B-UNK
experiments	B-UNK
were	O
conducted	O
in	O
BALB	O
/	O
c	B-UNK
mice	B-UNK
treated	B-UNK
with	O
PJ34	O
or	O
vehicle	B-UNK
.	O
Treatment	O
with	O
a	O
PJ34	O
significantly	B-UNK
improved	B-UNK
cardiac	B-UNK
dysfunction	B-UNK
and	O
increased	B-UNK
the	O
survival	B-UNK
of	O
the	O
animals	B-UNK
.	O
In	O
addition	O
PJ34	O
significantly	B-UNK
reduced	B-UNK
the	O
DOX	O
-	O
induced	B-UNK
increase	B-UNK
in	O
the	O
serum	B-UNK
lactate	B-UNK
dehydrogenase	B-UNK
and	O
creatine	B-CHEMICAL
kinase	B-UNK
activities	B-UNK
but	O
not	O
metalloproteinase	O
activation	B-UNK
in	O
the	O
heart	B-UNK
.	O
Thus	O
,	O
PARP	B-UNK
activation	B-UNK
contributes	B-UNK
to	O
the	O
cardiotoxicity	B-DISEASE
of	O
DOX	O
.	O
PARP	B-UNK
inhibitors	B-UNK
may	O
exert	O
protective	B-UNK
effects	B-UNK
against	O
the	O
development	B-UNK
of	O
severe	B-UNK
cardiac	B-UNK
complications	B-UNK
associated	B-UNK
with	O
the	O
DOX	O
treatment	B-UNK
.	O

Fluconazole	O
-	O
induced	B-UNK
torsade	B-UNK
de	B-UNK
pointes	O
.	O

OBJECTIVE	O
:	O
To	O
present	B-UNK
a	O
case	B-UNK
of	O
fluconazole	B-CHEMICAL
-	O
associated	B-UNK
torsade	B-UNK
de	B-UNK
pointes	O
(	O
TDP	O
)	O
and	O
discuss	O
fluconazole'	O
s	O
role	B-UNK
in	O
causing	B-UNK
TDP	O
.	O
CASE	B-UNK
SUMMARY	B-UNK
:	O
A	O
68-year	O
-	O
old	B-UNK
white	B-UNK
woman	B-UNK
with	O
Candida	O
glabrata	O
isolated	B-UNK
from	O
a	O
presacral	O
abscess	B-DISEASE
developed	B-UNK
TDP	O
eight	O
days	B-UNK
after	O
commencing	O
oral	B-UNK
fluconazole	B-CHEMICAL
The	O
patient	B-UNK
had	O
no	O
other	O
risk	B-UNK
factors	I-UNK
for	O
TDP	O
,	O
including	B-UNK
coronary	B-DISEASE
artery	I-DISEASE
disease	I-DISEASE
,	O
cardiomyopathy	B-DISEASE
,	O
congestive	B-DISEASE
heart	I-DISEASE
failure	I-DISEASE
,	O
and	O
electrolyte	B-UNK
abnormalities	B-DISEASE
There	O
was	O
a	O
temporal	B-UNK
association	B-UNK
between	O
the	O
initiation	O
of	O
fluconazole	B-CHEMICAL
and	O
TDP	O
.	O
The	O
TDP	O
resolved	B-UNK
when	O
fluconazole	B-CHEMICAL
was	O
discontinued	O
;	O
however	O
,	O
the	O
patient	B-UNK
continued	B-UNK
to	O
have	O
premature	O
ventricular	B-UNK
contractions	O
and	O
nonsustained	O
ventricular	B-DISEASE
tachycardia	I-DISEASE
(	O
NSVT	O
)	O
until	O
six	O
days	B-UNK
after	O
drug	B-UNK
cessation	B-UNK
DISCUSSION	O
:	O
Use	O
of	O
the	O
Naranjo	B-UNK
probability	B-UNK
scale	B-UNK
indicates	B-UNK
a	O
probable	B-UNK
relationship	B-UNK
between	O
the	O
use	B-UNK
of	O
fluconazole	B-CHEMICAL
and	O
the	O
development	B-UNK
of	O
TDP	O
.	O
The	O
possible	B-UNK
mechanism	B-UNK
is	O
depression	B-DISEASE
of	O
rapidly	B-UNK
activating	O
delayed	B-UNK
rectifier	O
potassium	B-CHEMICAL
currents	O
.	O
In	O
our	O
patient	B-UNK
,	O
there	O
was	O
no	O
other	O
etiology	O
identified	B-UNK
that	O
could	O
explain	O
QT	B-UNK
prolongation	B-UNK
or	O
TDP	O
The	O
complete	B-UNK
disappearance	O
of	O
NSVT	O
and	O
premature	O
ventricular	B-UNK
contractions	O
followed	B-UNK
by	O
normalization	O
of	O
QT	B-UNK
interval	B-UNK
after	O
the	O
drug	B-UNK
was	O
stopped	O
strongly	B-UNK
suggests	B-UNK
fluconazole	B-CHEMICAL
as	O
the	O
etiology	O
.	O
CONCLUSIONS	O
:	O
Clinicians	O
should	O
be	O
aware	O
that	O
fluconazole	B-CHEMICAL
,	O
even	O
at	B-DISEASE
low	B-UNK
doses	B-UNK
,	O
may	O
cause	B-UNK
prolongation	B-UNK
of	O
the	O
QT	B-UNK
interval	B-UNK
,	O
leading	B-UNK
to	O
TDP	O
.	O
Serial	O
electrocardiographic	B-UNK
monitoring	B-UNK
may	O
be	O
considered	B-UNK
when	O
fluconazole	B-CHEMICAL
is	O
administered	B-UNK
in	O
patients	B-UNK
who	O
are	O
at	B-DISEASE
risk	B-UNK
for	O
ventricular	B-UNK
arrhythmias	B-DISEASE
.	O

High	B-UNK
-	O
dose	B-UNK
methylprednisolone	B-CHEMICAL
may	O
do	O
more	O
harm	O
for	O
spinal	B-DISEASE
cord	I-DISEASE
injury	I-DISEASE
.	O

Because	O
of	O
the	O
National	B-UNK
Acute	B-UNK
Spinal	O
Cord	O
Injury	O
Studies	O
(	O
NASCIS	O
)	O
,	O
high	B-UNK
-	O
dose	B-UNK
methylprednisolone	B-CHEMICAL
became	O
the	O
standard	B-UNK
of	O
care	B-UNK
for	O
the	O
acute	B-UNK
spinal	B-DISEASE
cord	I-DISEASE
injury	I-DISEASE
.	O
In	O
the	O
NASCIS	O
,	O
there	O
was	O
no	O
mention	O
regarding	O
the	O
possibility	O
of	O
acute	B-UNK
corticosteroid	O
myopathy	B-DISEASE
that	O
high	B-UNK
-	O
dose	B-UNK
methylprednisolone	B-CHEMICAL
may	O
cause	B-UNK
.	O
The	O
dosage	B-UNK
of	O
methylprednisolone	B-CHEMICAL
recommended	B-UNK
by	O
the	O
NASCIS	O
3	O
is	O
the	O
highest	B-UNK
dose	B-UNK
of	O
steroids	B-CHEMICAL
ever	O
being	O
used	O
during	O
a	O
2-day	O
period	B-UNK
for	O
any	O
clinical	B-UNK
condition	B-UNK
.	O
We	O
hypothesize	O
that	O
it	O
may	O
cause	B-UNK
some	O
damage	B-UNK
to	O
the	O
muscle	B-UNK
of	O
spinal	B-DISEASE
cord	I-DISEASE
injury	I-DISEASE
patients	B-UNK
.	O
Further	O
,	O
steroid	B-UNK
myopathy	B-DISEASE
recovers	O
naturally	O
and	O
the	O
neurological	B-UNK
improvement	B-UNK
shown	B-UNK
in	O
the	O
NASCIS	O
may	O
be	O
just	O
a	O
recording	O
of	O
this	O
natural	O
motor	B-UNK
recovery	B-UNK
from	O
the	O
steroid	B-UNK
myopathy	B-DISEASE
,	O
instead	O
of	O
any	O
protection	B-UNK
that	O
methylprednisolone	B-CHEMICAL
offers	O
to	O
the	O
spinal	B-DISEASE
cord	I-DISEASE
injury	I-DISEASE
.	O
To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
discussion	O
considering	O
the	O
possibility	O
that	O
the	O
methylprednisolone	B-CHEMICAL
recommended	B-UNK
by	O
NASCIS	O
may	O
cause	B-UNK
acute	B-UNK
corticosteroid	O
myopathy	B-DISEASE
.	O

Probing	O
peripheral	B-UNK
and	O
central	B-UNK
cholinergic	B-UNK
system	B-UNK
responses	B-UNK
.	O

OBJECTIVE	O
:	O
The	O
pharmacological	B-UNK
response	B-UNK
to	O
drugs	B-UNK
that	O
act	O
on	O
the	O
cholinergic	B-UNK
system	B-UNK
of	O
the	O
iris	O
has	O
been	O
used	O
to	O
predict	O
deficits	B-UNK
in	O
central	B-UNK
cholinergic	B-UNK
functioning	B-UNK
due	O
to	O
diseases	B-DISEASE
such	O
as	O
Alzheimer'	O
s	O
disease	B-DISEASE
,	O
yet	O
correlations	O
between	O
central	B-UNK
and	O
peripheral	B-UNK
responses	B-UNK
have	O
not	O
been	O
properly	O
studied	B-UNK
.	O
This	O
study	B-UNK
assessed	B-UNK
the	O
effect	B-UNK
of	O
normal	B-UNK
aging	B-DISEASE
on	O
(	O
1	O
)	O
the	O
tropicamide	B-CHEMICAL
-	O
induced	B-UNK
increase	B-UNK
in	O
pupil	B-DISEASE
diameter	B-UNK
,	O
and	O
(	O
2	B-DISEASE
)	O
the	O
reversal	B-UNK
of	O
this	O
effect	B-UNK
with	O
pilocarpine	B-CHEMICAL
.	O
Scopolamine	O
was	O
used	O
as	O
a	O
positive	B-UNK
control	B-UNK
to	O
detect	B-UNK
age	B-UNK
-	O
dependent	B-UNK
changes	B-UNK
in	O
central	B-UNK
cholinergic	B-UNK
functioning	B-UNK
in	O
the	O
elderly	B-UNK
.	O
DESIGN	B-UNK
:	O
Randomized	O
double-blind	B-UNK
controlled	B-UNK
trial	B-UNK
.	O
PARTICIPANTS	O
:	O
Ten	O
healthy	B-UNK
elderly	B-UNK
(	O
mean	B-UNK
age	B-UNK
70	O
)	O
and	O
9	O
young	B-UNK
(	O
mean	B-UNK
age	B-UNK
33	O
)	O
volunteers	O
.	O
INTERVENTIONS	O
:	O
Pupil	O
diameter	B-UNK
was	O
monitored	B-UNK
using	O
a	O
computerized	O
infrared	O
pupillometer	O
over	O
4	O
hours	B-UNK
.	O
The	O
study	B-UNK
involved	B-UNK
4	O
sessions	O
.	O
In	O
1	O
session	O
,	O
tropicamide	B-CHEMICAL
(	O
20	O
microL	O
,	O
0.01	B-UNK
%	O
)	O
was	O
administered	B-UNK
to	O
one	O
eye	B-UNK
and	O
placebo	B-UNK
to	O
the	O
other	O
.	O
In	O
another	O
session	O
,	O
tropicamide	B-CHEMICAL
(	O
20	O
microL	O
,	O
0.01	B-UNK
%	O
)	O
was	O
administered	B-UNK
to	O
both	O
eyes	B-UNK
,	O
followed	B-UNK
23	O
minutes	B-UNK
later	B-UNK
by	O
the	O
application	B-UNK
of	O
pilocarpine	B-CHEMICAL
(	O
20	O
microL	O
,	O
0.1	B-UNK
%	O
)	O
to	O
one	O
eye	B-UNK
and	O
placebo	B-UNK
to	O
the	O
other	O
.	O
All	O
eye	B-UNK
drops	B-UNK
were	O
given	B-UNK
in	O
a	O
randomized	B-UNK
order	O
.	O
In	O
2	B-DISEASE
separate	B-UNK
sessions	O
,	O
a	O
single	B-UNK
dose	B-UNK
of	O
scopolamine	B-CHEMICAL
(	O
0.5	B-UNK
mg	I-UNK
,	O
intravenously	B-UNK
)	O
or	O
placebo	B-UNK
was	O
administered	B-UNK
,	O
and	O
the	O
effects	B-UNK
on	O
word	B-UNK
recall	B-UNK
were	O
measured	B-UNK
using	O
the	O
Buschke	B-UNK
Selective	I-UNK
Reminding	I-UNK
Test	O
over	O
2	B-DISEASE
hours	B-UNK
.	O
OUTCOME	B-UNK
MEASURES	B-UNK
:	O
Pupil	O
size	O
at	B-DISEASE
time	B-UNK
points	B-UNK
after	O
administration	B-UNK
of	O
tropicamide	B-CHEMICAL
and	O
pilocarpine	B-CHEMICAL
;	O
scopolamine	B-CHEMICAL
-	O
induced	B-UNK
impairment	B-UNK
in	O
word	B-UNK
recall	B-UNK
.	O
RESULTS	B-UNK
:	O
There	O
was	O
no	O
significant	B-UNK
difference	B-UNK
between	O
elderly	B-UNK
and	O
young	B-UNK
volunteers	O
in	O
pupillary	O
response	B-UNK
to	O
tropicamide	B-CHEMICAL
at	B-DISEASE
any	O
time	B-UNK
point	O
(	O
p	B-UNK
>	O
0.05	O
)	O
.	O
The	O
elderly	B-UNK
group	B-UNK
had	O
a	O
significantly	B-UNK
greater	B-UNK
pilocarpine	B-CHEMICAL
-	O
induced	B-UNK
net	O
decrease	B-UNK
in	O
pupil	B-DISEASE
size	O
85	O
,	O
125	O
,	O
165	O
and	O
215	O
minutes	B-UNK
after	O
administration	B-UNK
,	O
compared	B-UNK
with	O
the	O
young	B-UNK
group	B-UNK
(	O
p	B-UNK
<	I-UNK
0.05	O
)	O
.	O
Compared	O
with	O
the	O
young	B-UNK
group	B-UNK
,	O
the	O
elderly	B-UNK
group	B-UNK
had	O
greater	B-UNK
scopolamine	B-CHEMICAL
-	O
induced	B-UNK
impairment	B-UNK
in	O
word	B-UNK
recall	B-UNK
60	O
,	O
90	O
and	O
120	O
minutes	B-UNK
after	O
administration	B-UNK
(	O
p	B-UNK
<	I-UNK
0.05	O
)	O
.	O
CONCLUSION	O
:	O
There	O
is	O
an	O
age	B-UNK
-	O
related	B-UNK
pupillary	O
response	B-UNK
to	O
pilocarpine	B-CHEMICAL
that	O
is	O
not	O
found	B-UNK
with	O
tropicamide	B-CHEMICAL
.	O
Thus	O
,	O
pilocarpine	B-CHEMICAL
may	O
be	O
useful	B-UNK
to	O
assess	B-UNK
variations	O
in	O
central	B-UNK
cholinergic	B-UNK
function	B-UNK
in	O
elderly	B-UNK
patients	B-UNK
.	O

Acetazolamide	O
-	O
induced	B-UNK
Gerstmann	O
syndrome	B-DISEASE
.	O

Acute	B-UNK
confusion	B-DISEASE
induced	B-UNK
by	O
acetazolamide	B-CHEMICAL
is	O
a	O
well	O
known	B-UNK
adverse	B-UNK
drug	I-UNK
reaction	B-UNK
in	O
patients	B-UNK
with	O
renal	B-DISEASE
impairment	B-UNK
.	O
We	O
report	B-UNK
a	O
case	B-UNK
of	O
acetazolamide	B-CHEMICAL
-	O
induced	B-UNK
Gerstmann	O
syndrome	B-UNK
in	O
a	O
patient	B-UNK
with	O
normal	B-UNK
renal	B-DISEASE
function	B-UNK
,	O
to	O
highlight	O
predisposing	O
factors	B-UNK
that	O
are	O
frequently	B-UNK
overlooked	O
.	O

Hypomania	O
-	O
like	B-UNK
syndrome	B-UNK
induced	B-UNK
by	O
olanzapine	B-CHEMICAL
.	O

We	O
report	B-UNK
a	O
female	B-UNK
patient	B-UNK
with	O
a	O
diagnosis	B-UNK
of	O
a	O
not	O
otherwise	O
specified	O
psychotic	O
disorder	B-UNK
(	O
DSM	O
-	O
IV	B-UNK
)	O
who	O
developed	B-UNK
hypomania	O
shortly	B-UNK
after	O
the	O
introduction	O
of	O
olanzapine	B-CHEMICAL
treatment	B-UNK
.	O

Neutrophil	O
superoxide	B-UNK
and	O
hydrogen	B-CHEMICAL
peroxide	I-CHEMICAL
production	B-UNK
in	O
patients	B-UNK
with	O
acute	B-DISEASE
liver	I-DISEASE
failure	I-DISEASE
.	O

Defects	O
in	O
superoxide	B-UNK
and	O
hydrogen	B-CHEMICAL
peroxide	I-CHEMICAL
production	B-UNK
may	O
be	O
implicated	B-UNK
in	O
the	O
high	B-UNK
incidence	B-UNK
of	O
bacterial	B-DISEASE
infections	I-DISEASE
in	O
patients	B-UNK
with	O
acute	B-DISEASE
liver	I-DISEASE
failure	I-DISEASE
(	O
ALF	O
)	O
.	O
In	O
the	O
present	B-UNK
study	B-UNK
,	O
oxygen	B-CHEMICAL
radical	B-UNK
production	B-UNK
in	O
patients	B-UNK
with	O
ALF	O
due	O
to	O
paracetamol	B-UNK
overdose	B-UNK
was	O
compared	B-UNK
with	O
that	O
of	O
healthy	B-UNK
volunteers	O
.	O
Neutrophils	O
from	O
14	O
ALF	O
patients	B-UNK
were	O
stimulated	O
via	O
the	O
complement	B-UNK
receptors	B-UNK
using	O
zymosan	B-CHEMICAL
opsonized	O
with	O
ALF	O
or	O
control	B-UNK
serum	B-UNK
.	O
Superoxide	O
and	O
hydrogen	B-CHEMICAL
peroxide	I-CHEMICAL
production	B-UNK
by	O
ALF	O
neutrophils	O
stimulated	O
with	O
zymosan	B-CHEMICAL
opsonized	O
with	O
ALF	O
serum	B-UNK
was	O
significantly	B-UNK
reduced	B-UNK
compared	B-UNK
with	O
the	O
control	B-UNK
subjects	B-UNK
(	O
P	B-UNK
<	I-UNK
0.01	B-UNK
)	O
.	O
This	O
defect	B-UNK
persisted	B-UNK
when	O
zymosan	B-CHEMICAL
opsonized	O
by	O
control	B-UNK
serum	B-UNK
was	O
used	O
(	O
P	B-UNK
<	I-UNK
0.05	O
)	O
.	O
Superoxide	O
and	O
hydrogen	B-CHEMICAL
peroxide	I-CHEMICAL
production	B-UNK
in	O
neutrophils	O
stimulated	O
with	O
formyl	O
-	O
methionyl	B-CHEMICAL
-	I-CHEMICAL
leucyl	I-CHEMICAL
-	I-CHEMICAL
phenylalanine	I-CHEMICAL
(	O
fMLP	O
)	O
from	O
a	O
further	O
18	O
ALF	O
patients	B-UNK
was	O
unaffected	B-UNK
compared	B-UNK
with	O
control	B-UNK
neutrophils	O
.	O
Serum	B-UNK
C3	O
complement	B-UNK
levels	B-UNK
were	O
significantly	B-UNK
reduced	B-UNK
in	O
ALF	O
patients	B-UNK
compared	B-UNK
with	O
control	B-UNK
subjects	B-UNK
(	O
P	B-UNK
<	I-UNK
0.0005	O
)	O
.	O
These	O
results	B-UNK
demonstrate	B-UNK
a	O
neutrophil	O
defect	B-UNK
in	O
ALF	O
due	O
to	O
paracetamol	B-UNK
overdose	B-UNK
,	O
that	O
is	O
complement	B-UNK
dependent	B-UNK
but	O
independent	B-UNK
of	O
serum	B-UNK
complement	B-UNK
,	O
possibly	B-UNK
connected	O
to	O
the	O
complement	B-UNK
receptor	B-UNK
.	O

Absence	O
of	O
effect	B-UNK
of	O
sertraline	B-CHEMICAL
on	O
time	B-UNK
-	O
based	B-UNK
sensitization	B-UNK
of	O
cognitive	B-UNK
impairment	B-UNK
with	O
haloperidol	B-CHEMICAL
.	O

This	O
double-blind	B-UNK
,	O
randomized	B-UNK
,	O
placebo	B-UNK
-	O
controlled	B-UNK
study	B-UNK
evaluated	B-UNK
the	O
effects	B-UNK
of	O
haloperidol	B-CHEMICAL
alone	O
and	O
haloperidol	B-CHEMICAL
plus	B-UNK
sertraline	B-CHEMICAL
on	O
cognitive	B-UNK
and	O
psychomotor	B-UNK
function	B-UNK
in	O
24	O
healthy	B-UNK
male	B-UNK
subjects	B-UNK
.	O
METHOD	O
:	O
All	O
subjects	B-UNK
received	B-UNK
placebo	B-UNK
on	O
Day	O
1	O
and	O
haloperidol	B-CHEMICAL
2	B-DISEASE
mg	B-UNK
on	O
Days	O
2	B-DISEASE
and	O
25	O
.	O
From	O
Days	O
9	O
to	O
25	O
,	O
subjects	B-UNK
were	O
randomly	B-UNK
assigned	B-UNK
to	O
either	O
sertraline	B-CHEMICAL
(	O
12	O
subjects	B-UNK
)	O
or	O
placebo	B-UNK
(	O
12	O
subjects	B-UNK
)	O
;	O
the	O
sertraline	B-CHEMICAL
dose	B-UNK
was	O
titrated	B-UNK
from	O
50	O
to	O
200	O
mg	B-UNK
/	O
day	B-UNK
from	O
Days	O
9	O
to	O
16	O
,	O
and	O
remained	B-UNK
at	B-DISEASE
200	O
mg	B-UNK
/	O
day	B-UNK
for	O
the	O
final	O
10	O
days	B-UNK
of	O
the	O
drug	B-UNK
administration	B-UNK
period	B-UNK
.	O
Cognitive	B-UNK
function	B-UNK
testing	B-UNK
was	O
performed	B-UNK
before	O
dosing	B-UNK
and	O
over	O
a	O
24-hour	B-UNK
period	B-UNK
after	O
dosing	B-UNK
on	O
Days	O
1	O
,	O
2	B-DISEASE
,	O
and	O
25	O
.	O
RESULTS	B-UNK
:	O
Impairment	O
of	O
cognitive	B-UNK
function	B-UNK
was	O
observed	B-UNK
6	O
to	O
8	O
hours	B-UNK
after	O
administration	B-UNK
of	O
haloperidol	B-CHEMICAL
on	O
Day	O
2	B-DISEASE
but	O
was	O
not	O
evident	O
23	O
hours	B-UNK
after	O
dosing	B-UNK
.	O
When	O
single	B-UNK
-	O
dose	B-UNK
haloperidol	B-CHEMICAL
was	O
given	B-UNK
again	O
25	O
days	B-UNK
later	B-UNK
,	O
greater	B-UNK
impairment	B-UNK
with	O
earlier	B-UNK
onset	B-UNK
was	O
noted	O
in	O
several	O
tests	B-UNK
in	O
both	O
treatment	B-UNK
groups	B-UNK
,	O
suggesting	B-UNK
enhancement	O
of	O
this	O
effect	B-UNK
.	O
There	O
was	O
no	O
indication	O
that	O
sertraline	B-CHEMICAL
exacerbated	B-UNK
the	O
impairment	B-UNK
produced	B-UNK
by	O
haloperidol	B-CHEMICAL
since	O
an	O
equivalent	B-UNK
effect	B-UNK
also	O
occurred	B-UNK
in	O
the	O
placebo	B-UNK
group	B-UNK
.	O
Three	O
subjects	B-UNK
(	O
2	B-DISEASE
on	O
sertraline	B-CHEMICAL
and	O
1	O
on	O
placebo	B-UNK
)	O
withdrew	O
from	O
the	O
study	B-UNK
because	O
of	O
side	O
effects	B-UNK
.	O
Ten	O
subjects	B-UNK
in	O
each	O
group	B-UNK
reported	B-UNK
side	O
effects	B-UNK
related	B-UNK
to	O
treatment	B-UNK
.	O
The	O
side	O
effect	B-UNK
profiles	B-UNK
of	O
sertraline	B-CHEMICAL
and	O
of	O
placebo	B-UNK
were	O
similar	B-UNK
.	O
CONCLUSION	O
:	O
Haloperidol	O
produced	B-UNK
a	O
clear	B-UNK
profile	B-UNK
of	O
cognitive	B-UNK
impairment	B-UNK
that	O
was	O
not	O
worsened	O
by	O
concomitant	B-UNK
sertraline	B-CHEMICAL
administration	B-UNK
.	O

Ciprofloxacin	O
-	O
induced	B-UNK
nephrotoxicity	B-UNK
in	O
patients	B-UNK
with	O
cancer	B-UNK
.	O

Nephrotoxicity	O
associated	B-UNK
with	O
ciprofloxacin	B-CHEMICAL
is	O
uncommon	O
.	O
Five	O
patients	B-UNK
with	O
cancer	B-DISEASE
who	O
developed	B-UNK
acute	B-DISEASE
renal	I-DISEASE
failure	I-DISEASE
that	O
followed	B-UNK
treatment	B-UNK
with	O
ciprofloxacin	B-CHEMICAL
are	O
described	B-UNK
and	O
an	O
additional	B-UNK
15	O
cases	B-UNK
reported	B-UNK
in	O
the	O
literature	B-UNK
are	O
reviewed	B-UNK
.	O
Other	O
than	O
elevation	B-UNK
of	O
serum	B-UNK
creatinine	B-CHEMICAL
levels	B-UNK
,	O
characteristic	O
clinical	B-UNK
manifestations	B-UNK
and	O
abnormal	B-UNK
laboratory	B-UNK
findings	B-UNK
are	O
not	O
frequently	B-UNK
present	B-UNK
.	O
Allergic	O
interstitial	B-DISEASE
nephritis	I-DISEASE
is	O
believed	O
to	O
be	O
the	O
underlying	B-UNK
pathological	B-UNK
-	O
process	B-UNK
.	O
Definitive	O
diagnosis	B-UNK
requires	O
performance	B-UNK
of	O
renal	B-UNK
biopsy	B-UNK
,	O
although	O
this	O
is	O
not	O
always	O
feasible	O
.	O
An	O
improvement	B-UNK
in	O
renal	B-UNK
function	B-UNK
that	O
followed	B-UNK
the	O
discontinuation	B-UNK
of	O
the	O
offending	O
antibiotic	B-UNK
supports	O
the	O
presumptive	O
diagnosis	B-UNK
of	O
ciprofloxacin	B-CHEMICAL
-	O
induced	B-UNK
acute	B-DISEASE
renal	I-DISEASE
failure	I-DISEASE
.	O

Case	B-UNK
report	B-UNK
:	O
pentamidine	B-CHEMICAL
and	O
polymorphic	O
ventricular	B-DISEASE
tachycardia	I-DISEASE
revisited	O
.	O

Pentamidine	O
isethionate	O
has	O
been	O
associated	B-UNK
with	O
ventricular	B-UNK
tachyarrhythmias	O
,	O
including	B-UNK
torsade	B-UNK
de	B-UNK
pointes	O
.	O
This	O
article	O
reports	B-UNK
two	O
cases	B-UNK
of	O
this	O
complication	B-UNK
and	O
reviews	O
all	O
reported	B-UNK
cases	B-UNK
to	O
date	O
.	O
Pentamidine	O
-	O
induced	B-UNK
torsade	B-UNK
de	B-UNK
pointes	O
may	O
be	O
related	B-UNK
to	O
serum	B-UNK
magnesium	B-CHEMICAL
levels	B-UNK
and	O
hypomagnesemia	B-DISEASE
may	O
synergistically	O
induce	B-UNK
torsade	B-UNK
.	O
Torsade	O
de	B-UNK
pointes	O
occurred	B-UNK
after	O
an	O
average	B-UNK
of	O
10	O
days	B-UNK
of	O
treatment	B-UNK
with	O
pentamidine	B-CHEMICAL
.	O
In	O
these	O
patients	B-UNK
,	O
no	O
other	O
acute	B-UNK
side	O
effects	B-UNK
of	O
pentamidine	B-CHEMICAL
were	O
observed	B-UNK
.	O
Torsade	O
de	B-UNK
pointes	O
can	O
be	O
treated	B-UNK
when	O
recognized	B-UNK
early	B-UNK
,	O
possibly	B-UNK
without	O
discontinuation	B-UNK
of	O
pentamidine	B-CHEMICAL
.	O
When	O
QTc	B-UNK
interval	B-UNK
prolongation	B-UNK
is	O
observed	B-UNK
,	O
early	B-UNK
magnesium	B-CHEMICAL
supplementation	B-UNK
is	O
advocated	O
.	O

Time	O
dependence	B-DISEASE
of	O
plasma	B-UNK
malondialdehyde	B-CHEMICAL
,	O
oxypurines	O
,	O
and	O
nucleosides	B-CHEMICAL
during	O
incomplete	O
cerebral	B-UNK
ischemia	B-DISEASE
in	O
the	O
rat	B-UNK
.	O

Incomplete	O
cerebral	B-UNK
ischemia	B-DISEASE
(	O
30	O
min	B-UNK
)	O
was	O
induced	B-UNK
in	O
the	O
rat	B-UNK
by	O
bilaterally	B-UNK
clamping	O
the	O
common	B-UNK
carotid	B-UNK
arteries	B-UNK
.	O
Peripheral	O
venous	B-UNK
blood	B-UNK
samples	B-UNK
were	O
withdrawn	O
from	O
the	O
femoral	O
vein	O
four	O
times	B-UNK
(	O
once	O
every	O
5	O
min	B-UNK
)	O
before	O
ischemia	B-DISEASE
(	O
0	O
time	B-UNK
)	O
and	O
5	O
,	O
15	O
,	O
and	O
30	O
min	B-UNK
after	O
ischemia	B-DISEASE
.	O
Plasma	B-UNK
extracts	O
were	O
analyzed	B-UNK
by	O
a	O
highly	B-UNK
sensitive	B-UNK
high	B-UNK
-	O
performance	B-UNK
liquid	B-UNK
chromatographic	O
method	B-UNK
for	O
the	O
direct	B-UNK
determination	O
of	O
malondialdehyde	B-CHEMICAL
,	O
oxypurines	O
,	O
and	O
nucleosides	B-CHEMICAL
.	O
During	O
ischemia	B-DISEASE
,	O
a	O
time	B-UNK
-	O
dependent	B-UNK
increase	B-UNK
of	O
plasma	B-UNK
oxypurines	O
and	O
nucleosides	B-CHEMICAL
was	O
observed	B-UNK
.	O
Plasma	B-UNK
malondialdehyde	B-CHEMICAL
,	O
which	O
was	O
present	B-UNK
in	O
minimal	O
amount	O
at	B-DISEASE
zero	O
time	B-UNK
(	O
0.058	O
mumol	B-UNK
/	O
liter	O
plasma	B-UNK
;	O
SD	B-UNK
0.015	O
)	O
,	O
increased	B-UNK
after	O
5	O
min	B-UNK
of	O
ischemia	B-DISEASE
,	O
resulting	B-UNK
in	O
a	O
fivefold	O
increase	B-UNK
after	O
30	O
min	B-UNK
of	O
carotid	B-UNK
occlusion	B-UNK
(	O
0.298	O
mumol	B-UNK
/	O
liter	O
plasma	B-UNK
;	O
SD	B-UNK
0.078	O
)	O
.	O
Increased	B-UNK
plasma	B-UNK
malondialdehyde	B-CHEMICAL
was	O
also	O
recorded	B-UNK
in	O
two	O
other	O
groups	B-UNK
of	O
animals	B-UNK
subjected	O
to	O
the	O
same	O
experimental	B-UNK
model	B-UNK
,	O
one	O
receiving	B-UNK
20	O
mg	B-UNK
/	O
kg	B-UNK
b.w	O
.	O
of	O
the	O
cyclooxygenase	O
inhibitor	B-UNK
acetylsalicylate	O
intravenously	B-UNK
immediately	B-UNK
before	O
ischemia	B-DISEASE
,	O
the	O
other	O
receiving	B-UNK
650	O
micrograms	B-UNK
/	O
kg	B-UNK
b.w	O
.	O
of	O
the	O
hypotensive	B-UNK
drug	B-UNK
nitroprusside	B-CHEMICAL
at	B-DISEASE
a	O
flow	B-UNK
rate	B-UNK
of	O
103	O
microliters	O
/	O
min	B-UNK
intravenously	B-UNK
during	O
ischemia	B-DISEASE
,	O
although	O
in	O
this	O
latter	O
group	B-UNK
malondialdehyde	B-CHEMICAL
was	O
significantly	B-UNK
higher	B-UNK
.	O
The	O
present	B-UNK
data	B-UNK
indicate	B-UNK
that	O
the	O
determination	O
of	O
malondialdehyde	B-CHEMICAL
,	O
oxypurines	O
,	O
and	O
nucleosides	B-CHEMICAL
in	O
peripheral	B-UNK
blood	B-UNK
,	O
may	O
be	O
used	O
to	O
monitor	O
the	O
metabolic	B-UNK
alterations	B-UNK
of	O
tissues	B-UNK
occurring	B-UNK
during	O
ischemic	B-UNK
phenomena.(ABSTRACT	O
TRUNCATED	B-UNK
AT	O
250	O
WORDS	O
)	O

Cholinergic	O
toxicity	B-UNK
resulting	B-UNK
from	O
ocular	B-UNK
instillation	O
of	O
echothiophate	B-CHEMICAL
iodide	I-CHEMICAL
eye	B-UNK
drops	B-UNK
.	O

A	O
patient	B-UNK
developed	I-UNK
a	O
severe	B-UNK
cholinergic	B-UNK
syndrome	B-UNK
from	O
the	O
use	B-UNK
of	O
echothiophate	B-CHEMICAL
iodide	I-CHEMICAL
ophthalmic	B-UNK
drops	B-UNK
,	O
presented	B-UNK
with	O
profound	B-UNK
muscle	B-DISEASE
weakness	I-DISEASE
and	O
was	O
initially	B-UNK
given	B-UNK
the	O
diagnosis	B-UNK
of	O
myasthenia	B-DISEASE
gravis	I-DISEASE
.	O
Red	O
blood	B-UNK
cell	B-UNK
and	O
serum	B-UNK
cholinesterase	B-UNK
levels	B-UNK
were	O
severely	O
depressed	B-UNK
and	O
symptoms	B-UNK
resolved	B-UNK
spontaneously	B-UNK
following	B-UNK
discontinuation	B-UNK
of	O
the	O
eye	B-UNK
drops	B-UNK
.	O

Acute	B-UNK
renal	B-DISEASE
failure	I-DISEASE
in	O
high	B-UNK
dose	B-UNK
carboplatin	B-CHEMICAL
chemotherapy	B-UNK
.	O

Carboplatin	O
has	O
been	O
reported	B-UNK
to	O
cause	B-UNK
acute	B-DISEASE
renal	I-DISEASE
failure	I-DISEASE
when	O
administered	B-UNK
in	O
high	B-UNK
doses	B-UNK
to	O
adult	B-UNK
patients	B-UNK
.	O
We	O
report	B-UNK
a	O
4	O
1/2-year	O
-	O
old	B-UNK
girl	O
who	O
was	O
treated	B-UNK
with	O
high	B-UNK
-	O
dose	B-UNK
carboplatin	B-CHEMICAL
for	O
metastatic	B-UNK
parameningeal	O
embryonal	O
rhabdomyosarcoma	B-DISEASE
.	O
Acute	B-UNK
renal	B-DISEASE
failure	I-DISEASE
developed	B-UNK
followed	B-UNK
by	O
a	O
slow	O
partial	B-UNK
recovery	B-UNK
of	O
renal	B-UNK
function	B-UNK
.	O
Possible	O
contributing	B-UNK
factors	B-UNK
are	O
discussed	O
.	O

Endometrial	O
carcinoma	B-DISEASE
after	O
Hodgkin	O
disease	B-DISEASE
in	O
childhood	O
.	O

A	O
34-year	O
-	O
old	B-UNK
patient	B-UNK
developed	I-UNK
metastic	O
endometrial	B-UNK
carcinoma	B-DISEASE
after	O
Hodgkin	O
disease	B-DISEASE
in	O
childhood	O
.	O
She	O
had	O
ovarian	B-UNK
failure	B-UNK
after	O
abdominal	B-UNK
irradiation	O
and	O
chemotherapy	B-UNK
for	O
Hodgkin	O
disease	B-DISEASE
,	O
and	O
received	B-UNK
exogenous	B-UNK
estrogens	B-CHEMICAL
,	O
a	O
treatment	B-UNK
implicated	B-UNK
in	O
the	O
development	B-UNK
of	O
endometrial	B-DISEASE
cancer	I-DISEASE
in	O
menopausal	O
women	B-UNK
.	O
Young	O
women	B-UNK
on	O
replacement	O
estrogens	B-CHEMICAL
for	O
ovarian	B-UNK
failure	B-UNK
after	O
cancer	B-UNK
therapy	B-UNK
may	O
also	O
have	O
increased	B-UNK
risk	I-UNK
of	O
endometrial	B-UNK
carcinoma	B-DISEASE
and	O
should	O
be	O
examined	B-UNK
periodically	O
.	O

Induction	O
of	O
the	O
obstructive	B-DISEASE
sleep	I-DISEASE
apnea	I-DISEASE
syndrome	B-UNK
in	O
a	O
woman	B-UNK
by	O
exogenous	B-UNK
androgen	O
administration	B-UNK
.	O

We	O
documented	B-UNK
airway	B-UNK
occlusion	B-UNK
during	O
sleep	O
and	O
an	O
abnormally	O
high	B-UNK
supraglottic	O
resistance	B-UNK
while	O
awake	O
in	O
a	O
54-yr	O
-	O
old	B-UNK
woman	B-UNK
who	O
had	O
developed	B-UNK
physical	B-UNK
changes	B-UNK
and	O
the	O
syndrome	B-UNK
of	O
obstructive	B-DISEASE
sleep	I-DISEASE
apnea	I-DISEASE
while	O
being	O
administered	B-UNK
exogenous	B-UNK
androgens	B-CHEMICAL
.	O
When	O
the	O
androgens	B-CHEMICAL
were	O
withdrawn	O
,	O
the	O
patient'	O
s	O
physical	B-UNK
changes	B-UNK
,	O
symptoms	B-UNK
,	O
sleep	O
study	B-UNK
,	O
and	O
supraglottic	O
resistance	B-UNK
all	O
returned	B-UNK
to	O
normal	B-UNK
.	O
A	O
rechallenge	O
with	O
androgen	O
produced	B-UNK
symptoms	B-UNK
of	O
obstructive	B-DISEASE
sleep	I-DISEASE
apnea	I-DISEASE
that	O
abated	O
upon	O
withdrawal	B-UNK
of	O
the	O
hormone	B-UNK
.	O
Previous	B-UNK
reports	B-UNK
have	O
favored	O
a	O
role	B-UNK
of	O
androgens	B-CHEMICAL
in	O
the	O
pathogenesis	O
of	O
sleep	B-DISEASE
apnea	I-DISEASE
.	O
Our	O
report	B-UNK
provides	B-UNK
direct	B-UNK
evidence	B-UNK
for	O
this	O
role	B-UNK
.	O
Structural	O
and	O
functional	B-UNK
measurements	B-UNK
indicate	B-UNK
that	O
androgens	B-CHEMICAL
exert	O
a	O
permissive	O
or	O
necessary	O
action	B-UNK
on	O
the	O
structural	B-UNK
configuration	O
of	O
the	O
oropharynx	O
that	O
predisposes	O
to	O
obstruction	O
during	O
sleep	O
.	O
Development	O
of	O
the	O
obstructive	B-DISEASE
sleep	I-DISEASE
apnea	I-DISEASE
syndrome	B-UNK
must	O
be	O
considered	B-UNK
a	O
possible	B-UNK
side	O
effect	B-UNK
of	O
androgen	O
therapy	B-UNK
.	O

Effect	O
of	O
captopril	B-CHEMICAL
on	O
pre	B-UNK
-	O
existing	B-UNK
and	O
aminonucleoside	O
-	O
induced	B-UNK
proteinuria	B-DISEASE
in	O
spontaneously	B-UNK
hypertensive	B-UNK
rats	B-UNK
.	O

Proteinuria	O
is	O
a	O
side	O
effect	B-UNK
of	O
captopril	B-CHEMICAL
treatment	B-UNK
in	O
hypertensive	B-UNK
patients	B-UNK
.	O
The	O
possibility	O
of	O
reproducing	O
the	O
same	O
renal	B-UNK
abnormality	B-UNK
with	O
captopril	B-CHEMICAL
was	O
examined	B-UNK
in	O
SHR	O
.	O
Oral	O
administration	B-UNK
of	O
captopril	B-CHEMICAL
at	B-DISEASE
100	O
mg	B-UNK
/	O
kg	B-UNK
for	O
14	O
days	B-UNK
failed	B-UNK
to	O
aggravate	O
proteinuria	B-DISEASE
pre	B-UNK
-	O
existing	B-UNK
in	O
SHR	O
.	O
Also	O
,	O
captopril	B-CHEMICAL
treatment	B-UNK
failed	B-UNK
to	O
potentiate	O
or	O
facilitate	O
development	B-UNK
of	O
massive	O
proteinuria	B-DISEASE
invoked	O
by	O
puromycin	B-CHEMICAL
aminonucleoside	I-CHEMICAL
in	O
SHR	O
.	O
Captopril	O
had	O
little	B-UNK
or	O
no	O
demonstrable	O
effects	B-UNK
on	O
serum	B-UNK
electrolyte	B-UNK
concentrations	B-UNK
,	O
excretion	B-UNK
of	O
urine	B-DISEASE
,	O
sodium	B-CHEMICAL
and	O
potassium	B-CHEMICAL
,	O
endogenous	B-UNK
creatinine	B-CHEMICAL
clearance	B-UNK
,	O
body	B-DISEASE
weight	I-DISEASE
,	O
and	O
food	B-UNK
and	O
water	B-CHEMICAL
consumption	B-UNK
.	O
However	O
,	O
ketone	B-CHEMICAL
bodies	I-CHEMICAL
were	O
consistently	O
present	B-UNK
in	O
urine	B-DISEASE
and	O
several	O
lethalities	O
occurred	B-UNK
during	O
multiple	B-UNK
dosing	B-UNK
of	O
captopril	B-CHEMICAL
in	O
SHR	O
.	O

Epileptogenic	O
properties	B-UNK
of	O
enflurane	B-CHEMICAL
and	O
their	O
clinical	B-UNK
interpretation	O
.	O

Three	O
cases	B-UNK
of	O
EEG	O
changes	B-UNK
induced	B-UNK
by	O
single	B-UNK
exposure	B-UNK
to	O
enflurane	B-CHEMICAL
anesthesia	B-UNK
are	O
reported	B-UNK
.	O
In	O
one	O
patient	B-UNK
,	O
enflurane	B-CHEMICAL
administered	B-UNK
during	O
a	O
donor	B-UNK
nephrectomy	O
resulted	B-UNK
in	O
unexpected	O
partial	B-UNK
motor	B-UNK
seizures	B-DISEASE
.	O
Until	O
the	O
cause	B-UNK
of	O
the	O
seizures	B-DISEASE
was	O
correctly	O
identified	B-UNK
,	O
the	O
patient	B-UNK
was	O
inappropriately	O
treated	B-UNK
with	O
anticonvulsants	B-CHEMICAL
.	O
Two	O
other	O
patients	B-UNK
suffered	O
from	O
partial	B-UNK
,	O
complex	B-UNK
and	O
generalized	B-UNK
seizures	B-DISEASE
uncontrolled	B-UNK
by	O
medication	B-UNK
.	O
Epileptic	O
foci	O
delineated	O
and	O
activated	B-UNK
by	O
enflurane	B-CHEMICAL
were	O
surgically	O
ablated	O
and	O
the	O
patients	B-UNK
are	O
now	O
seizure	B-UNK
-	O
free	B-UNK
.	O
Previous	B-UNK
exposures	O
to	O
enflurane	B-CHEMICAL
have	O
to	O
be	O
disclosed	O
to	O
avoid	B-UNK
mistakes	O
in	O
clinical	B-UNK
interpretation	O
of	O
the	O
EEG	O
.	O
On	O
the	O
other	O
hand	B-DISEASE
,	O
enflurane	B-CHEMICAL
may	O
prove	O
to	O
be	O
a	O
safe	B-UNK
fast	O
acting	B-UNK
activator	B-UNK
of	O
epileptic	B-UNK
foci	O
during	O
corticography	O
or	O
depth	B-UNK
electrode	B-UNK
intraoperative	O
recordings	O
.	O

Reversible	O
cerebral	B-UNK
lesions	B-UNK
associated	B-UNK
with	O
tiazofurin	B-CHEMICAL
usage	B-UNK
:	O
MR	O
demonstration	O
.	O

Tiazofurin	O
is	O
an	O
experimental	B-UNK
chemotherapeutic	B-UNK
agent	B-UNK
currently	B-UNK
undergoing	B-UNK
clinical	B-UNK
evaluation	B-UNK
.	O
We	O
report	B-UNK
our	O
results	B-UNK
with	O
magnetic	B-UNK
resonance	I-UNK
(	O
MR	O
)	O
in	O
demonstrating	O
reversible	B-UNK
cerebral	B-UNK
abnormalities	B-DISEASE
concurrent	O
with	O
the	O
use	B-UNK
of	O
this	O
drug	B-UNK
.	O
The	O
abnormalities	B-DISEASE
on	O
MR	O
were	O
correlated	B-UNK
with	O
findings	B-UNK
on	O
CT	B-UNK
as	O
well	O
as	O
with	O
cerebral	B-UNK
angiography	B-UNK
.	O
The	O
utility	O
of	O
MR	O
in	O
the	O
evaluation	B-UNK
of	O
patients	B-UNK
receiving	B-UNK
this	O
new	B-UNK
agent	B-UNK
is	O
illustrated	O
.	O

Antagonism	O
of	O
diazepam	B-CHEMICAL
-	O
induced	B-UNK
sedative	B-UNK
effects	B-UNK
by	O
Ro15	O
-	O
1788	O
in	O
patients	B-UNK
after	O
surgery	B-UNK
under	O
lumbar	B-UNK
epidural	B-UNK
block	B-UNK
.	O
A	O
double-blind	B-UNK
placebo	B-UNK
-	O
controlled	B-UNK
investigation	O
of	O
efficacy	B-UNK
and	O
safety	B-UNK
.	O

The	O
aim	O
of	O
this	O
study	B-UNK
was	O
to	O
assess	B-UNK
the	O
efficacy	B-UNK
of	O
Ro15	O
-	O
1788	O
and	O
a	O
placebo	B-UNK
in	O
reversing	O
diazepam	B-CHEMICAL
-	O
induced	B-UNK
effects	B-UNK
after	O
surgery	B-UNK
under	O
epidural	B-UNK
block	B-UNK
,	O
and	O
to	O
evaluate	B-UNK
the	O
local	B-UNK
tolerance	B-UNK
and	O
general	B-UNK
safety	B-UNK
of	O
Ro15	O
-	O
1788	O
.	O
Fifty	O
-	O
seven	O
patients	B-UNK
were	O
sedated	O
with	O
diazepam	B-CHEMICAL
for	O
surgery	B-UNK
under	O
epidural	B-UNK
anaesthesia	B-UNK
.	O
Antagonism	O
of	O
diazepam	B-CHEMICAL
-	O
induced	B-UNK
effects	B-UNK
by	O
Ro15	O
-	O
1788	O
was	O
investigated	B-UNK
postoperatively	O
in	O
a	O
double-blind	B-UNK
placebo	B-UNK
-	O
controlled	B-UNK
trial	B-UNK
.	O
The	O
patient'	O
s	O
subjective	B-UNK
assessment	B-UNK
of	O
mood	B-UNK
rating	O
,	O
an	O
objective	B-UNK
test	B-UNK
of	O
performance	B-UNK
,	O
a	O
test	B-UNK
for	O
amnesia	B-DISEASE
,	O
and	O
vital	O
signs	B-UNK
were	O
recorded	B-UNK
for	O
up	O
to	O
300	O
min	B-UNK
after	O
administration	B-UNK
of	O
the	O
trial	B-UNK
drug	B-UNK
.	O
No	O
significant	B-UNK
differences	B-UNK
between	O
the	O
two	O
groups	B-UNK
were	O
observed	B-UNK
for	O
mood	B-UNK
rating	O
,	O
amnesia	B-DISEASE
,	O
or	O
vital	O
signs	B-UNK
.	O
The	O
Ro15	O
-	O
1788	O
group	B-UNK
showed	B-UNK
a	O
significant	B-UNK
improvement	B-UNK
in	O
the	O
performance	B-UNK
test	B-UNK
up	O
to	O
120	O
min	B-UNK
after	O
administration	B-UNK
of	O
the	O
drug	B-UNK
.	O
There	O
was	O
no	O
evidence	B-UNK
of	O
reaction	B-UNK
at	B-DISEASE
the	O
injection	B-UNK
site	B-UNK
.	O

Enhanced	O
stimulus	O
-	O
induced	B-UNK
neurotransmitter	B-UNK
overflow	I-UNK
in	O
epinephrine	B-CHEMICAL
-	O
induced	B-UNK
hypertensive	B-UNK
rats	B-UNK
is	O
not	O
mediated	B-UNK
by	O
prejunctional	O
beta-adrenoceptor	B-UNK
activation	B-UNK
.	O

The	O
present	B-UNK
study	B-UNK
examines	O
the	O
effect	B-UNK
of	O
6-day	O
epinephrine	B-CHEMICAL
treatment	B-UNK
(	O
100	O
micrograms	B-UNK
/	O
kg	B-UNK
per	O
h	B-UNK
,	O
s.c	B-UNK
.	O
)	O
on	O
stimulus	O
-	O
induced	B-UNK
(	O
1	O
Hz	O
)	O
endogenous	B-UNK
neurotransmitter	B-UNK
overflow	I-UNK
from	O
the	O
isolated	B-UNK
perfused	B-UNK
kidney	B-UNK
of	O
vehicle-	O
and	O
epinephrine	B-CHEMICAL
-	O
treated	B-UNK
rats	B-UNK
.	O
Renal	B-UNK
catecholamine	B-UNK
stores	O
and	O
stimulus	O
-	O
induced	B-UNK
overflow	B-UNK
in	O
the	O
vehicle	B-UNK
-	O
treated	B-UNK
group	B-UNK
consisted	B-UNK
of	O
norepinephrine	B-CHEMICAL
only	O
.	O
However	O
,	O
epinephrine	B-CHEMICAL
treatment	B-UNK
resulted	B-UNK
in	O
the	O
incorporation	O
of	O
epinephrine	B-CHEMICAL
into	O
renal	B-UNK
catecholamine	B-UNK
stores	O
such	O
that	O
approximately	B-UNK
40	O
%	O
of	O
the	O
catecholamine	B-UNK
present	B-UNK
was	O
epinephrine	B-CHEMICAL
while	O
the	O
norepinephrine	B-CHEMICAL
content	B-UNK
was	O
reduced	B-UNK
by	O
a	O
similar	B-UNK
degree	B-UNK
.	O
Total	O
tissue	B-UNK
catecholamine	B-UNK
content	B-UNK
of	O
the	O
kidney	B-UNK
on	O
a	O
molar	O
basis	B-UNK
was	O
unchanged	B-UNK
.	O
Stimulus	O
-	O
induced	B-UNK
fractional	B-UNK
overflow	B-UNK
of	O
neurotransmitter	O
from	O
the	O
epinephrine	B-CHEMICAL
-	O
treated	B-UNK
kidneys	B-UNK
was	O
approximately	B-UNK
twice	B-UNK
normal	B-UNK
and	O
consisted	B-UNK
of	O
both	O
norepinephrine	B-CHEMICAL
and	O
epinephrine	B-CHEMICAL
in	O
proportions	O
similar	B-UNK
to	O
those	O
found	B-UNK
in	O
the	O
kidney	B-UNK
.	O
This	O
difference	B-UNK
in	O
fractional	B-UNK
overflow	B-UNK
between	O
groups	B-UNK
was	O
not	O
affected	B-UNK
by	O
neuronal	B-UNK
and	O
extraneuronal	O
uptake	B-UNK
blockade	B-UNK
.	O
Propranolol	O
had	O
no	O
effect	B-UNK
on	O
stimulus	O
-	O
induced	B-UNK
overflow	B-UNK
in	O
either	O
group	B-UNK
.	O
Phentolamine	O
increased	B-UNK
stimulus	O
-	O
induced	B-UNK
overflow	B-UNK
in	O
both	O
groups	B-UNK
although	O
the	O
increment	O
in	O
overflow	B-UNK
was	O
greater	B-UNK
in	O
the	O
epinephrine	B-CHEMICAL
-	O
treated	B-UNK
group	B-UNK
.	O
In	O
conclusion	O
,	O
chronic	B-UNK
epinephrine	B-CHEMICAL
treatment	B-UNK
results	B-UNK
in	O
enhanced	B-UNK
fractional	B-UNK
neurotransmitter	B-UNK
overflow	I-UNK
.	O
However	O
,	O
neither	O
alterations	B-UNK
in	O
prejunctional	O
beta-adrenoceptor	B-UNK
influences	O
nor	O
alterations	B-UNK
in	O
neuronal	B-UNK
and	O
extraneuronal	O
uptake	B-UNK
mechanisms	B-UNK
appear	O
to	O
be	O
responsible	O
for	O
this	O
alteration	O
.	O
Furthermore	O
,	O
data	B-UNK
obtained	B-UNK
with	O
phentolamine	B-CHEMICAL
alone	O
do	O
not	O
suggest	B-UNK
alpha	B-UNK
-	O
adrenoceptor	B-UNK
desensitization	B-UNK
as	O
the	O
cause	B-UNK
of	O
the	O
enhanced	B-UNK
neurotransmitter	B-UNK
overflow	I-UNK
after	O
epinephrine	B-CHEMICAL
treatment	B-UNK
.	O

Ocular	O
manifestations	B-UNK
of	O
juvenile	B-DISEASE
rheumatoid	I-DISEASE
arthritis	I-DISEASE
.	O

We	O
followed	B-UNK
210	O
cases	B-UNK
of	O
juvenile	B-DISEASE
rheumatoid	I-DISEASE
arthritis	I-DISEASE
closely	O
for	O
eleven	O
years	B-UNK
.	O
Thirty	O
-	O
six	O
of	O
the	O
210	O
patients	B-UNK
(	O
17.2	O
%	O
)	O
developed	B-UNK
iridocyclitis	B-DISEASE
.	O
Iridocyclitis	O
was	O
seen	B-UNK
most	O
frequently	B-UNK
in	O
young	B-UNK
female	B-UNK
patients	B-UNK
(	O
0	O
to	O
4	O
years	B-UNK
)	O
with	O
the	O
monoarticular	O
or	O
pauciatricular	O
form	B-UNK
of	O
the	O
arthritis	B-DISEASE
.	O
However	O
,	O
30	O
%	O
of	O
the	O
patients	B-UNK
developed	B-UNK
uveitis	B-DISEASE
after	O
16	O
years	B-UNK
of	O
age	B-UNK
.	O
Although	O
61	O
%	O
of	O
patients	B-UNK
had	O
a	O
noncontributory	O
ocular	B-UNK
history	B-UNK
on	O
entry	O
,	O
42	O
%	O
had	O
active	B-UNK
uveitis	B-DISEASE
on	O
entry	O
.	O
Our	O
approach	B-UNK
was	O
effective	B-UNK
in	O
detecting	O
uveitis	B-DISEASE
in	O
new	B-UNK
cases	B-UNK
and	O
exacerbations	O
of	O
uveitis	B-DISEASE
in	O
established	B-UNK
cases	B-UNK
.	O
Forty	O
-	O
four	O
percent	O
of	O
patients	B-UNK
with	O
uveitis	B-DISEASE
had	O
one	O
or	O
more	O
identifiable	O
signs	B-UNK
or	O
symptoms	B-UNK
,	O
such	O
as	O
red	B-DISEASE
eye	I-DISEASE
,	O
ocular	B-UNK
pain	B-UNK
,	O
decreased	B-UNK
visual	B-UNK
acuity	B-UNK
,	O
or	O
photophobia	B-DISEASE
,	O
in	O
order	O
of	O
decreasing	B-UNK
frequency	B-UNK
.	O
Even	O
after	O
early	B-UNK
detection	O
and	O
prompt	B-UNK
treatment	B-UNK
,	O
41	O
%	O
of	O
cases	B-UNK
of	O
uveitis	B-DISEASE
did	O
not	O
respond	O
to	O
more	O
than	O
six	O
months	B-UNK
of	O
intensive	B-UNK
topical	B-UNK
treatment	B-UNK
with	O
corticosteroids	O
and	O
mydriatics	B-CHEMICAL
.	O
Despite	B-UNK
this	O
,	O
there	O
was	O
a	O
dramatic	B-UNK
decrease	B-UNK
in	O
the	O
50	O
%	O
incidence	B-UNK
of	O
blinding	O
complications	B-UNK
of	O
uveitis	B-DISEASE
cited	O
in	O
earlier	B-UNK
studies	B-UNK
.	O
Cataract	O
and	O
band	O
keratopathy	O
occurred	B-UNK
in	O
only	O
22	O
and	O
13	O
%	O
of	O
our	O
group	B-UNK
,	O
respectively	O
.	O
We	O
used	O
chloroquine	B-CHEMICAL
or	O
hydroxychloroquine	B-CHEMICAL
in	O
173	O
of	O
210	O
cases	B-UNK
and	O
found	B-UNK
only	O
one	O
case	B-UNK
of	O
chorioretinopathy	O
attributable	O
to	O
these	O
drugs	B-UNK
.	O
Systemically	O
administered	B-UNK
corticosteroids	O
were	O
used	O
in	O
75	O
of	O
210	O
cases	B-UNK
;	O
a	O
significant	B-UNK
number	B-UNK
of	O
posterior	B-UNK
subcapsular	O
cataracts	B-DISEASE
was	O
found	B-UNK
.	O
Typical	O
keratoconjunctivitis	B-DISEASE
sicca	I-DISEASE
developed	B-UNK
in	O
three	O
of	O
the	O
uveitis	B-DISEASE
cases	B-UNK
.	O
This	O
association	B-UNK
with	O
uveitis	B-DISEASE
and	O
JRA	O
was	O
not	O
noted	O
previously	B-UNK
.	O
Surgical	O
treatment	B-UNK
of	O
cataracts	B-DISEASE
,	O
band	O
keratopathy	O
,	O
and	O
glaucoma	B-DISEASE
achieved	B-UNK
uniformly	O
discouraging	O
results	B-UNK
.	O

Water	O
intoxication	O
associated	B-UNK
with	O
oxytocin	B-CHEMICAL
administration	B-UNK
during	O
saline	B-UNK
-	O
induced	B-UNK
abortion	B-DISEASE
.	O

Four	O
cases	B-UNK
of	O
water	B-DISEASE
intoxication	I-DISEASE
in	O
connection	O
with	O
oxytocin	B-CHEMICAL
administration	B-UNK
during	O
saline	B-UNK
-	O
induced	B-UNK
abortions	O
are	O
described	B-UNK
.	O
The	O
mechanism	B-UNK
of	O
water	B-DISEASE
intoxication	I-DISEASE
is	O
discussed	O
in	O
regard	O
to	O
these	O
cases	B-UNK
.	O
Oxytocin	O
administration	B-UNK
during	O
midtrimester	O
-	O
induced	B-UNK
abortions	O
is	O
advocated	O
only	O
if	O
it	O
can	O
be	O
carried	O
out	O
under	O
careful	O
observations	B-UNK
of	O
an	O
alert	O
nursing	O
staff	O
,	O
aware	O
of	O
the	O
symptoms	B-UNK
of	O
water	B-DISEASE
intoxication	I-DISEASE
and	O
instructed	O
to	O
watch	O
the	O
diuresis	B-UNK
and	O
report	B-UNK
such	O
early	B-UNK
signs	B-UNK
of	O
the	O
syndrome	B-UNK
as	O
asthenia	B-DISEASE
,	O
muscular	B-UNK
irritability	O
,	O
or	O
headaches	O
.	O
The	O
oxytocin	B-CHEMICAL
should	O
be	O
given	B-UNK
only	O
in	O
Ringers	O
lactate	B-UNK
or	O
,	O
alternately	O
,	O
in	O
Ringers	O
lactate	B-UNK
and	O
a	O
5	O
per	O
cent	O
dextrose	O
and	O
water	B-CHEMICAL
solutions	O
.	O
The	O
urinary	B-UNK
output	B-UNK
should	O
be	O
monitored	B-UNK
and	O
the	O
oxytocin	B-CHEMICAL
administration	B-UNK
discontinued	O
and	O
the	O
serum	B-UNK
electrolytes	B-CHEMICAL
checked	O
if	O
the	O
urinary	B-UNK
output	B-UNK
decreases	B-UNK
.	O
The	O
oxytocin	B-CHEMICAL
should	O
not	O
be	O
administered	B-UNK
in	O
excess	B-UNK
of	O
36	O
hours	B-UNK
.	O
If	O
the	O
patient	B-UNK
has	O
not	O
aborted	O
by	O
then	O
the	O
oxytocin	B-CHEMICAL
should	O
be	O
discontinued	O
for	O
10	O
to	O
12	O
hours	B-UNK
in	O
order	O
to	O
perform	O
electrolyte	B-UNK
determinations	O
and	O
correct	O
any	O
electrolyte	B-UNK
imbalance	O
.	O

